PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hasson, T; Mooseker, MS				Hasson, T; Mooseker, MS			Vertebrate unconventional myosins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review									YALE UNIV, DEPT PATHOL, NEW HAVEN, CT 06520 USA	Yale University	Hasson, T (corresponding author), YALE UNIV, DEPT BIOL, POB 6666, NEW HAVEN, CT 06520 USA.			HASSON, TAMA/0000-0002-5405-662X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038979, P30DK034989] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34989, DK38979] Funding Source: Medline; NIGMS NIH HHS [GM25387] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; BAHLER M, 1994, J CELL BIOL, V126, P375, DOI 10.1083/jcb.126.2.375; Bahler M, 1996, CURR OPIN CELL BIOL, V8, P18, DOI 10.1016/S0955-0674(96)80043-3; BALISH MF, 1995, BIOCHEM BIOPH RES CO, V211, P331, DOI 10.1006/bbrc.1995.1815; BEMENT WM, 1994, J MOL BIOL, V243, P356, DOI 10.1006/jmbi.1994.1662; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BRECKLER J, 1994, CELL MOTIL CYTOSKEL, V29, P312, DOI 10.1002/cm.970290404; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; COLLINS K, 1995, CELL MOTIL CYTOSKEL, V32, P151, DOI 10.1002/cm.970320216; Evans L. L., 1995, Molecular Biology of the Cell, V6, p145A; EVANS LL, 1995, P NATL ACAD SCI USA, V92, P10954, DOI 10.1073/pnas.92.24.10954; FOOTER M, 1994, J CELL SCI, V107, P1623; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Gillespie PG, 1996, NAT MED, V2, P27, DOI 10.1038/nm0196-27; GILLESPIE PG, 1993, NEURON, V11, P581, DOI 10.1016/0896-6273(93)90071-X; HAMMER JA, 1994, J MUSCLE RES CELL M, V15, P1, DOI 10.1007/BF00123827; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815; HASSON T, 1994, J CELL BIOL, V127, P425, DOI 10.1083/jcb.127.2.425; HEINTZELMAN MB, 1994, J CELL SCI, V107, P3535; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; Jaramillo F, 1995, NEURON, V15, P1227, DOI 10.1016/0896-6273(95)90003-9; KORN ED, 1996, IN PRESS J BIOL CHEM, V271; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Lewis AK, 1996, CELL MOTIL CYTOSKEL, V33, P130, DOI 10.1002/(SICI)1097-0169(1996)33:2<130::AID-CM5>3.3.CO;2-H; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; MOOSEKER MS, 1991, ORDERING MEMBRANE CY, P31; MORGAN NS, 1995, DEV BIOL, V172, P51, DOI 10.1006/dbio.1995.0005; MORGAN NS, 1994, J MOL BIOL, V239, P347, DOI 10.1006/jmbi.1994.1376; MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NASCIMENTO AAC, 1996, IN PRESS J BIOL CHEM; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P265, DOI 10.1016/S0968-0004(00)89040-4; PROVANCE DW, 1995, MOL BIOL CELL S, V6, pA146; Rayment I, 1996, J BIOL CHEM, V271, P15850, DOI 10.1074/jbc.271.27.15850; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; RUPPERT C, 1995, J CELL SCI, V108, P3775; SILVERS WK, 1979, COAT COLORS MICE, P83; Solc CK, 1994, AUDIT NEUROSCI, V1, P63; STOFFLER HE, 1995, J CELL BIOL, V129, P819, DOI 10.1083/jcb.129.3.819; WAGNER MC, 1992, J CELL BIOL, V119, P163, DOI 10.1083/jcb.119.1.163; Wang F., 1995, Molecular Biology of the Cell, V6, p29A; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WILLIAMS R, 1994, CELL MOTIL CYTOSKEL, V27, P41, DOI 10.1002/cm.970270105; Wirth JA, 1996, J CELL SCI, V109, P653; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c	51	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16431	16434		10.1074/jbc.271.28.16431	http://dx.doi.org/10.1074/jbc.271.28.16431			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8690736	hybrid			2022-12-27	WOS:A1996UX12600001
J	Olson, JS; Phillips, GN				Olson, JS; Phillips, GN			Kinetic pathways and barriers for ligand binding to myoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SPERM WHALE MYOGLOBIN; GEMINATE RECOMBINATION; CARBON-MONOXIDE; HEME-PROTEINS; MOLECULAR-DYNAMICS; XENON COMPLEX; MUTANTS; PICOSECOND; POCKET; NO		RICE UNIV,W M KECK CTR COMPUTAT BIOL,HOUSTON,TX 77005	Rice University	Olson, JS (corresponding author), RICE UNIV,DEPT BIOCHEM & CELL BIOL,MS 140,6100 MAIN ST,HOUSTON,TX 77005, USA.			Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47020] Funding Source: Medline; NIAMS NIH HHS [AR40252] Funding Source: Medline; NIGMS NIH HHS [GM35649] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI A, 1994, BIOCHEMISTRY-US, V33, P5128, DOI 10.1021/bi00183a017; BOLOGNESI M, 1982, J MOL BIOL, V158, P305, DOI 10.1016/0022-2836(82)90435-1; BRAUNSTEIN DP, 1993, BIOPHYS J, V65, P2447, DOI 10.1016/S0006-3495(93)81310-9; Carlson ML, 1996, BIOCHEMISTRY-US, V35, P1125, DOI 10.1021/bi951767k; CARLSON ML, 1994, BIOCHEMISTRY-US, V33, P10597, DOI 10.1021/bi00201a005; CARVER TE, 1990, J BIOL CHEM, V265, P20007; CORNELIUS PA, 1981, P NATL ACAD SCI-BIOL, V78, P7526, DOI 10.1073/pnas.78.12.7526; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; ELBER R, 1990, J AM CHEM SOC, V112, P9161, DOI 10.1021/ja00181a020; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; GIBSON QH, 1989, J BIOL CHEM, V264, P20155; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; HUANG XH, 1994, NAT STRUCT BIOL, V1, P226, DOI 10.1038/nsb0494-226; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; JOHNSON KA, 1989, J MOL BIOL, V207, P459, DOI 10.1016/0022-2836(89)90269-6; JONGEWARD KA, 1988, J AM CHEM SOC, V110, P380, DOI 10.1021/ja00210a011; LAI HH, 1995, PROTEINS, V22, P322, DOI 10.1002/prot.340220404; LIM M, 1995, SCIENCE, V269, P962, DOI 10.1126/science.7638619; LIM MH, 1995, J CHEM PHYS, V102, P4355, DOI 10.1063/1.469484; ORMOS P, 1988, P NATL ACAD SCI USA, V85, P8492, DOI 10.1073/pnas.85.22.8492; PERUTZ MF, 1989, TRENDS BIOCHEM SCI, V14, P42, DOI 10.1016/0968-0004(89)90039-X; PETRICH JW, 1994, J MOL BIOL, V238, P437, DOI 10.1006/jmbi.1994.1302; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; SASSAROLI M, 1986, J BIOL CHEM, V261, P6292; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; TENG TY, 1994, NAT STRUCT BIOL, V1, P701, DOI 10.1038/nsb1094-701; TIAN WD, 1993, J MOL BIOL, V233, P155, DOI 10.1006/jmbi.1993.1491; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; TILTON RF, 1988, J MOL BIOL, V199, P195, DOI 10.1016/0022-2836(88)90389-0; WALDA KN, 1994, BIOCHEMISTRY-US, V33, P2198, DOI 10.1021/bi00174a029; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123	38	283	286	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17593	17596		10.1074/jbc.271.30.17593	http://dx.doi.org/10.1074/jbc.271.30.17593			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8698688	hybrid			2022-12-27	WOS:A1996UY93500001
J	Lagrost, L; Athias, A; Herbeth, B; GuyardDangremont, V; Artur, Y; Paille, F; Gambert, P; Lallemant, C				Lagrost, L; Athias, A; Herbeth, B; GuyardDangremont, V; Artur, Y; Paille, F; Gambert, P; Lallemant, C			Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins - Physiological relevance in alcoholic patients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; PARTICLE-SIZE; HDL-SUBFRACTIONS; LIPID TRANSFERS; HEPATIC LIPASE; FATTY-ACIDS; CONVERSION; CONSUMPTION; REDUCTION; ETHANOL	The aim of the present study was to investigate the role of the cholesteryl ester transfer protein (CETP) and the phospholipid transfer protein (PLTP) in determining the size distribution of high density lipoproteins (ADL) in human plasma, Whereas both purified CETP and PLTP preparations were able to promote the size redistribution of isolated HDL(3), CETP favored the emergence of small HDL, while PLTP induced the formation of both small and large conversion products. When the total plasma lipoprotein fractions isolated from nine distinct subjects were incubated for 24 h at 37 degrees C with either purified PLTP or purified CETP, significant alterations in the relative proportions of the five distinct plasma HDL subpopulations, i.e., HDL(21) (9.71-12.90 nm), HDL(2a) (8.77-9.71 nm), HDL(3a) (8.17-8.77 nm), HDL(3b) (7.76-8.17 nm), and HDL(3c) (7.21-7.16 nm) were also observed, PLTP induced a significant increase in the relative abundance of HDL(2b) (8.66 +/- 2.34% versus 7.87 +/- 1.83% in controls; p < 0.01) and a significant decrease in the relative abundance of HDL(3a) (32.16 +/- 3.42% versus 37.87 +/- 2.62% in controls; p < 0.05). In contrast, CETP significantly reduced the relative proportion of HDL2a (33.03 +/- 2.53% versus 37.56 +/- 6.43% in controls; p < 0.01) but significantly increased the relative proportion of both HDL(3b) (21.36 +/- 6.97% versus 15.58 +/- 7.75% in controls; p < 0.01) and HDL(3b) (3.21 +/- 4.84% versus 1.13 +/- 0.56% in controls; p < 0.05). Finally, in order to assess further the physiological relevance of in vitro observations, CETP activity, PLTP activity, and HDL size distribution were determined in plasmas from 33 alcoholic patients entering a cessation program. Alcohol withdrawaI was associated with (i) a significant increase in plasma CETP activity (173.5 +/- 70.55 h/ml before versus 223.2 +/- 69.3%/h/ml after alcohol withdrawal, p = 0.0001), (ii) a significant reduction in plasma PLTP activity (473.9 +/- 203.7%/h/ml before versus 312.7 +/- 148.4%/h/ml after alcohol withdrawal, p = 0.0001), and (iii) a significant shift of large HDL(2b) and RDL(2a) toward small HDL(3b)and HDL(3c). On the one hand, changes in plasma CETP activity correlated negatively with changes in the proportion of HDL(2a) (r = -0.597, p = 0.0002) and positively with changes in the proportion of HDL(3b) (r = 0.457, p = 0.0075), On the other hand, changes in plasma PLTP activity correlated positively with changes in the proportion of RDL(2b) (r = 0.482, p = 0.0045) and negatively with changes in the proportion of HDL(3a) (r = -0.418, p = 0.0154), Taken together, data of the present study revealed that plasma PLTP and CETP can exert opposite effects on the size distribution of plasma HDL. PLTP can promote the formation of HDL(2b) particles at the expense of HDL(3a), while CETP can promote the formation of HDL(3b) particles at the expense of HDL(2a).	FAC MED,INSERM CJF 93 10,LAB BIOCHIM LIPOPROT,F-21033 DIJON,FRANCE; LAB CTR MED PREVENT,CNRS URA 597,F-54500 VANDOEUVRE NANCY,FRANCE; FAC MED & PHARM,FORMAT BIOCHIM PHARMACOL,F-21033 DIJON,FRANCE; CHRU,HOP FOURNIER,CTR ALCOOL,F-54000 NANCY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; CHU de Nancy			ARTUR, Yves E/A-8504-2019					AMARASURIYA RN, 1992, METABOLISM, V41, P827, DOI 10.1016/0026-0495(92)90162-4; BARTER PJ, 1990, BIOCHIM BIOPHYS ACTA, V1045, P81, DOI 10.1016/0005-2760(90)90206-D; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CHEUNG MC, 1991, J LIPID RES, V32, P383; CLAY MA, 1992, BIOCHIM BIOPHYS ACTA, V1124, P52, DOI 10.1016/0005-2760(92)90125-F; DAMEN J, 1982, BIOCHIM BIOPHYS ACTA, V712, P444, DOI 10.1016/0005-2760(82)90271-5; DAMEN J, 1980, BIOCHIM BIOPHYS ACTA, V620, P90, DOI 10.1016/0005-2760(80)90188-5; DANIELSSON B, 1978, SCAND J CLIN LAB INV, V38, P113, DOI 10.1080/00365517809156078; DECKELBAUM RJ, 1979, J BIOL CHEM, V254, P6079; GOLDBERG CS, 1984, J LIPID RES, V25, P714; GUYARDDANGREMONT V, 1994, CLIN CHIM ACTA, V231, P147, DOI 10.1016/0009-8981(94)90199-6; HAGIAGE M, 1992, METABOLISM, V41, P856, DOI 10.1016/0026-0495(92)90167-9; HANNUKSELA M, 1992, J LIPID RES, V33, P737; HANNUKSELA M, 1992, ALCOHOL ALCOHOLISM, V27, P557; HENNESSY LK, 1993, BIOCHEMISTRY-US, V32, P5759, DOI 10.1021/bi00073a006; HIRANO K, 1992, METABOLISM, V41, P1313, DOI 10.1016/0026-0495(92)90101-F; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; JOHANSSON J, 1991, ARTERIOSCLER THROMB, V11, P174, DOI 10.1161/01.ATV.11.1.174; LAGROST L, 1994, J BIOL CHEM, V269, P3189; LAGROST L, 1992, BIOCHIM BIOPHYS ACTA, V1126, P143, DOI 10.1016/0005-2760(92)90284-3; LAGROST L, 1995, ARTERIOSCL THROM VAS, V15, P1388, DOI 10.1161/01.ATV.15.9.1388; LAGROST L, 1994, BBA-LIPID LIPID MET, V1215, P209, DOI 10.1016/0005-2760(94)90047-7; LAGROST L, 1994, J LIPID RES, V35, P825; LAGROST L, 1990, J LIPID RES, V31, P1569; LAGROST L, 1993, ARTERIOSCLER THROMB, V13, P815, DOI 10.1161/01.ATV.13.6.815; LAGROST L, 1994, ARTERIOSCLER THROMB, V14, P1327, DOI 10.1161/01.ATV.14.8.1327; LAMISSE F, 1994, ALCOHOL ALCOHOLISM, V29, P25; LECOMTE E, 1994, AM J CLIN NUTR, V60, P255, DOI 10.1093/ajcn/60.2.255; LEE SP, 1982, EXPERIENTIA, V38, P914; LIANG HQ, 1994, J LIPID RES, V35, P1187; Lusa S, 1996, BIOCHEM J, V313, P275, DOI 10.1042/bj3130275; OKAMOTO Y, 1988, J LAB CLIN MED, V111, P482; PERIER C, 1983, CLIN CHEM, V29, P874; PULCINI T, 1995, BBA-LIPID LIPID MET, V1254, P13, DOI 10.1016/0005-2760(94)00156-S; PUSSINEN P, 1995, J LIPID RES, V36, P975; REDGRAVE TG, 1979, J CLIN INVEST, V64, P162, DOI 10.1172/JCI109435; SAVOLAINEN MJ, 1990, EUR J CLIN INVEST, V20, P593, DOI 10.1111/j.1365-2362.1990.tb01906.x; SCHNEIDER J, 1985, ATHEROSCLEROSIS, V57, P281, DOI 10.1016/0021-9150(85)90040-1; SILLANAUKEE P, 1993, EUR J CLIN INVEST, V23, P486, DOI 10.1111/j.1365-2362.1993.tb00795.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TALL AR, 1985, J LIPID RES, V26, P842; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TALL AR, 1983, J LIPID RES, V24, P277; TU AY, 1993, J BIOL CHEM, V268, P23098; VALIMAKI M, 1988, EUR J CLIN INVEST, V18, P472, DOI 10.1111/j.1365-2362.1988.tb01042.x; VALIMAKI M, 1993, EUR J CLIN INVEST, V23, P406, DOI 10.1111/j.1365-2362.1993.tb00783.x; VALIMAKI M, 1986, ATHEROSCLEROSIS, V59, P147, DOI 10.1016/0021-9150(86)90043-2; WILLIAMS PT, 1993, ARTERIOSCLER THROMB, V13, P1654, DOI 10.1161/01.ATV.13.11.1654	50	71	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19058	19065		10.1074/jbc.271.32.19058	http://dx.doi.org/10.1074/jbc.271.32.19058			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702577	hybrid			2022-12-27	WOS:A1996VB68400011
J	Thornhill, WB; Wu, MB; Jiang, XQ; Wu, XY; Morgan, PT; Margiotta, JF				Thornhill, WB; Wu, MB; Jiang, XQ; Wu, XY; Morgan, PT; Margiotta, JF			Expression of Kv1.1 delayed rectifier potassium channels in Lec mutant Chinese hamster ovary cell lines reveals a role for sialidation in channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDROTOXIN-BINDING PROTEIN; GOLGI VESICLE MEMBRANES; SHAKER K+-CHANNELS; SQUID GIANT-AXONS; SIALIC-ACID; SODIUM-CHANNELS; XENOPUS-OOCYTES; SURFACE-CHARGE; DIVALENT-CATIONS; CARDIAC MYOCYTES	Kv1.1 potassium (K+) channels contain significant amounts of negatively charged sialic acids, To examine the role of sialidation in K+ channel function. Chinese hamster ovary cell lines deficient in glycosylation (Lee mutants) were transfected with rat brain Kv1.1 cDNA, The K+ channel was functionally expressed in all cell lines, but the voltage dependence of activation (V-1/2) was shifted to more positive voltages and the activation kinetics were slower in the mutant cell lines compared with control, A similar positive shift in VM was recorded in control cells expressing Kv1.1 following treatment with sialidase or by raising extracellular Ca2+, In contrast, these treatments had little or no effect on the Lec mutants, which indicates that channel sialic acids appear to be the negative surface charges sensitive to Ca2+, The data suggest that sialic acid addition modifies Kv1.1 channel function, possibly by influencing the local electric field detected by its voltage sensor, but that these carbohydrates are not required for cell surface expression.			Thornhill, WB (corresponding author), CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,1 GUSTAVE LEVY PL,NEW YORK,NY 10029, USA.		Morgan, Peter/AAD-1891-2022		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024417, R01NS029633] Funding Source: NIH RePORTER; NINDS NIH HHS [NS29633, NS24417] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1990, P NATL ACAD SCI USA, V87, P7579, DOI 10.1073/pnas.87.19.7579; ARMSTRONG CM, 1981, PHYSIOL REV, V61, P644, DOI 10.1152/physrev.1981.61.3.644; ARMSTRONG CM, 1986, J GEN PHYSIOL, V87, P817, DOI 10.1085/jgp.87.5.817; ARMSTRONG CM, 1987, SCIENCE, V236, P712, DOI 10.1126/science.2437654; Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, V2; BARCHI RL, 1988, ANNU REV NEUROSCI, V11, P455, DOI 10.1146/annurev.ne.11.030188.002323; BAUMANN A, 1988, EMBO J, V7, P2457, DOI 10.1002/j.1460-2075.1988.tb03092.x; BEGENISICH T, 1988, TRENDS NEUROSCI, V11, P270, DOI 10.1016/0166-2236(88)90109-9; BENNET E, 1995, BIOPHYS J, V68, P152; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; CUKIERMAN S, 1988, J GEN PHYSIOL, V92, P431, DOI 10.1085/jgp.92.4.431; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; FERMINI B, 1991, AM J PHYSIOL, V260, pH735, DOI 10.1152/ajpheart.1991.260.3.H735; FERMINI B, 1990, J MEMBRANE BIOL, V114, P61, DOI 10.1007/BF01869385; FRANKENHAEUSER B, 1976, ACTA PHYSIOL SCAND, V96, P548, DOI 10.1111/j.1748-1716.1976.tb10225.x; FRANKENHAEUSER B, 1957, J PHYSIOL-LONDON, V137, P218, DOI 10.1113/jphysiol.1957.sp005808; GILLY WF, 1982, J GEN PHYSIOL, V79, P965, DOI 10.1085/jgp.79.6.965; HAHIN R, 1983, J GEN PHYSIOL, V82, P785, DOI 10.1085/jgp.82.6.785; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; INOUE I, 1981, J GEN PHYSIOL, V78, P43, DOI 10.1085/jgp.78.1.43; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KAGAWA Y, 1988, J BIOL CHEM, V263, P17508; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LENNARZ W, 1983, METHOD ENZYMOL, V98, P91; LEVIN G, 1995, J BIOL CHEM, V270, P14611, DOI 10.1074/jbc.270.24.14611; LEVINSON SR, 1986, ION CHANNELS NEURAL, P375; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOGOTHETIS DE, 1992, NEURON, V8, P531, DOI 10.1016/0896-6273(92)90281-H; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; MCDONAGH JC, 1990, J MOL CELL CARDIOL, V22, P1305, DOI 10.1016/0022-2828(90)90066-B; NEGISHI M, 1992, CARBOHYD RES, V236, P209, DOI 10.1016/0008-6215(92)85017-T; NEUMCKE B, 1984, PFLUG ARCH EUR J PHY, V401, P125, DOI 10.1007/BF00583872; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PERNEY T M, 1991, Current Opinion in Cell Biology, V3, P663, DOI 10.1016/0955-0674(91)90039-2; Pongs O, 1992, PHYSL REV S, V72, pS69; RECIOPINTO E, 1990, NEURON, V5, P675, DOI 10.1016/0896-6273(90)90221-Z; REHM H, 1989, FEBS LETT, V247, P28, DOI 10.1016/0014-5793(89)81233-5; REHM H, 1989, FEBS LETT, V249, P224, DOI 10.1016/0014-5793(89)80628-3; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; ROSENBERG RL, 1992, NATURE, V360, P166, DOI 10.1038/360166a0; RUDY B, 1991, Molecular and Cellular Neuroscience, V2, P89, DOI 10.1016/1044-7431(91)90001-5; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P5607, DOI 10.1021/bi00184a033; SCOTT VES, 1990, J BIOL CHEM, V265, P20094; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; TRIMMER JS, 1989, ANNU REV PHYSIOL, V51, P401, DOI 10.1146/annurev.physiol.51.1.401; Uebele VN, 1996, J BIOL CHEM, V271, P2406, DOI 10.1074/jbc.271.5.2406; WANN KT, 1994, EUR J NEUROSCI, V6, P607, DOI 10.1111/j.1460-9568.1994.tb00305.x; YEE HF, 1989, AM J PHYSIOL, V256, pC1267, DOI 10.1152/ajpcell.1989.256.6.C1267; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P279, DOI 10.1085/jgp.103.2.279	66	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19093	19098		10.1074/jbc.271.32.19093	http://dx.doi.org/10.1074/jbc.271.32.19093			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702582	hybrid			2022-12-27	WOS:A1996VB68400016
J	Webb, DL; Islam, MS; Efanov, AM; Brown, G; Kohler, M; Larsson, O; Berggren, PO				Webb, DL; Islam, MS; Efanov, AM; Brown, G; Kohler, M; Larsson, O; Berggren, PO			Insulin exocytosis and glucose-mediated increase in cytoplasmic free Ca2+ concentration in the pancreatic beta-cell are independent of cyclic ADP-ribose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE CA-2+ CONCENTRATION; INOSITOL TRISPHOSPHATE; SECRETING CELLS; RELEASE; CALCIUM; HYDROLYSIS; INHIBITION; RECEPTOR; FURA-2; ISLETS	Stimulation of pancreatic P-cells by glucose gives rise to an increase in the cytoplasmic free calcium concentration ([Ca2+](i)) and exocytosis of insulin. Cyclic adenosine 5'-diphosphate ribose (cADPR), a metabolite of beta-NAD(+), has been reported to increase [Ca2+](i) in pancreatic beta-cells by releasing Ca2+ from inositol 1,4,5-trisphosphate-insensitive intracellular stores. In the present study, we have examined the role of cADPR in glucose-mediated increases in [Ca2+](i) and insulin exocytosis. Dispersed ob/ob mouse beta-cell aggregates were either pressure microinjected with fura-2 salt or loaded with fura-2 acetoxymethyl ester, and [Ca2+](i) was monitored by microfluorimetry. Microinjection of beta-NAD(+) into fura-2-loaded beta-cells did not increase [Ca2+](i) nor did it alter the cells' subsequent [Ca2+](i) response to glucose. Cells microinjected with the cADPR antagonist 8NH(2)-cADPR increased [Ca2+](i) in response to glucose equally well as those injected with cADPR. Finally, the ability of cADPR to promote exocytosis of insulin ill electropermeabilized beta-cells was investigated. cADPR on its own did not increase insulin secretion nor did it potentiate Ca2+-induced insulin secretion. We conclude that cADPR neither plays a significance role in glucose-mediated increases in [Ca2+](i) nor interacts directly with the molecular mechanisms regulating exocytosis of insulin in normal pancreatic beta-cells.	KAROLINSKA INST, KAROLINSKA HOSP, DEPT MOL MED, ROLF LUFT CTR DIABET RES, S-17176 STOCKHOLM, SWEDEN	Karolinska Institutet; Karolinska University Hospital			Islam, Shahidul/K-3295-2019; Efanov, Alexander/R-3630-2019	Islam, Shahidul/0000-0002-9016-1881; Efanov, Alexander/0000-0002-8630-1503; Webb, Dominic-Luc/0000-0002-6979-9194; Berggren, Per-Olof/0000-0001-8991-413X; Kohler, Martin/0000-0001-6487-4303				ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ARKHAMMAR P, 1989, CELL CALCIUM, V10, P17, DOI 10.1016/0143-4160(89)90040-7; BERGGREN PO, 1993, ADV EXP MED BIOL, V334, P24; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; GALIONE A, 1993, SCIENCE, V259, P325, DOI 10.1126/science.8380506; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; ISLAM MS, 1992, FEBS LETT, V296, P287, DOI 10.1016/0014-5793(92)80306-2; ISLAM MS, 1993, SCIENCE, V262, P584, DOI 10.1126/science.8211188; KASS GEN, 1994, BIOCHEM J, V302, P5, DOI 10.1042/bj3020005; KNIGHT DE, 1986, BIOCHEM J, V234, P497, DOI 10.1042/bj2340497; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; NILSSON T, 1987, BIOCHEM J, V248, P329, DOI 10.1042/bj2480329; RUTTER GA, 1994, CELL CALCIUM, V16, P71, DOI 10.1016/0143-4160(94)90002-7; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TAKASAWA S, 1993, SCIENCE, V262, P585, DOI 10.1126/science.262.5133.585-a; TSIEN RY, 1980, BIOCHIM BIOPHYS ACTA, V599, P623, DOI 10.1016/0005-2736(80)90205-9; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; ZHANG A, 1991, J BIOL CHEM, V266, P21649; ZHOU YP, 1995, ENDOCRINOLOGY, V136, P3546, DOI 10.1210/en.136.8.3546	25	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19074	19079		10.1074/jbc.271.32.19074	http://dx.doi.org/10.1074/jbc.271.32.19074			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702579	hybrid			2022-12-27	WOS:A1996VB68400013
J	HammondsOdie, LP; Jackson, TR; Profit, AA; Blader, IJ; Turck, CW; Prestwich, GD; Theibert, AB				HammondsOdie, LP; Jackson, TR; Profit, AA; Blader, IJ; Turck, CW; Prestwich, GD; Theibert, AB			Identification and cloning of centaurin-alpha - A novel phosphatidylinositol 3,4,5-trisphosphate-binding protein from rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; KINASE-C; PHOSPHOINOSITIDE 3-KINASE; INOSITOL 1,3,4,5-TETRAKISPHOSPHATE; SACCHAROMYCES-CEREVISIAE; ACTIVATED NEUTROPHILS; SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORT; RECEPTOR; BINDING	Using an affinity resin and photoaffinity label based on phospholipid analogs of inositol 1,3,4,5-tetrakisphosphate (InsP(4)), we have isolated, characterized, and cloned a 46-kDa protein from rat brain, which we have named centaurin-alpha. Binding specificity was determined using displacement of 1-O-[H-3](3-[4-benzoyldihydrocinnamidyl]propyl)-InsP(4) photoaffinity labeling. Centaurin-alpha displayed highest affinity for phosphatidylinositol 3,4,5-trisphosphate (PtdInsP(3)) (IC50 = 120 nm), whereas InsP(4), PtdInsP(2), and InsP(3) bound with 5-, 12-, and >50-fold lower affinity, respectively. Screening a rat brain cDNA library with a polymerase chain reaction product, generated using partial amino acid sequence from tryptic peptides, yielded a full-length clone. The 2,450-base pair cDNA contained an open reading frame (ORF) encoding a novel protein of 419 amino acids. Northern analysis revealed a 2.5-kilobase transcript that is highly expressed in brain. The deduced sequence contains a novel putative zinc finger motif, 10 ankyrin-like repeats, and shows homology to recently identified yeast and mammalian Arf GTPase-activating proteins. Given the specificity of binding and enrichment in brain, centaurin-alpha is a candidate PtdInsP(3) receptor that may link the activation of phosphoinositide 3-kinase to downstream responses in the brain.	UNIV ALABAMA,NEUROBIOL RES CTR,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294; BABRAHAM INST,MOL SIGNALLING LAB,DEPT ZOOL,CAMBRIDGE CB2 3ES,ENGLAND; SUNY STONY BROOK,DEPT CHEM & BIOCHEM,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT CELL BIOL,STONY BROOK,NY 11794; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Hammonds-Odie, Latanya/0000-0001-7482-8239	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD032901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH050102, R01MH050102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER; NICHD NIH HHS [DDRC P50HD32901] Funding Source: Medline; NIMH NIH HHS [R01 MH050102, R29 MH050102, R29MH50102] Funding Source: Medline; NINDS NIH HHS [NS29632] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHAUDHARY A, 1995, TETRAHEDRON LETT, V6, P395; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COE JGS, 1994, MOL GEN GENET, V244, P661, DOI 10.1007/BF00282757; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; ESTEVEZ VA, 1991, J AM CHEM SOC, V113, P9885, DOI 10.1021/ja00026a043; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; IRELAND LS, 1994, EMBO J, V13, P3812, DOI 10.1002/j.1460-2075.1994.tb06692.x; Jackson TR, 1996, J CELL SCI, V109, P289; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; MICHELL RH, 1992, TRENDS BIOCHEM SCI, V17, P274, DOI 10.1016/0968-0004(92)90433-A; MITSUI K, 1994, MOL CELL BIOL, V14, P5569, DOI 10.1128/MCB.14.8.5569; MOUREY RJ, 1993, BIOCHEMISTRY-US, V32, P1719, DOI 10.1021/bi00058a004; NAKAMURA S, 1994, J BIOCHEM, V115, P1029, DOI 10.1093/oxfordjournals.jbchem.a124451; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OGAWA W, 1994, BBA-MOL CELL RES, V1224, P533, DOI 10.1016/0167-4889(94)90291-7; OKADA T, 1994, J BIOL CHEM, V269, P3568; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PRESTWICH GD, 1996, IN PRESS PHOTOCHEM P; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; REISER G, 1995, BIOCHEM BIOPH RES CO, V214, P20, DOI 10.1006/bbrc.1995.2251; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SINGH SS, 1993, BIOCHEM BIOPH RES CO, V195, P104, DOI 10.1006/bbrc.1993.2016; Standaert ML, 1996, BIOCHEM J, V313, P1039, DOI 10.1042/bj3131039; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STRICKER R, 1995, FEBS LETT, V370, P236, DOI 10.1016/0014-5793(95)00822-Q; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; THEIBERT AB, 1992, J BIOL CHEM, V267, P9071; TIMERMAN AP, 1992, P NATL ACAD SCI USA, V89, P12655; TOKER A, 1994, J BIOL CHEM, V269, P32358; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WHITNEY JA, 1995, CELL, V83, P703; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; ZHANG J, 1995, J BIOL CHEM, V270, P22807, DOI 10.1074/jbc.270.39.22807	67	138	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18859	18868		10.1074/jbc.271.31.18859	http://dx.doi.org/10.1074/jbc.271.31.18859			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702546	hybrid, Green Accepted			2022-12-27	WOS:A1996VB68300084
J	Pluta, AF; Earnshaw, WC				Pluta, AF; Earnshaw, WC			Specific interaction between human kinetochore protein CENP-C and a nucleolar transcriptional regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CENTROMERE; FACTOR HUBF; CELL-CYCLE; MOLECULAR-CLONING; BINDING PROTEIN; S-PHASE; CHROMOSOME; METAPHASE; MITOSIS; YEAST	CENP-C is a human kinetochore protein that was originally identified as a chromosomal autoantigen in patients with scleroderma spectrum disease. To bean to establish a comprehensive protein map of the human centromere, affinity chromatography was used to identify nuclear proteins that specifically interact with CENP-C. Whereas a number of polypeptides appeared to interact with the full-length CENP-C protein, only a pair of similarly sized proteins of similar to 100 kDa specifically interacted with the isolated carboxyl-terminal third of the CENP-C protein. Neither protein of the doublet bound to control affinity columns. Affinity purification and microsequence analysis of the proteins in the doublet identified them as the two highly related nucleolar transcription factors, UBF1 and UBF2 (also known as the nucleolar autoantigen NOR-90). Immunoblot analysis confirmed that both proteins also interacted with the full-length CENP-C polypeptide with similar affinities. Double indirect immunofluorescence using monospecific antibodies demonstrated that a subset of CENP-C and UBF/NOR-90 is colocalized at nucleoli of interphase HeLa cells, suggesting that the in vitro interaction detected by affinity chromatography may reflect an interaction that occurs in vivo. We discuss the implications of these findings in terms of the properties of interphase centromeres and the role of the nucleolus in scleroderma autoimmunity.	JOHNS HOPKINS UNIV,SCH MED,DEPT ANAT & CELL BIOL,BALTIMORE,MD 21205	Johns Hopkins University			Earnshaw, William/AAY-7438-2020	Earnshaw, William/0000-0002-7191-0621				ADOLPH KW, 1977, CELL, V12, P805, DOI 10.1016/0092-8674(77)90279-3; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BERNAT RL, 1991, HUMAN CENTROMERE PRO; BRAM RJ, 1987, MOL CELL BIOL, V7, P403, DOI 10.1128/MCB.7.1.403; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; BROWN MT, 1995, GENE, V160, P111, DOI 10.1016/0378-1119(95)00163-Z; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CASIANO CA, 1993, J CELL SCI, V106, P1045; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CHAN EKL, 1991, J EXP MED, V174, P1239, DOI 10.1084/jem.174.5.1239; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; CYERT MS, 1988, DEV BIOL, V129, P209, DOI 10.1016/0012-1606(88)90175-3; EARNSHAW WC, 1984, J CELL BIOL, V98, P352, DOI 10.1083/jcb.98.1.352; EARNSHAW WC, 1991, J CELL SCI, V98, P443; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1991, METHOD ENZYMOL, V208, P24; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JIANG WD, 1993, MOL CELL BIOL, V13, P4884, DOI 10.1128/MCB.13.8.4884; MATSUMOTO H, 1989, J CELL BIOL, V109, P1963; MATSUMOTO H, 1989, EXP CELL RES, V181, P181; MEIER UT, 1994, J CELL BIOL, V127, P1505, DOI 10.1083/jcb.127.6.1505; MELLOR J, 1990, EMBO J, V9, P4017, DOI 10.1002/j.1460-2075.1990.tb07623.x; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; MITCHISON TJ, 1985, J CELL BIOL, V101, P755, DOI 10.1083/jcb.101.3.755; MOROI Y, 1981, J CELL BIOL, V90, P254, DOI 10.1083/jcb.90.1.254; MURO Y, 1991, J INVEST DERMATOL, V97, P378, DOI 10.1111/1523-1747.ep12480836; OCHS RL, 1992, EXP CELL RES, V200, P339, DOI 10.1016/0014-4827(92)90181-7; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; PLUTA AF, 1992, J CELL BIOL, V116, P1081, DOI 10.1083/jcb.116.5.1081; Pollard KM, 1989, CLIN EXP RHEUMATO S3, V7, P57; RATTNER JB, 1993, CELL MOTIL CYTOSKEL, V26, P214, DOI 10.1002/cm.970260305; RODRIGUEZSANCHEZ JL, 1987, J IMMUNOL, V139, P2579; ROUSSEL P, 1993, J CELL SCI, V104, P327; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; TAN EM, 1988, CLIN IMMUNOL IMMUNOP, V47, P121, DOI 10.1016/0090-1229(88)90066-9; TOMKIEL J, 1994, J CELL BIOL, V125, P531, DOI 10.1083/jcb.125.3.531; WORDEMAN L, 1991, J CELL BIOL, V114, P285, DOI 10.1083/jcb.114.2.285; Yang CH, 1996, MOL CELL BIOL, V16, P3576; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; ZHU XL, 1995, MOL CELL BIOL, V15, P5017	51	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18767	18774		10.1074/jbc.271.31.18767	http://dx.doi.org/10.1074/jbc.271.31.18767			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702533	hybrid			2022-12-27	WOS:A1996VB68300071
J	Solomon, MS; Morgenthaler, PML; Turesky, RJ; Essigmann, JM				Solomon, MS; Morgenthaler, PML; Turesky, RJ; Essigmann, JM			Mutational and DNA binding specificity of the carcinogen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROCYCLIC AROMATIC-AMINES; ESCHERICHIA-COLI; MUTAGENIC SPECIFICITY; ADDUCT FORMATION; FRIED BEEF; N-2 ATOMS; 2-AMINO-3-METHYLIMIDAZO<4,5-F>QUINOLINE; GENE; TUMORS; GUANINE	The mutagenic specificity of 2-amino3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), a food-borne mutagen and carcinogen, was studied, Plasmid pK19 was modified by photolysis with the 2-azido form of the carcinogen, High pressure liquid chromatography confirmed that the photoactivated azide formed primarily C8 and N-2 guanyl adducts. Transformation of modified pK19 into excision repair competent Escherichia coli resulted in dose-dependent increases in genotoxicity and in mu tagenesis within the lacZ alpha target sequence. Upon induction of the SOS response, a 20-fold increase in mutation frequency over background was observed, A mutational spectrum for MeIQx, generated by sequencing 125 independent mutants, revealed base substitutions (41%), frameshifts (54%), and complex mutations (5.6%); >90% of the mutations occurred at G-C base pairs, Two hotspots were evident at runs of three or five G-C base pairs; similar to 60% of the mutations occurred at the hotspot sites, The hotspot at position 2532 produced mainly base substitutions, while that at position 2576 gave exclusively frameshift mutations, A polymerase inhibition assay mapped the sites of MeIQx adducts, Arrest sites were primarily at or one base 3' to a guanine residue, which correlated well with the distribution of mutations. No direct correlation was seen, however, between intensity of modification and hotspots for mutation.	MIT,WHITAKER COLL HLTH SCI & TECHNOL,DEPT CHEM,CAMBRIDGE,MA 02139; MIT,WHITAKER COLL HLTH SCI & TECHNOL,DIV TOXICOL,CAMBRIDGE,MA 02139; NESTEC LTD,NESTLE RES CTR,CH-1000 LAUSANNE 26,SWITZERLAND	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Nestle SA					NCI NIH HHS [R32-CA52127] Funding Source: Medline; NIEHS NIH HHS [F32-ES05582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA052127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMSON RH, 1990, JPN J CANCER RES, V81, P10, DOI 10.1111/j.1349-7006.1990.tb02500.x; AESCHBACHER HU, 1991, MUTAT RES, V259, P235, DOI 10.1016/0165-1218(91)90120-B; ENDO H, 1994, CANCER RES, V54, P3745; EVANS FE, 1980, CARCINOGENESIS, V1, P955, DOI 10.1093/carcin/1.11.955; FRANTZ CE, 1995, CARCINOGENESIS, V16, P367, DOI 10.1093/carcin/16.2.367; GARCIA A, 1993, P NATL ACAD SCI USA, V90, P5989, DOI 10.1073/pnas.90.13.5989; GUPTA PK, 1991, CARCINOGENESIS, V12, P819, DOI 10.1093/carcin/12.5.819; HUMPHREYS WG, 1992, P NATL ACAD SCI USA, V89, P8278, DOI 10.1073/pnas.89.17.8278; KAKIUCHI H, 1995, P NATL ACAD SCI USA, V92, P910, DOI 10.1073/pnas.92.3.910; KASAI H, 1980, P JPN ACAD B-PHYS, V56, P278, DOI 10.2183/pjab.56.278; KASAI H, 1981, CHEM LETT, P485, DOI 10.1246/cl.1981.485; KATO T, 1988, CARCINOGENESIS, V9, P71, DOI 10.1093/carcin/9.1.71; KOFFELSCHWARTZ N, 1984, J MOL BIOL, V177, P33, DOI 10.1016/0022-2836(84)90056-1; KOSAKARN P, 1993, CARCINOGENESIS, V14, P511, DOI 10.1093/carcin/14.3.511; KRISHNAMURTHY G, 1990, BIOCHEMISTRY-US, V29, P981, DOI 10.1021/bi00456a021; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LASKO DD, 1988, J BIOL CHEM, V263, P15429; MAKINO H, 1992, P NATL ACAD SCI USA, V89, P4850, DOI 10.1073/pnas.89.11.4850; MAKINO H, 1992, CANCER LETT, V62, P115, DOI 10.1016/0304-3835(92)90181-T; MALIA SA, 1995, BIOCHEMISTRY-US, V34, P96, DOI 10.1021/bi00001a012; Maniatis T, 1989, DECONTAMINATION DILU; MILLER EC, 1978, CANCER RES, V38, P1479; MOORE PD, 1981, P NATL ACAD SCI-BIOL, V78, P110, DOI 10.1073/pnas.78.1.110; OHANDLEY SF, 1993, BIOCHEMISTRY-US, V32, P2481, DOI 10.1021/bi00061a005; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; ROSS H, 1993, CANCER RES, V53, P1273; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; SNYDERWINE EG, 1993, CARCINOGENESIS, V14, P1389, DOI 10.1093/carcin/14.7.1389; TAKAYAMA S, 1984, GANN, V75, P467; TURESKY RJ, 1992, CHEM RES TOXICOL, V5, P479, DOI 10.1021/tx00028a005; TURESKY RJ, 1994, CHEM RES TOXICOL, V7, P752, DOI 10.1021/tx00042a007; TURESKY RJ, 1991, CARCINOGENESIS, V12, P1839, DOI 10.1093/carcin/12.10.1839; TURESKY RJ, 1990, CHEM RES TOXICOL, V3, P524, DOI 10.1021/tx00018a006; WAKABAYASHI K, 1992, CANCER RES, V52, pS2092; WATANABE M, 1993, CARCINOGENESIS, V14, P1149, DOI 10.1093/carcin/14.6.1149; WILD D, 1989, CARCINOGENESIS, V10, P335, DOI 10.1093/carcin/10.2.335; YAREMA KJ, 1994, J MOL BIOL, V236, P1034, DOI 10.1016/0022-2836(94)90010-8	39	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18368	18374		10.1074/jbc.271.31.18368	http://dx.doi.org/10.1074/jbc.271.31.18368			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702479	hybrid			2022-12-27	WOS:A1996VB68300017
J	Boland, K; Behrens, M; Choi, D; Manias, K; Perlmutter, DH				Boland, K; Behrens, M; Choi, D; Manias, K; Perlmutter, DH			The serpin-enzyme complex receptor recognizes soluble, nontoxic amyloid-beta peptide but not aggregated, cytotoxic amyloid-beta peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E; TYPE-4 ALLELE; SEC RECEPTOR; CELL-DEATH; PROTEIN; NEUROTOXICITY; TOXICITY; GLUTAMATE; BINDING; INVITRO	There is now extensive evidence that amyloid-beta peptide is toxic to neurons and that its cytotoxic effects can be attributed to a domain corresponding to amyloid-beta 25-35, GSNKGAIIGLM. We have shown recently that the serine proteinase inhibitor (serpin)-enzyme complex receptor (SEC-R), a receptor initially identified for binding of alpha 1-antitrypsin (alpha 1-AT) and other serine protease inhibitors, also recognizes the amyloid-beta 25-35 domain, In fact, by recognizing the amyloid-beta 25-35 domain, SEC-R mediates cell surface binding, internalization, and degradation of soluble amyloid-beta peptide, In this study, we examined the possibility that SEC-R mediates the neurotoxic effect of amyloid-beta peptide, A series of peptides based on the sequences of amyloid-beta peptide and alpha 1-AT was prepared soluble in dimethyl sulfoxide or insoluble in water and examined in assays for SEC-R binding, for cytotoxicity in neuronal PC12 cells and murine cortical neurons in primary culture, and for aggregation in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis, The results show that amyloid-beta peptide 25-35 and amyloid-a peptide 1-40 prepared soluble in dimethyl sulfoxide compete for binding to SEC-R, are nontoxic, and migrate as monomers in SDS-PAGE analysis, In contrast, the same peptides aged in water did not compete for binding to SEC-R but were toxic and migrated as aggregates in SDS-PAGE, An all-D-amyloid-beta 25-35 peptide was not recognized at all by SEC-R but retained full toxic/aggregating properties, Using a series of deleted, substituted, and chimeric am beta/alpha 1-AT peptides, toxicity correlated well with aggregation but poorly with SEC-R recognition, In a subclone of PC12 cells which developed resistance to the toxic effect of aggregated amyloid-beta 25-35 there was a 2.53 fold increase in the number of SEC-R molecules/cell compared with the parent PC12 cell line, These data show that SEC-R does not mediate the cytotoxic effect of aggregated amyloid-beta peptide, Rather, SEC-R could play a protective role by mediating clearance and catabolism of soluble, monomeric amyloid-beta peptide, if soluble amyloid-beta peptide proves to be an in vivo precursor of the insoluble, toxic peptide.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; ST LOUIS CHILDRENS HOSP,DIV GASTROENTEROL & NUTR,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)			Behrens, Maria I I/I-1083-2013	Behrens, Maria I I/0000-0003-0964-426X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011577] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-37784] Funding Source: Medline; NIA NIH HHS [AG11577] Funding Source: Medline; NINDS NIH HHS [NS30337] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BOLAND K, 1995, J BIOL CHEM, V270, P28022; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DAVISSALINAS J, 1995, J BIOL CHEM, V270, P20887, DOI 10.1074/jbc.270.36.20887; ERIKKSSON S, 1995, P NATL ACAD SCI USA, V92, P2312; FORLONI G, 1993, NEUROREPORT, V4, P523, DOI 10.1097/00001756-199305000-00015; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JOSLIN G, 1993, J BIOL CHEM, V268, P1886; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; JOSLIN G, 1992, J CLIN INVEST, V90, P1150, DOI 10.1172/JCI115934; JOSLIN G, 1991, J BIOL CHEM, V266, P11281; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; ROSE K, 1992, IN VITRO BIOL SYSTEM, P46; SCHUBERT D, 1992, P NATL ACAD SCI USA, V89, P8264, DOI 10.1073/pnas.89.17.8264; SCHWARZMAN AL, 1994, P NATL ACAD SCI USA, V91, P8386; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11283; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	30	75	76	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18032	18044		10.1074/jbc.271.30.18032	http://dx.doi.org/10.1074/jbc.271.30.18032			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663372	hybrid			2022-12-27	WOS:A1996UY93500068
J	Kirstein, M; Sanz, L; Quinones, S; Moscat, J; DiazMeco, MT; Saus, J				Kirstein, M; Sanz, L; Quinones, S; Moscat, J; DiazMeco, MT; Saus, J			Cross-talk between different enhancer elements during mitogenic induction of the human stromelysin-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; PHOSPHOLIPASE-C; RAT FIBROBLASTS; EXPRESSION; ONCOGENE; PROMOTER; FOS	Platelet-derived growth factor (PDGF) induces the expression of human stromelysin-1, a matrix metalloproteinase involved in tumor invasion and metastasis. Here it is shown that stromelysin-1 gene induction by PDGF depends on Ras and involves three previously identified promoter elements (the stromelysin-1 PDGF-responsive element (SPRE) site, the two head to-head polyomavirus enhancer A-binding protein 3 (PEA3) sites, and the activator protein-1 (AP-1) binding site). During mitogenic induction, these responsive elements appear to be organized in two independent transcriptional units, SPRE-AP-1 and PEA3-AP-1, which result from specific element cross talking. Interestingly, expression of a dominant negative mutant of Raf-1 significantly interfered with the induction through PEA3-AP-1 but not with that operating through SPRE-AP-1. Conversely, only the induction operating through SPRE-AP-1 was affected significantly by the expression of a dominant negative mutant of the atypical lambda/iota protein kinase C (lambda/iota PKC). These data strongly suggest that the signal triggered by PDGF flows through Ras and bifurcates toward two distinct pathways, one operating through Raf and involving PEA3-AP-1 and the other one Raf-independent, operating through lambda/iota PKC and SPRE-AP-1. Furthermore, we present evidence suggesting that the novel SPRE-binding transcription factor SPBP cross-couples with c-Jun to transactivate the SPRE site.	INST INVEST CITOLOG,FUNDAC VALENCIANA INVEST BIOMED,E-46010 VALENCIA,SPAIN; CTR BIOL MOL SEVERO OCHOA,E-28049 MADRID,SPAIN; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT ENVIRONM & COMMUNITY MED,PISCATAWAY,NJ 08854; UNIV VALENCIA,FAC FARM,DEPT BIOQUIM & BIOL MOLEC,E-46100 VALENCIA,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Valencia			Moscat, Jorge/A-7011-2009; Kirstein, Martina/L-9247-2014	Kirstein, Martina/0000-0001-8716-2309; Diaz-Meco, Maria/0000-0003-0147-0998; Saus, Juan/0000-0003-2082-1597				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; BORDEN P, 1994, GENE, V151, P315, DOI 10.1016/0378-1119(94)90677-7; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIAZMECO MT, 1991, J BIOL CHEM, V266, P22597; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; NICHOLSON R, 1989, BIOCHEMISTRY-US, V28, P5195, DOI 10.1021/bi00438a042; OTANI Y, 1990, EUR J BIOCHEM, V192, P75, DOI 10.1111/j.1432-1033.1990.tb19197.x; QUINONES S, 1994, BIOCHEM J, V302, P471, DOI 10.1042/bj3020471; QUINONES S, 1989, J BIOL CHEM, V264, P8339; SANZ L, 1994, J BIOL CHEM, V269, P10044; SANZ L, 1995, MOL CELL BIOL, V15, P3164; SREENATH T, 1992, CANCER RES, V52, P4942; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x	32	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18231	18236		10.1074/jbc.271.30.18231	http://dx.doi.org/10.1074/jbc.271.30.18231			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663478	hybrid			2022-12-27	WOS:A1996UY93500096
J	Pete, MJ; Exton, JH				Pete, MJ; Exton, JH			Purification of a lysophospholipase from bovine brain that selectively deacylates arachidonoyl-substituted lysophosphatidylcholine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; HYDROLYZING PHOSPHOLIPASE-A2; CANNABINOID RECEPTOR; ACID; CELLS; TRANSACYLASE; MEMBRANES; PROTEINS; LIVER	A high activity lysophospholipase A (lysoPLA) was purified from the soluble fraction of bovine brain, The separation included sequential DEAE-Sephacel, phenyl-Sepharose FF, heparin-Sepharose CL-GB, and Q-Sepharose FF column chromatography. Mono Q, Sephacryl S300HR, and hydroxylapatite column chromatography in the presence of the detergent CHAPS (3-[(3-cholami-dopropyl)-dimethylammonio]-1-propanesulfonate) and glycerol further purified the activity to 17,000-fold. The enzyme was purified to homogeneity by polyacrylamide gel electrophoresis using nondenaturing conditions, The pure enzyme migrated as a single polypeptide of 95 kDa mass by SDS-polyacrylamide gel electrophoresis and deacylated arachidonoyl-lysophosphatidylcholine (ara-lysoPC) at rate of 70 mu mol/(min mg), The enzyme showed selectivity for arachidonoyl-substituted lysoPC, since palmitoyl-lysoPC was deacylated at a much lower rate (7 mu mol/(min mg)), LysoPLA activity was maximal at pH 7.4-8.0 and was increased 1.3-fold by MgCl2 (5 mM). By including MgCl2, however, the range of optimal activity was expanded to pH values up to 9.0. The 95-kDa protein also deacylated arachidonoyl groups from 1-O-hexadecyl-2-arachidonoyl-PC (PLA(2) activity) at a rate of 15 mu mol/(min mg), Moreover, the deacylation of arachidonoyl groups from diacylPC was greatly increased by including purified bovine brain PLA(1) in the reaction mixture, Thus, the same 95-kDa polypeptide catalyzed both lysoPLA and PLA(2) activities, but the rate of arachidonoyl group deacylation was increased by prior sn-l deacylation, Finally, the 95-kDa polypeptide cross-reacted with antibodies raised against a human recombinant cPLA(2), implying that the 95-kDa protein is structurally similar to cPLA(2). Additionally, these data suggest that the combined actions of PLA(1) and the 95-kDa protein generate significant amounts of free arachidonic acid in the brain.	VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHYSIOL & MOLEC BIOPHYS,NASHVILLE,TN 37232	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007563] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32DK07563-08] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DAWSON RMC, 1983, BIOCHEM J, V209, P865, DOI 10.1042/bj2090865; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; DEJONG JGN, 1974, BIOCHIM BIOPHYS ACTA, V369, P50, DOI 10.1016/0005-2760(74)90191-X; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; FUJIMORI Y, 1993, EUR J BIOCHEM, V218, P629, DOI 10.1111/j.1432-1033.1993.tb18416.x; GARSETTI DE, 1992, BIOCHIM BIOPHYS ACTA, V1165, P229, DOI 10.1016/0005-2760(92)90191-W; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GROSS RW, 1983, J BIOL CHEM, V258, P5221; HIRASAWA K, 1981, EUR J BIOCHEM, V120, P53, DOI 10.1111/j.1432-1033.1981.tb05669.x; ITABE H, 1992, J BIOL CHEM, V267, P15319; KIM DK, 1991, BIOCHIM BIOPHYS ACTA, V1083, P80; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; MARTIN TW, 1987, J BIOL CHEM, V262, P13086; NALBONE G, 1985, J LIPID RES, V26, P104; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PETE MJ, 1994, J BIOL CHEM, V269, P19494; PETE MJ, 1995, BBA-LIPID LIPID MET, V1256, P367, DOI 10.1016/0005-2760(95)00047-G; Pete MJ, 1996, BBA-LIPID LIPID MET, V1299, P325, DOI 10.1016/0005-2760(95)00225-1; PIOMELLI D, 1990, TRENDS PHARMACOL SCI, V11, P367, DOI 10.1016/0165-6147(90)90182-8; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; ROOKE JA, 1976, J NEUROCHEM, V27, P613, DOI 10.1111/j.1471-4159.1976.tb12291.x; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; VENANCE L, 1995, NATURE, V376, P590, DOI 10.1038/376590a0; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZHANG Y, 1988, J BIOL CHEM, V263, P9965	30	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18114	18121		10.1074/jbc.271.30.18114	http://dx.doi.org/10.1074/jbc.271.30.18114			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663471	hybrid			2022-12-27	WOS:A1996UY93500079
J	Trofimova, M; Sprenkle, AB; Green, M; Sturgill, TW; Goebl, MG; Harrington, MA				Trofimova, M; Sprenkle, AB; Green, M; Sturgill, TW; Goebl, MG; Harrington, MA			Developmental and tissue-specific expression of mouse Pelle-like protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION PATHWAY; TRANSCRIPTION FACTOR; DROSOPHILA EMBRYO; DNA-BINDING; ACTIVATION; INHIBITION; SEQUENCES; CYTOKINES; SUBUNITS	The NF-kappa B/c-Rel proteins are a family of evolutionarily conserved transcription factors activated during development that in the adult, mediate many processes including the immune response, A high degree of sequence similarity is shared between the NF-kappa B/c-Rel family of transcription factors and the Drosophila Dorsal protein as well as between its cytoplasmic inhibitor, I kappa B alpha and the Drosophila Cactus protein, Genetic analyses of Dorsal have defined components of a signaling pathway for Dorsal activation, including a serine/threonine kinase, Pelle, placed upstream of Dorsal and Cactus, We demonstrate that this pathway is likely to be conserved in mammals by the isolation of a cDNA that encodes a novel mouse protein highly related to Pelle, mPLK (mouse Pelle-like protein kinase), Expression of mPLK mRNA is developmentally regulated in the mouse and in adult tissue mPLK expression is greatest in the liver, a tissue that expresses a high level of NF-kappa B, Recombinant mPLK produced in bacteria is a protein kinase capable of autophosphorylating and phosphorylating I kappa B alpha.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, DEPT MED, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA; UNIV VIRGINIA, HOWARD HUGHES MED INST, CHARLOTTESVILLE, VA 22908 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Howard Hughes Medical Institute; University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043972, R01GM043972, R29GM045460] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43972, GM45460] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; KOHCHI C, 1994, INT J BIOCHEM, V26, P111, DOI 10.1016/0020-711X(94)90203-8; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNO K, 1995, J BIOL CHEM, V270, P27914, DOI 10.1074/jbc.270.46.27914; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LOH YT, 1995, P NATL ACAD SCI USA, V92, P4181, DOI 10.1073/pnas.92.10.4181; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; TAVASSOLI M, 1988, ONTOGENY HEMOPOIESIS, P101; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	36	30	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17609	17612		10.1074/jbc.271.30.17609	http://dx.doi.org/10.1074/jbc.271.30.17609			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663605	hybrid			2022-12-27	WOS:A1996UY93500005
J	Kuriki, T; Kaneko, H; Yanase, M; Takata, H; Shimada, J; Handa, S; Takada, T; Umeyama, H; Okada, S				Kuriki, T; Kaneko, H; Yanase, M; Takata, H; Shimada, J; Handa, S; Takada, T; Umeyama, H; Okada, S			Controlling substrate preference and transglycosylation activity of neopullulanase by manipulating steric constraint and hydrophobicity in active center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-STEAROTHERMOPHILUS NEOPULLULANASE; SITE-DIRECTED MUTAGENESIS; ALPHA-AMYLASE; NUCLEOTIDE-SEQUENCE; THERMOSTABLE PULLULANASE; MOLECULAR-CLONING; ESCHERICHIA-COLI; BRANCHING ENZYME; TAKA-AMYLASE; GENE	The substrate specificity and the transglycosylation activity of neopullulanase was altered by site-directed mutagenesis on the basis of information from a three-dimensional structure predicted by computer-aided molecular modeling. According to the predicted three dimensional structure of the enzyme-substrate complex, it was most likely that Ile-358 affected the substrate preference of the enzyme, Replacing Ile-358 with Trp, which has a bulky side chain, reduced the acceptability of alpha-(1-->6)-branched oligo- and polysaccharides as substrates. The characteristics of the I358W-mutated enzyme were quite different from those of wild type neopullulanase and rather similar to those of typical starch-saccharifying alpha-amylase, In contrast, replacing Ile-358 with Val, which has a smaller side chain, increased the preference for alpha-(1-->6)-branched oligosaccharides and pullulan as substrates. The transglycosylation activity of neopullulanase appeared to be controlled by manipulating the hydrophobicity around the attacking water molecule, which is most likely used to cleave the glucosidic linkage in the hydrolysis reaction. We predicted three residues, Tyr-377, Met-375, and Ser-422, which were located on the entrance path of the water molecule might be involved, The transglycosylation activity of neopullulnase was increased by replacing one of the three residues with more hydrophobic amino acid residues; Y377F, M375L, and S422V. In contrast, the transglycosylation activity of the enzyme was decreased by replacing Tyr-377 with hydrophilic amino acid residues, Asp or Ser.	NEC CORP LTD, FUNDAMENTAL RES LABS, TSUKUBA, IBARAKI 305, JAPAN; EZAKI GLICO CO LTD, BIOCHEM RES LABS, NISHIYODOGAWA KU, OSAKA 555, JAPAN; NEC INFORMATEC SYST LTD, TSUKUBA, IBARAKI 305, JAPAN; KITASATO UNIV, SCH PHARMACEUT SCI, MINATO KU, TOKYO 108, JAPAN	NEC Corporation; Ezaki Glico Co., Ltd.; Kitasato University				Kaneko, Hiroki/0000-0002-7930-1038				BABA T, 1991, BIOCHEM BIOPH RES CO, V181, P87, DOI 10.1016/S0006-291X(05)81385-3; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; BROWN GM, 1979, ACTA CRYSTALLOGR B, V35, P656, DOI 10.1107/S0567740879004374; BUISSON G, 1987, EMBO J, V6, P3909, DOI 10.1002/j.1460-2075.1987.tb02731.x; COLEMAN RD, 1987, J BACTERIOL, V169, P4302, DOI 10.1128/jb.169.9.4302-4307.1987; GOLDSMITH E, 1982, J MOL BIOL, V156, P411, DOI 10.1016/0022-2836(82)90336-9; HEHRE EJ, 1971, ARCH BIOCHEM BIOPHYS, V142, P382, DOI 10.1016/0003-9861(71)90297-9; IMANAKA T, 1981, J BACTERIOL, V147, P776, DOI 10.1128/JB.147.3.776-786.1981; IMANAKA T, 1989, J BACTERIOL, V171, P369, DOI 10.1128/jb.171.1.369-374.1989; IMBERTY A, 1988, CARBOHYD RES, V181, P41, DOI 10.1016/0008-6215(88)84021-7; JESPERSEN HM, 1991, BIOCHEM J, V280, P51, DOI 10.1042/bj2800051; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; KANAOKA M, 1989, PROTEIN ENG, V2, P347, DOI 10.1093/protein/2.5.347; Kitahata S., 1982, J JPN SOC STARCH SCI, V29, P13; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; KLEIN C, 1992, BIOCHEMISTRY-US, V31, P8740, DOI 10.1021/bi00152a009; KOEHLER JEH, 1987, EUR BIOPHYS J BIOPHY, V15, P197, DOI 10.1007/BF00577068; KOSSMANN J, 1991, MOL GEN GENET, V230, P39, DOI 10.1007/BF00290648; Kubota M., 1991, DENPUN KAGAKU, V38, P141; KURIKI T, 1990, J FERMENT BIOENG, V69, P204, DOI 10.1016/0922-338X(90)90213-G; KURIKI T, 1993, J FERMENT BIOENG, V76, P184, DOI 10.1016/0922-338X(93)90005-S; KURIKI T, 1991, J BACTERIOL, V173, P6147, DOI 10.1128/jb.173.19.6147-6152.1991; KURIKI T, 1989, J GEN MICROBIOL, V135, P1521; KURIKI T, 1993, APPL ENVIRON MICROB, V59, P953, DOI 10.1128/AEM.59.4.953-959.1993; KURIKI T, 1988, J BACTERIOL, V170, P1554, DOI 10.1128/jb.170.4.1554-1559.1988; KURIKI T, 1988, APPL ENVIRON MICROB, V54, P2881, DOI 10.1128/AEM.54.11.2881-2883.1988; KURIKI T, 1992, J FERMENT BIOENG, V73, P198, DOI 10.1016/0922-338X(92)90160-V; KURIKI T, 1992, TRENDS GLYCOSCI GLYC, V4, P567; MACGREGOR EA, 1989, BIOCHEM J, V259, P145, DOI 10.1042/bj2590145; MATSUI I, 1991, BIOCHIM BIOPHYS ACTA, V1077, P416, DOI 10.1016/0167-4838(91)90560-M; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MATUURA Y, 1991, DENPUN KAGAKU, V38, P137; MELASNIEMI H, 1990, J GEN MICROBIOL, V136, P447, DOI 10.1099/00221287-136-3-447; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; OMICH K, 1988, HDB AMYLASE RELATED, P32; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMADA J, 1994, J COMPUT CHEM, V15, P28, DOI 10.1002/jcc.540150105; SUGANUMA T, 1978, J BIOCHEM-TOKYO, V84, P293, DOI 10.1093/oxfordjournals.jbchem.a132130; SWIFT HJ, 1991, ACTA CRYSTALLOGR B, V47, P535, DOI 10.1107/S0108768191001970; TAKATA H, 1992, J BIOL CHEM, V267, P18447; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMEZAWA Y, 1988, CHEM PHARM BULL, V36, P4652; WANG GF, 1993, EUR J BIOCHEM, V213, P1091, DOI 10.1111/j.1432-1033.1993.tb17858.x; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	48	81	83	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17321	17329		10.1074/jbc.271.29.17321	http://dx.doi.org/10.1074/jbc.271.29.17321			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663322	hybrid			2022-12-27	WOS:A1996UX94300053
J	Levine, TP; Rabouille, C; Kieckbusch, RH; Warren, G				Levine, TP; Rabouille, C; Kieckbusch, RH; Warren, G			Binding of the vesicle docking protein p115 to golgi membranes is inhibited under mitotic conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP DISSOCIATION INHIBITOR; HELA-CELLS; POTENT INHIBITOR; PLASMA-MEMBRANE; RAB PROTEINS; CYCLIN-A; TRANSPORT; FUSION; PHOSPHORYLATION; KINASE	The vesicle docking protein p115 showed saturable, high affinity binding to interphase Golgi membranes. The affinity of binding was up to 20-fold lower using membranes preincubated with mitotic cytosol. In contrast, binding was not affected by mitotic pretreatment of p115. The reduction in p115 binding was mediated by phosphorylation, could be induced by a cyclin-dependent kinase, and was fully reversible. A shift of p115 from membranes to cytosol was also found after fractionating mitotic cells. The functional significance of the decreased binding was addressed by in vitro mitotic incubations which disassemble Golgi cisternae, predominantly producing transport vesicles. The addition of excess p115 decreased loss of membrane from cisternae, indicating that p115's action is limiting while transport vesicles accumulate. The cessation of intra-Golgi traffic in mitosis has been hypothesized to result from an inhibition of membrane fusion while budding of transport vesicles continues. This process also contributes to mitotic Golgi disassembly. Our results imply that there is a mitotic modification to Golgi membranes leading to a reduction in the affinity of the p115 receptor. Reduced p115 binding may play a part in the inhibition of membrane fusion by preventing prior vesicle docking.	IMPERIAL CANC RES FUND, CELL BIOL LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK				Levine, Timothy/0000-0002-7231-0775				BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BIRKY CW, 1983, INT REV CYTOL, P49; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; FELIX MA, 1989, EMBO J, V8, P3059, DOI 10.1002/j.1460-2075.1989.tb08457.x; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GOW A, 1993, EUR J CELL BIOL, V61, P184; Hames BD., 1990, GEL ELECTROPHORESIS, P1; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V171, P189, DOI 10.1016/0006-291X(90)91375-3; HORIKAWA HPM, 1993, FEBS LETT, V330, P236, DOI 10.1016/0014-5793(93)80281-X; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; MACKAY D, 1993, FEBS LETT, V336, P549, DOI 10.1016/0014-5793(93)80874-T; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MISTELI T, 1995, J CELL BIOL, V130, P1027, DOI 10.1083/jcb.130.5.1027; MISTELI T, 1995, J CELL SCI, V108, P2715; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SLUSAREWICZ P, 1994, CELL BIOL LAB HDB, V1, P509; SLUSAREWICZ P, 1994, THESIS U LONDON; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOUTER E, 1993, J CELL BIOL, V122, P533, DOI 10.1083/jcb.122.3.533; STEELEMORTIMER O, 1993, FEBS LETT, V329, P313, DOI 10.1016/0014-5793(93)80244-O; STUART RA, 1993, J BIOL CHEM, V268, P4050; SZTUL E, 1993, J BIOL CHEM, V268, P1876; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANDERSLUIJS P, 1992, EMBO J, V11, P4379, DOI 10.1002/j.1460-2075.1992.tb05538.x; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WOODMAN PG, 1992, J CELL BIOL, V116, P331, DOI 10.1083/jcb.116.2.331; ZELIGS JD, 1979, J ULTRA MOL STRUCT R, V66, P53, DOI 10.1016/S0022-5320(79)80065-9	60	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17304	17311		10.1074/jbc.271.29.17304	http://dx.doi.org/10.1074/jbc.271.29.17304			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663393	hybrid			2022-12-27	WOS:A1996UX94300051
J	Lueder, DV; Phillips, MA				Lueder, DV; Phillips, MA			Characterization of Trypanosoma brucei gamma-glutamylcysteine synthetase, an essential enzyme in the biosynthesis of trypanothione (diglutathionylspermidine)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; ORNITHINE DECARBOXYLASE; GLUTATHIONE-REDUCTASE; CRITHIDIA-FASCICULATA; INHIBITION; CLONING; GENE; PROTEINS	The parasitic protozoan Trypanosoma brucei maintains redox balance by synthesizing a conjugate of glutathione and spermidine termed trypanothione, The first committed step in the biosynthesis of glutathione, and thereby trypanothione, is catalyzed by the enzyme gamma-glutamylcysteine synthetase (gamma GCS), We have cloned and sequenced the 2037-base pair gene coding for the catalytic subunit of T, brucei gamma GCS, T, brucei gamma GCS appears to be encoded by a single copy gene, A transcript of about 2.3 kilobases was observed in procyclic trypomastigotes, The deduced amino acid sequence of 679 amino acids shares 45, 41, and 36% sequence identity with mammalian, Caenorhabditis elegans, and yeast gamma GCS, respectively, The T. brucei gamma GCS gene was expressed in E. coli; the purified 77.4-kDa enzyme catalyzes the ligation of L-Glu to L-Cys with a k(cat) of 10 s(-1), confirming that the gene encodes the functional catalytic subunit of gamma GCS, The apparent K-m values measured for the three natural substrates L-Glu, L-Cys, and ATP are 0.24, 0.69, and 0.07 mM, respectively. Unlike the mammalian enzyme, L-alpha-aminobutyrate (apparent K-m = 10 mM) is a poor substitute for L-Cys in the T. brucei gamma GCS-catalyzed reaction, T. brucei gamma GCS is feedback-inhibited by glutathione (apparent K-I = 1.1 mM), and it is inactivated by cystamine and buthionine sulfoximine, The kinetic properties of recombinant T, brucei gamma GCS suggest that the substrate binding pocket and the mechanism of enzyme regulation differ from the mammalian enzyme, providing evidence that T, brucei gamma GCS could be a selective chemotherapeutic target for the treatment of trypanosomiasis.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Brekken, Deirdre/I-7999-2012	Brekken, Deirdre/0000-0003-2790-0108	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034432] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI34432] Funding Source: Medline; NIGMS NIH HHS [T32 GM07062] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRICK BA, 1981, J EXP MED, V153, P720, DOI 10.1084/jem.153.3.720; BEAMER RL, 1980, J BIOL CHEM, V255, P1732; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRUN R, 1979, ACTA TROP, V36, P289; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; FERNANDES AP, 1993, P NATL ACAD SCI USA, V90, P11608, DOI 10.1073/pnas.90.24.11608; FULTON JD, 1956, BIOCHEM J, V63, P475, DOI 10.1042/bj0630475; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; GIPP JJ, 1995, BIOCHEM BIOPH RES CO, V206, P584, DOI 10.1006/bbrc.1995.1083; GRIFFITH OW, 1977, BIOCHEM BIOPH RES CO, V79, P919, DOI 10.1016/0006-291X(77)91198-6; HENDERSON GB, 1987, MOL BIOCHEM PARASIT, V24, P39, DOI 10.1016/0166-6851(87)90113-7; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; HUANG CS, 1988, P NATL ACAD SCI USA, V85, P2464, DOI 10.1073/pnas.85.8.2464; HUSSEIN AS, 1995, MOL BIOCHEM PARASIT, V72, P57, DOI 10.1016/0166-6851(94)00064-T; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KIRCHHOFF LV, 1995, PRINCIPLES PRACTICE, P2442; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAY MJ, 1994, P NATL ACAD SCI USA, V91, P10059, DOI 10.1073/pnas.91.21.10059; MEISTER A, 1981, TRENDS BIOCHEM SCI, V6, P231, DOI 10.1016/0968-0004(81)90084-0; MEISTER A, 1989, GLUTATHIONE CHEM BIO, P368; MESHNICK SR, 1977, BIOCHEM PHARMACOL, V26, P1923, DOI 10.1016/0006-2952(77)90167-8; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; MUTOH N, 1995, J BIOCHEM, V117, P283, DOI 10.1093/jb/117.2.283; OHTAKE Y, 1991, YEAST, V7, P953, DOI 10.1002/yea.320070907; ORLOWSKI M, 1971, J BIOL CHEM, V246, P7095; OSTERMAN A, 1994, BIOCHEMISTRY-US, V33, P13662, DOI 10.1021/bi00250a016; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; PERELMAN D, 1990, MOL CELL BIOL, V10, P3284, DOI 10.1128/MCB.10.6.3284; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V83, P8073; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; SEELIG GF, 1984, J BIOL CHEM, V259, P3534; SEELIG GF, 1982, J BIOL CHEM, V257, P5092; SEKURA R, 1977, J BIOL CHEM, V252, P2599; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; SMITH AB, 1995, SCIENCE, V268, P284, DOI 10.1126/science.7716520; SMITH K, 1992, PROTEIN SCI, V1, P874, DOI 10.1002/pro.5560010705; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; WATANABE K, 1986, NUCLEIC ACIDS RES, V14, P4393, DOI 10.1093/nar/14.11.4393; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106; YAN N, 1990, J BIOL CHEM, V265, P1588	48	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17485	17490		10.1074/jbc.271.29.17485	http://dx.doi.org/10.1074/jbc.271.29.17485			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663359	hybrid			2022-12-27	WOS:A1996UX94300077
J	Nelson, JW; Zhu, J; Smith, CC; Kulka, M; Aurelian, L				Nelson, JW; Zhu, J; Smith, CC; Kulka, M; Aurelian, L			ATP and SH3 binding sites in the protein kinase of the large subunit of herpes simplex virus type 2 of ribonucleotide reductase (ICP10)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; DELETION MUTANT; DNA-SEQUENCE; DOMAINS; GRB2; TRANSFORMATION; REPLICATION; ACTIVATION	The large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is a multifunctional protein. It consists of a ribonucleotide reductase and a serine/threonine protein kinase (PK) domain, which has three proline rich motifs consistent with SH3-binding sites at positions 140, 149, and 396. We used site directed mutagenesis to identify amino acids required for kinase activity and interaction with signaling proteins. Mutation of Lys(176) or LyS(259) reduced PK activity (5-8-fold) and binding of the C-14-labeled ATP analog rho-fluorosulfonylbenzoyl 5'-adenosine (FSBA) but did not abrogate them. Enzymatic activity and FSBA binding were abrogated by mutation of both Lys residues, suggesting that either one can bind ATP. Mutation of GlU(209) (Ph catalytic motif III) virtually abrogated kinase activity in the presence of Mg2+ or Mn2+ ions, suggesting that Glu(209) functions in ion dependent Ph activity. ICP10 bound the adaptor protein Grb2 in vitro. Mutation of the ICP10 proline-rich motifs at positions 396 and 149 reduced Grb2 binding 20- and 2-fold, respectively, Binding was abrogated by mutation of both motifs. Grb2 binding to wild type ICP10 was competed by a peptide for the Grrb2 C-terminal SH3 motif, indicating that it involves the Grb2 C-terminal SH3.	UNIV MARYLAND,SCH MED,VIROL LAB,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,IMMUNOL LAB,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT PHARMACOL & EXPTL THERAPEUT,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT MICROBIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,MOL CELL BIOL PROGRAM,BALTIMORE,MD 21201; JOHNS HOPKINS MED INST,DEPT BIOCHEM,BALTIMORE,MD 21205	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine				Zhu, Jia/0000-0002-8676-5105	NATIONAL CANCER INSTITUTE [R01CA039691] Funding Source: NIH RePORTER; NCI NIH HHS [CA39691] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ANDERSON KP, 1981, J VIROL, V37, P1011, DOI 10.1128/JVI.37.3.1011-1027.1981; AURELIAN L, 1989, CANCER CEL, V7, P187; AVERETT DR, 1983, J BIOL CHEM, V258, P9831; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHUNG TD, 1990, VIROLOGY, V179, P168, DOI 10.1016/0042-6822(90)90286-Z; CHUNG TD, 1991, J GEN VIROL, V72, P1139, DOI 10.1099/0022-1317-72-5-1139; CHUNG TD, 1989, J VIROL, V63, P3389, DOI 10.1128/JVI.63.8.3389-3398.1989; COHEN JC, 1977, P SOC EXP BIOL MED, V155, P395, DOI 10.3181/00379727-155-39815; CONNER J, 1992, J VIROL, V66, P7511, DOI 10.1128/JVI.66.12.7511-7516.1992; COOPER J, 1995, J VIROL, V69, P4979, DOI 10.1128/JVI.69.8.4979-4985.1995; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DUTIA BM, 1983, J GEN VIROL, V64, P513, DOI 10.1099/0022-1317-64-3-513; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GATICA M, 1993, FEBS LETT, V315, P173, DOI 10.1016/0014-5793(93)81157-U; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GOLDSTEIN DJ, 1988, VIROLOGY, V166, P41, DOI 10.1016/0042-6822(88)90144-4; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; GOURDEAU N, 1994, NAT STRUCT BIOL, V1, P898; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HAYASHI Y, 1985, P NATL ACAD SCI USA, V82, P8493, DOI 10.1073/pnas.82.24.8493; HENRY BE, 1978, VIROLOGY, V89, P262, DOI 10.1016/0042-6822(78)90058-2; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HONNEGER AM, 1987, CELL, V51, P199; HUNTER JCR, 1995, VIROLOGY, V210, P345, DOI 10.1006/viro.1995.1351; HUNTER JCR, 1995, VIROLOGY, V7, P515; IWASAKA T, 1985, JPN J CANCER RES, V76, P946; JACOBSON JG, 1989, VIROLOGY, V173, P276, DOI 10.1016/0042-6822(89)90244-4; JARIWALLA RJ, 1980, P NATL ACAD SCI-BIOL, V77, P2279, DOI 10.1073/pnas.77.4.2279; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LANGELIER Y, 1981, J GEN VIROL, V57, P21, DOI 10.1099/0022-1317-57-1-21; LANKINEN H, 1982, J VIROL, V41, P893, DOI 10.1128/JVI.41.3.893-900.1982; LAPORTE DC, 1985, J BIOL CHEM, V260, P563; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUO JH, 1991, J BIOL CHEM, V266, P20976; LUO JH, 1992, J BIOL CHEM, V267, P9645; MCLAUCHLAN J, 1983, EMBO J, V2, P1953, DOI 10.1002/j.1460-2075.1983.tb01684.x; NIKAS I, 1986, Proteins Structure Function and Genetics, V1, P376, DOI 10.1002/prot.340010411; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Peng T, 1996, VIROLOGY, V216, P184, DOI 10.1006/viro.1996.0045; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PRESTON VG, 1988, VIROLOGY, V167, P458, DOI 10.1016/S0042-6822(88)90108-0; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SMITH CC, 1994, VIROLOGY, V200, P598, DOI 10.1006/viro.1994.1223; Smith CC, 1996, VIROLOGY, V217, P425, DOI 10.1006/viro.1996.0136; SMITH CC, 1992, J GEN VIROL, V73, P1417, DOI 10.1099/0022-1317-73-6-1417; SWAIN MA, 1986, J VIROL, V57, P802, DOI 10.1128/JVI.57.3.802-808.1986; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; WYMER JP, 1989, J VIROL, V63, P2773, DOI 10.1128/JVI.63.6.2773-2784.1989; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	63	26	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17021	17027		10.1074/jbc.271.29.17021	http://dx.doi.org/10.1074/jbc.271.29.17021			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663276	hybrid			2022-12-27	WOS:A1996UX94300009
J	Rogers, JA; Read, RD; Li, JZ; Peters, KL; Smithgall, TE				Rogers, JA; Read, RD; Li, JZ; Peters, KL; Smithgall, TE			Autophosphorylation of the Fes tyrosine kinase - Evidence for an intermolecular mechanism involving two kinase domain tyrosine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; FPS FES; V-FPS; MYELOID DIFFERENTIATION; PROTOONCOGENE PRODUCT; LEUKEMIA-CELLS; PROTEIN; EXPRESSION; PHOSPHORYLATION; RECEPTOR	The human c-fes proto oncogene encodes a cytoplasmic tyrosine kinase (Fes) that is associated with multiple hematopoietic cytokine receptors, Fes tyrosine autophosphorylation sites may regulate kinase activity and recruit downstream signaling proteins with SH2 domains, To localize the Fes autophosphorylation sites, full-length Fes and deletion mutants lacking either the unique N-terminal or SH2 domain were autophosphorylated in vitro and analyzed by CNBr cleavage, Identical phosphopeptides of 10 and 4 kDa were produced with all three proteins, localizing the tyrosine autophosphorylation sites to the C-terminal kinase domain, Substitution of kinase domain tyrosine residues 713 or 811 with phenylalanine resulted in a loss of the 10- and 4-kDa phosphopeptides, respectively, identifying these tyrosines as in vitro autophosphorylation sites, CNBr cleavage analysis of Fes isolated from (PO4)-P-32-labeled 293T cells showed that Tyr-713 and Tyr-811 are also autophosphorylated in vivo. Mutagenesis of Tyr-713 reduced both autophosphorylation of Tyr-811 and transphosphorylation of Bcr, a recently identified Fes substrate, supporting a major regulatory role for Tyr-713, Wild-type Fes transphosphorylated a kinase-inactive Fes mutant on Tyr-713 and Tyr-811, suggesting that Fes autophosphorylation occurs via an intermolecular mechanism analogous to receptor tyrosine kinases.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC, OMAHA, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center			Rogers, John/L-2798-2016		NCI NIH HHS [P30 CA36727, CA58667] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058667, P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI Y, 1995, J BIOL CHEM, V270, P15658, DOI 10.1074/jbc.270.26.15658; BARETTINO D, 1994, NUCLEIC ACIDS RES, V22, P541, DOI 10.1093/nar/22.3.541; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; CARE A, 1994, ONCOGENE, V9, P739; CARMIER JF, 1986, CELL, V44, P159, DOI 10.1016/0092-8674(86)90494-0; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FANG F, 1993, BIOCHEMISTRY-US, V32, P6995, DOI 10.1021/bi00078a026; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FELDMAN RA, 1989, J VIROL, V63, P5469, DOI 10.1128/JVI.63.12.5469-5474.1989; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; GREER PA, 1988, MOL CELL BIOL, V8, P578, DOI 10.1128/MCB.8.2.578; GROFFEN J, 1983, VIROLOGY, V125, P480, DOI 10.1016/0042-6822(83)90219-2; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HJERMSTAD SJ, 1993, BIOCHEMISTRY-US, V32, P10519, DOI 10.1021/bi00090a031; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MARU Y, 1995, MOL CELL BIOL, V15, P835; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITHGALL TE, 1992, BIOCHEMISTRY-US, V31, P4828, DOI 10.1021/bi00135a013; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; YU G, 1989, J BIOL CHEM, V264, P10276; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	63	63	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17519	17525		10.1074/jbc.271.29.17519	http://dx.doi.org/10.1074/jbc.271.29.17519			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663427	hybrid			2022-12-27	WOS:A1996UX94300082
J	Sato, K; Mori, H; Yoshida, M; Mizushima, S				Sato, K; Mori, H; Yoshida, M; Mizushima, S			Characterization of a potential catalytic residue, Asp-133, in the high affinity ATP-binding site of Escherichia coli SecA, translocation ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; PROTEIN TRANSLOCATION; MEMBRANE-VESICLES; PLASMA-MEMBRANE; PRESECRETORY PROTEINS; INVITRO TRANSLOCATION; PHENOTYPIC SELECTION; CRYSTAL-STRUCTURE; SIGNAL PEPTIDE; ALPHA-SUBUNITS	The high affinity ATP-binding site of SecA is located in its amino-terminal domain possessing amino acid sequences, the Walker A (GXXXXGKT) and B (ZZZZD) motifs, that are characteristic of a major class of nucleotide-binding sites (Walker, J. E., Saraste, M., Runswick, M. J., and Gay, N. J. (1982) EMBO J. 1,945-951). Recently, we proposed that proteins possessing a typical set of Walker A and B motifs contain a conserved Glu or Asp between the two motifs. This Glu or Asp acts as a ''catalytic residue'' that activates a water molecule for an in-line attack on the gamma-phosphate of ATP (Amano, T., Yoshida, M., Matsuo, Y., and Nishikawa, K. (1995) FEES Lett. 359, 1-5). In the present study, the aspartate residue at position 133 in Escherichia coli SecA, which could be the ''catalytic residue,'' was mutated to an asparagine. The mutant SecA (SecA D133N) protein was expressed in E. coli CK4706, encoding a duplication of the secA gene, and purified to homogeneity. The in vitro protein translocation activity and membrane vesicle stimulated ATPase activity of SecA D133N were drastically reduced. Proteolytic studies indicated that the conformational changes of the mutant SecA occurring on interaction with ATP, presecretory proteins, phospholipids, and membrane vesicles, were similar to those of wild-type Seek The mutant SecA allowed the signal peptide cleavage of proOmpA during translocation, indicating that the mutant retains the ability to bind ATP to perform the initial step of the translocation reaction. These data indicate that the carboxyl group of Asp-133 plays a role as a catalytic carboxylate, which activates a water molecule to attack gamma-phosphate of ATP, and the mutant lacking this residue cannot perform the total translocation but can still perform the initial step of the protein translocation.	TOKYO INST TECHNOL, RESOURCES UTILIZAT RES LAB, YOKOHAMA, KANAGAWA 226, JAPAN	Tokyo Institute of Technology	Sato, K (corresponding author), TOKYO UNIV PHARM & LIFE SCI, SCH LIFE SCI, HORINOUCHI 1432-1, HACHIOJI, TOKYO 19203, JAPAN.			Mori, Hiroyuki/0000-0002-0429-1269				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AKITA M, 1990, J BIOL CHEM, V265, P8164; AMANO T, 1994, FEBS LETT, V348, P93, DOI 10.1016/0014-5793(94)00588-5; AMANO T, 1994, FEBS LETT, V351, P1, DOI 10.1016/0014-5793(94)00796-9; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DATE T, 1990, GENE, V90, P141, DOI 10.1016/0378-1119(90)90450-6; DOTTAVIOMARTIN D, 1978, ANAL BIOCHEM, V87, P562, DOI 10.1016/0003-2697(78)90706-6; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; HANADA M, 1994, J BIOL CHEM, V269, P23625; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; KAWASAKI H, 1989, FEBS LETT, V242, P431, DOI 10.1016/0014-5793(89)80516-2; KAWASAKI S, 1993, J BIOL CHEM, V268, P8193; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; MATSUYAMA S, 1995, ADV CELL MOL BIOL M, V4, P61; MCFARLAND L, 1993, J BACTERIOL, V175, P2255, DOI 10.1128/JB.175.8.2255-2262.1993; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; OHTSUBO M, 1987, BIOCHEM BIOPH RES CO, V146, P705, DOI 10.1016/0006-291X(87)90586-9; OLIVER DB, 1982, J BACTERIOL, V150, P686, DOI 10.1128/JB.150.2.686-691.1982; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PANDL JP, 1988, P NATL ACAD SCI USA, V85, P8953; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; TOKUDA H, 1991, FEBS LETT, V279, P233, DOI 10.1016/0014-5793(91)80156-W; TOKUDA H, 1993, BIOCHEM BIOPH RES CO, V195, P1415, DOI 10.1006/bbrc.1993.2201; VANDERWOLK JPW, 1995, J BIOL CHEM, V270, P18975, DOI 10.1074/jbc.270.32.18975; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WICKNER WT, 1994, SCIENCE, V266, P1197, DOI 10.1126/science.7973701; WOLK JV, 1993, MOL MICROBIOL, V8, P31; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMANE K, 1987, J BIOL CHEM, V262, P2358; YAMANE K, 1988, J BIOL CHEM, V263, P5368; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOSHIDA M, 1995, FEBS LETT, V359, P1, DOI 10.1016/0014-5793(94)01438-7	53	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17439	17444		10.1074/jbc.271.29.17439	http://dx.doi.org/10.1074/jbc.271.29.17439			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663354	hybrid			2022-12-27	WOS:A1996UX94300071
J	Elia, G; DeMarco, A; Rossi, A; Santoro, MG				Elia, G; DeMarco, A; Rossi, A; Santoro, MG			Inhibition of HSP70 expression by calcium ionophore A23187 in human cells - An effect independent of the acquisition of DNA-binding activity by the heat shock transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; TUMOR PROMOTER; ACTIVATION; THAPSIGARGIN; HYPERTHERMIA; FLAVONOIDS; STRESS; BRAIN; PROSTAGLANDINS; FIBROBLASTS	Heat shock proteins (HSPs) are induced in mammalian cells in a variety of pathophysiological states and have an important role in cytoprotection in vitro and in vivo., In this study, we report that the calcium ionophore A23187, a glucose-regulated protein (GRP) inducer, dramatically inhibits HSP70 synthesis and HSP70 mRNA transcription after induction by heat shock, sodium arsenite, or prostaglandin A(1) treatment in human K562 cells, A23187 does not suppress, and it actually prolongs, the DNA-binding activity of the human heat shock transcription factor (HSF), while it alters HSF1 phosphorylation in heat shock-treated cells, To inhibit HSP70 expression, A23187 needs to be present during heat shock, while treatment before or after heat shock does not affect HSP70 mRNA transcription. The GRP inducer thapsigargin, which specifically inhibits the endoplasmic reticulum Ca2+-ATPase, has no effect on heat induced HSP70 synthesis, indicating that A23187 inhibitory activity is not due to depletion of intracellular calcium stores and is independent of the concomitant induction of GRP genes, Inhibition of HSP70 expression is correlated with alterations in HSF1 phosphorylation in heat-shocked cells, but not in sodium arsenite-treated cells, indicating that different mechanisms may be involved in mediating A23187 inhibitory activity.	CNR,INST EXPTL MED,I-00137 ROME,ITALY; UNIV LAQUILA,DEPT EXPTL MED,I-67100 LAQUILA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of L'Aquila			Elia, Giuliano/P-4725-2019; Elia, Giuliano/H-3438-2011	Elia, Giuliano/0000-0002-7941-223X; Elia, Giuliano/0000-0001-8216-9560; Santoro, Maria Gabriella/0000-0003-1432-4949; De Marco, Alessandra/0000-0001-7200-2257; ROSSI, ANTONIO/0000-0003-0383-3828				AMICI C, 1994, J VIROL, V68, P6890, DOI 10.1128/JVI.68.11.6890-6899.1994; AMICI C, 1995, CANCER RES, V55, P4452; AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; BANERJI SS, 1984, MOL CELL BIOL, V4, P2437, DOI 10.1128/MCB.4.11.2437; BENNARDINI F, 1995, BIOCHEM BIOPH RES CO, V208, P742, DOI 10.1006/bbrc.1995.1400; CHOI AMK, 1994, FASEB J, V8, P1048, DOI 10.1096/fasebj.8.13.7926370; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSGROVE JW, 1983, P NATL ACAD SCI-BIOL, V80, P569, DOI 10.1073/pnas.80.2.569; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; CUTHBERT AW, 1987, BRIT J PHARMACOL, V91, P503, DOI 10.1111/j.1476-5381.1987.tb11243.x; DAIBATA M, 1994, VIROLOGY, V198, P446, DOI 10.1006/viro.1994.1056; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; ELIA G, 1994, BIOCHEM J, V300, P201, DOI 10.1042/bj3000201; ELIA G, 1993, CANCER RES, V56, P210; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; FRANKLIN RA, 1994, J IMMUNOL, V153, P4890; HIGHTOWER LE, 1980, J CELL PHYSL, V102, P402; HOJ A, 1994, EMBO J, V13, P2617; HOSOKAWA N, 1992, MOL CELL BIOL, V12, P3490, DOI 10.1128/MCB.12.8.3490; HOSOKAWA N, 1990, CELL STRUCT FUNCT, V15, P393, DOI 10.1247/csf.15.393; HUCKLE WR, 1994, BIOCHEMISTRY-US, V33, P1518, DOI 10.1021/bi00172a031; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KANTENGWA S, 1991, BIOCHEM BIOPH RES CO, V180, P308, DOI 10.1016/S0006-291X(05)81293-8; KIM SH, 1993, BIOCHEM BIOPH RES CO, V193, P759, DOI 10.1006/bbrc.1993.1690; KOLLER M, 1991, BIOCHEM BIOPH RES CO, V175, P804, DOI 10.1016/0006-291X(91)91636-Q; LAMARCHE S, 1985, BIOCHEM BIOPH RES CO, V131, P868, DOI 10.1016/0006-291X(85)91320-8; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEE BS, 1995, P NATL ACAD SCI USA, V92, P7207, DOI 10.1073/pnas.92.16.7207; LEVINSON W, 1980, BIOCHIM BIOPHYS ACTA, V606, P170, DOI 10.1016/0005-2787(80)90108-2; LI WWF, 1993, J BIOL CHEM, V268, P12003; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MALHOTRA A, 1986, J CELL PHYSIOL, V128, P279, DOI 10.1002/jcp.1041280220; MARBER MS, 1994, J CLIN INVEST, V93, P1087, DOI 10.1172/JCI117059; MIVECHI NF, 1994, INT J HYPERTHER, V10, P371, DOI 10.3109/02656739409010281; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; Morimoto RI, 1990, STRESS PROTEINS BIOL; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; NAGAI N, 1995, BIOCHEM BIOPH RES CO, V208, P1099, DOI 10.1006/bbrc.1995.1447; NOWAK TS, 1990, J NEUROCHEM, V54, P451, DOI 10.1111/j.1471-4159.1990.tb01893.x; NOWAK TS, 1988, J NEUROCHEM, V50, P285, DOI 10.1111/j.1471-4159.1988.tb13262.x; POUYSSEGUR J, 1977, CELL, V11, P941, DOI 10.1016/0092-8674(77)90305-1; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; SANTORO MG, 1994, EXPERIENTIA, V50, P1039, DOI 10.1007/BF01923459; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SMITH PL, 1984, AM J PHYSIOL, V247, pG695, DOI 10.1152/ajpgi.1984.247.6.G695; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SUBJECK JR, 1986, AM J PHYSIOL, V250, pC1, DOI 10.1152/ajpcell.1986.250.1.C1; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330	56	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16111	16118		10.1074/jbc.271.27.16111	http://dx.doi.org/10.1074/jbc.271.27.16111			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663271	hybrid			2022-12-27	WOS:A1996UW35200040
J	Rayment I				Rayment, I			The structural basis of the myosin ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ACTOMYOSIN ATPASE; MUSCLE-CONTRACTION; BERYLLIUM FLUORIDE; F-19 NMR; COMPLEXES; HYDROLYSIS; VANADATE; FIBERS; INHIBITION; EXCHANGE		UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Rayment I (corresponding author), UNIV WISCONSIN, INST ENZYME RES, 1710 UNIV AVE, MADISON, WI 53705 USA.		rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035186] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35186] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADMIRAAL SJ, 1995, CHEM BIOL, V2, P729, DOI 10.1016/1074-5521(95)90101-9; BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BAGSHAW CR, 1973, BIOCHEM J, V133, P323, DOI 10.1042/bj1330323; BROWN ID, 1976, ACTA CRYSTALLOGR B, V32, P1957, DOI 10.1107/S0567740876006869; CHASE PB, 1993, J PHYSIOL-LONDON, V460, P231, DOI 10.1113/jphysiol.1993.sp019469; DALE MP, 1987, BIOCHEMISTRY-US, V26, P8365, DOI 10.1021/bi00399a051; DANTZIG JA, 1985, J GEN PHYSIOL, V86, P305, DOI 10.1085/jgp.86.3.305; DENG H, 1993, BIOCHEMISTRY-US, V32, P12984, DOI 10.1021/bi00211a006; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FISHER AJ, 1995, BIOPHYS J, V68, pS19; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; GOODNO CC, 1982, P NATL ACAD SCI-BIOL, V79, P21, DOI 10.1073/pnas.79.1.21; HENRY GD, 1993, BIOCHEMISTRY-US, V32, P10451, DOI 10.1021/bi00090a022; HERSCHLAG D, 1989, J AM CHEM SOC, V111, P7579, DOI 10.1021/ja00201a047; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LOWEY S, 1995, BIOPHYS J, V68, pS120; Lynn RW, 1971, BIOCHEMISTRY-US, V10, P4617; MARUTA S, 1993, J BIOL CHEM, V268, P7093; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; PHAN B, 1992, BIOCHEMISTRY-US, V31, P4787, DOI 10.1021/bi00135a007; RAY WJ, 1995, J AM CHEM SOC, V117, P6015, DOI 10.1021/ja00127a015; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Rayment I, 1996, ANNU REV PHYSIOL, V58, P671; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SCHWEINS T, 1994, NAT STRUCT BIOL, V1, P476, DOI 10.1038/nsb0794-476; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SLEEP JA, 1980, J BIOL CHEM, V255, P4094; SMITH CA, 1995, BIOCHEMISTRY-US, V34, P8973, DOI 10.1021/bi00028a005; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; TAYLOR EW, 1977, BIOCHEMISTRY-US, V16, P732, DOI 10.1021/bi00623a027; TRENTHAM DR, 1976, Q REV BIOPHYS, V9, P217, DOI 10.1017/S0033583500002419; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; WEBB MR, 1981, J BIOL CHEM, V256, P910; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996; WILSON GJ, 1995, BIOPHYS J, V68, P216, DOI 10.1016/S0006-3495(95)80177-3; WLODAWER A, 1983, P NATL ACAD SCI-BIOL, V80, P3628, DOI 10.1073/pnas.80.12.3628; Woodward SKA, 1995, BIOCHEMISTRY-US, V34, P16056, DOI 10.1021/bi00049a020; YOUNT RG, 1992, PHILOS T ROY SOC B, V336, P55, DOI 10.1098/rstb.1992.0044; YOUNT RG, 1995, BIOPHYS J, V68, pS44	44	95	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15850	15853		10.1074/jbc.271.27.15850	http://dx.doi.org/10.1074/jbc.271.27.15850			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663496	hybrid			2022-12-27	WOS:A1996UW35200002
J	Lindorfer, MA; Sherman, NE; Woodfork, KA; Fletcher, JE; Hunt, DF; Garrison, JC				Lindorfer, MA; Sherman, NE; Woodfork, KA; Fletcher, JE; Hunt, DF; Garrison, JC			G protein gamma subunits with altered prenylation sequences are properly modified when expressed in Sf9 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; ALPHA-SUBUNIT; MASS-SPECTROMETRY; PHOSPHOLIPASE-C; BOVINE BRAIN; ISOPRENYLATION; DIMERS; SYSTEM; GERANYLGERANYLTRANSFERASE; FARNESYLTRANSFERASE	The gamma subunits of heterotrimeric G proteins undergo post-translational prenylation and carboxylmethylation after formation of the beta gamma dimer, modifications that are essential for alpha-beta gamma, beta gamma-receptor, and beta gamma-effector interactions, We have determined the specific prenyl group present on the beta(1) gamma(1), beta(1) gamma(2), and beta(1) gamma(3) dimers purified from baculovirus-infected Sf9 cells by specific binding to G protein cu subunits immobilized on agarose, These recombinant dimers undergo the same post-translational modifications determined for gamma(1) and gamma(2) isolated from mammalian tissues, Furthermore, infection of Sf9 cells with a recombinant baculovirus encoding an alteration of the gamma(1), CaaX sequence (gamma(1)-S74L) resulted in geranylgeranylation of the resulting gamma(1) subunit, and alteration of the gamma(2) CaaX sequence to CAIS (gamma(2)-L71S) resulted in farnesylation, Both of these altered gamma subunits were able to associate stably with beta(1), and the resulting beta gamma dimer bound tightly to alpha-agarose and eluted specifically with aluminum fluoride, These results indicate that Sf9 insect cells properly process the CaaX motif in G protein gamma subunits and are a useful model system to study the role of prenylation in the protein-protein interactions in which the beta gamma subunits participate.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT CHEM,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia	Lindorfer, MA (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,BOX 448,CHARLOTTESVILLE,VA 22908, USA.		Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368; Sherman, Nicholas/0000-0003-3206-3113	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-19952] Funding Source: Medline; NIGMS NIH HHS [R01-GM-37537] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO T, 1993, J BIOL CHEM, V268, P20512; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CALDWELL GA, 1994, P NATL ACAD SCI USA, V91, P1275, DOI 10.1073/pnas.91.4.1275; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1992, J LIPID RES, V33, P1731; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; DIETRICH A, 1994, EUR J BIOCHEM, V219, P171, DOI 10.1111/j.1432-1033.1994.tb19927.x; FUKADA Y, 1995, METHOD ENZYMOL, V250, P91; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GRABER SG, 1996, METH NEUROSCI, V29, P207; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; HUNT DF, 1991, TECHNIQUES PROTEIN C, V2, P441; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KALMAN VK, 1995, J BIOL CHEM, V270, P14835, DOI 10.1074/jbc.270.24.14835; KALYANARAMAN S, 1995, BIOCHEM BIOPH RES CO, V216, P126, DOI 10.1006/bbrc.1995.2600; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; LOWE PN, 1992, BIOCHEM SOC T, V20, P484, DOI 10.1042/bst0200484; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MATSUDA T, 1994, J BIOL CHEM, V269, P30358; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MORISHITA R, 1992, EUR J BIOCHEM, V210, P1061, DOI 10.1111/j.1432-1033.1992.tb17512.x; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; PAGE M J, 1990, Methods (Orlando), V1, P221, DOI 10.1016/S1046-2023(05)80321-4; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TUINMAN AA, 1991, ANAL BIOCHEM, V193, P173, DOI 10.1016/0003-2697(91)90004-D; UEDA N, 1994, J BIOL CHEM, V269, P4388; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WILCOX MD, 1994, J BIOL CHEM, V269, P12508; WILCOX MD, 1995, BIOCHEM BIOPH RES CO, V212, P367, DOI 10.1006/bbrc.1995.1979; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; XUE CB, 1990, INT J PEPT PROT RES, V36, P362; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302	48	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18582	18587		10.1074/jbc.271.31.18582	http://dx.doi.org/10.1074/jbc.271.31.18582			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702508	hybrid			2022-12-27	WOS:A1996VB68300046
J	Chen, QM; Lin, TH; Der, CJ; Juliano, RL				Chen, QM; Lin, TH; Der, CJ; Juliano, RL			Integrin-mediated activation of mitogen activated protein (MAP) or extracellular signal-related kinase kinase (MEK) and kinase is independent of Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TYROSINE KINASE; CELL-ADHESION; CYTOPLASMIC DOMAIN; RAF-1 KINASE; PHOSPHORYLATION; TRANSDUCTION; PATHWAY; BINDING; MATRIX	The integrins are a family of cell surface receptors that mediate adhesive interactions with the extracellular matrix and also generate signals that influence cell growth and differentiation. Ligation and clustering of integrins causes activation and autophosphorylation of focal adhesion kinase (FAK), a cytoplasmic tyrosine kinase, and results in the transient activation of p42 and p44 mitogen-activated protein (MAP) kinases, Initial evidence has suggested that the integrin signaling pathway may share common elements with the canonical Pas signal transduction cascade activated by peptide mitogens such as epidermal growth factor (EGF), In this report we demonstrate that Raf-1 and MAP or extracellular signal-related kinase kinase (MEK), key cytoplasmic kinases of the Pas cascade, are activated subsequent to integrin-mediated adhesion of mouse NIH 3T3 fibroblasts, We also show that MAP kinase is downstream of MEK in the integrin signaling pathway, However, in contrast to the receptor tyrosine kinase signaling cascade, integrin-mediated signal transduction seems to be largely independent of Ras, Dominant negative inhibitors of Ras-dependent signaling failed to block integrin-mediated activation of MEK, In addition, while treatment with the peptide mitogen EGF clearly increased GTP-loading of Ras, little effect was observed in response to integrin dependent cell adhesion, Thus, integrin-mediated activation of MEK and MAP kinase in 3T3 cells occurs primarily by a mechanism that is distinct from the Ras signal transduction cascade.	UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Der, Channing/0000-0002-7751-2747	NHLBI NIH HHS [HL45100] Funding Source: Medline; NIGMS NIH HHS [GM26065] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGREZ M, 1994, J CELL BIOL, V127, P547, DOI 10.1083/jcb.127.2.547; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FORNARO M, 1995, J BIOL CHEM, V270, P24666, DOI 10.1074/jbc.270.42.24666; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GARDNER AM, 1994, METHOD ENZYMOL, V238, P259; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PICKETT CA, 1995, MOL CELL BIOL, V15, P6777; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; VAILLANCOURT RR, 1994, METHOD ENZYMOL, V238, P255; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	56	168	170	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18122	18127		10.1074/jbc.271.30.18122	http://dx.doi.org/10.1074/jbc.271.30.18122			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663436	hybrid			2022-12-27	WOS:A1996UY93500080
J	Hermoso, J; Pignol, D; Kerfelec, B; Crenon, I; Chapus, C; FontecillaCamps, JC				Hermoso, J; Pignol, D; Kerfelec, B; Crenon, I; Chapus, C; FontecillaCamps, JC			Lipase activation by nonionic detergents - The crystal structure of the porcine lipase-colipase-tetraethylene glycol monooctyl ether complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSE PANCREATIC LIPASE; MOLECULAR-REPLACEMENT; PROCOLIPASE COMPLEX; SULFHYDRYL-GROUPS; MESSENGER-RNA; BILE-SALTS; X-RAY; CLONING; CDNA; SEQUENCE	The crystal structure of the ternary porcine lipase-colipase-tetra ethylene glycol monooctyl ether (TGME) complex has been determined at 2.8 Angstrom resolution, The crystals belong to the cubic space group F23 with a = 289.1 Angstrom and display a strong pseudo-symmetry corresponding to a P23 lattice, Unexpectedly, the crystalline two-domain lipase is found in its open configuration, This indicates that in the presence of colipase, pure micelles of the nonionic detergent TGME are able to activate the enzyme; a process that includes the movement of an N-terminal domain loop (the flap), The effects of TGME and colipase have been confirmed by chemical modification of the active site serine residue using diisopropyl p-nitrophenylphosphate (E600), In addition, the presence of a TGME molecule tightly bound to the active site pocket shows that TGME acts as a substrate analog, thus possibly explaining the inhibitory effect of this nonionic detergent on emulsified substrate hydrolysis at submicellar concentrations, A comparison of the lipase-colipase interactions between our porcine complex and the human-porcine complex (van Tilbeurgh, H., Egloff, M.-P., Martinez, C., Rugani, N., Verger, R., and Cambillau, C. (1993) Nature 362, 814-820) indicates that except for one salt bridge interaction, they are conserved, Analysis of the superimposed complexes shows a 5.4 degrees rotation on the relative position of the N-terminal domains excepting the flap that moves in a concerted fashion with the C-terminal domain, This flexibility may be important for the binding of the complex to the water-lipid interface.	INST BIOL STRUCT JEAN PIERRE EBEL,CEA,CNRS,LAB CRISTALLOG & CRISTALLOGENESE PROT,F-38027 GRENOBLE 1,FRANCE; LAB BIOENERGET & INGN PROT,UPR 9036 CNRS,F-13002 MARSEILLE 9,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite			Hermoso, Juan/J-3433-2012	Hermoso, Juan/0000-0002-1862-8950; PIGNOL, David/0000-0002-8070-0319				ABOUSALHAM A, 1992, PROTEIN ENG, V5, P105, DOI 10.1093/protein/5.1.105; ALEMANGOMEZ JA, 1992, BIOCHEM BIOPH RES CO, V188, P964, DOI 10.1016/0006-291X(92)91326-L; BENKOUKA F, 1982, EUR J BIOCHEM, V128, P331; BORGSTRO.B, 1973, EUR J BIOCHEM, V37, P60, DOI 10.1111/j.1432-1033.1973.tb02957.x; BORGSTROM B, 1977, BIOCHIM BIOPHYS ACTA, V488, P381, DOI 10.1016/0005-2760(77)90197-7; BOURNE Y, 1994, J MOL BIOL, V238, P709, DOI 10.1006/jmbi.1994.1331; Brunger AT, 1988, CRYSTALLOGRAPHIC COM, V3, P126; CARRIERE F, 1994, FEBS LETT, V338, P63, DOI 10.1016/0014-5793(94)80117-7; CASTELLANO EE, 1992, J APPL CRYSTALLOGR, V25, P281, DOI 10.1107/S0021889891012773; CHAILLAN C, 1989, FEBS LETT, V257, P443, DOI 10.1016/0014-5793(89)81592-3; CHAPUS C, 1975, FEBS LETT, V58, P155, DOI 10.1016/0014-5793(75)80247-X; CHAPUS C, 1981, EUR J BIOCHEM, V115, P99; CHARLES M, 1974, BIOCHIM BIOPHYS ACTA, V359, P186, DOI 10.1016/0005-2795(74)90142-1; CHOTHIA C, 1982, BIOCHEMISTRY-US, V21, P3955, DOI 10.1021/bi00260a009; COLWELL NC, 1992, GENBANK L 06329; CRENON I, 1994, BBA-LIPID LIPID MET, V1213, P357, DOI 10.1016/0005-2760(94)00096-4; DECARO A, 1977, BIOCHIM BIOPHYS ACTA, V490, P411, DOI 10.1016/0005-2795(77)90016-2; DECARO J, 1981, BIOCHIM BIOPHYS ACTA, V671, P129, DOI 10.1016/0005-2795(81)90126-4; EGLOFF MP, 1995, BIOCHEMISTRY-US, V34, P2751, DOI 10.1021/bi00009a003; EGLOFF MP, 1995, PROTEIN SCI, V4, P44; ERLANSON C, 1977, BIOCHIM BIOPHYS ACTA, V489, P150, DOI 10.1016/0005-2760(77)90241-7; FOURNET B, 1987, EUR J BIOCHEM, V170, P369, DOI 10.1111/j.1432-1033.1987.tb13709.x; FUKUOKA S, 1990, NUCLEIC ACIDS RES, V18, P5549, DOI 10.1093/nar/18.18.5549; GARNER CW, 1972, J BIOL CHEM, V247, P561; GILLER T, 1992, J BIOL CHEM, V267, P16509; GRANON S, 1986, BIOCHIM BIOPHYS ACTA, V874, P54, DOI 10.1016/0167-4838(86)90101-9; GUIDONI A, 1981, BIOCHIM BIOPHYS ACTA, V660, P148, DOI 10.1016/0005-2744(81)90120-0; HJORTH A, 1993, BIOCHEMISTRY-US, V32, P4702, DOI 10.1021/bi00069a003; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KERFELEC B, 1992, EUR J BIOCHEM, V206, P279, DOI 10.1111/j.1432-1033.1992.tb16926.x; Kerfelec B, 1986, Pancreas, V1, P430, DOI 10.1097/00006676-198609000-00007; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1987, COMPUTATIONAL ASPECT, P39; LOMBARDO D, 1989, J MOL BIOL, V205, P259, DOI 10.1016/0022-2836(89)90380-X; LOWE ME, 1989, J BIOL CHEM, V264, P20042; MAHEGOUHIER N, 1988, BIOCHIM BIOPHYS ACTA, V962, P91, DOI 10.1016/0005-2760(88)90099-9; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MAYLIE MF, 1972, BIOCHIM BIOPHYS ACTA, V276, P162, DOI 10.1016/0005-2744(72)90017-4; MCPHERSON A, 1985, METHOD ENZYMOL, V114, P112; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PAYNE RM, 1994, AM J PHYSIOL, V266, pG914, DOI 10.1152/ajpgi.1994.266.5.G914; PLUMMER TH, 1973, J BIOL CHEM, V248, P7865; SIMS HF, 1992, GENBANK M 58369; THIRSTRUP K, 1994, BIOCHEMISTRY-US, V33, P2748, DOI 10.1021/bi00176a002; THIRSTRUP K, 1995, EUR J BIOCHEM, V227, P186, DOI 10.1111/j.1432-1033.1995.tb20375.x; VANDERMEERS A, 1975, FEBS LETT, V49, P334, DOI 10.1016/0014-5793(75)80779-4; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; VANTILBEURGH H, 1993, J MOL BIOL, V229, P552, DOI 10.1006/jmbi.1993.1054; VERGER R, 1971, BIOCHIM BIOPHYS ACTA, V242, P580, DOI 10.1016/0005-2744(71)90151-3; WALLACE A, BIOMOLECULAR STRUCTU; WICKER C, 1990, BIOCHEM BIOPH RES CO, V167, P130, DOI 10.1016/0006-291X(90)91740-J; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WINKLER FK, 1994, LIPASES THEIR STRUCT, P139; WISHART MJ, 1993, J BIOL CHEM, V268, P10303; 1979, 4 DAR LAB	58	181	186	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18007	18016		10.1074/jbc.271.30.18007	http://dx.doi.org/10.1074/jbc.271.30.18007			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663362	Green Submitted, hybrid			2022-12-27	WOS:A1996UY93500065
J	Wang, F; Gerzanich, V; Wells, GB; Anand, R; Peng, X; Keyser, K; Lindstrom, J				Wang, F; Gerzanich, V; Wells, GB; Anand, R; Peng, X; Keyser, K; Lindstrom, J			Assembly of human neuronal nicotinic receptor alpha 5 subunits with alpha 3, beta 2, and beta 4 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; MYASTHENIA-GRAVIS; MONOCLONAL-ANTIBODIES; XENOPUS-OOCYTES; KINETIC-PROPERTIES; CELL-LINE; SUBTYPES; GENE; EXPRESSION; TORPEDO	Nicotinic acetylcholine receptors formed from combinations of alpha 3, beta 2, beta 4, and alpha 5 subunits are found in chicken ciliary ganglion neurons and some human neuroblastoma cell lines, We studied the co-expression of various combinations of cloned human alpha 3, beta 2, beta 4, and alpha 5 subunits in Xenopus oocytes, Expression on the surface membrane was found only for combinations of alpha 3 beta 2, alpha 3 beta 4, alpha 3 beta 2 alpha 5, and alpha 3 beta 4 alpha 5 subunits but not for other combinations of one, two, or three of these subunits, alpha 5 subunits assembled inside the oocyte with beta 2 but not with alpha 3 subunits or other alpha 5 subunits, alpha 5 subunits coassembled very efficiently with alpha 3 beta 2 or alpha 3 beta 4 combinations, The presence of alpha 5 subunits had very little effect on the binding affinities for epibatidine of receptors containing also alpha 3 and beta 2 or alpha 3 and beta 4 subunits, The presence of alpha 5 subunits increased the rate of desensitization of both receptors containing also alpha 3 and beta 2 or alpha 3 and beta 4 subunits, In the case of receptors containing alpha 3 and beta 4 subunits, the addition of alpha 5 subunits had little effect on the responses to acetylcholine or nicotine, However, in the case of receptors containing alpha 3 and beta 2 subunits, the addition of alpha 5 subunits reduced the EC(50) for acetylcholine from 28 to 0.5 mu M and the EC,, for nicotine from 6.8 to 1.9 mu M, while increasing the efficacy of nicotine from 50% on alpha 3 beta 2 receptors to 100% on alpha 3 beta 2 alpha 5 receptors, Both alpha 3 beta 2 and alpha 3 beta 2 alpha 5 receptors expressed in oocytes sedimented at the same 11 S value as native alpha 3-containing receptors from the human neuroblastoma cell line SH-SY5Y, In the receptors from the neuroblastoma alpha 3, beta 2, and alpha 5 subunits were co-assembled, and 56% of the receptor subtypes containing alpha 3 subunits also contained beta 2 subunits, The beta 2 subunit-containing receptors from SH-SY5Y cells exhibited the high affinity for epibatidine characteristic of receptors formed from alpha 3 and beta 2 or alpha 3, beta 2, and alpha 5 subunits rather than the low affinity exhibited by receptors formed from alpha 3 and beta 4 or alpha 3, beta 4, and alpha 5 subunits, Nicotine, like the structurally similar toxin epibatidine, also distinguishes by binding affinity two subtypes of receptors containing alpha 3 subunits in SH-SY5Y cells, The affinities of alpha 3 beta 2 receptors expressed in oocytes were similar to the affinities of native alpha 3 containing receptors from SH-SY5Y cells for acetylcholine, cytisine, and 1,1-dimethyl-4-phenylpip erazinium.	UNIV PENN,SCH MED,DEPT NEUROSCI,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV ALABAMA,VIS SCI RES CTR,BIRMINGHAM,AL 35294	University of Pennsylvania; University of Pennsylvania; University of Alabama System; University of Alabama Birmingham			Wells, Gregg/AAU-7798-2021		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR006009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009642, R29NS033625] Funding Source: NIH RePORTER; NCRR NIH HHS [1 P41 RR06009] Funding Source: Medline; NINDS NIH HHS [NS 09642, NS33625] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; ANAND R, 1991, J BIOL CHEM, V266, P11192; ANAND R, 1993, BIOCHEMISTRY-US, V32, P9975, DOI 10.1021/bi00089a013; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P4272, DOI 10.1093/nar/18.14.4272; BARNARD EA, 1987, TRENDS NEUROSCI, V10, P502, DOI 10.1016/0166-2236(87)90130-5; BOULTER J, 1990, J BIOL CHEM, V265, P4472; CHINI B, 1992, P NATL ACAD SCI USA, V89, P1572, DOI 10.1073/pnas.89.5.1572; COHEN JB, 1991, J BIOL CHEM, V266, P23354; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; CONROY WG, 1992, NEURON, V9, P679, DOI 10.1016/0896-6273(92)90031-8; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; CRIADO M, 1985, P NATL ACAD SCI USA, V82, P2004, DOI 10.1073/pnas.82.7.2004; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; GERZANICH V, 1995, MOL PHARMACOL, V48, P774; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; HARA H, 1993, BIOCHEM BIOPH RES CO, V194, P1269, DOI 10.1006/bbrc.1993.1960; Horch HLW, 1995, J NEUROSCI, V15, P7778; KAO I, 1977, SCIENCE, V195, P74, DOI 10.1126/science.831257; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KEYSER KT, 1993, J NEUROSCI, V13, P442; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LENOVERE N, 1995, J MOL EVOL, V40, P155, DOI 10.1007/BF00167110; Lindstrom J, 1981, Methods Enzymol, V74 Pt C, P432; LINDSTROM J, 1988, ADV IMMUNOL, V42, P233, DOI 10.1016/S0065-2776(08)60847-0; LINDSTROM J, 1996, CONT NEUROLOGY SERIE; LINDSTROM J, 1994, CRC HDB RECEPTORS, P153; LUKAS RJ, 1993, MOL CELL NEUROSCI, V4, P1, DOI 10.1006/mcne.1993.1001; MIHOVILOVIC M, 1993, J IMMUNOL, V151, P6517; Palma E, 1996, J PHYSIOL-LONDON, V491, P151, DOI 10.1113/jphysiol.1996.sp021203; PAPKE RL, 1991, J PHYSIOL-LONDON, V440, P95, DOI 10.1113/jphysiol.1991.sp018698; PAPKE RL, 1989, J GEN PHYSIOL, V93, P785, DOI 10.1085/jgp.93.5.785; PAPKE RL, 1993, PROG NEUROBIOL, V41, P509, DOI 10.1016/0301-0082(93)90028-Q; PENG X, 1994, MOL PHARMACOL, V45, P546; RamirezLatorre J, 1996, NATURE, V380, P347, DOI 10.1038/380347a0; REGEV I, 1982, ACTA NEUROL SCAND, V65, P681, DOI 10.1111/j.1600-0404.1982.tb03122.x; ROSS RA, 1983, J NATL CANCER I, V71, P741; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; SPANDE TF, 1992, J AM CHEM SOC, V114, P3475, DOI 10.1021/ja00035a048; TUCKER DM, 1988, NEUROLOGY, V38, P1173, DOI 10.1212/WNL.38.8.1173; TZARTOS S, 1986, J NEUROIMMUNOL, V10, P235, DOI 10.1016/0165-5728(86)90105-0; TZARTOS S, 1987, J NEUROIMMUNOL, V15, P185, DOI 10.1016/0165-5728(87)90092-0; TZARTOS SJ, 1982, P NATL ACAD SCI-BIOL, V79, P188, DOI 10.1073/pnas.79.1.188; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; WHEATLEY LM, 1992, J IMMUNOL, V148, P3105; WHITING PJ, 1987, J NEUROIMMUNOL, V16, P205, DOI 10.1016/0165-5728(87)90075-0; WHITING PJ, 1988, J NEUROSCI, V8, P3395; WHITING PJ, 1987, J NEUROSCI, V7, P4005; ZURZOLO C, 1992, EMBO J, V11, P2337, DOI 10.1002/j.1460-2075.1992.tb05293.x	55	296	299	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17656	17665		10.1074/jbc.271.30.17656	http://dx.doi.org/10.1074/jbc.271.30.17656			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663494	hybrid			2022-12-27	WOS:A1996UY93500014
J	Wu, CH; Lee, MF; Liao, SC; Luo, SF				Wu, CH; Lee, MF; Liao, SC; Luo, SF			Sequencing analysis of cDNA clones encoding the American cockroach Cr-PI allergens - Homology with insect hemolymph proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMAN BLATTELLA-GERMANICA; MONOCLONAL-ANTIBODIES; ARTHROPOD HEMOCYANINS; CALLIPHORA-VICINA; PERIPLANETA-AMERICANA; TARANTULA HEMOCYANIN; MOLECULAR-CLONING; BRONCHIAL-ASTHMA; MAJOR ALLERGENS; RNA-POLYMERASE	A previous article described the isolation of several lambda gt22A cDNA clones expressing the American cockroach (Periplaneta americana) Cr-PI allergens recognized by both human atopic IgE antibodies and anti Cr-PI monoclonal antibodies (Wu, C, H., Lee, M. F., and Liao, S. C. (1995) J. Allergy Clin, Immunol, 96, 352-359), This article presents the nucleotide and deduced amino acid sequences of two cDNA clones encoding major allergens of P. americana, Clones C12 and C20 encode proteins of 685 and 631 amino acids with two potential N-glycosylation sites each, The predicted molecular weights for C12 and C20 cloned proteins are 79,300 and 75,500 with isoelectric point values of 6.26 and 6.63, which are compatible with the determined sizes (M(r) 78,000 and 72,000) and isoelectric point value (6.2) of the Cr-PI allergens of P. americana, A high degree of identity (69.1%), including several overlapped predicted central antigenic determinant residues, was found between two allergens, The anti-fusion protein antibody-based enzyme-linked immunosorbent assay was able to detect crude American cockroach extract, Cr-PI, recombinant proteins, and commercial cockroach extracts, which provides further evidence that two allergens share common antigen de terminants. Recombinant allergens of clones C12 and C20 both showed 47.4% skin reactivities on 19 cockroach-sensitive asthmatic patients. Unexpectedly, although no sequence similarity was found to other known allergens, two aromatic amino acid-rich allergens were found to have a striking sequence identity to insect storage proteins (20.1-33.9%), insect juvenile hormone-suppressible proteins (30.9-36.4%), and arthropod hemocyanins (29.7-34.6%), Results suggested that two prominent allergens of P. americana are ancestrally related to these insect hemolymph proteins and represent a new group of proteins in the hemocyanin superfamily, These data will now facilitate epitope-mapping studies, and the recombinant allergens may be valuable for diagnostic and therapeutic purposes.	CHANG GUNG MEM HOSP, DEPT INTERNAL MED, SECT RHEUMATOL ALLERGY & IMMUNOL, TAIPEI 10590, TAIWAN	Chang Gung Memorial Hospital	Wu, CH (corresponding author), TAICHUNG VET GEN HOSP, DEPT MED RES, 160 CHUNG KANG RD, SECT 3, TAICHUNG 40705, TAIWAN.							Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; BERNTON HS, 1984, J ALLERGY, V35, P505; BURKS AW, 1995, J CLIN INVEST, V96, P1715, DOI 10.1172/JCI118216; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FAHRENBACH WH, 1970, J CELL BIOL, V44, P445, DOI 10.1083/jcb.44.2.445; FUJII T, 1989, J BIOL CHEM, V264, P11020; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HELM RM, 1990, INT ARCH ALLER A IMM, V92, P154, DOI 10.1159/000235207; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; Jeng KCG, 1996, CLIN EXP ALLERGY, V26, P349, DOI 10.1111/j.1365-2222.1996.tb00102.x; JONES G, 1988, J BIOL CHEM, V263, P1089; JONES G, 1993, J BIOL CHEM, V268, P1284; JONES G, 1990, J BIOL CHEM, V265, P8596; KANG B, 1978, ANN ALLERGY, V41, P333; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KANG BC, 1991, J ALLERGY CLIN IMMUN, V87, P1073, DOI 10.1016/0091-6749(91)92152-Q; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; LAN JL, 1988, J ALLERGY CLIN IMMUN, V82, P736, DOI 10.1016/0091-6749(88)90072-3; LARSEN JN, 1992, MOL IMMUNOL, V29, P703, DOI 10.1016/0161-5890(92)90180-6; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V87, P574, DOI 10.1016/0091-6749(91)90017-I; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; LEVENBOOK L, 1984, INSECT BIOCHEM, V14, P77, DOI 10.1016/0020-1790(84)90086-6; Levenbook L., 1985, P307; LOMBARDERO M, 1994, CLIN EXP ALLERGY, V24, P765, DOI 10.1111/j.1365-2222.1994.tb00988.x; MAHANA W, 1993, J IMMUNOL METHODS, V161, P187, DOI 10.1016/0022-1759(93)90294-H; Marchand A M, 1966, Bol Asoc Med P R, V58, P49; MARKL J, 1989, J COMP PHYSIOL B, V159, P139, DOI 10.1007/BF00691734; MARKL J, 1992, J COMP PHYSIOL B, V162, P665, DOI 10.1007/BF00301616; MARKL J, 1990, INVERTEBRATE DIOXYGEN CARRIERS, P497; Marx R., 1983, P50; MENDOZA J, 1970, ANN ALLERGY, V28, P159; NAUMANN U, 1991, BIOCHEM BIOPH RES CO, V177, P963, DOI 10.1016/0006-291X(91)90632-H; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; ROBERTS DB, 1981, EXPERIENTIA, V37, P103, DOI 10.1007/BF01963174; RYAN RO, 1985, J BIOL CHEM, V260, P782; SAKURAI H, 1988, J BIOL CHEM, V263, P7876; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEINER O, 1992, INT ARCH ALLERGY IMM, V98, P93, DOI 10.1159/000236170; SCHELLER K, 1980, Z NATURFORSCH C, V35, P387; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; SCHULANER FA, 1970, PEDIATRICS, V45, P465; STANKUS R P, 1988, Journal of Allergy and Clinical Immunology, V81, P563, DOI 10.1016/0091-6749(88)90195-9; STANKUS RP, 1990, J ALLERGY CLIN IMMUN, V86, P781, DOI 10.1016/S0091-6749(05)80183-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUZUKI M, 1995, ALLERGY, V50, P23, DOI 10.1111/j.1398-9995.1995.tb02479.x; Telfer W.H., 1987, UCLA (University of California Los Angeles) Symposia on Molecular and Cellular Biology New Series, V49, P305; TELFER WH, 1983, INSECT BIOCHEM, V13, P601, DOI 10.1016/0020-1790(83)90034-3; THOMSON JA, 1975, ADV INSECT PHYSIOL, V11, P821; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; VOIT R, 1990, J BIOL CHEM, V265, P19447; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WILLOTT E, 1989, J BIOL CHEM, V264, P19052; Wu CH, 1996, ANN ALLERG ASTHMA IM, V76, P195, DOI 10.1016/S1081-1206(10)63422-9; WU CH, 1988, J ALLERGY CLIN IMMUN, V82, P727, DOI 10.1016/0091-6749(88)90071-1; WU CH, 1995, J ALLERGY CLIN IMMUN, V96, P352, DOI 10.1016/S0091-6749(95)70054-4; WU CH, 1993, CLIN EXP ALLERGY, V23, P493, DOI 10.1111/j.1365-2222.1993.tb03236.x; WU CH, 1990, CLIN EXP ALLERGY, V20, P675, DOI 10.1111/j.1365-2222.1990.tb02707.x; WYATT GR, 1978, ANNU REV BIOCHEM, V47, P779, DOI 10.1146/annurev.bi.47.070178.004023	68	75	82	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17937	17943		10.1074/jbc.271.30.17937	http://dx.doi.org/10.1074/jbc.271.30.17937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663281	hybrid			2022-12-27	WOS:A1996UY93500054
J	Yan, K; Gautam, N				Yan, K; Gautam, N			A domain on the G protein beta subunit interacts with both adenylyl cyclase 2 and the muscarinic atrial potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; HETEROTRIMERIC G-PROTEINS; GAMMA-SUBUNITS; K+ CHANNEL; PHOSPHOLIPASE-C; BINDING; STIMULATION; ACTIVATION; G(BETA-GAMMA); REGION	The G protein beta gamma complex modulates the function of a variety of effecters in biological signaling. However, the individual roles of the beta and gamma subunits in this interaction are unknown. Unlike in the case of the alpha subunit, domains on the beta gamma complex that contact effecters have not yet been identified. We show here using the yeast two-hybrid system that the beta subunit and not the gamma subunit interacts with domains specific to adenylyl cyclase type 2 (AC2) and the muscarinic receptor-gated atrial inwardly rectifying potassium channel, GIRK1. Different beta subunit types interact with these effector domains with different efficacies. Furthermore, an N-terminal fragment of 100 residues interacts with both these effector domains as effectively as the whole beta subunit. This domain includes the region where the beta subunit contacts with the alpha subunit in the crystal structure and may therefore explain the ability of the alpha subunit to shut off the activity of the beta gamma complex.	WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; DIETRICH A, 1994, EUR J BIOCHEM, V219, P171, DOI 10.1111/j.1432-1033.1994.tb19927.x; HAGA K, 1992, J BIOL CHEM, V267, P2222; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; INANOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022, DOI 10.1006/bbrc.1995.2072; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; TAKAO K, 1994, NEURON, V13, P747, DOI 10.1016/0896-6273(94)90041-8; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; Taylor JM, 1996, J BIOL CHEM, V271, P3336; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Yan K, 1996, J BIOL CHEM, V271, P7141, DOI 10.1074/jbc.271.12.7141	29	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17597	17600		10.1074/jbc.271.30.17597	http://dx.doi.org/10.1074/jbc.271.30.17597			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663592	hybrid			2022-12-27	WOS:A1996UY93500002
J	Davis, GJ; Bosron, WF; Stone, CL; OwusuDekyi, K; Hurley, TD				Davis, GJ; Bosron, WF; Stone, CL; OwusuDekyi, K; Hurley, TD			X-ray structure of human beta(3)beta(3) alcohol dehydrogenase - The contribution of ionic interactions to coenzyme binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LIVER ALCOHOL; HUMAN BETA-1-BETA-1; KINETIC CHARACTERIZATION; SUBSTITUTIONS; METABOLISM; RESOLUTION; VARIANTS	The three-dimensional structure of the human beta(3) beta(3) dimeric alcohol dehydrogenase (beta(3)) was determined to 2.4-Angstrom resolution. beta(3) was crystallized as a ternary complex with the coenzyme NAD(+) and the competitive inhibitor 4-iodopyrazole. beta(3) is a polymorphic variant at ADH2 that differs from beta(1) by a single amino acid substitution of Arg-369 --> Cys. The available x-ray structures of mammalian alcohol dehydrogenases show that the side chain of Arg-369 forms an ion pair with the NAD(H) pyrophosphate to stabilize the E NAD(H) complex. The Cys-369 side chain of beta(3) cannot form this interaction. The three-dimensional structures of beta(3) and beta(1) are virtually identical, with the exception that Cys-369 and two water molecules in beta(3) occupy the position of Arg-369 in beta(1) The two waters occupy the same positions as two guanidino nitrogens of Arg-369. Hence, the number of hydrogen bonding interactions between the enzyme and NAD(H) are the same for both isoenzymes. However, beta(3) differs from beta(1) by the loss of the electrostatic interaction between the NAD(H) pyrophosphate and the Arg-369 side chain, The equilibrium dissociation constants of beta(3) for NAD(+) and NADH are 350-fold and 4000-fold higher, respectively, than those for beta(1). These changes correspond to binding free energy differences of 3.5 kcal/mol for NAD(+) and 4.9 kcal/mol for NADH. Thus, the Arg-369 --> Cys substitution of beta(3) isoenzyme destabilizes the interaction between coenzyme and beta(3) alcohol dehydrogenase.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis				HURLEY, THOMAS/0000-0002-5942-1163	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K21AA000148, K21AA000150, R37AA007117] Funding Source: NIH RePORTER; NIAAA NIH HHS [R37-AA07117, K21-AA00150, K21-AA00148] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BOSRON WF, 1988, INT CONGR SER, V805, P31; BOSRON WF, 1986, HEPATOLOGY, V6, P502, DOI 10.1002/hep.1840060330; BOSRON WF, 1983, BIOCHEM GENET, V21, P735, DOI 10.1007/BF00498920; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURNELL JC, 1987, BIOCHEM BIOPH RES CO, V146, P1227, DOI 10.1016/0006-291X(87)90779-0; BURNELL JC, 1989, BIOCHEMISTRY-US, V28, P6810, DOI 10.1021/bi00443a005; Burnell JC, 1989, HUMAN METABOLISM ALC, V2, P65; Cleland W W, 1979, Methods Enzymol, V63, P103; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CRABB DW, 1983, ARCH BIOCHEM BIOPHYS, V224, P299, DOI 10.1016/0003-9861(83)90213-8; DAVIS GJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P307, DOI 10.1006/abbi.1994.1242; EDENBERG HJ, 1989, ENZYMOLOGY MOL BIOL, V2, P181; EDENBERG HJ, 1996, IN PRESS COMPREHENSI, V3; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; EKLUND H, 1982, BIOCHEMISTRY-US, V21, P4858, DOI 10.1021/bi00263a005; HURLEY TD, 1991, P NATL ACAD SCI USA, V88, P8149, DOI 10.1073/pnas.88.18.8149; HURLEY TD, 1992, BIOCHEM BIOPH RES CO, V183, P93, DOI 10.1016/0006-291X(92)91613-U; HURLEY TD, 1994, J MOL BIOL, V239, P415, DOI 10.1006/jmbi.1994.1382; HURLEY TD, 1990, J BIOL CHEM, V265, P16366; JORNVALL H, 1994, EXS, V71, P221; JORNVALL H, 1984, P NATL ACAD SCI-BIOL, V81, P3024, DOI 10.1073/pnas.81.10.3024; KUSNADI AR, 1989, HUMAN LIVER ALCOHOL, P51; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUMENG L, 1994, GASTROENTEROLOGY, V107, P572, DOI 10.1016/0016-5085(94)90185-6; LUZATTI V, 1952, ACTA CRYSTALLOGR, V5, P802; PLAPP BV, 1984, ARCH BIOCHEM BIOPHYS, V230, P30, DOI 10.1016/0003-9861(84)90083-3; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; STONE CL, 1993, J BIOL CHEM, V268, P892; STONE CL, 1993, ENZYMOLOGY MOL BIOL, V4, P429; WARSHEL A, 1991, ANNU REV BIOPHYS BIO, V20, P267, DOI 10.1146/annurev.biophys.20.1.267; WRAY W, 1981, ANAL BIOCHEM, V11, P97	32	40	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17057	17061		10.1074/jbc.271.29.17057	http://dx.doi.org/10.1074/jbc.271.29.17057			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663387	hybrid			2022-12-27	WOS:A1996UX94300014
J	Farrow, KN; Manning, N; Schaufele, F; GutierrezHartmann, A				Farrow, KN; Manning, N; Schaufele, F; GutierrezHartmann, A			The c-Jun delta-domain inhibits neuroendocrine promoter activity in a DNA sequence- and pituitary-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PROLACTIN PROMOTER; TRANSCRIPTION FACTOR AP-1; CELL-SPECIFIC INHIBITOR; PROTEIN-KINASE; HA-RAS; SIGNAL-TRANSDUCTION; ACTIVATION DOMAIN; V-JUN; PHOSPHORYLATION; GENE	'The transcription and transformation activity of c-Jun is governed by a 27-amino acid regulatory motif, labeled the delta-domain, which is deleted in v-Jun. We have previously shown that c-jun is a potent inhibitor of the rat prolactin (rPRL) promoter activity induced by either oncogenic Has or phorbol esters. Here, we have characterized the structural and cell-specific requirements for this c-Jun inhibitory response, and we show that this c-Jun inhibitory response mapped to the rPRL footprint II repressor site, was pituitary-specific and required the c-Jun delta-domain. Moreover, alteration of any one of these features (e.g., cis-element, trans-factor, or cell-specific background) switched c-Jun to a transcriptional activator of the rPRL promoter. In HeLa nonpituitary cells, c-Jun alone activated the rPRL promoter via the most proximal GHF-1/Pit-1 binding site, footprint I, and synergized with GHF-1. Finally, recombinant GHF-1 interacted directly with c-jun but not c-Fos proteins. These data provide important fundamental insights into the molecular mechanisms by which the c-Jun delta-domain functions as a modulatory switch and further imply that the functional role of c-Jun is dictated by cell-specific influences and the delta-domain motif.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,PROGRAM MOLEC BIOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,COLORADO CANC CTR,DENVER,CO 80262; UNIV CALIF SAN FRANCISCO,METAB RES UNIT HSW1143,SAN FRANCISCO,CA 94143	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California San Francisco			Gutierrez-Hartmann, Arthur/F-1295-2011	Farrow, Kathryn/0000-0002-8604-7023				ADLER V, 1992, J BIOL CHEM, V267, P17001; ALANI V, 1991, MOL CELL BIOL, V12, P6276; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CONRAD KE, 1992, ONCOGENE, V7, P1279; DAI TN, 1995, ONCOGENE, V10, P849; DEMDEN MC, 1992, MOL ENDOCRINOL, V6, P581, DOI 10.1210/me.6.4.581; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GUTIERREZHARTMANN A, 1987, P NATL ACAD SCI USA, V84, P5211, DOI 10.1073/pnas.84.15.5211; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KEECH CA, 1991, MOL CELL ENDOCRINOL, V78, P55, DOI 10.1016/0303-7207(91)90185-U; KEECH CA, 1992, MOL ENDOCRINOL, V6, P2059, DOI 10.1210/me.6.12.2059; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; OBERWETTER JM, 1993, MOL ENDOCRINOL, V7, P915, DOI 10.1210/me.7.7.915; RAJNARAYAN S, 1995, MOL ENDOCRINOL, V9, P502, DOI 10.1210/me.9.4.502; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670	47	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17139	17146		10.1074/jbc.271.29.17139	http://dx.doi.org/10.1074/jbc.271.29.17139			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663380	hybrid			2022-12-27	WOS:A1996UX94300026
J	Lindahl, B; Eriksson, L; Spillmann, D; Caterson, B; Lindahl, U				Lindahl, B; Eriksson, L; Spillmann, D; Caterson, B; Lindahl, U			Selective loss of cerebral keratan sulfate in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; SYNAPTIC VESICLES; PROTEOGLYCAN; OLIGOSACCHARIDES; BRAIN	Proteoglycans, especially heparan sulfate-substituted species, are known to be associated with the deposition of amyloid in Alzheimer's disease, We previously found that heparan sulfate from afflicted brains, and from control subjects, differed minimally in quantity and structure (Lindahl, B., Eriksson, L., and Lindahl, U. (1995) Biochem, J, 306, 177-184), In the present study, a glyco saminoglycan fraction, shown to contain heparan sulfate and keratan sulfate, was radiolabeled by partial N-deacetylation (hydrazinolysis) followed by re-N-acetylation using [H-3]acetic anhydride, Quantitation of the H-3-labeled polysaccharides, based on digestion with heparitinase I from Flavobacterium heparinum and keratanase from Pseudomonas sp., revealed that the amounts of keratan sulfate in Alzheimer cerebral cortex are reduced to less than half of control values. Moreover, a monoclonal antibody against a highly sulfated keratan sulfate epitope bound to the majority of the neurons in normal cortex but not in the diseased tissue. The lack of highly sulfated keratan sulfate structures may reflect a specific functional defect of the cells.	UNIV UPPSALA, DEPT MED & PHYSIOL CHEM, CTR BIOMED, S-75123 UPPSALA, SWEDEN; UNIV UPPSALA, DEPT PATHOL, S-75123 UPPSALA, SWEDEN; UNIV WALES COLL CARDIFF, SCH MOL & MED BIOSCI, CARDIFF CF1 3US, S GLAM, WALES	Uppsala University; Uppsala University; Cardiff University			Caterson, Bruce/A-8085-2010	Caterson, Bruce/0000-0001-6016-0661				BAHR BA, 1992, BIOCHEMISTRY-US, V31, P5778, DOI 10.1021/bi00140a013; Bertolotto A, 1995, Brain Res Dev Brain Res, V86, P233; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FUNDERBURGH JL, 1991, BIOCHEM SOC T, V19, P871, DOI 10.1042/bst0190871; Greiling H, 1994, EXS, V70, P101; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KRUSIUS T, 1986, J BIOL CHEM, V261, P8237; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LIU HM, 1987, J NEUROIMMUNOL, V14, P49, DOI 10.1016/0165-5728(87)90100-7; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MEHMET H, 1986, EUR J BIOCHEM, V157, P385, DOI 10.1111/j.1432-1033.1986.tb09680.x; SCRANTON TW, 1993, J NEUROCHEM, V61, P29, DOI 10.1111/j.1471-4159.1993.tb03535.x; SNOW AD, 1988, AM J PATHOL, V133, P456; SORRELL JM, 1990, HISTOCHEMISTRY, V94, P269	16	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					16991	16994		10.1074/jbc.271.29.16991	http://dx.doi.org/10.1074/jbc.271.29.16991			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663590	hybrid			2022-12-27	WOS:A1996UX94300003
J	Oancea, E; Meyer, T				Oancea, E; Meyer, T			Reversible desensitization of inositol trisphosphate-induced calcium release provides a mechanism for repetitive calcium spikes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE; ACINAR-CELLS; 1,4,5-TRISPHOSPHATE; OSCILLATIONS; CALMODULIN; STORES; PHOTOLYSIS; FEEDBACK; CHANNELS; RECEPTOR	Repetitive transient increases in cytosolic calcium concentration (calcium spikes or calcium oscillations) are a common mode of signal transduction in receptor-mediated cell activation. Repetitive calcium spikes are initiated by phospholipase C-mediated production of inositol 1,4,5-trisphosphate (InsP(3)) and are thought to be generated by a positive feedback mechanism in which calcium potentiates its own release, a negative feedback mechanism by which calcium release is terminated, and a slow recovery process that defines the time interval between calcium spikes. The molecular mechanisms that terminate each calcium spike and define the spike frequency are not yet known. Here we show, in intact rat basophilic leukemia cells, that calcium responses induced by InsP(3) are diminished for a period of 30-60 s following an InsP(3)-induced calcium spike. The sensitivity of calcium release for InsP(3) was probed by UV laser-mediated photorelease of InsP(3), and calcium responses were monitored by fluorescence calcium imaging. A maximal loss in sensitivity (desensitization) was observed for InsP(3) increases that resulted in a near maximal calcium spike and was expressed as an 80-100% reduction in the calcium response to an equal amount of InsP(3), released 10 s after the first UV pulse. When the amount of released InsP(3) in the second pulse was increased 2-3-fold, desensitization was overcome and a second calcium response of equal amplitude to the first was produced. A power dependence of 3.2 was measured between the amount of released InsP(3) and the amplitude of the triggered calcium response, explaining how a small decrease in InsP(3) sensitivity can lead to a nearly complete reduction in the calcium response. Desensitization was abolished by the addition of the calcium buffers BAPTA and EGTA and could be induced by microinjection of calcium, suggesting that it is a calcium-dependent process, Half-maximal desensitization was observed at a free calcium concentration of 290 nM and increased with a power of 3.7 with peak calcium concentration. These studies suggest that reversible desensitization of InsP(3)-induced calcium release serves as a ''saw-tooth'' parameter that controls the termination of each spike and the frequency of calcium spikes.	DUMC, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University				Meyer, Tobias/0000-0003-4339-3804	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048113, R55GM048113] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48113] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUKAL AJ, 1988, J BIOL CHEM, V263, P6087; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1992, J BIOL CHEM, V267, P17722; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; BOOTMAN MD, 1994, J BIOL CHEM, V269, P24783; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GIETZEN K, 1982, BIOCHEM J, V207, P541, DOI 10.1042/bj2070541; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HORNE JH, 1995, BIOCHEMISTRY-US, V34, P12738, DOI 10.1021/bi00039a033; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KEIZER J, 1992, BIOPHYS J, V61, P649, DOI 10.1016/S0006-3495(92)81870-2; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MEYER T, 1988, SCIENCE, V240, P653, DOI 10.1126/science.2452482; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; MUALLEM S, 1989, J BIOL CHEM, V264, P205; ODGEN DC, 1990, J PHYSIOL-LONDON, V422, P585; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; Parker I, 1996, BIOPHYS J, V70, P222, DOI 10.1016/S0006-3495(96)79565-6; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; TSE A, 1993, SCIENCE, V260, P82, DOI 10.1126/science.8385366; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0	32	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17253	17260		10.1074/jbc.271.29.17253	http://dx.doi.org/10.1074/jbc.271.29.17253			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663416	hybrid			2022-12-27	WOS:A1996UX94300044
J	Yoo, SH; Lewis, MS				Yoo, SH; Lewis, MS			Effects of pH and Ca2+ on heterodimer and heterotetramer formation by chromogranin A and chromogranin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; INTRACELLULAR STORES; VESICLE MEMBRANE; COIL TRANSITION; CALCIUM RELEASE; PROTEINS; MOBILIZATION; AGGREGATION; ENDOCRINE; SEQUENCE	The two major proteins of the secretory vesicles of neuroendocrine cells, chromogranin A (CGA) and chromogranin B (CGB), have been shown to undergo pH- and Ca2+-dependent conformational changes and aggregation and have been suggested to play essential roles during secretory vesicle biogenesis in the trans-Gels network, CGA has been shown to exist primarily in a tetrameric state at pH 5.5 and primarily in a dimeric state at pH 7.5, and CGB has been shown to exist in a monomeric state at both pH 5.5 and pH 7.5, Using purified CGA and CGB, it recently has been shown that CGA interacts with CGB at pH 5.5 (Yoo, S, H, (1996) J. Biol, Chem, 271, 1558-1565), In expanding this investigation, we have studied the temperature dependence of the pH-dependent interaction of CGA and CGB by analytical ultracentrifugation and found that two molecules of CGA bound to two molecules of CGB at pH 5.5 with Delta G(0) values of -43.6 kcal/mol in the absence of Ca2+ at 37 degrees C and -40.3 kcal/mol in the presence of 0.1 mM Ca2+, However, one molecule of CGA bound to one molecule of CGB at pH 7.5 with Delta G(0) values of -13.6 kcal/mol in the absence of Ca2+ at 37 degrees C, The magnitude of Delta G(0) values increased with increasing temperatures at both pH values, However, the values for enthalpy and entropy changes decreased with increasing temperatures in both pH levels, suggesting formation of more ordered structures, In the absence of Ca2+ at pH 5,5, the heterotetramerization reaction at 37 degrees C was entropically driven, whereas in the presence of Ca2+ (0.1 mM) the heterotetramerization was virtually an enthalpic reaction, On the other hand, the heterodimer formation in the absence of Ca2+ at pH 7.5 showed large negative enthalpy and entropy changes at 37 degrees C, indicating an enthalpic interaction compensated by entropic changes, In view of the interaction of tetrameric CGA with tetrameric inositol 1,4,5-trisphosphate (Ip(3)) receptor and the existence of heterotetrameric IP3 receptor in the cell, the heterotetramer formation by CGA and CGB not only raises the possibility of interaction between the heterotetrameric chromogranin and heterotetrameric IP3 receptor but also appears to reflect their important roles in the cell.	NIH,NATL CTR RES RESOURCES,BIOMED ENGN & INSTRUMENTAT PROGRAM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	Yoo, SH (corresponding author), NIDCD,NEUROCHEM LAB,NIH,5 RES COURT,2A37,BETHESDA,MD 20892, USA.							ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BAUER JW, 1991, BIOCHIM BIOPHYS ACTA, V1089, P124, DOI 10.1016/0167-4781(91)90094-3; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; HUTTON JC, 1989, DIABETOLOGIA, V32, P271, DOI 10.1007/BF00265542; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; LEWIS MS, 1994, MODERN ANAL ULTRACEN, P94; MATA M, 1989, J HISTOCHEM CYTOCHEM, V37, P971, DOI 10.1177/37.7.2525142; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MUALLEM S, 1989, J BIOL CHEM, V264, P205; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; OOI T, 1991, P NATL ACAD SCI USA, V88, P2859, DOI 10.1073/pnas.88.7.2859; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; SCHMID KW, 1989, HISTOCHEM J, V21, P365, DOI 10.1007/BF01798500; SCHOLTZ JM, 1991, P NATL ACAD SCI USA, V88, P2854, DOI 10.1073/pnas.88.7.2854; WEILER R, 1990, BRAIN RES, V532, P87, DOI 10.1016/0006-8993(90)91746-4; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; YOO SH, 1995, BIOCHEMISTRY-US, V34, P8680, DOI 10.1021/bi00027a017; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1994, J BIOL CHEM, V269, P12001; YOO SH, 1990, J BIOL CHEM, V265, P14414; Yoo SH, 1996, J BIOL CHEM, V271, P1558; YOO SH, 1995, J BIOL CHEM, V270, P12578, DOI 10.1074/jbc.270.21.12578; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8213, DOI 10.1021/bi00083a023; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030; YOO SH, 1993, BIOCHIM BIOPHYS ACTA, V1179, P239, DOI 10.1016/0167-4889(93)90078-4; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045	31	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17041	17046		10.1074/jbc.271.29.17041	http://dx.doi.org/10.1074/jbc.271.29.17041			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663344	hybrid			2022-12-27	WOS:A1996UX94300012
J	Komaromy, M; Azhar, S; Cooper, AD				Komaromy, M; Azhar, S; Cooper, AD			Chinese hamster ovary cells expressing a cell surface-anchored form of hepatic lipase - Characterization of low density lipoprotein and chylomicron remnant uptake and selective uptake of high density lipoprotein-cholesteryl ester	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED RAT-LIVER; HUMAN-FIBROBLASTS; BINDING; ADRENALS; PURIFICATION; METABOLISM; RECEPTOR; REMOVAL; INSITU; DEGRADATION	The enzyme hepatic lipase may play several roles in lipoprotein metabolism, Recent investigation has suggested a role for the enzyme in lipoprotein and/or lipoprotein lipid uptake, To study this, a simple isolated system that mimics the in vivo system would be desirable, The enzyme is secreted by the hepatic parenchymal cell but exists, and presumably exerts its effects, while bound to capillary endothelial cells in the liver, adrenal gland, and the ovary, We constructed a cDNA that encodes the expression of a chimeric protein composed of rat hepatic lipase and the signal sequence for the addition of the glycophosphatidylinositol (GPI) anchor from human decay-accelerating factor, When transfected into Chinese hamster ovary (CHO) cells this gave rise to a cell population that had immunoreactive hepatic lipase on the cell surface, Cloning of the transfected cells produced several cell lines that expressed the chimeric protein bound to the cell surface by a GPI anchor, This was documented by demonstrating incorporation of [H-3]ethanolamine into anti-hepatic lipase immunoprecipitable material; in addition, hepatic lipase was released from the cells by phosphatidylinositol-specific phospholipase C but not by heparin, Phosphatidylinositol-phospholipase C treatment of cells expressing the anchored lipase released material that comigrated with hepatic lipase on SDS-polyacrylamide gel electrophoresis and was immunoreactive with antibody to the cross-reacting determinant of GPI anchors, Cell lysates containing the anchored protein contained salt-resistant lipase activity, a known feature of the secreted hepatic lipase; thus it appears that these cells have a surface-anchored hepatic lipase molecule, Although it was not possible to demonstrate lipolysis by the enzyme while it was on the cell surface for technical reasons, the protein produced by these cells was active when studied in cell membranes, The ability of the cells to take up lipoproteins was studied, The cells demonstrated an increased affinity for low density lipoprotein (LDL) receptor mediated uptake of LDL, They did not, however, demonstrate any enhanced binding or removal of chylomicron remnants, With respect to LDL and remnants, the cells expressing anchored lipase behaved similarly to CHO cell that expressed secreted hepatic lipase, The cells expressing anchored hepatic lipase had a marked increase in the uptake of high density lipoprotein and high density lipoprotein cholesteryl ester when compared to that seen with CHO cells secreting hepatic lipase, This increase occurred primarily via the selective pathway, and was not reduced by addition of anti-LDL receptor or anti-hepatic lipase antibodies or the receptor-associated protein, Together the results suggest that hepatic lipase, when bound to the cell surface by a GPI anchor, plays a role in enhancing lipoprotein uptake. For LDL this may involve the provision of a second foot for particle binding, thus enhancing affinity for the LDL receptor, For chylomicron remnants an additional molecule or molecules are necessary to mediate this effect, For HDL, the enzyme facilitates uptake of cholesteryl ester primarily by the selective pathway.	PALO ALTO MED FDN,RES INST,PALO ALTO,CA 94301; STANFORD UNIV,DEPT MED,STANFORD,CA 94305; VET ADM PALO ALTO HLTH CARE,CTR GERIATR RES EDUC & CLIN,PALO ALTO,CA 94301	Palo Alto Medical Foundation Research Institute; Stanford University; Geriatric Research Education & Clinical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707, R01DK038318] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL39362] Funding Source: Medline; NIDDK NIH HHS [DK-38318, DK 38707] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ARBEENY CM, 1987, BIOCHIM BIOPHYS ACTA, V917, P9, DOI 10.1016/0005-2760(87)90277-3; AVIRAM M, 1988, J BIOL CHEM, V263, P15416; AZHAR S, 1989, BIOCHIM BIOPHYS ACTA, V1004, P61, DOI 10.1016/0005-2760(89)90213-0; AZHAR S, 1989, J LIPID RES, V30, P1799; AZHAR S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P148, DOI 10.1016/0005-2760(90)90041-U; BAMBERGER M, 1983, J LIPID RES, V24, P869; BENGTSSON G, 1980, FEBS LETT, V119, P290, DOI 10.1016/0014-5793(80)80274-2; BERRYMAN DE, 1995, J BIOL CHEM, V270, P24525, DOI 10.1074/jbc.270.41.24525; BILLHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212; BORENSZTAJN J, 1988, J LIPID RES, V29, P1087; CARAS IW, 1987, SCIENCE, V238, P1280, DOI 10.1126/science.2446389; CARAS IW, 1992, GPI MEMBRANE ANCHERS, P73; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHOI SSY, 1994, J LIPID RES, V35, P848; CHOI SY, 1993, J BIOL CHEM, V268, P15804; CONNELLY PW, 1990, ARTERIOSCLEROSIS, V10, P40, DOI 10.1161/01.ATV.10.1.40; COOPER AD, 1987, J LIPID RES, V28, P59; COOPER AD, 1978, J LIPID RES, V19, P635; deFaria E, 1996, J LIPID RES, V37, P197; DESPRES JP, 1988, AM J PHYSIOL, V254, pE667, DOI 10.1152/ajpendo.1988.254.5.E667; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; DOOLITTLE MH, 1991, ANAL BIOCHEM, V195, P364, DOI 10.1016/0003-2697(91)90342-Q; EHNHOLM C, 1986, PLASMA LIPOPROTEINS, P716; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HEGELE RA, 1993, ARTERIOSCLER THROMB, V13, P720, DOI 10.1161/01.ATV.13.5.720; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIXENBAUGH EA, 1993, ANAT REC, V235, P487, DOI 10.1002/ar.1092350402; Hooper NM, 1992, LIPID MODIFICATION P, P89; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; JAHN CE, 1981, FEBS LETT, V131, P366, DOI 10.1016/0014-5793(81)80405-X; JANSEN H, 1981, BIOCHEM J, V196, P739, DOI 10.1042/bj1960739; JANSEN H, 1978, BIOCHEM BIOPH RES CO, V85, P148, DOI 10.1016/S0006-291X(78)80022-9; JANSEN H, 1980, FEBS LETT, V112, P30, DOI 10.1016/0014-5793(80)80119-0; JANSEN H, 1981, METABOLISM, V30, P428, DOI 10.1016/0026-0495(81)90175-X; JENSEN GL, 1981, ANAL BIOCHEM, V113, P246, DOI 10.1016/0003-2697(81)90073-7; JI ZS, 1994, J BIOL CHEM, V269, P13429; JI ZS, 1993, J BIOL CHEM, V268, P10160; KADOWAKI H, 1992, J LIPID RES, V33, P1689; KOMAROMY MC, 1991, J LIPID RES, V32, P963; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; KRAPP A, 1995, J LIPID RES, V36, P23662; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRISETHERTON PM, 1980, J LIPID RES, V21, P435; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUUSI T, 1979, FEBS LETT, V98, P314, DOI 10.1016/0014-5793(79)80207-0; KUUSI T, 1979, BIOCHEM J, V181, P245, DOI 10.1042/bj1810245; LEBLOND L, 1993, J BIOL CHEM, V268, P1670; LEITERSDORF E, 1986, BIOCHIM BIOPHYS ACTA, V878, P320, DOI 10.1016/0005-2760(86)90239-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOWRI HO, 1992, J LIPID RES, V33, P1269; PICKER LJ, 1990, J IMMUNOL, V145, P3247; PIERCE A, 1992, J BIOL CHEM, V267, P3894; PITTMAN RC, 1984, J LIPID RES, V25, P1577; REAVEN E, 1995, J LIPID RES, V36, P1602; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; REDGRAVE TG, 1977, ATHEROSCLEROSIS, V28, P69, DOI 10.1016/0021-9150(77)90200-3; RINNINGER F, 1988, J LIPID RES, V29, P1179; RINNINGER F, 1994, ATHEROSCLEROSIS, V105, P145, DOI 10.1016/0021-9150(94)90044-2; SHAFI S, 1994, J LIPID RES, V35, P709; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; SULTAN F, 1990, BIOCHIM BIOPHYS ACTA, V1042, P150, DOI 10.1016/0005-2760(90)90071-5; TAVANGAR K, 1992, J CLIN INVEST, V90, P1672, DOI 10.1172/JCI116039; TWU JS, 1984, BIOCHIM BIOPHYS ACTA, V792, P330, DOI 10.1016/0005-2760(84)90201-7; WISHART R, 1990, BIOCHIM BIOPHYS ACTA, V1044, P375, DOI 10.1016/0005-2760(90)90083-A	68	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16906	16914		10.1074/jbc.271.28.16906	http://dx.doi.org/10.1074/jbc.271.28.16906			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663289	hybrid			2022-12-27	WOS:A1996UX12600073
J	Orth, K; Chinnaiyan, AM; Garg, M; Froelich, CJ; Dixit, VM				Orth, K; Chinnaiyan, AM; Garg, M; Froelich, CJ; Dixit, VM			The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; GENE CED-3; IL-1-BETA-CONVERTING ENZYME; INDUCTION; ENCODES	Phylogenetic analysis of the CED-3/ICE family of cysteine proteases suggests the existence of a subfamily most related to the Caenorhabditis elegans death gene ced-3 and includes Yama (CPP32, apopain), LAPS (Mch3, CMH1), and Mch2. Here, we show that Mch2 is processed from its zymogen form to a proteolytically active dimeric species during execution of the apoptotic program and by the cytotoxic T cell death protease granzyme B. Additionally, like Yama and LAP3, Mch2 functions downstream of the death inhibitors Bcl-2, Bcl-(xL), and CrmA. Importantly, Mch2, but not Yama or LAPS, is capable of cleaving lamin A to its signature apoptotic fragment, indicating that Mch2 is an apoptotic laminase.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; EVANSTON HOSP CORP,DEPT MED,EVANSTON,IL 60201; NORTHWESTERN UNIV,SCH MED,EVANSTON,IL 60201	University of Michigan System; University of Michigan; NorthShore University Health System; Northwestern University			Orth, Kim/AAV-4421-2021; dixit, vishva m/A-4496-2012	Orth, Kim/0000-0002-0678-7620; dixit, vishva m/0000-0001-6983-0326	NCI NIH HHS [CA68769, CA64803] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA068769, R01CA064803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CHINNAIYAN AM, 1996, IN PRESS CURR BIOL, V6; DUAN H, 1996, J BIOL CHEM, V271, P35013; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAYLAR C, 1996, P NATL ACAD SCI USA, V93, P2234; KERR JF, 1978, BRIT J CANCER, V26, P239; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	33	365	372	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16443	16446		10.1074/jbc.271.28.16443	http://dx.doi.org/10.1074/jbc.271.28.16443			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663580	hybrid			2022-12-27	WOS:A1996UX12600004
J	Pryzdial, ELG; Kessler, GE				Pryzdial, ELG; Kessler, GE			Kinetics of blood coagulation factor Xa alpha autoproteolytic conversion to factor Xa beta - Effect on inhibition by antithrombin, prothrombinase assembly, and enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED PROTEASE INACTIVATION; ACTIVATED FACTOR-X; FACTOR-VA; MOLECULAR RECOGNITION; FUNCTIONAL-PROPERTIES; BOVINE PROTHROMBIN; TRANSIENT KINETICS; THROMBIN; HEPARIN; MECHANISM	Autoproteolysis of blood coagulation factor Xa (FXa) results in the excision of a 4-kDa fragment (beta-peptide) from the intact subform, factor Xa alpha (FXa alpha), to yield factor Xa beta (FXa beta) In the preceding paper, we showed that generation of FXa beta leads to expression of a plasminogen binding site, FXa beta may consequently participate in fibrinolysis; therefore, the timing of subform conversion compared with thrombin production is important. In the current study we evaluated the kinetics of FXa beta generation, which showed that autoproteolysis of FXa alpha followed a second order mechanism where FXa alpha and FXa beta behaved as identical enzymes, Rate constants of 9 and 172 M(-1) s(-1) were derived, respectively, in the absence and presence of FXa alpha binding to procoagulant phospholipid. Under identical conditions the latter is estimated to be 6 orders of magnitude slower than thrombin generation by prothrombinase. Since heparin binding and prothrombin recognition have been previously attributed to a region of FXa alpha proximal to the beta-peptide, functional comparisons were conducted using homogeneous and stabilized preparations of FXa alpha and FXa beta. Comparisons included 1) the recognition of small substrates; 2) the rate of interaction with antithrombin/heparin; 3) the assembly of prothrombinase; and 4) the activation of prothrombin by prothrombinase, Although the beta-peptide neighbors a probable functional region in FXa alpha, conversion to FXa beta was not observed to influence these functions, The data support a model where FXa alpha is predominantly responsible for thrombin generation and where slow conversion to FXa beta coordinates coagulation and the initiation of fibrinolysis at sites of prothrombinase assembly.	UNIV OTTAWA,DEPT BIOCHEM,OTTAWA,ON K1G 4J5,CANADA	University of Ottawa	Pryzdial, ELG (corresponding author), UNIV OTTAWA,CANADIAN RED CROSS SOC,RES DEPT,1800 ALTA VISTA DR,OTTAWA,ON K1G 4J5,CANADA.							BAJAJ SP, 1973, J BIOL CHEM, V248, P7729; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BRICE BA, 1952, J OPT SOC AM, V41, P1033; CHATTOPADHYAY A, 1989, J BIOL CHEM, V264, P11035; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; EBY CS, 1992, BLOOD S, V80, P306; FUJIKAWA K, 1975, P NATL ACAD SCI USA, V72, P3359, DOI 10.1073/pnas.72.9.3359; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GIARDINO EC, 1993, CIRCULATION S, V4, P2240; Gutfreund H., 1972, ENZYMES PHYSICAL PRI, P116; HELDEBRANT CM, 1973, J BIOL CHEM, V248, P7149; HOLLENBACH S, 1994, THROMB HAEMOSTASIS, V71, P357; JACKSON CM, 1968, BIOCHEMISTRY-US, V7, P4492, DOI 10.1021/bi00852a046; JACKSON CM, 1968, BIOCHEMISTRY-US, V7, P4506, DOI 10.1021/bi00852a047; JESTY J, 1974, J BIOL CHEM, V249, P5614; JESTY J, 1974, J BIOL CHEM, V249, P509; JESTY J, 1973, BIOCHEM J, V131, P791, DOI 10.1042/bj1310791; Jesty J, 1976, Methods Enzymol, V45, P95; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KRISHNASWAMY S, 1994, METHOD ENZYMOL, V222, P260; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CD, 1989, BLOOD, V73, P185; LINK RP, 1982, ARCH BIOCHEM BIOPHYS, V215, P215, DOI 10.1016/0003-9861(82)90297-1; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MERTENS K, 1980, BIOCHEM J, V185, P647, DOI 10.1042/bj1850647; MESSIER TL, 1991, GENE, V99, P291, DOI 10.1016/0378-1119(91)90141-W; MIZUOCHI T, 1980, J BIOL CHEM, V255, P3526; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OMAR MN, 1987, J BIOL CHEM, V262, P9720; OWEN WG, 1974, J BIOL CHEM, V249, P594; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; PRYZDIAL ELG, 1995, J BIOL CHEM, V270, P17871, DOI 10.1074/jbc.270.30.17871; ROSING J, 1980, J BIOL CHEM, V255, P274; SHEFFIELD WP, 1994, MOL BIOL THROMBOSIS, P355; SINHA U, 1993, J BIOL CHEM, V268, P3048; THALER E, 1975, BRIT J HAEMATOL, V31, P233, DOI 10.1111/j.1365-2141.1975.tb00853.x	48	16	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16621	16626		10.1074/jbc.271.28.16621	http://dx.doi.org/10.1074/jbc.271.28.16621			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663222				2022-12-27	WOS:A1996UX12600033
J	Nickel, W; Helms, JB; Kneusel, RE; Wieland, FT				Nickel, W; Helms, JB; Kneusel, RE; Wieland, FT			Forskolin stimulates detoxification of Brefeldin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE; ADENYLATE-CYCLASE; GOLGI MEMBRANES; CELLS; PROTEIN; ACTIVATION; TRANSPORT; CAMP; ARF; RAT	Forskolin has been shown to prevent the effects brefeldin A (BFA) exerts on many mammalian cells with respect to the disassembly of the Golgi apparatus as well as an increase of sphingomyelin synthesis (Lippincott, S, J,, Glickman, J,, Donaldson, J, G,, Robbins, J., Kreis, T, E., Seamen, K. B,, Sheetz, M, P,, and Klausner, R, D, (1991) J, Cell Biol, 112, 567-577), It has been speculated that forskolin interferes with the action of BFA by competition for the binding of BFA to its target protein, which is most likely the Golgi-localized nucleotide exchange factor specific for ADP-ribosylation factor 1, Here we show that in vitro forskolin does not prevent inhibition of Golgi-catalyzed nucleotide exchange by BFA. Therefore it appears unlikely that forskolin and BFA bind to the same target protein, Using [H-3]BFA we have measured detoxification of BFA by Chinese hamster ovary (CHO) cells, BFA is secreted from CHO cells as cysteine and glutathione conjugates (Bruning, A, Ishikawa, T., Kneusel, R, FF., Matern, U,, Lottspeich, F,, and Wieland, F, T, (1992) J, Biol. Chem. 267, 7726-7732), We present evidence that forskolin treatment of CHO cells results in increased levels of Cys-EFA, the major FFA conjugate secreted by CHO cells, in the medium, Elevated levels of Cys-BFA are also found intracellularly, The effect of forskolin is shown to be independent of its ability to raise the intracellular concentration of cyclic AMP, Therefore, we suggest that the effect of forskolin on BFA-induced disassembly of the Golgi apparatus might be due to an enhanced detoxification of the drug.	UNIV FREIBURG, INST BIOL 2, D-79104 FREIBURG, GERMANY	University of Freiburg	Nickel, W (corresponding author), UNIV HEIDELBERG, INST BIOCHEM 1, NEUENHEIMER FELD 328, D-69120 HEIDELBERG, GERMANY.							BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BRUNING A, 1992, J BIOL CHEM, V267, P7726; BRUNING A, 1992, J BIOL CHEM, V267, P5052; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HEUSCHNEIDER G, 1989, P NATL ACAD SCI USA, V86, P2938, DOI 10.1073/pnas.86.8.2938; HOSHI T, 1988, SCIENCE, V240, P1652, DOI 10.1126/science.2454506; KASHIWAGI A, 1983, J BIOL CHEM, V258, P3685; LAURENZA A, 1991, METHOD ENZYMOL, V195, P52; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1991, J CELL BIOL, V112, P567, DOI 10.1083/jcb.112.4.567; MCHUGH EM, 1986, J BIOL CHEM, V261, P3103; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MORRIS DI, 1991, BIOCHEMISTRY-US, V30, P8371, DOI 10.1021/bi00098a014; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; RANDERATH K, 1970, ANAL BIOCHEM, V34, P188, DOI 10.1016/0003-2697(70)90100-4; SEAMON K, 1981, J BIOL CHEM, V256, P9799; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; TIETJEN KG, 1985, PHYSIOL PLANT PATHOL, V26, P241, DOI 10.1016/0048-4059(85)90024-4; WADLER S, 1988, CANCER RES, V48, P539	22	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15870	15873		10.1074/jbc.271.27.15870	http://dx.doi.org/10.1074/jbc.271.27.15870			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663452	hybrid			2022-12-27	WOS:A1996UW35200007
J	OBrien, MC; Flaherty, KM; McKay, DB				OBrien, MC; Flaherty, KM; McKay, DB			Lysine 71 of the chaperone protein Hsc70 is essential for ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; UNCOATING PROTEIN; STRUCTURAL BASIS; BINDING; FRAGMENT; DOMAIN	It has been proposed that lysine 71 of the bovine 70-kDa heat shock cognate protein might participate in catalysis of ATP hydrolysis by stabilizing an H2O molecule or an OH- ion for nucleophilic attack on the gamma-phosphate of the nucleotide (Flaherty, K, M., Wilbanks, S, M,, DeLuca-Flaherty, C., and McKay, D. B, (1994) J, Biol. Chem, 12899-12907; Wilbanks, S, M,, DeLuca-Flaherty, C,, and McKay, D, B. (1994) J. Biol. Chem, 269, 12893-12898), To test this hypothesis, lysine 71 of the ATPase fragment 70-kDa heat shock cognate protein has been mutated to glutamic acid, methionine, and alanine; and the kinetic and structural properties of the mutantproteins have been determined. All three mutant proteins are devoid of measurable ATP hydrolysis activity. Crystal structures of the mutant proteins have bben determined to a resolution of 1.7 Angstrom; all three have ATP in the nucleotide binding site. These data identify lysine 71 as a residue that is essential for chemical hydrolysis of ATP.	STANFORD UNIV,SCH MED,DEPT BIOL STRUCT,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305	Stanford University					NIGMS NIH HHS [GM-39928, GM 15141] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039928, F32GM015141] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; DELUCAFLAHERTY C, 1988, J MOL BIOL, V200, P749, DOI 10.1016/0022-2836(88)90487-1; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; OBRIEN MC, 1993, J BIOL CHEM, V268, P24323; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; STEIGEMANN W, 1974, THESIS TU MUNCHEN; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; WANG TF, 1993, J BIOL CHEM, V268, P26049; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251	23	110	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15874	15878		10.1074/jbc.271.27.15874	http://dx.doi.org/10.1074/jbc.271.27.15874			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663302	hybrid			2022-12-27	WOS:A1996UW35200008
J	Akbar, GKM; Dasari, VR; Webb, TE; Ayyanathan, K; Pillarisetti, K; Sandhu, AK; Athwal, RS; Daniel, JL; Ashby, B; Barnard, EA; Kunapuli, SP				Akbar, GKM; Dasari, VR; Webb, TE; Ayyanathan, K; Pillarisetti, K; Sandhu, AK; Athwal, RS; Daniel, JL; Ashby, B; Barnard, EA; Kunapuli, SP			Molecular cloning of a novel P2 purinoceptor from human erythroleukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE RECEPTOR; ATP RECEPTOR; EXPRESSION; INCREASE; COUPLES	Screening of a human erythroleukemia cell cDNA library with radiolabeled chicken P2Y(3) cDNA at low stringency revealed a cDNA clone encoding a novel G protein-coupled receptor with homology to P2 purinoceptors, This receptor, designated P2Y(7), has 352 amino acids and shares 23-30% amino acid identity with the P2Y(1)-P2Y(6) purinoceptors. The P2Y(7) cDNA was transiently expressed in COS-7 cells: binding studies thereon showed a very high affinity for ATP (37 +/- 6 nM), much less for UTP and ADP (similar to 1300 nM), and a novel rank order of affinities in the binding series studied of 8 nucleotides and suramin, The P2Y(7) receptor sequence appears to denote a different subfamily from that of all the other known P2Y purinoceptors, with only a few of their characteristic sequence motifs shared, The P2Y(7) receptor mRNA is abundantly present in the human heart and the skeletal muscle, moderately in the brain and liver, but not in the other tissues tested, The P2Y(7) receptor mRNA was also abundantly present in the rat heart and cultured neonatal rat cardiomyocytes, The P2Y(7) receptor is functionally coupled to phospholipase C in COS-7 cells transiently expressing this receptor, The P2Y(7) gene was shown to be localized to human chromosome 14. We have thus cloned a unique member of the P2Y purinoceptor family which probably plays a role in the regulation of cardiac muscle contraction.	TEMPLE UNIV,SCH MED,DEPT PHYSIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,SOL SHERRY THROMBOSIS RES CTR,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140; ROYAL FREE HOSP,SCH MED,MOL NEUROBIOL UNIT,LONDON NW3 2PF,ENGLAND	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Webb, Tania/AAT-9554-2020	Dasari, Venkat/0000-0001-9795-6567				AKBAR GKM, 1995, FASEB J, V9, P684; Ayyanathan K, 1996, BIOCHEM BIOPH RES CO, V218, P783, DOI 10.1006/bbrc.1996.0139; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; CHANG KG, 1995, J BIOL CHEM, V270, P26152, DOI 10.1074/jbc.270.44.26152; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; DASARI VR, 1996, SOMAT CELL MOLEC GEN, V21, P75; FILTZ TM, 1994, MOL PHARMACOL, V46, P8; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; HEILBRONN E, 1989, NEUROMUSCULAR JUNCTI, P395; HENDERSON DJ, 1995, BIOCHEM BIOPH RES CO, V212, P648, DOI 10.1006/bbrc.1995.2018; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KUNAPULI SP, 1994, BIOCHEM J, V298, P263, DOI 10.1042/bj2980263; LEGSSYER A, 1988, J PHYSIOL-LONDON, V401, P185, DOI 10.1113/jphysiol.1988.sp017157; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LU Z, 1991, J PHYSIOL-LONDON, V436, P45, DOI 10.1113/jphysiol.1991.sp018538; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; MANTELLI L, 1993, BRIT J PHARMACOL, V109, P1268, DOI 10.1111/j.1476-5381.1993.tb13759.x; NAKAHATA N, 1987, BIOCHEM J, V241, P337, DOI 10.1042/bj2410337; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; SCAMPS F, 1992, J GEN PHYSIOL, V100, P675, DOI 10.1085/jgp.100.4.675; SCAMPS F, 1994, BRIT J PHARMACOL, V113, P982, DOI 10.1111/j.1476-5381.1994.tb17089.x; Simon J, 1995, EUR J PHARM-MOLEC PH, V291, P281, DOI 10.1016/0922-4106(95)90068-3; WANG DS, 1993, CIRCULATION, V88, P431; Webb TE, 1996, BIOCHEM BIOPH RES CO, V219, P105, DOI 10.1006/bbrc.1996.0189; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; WEBB TE, 1996, IN PRESS MOL PHARM; ZHENG JS, 1993, AM J PHYSIOL, V264, pC1411, DOI 10.1152/ajpcell.1993.264.6.C1411	28	106	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18363	18367		10.1074/jbc.271.31.18363	http://dx.doi.org/10.1074/jbc.271.31.18363			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702478	hybrid			2022-12-27	WOS:A1996VB68300016
J	Blazquez, M; Fominaya, JM; Hofsteenge, J				Blazquez, M; Fominaya, JM; Hofsteenge, J			Oxidation of sulfhydryl groups of ribonuclease inhibitor in epithelial cells is sufficient for its intracellular degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT-BINDING INHIBITION; LEUCINE-RICH REPEATS; AMINO-ACID SEQUENCE; KAPPA-B; EXTINCTION COEFFICIENTS; ANGIOGENIN INHIBITOR; TRANSCRIPTION FACTOR; PORCINE LIVER; PROTEIN; STRESS	Ribonuclease inhibitor (RI) is a cytoplasmic protein (50 kDa) that inhibits a variety of pancreatic type RNases. The porcine inhibitor contains 30 cysteine residues, all of which occur in the reduced state. It is well known that in vitro modification of the thiol groups inactivates the protein and greatly increases its susceptibility to proteolysis. Here we show that oxidation of thiol groups in RI can also occur within the cell. Induction of an oxidative insult in cultured LLC-PK1 cells, either with a general oxidant, H2O2, or with a thiol-specific oxidant, diamide, led to the loss of RI activity. By using specific antibodies it was demonstrated that the decrease correlated with a decline in the amount of RI protein in the cells. Furthermore, analysis of RI mRNA levels and half life of the protein excluded inhibition of the synthesis of RI as the cause of its depletion. The results indicate that oxidation of thiol groups in RI is sufficient to cause its rapid inactivation and disappearance from the cell. Most likely this results from intracellular degradation of the protein.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AOKI Y, 1981, BIOCHEM J, V196, P699, DOI 10.1042/bj1960699; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; BHUYAN DK, 1994, METHOD ENZYMOL, V233, P630; BLACKBURN P, 1977, J BIOL CHEM, V252, P5904; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CAVALLI L, 1979, OPHTHALMIC RES, V11, P416, DOI 10.1159/000265044; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAS DK, 1994, METHOD ENZYMOL, V233, P601; FOMINAYA JM, 1988, BIOCHEM J, V253, P517, DOI 10.1042/bj2530517; FOMINAYA JM, 1992, J BIOL CHEM, V267, P24655; FOMINAYA JM, 1988, BIOCHIM BIOPHYS ACTA, V954, P216, DOI 10.1016/0167-4838(88)90074-X; GILBERT HF, 1990, ADV ENZYMOL, V63, P169; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GIRIJA NS, 1966, BIOCHEM J, V98, P562, DOI 10.1042/bj0980562; GRIBNAU AAM, 1969, ARCH BIOCHEM BIOPHYS, V130, P48, DOI 10.1016/0003-9861(69)90007-1; Harlow E., 1988, ANTIBODIES LAB MANUA; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P8537, DOI 10.1021/bi00423a006; HOFSTEENGE J, 1989, BIOCHEMISTRY-US, V28, P9806, DOI 10.1021/bi00451a040; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; JAHNGENHODGE J, 1994, METHOD ENZYMOL, V233, P512; KAWANOMOTO M, 1992, BIOCHIM BIOPHYS ACTA, V1129, P335, DOI 10.1016/0167-4781(92)90513-Y; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE FS, 1988, BIOCHEMISTRY-US, V27, P8545, DOI 10.1021/bi00423a007; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; LEE FS, 1993, PROG NUCLEIC ACID RE, V44, P1, DOI 10.1016/S0079-6603(08)60215-9; LEE FS, 1989, BIOCHEMISTRY-US, V28, P219, DOI 10.1021/bi00427a030; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; McConkey David J., 1994, Trends in Cell Biology, V4, P370, DOI 10.1016/0962-8924(94)90087-6; MEISTER A, 1995, METHOD ENZYMOL, V252, P26; MEISTER A, 1994, CANCER RES, V54, pS1969; ORTWERTH BJ, 1971, EXP EYE RES, V12, P120, DOI 10.1016/0014-4835(71)90136-9; ORTWERTH BJ, 1972, EXP EYE RES, V14, P114, DOI 10.1016/0014-4835(72)90056-5; PACIFICI RE, 1990, METHOD ENZYMOL, V186, P485; ROTH JS, 1956, BIOCHIM BIOPHYS ACTA, V21, P34, DOI 10.1016/0006-3002(56)90091-9; ROTH JS, 1958, J BIOL CHEM, V231, P1085; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHORTMAN K, 1962, BIOCHIM BIOPHYS ACTA, V55, P88; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1995, METHOD ENZYMOL, V258, P379; STORRIE B, 1990, METHOD ENZYMOL, V182, P220; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; VICENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827, DOI 10.1021/bi00489a046; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	51	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18638	18642		10.1074/jbc.271.31.18638	http://dx.doi.org/10.1074/jbc.271.31.18638			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702516	hybrid			2022-12-27	WOS:A1996VB68300054
J	Hernandez, VJ; Hsu, LM; Cashel, M				Hernandez, VJ; Hsu, LM; Cashel, M			Conserved region 3 of Escherichia coli sigma(70) is implicated in the process of abortive transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC UV5 PROMOTER; RNA-POLYMERASE; INITIATION; DNA; PURIFICATION; BINDING; SUBUNIT; COMPLEXES; INVITRO	Multiple-round in vitro transcription assays were performed using purified Escherichia coli RNA polymerase reconstituted with either wild-type or mutant sigma(70) proteins, These mutants, sigma(70)(P504L) and sigma(70)(S506F), bear single amino acid changes in conserved protein region 3, Behavior of the mutant enzymes on three test templates, bearing either the T7 Al, T5 N25, or T5 N25(antiDSR) promoter, were characterized, Transcription of all three promoter templates produced a pattern of specific abortive RNA species, which was qualitatively different for the mutants compared to the wild-type sigma(70) enzyme. Short abortive RNAs were produced at similar levels for mutant and wild-type enzymes, The production of longer abortive species was either reduced or increased by the mutant enzymes in a systematic manner that appears promoter specific, and could be RNA length- or promoter distance-dependent. The process of abortive RNA transcription is thought to be tightly associated with that of promoter clearance, However, promoter clearance from these templates appears only slightly affected by the mutant enzymes, These mutants implicated region 3 of sigma(70) in the process of abortive transcription and suggest that the sequence of enzymatic events leading to the production of abortive or full-length RNA may be separable.	MT HOLYOKE COLL, PROGRAM BIOCHEM, S HADLEY, MA 01075 USA	Mount Holyoke College	Hernandez, VJ (corresponding author), NICHHD, NIH,LMG,9000 ROCKVILLE PIKE,BLDG 6B, RM 316, BETHESDA, MD 20892 USA.							BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; GILL SC, 1991, J MOL BIOL, V220, P307, DOI 10.1016/0022-2836(91)90015-X; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HANSEN UM, 1980, J BIOL CHEM, V254, P5713; HERNANDEZ VJ, 1995, J MOL BIOL, V252, P536; JOHNSTON DE, 1976, RNA POLYM, P101; KAMMERER W, 1986, EMBO J, V5, P2995, DOI 10.1002/j.1460-2075.1986.tb04597.x; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MUNSON LM, 1981, BIOCHEMISTRY-US, V20, P2081, DOI 10.1021/bi00511a003; NGUYEN LH, 1993, PROTEIN EXPRES PURIF, V4, P425, DOI 10.1006/prep.1993.1056; Sambrook J., 2002, MOL CLONING LAB MANU; SEVERINOV K, 1994, J BIOL CHEM, V269, P20826; STEFANO JE, 1979, BIOCHEMISTRY-US, V18, P1063, DOI 10.1021/bi00573a020; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; STRICKLAND MS, 1988, BIOCHEMISTRY-US, V27, P5755, DOI 10.1021/bi00415a054; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUH WC, 1993, SCIENCE, V259, P358, DOI 10.1126/science.8420002; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; THOMPSON NE, 1992, BIOCHEMISTRY-US, V31, P7003, DOI 10.1021/bi00145a019	27	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18775	18779		10.1074/jbc.271.31.18775	http://dx.doi.org/10.1074/jbc.271.31.18775			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702534	hybrid			2022-12-27	WOS:A1996VB68300072
J	Marszalek, J; Zhang, WG; Hupp, TR; Margulies, C; Carr, KM; Cherry, S; Kaguni, JM				Marszalek, J; Zhang, WG; Hupp, TR; Margulies, C; Carr, KM; Cherry, S; Kaguni, JM			Domains of DnaA protein involved in interaction with DnaB protein, and in unwinding the Escherichia coli chromosomal origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP BINDING-SITE; P-LOOP MOTIF; RECA PROTEIN; REPLICATION ORIGIN; ADENYLATE KINASE; AMINO-ACIDS; INITIATION; RESOLUTION; ANTIBODY; COMPLEX	DnaA protein of Escherichia coli is a sequence-specific DNA-binding protein required for the initiation of DNA replication from the chromosomal origin, oriC, It is also required for replication of several plasmids including pSC101, F, P-1, and R6K. A collection of monoclonal antibodies to DnaA protein has been produced and the primary epitopes recognized by them have been determined, These antibodies have also been examined for the ability to inhibit activities of DNA binding, ATP binding, unwinding of oriC, and replication of both an oriC plasmid, and an M13 single-stranded DNA with a proposed hairpin structure containing a DnaA protein-binding site, Replication of the latter DNA is dependent on DnaA protein by a mechanism termed ABC priming, These studies suggest regions of DnaA protein involved in interaction with DnaB protein, and in unwinding of oriC, or low-affinity binding of ATP.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA; UNIV GDANSK, DEPT MOL BIOL, PL-80822 GDANSK, POLAND; UNIV DUNDEE, NINEWELLS MED SCH, DEPT PATHOL, DUNDEE DD1 4HN, SCOTLAND	Michigan State University; Fahrenheit Universities; University of Gdansk; University of Dundee			Marszalek, Jaroslaw/F-5824-2011	Marszalek, Jaroslaw/0000-0002-6978-1189; Kaguni, Jon/0000-0002-3096-4447	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033992] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33992, R01 GM033992] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPEL JR, 1990, J IMMUNOL, V144, P976; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; FLOWER AM, 1986, NUCLEIC ACIDS RES, V14, P8091, DOI 10.1093/nar/14.20.8091; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; GARNER MM, 1981, BIOCHEMISTRY-US, V20, P306, DOI 10.1021/bi00505a012; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GINES CE, 1995, J BACTERIOL, V177, P705; HANSEN FG, 1992, MOL GEN GENET, V234, P14, DOI 10.1007/BF00272340; Harlow E., 1988, ANTIBODIES LAB MANUA; HIROTA Y, 1968, COLD SPRING HARB SYM, V33, P677, DOI 10.1101/SQB.1968.033.01.077; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HUPP TR, 1993, J BIOL CHEM, V268, P13128; HWANG DS, 1988, J BIOL CHEM, V263, P10633; HWANG DS, 1992, J BIOL CHEM, V267, P23088; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KODAIRA M, 1983, MOL GEN GENET, V192, P80, DOI 10.1007/BF00327650; KOHIYAMA M, 1968, COLD SPRING HARB SYM, V33, P317, DOI 10.1101/SQB.1968.033.01.036; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; LOGAN KM, 1993, J MOL BIOL, V232, P1048, DOI 10.1006/jmbi.1993.1459; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MASAI H, 1990, J BIOL CHEM, V265, P15134; MESSER W, 1996, ESCHERICHIA COLI SAL, V2; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; MULLIN DA, 1983, MOL GEN GENET, V192, P73, DOI 10.1007/BF00327649; OKA A, 1980, MOL GEN GENET, V178, P9, DOI 10.1007/BF00267207; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PINILLA C, 1993, MOL IMMUNOL, V30, P577, DOI 10.1016/0161-5890(93)90032-7; ROTH A, 1995, EMBO J, V14, P2106, DOI 10.1002/j.1460-2075.1995.tb07202.x; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SMITH AD, 1992, ARCH BIOCHEM BIOPHYS, V292, P165, DOI 10.1016/0003-9861(92)90065-5; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STENZEL TT, 1987, CELL, V49, P709, DOI 10.1016/0092-8674(87)90547-2; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WALKER JR, 1982, P NATL ACAD SCI-BIOL, V79, P3340, DOI 10.1073/pnas.79.10.3340; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202; YUNG BYM, 1989, J BIOL CHEM, V264, P6146	44	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18535	18542		10.1074/jbc.271.31.18535	http://dx.doi.org/10.1074/jbc.271.31.18535			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702501	hybrid			2022-12-27	WOS:A1996VB68300039
J	Phelps, RG; Turner, AN; Rees, AJ				Phelps, RG; Turner, AN; Rees, AJ			Direct identification of naturally processed autoantigen-derived peptides bound to HLA-DR15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MOLECULES; ALPHA-3 CHAIN; IV COLLAGEN; HLA-DR; GOODPASTURE ANTIGEN; MHC; IMMUNODOMINANT; DETERMINANTS; RECOGNITION; TOLERANCE	Biochemical analysis of HLA class II-associated peptides from antigen pulsed cells is a potentially useful approach to the analysis of antigen processing and presentation because it examines directly which antigen-derived peptides are presented. This is especially advantageous in the analysis of self-antigen presentation where conventional approaches utilizing antigen-specific T cells may be biased by the presence of self-tolerance, However, successful biochemical analysis has been reported for only one exogenous antigen and no autoantigens. We have used a novel analytical approach coupling biochemical data with the reported properties of class II-associated peptides to characterize the peptides derived from a clinically relevant autoantigen presented on the disease-associated class II type. Incubating the target of autoimmune attack in patients with Goodpasture's disease, the 230-amino acid NC1 domain of the alpha 3 chain of type IV collagen (Goodpasture antigen, alpha 3(IV)NC1), with human B cells homozygous for HLA-DR15, the allele carried by 80% of patients, we find that alpha 3(IV)NC1 is presented as at least two sets of three to five peptides centered on common core sequences (nested sets). Synthetic peptides containing these core sequences bind to HLA-DR15 with intermediate affinity (IC50, 1.1-6 mu m).			Phelps, RG (corresponding author), UNIV ABERDEEN,DEPT MED & THERAPEUT,POLWARTH BLDG,ABERDEEN AB9 2ZD,SCOTLAND.			Turner, Neil/0000-0003-4547-873X				APPLE RJ, 1988, J IMMUNOL, V140, P3290; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BURNS AP, 1995, QJM-MON J ASSOC PHYS, V88, P93; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CABANIOLS JP, 1994, EUR J IMMUNOL, V24, P1743, DOI 10.1002/eji.1830240804; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CIBOTTI R, 1992, P NATL ACAD SCI USA, V89, P416, DOI 10.1073/pnas.89.1.416; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; FAIRCHILD PJ, 1993, INT IMMUNOL, V5, P1151, DOI 10.1093/intimm/5.9.1151; FALK K, 1994, IMMUNOGENETICS, V39, P230; GUO DC, 1986, J CHROMATOGR, V359, P499, DOI 10.1016/0021-9673(86)80102-9; HAMMER J, 1995, J EXP MED, V181, P1847, DOI 10.1084/jem.181.5.1847; HAMMER J, 1994, J EXP MED, V180, P2353, DOI 10.1084/jem.180.6.2353; HUEY B, 1993, KIDNEY INT, V44, P307, DOI 10.1038/ki.1993.245; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JENSEN PE, 1991, J EXP MED, V174, P1111, DOI 10.1084/jem.174.5.1111; KALLURI R, 1995, J AM SOC NEPHROL, V6, P1178; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MARRACK P, 1993, J EXP MED, V178, P2173, DOI 10.1084/jem.178.6.2173; Marshall K W, 1995, Biomed Pept Proteins Nucleic Acids, V1, P157; MOORE SEH, 1995, IMMUNOLOGY, V85, P523; MORRISON KE, 1991, AM J HUM GENET, V49, P545; NELSON CA, 1992, P NATL ACAD SCI USA, V89, P7380, DOI 10.1073/pnas.89.16.7380; PUSEY CD, 1987, LAB INVEST, V56, P23; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAUS J, 1988, J BIOL CHEM, V263, P13374; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THEOFILOPOULOS AN, 1995, IMMUNOL TODAY, V16, P90, DOI 10.1016/0167-5699(95)80095-6; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; VIGNALI DAA, 1993, EUR J IMMUNOL, V23, P1602, DOI 10.1002/eji.1830230731; VINER NJ, 1995, P NATL ACAD SCI USA, V92, P2214, DOI 10.1073/pnas.92.6.2214; VOGT AB, 1994, J IMMUNOL, V153, P1665; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279	36	32	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18549	18553		10.1074/jbc.271.31.18549	http://dx.doi.org/10.1074/jbc.271.31.18549			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702503	hybrid			2022-12-27	WOS:A1996VB68300041
J	Doolan, DL; Hedstrom, RC; Rogers, WO; Charoenvit, Y; Rogers, M; delaVega, P; Hoffman, SL				Doolan, DL; Hedstrom, RC; Rogers, WO; Charoenvit, Y; Rogers, M; delaVega, P; Hoffman, SL			Identification and characterization of the protective Hepatocyte erythrocyte protein 17 kDa gene of Plasmodium yoelii, homolog of Plasmodium falciparum exported protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEROZOITE SURFACE PROTEIN-1; HUMAN MALARIA PARASITE; BLOOD-STAGE ANTIGEN; MYCOBACTERIUM-TUBERCULOSIS; CIRCUMSPOROZOITE PROTEIN; HOST ERYTHROCYTE; SPOROZOITE; ANTIBODIES; SEQUENCE; DNA	We recently reported the discovery of a 17-kDa Plasmodium yoelii protein expressed in infected hepatocytes and erythrocytes, P. yoelii hepatocyte erythrocyte protein 17 (PyHEP17), and have demonstrated that this protein is a target of protective antibodies and T cells, Here, we report the identification and characterization of the gene encoding this protein and reveal that it is composed of two exons, Immunization of mice with PyHEP17 plasmid DNA induces antibodies, cytotoxic T lymphocytes, and protective immunity directed against the infected hepatocyte, Based on extensive sequence homology, expression pattern, and antigenic cross-reactivity, the Plasmodium falciparum homolog of PyHEP17 is identified as the protein known as exported protein-1 (PfExp-1), also called antigen 5.1, circumsporozoite related antigen, or QF116. Identity between PyHEP17 and PfExp-1 is 37% at the amino acid level (60/161 residues), mapping primarily to two regions within the second exon of 73% (16/22 residues) and 71% (25/35 residues) identity, On this basis, PfExp-1 is proposed as an important component of pre-erythrocytic human malaria vaccines.	UNIV MARYLAND,BALTIMORE,MD 21201; USN,MED RES INST,MALARIA PROGRAM,BETHESDA,MD 20889	University System of Maryland; University of Maryland Baltimore; Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy			Doolan, Denise L/F-1969-2015	Doolan, Denise/0000-0001-7354-8817				ABOUZEID C, 1988, J GEN MICROBIOL, V134, P531; ANDERSEN P, 1991, INFECT IMMUN, V59, P1558, DOI 10.1128/IAI.59.4.1558-1563.1991; BROWN HJ, 1991, MOL BIOCHEM PARASIT, V49, P99, DOI 10.1016/0166-6851(91)90133-Q; CHAROENVIT Y, 1995, EXP PARASITOL, V80, P419, DOI 10.1006/expr.1995.1054; CHAROENVIT Y, 1987, INFECT IMMUN, V55, P604, DOI 10.1128/IAI.55.3.604-608.1987; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPPEL RL, 1985, P NATL ACAD SCI USA, V82, P5121, DOI 10.1073/pnas.82.15.5121; DALY TM, 1992, MOL BIOCHEM PARASIT, V52, P279, DOI 10.1016/0166-6851(92)90061-N; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739; FARLEY PJ, 1993, GENE AMST, V151, P335; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUNTHER K, 1991, MOL BIOCHEM PARASIT, V46, P148; HARTIKKA J, 1996, IN PRESS HUM GENE TH, V7; HEDSTROM RC, 1990, B WORLD HEALTH ORGAN, V68, P152; HILL A, 1995, P NATL ACAD SCI USA, V92, P341, DOI 10.1073/pnas.92.2.341; HOFFMAN SL, 1987, SCIENCE, V237, P639, DOI 10.1126/science.3299709; HOLDER AA, 1985, NATURE, V317, P270, DOI 10.1038/317270a0; HOPE IA, 1985, NUCLEIC ACIDS RES, V13, P369, DOI 10.1093/nar/13.2.369; KARA U, 1990, MOL BIOCHEM PARASIT, V38, P19, DOI 10.1016/0166-6851(90)90200-6; KEEN JK, 1994, MOL BIOCHEM PARASIT, V65, P171, DOI 10.1016/0166-6851(94)90125-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAL AA, 1987, J BIOL CHEM, V262, P2937; LINGELBACH KR, 1993, EXP PARASITOL, V76, P318, DOI 10.1006/expr.1993.1039; MCKERROW JH, 1990, EXP PARASITOL, V70, P134, DOI 10.1016/0014-4894(90)90094-S; MICHIELS T, 1988, MICROB PATHOGENESIS, V5, P449, DOI 10.1016/0882-4010(88)90006-X; MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F; ORME IM, 1992, J IMMUNOL, V148, P189; RAPTIS A, 1989, INFECT IMMUN, V57, P1725, DOI 10.1128/IAI.57.6.1725-1730.1989; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; ROGERS WO, 1992, MOL BIOCHEM PARASIT, V53, P45, DOI 10.1016/0166-6851(92)90005-5; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ GI, 1994, EXP PARASITOL, V79, P59, DOI 10.1006/expr.1994.1060; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; SIMMONS D, 1987, EMBO J, V6, P485, DOI 10.1002/j.1460-2075.1987.tb04779.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8; TUNGPRADABKUL S, 1985, APPLICATION GENETIC, P51; UNANUE ER, 1992, CURR OPIN IMMUNOL, V4, P63, DOI 10.1016/0952-7915(92)90127-Z; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEBER JL, 1988, EXP PARASITOL, V66, P143, DOI 10.1016/0014-4894(88)90087-2; WORTMAN A, 1989, MICROB PATHOGENESIS, V6, P227, DOI 10.1016/0882-4010(89)90072-7; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	44	73	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17861	17868		10.1074/jbc.271.30.17861	http://dx.doi.org/10.1074/jbc.271.30.17861			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663412	hybrid			2022-12-27	WOS:A1996UY93500043
J	Bowen, MA; Bajorath, J; Siadak, AW; Modrell, B; Malacko, AR; Marquardt, H; Nadler, SG; Aruffo, A				Bowen, MA; Bajorath, J; Siadak, AW; Modrell, B; Malacko, AR; Marquardt, H; Nadler, SG; Aruffo, A			The amino-terminal immunoglobulin-like domain of activated leukocyte cell adhesion molecule binds specifically to the membrane-proximal scavenger receptor cysteine-rich domain of CD6 with a 1:1 stoichiometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T DIFFERENTIATION ANTIGEN; HUMAN LYMPHOCYTES-T; MONOCLONAL-ANTIBODY; SURFACE; SUPERFAMILY; EXPRESSION; GLYCOPROTEIN; PROTEIN; FAMILY; PHOSPHORYLATION	Activated leukocyte cell adhesion molecule (ALCAM) was recently identified as a ligand for CD6, a signaling receptor expressed on T cells, a subset of B cells, and some cells in the brain. Receptor-Ligand binding assays, antibody blocking experiments, and examination of the tissue distribution of these two cell surface proteins suggest that CD6-ALCAM interactions play an important role in mediating the binding of thymocytes to thymic epithelial cells and of T cells to activated leukocytes. Presently, the details of CD6-ALCAM interactions and of signaling through CD6 are unknown, A series of truncated human ALCAM and CD6 immunoglobulin fusion proteins were produced and tested in different binding assays to analyze ALCAM-CD6 interactions in more detail, In this study, we report that the amino-terminal Ig-like domain of human ALCAM specifically binds to the third membrane-proximal scavenger receptor cysteine-rich (SRCR) domain of human CD6. Using thrombin-cleaved Ig fusion proteins containing single or multiple ALCAM or CD6 domains, we were able to determine that the stoichiometry of the interaction between the amino-terminal ALCAM domains and the membrane-proximal CD6 SRCR domain is 1:1. These results provide the first example of an Ig-like domain mediating an interaction with an SRCR domain.			Bowen, MA (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.		Bajorath, Jürgen/F-7493-2014					ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ARUFFO A, 1991, J EXP MED, V174, P949, DOI 10.1084/jem.174.4.949; ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; BAJORATH J, 1995, PROTEIN SCI, V4, P1644, DOI 10.1002/pro.5560040822; BASTIN JM, 1981, CLIN EXP IMMUNOL, V46, P597; BOTT CM, 1993, INT IMMUNOL, V5, P783, DOI 10.1093/intimm/5.7.783; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; BURNS FR, 1991, NEURON, V7, P209, DOI 10.1016/0896-6273(91)90259-3; CARDENAS L, 1990, J IMMUNOL, V145, P1450; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; FARGEAS CA, 1995, J EXP MED, V182, P667, DOI 10.1084/jem.182.3.667; GANGEMI RMR, 1989, J IMMUNOL, V143, P2439; GUO Y, 1995, J EXP MED, V181, P1345, DOI 10.1084/jem.181.4.1345; KAMOUN M, 1981, J IMMUNOL, V127, P987; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KIENER PA, 1995, J IMMUNOL, V155, P4917; LANE RD, 1985, J IMMUNOL METHODS, V81, P223, DOI 10.1016/0022-1759(85)90207-8; LEDBETTER JA, 1989, MOL IMMUNOL, V26, P137, DOI 10.1016/0161-5890(89)90095-3; LINSLEY PS, 1995, RES IMMUNOL, V146, P130, DOI 10.1016/0923-2494(96)80246-X; MARESH GA, 1994, ARCH BIOCHEM BIOPHYS, V311, P95, DOI 10.1006/abbi.1994.1213; MAYER B, 1990, J NEUROIMMUNOL, V29, P193, DOI 10.1016/0165-5728(90)90162-G; MORIMOTO C, 1988, J IMMUNOL, V140, P2165; PATEL DD, 1995, J EXP MED, V181, P1563, DOI 10.1084/jem.181.4.1563; PEACH RJ, 1995, J BIOL CHEM, V270, P21181, DOI 10.1074/jbc.270.36.21181; PEDUZZI JD, 1994, BRAIN RES, V640, P296, DOI 10.1016/0006-8993(94)91885-6; PESANDO JM, 1986, J IMMUNOL, V137, P3689; POURQUIE O, 1992, P NATL ACAD SCI USA, V89, P5261, DOI 10.1073/pnas.89.12.5261; REINHERZ EL, 1982, CELL, V30, P735, DOI 10.1016/0092-8674(82)90278-1; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; SWACK JA, 1989, MOL IMMUNOL, V26, P1037, DOI 10.1016/0161-5890(89)90068-0; SWACK JA, 1991, J BIOL CHEM, V266, P7137; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; WEE SF, 1993, J EXP MED, V177, P219, DOI 10.1084/jem.177.1.219; WEE SF, 1994, CELL IMMUNOL, V158, P353, DOI 10.1006/cimm.1994.1282; WHITNEY GS, 1995, J BIOL CHEM, V270, P18187, DOI 10.1074/jbc.270.31.18187	36	86	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17390	17396		10.1074/jbc.271.29.17390	http://dx.doi.org/10.1074/jbc.271.29.17390			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663238	hybrid			2022-12-27	WOS:A1996UX94300064
J	Jarosch, E; Tuller, G; Daum, G; Waldherr, M; Voskova, A; Schweyen, RJ				Jarosch, E; Tuller, G; Daum, G; Waldherr, M; Voskova, A; Schweyen, RJ			Mrs5p, an essential protein of the mitochondrial intermembrane space, affects protein import into yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATIONAL ACTIVATOR PROTEINS; COLI SHUTTLE VECTORS; SACCHAROMYCES-CEREVISIAE; MEMBRANE-PROTEIN; INNER MEMBRANE; RESTRICTION SITES; SPLICING DEFECTS; GENE DISRUPTION; NUCLEAR; DNA	We have isolated a yeast nuclear gene that suppresses the previously described respiration-deficient mrs2-1 mutation when present on a multicopy plasmid, Elevated gene dosage of this new gene, termed MRS5, suppresses also the pet phenotype of a mitochondrial splicing-deficient group II intron mutation M1301. The MRS5 gene product, a 13-kDa protein of low abundance, shows no similarity to other known proteins and is associated with the inner mitochondrial membrane, protruding into the intermembrane space, MRS5 codes for an essential protein, as the disruption of this gene is lethal even during growth on fermentable carbon sources, Thus, the Mrs5 protein seems to be involved in mitochondrial key functions aside from oxidative energy conservation, which is dispensable in fermenting yeast cells, Depletion of MRs5p in yeast cells causes accumulation of unprocessed precursors of the mitochondrial hsp60 protein and defects in all cytochrome complexes, These findings suggest an essential role of Mrs5p in mitochondrial biogenesis.	UNIV VIENNA,INST MIKROBIOL & GENET,A-1030 VIENNA,AUSTRIA; GRAZ TECH UNIV,INST BIOCHEM & LEBENSMITTELCHEM,A-8010 GRAZ,AUSTRIA	University of Vienna; Graz University of Technology				Jarosch, Ernst/0000-0002-5897-3492				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUGUSTIN S, 1990, THESIS U VIENNA; BAJWA W, 1984, NUCLEIC ACIDS RES, V12, P7721, DOI 10.1093/nar/12.20.7721; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CIRIACY M, 1976, MOL GEN GENET, V145, P327, DOI 10.1007/BF00325831; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEKKER PJT, 1993, FEBS LETT, V330, P66, DOI 10.1016/0014-5793(93)80921-G; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; *GEN COMP GROUP, 1994, GEN COMP GROUP VERS; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; JANITOR M, 1993, CURR GENET, V24, P307, DOI 10.1007/BF00336781; JANITOR M, 1995, YEAST, V11, P1223, DOI 10.1002/yea.320111302; KOLL H, 1987, CURR GENET, V12, P503; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; KOVACOVA V, 1968, BIOCHIM BIOPHYS ACTA, V162, P157, DOI 10.1016/0005-2728(68)90097-2; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLOYD AT, 1992, NUCLEIC ACIDS RES, V20, P5289, DOI 10.1093/nar/20.20.5289; MAARSE AC, 1992, EMBO J, V11, P3619, DOI 10.1002/j.1460-2075.1992.tb05446.x; MAARSE AC, 1994, FEBS LETT, V349, P215, DOI 10.1016/0014-5793(94)00669-5; MCCONNELL SJ, 1992, J CELL BIOL, V118, P385, DOI 10.1083/jcb.118.2.385; MCCONNELL SJ, 1990, J CELL BIOL, V111, P967, DOI 10.1083/jcb.111.3.967; MCMULLIN TW, 1993, J BIOL CHEM, V268, P11737; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MICHAELIS U, 1991, MOL GEN GENET, V230, P177, DOI 10.1007/BF00290666; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; RAGNINI A, 1994, CURR GENET, V26, P308, DOI 10.1007/BF00310494; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RYAN KR, 1994, MOL BIOL CELL, V5, P529, DOI 10.1091/mbc.5.5.529; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; VANDYCK E, 1995, MOL GEN GENET, V246, P426, DOI 10.1007/BF00290446; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WALDHERR M, 1993, CURR GENET, V24, P301, DOI 10.1007/BF00336780; WIESENBERGER G, 1991, J MOL BIOL, V217, P23, DOI 10.1016/0022-2836(91)90608-9; WIESENBERGER G, 1992, J BIOL CHEM, V267, P6963; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	48	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17219	17225		10.1074/jbc.271.29.17219	http://dx.doi.org/10.1074/jbc.271.29.17219			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663351	hybrid			2022-12-27	WOS:A1996UX94300039
J	Kotenko, SV; Izotova, LS; Pollack, BP; Muthukumaran, G; Paukku, K; Silvennoinen, O; Ihle, JN; Pestka, S				Kotenko, SV; Izotova, LS; Pollack, BP; Muthukumaran, G; Paukku, K; Silvennoinen, O; Ihle, JN; Pestka, S			Other kinases can substitute for Jak2 in signal transduction by interferon-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; MUTANT-CELL LINE; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; IL-2 RECEPTOR; ACCESSORY FACTOR; GROWTH-HORMONE; GENE FAMILY; ERYTHROPOIETIN RECEPTOR; PROLACTIN RECEPTORS	Each cytokine which utilizes the Jak-Stat signal transduction pathway activates a distinct combination of members of the Jak and Stat families. Thus, either the Jaks, the Stats, or both could contribute to the specificity of ligand action. With the use of chimeric receptors involving the interferon gamma receptor (IFN-gamma R) complex as a model system, we demonstrate that Jak2 activation is not an absolute requirement for IFN-gamma signaling. Other members of the Jak family can functionally substitute for Jak2. IFN-gamma can signal through the activation of Jak family members other than Jak2 as measured by Statl alpha homodimerization and major histocompatibility complex class I antigen expression. This indicates that Jaks are interchangeable and indiscriminative in the Jak-Stat signal transduction pathway. The necessity for the activation of one particular kinase during signaling can be overcome by recruiting another kinase to the receptor complex. The results may suggest that the Jaks do not contribute to the specificity of signal transduction in the Jak-Stat pathway to the same degree as Stats.	HELSINKI UNIV, DEPT VIROL, HELSINKI, FINLAND; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	University of Helsinki; St Jude Children's Research Hospital	Kotenko, SV (corresponding author), UNIV MED & DENT NEW JERSEY, DEPT MOLEC GENET & MICROBIOL, ROBERT WOOD JOHNSON MED SCH, PISCATAWAY, NJ 08854 USA.				NATIONAL CANCER INSTITUTE [R01CA046465, R01CA052363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036450] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA46465, R01-CA52363] Funding Source: Medline; NIAID NIH HHS [R01 AI36450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; AQUET M, 1988, CELL, V55, P273; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BACH EA, 1995, FASEB J, V9, pA1021; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; BRISCOE J, 1995, J INTERFERON CYTOKIN, V15, pS56; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CLEARY CM, 1994, J BIOL CHEM, V269, P18747; COHEN B, 1995, MOL CELL BIOL, V15, P4208; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DASILVA L, 1994, J BIOL CHEM, V269, P18267; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; EMANUEL S, 1995, THESIS RUTGERS U; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1995, J LEUKOCYTE BIOL, V57, P529, DOI 10.1002/jlb.57.4.529; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; HO ASY, 1995, MOL CELL BIOL, V15, P5043; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; JUNG V, 1988, SOMAT CELL MOLEC GEN, V14, P583, DOI 10.1007/BF01535312; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; KUMAR CS, 1989, J BIOL CHEM, V264, P17939; LAI SY, 1995, FASEB J, V9, pA1021; LANGER JA, 1994, P NATL ACAD SCI USA, V91, P5818, DOI 10.1073/pnas.91.13.5818; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LIM J, 1995, THESIS RUTGERS U PIS; LIU Y, 1994, J IMMUNOL, V152, P1821; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; LUTFALLA G, 1993, GENOMICS, V16, P366, DOI 10.1006/geno.1993.1199; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARIANO TM, 1991, RECEPTOR BINDING STU, P95; MARSTERS SA, 1995, P NATL ACAD SCI USA, V92, P5401, DOI 10.1073/pnas.92.12.5401; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; MUTHUKUMARAN G, 1995, J INTERFERON CYTOKIN, V15, pS70; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RASHIDBAIGI A, 1986, P NATL ACAD SCI USA, V83, P384, DOI 10.1073/pnas.83.2.384; REHBERG E, 1982, J BIOL CHEM, V257, P1497; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SOH JM, 1994, J BIOL CHEM, V269, P18102; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TIAN SS, 1994, BLOOD, V84, P1760; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	99	82	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17174	17182		10.1074/jbc.271.29.17174	http://dx.doi.org/10.1074/jbc.271.29.17174			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663414	hybrid			2022-12-27	WOS:A1996UX94300032
J	Nikovits, W; Wang, GF; Feldman, JL; Miller, JB; Wade, R; Nelson, L; Stockdale, FE				Nikovits, W; Wang, GF; Feldman, JL; Miller, JB; Wade, R; Nelson, L; Stockdale, FE			Isolation and characterization of an avian slow myosin heavy chain gene expressed during embryonic skeletal muscle fiber formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY REGULATED EXPRESSION; CELL-SPECIFIC EXPRESSION; ENHANCER-BINDING FACTOR; MESSENGER-RNAS; ALPHA-MYOSIN; THYROID-HORMONE; CARDIAC-MUSCLE; RETINOIC ACID; BETA; SEQUENCE	We have isolated and begun characterization of the quail slow myosin heavy chain (My HC) 3 gene, the first reported avian slow MyHC gene. Expression of slow MyHC 3 in skeletal muscle is restricted to the embryonic period of development, when the fiber pattern of future fast and slow muscle is established. In embryonic hind limb development, slow My HC 3 gene expression coincides with slow muscle fiber formation as distinguished by slow MyHC-specific antibody staining. In addition to expression in embryonic appendicular muscle, slow MyHC 3 is expressed continuously in the atria. Transfection of slow My HC 3 promoter-reporter constructs into embryonic myoblasts that form slow MyHC expressing fibers identified two regions regulating expression of this gene in skeletal muscle, The proximal promoter, containing potential muscle specific regulatory motifs, permits expression of a reporter gene in embryonic slow muscle fibers, while a distal element, located greater than 2600 base pairs upstream, further enhances expression 5-fold. The slow muscle fiber-restricted expression of slow MyHC 3 during embryonic development, and expression of slow MyHC 3 promoter-reporter constructs in embryonic muscle fibers in vitro, makes this gene a useful marker to study the mechanism establishing the slow fiber lineage in the embryo.	STANFORD UNIV, SCH MED, DEPT MED, STANFORD, CA 94305 USA	Stanford University				Miller, Jeffrey/0000-0001-5273-2201	NATIONAL CANCER INSTITUTE [T32CA009287] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG002822] Funding Source: NIH RePORTER; NCI NIH HHS [CA09287] Funding Source: Medline; NIA NIH HHS [AG02822] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADOLPH EA, 1993, J BIOL CHEM, V268, P5349; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; ASAKURA A, 1993, MOL CELL BIOL, V13, P7153, DOI 10.1128/MCB.13.11.7153; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BANDMAN E, 1982, DEV BIOL, V93, P508, DOI 10.1016/0012-1606(82)90138-5; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; CROW MT, 1986, DEV BIOL, V118, P333, DOI 10.1016/0012-1606(86)90002-3; CROW MT, 1986, DEV BIOL, V113, P238, DOI 10.1016/0012-1606(86)90126-0; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DIMARIO JX, 1993, NATURE, V362, P165, DOI 10.1038/362165a0; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EVANS D, 1988, DEV BIOL, V127, P376, DOI 10.1016/0012-1606(88)90324-7; FLINK IL, 1992, J BIOL CHEM, V267, P9917; FRIEDMAN DJ, 1984, P NATL ACAD SCI-BIOL, V81, P3044, DOI 10.1073/pnas.81.10.3044; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GULICK J, 1991, J BIOL CHEM, V266, P9180; GULICK J, 1987, EUR J BIOCHEM, V169, P79, DOI 10.1111/j.1432-1033.1987.tb13583.x; HOH JFY, 1976, BIOCHEM J, V157, P87, DOI 10.1042/bj1570087; HOH JFY, 1979, FEBS LETT, V98, P267, DOI 10.1016/0014-5793(79)80197-0; HUGHES SM, 1993, DEV BIOL, V158, P183, DOI 10.1006/dbio.1993.1178; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KENNEDY JM, 1986, J CELL BIOL, V103, P977, DOI 10.1083/jcb.103.3.977; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KROPP K, 1986, J BIOL CHEM, V261, P6613; KROPP KE, 1987, J BIOL CHEM, V262, P16536; LIEW CC, 1990, NUCLEIC ACIDS RES, V18, P3647, DOI 10.1093/nar/18.12.3647; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; Maniatis T., 1982, MOL CLONING; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MATSUDA R, 1982, DIFFERENTIATION, V23, P36, DOI 10.1111/j.1432-0436.1982.tb01265.x; MCNALLY EM, 1989, J MOL BIOL, V210, P665, DOI 10.1016/0022-2836(89)90141-1; MILLER DM, 1986, P NATL ACAD SCI USA, V83, P2305, DOI 10.1073/pnas.83.8.2305; MILLER JB, 1985, J CELL BIOL, V101, P1643, DOI 10.1083/jcb.101.5.1643; MILLER JB, 1986, P NATL ACAD SCI USA, V83, P3860, DOI 10.1073/pnas.83.11.3860; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; NARUSAWA M, 1987, J CELL BIOL, V104, P447, DOI 10.1083/jcb.104.3.447; PAGE S, 1992, DEV BIOL, V154, P118, DOI 10.1016/0012-1606(92)90053-J; PARKERTHORNBURG J, 1992, DEV BIOL, V150, P99, DOI 10.1016/0012-1606(92)90010-E; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PIEROBON BORMIOLI S, 1980, J CELL BIOL, V85, P672, DOI 10.1083/jcb.85.3.672; REISER PJ, 1988, DEV BIOL, V129, P400, DOI 10.1016/0012-1606(88)90387-9; ROBBINS J, 1986, J BIOL CHEM, V261, P6606; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; SCHAFER DA, 1987, CELL, V48, P659, DOI 10.1016/0092-8674(87)90244-3; STOCKDALE FE, 1992, DEV BIOL, V154, P284, DOI 10.1016/0012-1606(92)90068-R; STREHLER EE, 1986, J MOL BIOL, V190, P291, DOI 10.1016/0022-2836(86)90003-3; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; TAKEDA S, 1992, J BIOL CHEM, V267, P16957; TERMIN A, 1989, HISTOCHEMISTRY, V92, P453, DOI 10.1007/BF00524756; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; UMEDA PK, 1981, P NATL ACAD SCI-BIOL, V78, P2843, DOI 10.1073/pnas.78.5.2843; VIVARELLI E, 1988, J CELL BIOL, V107, P2191, DOI 10.1083/jcb.107.6.2191; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; YUTZEY KE, 1994, DEVELOPMENT, V120, P871; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	63	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17047	17056		10.1074/jbc.271.29.17047	http://dx.doi.org/10.1074/jbc.271.29.17047			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663323	hybrid			2022-12-27	WOS:A1996UX94300013
J	Rzymkiewicz, DM; Tetsuka, T; DaphnaIken, D; Srivastava, S; Morrison, AR				Rzymkiewicz, DM; Tetsuka, T; DaphnaIken, D; Srivastava, S; Morrison, AR			Interleukin-1 beta activates protein kinase C zeta in renal mesangial cells - Potential role in prostaglandin E(2) up-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-INDUCED DIFFERENTIATION; PHORBOL ESTER; SIGNAL-TRANSDUCTION; PC12 CELLS; RAT; ALPHA; ISOENZYMES; EXPRESSION; INHIBITION; EPSILON	Protein kinase C (PKC) plays a rob in signal transduction mediated by interleukin-1 beta (IL-1 beta) leading to the increase in prostaglandin E(2) (PGE(2)) production. In the present study we suggest that there are at least two distinct PKC isotypes involved in the signaling mechanism. Staurosporine potentiated the effect of IL-1 beta on coxII mRNA expression while calphostin C totally inhibited mRNA expression. The down-regulation of PKC by growing mesangial cells in the presence of phorbol 12-myristate 13-acetate for 24 h failed to modify the upregulated response in PGE(2) formation by IL-1 beta. Furthermore, incubation of mesangial cells with IL-1 beta causes translocation of PKC zeta from cytosol to a presumed membrane compartment, and this translocation phenomenon was not inhibited by incubating the cells with staurosporine but was inhibited with calphostin C. Gel retardation assays also demonstrated that staurosporine did not inhibit the IL-1 beta-stimulated binding of nuclear extracts to the NF kappa B motif. In contrast, calphostin C inhibited binding to the kappa B motif in a dose-dependent manner. Finally, antisense oligonucleotides to PKC zeta partially inhibited the IL-1 beta-induced PGE(2) formation while control sense oligonucleotides were without effect. Taken together, these data suggest that PKC zeta is involved in the IL-1 beta signaling responses.	WASHINGTON UNIV, DEPT MED, SCH MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT MOLEC BIOL, SCH MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT PHARMACOL, SCH MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [HL 20787] Funding Source: Medline; NIDDK NIH HHS [DK 38111] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL020787] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038111] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; COLEMAN ES, 1994, J MOL NEUROSCI, V5, P39, DOI 10.1007/BF02736693; COYNE DW, 1992, AM J PHYSIOL, V263, pF97, DOI 10.1152/ajprenal.1992.263.1.F97; DANG PMC, 1994, FEBS LETT, V349, P338, DOI 10.1016/0014-5793(94)00700-4; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; Folgueira L, 1996, J VIROL, V70, P223, DOI 10.1128/JVI.70.1.223-231.1996; HABIB T, 1994, J BIOL CHEM, V269, P25243; HATA A, 1993, J BIOL CHEM, V268, P9122; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUWILER A, 1991, BIOCHEM BIOPH RES CO, V180, P1422, DOI 10.1016/S0006-291X(05)81355-5; HUWILER A, 1991, BIOCHEM J, V279, P441, DOI 10.1042/bj2790441; HUWILER A, 1992, FEBS LETT, V300, P259, DOI 10.1016/0014-5793(92)80858-E; LARIVEE P, 1994, AM J RESP CELL MOL, V11, P199, DOI 10.1165/ajrcmb.11.2.8049080; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; REDDY ST, 1994, J BIOL CHEM, V269, P15473; RZYMKIEWICZ DM, 1995, KIDNEY INT, V47, P1354, DOI 10.1038/ki.1995.191; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TISCHLER AS, 1991, J BIOL CHEM, V266, P1141; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WOLF M, 1985, J BIOL CHEM, V260, P5718; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395	29	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17241	17246		10.1074/jbc.271.29.17241	http://dx.doi.org/10.1074/jbc.271.29.17241			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663336	hybrid			2022-12-27	WOS:A1996UX94300042
J	Sun, WM; Williams, CH; Massey, V				Sun, WM; Williams, CH; Massey, V			Site-directed mutagenesis of glycine 99 to alanine in L-lactate monooxygenase from Mycobacterium smegmatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINACH GLYCOLATE OXIDASE; AMINO-ACID-SEQUENCE; ACTIVE-SITE; ESCHERICHIA-COLI; BAKERS-YEAST; FLAVOCYTOCHROME-B2; MECHANISM; SUBSTRATE; DEHYDROGENASE; FLAVOPROTEINS	L-Lactate monooxygenase (LMO) hom Mycobacterium smegmatis was mutated at glycine 99 to alanine, and the properties of the resulting mutant (referred to as G99A) were studied, Mutant G99A of LMO was designed to test the postulate that the smaller glycine residue in the vicinity of the alpha-carbon methyl group of lactate in wild-type LMO has less steric hindrance, leading to the retention and oxidative decarboxylation of pyruvate in the active site, a unique property of LMO in contrast to other members of the FMN-dependent oxidase/dehydrogenase family, G99A has been shown to be readily reduced by L-lactate at a rate similar to that of the wild-type enzyme. The binding of pyruvate to reduced G99A is 4-fold weaker than that to the wild-type enzyme. A dramatic change of this mutation is that G99A has a much lower oxygen reactivity than the wild-type enzyme. Pyruvate-bound reduced G99A reacts with O-2 at a rate similar to 10(5)-fold slower than the wild-type enzyme, and free reduced G99A reacts with O-2 at a rate similar to 100-fold slower than the wild-type enzyme. Due to the very low oxygen reactivity of the pyruvate-bound reduced enzyme, G99A has been shown to catalyze the oxidation of L-lactate to pyruvate and hydrogen peroxide instead of acetate, carbon dioxide, and water, the normal decarboxylation products of pyruvate and hydrogen peroxide. Thus, the mutation alters the enzyme from its L-lactate monooxygenase activity to L-lactate oxidase activity, However, compared with L-lactate oxidase, G99A has a much lower reactivity toward oxygen Our results also reveal that the small steric change around N-5 of the flavin causes a profound change in the electronic distribution in the catalytic cavity of the enzyme and imply that electrostatic interactions in the active site provide an important factor for control of O-2 reactivity.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; DEPT VET AFFAIRS MED CTR,ANN ARBOR,MI 48105	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21444, GM 11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bevington P. R., 1969, DATA REDUCTION ERROR, P235; CEDERLUND E, 1988, EUR J BIOCHEM, V173, P523, DOI 10.1111/j.1432-1033.1988.tb14029.x; CHOONG YS, 1980, J BIOL CHEM, V255, P8672; DUNFORD HB, 1982, ADV INORG BIOCHEM, V4, P41; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; GHISLA S, 1976, BIOCHEMISTRY-US, V15, P1791, DOI 10.1021/bi00654a002; GHISLA S, 1975, J BIOL CHEM, V250, P577; GHISLA S, 1979, J BIOL CHEM, V254, P662; GHISLA S, 1976, FLAVINS FLAVOPROTEIN, P213; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; GIEGEL DA, 1990, J BIOL CHEM, V265, P6626; HAYAISHI O, 1957, J AM CHEM SOC, V79, P4809, DOI 10.1021/ja01574a060; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE KHD, 1991, J BIOL CHEM, V266, P20877; LEDERER F, 1985, EUR J BIOCHEM, V152, P419, DOI 10.1111/j.1432-1033.1985.tb09213.x; LEDERER F, 1991, CHEM BIOCH FLAVOENZY, V2, P153; LINDQVIST Y, 1989, J BIOL CHEM, V264, P3624; LOCKRIDGE O, 1972, J BIOL CHEM, V247, P8097; MAEDAYORITA K, 1995, BIOCHIMIE, V77, P631, DOI 10.1016/0300-9084(96)88178-8; MANSTEIN DJ, 1988, BIOCHEMISTRY-US, V27, P2300, DOI 10.1021/bi00407a009; MANSTEIN DJ, 1986, BIOCHEMISTRY-US, V25, P6807, DOI 10.1021/bi00370a012; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; MASSEY V, 1980, J BIOL CHEM, V255, P2796; MASSEY V, 1977, J BIOL CHEM, V252, P5612; Muh U, 1994, FLAVINS AND FLAVOPROTEINS 1993, P201; MUH U, 1994, J BIOL CHEM, V269, P7982; MUH U, 1994, J BIOL CHEM, V269, P7994; MUH U, 1994, J BIOL CHEM, V269, P7989; SCHONBRUNN A, 1976, BIOCHEMISTRY-US, V15, P1798, DOI 10.1021/bi00654a003; SMEKAL O, 1993, BIOCHEM J, V290, P103, DOI 10.1042/bj2900103; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; SULLIVAN PA, 1977, BIOCHEM J, V165, P375, DOI 10.1042/bj1650375; SULLIVAN PA, 1968, BIOCHEM J, V110, P363, DOI 10.1042/bj1100363; TSOU AY, 1990, BIOCHEMISTRY-US, V29, P9856, DOI 10.1021/bi00494a015; VOLOKITA M, 1987, J BIOL CHEM, V262, P15825; WALSH CT, 1971, J BIOL CHEM, V246, P6855; WALSH CT, 1972, J BIOL CHEM, V247, P6004; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; XIA ZX, 1987, P NATL ACAD SCI USA, V84, P2629, DOI 10.1073/pnas.84.9.2629	39	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17226	17233		10.1074/jbc.271.29.17226	http://dx.doi.org/10.1074/jbc.271.29.17226			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663383	hybrid			2022-12-27	WOS:A1996UX94300040
J	Jiang, N; He, TC; Miyajima, A; Wojchowski, DM				Jiang, N; He, TC; Miyajima, A; Wojchowski, DM			The box1 domain of the erythropoietin receptor specifies Janus kinase 2 activation and functions mitogenically within an interleukin 2 beta-receptor chimera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; CYTOKINE RECEPTORS; SIGNAL-TRANSDUCTION; TYROSINE KINASES; GROWTH; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; SUPERFAMILY; JAK	Several distinct classes of cytokine receptors engage Jak kinases as primary effecters. Among type 1 receptors, Janus activated kinase (Jak) recruitment is mediated by membrane-proximal cytoplasmic domains, which typically contain conserved box motifs. In the erythropoietin receptor (Epo-R), two such motifs (box1 and box2) have been suggested to be essential for the activation of Jak2 and mitogenesis, Presently, an Epo-R chimera containing the extracellular and box1 domains of the Epo-R (Jak2-associated receptor) and the box2 and carboxyl-terminal domains of the interleukin 2 beta-receptor (IL2 beta-R; a Jak1-associated subunit) is shown to activate Jak2. Interestingly, Jak2 also was activated in FDC-beta 1 cells by a control Epo-R chimera containing the complete IL2 beta-R cytoplasmic domain, and mitogenesis was supported by each of these above chimeras. By comparison, in BaF3 cells expressing IL2 receptor alpha and gamma subunits, an ectopically expressed IL2 beta-R chimera containing the box1 domain of the Epo-R, activated Jak2 and Jak3 and was as mitogenically active as the wild-type IL2 beta-R (Jak1 and Jak3 activation). Thus, the box1 domain of the Epo-R specifies Jak2 activation and functions efficiently within a heterologous IL2 receptor complex that normally activates Jak1 and Jak8.	PENN STATE UNIV,GRAD PROGRAM PATHOBIOL & VET SCI,UNIVERSITY PK,PA 16802; PENN STATE UNIV,GRAD PROGRAM GENET,UNIVERSITY PK,PA 16802; PENN STATE UNIV,GRAD PROGRAM BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802; PENN STATE UNIV,CTR GENE REGULAT,UNIVERSITY PK,PA 16802; UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,TOKYO,JAPAN	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Tokyo					NHLBI NIH HHS [HL03042] Funding Source: Medline; NIDDK NIH HHS [DK40242] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040242, R01DK040242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHIBA T, 1993, NATURE, V362, P646, DOI 10.1038/362646a0; CHIBA T, 1992, BIOCHEM BIOPH RES CO, V186, P1236, DOI 10.1016/S0006-291X(05)81538-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOSI P, 1993, J BIOL CHEM, V268, P12617; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; EDERY M, 1994, MOL CELL ENDOCRINOL, V102, P39, DOI 10.1016/0303-7207(94)90095-7; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; HE TC, 1994, J BIOL CHEM, V269, P18291; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANO H, 1995, BLOOD, V85, P343; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA O, 1994, J BIOL CHEM, V269, P614; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WILKS AF, 1994, BIOESSAYS, V16, P313, DOI 10.1002/bies.950160505; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOJCHOWSKI DM, 1993, STEM CELLS, V11, P381, DOI 10.1002/stem.5530110505; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	39	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16472	16476		10.1074/jbc.271.28.16472	http://dx.doi.org/10.1074/jbc.271.28.16472			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663338	hybrid			2022-12-27	WOS:A1996UX12600010
J	Krause, U; Rider, MH; Hue, L				Krause, U; Rider, MH; Hue, L			Protein kinase signaling pathway triggered by cell swelling and involved in the activation of glycogen synthase and Acetyl-CoA carboxylase in isolated rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; SKELETAL-MUSCLE; GROWTH-FACTOR; S6 KINASE; LIVER; MECHANISM; GLUCOSE; PURIFICATION; STIMULATION; INHIBITION	Incubation of isolated hepatocytes with glutamine or proline or in hypotonic media is known to activate glycogen synthase and acetyl-CoA carboxylase as a result of cell swelling, We report here that the same experimental conditions caused an activation of phosphatidylinositol 3-kinase and p70 ribosomal protein S6 kinase (p70 S6 kinase) but did not modify the activity of p42 mitogen activated protein kinase, In addition, rapamycin, an inhibitor of p70 S6 kinase activation, prevented the amino acid and hypotonicity-induced activation of p70 S6 kinase but did not block the activation of glycogen synthase and acetyl-CoA carboxylase, thus ruling out p70 Se kinase as a necessary component in the activation pathway, By contrast, wortmannin or LY294002, inhibitors of phosphatidylinositol 3-kinase, completely blocked the activation of phosphatidylinositol 3-kinase and p70 S6 kinase and partly blocked the activation of glycogen synthase and acetyl-CoA carboxylase, Therefore, phosphatidylinositol 3-kinase might be a component of the signaling pathway that is triggered by cell swelling and is responsible, at least in part, for the activation of glycogen synthase and acetyl CoA carboxylase, Incubation of hepatocytes with 0.1 mu M epidermal growth factor doubled the activity of p42 mitogen-activated protein kinase without activating glycogen synthase.	UNIV LOUVAIN,SCH MED,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; INT INST CELLULAR & MOLEC PATHOL,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								AGIUS L, 1994, BIOCHEM SOC T, V22, P516, DOI 10.1042/bst0220516; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BAQUET A, 1991, BIOCHEM J, V278, P887, DOI 10.1042/bj2780887; BAQUET A, 1990, J BIOL CHEM, V265, P955; BAQUET A, 1993, EUR J BIOCHEM, V217, P1083, DOI 10.1111/j.1432-1033.1993.tb18340.x; BIJLEVELD C, 1987, BIOCHIM BIOPHYS ACTA, V918, P274, DOI 10.1016/0005-2760(87)90231-1; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; BORTHWICK AC, 1990, BIOCHEM J, V270, P795, DOI 10.1042/bj2700795; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BURGERING MT, 1995, NATURE, V276, P599; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gaussin V, 1996, BIOCHEM J, V316, P217, DOI 10.1042/bj3160217; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; HERS HG, 1976, ANNU REV BIOCHEM, V45, P167, DOI 10.1146/annurev.bi.45.070176.001123; HUE L, 1978, BIOCHEM J, V176, P791, DOI 10.1042/bj1760791; HUE L, 1975, BIOCHEM J, V152, P105, DOI 10.1042/bj1520105; ITOH T, 1995, FEBS LETT, V373, P123, DOI 10.1016/0014-5793(95)01028-D; KOHN AD, 1995, AMBO J, V14, P4288; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LAVOINNE A, 1987, BIOCHEM J, V248, P429, DOI 10.1042/bj2480429; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; LINN TC, 1981, ARCH BIOCHEM BIOPHYS, V209, P613, DOI 10.1016/0003-9861(81)90320-9; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MEIJER AJ, 1992, J BIOL CHEM, V267, P5823; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; PELECH SL, 1986, P NATL ACAD SCI USA, V83, P5968, DOI 10.1073/pnas.83.16.5968; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; STALMANS W, 1976, CURR TOP CELL REGUL, V11, P51; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; TILLY BC, 1993, J BIOL CHEM, V268, P19919; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729	45	98	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16668	16673		10.1074/jbc.271.28.16668	http://dx.doi.org/10.1074/jbc.271.28.16668			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663301	hybrid			2022-12-27	WOS:A1996UX12600040
J	PuzonMcLaughlin, W; Yednock, TA; Takada, Y				PuzonMcLaughlin, W; Yednock, TA; Takada, Y			Regulation of conformation and ligand binding function of integrin alpha 5 beta 1 by the beta 1 cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBRONECTIN RECEPTOR; SITE-DIRECTED MUTAGENESIS; PLATELET GLYCOPROTEIN-IIB; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; CROSS-LINKING; GPIIB-IIIA; T-CELLS; SUBUNIT; ADHESION	We have studied the role of the cytoplasmic domain in the conformation and affinity modulation of the integrin beta 1. Expression of a conformation dependent anti-beta 1 antibody 15/7 correlates with activation in wild-type beta 1. Truncation of 16 carboxyl-terminal residues in the cytoplasmic domain (the 762t beta 1 mutant) induces constitutive expression of the 15/7 epitope at a high level (which probably reflects a major conformational change of the extracellular domain) but does not activate ligand binding. The dissociation of epitope expression and affinity suggests that the epitope expression reflects the conformation of nonligand binding sites of the extracellular domain of beta 1 but does not necessarily reflect that of the ligand binding sites. Indeed we discovered that the 15/7 epitope is in fact located in the nonligand binding region of beta 1 (within residues 354-425). The 762t mutant has apparently normal alpha/beta association, suggesting that the overexpression of the 15/7 epitope is not due to alpha/beta dissociation. The data suggest that the carboxyl-terminal 16 residues of the beta 1 cytoplasmic domain are critical for properly modulating conformation and affinity of beta 1 integrins.	Scripps Res Inst, RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; ATHENA NEUROSCI, San Francisco, CA 94080 USA	Scripps Research Institute				takada, yoshikazu/0000-0001-5481-9589	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049899, R01GM047157] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49899, GM47157] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; ALTIERI DC, 1988, J IMMUNOL, V141, P2656; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; BALZAC F, 1994, J CELL BIOL, V127, P557, DOI 10.1083/jcb.127.2.557; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BENNETT JS, 1993, J BIOL CHEM, V268, P3580; CARLOS TM, 1994, BLOOD, V84, P2068; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CROWE DT, 1994, J BIOL CHEM, V269, P14411; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GULINO D, 1995, EUR J BIOCHEM, V227, P108, DOI 10.1111/j.1432-1033.1995.tb20365.x; HAAS TA, 1993, THROMB HAEMOSTASIS, V69, P1022; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; Hemler M.E, 1994, INTEGRINS BIOL PROBL, P1; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KODANDAPANI R, 1995, J BIOL CHEM, V270, P2268, DOI 10.1074/jbc.270.5.2268; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PHILLIPS DR, 1988, BLOOD, V71, P831; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RINDERKNECHT H, 1962, NATURE, V193, P167, DOI 10.1038/193167b0; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SHIH DT, 1993, J CELL BIOL, V122, P1361, DOI 10.1083/jcb.122.6.1361; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAUB R, 1989, J BIOL CHEM, V264, P259; THE TH, 1970, IMMUNOLOGY, V18, P865; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; WAYNER EA, 1992, J CELL BIOL, V116, P489, DOI 10.1083/jcb.116.2.489; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; YAMADA A, 1991, EUR J IMMUNOL, V21, P319, DOI 10.1002/eji.1830210212; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	62	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16580	16585		10.1074/jbc.271.28.16580	http://dx.doi.org/10.1074/jbc.271.28.16580			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663265				2022-12-27	WOS:A1996UX12600026
J	Graichen, R; Losch, A; Appel, D; KochBrandt, C				Graichen, R; Losch, A; Appel, D; KochBrandt, C			Glycolipid-independent sorting of a secretory glycoprotein to the apical surface of polarized epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORED PROTEINS; MEMBRANE ANCHOR; MDCK CELLS; COMPLEX; LINE; BIOSYNTHESIS; TRANSPORT; CAVEOLAE	Proteins attached to the membrane by a glycosylphosphatidylinositol (GPI)-anchor cluster together with glycolipids in detergent-insoluble complexes at the site of sorting in the trans-Golgi network. This process has been shown to be critical for the targeting of these proteins to the apical cell surface in polarized epithelial cells, We show in this study that gp80 (clusterin), an apically secreted glycoprotein, is not included in detergent-insoluble complexes in Madin-Darby canine kidney cells, Furthermore in Fisher rat thyroid cells, which target GPI-anchored proteins preferentially to the basolateral cell surface, gp80 is secreted apically, Together these results suggest that this secretory glycoprotein and GPI-linked proteins use different mechanisms to reach the apical membrane.	UNIV MAINZ, INST BIOCHEM, D-55099 MAINZ, GERMANY	Johannes Gutenberg University of Mainz								APPEL D, 1994, J CELL SCI, V107, P553; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown Deborah A., 1992, Trends in Cell Biology, V2, P338; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; HANNAN LA, 1993, J CELL BIOL, V120, P353, DOI 10.1083/jcb.120.2.353; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MATLIN K S, 1992, Current Opinion in Cell Biology, V4, P623; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; MEISS HK, 1982, MOL CELL BIOL, V2, P1287, DOI 10.1128/MCB.2.10.1287; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MUSTO NA, 1993, EXP CELL RES, V209, P271, DOI 10.1006/excr.1993.1311; PARCZYK K, 1991, FEBS LETT, V278, P267, DOI 10.1016/0014-5793(91)80132-M; PICCIONI R, 1982, METHODS CHLOROPLAST, P985; PILARSKY C, 1993, BIOCHIM BIOPHYS ACTA, V1179, P306, DOI 10.1016/0167-4889(93)90086-5; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; ULLRICH O, 1991, J BIOL CHEM, V266, P3518; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VAN MEER G, 1988, J CELL BIOCHEM, V36, P51, DOI 10.1002/jcb.240360106; WAGNER M, 1995, EUR J CELL BIOL, V67, P84; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	37	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15854	15857		10.1074/jbc.271.27.15854	http://dx.doi.org/10.1074/jbc.271.27.15854			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663455	hybrid			2022-12-27	WOS:A1996UW35200003
J	Bolin, DJ; Jonas, A				Bolin, DJ; Jonas, A			Sphingomyelin inhibits the lecithin-cholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HUMAN-PLASMA LECITHIN; DISCOIDAL COMPLEXES; MICELLAR COMPLEXES; PHOSPHATIDYLCHOLINE; MEMBRANES; BILAYERS; ESTERIFICATION; LIPIDS; SIZE	Lecithin-cholesterol acyltransferase (LCAT) catalyzes the formation of cholesterol esters on high density lipoproteins (HDL) and plays a critical role in reverse cholesterol transport, Sphingomyelin, an important constituent of HDL, may regulate the activity of LCAT at any of the key steps of the enzymatic reaction: binding of LCAT to the interface, activation by apo A-I, or inhibition at the catalytic site, In order to clarify the Pole of sphingomyelin in the regulation of the LCAT reaction and its effects on the structure of apolipoprotein A-I, we prepared reconstituted HDL (rHDL) containing egg phosphatidylcholine, cholesterol, apolipoprotein A-I, and up to 22 mol % sphingomyelin, Because the interfacial properties of substrate particles can dramatically affect LCAT binding and kinetics, we also prepared and analyzed proteoliposome substrates having the same components as the rHDL, except for a 4-fold higher ratio of phospholipid to apolipoprotein A-I. The reaction kinetics of LCAT with the rHDL particles revealed no significant, change in the apparent V-max but showed a concentration-dependent increase in slope of the reciprocal plots and in the apparent K-m values with sphingomyelin content, The dissociation constant (K-d) for LCAT with these particles increased linearly with sphingomyelin content. up to 22 mol %, changing in parallel with the apparent K-m values. No structural changes of apolipoprotein A-I were detected in the particles with increasing content of sphingomyelin, but fluorescence results with lipophilic probes revealed that significant changes in the acyl chain, backbone, and head group regions of the Lipid bilayer of the particles are introduced by the addition of sphingomyelin. On the other-hand, the proteoliposome substrates also had increased K-d values for LCAT at high sphingomyelin contents but compared with the rHDL particles had a 6-10-fold lower affinity for LCAT binding and exhibited kinetics consistent with competitive inhibition by sphingomyelin at the active site, These results show conclusively that the dominant mechanism for the inhibition of LCAT activity with rHDL particles by sphingomyelin is the impaired binding of the enzyme to the interface. The results also underscore the significant differences in the enzyme reaction kinetics with different substrate particles.	UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029939, R01HL016059] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 29939, HL 16059] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMSSON S, 1977, STRUCTURE BIOL MEMBR, P1; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BARENHOLZ Y, 1984, PHYSL MEMBRANE FLUID, P131; BARENHOLZ Y, 1982, PHOSPHOLIPIDS, P129; BARTER PJ, 1985, ATHEROSCLEROSIS, V58, P97, DOI 10.1016/0021-9150(85)90058-9; BOLIN DJ, 1994, J BIOL CHEM, V269, P7429; BONOMO EA, 1990, BIOCHEMISTRY-US, V29, P5094, DOI 10.1021/bi00473a014; CALHOUN WI, 1979, BIOCHEMISTRY-US, V18, P1717, DOI 10.1021/bi00576a013; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; DORY L, 1983, P NATL ACAD SCI-BIOL, V80, P3489, DOI 10.1073/pnas.80.11.3489; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; GLOMSET JA, 1972, BLOOD LIPIDS LIPOPRO, P745; GWYNNE J, 1974, J BIOL CHEM, V249, P2411; JONAS A, 1985, J BIOL CHEM, V260, P2757; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; JONAS A, 1993, BIOCHIM BIOPHYS ACTA, V1166, P202, DOI 10.1016/0005-2760(93)90098-T; JONAS A, 1983, J BIOL CHEM, V258, P335; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1984, J BIOL CHEM, V259, P6369; JONAS A, 1982, BIOCHEMISTRY-US, V21, P6867, DOI 10.1021/bi00269a037; LEROY A, 1993, J BIOL CHEM, V268, P4798; LICHTENBERG D, 1981, BIOCHEMISTRY-US, V20, P3462, DOI 10.1021/bi00515a024; LIU M, 1992, J BIOL CHEM, V267, P5139; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044; MASSEY JB, 1985, J BIOL CHEM, V260, P1719; MASSEY JB, 1985, BIOCHEMISTRY-US, V24, P6973, DOI 10.1021/bi00345a033; MATZ CE, 1982, J BIOL CHEM, V257, P4541; NICHOLS AV, 1976, BIOCHIM BIOPHYS ACTA, V446, P226, DOI 10.1016/0005-2795(76)90113-6; POWNALL HJ, 1985, J BIOL CHEM, V260, P2146; REICHL D, 1992, BIOCHIM BIOPHYS ACTA, V1127, P28, DOI 10.1016/0005-2760(92)90197-4; Rye KA, 1996, J BIOL CHEM, V271, P4243; SCHMIDT CF, 1977, BIOCHEMISTRY-US, V16, P2649, DOI 10.1021/bi00631a011; SHEETZ MP, 1972, BIOCHEMISTRY-US, V11, P4573, DOI 10.1021/bi00774a024; SKIPSKI V, 1992, BLOOD LIPIDS LIPOPRO, P471; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SMALL DM, 1986, PHYSICAL CHEM LIPIDS, P382; SUBBAIAH PV, 1993, J BIOL CHEM, V268, P20156; SWANEY JB, 1983, J BIOL CHEM, V258, P1254; VERGER R, 1973, J BIOL CHEM, V248, P4023; WALD JH, 1990, J BIOL CHEM, V265, P20044; WEBER G, 1979, BIOCHEMISTRY-US, V18, P3075, DOI 10.1021/bi00581a025; WONG L, 1992, J CLIN INVEST, V90, P2370, DOI 10.1172/JCI116127; ZORICH NL, 1987, BIOCHIM BIOPHYS ACTA, V919, P181, DOI 10.1016/0005-2760(87)90206-2	45	102	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19152	19158		10.1074/jbc.271.32.19152	http://dx.doi.org/10.1074/jbc.271.32.19152			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702592	hybrid			2022-12-27	WOS:A1996VB68400026
J	Lugemwa, FN; Sarkar, AK; Esko, JD				Lugemwa, FN; Sarkar, AK; Esko, JD			Unusual beta-D-xylosides that prime glycosaminoglycans in animal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; HEPARAN-SULFATE BIOSYNTHESIS; GENE-SPECIFIED GLYCOSYLTRANSFERASES; HUMAN SKIN FIBROBLASTS; BLOOD-GROUP-A; CHONDROITIN SULFATE; ACCEPTOR ALPHA-L-FUCP-(1->2)-BETA-D-GALP-OR; PROTEIN INTERACTIONS; RECOGNITION; OLIGOSACCHARIDE	The biosynthesis of glycosaminoglycans (GAG) takes place while the polysaccharide chains are usually attached to a proteoglycan core protein, Cells also will assemble GAG chains on beta-D-xylosides containing hydrophobic aglycones, In order to evaluate the relationship of the structure of the sugar to priming activity of the glycoside, we synthesized beta-D-xyloside analogs in which the hydroxyls were substituted with hydrogen, fluorine, -O-methyl, amino, -O-isopropyl, and -O-benzyl groups, Epimers at the 2-, 3-, and 8-position of xylose also were made, Their ability to prime GAGs was tested in Chinese hamster ovary cells by measuring (SO4)-S-35 incorporation into polysaccharide chains and by assaying the transfer of galactose to the xylosides by galactosyltransferase I (UDP-D-galactose:xylose beta 1-4-galactosyltransferase) in vitro, All of the analogs failed to act as primers of GAGs in vivo and as substrates in vitro with the following exceptions, Substitution of 2-OH and 3-OH with -OCH3 were active at high concentration (1 mM), but the deoxygenated derivatives were inactive, Efficient priming also occurred on a derivative with fluorine instead of the 3-OH group, suggesting that the oxygen atoms at C-2 and C-3 were involved as hydrogen bond accepters, Methylated and deoxy analogs at C-4 were inactive, due to the loss of the acceptor hydroxyl group, Interestingly, benzyl-beta-D-threo-pentopyranos-4-uloside (4-keto derivative) and benzyl-4-methyl-beta-D-xyloside, with a methyl group in place of an axial hydrogen at C-4, primed GAG chains, Priming by these unusual xylosides suggests the possibility of designing inhibitors of GAG synthesis based on xyloside analogs with reactive groups in key positions.	UNIV ALABAMA,SCH MED,DEPT BIOCHEM & MOL GENET,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NCI NIH HHS [CA46462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAME KJ, 1989, J BIOL CHEM, V264, P8059; DEBRUYN A, 1975, CARBOHYD RES, V41, P290, DOI 10.1016/S0008-6215(00)87027-5; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; FRITZ TA, 1994, J BIOL CHEM, V269, P300; GAHKOKIDZE AM, 1946, CHEM ABSTR, V40, P4673; GAHKOKIDZE AM, 1945, ZH OBSHCH KHIM, V15, P530; GAREGG PJ, 1960, ACTA CHEM SCAND, V14, P12; HAM RG, 1965, P NATL ACAD SCI USA, V53, P288, DOI 10.1073/pnas.53.2.288; HELTING T, 1969, J BIOL CHEM, V244, P2790; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; INOUE S, 1993, J BIOL CHEM, V268, P5894; IZUMI J, 1994, J BIOCHEM-TOKYO, V116, P524, DOI 10.1093/oxfordjournals.jbchem.a124556; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JEANLOZ R, 1948, J AM CHEM SOC, V70, P4055, DOI 10.1021/ja01192a026; KANIE O, 1993, CARBOHYD RES, V243, P139, DOI 10.1016/0008-6215(93)84087-M; KHAN SH, 1993, J BIOL CHEM, V268, P2468; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOLSET SO, 1990, BIOCHEM J, V265, P637, DOI 10.1042/bj2650637; Levene PA, 1929, J BIOL CHEM, V83, P803; LINKER T, 1993, CARBOHYD RES, V245, P323, DOI 10.1016/0008-6215(93)80081-O; LOWARY TL, 1993, CARBOHYD RES, V249, P163, DOI 10.1016/0008-6215(93)84068-H; LOWARY TL, 1994, CARBOHYD RES, V251, P33, DOI 10.1016/0008-6215(94)84275-2; LOWARY TL, 1994, CARBOHYD RES, V256, P257, DOI 10.1016/0008-6215(94)84212-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; MANZI A, 1995, J BIOL CHEM, V270, P9154, DOI 10.1074/jbc.270.16.9154; NAKAMURA T, 1994, BIOCHEM J, V304, P731, DOI 10.1042/bj3040731; OGAWA S, 1995, CARBOHYD RES, V271, P197, DOI 10.1016/0008-6215(95)00083-6; OKAYAMA M, 1973, J BIOCHEM-TOKYO, V74, P1069; OVEREND WG, 1950, J CHEM SOC, P671, DOI 10.1039/jr9500000671; PALCIC MM, 1989, J BIOL CHEM, V264, P17174; RIO S, 1991, CARBOHYD RES, V219, P71, DOI 10.1016/0008-6215(91)89043-F; ROBINSON HC, 1975, BIOCHEM J, V148, P25, DOI 10.1042/bj1480025; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; ROSENFELD L, 1976, CARBOHYD RES, V46, P155, DOI 10.1016/S0008-6215(00)83542-9; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SARKAR AK, 1995, P NATL ACAD SCI USA, V92, P3323, DOI 10.1073/pnas.92.8.3323; SCHWARTZ NB, 1974, P NATL ACAD SCI USA, V71, P4047, DOI 10.1073/pnas.71.10.4047; SHIBATA S, 1995, J BIOL CHEM, V270, P13794, DOI 10.1074/jbc.270.23.13794; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; WERMUTH B, 1982, EUR J BIOCHEM, V127, P279, DOI 10.1111/j.1432-1033.1982.tb06867.x; ZHANG L, 1995, J BIOL CHEM, V270, P12557, DOI 10.1074/jbc.270.21.12557; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; ZHANG LJ, 1995, J BIOL CHEM, V270, P27127, DOI 10.1074/jbc.270.45.27127	50	43	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19159	19165		10.1074/jbc.271.32.19159	http://dx.doi.org/10.1074/jbc.271.32.19159			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702593	hybrid			2022-12-27	WOS:A1996VB68400027
J	Magnuson, P; Lehnherr, H; Mukhopadhyay, G; Yarmolinsky, MB				Magnuson, P; Lehnherr, H; Mukhopadhyay, G; Yarmolinsky, MB			Autoregulation of the plasmid addiction operon of bacteriophage P1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSOR-OPERATOR COMPLEX; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; ARC REPRESSOR; F-PLASMID; SECONDARY-STRUCTURE; CRYSTAL-STRUCTURE; CLONING VECTORS; GEL RETARDATION; DNA RECOGNITION	The P1 plasmid addiction operon increases the apparent stability of a plasmid that carries it by killing plasmid-free (cured) segregants. The operon consists of a gene encoding an endotoxin responsible for death on curing (dec), preceded by a gene encoding a relatively unstable antidote that can prevent host death (phd). When the copy number of the operon was increased, expression of a lacZ reporter fused to the promoter of the operon decreased, indicating that expression of the operon was stabilized by an autoregulatory circuit. Transcription of the lacZ reporter was repressed about 10-fold when phd, without dec, was expressed from an exogenous promoter, DNase I footprinting showed that Phd binds a perfect 10-base pair palindromic DNA sequence and, at higher concentrations, an adjacent, imperfect palindrome. The palindromic sites are located between the -10 region of the putative promoter and the start codon of phd. Electrophoretic mobility of DNA containing the promoter region was retarded in the presence of Phd and further retarded in the presence of Phd and Dec. When doc was co-expressed with phd, repression of the lacZ fusion was enhanced more than 100-fold. Thus, both products of the addiction operon participate in its autoregulation.	NCI,BIOCHEM LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								Arber W., 1983, LAMBDA, P433; BERNARD P, 1991, MOL GEN GENET, V226, P297, DOI 10.1007/BF00273616; BOWIE JU, 1990, J MOL BIOL, V211, P5, DOI 10.1016/0022-2836(90)90004-6; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BROWN BM, 1993, BIOCHEMISTRY-US, V32, P1354, DOI 10.1021/bi00056a022; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLERGET M, 1991, NEW BIOL, V3, P780; DAVIS TL, 1992, MOL MICROBIOL, V6, P1981, DOI 10.1111/j.1365-2958.1992.tb01371.x; DEFEYTER R, 1989, MOL GEN GENET, V218, P481, DOI 10.1007/BF00332413; EBERL L, 1994, MOL MICROBIOL, V12, P131, DOI 10.1111/j.1365-2958.1994.tb01002.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HASUNUMA K, 1977, MOL GEN GENET, V154, P225, DOI 10.1007/BF00571277; HOCHSCHILD A, 1991, METHOD ENZYMOL, V208, P343; IIDA S, 1980, MOL GEN GENET, V177, P261, DOI 10.1007/BF00267437; JENSEN RB, 1995, MOL MICROBIOL, V17, P205, DOI 10.1111/j.1365-2958.1995.mmi_17020205.x; Johnson EP, 1996, J BACTERIOL, V178, P1420, DOI 10.1128/jb.178.5.1420-1429.1996; LANE D, 1992, MICROBIOL REV, V56, P509, DOI 10.1128/MMBR.56.4.509-528.1992; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEHNHERR H, 1993, J MOL BIOL, V233, P414, DOI 10.1006/jmbi.1993.1521; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NORDSTROM K, 1989, ANNU REV GENET, V23, P37, DOI 10.1146/annurev.genet.23.1.37; PHILLIPS SEV, 1989, NATURE, V341, P711, DOI 10.1038/341711a0; PRENTKI P, 1977, MOL GEN GENET, V152, P71, DOI 10.1007/BF00264942; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; ROBERTS RC, 1993, J BIOL CHEM, V268, P27109; ROSNER JL, 1972, VIROLOGY, V48, P679, DOI 10.1016/0042-6822(72)90152-3; RUIZECHEVARRIA MJ, 1991, MOL MICROBIOL, V5, P2685, DOI 10.1111/j.1365-2958.1991.tb01977.x; RUIZECHEVARRIA MJ, 1991, MOL GEN GENET, V225, P355, DOI 10.1007/BF00261674; SALMON MA, 1994, MOL GEN GENET, V244, P530, DOI 10.1007/BF00583904; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Silhavy T. J., 1984, EXPT GENE FUSIONS; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; TAM JE, 1989, J BACTERIOL, V171, P2353, DOI 10.1128/jb.171.5.2353-2360.1989; TAM JE, 1989, MOL GEN GENET, V219, P26, DOI 10.1007/BF00261153; TSUCHIMOTO S, 1993, MOL GEN GENET, V237, P81, DOI 10.1007/BF00282787; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	44	60	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18705	18710		10.1074/jbc.271.31.18705	http://dx.doi.org/10.1074/jbc.271.31.18705			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702525	hybrid			2022-12-27	WOS:A1996VB68300063
J	Schissel, SL; Schuchman, EH; Williams, KJ; Tabas, I				Schissel, SL; Schuchman, EH; Williams, KJ; Tabas, I			Zn2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; NIEMANN-PICK DISEASE; MOUSE PERITONEAL-MACROPHAGES; NEUTRAL SPHINGOMYELINASE; NUCLEOTIDE-SEQUENCE; MISSENSE MUTATION; LYSOSOMAL-ENZYMES; RAT-BRAIN; CHOLESTEROL; ACCUMULATION	Mammalian sphingomyelinases have been implicated in many important physiological and pathophysiological processes. Although several mammalian sphingomyelinases have been identified and studied, one of these, an acidic Zn2+-stimulated sphingomyelinase (Zn-SMase) originally found in fetal bovine serum, has received little attention since its first and only report 7 years ago. We now show that Zn-SMase activity is secreted by human and murine macrophages, human skin fibroblasts, microglial cells, and several other cells in culture and is markedly up-regulated during differentiation of human monocytes to macrophages. Remarkably, peritoneal macrophages from mice in which the acid SMase gene had been disrupted by homologous recombination secreted no Zn-SMase activity, indicating that this enzyme and the intracellular lysosomal SMase, which is Zn-independent, arise from the same gene, Furthermore, skin fibroblasts from patients with types A and B Niemann-Pick disease, which are known to lack lysosomal SMase activity, also lack Zn-SMase activity in their conditioned media. Chinese hamster ovary cells stably transfected with a cDNA encoding lysosomal SMase massively overexpress both cellular lysosomal SMase and secreted Zn-SMase activities. Thus, Zn-SMase arises independently of alternative splicing, suggesting a post-translational process. In summary, a wide variety of cell types secrete Zn-SMase activity, which arises from the same gene as lysosomal SMase. This secreted enzyme may play roles in physiological and pathophysiological processes involving extracellular sphingomyelin hydrolysis.	COLUMBIA UNIV, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT ANAT & CELL BIOL, NEW YORK, NY 10032 USA; CUNY MT SINAI SCH MED, DEPT HUMAN GENET, NEW YORK, NY 10029 USA; THOMAS JEFFERSON UNIV, DIV ENDOCRINOL DIABET & METAB DIS, DORRANCE H HAMILTON RES LABS, PHILADELPHIA, PA 19107 USA	Columbia University; Columbia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Jefferson University				Williams, Kevin Jon/0000-0002-0000-2159	NHLBI NIH HHS [HL39703, HL21006] Funding Source: Medline; NICHD NIH HHS [HD28607] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD028607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028607] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039703, P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD TY, 1985, J LIPID RES, V26, P1160; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BAUER J, 1994, J NEUROSCI RES, V38, P365, DOI 10.1002/jnr.490380402; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BOTTALICO LA, 1993, J BIOL CHEM, V268, P8569; Brady R. O., 1983, METABOLIC BASIS INHE, P831; CHATTERJEE S, 1991, METHOD ENZYMOL, V197, P540; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; DONANGELO CM, 1981, CLIN CHIM ACTA, V113, P201, DOI 10.1016/0009-8981(81)90154-6; FOGELMAN AM, 1981, J LIPID RES, V22, P1131; Frederickson C. J., 1994, Biological Signals, V3, P127; GATT S, 1978, J NEUROCHEM, V31, P547, DOI 10.1111/j.1471-4159.1978.tb02671.x; GUYTON JR, 1996, J LIPID RES, V16, P4; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HARTUNG HP, 1992, J NEUROIMMUNOL, V40, P197, DOI 10.1016/0165-5728(92)90134-7; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HEINEMANN T, 1994, J LIPID RES, V35, P2200; HOFF HF, 1985, ANN NY ACAD SCI, V454, P183, DOI 10.1111/j.1749-6632.1985.tb11857.x; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; KAKAJIMA K, 1989, BIOMED RES, V10, P411; KHOO JC, 1989, BIOCHIM BIOPHYS ACTA, V1012, P215, DOI 10.1016/0167-4889(89)90099-2; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; LEVADE T, 1986, J CLIN CHEM CLIN BIO, V24, P205; LEVRAN O, 1991, P NATL ACAD SCI USA, V88, P3748, DOI 10.1073/pnas.88.9.3748; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAROUDAS A, 1988, BIOPHYS CHEM, V32, P257, DOI 10.1016/0301-4622(88)87012-1; MARUYAMA EN, 1989, J NEUROCHEM, V52, P611, DOI 10.1111/j.1471-4159.1989.tb09163.x; MENDIS S, 1989, BIOL TRACE ELEM RES, V22, P251, DOI 10.1007/BF02916613; Menkin V, 1934, AM J PATHOL, V10, P193; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; NIEVELSTEIN PFEM, 1991, ARTERIOSCLER THROMB, V11, P1795, DOI 10.1161/01.ATV.11.6.1795; Nolan C M, 1987, Adv Exp Med Biol, V225, P199; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OKWU AK, 1994, J LIPID RES, V35, P644; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; PORN MI, 1995, BIOCHEM J, V308, P269; SCHISSEL SL, 1994, CIRCULATION, V90, P403; SCHUCHMAN EH, 1992, GENOMICS, V12, P197, DOI 10.1016/0888-7543(92)90366-Z; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; Skiba PJ, 1996, J BIOL CHEM, V271, P13392, DOI 10.1074/jbc.271.23.13392; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SMITH EB, 1979, ADV EXP MED BIOL, V115, P245; Smith H C, 1993, Semin Cell Biol, V4, P267, DOI 10.1006/scel.1993.1032; SPENCE MW, 1993, ADV LIPID RES, V26, P3; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; SRIPADA PK, 1987, J LIPID RES, V28, P710; SVENSSON M, 1993, BRAIN RES BULL, V30, P499, DOI 10.1016/0361-9230(93)90284-I; TABAS I, 1993, J BIOL CHEM, V268, P20419; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; Takahashi Tsutomu, 1992, Human Mutation, V1, P70, DOI 10.1002/humu.1380010111; TAKEDA A, 1994, BRAIN RES, V658, P252, DOI 10.1016/S0006-8993(09)90032-4; TAPPER H, 1992, BIOCHEM J, V281, P245, DOI 10.1042/bj2810245; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; XU XX, 1991, J BIOL CHEM, V266, P24849	60	246	266	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18431	18436		10.1074/jbc.271.31.18431	http://dx.doi.org/10.1074/jbc.271.31.18431			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702487	hybrid			2022-12-27	WOS:A1996VB68300025
J	Valiquette, M; Vu, HK; Yue, SY; Wahlestedt, C; Walker, P				Valiquette, M; Vu, HK; Yue, SY; Wahlestedt, C; Walker, P			Involvement of trp-284, val-296, and val-297 of the human delta-opioid receptor in binding of delta-selective ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTINOCICEPTION; PLASMID; CDNA; RATS	Given the high homology in amino acid sequence between the delta-opioid receptor and the two other types (mu and kappa), distinct residues in this receptor may confer its selectivity to some ligands, In order to identify molecular determinants in the human delta receptor responsible for the selectivity of delta-selective ligands, two different delta/mu chimeras were constructed, In the first one, the delta sequence from the top of transmembrane 5 to the C terminus was replaced by the equivalent Ir sequence, and in the second one, 13 consecutive residues in the third extracellular loop region of the delta receptor were replaced by the mu counterpart, These two chimeras retained the ability to bind the nonselective bremazocine but completely lost the ability to bind different delta-selective ligands, These results suggested that the region of the third extracellular loop of the delta receptor is crucial for the type selectivity, Furthermore, an alanine scan was performed by site-directed mutagenesis of 20 amino acids located in or proximal to the third extracellular loop, Among all the point mutations, only mutations of Trp-284, Val-296, or Val-297 significantly decreased the binding of delta-selective ligands tested, Moreover, combined mutation of Trp-284, Val-296, and Val-297 considerably decreased the affinities of the receptor for delta-selective ligands compared with the single point mutations, These findings suggest that Trp-284, Val-296, and Val-297 are crucial residues involved in the delta receptor type selectivity.	ASTRA PAIN RES UNIT,MONTREAL,PQ H4P 2R2,CANADA				Wahlestedt, Claes/A-7039-2009					Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Befort K, 1996, J BIOL CHEM, V271, P10161, DOI 10.1074/jbc.271.17.10161; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COWAN A, 1988, J PHARMACOL EXP THER, V246, P950; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Ellison Neil M., 1993, P185; FUKUDA K, 1995, J BIOL CHEM, V270, P6702, DOI 10.1074/jbc.270.12.6702; Heyman J S, 1986, NIDA Res Monogr, V75, P442; HEYMAN JS, 1987, BRAIN RES, V420, P100, DOI 10.1016/0006-8993(87)90244-7; HEYMAN JS, 1988, TRENDS PHARMACOL SCI, V9, P134, DOI 10.1016/0165-6147(88)90195-2; HJORTH SA, 1995, MOL PHARMACOL, V47, P1089; Jaffe JH, 1990, PHARMACOL BASIS THER, P485; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KNAPP RJ, 1994, LIFE SCI, V54, pPL463, DOI 10.1016/0024-3205(94)90138-4; KONG HY, 1993, J BIOL CHEM, V268, P23055; LUTZ RA, 1992, J RECEPTOR RES, V12, P267, DOI 10.3109/10799899209074796; MALDONADO R, 1992, NEUROPHARMACOLOGY, V31, P1231, DOI 10.1016/0028-3908(92)90051-P; MANSSON E, 1994, BIOCHEM BIOPH RES CO, V202, P1431, DOI 10.1006/bbrc.1994.2091; MENG F, 1995, J BIOL CHEM, V270, P12730, DOI 10.1074/jbc.270.21.12730; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; PFEIFFER A, 1986, SCIENCE, V233, P774, DOI 10.1126/science.3016896; PORTOGHESE PS, 1993, HDB EXP PHARM, V104, P276; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SIMON EJ, 1991, MED RES REV, V11, P357, DOI 10.1002/med.2610110402; UNTERWALD E, 1987, EUR J PHARMACOL, V133, P275, DOI 10.1016/0014-2999(87)90023-9; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; Wang WW, 1995, P NATL ACAD SCI USA, V92, P12436, DOI 10.1073/pnas.92.26.12436	29	98	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18789	18796		10.1074/jbc.271.31.18789	http://dx.doi.org/10.1074/jbc.271.31.18789			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702536	hybrid			2022-12-27	WOS:A1996VB68300074
J	King, APJ; Tseng, MJ; Logsdon, CD; Billestrup, N; CarterSu, C				King, APJ; Tseng, MJ; Logsdon, CD; Billestrup, N; CarterSu, C			Distinct cytoplasmic domains of the growth hormone receptor are required for glucocorticoid- and phorbol ester-induced decreases in growth hormone (GH) binding - These domains are different from that reported for GH-induced receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; OSTEOBLAST-LIKE CELLS; RAT INSULINOMA CELLS; TRANSFERRIN RECEPTOR; FACTOR-I; PLASMA-MEMBRANE; DOWN-REGULATION; EGF RECEPTOR; 3T3-F442A FIBROBLASTS; MEDIATED ENDOCYTOSIS	Glucocorticoids inhibit growth in children and antagonize the growth-promoting action of GH in peripheral tissues, Recently, they have been shown to decrease GH binding, In this study we examine the molecular mechanisms by which the glucocorticoid dexamethasone (HEX) and the phorbol ester phorbol myristate acetate (PMA) decrease cellular GH binding, In 3T3-F442A fibroblasts, DEX and PMA decrease the number of GH receptors (GHRs) capable of binding GH by 50% (t(1/2) = 6 h) and 70% (t(1/2) = 15 min), respectively, Neither appear to de crease the total number of cellular GHR, Rather, they appear to redistribute GHRs away from the plasma membrane or inactivate GHRs on the membrane such that they cannot bind GH, DEX and PIMA also decrease GH-induced tyrosyl phosphorylation of GHR and JAK2 with a magnitude and time course correlating with that of inhibition of GH binding, DEX- and PMA-induced reductions of GH binding are also observed in a Chinese hamster ovary (CHO) cell line stably transfected with a rat liver GHR cDNA, further arguing that DEX and PMA act post-translationally on GHR, Using mutant GHRs stably expressed in CHO cells, amino acids 455-506 and tyrosines 333 and/or 338 of GHR were shown to be required for maximal DEX-induced inhibition of GH binding, DEX decreased GH binding to a GHR mutant F346A, which is reported to be deficient in ligand-induced internalization, suggesting that HEX decreases GH binding by a mechanism distinct from that of ligand-induced GHR internalization. PMA reduced GH binding to CHO cells expressing all GHR mutants tested, However, deletion of the C terminal 132 amino acids decreased this effect, suggesting that at least one component of PMA action on GHR requires amino acids 507-658. These data suggest that distinct pathways mediate the effects of GH, DEX, and PMA on GHR number in the plasma membrane.	UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; HAGEDORN RES LAB,DK-2820 GENTOFTE,DENMARK	University of Michigan System; University of Michigan; Novo Nordisk; Hagedorn Research Institute				Billestrup, Nils/0000-0002-4968-8067; King, Anthony/0000-0002-0764-9625	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008322] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48283] Funding Source: Medline; NIGMS NIH HHS [GM08322] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; BACKER JM, 1991, BIOCHEM PHARMACOL, V41, P1267, DOI 10.1016/0006-2952(91)90097-O; Becks H, 1944, ENDOCRINOLOGY, V34, P311, DOI 10.1210/endo-34-5-311; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; CAPPS GG, 1989, J CELL BIOL, V108, P1317, DOI 10.1083/jcb.108.4.1317; CARTERSU C, 1985, J BIOL CHEM, V260, P1091; CARTERSU C, 1985, AM J PHYSIOL, V248, pE215, DOI 10.1152/ajpendo.1985.248.2.E215; CARTERSU C, 1987, AM J PHYSIOL, V252, pE441, DOI 10.1152/ajpendo.1987.252.4.E441; CHEN TL, 1991, CALCIFIED TISSUE INT, V48, P278, DOI 10.1007/BF02556380; DELANY AM, 1995, ENDOCRINOLOGY, V136, P4776, DOI 10.1210/en.136.11.4776; EDEN S, 1982, ENDOCRINOLOGY, V111, P1505, DOI 10.1210/endo-111-5-1505; FALLON RJ, 1986, J BIOL CHEM, V261, P5081; FEARN JC, 1985, CELL, V40, P991, DOI 10.1016/0092-8674(85)90359-9; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; GORIN E, 1984, ENDOCRINOLOGY, V115, P467, DOI 10.1210/endo-115-2-467; GORIN E, 1985, ENDOCRINOLOGY, V116, P1796, DOI 10.1210/endo-116-5-1796; HORNER HC, 1987, J BIOL CHEM, V262, P17696; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; KING APJ, 1995, ENDOCRINOLOGY, V136, P4796, DOI 10.1210/en.136.11.4796; LEE LS, 1978, SCIENCE, V202, P313, DOI 10.1126/science.308698; LEE PDK, 1993, P SOC EXP BIOL MED, V204, P4; LILES WC, 1986, J BIOL CHEM, V261, P5307; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LOGSDON CD, 1984, BIOCHEM J, V223, P893, DOI 10.1042/bj2230893; LUO JM, 1989, ENDOCRINOLOGY, V125, P165, DOI 10.1210/endo-125-1-165; MADDON PJ, 1988, CELL, V54, P865, DOI 10.1016/S0092-8674(88)91241-X; MAY WS, 1987, J BIOL CHEM, V262, P16710; MCCARTHY TL, 1990, ENDOCRINOLOGY, V126, P1569, DOI 10.1210/endo-126-3-1569; MCCLAIN DA, 1988, J BIOL CHEM, V263, P8904; MCGRAW TE, 1988, J CELL BIOL, V106, P1061, DOI 10.1083/jcb.106.4.1061; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; MOLDRUP A, 1991, J BIOL CHEM, V266, P17441; MURPHY LJ, 1984, ENDOCRINOLOGY, V115, P1625, DOI 10.1210/endo-115-4-1625; OKADA S, 1995, 77 ANN M END SOC JUN, P80; OKAZAKI R, 1994, ENDOCRINOLOGY, V134, P126, DOI 10.1210/en.134.1.126; PRICE WA, 1992, ENDOCRINOLOGY, V130, P1424, DOI 10.1210/en.130.3.1424; QUAIFE C, 1986, DEV BIOL, V118, P549, DOI 10.1016/0012-1606(86)90025-4; ROBINSON JM, 1987, J CELL BIOL, V105, P417, DOI 10.1083/jcb.105.1.417; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; ROUPAS P, 1987, ENDOCRINOLOGY, V120, P2158, DOI 10.1210/endo-120-5-2158; ROUPAS P, 1988, MOL CELL ENDOCRINOL, V57, P93, DOI 10.1016/0303-7207(88)90037-8; RYDZIEL S, 1995, ENDOCRINOLOGY, V136, P4254, DOI 10.1210/en.136.10.4254; SADEGHI H, 1990, MOL ENDOCRINOL, V4, P1799, DOI 10.1210/mend-4-12-1799; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SUZUKI K, 1990, J BIOL CHEM, V265, P11320; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; TSENG MJ, 1995, J BIOL CHEM, V270, P18858, DOI 10.1074/jbc.270.32.18858; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VANDERKUUR JA, 1995, J BIOL CHEM, V270, P21738, DOI 10.1074/jbc.270.37.21738; WEYER B, 1985, MOL CELL ENDOCRINOL, V41, P85, DOI 10.1016/0303-7207(85)90145-5; ZERIAL M, 1987, EMBO J, V6, P2661, DOI 10.1002/j.1460-2075.1987.tb02557.x	54	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18088	18094		10.1074/jbc.271.30.18088	http://dx.doi.org/10.1074/jbc.271.30.18088			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663346	hybrid			2022-12-27	WOS:A1996UY93500075
J	Zelicof, A; Protopopov, V; David, D; Lin, XY; Lustgarten, V; Gerst, JE				Zelicof, A; Protopopov, V; David, D; Lin, XY; Lustgarten, V; Gerst, JE			Two separate functions are encoded by the carboxyl-terminal domains of the yeast cyclase-associated protein and its mammalian homologs - Dimerization and actin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE ADENYLYL CYCLASE; SACCHAROMYCES-CEREVISIAE; RAS PROTEINS; CAP; IDENTIFICATION; PROFILIN; CLONING; COMPLEX; FAMILY	The yeast adenylyl cyclase-associated protein, CAP, was identified as a component of the RAS-activated cyclase complex. CAP consists of two functional domains separated by a proline-rich region, One domain, which localizes to the amino terminus, mediates RAS signaling through adenylyl cyclase, while a domain at the carboxyl terminus is involved in the regulation of cell growth and morphogenesis. Recently, the carboxyl terminus of yeast CAP was shown to sequester actin, but whether this function has been conserved, and is the sole function of this domain, is unclear, Here, we demonstrate that the carboxyl-terminal domains of CAP and CAP homologs have two separate functions, We show that carboxyl-terminals of both yeast CAP and a mammalian CAP homolog, MCH1, bind to actin, We also show that this domain contains a signal for dimerization, allowing both CAP and MCH1 to form homodimers and heterodimers. The properties of actin binding and dimerization are mediated by separate regions on the carboxyl terminus; the last 27 amino acids of CAP being critical for actin binding, Finally, we present evidence that links a segment of the proline rich region of CAP to its localization in yeast, Together, these results suggest that all three domains of CAP proteins are functional.	WEIZMANN INST SCI,DEPT MOLEC GENET,IL-76100 REHOVOT,ISRAEL; CUNY MT SINAI SCH MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10029	Weizmann Institute of Science; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; AMBERG DC, 1995, NAT STRUCT BIOL, V2, P28, DOI 10.1038/nsb0195-28; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; COUVE A, 1994, J BIOL CHEM, V269, P23391; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; FINKEL T, 1994, P NATL ACAD SCI USA, V91, P1510, DOI 10.1073/pnas.91.4.1510; FREEMAN NL, 1995, J BIOL CHEM, V270, P5680, DOI 10.1074/jbc.270.10.5680; Freeman NL, 1996, MOL CELL BIOL, V16, P548; Geiger B, 1989, CURR OPIN CELL BIOL, V1, P103, DOI 10.1016/S0955-0674(89)80045-6; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; GIESELMANN R, 1992, FEBS LETT, V298, P149, DOI 10.1016/0014-5793(92)80043-G; KAWAMUKAI M, 1992, MOL BIOL CELL, V3, P167, DOI 10.1091/mbc.3.2.167; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; MATVIW H, 1992, MOL CELL BIOL, V12, P5033, DOI 10.1128/MCB.12.11.5033; Miller J.H., 1972, EXPT MOL GENETICS; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Rose MD., 1990, METHODS YEAST GENETI; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; VOJTEK AB, 1993, J CELL SCI, V105, P777; WANG J, 1992, MOL CELL BIOL, V12, P4937, DOI 10.1128/MCB.12.11.4937; WANG J, 1993, MOL CELL BIOL, V13, P4087, DOI 10.1128/MCB.13.7.4087; YU G, 1994, J CELL SCI, V107, P1671; ZELICOF A, 1993, J BIOL CHEM, V268, P13448	32	53	54	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18243	18252		10.1074/jbc.271.30.18243	http://dx.doi.org/10.1074/jbc.271.30.18243			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663401	hybrid			2022-12-27	WOS:A1996UY93500098
J	Lin, YL; Chen, C; Keshav, KF; Winchester, E; Dutta, A				Lin, YL; Chen, C; Keshav, KF; Winchester, E; Dutta, A			Dissection of functional domains of the human DNA replication protein complex replication protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; POLYMERASE-ALPHA-PRIMASE; SIMIAN VIRUS-40 DNA; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; T-ANTIGEN; SUBUNIT; INVITRO; PHOSPHORYLATION; EXTRACTS	Replication protein A (RPA) is a mammalian single-stranded DNA binding factor essential for DNA replication, repair, and recombination. It is composed of three subunits of 70, 34, and 13 kDa (Rpa1, Rpa2, and Rpa3, respectively), Deletion mapping of the Rpa2 subunit identified the domain required for interaction with Rpa1 and Rpa3 which does not include the N-terminal domain that is phosphorylated during S phase, Deletion mapping of Rpa1 defined three domains. The C-terminal third of the Rpa1 polypeptide binds Rpa2 which itself forms a bridge between Rpa1 and Rpa3, The N-terminal third of Rpa1 bound single-stranded DNA under low stringency conditions only (0.1 M NaCl), while a central domain binds to single-stranded DNA under both low and high stringency conditions (0.5 M NaCl), Binding to p53 requires the N-terminal third of Rpa1 with some contribution from the C-terminal third. The evolutionarily conserved putative zinc finger near the C terminus of Rpa1 was not required for binding to single-stranded DNA, Rpa2, or p53, However, all three subdomains of Rpa1 and the zinc finger were essential for supporting DNA replication in vitro. These experiments are a first step toward defining peptide components responsible for the many functions of the RPA protein complex.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV MOLEC ONCOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital			Chen, Clark C/C-8714-2013; Dutta, Anindya/P-3203-2016	Chen, Clark C/0000-0001-6258-9277; Dutta, Anindya/0000-0002-4319-0073	NCI NIH HHS [R01 CA060499-02S1, CA60499, R01 CA060499] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KESHAV KF, 1995, MOL CELL BIOL, V15, P3119; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; MELENDY T, 1993, J BIOL CHEM, V268, P3389; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; UMBRICHT CB, 1993, J BIOL CHEM, V268, P6131; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	30	76	77	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17190	17198		10.1074/jbc.271.29.17190	http://dx.doi.org/10.1074/jbc.271.29.17190			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663296	hybrid			2022-12-27	WOS:A1996UX94300034
J	Wang, ZY; Wang, XL; Rana, TM				Wang, ZY; Wang, XL; Rana, TM			Protein orientation in the Tat-TAR complex determined by psoralen photocross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANS-ACTIVATOR GENE; LONG TERMINAL REPEAT; HIV-1 TAT; MESSENGER-RNA; TYPE-1; ELEMENT; LOOP; TRANSCRIPTION; SEQUENCE	Replication of human immunodeficiency virus type 1 (HIV-1) requires specific interactions of Tat protein with the trans-activation responsive region (TAR) RNA, a 59-base stem-loop structure located at the 5'-end of all HIV mRNAs. We have used a new method based on psoralen photochemistry to identify a specific contact between a fragment of Tat protein (residues 38-72) and TAR RNA. We synthesized a 35 amino acid fragment containing arginine-rich RNA-binding domain of Tat (38-72), and replaced Arg(57) With Cys to introduce a unique thiol group (SH) in our model peptide, A psoralen derivative, which can react with thiol groups, was synthesized and used for specific chemical modification of Cys(57)-Tat-(38-72). We used this psoralen-Tat conjugate (psoralen-Cys(57)-Tat-(38-72)) to form a specific complex with TAR RNA, Upon near-ultraviolet irradiation (360 nm), this synthetic psoralen-peptide cross-linked to a single site in the TAR RNA sequence. The RNA-protein complex was purified and the cross-link site on TAR RNA was determined by RNA sequencing, which revealed that Cys(57) Of Tat is close to U31 of TAR RNA, Our results provide high-resolution proximity and orientation information about Tat-TAR complex, Such psoralen-peptide conjugates provide a new class of probes for sequence-specific protein-nucleic acid interactions and could be used to selectively control gene expression or to induce site-directed mutations.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,MOL BIOL & BIOCHEM GRAD PROGRAM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick					NIAID NIH HHS [AI 34785] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034785] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; ACHARIAS M, 1995, P NATL AC SCI US, V92, P6052; BAYER P, 1995, J MOL BIOL, V247, P529, DOI 10.1016/S0022-2836(05)80133-0; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DELLING U, 1991, P NATL ACAD SCI USA, V88, P6234, DOI 10.1073/pnas.88.14.6234; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; GATIGNOL A, 1989, P NATL ACAD SCI USA, V86, P7828, DOI 10.1073/pnas.86.20.7828; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; NEENHOLD HR, 1995, BIOCHEMISTRY-US, V34, P6303, DOI 10.1021/bi00019a007; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SHELINE CT, 1991, GENE DEV, V5, P2508, DOI 10.1101/gad.5.12b.2508; SIDEROVSKI DP, 1992, NUCLEIC ACIDS RES, V20, P5311, DOI 10.1093/nar/20.20.5311; TAN RY, 1992, BIOCHEMISTRY-US, V31, P10288, DOI 10.1021/bi00157a016; WANG ZY, 1995, J AM CHEM SOC, V117, P5438, DOI 10.1021/ja00125a002; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WU F, 1991, GENE DEV, V5, P2128, DOI 10.1101/gad.5.11.2128	31	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					16995	16998		10.1074/jbc.271.29.16995	http://dx.doi.org/10.1074/jbc.271.29.16995			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663586	hybrid			2022-12-27	WOS:A1996UX94300004
J	Meisinger, C; Zeschnigk, C; Grothe, C				Meisinger, C; Zeschnigk, C; Grothe, C			In vivo and in vitro effect of glucocorticoids on fibroblast growth factor (FGF)-2 and FGF receptor 1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED CHROMAFFIN CELLS; MOLECULAR-WEIGHT FORMS; CENTRAL-NERVOUS-SYSTEM; ADULT-RAT BRAIN; ADRENAL-GLAND; NEURONAL DIFFERENTIATION; PC12 CELLS; BASIC FGF; NEURITE OUTGROWTH; BFGF	In order to clarify the physiological function of fibroblast growth factor (FGF-2) in the adrenal medulla the regulation of FGF-2 and FGF receptor 1 (FGFR1) was studied in vitro and in vivo in response to glucocorticoids. To assess the effects of glucocorticoids, in vivo extracts of adrenal medulla and adrenal cortex were analyzed by RNase protection assay and Western blot analysis, PC12 cells were chosen as a model system to study the effects of glucocorticoids in vitro. In PC12 cells, dexamethasone (DEX) was found to stimulate dramatically the expression of both FGF-S mRNA and protein. Western blot analysis revealed that exclusively the 21-kDa FGF-8 isoform was enhanced. In contrast to the FGF-2 mRNA level FGFR1 was not affected by treatment with glucocorticoids. In vivo FGF-2 mRNA level and 21-kDa FGF-2 isoform level are significantly enhanced in the adrenal medulla 24 h after DEX injection. In vivo application of DEX leads to an increase of the medullary and cortical FGFR1 transcript levels, Glucocorticoid effects on FGF-2 expression were not Found in adrenal cortex, heart, skeletal muscle, and kidney, respectively, in vivo and in L6 rat myoblasts in vitro. In addition to adrenal medullary cells glucocorticoids elevated the FGF-2 mRNA and protein level also in vivo in the brain and in, vitro in immortalized Schwann cells. The present results suggest that the 21-kDa FGF-8 isoform mediates a physiological function specific for neuronal tissue which is modulated by glucocorticoids.	UNIV FREIBURG,INST ANAT 2,D-79104 FREIBURG,GERMANY	University of Freiburg			Meisinger, Chris/J-1110-2014	Meisinger, Chris/0000-0002-8326-3548				Anderson D J, 1993, Curr Opin Neurobiol, V3, P8, DOI 10.1016/0959-4388(93)90028-W; Baird Andrew, 1994, Current Opinion in Neurobiology, V4, P78, DOI 10.1016/0959-4388(94)90035-3; BARBANY G, 1992, EUR J NEUROSCI, V4, P396, DOI 10.1111/j.1460-9568.1992.tb00888.x; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BLOTTNER D, 1989, EUR J NEUROSCI, V1, P471, DOI 10.1111/j.1460-9568.1989.tb00353.x; Bohlen P., 1989, MACROPHAGE DERIVED C, V1, P204; BOHN MC, 1981, DEV BIOL, V82, P1, DOI 10.1016/0012-1606(81)90423-1; BOTTENSTEIN JE, 1980, EXP CELL RES, V125, P183, DOI 10.1016/0014-4827(80)90202-5; Brigstock DR, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011009; CADAY CG, 1990, DEV BRAIN RES, V52, P241, DOI 10.1016/0165-3806(90)90240-Y; CHAO HM, 1994, MOL BRAIN RES, V26, P271, DOI 10.1016/0169-328X(94)90099-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; ERNFORS P, 1990, J NEUROSCI RES, V27, P10, DOI 10.1002/jnr.490270103; EVANS RM, 1989, NEURON, V2, P1105, DOI 10.1016/0896-6273(89)90177-3; FRODIN M, 1994, P NATL ACAD SCI USA, V91, P1771, DOI 10.1073/pnas.91.5.1771; GIORDANO S, 1992, DEV BIOL, V152, P293, DOI 10.1016/0012-1606(92)90136-5; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOMEZPINILLA F, 1992, J NEUROSCI, V12, P345; Gould E, 1993, Curr Opin Neurobiol, V3, P676, DOI 10.1016/0959-4388(93)90138-O; GROTHE C, 1995, NEUROSCI LETT, V197, P175, DOI 10.1016/0304-3940(95)11917-L; GROTHE C, 1989, J HISTOCHEM CYTOCHEM, V37, P1877, DOI 10.1177/37.12.2685112; GROTHE C, 1995, J COMP NEUROL, V353, P18, DOI 10.1002/cne.903530104; GROTHE C, 1991, J COMP NEUROL, V305, P328, DOI 10.1002/cne.903050213; GROTHE C, 1990, FEBS LETT, V260, P35, DOI 10.1016/0014-5793(90)80059-R; GROTHE C, 1990, HISTOCHEMISTRY, V94, P141, DOI 10.1007/BF02440180; IP NY, 1994, NEURON, V13, P443, DOI 10.1016/0896-6273(94)90359-X; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; LILLIEN LE, 1985, EXP CELL RES, V161, P255, DOI 10.1016/0014-4827(85)90083-7; LINDHOLM D, 1992, EUR J NEUROSCI, V4, P404, DOI 10.1111/j.1460-9568.1992.tb00889.x; LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MCKEEHAN WL, 1994, MOL REPROD DEV, V39, P69, DOI 10.1002/mrd.1080390112; Meisinger C, 1996, MOL BRAIN RES, V36, P70, DOI 10.1016/0169-328X(95)00246-O; MORGAN L, 1994, DEVELOPMENT, V120, P1399; MOSCATELLI D, 1987, P NATL ACAD SCI USA, V84, P5778, DOI 10.1073/pnas.84.16.5778; NEUBERGER TJ, 1994, J NEUROSCI RES, V38, P300, DOI 10.1002/jnr.490380308; NEUFELD G, 1987, ENDOCRINOLOGY, V121, P597, DOI 10.1210/endo-121-2-597; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; POLLOCK JD, 1990, J NEUROSCI, V10, P2626; PRESTA M, 1988, BIOCHEM BIOPH RES CO, V155, P1161, DOI 10.1016/S0006-291X(88)81262-2; PUCHACZ E, 1993, BRAIN RES, V610, P39, DOI 10.1016/0006-8993(93)91214-D; QUATRO N, 1991, CELL REGUL, V2, P699; RANE SG, 1994, J NEUROSCI RES, V38, P590, DOI 10.1002/jnr.490380511; RIVA MA, 1995, J NEUROCHEM, V64, P2526; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SAPOLSKY RM, 1991, EXP NEUROL, V114, P246, DOI 10.1016/0014-4886(91)90041-A; SCHUBERT D, 1987, J CELL BIOL, V104, P635, DOI 10.1083/jcb.104.3.635; SEIDL K, 1989, DEV BIOL, V136, P481, DOI 10.1016/0012-1606(89)90273-X; SHERMAN L, 1991, ANN NY ACAD SCI, V638, P470, DOI 10.1111/j.1749-6632.1991.tb49072.x; SMITH MA, 1995, J NEUROSCI, V15, P1768, DOI 10.1523/JNEUROSCI.15-03-01768.1995; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; STAPF C, 1996, NEUROSCIENCE, V69, P1253; STARK KL, 1991, DEVELOPMENT, V113, P641; STEMPLE DL, 1988, NEURON, V1, P517, DOI 10.1016/0896-6273(88)90182-1; TENNEKOON GI, 1987, J CELL BIOL, V105, P2315, DOI 10.1083/jcb.105.5.2315; TISCHLER AS, 1993, J NEUROSCI, V13, P1533; TOGARI A, 1985, J NEUROSCI, V5, P307; UNSICKER K, 1992, DEV BRAIN RES, V65, P211, DOI 10.1016/0165-3806(92)90181-U; UNSICKER K, 1978, P NATL ACAD SCI USA, V75, P3498, DOI 10.1073/pnas.75.7.3498; Unsicker K, 1992, Curr Opin Neurobiol, V2, P671, DOI 10.1016/0959-4388(92)90037-L; WEISE B, 1993, J NEUROSCI RES, V34, P442, DOI 10.1002/jnr.490340409; WESTERMANN R, 1990, J NEUROCHEM, V55, P285, DOI 10.1111/j.1471-4159.1990.tb08850.x; YAMAGUCHI TP, 1995, CURR OPIN GENET DEV, V5, P485, DOI 10.1016/0959-437X(95)90053-J; ZHANG SM, 1995, J NEUROSCI RES, V40, P241, DOI 10.1002/jnr.490400213	70	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16520	16525		10.1074/jbc.271.28.16520	http://dx.doi.org/10.1074/jbc.271.28.16520			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663254	hybrid			2022-12-27	WOS:A1996UX12600018
J	Prasad, R; Singhal, RK; Srivastava, DK; Molina, JT; Tomkinson, AE; Wilson, SH				Prasad, R; Singhal, RK; Srivastava, DK; Molina, JT; Tomkinson, AE; Wilson, SH			Specific interaction of DNA polymerase beta and DNA ligase I in a multiprotein base excision repair complex from bovine testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC ABASIC SITE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; CATALYTIC DOMAIN; HUMAN-CELLS; REPLICATION; RESIDUES; IDENTIFICATION; MECHANISM; EXTRACT	Base excision repair (EER) is a cellular defense mechanism repairing modified bases in DNA. Recently, a G:U repair reaction has been reconstituted with several purified enzymes from Escherichia coli (Dianov, G,, and Lindahl, T. (1994) Curr. Biol. 4, 1069-1076), Using bovine testis crude nuclear extract, we have shown that G:U is repaired efficiently in vitro, and DNA polymerase beta (beta-pol) is responsible for the single nucleotide gap-filling synthesis (Singhal, R. It., Prasad, R,, and Wilson, S, H. (1995) J, Biol, Chem, 270, 949-957), To investigate potential interaction of beta-pol with other BER protein(s), we developed affinity chromatography matrices by cross-linking purified rat beta-pol or antibody against beta-pol to solid supports. Crude nuclear extract from bovine testis was applied to these affinity columns, which were then extensively washed, Proteins that bound specifically to the affinity columns were co-eluted in a complex with beta-pol, This complex had a molecular mass of approximately 180 kDa and was able to conduct the complete uracil-initiated EER reaction, The EER complex contained both beta-pol. and DNA ligase I. An antibody to beta-pol was able to shift the complex in sucrose gradients to a much larger molecular mass (>300 kDa) that again contained both beta-pol and DNA ligase I, Furthermore, DNA ligase I and beta-pol were co-immunoprecipitated from the testis nuclear extract with anti beta-pol IgG, Thus, we conclude that beta-pol and DNA ligase I are components of a multiprotein complex that performs BER.	UNIV TEXAS, MED BRANCH, SEALY CTR MOLEC SCI, GALVESTON, TX 77555 USA; UNIV TEXAS, HLTH SCI CTR, CTR MOLEC MED, INST BIOTECHNOL, SAN ANTONIO, TX 78245 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Health San Antonio			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006492, R01ES006839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047251, R29GM047251] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 06492, ES 06839] Funding Source: Medline; NIGMS NIH HHS [GM 47251] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; Barnes DE, 1993, CURR OPIN CELL BIOL, V5, P424, DOI 10.1016/0955-0674(93)90007-D; Beard WA, 1995, METHOD ENZYMOL, V262, P98; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; DATE T, 1990, BIOCHEMISTRY-US, V29, P3075; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DOETSCH PW, 1986, BIOCHEMISTRY-US, V25, P2212, DOI 10.1021/bi00356a054; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; FRANKLIN WA, 1988, EMBO J, V7, P3617, DOI 10.1002/j.1460-2075.1988.tb03240.x; FRY M, 1986, ANIMAL CELL DNA POLY, P75; HAMMOND RA, 1990, BIOCHEMISTRY-US, V29, P286, DOI 10.1021/bi00453a039; Harlow E., 1988, ANTIBODIES LAB MANUA; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; HUSAIN I, 1995, J BIOL CHEM, V270, P9683, DOI 10.1074/jbc.270.16.9683; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; KIM SJ, 1994, J MOL BIOL, V244, P224, DOI 10.1006/jmbi.1994.1720; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI CG, 1994, NUCLEIC ACIDS RES, V22, P632, DOI 10.1093/nar/22.4.632; LINDAHL T, 1995, PHILOS T ROY SOC B, V347, P57, DOI 10.1098/rstb.1995.0009; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LJUNGQUIST S, 1994, MUTAT RES, V314, P177, DOI 10.1016/0921-8777(94)90081-7; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1991, MOL CELL BIOL, V11, P4441, DOI 10.1128/MCB.11.9.4441; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MATSUMOTO Y, 1989, MOL CELL BIOL, V9, P3750, DOI 10.1128/MCB.9.9.3750; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PRICE A, 1991, BIOCHEMISTRY-US, V30, P8631, DOI 10.1021/bi00099a020; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SRIVASTAVA DK, 1995, J BIOL CHEM, V270, P16402, DOI 10.1074/jbc.270.27.16402; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; SWEASY JB, 1995, J BACTERIOL, V177, P2923, DOI 10.1128/jb.177.10.2923-2925.1995; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; WEI YF, 1995, MOL CELL BIOL, V15, P3206; WIDEN SG, 1991, BIOCHEMISTRY-US, V30, P6296, DOI 10.1021/bi00239a031; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199	52	221	224	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16000	16007		10.1074/jbc.271.27.16000	http://dx.doi.org/10.1074/jbc.271.27.16000			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663274	hybrid			2022-12-27	WOS:A1996UW35200026
J	Servant, MJ; Giasson, E; Meloche, S				Servant, MJ; Giasson, E; Meloche, S			Inhibition of growth factor-induced protein synthesis by a selective MEK inhibitor in aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE-KINASE; TYROSINE PHOSPHORYLATION; IN-VITRO; ACTIVATION; RAF; P44(MAPK); PROGRESS; INVITRO; INSULIN	A common response of cells to mitogenic and hypertrophic factors is the activation of high rates of protein synthesis. To investigate the molecular basis of this action, we have used the recently developed MAP kinase/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor PD 98059 to examine the involvement of the ERK pathway in the regulation of global protein synthesis by growth factors in rat aortic smooth muscle cells (SMC). Incubation with PD 98059 blocked angiotensin II (AII)-dependent phosphorylation and enzymatic activity of both MEK1 and MEK2 isoforms, leading to inhibition of the phosphorylation and activation of p44(mapk) and p42(mapk). The compound was found to selectively inhibit activation of the ERK pathway by AII, but not the stimulation of p70 S6 kinase, phospholipase C, or tyrosine phosphorylation. Most importantly, treatment of aortic SMC with PD 98059 potently inhibited AII-stimulated protein synthesis with a half-maximal inhibitory concentration of 4.3 mu M. The effect of PD 98059 was not restricted to AII, since the compound also blocked to various extent the induction of protein synthesis by growth factors acting through tyrosine kinase receptors, G protein-coupled receptors, or protein kinase C, These results provide strong evidence that activation of ERK isoforms is an obligatory step for growth factor-induced protein synthesis in aortic SMC.	UNIV MONTREAL,DEPT PHARMACOL,MONTREAL,PQ H2W 1T8,CANADA	Universite de Montreal	Servant, MJ (corresponding author), HOP HOTEL DIEU,CTR RECH,3850 ST URBAIN ST,MONTREAL,PQ H2W 1T8,CANADA.							Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Catt KJ, 1993, CELLULAR MOL BIOL RE, P307; Chiu A T, 1991, Receptor, V1, P133; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; EDWARDS DR, 1994, TRENDS PHARMACOL SCI, V15, P239, DOI 10.1016/0165-6147(94)90318-2; FUKUDA M, 1995, ONCOGENE, V11, P239; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIASSON E, 1995, J BIOL CHEM, V270, P5225, DOI 10.1074/jbc.270.10.5225; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; KOZMA SC, 1992, REV PHYSIOL BIOCH P, V119, P123; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEDUC I, 1995, J BIOL CHEM, V270, P4401, DOI 10.1074/jbc.270.9.4401; LEDUC L, 1995, MOL PHARMACOL, V48, P582; LENORMAND P, 1993, ADV SEC MESS PHOSPH, V28, P237; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PATTON WF, 1995, J BIOL CHEM, V270, P21404, DOI 10.1074/jbc.270.36.21404; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RAMAKRISHNA S, 1988, J BIOL CHEM, V263, P12677; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SERVANT M, 1995, BIOCHEM J, V305, P103, DOI 10.1042/bj3050103; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; SUTHERLAND C, 1993, EUR J BIOCHEM, V217, P715, DOI 10.1111/j.1432-1033.1993.tb18297.x; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TSUDA T, 1991, FEBS LETT, V285, P44, DOI 10.1016/0014-5793(91)80721-E; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; TURLA MB, 1991, CIRC RES, V68, P288, DOI 10.1161/01.RES.68.1.288; TURNER CE, 1995, J CELL SCI, V108, P333; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625	73	140	141	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16047	16052		10.1074/jbc.271.27.16047	http://dx.doi.org/10.1074/jbc.271.27.16047			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663242	hybrid			2022-12-27	WOS:A1996UW35200032
J	Li, DX; Dobrowolska, G; Krebs, EG				Li, DX; Dobrowolska, G; Krebs, EG			The physical association of casein kinase 2 with nucleolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TUMOR SUPPRESSOR PROTEIN; HEAT-SHOCK PROTEIN; II ACTIVITY; CELLULAR-REGULATION; MOLECULAR-COMPLEX; ALPHA-SUBUNIT; BETA-SUBUNIT; CHO CELLS; PHOSPHORYLATION	CK2 (formerly called casein kinase 2) is a ubiquitous messenger-independent serine/threonine protein kinase implicated in cell growth and proliferation. To investigate the regulation and functions of this enzyme, experiments were carried out to search for CK2-interacting proteins. The methods employed included an overlay technique, co-purification, co-immunoprecipitation, and the use of glutathione S-transferase (GST) CK2 fusion proteins, By the CK2 overlay technique, one protein of 110 kDa was found to bind to CK2 with very high affinity. The binding was inhibited by CK2 effectors such as heparin, polyarginine, and histone H1, but was not affected by the CK2 substrate, casein. Protein p110 was also detected by co-immunoprecipitation using anti-CK2 antiserum, suggesting an in vivo association of this protein with CK2. Go-purification of p110 with CK2 from Sf-9 cells that overexpressed CK2 was also observed through sequential chromatographic steps. Using GST fusion proteins of CK2, the CK2-p110 interaction was investigated further and was found to occur primarily through CK2 alpha or alpha' subunits, but not the beta subunit. Protein p110 was purified from 3T3 LI mouse fibroblast cell lines using a GST-CK2 affinity resin. Amino acid sequence analysis of peptides obtained from the protein indicated that it is the nuclear protein, nucleolin. Furthermore, p110 was recognized by anti-nucleolin antiserum. At present, the physiological significance of the strong interaction between CK2 and nucleolin, an excellent substrate for the enzyme, is not clear. However, this association may be important for regulating rDNA transcription.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle				Dobrowolska, Grazyna/0000-0002-2598-9666	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042528] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42528] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AGOSTINIS P, 1992, J BIOL CHEM, V267, P9732; ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6626; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOUCHE G, 1994, CELL MOL BIOL RES, V40, P547; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; BOURBON HM, 1988, J MOL BIOL, V200, P627, DOI 10.1016/0022-2836(88)90476-7; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CSERMELY P, 1993, J BIOL CHEM, V268, P9747; DEBENEDETTE M, 1991, J IMMUNOL, V147, P2839; DELPECH M, 1986, EUR J BIOCHEM, V160, P333, DOI 10.1111/j.1432-1033.1986.tb09976.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIAZNIDO J, 1992, SEC MESS PHOSPHOPROT, V14, P39; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; DOUGHERTY JJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P74, DOI 10.1016/0167-4889(87)90067-X; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; ESCANDE ML, 1985, BIOL CELL, V53, P99, DOI 10.1111/j.1768-322X.1985.tb00359.x; FILHOL O, 1992, J BIOL CHEM, V267, P20577; GUAZON PT, 1991, ADV 2 MESSENGER PHOS, V23, P126; HEI YJ, 1994, BIOCHEM CELL BIOL, V72, P49, DOI 10.1139/o94-008; HEINE MA, 1993, MOL BIOL CELL, V4, P1189, DOI 10.1091/mbc.4.11.1189; HERRERA AH, 1986, BIOCHEMISTRY-US, V25, P6258, DOI 10.1021/bi00368a063; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JIN YJ, 1993, P NATL ACAD SCI USA, V90, P7769, DOI 10.1073/pnas.90.16.7769; JORDAN G, 1987, NATURE, V329, P489, DOI 10.1038/329489a0; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; LUDEMANN R, 1993, J BIOL CHEM, V268, P17413; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1985, BIOCHIM BIOPHYS ACTA, V846, P248, DOI 10.1016/0167-4889(85)90072-2; MIYATA Y, 1995, BIOCHEMISTRY-US, V34, P8123, DOI 10.1021/bi00025a019; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SARNO S, 1995, BIOCHEM BIOPH RES CO, V206, P171, DOI 10.1006/bbrc.1995.1024; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; Stone K.L., 1992, TECHNIQUES PROTEIN C, P23; SUZUKI N, 1987, J BIOL CHEM, V262, P4696; SUZUKI N, 1992, J STEROID BIOCHEM, V42, P305, DOI 10.1016/0960-0760(92)90133-4; SUZUKI T, 1993, BIOCHEM J, V289, P109, DOI 10.1042/bj2890109; TAWFIC S, 1994, J BIOL CHEM, V269, P7489; WARRENER P, 1991, BIOCHEM BIOPH RES CO, V180, P716, DOI 10.1016/S0006-291X(05)81124-6; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068	58	71	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15662	15668		10.1074/jbc.271.26.15662	http://dx.doi.org/10.1074/jbc.271.26.15662			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663258	hybrid			2022-12-27	WOS:A1996UV29900055
J	Rossi, A; Bonaventure, J; Delezoide, AL; Cetta, G; SupertiFurga, A				Rossi, A; Bonaventure, J; Delezoide, AL; Cetta, G; SupertiFurga, A			Undersulfation of proteoglycans synthesized by chondrocytes from a patient with achondrogenesis type 1B homozygous for an L483P substitution in the diastrophic dysplasia sulfate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALGINATE BEADS; ARTICULAR CHONDROCYTES; CHONDROITIN SULFATE; BRACHYMORPHIC MICE; CARTILAGE MATRIX; AGGRECAN GENE; CORE PROTEIN; COLLAGEN; CELLS; CYSTEINE	Achondrogenesis type 1B is an autosomal recessive, lethal chondrodysplasia caused by mutations in the gene encoding a sulfate/chloride antiporter of the cell membrane (Superti-Furga, A., Hastbacka, J., Wilcox, W. R., Cohn, D. H., van der Harten, J. J., Rossi, A., Blau, N., Rimoin, D. L., Steinmann, B., Lander, E. S., and Gitzelmann, R. (1996) Not. Genet. 12, 100-102). To ascertain the consequences of the sulfate transport defect on proteoglycan synthesis, we studied the structure and sulfation of proteoglycans in cartilage tissue and in fibroblast and chondrocyte cultures from a fetus with achondrogenesis 1B. Proteoglycans extracted from epiphyseal cartilage and separated on agarose gels migrated more slowly than controls and stained poorly with alcian blue. The patient's cultured cells showed reduced incorporation of [S-35]sulfate relative to [H-3]glucosamine, impaired uptake of sulfate, and higher resistance to chromate toxicity compared to control cells. Epiphyseal chondrocytes cultured in alginate beads synthesized proteoglycans of normal molecular size as judged by gel filtration chromatography, but undersulfated as judged by ion exchange chromatography and by the amount of nonsulfated disaccharide. High performance liquid chromatography analysis of chondroitinase-digested proteoglycans showed that sulfated disaccharides were present, although in reduced amounts, indicating that at least in vitro, other sources of sulfate can partially compensate for sulfate deficiency. A t1475c transition causing a L483P substitution in the eleventh transmembrane domain of the sulfate/chloride antiporter was present on both alleles in the patient who was the product of a consanguineous marriage. The results indicate that the defect of sulfate transport is expressed in both chondrocytes and fibroblasts and results in the synthesis of proteoglycans bearing glycosaminoglycan chains which are poorly sulfated but of normal length.	HOP NECKER ENFANTS MALAD,CNRS ER 88,INSERM U393,UNITE RECH HANDICAPS GENET ENFANT,F-75743 PARIS,FRANCE; UNIV ZURICH,DEPT PEDIAT,DIV METAB & MOL DIS,CH-8032 ZURICH,SWITZERLAND	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Zurich	Rossi, A (corresponding author), UNIV PAVIA,DIPARTIMENTO BIOCHIM ALESSANDRO CASTELLANI,VIA TARAMELLI 3B,I-27100 PAVIA,ITALY.		Rossi, Antonio/E-9935-2012; superti-furga, andrea/E-9162-2015	superti-furga, andrea/0000-0002-3543-7531				BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BONAVENTURE J, 1995, BIOCHEM J, V307, P823, DOI 10.1042/bj3070823; BONAVENTURE J, 1994, EXP CELL RES, V212, P97, DOI 10.1006/excr.1994.1123; BOROCHOWITZ Z, 1988, J PEDIATR-US, V112, P23, DOI 10.1016/S0022-3476(88)80113-6; CHAN D, 1993, J BIOL CHEM, V268, P15238; ELGAVISH A, 1985, J CELL PHYSIOL, V125, P243, DOI 10.1002/jcp.1041250211; ESKO JD, 1986, J BIOL CHEM, V261, P5725; FRACCARO M, 1952, FOLIA HERED PATHOL, V1, P190; FREISINGER P, 1994, AM J MED GENET, V49, P439, DOI 10.1002/ajmg.1320490418; GELLER DH, 1987, J BIOL CHEM, V262, P7374; GUO JF, 1989, CONNECT TISSUE RES, V19, P277, DOI 10.3109/03008208909043901; HARPER GS, 1987, J BIOL CHEM, V262, P5637; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HAUSELMANN HJ, 1994, J CELL SCI, V107, P17; HAUSELMANN HJ, 1992, MATRIX, V12, P116; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; Heinegard Dick, 1993, P189; Horton William A., 1993, P641; HUMPHRIES DE, 1988, BIOCHEM J, V252, P305, DOI 10.1042/bj2520305; IMAI Y, 1994, ARCH BIOCHEM BIOPHYS, V312, P392, DOI 10.1006/abbi.1994.1324; ITO K, 1982, J BIOL CHEM, V257, P917; KELLER JM, 1987, BIOCHIM BIOPHYS ACTA, V926, P139, DOI 10.1016/0304-4165(87)90230-3; LI H, 1993, J BIOL CHEM, V268, P23504; MORALES TI, 1988, J BIOL CHEM, V263, P3632; ORKIN RW, 1976, DEV BIOL, V50, P82, DOI 10.1016/0012-1606(76)90069-5; REILE H, 1990, ANAL BIOCHEM, V187, P262, DOI 10.1016/0003-2697(90)90454-H; Sambrook J., 2002, MOL CLONING LAB MANU; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; SOBUE M, 1978, J BIOL CHEM, V253, P6190; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRANGER J, 1992, EUR J PEDIATR, V151, P407; SUGAHARA K, 1982, ARCH BIOCHEM BIOPHYS, V214, P589, DOI 10.1016/0003-9861(82)90064-9; SupertiFurga A, 1996, NAT GENET, V12, P100, DOI 10.1038/ng0196-100; SUPERTIFURGA A, 1994, AM J HUM GENET, V55, P1137; van der Harten H J, 1988, Pediatr Pathol, V8, P571; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; WIEDEMANN HR, 1974, Z KINDERHEILKD, V116, P223, DOI 10.1007/BF00436949; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4	39	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18456	18464		10.1074/jbc.271.31.18456	http://dx.doi.org/10.1074/jbc.271.31.18456			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702490	hybrid			2022-12-27	WOS:A1996VB68300028
J	Seykora, JT; Myat, MM; Allen, LAH; Ravetch, JV; Aderem, A				Seykora, JT; Myat, MM; Allen, LAH; Ravetch, JV; Aderem, A			Molecular determinants of the myristoyl-electrostatic switch of MARCKS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SUBSTRATE MARCKS; BACTERIAL LIPOPOLYSACCHARIDE; MEMBRANE ASSOCIATION; CELLULAR SUBSTRATE; PLASMA-MEMBRANE; 87-KDA PROTEIN; BOVINE BRAIN; CLONING; PHOSPHORYLATION	MARCKS is a protein kinase C (PKC) substrate which binds calcium/calmodulin and actin, and which has been implicated in cell motility, phagocytosis, membrane traffic, and mitogenesis, MARCKS cycles on and off the membrane via a myristoyl electrostatic switch (McLaughlin, S., and Aderem, A. (1995) Trends Biochem, Sci, 20, 272-276), Here we define the molecular determinants of the myristoyl-electrostatic switch. Mutation of the N-terminal glycine results in a nonmyristoylated form of MARCKS which does not bind membranes and is poorly phosphorylated, This indicates that myristic acid targets MARCKS to the membrane, where it is efficiently phosphorylated by PKC, A chimeric protein in which the N terminus of MARCKS is replaced by a sequence, which is doubly palmitoylated, is phosphorylated by PKC but not released from the membrane, Thus two palmitic acid moieties confer sufficient membrane binding energy to render the second, electrostatic membrane binding site superfluous, Mutation of the PKC phosphorylation sites results in a mutant which does not translocate from the membrane to the cytosol, A mutant in which the intervening sequence between the myristoyl moiety and the basic effector domain is deleted, is not displaced from the membrane by PKC dependent phosphorylation, fulfilling a theoretical prediction of the model, In addition to the nonspecific membrane binding interactions conferred by the myristoyl-electrostatic switch, indirect immunofluorescence microscopy demonstrates that specific protein-protein interactions also specify the intracellular localization of MARCKS.	ROCKEFELLER UNIV,LAB SIGNAL TRANSDUCT,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,DEWITT WALLACE RES LAB,NEW YORK,NY 10021	Rockefeller University; Memorial Sloan Kettering Cancer Center			Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025032, R37AI025032] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 25032] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Chang S, 1996, J BIOL CHEM, V271, P1174, DOI 10.1074/jbc.271.2.1174; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; MANENTI S, 1992, J BIOL CHEM, V267, P22310; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Myat M. M., 1994, Molecular Biology of the Cell, V5, p295A; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PIETZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; Sambrook J., 2002, MOL CLONING LAB MANU; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	39	97	99	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18797	18802		10.1074/jbc.271.31.18797	http://dx.doi.org/10.1074/jbc.271.31.18797			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702537	hybrid			2022-12-27	WOS:A1996VB68300075
J	Wiemer, EAC; Luers, GH; Faber, KN; Wenzel, T; Veenhuis, M; Subramani, S				Wiemer, EAC; Luers, GH; Faber, KN; Wenzel, T; Veenhuis, M; Subramani, S			Isolation and characterization of Pas2p, a peroxisomal membrane protein essential for peroxisome biogenesis in the methylotrophic yeast Pichia pastoris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVE SELECTION PROCEDURE; HAMSTER OVARY CELLS; SACCHAROMYCES-CEREVISIAE; TARGETING SIGNAL; HANSENULA-POLYMORPHA; 3-KETOACYL-COA THIOLASE; IMPORT DEFICIENCIES; ASSEMBLY MUTANTS; 3-OXOACYL-COA THIOLASE; ZELLWEGER SYNDROME	The pas2 mutant of the methylotrophic yeast Pichia pastoris is characterized by a deficiency in peroxisome biogenesis. We have cloned the PpPAS2 gene by functional complementation and show that it encodes a protein of 455 amino acids with a molecular mass of 52 kDa. In a Pppas2 null mutant, import of both peroxisomal targeting signal 1 (PTS1)- and PTS2-containing proteins is impaired as shown by biochemical fractionation and fluorescence microscopy. No morphologically distinguishable peroxisomal structures could be detected by electron microscopy in Pppas2 null cells induced on methanol and oleate, suggesting that PpPas2p is involved in the early stages of peroxisome biogenesis. PpPas2p is a peroxisomal membrane protein (PMP) and is resistant to extraction by 1 M NaCl or alkaline sodium carbonate, suggesting that it is a peroxisomal integral membrane protein. Two hydrophobic domains can be distinguished which may be involved in anchoring PpPas2p to the peroxisomal membrane. PpPas2p is homologous to the Saccharomyces cerevisiae Pas3p. The first 40 amino acids of PpPas2p, devoid of the hydrophobic domains, are sufficient to target a soluble fluorescent reporter protein to the peroxisomal membrane, with which it associates tightly, A comparison with the membrane peroxisomal targeting signal of PMP47 of Candida boidinii revealed a stretch of positively charged amino acids common to both sequences. The role of peroxisomal membrane targeting signals and transmembrane domains in anchoring PMPs to the peroxisomal membrane is discussed.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV GRONINGEN,CTR BIOL,LAB ELECTRON MICROSCOPY,NL-9751 NN HAREN,NETHERLANDS	University of California System; University of California San Diego; University of Groningen				Wiemer, Erik/0000-0002-0673-7236	NICHD NIH HHS [NIHDK41737] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; CREGG JM, 1990, YEAST, V6, P87, DOI 10.1002/yea.320060202; DIESTELKOTTER P, 1993, J CELL BIOL, V123, P1717, DOI 10.1083/jcb.123.6.1717; ELGERSMA Y, 1993, GENETICS, V135, P731; ERDMANN R, 1994, YEAST, V10, P935, DOI 10.1002/yea.320100708; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P519; FABER KN, 1995, FEBS LETT, V357, P115, DOI 10.1016/0014-5793(94)01317-T; GLOVER JR, 1994, J BIOL CHEM, V269, P7558; GOULD SJ, 1992, YEAST, V8, P613, DOI 10.1002/yea.320080805; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HEYMAN JA, 1994, J CELL BIOL, V127, P1259, DOI 10.1083/jcb.127.5.1259; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; HOHFELD J, 1992, MEMBRANE BIOGENESIS, P185; Imanaka T, 1996, J BIOL CHEM, V271, P3706; KALISH JE, 1995, MOL CELL BIOL, V15, P6406; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; KUAN J, 1993, RES MICROBIOL, V144, P671, DOI 10.1016/0923-2508(93)90073-B; Kunau W.-H., 1987, PEROXISOMES BIOL MED, P128; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LIU H, 1992, J BACTERIOL, V174, P4943, DOI 10.1128/JB.174.15.4943-4951.1992; LIU H, 1995, J BIOL CHEM, V270, P10940, DOI 10.1074/jbc.270.18.10940; MADDEN EA, 1987, ANAL BIOCHEM, V163, P350, DOI 10.1016/0003-2697(87)90235-1; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MCCAMMON MT, 1994, J CELL BIOL, V124, P915, DOI 10.1083/jcb.124.6.915; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; McNew JA, 1996, TRENDS BIOCHEM SCI, V21, P54, DOI 10.1016/S0968-0004(96)80181-2; Monosov EZ, 1996, J HISTOCHEM CYTOCHEM, V44, P581, DOI 10.1177/44.6.8666743; MOTLEY A, 1994, J CELL BIOL, V125, P755, DOI 10.1083/jcb.125.4.755; NUTTLEY WM, 1993, YEAST, V9, P507, DOI 10.1002/yea.320090506; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; RAPP S, 1993, EXP CELL RES, V205, P59, DOI 10.1006/excr.1993.1058; RICKEY C, 1990, MOL BIOL REP, V9, P2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; SLOT JW, 1984, IMMUNOLABELLING ELEC, P129; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPONG AP, 1993, J CELL BIOL, V123, P535, DOI 10.1083/jcb.123.3.535; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TAN XQ, 1995, J CELL BIOL, V128, P307, DOI 10.1083/jcb.128.3.307; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VANDERLEIJ I, 1992, J CELL BIOL, V119, P153, DOI 10.1083/jcb.119.1.153; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; VEENHUIS M, 1992, CELL BIOCHEM FUNCT, V10, P175, DOI 10.1002/cbf.290100307; WENDLAND M, 1993, J CELL BIOL, V120, P675, DOI 10.1083/jcb.120.3.675; Wiemer E A, 1994, Mol Genet Med, V4, P119; WIEMER EAC, 1989, EUR J CELL BIOL, V50, P407; ZHANG JW, 1993, J CELL BIOL, V123, P1133, DOI 10.1083/jcb.123.5.1133; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65; Zhang JW, 1996, J CELL BIOL, V132, P325, DOI 10.1083/jcb.132.3.325	61	106	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18973	18980		10.1074/jbc.271.31.18973	http://dx.doi.org/10.1074/jbc.271.31.18973			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702562	hybrid, Green Published			2022-12-27	WOS:A1996VB68300100
J	Cooper, JT; Stroka, DM; Brostjan, C; Palmetshofer, A; Bach, FH; Ferran, C				Cooper, JT; Stroka, DM; Brostjan, C; Palmetshofer, A; Bach, FH; Ferran, C			A20 blocks endothelial cell activation through a NF-kappa B-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEIN; LEUKOCYTE ADHESION MOLECULE-1; E-SELECTIN PROMOTER; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; REGULATORY SYSTEM; ALPHA; EXPRESSION; ANTIOXIDANT; INDUCTION	The A20 gene product is a novel zinc finger protein originally described as a tumor necrosis factor alpha (TNF)-inducible early response gene in human umbilical vein endothelial cells (HUVEC), Its described function is to block TNF-induced apoptosis in fibroblasts and B lymphocytes, but more recently it has also been shown to play a role in lymphoid cell maturation. The mechanism of action of A20 is unknown, The aim of our study was to assess the effect of A20 upon endothelial cell activation, By transfecting bovine aortic endothelial cells (BAEC) with A20 as well as reporter constructs consisting of the promoters of genes known to be up-regulated during endothelial cell activation, i.e. E selectin, interleukin (IL)-8, tissue factor (TF), and inhibitor of nuclear factor kappa B alpha (I kappa B alpha), we demonstrate that A20 expression inhibits gene up-regulation associated with TNF, lipopolysaccharide (LPS), phorbol 12-myristate 13 acetate (PMA), and hydrogen peroxide (H2O2)-induced endothelial cell (EC) activation. The mechanism of action of A20 is in part, or totally, due to the blockade of nuclear factor kappa B (NF-kappa B), as shown by its ability to suppress the activity of a NF-KB reporter, This effect is specific, as A20 does not block a noninducible, constitutively expressed reporter, Rous sarcoma virus-luciferase (RSV-LUC); nor does it block the c-Tat-inducible, NF-kappa B-independent reporter, human immunodeficiency virus-chloramphenicol acetyltransferase (HIV-CAT). How A20 blocks NF-kappa B is unclear, although we demonstrate that it does not affect p65 (RelA)-mediated gene transactivation, The inhibition of endothelial cell activation by A20 is a novel function for A20.	HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, SANDOZ CTR IMMUNOBIOL, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Novartis; Sandoz			Stroka, Deborah M/F-1806-2013	Brostjan, Christine/0000-0003-1462-5397; Stroka, Deborah/0000-0002-3517-3871; COOPER, JEFFREY/0000-0002-5732-5143				BACH FH, 1994, IMMUNOL REV, V141, P5, DOI 10.1111/j.1600-065X.1994.tb00870.x; BACH FH, 1995, NAT MED, V1, P869, DOI 10.1038/nm0995-869; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BRAY TM, 1990, FREE RADICAL BIO MED, V8, P281, DOI 10.1016/0891-5849(90)90076-U; CHENG Q, 1994, J BIOL CHEM, V269, P13551; COLLINS T, 1993, TRENDS CARDIOVAS MED, V3, P92, DOI 10.1016/1050-1738(93)90030-A; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; FERRAN C, 1995, BIOCHEM BIOPH RES CO, V214, P212, DOI 10.1006/bbrc.1995.2277; GERRITSEN ME, 1993, FASEB J, V7, P523, DOI 10.1096/fasebj.7.6.8472891; GRILLI M, 1993, INT REV CYTOL, V143, P1; HENNIG B, 1993, ANN NY ACAD SCI, V686, P99, DOI 10.1111/j.1749-6632.1993.tb39161.x; Jaattela M, 1996, J IMMUNOL, V156, P1166; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LARUE KEA, 1994, J EXP MED, V180, P2269, DOI 10.1084/jem.180.6.2269; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SICA A, 1990, IMMUNOLOGY, V69, P548; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEWARI M, 1995, J IMMUNOL, V154, P1699; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; ZIMMERMANN K, 1991, VIROLOGY, V182, P874, DOI 10.1016/0042-6822(91)90633-M	38	224	233	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18068	18073		10.1074/jbc.271.30.18068	http://dx.doi.org/10.1074/jbc.271.30.18068			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663499	hybrid			2022-12-27	WOS:A1996UY93500072
J	Jiang, BH; Rue, E; Wang, GL; Roe, R; Semenza, GL				Jiang, BH; Rue, E; Wang, GL; Roe, R; Semenza, GL			Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR NUCLEAR TRANSLOCATOR; ENDOTHELIAL GROWTH-FACTOR; ERYTHROPOIETIN GENE-EXPRESSION; LACTATE-DEHYDROGENASE-A; TRANSCRIPTIONAL ACTIVATION; DIOXIN RECEPTOR; FACTOR-I; MESSENGER-RNA; PROTEIN ARNT; C-JUN	Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric basic helix-loop-helix transcription factor that regulates hypoxia-inducible genes including the human erythropoietin (EPO) gene, In this study, we report structural features of the HIF-1 alpha subunit that are required for heterodimerization, DNA binding, and transactivation. The HIF-1 alpha and HIF-1 beta (ARNT; aryl hydrocarbon receptor nuclear translocator) subunits were coimmunoprecipitated from nuclear extracts, indicating that these proteins heterodimerize in the absence of DNA, In vitro-translated HIF-1 alpha and HIF-1 beta generated a HIF-1/DNA complex with similar electrophoretic mobility and sequence specificity as HIF-1 present in nuclear extracts from hypoxic cells, Compared to 826-amino acid, full-length HIF-1 alpha, amino acids 1-166 mediated heterodimerization with HIF-1 beta (ARNT), but amino acids 1-390 were required for optimal DNA binding, A deletion involving the basic domain of HIF-1 alpha eliminated DNA binding without affecting heterodimerization, In cotransfection assays, forced expression of recombinant HIF-1 alpha and HIF-1 beta (ARNT) activated transcription of reporter genes containing EPO enhancer sequences with intact, but not mutant, HIF-1 binding sites, Deletion of the car boxy terminus of HIF-1 alpha (amino acids 391-826) markedly decreased the ability of recombinant HIF-1 to activate transcription, Overexpression of a HIF-1 alpha construct with deletions of the basic domain and carboxy terminus blocked reporter gene activation by endogenous HIF-1 in hypoxic cells.	JOHNS HOPKINS UNIV HOSP, SCH MED, DEPT PEDIAT, CTR GENET MED, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV HOSP, SCH MED, DEPT MED, CTR GENET MED, BALTIMORE, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine				Jiang, Bing-Hua/0000-0003-4526-2031	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039869] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK39869] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; BECK I, 1993, BLOOD, V82, P704; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; FANDREY J, 1993, BLOOD, V81, P617; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1991, BLOOD, V77, P271; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KRANTZ SB, 1991, BLOOD, V77, P419; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LI H, 1994, J BIOL CHEM, V269, P28098; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; Murre  C., 1992, TRANSCRIPTIONAL REGU, P861; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; RATCLIFFE PJ, 1993, KIDNEY INT, V44, P887, DOI 10.1038/ki.1993.327; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, HEMATOL ONCOL CLIN N, V8, P863, DOI 10.1016/S0889-8588(18)30134-5; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343	39	858	918	4	53	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17771	17778		10.1074/jbc.271.30.17771	http://dx.doi.org/10.1074/jbc.271.30.17771			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663540	hybrid			2022-12-27	WOS:A1996UY93500030
J	Osawa, H; Robey, RB; Printz, RL; Granner, DK				Osawa, H; Robey, RB; Printz, RL; Granner, DK			Identification and characterization of basal and cyclic AMP response elements in the promoter of the rat hexokinase II genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT-BINDING-FACTOR; BROWN ADIPOSE-TISSUE; NUCLEAR FACTOR CREB; MHC CLASS-II; NF-Y; SOMATOSTATIN GENE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; MAXIMUM CAPACITY; MAMMALIAN-CELLS	Hexokinases catalyze the phosphorylation of glucose and initiate cellular glucose metabolism. Hexokinase II (HKII) is the principal hexokinase isoform in skeletal muscle, heart, and adipose tissue. Isoproterenol and exogenous cyclic AMP (cAMP) increase HKII gene transcription in L6 myotubes. Various segments of the HKII promoter that direct the expression of the chloramphenicol acetyltransferase reporter gene were transfected into L6 myotubes to identify basal and cAMP response elements. The 5'-flanking region that extends 90 base pairs upstream of the transcription start site includes a CCAAT box and a cAMP response element (CRE); both contribute to basal promoter activity and each provides an independent, maximal response 60 cAMP. An inverted CCAAT motif, or Y box, located just upstream of the CCAAT box, contributes to basal promoter activity but is not involved in the cAMP response. Home- and heterodimers composed of the CRE-binding protein and activating transcription factor-1 bind specifically to the CRE. The Y box and the CCAAT box specifically bind the factor NF-Y (also known as CBF).	VANDERBILT UNIV,SCH MED,DEPT PHYSIOL & MOLEC BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University			Robey, R. Brooks/J-7099-2013	Robey, R. Brooks/0000-0001-5059-3965	NIDDK NIH HHS [DK 35107, DK46867, DK42502] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035107, R01DK046867, R37DK035107] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTS AS, 1994, J BIOL CHEM, V269, P7623; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BELL GI, 1993, J BIOL CHEM, V268, P19161; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; COONEY GJ, 1982, FEBS LETT, V148, P198, DOI 10.1016/0014-5793(82)80807-7; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DEVLIN JT, 1992, DIABETES CARE, V15, P1690, DOI 10.2337/diacare.15.11.1690; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DONG YH, 1993, NUCLEIC ACIDS RES, V21, P771, DOI 10.1093/nar/21.3.771; DORN A, 1987, P NATL ACAD SCI USA, V84, P6249, DOI 10.1073/pnas.84.17.6249; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; HARRI MNE, 1975, ACTA PHYSIOL SCAND, V95, P391, DOI 10.1111/j.1748-1716.1975.tb10066.x; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUANG L, 1994, J VIROL, V68, P2108, DOI 10.1128/JVI.68.4.2108-2117.1994; ICHIHARA J, 1995, BBA-GENE STRUCT EXPR, V1260, P365, DOI 10.1016/0167-4781(94)00226-S; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; KATZEN HM, 1965, P NATL ACAD SCI USA, V54, P1218, DOI 10.1073/pnas.54.4.1218; KINANE TB, 1993, J BIOL CHEM, V268, P24669; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LI XY, 1992, NUCLEIC ACIDS RES, V20, P1087, DOI 10.1093/nar/20.5.1087; LIU F, 1993, J BIOL CHEM, V268, P6714; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; ODOHERTY RM, 1994, AM J PHYSIOL, V266, pE171; ODOHERTY RM, 1994, MED SCI SPORT EXER S, V26, pS90; OSAWA H, 1995, DIABETES, V44, P1426, DOI 10.2337/diabetes.44.12.1426; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Robey RB, 1996, BIOTECHNIQUES, V20, P40; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SUZUKI H, 1990, ANAT RECORD, V226, P314, DOI 10.1002/ar.1092260307; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; THELEN AP, 1991, ARCH BIOCHEM BIOPHYS, V286, P645, DOI 10.1016/0003-9861(91)90094-Y; TRONCHE F, 1991, J MOL BIOL, V221, P31; VANHUIJSDUIJNEN RAMH, 1987, NUCLEIC ACIDS RES, V15, P7265, DOI 10.1093/nar/15.18.7265; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VILEN BJ, 1991, MOL CELL BIOL, V11, P2406, DOI 10.1128/MCB.11.5.2406; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; WUARIN J, 1990, J MOL BIOL, V214, P865, DOI 10.1016/0022-2836(90)90341-I; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOUNG P, 1984, FEBS LETT, V176, P16, DOI 10.1016/0014-5793(84)80903-5	71	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17296	17303		10.1074/jbc.271.29.17296	http://dx.doi.org/10.1074/jbc.271.29.17296			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663388	hybrid			2022-12-27	WOS:A1996UX94300050
J	Ribeiro, RCJ; Cavalieri, RR; Lomri, N; Rahmaoui, CM; Baxter, JD; Scharschmidt, BF				Ribeiro, RCJ; Cavalieri, RR; Lomri, N; Rahmaoui, CM; Baxter, JD; Scharschmidt, BF			Thyroid hormone export regulates cellular hormone content and response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CELLS; NATRIURETIC FACTOR GENE; L-TRI-IODOTHYRONINE; P-GLYCOPROTEIN; ISOLATED HEPATOCYTES; TRANSPORT; TRIIODOTHYRONINE; DEXAMETHASONE; RESISTANCE; EXPRESSION	Actions of thyroid hormones (THs) are determined by intracellular free hormone concentration, Here we report that enhanced TH extrusion via a saturable, cold-sensitive mechanism lowers intracellular TH and causes TH resistance in hepatoma cells, Since these cells overexpress multidrug resistance P-glycoproteins and TH extrusion and resistance are blunted by verapamil, P-glycoproteins may mediate this resistance, Verapamil-inhibitable TH efflux was also found in primary hepatocytes, cardiocytes, and fibroblasts. These findings demonstrate that TH extrusion can modulate TH availability and action in mammalian cells.	UNIV CALIF SAN FRANCISCO,DIV GASTROENTEROL,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,VET AFFAIRS MED CTR,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ribeiro, RCJ (corresponding author), UNIV CALIF SAN FRANCISCO,METAB RES UNIT,HSW 1141,POB 0540,SAN FRANCISCO,CA 94143, USA.				NIDDK NIH HHS [DK41842, DK26270, DK26743] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743, R01DK026270, R01DK041842] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAI K, 1995, STEROIDS, V60, P173, DOI 10.1016/0039-128X(94)00007-Y; BECKPECCOZ P, 1994, THYROID, V4, P225, DOI 10.1089/thy.1994.4.225; Bissell D M, 1980, Ann N Y Acad Sci, V349, P85, DOI 10.1111/j.1749-6632.1980.tb29518.x; BLONDEAU JP, 1988, J BIOL CHEM, V263, P2685; BOURGEOIS S, 1993, MOL ENDOCRINOL, V7, P840, DOI 10.1210/me.7.7.840; BROWN RS, 1995, P NATL ACAD SCI USA, V92, P5421, DOI 10.1073/pnas.92.12.5421; CAVALIERI RR, 1984, ENDOCRINOLOGY, V114, P215, DOI 10.1210/endo-114-1-215; CHALMERS DK, 1993, J MED CHEM, V36, P1272, DOI 10.1021/jm00061a019; DOCTER R, 1988, ENDOCRINOLOGY, V123, P1520, DOI 10.1210/endo-123-3-1520; ECKEL J, 1979, BIOCHEM J, V182, P473, DOI 10.1042/bj1820473; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HENNEMANN G, 1986, ENDOCRINOLOGY, V119, P1870, DOI 10.1210/endo-119-4-1870; KRAGIE L, 1992, ENDOCRINOLOGY, V130, P1211, DOI 10.1210/en.130.3.1211; Kralli A, 1996, J BIOL CHEM, V271, P17152, DOI 10.1074/jbc.271.29.17152; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; KRENNING EP, 1978, FEBS LETT, V91, P113, DOI 10.1016/0014-5793(78)80029-5; KRENNING EP, 1982, FEBS LETT, V140, P229, DOI 10.1016/0014-5793(82)80900-9; LAKSHMANAN M, 1992, BIOCHIM BIOPHYS ACTA, V1133, P213, DOI 10.1016/0167-4889(92)90071-I; LAPOINTE MC, 1988, J BIOL CHEM, V263, P9075; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; MENDEL CM, 1989, ENDOCR REV, V10, P232, DOI 10.1210/edrv-10-3-232; MITCHELL AM, 1992, MOL CELL ENDOCRINOL, V87, P139, DOI 10.1016/0303-7207(92)90242-X; MOORADIAN AD, 1985, ENDOCRINOLOGY, V117, P2449, DOI 10.1210/endo-117-6-2449; MORENO M, 1994, ENDOCRINOLOGY, V135, P1004, DOI 10.1210/en.135.3.1004; MOVIUS EG, 1989, ENDOCRINOLOGY, V124, P1988, DOI 10.1210/endo-124-4-1988; MULLER B, 1995, NEW ENGL J MED, V333, P964, DOI 10.1056/NEJM199510123331503; NELSON EJ, 1992, ENDOCRINOLOGY, V130, P3246, DOI 10.1210/en.130.6.3246; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; OPPENHEIMER JH, 1985, J CLIN INVEST, V75, P147, DOI 10.1172/JCI111667; RAO GS, 1981, BIOCHEM J, V198, P457, DOI 10.1042/bj1980457; RAO GS, 1976, BIOCHEM BIOPH RES CO, V73, P98, DOI 10.1016/0006-291X(76)90502-7; RENNER EL, 1989, J CLIN INVEST, V83, P1225, DOI 10.1172/JCI114005; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; SAEKI T, 1993, J BIOL CHEM, V268, P6077; SCHARSCHMIDT BF, 1981, P NATL ACAD SCI-BIOL, V78, P986, DOI 10.1073/pnas.78.2.986; TOPLISS DJ, 1993, METABOLISM, V42, P376, DOI 10.1016/0026-0495(93)90090-B; UEDA K, 1992, J BIOL CHEM, V267, P24248; VANKALKEN CK, 1993, BRIT J CANCER, V67, P284, DOI 10.1038/bjc.1993.54; WOLF DC, 1992, INT J CANCER, V52, P141, DOI 10.1002/ijc.2910520125; WU JP, 1989, J BIOL CHEM, V264, P6472; ZEMEL LR, 1988, ACTA ENDOCRINOL-COP, V117, P392, DOI 10.1530/acta.0.1170392	43	44	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17147	17151		10.1074/jbc.271.29.17147	http://dx.doi.org/10.1074/jbc.271.29.17147			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663353	hybrid			2022-12-27	WOS:A1996UX94300027
J	Lee, SL; Steinberg, RA				Lee, SL; Steinberg, RA			Pathways for degradation of the catalytic subunit of cAMP-dependent protein kinase differ in wild-type and kinase-negative S49 mouse lymphoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ALPHA; CYTOPLASMIC CHAPERONIN; MESSENGER-RNA; UBIQUITIN; EXPRESSION; COMPLEX; MUTANT; SYSTEM; CONJUGATION; PROTEASES	The catalytic subunit of cAMP-dependent protein kinase radiolabeled with [S-35]methionine in wild-type S49 mouse lymphoma cells was degraded with half-lives of similar to 9.2 h in unstimulated cells and similar to 4.5 h in cells stimulated with a membrane-permeable cAMP analog. Turnover in kinase-negative mutant cells was about three times faster than in stimulated wild-type cells and appeared to involve a unique 47-kDa intermediate. Levels of catalytic subunit protein revealed by Western immunoblotting were consistent with the measured differences in turnover, but whereas the protein was mostly soluble in wild-type cell extracts, it was almost entirely insoluble in the mutant cell extracts. A substantial fraction of the catalytic subunit labeled in a 5-min pulse was soluble in kinase negative cell extracts, but most of this material was rendered insoluble by incubating the cells for an additional 30 min before extraction. Degradation of the catalytic subunit in kinase-negative, but not in wild-type, cells was inhibited strongly by two specific peptide aldehyde inhibitors of the proteasomal chymotrypsin-like activity. An inhibitor of the proteasomal protease that prefers branched-chain amino acids had less of an effect on catalytic subunit degradation in the mutant cells.	UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, OKLAHOMA CITY, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center								BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHIN DT, 1982, P NATL ACAD SCI-BIOL, V79, P5857, DOI 10.1073/pnas.79.19.5857; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HADARI T, 1992, J BIOL CHEM, V267, P719; HEMMINGS BA, 1986, FEBS LETT, V196, P126, DOI 10.1016/0014-5793(86)80226-5; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOUGE G, 1990, MOL ENDOCRINOL, V4, P481, DOI 10.1210/mend-4-3-481; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SL, 1996, MOL CELL ENDOCRINOL, V116, P233, DOI 10.1016/0303-7207(95)03719-5; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLSEN SR, 1989, J BIOL CHEM, V264, P18662; ORELLANA SA, 1990, J BIOL CHEM, V265, P3048; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RICHARDSON JM, 1990, J BIOL CHEM, V265, P13635; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SHAEFFER JR, 1995, BIOCHEMISTRY-US, V34, P4015, DOI 10.1021/bi00012a020; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; STEINBERG RA, 1983, METHOD ENZYMOL, V99, P233; STEINBERG RA, 1978, CELL, V15, P1351, DOI 10.1016/0092-8674(78)90060-0; STEINBERG RA, 1991, MOL CELL BIOL, V11, P705, DOI 10.1128/MCB.11.2.705; TASKEN K, 1993, J BIOL CHEM, V268, P23483; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; WETTERS TV, 1983, CELL, V35, P311, DOI 10.1016/0092-8674(83)90234-9; Zilversmit DB, 1943, J GEN PHYSIOL, V26, P325, DOI 10.1085/jgp.26.3.325	35	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16553	16558		10.1074/jbc.271.28.16553	http://dx.doi.org/10.1074/jbc.271.28.16553			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663257	hybrid			2022-12-27	WOS:A1996UX12600022
J	Berry, DM; Antochi, R; Bhatia, M; MecklingGill, KA				Berry, DM; Antochi, R; Bhatia, M; MecklingGill, KA			1,25-dihydroxyvitamin D-3 stimulates expression and translocation of protein kinase C alpha and C delta via a nongenomic mechanism and rapidly induces phosphorylation of a 33-kDa protein in acute promyelocytic NB4 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOMIC BIOLOGICAL RESPONSES; INDUCED DIFFERENTIATION; BINDING PROTEIN; IN-VITRO; LEUKEMIA; SUBSTRATE; 1-ALPHA,25-DIHYDROXYVITAMIN-D3; IDENTIFICATION; PURIFICATION; MATURATION	1,25-Dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) primes NB4 cells for 12-O-tetradecanoylphorbol-13-acetate-induced monocytic differentiation in a dose- and sequence-dependent fashion, Experiments utilizing 1,25-(OH)(2)D-3 analogues and kinase/phosphatase inhibitors suggested that tyrosine kinase and serine/threonine phosphorylation cascades, rather than vitamin D-3 receptor-mediated signals, were involved in 1,25-(OH)(2)D-3 action. Here we show that NB4 cells express the alpha and delta (but not the beta, epsilon, and theta) isoforms of protein kinase C (PKC). Both authentic 1,25-(OH)(2)D-3 and the nongenomic analogue 1 alpha,25-dihydroxyprevitamin D-3 (HF) increased expression of PKC alpha and PKC delta. PKC alpha and PKC delta were translocated to the nucleus of the cell in response to 1,25-(OH)(2)D-3 or HF. The effects of HF were attenuated by the nongenomic antagonist 1 beta,25-dihydroxyvitamin D-3, suggesting that changes in PKC expression are mediated by a nongenomic signaling pathway. Consistent with the involvement of serine, threonine, and tyrosine phosphorylation cascades mediating 1,25-(OH)(2)D-3 action, enhanced phosphorylation of a variety of cellular proteins at serine and threonine residues and the specific enhanced phosphotyrosyl content of a 33-kDa protein (vdrp33) were observed immediately after 1,25-(OH)(2)D-3 addition. We propose that 1,25-(OH)(2)D-3 primes NB4 cells for 12-O-tetradecanoylphorbol-13-acetate-induced monocytic differentiation by increasing the expression of specific PRC isoforms and inducing the specific phosphorylation of key protein signaling intermediates.	UNIV GUELPH,DEPT HUMAN BIOL & NUTR SCI,GUELPH,ON N1G 2W1,CANADA	University of Guelph								AIHARA H, 1991, P NATL ACAD SCI USA, V88, P11062, DOI 10.1073/pnas.88.24.11062; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P7589, DOI 10.1021/bi00420a003; BHATIA M, 1995, BIOCHEM J, V308, P131, DOI 10.1042/bj3080131; BHATIA M, 1994, LEUKEMIA, V8, P1744; Bhatia M, 1996, EXP CELL RES, V222, P61, DOI 10.1006/excr.1996.0008; BHATIA M, 1995, J BIOL CHEM, V270, P15962, DOI 10.1074/jbc.270.27.15962; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHEN TC, 1993, J NUTR BIOCHEM, V4, P49, DOI 10.1016/0955-2863(93)90020-W; CIMLER BM, 1985, J BIOL CHEM, V260, P784; DELVA L, 1993, BLOOD, V82, P2175; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; ELDAR H, 1992, MOL BIOL CELL, V3, P1049, DOI 10.1091/mbc.3.9.1049; GAMARD CJ, 1994, CELL GROWTH DIFFER, V5, P405; GUPTAROY B, 1992, J BIOL CHEM, V267, P15326; HASS R, 1993, CELL GROWTH DIFFER, V4, P657; JONES G, 1993, TRENDS ENDOCRIN MET, V4, P297, DOI 10.1016/1043-2760(93)90049-K; JURUTKA PW, 1993, BIOCHEMISTRY-US, V32, P8184, DOI 10.1021/bi00083a019; KINDREGAN HC, 1994, J BIOL CHEM, V269, P27756; KOBAYASHI T, 1993, BIOCHEM BIOPH RES CO, V196, P487, DOI 10.1006/bbrc.1993.2276; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LANOTTE M, 1991, BLOOD, V77, P1080; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; NORMAN AW, 1993, J BIOL CHEM, V268, P13811; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; OMAY SB, 1995, CANCER RES, V55, P774; RYVES WJ, 1994, CARCINOGENESIS, V15, P2501, DOI 10.1093/carcin/15.11.2501; Studzinski George P., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P279; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; YADA Y, 1989, BIOCHEM BIOPH RES CO, V163, P1517, DOI 10.1016/0006-291X(89)91152-2	34	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16090	16096		10.1074/jbc.271.27.16090	http://dx.doi.org/10.1074/jbc.271.27.16090			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663234	hybrid			2022-12-27	WOS:A1996UW35200037
J	Nakano, H; Oshima, H; Chung, W; WilliamsAbbott, L; Ware, CF; Yagita, H; Okumura, K				Nakano, H; Oshima, H; Chung, W; WilliamsAbbott, L; Ware, CF; Yagita, H; Okumura, K			TRAF5, an activator of NF-kappa B and putative signal transducer for the lymphotoxin-beta receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Tumor necrosis factor (TNF) receptor-associated factors (TRAFs) are signal transducers for several members of the TNF receptor superfamily. We have identified a novel member of the TRAF family by degenerate oligonucleotide polymerase chain reaction amplification that contains a zinc RING finger and zinc finger motifs, a coiled-coil region, and a C-terminal ''TRAF'' homology domain. In vitro translated TRAF5 binds to the cytoplasmic region of the lymphotoxin-beta receptor (LT-beta R) but not to several other related receptors including CD40, both TNF receptors, Fas, and nerve growth factor receptor. TRAF5 and LT-beta R coimmunoprecipitate when overexpressed in COS7 cells. TRAF5 mRNA expression is found in all visceral organs and overlaps with LT-beta R. These features distinguish TRAF5 from the other members of the TRAF family. The transcription factor NF-kappa B is activated in HEK293 cells by overexpression of full length TRAF5 but not a truncated form lacking the zinc binding region, Furthermore, overexpression of LT-beta R in HEK293 cells also results in activation of NF-kappa B, which is partially inhibited by the truncated TRAF5 mutant. These results show TRAF5 is functionally similar to TRAF2 in that both mediate activation NF-kappa B and implicate TRAF5 as a signal transducer for LT-beta R.	UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521	University of California System; University of California Riverside	Nakano, H (corresponding author), JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,BUNKYO KU,2-1-1 HONGO,TOKYO 113,JAPAN.			Nakano, Hiroyasu/0000-0003-4843-1427	NIAID NIH HHS [AI33068] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033068, R37AI033068] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAENS M, 1995, GENOMICS, V29, P44, DOI 10.1006/geno.1995.1213; Baker SJ, 1996, ONCOGENE, V12, P1; BANKS TA, 1995, J IMMUNOL, V155, P1685; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; ECK MJ, 1992, J BIOL CHEM, V267, P2119; FORCE WR, 1995, J IMMUNOL, V155, P5280; FORCE WR, 1994, J BIOL CHEM, V269, P8863; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; KOOTEN CV, 1996, ADV IMMUNOL, V61, P1; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NAKANO H, 1994, NUCLEIC ACIDS RES, V22, P543, DOI 10.1093/nar/22.3.543; NAKANO H, 1994, MOL CELL BIOL, V14, P1213, DOI 10.1128/MCB.14.2.1213; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Togni PD, 1994, SCIENCE, V264, P703; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175	33	298	308	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14661	14664		10.1074/jbc.271.25.14661	http://dx.doi.org/10.1074/jbc.271.25.14661			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663299	hybrid			2022-12-27	WOS:A1996UT10600004
J	Ye, Q; Worman, HJ				Ye, Q; Worman, HJ			Interaction between an integral protein of the nuclear envelope inner membrane and human chromodomain proteins homologous to Drosophila HP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMIN-B-RECEPTOR; NONHISTONE CHROMOSOMAL PROTEIN; PRIMARY BILIARY-CIRRHOSIS; HETEROCHROMATIN PROTEIN; PHOSPHORYLATION; IDENTIFICATION; AUTOANTIBODIES; MELANOGASTER; MITOSIS; KINASE	At the nuclear envelope in higher eukaryotic cells, the nuclear lamina and the heterochromatin are adjacent to the inner nuclear membrane, and their attachment is presumably mediated by integral membrane proteins. In a yeast two hybrid screen, the nucleoplasmic domain of lamin B receptor (LBR), an integral protein of the inner nuclear membrane, associated with two human polypeptides homologous to Drosophila HP1, a heterochromatin protein involved in position-effect variegation. LBR fusion proteins bound to HP1 proteins synthesized by in vitro translation and present in cell lysates. Antibodies against LBR also co-immunoprecipitated HP1 proteins from cell extracts. LBR can interact with chromodomain proteins that are highly conserved in eukaryotic species and may function in the attachment of heterochromatin to the inner nuclear membrane in cells.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032	Columbia University; Columbia University								AASLAND R, 1995, NUCLEIC ACIDS RES, V23, P3168; APPELBAUM J, 1990, J BIOL CHEM, V265, P4181; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; CHAUDHARY N, 1993, J CELL BIOL, V122, P295, DOI 10.1083/jcb.122.2.295; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CLARK RF, 1992, NUCLEIC ACIDS RES, V22, P6067; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; COPPEL RL, 1988, P NATL ACAD SCI USA, V85, P7317, DOI 10.1073/pnas.85.19.7317; COURVALIN JC, 1990, J EXP MED, V172, P961, DOI 10.1084/jem.172.3.961; COURVALIN JC, 1992, J BIOL CHEM, V267, P19035; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EISSENBERG JC, 1994, J BIOL CHEM, V269, P21315; EISSENBERG JC, 1990, P NATL ACAD SCI USA, V87, P9923, DOI 10.1073/pnas.87.24.9923; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; MATHOG D, 1984, NATURE, V308, P414, DOI 10.1038/308414a0; Muller HJ, 1930, J GENET, V22, P299, DOI 10.1007/BF02984195; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; NICKOWITZ RE, 1994, GASTROENTEROLOGY, V106, P193, DOI 10.1016/S0016-5085(94)95333-3; PADDY MR, 1990, CELL, V62, P89, DOI 10.1016/0092-8674(90)90243-8; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; SAUNDERS WS, 1993, J CELL SCI, V104, P573; SCHULER E, 1994, J BIOL CHEM, V269, P11312; SIMOS G, 1992, EMBO J, V11, P4027, DOI 10.1002/j.1460-2075.1992.tb05496.x; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; WORMAN HJ, 1990, J CELL BIOL, V111, P1534; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676; YE Q, 1994, J BIOL CHEM, V269, P11306	35	330	336	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14653	14656		10.1074/jbc.271.25.14653	http://dx.doi.org/10.1074/jbc.271.25.14653			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663349	hybrid			2022-12-27	WOS:A1996UT10600002
J	Chandel, NS; Budinger, GRS; Schumacker, PT				Chandel, NS; Budinger, GRS; Schumacker, PT			Molecular oxygen modulates cytochrome c oxidase functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; ELECTRON-TRANSFER; HEPATOCYTES; OXIDATION; TURNOVER	This study sought to determine whether molecular oxygen interacts with cytochrome c oxidase to modify its catalytic activity, Such an interaction could explain the observation that mitochondria incubated under low O-2 concentrations exhibit a reversible suppression of State 3 respiration, Oxidized bovine heart cytochrome c oxidase was incubated in oxygen concentrations of < 50 mu M for 4 h, The enzyme exhibited a reversible decrease in V-max after incubation, compared with control enzyme incubated at higher oxygen concentrations, This change was accompanied by a small increase in the apparent K-m of the enzyme for both cytochrome c and oxygen, although the optical absorption spectra of oxidized, cycling, or reduced enzyme were not affected, Spectroscopy studies after 4 h of incubation revealed that heme a(3) was 33% reduced during cycling at [O-2] = 25 mu M whereas enzyme at [O-2] = 135 mu M was only 18% reduced, suggesting that the site of inhibition occurred at the electron transfer step between heme a(2) and O-2. These results provide a mechanistic explanation for the observation that intact cells or mitochondria exhibit a reversible inhibition of respiration during prolonged exposure to [O-2] < 25 mM, by demonstrating that the catalytic activity of cytochrome c oxidase function is similarly inhibited, possibly through an allosteric effect of molecular O-2 on the enzyme.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of Chicago				Schumacker, Paul T/0000-0001-9591-2034	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035440, R01HL032646, R55HL032646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32646, HL35440] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRUNORI M, 1995, BIOCHIMIE, V77, P668, DOI 10.1016/0300-9084(96)88182-X; BUDINGER GRS, 1996, AM J PHYSIOL, V14, pL37; CHANDEL N, 1995, AM J PHYSIOL-LUNG C, V268, pL918, DOI 10.1152/ajplung.1995.268.6.L918; COOPER CE, 1990, BIOCHIM BIOPHYS ACTA, V1017, P187, DOI 10.1016/0005-2728(90)90184-6; COPELAND RA, 1991, P NATL ACAD SCI USA, V88, P7281, DOI 10.1073/pnas.88.16.7281; CORNISHBOWDEN A, 1976, PRINCIPLES ENZYME KI; DIPAOLO ML, 1994, J BIOCHEM BIOPH METH, V28, P205, DOI 10.1016/0165-022X(94)90017-5; EINARSDOTTIR O, 1995, BBA-BIOENERGETICS, V1229, P129, DOI 10.1016/0005-2728(94)00196-C; ERREDE B, 1976, P NATL ACAD SCI USA, V73, P113, DOI 10.1073/pnas.73.1.113; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; FLEMING JE, 1983, INT J PEPT PROT RES, V22, P565; HARTZELL CR, 1974, BIOCHIM BIOPHYS ACTA, V368, P318, DOI 10.1016/0005-2728(74)90178-9; HILL BC, 1991, J BIOL CHEM, V266, P2219; HILL BC, 1994, J BIOL CHEM, V269, P2419; JONES DP, 1978, J BIOL CHEM, V253, P4874; LONGMUIR IS, 1957, BIOCHEM J, V65, P378, DOI 10.1042/bj0650378; MINNAERT K, 1961, BIOCHIM BIOPHYS ACTA, V50, P23, DOI 10.1016/0006-3002(61)91055-1; SCHUMACKER PT, 1993, AM J PHYSIOL, V265, pL395, DOI 10.1152/ajplung.1993.265.4.L395; SHERMAN D, 1991, P NATL ACAD SCI USA, V88, P4265, DOI 10.1073/pnas.88.10.4265; SINJORGO KMC, 1986, BIOCHIM BIOPHYS ACTA, V850, P108, DOI 10.1016/0005-2728(86)90014-9; SMITH L, 1956, ARCH BIOCHEM BIOPHYS, V63, P403, DOI 10.1016/0003-9861(56)90055-8; Wikstrom M., 1981, CYTOCHROME OXIDASE S; WILSON DF, 1988, J BIOL CHEM, V263, P2712; YONETANI T, 1965, J BIOL CHEM, V240, P3392	25	114	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18672	18677		10.1074/jbc.271.31.18672	http://dx.doi.org/10.1074/jbc.271.31.18672			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702521	hybrid			2022-12-27	WOS:A1996VB68300059
J	Patel, SB; Grundy, SM				Patel, SB; Grundy, SM			Interactions between microsomal triglyceride transfer protein and apolipoprotein B within the endoplasmic reticulum in a heterologous expression system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEP G2 CELLS; CARBOXYL-TERMINAL TRUNCATION; PRE-GOLGI COMPARTMENT; CONTAINING LIPOPROTEINS; QUALITY-CONTROL; GENE DEFECTS; LIVER-CELL; SECRETION; MEMBRANE; CALNEXIN	When apolipoprotein B (apoB) is expressed in heterologous cells, it is not secreted but retained and de graded within the endoplasmic reticulum (ER), We have previously characterized carboxyl-terminal truncated forms of apoB expressed in COS cells and have shown that these proteins were readily synthesized but retained within the ER and degraded, if the size of the truncated protein was larger than apoB 29, Below this size, the smaller the size of the apoB truncates, the greater the extent of secretion, although > 50% of these smaller proteins were also degraded within the ER, In the present study, we demonstrate that this secretory defect can be overcome by coexpression with microsomal triglyceride transfer protein (MTP); moreover, this complementation is inversely related to the size of apoB, Secretion of apoBs larger than B29 required the coexpression of MTP and, in the presence of MTP, was oleate-responsive, MTP, in the presence or absence of oleate supplementation, had little or no effect on the secretion of the shorter truncates, We discovered, however, that MTP was physically associated with all forms of apoB intracellularly (B13-B41), The association of MTP with apoB 41 was stable to high salt washing, as well as to low pH, suggesting that these interactions may be hydrophobic in nature, In addition to the interaction with MTP, apoB was also found to be associated with calnexin, confirming previous studies, and with proteins bearing the KDEL retention signal, However, studies on overexpression of human calnexin and tunicamycin inhibition of glycosylation showed that interaction with calnexin was not necessary for the formation or secretion of apoB 41-containing lipoproteins; moreover, in the presence of MTP, the association of calnexin with apoB 41 was transient or absent, These data suggest that for apoB to attain a folded state sufficient to escape the quality control of the ER, it needs to obtain neutral lipid (supplied by MTP), as well as its ability to keep it packaged as a rudimentary lipoprotein, dependent on its size being larger than B29.	UNIV TEXAS,SW MED CTR,CTR HUMAN NUTR,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT CLIN NUTR,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Patel, SB (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,Y3 208,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.			Patel, Shailendra/0000-0003-0046-5513	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029252, R37HL029252] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-29252] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; DAVID V, 1993, J BIOL CHEM, V268, P9585; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FOLCH J, 1957, J BIOL CHEM, V226, P497; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; KANE JP, 1980, P NATL ACAD SCI-BIOL, V77, P2465, DOI 10.1073/pnas.77.5.2465; KLAUSNER R D, 1989, New Biologist, V1, P3; KRUL ES, 1988, J LIPID RES, V29, P937; LABELLE M, 1990, BIOCHIM BIOPHYS ACTA, V1046, P288, DOI 10.1016/0005-2760(90)90243-Q; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LODISH HF, 1988, J BIOL CHEM, V263, P2107; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PATEL S, 1994, ATHEROSCLEROSIS, V108, P201, DOI 10.1016/0021-9150(94)90115-5; PATEL SB, 1995, J LIPID RES, V36, P2090; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PESSAH M, 1991, J CLIN INVEST, V87, P367, DOI 10.1172/JCI114996; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SATO R, 1990, J BIOL CHEM, V265, P11880; SCHUMAKER VN, 1994, ADV PROTEIN CHEM, V45, P205; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SIUTAMANGANO P, 1982, J BIOL CHEM, V257, P4292; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; WETTERAU JR, 1992, SCIENCE, V258, P999; WHITE AL, 1992, J BIOL CHEM, V267, P15657; YAO ZM, 1991, J BIOL CHEM, V266, P3300	48	93	93	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18686	18694		10.1074/jbc.271.31.18686	http://dx.doi.org/10.1074/jbc.271.31.18686			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702523	hybrid			2022-12-27	WOS:A1996VB68300061
J	Asai, N; Murakami, H; Iwashita, T; Takahashi, M				Asai, N; Murakami, H; Iwashita, T; Takahashi, M			A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with Shc adaptor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RET PROTOONCOGENE PRODUCTS; KINASE-ACTIVITY; PDGF RECEPTOR; DOMAIN; ACTIVATION; SEQUENCE; DISEASE; PHOSPHORYLATION; NEUROBLASTOMA; PP60C-SRC	Germ line mutations of the ret proto-oncogene are associated with the development of three dominantly inherited neoplastic disorders, multiple endocrine neoplasia (MEN) 2A, MEN 2B, and familial medullary thyroid carcinoma, It has been demonstrated that the mutations result in constitutive activation of the Ret protein, leading to transformation of MH 3T3 cells, In the present study we investigated the role of tyrosine residues present in the carboxyl-terminal sequence for the transforming activity of Ret with the MEN 2A or MEN 2B mutation (MENSA-Ret or MEN2B-Ret). Substitution of phenylalanine for tyrosine 1062 (designated Y1062F) markedly impaired the transforming activity of both MEN2A-Ret and MEN2B-Ret, whereas substitution or deletion for four other tyrosines (codons 981, 1015, 1090, and 1096) did not affect their activity, The She adaptor proteins bound to the MEN2A-Ret and MEN2B-Ret proteins and were phosphorylated on tyrosine in the transfectants. The binding of She to the Y1062F mutant proteins was reduced by approximately 80%, indicating that tyrosine 1062 is a major binding site for She. In addition, phosphopeptide analysis of MENSA-Ret demonstrated that tyrosine 1062 represents an autophosphorylation site of the mutant Ret proteins.	NAGOYA UNIV, SCH MED, DEPT PATHOL, SHOWA KU, NAGOYA, AICHI 466, JAPAN	Nagoya University			TAKAHASHI, Masahide/I-7244-2014; Takahashi, Masahide/AAN-4770-2020; ASAI, Naoya/I-7377-2014	Takahashi, Masahide/0000-0002-2803-2683; 				ASAI N, 1995, MOL CELL BIOL, V15, P1613; Borrello MG, 1995, ONCOGENE, V11, P2419; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; Geer P.V.D., 1991, MOL CELL BIOL, V11, P4698; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IWAMOTO T, 1993, ONCOGENE, V8, P1087; Iwashita T, 1996, ONCOGENE, V12, P481; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1995, CRIT REV ONCOGENESIS, V6, P35, DOI 10.1615/CritRevOncog.v6.i1.30; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	154	154	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17644	17649		10.1074/jbc.271.30.17644	http://dx.doi.org/10.1074/jbc.271.30.17644			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663426	hybrid			2022-12-27	WOS:A1996UY93500012
J	Dyck, JRB; Gao, G; Widmer, J; Stapleton, D; Fernandez, CS; Kemp, BE; Witters, LA				Dyck, JRB; Gao, G; Widmer, J; Stapleton, D; Fernandez, CS; Kemp, BE; Witters, LA			Regulation of 5-'AMP-activated protein kinase activity by the noncatalytic beta and gamma subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; YEAST SNF1; SACCHAROMYCES-CEREVISIAE; FATTY-ACID; METABOLISM; FAMILY; PURIFICATION; INHIBITION; REDUCTASE; CASCADE	The mammalian 5'-AMP-activated protein kinase is a heterotrimer consisting of an a catalytic subunit and beta and gamma noncatalytic subunits, each of which is represented in a larger isoprotein family, related to the SNF1 kinase and its interacting proteins in yeast, In this study, we have used mammalian cell transfection to compare the activities of the two alpha subunit isoforms, alpha-1 and alpha-2, and to study the influence of the noncatalytic subunits on enzyme subunit association and activity, Expression of epitope tagged protein subunits in COS7 cells indicates detectable but low level kinase activity for each of the two catalytic alpha subunits, Co expression of alpha subunits with the beta or gamma subunits modestly increases kinase activity accompanied by the formation of alpha/beta or alpha/gamma heterodimers. Go-expression of all three subunits, however, is accompanied by a 50-110-fold increase in kinase activity with the formation of a heterotrimeric complex, In addition to binding of each noncatalytic subunit to the or subunit, the beta and gamma subunits bind to each other, likely resulting in a more stable heterotrimeric complex, The increase in kinase activity associated with expression of this heterotrimer is due both to an increase in enzyme-specific activity (units/enzyme mass) and to an apparent enhanced alpha subunit expression, Go-expression of a catalytically defective alpha subunit or the beta/gamma-binding COOH-terminal domain of the alpha subunit results in reduced heterotrimeric kinase activity, The synergistic positive regulatory roles for both the noncatalytic beta and gamma subunits of 5'-AMP-activated protein kinase contrasts with the Snf1p kinase, where only heterodimers of Snf1p and Snf4p seem to be required for maximum kinase activity.	DARTMOUTH COLL SCH MED,DEPT MED,ENDOCRINE METAB DIV,HANOVER,NH 03755; DARTMOUTH COLL SCH MED,DEPT BIOCHEM,ENDOCRINE METAB DIV,HANOVER,NH 03755; ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA	Dartmouth College; Dartmouth College; St. Vincent's Institute of Medical Research			Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082; Dyck, Jason/0000-0002-7045-2884	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35712] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CARLING D, 1994, J BIOL CHEM, V269, P11442; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; DAVIES SP, 1994, EUR J BIOCHEM, V223, P351, DOI 10.1111/j.1432-1033.1994.tb19001.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAO G, 1995, BBA-MOL CELL RES, V1266, P73, DOI 10.1016/0167-4889(94)00222-Z; Gao G, 1996, J BIOL CHEM, V271, P8675, DOI 10.1074/jbc.271.15.8675; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARDIE DG, 1992, BIOESSAYS, V14, P699, DOI 10.1002/bies.950141011; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; LOUIS NA, 1992, J BIOL CHEM, V267, P2287; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SATOH M, 1995, EUR J CELL BIOL, V66, P27; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; WILEMAN T, 1993, J CELL BIOL, V122, P67, DOI 10.1083/jcb.122.1.67; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; WOODS A, 1994, J BIOL CHEM, V269, P19509; YANG XL, 1994, EMBO J, V13, P5878, DOI 10.1002/j.1460-2075.1994.tb06933.x; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382	28	162	167	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17798	17803		10.1074/jbc.271.30.17798	http://dx.doi.org/10.1074/jbc.271.30.17798			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663446	hybrid			2022-12-27	WOS:A1996UY93500034
J	Hoffmann, A; Roeder, RG				Hoffmann, A; Roeder, RG			Cloning and characterization of human TAF20/15 - Multiple interactions suggest a central role in TFIID complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TATA-BINDING PROTEIN; TRANSCRIPTION FACTOR ATF; IMMEDIATE EARLY PROTEIN; CONSERVED CORE DOMAIN; PROMOTER INTERACTIONS; MOLECULAR-CLONING; PREINITIATION COMPLEX; ACCURATE INITIATION; BASAL TRANSCRIPTION	TFIID is a multiprotein complex that plays a central role in the initiation and regulation of class II transcription. Transcription factor IID (TFIID) nucleates transcription initiation complex formation by direct core promoter binding and mediates the action of transcriptional activators, in part via direct interactions with them. Molecular studies of the TFIID complex have identified multiple subunits whose potential interactions can be recapitulated in vitro with recombinant polypeptides, Here we report the cloning of human TATA box binding protein (TBP)-associated factor 20 (TAF20) and the consequent identification of an additional, related TFIID subunit, human TAF15 (hTAF15), Multiple TAF20/15 interactions have been detected within native TFIID preparations and further analyzed with recombinant subunits. Along with the demonstration of a high affinity association between TAF20/15 and TBP, the present results suggest that hTAF20/15 may complement hTAF250 in directing the association of TAFs with TBP to form a TFIID complex. Finally, we present detailed mutagenesis studies that reveal multiple, distinct interaction surfaces on the presumed globular domain of hTAF20/15 and may be used, in conjunction with structural data, to model the architecture of the TFIID multiprotein complex.	ROCKEFELLER UNIV, BIOCHEM & MOLEC BIOL LAB, NEW YORK, NY 10021 USA	Rockefeller University								ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; HOFFMANN A, 1994, MOL CHARACTERIZATION; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MENGUS G, 1995, EMBO J, V14, P1520, DOI 10.1002/j.1460-2075.1995.tb07138.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WEIL PA, 1979, CELL, V18, P469; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZAWEL Z, 1993, PROG NUCL ACIDS RES, V44, P67; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	47	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18194	18202		10.1074/jbc.271.30.18194	http://dx.doi.org/10.1074/jbc.271.30.18194			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663456	hybrid			2022-12-27	WOS:A1996UY93500091
J	Albury, MS; Dudley, P; Watts, FZ; Moore, AL				Albury, MS; Dudley, P; Watts, FZ; Moore, AL			Targeting the plant alternative oxidase protein to Schizosaccharomyces pombe mitochondria confers cyanide-insensitive respiration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SAUROMATUM-GUTTATUM SCHOTT; RESISTANT RESPIRATION; ELECTRON-TRANSPORT; HANSENULA-ANOMALA; CLONING; CDNA; GENE; PATHWAY; IMPORT; POOL	The Sauromatum guttatum alternative oxidase has been expressed in Schizosaccharomyces pombe under the control of the thiamine repressible nmt1 promoter. Alternative oxidase protein and activity were detected both in spheroplasts and isolated mitochondria, indicating that the enzyme is expressed in a functional form and confers cyanide-resistant respiration to S. pombe, which is sensitive to inhibition by octyl-gallate. Protein import studies revealed that the precursor form of the alternative oxidase protein is efficiently imported into isolated mitochondria and processed to its mature form comparable to that observed with potato mitochondria. Western blot analysis and respiratory studies revealed that the alternative oxidase protein is expressed in the inner mitochondrial membrane in its reduced (active) form, Treatment of mitochondria with diamide and dithiothreitol resulted in interconversion of the reduced and oxidized species and modulation of respiratory activity. The addition of pyruvate did not effect either the respiratory rate or expression of the reduced species of the protein, To our knowledge this is the first time that the alternative oxidase has been effectively targeted to and integrated into the inner mitochondrial membrane of S. pombe, and we conclude that the expression of a single polypeptide is sufficient for alternative oxidase activity.	UNIV SUSSEX,SCH BIOL SCI,DEPT BIOCHEM,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND	University of Sussex								DAY DA, 1995, AUST J PLANT PHYSIOL, V22, P497, DOI 10.1071/PP9950497; DRY IB, 1989, ARCH BIOCHEM BIOPHYS, V273, P148, DOI 10.1016/0003-9861(89)90173-2; ELTHON TE, 1989, PLANT PHYSIOL, V89, P1311, DOI 10.1104/pp.89.4.1311; ELTHON TE, 1989, PLANTA, V180, P82, DOI 10.1007/BF02411413; HOEFNAGEL MHN, 1995, EUR J BIOCHEM, V233, P531, DOI 10.1111/j.1432-1033.1995.531_2.x; HOEFNAGEL MHN, 1995, ARCH BIOCHEM BIOPHYS, V318, P394, DOI 10.1006/abbi.1995.1245; KEARNS A, 1992, PLANT PHYSIOL, V99, P712, DOI 10.1104/pp.99.2.712; KUMAR AM, 1992, P NATL ACAD SCI USA, V89, P10842, DOI 10.1073/pnas.89.22.10842; LAEMMLI UK, 1970, NATURE, V227, P415; Leach GR, 1996, BIOCHEM J, V317, P313, DOI 10.1042/bj3170313; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCINTOSH L, 1994, PLANT PHYSIOL, V105, P781, DOI 10.1104/pp.105.3.781; MINAGAWA N, 1990, FEBS LETT, V264, P149, DOI 10.1016/0014-5793(90)80787-J; MOORE AL, 1988, FEBS LETT, V235, P76, DOI 10.1016/0014-5793(88)81237-7; MOORE AL, 1992, YEAST, V8, P923, DOI 10.1002/yea.320081103; MOORE AL, 1995, J BIOENERG BIOMEMBR, V27, P367, DOI 10.1007/BF02109999; MOORE AL, 1994, ANNU REV PLANT PHYS, V45, P545, DOI 10.1146/annurev.pp.45.060194.002553; MOORE AL, 1991, BIOCHIM BIOPHYS ACTA, V1059, P121, DOI 10.1016/S0005-2728(05)80197-5; MOORE AL, 1991, PLANT PHYSIOL, V95, P34, DOI 10.1104/pp.95.1.34; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; MURRAY JM, 1991, NUCLEIC ACIDS RES, V19, P3525, DOI 10.1093/nar/19.13.3525; Nordlund P, 1995, CURR OPIN STRUC BIOL, V5, P758, DOI 10.1016/0959-440X(95)80008-5; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; RHOADS DM, 1991, P NATL ACAD SCI USA, V88, P2122, DOI 10.1073/pnas.88.6.2122; RIBAS-CARBO M, 1995, ARCH BIOCHEM BIOPHYS, V317, P156, DOI 10.1006/abbi.1995.1148; SAKAJO S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P102; Sambrook J., 2002, MOL CLONING LAB MANU; SIEDOW JN, 1995, FEBS LETT, V362, P10, DOI 10.1016/0014-5793(95)00196-G; SIEDOW JN, 1995, PLANT CELL, V7, P821, DOI 10.1105/tpc.7.7.821; SIEDOW JN, 1993, BIOCHIM BIOPHYS ACTA, V1142, P165, DOI 10.1016/0005-2728(93)90098-Z; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMBACH AL, 1993, PLANT PHYSIOL, V103, P845, DOI 10.1104/pp.103.3.845; VANDENBERGEN CWM, 1994, EUR J BIOCHEM, V226, P1071; VANLERBERGHE GC, 1995, PLANT PHYSIOL, V109, P353, DOI 10.1104/pp.109.2.353; WAGNER AM, 1995, PHYSIOL PLANTARUM, V95, P318, DOI 10.1111/j.1399-3054.1995.tb00844.x; WATTS FZ, 1992, PLANT MOL BIOL, V18, P23, DOI 10.1007/BF00018453; WEBER A, 1995, BIOCHEMISTRY-US, V34, P2621, DOI 10.1021/bi00008a028; Whelan J, 1996, PLANTA, V198, P197, DOI 10.1007/BF00206244; WHITEHOUSE DG, 1989, PLANT PHYSIOL, V91, P487, DOI 10.1104/pp.91.2.487	41	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17062	17066		10.1074/jbc.271.29.17062	http://dx.doi.org/10.1074/jbc.271.29.17062			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663588	hybrid			2022-12-27	WOS:A1996UX94300015
J	Herrlich, A; Kuhn, B; Grosse, R; Schmid, A; Schultz, G; Gudermann, T				Herrlich, A; Kuhn, B; Grosse, R; Schmid, A; Schultz, G; Gudermann, T			Involvement of G(s) and G(i) proteins in dual coupling of the luteinizing hormone receptor to adenylyl cyclase and phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; BETA-GAMMA-SUBUNITS; LEYDIG TUMOR-CELLS; ALPHA-SUBUNITS; CA2+ MOBILIZATION; ACTIVATION; GONADOTROPIN; CLONING; IDENTIFICATION; VASOPRESSIN	Binding of lutropin/choriogonadotropin to its cognate receptor results in the activation of adenylyl cyclase and phospholipase C, The mechanism underlying the generation of this bifurcating signal is presently not known. To analyze the coupling mechanism of the LH receptor, activated G proteins were labeled with [alpha-P-32]GTP azidoanilide and identified by selective immunoprecipitation, In membranes of bovine corpora lutea and of L cells stably expressing the murine LH receptor (LHR cells), human chorionic gonadotropin (hCG) led to incorporation of the label into alpha(s) and alpha(i2). Stimulation of LHR cells or of L cells expressing the M(5) muscarinic receptor (LM5 cells) with the respective agonist resulted in activation of phospholipase C in both cell lines, However, alpha(q) and alpha(11) were only labeled upon stimulation of the Ms muscarinic receptor, Agonist-induced Ca2+ mobilization and inositol phosphate accumulation were partially sensitive to pertussis toxin, and the expression of the beta gamma-stimulable phospholipase C isoforms beta 2 and beta 3 could be demonstrated in LHR cells, Overexpression of phospholipase C-beta 2 led to increased hCG-stimulated inositol phosphate accumulation, and expression of a beta-ARK1 C-terminal polypeptide effectively suppressed hCG-mediated phosphatidylinositol hydrolysis, Thus, the LH receptor couples to both G(s) and G(i), and beta gamma-subunits released from either G protein contribute to the stimulation of phospholipase C-beta isoforms.	FREE UNIV BERLIN, INST PHARMAKOL, D-14195 BERLIN, GERMANY	Free University of Berlin				Grosse, Robert/0000-0002-3380-5273				ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; ASCOLI M, 1989, J BIOL CHEM, V264, P6674; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BRISTOL JA, 1994, TRENDS ENDOCRIN MET, V5, P402, DOI 10.1016/1043-2760(95)92522-K; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS JS, 1987, J BIOL CHEM, V262, P8515; EASON MG, 1992, J BIOL CHEM, V267, P15795; FAURE M, 1994, J BIOL CHEM, V269, P7851; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUDERMANN T, 1992, MOL ENDOCRINOL, V6, P272, DOI 10.1210/me.6.2.272; GUDERMANN T, 1995, MOL CELL ENDOCRINOL, V110, P125, DOI 10.1016/0303-7207(95)03538-I; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; GUERMANN T, 1996, ANN REV PHARM TOXICO, V36, P429; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIPKIN RW, 1993, MOL ENDOCRINOL, V7, P823, DOI 10.1210/me.7.7.823; HIPKIN RW, 1995, MOL ENDOCRINOL, V9, P151, DOI 10.1210/me.9.2.151; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; INOUE Y, 1989, J BIOL CHEM, V264, P8504; JHON DY, 1993, J BIOL CHEM, V268, P6654; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LAUGWITZ KL, 1994, METHOD ENZYMOL, V237, P283; LAUGWITZ KL, 1993, NEURON, V10, P23; LEUNG PCK, 1992, ENDOCR REV, V13, P476, DOI 10.1210/er.13.3.476; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LIAO CF, 1990, J BIOL CHEM, V265, P11273; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; OFFERMANNS S, 1991, METHOD ENZYMOL, V195, P286; PARK D, 1992, J BIOL CHEM, V267, P16048; PRATHER PL, 1994, J BIOL CHEM, V269, P21293; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; QUINTANA J, 1994, J BIOL CHEM, V269, P8772; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; ROSENTHAL W, 1983, THESIS J LIEBIG U GI; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMID A, 1995, EUR J BIOCHEM, V228, P23, DOI 10.1111/j.1432-1033.1995.tb20223.x; SHI H, 1995, MOL ENDOCRINOL, V9, P734, DOI 10.1210/me.9.6.734; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TOMIC M, 1995, ENDOCRINOLOGY, V136, P3422, DOI 10.1210/en.136.8.3422; VANSANDE J, 1990, MOL CELL ENDOCRINOL, V74, pR1, DOI 10.1016/0303-7207(90)90209-Q; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WU DQ, 1995, J BIOL CHEM, V270, P16008, DOI 10.1074/jbc.270.27.16008; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141; ZHU X, 1993, J BIOL CHEM, V268, P1723; ZHU X, 1994, MOL PHARMACOL, V46, P460	54	117	121	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16764	16772		10.1074/jbc.271.28.16764	http://dx.doi.org/10.1074/jbc.271.28.16764			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663226	hybrid			2022-12-27	WOS:A1996UX12600055
J	Wong, EFS; Brar, SK; Sesaki, H; Yang, CZ; Siu, CH				Wong, EFS; Brar, SK; Sesaki, H; Yang, CZ; Siu, CH			Molecular cloning and characterization of DdCAD-1, a Ca2+-dependent cell-cell adhesion molecule, in Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; SITE-A GLYCOPROTEIN; SURFACE GLYCOPROTEIN; 3-DIMENSIONAL STRUCTURE; MYXOCOCCUS-XANTHUS; CAMP SECRETION; SEQUENCE; CONTACT; IDENTIFICATION; EXPRESSION	Dictyostelium discoideum expresses EDTA-sensitive cell-cell adhesion sites soon after the initiation of development, and a Ca2+-binding protein of M(r) 24,000 (designated DdCAD-1) has been implicated in this type of adhesiveness, We have previously purified DdCAD-1 to homogeneity and characterized its cell binding activity (Brar, S. K., and Siu, C,-H. (1993) J. Biol. Chem, 268, 24902-24909), In this report, we describe the cloning of DdCAD-1 cDNAs, DNA sequencing revealed a single open reading frame coding for a polypeptide containing 213 amino acids, The identity of the cDNA was confirmed by amino acid sequences of two cyanogen bromide peptides, The deduced amino acid sequence of DdCAD-1 exhibits a relatively high degree of sequence similarity with members of the cadherin family and protein S of Myxococcus xanthus. Unlike the other cadherins, the carboxyl-terminal region of DdCAD-1 contains a Ca2+-binding motif. Although analyses of the sequence suggest that the polypeptide lacks a signal peptide sequence and a transmembrane domain, immunofluorescence microscopy demonstrates the association of DdCAD-1 with the ecto-surface of the plasma membrane, To investigate the structure/function relationships of DdCAD-1, glutathione S-transferase fusion proteins containing different DdCAD-1 fragments were expressed and assayed for their Ca-45(2+) and cell binding activities, These studies revealed that the cell binding activity is dependent on the amino-terminal segment and not the carboxyl-terminal Ca2+-binding domain and showed additional Ca2+-binding site(s) within the amino terminal segment.	UNIV TORONTO,CHARLES H BEST INST,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5G 1L6,CANADA	University of Toronto; University of Toronto								AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BAGBY S, 1994, BIOCHEMISTRY-US, V33, P2409, DOI 10.1021/bi00175a009; BAGBY S, 1994, STRUCTURE, V2, P107, DOI 10.1016/S0969-2126(00)00013-7; BAGBY S, 1994, P NATL ACAD SCI USA, V91, P4208; BEUG H, 1973, J CELL BIOL, V56, P647, DOI 10.1083/jcb.56.3.647; BLASCHUK OW, 1995, ENDOCRINE, V3, P83, DOI 10.1007/BF02990057; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BRAR SK, 1993, J BIOL CHEM, V268, P24902; BRAR SK, 1994, THESIS U TORONTO TOR; BRODIE C, 1983, CELL, V32, P1115, DOI 10.1016/0092-8674(83)90295-7; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1979, BIOPHYS J, V26, P367, DOI 10.1016/S0006-3495(79)85259-5; DAMSKY CH, 1983, CELL, V34, P455, DOI 10.1016/0092-8674(83)90379-3; DESBARATS L, 1994, J CELL SCI, V107, P1705; DESBARATS L, 1992, J BIOL CHEM, V267, P19655; DWORKIN M, 1964, SCIENCE, V146, P243, DOI 10.1126/science.146.3641.243; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; FONTANA DR, 1989, DIFFERENTIATION, V41, P184, DOI 10.1111/j.1432-0436.1989.tb00746.x; FONTANA DR, 1991, DEV GENET, V12, P54, DOI 10.1002/dvg.1020120111; FONTANA DR, 1995, PRINCIPLES CELL ADHE, P63; FONTANA DR, 1990, MOL CELL BIOL, V11, P468; GAO EN, 1992, J BIOL CHEM, V267, P9409; GARROD DR, 1972, EXP CELL RES, V72, P588, DOI 10.1016/0014-4827(72)90041-9; GELTOSKY JE, 1979, CELL, V18, P391, DOI 10.1016/0092-8674(79)90058-8; GERISCH G, 1961, EXP CELL RES, V25, P535, DOI 10.1016/0014-4827(61)90189-6; GERISCH G, 1980, CURR TOP DEV BIOL, V14, P234; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; INOUYE M, 1979, P NATL ACAD SCI USA, V76, P209, DOI 10.1073/pnas.76.1.209; INOUYE S, 1983, P NATL ACAD SCI-BIOL, V80, P6829, DOI 10.1073/pnas.80.22.6829; KAMBOJ RK, 1989, CELL, V59, P615, DOI 10.1016/0092-8674(89)90007-X; KAMBOJ RK, 1988, J CELL BIOL, V107, P1835, DOI 10.1083/jcb.107.5.1835; KIMMEL AR, 1983, NUCLEIC ACIDS RES, V11, P541, DOI 10.1093/nar/11.2.541; KNECHT DA, 1987, DEV BIOL, V121, P277, DOI 10.1016/0012-1606(87)90160-6; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LAM TY, 1981, DIFFERENTIATION, V20, P22, DOI 10.1111/j.1432-0436.1981.tb01151.x; Loomis W F, 1991, Antisense Res Dev, V1, P255; LOOMIS WF, 1988, DEV GENET, V9, P549, DOI 10.1002/dvg.1020090431; LOOMIS WF, 1993, CURR TOP DEV BIOL, V28, P1, DOI 10.1016/S0070-2153(08)60208-2; LOOMIS WF, 1990, P NATL ACAD SCI USA, V87, P886, DOI 10.1073/pnas.87.3.886; MA PCC, 1990, MOL CELL BIOL, V10, P3297, DOI 10.1128/MCB.10.7.3297; MANN SKO, 1989, P NATL ACAD SCI USA, V86, P1924, DOI 10.1073/pnas.86.6.1924; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATSUNAGA T, 1987, SCAND J IMMUNOL, V25, P485, DOI 10.1111/j.1365-3083.1987.tb02220.x; MCTIGUE MA, 1995, J MOL BIOL, V246, P21, DOI 10.1006/jmbi.1994.0061; MULLER K, 1978, NATURE, V274, P445, DOI 10.1038/274445a0; NOEGEL A, 1986, EMBO J, V5, P1473, DOI 10.1002/j.1460-2075.1986.tb04384.x; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; POLJAK RJ, 1974, P NATL ACAD SCI USA, V71, P3440, DOI 10.1073/pnas.71.9.3440; REDIES C, 1995, EXP CELL RES, V220, P243, DOI 10.1006/excr.1995.1313; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SIN CH, 1985, J BIOL CHEM, V260, P16030; Siu C.-H., 1988, P119; SIU CH, 1990, DEV GENET, V11, P377, DOI 10.1002/dvg.1020110509; SIU CH, 1988, BIOCHEM CELL BIOL, V66, P1089, DOI 10.1139/o88-126; SIU CH, 1992, J CELL PHYSIOL, V152, P157, DOI 10.1002/jcp.1041520120; SIU CH, 1987, J CELL BIOL, V105, P2523, DOI 10.1083/jcb.105.6.2523; SIU CH, 1983, P NATL ACAD SCI-BIOL, V80, P6596, DOI 10.1073/pnas.80.21.6596; SIU CH, 1990, BIOESSAYS, V12, P357, DOI 10.1002/bies.950120802; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Sussman M., 1966, METHOD CELL PHYSIOL, V2, P397; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Walsh FS, 1993, CURR OPIN CELL BIOL, V5, P791, DOI 10.1016/0955-0674(93)90027-N; WARRICK HM, 1988, NUCLEIC ACIDS RES, V16, P6617, DOI 10.1093/nar/16.14.6617; WONG LM, 1986, P NATL ACAD SCI USA, V83, P4248, DOI 10.1073/pnas.83.12.4248	75	70	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16399	16408		10.1074/jbc.271.27.16399	http://dx.doi.org/10.1074/jbc.271.27.16399			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663243	hybrid			2022-12-27	WOS:A1996UW35200080
J	Sugano, M; Makino, N				Sugano, M; Makino, N			Changes in plasma lipoprotein cholesterol levels by antisense oligodeoxynucleotides against cholesteryl ester transfer protein in cholesterol-fed rabbits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TRANSGENIC MICE; FAMILIAL HYPERALPHALIPOPROTEINEMIA; DENSITY LIPOPROTEINS; NUCLEIC-ACIDS; IN-VIVO; GENE; RECEPTOR; OLIGONUCLEOTIDES; DEFICIENCY	Cholesteryl ester transfer protein (CETP) is the enzyme that facilitates the transfer of cholesteryl ester from high density lipoprotein (HDL) to apoB-containing. lipoproteins and also affects the low density lipoprotein metabolism, On the other hand, the liver is the major tissue responsible for the production of CETP (CETP mRNA) in rabbits, To test the hypothesis that a reduction of CETP mRNA in the liver by antisense oligodeoxynucleotides (ODNs) may affect the plasma lipoprotein cholesterol levels, we intravenously injected antisense ODNs against rabbit CETP coupled with asialoglycoprotein carrier molecules, which serve as an important method to regulate liver gene expression, to cholesterol-fed rabbits via their ear veins, All rabbits were fed a standard rabbit chow supplement with 0.1% cholesterol for 10 weeks before and throughout the experiment, After injecting rabbits with antisense ODNs, the plasma total cholesterol concentrations and plasma CETP activities all decreased at 24, 48, and 96 h, whereas the plasma HDL cholesterol concentrations increased at 48 h, A reduction in the hepatic CETP mRNA was also observed at 6, 24, and 48 h after tire injection with antisense ODNs, However, in the rabbits injected with sense ODNs, the plasma total and HDL cholesterol concentrations and the plasma CETP activities did not significantly change, and the hepatic CETP mRNA did not change either throughout: the experimental period. Although the exact role of CETP in the development of atherosclerosis remains to be clarified, these findings showed for the first time that the intravenous injection with antisense ODNs against CETP coupled to asialoglycoprotein carrier molecules targeted to the liver could thus inhibit plasma CETP activity and, as a result, could induce a decrease in the plasma low density lipoprotein and very low density lipoprotein cholesterol and an increase in the plasma HDL cholesterol in cholesterol-fed rabbits.			Sugano, M (corresponding author), KYUSHU UNIV, MED INST BIOREGULAT, DEPT BIOCLIMATOL & MED, 4546 TSURUMIHARA, BEPPU, OITA 874, JAPAN.							BROWN ML, 1989, NATURE, V342, P448, DOI 10.1038/342448a0; CHIOU HC, 1994, NUCLEIC ACIDS RES, V22, P5439, DOI 10.1093/nar/22.24.5439; FIELDING CJ, 1995, J LIPID RES, V36, P211; HA YC, 1982, COMP BIOCHEM PHYS B, V71, P265, DOI 10.1016/0305-0491(82)90252-8; HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255; HAYEK T, 1992, J CLIN INVEST, V90, P505, DOI 10.1172/JCI115887; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HESLER CB, 1987, J BIOL CHEM, V262, P2275; IKEWAKI K, 1995, J CLIN INVEST, V96, P1573, DOI 10.1172/JCI118196; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; JIANG XC, 1993, J BIOL CHEM, V268, P27406; KOIZUMI J, 1985, ATHEROSCLEROSIS, V58, P175, DOI 10.1016/0021-9150(85)90064-4; LINLEE YC, 1985, BIOCHEMISTRY-US, V24, P3751, DOI 10.1021/bi00335a050; LU XM, 1994, J NUCL MED, V35, P269; MANN CJ, 1991, J CLIN INVEST, V88, P2059, DOI 10.1172/JCI115535; MAROTTI KR, 1993, NATURE, V364, P73, DOI 10.1038/364073a0; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; NAGASHIMA M, 1988, J LIPID RES, V29, P1643; PAPE ME, 1991, ARTERIOSCLER THROMB, V11, P1759, DOI 10.1161/01.ATV.11.6.1759; PIWNICAWORMS D, 1994, J NUCL MED, V35, P1064; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; SAITO F, 1984, METABOLISM, V33, P629, DOI 10.1016/0026-0495(84)90061-1; SPADY DK, 1985, J LIPID RES, V26, P465; SPADY DK, 1983, P NATL ACAD SCI-BIOL, V80, P3499, DOI 10.1073/pnas.80.11.3499; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; SUGANO M, 1991, CIRCULATION, V84, pA378; TALL AR, 1986, J LIPID RES, V27, P361; TOMITA N, 1995, HYPERTENSION, V26, P131, DOI 10.1161/01.HYP.26.1.131; WARNICK GR, 1978, J LIPID RES, V19, P65; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1991, J BIOL CHEM, V266, P14338; YEN FT, 1989, J CLIN INVEST, V83, P2018, DOI 10.1172/JCI114112; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	35	43	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19080	19083		10.1074/jbc.271.32.19080	http://dx.doi.org/10.1074/jbc.271.32.19080			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702580	hybrid			2022-12-27	WOS:A1996VB68400014
J	Li, Q; Jungmann, V; Kiyatkin, A; Low, PS				Li, Q; Jungmann, V; Kiyatkin, A; Low, PS			Prostaglandin E(2) stimulates a Ca2+-dependent K+ channel in human erythrocytes and alters cell volume and filterability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRREVERSIBLY SICKLED CELLS; MEMBRANE NUCLEAR FILTERS; RED BLOOD-CELLS; GEOMETRICAL PARAMETERS; MECHANICAL-PROPERTIES; THEORETICAL-MODEL; AGGREGATION; INHIBITION; TRANSPORT; CLOTRIMAZOLE	To understand the mechanism by which human red blood cells (RBCs) contribute to hemostasis and thrombosis, we have examined the effects of metabolites released by activated platelets on intact RBCs, Prostaglandin E(2) (PGE(2)), a signal molecule produced by activated platelets, was observed to lower the filterability of human erythrocytes by similar to 30% at 10(-10) M. PGE(2) also caused a reduction in mean cell volume of similar to 10%. The shrinkage of red cells after PGE(2) treatment was confirmed by documenting a decrease in osmotic fragility and an increase in cell density following exposure to the hormone. Careful analysis, however, revealed that only similar to 15% of the erythrocytes responded to stimulation with PGE(2). Examination of the cause of cell shrinkage showed that induction of a PGE(2)-stimulated K+ efflux pathway leading to rapid loss of cellular K+ was responsible, The PGE(2)-stimulated K+ loss was also observed to be Ca2+-dependent, suggesting the possible involvement of the Gardos channel, Gardos channel participation was supported by the observation that two Gardos channel inhibitors, charybdotoxin and clotrimazole, independently blocked the PGE(2)-stimulated K+ efflux, Further evidence for Gardos channel activation came from experiments aimed at characterizing the efflux pathway followed by the obligatory counterion. Thus, K+ efflux was readily stimulated even when NOB was substituted for Cl-, suggesting that neither KCl cotransport nor Na/K/2Cl cotransport plays a prominent role in the PGE(2)-induced cell shrinkage, Further, the anion transporter band 3 was implicated as the counterion efflux route, since DIDS inhibited the PGE(2) stimulated cell volume change without blocking the change in membrane potential, Taken together, we propose that release of PGE(2) by activated platelets constitutes part of a mechanism by which activated platelets may recruit adjacent erythrocytes to assist in clot formation.	PURDUE UNIV, DEPT CHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus			Kiyatkin, Anatoly/A-8707-2009	Kiyatkin, Anatoly/0000-0002-5060-6081; Low, Philip/0000-0001-9042-5528	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024417, R01GM024417] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24417] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JE, 1971, SCIENCE, V174, P512, DOI 10.1126/science.174.4008.512; Ambrosioni E, 1993, Ann Ital Med Int, V8 Suppl, p59S; ATAULLAHANOV FI, 1994, BIOFIZIKA+, V39, P672; BRUGNARA C, 1993, J BIOL CHEM, V268, P8760; BRUGNARA C, 1995, J PHARMACOL EXP THER, V273, P266; BRUGNARA C, 1993, J CLIN INVEST, V92, P520, DOI 10.1172/JCI116597; CORASH LM, 1974, J LAB CLIN MED, V84, P147; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; DOWNEY GP, 1995, J CELL PHYSIOL, V163, P96, DOI 10.1002/jcp.1041630111; Duke WW, 1910, J AMER MED ASSOC, V55, P1185, DOI 10.1001/jama.1910.04330140029009; FUNDER J, 1967, ACTA PHYSIOL SCAND, V71, P113, DOI 10.1111/j.1748-1716.1967.tb03716.x; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P653, DOI 10.1016/0006-3002(58)90124-0; GECK P, 1980, BIOCHIM BIOPHYS ACTA, V600, P432, DOI 10.1016/0005-2736(80)90446-0; GLADER BE, 1978, BLOOD, V51, P983; HELLEM AJ, 1961, BRIT J HAEMATOL, V7, P42, DOI 10.1111/j.1365-2141.1961.tb00318.x; HELLEM ARVID JOHN, 1960, SCAND JOUR CLIN AND LAB INVEST, V12, P1; HLADKY SB, 1976, J PHYSIOL-LONDON, V263, P287, DOI 10.1113/jphysiol.1976.sp011632; JOHNSON RM, 1992, BIOCHIM BIOPHYS ACTA, V1107, P314, DOI 10.1016/0005-2736(92)90418-L; KAJI DM, 1993, AM J PHYSIOL, V264, pC376, DOI 10.1152/ajpcell.1993.264.2.C376; LISOVSKAYA IL, 1994, BIOFIZIKA+, V39, P864; LIVIO M, 1982, LANCET, V2, P1013; MORRIS GP, 1984, CAN J PHYSIOL PHARM, V62, P1065, DOI 10.1139/y84-178; MULLANEY PF, 1970, BIOPHYS J, V10, P764, DOI 10.1016/S0006-3495(70)86334-2; MUSTARD JF, 1970, PHARMACOL REV, V22, P97; NAKAHATA N, 1992, FOLIA PHARMACOL JPN, V99, P1, DOI 10.1254/fpj.99.1; OHNISHI ST, 1989, BIOCHIM BIOPHYS ACTA, V1010, P199; RASMUSSEN H, 1975, BIOCHIM BIOPHYS ACTA, V411, P63, DOI 10.1016/0304-4165(75)90285-8; SANIABADI AR, 1985, THROMB RES, V38, P225, DOI 10.1016/0049-3848(85)90150-1; SANTOS MT, 1991, J CLIN INVEST, V87, P571, DOI 10.1172/JCI115032; SMITH JB, 1973, J CLIN INVEST, V52, P965, DOI 10.1172/JCI107262; TOKUDA H, 1992, PROSTAGLANDINS, V43, P271, DOI 10.1016/0090-6980(92)90095-B; TOMIMOTO Y, 1991, NIPPON JINZO GAKKAIS, V30, P1141; TORIYAMA K, 1992, PROSTAG LEUKOTR ESS, V46, P15, DOI 10.1016/0952-3278(92)90053-L; VALLES J, 1991, BLOOD, V78, P154; ZOLTAY G, 1994, NEUROCHEM RES, V19, P1211, DOI 10.1007/BF00965158	35	79	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18651	18656		10.1074/jbc.271.31.18651	http://dx.doi.org/10.1074/jbc.271.31.18651			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702518	hybrid			2022-12-27	WOS:A1996VB68300056
J	Mignaco, JA; Barrabin, H; Scofano, HM				Mignaco, JA; Barrabin, H; Scofano, HM			Effects of photo-oxidizing analogs of fluorescein on the sarcoplasmic reticulum Ca2+-ATPase - Functional consequences for substrate hydrolysis and effects on the partial reactions of the hydrolytic cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING SITES; CALCIUM ADENOSINE-TRIPHOSPHATASE; (NA+ + K+)-ATPASE; ATP-BINDING; CA-ATPASE; CA-2+ TRANSPORT; PLASMA-MEMBRANE; CATALYTIC SITE; ACTIVE-SITE; CA-2+-ATPASE	Erythrosin B was used to photo oxidize the sarcoplasmic reticulum Ca2+-ATPase. The ATPase activity is rapidly and irreversibly inhibited by photo-oxidation with erythrosin. This inhibition is protected by the presence of ATP during the photo-oxidation period. After photooxidation, the steady-state phosphorylation by ATP remains almost unchanged, whereas phosphorylation by inorganic phosphate is impaired, The pseudo-first order rate constants for phosphorylation by 15 mu M ATP at 25 degrees C are strongly inhibited when starting from either a Ca2+-bound or a Ca2+-free enzyme form, decreasing from 145 to 23 s(-1) for the Ca2+-bound form and from 50 to 18 s(-1) for the Ca2+-free form. Concurrently, the rate constants for dephosphorylation are also severely inhibited, changing from a fast double exponential to a very slow single exponential decay in the reverse direction and from a moderately slow single to a very slow single exponential decay in the forward direction. Ca2+ binding data show that the phosphorylated intermediate formed by the photo-oxidized enzyme contains two occluded Ca2+, and TNP-ATP fluorescence measurements indicate that it accumulates in a E(1)-P . Ca-2-like conformation. Protection by ADP against glutaraldehyde-induced cross-linking indicates that ADP binding to Ca2+-ATPase is not impaired by photo-oxidation nor by free erythrosin. These data support the view that an ADP-insensitive, Ca2+-bound, slowly interconverting phosphoenzyme is formed. Thus, photo-oxidation with erythrosin B leads to impairment of phosphoryl transfer reactions and related conformational changes.	FED UNIV RIO DE JANEIRO, CCS, ICB, DEPT BIOQUIM MED, BR-21941590 RIO DE JANEIRO, BRAZIL	Universidade Federal do Rio de Janeiro			Mignaco, Julio A/J-3469-2013	Mignaco, Julio A/0000-0002-8491-092X				ALONSO GL, 1990, J THEOR BIOL, V147, P161, DOI 10.1016/S0022-5193(05)80050-5; BERMAN MC, 1986, J BIOL CHEM, V261, P6494; BIRMACHU W, 1990, BIOCHEMISTRY-US, V29, P3904, DOI 10.1021/bi00468a017; BISHOP JE, 1987, J BIOL CHEM, V262, P4658; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; COAN C, 1990, J BIOL CHEM, V265, P5376; COFFEY RL, 1975, ARCH BIOCHEM BIOPHYS, V170, P37, DOI 10.1016/0003-9861(75)90095-8; DAGLORIA M, 1976, J BIOL CHEM, V251, P3629; DAIHO T, 1994, J BIOL CHEM, V269, P11060; DEMICHELIS MI, 1993, BOT ACTA, V106, P20, DOI 10.1111/j.1438-8677.1993.tb00333.x; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUJIMORI T, 1992, J BIOL CHEM, V267, P18466; GATTO C, 1993, AM J PHYSIOL, V264, pC1577, DOI 10.1152/ajpcell.1993.264.6.C1577; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; HALLIWELL B, 1989, FREE RADICAL BIO MED, P69; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HECHT JP, 1990, COMPUT METH PROG BIO, V33, P13, DOI 10.1016/0169-2607(90)90018-5; HELMICHDEJONG ML, 1986, BIOCHIM BIOPHYS ACTA, V858, P254, DOI 10.1016/0005-2736(86)90330-5; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1982, Z NATURFORSCH C, V37, P685; JACOBSBERG L, 1975, J BIOL CHEM, V250, P9238; KESSLER RJ, 1986, ANAL BIOCHEM, V158, P117, DOI 10.1016/0003-2697(86)90598-1; KNOWLES AF, 1975, J BIOL CHEM, V250, P1949; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LACAPERE JJ, 1993, BIOCHEMISTRY-US, V32, P3414, DOI 10.1021/bi00064a027; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN TI, 1977, ANAL BIOCHEM, V77, P10, DOI 10.1016/0003-2697(77)90284-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBLAD RL, 1984, CHEM REAGENTS PROTEI, V1, P105; MARTONOSI A, 1973, COLD SPRING HARB SYM, V37, P455, DOI 10.1101/SQB.1973.037.01.057; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; MIGNACO J, 1990, BIOCHIM BIOPHYS ACTA, V1039, P305, DOI 10.1016/0167-4838(90)90263-F; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MORRIS SJ, 1982, BIOCHEM BIOPH RES CO, V104, P1306, DOI 10.1016/0006-291X(82)91392-4; MUGICA H, 1984, ACTA PHYSIOL PHARM L, V34, P163; MUNKONGE F, 1988, BIOCHEMISTRY-US, V27, P6800, DOI 10.1021/bi00418a023; MURPHY AJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P57, DOI 10.1016/0005-2736(88)90457-9; NAKAMURA Y, 1986, J BIOL CHEM, V261, P3090; NESLUND GG, 1984, CURR TOP CELL REGUL, V24, P447; PAPP S, 1987, BIOPHYS J, V51, P205, DOI 10.1016/S0006-3495(87)83326-X; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; PICK U, 1981, EUR J BIOCHEM, V121, P187, DOI 10.1111/j.1432-1033.1981.tb06448.x; PICKART CM, 1984, J BIOL CHEM, V259, P1629; PICKART CM, 1982, J BIOL CHEM, V257, P5319; RAY WJ, 1962, J BIOL CHEM, V237, P2493; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SKOU JC, 1983, BIOCHIM BIOPHYS ACTA, V727, P101, DOI 10.1016/0005-2736(83)90373-5; SKOU JC, 1981, BIOCHIM BIOPHYS ACTA, V647, P232, DOI 10.1016/0005-2736(81)90251-0; SOMERVILLE LL, 1977, BIOCHIM BIOPHYS ACTA, V481, P493, DOI 10.1016/0005-2744(77)90282-0; STAHL N, 1987, BIOCHEMISTRY-US, V26, P7654, DOI 10.1021/bi00398a019; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; STUART J, 1992, ARCH BIOCHEM BIOPHYS, V292, P512, DOI 10.1016/0003-9861(92)90024-Q; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; TERUEL JA, 1987, J BIOL CHEM, V262, P13055; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VOSS J, 1991, BIOCHEMISTRY-US, V30, P7498, DOI 10.1021/bi00244a019; WACH A, 1991, EUR J BIOCHEM, V201, P91, DOI 10.1111/j.1432-1033.1991.tb16260.x; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9; WASSARMAN PM, 1971, J MOL BIOL, V60, P509, DOI 10.1016/0022-2836(71)90185-9; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; YIP BP, 1976, J BIOL CHEM, V251, P7157; YU BP, 1974, BIOCHEMISTRY-US, V13, P5083, DOI 10.1021/bi00722a004; YU BP, 1967, NATURE, V216, P822, DOI 10.1038/216822a0	74	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18423	18430		10.1074/jbc.271.31.18423	http://dx.doi.org/10.1074/jbc.271.31.18423			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702486	hybrid			2022-12-27	WOS:A1996VB68300024
J	Luo, W; Skalnik, DG				Luo, W; Skalnik, DG			CCAAT displacement protein competes with multiple transcriptional activators for binding to four sites in the proximal gp91(phox) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; SENSORY ORGAN IDENTITY; DROSOPHILA WING MARGIN; LEUKEMIA CELL-LINE; DNA-BINDING; HOMEODOMAIN PROTEIN; GENE-TRANSCRIPTION; CD11B PROMOTER; CUT REPEATS; GLOBIN GENE	CCAAT displacement protein (CDP) competes with transcriptional activating proteins for binding to each of four elements within the myeloid-specific gp91(phox) promoter. CDP exhibits the strongest affinity for a site centered at -110 base pairs (bp) of the promoter and progressively weaker affinities for three more distal binding sites. CDP binding to each site is down-regulated during terminal phagocytic differentiation, coincident with induction of gp91(phox) expression, Deletion of the high affinity CDP-binding site at -110 bp leads to inappropriate gp91(phox) promoter activity in HeLa, K562, and HEL cells. An overlapping binding site for the CCAAT box-binding factor CP1 is required for derepressed promoter activity in HeLa and K562 cells, but is dispensable in HEL cells, indicating that different cell types require distinct cis-elements for gp91(phox) pro meter activity, Derepressed gp91(phox) promoter activity is further increased upon removal of a second CDP-binding site centered at -150 bp, revealing that CDP represses gp91(phox) expression via multiple cis-elements, We present a model in which restriction of gp91(phox) expression to mature myeloid cells involves competition between transcriptional activators and repressors for binding to multiple sites within the promoter.	INDIANA UNIV,SCH MED,SECT PEDIAT HEMATOL ONCOL,HERMAN B WELLS CTR PEDIAT RES,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT PEDIAT,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MOL BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL CANCER INSTITUTE [R29CA058947, R01CA058947] Funding Source: NIH RePORTER; NCI NIH HHS [CA58947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHNE B, 1994, J BIOL CHEM, V269, P17794; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; AUSTIN RJ, 1995, MOL CELL BIOL, V15, P4683; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BLOCHLINGER K, 1993, DEVELOPMENT, V117, P441; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN HM, 1993, J BIOL CHEM, V268, P8230; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EKLUND EA, 1995, J BIOL CHEM, V270, P8267, DOI 10.1074/jbc.270.14.8267; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; GEY GO, 1952, CANCER RES, V12, P264; HARADA R, 1994, J BIOL CHEM, V269, P2062; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; INNIS MA, 1990, PCR PROTOCOLS; JACK J, 1992, GENETICS, V131, P353; JACK J, 1991, DEVELOPMENT, V113, P735; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; KURIBAYASHI F, 1995, BIOCHEM BIOPH RES CO, V209, P146, DOI 10.1006/bbrc.1995.1482; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MACLEOD K, 1991, MOL CELL BIOL, V11, P4324, DOI 10.1128/MCB.11.9.4324; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; NEWBURGER PE, 1994, J CLIN INVEST, V94, P1205, DOI 10.1172/JCI117437; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORKIN SH, 1992, BLOOD, V80, P575; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sambrook J., 2002, MOL CLONING LAB MANU; SIMON AM, 1993, MOL CELL BIOL, V13, P5133, DOI 10.1128/MCB.13.9.5133; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SKALNIK DG, 1991, P NATL ACAD SCI USA, V88, P8505, DOI 10.1073/pnas.88.19.8505; SUPERTIFURGA G, 1989, BIOCHIM BIOPHYS ACTA, V1007, P237, DOI 10.1016/0167-4781(89)90046-8; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P7895, DOI 10.1073/pnas.89.17.7895; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TENHARMSEL A, 1993, MOL CELL BIOL, V13, P2742, DOI 10.1128/MCB.13.5.2742; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TUCKER KA, 1987, BLOOD, V70, P372; VALARCHE I, 1993, DEVELOPMENT, V119, P881; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XU WH, 1995, MOL CELL BIOL, V15, P5369; YOON SO, 1994, J BIOL CHEM, V269, P18453; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	60	91	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18203	18210		10.1074/jbc.271.30.18203	http://dx.doi.org/10.1074/jbc.271.30.18203			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663528	hybrid			2022-12-27	WOS:A1996UY93500092
J	Schlossmann, J; Lill, R; Neupert, W; Court, DA				Schlossmann, J; Lill, R; Neupert, W; Court, DA			Tom71, a novel homologue of the mitochondrial preprotein receptor Tom70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; SIGNAL-ANCHOR SEQUENCE; ADP ATP CARRIER; PRECURSOR PROTEINS; YEAST MITOCHONDRIA; IMPORT RECEPTOR; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; INNER MEMBRANE; TRANSLOCATION	The protein Tom71 is encoded by the open reading frame YHR117w (yeast chromosome VIII) and shares 53% amino acid sequence identity with Tom70, a protein import receptor of the mitochondrial outer membrane, We investigated the cellular function of Tom71 and addressed the question of whether Tom71 and Tom70 fulfill similar functions, Like Tom70, Tom71 is anchored to the mitochondrial outer membrane via its N terminus, thereby exposing a large C-terminal domain to the cytosol, Tom71 is associated with the protein import complex of this membrane and can be cross-linked to a protein with a molecular mass of 30-35 kDa, Disruption of the TOM71 gene does not reduce cell growth, except on nonfermentable carbon sources at elevated temperatures, Deletion of both the TOM71 and TOM70 genes does not acerbate this growth defect, In vitro import studies demonstrated no functional requirement for Tom71 in the import of several preproteins destined for each of the mitochondrial subcompartments, In particular, the import of Tom70-dependent preproteins is minimally affected by the deletion of Tom71, irrespective of the presence or absence of the Tom70 receptor, Thus, despite their strikingly similar biochemical properties, Tom71 and Tom70 do not perform identical functions.	UNIV MUNICH, INST PHYSIOL CHEM PHYS BIOCHEM & ZELLBIOL, D-80336 MUNICH, GERMANY	University of Munich			Schlossmann, Jens/I-7743-2016	Schlossmann, Jens/0000-0002-2550-6839; Lill, Roland/0000-0002-8345-6518; Court, Deborah A./0000-0003-1919-8339				BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; DAUM G, 1982, J BIOL CHEM, V257, P3028; DIETMEIER K, 1993, J BIOL CHEM, V268, P25958; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; Hannavy K, 1993, CURR OPIN CELL BIOL, V5, P694, DOI 10.1016/0955-0674(93)90142-D; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; HASE T, 1983, EMBO J, V2, P2169, DOI 10.1002/j.1460-2075.1983.tb01718.x; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; MILLAR DG, 1993, J BIOL CHEM, V268, P18403; MOCZKO M, 1994, J BIOL CHEM, V269, P9045; MOCZKO M, 1992, FEBS LETT, V310, P265, DOI 10.1016/0014-5793(92)81345-M; NAKAI M, 1995, FEBS LETT, V357, P202; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; RAMAGE L, 1993, EMBO J, V12, P4115, DOI 10.1002/j.1460-2075.1993.tb06095.x; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; RODRIGUEZCOUSINO N, 1995, YEAST, V11, P581, DOI 10.1002/yea.320110608; ROSE MD, 1993, METHODS YEAST GENETI; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHLOSSMANN J, 1995, J BIOL CHEM, V270, P27116, DOI 10.1074/jbc.270.45.27116; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465	50	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17890	17895		10.1074/jbc.271.30.17890	http://dx.doi.org/10.1074/jbc.271.30.17890			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663394	hybrid			2022-12-27	WOS:A1996UY93500047
J	Annila, A; Lehtimaki, J; Mattila, K; Eriksson, JE; Sivonen, K; Rantala, TT; Drakenberg, T				Annila, A; Lehtimaki, J; Mattila, K; Eriksson, JE; Sivonen, K; Rantala, TT; Drakenberg, T			Solution structure of nodularin - An inhibitor of serine/threonine-specific protein phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC PEPTIDE TOXIN; MICROCYSTIN-LR; DIHYDROMICROCYSTIN-LR; HEPATOCELLULAR UPTAKE; AQUEOUS-SOLUTIONS; NMR-SPECTRA; BALTIC SEA; SPUMIGENA; DYNAMICS; POTENT	The three dimensional solution structure of nodularin was studied by NMR and molecular dynamics simulations. The conformation in water was determined from the distance and dihedral data by distance geometry and refined by iterative relaxation matrix analysis. The cyclic backbone adopts a well defined conformation but the remote parts of the side chains of arginine as well as the amino acid derivative Adda have a large spatial dispersion. For the unusual amino acids the partial charges were calculated and nodularin was subjected to molecular dynamic simulations in water. A good agreement was found between experimental and computational data with hydrogen bonds, solvent accessibility, molecular motion, and conformational exchange. The three-dimensional structure resembles very closely that of microcystin-LR in the chemically equivalent segment. Therefore, it is expected that the binding of both microcystins and nodularins to serine/threonine specific protein phosphatases is similar on an atomic level.	UNIV HELSINKI, DEPT APPL CHEM & MICROBIOL, FIN-00014 HELSINKI, FINLAND; UNIV OULU, DEPT PHYS SCI, FIN-90571 OULU, FINLAND; UNIV OULU, DIV BIOPHYS, FIN-90571 OULU, FINLAND; UNIV OULU, DIV PHYS, FIN-90571 OULU, FINLAND; TURKU CTR BIOTECHNOL, FIN-20150 TURKU, FINLAND	University of Helsinki; University of Oulu; University of Oulu; University of Oulu	Annila, A (corresponding author), VTT CHEM TECHNOL, POB 1401, FIN-02044 Espoo, FINLAND.		Rantala, Tapio T./B-7789-2013	Rantala, Tapio T./0000-0001-8581-502X; Sivonen, Kaarina/0000-0002-2904-0458				BAGU JR, 1995, STRUCT BIOL, V2, P114; BARFORD D, 1994, J MOL BIOL, V235, P763, DOI 10.1006/jmbi.1994.1027; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; *BIOS TECHN, 1994, NMRCHIT US GUID, V5; *BIOS TECHN, 1993, DMOL US GUID, V5; BOELENS R, 1988, J MOL STRUCT, V173, P299, DOI 10.1016/0022-2860(88)80062-0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; Bystrov V. F., 1976, PROGR NMR SPECTROSCO, V10, P41; Carmichael W. W., 1998, HDB NATURAL TOXINS, V3, P121; CARMICHAEL WW, 1988, APPL ENVIRON MICROB, V54, P2257, DOI 10.1128/AEM.54.9.2257-2263.1988; CARMICHAEL WW, 1988, TOXICON, V26, P971, DOI 10.1016/0041-0101(88)90195-X; CAVANAGH J, 1990, J MAGN RESON, V88, P72, DOI 10.1016/0022-2364(90)90109-M; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DESILVA ED, 1992, TETRAHEDRON LETT, V33, P1561, DOI 10.1016/S0040-4039(00)91674-5; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; ERIKSSON JE, 1992, P NATL ACAD SCI USA, V89, P11093, DOI 10.1073/pnas.89.22.11093; ERIKSSON JE, 1990, BIOCHIM BIOPHYS ACTA, V1025, P60, DOI 10.1016/0005-2736(90)90190-Y; ERIKSSON JE, 1990, BIOCHEM BIOPH RES CO, V173, P1347, DOI 10.1016/S0006-291X(05)80936-2; ERIKSSON JE, 1988, TOXICON, V26, P161, DOI 10.1016/0041-0101(88)90168-7; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HALKIDES CJ, 1995, J BIOMOL NMR, V5, P362; HARADA K, 1990, CHEM RES TOXICOL, V3, P473, DOI 10.1021/tx00017a014; HAVEL TF, 1979, BIOPOLYMERS, V18, P73, DOI 10.1002/bip.1979.360180108; HIRSHFELD FL, 1977, THEOR CHIM ACTA, V44, P129, DOI 10.1007/BF00549096; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; JORGENSEN WL, 1982, J CHEM PHYS, V77, P4156, DOI 10.1063/1.444325; LAAKSONEN L, 1992, J MOL GRAPHICS, V10, P33, DOI 10.1016/0263-7855(92)80007-Z; LEHTIMAKI J, 1994, ARCH HYDROBIOL, V130, P269; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; Martin M. L., 1980, PRACTICAL NMR SPECTR; MATSUSHIMA R, 1990, BIOCHEM BIOPH RES CO, V171, P867, DOI 10.1016/0006-291X(90)91226-I; MCINTYRE L, 1992, J MAGN RESON, V96, P425, DOI 10.1016/0022-2364(92)90098-R; MELLGREN G, 1993, EXP CELL RES, V205, P293, DOI 10.1006/excr.1993.1089; MERILUOTO JAO, 1990, TOXICON, V28, P1439, DOI 10.1016/0041-0101(90)90157-3; *MOL SIM INC, 1992, CHARMM; *MOL SIM INC, 1994, QUANT; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; NAMIKOSHI M, 1994, J ORG CHEM, V59, P2349, DOI 10.1021/jo00088a014; NISHIWAKIMATSUSHIMA R, 1992, J CANCER RES CLIN, V118, P420, DOI 10.1007/BF01629424; RANTALA TT, 1986, CHEM PHYS, V109, P261, DOI 10.1016/0301-0104(86)87056-2; RINEHART KL, 1988, J AM CHEM SOC, V110, P8557, DOI 10.1021/ja00233a049; ROUHIAINEN L, 1995, J BACTERIOL, V177, P6021, DOI 10.1128/jb.177.20.6021-6026.1995; RUDOLPHBOHNER S, 1994, FEBS LETT, V349, P319, DOI 10.1016/0014-5793(94)00680-6; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; SIVONEN K, 1989, APPL ENVIRON MICROB, V55, P1990, DOI 10.1128/AEM.55.8.1990-1995.1989; SIVONEN K, 1989, HYDROBIOLOGIA, V185, P3, DOI 10.1007/BF00006062; SODANO P, 1993, J MAGN RESON SER A, V104, P88, DOI 10.1006/jmra.1993.1192; STATES DJ, 1982, J MAGN RESON, V55, P151; Trogen GB, 1996, BIOCHEMISTRY-US, V35, P3197, DOI 10.1021/bi952368s; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; VOSKO SH, 1980, CAN J PHYS, V58, P1200, DOI 10.1139/p80-159; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; [No title captured]	58	47	52	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16695	16702		10.1074/jbc.271.28.16695	http://dx.doi.org/10.1074/jbc.271.28.16695			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663277	hybrid			2022-12-27	WOS:A1996UX12600045
J	Blackhart, BD; Emilsson, K; Nguyen, D; Teng, W; Martelli, AJ; Nystedt, S; Sundelin, J; Scarborough, RM				Blackhart, BD; Emilsson, K; Nguyen, D; Teng, W; Martelli, AJ; Nystedt, S; Sundelin, J; Scarborough, RM			Ligand cross-reactivity within the protease-activated receptor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THROMBIN RECEPTOR; MOLECULAR-CLONING; AGONIST PEPTIDES; SMOOTH-MUSCLE; PLATELET; PHENYLALANINE; ENDOTHELIUM; MECHANISM	Recently, a second member of the protease-activated receptor (PAR) family, named PAR-2, has been identified, Similar to the thrombin receptor, PAR-2 appears to be activated by proteolytic-mediated exposure of a ''tethered ligand'' sequence and can also be activated by the corresponding synthetic peptides, Similarities in the amino acid sequence of the receptors' tethered ligand sequences suggest that their respective agonist peptides might not be absolutely specific for their particular receptors, To test this, the receptor specificity of each agonist has been determined by measuring the responses of Xenopus oocytes expressing the thrombin receptor or PAR-2 to agonist peptides or enzymes, Thrombin receptors responded to thrombin, the human thrombin receptor-activating peptide SFLLRNP-NH2 (TRAP) (EC(50) = 0.1 mu m), and Xenopus TRAP, TFRIFD-NH2 (EC(50) = 1 mu M), but did not show any increase in calcium efflux over control levels with trypsin (50 mu M) or PAR-2 agonist peptides (100 mu M). Human and murine PAR-2 receptors responded comparably to human and murine PAR-2 agonist peptides (SLIGKVD and SLIGRL, respectively) (EC(50) = 0.5-2.0 mu M) and trypsin, but not to thrombin, PAR-2 was also found to be responsive to TRAP (EC(50) = 1 mu M) but was unresponsive to Xenopus TRAP (50 mu M). Responses to additional peptide agonist analogs suggest that an amino-terminal serine is critical for PAR-2 agonist activity.	LUND UNIV,WALLENBERG LAB,DIV MOLEC NEUROBIOL,S-22007 LUND,SWEDEN	Lund University	Blackhart, BD (corresponding author), COR THERAPEUT INC,256 E GRAND AVE,S SAN FRANCISCO,CA 94080, USA.							ANTONACCIO MJ, 1994, EUR J PHARMACOL, V256, P37, DOI 10.1016/0014-2999(94)90613-0; BAHOU WF, 1993, BLOOD, V82, P1532, DOI 10.1182/blood.V82.5.1532.bloodjournal8251532; BLACKHART BD, 1994, GROWTH FACTORS, V11, P17, DOI 10.3109/08977199409015048; CHAO BH, 1992, BIOCHEMISTRY-US, V31, P6175, DOI 10.1021/bi00142a001; CHEN J, 1994, J BIOL CHEM, V269, P16041; CONNOLLY TM, 1994, THROMB HAEMOSTASIS, V72, P627; COUGHLIN SR, 1994, P NATL ACAD SCI USA, V91, P9200, DOI 10.1073/pnas.91.20.9200; COUGHLIN SR, 1992, Patent No. 9214750; DERIAN CK, 1995, GHROMB RES, V78, P505; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; Hollenberg MD, 1996, MOL PHARMACOL, V49, P229; HOLLENBERG MD, 1993, MOL PHARMACOL, V43, P921; JENKINS AL, 1995, J CELL SCI, V108, P3059; JENKINS AL, 1994, J BIOL CHEM, V269, P17104; JONES LG, 1989, MOL PHARMACOL, V36, P142; MURAMATSU I, 1992, CAN J PHYSIOL PHARM, V70, P996, DOI 10.1139/y92-137; NATARAJAN S, 1985, INT J PEPT PROT RES, V45, P141; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NOSE T, 1993, BIOCHEM BIOPH RES CO, V193, P694, DOI 10.1006/bbrc.1993.1680; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PICKETT WC, 1976, BIOCHEM J, V160, P405, DOI 10.1042/bj1600405; SABO T, 1992, BIOCHEM BIOPH RES CO, V188, P604, DOI 10.1016/0006-291X(92)91099-C; SANTULLI RJ, 1995, P NATL ACAD SCI USA, V92, P9151, DOI 10.1073/pnas.92.20.9151; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; Seiler SM, 1996, MOL PHARMACOL, V49, P190; SHIMOHIGASHI Y, 1994, BIOCHEM BIOPH RES CO, V203, P366, DOI 10.1006/bbrc.1994.2191; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TESFAMARIAM B, 1994, CIRC RES, V74, P930, DOI 10.1161/01.RES.74.5.930; TESFAMARIAM B, 1993, AM J PHYSIOL, V265, pH1744, DOI 10.1152/ajpheart.1993.265.5.H1744; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; YANG SG, 1992, LIFE SCI, V51, P1325, DOI 10.1016/0024-3205(92)90631-X	35	202	211	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16466	16471		10.1074/jbc.271.28.16466	http://dx.doi.org/10.1074/jbc.271.28.16466			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663335	hybrid			2022-12-27	WOS:A1996UX12600009
J	Bitting, L; Naidu, A; Cordell, B; Murphy, GM				Bitting, L; Naidu, A; Cordell, B; Murphy, GM			beta-amyloid peptide secretion by a microglial cell line is induced by beta-amyloid-(25-35) and lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; MESSENGER-RNA; QUANTIFICATION; EXPRESSION; ASTROCYTES; DEPOSITS; PLAQUES; DOMAIN; BRAIN	beta-Amyloid protein (beta AP) deposition is a neuropathologic hallmark of Alzheimer's disease (AD). Yet, the source of cerebral beta AP in AD is controversial. We examined the production of beta AP by the BV-2 immortalized microglial cell Line using a sensitive enzyme immunoassay. Constitutive production of beta AP was detected in conditioned media from unstimulated BV-2 cells. Further, production of beta AP was induced by treatment of cultures by lipopolysaccharide (LPS) or beta AP-(25-35) and was inhibited by the calpain protease inhibitor MDL 28170. Treatment of BV-2 cells with LPS or beta AP-(25-35) did not affect cell-associated beta-amyloid precursor protein levels. These findings suggest that microglia may be an important source of beta AP in AD, and that microglial production of beta AP may be augmented by proinflammatory stimuli or by beta AP itself.	STANFORD UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,NEUROSCI RES LABS,STANFORD,CA 94305; SCIOS NOVA INC,MT VIEW,CA 94043	Stanford University; Scios								ALLEN JS, 1991, NEUROSCI LETT, V132, P109, DOI 10.1016/0304-3940(91)90445-Y; ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; Auger M. J., 1992, MACROPHAGE, P1; BANATI RB, 1993, GLIA, V9, P199, DOI 10.1002/glia.440090305; BITTING L, 1994, NEUROSCI LETT, V165, P117, DOI 10.1016/0304-3940(94)90723-4; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CRAS P, 1990, AM J PATHOL, V137, P241; DAVIS JB, 1992, BIOCHEM BIOPH RES CO, V189, P1096, DOI 10.1016/0006-291X(92)92317-Q; DAVISSALINAS J, 1995, J NEUROCHEM, V65, P931; DICKSON DW, 1991, LAB INVEST, V64, P135; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GARDELLA JE, 1992, LAB INVEST, V67, P303; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1991, J NEUROSCI, V11, P3783; HAGA S, 1989, ACTA NEUROPATHOL, V77, P569, DOI 10.1007/BF00687883; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; KLEGERIS A, 1994, BIOCHEM BIOPH RES CO, V199, P984, DOI 10.1006/bbrc.1994.1326; MCGEER PL, 1992, NEUROLOGY, V42, P447, DOI 10.1212/WNL.42.2.447; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MONNING U, 1994, FEBS LETT, V342, P267, DOI 10.1016/0014-5793(94)80514-8; MORATO E, 1993, FEBS LETT, V336, P275, DOI 10.1016/0014-5793(93)80819-G; MRAK RE, 1995, HUM PATHOL, V26, P816, DOI 10.1016/0046-8177(95)90001-2; MURPHY GM, 1993, J NEUROSCI RES, V35, P643, DOI 10.1002/jnr.490350607; MURPHY GM, 1995, NEUROSCI LETT, V196, P153, DOI 10.1016/0304-3940(95)11862-Q; NAIDU A, 1995, J BIOL CHEM, V270, P1369, DOI 10.1074/jbc.270.3.1369; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; Schmechel D E, 1988, Alzheimer Dis Assoc Disord, V2, P96, DOI 10.1097/00002093-198802020-00002; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SOLA C, 1993, NEUROSCIENCE, V53, P267, DOI 10.1016/0306-4522(93)90304-X; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; Wisniewski HM, 1973, PROGR NEUROPATHOLOGY, V2, P1; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; ZHONG ZY, 1994, J BIOL CHEM, V269, P12179	40	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16084	16089		10.1074/jbc.271.27.16084	http://dx.doi.org/10.1074/jbc.271.27.16084			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663228	hybrid			2022-12-27	WOS:A1996UW35200036
J	Ito, A; Mukaiyama, A; Itoh, Y; Nagase, H; Thogersen, IB; Enghild, JJ; Sasaguri, Y; Mori, Y				Ito, A; Mukaiyama, A; Itoh, Y; Nagase, H; Thogersen, IB; Enghild, JJ; Sasaguri, Y; Mori, Y			Degradation of interleukin 1 beta by matrix metalloproteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN INTERLEUKIN-1-BETA; RHEUMATOID SYNOVIAL FIBROBLASTS; SEQUENCE SPECIFICITIES; CLEAVAGE SITES; COLLAGENASE; STROMELYSIN; PURIFICATION; INHIBITORS; EXPRESSION; ARTHRITIS	Matrix metalloproteinases (MMPs) and interleukin 1 (IL-1) are implicated in inflammation and tissue destruction, where IL-1 is a potent stimulator of connective tissue cells to produce the extracellular matrix-degrading MMPs. Here, we report that IL-1 beta, but not IL-1 alpha, is degraded by MMP-1 (interstitial collagenase), MMP-2 (gelatinase A), MMP-3 (stromelysin 1), and MMP-9 (gelatinase B). This degradation was effectively blocked by tissue inhibitor of metalloproteinases (TIMP)-1. When IL-1 beta was treated with MMPs it lost the ability to enhance the synthesis of prostaglandin E(2) and pro-MMP-3 in human fibroblasts. The primary cleavage site of IL-1 beta by MMP-2 was identified at the Glu(25)-Leu(26) bond. These results suggest that IL-1 beta stimulates connective tissue cells to produce MMPs, but activated MMPs in turn negatively regulate the activity of IL-1 beta.	UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, KANSAS CITY, KS 66160 USA; DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA; UNIV OCCUPAT & ENVIRONM HLTH, SCH MED, DEPT PATHOL 2, KITAKYUSHU, FUKUOKA 807, JAPAN	University of Kansas; University of Kansas Medical Center; Duke University; University of Occupational & Environmental Health - Japan	Ito, A (corresponding author), TOKYO COLL PHARM, DEPT BIOCHEM, 1432 HORINOUCHI, HACHIOJI, TOKYO 19203, JAPAN.			Itoh, Yoshifumi/0000-0002-2128-2823; Enghild, Jan Johannes/0000-0001-9292-9172	NHLBI NIH HHS [HL49542] Funding Source: Medline; NIAMS NIH HHS [AR 39819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049542] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AREND WP, 1990, ARTHRITIS RHEUM-US, V33, P305, DOI 10.1002/art.1780330302; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; DESROCHERS PE, 1991, J CLIN INVEST, V87, P2258, DOI 10.1172/JCI115262; DINARELLO CA, 1992, CHEM IMMUNOL, V51, P1; ENGHILD JJ, 1989, J BIOL CHEM, V264, P8779; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; ITO A, 1991, J BIOL CHEM, V266, P13598; KIKUMOTO Y, 1987, BIOCHEM BIOPH RES CO, V147, P315, DOI 10.1016/S0006-291X(87)80123-7; KIMURA A, 1991, IMMUNOL LETT, V28, P109, DOI 10.1016/0165-2478(91)90107-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MAST AE, 1991, J BIOL CHEM, V266, P15810; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MITCHELL TI, 1993, BIOCHIM BIOPHYS ACTA, V1156, P245, DOI 10.1016/0304-4165(93)90038-A; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; Nagase H., 1996, ZINC METALLOPROTEINA; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; NIEDZWIECKI L, 1992, BIOCHEMISTRY-US, V31, P12618, DOI 10.1021/bi00165a011; NISHIDA T, 1987, BIOCHEM BIOPH RES CO, V143, P345, DOI 10.1016/0006-291X(87)90671-1; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OKADA Y, 1986, J BIOL CHEM, V261, P14245; PEI DQ, 1994, J BIOL CHEM, V269, P25849; PIERART ME, 1988, J IMMUNOL, V140, P3808; PRIESTLE JP, 1988, EMBO J, V7, P339, DOI 10.1002/j.1460-2075.1988.tb02818.x; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; TAKAHASHI S, 1993, BIOCHIM BIOPHYS ACTA, V1220, P57, DOI 10.1016/0167-4889(93)90097-9; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; TETLOW LC, 1993, RHEUMATOL INT, V13, P53, DOI 10.1007/BF00307734; THRAILKILL KM, 1995, ENDOCRINOLOGY, V136, P3527, DOI 10.1210/en.136.8.3527; WALAKOVITS LA, 1992, ARTHRITIS RHEUM, V35, P35, DOI 10.1002/art.1780350106; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	38	314	328	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14657	14660		10.1074/jbc.271.25.14657	http://dx.doi.org/10.1074/jbc.271.25.14657			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663297	hybrid			2022-12-27	WOS:A1996UT10600003
J	Dong, LM; Weisgraber, KH				Dong, LM; Weisgraber, KH			Human apolipoprotein E4 domain interaction - Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA-LIPOPROTEINS; RECEPTOR-BINDING ACTIVITY; CORONARY HEART-DISEASE; ALZHEIMERS-DISEASE; E ISOFORMS; AQUEOUS-SOLUTION; E POLYMORPHISM; E APOPROTEIN; IN-VITRO; A-I	Human apolipoprotein (apo) E contains an amino- and a carboxyl-terminal domain, which are connected by a hinge region (approximately residues 165 to 215), The interaction of the two domains has been suggested to be responsible for the apoE4-binding preference for very low density lipoproteins (VLDL), In the absence of this interaction in apoE3, the preference is for high density lipoproteins (HDL), To exclude the possibility that the interaction of apoE with other apolipoproteins on the native particles may contribute to the isoform-specific preferences, VLDL like emulsion particles were incubated with apoE, and the lipid-bound apoE was separated from free apoE on a Superose 6 column, The apoE4 bound more effectively to these particles than did apoE3, indicating that the apoE4 preference for VLDL is due not to interactions with other apolipoproteins but to an intrinsic property of apoE4, likely related to domain interaction, Previously, arginine 61 was shown to be critical for the isoform preferences, suggesting that it interacted with an acidic residue(s) in the carboxyl terminus. Substitution of arginine 61 with lysine did not alter the preference of apoE4 for VLDL, demonstrating that a positive charge rather than a specific requirement for arginine is critical for domain interaction, To identify the acidic residue(s) in the carboxyl terminus interacting with arginine 61, the six acidic residues (244, 245, 255, 266, 270, and 271) in a region known to be important for both lipoprotein association and isoform-specific preferences were substituted individually with alanine in apoE4, Only substitution of glutamic acid 255 altered the preference of apoE4 from VLDL to HDL, indicating that this was the sole residue in the carboxyl terminus that interacts with arginine 61, The participation of the hinge region in domain interaction was examined with internal deletion mutants, Deletion of the residues 186-202 or 186-223, representing major portions of the hinge region, had no effect on the apoE4 preference for VLDL, This suggests that the hinge region may act as a spacer that connects the two domains, Further deletion into the carboxyl-terminal domain (to residue 244) results in a loss of apoE4 VLDL binding, These studies establish that interaction of arginine 61 and glutamic acid 255 mediates apoE4 domain interaction.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Bergeron N, 1996, J CLIN INVEST, V97, P65, DOI 10.1172/JCI118408; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DONG LM, 1994, J BIOL CHEM, V269, P22358; GIANTURCO SH, 1983, J BIOL CHEM, V258, P4526; GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; INNERARITY TL, 1984, J BIOL CHEM, V259, P7261; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; LALAZAR A, 1989, J BIOL CHEM, V264, P8447; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mahley Robert W., 1995, Current Opinion in Lipidology, V6, P86, DOI 10.1097/00041433-199504000-00005; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MULLER HW, 1985, SCIENCE, V228, P499, DOI 10.1126/science.3983637; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; PITAS RE, 1987, J BIOL CHEM, V262, P14352; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; RALL SC, 1986, METHOD ENZYMOL, V128, P273; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SEGREST JP, 1992, J LIPID RES, V33, P141; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPOONER PJR, 1988, J BIOL CHEM, V263, P1444; STEINMETZ A, 1989, ARTERIOSCLEROSIS, V9, P405, DOI 10.1161/01.ATV.9.3.405; STENGARD JH, 1995, CIRCULATION, V91, P265, DOI 10.1161/01.CIR.91.2.265; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; TIRET L, 1994, ARTERIOSCLER THROMB, V14, P1617, DOI 10.1161/01.ATV.14.10.1617; UTERMANN G, 1979, CLIN GENET, V15, P63; WARDELL MR, 1989, J BIOL CHEM, V264, P21205; WEINTRAUB MS, 1987, J CLIN INVEST, V80, P1571, DOI 10.1172/JCI113243; WEISGRABER KH, 1994, CURR OPIN STRUC BIOL, V4, P507, DOI 10.1016/S0959-440X(94)90212-7; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WEISGRABER KH, 1996, IN PRESS FASEB J; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON PWF, 1995, CLIN CHEM, V41, P165; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030	47	256	263	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19053	19057		10.1074/jbc.271.32.19053	http://dx.doi.org/10.1074/jbc.271.32.19053			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702576	hybrid			2022-12-27	WOS:A1996VB68400010
J	Pickard, RT; Chiou, XG; Strifler, BA; DeFelippis, MR; Hyslop, PA; Tebbe, AL; Yee, YK; Reynolds, LJ; Dennis, EA; Kramer, RM; Sharp, JD				Pickard, RT; Chiou, XG; Strifler, BA; DeFelippis, MR; Hyslop, PA; Tebbe, AL; Yee, YK; Reynolds, LJ; Dennis, EA; Kramer, RM; Sharp, JD			Identification of essential residues for the catalytic function of 85-kDa cytosolic phospholipase A(2) - Probing the role of histidine, aspartic acid, cysteine, and arginine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PLATELET-ACTIVATING-FACTOR; ACTIVE-SITE; SERINE PROTEASES; ESCHERICHIA-COLI; ACYL-TRANSFER; TRIAD FORMS; MECHANISM; HYDROLYSIS; LIPASE	Cytosolic phospholipase A(2) (cPLA(2)) hydrolyzes the sna-acyl ester bond of phospholipids and shows a preference for arachidonic acid-containing substrates. We found previously that Ser-228 is essential for enzyme activity and is likely to function as a nucleophile in the catalytic center of the enzyme (Sharp, J. D., White, D. L., Chiou, X. G., Goodson, T., Gamboa, G. C., McClure, D., Burgett, S., Hoskins, J., Skatrud, P. L., Sportsman, J. R., Becker, G. W., Kang, L. H., Roberts, E. F., and Kramer, R. M. (1991) J. Biol. Chem. 266, 14850-14853). cPLA, contains a catalytic aspartic acid motif common to the subtilisin family of serine proteases. Substitution within this motif of Ala for Asp-549 completely inactivated the enzyme, and substitutions with either glutamic acid or asparagine reduced activity 2000- and 300-fold, respectively. Additionally, using mutants with cysteine replaced by alanine, we found that Cys-331 is responsible for the enzyme's sensitivity to N-ethylmaleimide, Surprisingly, substituting alanine for any of the 19 histidines did not produce inactive enzyme, demonstrating that a classical serine-histidine-aspartate mechanism does not operate in this hydrolase. We found that substituting alanine or histidine for Arg-200 did produce inactive enzyme, while substituting lysine reduced activity 200-fold. Results obtained with the lysine mutant (R200K) and a coumarin ester substrate suggest no specific interaction between Arg-200 and the phosphoryl group of the phospholipid substrate. Arg-200, Ser-228, and Asp-549 are conserved in cPLA, from six species and also in four nonmammalian phospholipase B enzymes. Our results, supported by circular dichroism, provide evidence that Asp-549 and Arg-200 are critical to the enzyme's function and suggest that the cPLA(2) catalytic center is novel.	ELI LILLY & CO, LILLY CORP CTR, LILLY RES LABS, INDIANAPOLIS, IN 46285 USA; UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA	Eli Lilly; University of California System; University of California San Diego			Dennis, Edward A./M-5554-2019	Dennis, Edward A./0000-0003-3738-3140	NIGMS NIH HHS [GM-51606] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES RH, 1992, BIOCHEMISTRY-US, P71; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BECKER GW, 1994, BIO-TECHNOL, V12, P69, DOI 10.1038/nbt0194-69; BLOW D, 1990, NATURE, V343, P694, DOI 10.1038/343694a0; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CARTER P, 1988, NATURE, V332, P764; CHEAH KC, 1990, J BIOL CHEM, V265, P7180; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Damblon C, 1996, P NATL ACAD SCI USA, V93, P1747, DOI 10.1073/pnas.93.5.1747; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; DUPUREUR CM, 1990, J AM CHEM SOC, V112, P7074, DOI 10.1021/ja00175a060; FAUSTINELLA F, 1992, BIOCHEMISTRY-US, V31, P7219, DOI 10.1021/bi00147a002; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; HUANG Z, 1994, ANAL BIOCHEM, V222, P110, DOI 10.1006/abio.1994.1461; HUTCHISON CA, 1978, J BIOL CHEM, V253, P6551; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KRAMER RM, 1988, BIOCHIM BIOPHYS ACTA, V959, P269, DOI 10.1016/0005-2760(88)90200-7; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRAMER RM, 1995, AGENT ACTION SUPPL, V46, P65; KUIPERS OP, 1990, PROTEIN ENG, V4, P199, DOI 10.1093/protein/4.2.199; KUMAR A, 1994, PROTEIN SCI, V3, P2082, DOI 10.1002/pro.5560031121; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LI B, 1994, BIOCHEMISTRY-US, V33, P8594, DOI 10.1021/bi00194a026; Li B, 1996, BIOCHEMISTRY-US, V35, P3156, DOI 10.1021/bi952141x; LIN LL, 1989, J MOL BIOL, V210, P439, DOI 10.1016/0022-2836(89)90121-6; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LUGTIGHEID RB, 1993, EUR J BIOCHEM, V213, P517, DOI 10.1111/j.1432-1033.1993.tb17789.x; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; PHILLIPS MA, 1990, J BIOL CHEM, V265, P20692; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHARP JD, 1994, J BIOL CHEM, V269, P23250; SIEZEN RJ, 1991, PROTEIN ENG, V4, P19; SLILATY SN, 1991, PROTEIN ENG, V4, P919, DOI 10.1093/protein/4.8.919; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAMAI K, 1991, BIOCHEM BIOPH RES CO, V179, P790, DOI 10.1016/0006-291X(91)91886-H; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VERHEIJ HM, 1980, BIOCHEMISTRY-US, V19, P743, DOI 10.1021/bi00545a021; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; Yuan L, 1996, J BIOL CHEM, V271, P3417	57	93	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19225	19231		10.1074/jbc.271.32.19225	http://dx.doi.org/10.1074/jbc.271.32.19225			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702602	hybrid			2022-12-27	WOS:A1996VB68400036
J	Rana, A; Gallo, K; Godowski, P; Hirai, S; Ohno, S; Zon, L; Kyriakis, JM; Avruch, J				Rana, A; Gallo, K; Godowski, P; Hirai, S; Ohno, S; Zon, L; Kyriakis, JM; Avruch, J			The mixed lineage kinase SPRK phosphorylates and activates the stress-activated protein kinase activator, SEK-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; AMINO-TERMINAL KINASES; C-JUN; MAP KINASES; IDENTIFICATION; CASCADE; GTPASES; DOMAIN; CDC42; RAS	SPRK (also called PTK-1 and MLK-3), a member of the mixed lineage kinase subfamily of (Ser/Thr) protein kinases, encodes an amino-terminal SH3 domain followed by a kinase catalytic domain, two leucine zippers interrupted by a short spacer, a Rac/Cdc42 binding domain, and a long carboxyl-terminal proline-rich region. We report herein that SPRK activates the stress-activated protein kinases (SAPKs) but not ERK-1 during transient expression in COS cells; the p38 kinase is activated modestly (1.3-2 fold) but consistently. SPRK also activates cotransfected SEK 1/MKK-4, a dual specificity kinase which phosphorylates and activates SAPK. Reciprocally, expression of mutant, inactive SEK-1 inhibits completely the basal and SPRK-activated SAPK activity. Immunoprecipitated recombinant SPRK is able to phosphorylate and activate recombinant SEK-1 in vitro to an extent comparable to that achieved by MEK kinase-1. These results identify SPRK as a candidate upstream activator of the stress-activated protein kinases, acting through the phosphorylation and activation of SEK-1.	MASSACHUSETTS GEN HOSP,MED SERV,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; MICHIGAN STATE UNIV,DEPT PHYSIOL,E LANSING,MI 48824; GENENTECH INC,DEPT BIOL MOL,S SAN FRANCISCO,CA 94080; YOKOHAMA CITY UNIV,SCH MED,DEPT BIOL MOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Michigan State University; Roche Holding; Genentech; Yokohama City University; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute	Rana, A (corresponding author), MASSACHUSETTS GEN HOSP,DIABET UNIT,149 13TH ST,CHARLESTOWN,MA 02129, USA.		Ohno, Shigeo/B-1768-2010; Rana, Ajay/ABE-3739-2020	Ohno, Shigeo/0000-0002-1294-5269; Rana, Ajay/0000-0003-0951-2566				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EZOE K, 1994, ONCOGENE, V9, P935; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hirai S, 1996, ONCOGENE, V12, P641; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; ING YL, 1994, ONCOGENE, V9, P1745; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	31	204	208	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19025	19028		10.1074/jbc.271.32.19025	http://dx.doi.org/10.1074/jbc.271.32.19025			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702571	Green Published, hybrid			2022-12-27	WOS:A1996VB68400005
J	Wilkins, JF; Bitensky, MW; Willardson, BM				Wilkins, JF; Bitensky, MW; Willardson, BM			Regulation of the kinetics of phosducin phosphorylation in retinal rods	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PHOTO-EXCITED RHODOPSIN; BETA-GAMMA-SUBUNITS; OUTER SEGMENTS; PHOTOEXCITED RHODOPSIN; 48-KDA PROTEIN; PINEAL-GLAND; CYCLIC-GMP; LIGHT; BINDING	Phosducin (Pd) is a widely expressed phosphoprotein that regulates G-protein (G) signaling, Unphosphorylated Pd binds to G beta gamma subunits and blocks their interaction with G alpha, This binding sequesters G beta gamma and inhibits both receptor-mediated activation of G alpha and direct interactions between G beta gamma and effector enzymes. When phosphorylated by cAMP-dependent protein kinase, Pd does not affect these functions of G beta gamma. To further understand the role of Pd in regulating G-protein signaling in retinal rod photoreceptor cells, we have measured the abundance of Pd in rods and examined factors that control the rate of Pd phosphorylation, Pd is expressed at a copy number comparable to that for the rod G-protein, transducin (G(t)). The ratio of rhodopsin (Rho) to Pd is 15.5 +/- 3.5 to 1, The rate of Pd phosphorylation in rod outer segment preparations was dependent on [cAMP]. K-1/2 for cAMP was 0.56 +/- 0.09 mu M, and the maximal rate of phosphorylation was similar to 500 pmol PO4 incorporated/min/nmol Rho, In the presence of G(t) beta gamma this rate was decreased similar to 50-fold. From these data, one can estimate a t(1/2) of similar to 3 min for the rephosphorylation of Pd in rods during the recovery period after a light response. This relatively slow rephosphorylation of the Pd . G(t) beta gamma complex may provide a period of molecular memory in which sensitivity to further light stimuli is reduced as a result of sequestration of G(t) beta gamma by Pd.	LOS ALAMOS NATL LAB,DIV PHYS,BIOPHYS GRP,LOS ALAMOS,NM 87545	United States Department of Energy (DOE); Los Alamos National Laboratory			Wilkins, Jon/A-4984-2009	Wilkins, Jon/0000-0001-6405-6538; Willardson, Barry/0000-0002-8503-2268	NEI NIH HHS [EY 06816] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABE T, 1990, GENE, V91, P209, DOI 10.1016/0378-1119(90)90090-E; BAEHR W, 1982, J BIOL CHEM, V257, P6452; BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BEEBE SJ, 1992, J BIOL CHEM, V267, P25505; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BLAYZINSKI C, 1984, EXP EYE RES, V38, P279; BLAZYNSKI C, 1986, J BIOL CHEM, V261, P14142; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHENG HC, 1986, J BIOL CHEM, V261, P989; COTE RH, 1984, J BIOL CHEM, V259, P9635; CRAFT CM, 1991, GENOMICS, V10, P400, DOI 10.1016/0888-7543(91)90325-9; DEVRIES GW, 1978, J NEUROCHEM, V31, P1345, DOI 10.1111/j.1471-4159.1978.tb06559.x; HAMM H, 1990, J GEN PHYSIOL, V95, P545, DOI 10.1085/jgp.95.3.545; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HAWES BE, 1994, J BIOL CHEM, V269, P29825; HAWKES R, 1982, ANAL BIOCHEM, V123, P143, DOI 10.1016/0003-2697(82)90634-0; HEKMAN M, 1994, FEBS LETT, V343, P120, DOI 10.1016/0014-5793(94)80302-1; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KUHN H, 1981, P NATL ACAD SCI-BIOL, V78, P6873, DOI 10.1073/pnas.78.11.6873; KUO CH, 1993, BIOCHEM BIOPH RES CO, V191, P1097, DOI 10.1006/bbrc.1993.1329; KUO CH, 1989, MOL BRAIN RES, V6, P1, DOI 10.1016/0169-328X(89)90022-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1984, BIOCHEMISTRY-US, V23, P1972, DOI 10.1021/bi00304a014; LEE RH, 1992, J BIOL CHEM, V267, P25104; MCNAUGHTON PA, 1990, PHYSIOL REV, V70, P847, DOI 10.1152/physrev.1990.70.3.847; MIKI N, 1975, J BIOL CHEM, V250, P6320; NAKATANI K, 1988, J PHYSIOL-LONDON, V395, P731, DOI 10.1113/jphysiol.1988.sp016943; PFISTER C, 1983, EUR J BIOCHEM, V136, P489, DOI 10.1111/j.1432-1033.1983.tb07767.x; PFISTER C, 1985, SCIENCE, V228, P891, DOI 10.1126/science.2988124; SCHNETKAMP PPM, 1979, BIOCHIM BIOPHYS ACTA, V552, P379, DOI 10.1016/0005-2736(79)90182-2; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAL M, 1985, J BIOL CHEM, V260, P9976; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Willardson BM, 1996, P NATL ACAD SCI USA, V93, P1475, DOI 10.1073/pnas.93.4.1475; WOODRUFF ML, 1979, J GEN PHYSIOL, V73, P629, DOI 10.1085/jgp.73.5.629; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	41	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19232	19237		10.1074/jbc.271.32.19232	http://dx.doi.org/10.1074/jbc.271.32.19232			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702603	hybrid			2022-12-27	WOS:A1996VB68400037
J	Kim, J; Parvin, JD; Shykind, BM; Sharp, PA				Kim, J; Parvin, JD; Shykind, BM; Sharp, PA			A negative cofactor containing Dr1/p19 modulates transcription with TFIIA in a promoter-specific fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE-TRANSCRIPTION; BASAL TRANSCRIPTION; GLOBAL REPRESSOR; TBP-BINDING; YEAST; DNA; COMPLEX	An activity that modulated the relative levels of transcription from the adenovirus major late promoter (MLP), and the immunoglobulin heavy chain mu promoter (mu) was purified as a 90-kDa factor, This factor is suggested to be a heterotetramer of two subunits: a 20-kDa polypeptide identical to the previously described Dr1/p19 and a novel 30-kDa polypeptide. The Dr1/p19 protein has been characterized as a repressor of transcription, and the 30-kDa protein is related to a recently identified yeast gene proposed to encode a repressor of transcription, The 90-kDa factor forms a complex with TATA-binding protein on DNA and at high concentrations of both factors protects over a 150-base pair region around the promoter from DNase I cleavage, The conformation of this complex as assayed by footprinting analysis is altered by the transcription factor TFIIA on the MLP but not on the mu promoter. Similarly, TFIIA reverses the repression of transcription by the 90-kDa factor on the MLP but not on the mu promoter, Thus, the interactions of TATA-binding protein, TFIIA, and the 90-kDa factor are promoter-specific.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Parvin, Jeffrey D/C-8955-2009		NCI NIH HHS [P30-CA14051, P01-CA42063] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014051, P01CA042063] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CARTHEW RW, 1988, J BIOL CHEM, V263, P17128; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CHEN S, 1993, GENETICS, V134, P701; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; Croston GE, 1993, CURR OPIN CELL BIOL, V5, P417, DOI 10.1016/0955-0674(93)90006-C; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; INOSTROZA JA, 1992, CELL, V70, P477; KIM TK, 1995, J BIOL CHEM, V270, P10976, DOI 10.1074/jbc.270.18.10976; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; SWANSON MS, 1992, GENETICS, V132, P325; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; XING YY, 1993, EMBO J, V12, P4647, DOI 10.1002/j.1460-2075.1993.tb06153.x; YAMASHITA I, 1993, MOL GEN GENET, V241, P616, DOI 10.1007/BF00279904; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	36	19	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18405	18412		10.1074/jbc.271.31.18405	http://dx.doi.org/10.1074/jbc.271.31.18405			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702484	hybrid			2022-12-27	WOS:A1996VB68300022
J	Fisher, M; Gokhman, I; Pick, U; Zamir, A				Fisher, M; Gokhman, I; Pick, U; Zamir, A			A salt-resistant plasma membrane carbonic anhydrase is induced by salt in Dunaliella salina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CAROTENE ACCUMULATION; CHLAMYDOMONAS-REINHARDTII; NUCLEOTIDE-SEQUENCE; CDNA; EXPRESSION; GENE; CO2; TERTIOLECTA; TRANSPORT; BARDAWIL	The mechanisms allowing proliferation of the unicellular green alga Dunaliella salina in up to saturating NaCl concentrations are only partially understood at present. Previously, the level of a plasma membrane M(r) 60,000 protein, p60, was found to increase with rising external salinities, Based on cDNA cloning and enzymatic assays, it is now shown that p60 is an internally duplicated carbonic anhydrase, with each repeat homologous to animal and Chlamydomonas reinhardtii carbonic anhydrases, but exceptional in the excess of acidic over basic residues, Increasing salinities, alkaline shift, or removal of bicarbonate induced in D, salina parallel increases in the levels of p60, its mRNA, and external carbonic anhydrase activity, Moreover, purified p60 exhibited carbonic anhydrase activity comparable to other carbonic anhydrases. A p60-enriched soluble preparation showed maximal carbonic anhydrase activity at similar to 1.0 M NaCl and retained considerable activity at higher salt concentrations, In contrast, a similar preparation from C, reinhardtii was similar to 90% inhibited in 0.6 M NaCl. These results identified p60 as a structurally novel carbonic anhydrase transcriptionally regulated by CO2 availability and exhibiting halophilic-like characteristics, This enzyme is potentially suited to optimize CO2 uptake by cells growing in hypersaline media.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								AVRON M, 1986, TRENDS BIOCHEM SCI, V11, P5, DOI 10.1016/0968-0004(86)90218-5; BADGER MR, 1994, ANNU REV PLANT PHYS, V45, P369, DOI 10.1146/annurev.pp.45.060194.002101; BARLOW JH, 1987, NUCLEIC ACIDS RES, V15, P2386, DOI 10.1093/nar/15.5.2386; BENAMOTZ A, 1983, PLANT PHYSIOL, V72, P593, DOI 10.1104/pp.72.3.593; BOOTH WA, 1991, PHYCOLOGIA, V30, P220, DOI 10.2216/i0031-8884-30-2-220.1; BROWN AD, 1987, ARCH MICROBIOL, V147, P309, DOI 10.1007/BF00406125; BUNDY HF, 1986, COMP BIOCHEM PHYS B, V84, P63, DOI 10.1016/0305-0491(86)90272-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DYM O, 1995, SCIENCE, V267, P1344, DOI 10.1126/science.267.5202.1344; FINEL M, 1984, PLANT PHYSIOL, V74, P766, DOI 10.1104/pp.74.4.766; FISHER M, 1994, PLANT PHYSIOL, V106, P1359, DOI 10.1104/pp.106.4.1359; FUJIWARA S, 1990, P NATL ACAD SCI USA, V87, P9779, DOI 10.1073/pnas.87.24.9779; FUKUZAWA H, 1990, P NATL ACAD SCI USA, V87, P4383, DOI 10.1073/pnas.87.11.4383; GOYAL A, 1992, MAR BIOL, V113, P349, DOI 10.1007/BF00349158; HUSIC HD, 1990, PLANT PHYSIOL, V94, P380, DOI 10.1104/pp.94.1.380; HUSIC HD, 1990, CAN J BOT, V69, P1079; ISHIDA S, 1993, EUR J BIOCHEM, V214, P9, DOI 10.1111/j.1432-1033.1993.tb17890.x; KAMO T, 1990, EUR J BIOCHEM, V192, P557, DOI 10.1111/j.1432-1033.1990.tb19261.x; KATZ A, 1986, FEBS LETT, V202, P141, DOI 10.1016/0014-5793(86)80665-2; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8135; LATORELLA AH, 1973, J PHYCOL, V9, P273; LERS A, 1990, PLANT PHYSIOL, V93, P389, DOI 10.1104/pp.93.2.389; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MONTGOMERY JC, 1987, NUCLEIC ACIDS RES, V15, P4687, DOI 10.1093/nar/15.11.4687; PICK U, 1986, PLANT PHYSIOL, V81, P92, DOI 10.1104/pp.81.1.92; RAINES CA, 1992, PLANT MOL BIOL, V20, P1143, DOI 10.1007/BF00028900; RAMAZANOV Z, 1992, PHYSIOL PLANTARUM, V85, P121; RILEY JP, 1971, INTRO MARINE CHEM, P121; SADKA A, 1991, PLANT PHYSIOL, V95, P822, DOI 10.1104/pp.95.3.822; Sambrook J., 2002, MOL CLONING LAB MANU; SASS E, 1977, MAR CHEM, V5, P183, DOI 10.1016/0304-4203(77)90006-8; SKIRROW G, 1975, CHEM OCEANOGR, V2, P58; SULTEMEYER D, 1993, PHYSIOL PLANTARUM, V88, P179, DOI 10.1111/j.1399-3054.1993.tb01776.x; SULTEMEYER DF, 1989, PLANT PHYSIOL, V89, P1213, DOI 10.1104/pp.89.4.1213; TACHIKI A, 1992, BIOSCI BIOTECH BIOCH, V56, P794, DOI 10.1271/bbb.56.794; WADE R, 1986, P NATL ACAD SCI USA, V83, P9571, DOI 10.1073/pnas.83.24.9571	39	103	132	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17718	17723		10.1074/jbc.271.30.17718	http://dx.doi.org/10.1074/jbc.271.30.17718			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663366	hybrid			2022-12-27	WOS:A1996UY93500022
J	Gibbins, J; Asselin, J; Farndale, R; Barnes, M; Law, CL; Watson, SP				Gibbins, J; Asselin, J; Farndale, R; Barnes, M; Law, CL; Watson, SP			Tyrosine phosphorylation of the Fc receptor gamma-chain in collagen-stimulated platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM-AGGLUTININ; AFFINITY IGE RECEPTOR; GLYCOPROTEIN-IV; KINASE P72(SYK); PHOSPHOLIPASE C-GAMMA-2; CALCIUM MOBILIZATION; IMMUNOGLOBULIN-G; AGGREGATION; ACTIVATION; DEFICIENT	Stimulation of platelets by the extracellular matrix protein collagen leads to activation of a tyrosine kinase-dependent mechanism resulting in secretion and aggregation. Tyrosine phosphorylation of the tyrosine kinase Syk. and phospholipase C(gamma)2 are early events in collagen-induced activation. We recently proposed that collagen-signaling in platelets involves a receptor or a receptor-associated protein containing an immunoreceptor tyrosine based activation motif (ITAM) enabling interaction with Syk. In this report we show that collagen stimulation of platelets causes rapid tyrosine phosphorylation of the ITAM containing Fe receptor gamma-chain and that this is precipitated by the tandem Src homology 2 (SH2) domains of Syk expressed as a fusion protein. In addition we demonstrate an association between the Fc receptor gamma-chain with endogenous Syk in collagen stimulated platelets. The Fc receptor gamma-chain undergoes tyrosine phosphorylation in platelets stimulated by a collagen-related peptide which does not bind the integrin alpha(2) beta(1) and by the lectin wheat germ agglutinin. In contrast, cross-linking of the platelet low affinity receptor for immune complexes, Fc gamma RIIA, or stimulation by thrombin does not induce phosphorylation of the Fc receptor gamma-chain. The present results provide a molecular basis for collagen activation of platelets which is independent of the integrin alpha(2) beta(1) and involves phosphorylation of the Pc receptor gamma-chain, its association with Syk and subsequent phosphorylation of phospholipase C(gamma)2. Collagen is the first example of a nonimmune receptor stimulus to signal through a pathway closely related to signaling by immune receptors.	UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; STRANGEWAYS RES LAB,CAMBRIDGE CB1 4RN,ENGLAND; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195	University of Cambridge; University of Washington; University of Washington Seattle	Gibbins, J (corresponding author), UNIV OXFORD,DEPT PHARMACOL,MANSFIELD RD,OXFORD OX1 3QT,ENGLAND.		Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423; Gibbins, Jonathan/0000-0002-0372-5352	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CHIANG TM, 1982, J BIOL CHEM, V257, P7581; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; DANIEL JL, 1994, THROMB HAEMOSTASIS, V71, P353; DECKMYN H, 1992, BLOOD, V79, P1466, DOI 10.1182/blood.V79.6.1466.bloodjournal7961466; DUCHEMIN AM, 1994, J BIOL CHEM, V269, P12111; DURDEN DL, 1994, BIOCHEM J, V299, P569, DOI 10.1042/bj2990569; EISEMAN E, 1992, NATURE, V355, P78; GANGULY CL, 1985, BIOCHEM BIOPH RES CO, V132, P313, DOI 10.1016/0006-291X(85)91024-1; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; Higashihara M, 1985, FEBS Lett, V183, P433; INAZU T, 1991, BIOCHEM BIOPH RES CO, V174, P1154, DOI 10.1016/0006-291X(91)91541-J; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; Jouvin M H, 1995, Semin Immunol, V7, P29, DOI 10.1016/1044-5323(95)90005-5; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KEHREL B, 1993, BLOOD, V82, P3364; KIHARA H, 1994, J BIOL CHEM, V269, P22427; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; MCKEOWN L, 1994, BLOOD, V83, P2866, DOI 10.1182/blood.V83.10.2866.2866; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON HC, 1995, J BIOL CHEM, V270, P29781; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; OHTA S, 1992, BIOCHEM BIOPH RES CO, V185, P1128, DOI 10.1016/0006-291X(92)91743-A; PAOLINI R, 1995, J EXP MED, V181, P247, DOI 10.1084/jem.181.1.247; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RYO R, 1992, AM J HEMATOL, V39, P25, DOI 10.1002/ajh.2830390107; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; YATOMI Y, 1993, BIOCHEM BIOPH RES CO, V191, P453, DOI 10.1006/bbrc.1993.1239	38	190	193	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18095	18099		10.1074/jbc.271.30.18095	http://dx.doi.org/10.1074/jbc.271.30.18095			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663460	hybrid			2022-12-27	WOS:A1996UY93500076
J	Gu, HH; Ahn, J; Caplan, MJ; Blakely, RD; Levey, AI; Rudnick, G				Gu, HH; Ahn, J; Caplan, MJ; Blakely, RD; Levey, AI; Rudnick, G			Cell-specific sorting of biogenic amine transporters expressed in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; HIPPOCAMPAL-NEURONS; UPTAKE SITES; MDCK CELLS; NOREPINEPHRINE TRANSPORTER; SUBSTANTIA-NIGRA; POLARIZED CELLS; DOPAMINE; SEROTONIN; COCAINE	We have utilized polarized epithelial cells stably expressing neurotransmitter transporters to analyze the sorting behavior of these membrane proteins. The transporters for serotonin (5-HT), dopamine (DA), and norepinephrine (NE) are expected to be present in situ in the most distal extremities of axonal membranes, where they terminate the action of their biogenic amine substrates. Both Madin-Darby canine kidney (MDCK) and LLC-PK1 cells were stably transfected with cDNAs encoding either the rat 5-HT transporter (SERT), the human NE transporter (NET), or the rat or human DA transporter (DAT), These cells were grown on permeable filter supports, and the transporters were localized by three independent techniques, Confocal immunofluorescence microscopy indicated that each of the transporters expressed in LLC-PK1 cells was sorted to the basolateral membrane, co-localizing with the Na+/K+-ATPase. In MDCK cells, however, DAT was located primarily on the apical surface, while SERT and NET were found on the basolateral membranes, Cell surface biotinylation using an impermeant biotinylating reagent confirmed the immunocytochemistry results, Thus, SERT and NET in MDCK cells were labeled more efficiently from the basolateral medium than the apical medium, and DAT in MDCK cells was labeled more efficiently from the apical side than the basolateral side, Transport measurements in transfected MDCK cells agreed with the immunocytochemistry and biotinylation results, These results suggest the existence of cell-specific mechanisms that discriminate between neurotransmitter transporters for surface expression and render unlikely any simple hypothesis that sorting mechanisms in neurons and epithelia are identical.	YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, NEW HAVEN, CT 06510 USA; EMORY UNIV, SCH MED, DEPT ANAT & CELL BIOL, ATLANTA, GA 30322 USA; EMORY UNIV, SCH MED, DEPT NEUROL, ATLANTA, GA 30322 USA	Yale University; Yale University; Emory University; Emory University			Levey, Allan/F-2104-2011	Levey, Allan/0000-0002-3153-502X; Caplan, Michael/0000-0001-5768-4405	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390, R01DA008213] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-07390, DA-08213] Funding Source: Medline; NIGMS NIH HHS [GM-42136] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn J, 1996, J BIOL CHEM, V271, P6917, DOI 10.1074/jbc.271.12.6917; BALKOVETZ DF, 1989, J BIOL CHEM, V264, P2195; BARR LC, 1992, J CLIN PSYCHIAT, V53, P17; BERGER UV, 1992, EUR J PHARMACOL, V215, P153, DOI 10.1016/0014-2999(92)90023-W; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; CAPLAN M, 1989, FUNCTIONAL EPITHELIA, P71; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; CHERAMY A, 1981, NATURE, V289, P537, DOI 10.1038/289537a0; CHO AK, 1990, SCIENCE, V249, P631, DOI 10.1126/science.249.4969.631; CILIAX BJ, 1995, J NEUROSCI, V15, P1714, DOI 10.1523/JNEUROSCI.15-03-01714.1995; COPPEN AJ, 1990, J CLIN PSYCHIAT, V51, P3; DESOUZA EB, 1987, SYNAPSE, V1, P488, DOI 10.1002/syn.890010513; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; GEFFEN LB, 1976, NATURE, V260, P258, DOI 10.1038/260258a0; GIROS B, 1994, J BIOL CHEM, V269, P15985; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; GOTTARDI CJ, 1994, CURR TOP MEMBR, V41, P143, DOI 10.1016/S0070-2161(08)60458-X; GU H, 1994, J BIOL CHEM, V269, P7124; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; Hersch S. M., 1995, Society for Neuroscience Abstracts, V21, P781; Lee F. J. S., 1995, Society for Neuroscience Abstracts, V21, P374; LITTLE KY, 1993, J NEUROCHEM, V61, P1996, DOI 10.1111/j.1471-4159.1993.tb07435.x; LOPEZIBOR JJ, 1992, INT CLIN PSYCHOPHARM, V7, P5, DOI 10.1097/00004850-199210002-00003; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; NELSON N, 1994, J EXP BIOL, V196, P213; Nirenberg MJ, 1996, J NEUROSCI, V16, P436; PEREZVELAZQUEZ JL, 1993, NATURE, V361, P457, DOI 10.1038/361457a0; PIETRINI G, 1994, J BIOL CHEM, V269, P4668; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; QIAN Y, 1995, J NEUROSCI, V15, P1261; RADIAN R, 1990, J NEUROSCI, V10, P1319; RAMAMOORTHY S, 1993, BIOCHEMISTRY-US, V32, P1346, DOI 10.1021/bi00056a021; RICHFIELD EK, 1991, BRAIN RES, V540, P1, DOI 10.1016/0006-8993(91)90486-F; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; TATE CG, 1994, J BIOL CHEM, V269, P26303; TEJANIBUTT SM, 1992, J PHARMACOL EXP THER, V260, P427; VEYHL M, 1993, J BIOL CHEM, V268, P25041; YAMAUCHI A, 1991, AM J PHYSIOL, V261, pF197, DOI 10.1152/ajprenal.1991.261.1.F197	45	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18100	18106		10.1074/jbc.271.30.18100	http://dx.doi.org/10.1074/jbc.271.30.18100			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663573	hybrid			2022-12-27	WOS:A1996UY93500077
J	Shimomura, A; Ogawa, Y; Kitani, T; Fujisawa, H; Hagiwara, M				Shimomura, A; Ogawa, Y; Kitani, T; Fujisawa, H; Hagiwara, M			Calmodulin-dependent protein kinase II potentiates transcriptional activation through activating transcription factor 1 but not cAMP response element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS TRANSCRIPTION; FACTOR CREB; GENE-EXPRESSION; SOMATOSTATIN GENE; NUCLEAR FACTOR; PHOSPHORYLATION; CBP; IV	Activating transcription factor 1 (ATF1) and the cAMP response element binding protein (CREB) are members of the CREB/ATF family implicated in cAMP- and calcium-induced transcriptional activation, Although ATF1 and CREB share extensive homology, the function of ATF1 is poorly understood, Its phosphorylation state and activation by Ca2+- and calmodulin dependent protein kinase (CaMK) II were therefore examined, Phosphopeptide mapping analysis and Western blotting studies demonstrated that in vitro, CaMK II phosphorylates only Ser(63) (corresponding to Ser(133) of CREB), which is essential for the activation, and not Ser(72) (corresponding to Ser(142) Of CREB), which is a negative regulation site. Both ATF1 and CREB bound CBP in a phospho rylation-dependent manner, As expected from these in vitro studies, transient transfection studies revealed that ATF1 is activated by CaMK II, Our findings suggest that CaMK II mediates transactivation of cAMP responsive genes via ATF1.	NAGOYA UNIV,SCH MED,DEPT ANAT,NAGOYA,AICHI 466,JAPAN; ASAHIKAWA MED COLL,DEPT BIOCHEM,ASAHIKAWA,HOKKAIDO 078,JAPAN	Nagoya University; Asahikawa Medical College			Ogawa, Yasushi/I-1140-2012; Ogawa, Yasushi/M-8900-2014	Ogawa, Yasushi/0000-0003-3553-9607				ALBERTS AS, 1994, J BIOL CHEM, V269, P7623; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FLINT KJ, 1991, ONCOGENE, V6, P2019; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LIU F, 1993, J BIOL CHEM, V268, P6714; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P4166, DOI 10.1093/nar/21.18.4166; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; YOSHIDA K, 1995, J NEUROCHEM, V65, P1499	21	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17957	17960		10.1074/jbc.271.30.17957	http://dx.doi.org/10.1074/jbc.271.30.17957			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663317	hybrid			2022-12-27	WOS:A1996UY93500057
J	Wasmeier, C; Hutton, JC				Wasmeier, C; Hutton, JC			Molecular cloning of phogrin, a protein-tyrosine phosphatase homologue localized to insulin secretory granule membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; RAT; IDENTIFICATION; EXPRESSION; BIOSYNTHESIS; LANGERHANS; ISLETS; EXOCYTOSIS; INHIBITORS; VESICLES	An insulin granule membrane protein-tyrosine phosphatase (PTP) homologue, phogrin, was cloned by expression screening of a rat insulinoma cDNA library, The 3723-base pair cDNA encoded a transmembrane glycoprotein of 1004 amino acids (M(r) 111876) that underwent post-translational proteolysis to 60-64-kDa products after a 30-min delay. The kinetics of proteolytic conversion (t(1/2) = 45 min) and turnover (t(1/2) = 12 h) were consistent with sorting and conversion in a late compartment of the secretory pathway. Studies on the native beta-cell protein suggested that the COOH-terminal PTP domain was on the cytosolic face of the secretory granule, The lumenal segment was comprised of a pro tease-resistant globular domain of around 25 kDa, Its localization and topology is thus consistent with a transmembrane receptor function related to granule biogenesis, exocytosis, or subsequent membrane recovery, and it should prove to be a useful cell biological marker for the granule membrane. High expression of the mRNA (5.4 kilobases) and protein was evident in islets, pancreatic alpha- and beta-cell tumor lines, brain cells, and other cells of neuroendocrine lineage. It is closely related to the diabetic autoantigen ICA512 (IA-2) (42% identity overall; 80% in the 260-amino acid PTP domain) and thus a potential target of autoimmunity in diabetes mellitus.	UNIV COLORADO,HLTH SCI CTR,BARBARA DAVIS CTR CHILDHOOD DIABET,DENVER,CO 80262; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; BRAND SH, 1991, J BIOL CHEM, V266, P18949; BRESSAN GM, 1987, NUCLEIC ACIDS RES, V15, P10056, DOI 10.1093/nar/15.23.10056; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; GRIMALDI KA, 1987, BIOCHEM J, V245, P567, DOI 10.1042/bj2450567; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; GUEST PC, 1992, J BIOL CHEM, V267, P22401; GUEST PC, 1989, BIOCHEM J, V264, P503, DOI 10.1042/bj2640503; HALBAN PA, 1994, BIOCHEM J, V299, P1; HUTTON JC, 1987, BIOCHEM J, V244, P449, DOI 10.1042/bj2440449; HUTTON JC, 1982, DIABETOLOGIA, V23, P365; JENA BP, 1991, J BIOL CHEM, V266, P17744; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; LAN MS, 1994, DNA CELL BIOL, V13, P505, DOI 10.1089/dna.1994.13.505; LU J, 1994, BIOCHEM BIOPH RES CO, V204, P930, DOI 10.1006/bbrc.1994.2549; MOUREY RJ, 1994, CURR OPIN GENET DEV, V4, P31, DOI 10.1016/0959-437X(94)90088-4; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; NISHIBORI M, 1993, J CLIN INVEST, V91, P1775, DOI 10.1172/JCI116388; PAPINI E, 1995, J BIOL CHEM, V270, P1332, DOI 10.1074/jbc.270.3.1332; RABIN DU, 1992, DIABETES, V41, P183, DOI 10.2337/diabetes.41.2.183; RABIN DU, 1994, J IMMUNOL, V152, P3183; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; ROEP BO, 1990, NATURE, V345, P632, DOI 10.1038/345632a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANTINI F, 1993, J BIOL CHEM, V268, P22716; SCHEELE GA, 1982, SECRETORY GRANULE, P213; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORENSON RL, 1994, ENDOCRINOLOGY, V134, P1975, DOI 10.1210/en.134.4.1975; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TOOKE NE, 1984, BIOCHEM J, V219, P471, DOI 10.1042/bj2190471; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; WALCHSOLIMENA C, 1993, J NEUROSCI, V13, P3895; Winkler H, 1982, SECRETORY GRANULE, P3	42	189	197	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18161	18170		10.1074/jbc.271.30.18161	http://dx.doi.org/10.1074/jbc.271.30.18161			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663434	hybrid			2022-12-27	WOS:A1996UY93500086
J	Welihinda, AA; Kaufman, RJ				Welihinda, AA; Kaufman, RJ			The unfolded protein response pathway in Saccharomyces cerevisiae - Oligomerization and trans-phosphorylation of Ire1p (Ern1p) are required for kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEIN; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; INDUCTION; YEAST; PHOSPHATASE; SEQUENCE; ENCODES	In eukaryotic cells, accumulation of unfolded proteins in the endoplasmic reticulum (ER) results in a transcriptional induction of a number of ER chaperone proteins. In Saccharomyces cerevisiae, the putative transmembrane receptor kinase, Ire1p (Ern1p), has been implicated as the sensor of unfolded proteins in the ER that initiates transmittance of the unfolded protein signal from the ER to the nucleus. We have shown that the cytoplasmic domain of Ire1p receptor indeed has intrinsic Ser/Thr kinase activity and contains Ser/Thr phosphorylation sites as well. The cytoplasmic domain is also shown to form oligomers in vivo and in vitro. The ability to form oligomers primarily resides within the last 130 amino acids of the cytoplasmic domain, a region that is dispensable for in vitro kinase activity of the receptor. Oligomerization of the cytoplasmic domains is required for receptor trans-phosphorylation and subsequent activation of the kinase function. The activated kinase may transmit the unfolded protein signal from the ER to the nucleus to activate the transcription of the chaperone genes in the nucleus.	UNIV MICHIGAN, MED CTR, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan				Welihinda, Ajith/0000-0002-0049-0850				BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; DORNER AJ, 1992, EMBO J, V11, P1562; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARDWICK KG, 1990, EMBO J, V6, P620; Harlow E., 1988, ANTIBODIES LAB MANUA; IZUKA M, 1989, J BACTERIOL, V171, P6039; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; NIKAWA JI, 1992, MOL MICROBIOL, V6, P1441, DOI 10.1111/j.1365-2958.1992.tb00864.x; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; OOI J, 1995, ONCOGENE, V10, P1621; PARTALEDIS JA, 1993, P NATL ACAD SCI USA, V90, P5450, DOI 10.1073/pnas.90.12.5450; PICCOLOMINI R, 1989, J GEN MICROBIOL, V135, P3119; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rowling P J, 1993, Subcell Biochem, V21, P41; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Sherman F., 1986, METHODS YEAST GENETI; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307	32	144	155	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18181	18187		10.1074/jbc.271.30.18181	http://dx.doi.org/10.1074/jbc.271.30.18181			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663458	hybrid			2022-12-27	WOS:A1996UY93500089
J	Bankston, LA; Guidotti, G				Bankston, LA; Guidotti, G			Characterization of ATP transport into chromaffin granule ghosts - Synergy of ATP and serotonin accumulation in chromaffin granule ghosts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN SYNAPTIC VESICLES; BOVINE ADRENAL-MEDULLA; GLUTAMATE UPTAKE; ENDOPLASMIC-RETICULUM; CEREBRAL-CORTEX; MEMBRANE; PROTON; CATECHOLAMINE; CELLS; TRANSLOCATION	ATP is an excitatory neurotransmitter that is stored and cosecreted with catecholamines from cells of the adrenal medulla, While the transport of catecholamines into chromaffin granule ghosts has been extensively characterized, there is little information on the mechanism of ATP transport into these structures, Here Fee show that ATP transport is driven by the electrical component of the electrochemical proton gradient created by the chromaffin granule membrane H+-ATPase, and that the accumulated nucleotide is released from the vesicles by inhibition of the H+-ATPase, GTP and UTP are also substrates for this transporter, distinguishing it from the mitochondrial ADP/ATP exchanger, Accumulation of ADP and ATP (rather than exchange with intravesicular ATP) is demonstrated by high pressure liquid chromatography measurements, The anion transport inhibitor 4,4-diisothiocyanatostilbene-2,2-disulfonic acid (K-i = 27 mu M) inhibits ATP transport, while atractyloside, the inhibitor of the mitochondrial ATP/ADP exchanger, is a very poor inhibitor, Finally, we have demonstrated a synergy between the accumulation of ATP and that of serotonin (i.e. more of each solute accumulates when the two are accumulated together), supporting the view that there is an interaction between serotonin and ATP that reduces their effective concentration within the ghosts.	HARVARD UNIV,DEPT CELLULAR & MOLEC BIOL,CAMBRIDGE,MA 02138	Harvard University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007598] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL08893] Funding Source: Medline; NIGMS NIH HHS [5T32GM07598-14] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERER W, 1978, BIOCHEM J, V172, P353, DOI 10.1042/bj1720353b; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P227, DOI 10.1007/BF01870089; CAPASSO JM, 1989, J BIOL CHEM, V264, P5233; CAUGHEY B, 1987, J NEUROCHEM, V49, P563, DOI 10.1111/j.1471-4159.1987.tb02901.x; CIDON S, 1989, J BIOL CHEM, V264, P8281; CIDON S, 1986, J BIOL CHEM, V261, P9222; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FILLINGAME RH, 1980, ANNU REV BIOCHEM, V49, P1079, DOI 10.1146/annurev.bi.49.070180.005243; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GRUNINGER HA, 1983, NEUROSCIENCE, V9, P917, DOI 10.1016/0306-4522(83)90280-4; HILLARP NA, 1958, ACTA PHYSIOL SCAND, V42, P321, DOI 10.1111/j.1748-1716.1958.tb01566.x; HILLARP NA, 1959, ACTA PHYSIOL SCAND, V45, P328, DOI 10.1111/j.1748-1716.1959.tb01705.x; JOHNSON RG, 1979, J BIOL CHEM, V254, P3750; JOHNSON RG, 1981, J BIOL CHEM, V256, P5773; KIRSHNER N, 1962, J BIOL CHEM, V237, P2311; KLINGENBERG M, 1985, ENZYMES BIOL MEMBR, V4, P511; KOPELL WN, 1982, J BIOL CHEM, V257, P5707; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MAYINGER P, 1993, EMBO J, V12, P659, DOI 10.1002/j.1460-2075.1993.tb05699.x; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; NAITO S, 1985, J NEUROCHEM, V44, P99, DOI 10.1111/j.1471-4159.1985.tb07118.x; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; PHILLIPS JH, 1974, BIOCHEM J, V144, P311, DOI 10.1042/bj1440311; PHILLIPS JH, 1978, BIOCHEM J, V170, P673, DOI 10.1042/bj1700673; PHILLIPS JH, 1980, BIOCHEM J, V192, P273, DOI 10.1042/bj1920273; POGOLOTTI AL, 1982, ANAL BIOCHEM, V126, P335, DOI 10.1016/0003-2697(82)90524-3; POISNER AM, 1982, SECRETORY GRANULE; RAINNIE DG, 1994, SCIENCE, V263, P689, DOI 10.1126/science.8303279; SCHULDINER S, 1978, P NATL ACAD SCI USA, V75, P3713, DOI 10.1073/pnas.75.8.3713; SHIOI J, 1989, BIOCHEM J, V258, P499, DOI 10.1042/bj2580499; SHIOI J, 1990, BIOCHEM J, V267, P63, DOI 10.1042/bj2670063; SILLERO MAG, 1994, BIOCHIMIE, V76, P404; WEBER A, 1983, BIOCHEM J, V210, P789, DOI 10.1042/bj2100789; WEBER A, 1981, NEUROSCIENCE, V6, P2269, DOI 10.1016/0306-4522(81)90016-6	37	66	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17132	17138		10.1074/jbc.271.29.17132	http://dx.doi.org/10.1074/jbc.271.29.17132			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663306	hybrid			2022-12-27	WOS:A1996UX94300025
J	Sierralta, J; Fill, M; SuarezIsla, BA				Sierralta, J; Fill, M; SuarezIsla, BA			Functionally heterogenous ryanodine receptors in avian cerebellum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM RELEASE CHANNEL; FOOT PROTEIN ISOFORMS; BRAIN MICROSOMAL-MEMBRANES; SKELETAL-MUSCLE; H-3 RYANODINE; CA-2+ RELEASE; BINDING-SITES; RAT-BRAIN; PURKINJE NEURONS	The functional heterogeneity of the ryanodine receptor (RyR) channels in avian cerebellum was defined, Heavy endoplasmic reticulum microsomes had significant levels of ryanodine and inositol 1,4,5-trisphosphate binding. Scatchard analysis and kinetic studies indicated the existence of at least two distinct ryanodine binding sites, Ryanodine binding was calcium-dependent but was not significantly enhanced by caffeine, Incorporation of microsomes into planar lipid bilayers revealed ion channels with pharmacological features (calcium, magnesium, ATP, and caffeine sensitivity) similar to the RyR channels found in mammalian striated muscle, Despite a wide range of unitary conductances (220-500 picosiemens, symmetrical cesium methanesulfonate), ryanodine locked both channels into a characteristic slow gating subconductance state, positively identifying them as RyR channels. Two populations of avian RyR channels were functionally distinguished by single channel calcium sensitivity, One population was defined by a bell-shaped calcium sensitivity analogous to the skeletal muscle RyR isoform (type I). The calcium sensitivity of the second RyR population was sigmoidal and analogous to the cardiac muscle RyR isoform (type II), These data show that there are at least two functionally distinct RyR channel populations in avian cerebellum, This leads to the possibility that these functionally distinct RyR channels are involved in different intracellular calcium signaling pathways.	UNIV CHILE,FAC MED,DEPT FISIOL & BIOFIS,SANTIAGO 7,CHILE; LOYOLA UNIV,DEPT PHYSIOL,MAYWOOD,IL 60153	Universidad de Chile; Loyola University Chicago			Sierralta, Jimena Alejandra/AAG-8877-2021; Sierralta, Jimena/A-7591-2008	Sierralta, Jimena/0000-0002-0257-146X	NINDS NIH HHS [NS29640] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM111397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029640] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIREY JA, 1993, BIOCHEMISTRY-US, V32, P5739, DOI 10.1021/bi00073a003; AIREY JA, 1990, J BIOL CHEM, V265, P14187; ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; BUCK E, 1992, J BIOL CHEM, V267, P23560; BULL R, 1993, FEBS LETT, V331, P223, DOI 10.1016/0014-5793(93)80341-Q; BULL R, 1989, BIOPHYS J, V56, P749, DOI 10.1016/S0006-3495(89)82722-5; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; CHU A, 1993, J MEMBRANE BIOL, V135, P49; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; FILL M, 1990, BIOPHYS J, V50, P471; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GYORKE S, 1994, BIOPHYS J, V66, P1879; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; LAI FA, 1992, BIOCHEM J, V288, P553, DOI 10.1042/bj2880553; MCPHERSON P, 1990, J BIOL CHEM, V265, P18464; MURAYAMA T, 1992, J BIOCHEM, V112, P514, DOI 10.1093/oxfordjournals.jbchem.a123931; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OBRIEN J, 1995, BIOPHYS J, V68, P471, DOI 10.1016/S0006-3495(95)80208-0; OGAWA Y, 1994, CRIT REV BIOCHEM MOL, V29, P229, DOI 10.3109/10409239409083482; OGAWA Y, 1990, J BIOCHEM-TOKYO, V107, P894, DOI 10.1093/oxfordjournals.jbchem.a123144; OLIVARES EB, 1991, BIOPHYS J, V59, P1153, DOI 10.1016/S0006-3495(91)82331-1; OUYANG Y, 1993, BRAIN RES, V620, P629; PADUA RA, 1991, BRAIN RES, V542, P135, DOI 10.1016/0006-8993(91)91007-N; PADUA RA, 1994, J NEUROCHEM, V62, P2340; PERCIVAL AL, 1994, BIOPHYS J, V67, P1834, DOI 10.1016/S0006-3495(94)80665-4; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; SHARP AH, 1993, J NEUROSCI, V13, P3051; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUAREZISLA BA, 1988, BIOPHYS J, V54, P737, DOI 10.1016/S0006-3495(88)83009-1; SUTKO JL, 1991, J CELL BIOL, V113, P793, DOI 10.1083/jcb.113.4.793; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; VOLPE P, 1991, EMBO J, V10, P3183, DOI 10.1002/j.1460-2075.1991.tb04880.x; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WANG JP, 1993, J BIOL CHEM, V268, P20974; ZIMANYI I, 1992, MOL PHARMACOL, V42, P1049; ZIMANYI I, 1991, J PHARMACOL EXP THER, V256, P938; ZIMANYI I, 1991, BRAIN RES, V561, P181, DOI 10.1016/0006-8993(91)91594-Q	40	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17028	17034		10.1074/jbc.271.29.17028	http://dx.doi.org/10.1074/jbc.271.29.17028			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663321	hybrid			2022-12-27	WOS:A1996UX94300010
J	Broome, MA; Hunter, T				Broome, MA; Hunter, T			Requirement for c-Src catalytic activity and the SH3 domain in platelet-derived growth factor BB and epidermal growth factor mitogenic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY TYROSINE KINASES; PHOSPHORYLATION; PP60C-SRC; PROTEIN; ASSOCIATION; FIBROBLASTS; RECEPTOR; CELLS; MUTAGENESIS; CONTAINS	The Src family protein-tyrosine kinases are required for mitogenic signaling from the platelet-derived growth factor (PDGF), colony stimulating factor-1, and epidermal growth factor (EGF) receptor protein-tyrosine kinases (RPTK) (Twamley-Stein, G. M., Pepperkok, R., Ansorge, W., and Courtneidge, S. A. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 7696-7700; Roche, S., Koegl, M., Barone, M. V., Roussel, M. F., and Courtneidge, S. A. (1995) Mel. Cell. Biol. 15, 1102-1109). In NIH3T3 fibroblasts, c-Src, Fyn, and c-Yes associate with the activated PDGF receptor, are substrates for receptor phosphorylation, and are themselves activated. Src family catalytic function is required for RPTK mitogenic signaling as evidenced by the SH2-dependent dominant negative phenotype exhibited by kinase-inactive Src and Fyn mutants (Twamley-Stein, G. M., Pepperkok, R., Ansorge, W., and Courtneidge, S. A. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 7696-7700). Here, we have generated clonal Src(-) murine fibroblast cell lines overexpressing various murine c-Src mutants and studied the effect of these mutant Src proteins on PDGF- and EGF-induced mitogenesis. Two c-Src SH3 domain mutants, Y133F and Y138F, each inhibited PDGF BB- and EGF-induced DNA synthesis in quiescent cells. This demonstrates an involvement of the Src SH3 domain in PDGF beta and EGF receptor mitogenic signaling. Since both Tyr-133 and Tyr-138 are located on the ligand binding surface of the SH3 domain, these results suggest that the c-Src SH3 domain is required for PDGF and EGF mitogenic signaling. The dominant negative effect of either single mutant on PDGF receptor signaling was reversed by a second SH2-inactivating mutation. We conclude that the c-Src SH3 domain function requires the SH2 domain in the case of the PDGF receptor, presumably because binding of c-Src to the receptor via its SH2 domain is a prerequisite for the SH3 domain function. In contrast, SH2 function is apparently not essential for the SH3 function in EGF receptor signaling.	SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	Salk Institute; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780, CA14195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOL DE, 1992, P NATL ACAD SCI USA, V89, P5422, DOI 10.1073/pnas.89.12.5422; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; ESPINO PC, 1990, ONCOGENE, V5, P283; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KARN J, 1989, ONCOGENE, V4, P773; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MOOLENAAR WH, 1992, COLD SPRING HARB SYM, V57, P163, DOI 10.1101/SQB.1992.057.01.021; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; OKADA M, 1993, J BIOL CHEM, V268, P18070; OKAMURA H, 1994, ONCOGENE, V9, P2293; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Potts W M, 1988, Oncogene Res, V3, P343; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SORIANO P, 1991, CELL, V64, P6983; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; TOSHIMA J, 1995, BIOCHEM BIOPH RES CO, V209, P656, DOI 10.1006/bbrc.1995.1549; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WILSON LK, 1990, ONCOGENE, V5, P1471; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	52	121	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16798	16806		10.1074/jbc.271.28.16798	http://dx.doi.org/10.1074/jbc.271.28.16798			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663329	hybrid			2022-12-27	WOS:A1996UX12600059
J	Fang, H; Panzner, S; Mullins, C; Hartmann, E; Green, N				Fang, H; Panzner, S; Mullins, C; Hartmann, E; Green, N			The homologue of mammalian SPC12 is important for efficient signal peptidase activity in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SEC11 PROTEIN; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; SHUTTLE VECTORS; HOST STRAINS; GENE; PURIFICATION; GLYCOPROTEIN; SEQUENCE; MEMBRANE	The multisubunit signal peptidase catalyzes the cleavage of signal peptides and the degradation of some membrane proteins within the endoplasmic reticulum (ER). The only subunit of this enzyme functionally examined to date, yeast Sec11p, is related to signal peptidase I from bacteria. Since bacterial signal peptidase is capable of processing both prokaryotic and eukaryotic signal sequences as a monomer, it is unclear why the analogous enzyme in the ER contains proteins unrelated to signal peptidase I. To address this issue, the gene encoding Spc1p, the yeast homologue to mammalian SPC12, is isolated from the yeast Saccharomyces cerevisiae, Spc1p co-purifies and genetically interacts with Sec11p, but unlike Sec11p, Spc1p is not required for cell growth or the proteolytic processing of tested proteins in yeast, This indicates that only a subset of the ER signal peptidase subunits is required for signal peptidase and protein degradation activities in vivo. Through both genetic and biochemical criteria. Spc1p appears, however, to be important for efficient signal peptidase activity.	MAX DELBRUCK CTR MOLEC MED,D-13125 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Fang, H (corresponding author), VANDERBILT UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,221 KIRKLAND HALL,NASHVILLE,TN 37232, USA.		Hartmann, Enno/C-5687-2013		NCI NIH HHS [2 T32 CA09425] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER RK, 1987, BIOCHEMISTRY-US, V26, P8561, DOI 10.1021/bi00400a010; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; ESNAULT Y, 1993, EMBO J, V12, P4283; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FANG H, 1994, MOL BIOL CELL, V5, P933, DOI 10.1091/mbc.5.9.933; GREEN N, 1992, MOL CELL BIOL, V12, P276, DOI 10.1128/MCB.12.1.276; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; GREENBURG G, 1994, J BIOL CHEM, V269, P25354; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; INNIS MA, 1984, P NATL ACAD SCI USA, V81, P4308; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1442; KALIES KU, 1996, J BIOL CHEM, V271, P4325; KURIHARA T, 1993, MOL BIOL CELL, V4, P919, DOI 10.1091/mbc.4.9.919; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIVELY MO, 1994, SIGNAL PEPTIDASES, P59; MULLIS C, 1995, J BIOL CHEM, V270, P17143; NEWSOME AL, 1992, BIOCHEM J, V282, P447, DOI 10.1042/bj2820447; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; SHERMAN F, 1986, METHODS YEAST GENETI, P127; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENS TB, 1982, CELL, V30, P443; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; Von Heijne Gunnar, 1994, V22, P1; YADEAU JT, 1991, P NATL ACAD SCI USA, V88, P517, DOI 10.1073/pnas.88.2.517; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YU F, 1984, FEBS LETT, V173, P264, DOI 10.1016/0014-5793(84)81060-1; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973	42	26	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16460	16465		10.1074/jbc.271.28.16460	http://dx.doi.org/10.1074/jbc.271.28.16460			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663399	hybrid			2022-12-27	WOS:A1996UX12600008
J	Fujino, T; Kang, MJ; Suzuki, H; Iijima, H; Yamamoto, T				Fujino, T; Kang, MJ; Suzuki, H; Iijima, H; Yamamoto, T			Molecular characterization and expression of rat acyl-CoA synthetase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; NUCLEOTIDE-SEQUENCE; BACILLUS-BREVIS; CLONING; GENE; DNA; PURIFICATION; BRAIN; CDNA; INHIBITORS	Isolation and characterization of a rat brain cDNA identified a third acyl-CoA synthetase (ACS) designated ACS3. The deduced amino acid sequence of the cDNA revealed that ACS3 consists of 720 amino acids and exhibits a structural architecture common to ACSs from various origins, ACS3 expressed in COS cells was purified to near homogeneity, The purified ACS3 resolved by SDS-polyacrylamide gel electrophoresis into two major proteins of 79 and 80 kDa. Cell-free translation of a synthetic mRNA encoding the entire region of ACS3 revealed that the two isoforms were derived from the same mRNA, The purified ACS3 utilizes laurate and myristate most efficiently among C-8-C-22 saturated fatty acids and arachidonate and eicosapentaenoate among C-16-C-20 unsaturated fatty acids, Northern blot analysis revealed that ACS3 mRNA is most abundant in brain and, to a much lesser extent, in lung, adrenal gland, kidney, and small intestine. During the development of the rat brain, expression of ACS3 mRNA reached a maximum level at 15 days after birth and then declined gradually to 10% of the maximum in the adult brain.	TOHOKU UNIV,CTR GENE RES,AOBA KU,SENDAI,MIYAGI 981,JAPAN	Tohoku University								ABE T, 1992, J BIOCHEM-TOKYO, V111, P123, DOI 10.1093/oxfordjournals.jbchem.a123707; BAZAN NG, 1986, PROG LIPID RES, V25, P595, DOI 10.1016/0163-7827(86)90122-0; BRONFMAN M, 1989, BIOCHEM BIOPH RES CO, V159, P1026, DOI 10.1016/0006-291X(89)92211-0; CONNERTON IF, 1990, MOL MICROBIOL, V4, P451, DOI 10.1111/j.1365-2958.1990.tb00611.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIEZ B, 1990, J BIOL CHEM, V265, P16358; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HORI K, 1989, J BIOCHEM-TOKYO, V106, P639, DOI 10.1093/oxfordjournals.jbchem.a122909; Kabara J J, 1973, Prog Brain Res, V40, P363; KLUXEN FW, 1993, ANAL BIOCHEM, V208, P352, DOI 10.1006/abio.1993.1060; KURIBAYASHIOHTA K, 1993, BIOCHIM BIOPHYS ACTA, V1156, P204, DOI 10.1016/0304-4165(93)90137-W; LI QL, 1990, J BIOCHEM-TOKYO, V107, P699, DOI 10.1093/oxfordjournals.jbchem.a123111; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZOYA E, 1988, EUR J BIOCHEM, V176, P661, DOI 10.1111/j.1432-1033.1988.tb14328.x; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; REDDY TS, 1984, INT J DEV NEUROSCI, V2, P447, DOI 10.1016/0736-5748(84)90046-7; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASTRY PS, 1985, PROG LIPID RES, V24, P69, DOI 10.1016/0163-7827(85)90011-6; SINGH I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P44, DOI 10.1016/0005-2760(93)90174-8; SINGH I, 1988, BIOCHIM BIOPHYS ACTA, V963, P509, DOI 10.1016/0005-2760(88)90319-0; SMITH DJ, 1990, EMBO J, V9, P2743, DOI 10.1002/j.1460-2075.1990.tb07461.x; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TANAKA T, 1979, EUR J BIOCHEM, V98, P165, DOI 10.1111/j.1432-1033.1979.tb13173.x; TOH H, 1991, Protein Sequences and Data Analysis, V4, P111; WANDERS RJA, 1987, BIOCHIM BIOPHYS ACTA, V919, P21, DOI 10.1016/0005-2760(87)90213-X; WECKERMANN R, 1988, NUCLEIC ACIDS RES, V16, P11841, DOI 10.1093/nar/16.24.11841; WILSON DB, 1982, J BIOL CHEM, V257, P3510; WOOD KV, 1989, SCIENCE, V244, P700, DOI 10.1126/science.2655091	36	159	162	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16748	16752		10.1074/jbc.271.28.16748	http://dx.doi.org/10.1074/jbc.271.28.16748			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663269	hybrid			2022-12-27	WOS:A1996UX12600052
J	Masaki, R; Yamamoto, A; Tashiro, Y				Masaki, R; Yamamoto, A; Tashiro, Y			Membrane topology and retention of microsomal aldehyde dehydrogenase in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOCYTES; GOLGI-COMPLEX; VESICULAR TRANSPORT; BREFELDIN-A; PROTEINS; CYTOCHROME-P-450; LIVER; ER; REDISTRIBUTION; GLYCOSYLATION	Microsomal aldehyde dehydrogenase (msALDH) is anchored to the endoplasmic reticulum (ER) membrane by the hydrophobic domain at its carboxyl terminus, and most of the molecule is exposed to the cytoplasm (Masaki, R., Yamamoto, A., and Tashiro, Y. (1994) J. Cell Biol, 126, 1407-1420), To determine the membrane topology and the intracellular localization of msALDH, the amino-terminal region of bovine opsin containing N-glycosylation sites was fused to the carboxyl terminus of msALDH, and three chimeric proteins with extensions of different sizes were expressed in COS cells, Indirect immunofluorescence microscopy showed the ER localization of all of the chimeric proteins similar to wildtype msALDH. Immunoblotting revealed that the two chimeric proteins containing longer extensions, those with the N-glycosylation site at distances of 13 and 21 amino acids from the membrane anchor, respectively, were glycosylated, These results indicate that the membrane binding domain of msALDH spans the bilayer of the ER, The carbohydrate chain of the chimeras was sensitive to endoglycosidase H but resistant to endoglycosidase D. Upon treatment of transfected COS cells with brefeldin A, the carbohydrate chain was processed to an endoglycosidase II-resistant form, presumably by cis/medial Golgi-specific enzymes redistributed in the ER, These biochemical results in addition to immunofluorescence microscopic observations suggest that msALDH is retained in the ER by blockading of the exit from the ER.	KANSAI MED UNIV,LIVER RES CTR,DIV CELL BIOL,MORIGUCHI,OSAKA 570,JAPAN	Kansai Medical University	Masaki, R (corresponding author), KANSAI MED UNIV,DEPT PHYSIOL,10-15 FUMIZONO CHO,MORIGUCHI,OSAKA 570,JAPAN.							AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; AHN KS, 1993, J BIOL CHEM, V268, P18726; BARNUN S, 1980, P NATL ACAD SCI-BIOL, V77, P965, DOI 10.1073/pnas.77.2.965; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; FUJIIKURIYAMA Y, 1979, J CELL BIOL, V81, P510, DOI 10.1083/jcb.81.3.510; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; INOUE A, 1992, J BIOL CHEM, V267, P10613; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KOU CH, 1986, MOL BRAIN RES, V1, P251; KRAMER W, 1987, METHOD ENZYMOL, V154, P350; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MIYAUCHI K, 1991, J BIOL CHEM, V266, P19536; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; MURAKAMI K, 1994, J BIOCHEM, V116, P164, DOI 10.1093/oxfordjournals.jbchem.a124489; NILSSON I, 1993, J BIOL CHEM, V268, P5798; OZOLS J, 1982, BIOCHIM BIOPHYS ACTA, V704, P163, DOI 10.1016/0167-4838(82)90143-1; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; ROBBINS PW, 1977, CELL, V12, P893, DOI 10.1016/0092-8674(77)90153-2; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOZAWA O, 1993, J BIOL CHEM, V268, P21399; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; SZCZESNASKORUPA E, 1995, J BIOL CHEM, V270, P24327, DOI 10.1074/jbc.270.41.24327; SZCZESNASKORUPA E, 1993, J BIOL CHEM, V268, P1757; TAKAGI Y, 1985, J BIOCHEM-TOKYO, V98, P1647, DOI 10.1093/oxfordjournals.jbchem.a135435; VERGERES G, 1995, J BIOL CHEM, V270, P3414, DOI 10.1074/jbc.270.7.3414; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; Yamamoto A, 1996, J CELL SCI, V109, P1727; YAMAMOTO A, 1985, J CELL BIOL, V101, P1733, DOI 10.1083/jcb.101.5.1733	37	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16939	16944		10.1074/jbc.271.28.16939	http://dx.doi.org/10.1074/jbc.271.28.16939			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663312	hybrid			2022-12-27	WOS:A1996UX12600078
J	Laderman, KA; Penny, JR; Mazzucchelli, F; Bresolin, N; Scarlato, G; Attardi, G				Laderman, KA; Penny, JR; Mazzucchelli, F; Bresolin, N; Scarlato, G; Attardi, G			Aging-dependent functional alterations of mitochondrial DNA (mtDNA) from human fibroblasts transferred into mtDNA-less cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRADIENT GEL-ELECTROPHORESIS; AGE-ASSOCIATED ACCUMULATION; DEGENERATIVE DISEASES; HUMAN BRAIN; PROTEIN-SYNTHESIS; OXIDATIVE DAMAGE; HUMAN HEARTS; DELETIONS; MUTATIONS; TISSUES	To investigate the role that aging-dependent accumulation of mitochondrial DNA (mtDNA) mutations plays in the senescence processes, mitochondria from fibroblasts of 21 normal human individuals between 20 weeks (fetal) and 103 years of age were introduced into human mtDNA-less (rho degrees) 206 cells by cytoplast x rho degrees cell fusion, and 7-31 transformant clones were isolated from each fusion, A slight cell donor age-dependent decrease in growth rate was detected in the transformants. Using an O-2 consumption rate of 1 fmol/min/cell, which was not observed in any transformant among 158 derived from individuals 20 weeks (fetal) to 37 years of age, as a cutoff to identify respiratory-deficient clones, 11 such clones were found among 198 transformants derived from individuals 39-103 years of age. Furthermore, conventional and nonparametric analysis of the respiratory rates of 356 clones revealed a very significant decrease with donor age, In other analyses, a very significant age-dependent decline in the mtDNA content of the clones was observed, without, however, any significant correlation with the decrease in O-2 consumption rate in the defective transformants, These observations clearly indicate the occurrence in the fibroblast-derived trans formants of two independent, age-related functional alterations of mtDNA, presumably resulting from structural damage to this genome.	CALTECH,DIV BIOL,PASADENA,CA 91125; UNIV MILAN,IST CLIN NEUROL,CTR DINO FERRARI,I-20122 MILAN,ITALY; UNIV MILAN,IST CLIN NEUROL,CTR DINO FERRARI,OSPED MAGGIORE POLICLIN,IRCCS,I-20122 MILAN,ITALY	California Institute of Technology; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan				Bresolin, Nereo/0000-0001-6694-3595	NIA NIH HHS [AG12117-05, AG05612-03] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [F32AG005612] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAMS ES, 1992, METHOD ENZYMOL, V212, P71; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Bentlage HACM, 1996, HUM MOL GENET, V5, P197, DOI 10.1093/hmg/5.2.197; BOURGERON T, 1993, J BIOL CHEM, V268, P19369; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHOMYN A, 1994, AM J HUM GENET, V54, P966; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370; CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; COSTES B, 1993, HUM MOL GENET, V2, P393, DOI 10.1093/hmg/2.4.393; Gibbons J.D., 1993, NONPARAMETRIC STAT I, P30; GONZALEZ IL, 1985, P NATL ACAD SCI USA, V82, P7666, DOI 10.1073/pnas.82.22.7666; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HAYAKAWA M, 1991, BIOCHEM BIOPH RES CO, V179, P1023, DOI 10.1016/0006-291X(91)91921-X; HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1994, J BIOL CHEM, V269, P6878; HOFHAUS G, 1995, MOL CELL BIOL, V15, P964; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; MIQUEL J, 1992, MUTAT RES, V275, P209, DOI 10.1016/0921-8734(92)90024-J; MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8; MULLERHOCKER J, 1992, BRAIN PATHOL, V2, P149, DOI 10.1111/j.1750-3639.1992.tb00683.x; MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9; MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167; MULLERHOCKER J, 1993, VIRCHOWS ARCH A, V422, P7, DOI 10.1007/BF01605127; Norwood T. H., 1982, TECHNIQUES SOMATIC C, P35; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PIKO L, 1988, MECH AGEING DEV, V43, P279, DOI 10.1016/0047-6374(88)90037-1; REIS RJS, 1983, J BIOL CHEM, V258, P9078; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SIMONETTI S, 1992, BIOCHIM BIOPHYS ACTA, V1180, P113, DOI 10.1016/0925-4439(92)90059-V; SOONG NW, 1992, NAT GENET, V2, P318; SUGIYAMA S, 1991, BIOCHEM BIOPH RES CO, V180, P894, DOI 10.1016/S0006-291X(05)81149-0; TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; VEOMETT GE, 1982, TECHNIQUES SOMATIC C, P67; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0; YONEDA M, 1984, MOL CELL BIOL, V14, P2899; ZHANG C, 1992, FEBS LETT, V297, P34, DOI 10.1016/0014-5793(92)80321-7	50	80	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15891	15897		10.1074/jbc.271.27.15891	http://dx.doi.org/10.1074/jbc.271.27.15891			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663253	hybrid, Green Accepted			2022-12-27	WOS:A1996UW35200011
J	Mano, I; Lamed, Y; Teichberg, VI				Mano, I; Lamed, Y; Teichberg, VI			A Venus flytrap mechanism for activation and desensitization of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE-BINDING PROTEIN; AMPA KAINATE RECEPTORS; RAT HIPPOCAMPAL SLICES; SYNAPTIC TRANSMISSION; GLUTAMATE; NEURONS; CHANNELS; PATCHES; LIGAND	Desensitization of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) subtype of glutamate receptor channels is an important process shaping the time course of synaptic excitation. Upon desensitization, the receptor channel closes and the agonist affinity increases. So far, the nature of the structural rearrangements leading to these events was unknown. On the basis of the structural homology of the ligand binding domains of AMPA receptors and of the bilobated bacterial periplasmic proteins, we now show that agonist interaction with one lobe of the GluR1 subunit of homomeric AMPA receptors controls channel activation while additional interactions with the other lobe cause channel desensitization. Accordingly, we suggest that the transition of the AMPA receptor channel to the desensitized state involves the agonist-mediated stabilization of the closed lobe conformation of its binding domain and is a process akin to that used by the venus flytrap.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; BENVENISTE M, 1995, J PHYSIOL-LONDON, V483, P367, DOI 10.1113/jphysiol.1995.sp020591; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; DANI JA, 1995, CURR OPIN NEUROBIOL, V5, P310, DOI 10.1016/0959-4388(95)80043-3; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; JONAS P, 1992, J PHYSIOL-LONDON, V455, P143, DOI 10.1113/jphysiol.1992.sp019294; KANG CH, 1991, J BIOL CHEM, V266, P23893; KISKIN NI, 1990, EUR J NEUROSCI, V2, P461, DOI 10.1111/j.1460-9568.1990.tb00437.x; KISKIN NI, 1986, NEUROSCI LETT, V63, P225, DOI 10.1016/0304-3940(86)90360-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; LARSON J, 1994, NEUROREPORT, V5, P389, DOI 10.1097/00001756-199401120-00004; LI F, 1995, MOL PHARMACOL, V47, P148; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MAYER ML, 1989, P NATL ACAD SCI USA, V86, P1411, DOI 10.1073/pnas.86.4.1411; MOSBACHER J, 1994, SCIENCE, V266, P1059, DOI 10.1126/science.7973663; OH BH, 1993, J BIOL CHEM, V268, P11348; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Paas Y, 1996, EMBO J, V15, P1548, DOI 10.1002/j.1460-2075.1996.tb00499.x; PARSONS CG, 1994, NEUROPHARMACOLOGY, V33, P589, DOI 10.1016/0028-3908(94)90163-5; PARTIN KM, 1995, NEURON, V14, P833, DOI 10.1016/0896-6273(95)90227-9; PARTIN KM, 1994, MOL PHARMACOL, V46, P129; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; PATNEAU DK, 1991, NEURON, V6, P785, DOI 10.1016/0896-6273(91)90175-Y; PATNEAU DK, 1993, J NEUROSCI, V13, P3496; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; THIO LL, 1991, J NEUROSCI, V11, P3430; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; UCHINO S, 1992, FEBS LETT, V308, P253, DOI 10.1016/0014-5793(92)81286-U; VYKLICKY L, 1991, NEURON, V7, P971, DOI 10.1016/0896-6273(91)90342-W; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; YAMADA KA, 1993, J NEUROSCI, V13, P3904	38	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15299	15302		10.1074/jbc.271.26.15299	http://dx.doi.org/10.1074/jbc.271.26.15299			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663365	hybrid			2022-12-27	WOS:A1996UV29900001
J	Cui, Z; Houweling, M; Chen, MH; Record, M; Chap, H; Vance, DE; Terce, F				Cui, Z; Houweling, M; Chen, MH; Record, M; Chap, H; Vance, DE; Terce, F			A genetic defect in phosphatidylcholine biosynthesis triggers apoptosis in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITION	We have investigated the cell death of a Chinese hamster ovary mutant (MT-58) with a thermo-sensitive CTP: phosphocholine cytidylyltransferase, the rate-limiting enzyme of the CDP choline pathway for phosphatidylcholine biosynthesis (Esko, J. D., Wermuth, M. M., and Raetz, C. R. H. (1981) J. Biol. Chem, 256, 7388-7393), After MT-58 cells were shifted to the restrictive temperature of 40 degrees C, the cytidylyltransferase was inactivated immediately leading to a decrease in phosphatidylcholine biosynthesis and cell death, DNA content and number of cells in the S phase decreased significantly in the dying MT-58 cells according to flow cytometrical analyses, The fragmentation of genomic DNA was detected by DNA ladders in agarose gel and release of the prelabeled genomic DNA into cytosolic fractions 14 h after the temperature shift, The dying cells underwent a dramatic reduction of cellular volume while maintaining the membrane containment of cellular contents, These events indicated that the inactivation of cytidylyltransferase triggered apoptosis in Chinese hamster ovary cells, This is the first report that apoptosis was induced in cultured cells, not by an added agent, but by a mutation in phospholipid biosynthesis.	HOP PURPAN, INSERM, U326, F-31059 TOULOUSE, FRANCE; UNIV ALBERTA, LIPID & LIPOPROT RES GRP, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, SURG MED RES INST, EDMONTON, AB T6G 2S2, CANADA	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Alberta; University of Alberta; University of Alberta			Tercé, François/M-5863-2018; RECORD, Michel/G-3493-2017	Tercé, François/0000-0003-4488-2167; RECORD, Michel/0000-0003-1893-0022				BAUMGARTNERPARZER SM, 1995, DIABETES, V44, P1323, DOI 10.2337/diabetes.44.11.1323; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; BUSCH D, 1989, MUTAGENESIS, V4, P349, DOI 10.1093/mutage/4.5.349; EARNSHAW WC, 1995, TRENDS CELL BIOL, V5, P217, DOI 10.1016/S0962-8924(00)89006-6; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1980, P NATL ACAD SCI-BIOL, V77, P5192, DOI 10.1073/pnas.77.9.5192; ESKO JD, 1981, J BIOL CHEM, V256, P7388; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; HAUG JS, 1994, BBA-MOL CELL RES, V1223, P133, DOI 10.1016/0167-4889(94)90082-5; HOUWELING M, 1995, J BIOL CHEM, V270, P16277, DOI 10.1074/jbc.270.27.16277; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJNO G, 1995, AM J PATHOL, V146, P3; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MEYN MS, 1995, CANCER RES, V55, P5991; OISHI K, 1988, BIOCHEM BIOPH RES CO, V157, P1000, DOI 10.1016/S0006-291X(88)80973-2; Osborne Barbara A., 1994, Trends in Cell Biology, V4, P394; PAVLIDIS P, 1994, CELL, V79, P23, DOI 10.1016/0092-8674(94)90397-2; POWIS G, 1992, CANCER RES, V52, P2835; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SCHWARTZ LM, 1995, METHOD CELL BIOL, V46, P107; TERCE F, 1994, J LIPID RES, V35, P2130; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; Vance D E, 1981, Methods Enzymol, V71 Pt C, P576; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; Vindelov L, 1990, Methods Cell Biol, V33, P127	33	182	187	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14668	14671		10.1074/jbc.271.25.14668	http://dx.doi.org/10.1074/jbc.271.25.14668			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663247	hybrid			2022-12-27	WOS:A1996UT10600006
J	Liu, YC; Elly, C; Yoshida, H; BonnefoyBerard, N; Altman, A				Liu, YC; Elly, C; Yoshida, H; BonnefoyBerard, N; Altman, A			Activation-modulated association of 14-3-3 proteins with Cbl in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V-CBL; TRANSFORMATION; ONCOGENE	14-3-3 proteins have recently been implicated in the regulation of intracellular signaling pathways via their interaction with several oncogene and protooncogene products. We found recently that 14-3-3 associates with several tyrosine-phosphorylated proteins and phosphatidylinositol 3-kinase (PI3-K) in T cells. We report here the identification of the 120-kDa 14-3-3 tau-binding phosphoprotein present in activated T cell lysates as Cbl, a protooncogene product of unknown function which was found recently to be a major protein-tyrosine kinase (PTK) substrate, and to interact with several signaling molecules including PI3-K, in T lymphocytes. The association between 14-3-3 tau and Cbl was detected both in vitro and in intact T cells and, in contrast to Raf-1, was markedly increased following T cell activation. The use of truncated 14-3-3 tau fusion proteins demonstrated that the 15 C-terminal residues are required for the association between 14-3-3 and three of its target proteins, namely, Cbl, Raf-1, and PI3-K. The findings that 14-3-3 tau binds both PI3-K and Cbl, together with recent reports of an association between Cbl and PI3-K, suggest that 14-3-3 dimers play a critical role in signal transduction processes by promoting and coordinating protein-protein interactions of signaling proteins.	LA JOLLA INST ALLERGY & IMMUNOL, DIV CELL BIOL, LA JOLLA, CA 92037 USA; LA JOLLA INST ALLERGY & IMMUNOL, DIV IMMUNOBIOL, LA JOLLA, CA 92037 USA; INST CYTOSIGNAL RES INC, TOKYO 140, JAPAN	La Jolla Institute for Immunology; La Jolla Institute for Immunology			Bonnefoy, Nathalie/J-2536-2012	Bonnefoy, Nathalie/0000-0003-4814-6722; LIU, YUN-CAI/0000-0002-0996-7109	NCI NIH HHS [CA35299] Funding Source: Medline; NIGMS NIH HHS [GM50819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; JONES DHA, 1995, J MOL BIOL, V245, P375, DOI 10.1006/jmbi.1994.0031; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LIU YC, 1994, P NATL ACAD SCI USA, V91, P11227, DOI 10.1073/pnas.91.23.11227; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROTH D, 1994, BIOCHEM J, V301, P305, DOI 10.1042/bj3010305; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	37	99	106	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14591	14595		10.1074/jbc.271.24.14591	http://dx.doi.org/10.1074/jbc.271.24.14591			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663231	hybrid			2022-12-27	WOS:A1996UQ66000096
J	Eiserich, JP; Cross, CE; Jones, AD; Halliwell, B; vanderVliet, A				Eiserich, JP; Cross, CE; Jones, AD; Halliwell, B; vanderVliet, A			Formation of nitrating and chlorinating species by reaction of nitrite with hypochlorous acid - A novel mechanism for nitric oxide-mediated protein modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYL RADICAL PRODUCTION; HUMAN-NEUTROPHILS; AQUEOUS-SOLUTION; NITROGEN-OXIDES; SYNOVIAL-FLUID; ONE-ELECTRON; L-ARGININE; PEROXYNITRITE; SUPEROXIDE; OXIDATION	Detection of 3-nitrotyrosine has served as an in vivo marker for the production of the cytotoxic species peroxynitrite (ONOO-). We show here that reaction of nitrite (NO2-), the autoxidation product of nitric oxide ((NO)-N-.), with hypochlorous acid (HOCl) forms reactive intermediate species that are also capable of nitrating phenolic substrates such as tyrosine and 4-hydroxy-phenylacetic acid, with maximum yields obtained at physiological pH. Monitoring the reaction of NO2- with HOCl by continuous flow photodiode array spectrophotometry indicates the formation of a transient species with spectral characteristics similar to those of nitryl chloride (Cl-NO2). Reaction of synthetic Cl-NO2 with N-acetyl-L-tyrosine results in the formation of 3-chlorotyrosine and 3-nitrotyrosine in ratios that are similar to those obtained by the NO2-/HOCl reaction (4:1). Tyrosine residues in bovine serum albumin are also nitrated and chlorinated by NO2-/HOCl and synthetic Cl-NO2. The reaction of N-acetyl-L-tyrosine with NO2-/HOCl or authentic Cl-NO2 also produces dityrosine, suggesting that free radical intermediates are involved in the reaction mechanism. Our data indicate that while chlorination reactions of Cl-NO2 are mediated by direct electrophilic addition to the aromatic ring, a free radical mechanism appears to be operative in nitrations mediated by NO,1 HOCl or Cl-NO2, probably involving the combination of nitrogen dioxide ((NO2)-N-.) and tyrosyl radical. We propose that NO2- reacts with HOCl by Cl+ transfer to form both cis- and trans-chlorine nitrite (Cl-ONO) and CI-NO2 as intermediates that modify tyrosine by either direct re action or after decomposition to reactive free and solvent-caged Cl-. and (NO2)-N-. as reactive species. Formation of Cl-NO2 and/or Cl-ONO in vivo may represent previously unrecognized mediators of inflammation-mediate protein modification and tissue injury, and offers an additional mechanism of tyrosine nitration independent of ONOO-.	UNIV CALIF DAVIS,FACIL ADV INSTRUMENTAT,DAVIS,CA 95616; UNIV LONDON KINGS COLL,PHARMACOL GRP,NEURODEGENERAT DIS RES CTR,LONDON SW3 6LX,ENGLAND	University of California System; University of California Davis; University of London; King's College London	Eiserich, JP (corresponding author), UNIV CALIF DAVIS,DEPT INTERNAL MED,DIV PULM CRIT CARE MED,MED SPONSORED PROGRAMS,TB 150,DAVIS,CA 95616, USA.		Jones, Arthur D/C-2670-2013; Halliwell, Barry/C-8318-2009	Jones, A. Daniel/0000-0002-7408-6690	NHLBI NIH HHS [HL47628] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047628] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANBAR M, 1958, J AM CHEM SOC, V80, P1073, DOI 10.1021/ja01538a015; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CHESTER AH, 1990, LANCET, V336, P897, DOI 10.1016/0140-6736(90)92269-N; COLLIS MJ, 1958, J CHEM SOC, P445; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; EISERICH JP, 1995, BIOCHEM J, V310, P745, DOI 10.1042/bj3100745; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538, DOI 10.1164/ajrccm.149.2.7508323; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GINTZ FP, 1958, J CHEM SOC, P445, DOI 10.1039/jr9580000445; GOLDSTEIN S, 1995, INORG CHEM, V34, P4041, DOI 10.1021/ic00120a006; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HALFPENNY E, 1952, J CHEM SOC, P939, DOI 10.1039/jr9520000939; HASZELDINE RN, 1953, J CHEM SOC, P2525, DOI 10.1039/jr9530002525; HOOPER DC, 1995, P NATL ACAD SCI USA, V92, P5312, DOI 10.1073/pnas.92.12.5312; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; ISHIROPOULOS H, 1995, FEBS LETT, V364, P279; JOHNSON DW, 1991, INORG CHEM, V30, P4845, DOI 10.1021/ic00025a031; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; Kettle AJ, 1996, FEBS LETT, V379, P103, DOI 10.1016/0014-5793(95)01494-2; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Kono Y, 1995, BIOCHEM MOL BIOL INT, V36, P275; KOOY NW, 1994, ARCH BIOCHEM BIOPHYS, V310, P352, DOI 10.1006/abbi.1994.1178; KOPPENOL WH, 1994, FEBS LETT, V347, P5, DOI 10.1016/0014-5793(94)00494-3; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; LEE TJ, 1994, J PHYS CHEM-US, V98, P111, DOI 10.1021/j100052a019; LEPOIVRE M, 1994, J BIOL CHEM, V269, P21891; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MILES AM, 1995, J LEUKOCYTE BIOL, V58, P616, DOI 10.1002/jlb.58.5.616; MILLER RA, 1995, J INVEST MED, V43, P39; MOHAMMED JR, 1988, J LAB CLIN MED, V112, P711; MONCADA S, 1991, PHARMACOL REV, V43, P109; NICKELSEN MG, 1991, CHEM RES TOXICOL, V4, P94, DOI 10.1021/tx00019a013; OBERMEYER A, 1995, J AM CHEM SOC, V117, P7887, DOI 10.1021/ja00135a006; PERRIN CL, 1977, J AM CHEM SOC, V99, P5516, DOI 10.1021/ja00458a065; PRICE CC, 1953, J AM CHEM SOC, V75, P3276, DOI 10.1021/ja01109a510; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; PRYOR WA, 1994, P NATL ACAD SCI USA, V91, P11173, DOI 10.1073/pnas.91.23.11173; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SHECHTER H, 1952, J AM CHEM SOC, V74, P3052, DOI 10.1021/ja01132a029; SQUADRITO GL, 1995, CHEM-BIOL INTERACT, V96, P203, DOI 10.1016/0009-2797(94)03591-U; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; TEVAULT DE, 1977, J CHEM PHYS, V67, P3777, DOI 10.1063/1.435319; TSAI JHM, 1994, J AM CHEM SOC, V116, P4115, DOI 10.1021/ja00088a072; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; VANDERVLIET A, 1994, FEBS LETT, V339, P89, DOI 10.1016/0014-5793(94)80391-9; WARDMAN P, 1989, J PHYS CHEM REF DATA, V18, P1637, DOI 10.1063/1.555843; WATSON WD, 1974, J ORG CHEM, V39, P1160, DOI 10.1021/jo00922a034; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660; Winterbourn C.C., 1990, OXYGEN RADICALS SYST, P31	64	367	373	3	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19199	19208		10.1074/jbc.271.32.19199	http://dx.doi.org/10.1074/jbc.271.32.19199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702599	hybrid			2022-12-27	WOS:A1996VB68400033
J	Benaroudj, N; Triniolles, F; Ladjimi, MM				Benaroudj, N; Triniolles, F; Ladjimi, MM			Effect of nucleotides, peptides, and unfolded proteins on the self-association of the molecular chaperone HSC70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK COGNATE PROTEIN; UNCOATING ATPASE; ESCHERICHIA-COLI; CLATHRIN TRISKELIA; BINDING DOMAIN; HSP70; PURIFICATION; AGGREGATION; KINETICS; HYDROLYSIS	In a previous study, we showed that the molecular chaperone HSC70 self-associates in solution in a reversible and likely unlimited fashion, Here, we examine the influence of nucleotides, nucleotide analogs, peptides, and unfolded proteins on the self-association properties of this protein. Whereas in the presence of ADP, HSC70 exists as a slow, concentration- and temperature-dependent monomer-oligomer equilibrium, in the presence of ATP, the protein is essentially monomeric, indicating that ATP shifts this equilibrium toward the monomer by stabilizing the monomer, Dissociation of oligomers into monomers is also obtained with the slowly hydrolyzable ATP analogs, adenosine 5'-O-(thiotriphosphate) and 5'-adenylyl-beta,gamma-imidodiphosphate, or the complex between ADP and the phosphate analog, BeF3, indicating that binding but not hydrolysis of ATP is necessary and sufficient for the stabilization of HSC70 monomer, Furthermore, binding of short peptides or permanently unfolded proteins to thepeptide binding site of HSC70 promotes the dissociation of oligomers into monomers, suggesting that protein substrates are able to compete with HSC70 for the same binding site, Because the release of peptides or unfolded proteins from HSC70 has also been shown to require ATP binding, these results indicate that dissociation of oligomers is controlled by a mechanism similar to that of release of protein substrates and suggest that binding of HSC70 to itself occurs via the peptide binding site and mimics binding of HSC70 to protein substrates.	CNRS,LAB ENZYMOL & BIOCHIM STRUCT,F-91198 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay				Benaroudj, Nadia/0000-0002-6475-0041				ANDERSON JV, 1994, PLANT PHYSIOL, V104, P1371, DOI 10.1104/pp.104.4.1371; BENAROUDJ N, 1994, EUR J BIOCHEM, V221, P121, DOI 10.1111/j.1432-1033.1994.tb18720.x; BENAROUDJ N, 1994, BIOCHEMISTRY-US, V34, P15282; BHATTACHARYYA T, 1995, J BIOL CHEM, V270, P1705, DOI 10.1074/jbc.270.4.1705; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHEETHAM ME, 1994, EUR J BIOCHEM, V226, P99, DOI 10.1111/j.1432-1033.1994.tb20030.x; CYR DM, 1992, J BIOL CHEM, V267, P20927; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; GAO BC, 1993, J BIOL CHEM, V268, P8507; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; GUIDON PT, 1986, BIOCHEMISTRY-US, V25, P3231, DOI 10.1021/bi00359a023; HA JH, 1994, BIOCHEMISTRY-US, V33, P14625, DOI 10.1021/bi00252a031; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; KIEFHABER T, 1991, BIO-TECHNOL, V9, P825, DOI 10.1038/nbt0991-825; KIM DH, 1992, J CELL PHYSIOL, V153, P353, DOI 10.1002/jcp.1041530215; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; KWON OS, 1994, J BIOL CHEM, V269, P266; LAM KT, 1992, BIOCHEM BIOPH RES CO, V184, P167, DOI 10.1016/0006-291X(92)91174-O; LIN TH, 1991, J BIOL CHEM, V266, P1635; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; MCKAY DB, 1994, BIOL HEAT SHOCK PROT, P153; MORSHAUSER RC, 1995, BIOCHEMISTRY-US, V34, P6261, DOI 10.1021/bi00019a001; ORSINI G, 1978, J BIOL CHEM, V253, P3453; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, FEBS LETT, V336, P124, DOI 10.1016/0014-5793(93)81624-9; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; RANDALL LL, 1995, TRENDS BIOCHEM SCI, V20, P65, DOI 10.1016/S0968-0004(00)88959-8; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; UNGEWICKELL E, 1985, EMBO J, V4, P3385, DOI 10.1002/j.1460-2075.1985.tb04094.x; WANG C, 1993, BIOCHEM J, V294, P69, DOI 10.1042/bj2940069; WANG TF, 1993, J BIOL CHEM, V268, P26049; WILBANKS SM, 1994, J BIOL CHEM, V269, P12893; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P12095, DOI 10.1021/bi00038a002; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007; [No title captured]; [No title captured]	57	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18471	18476		10.1074/jbc.271.31.18471	http://dx.doi.org/10.1074/jbc.271.31.18471			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702492	hybrid			2022-12-27	WOS:A1996VB68300030
J	Narayan, S; He, F; Wilson, SH				Narayan, S; He, F; Wilson, SH			Activation of the human DNA polymerase beta promoter by a DNA-alkylating agent through induced phosphorylation of cAMP response element-binding protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CREB; HAMSTER OVARY CELLS; GENE-TRANSCRIPTION; II TRANSCRIPTION; KINASE-A; RNA; EXTRACT; REPAIR; INDUCTION; EXCISION	Treatment of cells with the DNA-alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) induces expression of the endogenous mammalian DNA polymerase beta (beta-pol) gene and of the cloned promoter in transient expression studies, The lone cAMP response element (CRE) in the core promoter, along with functional protein kinase A, is critical for the MNNG-induced upregulation, Recently, we described a kinetic mechanism for transcriptional regulation of the beta-pol promoter in vitro and found that CRE-binding protein (CREB) from MNNG-treated cells differentially up-regulates the promoter by stimulating formation of closed preinitiation complex (RP(c)), Here, using a CRE-dependent chimeric beta-pol promoter, we purified the RP(c) assembled with nuclear extract from MNNG-treated and control HeLa cells, Comparison of proteins in the purified RP(c) samples revealed that the MNNG induction is associated with a strong increase in the Ser(133)-phosphorylated form of recombinant CREB (CREB-1), CREB depletion of the nuclear extracts diminished transcriptional activity, and addition of purified Ser(133)-phosphorylated CREB-1 restored activity, whereas unphosphorylated CREB-1 did not, Addition of phosphorylated CREB-1 to the control cell extract mimicked the MNNG-induced up-regulation of transcriptional activity, These results indicate that phosphorylation of CREB-1 is the probable mechanism of activation of the beta-pol promoter after treatment of cells with the DNA-alkylating agent MNNG.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006492] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06492] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBERTS AS, 1994, J BIOL CHEM, V269, P7623; ARIAS JA, 1989, J BIOL CHEM, V264, P3223; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CHEN KH, 1995, GENE, V164, P323, DOI 10.1016/0378-1119(95)00498-U; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DELMAS V, 1994, REV PHYSIOL BIOCH P, V124, P1, DOI 10.1007/BFb0031030; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; ENGLANDER EW, 1992, NUCLEIC ACIDS RES, V20, P5527, DOI 10.1093/nar/20.21.5527; ENGLANDER EW, 1992, DNA CELL BIOL, V11, P61, DOI 10.1089/dna.1992.11.61; ENGLANDER EW, 1992, CURR PERSPECT MOL CE, V1, P111; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; He F, 1996, BIOCHEMISTRY-US, V35, P1775, DOI 10.1021/bi9525987; JENKINS TM, 1992, SCIENCE, V258, P745; KEDAR PS, 1991, P NATL ACAD SCI USA, V88, P3729, DOI 10.1073/pnas.88.9.3729; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; MATSUMOTO Y, 1989, MOL CELL BIOL, V9, P3750, DOI 10.1128/MCB.9.9.3750; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; NARAYAN S, 1994, J BIOL CHEM, V269, P12755; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SRIVASTAVA DK, 1995, J BIOL CHEM, V270, P16402, DOI 10.1074/jbc.270.27.16402; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; SUN PQ, 1992, MOL ENDOCRINOL, V6, P1858, DOI 10.1210/me.6.11.1858; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WIDEN SG, 1988, J BIOL CHEM, V263, P16992; YAMAGUCHI M, 1994, EUR J BIOCHEM, V221, P227, DOI 10.1111/j.1432-1033.1994.tb18733.x; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	39	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18508	18513		10.1074/jbc.271.31.18508	http://dx.doi.org/10.1074/jbc.271.31.18508			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702497	hybrid			2022-12-27	WOS:A1996VB68300035
J	Parent, CA; Devreotes, PN				Parent, CA; Devreotes, PN			Constitutively active adenylyl cyclase mutant requires neither G proteins nor cytosolic regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; DICTYOSTELIUM DEVELOPMENT; RAT-BRAIN; EXPRESSION; DISCOIDEUM; RECEPTOR; SYSTEM; CRAC	Receptor-mediated G protein-linked adenylyl cyclase systems are universal signal transducers. We exploited the essential role of this cascade in Dictyostelium development to screen for random mutations in the catalytic component, ACA. This enzyme is activated by G protein beta gamma-subunits acting in concert with a novel cytosolic regulator, CRAC. By suppression of the CRAC-null phenotype, we isolated constitutively active versions of the enzyme that require neither exogenous stimuli nor in ternal regulators. One mutant displayed a 15-fold increase in its V-max. It harbors a single amino acid substitution (L394S) affecting a conserved residue located in the first cytoplasmic loop near the N-terminal hydrophobic domain of ACA. The screening procedure can be adapted for isolation of constitutive mutations in mammalian adenylyl cyclases.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University								BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; CALI JJ, 1994, J BIOL CHEM, V269, P12190; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; INSALL R, 1994, J CELL BIOL, V126, P1537, DOI 10.1083/jcb.126.6.1537; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LILLY PJ, 1995, J CELL BIOL, V129, P1659, DOI 10.1083/jcb.129.6.1659; NELLEN W, 1987, METHOD CELL BIOL, V28, P67; PARENT CA, 1995, J BIOL CHEM, V270, P22693, DOI 10.1074/jbc.270.39.22693; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Premont RT, 1996, J BIOL CHEM, V271, P13900, DOI 10.1074/jbc.271.23.13900; PUPILLO M, 1992, MOL BIOL CELL, V3, P1229, DOI 10.1091/mbc.3.11.1229; RAYMOND JR, 1994, AM J PHYSIOL, V266, pF163, DOI 10.1152/ajprenal.1994.266.2.F163; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941	31	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18333	18336		10.1074/jbc.271.31.18333	http://dx.doi.org/10.1074/jbc.271.31.18333			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702473	hybrid			2022-12-27	WOS:A1996VB68300011
J	Suzuki, H; ONeill, BC; Suzuki, Y; Denisenko, ON; Bomsztyk, K				Suzuki, H; ONeill, BC; Suzuki, Y; Denisenko, ON; Bomsztyk, K			Activation of a nuclear DNA-binding protein recognized by a transcriptional element, bcn-1, from the laminin B2 chain gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSFORMING GROWTH FACTOR-BETA-1; GLOMERULAR EPITHELIAL-CELLS; MESANGIAL CELLS; BASEMENT-MEMBRANES; EXTRACELLULAR-MATRIX; RESPONSIVE ELEMENT; SYNAPTIC CLEFT; PHORBOL ESTER; EXPRESSION	Treatment of mesangial cells with either phorbol 12-myristate 13-acetate (PMA) or interleukin-1 beta induces an increase in laminin B2 chain mRNA levels, In other systems, activation of gene expression by these agents is transcriptionally mediated, To identify transcription factors that control expression of laminin B2 chain gene, we employed a strategy consisting of a computer-based analysis of murine and human gene promoter sequences and gel shift assays, Although overall the laminin B2 chain promoters from the two species have low sequence similarity, the mouse promoter contained sequences that were also contained in one motif, 5'-CCCCGCCCACCTCGCGCGC-3', designated bcn-1, from the human promoter. Treatment of mesangial cells with either PMA or interleukin-1 beta induced a transient increase in nuclear DNA binding activity, designated BCN-1, recognized the bcn-1 motif in a gel shift assay, A single nucleotide replacement in the bcn-1 motif abolished DNA binding, indicating that bcn-1 . BCN-1 complex formation is highly specific, In transient transfections, the ability of PMA to induce the laminin B2 chain promoter was abolished by mutating the bcn-1 motif. These results suggest that the bcn-1 element and its cognate inducible BCN-1 protein regulate laminin B2 chain gene transcription.	UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045978, R01DK045978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045134, P01GM042508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45978] Funding Source: Medline; NIGMS NIH HHS [GM45134, GM42508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSON DR, 1986, J PATHOL, V149, P257, DOI 10.1002/path.1711490402; ABRAHAMSON DR, 1993, KIDNEY INT, V43, P73, DOI 10.1038/ki.1993.13; ADLER S, 1986, J CLIN INVEST, V77, P762, DOI 10.1172/JCI112372; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BHANDARI B, 1995, J BIOL CHEM, V270, P5541, DOI 10.1074/jbc.270.10.5541; BOMSZTYK K, 1991, CELL REGUL, V2, P329, DOI 10.1091/mbc.2.4.329; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAMPBELL MJ, 1995, BIOTECHNIQUES, V18, P1027; CHEDID M, 1991, J IMMUNOL, V147, P867; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURKIN ME, 1988, BIOCHEMISTRY-US, V27, P5198, DOI 10.1021/bi00414a038; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; EKBLOM P, 1991, AM J KIDNEY DIS, V17, P603, DOI 10.1016/S0272-6386(12)80329-5; FLOEGE J, 1992, LAB INVEST, V66, P485; FUKATSU A, 1988, HUM PATHOL, V19, P64, DOI 10.1016/S0046-8177(88)80317-4; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN TL, 1992, J BIOL CHEM, V267, P2014; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; ISAKA Y, 1993, J CLIN INVEST, V92, P2597, DOI 10.1172/JCI116874; IWASAKI T, 1993, CYTOKINE, V5, P416, DOI 10.1016/1043-4666(93)90031-Y; JOHNSON R, 1992, J AM SOC NEPHROL, V2, P1388; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; KALLUNKI T, 1991, J BIOL CHEM, V266, P221; LOVETT DH, 1988, J CLIN INVEST, V82, P115, DOI 10.1172/JCI113558; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MATSUO S, 1986, AM J PATHOL, V122, P36; MELCION C, 1982, TRANSPLANT P, V14, P559; NAKAMURA T, 1992, KIDNEY INT, V41, P1213, DOI 10.1038/ki.1992.183; OGAWA K, 1988, J BIOL CHEM, V263, P8384; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; RICHARDSON CA, 1995, AM J PHYSIOL-RENAL, V268, pF273, DOI 10.1152/ajprenal.1995.268.2.F273; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SMITH JD, 1988, J BIOL CHEM, V263, P8300; STRULOVICI B, 1989, IMMUNOLOGY, V67, P210; TIMPL R, 1979, J BIOL CHEM, V254, P9933; VADEN HGB, 1993, AM J PHYSIOL, V256, pF293; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	49	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18981	18988		10.1074/jbc.271.31.18981	http://dx.doi.org/10.1074/jbc.271.31.18981			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702563	hybrid			2022-12-27	WOS:A1996VB68300101
J	Dahl, E; Manthey, D; Chen, Y; Schwarz, HJ; Chang, YS; Lalley, PA; Nicholson, BJ; Willecke, K				Dahl, E; Manthey, D; Chen, Y; Schwarz, HJ; Chang, YS; Lalley, PA; Nicholson, BJ; Willecke, K			Molecular cloning and functional expression of mouse connexin-30, a gap junction gene highly expressed in adult brain and skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATIC-CELL HYBRIDIZATION; CHROMOSOMAL ASSIGNMENTS; PROTEINS; SEQUENCE; VOLTAGE; RNA; XENOPUS; FAMILY; LIVER; CONDUCTANCE	A new gap junction gene isolated from the mouse genome codes for a connexin protein of 261 amino acids, Because of its theoretical molecular mass of 30.366 kDa, it is named connexin-30. Within the connexin gene family, this protein is most closely related to connexin-ae (77% amino acid sequence identity). The coding region of mouse connexin-30 is uninterrupted by introns and is detected in the mouse genome as a single copy gene that is assigned to mouse chromosome 14 by analysis of mouse x hamster somatic cell hybrids. Abundant amounts of connexin-30 mRNA (two transcripts of 2.0 and 2.3 kilobase pairs) were found after 4 weeks of postnatal development in mouse brain and skin, Microinjection of connexin-30 cRNA into Xenopus oocytes induced formation of functional gap junction channels that gated somewhat asymmetrically in response to transjunctional voltage and at significantly lower voltage (V-o = +38 and -46 mV) than the closely homologous connexin-26 channels (V-o = 89 mV). Heterotypic pairings of connexin-30 with connexin-as and connexin-32 produced channels with highly asymmetric and rectifying voltage gating, respectively. This suggests that the polarity of voltage gating and the cationic selectivity of connexin-30 are similar to those of its closest homologue, connexin-26.	UNIV BONN, INST GENET, MOLEK BIOL ABT, D-53117 BONN, GERMANY; GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT GMBH, D-85764 OBERSCHLEISSHEIM, GERMANY; SUNY BUFFALO, DEPT BIOL SCI, BUFFALO, NY 14260 USA; ROCHESTER INST TECHNOL, NATL TECH INST DEAF, ROCHESTER, NY 14623 USA	University of Bonn; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Rochester Institute of Technology				Nicholson, Bruce/0000-0003-1649-7173; Chen-Izu, Ye/0000-0003-4818-9570	NATIONAL CANCER INSTITUTE [R01CA048049] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048773] Funding Source: NIH RePORTER; NCI NIH HHS [CA-48049] Funding Source: Medline; NHLBI NIH HHS [HL-48773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BEYER EC, 1993, INT REV CYTOL C, V173, P1; BRUZZONE R, 1993, MOL BIOL CELL, V4, P7, DOI 10.1091/mbc.4.1.7; BUKAUSKAS FF, 1995, PFLUG ARCH EUR J PHY, V429, P870, DOI 10.1007/BF00374812; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHL G, 1992, BIOPHYS J, V62, P172, DOI 10.1016/S0006-3495(92)81803-9; DERMIETZEL R, 1989, P NATL ACAD SCI USA, V86, P10148, DOI 10.1073/pnas.86.24.10148; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; EBIHARA L, 1989, SCIENCE, V243, P1194, DOI 10.1126/science.2466337; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; FISHMAN GI, 1991, GENOMICS, V10, P250, DOI 10.1016/0888-7543(91)90507-B; GIMLICH RL, 1988, J CELL BIOL, V107, P1065, DOI 10.1083/jcb.107.3.1065; GIMLICH RL, 1990, J CELL BIOL, V110, P597, DOI 10.1083/jcb.110.3.597; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HARLEY CB, 1987, GENE ANAL TECH, V4, P17, DOI 10.1016/0735-0651(87)90013-6; HARRIS AL, 1981, J GEN PHYSIOL, V77, P95, DOI 10.1085/jgp.77.1.95; HENNEMANN H, 1992, EUR J CELL BIOL, V57, P51; HENNEMANN H, 1992, EUR J CELL BIOL, V58, P81; HENNEMANN H, 1992, J BIOL CHEM, V267, P17225; HENNEMANN H, 1992, J CELL BIOL, V117, P1299, DOI 10.1083/jcb.117.6.1299; JOHN SA, 1991, BIOCHEM BIOPH RES CO, V178, P1312, DOI 10.1016/0006-291X(91)91037-D; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MORENO AP, 1994, BIOPHYS J, V67, P113, DOI 10.1016/S0006-3495(94)80460-6; NEUHAUS IM, 1995, GENE, V158, P257, DOI 10.1016/0378-1119(94)00899-4; PAUL DL, 1995, CURR OPIN CELL BIOL, V7, P665, DOI 10.1016/0955-0674(95)80108-1; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHWARZ HJ, 1994, SOMAT CELL MOLEC GEN, V20, P243, DOI 10.1007/BF02254763; SCHWARZ HJ, 1992, SOMAT CELL MOLEC GEN, V18, P351, DOI 10.1007/BF01235758; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sohl G, 1996, EUR J CELL BIOL, V69, P267; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VERSELIS VK, 1994, NATURE, V368, P348, DOI 10.1038/368348a0; WHITE TW, 1995, KIDNEY INT, V48, P1148, DOI 10.1038/ki.1995.398; WHITE TW, 1992, MOL BIOL CELL, V3, P711, DOI 10.1091/mbc.3.7.711; WILLECKE K, 1991, EUR J CELL BIOL, V56, P1; WILLECKE K, 1991, J CELL BIOL, V114, P1049, DOI 10.1083/jcb.114.5.1049; YANCEY SB, 1989, J CELL BIOL, V108, P2241, DOI 10.1083/jcb.108.6.2241; YU W, 1994, P ROY SOC B-BIOL SCI, V255, P125, DOI 10.1098/rspb.1994.0018; ZHANG JT, 1994, J MEMBRANE BIOL, V139, P15; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391	45	158	167	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17903	17910		10.1074/jbc.271.30.17903	http://dx.doi.org/10.1074/jbc.271.30.17903			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663509	hybrid			2022-12-27	WOS:A1996UY93500049
J	Martin, A; Brown, FD; Hodgkin, MN; Bradwell, AJ; Cook, SJ; Hart, M; Wakelam, MJO				Martin, A; Brown, FD; Hodgkin, MN; Bradwell, AJ; Cook, SJ; Hart, M; Wakelam, MJO			Activation of phospholipase D and phosphatidylinositol 4-phosphate 5-kinase in HL60 membranes is mediated by endogenous Arf but not Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; EXCHANGE; BOMBESIN; CELLS	Membrane-associated phospholipase D (PLD) in HL60 cells can be activated by the small GTP-binding proteins Arf and RhoA, but polyphosphorylated inositol lipids were required for maximum activity, The intact lipid was required because neither inositol 1,4,5-trisphosphate nor stearoyl-arachidonyl glycerol could substitute for phosphatidylinositol 4,5-bisphosphate (PIP2), Arf-stimulated but not Rho-stimulated PLD activity was increased by the inclusion of Mg2+ and ATP, ATP-dependent PLD activation occurred when phosphatidylinositol 4-phosphate (PIP), PIP2, or phosphatidylinositol 3,4,5-trisphosphate (PIP3) were included, but PIP2 formation was only detected with PIP; no PIP3 production was detected under any conditions, Therefore, the ATP-dependent increase in PLD activity cannot be explained by PIP2 or PIP3 formation, Association of endogenous Arf and RhoA with membranes was increased by incubation with GTP gamma S, This treatment increased membrane PLD and PIP kinase activities in the absence of exogenous p21 proteins, Reduction of Arf translocation suppressed the increase in PLD and PIP kinase activities, whereas complete removal of Rho but not Arf from membranes with RhoGDI was without effect on PLD activity but increased PIP kinase activity, Therefore, although recombinant Arf and Rho can activate PLD and PIP kinase in HL60 cells, it is the endogenous Arf but not Rho that regulates PLD, and thus a role for Rho in the physiological regulation of PLD in HL60 cells is unlikely.	UNIV BIRMINGHAM,INST CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT IMMUNOL,IMMUNO DIAGNOST RES LAB,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; ONYX PHARMACEUT,RICHMOND,CA 94806	University of Birmingham; University of Birmingham				Wakelam, Michael/0000-0003-4059-9276; Hart, Matthew/0000-0002-2683-480X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANNO Y, 1987, BIOCHEM BIOPH RES CO, V146, P861, DOI 10.1016/0006-291X(87)90610-3; BOKOCH GM, 1994, J BIOL CHEM, V269, P31694; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; COOK SJ, 1992, REV PHYSL BIOCH PHAR, V119, P14; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Harian J. E., 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HODGKIN M, 1994, BIOCHEM J, V297, P637, DOI 10.1042/bj2970637; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MARTIN A, 1994, SIGNAL ACTIVATED PHO, P139; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0	21	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17397	17403		10.1074/jbc.271.29.17397	http://dx.doi.org/10.1074/jbc.271.29.17397			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663246	hybrid			2022-12-27	WOS:A1996UX94300065
J	Molkentin, JD; Li, L; Olson, EN				Molkentin, JD; Li, L; Olson, EN			Phosphorylation of the MADS-box transcription factor MEF2C enhances its DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC EXPRESSION; HEAVY-CHAIN GENE; CASEIN KINASE-II; MYOGENIC LINEAGE; SITE; IDENTIFICATION; EMBRYOGENESIS; PROTEINS; ELEMENTS; MESODERM	Members of the myocyte enhancer factor-2 (MEF2) family of transcription factors activate muscle gene expression by binding an A/T-rich DNA sequence in the control regions of muscle-specific genes. There are four MEF2 factors in vertebrates, MEF2A-D, which share homology in an amino-terminal MADS domain and an adjacent region known as the MEF2 domain, that together mediate DNA binding and dimerization. We show that serine 59 located between the MADS and MEF2 domains of MEF2C is phosphorylated in vivo and can be phosphorylated in vitro by casein kinase-II (CKII). Phosphorylation of this site enhanced the DNA binding and transcriptional activity of MEF2C by increasing its DNA binding activity 5-fold. In vivo P-32 labeling experiments showed that serine 59 is the only phosphorylation site in the MADS and MEF2 domains, Mutagenesis of this serine to an aspartic acid resulted in an increase in DNA binding and transcriptional activity of MEF2 comparable to that observed when this site was phosphorylated, suggesting that phosphorylation augments DNA binding activity by introducing negative charge, This phosphorylation site, which corresponds to a CKII recognition site, is conserved in all known MEF2 factors in organisms ranging from flies to humans, consistent with its importance for the functions of MEF2C.	UNIV TEXAS,SW MED CTR,DEPT MOLEC BIOL & ONCOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HUMAN CTR BASIC CANC RES,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Molkentin, Jeffery/0000-0002-3558-6529				BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	36	87	91	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17199	17204		10.1074/jbc.271.29.17199	http://dx.doi.org/10.1074/jbc.271.29.17199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663403	hybrid			2022-12-27	WOS:A1996UX94300035
J	Fuchs, M; Muller, T; Lerch, MM; Ullrich, A				Fuchs, M; Muller, T; Lerch, MM; Ullrich, A			Association of human protein tyrosine phosphatase kappa with members of the armadillo family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEGMENT POLARITY GENE; CELL CELL-ADHESION; UVOMORULIN-CATENIN COMPLEX; BETA-CATENIN; E-CADHERIN; N-CADHERIN; RECEPTOR; PHOSPHORYLATION; PLAKOGLOBIN; PHOSPHOTYROSINE	We have identified a human receptor-like protein-tyrosine phosphatase (PTP) in the mammary carcinoma cell line SK-BR-3, which represents the human homolog of murine PTP kappa (Jiang, Y.-P., Wang, H., D'Eustachio, P., Musacchio, J. M., Schlessinger, J., and Sap, J. (1993) Mot. Cell, Biol, 13, 2942-2951) and was therefore termed hPTP kappa. We show here that hPTP kappa expression is dependent on cell density and find it colocalized with two members of the arm family of proteins, beta-catenin and gamma-catenin/plakoglobin, at adherens junctions, Using both in vitro and in vivo binding assays, we demonstrate specific complex formation between endogenous hPTP kappa and beta- and gamma-catenin/plakoglobin. In addition, we present evidence that suggests that beta-catenin may represent a substrate for the catalytic activity of hPTP kappa, The identification of specific binding partners for this receptor-like PTP provides insight into the mechanisms of its biological action and suggests a role for hPTP kappa in the regulation of processes involving cell contact and adhesion such as growth control, tumor invasion, and metastasis.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society			Lerch, Markus M./E-2206-2016	Lerch, Markus M./0000-0002-9643-8263				ABERLE H, 1994, J CELL SCI, V107, P3655; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Brady-Kalnay S, 1994, ADV PROTEIN PHOSPHAT, V8, P241; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8345; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; GEIGER B, 1992, ANN REV CELL BIOL, V8, P207; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; MANSKE M, 1994, INT REV CYTOL, V155, P49, DOI 10.1016/S0074-7696(08)62096-3; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1994, MOL CELL BIOL, V14, P1; SCHLESSINGER J, 1992, NEURON, V9, P1; SERGIENKO EA, 1992, FEBS LETT, V304, P21, DOI 10.1016/0014-5793(92)80580-A; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOMMERS CL, 1994, CANCER RES, V54, P3544; STREULI M, 1988, J EXP MED, V168, P1553; STREULI M, 1992, EMBO J, V11, P697; SU LK, 1993, SCIENCE, V262, P1374; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TIAN SS, 1994, J BIOL CHEM, V269, P28478; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; YAN H, 1993, J BIOL CHEM, V268, P24880; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	74	181	183	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16712	16719		10.1074/jbc.271.28.16712	http://dx.doi.org/10.1074/jbc.271.28.16712			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663237	hybrid			2022-12-27	WOS:A1996UX12600047
J	Jeong, SW; Lang, WH; Reeder, RH				Jeong, SW; Lang, WH; Reeder, RH			The yeast transcription terminator for RNA polymerase I is designed to prevent polymerase slippage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' END FORMATION; ESCHERICHIA-COLI; ELONGATION; BINDING; SPACER; SITES	A transcription terminator for RNA polymerase I (poll) in the yeast, Saccharomyces cerevisiae, is composed of two essential elements, the 11bp binding site for Reb1p and an upstream T-rich element coding for the last 10-12 nucleotides of the terminated transcript. We now show that, if the upstream element is changed to homopolymer T residues, poll undergoes iterative slippage, long poly(U) tails are added to the transcript, and termination is impaired, Reinsertion of one or two non-T residues within a critical region prevents iterative slippage and reinstates termination, A survey of naturally occurring terminators reveals that many contain T-rich upstream regions with non-T residues situated appropriately to prevent slippage, We discuss the possibility that the first step in slippage, backward sliding of both the transcript and the catalytic center of the polymerase, may be an obligatory step in the normal termination process.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98109	Fred Hutchinson Cancer Center				Jeong, Shinwu/0000-0002-4847-813X	NIGMS NIH HHS [GM41792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; CHAMBERLIN M, 1964, J MOL BIOL, V8, P708, DOI 10.1016/S0022-2836(64)80120-0; EVERS R, 1995, EMBO J, V14, P1248, DOI 10.1002/j.1460-2075.1995.tb07108.x; EVERS R, 1995, P NATL ACAD SCI USA, V92, P5827, DOI 10.1073/pnas.92.13.5827; GRUMMT I, 1986, CELL, V45, P837, DOI 10.1016/0092-8674(86)90558-1; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; JEONG SW, 1995, MOL CELL BIOL, V15, P5929; KANG JJ, 1995, J BIOL CHEM, V270, P28723, DOI 10.1074/jbc.270.48.28723; KUHN A, 1990, NATURE, V344, P559, DOI 10.1038/344559a0; LABHART P, 1990, NUCLEIC ACIDS RES, V18, P5271, DOI 10.1093/nar/18.17.5271; LABHART P, 1986, CELL, V45, P431, DOI 10.1016/0092-8674(86)90329-6; LANG WH, 1994, CELL, V79, P527, DOI 10.1016/0092-8674(94)90261-5; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; LANG WH, 1995, P NATL ACAD SCI USA, V92, P9781, DOI 10.1073/pnas.92.21.9781; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; REEDER RH, 1994, MOL MICROBIOL, V12, P11, DOI 10.1111/j.1365-2958.1994.tb00989.x; SEVERINOV K, 1994, J BIOL CHEM, V269, P31701; WAGNER LA, 1990, NUCLEIC ACIDS RES, V18, P3529, DOI 10.1093/nar/18.12.3529; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032	21	15	15	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16104	16110		10.1074/jbc.271.27.16104	http://dx.doi.org/10.1074/jbc.271.27.16104			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663252	hybrid			2022-12-27	WOS:A1996UW35200039
J	Arnaud, M; Debarbouille, M; Rapoport, G; Saier, MH; Reizer, J				Arnaud, M; Debarbouille, M; Rapoport, G; Saier, MH; Reizer, J			In vitro reconstitution of transcriptional antitermination by the SacT and SacY proteins of Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCOSIDE UTILIZATION; SUGAR PHOSPHOTRANSFERASE SYSTEM; ESCHERICHIA-COLI; BGL OPERON; NUCLEOTIDE-SEQUENCE; PHOSPHORYLATION; PHOSPHOENOLPYRUVATE; FAMILY; GENES; LEVANSUCRASE	Expression of the sacPA and sacB genes of Bacillus subtilis is positively modulated by transcriptional regulatory proteins encoded by the sacT and sacY genes, respectively. Previous genetic studies led to the suggestion that SacT and SacY function as nascent mRNA binding proteins preventing early termination of transcription at terminators located in the leader regions of the corresponding genes. Here we report the overproduction, purification to near homogeneity, and characterization of the two antiterminators, SacT and SacY. Using mRNA band migration retardation assays and a reconstituted transcriptional antitermination system, the mRNA binding functions and antitermination activities of purified SacT and SacY are demonstrated under in vitro conditions. The results establish for the first time that members of the BglG family of antiterminators function in antitermination in the absence of other proteins in vitro. Purified SacT is shown to be phosphorylated by phosphoenolpyruvate in a phosphotransferase-catalyzed reaction dependent on Enzyme I and HPr. Unexpectedly, the purified SacT is shown to be functional in mRNA binding and in transcriptional antitermination independently of its phosphorylation state.	INST PASTEUR,URA 1300 CNRS,UNITE BIOCHIM MICROBIENNE,F-75724 PARIS 15,FRANCE; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of California System; University of California San Diego					NIAID NIH HHS [AI GM21702-13A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021702] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; AMSTERCHODER O, 1989, CELL, V58, P847, DOI 10.1016/0092-8674(89)90937-9; AMSTERCHODER O, 1993, J CELL BIOCHEM, V51, P83, DOI 10.1002/jcb.240510115; ARNAUD M, 1992, J BACTERIOL, V174, P3161, DOI 10.1128/jb.174.10.3161-3170.1992; AYMERICH S, 1987, MOL GEN GENET, V208, P114, DOI 10.1007/BF00330431; AYMERICH S, 1992, P NATL ACAD SCI USA, V89, P10410, DOI 10.1073/pnas.89.21.10410; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BARDOWSKI J, 1994, J BACTERIOL, V176, P5681, DOI 10.1128/JB.176.18.5681-5685.1994; BELFORT M, 1995, J BACTERIOL, V177, P3897, DOI 10.1128/jb.177.14.3897-3903.1995; CRUTZ AM, 1990, J BACTERIOL, V172, P1043, DOI 10.1128/jb.172.2.1043-1050.1990; DEBARBOUILLE M, 1990, J BACTERIOL, V172, P3966, DOI 10.1128/jb.172.7.3966-3973.1990; DEBARBOUILLE M, 1991, P NATL ACAD SCI USA, V88, P2212, DOI 10.1073/pnas.88.6.2212; ELHASSOUNI M, 1992, J BACTERIOL, V174, P765, DOI 10.1128/jb.174.3.765-777.1992; FRIEDMAN DI, 1995, MOL MICROBIOL, V18, P191, DOI 10.1111/j.1365-2958.1995.mmi_18020191.x; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HEINRICH T, 1995, J BACTERIOL, V177, P3793, DOI 10.1128/jb.177.13.3793-3800.1995; HENKIN TM, 1994, MOL MICROBIOL, V13, P381, DOI 10.1111/j.1365-2958.1994.tb00432.x; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; KRUGER S, 1995, J BACTERIOL, V177, P5590; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTOO RL, 1983, ANAL BIOCHEM, V128, P245, DOI 10.1016/0003-2697(83)90372-X; NAGAI K, 1994, RNA PROTEIN INTERACT, P52; PTASHNE M, 1992, GENETIC SWITCH PHAGE, P50; REDDY P, 1989, NUCLEIC ACIDS RES, V17, P10473, DOI 10.1093/nar/17.24.10473; Rees WA, 1996, P NATL ACAD SCI USA, V93, P342, DOI 10.1073/pnas.93.1.342; REIZER J, 1992, J BIOL CHEM, V267, P9158; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SCHNETZ K, 1990, P NATL ACAD SCI USA, V87, P5074, DOI 10.1073/pnas.87.13.5074; SCHNETZ K, 1988, EMBO J, V7, P3271, DOI 10.1002/j.1460-2075.1988.tb03194.x; SCHNETZ K, 1987, J BACTERIOL, V169, P2579, DOI 10.1128/jb.169.6.2579-2590.1987; Schnetz K, 1996, J BACTERIOL, V178, P1971, DOI 10.1128/jb.178.7.1971-1979.1996; STULKE J, 1995, J BACTERIOL, V177, P6928; SUTRINA SL, 1990, J BIOL CHEM, V265, P18581; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; ZUBER M, 1987, P NATL ACAD SCI USA, V84, P4514, DOI 10.1073/pnas.84.13.4514; ZUKOWSKI MM, 1990, GENE, V90, P153, DOI 10.1016/0378-1119(90)90453-X	38	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18966	18972		10.1074/jbc.271.31.18966	http://dx.doi.org/10.1074/jbc.271.31.18966			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702561	hybrid			2022-12-27	WOS:A1996VB68300099
J	Fauman, EB; Yuvaniyama, C; Schubert, HL; Stuckey, JA; Saper, MA				Fauman, EB; Yuvaniyama, C; Schubert, HL; Stuckey, JA; Saper, MA			The x-ray crystal structures of Yersinia tyrosine phosphatase with bound tungstate and nitrate - Mechanistic implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE; PHOSPHORYL-TRANSFER; VIRULENCE DETERMINANT; TRANSITION-STATE; HYDROLYSIS; INTERMEDIATE; CATALYSIS; PROTEINS; CYSTEINE; DETECTOR	X-ray crystal structures of the Yersinia tyrosine phosphatase (PTPase) in complex with tungstate and nitrate have been solved to 2.4-Angstrom resolution, Tetrahedral tungstate, WO42-, is a competitive inhibitor of the enzyme and is isosteric with the substrate and product of the catalyzed reaction, Planar nitrate, NO3-, is isosteric with the PO3 moiety of a phosphotransfer transition state, The crystal structures of the Yersinia PTPase with and without ligands, together with biochemical data, permit modeling of key steps along the reaction pathway, These energy-minimized models are consistent with a general acid-catalyzed, in-line displacement of the phosphate moiety to Cys(403) On the enzyme, followed by attack by a nucleophilic water molecule to release orthophosphate, This nucleophilic water molecule is identified in the crystal structure of the nitrate complex, The active site structure of the PTPase is compared to alkaline phosphatase, which employs a similar phosphomonoester hydrolysis mechanism, Both enzymes must stabilize charges at the nucleophile, the PO3 moiety of the transition state, and the leaving group, Both an associative (bond formation preceding bond cleavage) and a dissociative (bond cleavage preceding bond formation) mechanism were modeled, but a dissociative-like mechanism is favored for steric and chemical reasons, Since nearly all of the 47 invariant or highly conserved residues of the PTPase domain are clustered at the active site, we suggest that the mechanism postulated for the Yersinia enzyme is applicable to all the PTPases.	UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Fauman, Eric/AAC-8275-2020	Fauman, Eric/0000-0002-9739-0249	NIAID NIH HHS [AI34095] Funding Source: Medline; NIAMS NIH HHS [P60-AR20557] Funding Source: Medline; NIDDK NIH HHS [DK18849] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018849] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERFELDT S, 1960, ACTA CHEM SCAND, V14, P1980, DOI 10.3891/acta.chem.scand.14-1980; BASCH H, 1991, J MOL STRUC-THEOCHEM, V235, P277; Benkovic S. J, 1973, ENZYMES, P201; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BROWNER MF, 1992, BIOCHEMISTRY-US, V31, P11297, DOI 10.1021/bi00161a006; BRUNGER AT, 1987, XPLOR VERSION 3 1; CAUGHLAN CN, 1967, INORG CHEM, V6, P1998, DOI 10.1021/ic50057a014; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; CLELAND WW, 1990, FASEB J, V4, P2899, DOI 10.1096/fasebj.4.11.2199287; COLEMAN JE, 1992, ANNU REV BIOPH BIOM, V21, P441, DOI 10.1146/annurev.biophys.21.1.441; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GLOWIAK T, 1986, J CRYST SPECTROSC, V16, P79, DOI 10.1007/BF01566048; GLOWIAK T, 1985, ACTA CRYSTALLOGR C, V41, P324, DOI 10.1107/S010827018500378X; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HASSETT A, 1982, BIOCHEMISTRY-US, V21, P6335, DOI 10.1021/bi00268a002; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; HERR EB, 1957, BIOCHIM BIOPHYS ACTA, V25, P219, DOI 10.1016/0006-3002(57)90456-0; HERSCHLAG D, 1989, J AM CHEM SOC, V111, P7579, DOI 10.1021/ja00201a047; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P5172, DOI 10.1021/bi00473a025; HERSCHLAG D, 1987, J AM CHEM SOC, V109, P4665, DOI 10.1021/ja00249a033; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES JP, 1991, BIOCHEMISTRY-US, V30, P3634, DOI 10.1021/bi00229a007; JONES PG, 1984, ACTA CRYSTALLOGR C, V40, P550, DOI 10.1107/S0108270184004820; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KARLE JM, 1991, ACTA CRYSTALLOGR C, V47, P1241; KENNARD O, 1979, ACTA CRYSTALLOGR B, V35, P2331; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KOSTER AS, 1969, ACTA CRYSTALL B-STRU, VB 25, P1704, DOI 10.1107/S0567740869004602; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MICHIELS T, 1988, MICROB PATHOGENESIS, V5, P449, DOI 10.1016/0882-4010(88)90006-X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PAULING L, 1947, J AM CHEM SOC, V69, P542, DOI 10.1021/ja01195a024; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SCHUBERT HL, 1995, PROTEIN SCI, V4, P1904, DOI 10.1002/pro.5560040924; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; WEISS PM, 1989, J AM CHEM SOC, V111, P1928, DOI 10.1021/ja00187a084; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16389, DOI 10.1021/bi00050a020; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1994, J BIOL CHEM, V269, P8140; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007	50	107	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18780	18788		10.1074/jbc.271.31.18780	http://dx.doi.org/10.1074/jbc.271.31.18780			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702535	hybrid			2022-12-27	WOS:A1996VB68300073
J	Fukuda, M; Mikoshiba, K				Fukuda, M; Mikoshiba, K			Structure-function relationships of the mouse Gap1(m) - Determination of the inositol 1,3,4,5-tetrakisphosphate-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; 1,4,5-TRISPHOSPHATE BINDING DOMAIN; SQUID GIANT SYNAPSE; SIGNALING PROTEINS; TYROSINE KINASE; GENE-PRODUCT; PH DOMAIN; TRISPHOSPHATE; RECEPTOR; CALCIUM	Gap1(IP4BP), one of a member of Ras GTPase-activating proteins, has been identified as a specific inositol 1,3,4,5-tetrakisphosphate (IP4)-binding protein (Cullen, P. J., Hsuan, J, J., Truong, O., Letcher, A, J,, Jackson, T, R., Dawson, A. P., and Irvine, R. F. (1995) Nature 386, 527-530). In this paper we describe Gap1(m), which is closely related to Gap1(IP4BP), to also be an IP4-binding protein and show that the pleckstrin homology domain (PH) is the central IP4-binding domain by expressing fragments of the mouse Gap1(m) in Escherichia coli as fusion proteins and examining their activities. However, in addition to the PH domain, an adjacent GAP-related domain and carboxyl terminus are required for high affinity specific IP4 binding. The PH domain is highly conserved in the Gap1 family and also has striking homology to the amino-terminal region of Bruton's tyrosine kinase. Substitution of Cys for Arg at position 628 in the PH domain corresponding to the mutation of Bruton's tyrosine kinase observed in X-linked immunodeficiency mice results in a dramatic reduction of IP4 binding activity as well as phospholipid binding capacity of Gap1(m). This mutant also showed the GAP activity against Ha-Pas to be similar to that of the wild type Gap1(m). Our results suggest that the PH domain of Gap1(m) functions as a modulatory domain of GAP activity by binding IF4 and phospholipids.	UNIV TOKYO,INST MED SCI,DEPT MOL NEUROBIOL,TOKYO 108,JAPAN; ERATO,CALCIOSIGNAL NET PROJECT,MEGURO KU,TOKYO 153,JAPAN	University of Tokyo	Fukuda, M (corresponding author), RIKEN,INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOL NEUROBIOL LAB,3-1-1 KOYADAI,TSUKUBA,IBARAKI 305,JAPAN.		Mikoshiba, Katsuhiko/N-7943-2015; Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				BABA H, 1995, J NEUROSCI RES, V41, P846, DOI 10.1002/jnr.490410615; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; CULLEN PJ, 1995, BIOCHEM J, V305, P139, DOI 10.1042/bj3050139; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; CULLEN PJ, 1995, FEBS LETT, V358, P240, DOI 10.1016/0014-5793(94)01435-4; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; ELY JA, 1990, BIOCHEM J, V268, P333, DOI 10.1042/bj2680333; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASIAM RJ, 1993, NATURE, V363, P309; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; HIRATA M, 1994, BIOCHEM BIOPH RES CO, V205, P1563, DOI 10.1006/bbrc.1994.2845; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1987, BIOCHEM BIOPH RES CO, V146, P284, DOI 10.1016/0006-291X(87)90723-6; LI C, NATURE, V385, P594; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MAEKAWA M, 1993, J BIOL CHEM, V268, P22948; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; MOCHIDA S, 1995, SAT S 15 ISN M JUN 2, P124; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OHARAIMAIZUMI M, 1995, SAT S 15 ISN M JUN 2, P125; PARKER I, 1987, PROC R SOC SER B-BIO, V232, P59, DOI 10.1098/rspb.1987.0061; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YOO SH, 1991, BIOCHEM J, V278, P381, DOI 10.1042/bj2780381	39	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18838	18842		10.1074/jbc.271.31.18838	http://dx.doi.org/10.1074/jbc.271.31.18838			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702543	hybrid			2022-12-27	WOS:A1996VB68300081
J	Liang, BT; Morley, JF				Liang, BT; Morley, JF			A new cyclic AMP-independent, G(s)-mediated stimulatory mechanism via the adenosine A(2a) receptor in the intact cardiac cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CHICK HEART-CELLS; VENTRICULAR CELLS; ADENYLATE-CYCLASE; CAMP; MYOCYTES; PHOSPHORYLATION; MODULATION; CARDIOMYOCYTES; PURINOCEPTORS	The objectives of this study were to investigate the mechanism underlying the adenosine A(2a) receptor (A(2a)R)-mediated positive inotropic response and to define its contractile function using chick embryo ventricular cells as a model, Activation of the A(2a)R caused a marked stimulation of calcium entry and cell contractility, which were blocked by verapamil or nifedipine, The effects elicited by maximal concentrations of the A(2a)R agonist 2-[4-(2-carboxyethyl)phenylethylamino]-5'-N-ethylcarboxamidoadenosine and the beta-adrenergic agonist isoproterenol were additive, indicating that the two receptors do not share a common stimulatory mechanism, The cAMP antagonist (R(p))-adenosine cyclic 3':5'-monophosphorothioate was ineffective in inhibiting the A(2a)R-mediated stimulation of contractility or the L-type calcium channel, while it completely abolished the iso-proterenol effects, Activation of the A(2a)R had no effect on Na+/Ca2+ exchange or inositol 1,4,5-trisphosphate accumulation, Blocking of the A(2a)R resulted in unopposed A(1) receptor-mediated inhibitory effects and led to an inhibition of basal contractility and an enhanced anti-adrenergic effect by A(1) agonist, The adenosine A(2a) receptor mediates a new cyclic AMP-independent mechanism and a new contractile function in the cardiac cell.	UNIV PENN,MED CTR,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DIV CARDIOVASC,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	Liang, BT (corresponding author), UNIV PENN,MED CTR,DEPT MED,504 JOHNSON PAVIL,3610 HAMILTON WALK,PHILADELPHIA,PA 19104, USA.				NHLBI NIH HHS [R01-HL48225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048225] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRY WH, 1982, J PHYSIOL-LONDON, V325, P243, DOI 10.1113/jphysiol.1982.sp014148; BELARDINELLI LB, 1989, PROG CARDIOVASC DIS, V32, P93; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; BRUNS RF, 1986, MOL PHARMACOL, V29, P331; BUCKNER R, 1984, BRIT J PHARMACOL, V82, P223; CONNELLY PA, 1987, J BIOL CHEM, V262, P4324; DEHAAN RL, 1967, DEV BIOL, V16, P216, DOI 10.1016/0012-1606(67)90025-5; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GALPER JB, 1978, P NATL ACAD SCI USA, V75, P5831, DOI 10.1073/pnas.75.12.5831; GU ZF, 1992, AM J PHYSIOL, V263, pG360, DOI 10.1152/ajpgi.1992.263.3.G360; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; KAMEYAMA M, 1986, PFLUG ARCH EUR J PHY, V407, P123, DOI 10.1007/BF00580662; LAURENT S, 1985, CIRC RES, V56, P676, DOI 10.1161/01.RES.56.5.676; LAURENT S, 1986, J CLIN INVEST, V77, P1436, DOI 10.1172/JCI112455; LIANG BT, 1992, TRENDS CARDIOVAS MED, V2, P100, DOI 10.1016/1050-1738(92)90014-J; LIANG BT, 1986, J BIOL CHEM, V261, P9011; LIANG BT, 1995, CIRC RES, V76, P242, DOI 10.1161/01.RES.76.2.242; LIANG BT, 1989, J PHARMACOL EXP THER, V249, P775; MARSH JD, 1985, CIRC RES, V57, P171, DOI 10.1161/01.RES.57.1.171; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; OTANI H, 1988, CIRC RES, V62, P8, DOI 10.1161/01.RES.62.1.8; PELZER S, 1993, J PHYSIOL-LONDON, V459, pP228; PEREIRA ME, 1987, J BIOL CHEM, V262, P6093; STEINBERG SF, 1987, ENDOCRINOLOGY, V120, P1889, DOI 10.1210/endo-120-5-1889; STILES GL, 1992, J BIOL CHEM, V267, P6451; STIMERS JR, 1991, J GEN PHYSIOL, V98, P815, DOI 10.1085/jgp.98.4.815; WALSH DA, 1979, BIOCHEMISTRY-US, V18, P871, DOI 10.1021/bi00572a021; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; XU D, 1992, CIRC RES, V70, P56, DOI 10.1161/01.RES.70.1.56; XU H, 1992, NUCLEIC ACIDS RES, V20, P6425, DOI 10.1093/nar/20.23.6425; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999	33	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18678	18685		10.1074/jbc.271.31.18678	http://dx.doi.org/10.1074/jbc.271.31.18678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702522	hybrid			2022-12-27	WOS:A1996VB68300060
J	Erhardt, P; Cooper, GM				Erhardt, P; Cooper, GM			Activation of the CPP32 apoptotic protease by distinct signaling pathways with differential sensitivity to Bcl-x(L)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ELEGANS; BCL-2; SURVIVAL; ENCODES	In the absence of growth factors, many types of mam malian cells undergo apoptosis. We and others have shown recently that growth factors promote cell survival by activating phosphatidylinositol 3-kinase (PI 3-kinase) in several cell types, In the present study, we have compared downstream elements of the apoptotic pathways induced by PI 3-kinase inhibitors and other stimuli. In U937 cells, both PI 3-kinase inhibitors (wortmannin and LY294002) and etoposide activated the CPP32 apoptotic protease by cleavage to active p17 subunits, In contrast, treatment with tumor necrosis factor alpha (TNF alpha) resulted in the accumulation of a distinct active CPP32 subunit, p20. Furthermore, overexpression of Bcl-x(L) blocked DNA fragmentation, CPP32 activation and cleavage of poly(ADP ribose) polymerase in U937 cells treated with both PI 3-kinase inhibitors and etoposide, but not in cells treated with TNF alpha. Distinct patterns of CPP32 activation and differential sensitivities to Bcl-x(L) thus distinguish the cell death pathways activated by PI 3-kinase inhibition and DNA damage from that activated by TNF alpha.	DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER; NCI NIH HHS [CA18689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; CAI YC, 1995, IMMUNITY, V3, P417, DOI 10.1016/1074-7613(95)90171-X; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; JAATTELA M, 1995, ONCOGENE, V10, P2297; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MEMON SA, 1995, J IMMUNOL, V155, P4644; Minshall C, 1996, J IMMUNOL, V156, P939; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YAO R, 1996, IN PRESS ONCOGENE; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	39	120	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17601	17604		10.1074/jbc.271.30.17601	http://dx.doi.org/10.1074/jbc.271.30.17601			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663611	hybrid			2022-12-27	WOS:A1996UY93500003
J	Gelissen, IC; Brown, AJ; Mander, EL; Kritharides, L; Dean, RT; Jessup, W				Gelissen, IC; Brown, AJ; Mander, EL; Kritharides, L; Dean, RT; Jessup, W			Sterol efflux is impaired from macrophage foam cells selectively enriched with 7-ketocholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; OXIDATION-PRODUCTS; UNESTERIFIED CHOLESTEROL; APOLIPOPROTEINS; OXYSTEROLS; MEMBRANES; CLEAVAGE; ESTER; LDL	The aim of the present study was to investigate whether impairment of cholesterol efflux previously found from mouse peritoneal macrophages loaded with oxidized low density lipoprotein (OxLDL) could be ascribed to the presence of oxysterols in these cells, 7-Ketocholesterol (7KC), the major oxysterol present in OxLDL-loaded cells, was selectively incorporated into unoxidized LDL, which was subsequently acetylated to produce a high uptake form, Mouse macrophages incubated with 7KC-enriched acetylated LDL (7kAcLDL) did not reveal cytotoxicity judged by cell protein and trypan blue exclusion, A large proportion of cellular 7KC was esterified, indicating that it is a substrate for acyl CoA: cholesterol acyltransferase. Cholesterol efflux from mouse macrophages loaded with 7kAcLDL, using apoA-I as a sterol acceptor, was impaired in cells containing >50 nmol of 7KC/mg of cell protein compared with cells loaded with oxysterol-free acetylated LDL, Thus impairment of cholesterol efflux could be reproduced in cells loaded with 7kAcLDL containing similar proportions of 7KC as OxLDL, 7KC itself was exported very poorly, even when the levels of 7KC in the cells were low. These results suggest that oxysterols present in foam cells in vitro can affect reverse sterol transport and may be potentially important in foam cell formation in vivo.			Gelissen, IC (corresponding author), HEART RES INST,CELL BIOL UNIT,145 MISSENDEN RD,CAMPERDOWN,NSW 2050,AUSTRALIA.		Kritharides, Leonard/AAQ-2720-2020	Dean, Roger Thornton/0000-0002-8859-8902				ADDIS PB, 1993, CAN J CARDIOL, V9, pB6; ADDIS PB, 1989, FREE RADICAL BIO MED, V7, P179, DOI 10.1016/0891-5849(89)90011-7; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; BREUER O, 1995, J LIPID RES, V36, P2275; Brown AJ, 1996, J LIPID RES, V37, P320; CARPENTER KLH, 1995, BBA-LIPID LIPID MET, V1256, P141, DOI 10.1016/0005-2760(94)00247-V; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; CLARE K, 1995, ATHEROSCLEROSIS, V118, P67, DOI 10.1016/0021-9150(95)05594-M; ESTERBAUER H, 1991, AM J CLIN NUTR, V53, pS314, DOI 10.1093/ajcn/53.1.314S; FONG LG, 1987, J LIPID RES, V28, P1466; HARA H, 1991, J BIOL CHEM, V266, P3080; JAILAL I, 1991, ARTERIOSCLER THROMB, V11, P482; KAN CC, 1992, BIOCHEMISTRY-US, V31, P1866, DOI 10.1021/bi00121a040; KANDUTSCH AA, 1973, J BIOL CHEM, V248, P8408; KILSDONK EPC, 1995, J LIPID RES, V36, P505; KRITHARIDES L, 1995, ARTERIOSCL THROM VAS, V15, P276, DOI 10.1161/01.ATV.15.2.276; KRITHARIDES L, 1993, ANAL BIOCHEM, V213, P79, DOI 10.1006/abio.1993.1389; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFEVRE M, 1988, J LIPID RES, V29, P1139; MANDER EL, 1994, BBA-LIPID LIPID MET, V1212, P80, DOI 10.1016/0005-2760(94)90192-9; MAOR I, 1994, J LIPID RES, V35, P803; MAOR I, 1995, ARTERIOSCL THROM VAS, V15, P1378, DOI 10.1161/01.ATV.15.9.1378; MATTSSONHULTEN L, 1996, J CLIN INVEST, V97, P461; ORAM JF, 1991, ARTERIOSCLER THROMB, V11, P403, DOI 10.1161/01.ATV.11.2.403; ROHEIM PS, 1990, EUR HEART J, V11, P225, DOI 10.1093/eurheartj/11.suppl_E.225; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; RYE KA, 1990, BIOCHIM BIOPHYS ACTA, V1042, P227, DOI 10.1016/0005-2760(90)90013-N; SMITH LL, 1989, FREE RADICAL BIO MED, V7, P285, DOI 10.1016/0891-5849(89)90136-6; SNEDECOR GW, 1980, STATISTICAL METHODS, P83; SZEDLACSEK SE, 1995, J BIOL CHEM, V270, P11812, DOI 10.1074/jbc.270.20.11812; TABAS I, 1995, CURR OPIN LIPIDOL, V6, P260, DOI 10.1097/00041433-199510000-00004; THEUNISSEN JJH, 1986, BIOCHIM BIOPHYS ACTA, V860, P66, DOI 10.1016/0005-2736(86)90499-2; VANREYK DM, 1995, FREE RADICAL RES, V23, P533, DOI 10.3109/10715769509065274; WARNICK GR, 1982, CLIN CHEM, V28, P1379; ZHANG HF, 1990, J LIPID RES, V31, P1361	35	120	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17852	17860		10.1074/jbc.271.30.17852	http://dx.doi.org/10.1074/jbc.271.30.17852			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663356	hybrid			2022-12-27	WOS:A1996UY93500042
J	Morana, SJ; Wolf, CM; Li, JF; Reynolds, JE; Brown, MK; Eastman, A				Morana, SJ; Wolf, CM; Li, JF; Reynolds, JE; Brown, MK; Eastman, A			The involvement of protein phosphatases in the activation of ICE/CED-3 protease, intracellular acidification, DNA digestion, and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETOPOSIDE-INDUCED APOPTOSIS; DEATH GENE CED-3; CELL-DEATH; NA+/H+ ANTIPORTER; OKADAIC ACID; RETINOBLASTOMA PROTEIN; CALYCULIN-A; PHOSPHORYLATION; INHIBITOR; MECHANISM	Many events in apoptosis have been identified but their temporal relationships remain obscure, Apoptosis in human ML-1 cells induced by etoposide is characterized by intracellular acidification, enhanced Hoechst 33342 fluorescence, DNA digestion, chromatin condensation, and proteolysis of poly(ADP-ribose) polymerase, This proteolysis is a marker for the action of ICE/CED-3 proteases, which are critical activators of apoptosis, We observed that three serine/threonine protein phosphatase inhibitors, okadaic acid, calyculin A, and cantharidin, din, prevented all of these apoptotic characteristics. To determine which protein phosphatase was involved, we investigated the dephosphorylation of the retinoblastoma susceptibility protein Rb, a substrate for protein phosphatase 1 but not protein phosphatase 2A. Rb was dephosphorylated during apoptosis, and each inhibitor prevented this dephosphorylation at the same concentrations that prevented apoptosis, No increase in protein phosphatase 1 activity was observed in apoptotic cells suggesting that dephosphorylation of Rb may result from loss of Rb kinase activity in the presence of a constant level of protein phosphatase activity, Long term inhibition of protein phosphatase 1 (> 8 h) also led to the appearance of dephosphorylated Rb, cleavage of poly(ADP-ribose) polymerase and apoptosis, suggesting these events are not solely dependent upon protein phosphatase 1, Rb dephosphorylation was also observed in several other models of apoptosis, Hence, an imbalance between protein phosphatase 1 and Rb kinase may be a common means to activate ICE/CED-3 proteases resulting in the subsequent events of apoptosis.	DARTMOUTH COLL SCH MED, DEPT PHARMACOL & TOXICOL, HANOVER, NH 03755 USA; DARTMOUTH COLL SCH MED, NORRIS COTTON CANC CTR, HANOVER, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center					NATIONAL CANCER INSTITUTE [P30CA023108, R55CA050224, R01CA050224, T32CA009658] Funding Source: NIH RePORTER; NCI NIH HHS [CA50224, CA23108, CA09658] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRY MA, 1993, CANCER RES, V53, P2349; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BARRY MA, 1992, BIOCHEM BIOPH RES CO, V186, P782, DOI 10.1016/0006-291X(92)90814-2; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DOU QP, 1995, CANCER RES, V55, P5222; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; DUKE RC, 1992, CURRENT PROTOCOLS IM, V1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EASTMAN A, 1995, METHOD CELL BIOL, V46, P41; EASTMAN A, 1995, SEMIN CANCER BIOL, V6, P45, DOI 10.1006/scbi.1995.0006; GUIZOUARN H, 1995, AM J PHYSIOL-CELL PH, V268, pC434, DOI 10.1152/ajpcell.1995.268.2.C434; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; LI YM, 1993, BIOCHEM PHARMACOL, V46, P1435, DOI 10.1016/0006-2952(93)90109-A; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; MALY K, 1989, J BIOL CHEM, V264, P11839; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MORANA S, 1994, INT J ONCOL, V5, P153; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ORMEROD MG, 1993, CYTOMETRY, V14, P595, DOI 10.1002/cyto.990140603; PEREZSALA D, 1995, J BIOL CHEM, V270, P6235, DOI 10.1074/jbc.270.11.6235; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REBOLLO A, 1995, EXP CELL RES, V218, P581, DOI 10.1006/excr.1995.1195; REYNOLDS JE, 1996, IN PRESS EXP CELL RE, V225; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SONG QZ, 1992, J CELL PHYSIOL, V153, P550, DOI 10.1002/jcp.1041530316; SONG QZ, 1993, BIOCHEM BIOPH RES CO, V190, P47, DOI 10.1006/bbrc.1993.1009; SORENSON CM, 1988, CANCER RES, V48, P4484; SWANN K, 1985, NATURE, V314, P274, DOI 10.1038/314274a0; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Troppmair J, 1992, Curr Top Microbiol Immunol, V182, P453; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	44	133	135	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18263	18271		10.1074/jbc.271.30.18263	http://dx.doi.org/10.1074/jbc.271.30.18263			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663484	hybrid			2022-12-27	WOS:A1996UY93500100
J	Sala, A; Bolla, M; Zarini, S; MullerPeddinghaus, R; Folco, G				Sala, A; Bolla, M; Zarini, S; MullerPeddinghaus, R; Folco, G			Release of leukotriene A(4) versus leukotriene B-4 from human polymorphonuclear leukocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; PLATELET-ACTIVATING-FACTOR; FORMING ESCHERICHIA-COLI; HUMAN-ENDOTHELIAL CELLS; NEUTROPHIL; BIOSYNTHESIS; GENERATION; IDENTIFICATION; ADHESION; PATHWAY	The reactive intermediate formed by 5-lipoxygenase metabolism of arachidonic acid, leukotriene A(4), is known to be released from cells and subsequently taken up by other cells for biochemical processing, The objective of this study was to determine the relative amount of leukotriene A(4) synthesized by human polymorphonuclear leukocytes (PMNL) that is available for transcellular biosynthetic processes, This was accomplished by diluting cell suspensions and measuring the relative amounts of enzymatic versus nonenzymatic leukotriene A(4)-derived metabolites after challenge with the Ca2+ ionophore A23187, Nonenzymatic leukotriene A(4)-derived metabolites were used as a quantitative index of the amount of leukotriene A(4) released into the extracellular milieu, The results obtained demonstrated that in human PMNL, the relative amounts of nonenzymatic versus enzymatic leukotriene A(4)-derived metabolites increased with decreasing cell concentrations, After a 20-fold dilution of PMNL in cell preparations, a doubling in the amount of nonenzymatic leukotriene A(4)-derived metabolites was observed following challenge (from 53.9 +/- 1.3 to 110.4 +/- 8.9 pmol/10(6) PMNL, p < 0.01). Reduction of possible cell-cell interactions by dilution suggested that over 50% of leukotriene A(4) synthesized is released from the PMNL, These data provide evidence that, in human PMNL preparations, transfer of leukotriene A(4) to neighboring PMNL is taking place, resulting in additional formation of leukotriene B-4 and its omega-oxidized metabolites 20-hydroxy- and 20 carboxy-leukotriene B-4. Neutrophil reuptake of extracellular leukotriene A(4) leads to an underestimation of the fraction of leukotriene A(4) that is in fact available for transcellular metabolism when tight cell-cell interactions occur, such as during PMNL adhesion to the microvascular endothelium and diapedesis.	UNIV MILAN,SCH PHARM,CTR CARDIOPULM PHARMACOL,INST PHARMACOL SCI,I-20133 MILAN,ITALY; BAYER AG,PHARMA RES CTR,D-42096 WUPPERTAL,GERMANY	University of Milan; Bayer AG			Sala, Angelo/H-5478-2019	Zarini, Simona/0000-0002-7460-3299; Sala, Angelo/0000-0001-9290-0257				BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P3213, DOI 10.1073/pnas.76.7.3213; BORGEAT P, 1979, J BIOL CHEM, V254, P7865; BORGEAT P, 1985, ADV LIPID RES, V21, P47; BRADY HR, 1992, BIOCHEM BIOPH RES CO, V186, P1307, DOI 10.1016/S0006-291X(05)81548-7; CLAESSON HE, 1988, EUR J BIOCHEM, V173, P93, DOI 10.1111/j.1432-1033.1988.tb13971.x; CLUZEL M, 1989, J IMMUNOL, V143, P3659; DAHINDEN CA, 1985, P NATL ACAD SCI USA, V82, P6632, DOI 10.1073/pnas.82.19.6632; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DELACLOS BF, 1984, PROSTA LEUKOTR MED, V13, P47, DOI 10.1016/0262-1746(84)90101-X; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FEINMARK SJ, 1987, BIOCHIM BIOPHYS ACTA, V922, P125, DOI 10.1016/0005-2760(87)90146-9; FITZPATRICK FA, 1982, J BIOL CHEM, V257, P4680; GRAVEL J, 1993, ARCH BIOCHEM BIOPHYS, V306, P469, DOI 10.1006/abbi.1993.1539; GRIMMINGER F, 1990, J IMMUNOL, V144, P1866; GRIMMINGER F, 1990, J EXP MED, V172, P1115, DOI 10.1084/jem.172.4.1115; HANSSON G, 1981, FEBS LETT, V130, P107, DOI 10.1016/0014-5793(81)80676-X; KLAUSNER RD, 1979, NATURE, V281, P82, DOI 10.1038/281082a0; MACLOUF J, 1989, BLOOD, V74, P703; MACLOUF JA, 1988, J BIOL CHEM, V263, P174; MARCUS AJ, 1980, J CLIN INVEST, V66, P979, DOI 10.1172/JCI109967; MCDONALD PP, 1994, BRIT J PHARMACOL, V111, P852, DOI 10.1111/j.1476-5381.1994.tb14816.x; MCGEE JE, 1986, P NATL ACAD SCI USA, V83, P1349, DOI 10.1073/pnas.83.5.1349; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; PALMENTIER R, 1995, INFLAMM RES, V44, pS259; POWELL WS, 1984, J BIOL CHEM, V259, P3082; RADMARK O, 1980, BIOCHEM BIOPH RES CO, V92, P954, DOI 10.1016/0006-291X(80)90795-0; Rossoni G, 1996, J PHARMACOL EXP THER, V276, P335; SALA A, 1993, BRIT J PHARMACOL, V110, P1206, DOI 10.1111/j.1476-5381.1993.tb13943.x; Sala A, 1996, BLOOD, V87, P1824; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SEEGER W, 1991, AM REV RESPIR DIS, V143, P797, DOI 10.1164/ajrccm/143.4_Pt_1.797; SHAK S, 1984, J BIOL CHEM, V259, P181; SHIMIZU T, 1984, P NATL ACAD SCI-BIOL, V81, P689, DOI 10.1073/pnas.81.3.689; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; ZIMMERMAN GA, 1986, P NATL ACAD SCI USA, V83, P2204	35	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17944	17948		10.1074/jbc.271.30.17944	http://dx.doi.org/10.1074/jbc.271.30.17944			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663438	hybrid			2022-12-27	WOS:A1996UY93500055
J	Wang, Y; Sostman, A; Roman, R; Stribling, S; Vigna, S; Hannun, Y; Raymond, J; Fitz, JG				Wang, Y; Sostman, A; Roman, R; Stribling, S; Vigna, S; Hannun, Y; Raymond, J; Fitz, JG			Metabolic stress opens K+ channels in hepatoma cells through a Ca2+- and protein kinase C alpha-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; RAT-LIVER; MUSCLE-CELLS; HEPATOCYTES; CALCIUM; INHIBITION; CATION; ATP; CYTOTOXICITY; CONDUCTANCE	These studies of a model liver cell line evaluate the mechanisms responsible for regulated release of K+ ions during metabolic stress, Metabolic inhibition of HTC hepatoma cells by exposure to 2,4-dinitrophenol (50 mu M) and 2-deoxy-D-glucose (10 mM) stimulated outward currents carried by K+ of 974 +/- 75 pA at 0 mV (n = 20, p < 0.001), Currents were inhibited by chelation of intracellular Ca2+ or exposure to apamin (50 nM), an inhibitor of SKCa channels, In cell-attached recordings from intact cells, removal of metabolic substrates (25/28 cells) or exposure to metabolic inhibitors (32/40 cells) opened K+-selective channels with a conductance of 6.5 +/- 0.2 pS, Channels had an open probability of 0.31 +/- 0.08 and opened in bursts averaging 3.55 +/- 0.27 ms in duration (n = 6), Metabolic stress was associated with rapid translocation of the alpha isoform of protein kinase C (PKC alpha) from cytosol to membrane; and down-regulation of PKC alpha by phorbol esters or exposure to the PKC inhibitor chelerythrine (10 mu M) each inhibited currents, Moreover, intracellular perfusion with purified PKC alpha activated currents in a Ca2+- and concentration-dependent manner, These findings indicate that metabolic stress leads to opening of apamin-sensitive SKCa, channels in hepatoma cells through a Ca2+- and PKC-dependent mechanism and suggest that PKC alpha may be selectively involved in the response, This mechanism functionally couples the metabolic state of cells to membrane K+ permeability and represents a potential target for modification of liver injury associated with ischemia and preservation.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA	Duke University					NIDDK NIH HHS [DK43278, DK46082] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK046082, R01DK046082, R01DK043278] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNARD GF, 1984, J CLIN INVEST, V74, P173, DOI 10.1172/JCI111399; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BREDT DS, 1989, BIOCHEM BIOPH RES CO, V159, P376; CAPIOD T, 1989, J PHYSIOL-LONDON, V409, P285, DOI 10.1113/jphysiol.1989.sp017497; CHANG D, 1988, COMPUT BIOL MED, V18, P351, DOI 10.1016/0010-4825(88)90022-4; CURRIN RT, 1991, FASEB J, V5, P207, DOI 10.1096/fasebj.5.2.2004664; DENGLER WA, 1995, ANTI-CANCER DRUG, V6, P522, DOI 10.1097/00001813-199508000-00005; FITZ JG, 1994, AM J PHYSIOL, V266, pG677, DOI 10.1152/ajpgi.1994.266.4.G677; FITZ JG, 1994, AM J PHYSIOL, V266, pG544, DOI 10.1152/ajpgi.1994.266.4.G544; FITZ JG, 1987, AM J PHYSIOL, V252, pG56, DOI 10.1152/ajpgi.1987.252.1.G56; FITZ JG, 1992, P NATL ACAD SCI USA, V89, P4197, DOI 10.1073/pnas.89.9.4197; FRIEDMANN N, 1980, BIOCHIM BIOPHYS ACTA, V596, P180, DOI 10.1016/0005-2736(80)90352-1; GASBARRINI A, 1992, J BIOL CHEM, V267, P6654; GETTYS TW, 1994, ANAL BIOCHEM, V220, P82, DOI 10.1006/abio.1994.1302; GRAF J, 1983, AM J PHYSIOL, V244, pG233, DOI 10.1152/ajpgi.1983.244.3.G233; GROSCHNER K, 1991, PFLUG ARCH EUR J PHY, V417, P517, DOI 10.1007/BF00370948; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLBRUCKER C, 1993, EUR J BIOCHEM, V211, P449, DOI 10.1111/j.1432-1033.1993.tb17570.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEATON JH, 1984, J BIOL CHEM, V259, P2396; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOWARD LD, 1987, J MEMBRANE BIOL, V100, P53, DOI 10.1007/BF02209140; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KEHRER JP, 1990, TOXICOL APPL PHARM, V106, P165, DOI 10.1016/0041-008X(90)90238-P; KOMARU T, 1991, CIRC RES, V69, P1146, DOI 10.1161/01.RES.69.4.1146; LIDOFSKY SD, 1993, J BIOL CHEM, V268, P14632; LIDOFSKY SD, 1995, IN PRESS P NATL ACAD; LYNCH CJ, 1984, PHARMACOLOGY, V28, P74, DOI 10.1159/000137952; MATSUMURA T, 1984, EUR J BIOCHEM, V140, P229, DOI 10.1111/j.1432-1033.1984.tb08091.x; METS B, 1993, HEPATOLOGY, V17, P668, DOI 10.1002/hep.1840170422; MILLER AL, 1993, AM J PHYSIOL, V265, pH2184, DOI 10.1152/ajpheart.1993.265.6.H2184; MURTHY KS, 1992, J PHARMACOL EXP THER, V260, P90; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; ROSSER BG, 1995, GASTROENTEROLOGY, V108, P252, DOI 10.1016/0016-5085(95)90032-2; SILBERBERG SD, 1992, PFLUG ARCH EUR J PHY, V420, P118, DOI 10.1007/BF00378653; STABEL S, 1991, METHOD ENZYMOL, V200, P670; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; TOHKIN M, 1988, JPN J PHARMACOL, V46, P61, DOI 10.1254/jjp.46.61; WANG K, 1992, AM J PHYSIOL, V262, pG566; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WONDERGEM R, 1980, J CELL PHYSIOL, V104, P53, DOI 10.1002/jcp.1041040109; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877	43	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18107	18113		10.1074/jbc.271.30.18107	http://dx.doi.org/10.1074/jbc.271.30.18107			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663472	hybrid			2022-12-27	WOS:A1996UY93500078
J	Zhang, L; Plow, EF				Zhang, L; Plow, EF			Overlapping, but not identical, sites are involved in the recognition of C3bi, neutrophil inhibitory factor, and adhesive ligands by the alpha(M)beta(2) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAC-1 CD11B CD18; I-DOMAIN; CR3 CD11B/CD18; BINDING-SITE; A-DOMAIN; COMPLEMENT RECEPTOR; BETA-2 INTEGRINS; CATION-BINDING; ADHERENCE; SUBUNIT	The alpha(M) beta(2) (CD11b/CD18, Mac-1) integrin receptor binds numerous ligands, including neutrophil inhibitory factor (NIF), C3bi, and certain immobilized protein substrates, represented by denatured ovalbumin. These ligands share no obvious structural similarities, yet their interactions with receptor are inhibited by NIF and involve the I domain, a stretch of similar to 200 amino acids in the alpha(M) subunit. Recombinant wild-type and mutant forms of alpha(M) beta(2) have been used to compare the recognition requirements of these ligands. The various constructs were expressed efficiently on the surface of human embryonic kidney 293 cells and formed alpha .beta heterodimeric complexes. The wild-type transfectants bound the three ligands in a similar fashion to naturally occurring alpha(M) beta(2). NIF inhibited these interactions, and deletion of the D(248)PLGY from within the I domain abolished binding of all three ligands, suggesting an overlapping recognition specificity. A single point mutation of Ser(138) to Ala in the beta(2) subunit abolished C3bi binding and cell adhesion but did not affect NIF binding. A switch of the R(281)QELNTI sequence in helix 6 of the alpha(M) I domain to the corresponding sequence in the I domain of the alpha(L) (QETLHKF) subunit completely abrogated adhesion while not affecting C3bi and NIF binding. The two mutant receptors also did not support activation-dependent adhesion to fibrinogen. Thus, the contact sites for NIF, C3bi, and adhesive proteins, represented by denatured ovalbumin and fibrinogen, in alpha(M) beta(2) are overlapping but not identical.			Zhang, L (corresponding author), CLEVELAND CLIN FDN,DEPT MOL CARDIOL,JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NHLBI NIH HHS [HL38292] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038292] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ANDERSON DC, 1986, J IMMUNOL, V137, P15; ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; ARNAOUT MA, 1990, BLOOD, V75, P1037; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; BOHNSACK JF, 1992, J IMMUNOL, V149, P1340; DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DIRENZO L, 1991, EUR J IMMUNOL, V21, P1755, DOI 10.1002/eji.1830210726; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KERN A, 1994, J BIOL CHEM, V269, P22811; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; MCNALLY AK, 1994, P NATL ACAD SCI USA, V91, P10119, DOI 10.1073/pnas.91.21.10119; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOYLE M, 1994, J BIOL CHEM, V269, P10008; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; ORTLEPP S, 1995, EUR J IMMUNOL, V25, P637, DOI 10.1002/eji.1830250302; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; RANDI AM, 1994, J BIOL CHEM, V269, P12395; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; ROSS GD, 1982, J EXP MED, V155, P96, DOI 10.1084/jem.155.1.96; RUSSELL DG, 1988, J EXP MED, V168, P279, DOI 10.1084/jem.168.1.279; SCHMALSTIEG FC, 1988, PEDIATR INFECT DIS J, V867, P872; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VONASMUTH EJU, 1991, J IMMUNOL, V147, P3869; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; ZHANG L, 1990, BIOCHEMISTRY-US, V29, P10828, DOI 10.1021/bi00500a016; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	38	85	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18211	18216		10.1074/jbc.271.30.18211	http://dx.doi.org/10.1074/jbc.271.30.18211			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663418	hybrid			2022-12-27	WOS:A1996UY93500093
J	Collins, LR; Minden, A; Karin, M; Brown, JH				Collins, LR; Minden, A; Karin, M; Brown, JH			G alpha(12) stimulates c-Jun NH2-terminal kinase through the small G proteins Ras and Rac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION DOMAIN; CELLS; JNK; PHOSPHORYLATION; TRANSFORMATION; PROLIFERATION; FIBROBLASTS; MITOGENESIS; INHIBITION; INDUCTION	The pertussis toxin (PTX) insensitive heterotrimeric G protein G(12) has been implicated in mitogenesis and transformation, but its direct effecters remain unknown, To define potential signaling pathways utilized by G(12), we expressed an activated mutant of its alpha subunit, G alpha(12)(Q229L), in HEK293 cells and examined its effects on Ras and mitogen-activated protein kinases (MAPKs), Transient expression of activated G alpha(12) increased the percentage of has in the active, GTP-bound state, stimulated c-Jun NH2-terminal kinase (JNK) activity, and enhanced the transcriptional activity of c-Jun, Dominant negative Ras (N17Ras) inhibited G alpha(12)-mediated JNK activation in NIH3T3 cells but failed to do so in HEK293 cells, In contrast, dominant negative Rac (N17Rac1) inhibited JNK activation by G alpha(12), in HEK293 cells as well as three other cell lines. In 1321N1 cells, where thrombin stimulates G(12)-dependent mitogenesis, coexpression of N17Rac1 or a dominant negative mutant of MEKK1 (MEKK Delta(K432M)) inhibits c-Jun/AP-1 sensitive reporter gene expression stimulated by thrombin or G alpha(12). These data demonstrate that the alpha subunit of the heterotrimeric G protein G(12), like tyrosine kinase growth factor receptors, activates has and recruits a signal transduction pathway involving the small GTP-binding protein Rac that leads to JNK activation.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NHLBI NIH HHS [HL35018] Funding Source: Medline; NIGMS NIH HHS [GM17277, GM36927] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL035018] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036927, R56GM036927, F31GM017277] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HERBERT JM, 1994, BIOCHEM J, V303, P227, DOI 10.1042/bj3030227; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; ITO A, 1995, FEBS LETT, V368, P183, DOI 10.1016/0014-5793(95)00643-N; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; OBBERGHENSCHILL.EV, 1985, EMBO J, V4, P2927; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; POST GR, 1996, IN PRESS MOL BIOL CE; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396	37	135	137	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17349	17353		10.1074/jbc.271.29.17349	http://dx.doi.org/10.1074/jbc.271.29.17349			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663428	hybrid			2022-12-27	WOS:A1996UX94300057
J	Medh, JD; Bowen, SL; Fry, GL; Ruben, S; Andracki, M; Inoue, I; Lalouel, JM; Strickland, DK; Chappell, DA				Medh, JD; Bowen, SL; Fry, GL; Ruben, S; Andracki, M; Inoue, I; Lalouel, JM; Strickland, DK; Chappell, DA			Lipoprotein lipase binds to low density lipoprotein receptors and induces receptor-mediated catabolism of very low density lipoproteins in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; CHYLOMICRON-REMNANT CLEARANCE; HEPARAN-SULFATE PROTEOGLYCANS; SMOOTH-MUSCLE CELLS; IN-VITRO; MONOCLONAL-ANTIBODIES; HEPATIC LIPASE; BOVINE-MILK; ALPHA(2)-MACROGLOBULIN RECEPTOR	Lipoprotein lipase (LPL), the major enzyme responsible for the hydrolysis of plasma triglycerides, promotes binding and catabolism of triglyceride-rich lipoproteins by various cultured cells, Recent studies demonstrate that LPL binds to three members of the low density lipoprotein (LDL) receptor family, including the LDL receptor-related protein (LRP), GP330/LRP-2, and very low density lipoprotein (VLDL) receptors and induces receptor-mediated lipoprotein catabolism. We show here that LDL receptors also bind LPL and mediate LPL-dependent catabolism of large VLDL with S-f 100-400. Up-regulation of LDL receptors by lovastatin treatment of normal human foreskin fibroblasts (FSF cells) resulted in an increase in LPL-induced VLDL binding and catabolism to a level that was 10-15-fold greater than in LDL receptor-negative fibroblasts, despite similar LRP activity in both cell lines, This indicates that the contribution of LRP to LPL-dependent degradation of VLDL is small when LDL receptors are maximally up-regulated, Furthermore studies in LRP-deficient murine embryonic fibroblasts showed that the level of LPL-dependent degradation of VLDL was similar to that in normal murine embryonic fibroblasts. LPL also promoted the internalization of protein-free triglyceride emulsions; lovastatin-treatment resulted in a-fold higher uptake in FSF cells, indicating that LPL itself could bind to LDL receptors, However, the lower induction of emulsion catabolism as compared with native VLDL suggests that LPL-induced catabolism via LDL receptors is only partially dependent on receptor binding by LPL and instead is primarily due to activation of apolipoproteins such as apoE, A fusion protein between glutathione S-transferase and the catalytically inactive carboxyl-terminal domain of LPL (GST-LPLC) also induced binding and catabolism of VLDL, However GST-LPLC was not as active as native LPL, indicating that lipolysis is required for a maximal LPL effect, Mutations of critical tryptophan residues in GST-LPLC that abolished binding to VLDL converted the protein to an inhibitor of lipoprotein binding to LDL receptors, In solid-phase assays using immobilized receptors, LDL receptors bound to LPL in a dose-dependent manner, Both LPL and GST-LPLC promoted binding of VLDL to LDL receptor-coated wells, These results indicate that LPL binds to LDL receptors and suggest that the carboxyl-terminal domain of LPL contributes to this interaction.	UNIV UTAH,SALT LAKE CITY,UT 84248; AMER RED CROSS,ROCKVILLE,MD 20855	Utah System of Higher Education; University of Utah; American Red Cross	Medh, JD (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,17 MRC,IOWA CITY,IA 52242, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49264] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; AVIRAM M, 1988, J BIOL CHEM, V263, P15416; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENSADOUN A, 1991, ANNU REV NUTR, V11, P217, DOI 10.1146/annurev.nu.11.070191.001245; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOWLER A, 1991, BIOCHEM J, V276, P381, DOI 10.1042/bj2760381; BROWN MS, 1978, J BIOL CHEM, V253, P1121; CATAPANO AL, 1979, J BIOL CHEM, V254, P1007; CHAPPELL DA, 1991, J BIOL CHEM, V266, P19296; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHAPPELL DA, 1993, J BIOL CHEM, V268, P25487; CHAPPELL DA, 1992, J BIOL CHEM, V267, P270; CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001; CHAPPELL DA, 1988, J CLIN INVEST, V82, P628, DOI 10.1172/JCI113642; CHENG CF, 1981, J BIOL CHEM, V256, P2893; CHUNG BH, 1994, ARTERIOSCLER THROMB, V14, P622, DOI 10.1161/01.ATV.14.4.622; COOPER AD, 1992, SEMIN LIVER DIS, V12, P386, DOI 10.1055/s-2008-1040408; COREY JE, 1977, ATHEROSCLEROSIS, V27, P201, DOI 10.1016/0021-9150(77)90057-0; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; EVANS AJ, 1992, J BIOL CHEM, V267, P10743; GIANTURCO SH, 1993, ARTERIOSCLER THROMB, V13, P472, DOI 10.1161/01.ATV.13.4.472; GIBSON JC, 1987, ARTERIOSCLEROSIS, V7, P401, DOI 10.1161/01.ATV.7.4.401; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAMILTONATTWELL VL, 1986, J MICROSC, V145, P347; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; HUSSAIN MM, 1995, J BIOL CHEM, V270, P8578, DOI 10.1074/jbc.270.15.8578; ISHIBASHI S, 1990, J BIOL CHEM, V265, P3040; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; JAFFE EA, 1980, TRANSPL P, V12, P49; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; KUTT H, 1989, BIOCHIM BIOPHYS ACTA, V1009, P229, DOI 10.1016/0167-4781(89)90107-3; LABARCA C, 1980, ANAL CHEM, V133, P437; LALOUEL JM, 1992, CURR OPIN LIPIDOL, V3, P86; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGOWAN MW, 1983, CLIN CHEM, V29, P538; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; MULDER M, 1993, J BIOL CHEM, V268, P9369; MUSLINER TA, 1979, BIOCHIM BIOPHYS ACTA, V575, P227; NORDENSTROM J, 1991, EUR J CLIN INVEST, V21, P580, DOI 10.1111/j.1365-2362.1991.tb01412.x; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; OSTLUNDLINDQVIST AM, 1983, ARTERIOSCLEROSIS, V3, P433, DOI 10.1161/01.ATV.3.5.433; PETERSON J, 1985, BIOCHIM BIOPHYS ACTA, V837, P262, DOI 10.1016/0005-2760(85)90049-9; RAPP JH, 1994, ARTERIOSCLER THROMB, V14, P1767, DOI 10.1161/01.ATV.14.11.1767; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; RUTLEDGE JC, 1994, J LIPID RES, V35, P1152; Santamarina-Fojo Silvia, 1994, Current Opinion in Lipidology, V5, P117; SANTAMARINAFOJO S, 1991, JAMA-J AM MED ASSOC, V265, P904, DOI 10.1001/jama.265.7.904; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SCHONFELD G, 1979, J CLIN INVEST, V64, P1288, DOI 10.1172/JCI109584; SKARLATOS SI, 1993, J CLIN ENDOCR METAB, V76, P793, DOI 10.1210/jc.76.3.793; STEIN O, 1993, ATHEROSCLEROSIS, V99, P15, DOI 10.1016/0021-9150(93)90046-W; TABAS I, 1993, J BIOL CHEM, V268, P20419; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TENG B, 1985, J BIOL CHEM, V260, P5067; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; VANDRIEL IR, 1989, J BIOL CHEM, V264, P9533; VILARO S, 1986, BIOCHEM J, V236, P273, DOI 10.1042/bj2360273; VILELLA E, 1993, J LIPID RES, V34, P1555; VOYTA JC, 1985, J BIOL CHEM, V260, P893; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13285; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLIAMS SE, 1993, J BIOL CHEM, V268, P8653; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	80	65	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17073	17080		10.1074/jbc.271.29.17073	http://dx.doi.org/10.1074/jbc.271.29.17073			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663292	hybrid			2022-12-27	WOS:A1996UX94300017
J	Ng, LC; ONeill, E; Shingler, V				Ng, LC; ONeill, E; Shingler, V			Genetic evidence for interdomain regulation of the phenol-responsive sigma(54)-dependent activator DmpR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; GRAM-NEGATIVE BACTERIA; BACILLUS-SUBTILIS; TRANSCRIPTIONAL ACTIVATOR; NUCLEOTIDE-SEQUENCE; FUNCTIONAL-ANALYSIS; CATABOLIC PATHWAY; ATPASE ACTIVITY; NTRC FAMILY; IN-VITRO	The sigma(54)-dependent DmpR activator regulates transcription of the dmp operon that encodes the enzymes for catabolism of (methyl)phenols. DmpR is expressed constitutively, but its transcriptional promoting activity is controlled positively in direct response to the presence of aromatic pathway substrates (effecters), DmpR has a distinct domain structure with the amino terminal A-domain controlling the specificity of activation of the regulator by aromatic effecters (signal reception), a central C-domain mediating an ATPase activity essential for transcriptional activation, and a carboxyl-terminal D-domain involved in DNA binding, Deletion of the A-domain has been shown previously to result in an effector-independent transcriptional activator with constitutive ATPase activity, These results, in conjunction with the location of mutations within the A- and C domains which exhibit an effector-independent (semiconstitutive) property, have led to a working model in which the A domain serves to mask the ATPase and transcriptional promoting activity of the C-domain in the absence of effectors. To investigate the mechanism by which the A-domain exerts its repressive effect, we developed a genetic system to select positively for intramolecular second site revertants of DmpR. The results demonstrate (i) that mutations within the A-domain can suppress the semiconstitutive activity of C-domain located mutations and vice versa; (ii) that the C-domain located mutations do not influence the intrinsic ATPase and transcriptional promoting property of the C-domain in the absence of the A-domain; and (iii) that semiconstitutive mutations of the A- and C-domain have an additive effect. Taken together these results support a model in which the A-domain represses the function(s) of the C-domain by direct interactions between residues of the two domains.			Ng, LC (corresponding author), UMEA UNIV,DEPT CELL & MOLEC BIOL,S-90187 UMEA,SWEDEN.			Shingler, Victoria/0000-0002-7349-1678				ABRIL MA, 1989, J BACTERIOL, V171, P6782, DOI 10.1128/jb.171.12.6782-6790.1989; AUSTIN S, 1994, J BIOL CHEM, V269, P18141; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; BERGER DK, 1994, P NATL ACAD SCI USA, V91, P103, DOI 10.1073/pnas.91.1.103; CHOI SH, 1991, P NATL ACAD SCI USA, V88, P11115, DOI 10.1073/pnas.88.24.11115; DELGADO A, 1994, J BIOL CHEM, V269, P8059; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; FIEDLER U, 1995, EMBO J, V14, P3696, DOI 10.1002/j.1460-2075.1995.tb00039.x; FRANKLIN FCH, 1981, P NATL ACAD SCI-BIOL, V78, P7458, DOI 10.1073/pnas.78.12.7458; GAY P, 1985, J BACTERIOL, V164, P918, DOI 10.1128/JB.164.2.918-921.1985; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOPP TP, 1988, BIOTECHNOLOGY, V6, P204; HOPPER S, 1995, J BACTERIOL, V177, P2798, DOI 10.1128/jb.177.10.2798-2803.1995; HUALA E, 1992, J BACTERIOL, V174, P1428, DOI 10.1128/jb.174.4.1428-1431.1992; IRETON K, 1993, GENE DEV, V7, P283, DOI 10.1101/gad.7.2.283; KAHN D, 1991, MOL MICROBIOL, V5, P87; MARTINVERSTRAETE I, 1994, J MOL BIOL, V241, P178, DOI 10.1006/jmbi.1994.1487; MENON KP, 1990, P NATL ACAD SCI USA, V87, P3708, DOI 10.1073/pnas.87.10.3708; METTKE I, 1995, J BACTERIOL, V177, P5056, DOI 10.1128/jb.177.17.5056-5061.1995; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; NORTH AK, 1993, J BACTERIOL, V175, P4267, DOI 10.1128/JB.175.14.4267-4273.1993; PAVEL H, 1994, J BACTERIOL, V176, P7550, DOI 10.1128/JB.176.24.7550-7557.1994; PEREZMARTIN J, 1994, MICROBIOL REV, V58, P268; PEREZMARTIN J, 1995, J BACTERIOL, V177, P3758, DOI 10.1128/jb.177.13.3758-3763.1995; PEREZMARTIN J, 1995, P NATL ACAD SCI USA, V92, P9392, DOI 10.1073/pnas.92.20.9392; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Porter SC, 1995, 2 COMPONENT SIGNAL T, P147; POWLOWSKI J, 1994, BIODEGRADATION, V5, P1; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 2002, MOL CLONING LAB MANU; SHINGLER V, 1992, J BACTERIOL, V174, P711, DOI 10.1128/jb.174.3.711-724.1992; Shingler V, 1996, MOL MICROBIOL, V19, P409, DOI 10.1046/j.1365-2958.1996.388920.x; SHINGLER V, 1994, J BACTERIOL, V176, P1555, DOI 10.1128/jb.176.6.1555-1560.1994; SHINGLER V, 1993, J BACTERIOL, V175, P1596, DOI 10.1128/JB.175.6.1596-1604.1993; SHINGLER V, 1995, MOL MICROBIOL, V17, P505, DOI 10.1111/j.1365-2958.1995.mmi_17030505.x; STEINMETZ M, 1985, MOL GEN GENET, V200, P220, DOI 10.1007/BF00425427; SZE CC, 1996, IN PRESS J BACTERIOL, V178; WANG JT, 1995, SCIENCE, V270, P992, DOI 10.1126/science.270.5238.992; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N	41	36	39	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17281	17286		10.1074/jbc.271.29.17281	http://dx.doi.org/10.1074/jbc.271.29.17281			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663326	hybrid			2022-12-27	WOS:A1996UX94300048
J	Erpel, T; Alonso, G; Roche, S; Courtneidge, SA				Erpel, T; Alonso, G; Roche, S; Courtneidge, SA			The Src SH3 domain is required for DNA synthesis induced by platelet-derived growth factor and epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; FAMILY TYROSINE KINASES; C-SRC; MITOGENIC RESPONSIVENESS; SIGNAL-TRANSDUCTION; RECEPTOR; PROTEIN; GRB2; RAS; ASSOCIATION	The Src family of protein tyrosine kinases has been implicated in the response of cells to platelet-derived growth factor (PDGF) or epidermal growth factor (EGF). We recently described a microinjection approach that we used to demonstrate that kinase activity of Src family members is required for PDGF- and EGF-induced S-phase entry of fibroblasts. We have now used this approach to ask whether a functional SH3 domain of Src is required to transduce the mitogenic signal upon PDGF or EGF stimulation. Microinjection of plasmids encoding Src mutants lacking the SH3 domain (Src Delta SH3) or point-mutated within the ligand binding surface of the SH3 domain, but with intact kinase domains, inhibited the mitogenic effect of PDGF and EGF in fibroblasts. Src Delta SH3 could still associate with the PDGF receptor, suggesting that the inhibitory effect of the Src SH3 mutants was brought about by a failure of the PDGF receptor Src Delta SH3 complex to relay the mitogenic signal further downstream. Chimeric molecules in which the Src SH3 domain was replaced with that of spectrin or Lck also blocked PDGF-induced DNA synthesis, whereas a chimera containing the Fyn SH3 domain did not. These data suggest that the Src or Fyn SH3 domain is required either for correct substrate selection or to recruit other proteins to the PDGF receptor.	EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, D-69012 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)				roche, serge/0000-0003-3413-3859				ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; OKADA M, 1993, J BIOL CHEM, V268, P18070; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHILLING K, 1991, P NATL ACAD SCI USA, V88, P5665, DOI 10.1073/pnas.88.13.5665; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WEERNINK PAO, 1994, FEBS LETT, V352, P296, DOI 10.1016/0014-5793(94)00977-5; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16807	16812		10.1074/jbc.271.28.16807	http://dx.doi.org/10.1074/jbc.271.28.16807			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663328	hybrid			2022-12-27	WOS:A1996UX12600060
J	David, M; Zhou, GC; Pine, R; Dixon, JE; Larner, AC				David, M; Zhou, GC; Pine, R; Dixon, JE; Larner, AC			The SH2 domain-containing tyrosine phosphatase PTP1D is required for interferon alpha/beta-induced gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; TRANSCRIPTION FACTOR ISGF3; GAMMA SIGNAL-TRANSDUCTION; INVITRO ACTIVATION; KINASE; RECEPTOR; PHOSPHORYLATION; CORKSCREW; PATHWAY; HOMOLOG	Interferons (IFNs) induce early response genes by stimulating Janus family (Jak) tyrosine kinases, leading to tyrosine phosphorylation of Stat (signal transducer and activator of transcription) proteins. Previous studies demonstrated that a protein-tyrosine phosphatase (PTP) is required for activation of the ISGF3 transcription complex by IFN alpha/beta, but the specific PTP responsible remained unidentified. We now show that the SH2 domain containing tyrosine phosphatase PTP1D (also designated as SHPTP2, SHPTP3, PTP2C, or Syp) is constitutively associated with the IFN alpha/beta receptor and becomes tyrosine-phosphorylated in response to ligand. Furthermore, transient expression of a phosphatase-inactive mutant or the COOH-terminal SH2 domain of PTP1D causes a dominant negative effect on IFN alpha/beta-induced early response gene expression. These results provide strong evidence that PTP1D functions as a positive regulator of the IFN alpha/beta-induced Jak/Stat signal transduction pathway.	US FDA,DIV CYTOKINE BIOL,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; PUBL HLTH RES INST,NEW YORK,NY 10016	US Food & Drug Administration (FDA); University of Michigan System; University of Michigan					PHS HHS [18849] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DAVID M, 1993, J BIOL CHEM, V268, P6593; David M, 1996, J BIOL CHEM, V271, P4585; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; FELDMAN G, 1994, J BIOL CHEM, V264, P10747; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	37	94	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15862	15865		10.1074/jbc.271.27.15862	http://dx.doi.org/10.1074/jbc.271.27.15862			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663536	hybrid			2022-12-27	WOS:A1996UW35200005
J	Fine, SM; Angel, RA; Perry, SW; Epstein, LG; Rothstein, JD; Dewhurst, S; Gelbard, HA				Fine, SM; Angel, RA; Perry, SW; Epstein, LG; Rothstein, JD; Dewhurst, S; Gelbard, HA			Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes - Implications for pathogenesis of HIV-1 dementia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; FACTOR RECEPTORS; CYTOKINES; BINDING; BRAIN	Human immunodeficiency virus (HIV) infection is commonly associated with neurological disease that occurs in the apparent absence of extensive infection of brain cells by HIV, suggesting that indirect mechanisms account for neuropathogenesis in the CNS, perhaps including changes in the normal neuroprotective functions of astrocytes. To test this hypothesis, we examined the effect of the pro-inflammatory cytokine, tumor necrosis factor alpha (TNF alpha), produced by HIV-1-infected macrophages and microglia, on glutamate transport by primary human fetal astrocytes (PHFAs). A dose-dependent inhibition of high affinity glutamate uptake sites was observed 12-24 h after addition of exogenous recombinant human TNF alpha to PHFAs. This effect was specific since it was blocked by a neutralizing monoclonal antibody directed against TNF alpha. Furthermore, the inhibitory effect was reproduced by a monoclonal antibody that is an agonist at the 55-kDa TNF receptor. These results suggest that the neurotoxic effects of TNF alpha may be due in part to its ability to inhibit glutamate uptake by astrocytes, which in turn may result in excitotoxic concentrations of glutamate in synapses.	UNIV ROCHESTER,MED CTR,DEPT NEUROL,ROCHESTER,NY 14842; UNIV ROCHESTER,MED CTR,DEPT MED INFECT DIS,ROCHESTER,NY 14842; UNIV ROCHESTER,MED CTR,DEPT MICROBIOL & IMMUNOL,ROCHESTER,NY 14842; UNIV ROCHESTER,MED CTR,DEPT PEDIAT,ROCHESTER,NY 14842; UNIV ROCHESTER,MED CTR,DEPT PHYSIOL & PHARMACOL,ROCHESTER,NY 14842; UNIV ROCHESTER,MED CTR,CTR CANC,ROCHESTER,NY 14842; JOHNS HOPKINS UNIV,DEPT NEUROL,BALTIMORE,MD 21287	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester; Johns Hopkins University			Gelbard, Harris/M-9260-2019; rothstein, jeffrey d/C-9470-2013	Epstein, Leon/0000-0003-4264-3867; Dewhurst, Stephen/0000-0001-7729-7920; Gelbard, Harris/0000-0001-5095-7976; Perry, Seth W/0000-0002-1503-6634	NIAID NIH HHS [KO4 AI01240, T32-AI08894] Funding Source: Medline; NINDS NIH HHS [P01 NS31492-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI001240, F32AI008894] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS031492] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BACELLAR H, 1994, NEUROLOGY, V44, P1892, DOI 10.1212/WNL.44.10.1892; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BENOS DJ, 1994, P NATL ACAD SCI USA, V91, P494, DOI 10.1073/pnas.91.2.494; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; BREW BJ, 1995, ANN NEUROL, V38, P563, DOI 10.1002/ana.410380404; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CASADO M, 1993, J BIOL CHEM, V268, P27313; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FLOTT B, 1991, GLIA, V4, P293, DOI 10.1002/glia.440040307; GELBARD HA, 1993, DEV NEUROSCI-BASEL, V15, P417, DOI 10.1159/000111367; GELBARD HA, 1994, J VIROL, V68, P4628, DOI 10.1128/JVI.68.7.4628-4635.1994; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; NOKTA MA, 1995, VIROLOGY, V205, P590; PIANI D, 1993, J NEUROIMMUNOL, V48, P99, DOI 10.1016/0165-5728(93)90063-5; PIANI D, 1994, J IMMUNOL, V152, P3578; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Sambrook J., 2002, MOL CLONING LAB MANU; SHALABY MR, 1990, J EXP MED, V172, P1517, DOI 10.1084/jem.172.5.1517; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; VOLTERRA A, 1994, MOL PHARMACOL, V46, P986; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; ZERANGUE N, 1995, J BIOL CHEM, V270, P6433, DOI 10.1074/jbc.270.12.6433	28	269	282	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15303	15306		10.1074/jbc.271.26.15303	http://dx.doi.org/10.1074/jbc.271.26.15303			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663435	hybrid			2022-12-27	WOS:A1996UV29900002
J	Fowlkes, JL; Serra, DM				Fowlkes, JL; Serra, DM			Characterization of glycosaminoglycan-binding domains present in insulin-like growth factor-binding protein-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-I; POTENTIATION; MECHANISM; CELLS	Matrix metalloproteinase 3 cleaves insulin-like growth factor-binding protein 3 (IGFBP-3) into six fragments, four of which bind heparin-Sepharose (Fowlkes, J. L., Enghild, J. J., Suzuki, K., and Nagase, H. (1994) J. Biol. Chem. 269, 25742-25746). Sequence analysis of IGFBP-3 heparin-binding fragments shows that all fragments contain at least one of two highly basic, putative heparin-binding consensus sequences present in IGFBP-3. Epitope-specific antibodies generated against synthetic peptides containing these domains recognized IGFBP-3, yet were significantly inhibited from binding in the presence of heparin, demonstrating that these regions of IGFBP-3 contain functional heparin binding domains, IGFBP-3 peptides containing one of the two heparin-binding consensus sequences bound heparin in a solid phase binding assay in a dose-dependent and saturable manner. However, the IGFBP-3 peptide containing the heparin-binding consensus sequence (KK)-K-149-GHA(153) bound heparin with similar to 4-fold less affinity than the IGFBP-3 peptide containing the longer heparin-binding consensus sequence (219)YKKKQCRP(226). Examination of several well characterized glycosaminoglycans to inhibit the binding of heparin to both heparin-binding IGFBP-3 peptides revealed that the most potent inhibitors were heparin, heparan sulfate, and dermatan sulfate; chondroitin sulfate A and hyaluronic acid were intermediate in their inhibitory activities; and chondroitin sulfate C caused no inhibition, These studies identify and characterize the glycosaminoglycan-binding domains in IGFBP-3, providing a basis for the better understanding of IGFBP-3 glycosaminoglycan interactions at the cellular and extracellular interface.			Fowlkes, JL (corresponding author), DUKE UNIV, MED CTR, DEPT PEDIAT, DIV ENDOCRINOL, BOX 3080, DURHAM, NC 27710 USA.				NIDDK NIH HHS [DK02276] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002276] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRESS DL, 1995, J BIOL CHEM, V270, P28289; ARAI T, 1994, J BIOL CHEM, V269, P20388; Arai T, 1996, J BIOL CHEM, V271, P6099, DOI 10.1074/jbc.271.11.6099; Bach LA, 1995, DIABETES REV, V3, P38; BAR RS, 1994, INT CONGR SER, V1056, P237; BOOTH BA, 1995, GROWTH REGULAT, V2, P1; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CONOVER CA, 1992, ENDOCRINOLOGY, V130, P3191, DOI 10.1210/en.130.6.3191; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CONOVER CA, 1991, ENDOCRINOLOGY, V129, P3259, DOI 10.1210/endo-129-6-3259; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FOWLKES JL, 1995, J BIOL CHEM, V270, P27481, DOI 10.1074/jbc.270.46.27481; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; FOWLKES JL, 1994, ENDOCRINOLOGY, V135, P2810, DOI 10.1210/en.135.6.2810; HODGKINSON SC, 1994, J MOL ENDOCRINOL, V13, P105, DOI 10.1677/jme.0.0130105; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOST C, 1992, J BIOL CHEM, V267, P12098; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONG SR, 1992, MOL ENDOCRINOL, V6, P870, DOI 10.1210/me.6.6.870; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MCCUSKER RH, 1990, J CELL PHYSL, V144, P2444; OH YM, 1993, J BIOL CHEM, V268, P14964; Rechler Matthew M., 1995, P155; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; SMITH EP, 1994, ENDOCRINOLOGY, V135, P359, DOI 10.1210/en.135.1.359; SOMMER A, 1991, MODERN CONCEPTS INSU, P715; TRESSEL TJ, 1991, BIOCHEM BIOPH RES CO, V178, P625, DOI 10.1016/0006-291X(91)90154-Y; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; YU Q, 1995, BIOTECHNIQUES, V19, P122	31	58	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14676	14679		10.1074/jbc.271.25.14676	http://dx.doi.org/10.1074/jbc.271.25.14676			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663298	hybrid			2022-12-27	WOS:A1996UT10600008
J	Monteclaro, FS; Charo, IF				Monteclaro, FS; Charo, IF			The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1 alpha receptor, confers chemokine selectivity - Evidence for a two-step mechanism for MCP-1 receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOATTRACTANT PROTEIN-1 RECEPTOR; FORMYL PEPTIDE RECEPTOR; LIGAND-BINDING; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; THROMBIN-RECEPTOR; A RECEPTOR; IDENTIFICATION; CELLS; CHORIOGONADOTROPIN	The chemoattractant cytokines, MCP-1 (monocyte chemoattractant protein) and MIP-1 alpha (macrophage inflammatory protein), are recognized by highly homologous but distinct receptors, To identify receptor domains involved ill determining ligand specificity, we created a series of chimeric MCP-1 and RANTES (regulated on activation, normal T cell expressed and secreted)/MIP-1 alpha receptors that progressively interchanged the amino terminus and each of the three extracellular loops. Radiolabeled MCP-1 bound with high affinity to the wild-type MCP-1 receptor, but not to the RANTES/MLP-1 alpha receptor (C-C CKR-1), Chimeras that retained the amino-terminal extension of the MCP-I receptor bound MCP-1 with high affinity, In contrast, chimeric MCP-I receptors, in which the wild-type amino terminus was replaced with the corresponding portion of the RANTES/MIP-1 alpha: receptor, bound MIP-1 with low affinity, These data indicate that the amino terminus of the MCP-1 receptor is necessary for high affinity binding of the ligand, Very different results were obtained using the RANTES/MIP-1 alpha: receptor, Radiolabeled MIP-1 alpha bound with high affinity to chimeras that expressed the extracellular loops of the RANTES/MIP-1 alpha receptor, In contrast to the MCP-1 receptor; substitution of the wild-type amino-terminal extension had little or no effect on MIP-1 alpha binding, For the MCP-1, but not the RANTES/MIP-1 alpha receptor, the presence of the wild-type amino terminus also significantly lowered the ligand concentration required for maximal signaling, We conclude that the amino-terminal extension of the MCP-1 receptor, but not the RANTES/MIP-1 alpha receptor, is critically involved in ligand binding and signal transduction. These data reveal significant functional differences between the two C-C chemokine receptors and suggest a two-step mechanism for activation of the MCP-1 receptor.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL52773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052773] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI M, 1994, EUR J BIOCHEM, V220, P37, DOI 10.1111/j.1432-1033.1994.tb18596.x; Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FRANCI C, 1995, J IMMUNOL, V154, P6511; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUGLI TE, 1981, MOL CELL BIOCHEM, V41, P59; ISHII K, 1993, J BIOL CHEM, V268, P9780; JI I, 1991, J BIOL CHEM, V266, P13076; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; MERY L, 1994, J BIOL CHEM, V269, P3457; MOYLE WR, 1991, J BIOL CHEM, V266, P10807; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; QUEBENBERGER O, 1993, J BIOL CHEM, V268, P18167; RADEL SJ, 1994, INFECT IMMUN, V62, P1726, DOI 10.1128/IAI.62.5.1726-1732.1994; SCHALL TJ, 1994, CYTOKINE HDB, P419; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; VADDI K, 1994, J IMMUNOL, V153, P4721; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; WALKER P, 1994, J BIOL CHEM, V269, P2863; XUE JC, 1994, J BIOL CHEM, V269, P30195	41	184	188	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19084	19092		10.1074/jbc.271.32.19084	http://dx.doi.org/10.1074/jbc.271.32.19084			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702581	hybrid			2022-12-27	WOS:A1996VB68400015
J	Mikhailov, VS; Bogenhagen, DF				Mikhailov, VS; Bogenhagen, DF			Effects of Xenopus laevis mitochondrial single-stranded DNA-binding protein on primer-template binding and 3'->5' exonuclease activity of DNA polymerase gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; REPLICATION; SSB; STIMULATION; SEQUENCE	Mitochondrial DNA (mtDNA) is replicated by DNA polymerase gamma by a strand displacement mechanism involving mitochondrial single-stranded DNA-binding protein (mtSSB). mtSSB stimulates the overall rate of DNA synthesis on singly-primed M13 DNA mainly by stimulating the processivity of DNA synthesis rather than by stimulating primer recognition, We used electrophoretic mobility shift methods to study the effects of mtSSB on primer template recognition by DNA pol gamma, Preliminary experiments showed that single mtSSB tetramers bind tightly to oligo(dT) single strands containing 32 to 48 residues. An oligonucleotide primer-template was designed with an 18-mer primer annealed to the 3'-portion of a 71-mer template containing 40 dT residues at its 5'-end as a binding site for mtSSB. DNA pol gamma bound to this primer-template either in the absence or presence of mtSSB in complexes that remained intact and enzymatically active following native gel electrophoresis. Association of mtSSB with the 5'-dT(40)-tail in the 18:71-mer primer-template reduced the binding of DNA polymerase gamma and the efficiency of primer extension. Binding of mtSSB to single-stranded DNA was also observed to block the action of the 3'-->5' exonuclease of DNA polymerase gamma. The size of fragments protected from 3'-->5' exonuclease trimming increases with increasing ionic strength in a manner consistent with the known salt dependence of the binding site size of Escherichia coli SSB.	RUSSIAN ACAD SCI,KOLTZOV INST DEV BIOL,MOSCOW 117808,RUSSIA	Russian Academy of Sciences; Koltzov Institute of Developmental Biology of the Russian Academy of Sciences	Mikhailov, VS (corresponding author), SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794, USA.		Mikhailov, Victor S/O-2063-2016	Mikhailov, Victor/0000-0002-3324-8921	NIEHS NIH HHS [P01ES04068] Funding Source: Medline; NIGMS NIH HHS [GM29681] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029681] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIRNS SS, 1987, THESIS STATE U NEW Y; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; CURTH U, 1994, EUR J BIOCHEM, V221, P435, DOI 10.1111/j.1432-1033.1994.tb18756.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; GENUARIO R, 1993, CELL MOL BIOL RES, V39, P625; GHRIR R, 1991, ARCH BIOCHEM BIOPHYS, V291, P395, DOI 10.1016/0003-9861(91)90152-9; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HOKE GD, 1990, ARCH BIOCHEM BIOPHYS, V282, P116, DOI 10.1016/0003-9861(90)90094-F; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; LOHMAN TM, 1988, TRENDS BIOCHEM SCI, V13, P250; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MAHOUNGOU C, 1988, FEBS LETT, V235, P267, DOI 10.1016/0014-5793(88)81276-6; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MIGNOTTE B, 1985, NUCLEIC ACIDS RES, V13, P1703, DOI 10.1093/nar/13.5.1703; MIGNOTTE B, 1988, EUR J BIOCHEM, V174, P479, DOI 10.1111/j.1432-1033.1988.tb14123.x; PAVCO PA, 1985, J CELL BIOL, V100, P258, DOI 10.1083/jcb.100.1.258; SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; THOMMES P, 1995, J BIOL CHEM, V270, P21137, DOI 10.1074/jbc.270.36.21137; TIRANTI V, 1991, NUCLEIC ACIDS RES, V19, P4291, DOI 10.1093/nar/19.15.4291; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; VANTUYLE GC, 1985, J CELL BIOL, V100, P251, DOI 10.1083/jcb.100.1.251; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P860, DOI 10.1074/jbc.270.2.860; ZEVIANI M, 1992, J INHERIT METAB DIS, V15, P456, DOI 10.1007/BF01799604	29	28	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18939	18946		10.1074/jbc.271.31.18939	http://dx.doi.org/10.1074/jbc.271.31.18939			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702557	hybrid			2022-12-27	WOS:A1996VB68300095
J	Chang, W; Zhou, W; Theill, LE; Baxter, JD; Schaufele, F				Chang, W; Zhou, W; Theill, LE; Baxter, JD; Schaufele, F			An activation function in Pit-1 required selectively for synergistic transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE GENE; RESPONSE ELEMENTS; CYCLIC-AMP; PROMOTER; RECEPTOR; BINDING; EXPRESSION; PROTEIN; DOMAINS; DNA	Synergistic transcription activation is a key component in the generation of the spectrum of eukaryotic promoter activities by a limited number of transcription factors, Various mechanisms could account for synergy, but a central question remains of whether synergism requires transcription factor functions that differ from those that direct independent activation, The rat growth hormone promoter is synergistically activated by the pituitary-specific transcription factor, Pit-1, and the thyroid hormone receptor (TR), Mutations that disrupted the previously described DNA binding and transcriptional activation domains of both Pit-1 and TR reduced Pit-1/TR synergy in parallel with their effects on the much weaker, independent Pit-1 and TR activations of the rat growth hormone promoter, Thus, Pit-1 and TR amplify each other's intrinsic activities, Mutations of Pit-1 that selectively inhibited synergism with the TR without affecting independent Pit-1 activity were also identified, Pit-1/TR synergy is therefore a consequence of a novel synergism-selective activity and synergism-independent Pit-1 and TR functions.	UNIV CALIF SAN FRANCISCO,METAB RES UNIT,SAN FRANCISCO,CA 94143; AMGEN INC,THOUSAND OAKS,CA 91320	University of California System; University of California San Francisco; Amgen								ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHANG CB, 1994, MOL CELL BIOL, V14, P5175, DOI 10.1128/MCB.14.8.5175; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; GAIDDON C, 1995, ENDOCRINOLOGY, V136, P4331, DOI 10.1210/en.136.10.4331; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GETZENBERG RH, 1994, J CELL BIOCHEM, V55, P22, DOI 10.1002/jcb.240550105; HAUGEN BR, 1993, J BIOL CHEM, V268, P20818; HERBOMEL P, 1990, New Biologist, V2, P1063; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; JOUNG JK, 1994, SCIENCE, V265, P1863, DOI 10.1126/science.8091212; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KUNSCH C, 1994, J IMMUNOL, V153, P153; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; LACASSE EC, 1993, ENDOCRINOLOGY, V132, P1017, DOI 10.1210/en.132.3.1017; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MULLER M, 1991, MOL ENDOCRINOL, V5, P1498, DOI 10.1210/mend-5-10-1498; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; NISHIZUKA Y, 1983, TRENDS BIOCHEM SCI, V8, P13, DOI 10.1016/0968-0004(83)90061-0; OHASHI Y, 1994, MOL CELL BIOL, V14, P2731, DOI 10.1128/MCB.14.4.2731; OLIVIERO S, 1991, P NATL ACAD SCI USA, V88, P224, DOI 10.1073/pnas.88.1.224; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RHODES SJ, 1994, CURR OPIN GENET DEV, V4, P709, DOI 10.1016/0959-437X(94)90138-S; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SCHAUFELE F, 1994, PITUITARY GLAND, P91; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SZYMANSKI P, 1995, EMBO J, V14, P2229, DOI 10.1002/j.1460-2075.1995.tb07217.x; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TANSEY WP, 1993, J BIOL CHEM, V268, P14906; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TIAN J, 1995, MOL CELL ENDOCRINOL, V112, P249, DOI 10.1016/0303-7207(95)03614-D; WEST BL, 1987, MOL CELL BIOL, V7, P1193, DOI 10.1128/MCB.7.3.1193; WU KJ, 1994, J BIOL CHEM, V269, P1177; YE ZS, 1987, J BIOL CHEM, V262, P6313	50	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17733	17738		10.1074/jbc.271.30.17733	http://dx.doi.org/10.1074/jbc.271.30.17733			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663468	hybrid			2022-12-27	WOS:A1996UY93500024
J	Chillaron, J; Estevez, R; Mora, C; Wagner, CA; Suessbrich, H; Lang, F; Gelpi, JL; Testar, X; Busch, AE; Zorzano, A; Palacin, M				Chillaron, J; Estevez, R; Mora, C; Wagner, CA; Suessbrich, H; Lang, F; Gelpi, JL; Testar, X; Busch, AE; Zorzano, A; Palacin, M			Obligatory amino acid exchange via systems b(o,+)-like and y(+)L-like - A tertiary active transport mechanism for renal reabsorption of cystine and dibasic amino acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; PROXIMAL STRAIGHT TUBULES; RABBIT KIDNEY CORTEX; RAT-KIDNEY; EXPRESSION CLONING; HUMAN ERYTHROCYTES; HEAVY-CHAIN; LYSINE TRANSPORT; MESSENGER-RNA; HIGH-AFFINITY	Mutations in the rBAT gene cause type I cystinuria, a common inherited aminoaciduria of cystine and dibasic amino acids due to their defective renal and intestinal reabsorption (Calonge, M. J., Gasparini, P., Chillaron, J., Chillon, M., Gallucci, M., Rousaud, F., Zelante, L., Testar, X., Dallapiccola, B., Di Silverio, F., Barcelo, P., Estivill, X., Zorzano, A., Nunes, V., and Palacin, M. (1994) Not. Genet. 6, 420-426; Calonge, M. J., Volipini, V., Bisceglia, L., Rousaud, F., De Sanctis, L., Beccia, E., Zelante, L., Testar, X., Zorzano, A., Estivill, X., Gasparini, P., Nunes, V., and Palacin, M. (1995) Proc. Natl. Acad. Sci. U.S.A. 92, 9667-9671). One important question that remains to be clarified is how the apparently non-concentrative system b(o,+)-like, associated with rBAT expression, participates in the active renal reabsorption of these amino acids. Several studies have demonstrated exchange of amino acids induced by rBAT in Xenopus oocytes. Here we offer evidence that system b(o,+)-like is an obligatory amino acid exchanger in oocytes and in the ''renal proximal tubular'' cell line OK. System b(o,+)-like showed a 1:1 stoichiometry of exchange, and the hetero-exchange dibasic (inward) with neutral (outward) amino acids were favored in oocytes. Obligatory exchange of amino acids via system b(o,+)-like fully explained the amino acid-induced current in rBAT-injected oocytes. Exchange via system b(o,+)-like is coupled enough to ensure a specific accumulation of substrates until the complete replacement of the internal oocyte substrates. Due to structural and functional analogies of the cell surface antigen 4F2hc to rBAT, we tested for amino acid exchange via system y(+)L-like. 4F2hc-injected oocytes accumulated substrates to a level higher than CAT1-injected oocytes (i.e. oocytes expressing system y(+)) and showed exchange of amino acids with the substrate specificity of system y(+)L and L-leucine-induced outward currents in the absence of extracellular sodium. In contrast to L-arginine, system y(+)L-like did not mediate measurable L-leucine efflux from the oocyte. We propose a role of systems b(o,+)-like and y(+)L-like in the renal reabsorption of cystine and dibasic amino acids that is based on their active tertiary transport mechanism and on the apical and basolateral localization of rBAT and 4F2hc, respectively, in the epithelial cells of the proximal tubule of the nephron.	UNIV BARCELONA,FAC BIOL,DEPT BIOCHEM & MOLEC BIOL,BARCELONA 08028,SPAIN; UNIV TUBINGEN,INST PHYSIOL 1,D-72076 TUBINGEN,GERMANY	University of Barcelona; Eberhard Karls University of Tubingen			Zorzano, Antonio/R-5479-2018; Palacín, Manuel/G-9786-2015; Mora, Conchi/A-8280-2010; Chillaron, Josep/ABF-7663-2021; Estevez, Raul/D-8610-2015; Gelpi, Josep Lluis/M-6401-2013	Mora, Conchi/0000-0002-5644-0537; Chillaron, Josep/0000-0003-3068-7598; Estevez, Raul/0000-0003-1579-650X; Gelpi, Josep Lluis/0000-0002-0566-7723; Palacin, Manuel/0000-0002-8670-293X				AHMED A, 1995, J BIOL CHEM, V270, P8482, DOI 10.1074/jbc.270.15.8482; ANGELO S, 1994, J MEMBRANE BIOL, V141, P183; BERTRAN J, 1993, J BIOL CHEM, V268, P14842; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; BERTRAN J, 1992, BIOCHEM J, V281, P717, DOI 10.1042/bj2810717; BIBER J, 1985, AM J PHYSIOL, V249, pC430, DOI 10.1152/ajpcell.1985.249.5.C430; BUSCH AE, 1994, J BIOL CHEM, V269, P25581; BUSCH AE, 1992, J PHYSIOL-LONDON, V450, P455; CALONGE MJ, 1995, HUM GENET, V95, P633; CALONGE MJ, 1995, P NATL ACAD SCI USA, V92, P9667, DOI 10.1073/pnas.92.21.9667; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; CHA S, 1968, J BIOL CHEM, V243, P820; CHEESEMAN C, 1992, AM J PHYSIOL, V263, pR482, DOI 10.1152/ajpregu.1992.263.3.R482; CHEESEMAN CI, 1983, J PHYSIOL-LONDON, V338, P87, DOI 10.1113/jphysiol.1983.sp014662; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; COADY MJ, 1994, FEBS LETT, V356, P174, DOI 10.1016/0014-5793(94)01262-8; DEVES R, 1993, J PHYSIOL-LONDON, V468, P753, DOI 10.1113/jphysiol.1993.sp019799; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; ELENO N, 1994, J PHYSIOL-LONDON, V479, P291, DOI 10.1113/jphysiol.1994.sp020296; FEI YJ, 1995, BIOCHEMISTRY-US, V34, P8744, DOI 10.1021/bi00027a025; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; GASPARINI P, 1995, AM J HUM GENET, V57, P781; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; HEMLER ME, 1982, J IMMUNOL, V129, P623; KAVANAUGH MP, 1993, BIOCHEMISTRY-US, V32, P5781, DOI 10.1021/bi00073a009; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KOYAMA H, 1978, IN VITRO CELL DEV B, V14, P239; LEE WS, 1993, J CLIN INVEST, V91, P1959, DOI 10.1172/JCI116415; MIYAMOTO K, 1995, BIOCHEM J, V310, P951, DOI 10.1042/bj3100951; Mora C, 1996, J BIOL CHEM, V271, P10569, DOI 10.1074/jbc.271.18.10569; MUNCK BG, 1969, BIOCHIM BIOPHYS ACTA, V183, P182, DOI 10.1016/0005-2736(69)90142-4; PALACIN M, 1994, J EXP BIOL, V196, P123; PICKEL VM, 1993, P NATL ACAD SCI USA, V90, P7779, DOI 10.1073/pnas.90.16.7779; PRAS E, 1994, NAT GENET, V6, P415, DOI 10.1038/ng0494-415; QUACKENBUSH EJ, 1986, J IMMUNOL, V136, P118; ROSENBERG LE, 1965, NEW ENGL J MED, V273, P1239, DOI 10.1056/NEJM196512022732303; ROSENBERG LE, 1966, J CLIN INVEST, V45, P365, DOI 10.1172/JCI105351; SCHAFER JA, 1984, PFLUG ARCH EUR J PHY, V401, P143, DOI 10.1007/BF00583874; SEGAL S, 1995, METABOLIC MOL BASES, V3, P581; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; TAYLOR MA, 1987, DEV BIOL, V124, P287, DOI 10.1016/0012-1606(87)90480-5; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; WANG Y, 1995, FEBS LETT, V368, P389, DOI 10.1016/0014-5793(95)00685-3; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; YAN N, 1992, P NATL ACAD SCI USA, V89, P9982, DOI 10.1073/pnas.89.21.9982	50	145	146	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17761	17770		10.1074/jbc.271.30.17761	http://dx.doi.org/10.1074/jbc.271.30.17761			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663357	Green Published, hybrid			2022-12-27	WOS:A1996UY93500029
J	Kawamoto, S				Kawamoto, S			Neuron-specific alternative splicing of nonmuscle myosin II heavy chain-B pre-mRNA requires a cis-acting intron sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; GENE; EXON; MOLECULE; CLONING; ISOFORM; ELEMENT; REGION; CELLS; SITE	In addition to the ubiquitously expressed form of nonmuscle myosin II heavy chain-B (MHC-B), the existence of a neuron-specific MHC-B isoform, which contains a 30-nucleotide inserted sequence near the ATP binding region, has been reported (Takahashi, M,, Kawamoto, S,, and Adelstein, R, S, (1992) J. Biol, Chem, 267, 17864-17871), In this study, the genomic location of the neuron-specific inserted 30-nucleotide sequence found in the cDNA is determined to be a single cassette type exon, N30, in the human nonmuscle MHC-B gene, Inclusion or exclusion of exon N30 is cell type-specific, with inclusion being restricted to neuronal cells and being regulated during cell differentiation. Expression of a minigene construct that contains the alternative exon N30 along with the flanking introns and exons was studied in human neuronal retinoblastoma Y79 cells, Inclusion of the N30 exon in the mRNA from the transfected minigene occurs in differentiated Y79 cells that have been treated with butyrate but not in the undifferentiated Y79 cells and non-neuronal cell lines, Systematic deletion and mutation analysis of the minigene construct established that neuron-specific N30 exon recognition requires a cis-acting RNA sequence located similar to 1.5 kilobases downstream of the N30 exon.			Kawamoto, S (corresponding author), NHLBI,NIH,MOLEC CARDIOL LAB,BLDG 10,RM 8N202,10 CTR DR,MSC 1762,BETHESDA,MD 20892, USA.							BABIJ P, 1991, P NATL ACAD SCI USA, V88, P10676, DOI 10.1073/pnas.88.23.10676; BABIJ P, 1993, NUCLEIC ACIDS RES, V21, P1467, DOI 10.1093/nar/21.6.1467; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; DIRKSEN WP, 1994, J BIOL CHEM, V269, P6431; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; ITOH K, 1995, J BIOL CHEM, V270, P14533, DOI 10.1074/jbc.270.24.14533; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1994, J BIOL CHEM, V269, P15101; Mansfield SG, 1996, J MOL BIOL, V255, P98; MIN HS, 1995, GENE DEV, V9, P2659, DOI 10.1101/gad.9.21.2659; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SPUDICH JA, 1989, CELL REGUL, V1, P1; STAMM S, 1994, NUCLEIC ACIDS RES, V22, P1515, DOI 10.1093/nar/22.9.1515; TACKE R, 1991, GENE DEV, V5, P1416, DOI 10.1101/gad.5.8.1416; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; WIECHMANN AF, 1990, J NEUROCHEM, V55, P208, DOI 10.1111/j.1471-4159.1990.tb08840.x; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	28	67	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17613	17616						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663598				2022-12-27	WOS:A1996UY93500006
J	Nara, T; Kawagishi, I; Nishiyama, S; Homma, M; Imae, Y				Nara, T; Kawagishi, I; Nishiyama, S; Homma, M; Imae, Y			Modulation of the thermosensing profile of the Escherichia coli aspartate receptor Tar by covalent modification of its methyl-accepting sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; BACTERIAL CHEMOTAXIS; SIGNAL-TRANSDUCTION; SENSORY RECEPTOR; ETHYLENE-GLYCOL; GENE-PRODUCT; CHEMORECEPTOR; MUTANTS; COMPLEX; TSR	The Escherichia coli aspartate receptor Tar is involved in the thermotactic response, We have studied how its thermosensing function is affected by the modification of the four methyl-accepting residues (Gln(295), Glu(302), Gln(309), and Glu(491)), which play essential roles in adaptation, We found that the primary translational product of tar mediates a chemoresponse, but not a thermoresponse, and that Tar comes to function as a thermoreceptor, once Gln(295) or Gln(309) is deamidated. This is the first identification of a thermosensing-specific mutant form, suggesting that the methylation sites of Tar constitute at least a part of the region required for thermoreception, signaling, or both, We have also investigated the inverted thermoresponse mediated by Tar in the presence of aspartate, We found that, whereas the deamidated-and-unmethylated form functions as a warm receptor, eliciting a smooth-swimming signal upon increase of temperature, the heavily methylated form functions as a cold receptor, eliciting a smooth-swimming signal upon decrease of temperature, Thus, it is suggested that Tar exists in at least three distinct states, each of which allows it to function as a warm, cold, or null thermoreceptor, depending on the modification patterns of its methylation sites.	NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGANO 46401,JAPAN	Nagoya University								AMES P, 1994, J BACTERIOL, V176, P6340, DOI 10.1128/jb.176.20.6340-6348.1994; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BURROWS GG, 1989, J BIOL CHEM, V264, P17309; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; GARDINA P, 1992, J BACTERIOL, V174, P1528, DOI 10.1128/jb.174.5.1528-1536.1992; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GOMI S, 1993, J BIOCHEM-TOKYO, V133, P208; GOMI S, 1994, OLFACTION TASTE, V9, P210; HAZELBAUER GL, 1990, SOC GENERAL MICROBIO, V46, P107; HEDBLOM ML, 1980, J BACTERIOL, V144, P1048, DOI 10.1128/JB.144.3.1048-1060.1980; IMAE Y, 1984, J BACTERIOL, V159, P368, DOI 10.1128/JB.159.1.368-374.1984; Imae Y., 1985, SENSING RESPONSE MIC, P73; IWAMA T, 1995, J BACTERIOL, V177, P2218, DOI 10.1128/jb.177.8.2218-2221.1995; KEHRY MR, 1983, P NATL ACAD SCI-BIOL, V80, P3599, DOI 10.1073/pnas.80.12.3599; KEHRY MR, 1982, J BIOL CHEM, V257, P378; KOSSMANN M, 1988, J BACTERIOL, V170, P4516, DOI 10.1128/jb.170.10.4516-4521.1988; KRIKOS A, 1985, P NATL ACAD SCI USA, V82, P1326, DOI 10.1073/pnas.82.5.1326; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE L, 1990, J BACTERIOL, V172, P377, DOI 10.1128/JB.172.1.377-382.1990; LEE L, 1988, J BACTERIOL, V170, P4769, DOI 10.1128/jb.170.10.4769-4774.1988; LIN LN, 1994, BIOCHEMISTRY-US, V33, P6564, DOI 10.1021/bi00187a025; Macnab R. M., 1987, ESCHERICHIA COLI SAL, V1, P732; MADDOCK JR, 1993, SCIENCE, V259, P1717; MAEDA K, 1979, P NATL ACAD SCI USA, V76, P91, DOI 10.1073/pnas.76.1.91; MANSON MD, 1992, ADV MICROB PHYSIOL, V33, P277, DOI 10.1016/S0065-2911(08)60219-2; MCCLEARY WR, 1993, J BACTERIOL, V175, P2793, DOI 10.1128/JB.175.10.2793-2798.1993; MIZUNO T, 1984, J BACTERIOL, V159, P360, DOI 10.1128/JB.159.1.360-367.1984; NARA T, 1991, J BACTERIOL, V173, P1120, DOI 10.1128/jb.173.3.1120-1124.1991; OOSAWA K, 1983, J BACTERIOL, V154, P104, DOI 10.1128/JB.154.1.104-112.1983; OOSAWA K, 1988, J BACTERIOL, V170, P2521, DOI 10.1128/jb.170.6.2521-2526.1988; OOSAWA K, 1984, J BACTERIOL, V157, P576, DOI 10.1128/JB.157.2.576-581.1984; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SHERRIS D, 1981, P NATL ACAD SCI-BIOL, V78, P6051, DOI 10.1073/pnas.78.10.6051; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; SPRINGER WR, 1977, P NATL ACAD SCI USA, V74, P533, DOI 10.1073/pnas.74.2.533; STEWART RC, 1987, CHEM REV, V87, P997, DOI 10.1021/cr00081a007; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; TATSUNO I, 1994, MOL MICROBIOL, V14, P755, DOI 10.1111/j.1365-2958.1994.tb01312.x; TERWILLIGER TC, 1984, J BIOL CHEM, V259, P7719; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988	45	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17932	17936		10.1074/jbc.271.30.17932	http://dx.doi.org/10.1074/jbc.271.30.17932			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663384	hybrid			2022-12-27	WOS:A1996UY93500053
J	Surette, MG; Stock, JB				Surette, MG; Stock, JB			Role of alpha-helical coiled-coil interactions in receptor dimerization, signaling, and adaptation during bacterial chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; BACTERIOPHAGE-T7 RNA-POLYMERASE; ESCHERICHIA-COLI; ASPARTATE RECEPTOR; KINASE-ACTIVITY; SALMONELLA-TYPHIMURIUM; CYTOPLASMIC DOMAIN; CRYSTAL-STRUCTURE; CROSS-LINKING; CHEA PROTEIN	The aspartate receptor, Tar, is a member of a large family of signal transducing membrane receptors that interact with CheA and CheW proteins to mediate the chemotactic responses of bacteria, A highly conserved cytoplasmic region, the signaling domain, is flanked by two sequences, methylated helices 1 and 2 (MH1 and MH2), that are predicted to form alpha-helical coiled-coils, MH1 and MH2 contain glutamine and glutamate residues that are subject to deamidation, methylation, and demethylation. We show that the signaling domain is an independently folding unit that binds CheW, When expressed in vivo the signaling domain inhibits CheA kinase activity, but if MH1 or an unrelated leucine zipper coiled-coil sequence is attached to the signaling domain, CheA is activated, A construct that contains a leucine zipper fused to MH1-signaling domain-MH2 also activates the kinase, both in vivo and in vitro, and this activation is regulated by the level of glutamate modification, These findings support a model for receptor signaling where aspartate binding controls the relative orientation of receptor monomers to favor the formation of coiled-coils between MH1 and/or MH2 between subunits, Glutamate modification may stabilize these coiled-coils by reducing electrostatic repulsion between helices.	PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Princeton University					NIAID NIH HHS [AI20980] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020980] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES P, 1994, J BACTERIOL, V176, P6340, DOI 10.1128/jb.176.20.6340-6348.1994; BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; BUSTOS SA, 1993, P NATL ACAD SCI USA, V90, P5638, DOI 10.1073/pnas.90.12.5638; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; COPELAND RA, 1994, METHODS PROTEIN ANAL, P195; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; GU J, 1994, BIOTECHNIQUES, V17, P257; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hazelbauer GL, 1992, CURR OPIN STRUC BIOL, V2, P505; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KAPLAN N, 1988, J BACTERIOL, V170, P5134, DOI 10.1128/jb.170.11.5134-5140.1988; KIM SH, 1994, PROTEIN SCI, V3, P159; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE GF, 1995, P NATL ACAD SCI USA, V92, P3391, DOI 10.1073/pnas.92.8.3391; LEE GF, 1995, P NATL ACAD SCI USA, V92, P5416, DOI 10.1073/pnas.92.12.5416; LIU JD, 1991, J BACTERIOL, V173, P4941, DOI 10.1128/jb.173.16.4941-4951.1991; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MONERA OD, 1993, J BIOL CHEM, V268, P19218; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; NINFA EG, 1991, J BIOL CHEM, V266, P9764; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SCOTT WG, 1993, J MOL BIOL, V232, P555, DOI 10.1006/jmbi.1993.1411; SEELEY SK, 1994, BIOPHYS J, V66, pA172; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; STOCK A, 1988, P NATL ACAD SCI USA, V85, P1403, DOI 10.1073/pnas.85.5.1403; STOCK A, 1985, P NATL ACAD SCI USA, V82, P7989, DOI 10.1073/pnas.82.23.7989; STOCK A, 1987, J BIOL CHEM, V262, P535; STOCK AM, 1987, J BACTERIOL, V169, P3301, DOI 10.1128/jb.169.7.3301-3311.1987; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; Stock JB, 1996, ESCHERICHIA COLI SAL, P1103; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; SWANSON RV, 1993, MOL MICROBIOL, V8, P435, DOI 10.1111/j.1365-2958.1993.tb01588.x; SWANSON RV, 1993, BIOCHEMISTRY-US, V32, P7623, DOI 10.1021/bi00081a004; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WOLFE AJ, 1993, P NATL ACAD SCI USA, V90, P1518, DOI 10.1073/pnas.90.4.1518; WU ZN, 1994, PROTEIN ENG, V7, P1137, DOI 10.1093/protein/7.9.1137; YEH JI, 1993, J BIOL CHEM, V268, P9787	55	84	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17966	17973		10.1074/jbc.271.30.17966	http://dx.doi.org/10.1074/jbc.271.30.17966			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663397	hybrid			2022-12-27	WOS:A1996UY93500059
J	Yao, KW; Schulz, H				Yao, KW; Schulz, H			Intermediate channeling on the trifunctional beta-oxidation complex from pig heart mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; RAT-LIVER MITOCHONDRIA; ACYL-COA DEHYDROGENASE; CHAIN; COENZYME; PURIFICATION; ENZYMES; <U-C-14>HEXADECANOATE; DERIVATIVES; THIOLASE	The kinetic properties of the purified trifunctional beta-oxidation complex (TOC) from pig heart mitochondria were analyzed with the aim of elucidating the functional consequence of having three sequentially acting enzymes of beta-oxidation associated in one complex, The kinetic parameters of TOC and of the component enzymes of TOC, long-chain enoyl-CoA hydratase, long-chain 3-hydroxyacyl-CoA dehydrogenase, and long-chain 3-ketoacyl-CoA thiolase, were determined with substrates having acyl chains with 16 carbon atoms, Quantification by high performance liquid chromatography of intermediates formed during the degradation of 2-trans-hexadecanoyl-CoA to myristoyl-CoA and acetyl-CoA by TOC revealed the accumulation of 3-hydroxyhexadecanoyl-CoA, whereas 3-ketohexadecanoyl-CoA was undetectable, The observed rates of NADH and acetyl-CoA formation were higher than the theoretical rates calculated by use of the kinetic parameters and measured concentrations of intermediates, When the sequence of reactions catalyzed by TOC was inhibited by acetyl-CoA, the steady-state concentration of the 3-hydroxyacyl-CoA intermediate was not affected, whereas a small amount of 3-ketohexadecanoyl-CoA was detected, The differences between observed and predicted reaction rates and between measured and expected concentrations of intermediates are best explained by the operation of a channeling mechanism. As a consequence of intermediate channeling between the active sites on the complex, more coenzyme A is available in the mitochondrial matrix and metabolites like 3-ketoacyl-CoA thioesters, which are strong inhibitors of several beta-oxidation enzymes, do not accumulate.	CUNY CITY COLL,DEPT CHEM,NEW YORK,NY 10031	City University of New York (CUNY) System; City College of New York (CUNY)					NCRR NIH HHS [RR03060] Funding Source: Medline; NHLBI NIH HHS [HL18089, HL30847] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030847, R01HL018089] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARPENTER K, 1992, BIOCHEM BIOPH RES CO, V183, P443, DOI 10.1016/0006-291X(92)90501-B; DAVIDSON B, 1982, ARCH BIOCHEM BIOPHYS, V213, P155, DOI 10.1016/0003-9861(82)90450-7; EATON S, 1993, BIOCHEM J, V289, P161, DOI 10.1042/bj2890161; EATON S, 1994, EUR J BIOCHEM, V220, P671, DOI 10.1111/j.1432-1033.1994.tb18668.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FONG JC, 1981, METHOD ENZYMOL, V70, P390; FREUND K, 1985, BIOCHEMISTRY-US, V24, P5996, DOI 10.1021/bi00342a046; GARLAND PB, 1965, BIOCHEM J, V97, P587, DOI 10.1042/bj0970587; GARLAND PB, 1967, MITOCHONDRIAL STRUCT, P385; Greville G D, 1968, Essays Biochem, V4, P155; HANSFORD RG, 1975, J BIOL CHEM, V250, P8361; HE XY, 1992, ARCH BIOCHEM BIOPHYS, V298, P527, DOI 10.1016/0003-9861(92)90445-3; HE XY, 1989, ANAL BIOCHEM, V180, P105, DOI 10.1016/0003-2697(89)90095-X; IZAI K, 1992, J BIOL CHEM, V267, P1027; JIN SJ, 1992, J BIOL CHEM, V267, P119; KLER RS, 1991, J BIOL CHEM, V266, P22932; LUO MJ, 1993, ARCH BIOCHEM BIOPHYS, V304, P266, DOI 10.1006/abbi.1993.1348; NADA MA, 1995, J BIOL CHEM, V270, P530, DOI 10.1074/jbc.270.2.530; POWELL PJ, 1987, BIOCHEMISTRY-US, V26, P3704, DOI 10.1021/bi00386a066; SCHIFFERDECKER J, 1974, LIFE SCI, V14, P1487, DOI 10.1016/0024-3205(74)90159-3; SCHULZ H, 1994, J NUTR, V124, P165, DOI 10.1093/jn/124.2.165; STAACK H, 1978, J BIOL CHEM, V253, P1827; STANLEY KK, 1975, BIOCHEM J, V150, P77, DOI 10.1042/bj1500077; SUMEGI B, 1991, BIOCHIM BIOPHYS ACTA, V1081, P121, DOI 10.1016/0005-2760(91)90016-B; THORPE C, 1986, ANAL BIOCHEM, V155, P391, DOI 10.1016/0003-2697(86)90452-5; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; WANG CS, 1975, ANAL BIOCHEM, V63, P414, DOI 10.1016/0003-2697(75)90363-2; WATMOUGH NJ, 1989, BIOCHEM J, V262, P261, DOI 10.1042/bj2620261	28	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17816	17820		10.1074/jbc.271.30.17816	http://dx.doi.org/10.1074/jbc.271.30.17816			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663442	hybrid			2022-12-27	WOS:A1996UY93500037
J	Kohrman, DC; Harris, JB; Meisler, MH				Kohrman, DC; Harris, JB; Meisler, MH			Mutation detection in the med and med(J) alleles of the sodium channel Scn8a - Unusual splicing due to a minor class AT-AC intron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR ENDPLATE DISEASE; PRE-MESSENGER RNA; SPASTIC MOUSE; L1 ELEMENT; U1 SNRNA; GENE; INSERTION; SEQUENCES; MUSCLE; SITES	Analysis of a transgene-induced mutation at the mouse med locus led to the identification of the novel voltage-gated sodium channel gene Scn8a (Burgess, D, L., Kohrman, D. C., Gait, J., Plummer, N. W,, Jones, J. M., Spear, B,, and Meisler, M. H. (1995) Naf. Genet. 10, 461-465), We now report the identification of splicing defects in two spontaneous mutations of Scn8a, The original med mutation was caused by insertion of a truncated LINE element into exon 2 of Scn8a, The med transcript is spliced from exon 1 to a cryptic acceptor site in intron 2. A I-base pair deletion within the 5' donor site of exon 3 in the med(J) allele results in splicing from exon 1 to exon 4, Both mutant transcripts have altered reading frames with premature stop codons close to the N terminus of the protein. Loss of Scn8a expression results in progressive paralysis and early death, Intron 2 of Scn8a is flanked by minor class AT-AC splice sites, The observed splicing patterns of the med and med(J) mutant transcripts provide the first evidence for preferential in vivo splicing between donor and acceptor sites of the same class, The apparent functional incompatibility may be a consequence of the different composition of spliceosomes bound to major and minor splice sites.	UNIV MICHIGAN,DEPT HUMAN GENET,SCH MED,ANN ARBOR,MI 48109; NEWCASTLE GEN HOSP,REG NEUROL CTR,MUSCULAR DYSTROPHY GRP,RES LABS,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	University of Michigan System; University of Michigan; Newcastle General Hospital					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024872] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24872] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANGAUTPETIT D, 1982, PROC R SOC SER B-BIO, V215, P117, DOI 10.1098/rspb.1982.0031; BEECHEY CV, 1984, MOUSE NEWS LETT, V71, P28; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BURGESS DL, 1995, NAT GENET, V10, P461, DOI 10.1038/ng0895-461; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; DICK DJ, 1985, NEUROPATH APPL NEURO, V11, P141; DOMBROSKI BA, 1991, SCIENCE, V254, P1805, DOI 10.1126/science.1662412; Duchen L. W., 1967, J PHYSL, V189, P4; DUCHEN LW, 1971, J PHYSIOL-LONDON, V212, P535, DOI 10.1113/jphysiol.1971.sp009340; FURDON PJ, 1988, MOL CELL BIOL, V8, P860, DOI 10.1128/MCB.8.2.860; GEORGE AL, 1993, GENOMICS, V15, P598, DOI 10.1006/geno.1993.1113; GOLDSTEIN LA, 1996, EXP NEUROL, V139, P328; GREEN M, 1989, CATALOG MUTANT GENES, P234; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; Hall SL, 1996, SCIENCE, V271, P1716, DOI 10.1126/science.271.5256.1716; HARRIS JB, 1974, EXP NEUROL, V42, P169, DOI 10.1016/0014-4886(74)90015-6; HARRIS JB, 1986, J NEUROL SCI, V76, P239, DOI 10.1016/0022-510X(86)90172-3; HARRIS JB, 1992, J NEUROL SCI, V110, P186, DOI 10.1016/0022-510X(92)90027-I; HILLE B, 1992, IONIC CHANNELS EXCIT, P525; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; HUTCHISON CA, 1983, MOBILE GENETIC ELEME, P593; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; KOHRMAN DC, 1995, GENOMICS, V26, P171, DOI 10.1016/0888-7543(95)80198-U; KRAWCZAK M, 1991, HUM GENET, V86, P425; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; MCCLATCHEY AI, 1992, HUM MOL GENET, V1, P521; MULHARDT C, 1994, NEURON, V13, P1003, DOI 10.1016/0896-6273(94)90265-8; NAKAI K, 1994, GENE, V141, P171, DOI 10.1016/0378-1119(94)90567-3; NARITA N, 1993, J CLIN INVEST, V91, P1962; SCHALLER KL, 1995, J NEUROSCI, V15, P3231; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sidman R L, 1979, Ann N Y Acad Sci, V317, P497, DOI 10.1111/j.1749-6632.1979.tb37382.x; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; STEPHENS RM, 1992, J MOL BIOL, V228, P1124, DOI 10.1016/0022-2836(92)90320-J; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; WEINSTEIN SP, 1980, J PHYSIOL-LONDON, V307, P453, DOI 10.1113/jphysiol.1980.sp013446; ZACKS SI, 1977, LAB INVEST, V36, P303; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	44	122	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17576	17581		10.1074/jbc.271.29.17576	http://dx.doi.org/10.1074/jbc.271.29.17576			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663325	hybrid			2022-12-27	WOS:A1996UX94300089
J	Reed, RB; Sandberg, M; Jahnsen, T; Lohmann, SM; Francis, SH; Corbin, JD				Reed, RB; Sandberg, M; Jahnsen, T; Lohmann, SM; Francis, SH; Corbin, JD			Fast and slow cyclic nucleotide-dissociation sites in cAMP-dependent protein kinase are transposed in type I beta cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ACTIVATOR PROTEIN; PIG CORONARY-ARTERIES; AMINO-ACID-SEQUENCE; BINDING-SITES; REGULATORY SUBUNIT; BOVINE AORTA; PREDICTED STRUCTURES; EXPRESSION; RESOLUTION; DOMAINS	Both cyclic GMP-dependent protein kinase (cGK) and cyclic AMP-dependent protein kinase (cAK) contain two distinct cyclic nucleotide-binding sites referred to as fast and slow sites based on cyclic nucleotide dissociation behavior, In cAK, the fast site lies amino-terminal to the slow site, and sequence homologies between cAK and cGK have suggested similar positioning for the sites in cGK, Recombinant human type I beta cGK (wild type (WT) cGK) was overexpressed, and the properties of purified WT cGK and native type I beta cGK were similar, cGK was mutated singly at Thr-193 (T193A, T193V, and T193S) and Thr-317 (T317A, T317V, and T317S), which have been predicted to provide cGMP specificity in the cGMP-binding sites of cGK; a double mutant (T193A/T317A) was produced also, Compared with WT cGK, half-maximal activation (K-alpha) of mutant cGKs by cGMP was increased 2- (T317A), 27- (T193A), or 63-fold (T193A/T317A), but the K-alpha for cAMP of these mutants was essentially unchanged, The T193A and T193V mutants had a large increase in the rate of the slow component of [H-3]cGMP dissociation, but in the T317A and T317V mutants, there was no change in the slow component, The T193S and T317S mutants had only minor effects on [H-3]cGMP dissociation, thus establishing the importance of the hydroxyl group of Thr-193 and -317 for cGMP binding to cGK, Thus, in type IP cGK, the slow cGMP-binding site is identified as the amino-terminal site in contrast to the order assigned to the fast and slow cAMP-binding sites of cAK.	VANDERBILT UNIV, SCH MED, DEPT PHYSIOL & MOLEC BIOPHYS, NASHVILLE, TN 37232 USA; UNIV OSLO, INST MED BIOCHEM, N-0317 OSLO, NORWAY; UNIV WURZBURG, MED CLIN, LAB CLIN BIOCHEM, D-8700 WURZBURG, GERMANY	Vanderbilt University; University of Oslo; University of Wurzburg				Sandberg, Marten/0000-0002-4812-0103	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007563, R01DK040029] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40029, 5T32DK07563-05] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTENHOFEN W, 1991, P NATL ACAD SCI USA, V88, P9868, DOI 10.1073/pnas.88.21.9868; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUBIS J, 1987, BIOCHEMISTRY-US, V26, P3478, DOI 10.1021/bi00386a035; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; CORBIN JD, 1986, J BIOL CHEM, V261, P1208; CORBIN JD, 1981, J BIOL CHEM, V256, P1671; DOSKELAND SO, 1978, BIOCHEM BIOPH RES CO, V83, P542, DOI 10.1016/0006-291X(78)91024-0; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; DOSKELAND SO, 1983, BIOCHEMISTRY-US, V22, P1094; DOSKELAND SO, 1987, J BIOL CHEM, V262, P3534; ELHUSSEINI AED, 1995, J NEUROCHEM, V64, P2814; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P332; GLASS DB, 1982, J BIOL CHEM, V257, P1196; HOFMANN F, 1985, EUR J BIOCHEM, V147, P361, DOI 10.1111/j.1432-1033.1985.tb08758.x; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; JIANG H, 1992, J BIOL CHEM, V267, P1015; KUMAR VD, 1992, BIOCHEMISTRY-US, V31, P4643, DOI 10.1021/bi00134a015; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; MCKAY DB, 1982, J BIOL CHEM, V257, P9518; OGREID D, 1981, FEBS LETT, V129, P287, DOI 10.1016/0014-5793(81)80185-8; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P161; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; RANNELS SR, 1983, METHOD ENZYMOL, V99, P168; RANNELS SR, 1980, J BIOL CHEM, V255, P7085; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5468; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SHABB JB, 1991, J BIOL CHEM, V266, P24320; SHABB JB, 1990, J BIOL CHEM, V265, P16031; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; UHLER MD, 1993, J BIOL CHEM, V268, P13586; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WOLFE L, 1989, J BIOL CHEM, V264, P7734; WOLFE L, 1989, J BIOL CHEM, V264, P4157; WOODFORD TA, 1989, J BIOL CHEM, V264, P13321; ZORN M, 1995, FEBS LETT, V362, P291, DOI 10.1016/0014-5793(95)00261-7	46	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17570	17575		10.1074/jbc.271.29.17570	http://dx.doi.org/10.1074/jbc.271.29.17570			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663415	hybrid			2022-12-27	WOS:A1996UX94300088
J	Brady, WA; Kokoris, MS; Fitzgibbon, M; Black, ME				Brady, WA; Kokoris, MS; Fitzgibbon, M; Black, ME			Cloning, characterization, and modeling of mouse and human guanylate kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSOR GENE; PROTEIN; PHOSPHORYLATION; MONOPHOSPHATE; SEQUENCE; HOMOLOG; PRODUCT; BRAIN; YEAST; GMP	Guanylate kinase catalyzes the phosphorylation of either GMP to GDP or dGMP to dGDP and is an essential enzyme in nucleotide metabolism pathways, Despite its involvement in antiviral drug activation in humans and in mouse model systems and as a target for chemotherapy, the human and mouse primary structures have never been elucidated, Full-length cDNA clones encoding enzymatically active guanylate kinase were isolated from mouse B-cell lymphoma and human peripheral blood lymphocyte cDNA libraries, Multiple tissue Northern blots demonstrated an mRNA species of approximately 1 kilobase for both mice and humans in all tissue types examined, The mouse cDNA is predicted to encode a 198-amino acid protein with a molecular mass of 21,904 daltons, The human cDNA is predicted to encode a 197-amino acid protein with a molecular mass of 21,696 daltons, These proteins share 88% sequence identity with each other and 52-54% identity with the yeast guanylate kinase. Molecular modeling using the yeast diffraction coordinates indicates a high degree of conservation within the active site and maintenance of the overall structural integrity, despite a lack of similarity along the periphery of the enzyme.	DARWIN MOLEC CORP,BOTHELL,WA 98021									Agarwal K C, 1978, Methods Enzymol, V51, P483; BERGER A, 1989, EUR J BIOCHEM, V184, P433, DOI 10.1111/j.1432-1033.1989.tb15035.x; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; BOEHME RE, 1984, J BIOL CHEM, V259, P2346; BRYANT PJ, 1992, CELL, V68, P621, DOI 10.1016/0092-8674(92)90136-Z; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALLAPICCOLA B, 1980, ANN GENET-PARIS, V23, P83; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; GAIDAROV IO, 1993, FEBS LETT, V335, P81, DOI 10.1016/0014-5793(93)80444-Y; GENTRY D, 1993, J BIOL CHEM, V268, P14316; Harlow E., 1988, ANTIBODIES LAB MANUA; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Kawasaki E S, 1990, AMPLIFICATION RNA PC, P21; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KONRAD M, 1992, J BIOL CHEM, V267, P25652; MIECH RP, 1969, MOL PHARMACOL, V5, P30; MILLER WH, 1980, J BIOL CHEM, V255, P7204; Mueller Bettina M., 1995, Journal of Neuroscience, V15, P2354; NAVE JF, 1992, ARCH BIOCHEM BIOPHYS, V295, P253, DOI 10.1016/0003-9861(92)90515-X; PAPPU HR, 1988, FOCUS IDAHO, V11, P6; Sambrook J., 2002, MOL CLONING LAB MANU; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZSCHOCKE PD, 1993, EUR J BIOCHEM, V213, P263, DOI 10.1111/j.1432-1033.1993.tb17757.x	27	44	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16734	16740		10.1074/jbc.271.28.16734	http://dx.doi.org/10.1074/jbc.271.28.16734			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663313	hybrid			2022-12-27	WOS:A1996UX12600050
J	Gao, BC; Eisenberg, E; Greene, L				Gao, BC; Eisenberg, E; Greene, L			Effect of constitutive 70-kDa heat shock protein polymerization on its interaction with protein substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE BIP; UNCOATING ATPASE; COATED VESICLES; CLATHRIN; DISSOCIATION; GRP78	Constitutive 70-kDa heat shock protein (hsc70) is a mixture of monomers and oligomers in ADP, while in ATP it is monomeric unless certain DnaJ homologs are present which induce hsc70 to form large polymers in an ATP-dependent reaction. A key question regarding polymerized hsc70 is whether it is able to bind protein substrates. Polymerized BiP, the hsc70 present in the endoplasmic reticulum, has been found to bind substrates in vitro although substrates appear to bind only to monomeric BiP in vivo. In this study, we investigated whether substrate binds to polymerized cytoplasmic hsc70 in vitro. Although both stoichiometric ATP and high concentrations of cytochrome c peptide monomerized hsc70, direct binding studies provided no evidence that cytochrome c peptide binds to polymerized hsc70. Furthermore, the time course of cytochrome c peptide and clathrin binding to hsc70 suggested that rather than binding to polymerized hsc70, they monomerized it by reducing free monomer, thereby shifting the monomer-polymer equilibrium toward monomer. We conclude that peptide and protein substrates bind at least an order of magnitude more weakly to polymerized hsc70 than to monomer, suggesting that polymerization of hsc70 in vivo, perhaps by DnaJ homologs, may store it in an inactive form.			Gao, BC (corresponding author), NHLBI,CELL BIOL LAB,NIH,BLDG 3,ROOM B1-22,3 CTR DR,MSC,BETHESDA,MD 20892, USA.							BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BROT N, 1994, P NATL ACAD SCI USA, V91, P12120, DOI 10.1073/pnas.91.25.12120; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; CHEETHAM ME, 1994, EUR J BIOCHEM, V226, P99, DOI 10.1111/j.1432-1033.1994.tb20030.x; CYR DM, 1992, J BIOL CHEM, V267, P20927; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GAO BC, 1991, J BIOL CHEM, V266, P19565; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; GAO BC, 1993, J BIOL CHEM, V268, P8507; GAO BC, 1995, BIOCHEMISTRY-US, V34, P11882, DOI 10.1021/bi00037a028; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; GREENE LE, 1990, J BIOL CHEM, V265, P6682; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; King C., 1995, Molecular Biology of the Cell, V6, p411A; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; PALLEROS DR, 1993, FEBS LETT, V336, P124, DOI 10.1016/0014-5793(93)81624-9; PRASAD K, 1994, J BIOL CHEM, V269, P6931; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; TOLEDO H, 1993, P NATL ACAD SCI USA, V90, P2505, DOI 10.1073/pnas.90.6.2505; UNANUE ER, 1995, J BIOL CHEM, V270, P26670	25	52	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16792	16797		10.1074/jbc.271.28.16792	http://dx.doi.org/10.1074/jbc.271.28.16792			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663341	hybrid			2022-12-27	WOS:A1996UX12600058
J	Schrock, RD; Alberts, B				Schrock, RD; Alberts, B			Processivity of the gene 41 DNA helicase at the bacteriophage T4 DNA replication fork	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA PRIMER SYNTHESIS; LEADING-STRAND; PROTEINS; POLYMERASE; APPARATUS; TEMPLATE; SEQUENCE; INVITRO; STARTS; SYSTEM	The gene 41 protein is the DNA helicase associated with the bacteriophage T4 DNA replication fork. This protein is a major component of the primosome, being essential for coordinated leading and lagging strand DNA synthesis, Models suggest that such DNA helicases are loaded only onto DNA at origins of replication, and that they remain with the ensuing replication fork until replication is terminated. To test this idea, we have measured the extent of processivity of the 41 protein in the context of an in vitro DNA replication system composed of eight purified proteins (the gene 43, 44/62, 45, 32, 41, 59, and 61 proteins), After starting DNA replication in the presence of these proteins, we diluted the 41 helicase enough to prevent any association of new helicase molecules and analyzed the replication products, We measured an association half-life of 11 min, revealing that the 41 protein is processive enough to finish replicating the entire 169-kilobase T4 genome at the observed replication rate of similar to 400 nucleotides/s. This processivity of the 41 protein does not require the 59 protein, the protein that catalyzes 41 protein assembly onto 32 protein-covered single-stranded DNA, The stability we measure for the 41 protein as part of the replication fork is greater than estimated for it alone on single-stranded DNA, We suggest that the 41 protein interacts with the polymerase holoenzyme at the fork, both stabilizing the other protein components and being stabilized thereby.			Schrock, RD (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024020, R37GM024020] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; ALBERTS BM, 1980, ICN UCLA S MOL CELL, V19, P449; BARRY J, 1994, J BIOL CHEM, V269, P33063; BARRY J, 1994, J BIOL CHEM, V269, P33049; BEDINGER P, 1983, CELL, V34, P115, DOI 10.1016/0092-8674(83)90141-1; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1989, J BIOL CHEM, V264, P12220; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; EPSTEIN RH, 1963, COLD SPRING HARB SYM, V28, P375, DOI 10.1101/SQB.1963.028.01.053; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; HUANG CC, 1981, J BIOL CHEM, V256, P4087; KORNBERG A, 1992, DNA REPLICATION, P275; KREUZER KN, 1994, MOL BIOL BACTERIOPHA, P28; LIU CC, 1981, J BIOL CHEM, V256, P2813; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; LIU CC, 1981, J BIOL CHEM, V256, P2821; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; NAKAI H, 1988, J BIOL CHEM, V263, P9818; Nossal Nancy G., 1994, P43; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; WERNER R, 1968, J MOL BIOL, V33, P679, DOI 10.1016/0022-2836(68)90313-6; WU CA, 1992, J BIOL CHEM, V267, P4030; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100	30	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16678	16682		10.1074/jbc.271.28.16678	http://dx.doi.org/10.1074/jbc.271.28.16678			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663273	hybrid			2022-12-27	WOS:A1996UX12600042
J	Verkruyse, LA; Hofmann, SL				Verkruyse, LA; Hofmann, SL			Lysosomal targeting of palmitoyl-protein thioesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; INFANTILE TYPE; PURIFICATION; RECEPTOR; STORAGE	Palmitoyl-protein thioesterase is a newly described long chain fatty-acid hydrolase that removes fatty acyl groups from modified cysteines in proteins. We have recently identified palmitoyl-protein thioesterase as the defective enzyme in the recessive hereditary neurological degenerative disorder infantile neuronal ceroid Lipofuscinosis (Vesa, J., Hellsten, E., Verkruyse, L. A., Camp, L. A. Rapola, J., Santavuori, P., Hofmann, S. L., and Peltonen, L. (1995) Nature 376, 584-587). A defect in a lysosomal enzyme had been postulated for the disease, but until recently, the relevant defective lysosomal enzyme had not been identified. In this paper, we present evidence for the lysosomal localization of palmitoyl-protein thioesterase. We show that COS cells take up exogenously supplied palmitoyl-protein thioesterase intracellularly and that the cellular uptake is blocked by mannose 6-phosphate, a hallmark of lysosomal enzyme trafficking. The enzyme contains endoglycosidase H-sensitive oligosaccharides that contain phosphate groups. Furthermore, palmitoyl-protein thioesterase cosediments with lysosomal enzyme markers by Percoll density gradient centrifugation. Interestingly, the pH optimum for the enzyme is in the neutral range, a property shared by two other lysosomal enzymes that remove post-translational protein modifications. These findings suggest that palmitoyl-protein thioesterase is a lysosomal enzyme and that infantile neuronal ceroid lipofuscinosis is properly classified as a lysosomal storage disorder.	UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL CANCER INSTITUTE [R01CA061823] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armstrong D, 1981, AGE PIGMENTS, P355; BUTOR C, 1995, J CELL SCI, V108, P2213; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; HALTIA M, 1973, J NEUROL SCI, V18, P269, DOI 10.1016/0022-510X(73)90076-2; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HIGA HH, 1989, J BIOL CHEM, V264, P19435; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; RAPOLA J, 1973, BRAIN, V96, P833, DOI 10.1093/brain/96.4.833; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; SANTAVUORI P, 1974, DEV MED CHILD NEUROL, V16, P644; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TAYAMA M, 1992, J MOL NEUROSCI, V3, P171, DOI 10.1007/BF03380135; TOLLERSRUD OK, 1989, BIOCHEM J, V260, P101, DOI 10.1042/bj2600101; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYYNELA J, 1993, FEBS LETT, V330, P8, DOI 10.1016/0014-5793(93)80908-D; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; WEDEGAERTNER P, 1994, FASEB J, V8, pA1430; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001	28	203	205	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15831	15836		10.1074/jbc.271.26.15831	http://dx.doi.org/10.1074/jbc.271.26.15831			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663305	hybrid			2022-12-27	WOS:A1996UV29900079
J	Jacob, M; Weech, PK; Salesse, C				Jacob, M; Weech, PK; Salesse, C			Presence of a light-independent phospholipase A(2) in bovine retina but not in rod outer segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT EPITHELIAL-CELLS; CYTOSOLIC PHOSPHOLIPASE-A2; MOLECULAR MECHANISM; G-PROTEINS; PURIFICATION; MEMBRANES; RAT; TRANSDUCIN; ACTIVATION; INHIBITION	Rod outer segments (ROS) are responsible for the visual transduction process, Rhodopsin, which constitutes 85-90% of ROS proteins, absorbs light photons, changes its conformation, and then binds to a heterotrimeric G-protein called transducin, As a consequence, transducin dissociates into T alpha and T beta gamma subunits, The presence in ROS of a phospholipase A, (PLA,) stimulated by light and guanosine 5'-O-(3-thio)triphosphate was first demonstrated in 1987 (Jelsema, C. L. (1987) J. Biol, Chem, 262, 163-168), This led that author to conclude that ROS PLA(2) could be involved in the phototransduction process, and raised the possibility of receptor-mediated activation of PLA(2) via G-proteins in cell types other than rods, However, the biochemical characteristics and the role of this PLA(2) have not been fully elucidated, We have tried to reproduce some of the results previously reported in order to further characterize this enzyme, We have found that, in our hands, there is neither light-dependent nor GTP-dependent PLA(2) activity in intact purified ROS, We also failed to detect PLA(2) activity in those ROS preparations, Nevertheless, we detected significant amounts of PLA(2) activity in two subretinal fractions adjacent to ROS: RPE (enriched with retinal pigment epithelial cells) and P200 (presumably containing neuronal cells, Muller cells, and rod inner segments), The enzyme present both in RPE and P200 is light- and GTP-independent, Ca2+- and Mg2+-independent, and seems to be optimally active in the alkaline pH range, Our results suggest that there is, if any, vanishingly little PLA(2) or PLA(1) activity in intact purified ROS and that the activity levels previously reported in the literature could have been due to a contamination by either RPE or P200. This is supported by our observation that some contaminated ROS preparations were ''PLA(2) active.''	UNIV QUEBEC,CTR RECH PHOTOBIOPHYS,TROIS RIVIERES,PQ G9A 5H7,CANADA; MERCK FROSST CTR THERAPEUT RES,POINTE CLAIRE,PQ M9R 4P8,CANADA	University of Quebec; University of Quebec Trois Rivieres; Merck & Company				Salesse, Christian/0000-0003-1795-7338				APITZCASTRO RJ, 1979, BIOCHEM BIOPH RES CO, V91, P63, DOI 10.1016/0006-291X(79)90583-7; AXELROD J, 1995, TRENDS NEUROSCI, V18, P64; BERMAN ER, 1974, INVEST OPHTH VISUAL, V13, P675; CASTAGNET PI, 1993, EXP EYE RES, V56, P709, DOI 10.1006/exer.1993.1088; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; FEENEYBURNS L, 1982, METHOD ENZYMOL, V81, P95; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; GARDINER FJ, 1968, ELECTROOPTICS HDB CO; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; HARGRAVE PA, 1993, METHODS NEUROSCI, V15; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HELLER J, 1980, EXP EYE RES, V30, P481, DOI 10.1016/0014-4835(80)90032-9; HIRASHIMA Y, 1992, J NEUROCHEM, V59, P708, DOI 10.1111/j.1471-4159.1992.tb09426.x; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; JELSEMA CL, 1987, J BIOL CHEM, V262, P163; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; JORDAN LM, 1992, J CHROMATOGR, V597, P299, DOI 10.1016/0021-9673(92)80124-D; JUNG H, 1994, GRAEF ARCH CLIN EXP, V232, P167, DOI 10.1007/BF00176787; KRAMER RM, 1978, BIOCHIM BIOPHYS ACTA, V507, P381, DOI 10.1016/0005-2736(78)90348-6; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KREBS W, 1977, EXP EYE RES, V25, P511, DOI 10.1016/0014-4835(77)90180-4; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; MARSHALL LA, 1992, BIOCHEM PHARMACOL, V44, P1849, DOI 10.1016/0006-2952(92)90081-S; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MCCONNELL DG, 1981, J BIOL CHEM, V256, P4913; MCDOWELL JH, 1977, BIOCHEMISTRY-US, V16, P4054, DOI 10.1021/bi00637a018; MILJANICH GP, 1978, THESIS U CALIFORNIA; NEAGOS GR, 1993, AM J PHYSIOL, V264, pL261, DOI 10.1152/ajplung.1993.264.3.L261; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; New R.R.C., 1990, LIPOSOMES PRACTICAL, P44; PETIT K, 1992, BIOCHIM BIOPHYS ACTA, V1125, P150, DOI 10.1016/0005-2760(92)90039-X; PFISTER C, 1993, CELL SIGNAL, V5, P235, DOI 10.1016/0898-6568(93)90015-E; PIND S, 1987, BIOCHIM BIOPHYS ACTA, V901, P78, DOI 10.1016/0005-2736(87)90258-6; RAUBACH RA, 1974, VISION RES, V14, P335, DOI 10.1016/0042-6989(74)90092-3; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; RONKKO S, 1992, INT J BIOCHEM, V24, P869, DOI 10.1016/0020-711X(92)90091-E; SALESSE C, 1984, ANAL BIOCHEM, V142, P258, DOI 10.1016/0003-2697(84)90462-7; SCHNETKAMP PPM, 1981, BIOCHIM BIOPHYS ACTA, V672, P307, DOI 10.1016/0304-4165(81)90298-1; SEHRAN CN, 1994, BIOCHIM BIOPHYS ACTA, V1212, P1; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3; ULEVITCH RJ, 1988, J BIOL CHEM, V263, P3079; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; ZIMMERMAN WF, 1982, METHOD ENZYMOL, V81, P52; ZIMMERMAN WF, 1988, EXP EYE RES, V47, P247, DOI 10.1016/0014-4835(88)90008-5; Zinn K., 1979, RETINAL PIGMENT EPIT, P3	50	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19209	19218		10.1074/jbc.271.32.19209	http://dx.doi.org/10.1074/jbc.271.32.19209			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702600	hybrid			2022-12-27	WOS:A1996VB68400034
J	Mitchell, DC; Lawrence, JTR; Litman, BJ				Mitchell, DC; Lawrence, JTR; Litman, BJ			Primary alcohols modulate the activation of the G protein-coupled receptor rhodopsin by a lipid-mediated mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN PHOSPHATIDYLCHOLINE VESICLES; HIGHER-ORDER ANALYSIS; METARHODOPSIN-II; ACETYLCHOLINE-RECEPTOR; RECOMBINANT MEMBRANES; GENERAL-ANESTHETICS; ANISOTROPY DECAY; EQUILIBRIUM; BOVINE; CHOLESTEROL	The visual pigment rhodopsin is a prototypical member of the G protein-coupled receptor superfamily. In this study, we have investigated the effect of a series of n-alcohols on the formation of metarhodopsin II (MII), the photoactivated conformation of rhodopsin, which binds and activates transducin. When rhodopsin was photolyzed in the presence of several n-alcohols, increased MII formation was observed in the order ethanol > butanol > hexanol, whereas longer chain n-alcohols inhibited MII formation with decanol > octanol, The magnitude of the stimulatory effects was greater in a more highly unsaturated phospholipid, Alcohols, which enhanced MII formation also increased phospholipid acyl chain packing free volume, while those that decreased this bilayer property inhibited MII formation, An apparent discontinuity in the effect of these alcohols results when their potency is calculated in terms of the total aqueous alcohol concentration. In sharp contrast, a continuous variation in their behavior is observed, when their potency is calculated in terms of the amount of alcohol partitioned in the membrane, Our findings strongly support a lipid-mediated mechanism of action for alcohols on rhodopsin and, by analogy, for other G protein-coupled receptors.	NIAAA,SECT FLUORESCENCE STUDIES,LAB MEMBRANE BIOCHEM & BIOPHYS,DIV INTRAMURAL CLIN & BIOL RES,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)								[Anonymous], [No title captured]; APPLEBURY ML, 1984, VISION RES, V24, P1445, DOI 10.1016/0042-6989(84)90305-5; ATTWOOD PV, 1980, FEBS LETT, V119, P323, DOI 10.1016/0014-5793(80)80281-X; BARRY JA, 1994, BIOCHEMISTRY-US, V33, P8082, DOI 10.1021/bi00192a013; CHIN JJ, 1977, MOL PHARMACOL, V13, P4352; COVARRUBIAS M, 1995, J BIOL CHEM, V270, P19408, DOI 10.1074/jbc.270.33.19408; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; FIRESTONE LL, 1994, MOL PHARMACOL, V46, P508; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; GIBSON NJ, 1993, BIOCHEMISTRY-US, V32, P2438, DOI 10.1021/bi00060a040; JACKSON ML, 1985, BIOCHIM BIOPHYS ACTA, V812, P369, DOI 10.1016/0005-2736(85)90311-6; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; LI CY, 1994, P NATL ACAD SCI USA, V91, P8200, DOI 10.1073/pnas.91.17.8200; LITMAN BJ, 1982, METHOD ENZYMOL, V81, P150; Litman BJ, 1996, LIPIDS, V31, pS193, DOI 10.1007/BF02637075; MATHEWS RG, 1963, J GEN PHYSIOL, V47, P215; MCCREERY MJ, 1978, NEUROPHARMACOLOGY, V17, P451, DOI 10.1016/0028-3908(78)90050-3; MCKENZIE D, 1995, BRIT J PHARMACOL, V115, P275, DOI 10.1111/j.1476-5381.1995.tb15874.x; Meyer H, 1901, ARCH EXP PATHOL PHAR, V46, P338, DOI 10.1007/BF01978064; MILLER KW, 1989, P NATL ACAD SCI USA, V86, P1084, DOI 10.1073/pnas.86.3.1084; MILLER KW, 1985, INT REV NEUROBIOL, V270, P1; MITCHELL DC, 1992, BIOCHEMISTRY-US, V31, P662, DOI 10.1021/bi00118a005; MITCHELL DC, 1994, BIOCHEMISTRY-US, V33, P12752, DOI 10.1021/bi00209a004; MITCHELL DC, 1990, BIOCHEMISTRY-US, V29, P9143, DOI 10.1021/bi00491a007; OBRIEN DF, 1977, BIOCHEMISTRY-US, V16, P1295, DOI 10.1021/bi00626a009; Overton E., 1901, STUDIEN NARKOSE; SLATER SJ, 1993, NATURE, V364, P82, DOI 10.1038/364082a0; SMITH HG, 1982, METHOD ENZYMOL, V81, P57; STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3; STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5121, DOI 10.1021/bi00390a034; STRAUME M, 1990, BIOCHEMISTRY-US, V29, P9135, DOI 10.1021/bi00491a006; STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5113, DOI 10.1021/bi00390a033; WIEDMANN TS, 1988, BIOCHEMISTRY-US, V27, P6469, DOI 10.1021/bi00417a041	34	66	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19033	19036		10.1074/jbc.271.32.19033	http://dx.doi.org/10.1074/jbc.271.32.19033			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702573	hybrid			2022-12-27	WOS:A1996VB68400007
J	Hemenway, CS; Heitman, J				Hemenway, CS; Heitman, J			Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-ALPHA; CYCLOPHILIN HOMOLOG NINAA; HAMSTER OVARY CELLS; MULTIDRUG-RESISTANCE; SACCHAROMYCES-CEREVISIAE; CYCLOSPORINE-A; STE6 GENE; SIGNAL-TRANSDUCTION; MAMMALIAN PROTEIN; RECEPTOR COMPLEX	The mammalian P-glycoprotein (Pgp) is a similar to 170-kDa membrane protein that mediates multidrug resistance in many chemotherapy-resistant tumors by effluxing toxic compounds from the cell, Pgp homologs are expressed in many organisms, from bacteria to yeast and mammals, Previous studies established a model system to analyze the function of murine, human, and Plasmodium falciparum Pgp by heterologous expression in the yeast Saccharomyces cerevisiae, However, such studies have been hampered by the inherent resistance of yeast cells to chemotherapeutic agents, We find that an erg6 mutation, which blocks the final synthetic step of the membrane sterol ergosterol, renders yeast sensitive to anthracyclines and dactinomycin, clinically relevant Pgp substrates, We demonstrate that expression of the murine mdr3 gene confers dactinomycin resistance in both the erg6 mutant yeast strain and in an erg6 rad52 DNA repair mutant yeast strain, Similarly, murine mdr3 expression confers resistance to the immunosuppressants cyclosporin A (CsA) and FK506 in a CsA-FR506-sensitive vph6 mutant yeast strain, CsA and FK506 are known to partially overcome Pgp-mediated drug resistance, suggesting the targets of these drugs might regulate Pgp function, We find that both murine mdr3 and the yeast Pgp homolog STE6 function in yeast mutants lacking the CsA target proteins cyclophilin A and calcineurin, In contrast, murine mdr3 function was severely compromised in yeast mutants lacking the FK506/rapamycin target protein FKBP12. Both wild-type FKBP12 and an F43Y FKBP12 mutant with reduced prolyl isomerase activity supported mdr3 function, Our results support the model that immunosuppressants reverse multidrug resistance by competing with other Pgp substrates but reveal that inhibition of FKBP12-dependent Pgp function may also contribute to reversal of multidrug resistance by FK506 and rapamycin.	DUKE UNIV,MED CTR,DEPT GENET,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	Duke University; Duke University; Duke University; Howard Hughes Medical Institute; Duke University			Heitman, Joseph/ABC-6006-2021		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007031] Funding Source: NIH RePORTER; NIEHS NIH HHS [5 T32 ES07031-15] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AHMAD S, 1993, MOL PHARMACOL, V43, P858; AHMAD S, 1994, BIOCHEMISTRY-US, V33, P10313, DOI 10.1021/bi00200a011; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALLIKMETS R, 1993, LEUKEMIA, V7, P513; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; ARCECI RJ, 1992, BLOOD, V80, P1528; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BATES SE, 1993, BIOCHEMISTRY-US, V32, P9156, DOI 10.1021/bi00086a022; BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BREUDER T, 1994, P NATL ACAD SCI USA, V91, P5372, DOI 10.1073/pnas.91.12.5372; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; Cardenas Maria E., 1994, Perspectives in Drug Discovery and Design, V2, P103, DOI 10.1007/BF02171739; CARDENAS ME, 1995, EMBO J, V14, P2772, DOI 10.1002/j.1460-2075.1995.tb07277.x; CARDENAS ME, 1995, J BIOL CHEM, V270, P20997, DOI 10.1074/jbc.270.36.20997; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; CHAMBERS TC, 1992, MOL PHARMACOL, V41, P1008; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; DENOBEL JG, 1991, YEAST, V7, P313, DOI 10.1002/yea.320070402; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; ENG WK, 1988, MOL PHARMACOL, V34, P755; EPAND RF, 1991, ANTI-CANCER DRUG DES, V6, P189; FOOR F, 1992, NATURE, V360, P682; FOXWELL BMJ, 1989, MOL PHARMACOL, V36, P543; GABER RF, 1989, MOL CELL BIOL, V9, P3447, DOI 10.1128/MCB.9.8.3447; GAVERIAUX C, 1989, BRIT J CANCER, V60, P867, DOI 10.1038/bjc.1989.381; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; HAMADA H, 1987, CANCER RES, V47, P2860; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1992, NEW BIOL, V4, P448; HEMENWAY CS, 1995, GENETICS, V141, P833; JACHEZ B, 1993, ANTI-CANCER DRUG, V4, P223, DOI 10.1097/00001813-199304000-00015; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KUCHLER K, 1992, P NATL ACAD SCI USA, V89, P2302, DOI 10.1073/pnas.89.6.2302; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LARSSON R, 1992, ANTICANCER RES, V12, P1581; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; MIZUNO K, 1992, ANTICANCER RES, V12, P21; NAITO M, 1992, CANCER CHEMOTH PHARM, V29, P195, DOI 10.1007/BF00686252; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; ORR GA, 1993, J BIOL CHEM, V268, P25054; POURTIERMANZANEDO A, 1991, ANTI-CANCER DRUG, V2, P279, DOI 10.1097/00001813-199106000-00010; RAO US, 1994, MOL PHARMACOL, V45, P773; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RAYMOND M, 1994, MOL CELL BIOL, V14, P277, DOI 10.1128/MCB.14.1.277; Rose MD., 1990, METHODS YEAST GENETI; Ruetz S, 1996, J BIOL CHEM, V271, P4154; RUETZ S, 1993, P NATL ACAD SCI USA, V90, P11588, DOI 10.1073/pnas.90.24.11588; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SABATINI DM, 1995, J BIOL CHEM, V270, P20875, DOI 10.1074/jbc.270.36.20875; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SAEKI T, 1991, AGR BIOL CHEM TOKYO, V55, P1859, DOI 10.1080/00021369.1991.10870860; SAEKI T, 1993, J BIOL CHEM, V268, P6077; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; TAMAI I, 1990, J BIOL CHEM, V265, P16509; TIMERMAN AP, 1995, J BIOL CHEM, V270, P2451, DOI 10.1074/jbc.270.6.2451; TWENTYMAN PR, 1988, BRIT J CANCER, V57, P254, DOI 10.1038/bjc.1988.55; TWENTYMAN PR, 1987, BRIT J CANCER, V56, P55, DOI 10.1038/bjc.1987.153; VOLKMAN SK, 1995, P NATL ACAD SCI USA, V92, P8921, DOI 10.1073/pnas.92.19.8921; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263; ZHU DH, 1995, J BIOL CHEM, V270, P24831, DOI 10.1074/jbc.270.42.24831; [No title captured]	76	49	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18527	18534		10.1074/jbc.271.31.18527	http://dx.doi.org/10.1074/jbc.271.31.18527			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702500	hybrid			2022-12-27	WOS:A1996VB68300038
J	Park, MS; Ludwig, DL; Stigger, E; Lee, SH				Park, MS; Ludwig, DL; Stigger, E; Lee, SH			Physical interaction between human RAD52 and RPA is required for homologous recombination in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; SIMIAN VIRUS-40 DNA; NUCLEOTIDE EXCISION-REPAIR; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; SV40 ORIGIN; INVITRO; EXPRESSION; INITIATION; POLYMERASE	The yeast RAD52 protein is essential for DNA double-strand break repair, and meiotic and mitotic recombination, RPA is a protein complex of three subunits (70, 34, and II kDa) that has been shown to be involved in DNA replication, nucleotide excision repair, and homologous recombination. Here, we demonstrate a physical interaction between human RAD52 and RPA in vivo and in vitro, In addition, the domain (amino acids 221-280) in RAD52 protein that mediates the interaction with the 34-kDa subunit of RPA was also determined, Overexpression of mutant RAD52 proteins lacking the interaction domain (amino acids 221-240, 241-260, and 261-280) failed to induce homologous recombination in monkey cells, We have previously shown that overexpression of human RAD52 induced homologous recombination in these cells, These results suggest that direct physical interactions between RAD52 and RPA are essential for homologous recombination in mammalian cells.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOL BIOL, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital	Park, MS (corresponding author), LOS ALAMOS NATL LAB, DIV LIFE SCI, M888, LOS ALAMOS, NM 87545 USA.		Park, Min Sung/HCH-2207-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052358] Funding Source: NIH RePORTER; NIGMS NIH HHS [1RO1 GM52358] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; Kim DK, 1996, J BIOL CHEM, V271, P15124, DOI 10.1074/jbc.271.25.15124; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LEE SH, 1995, J BIOL CHEM, V270, P21800, DOI 10.1074/jbc.270.37.21800; LI L, 1995, MOL CELL BIOL, V15, P5396; LUDWIG DL, 1994, SOMAT CELL MOLEC GEN, V20, P11, DOI 10.1007/BF02257482; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; PARK MS, 1995, J BIOL CHEM, V270, P15467, DOI 10.1074/jbc.270.26.15467; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RESNICK M A, 1987, P157; SANCAR A, 1994, SCIENCE, V266, P1953; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SHINOHARA A, 1995, CELL, V270, P15467; SMITH J, 1995, MOL CELL BIOL, V15, P1632; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	37	178	185	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18996	19000		10.1074/jbc.271.31.18996	http://dx.doi.org/10.1074/jbc.271.31.18996			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702565	hybrid			2022-12-27	WOS:A1996VB68300103
J	Sgroi, D; Nocks, A; Stamenkovic, I				Sgroi, D; Nocks, A; Stamenkovic, I			A single N-linked glycosylation site is implicated in the regulation of ligand recognition by the I-type lectins CD22 and CR33	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; MYELIN-ASSOCIATED GLYCOPROTEIN; HUMAN TRANSFERRIN RECEPTORS; IMMUNOGLOBULIN SUPERFAMILY; NATURAL LIGANDS; SIALIC ACIDS; B-CELLS; BINDING; OLIGOSACCHARIDE; SIALOADHESIN	CD22 is an immunoglobulin superfamily B lymphocyte-specific adhesion receptor and a member of the recently identified I-type class of lectins, Recent work has shown that CD22 specifically recognizes sialic acid linked alpha 2,6 to terminal N-linked oligosaccharides on selected cell surface glycoproteins, CD22-ligand interaction is regulated by the activity of a beta-galactoside alpha 2,6-sialyltransferase that can inactivate CD22-mediated binding by sialylating the CD22 receptor itself. These observations suggest that N-linked glycosylation sites on the CD22 molecule may play a role in the regulation of CD22-mediated adhesion. In this work we have performed site-specific mutagenesis of potential N-linked glycosylation sites on CD22 in an effort to determine whether they might be involved in ligand recognition. We show that mutation of a single potential N-linked glycosylation site in the first immunoglobulin domain of CD22 completely abrogates ligand recognition, Interestingly, this site is characterized by the sequence NCT, where the cysteine is thought to be involved in an intrachain disulfide bond. Site-directed mutagenesis of similar NC(T/S) motifs in the first or second Ig domains of the I-type lectins myelin-associated glycoprotein, and sialoadhesin did not disrupt their ability to mediate sialic acid binding. In contrast, mutation of a NCS motif in the first Ig domain of the I-type lectin CD33 unmasked its sialic acid binding activity. These observations suggest that a single N-linked glycosylation site located at a similar position in the CD22 and CD33 glycoproteins is critical for regulating ligand recognition by both receptors.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02129	Harvard University; Harvard Medical School; Massachusetts General Hospital			Sgroi, Dennis/AAV-2487-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048614] Funding Source: NIH RePORTER; NIAID NIH HHS [AI/01252] Funding Source: Medline; NIGMS NIH HHS [GM/AI 48614] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARTOLAZZI A, 1996, J CELL BIOL, V132, P119; BRAESCHANDERSEN S, 1994, J BIOL CHEM, V269, P11783; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; EGGENS I, 1989, J BIOL CHEM, V264, P9476; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; ENGEL P, 1995, J EXP MED, V181, P1581, DOI 10.1084/jem.181.4.1581; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; HANASAKI K, 1995, J BIOL CHEM, V270, P7543, DOI 10.1074/jbc.270.13.7543; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOE MH, 1992, J BIOL CHEM, V267, P4916; HUNT RC, 1989, J BIOL CHEM, V264, P9643; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; MOLDENHAUER G, 1986, LEUKOCYTE TYPING 2, V2, P97; PLAAS AHK, 1993, J BIOL CHEM, V268, P26634; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1994, J BIOL CHEM, V269, P10628; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; RECNY MA, 1992, J BIOL CHEM, V267, P22428; SGROI D, 1993, J BIOL CHEM, V268, P7011; SGROI D, 1995, P NATL ACAD SCI USA, V92, P4026, DOI 10.1073/pnas.92.9.4026; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; STAMENKOVIC I, 1990, NATURE, V345, P74, DOI 10.1038/345074a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; WILSON GL, 1991, J EXP MED, V173, P137, DOI 10.1084/jem.173.1.137; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; YANG B, 1993, J BIOL CHEM, V268, P7435	30	35	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18803	18809		10.1074/jbc.271.31.18803	http://dx.doi.org/10.1074/jbc.271.31.18803			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702538	hybrid			2022-12-27	WOS:A1996VB68300076
J	Shimoni, Y; Galili, G				Shimoni, Y; Galili, G			Intramolecular disulfide bonds between conserved cysteines in wheat gliadins control their deposition into protein bodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEED STORAGE PROTEINS; ENDOPLASMIC-RETICULUM; TRANSPORT; EXPRESSION; ISOMERASE; BIP	Following synthesis, wheat gliadin storage proteins are deposited into protein bodies inside the endomembrane system in a way that enables not only their efficient accumulation and dehydration during seed maturation, but also their rapid rehydration and degradation during germination. In the present report, we studied the mechanism of gliadin deposition and whether it was controlled by the conformation of these proteins. Although gliadins are generally known to be insoluble in aqueous solutions, sucrose gradient analysis showed that a considerable amount of these proteins appeared as relatively soluble monomers in developing grains, In vitro reduction of the intramolecular disulfide bonds that are present in natural monomeric gliadins caused their precipitation into insoluble aggregates, In addition, pulse-chase experiments in the absence or presence of reducing agents showed that formation of intramolecular disulfide bonds also played a major role in folding and deposition of the gliadins in vivo, Our results imply that following sequestration into the endoplasmic reticulum, the gliadins fold into relatively soluble monomers, which are incompetent for rapid aggregation and gradually assemble into protein bodies, This pattern of deposition apparently depends on the conformation of the gliadins, which is stabilized by in tramolecular disulfide bonds formed between the conserved cysteines, The contribution of this study to the understanding of the evolution and function of gliadins is discussed.			Shimoni, Y (corresponding author), WEIZMANN INST SCI,DEPT PLANT GENET,IL-76100 REHOVOT,ISRAEL.							ALTSCHULER Y, 1994, J BIOL CHEM, V269, P6677; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CHARBONNIER L, 1980, J SCI FOOD AGR, V31, P54, DOI 10.1002/jsfa.2740310109; CHRISPEELS MJ, 1991, ANNU REV PLANT PHYS, V42, P21, DOI 10.1146/annurev.pp.42.060191.000321; COLE EW, 1984, BIOCHIM BIOPHYS ACTA, V787, P244, DOI 10.1016/0167-4838(84)90315-7; DAMICO L, 1992, PLANT J, V2, P443; GALILI G, 1995, J CELL BIOCH SA, V19, P132; Galili Gad, 1993, Trends in Cell Biology, V3, P437, DOI 10.1016/0962-8924(93)90033-W; GILLIKIN JW, 1995, METHOD CELL BIOL, P309; Kasarda D.D., 1989, WHEAT UNIQUE, V277, P302; Kreis M., 1985, Oxford Surveys of Plant Molecular and Cell Biology, V2, P253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI XX, 1993, SCIENCE, V262, P1054, DOI 10.1126/science.8235623; PAYNE PI, 1987, ANNU REV PLANT PHYS, V38, P141, DOI 10.1146/annurev.pp.38.060187.001041; PEDRAZZINI E, 1994, PLANT J, V5, P103, DOI 10.1046/j.1365-313X.1994.5010103.x; PENCE JW, 1954, CEREAL CHEM, V31, P29; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; RUBIN R, 1992, PLANT PHYSIOL, V99, P718, DOI 10.1104/pp.99.2.718; SHANI N, 1994, J BIOL CHEM, V269, P8924; SHEWRY PR, 1995, PLANT CELL, V7, P945, DOI 10.1105/tpc.7.7.945; SHEWRY PR, 1995, SEED DEV GERMINATION, P45; SHORROSH BS, 1993, PLANT PHYSIOL, V103, P719, DOI 10.1104/pp.103.3.719; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; VITALE A, 1993, J EXP BOT, V44, P1417, DOI 10.1093/jxb/44.9.1417; VITALE A, 1995, J CELL BIOCH A S, V19, P132; Vitale A., 1995, SEED DEV GERMINATION, P73	26	33	39	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18869	18874		10.1074/jbc.271.31.18869	http://dx.doi.org/10.1074/jbc.271.31.18869			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702547	hybrid			2022-12-27	WOS:A1996VB68300085
J	Singh, RJ; Hogg, N; Joseph, J; Kalyanaraman, B				Singh, RJ; Hogg, N; Joseph, J; Kalyanaraman, B			Mechanism of nitric oxide release from S-nitrosothiols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-ALBUMIN; PLATELET ACTIVATION; L-CYSTEINE; GLUTATHIONE; NITROSOGLUTATHIONE; THIOLS; DECOMPOSITION; NITROSATION; KINETICS; OXYGEN	S-Nitrosothiols have many biological activities and have been suggested to be intermediates in signal transduction. The mechanism and products of S-nitrosothiol decomposition are of great significance to the understanding of nitric oxide ((NO)-N-.) biochemistry. S-Nitrosothiols are stable compounds at 37 degrees C and pH 7.4 in the presence of transition metal ion chelators. The presence of trace transition metal ions (present in all buffers) stimulates the catalytic breakdown of S-nitrosothiols to (NO)-N-. and disulfide. Thiyl radicals are not formed as intermediates in this process; Photolysis of S-nitrosothiols results in the formation of (NO)-N-. and disulfide via the intermediacy of thiyl radicals. Reduced metal ion (e.g, Cu+) decomposes S-nitrosothiols more rapidly than oxidized metal ion (e.g. Cu2+) indicating that reducing agents such as glutathione and ascorbate can stimulate decomposition of S-nitrosothiol by chemical reduction of contaminating transition metal ions. Transnitrosation can also stimulate S-nitrosothiol decomposition if the product S-nitrosothiol is more susceptible to transition metal ion-catalyzed decomposition than the parent S-nitrosothiol. Equilibrium constants for the transnitrosation reactions of reduced glutathione, either with S-nitroso-N-acetyl-DL-penicillamine or with S-nitroso-L-cysteine indicate that S-nitrosoglutathione formation is favored. The biological relevance of S-nitrosothiol decomposition is discussed.	MED COLL WISCONSIN,BIOPHYS RES INST,MILWAUKEE,WI 53226	Medical College of Wisconsin					NATIONAL CANCER INSTITUTE [P01CA049089] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL045058] Funding Source: NIH RePORTER; NCI NIH HHS [CA49089] Funding Source: Medline; NCRR NIH HHS [RR01008] Funding Source: Medline; NHLBI NIH HHS [HL45058] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; ASKEW SC, 1995, J CHEM SOC PERK T 2, P741, DOI 10.1039/p29950000741; BARNETT DJ, 1995, J CHEM SOC PERK T 2, P1279, DOI 10.1039/p29950001279; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; BONNER FT, 1986, INORG CHEM, V25, P2676; BUETTNER GR, 1985, FEBS LETT, V177, P295; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; DEBELDER AJ, 1994, CARDIOVASC RES, V28, P691; DEMASTER EG, 1995, BIOCHEMISTRY-US, V34, P11494, DOI 10.1021/bi00036a023; ELLIOTT SJ, 1995, FREE RADICAL BIO MED, V19, P649, DOI 10.1016/0891-5849(95)00080-H; FEELISCH M, 1994, NATURE, V368, P62, DOI 10.1038/368062a0; FEELISCH M, 1991, J CARDIOVASC PHARM, V17, pS25, DOI 10.1097/00005344-199117003-00006; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GIRARD P, 1993, FEBS LETT, V320, P7, DOI 10.1016/0014-5793(93)81645-G; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HOGG N, 1995, FREE RADICAL RES, V22, P47, DOI 10.3109/10715769509147527; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; JOSEPHY PD, 1984, TETRAHEDRON LETT, V25, P1685, DOI 10.1016/S0040-4039(01)81144-8; KONOREV EA, 1995, J PHARMACOL EXP THER, V274, P200; KOTAKE Y, 1994, FREE RADICAL BIO MED, V17, P215, DOI 10.1016/0891-5849(94)90077-9; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MATHEWS WR, 1993, J PHARMACOL EXP THER, V267, P1529; MCANINLY J, 1993, J CHEM SOC CHEM COMM, P1758, DOI 10.1039/c39930001758; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; MIKUNI T, 1991, BIOCHEM INT, V24, P585; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; PARK JW, 1993, BIOCHEM MOL BIOL INT, V30, P885; PIETRAFORTE D, 1995, BIOCHEMISTRY-US, V34, P7177, DOI 10.1021/bi00021a032; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; SEXTON DJ, 1994, PHOTOCHEM PHOTOBIOL, V59, P463, DOI 10.1111/j.1751-1097.1994.tb05065.x; SINGH RJ, 1995, FEBS LETT, V360, P47, DOI 10.1016/0014-5793(95)00065-H; SMIRNOVA TI, 1995, MAGNET RESON MED, V33, P801, DOI 10.1002/mrm.1910330610; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; ULLMAN EF, 1972, J AM CHEM SOC, V94, P7049, DOI 10.1021/ja00775a031; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007; [No title captured]	45	483	494	7	64	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18596	18603		10.1074/jbc.271.31.18596	http://dx.doi.org/10.1074/jbc.271.31.18596			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702510	hybrid			2022-12-27	WOS:A1996VB68300048
J	Szallasi, Z; Bogi, K; Gohari, S; Biro, T; Acs, P; Blumberg, PM				Szallasi, Z; Bogi, K; Gohari, S; Biro, T; Acs, P; Blumberg, PM			Non-equivalent roles for the first and second zinc fingers of protein kinase C delta - Effect of their mutation on phorbol ester-induced translocation in NIH 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAIN; DIFFERENTIAL REGULATION; BINDING; PHOSPHOLIPIDS; ACTIVATION; ISOZYMES; REGION; GAMMA	Classical and novel protein kinase C (PKC) isozymes contain two, so-called cysteine-rich zinc finger domains that represent the binding sites for phorbol esters and the diacylglycerols, X-ray crystallographic, mutational, and modeling studies are providing detailed understanding of the interactions between the phorbol esters and individual PKC zinc fingers, In the present study, we explore the roles of the individual zinc fingers in the context of the intact enzyme, Our approach was to mu tate either the first, the second, or both zinc fingers of PKC delta, to express the mutated enzyme in NIH 3T3 cells, and to monitor the effect of the mutations on the dose-response curve for translocation induced by phorbol 12-myristate 13-acetate. The introduced mutations change into glycine the consensus proline in the phorbol ester binding loop of the zinc finger; in the isolated zinc finger, this mutation causes a 125-fold decrease in phorbol ester binding affinity, We observed that mutation in the first zinc finger caused almost no shift in the dose-response curve for translocation; mutation in the second zinc finger caused a al-fold shift, whereas mutation in both zinc fingers caused a 138-fold shift, We conclude that the zinc fingers in the intact PRC are not equivalent and that the second zinc finger plays the predominant role in translocation of protein kinase C gamma in response to phorbol 12-myristate 13-acetate, Our findings have important implications for the understanding and design of PKC inhibitors targeted to the zinc finger domains.	NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,MOL MECHANISMS TUMOR PROMOT SECT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Szallasi, Zoltan/0000-0001-5395-7509				BURNS DJ, 1991, J BIOL CHEM, V266, P18330; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; ICHIKAWA S, 1995, J BIOCHEM-TOKYO, V117, P566, DOI 10.1093/oxfordjournals.jbchem.a124745; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; SHIEH HL, 1995, MOL CARCINOGEN, V12, P166, DOI 10.1002/mc.2940120308; Slater SJ, 1996, J BIOL CHEM, V271, P4627; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; SZALLASI Z, 1995, MOL PHARMACOL, V47, P258; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	16	127	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18299	18301		10.1074/jbc.271.31.18299	http://dx.doi.org/10.1074/jbc.271.31.18299			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702464	hybrid			2022-12-27	WOS:A1996VB68300002
J	Toke, DA; Martin, CE				Toke, DA; Martin, CE			Isolation and characterization of a gene affecting fatty acid elongation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; NEUROSPORA-CRASSA; SYNTHASE; YEAST; PROTEIN; BIOSYNTHESIS; DESATURASE; SEQUENCE; SYSTEM; GOLGI	Fatty acid elongation defective mutants were isolated from Saccharomyces cerevisiae by mutagenizing strains that were defective in fatty acid synthase (FAS) activity, Cells of the fatty acid synthase-defective strains can grow when supplemented with tetradecanoic acid (14:0) due to the presence of membrane bound elongation systems that can extend the 14 carbon fatty acid to longer chain species, After mutagenesis and rescue on medium containing a mixture of 14:0, 16:0 and 18:0, cells were screened for their inability to grow on medium containing only 14:0, From 150,000 colonies, four stable isolates were identified, all of which appear to represent the same complementation group, Gas chromatography of lipid extracts from mutant elo1-1 (designated as elongation defective) cells grown with long or medium chain fatty acids indicates that it fails to efficiently elongate (12, 13, or 14) carbon fatty acids, A gene disrupted fas2 Delta::LEU2;elo1 Delta::HIS3 mutant incorporates 14-18-carbon fatty acids into membrane lipids, indicating that fatty acid transport is not affected by the mutation, Molecular cloning and sequence analysis of the ELO1 gene suggests that the encoded protein is a membrane bound polypeptide that contains at least five potential membrane spanning regions and a presumptive NADPH binding site, Analysis of the ELO1 mRNA levels indicates that the gene is expressed in cells grown on fatty acid deficient medium, It is rapidly induced in wild type cells that are supplemented with 14:0 and is repressed when cells are supplied with 16- and 18-carbon fatty acids.	RUTGERS STATE UNIV,DEPT BIOL SCI,BUR BIOL RES,NELSON BIOL LABS,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045768] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON LR, 1983, BIOCHIM BIOPHYS ACTA, V735, P252, DOI 10.1016/0005-2736(83)90300-0; AARONSON LR, 1982, BIOCHIM BIOPHYS ACTA, V713, P456, DOI 10.1016/0005-2760(82)90265-X; AARONSON LR, 1988, J BIOL CHEM, V263, P14552; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BESSOULE JJ, 1988, EUR J BIOCHEM, V177, P207, DOI 10.1111/j.1432-1033.1988.tb14363.x; BROWSE J, 1986, PLANT PHYSIOL, V81, P859, DOI 10.1104/pp.81.3.859; CHIRALA SS, 1992, P NATL ACAD SCI USA, V89, P10232, DOI 10.1073/pnas.89.21.10232; Choi JY, 1996, J BIOL CHEM, V271, P3581; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; FOX BG, 1994, BIOCHEMISTRY-US, V33, P12776, DOI 10.1021/bi00209a008; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HOLZER KP, 1989, P NATL ACAD SCI USA, V86, P4387, DOI 10.1073/pnas.86.12.4387; JAMES DW, 1995, PLANT CELL, V7, P309, DOI 10.2307/3869853; JAYAKUMAR A, 1995, P NATL ACAD SCI USA, V92, P8695, DOI 10.1073/pnas.92.19.8695; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MOHAMED AH, 1988, J BIOL CHEM, V263, P12315; NAGIEC MM, 1993, J BIOL CHEM, V268, P22156; OSEI P, 1989, J BIOL CHEM, V264, P6844; ROGGENKAMP R, 1980, P NATL ACAD SCI-BIOL, V77, P1814, DOI 10.1073/pnas.77.4.1814; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHWEIZER E, 1978, MOL CELL BIOCHEM, V21, P95; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Sherman F., 1982, METHODS YEAST GENETI; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P322; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; [No title captured]	32	155	162	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18413	18422		10.1074/jbc.271.31.18413	http://dx.doi.org/10.1074/jbc.271.31.18413			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702485	hybrid			2022-12-27	WOS:A1996VB68300023
J	Chai, YC; Howe, PH; DiCorleto, PE; Chisolm, GM				Chai, YC; Howe, PH; DiCorleto, PE; Chisolm, GM			Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells - Evidence for release of fibroblast growth factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; OXIDATIVELY MODIFIED LDL; ENDOTHELIAL-CELLS; ATHEROSCLEROTIC LESIONS; PERITONEAL-MACROPHAGES; ALPHA-TOCOPHEROL; MESSENGER-RNA; DNA-SYNTHESIS; EXPRESSION; PROLIFERATION	We have previously shown that oxidized low density lipoprotein (LDL) but not native LDL stimulated DNA synthesis in cultured smooth muscle cells (SMC) and that alpha-tocopherol (vitamin E) inhibited this proliferative response (Lafont, A., Chai, Y. C., Cornhill, J, F., Whitlow, P. L., Howe, P. H., and Chisolm, G. M. (1995) J. Chin, Invest. 95, 1018-1025). The moiety of oxidized LDL that stimulates DNA synthesis and the cellular mechanism for this potentially mitogenic effect are not known. We now report that lipid fractions containing lysophospholipids from oxidized LDL or phospholipase A(2)-treated native LDL stimulated SMC DNA synthesis as did palmitoyl lysophosphatidylcholine (lysoPC). Protein kinase C inhibitors and down regulation of protein kinase C activity by phorbol ester inhibited oxidized LDL- and lysoPC-induced DNA synthesis. A neutralizing monoclonal antibody against fibroblast growth factor-a significantly inhibited oxidized LDL and lysoPC-induced DNA synthesis in SMC; irrelevant antibodies were ineffective. Vitamin E inhibited the DNA synthesis stimulated by lysoPC, an observation that distinguished this effect from DNA synthesis induced by another detergent, digitonin, These results suggest that oxidized LDL and its lysoPC moiety stimulate SMC to enter the cell cycle via an oxidative mechanism that causes the release of fibroblast growth factor-2 and a subsequent autocrine or paracrine response.	CLEVELAND CLIN FDN, RES INST, DEPT CELL BIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047852, P01HL029582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 29582, HL 47852] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; AUGE N, 1995, BIOCHEM J, V309, P1015, DOI 10.1042/bj3091015; BROWN BG, 1976, CIRC RES, V39, P415, DOI 10.1161/01.RES.39.3.415; CHATTERJEE S, 1992, MOL CELL BIOCHEM, V111, P143; CHEN Y, 1995, ATHEROSCLEROSIS, V112, P69, DOI 10.1016/0021-9150(94)05400-D; Cheng GC, 1996, CIRCULATION, V93, P99, DOI 10.1161/01.CIR.93.1.99; CHISOLM GM, 1994, P NATL ACAD SCI USA, V91, P11452, DOI 10.1073/pnas.91.24.11452; CHISOLM GM, 1996, ATHEROSCLEROSIS CORO, P129; COFFEY MD, 1995, J CLIN INVEST, V96, P1866, DOI 10.1172/JCI118232; CUTHBERT JA, 1986, BIOCHIM BIOPHYS ACTA, V876, P210, DOI 10.1016/0005-2760(86)90276-6; DAMORE PA, 1990, CANCER METAST REV, V9, P227, DOI 10.1007/BF00046362; DRAKE TA, 1991, AM J PATHOL, V138, P601; FISCHERDZOGA K, 1976, EXP MOL PATHOL, V24, P346, DOI 10.1016/0014-4800(76)90070-8; FUKUO K, 1995, J CLIN INVEST, V95, P669, DOI 10.1172/JCI117712; HAMILTON TA, 1990, J IMMUNOL, V144, P2343; HAMILTON TA, 1995, J CLIN INVEST, V95, P2020, DOI 10.1172/JCI117887; Hatch F T, 1968, Adv Lipid Res, V6, P1; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; JOUGASAKI M, 1992, CIRC RES, V71, P614, DOI 10.1161/01.RES.71.3.614; KENT KC, 1995, CIRC RES, V77, P231, DOI 10.1161/01.RES.77.2.231; KLAGSBRUN M, 1989, ARTERIOSCLEROSIS, V9, P269, DOI 10.1161/01.ATV.9.3.269; KOSUGI K, 1987, J CELL PHYSIOL, V130, P311, DOI 10.1002/jcp.1041300302; KRAEMER R, 1993, J BIOL CHEM, V268, P8040; KUZUYA M, 1991, J LIPID RES, V32, P197; LAFONT AM, 1995, J CLIN INVEST, V95, P1018, DOI 10.1172/JCI117746; LOCHER R, 1992, BIOCHEM BIOPH RES CO, V183, P156, DOI 10.1016/0006-291X(92)91622-W; MALDEN LT, 1991, J BIOL CHEM, V266, P13901; MANGIN EL, 1993, CIRC RES, V72, P161, DOI 10.1161/01.RES.72.1.161; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; OZER NK, 1993, FEBS LETT, V322, P307, DOI 10.1016/0014-5793(93)81592-N; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; REDDY KB, 1993, J CELL PHYSIOL, V156, P48, DOI 10.1002/jcp.1041560108; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SHIRHATTI V, 1985, ANAL BIOCHEM, V147, P410, DOI 10.1016/0003-2697(85)90290-8; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; STIKORAHM A, 1992, ARTERIOSCLER THROMB, V12, P1099, DOI 10.1161/01.ATV.12.9.1099; TAKAGI Y, 1988, ATHEROSCLEROSIS, V74, P227, DOI 10.1016/0021-9150(88)90241-9; THOMAS CE, 1992, BIOCHIM BIOPHYS ACTA, V1128, P50, DOI 10.1016/0005-2760(92)90256-U; WEISS RH, 1993, J BIOL CHEM, V268, P5724; WELTZIEN HU, 1977, BIOCHIM BIOPHYS ACTA, V466, P411, DOI 10.1016/0005-2736(77)90334-0; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; WINKLES JA, 1993, AM J PATHOL, V143, P518; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YOKODE M, 1988, J CLIN INVEST, V81, P720, DOI 10.1172/JCI113377; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331	57	134	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17791	17797		10.1074/jbc.271.30.17791	http://dx.doi.org/10.1074/jbc.271.30.17791			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663300	hybrid			2022-12-27	WOS:A1996UY93500033
J	Deeney, JT; Cunningham, BA; Chheda, S; Bokvist, K; JunttiBerggren, L; Lam, K; Korchak, HM; Corkey, BE; Berggren, PO				Deeney, JT; Cunningham, BA; Chheda, S; Bokvist, K; JunttiBerggren, L; Lam, K; Korchak, HM; Corkey, BE; Berggren, PO			Reversible Ca2+-dependent translocation of protein kinase C and glucose-induced insulin release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; K+ CHANNELS; FREE CA2+; B-CELL; SECRETION; ISLETS; DIACYLGLYCEROL; ACTIVATION; CA-2+; INHIBITION	It has been reported that protein kinase C (PKC) interacts at multiple sites in beta-cell stimulus-secretion coupling, Nevertheless, there is still controversy concerning the importance of this enzyme in glucose-induced insulin release, The present study was undertaken to clarify whether glucose, directly, or through changes in cytoplasmic free Ca2+ concentration, [Ca2+](i), could promote translocation of PKC from the soluble to the membrane compartment, Whereas glucose, which increases [Ca2+](i), did not affect long-term distribution of PKC activity between soluble and membrane fractions, this distribution was reversibly affected acutely by the Ca2+ concentration in the extraction media, Translocation of PKC to the membrane by incubation of HIT cells for 10 min in the presence of 20 nM phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) resulted in a 5-fold increase in glucose-induced insulin release, This was prevented by 50 nM concentration of the PKC inhibitor staurosporine, provided that the cells were exposed to the inhibitor before the phorbol ester, Cells pretreated with TPA demonstrated increased insulin secretion in response to glucose for several hours, This time course extended beyond the disappearance of [H-3] TPA from the cells, which was complete after 1 h, Activation of PKC increased both average insulin release and the amplitude of oscillations a-fold, but did not affect oscillation frequency, The stimulatory effect of increased PKC activity on insulin release was not matched by changes in [Ca2+](i), We suggest that stimulation of the pancreatic beta-cell with glucose promotes transient translocation of certain PKC isoforms from the cytoplasm to the plasma membrane as a direct consequence of the increase in [Ca2+](i). Such a translocation may promote phosphorylation of one or several proteins involved in the regulation of the beta-cell stimulus-secretion coupling, This results in potentiation of glucose-induced activation of insulin exocytosis, an effect then not mediated by an increase in [Ca2+](i) per se, Hence, pulsatile insulin release can be obtained under conditions where overall [Ca2+](i) does not change, challenging the view that oscillations in [Ca2+](i) are indeed driving the oscillations in hormone release.	KAROLINSKA INST,KAROLINSKA HOSP,DEPT MOLEC MED,ROLF LUFT CTR DIABET RES,S-17176 STOCKHOLM,SWEDEN; BOSTON UNIV,MED CTR,DIABET & METAB UNIT,BOSTON,MA 02118; UNIV PENN,CHILDRENS HOSP,DIV IMMUNOL,PHILADELPHIA,PA 19104	Karolinska Institutet; Karolinska University Hospital; Boston University; University of Pennsylvania; Childrens Hospital of Philadelphia			; Corkey, Barbara/E-7712-2015	Berggren, Per-Olof/0000-0001-8991-413X; Deeney, Jude/0000-0003-0988-9419; Corkey, Barbara/0000-0002-5467-1630	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035914, P30DK046200, R37DK035914, R56DK035914] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35914, DK-46200] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ARKHAMMAR P, 1989, BIOCHEM J, V264, P207, DOI 10.1042/bj2640207; ARKHAMMAR P, 1994, J BIOL CHEM, V269, P2743; BERGGREN PO, 1994, BIOCHEM SOC T, V22, P12, DOI 10.1042/bst0220012; BERGGREN PO, 1989, BIOCHEM BIOPH RES CO, V165, P416, DOI 10.1016/0006-291X(89)91086-3; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; EASOM RA, 1989, BIOCHEM J, V264, P27, DOI 10.1042/bj2640027; EASOM RA, 1990, J BIOL CHEM, V265, P14938; EFENDIC S, 1993, J INT MED, V229, P9; GANESAN S, 1992, J CELL BIOL, V119, P313, DOI 10.1083/jcb.119.2.313; GANESAN S, 1990, P NATL ACAD SCI USA, V87, P9893, DOI 10.1073/pnas.87.24.9893; HOWELL SL, 1990, BIOCHEM SOC T, V18, P114, DOI 10.1042/bst0180114; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; KINDMARK H, 1992, FEBS LETT, V303, P85, DOI 10.1016/0014-5793(92)80483-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGO EA, 1991, J BIOL CHEM, V266, P9314; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; METZ SA, 1988, DIABETES, V37, P3, DOI 10.2337/diabetes.37.1.3; Nilsson T, 1996, BIOCHEM J, V314, P91, DOI 10.1042/bj3140091; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1145; PHILLIPS WA, 1989, J BIOL CHEM, V264, P8361; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; REGAZZI R, 1989, J BIOL CHEM, V264, P9939; SLATER SJ, 1994, J BIOL CHEM, V269, P17160; SZALLASI Z, 1994, J BIOL CHEM, V269, P27159; THAMS P, 1990, BIOCHEM J, V265, P777, DOI 10.1042/bj2650777; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOLF BA, 1989, BIOCHEMISTRY-US, V28, P4291, DOI 10.1021/bi00436a026; WOLF BA, 1990, J CLIN INVEST, V85, P482, DOI 10.1172/JCI114463; WOLLHEIM CB, 1988, EMBO J, V7, P2443, DOI 10.1002/j.1460-2075.1988.tb03090.x; WOLLHEIM CB, 1990, FEBS LETT, V268, P376, DOI 10.1016/0014-5793(90)81289-Z; ZAITSEV SV, 1995, P NATL ACAD SCI USA, V92, P9712, DOI 10.1073/pnas.92.21.9712; ZAWALICH WS, 1991, BIOCHEM J, V278, P49, DOI 10.1042/bj2780049	35	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18154	18160		10.1074/jbc.271.30.18154	http://dx.doi.org/10.1074/jbc.271.30.18154			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663368	hybrid			2022-12-27	WOS:A1996UY93500085
J	Giartosio, A; Erent, M; Cervoni, L; Morera, S; Janin, J; Konrad, M; Lascu, I				Giartosio, A; Erent, M; Cervoni, L; Morera, S; Janin, J; Konrad, M; Lascu, I			Thermal stability of hexameric and tetrameric nucleoside diphosphate kinases - Effect of subunit interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; DICTYOSTELIUM-DISCOIDEUM; ESCHERICHIA-COLI; NUCLEOSIDEDIPHOSPHATE KINASE; CRYSTAL-STRUCTURE; ACTIVE-SITE; PROTEIN; DROSOPHILA; RESOLUTION; DENATURATION	The eukaryotic nucleoside diphosphate (NDP) kinases are hexamers, while the bacterial NDP kinases are tetramers made of small, single domain subunits. These enzymes represent an ideal model for studying the effect of subunit interaction on protein stability, The thermostability of NDP kinases of each class was studied by differential scanning calorimetry and biochemical methods, The hexameric NDP kinase from Dictyostelium discoideum displays one single, irreversible differential scanning calorimetry peak (T-m 62 degrees C) over a broad protein concentration, indicating a single step denaturation, The thermal stability of the protein was increased by ADP. The P105G substitution, which affects a loop implicated in subunit contacts, yields a protein that reversibly dissociates to folded monomers at 38 degrees C before the irreversible denaturation occurs (T-m 47 degrees C). ADP delays the dissociation, but does not change the T-m. These data indicate a ''coupling'' of the quaternary structure with the tertiary structure in the wild-type, but not in the mutated protein, We describe the x-ray structure of the P105G mutant at 2.2-Angstrom resolution. It is very similar to that of the wild-type protein, Therefore, a minimal change in the structure leads to a dramatic change of protein thermostability. The NDP kinase from Escherichia coli behaves like the P105G mutant of the Dictyostelium NDP kinase, The detailed study of their thermostability is important, since biological effects of thermolabile NDP kinases have been described in several organisms.	UNIV BORDEAUX 2, IBGC, CNRS, F-33077 BORDEAUX, FRANCE; UNIV ROMA LA SAPIENZA, CNR, DIPARTIMENTO SCI BIOCHIM A ROSSI FANELLI, I-00185 ROME, ITALY; UNIV ROMA LA SAPIENZA, CNR, CTR MOL BIOL, I-00185 ROME, ITALY; UNIV PARIS SUD, UMR 9920 CNRS, STRUCT BIOL LAB, F-91198 GIF SUR YVETTE, FRANCE; MAX PLANCK INST BIOPHYS CHEM, DEPT MOLEC GENET, D-37018 GOTTINGEN, GERMANY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; UDICE-French Research Universities; Universite Paris Saclay; Max Planck Society			Janin, Joel/I-2958-2012					ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARREA G, 1989, ANAL BIOCHEM, V180, P181, DOI 10.1016/0003-2697(89)90109-7; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; DICKINSON JR, 1981, EUR J BIOCHEM, V119, P341, DOI 10.1111/j.1432-1033.1981.tb05613.x; ERHARDT J, 1995, EUR J BIOCHEM, V230, P614; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GINTHER CL, 1974, J BACTERIOL, V118, P1020, DOI 10.1128/JB.118.3.1020-1026.1974; GITTELMAN MS, 1990, BIOCHEMISTRY-US, V29, P7011, DOI 10.1021/bi00482a009; GRANT SK, 1992, BIOCHEMISTRY-US, V31, P9491, DOI 10.1021/bi00154a023; HORTON N, 1992, PROTEIN SCI, V1, P169; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JOHNSON CR, 1995, BIOCHEMISTRY-US, V34, P5309, DOI 10.1021/bi00016a002; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWON OS, 1993, J BIOL CHEM, V268, P7912; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LASCU I, 1983, EUR J BIOCHEM, V135, P497, DOI 10.1111/j.1432-1033.1983.tb07679.x; LASCU I, 1993, J BIOL CHEM, V268, P20268; LASCU I, 1992, J BIOL CHEM, V267, P12775; LASCU I, 1994, J BIOL CHEM, V269, P7046; Leslie AGW, 1986, PROTEIN CRYSTALLOGR, V18, P33; LIANG H, 1991, BIOCHEMISTRY-US, V30, P2772, DOI 10.1021/bi00225a006; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; MORERA S, 1995, BIOCHEMISTRY-US, V34, P11062, DOI 10.1021/bi00035a011; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; MORERA S, 1994, J MOL BIOL, V243, P873, DOI 10.1006/jmbi.1994.1689; OHTSUKI K, 1984, BIOCHEM INT, V8, P715; Privalov P L, 1986, Methods Enzymol, V131, P4; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; STEIF C, 1993, BIOCHEMISTRY-US, V32, P3867, DOI 10.1021/bi00066a005; STURTEVANT AH, 1956, GENETICS, V41, P118; STURTEVANT JM, 1987, ANNU REV PHYS CHEM, V38, P463, DOI 10.1146/annurev.pc.38.100187.002335; TEPPER AD, 1994, J BIOL CHEM, V269, P32175; TESCHNER W, 1990, FEBS LETT, V267, P96, DOI 10.1016/0014-5793(90)80297-V; TROLL H, 1993, J BIOL CHEM, V268, P25469; WALLET V, 1992, THESIS U PARIS 6; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; WETZEL R, 1992, PROTEIN ENG PRACTICA, P191; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673; ZHUANG P, 1994, BIOCHEMISTRY-US, V33, P4237, DOI 10.1021/bi00180a018; ZINYK DL, 1993, NAT GENET, V4, P195, DOI 10.1038/ng0693-195	46	42	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17845	17851		10.1074/jbc.271.30.17845	http://dx.doi.org/10.1074/jbc.271.30.17845			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663370	hybrid			2022-12-27	WOS:A1996UY93500041
J	Schwarz, M; Lund, EG; Setchell, KDR; Kayden, HJ; Zerwekh, JE; Bjorkhem, I; Herz, J; Russell, DW				Schwarz, M; Lund, EG; Setchell, KDR; Kayden, HJ; Zerwekh, JE; Bjorkhem, I; Herz, J; Russell, DW			Disruption of cholesterol 7 alpha-hydroxylase gene in mice .2. Bile acid deficiency is overcome by induction of oxysterol 7 alpha-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPIDS; RATS	Past experiments and current paradigms of cholesterol homeostasis suggest that cholesterol 7 alpha-hydroxylase plays a crucial role in sterol metabolism by controlling the conversion of cholesterol into bile acids, Consistent with this conclusion, we show in the accompanying paper that mice deficient in cholesterol 7 alpha-hydroxylase (Cyp7(-/-) mice) exhibit a complex phenotype consisting of abnormal lipid excretion, skin pathologies, and behavioral irregularities (Ishibashi, S., Schwarz, M., Frykman, P, K., Herz, J., and Russell, D. W. (1996) J. Biol. Chem, 261, 18017-18023), Aspects of lipid metabolism in the Cyp7(-/-) mice are characterized here to deduce the physiological basis of this phenotype. Serum lipid, cholesterol, and lipoprotein contents are indistinguishable between wild-type and Cyp7(-/-) mice, Vitamin D-3 and E levels are low to undetectable in knockout animals, Stool fat content is significantly elevated in newborn Cyp7(-/-) mice and gradually declines to wild-type levels at 28 days of age, Several species of 7 alpha-hydroxylated bile acids are detected in the bile and stool of adult Cyp7(-/-) animals, A hepatic oxysterol 7 alpha-hydroxylase enzyme activity that may account for the 7 alpha-hydroxylated bile acids is induced between days 21 and 30 in both wild-type and deficient mice, An anomalous oily coat in the Cyp7(-/-) animals is due to the presence of excess monoglyceride esters in the fur, These data show that 7 alpha-hydroxylase and the pathway of bile acid synthesis initiated by this enzyme are essential for proper absorption of dietary lipids and fat-soluble vitamins in newborn mice, but not for the maintenance of serum cholesterol and lipid levels, In older animals, an alternate pathway of bile acid synthesis involving an inducible oxysterol 7 alpha-hydroxylase plays a crucial role in lipid and bile acid metabolism.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235; CHILDRENS HOSP,MED CTR,DEPT PEDIAT,CINCINNATI,OH 45229; NYU,MED CTR,DEPT MED,NEW YORK,NY 10016; KAROLINSKA INST,HUDDINGE HOSP,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Cincinnati Children's Hospital Medical Center; New York University; Karolinska Institutet				Bjorkhem, Ingemar/0000-0001-6087-9190; Russell, David/0000-0002-0277-403X; Bjorkhem, Ingemar/0000-0002-0575-9425	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948, P01 HL020948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AXELSON M, 1990, J STEROID BIOCHEM, V36, P631, DOI 10.1016/0022-4731(90)90182-R; AXELSON M, 1992, J BIOL CHEM, V267, P1701; BERGSTROM S, 1959, ACTA CHEM SCAND, V13, P776, DOI 10.3891/acta.chem.scand.13-0776; BJORKHEM I, 1992, J LIPID RES, V33, P455; DANIELSSON H, 1967, EUR J BIOCHEM, V2, P44, DOI 10.1111/j.1432-1033.1967.tb00103.x; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; GRIGOR MR, 1977, LIPID METABOLISM MAM, P209; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIBASHI S, 1996, J BIOL CHEM, V261, P18017; LUND E, 1991, J BIOL CHEM, V266, P4929; NICOLAIDES N, 1970, LIPIDS, V5, P299, DOI 10.1007/BF02531461; PAYNE DW, 1995, J BIOL CHEM, V270, P18888, DOI 10.1074/jbc.270.32.18888; POPOFF SN, 1994, BONE, V15, P515, DOI 10.1016/8756-3282(94)90275-5; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SAKHAEE K, 1994, J UROLOGY, V152, P324, DOI 10.1016/S0022-5347(17)32730-1; SCHENCK GO, 1957, LIEBIGS ANN CHEM, V603, P46; SCHENCK GO, 1958, ANGEW CHEM, V19, P595; SETCHELL KDR, 1995, BIOCHEMISTRY-US, V34, P4169, DOI 10.1021/bi00013a004; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; STEWART ME, 1991, ADV LIPID RES, V24, P263; SUCHY FJ, 1982, PEDIATR RES, V16, P282, DOI 10.1203/00006450-198204000-00007; TOLL A, 1994, EUR J BIOCHEM, V224, P309, DOI 10.1111/j.1432-1033.1994.00309.x; TRABER MG, 1987, AM J CLIN NUTR, V46, P488, DOI 10.1093/ajcn/46.3.488; UCHIDA K, 1984, J LIPID RES, V25, P236; ZHANG J, 1995, BBA-LIPID LIPID MET, V1256, P353	26	220	222	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18024	18031		10.1074/jbc.271.30.18024	http://dx.doi.org/10.1074/jbc.271.30.18024			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663430	Green Accepted, hybrid			2022-12-27	WOS:A1996UY93500067
J	Tedin, K; Blasi, U				Tedin, K; Blasi, U			The RNA chain elongation rate of the lambda late mRNA is unaffected by high levels of ppGpp in the absence of amino acid starvation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							COLI RIBOSOMAL-RNA; GUANOSINE 5'-DIPHOSPHATE 3'-DIPHOSPHATE; GROWTH-RATE CONTROL; DIFFERENTIAL STRINGENT CONTROL; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; FEEDBACK-REGULATION; COLIPHAGE LAMBDA; TRANSCRIPTION-TERMINATION; PROTEIN-SYNTHESIS	In this study, the effects of high levels of guanosine tetraphosphate (ppGpp) on the decay and RNA chain elongation kinetics of the bacteriophage lambda late transcript in Escherichia coli were examined in the absence of amino acid starvation. The accumulation, mRNA decay kinetics, and RNA chain elongation rate of the lambda late mRNA were determined after heat induction of lambda cI857 lysogens in the presence of high levels of ppGpp induced from a RelA alpha fragment-overproducing plasmid. The accumulation kinetics and elongation rate determinations of the late mRNA were made at long times after induction to allow a new steady state of transcriptional activities under conditions of elevated intracellular levels of ppGpp. The results indicate no prolonged or significant effect on either mRNA decay or the RNA chain elongation rate of the late mRNA as a result of elevated ppGpp levels. Surprisingly, the RNA chain elongation rate determinations indicate an RNA polymerase processivity of approximately 90-100 nucleotides/s for the lambda late transcript despite the presence of high levels of ppGpp. The results are discussed in terms of various models for regulation of stable and messenger RNA synthesis in E. coli.			Tedin, K (corresponding author), UNIV VIENNA, INST GENET & MICROBIOL, DR BOHR GASSE 9, A-1030 VIENNA, AUSTRIA.			Tedin, Karsten/0000-0003-2109-0730				ALFOLDI L, 1962, J MOL BIOL, V5, P348, DOI 10.1016/S0022-2836(62)80077-1; ALMOND N, 1989, MOL GEN GENET, V216, P195, DOI 10.1007/BF00334356; Arber W., 1983, LAMBDA, P433; BARACCHINI E, 1991, J BIOL CHEM, V266, P11753; BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; BARACCHINI E, 1987, ANAL BIOCHEM, V167, P245, DOI 10.1016/0003-2697(87)90160-6; BEDWELL DM, 1986, MOL GEN GENET, V204, P17, DOI 10.1007/BF00330181; BREMER H, 1968, J MOL BIOL, V38, P163, DOI 10.1016/0022-2836(68)90404-X; BREMER H, 1995, BBA-GENE STRUCT EXPR, V1262, P15, DOI 10.1016/0167-4781(95)00042-F; Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; BREMER H, 1988, NATO ADV SCI I SER H, V14, P63; BRUNSCHEDE H, 1977, J BACTERIOL, V129, P1020, DOI 10.1128/JB.129.2.1020-1033.1977; BURT DW, 1982, MOL GEN GENET, V185, P462, DOI 10.1007/BF00334141; CASHEL M, 1969, J BIOL CHEM, V244, P3133; CASHEL M, 1975, ANNU REV MICROBIOL, V29, P301, DOI 10.1146/annurev.mi.29.100175.001505; CHAMPOUX JJ, 1970, COLD SPRING HARB SYM, V35, P319, DOI 10.1101/SQB.1970.035.01.042; CHASHEL M, 1969, NATURE, V221, P838, DOI 10.1038/221838a0; CHOWDHURY DM, 1973, NATURE-NEW BIOL, V241, P196, DOI 10.1038/newbio241196a0; COLE JR, 1987, J MOL BIOL, V198, P383, DOI 10.1016/0022-2836(87)90288-9; COLE JR, 1988, NATO ADV SCI I SER H, V14, P56; CONDON C, 1993, EMBO J, V12, P4305, DOI 10.1002/j.1460-2075.1993.tb06115.x; CONDON C, 1995, MICROBIOL REV, V59, P623, DOI 10.1128/MMBR.59.4.623-645.1995; DALBOW DG, 1973, J MOL BIOL, V75, P181, DOI 10.1016/0022-2836(73)90537-8; DOVE WF, 1966, J MOL BIOL, V19, P187, DOI 10.1016/S0022-2836(66)80060-8; DOVE WF, 1971, BACTERIOPHAGE LAMBDA, P747; Echols H., 1971, BACTERIOPHAGE LAMBDA, P247; FIIL N, 1968, J BACTERIOL, V95, P729, DOI 10.1128/JB.95.2.729-731.1968; FIIL NP, 1972, J MOL BIOL, V71, P769; FORBES D, 1982, J MOL BIOL, V160, P549, DOI 10.1016/0022-2836(82)90314-X; Furth M., 1983, LAMBDA 2, P145; GAAL T, 1990, P NATL ACAD SCI USA, V87, P5533, DOI 10.1073/pnas.87.14.5533; GLASER G, 1983, NATURE, V302, P74, DOI 10.1038/302074a0; Goldberg A R, 1969, Virology, V38, P200, DOI 10.1016/0042-6822(69)90148-2; GOURSE RL, 1983, CELL, V32, P1347, DOI 10.1016/0092-8674(83)90315-X; HASE T, 1989, MOL GEN GENET, V216, P120, DOI 10.1007/BF00332239; HASELTIN.WA, 1972, NATURE, V238, P381, DOI 10.1038/238381a0; HEINEMEYER EA, 1978, P NATL ACAD SCI USA, V75, P4180, DOI 10.1073/pnas.75.9.4180; HERNANDEZ VJ, 1993, J BIOL CHEM, V268, P10851; HERNANDEZ VJ, 1991, J BIOL CHEM, V266, P5991; HERNANDEZ VJ, 1990, J BIOL CHEM, V265, P11605; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; Jinks-Robertson S., 1987, ESCHERICHIA COLI SAL, P1358; JINKSROBERTSON S, 1983, CELL, V33, P865, DOI 10.1016/0092-8674(83)90029-6; JOBLING MG, 1990, NUCLEIC ACIDS RES, V18, P5315, DOI 10.1093/nar/18.17.5315; KAJITANI M, 1984, J BIOL CHEM, V259, P1951; KINGSTON RE, 1981, CELL, V27, P523, DOI 10.1016/0092-8674(81)90394-9; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAFFLER T, 1974, CELL, V1, P27, DOI 10.1016/0092-8674(74)90151-2; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; LAZZARINI RA, 1971, J BIOL CHEM, V246, P4381; LITTLE R, 1982, ANAL BIOCHEM, V126, P381, DOI 10.1016/0003-2697(82)90531-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUK KC, 1983, MOL GEN GENET, V189, P289, DOI 10.1007/BF00337819; MANOR H, 1969, J MOL BIOL, V39, P1, DOI 10.1016/0022-2836(69)90329-5; MATSUBARA K, 1981, PLASMID, V5, P32, DOI 10.1016/0147-619X(81)90076-7; MATZURA H, 1973, J MOL BIOL, V74, P9, DOI 10.1016/0022-2836(73)90350-1; METZGER S, 1989, J BIOL CHEM, V264, P21146; MIZUSHIMASUGANO J, 1985, EMBO J, V4, P1053, DOI 10.1002/j.1460-2075.1985.tb03738.x; MIZUSHIMASUGANO J, 1983, MOL GEN GENET, V189, P185, DOI 10.1007/BF00337802; MOLIN S, 1976, P 9 A BENZ S, P333; MORGAN EA, 1986, J BACTERIOL, V168, P1; MUELLER K, 1968, J MOL BIOL, V38, P329, DOI 10.1016/0022-2836(68)90390-2; MURIALDO H, 1972, VIROLOGY, V48, P785, DOI 10.1016/0042-6822(72)90162-6; Nomura M, 1987, RNA POLYMERASE REGUL, P137; OWENS JR, 1987, BIOCHEM BIOPH RES CO, V142, P964, DOI 10.1016/0006-291X(87)91508-7; PEDERSEN S, 1978, MOL GEN GENET, V166, P329, DOI 10.1007/BF00267626; PETRENKO LA, 1989, GENE, V78, P85, DOI 10.1016/0378-1119(89)90316-8; PRIMAKOFF P, 1979, P NATL ACAD SCI USA, V76, P1726, DOI 10.1073/pnas.76.4.1726; PRIMAKOFF P, 1981, J BACTERIOL, V145, P410, DOI 10.1128/JB.145.1.410-416.1981; RAY PN, 1974, J MOL BIOL, V85, P163, DOI 10.1016/0022-2836(74)90135-1; RAY PN, 1975, NATURE, V253, P647, DOI 10.1038/253647a0; REDDY PS, 1995, MOL MICROBIOL, V15, P255, DOI 10.1111/j.1365-2958.1995.tb02240.x; REINESS G, 1975, P NATL ACAD SCI USA, V72, P2881, DOI 10.1073/pnas.72.8.2881; RIGGS DL, 1986, P NATL ACAD SCI USA, V83, P9333, DOI 10.1073/pnas.83.24.9333; ROBERTS JW, 1975, P NATL ACAD SCI USA, V72, P3300, DOI 10.1073/pnas.72.9.3300; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; RYALS J, 1982, J BACTERIOL, V150, P168, DOI 10.1128/JB.150.1.168-179.1982; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAMPSON LL, 1988, P NATL ACAD SCI USA, V85, P5439, DOI 10.1073/pnas.85.15.5439; SARMIENTOS P, 1983, P NATL ACAD SCI-BIOL, V80, P7010, DOI 10.1073/pnas.80.22.7010; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SCHREIBER G, 1991, J BIOL CHEM, V266, P3760; SHEPHERD N, 1980, J BACTERIOL, V143, P1332, DOI 10.1128/JB.143.3.1332-1344.1980; SHEPHERD NS, 1980, J BACTERIOL, V141, P1098, DOI 10.1128/JB.141.3.1098-1108.1980; SQUIRES CL, 1993, P NATL ACAD SCI USA, V90, P970, DOI 10.1073/pnas.90.3.970; STENT GS, 1961, P NATL ACAD SCI USA, V47, P2005, DOI 10.1073/pnas.47.12.2005; STEPHENS JC, 1975, P NATL ACAD SCI USA, V72, P4389, DOI 10.1073/pnas.72.11.4389; SVITIL AL, 1993, J BIOL CHEM, V268, P2307; SZALEWSKAPALASZ A, 1994, EMBO J, V13, P5779, DOI 10.1002/j.1460-2075.1994.tb06916.x; TEDIN K, 1992, J BIOL CHEM, V267, P2337; TRAVERS A, 1976, MOL GEN GENET, V147, P225, DOI 10.1007/BF00267575; VANOOYEN AJJ, 1975, NATURE, V254, P530, DOI 10.1038/254530a0; VANOOYEN AJJ, 1976, CELL, V8, P123, DOI 10.1016/0092-8674(76)90193-8; VOGEL U, 1995, J BIOL CHEM, V270, P18335, DOI 10.1074/jbc.270.31.18335; VOGEL U, 1994, J BACTERIOL, V176, P2807, DOI 10.1128/JB.176.10.2807-2813.1994; VOGEL U, 1994, J BIOL CHEM, V269, P16236; VOGEL U, 1992, MOL MICROBIOL, V6, P2191, DOI 10.1111/j.1365-2958.1992.tb01393.x; WEGRZYN G, 1991, MOL GEN GENET, V225, P94, DOI 10.1007/BF00282646; XIAO H, 1991, J BIOL CHEM, V266, P5980; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YOUNG RY, 1992, MICROBIOL REV, V56, P430, DOI 10.1128/MMBR.56.3.430-481.1992; ZACHARIAS M, 1989, EMBO J, V8, P3357, DOI 10.1002/j.1460-2075.1989.tb08498.x	103	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17675	17686		10.1074/jbc.271.30.17675	http://dx.doi.org/10.1074/jbc.271.30.17675			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663373	hybrid			2022-12-27	WOS:A1996UY93500016
J	Wong, EV; Schaefer, AW; Landreth, G; Lemmon, V				Wong, EV; Schaefer, AW; Landreth, G; Lemmon, V			Involvement of p90(rsk) in neurite outgrowth mediated by the cell adhesion molecule L1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 PHEOCHROMOCYTOMA CELLS; 2ND MESSENGER SYSTEMS; RIBOSOMAL S6 KINASE; PROTEIN-KINASE; NERVOUS-SYSTEM; L1-LIKE MOLECULE; IMMUNOGLOBULIN SUPERFAMILY; SIGNAL-TRANSDUCTION; NILE GLYCOPROTEIN; N-CAM	L1 is a neural cell adhesion molecule that has been shown to help guide nascent axons to their targets, This guidance is based on specific interactions of L1 with its binding partners and is likely to involve signaling cascades that alter cytoskeletal elements in response to these binding events. We have examined the phosphorylation of L1 and the role it may have in L1-directed neurite outgrowth. Cytosolic extracts from nerve growth factor-stimulated PC12 cells were fractionated by anion-exchange chromatography, and an activity was found that phosphorylated the cytoplasmic domain of L1. This activity was then assayed using a battery of L1-derived synthetic peptides, Based on these peptide assays and sequencing of radiolabeled L1 proteolytic fragments, the phosphorylation site was determined to be Ser(1152). Western blot analysis demonstrated that the L1 kinase activity from PC12 cells that phosphorylated this site was co-eluted with the S6 kinase, p90(rsk), Moreover, S6 kinase activity and p90(rsk) immunoreactivity co-immunoprecipitate with L1 from brain, and metabolic labeling studies have demonstrated that Ser(1152) is phosphorylated in vivo in the developing rat brain. The phosphorylation site is located in a region of high conservation between mammalian L1 sequences as well as L1-related molecules in vertebrates from fish to birds, We performed studies to investigate the functional significance of this phosphorylation, Neurons were loaded with peptides that encompass the phosphorylation site, as well as the flanking regions, and their effects on neurite outgrowth were observed. The peptides, which include Ser(1152), inhibit neurite outgrowth on L1 but not on a control substrate, laminin. A nonphosphorylatable peptide carrying a Ser to Ala mutation did not affect neurite outgrowth on either substrate, These data demonstrate that the membrane-proximal 15 amino acids of the cytoplasmic domain of L1 are important for neurite outgrowth on L1, and the interactions it mediates may be regulated by phosphorylation of Ser(1152).	CASE WESTERN RESERVE UNIV,DEPT NEUROSCI,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT NEUROL,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University			Lemmon, Vance/A-2565-2008; Lemmon, Vance/A-7410-2010	Lemmon, Vance/0000-0003-3550-7576	NEI NIH HHS [R01 EY005285] Funding Source: Medline; PHS HHS [31987, 5285] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005285] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUMMENDORF T, 1993, NEURON, V10, P711; Burden-Gulley Susan M., 1995, Seminars in Developmental Biology, V6, P79, DOI 10.1016/S1044-5781(06)80017-4; BURDENGULLEY SM, 1995, J NEUROSCI, V15, P4370; BURDENGULLEY SM, 1996, IN PRESS CELL MOTIL; CALVO V, 1992, EUR J IMMUNOL, V22, P457, DOI 10.1002/eji.1830220225; CERVELLO M, 1991, P NATL ACAD SCI USA, V88, P10548, DOI 10.1073/pnas.88.23.10548; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DAVIS JQ, 1993, J CELL BIOL, V121, P121, DOI 10.1083/jcb.121.1.121; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; DOHERTY P, 1994, J NEUROCHEM, V62, P2124; Doherty Patrick, 1994, Current Opinion in Neurobiology, V4, P49, DOI 10.1016/0959-4388(94)90031-0; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FAISSNER A, 1984, DEV BRAIN RES, V15, P69, DOI 10.1016/0165-3806(84)90141-X; FELSENFELD DP, 1994, NEURON, V12, P675, DOI 10.1016/0896-6273(94)90222-4; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; Goldman SA, 1996, MOL CELL NEUROSCI, V7, P29, DOI 10.1006/mcne.1996.0003; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GRUMET M, 1991, J CELL BIOL, V113, P1399, DOI 10.1083/jcb.113.6.1399; GRUMET M, 1984, P NATL ACAD SCI-BIOL, V81, P267, DOI 10.1073/pnas.81.1.267; HLAVIN ML, 1991, GENOMICS, V11, P416, DOI 10.1016/0888-7543(91)90150-D; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; ITOH K, 1992, BRAIN RES, V580, P233, DOI 10.1016/0006-8993(92)90949-A; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LANDMESSER L, 1988, DEV BIOL, V130, P645, DOI 10.1016/0012-1606(88)90358-2; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; LEMMON V, 1986, J NEUROSCI, V6, P2987; LINDNER J, 1983, NATURE, V305, P427, DOI 10.1038/305427a0; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NOVAKHOFER I, 1984, J BIOL CHEM, V259, P5995; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; PAYNE HR, 1992, CELL MOTIL CYTOSKEL, V21, P65, DOI 10.1002/cm.970210108; PRINCE JT, 1989, J NEUROSCI, V9, P1825; RADER C, 1993, EUR J BIOCHEM, V215, P133, DOI 10.1111/j.1432-1033.1993.tb18015.x; RATHJEN FG, 1987, CELL, V51, P841, DOI 10.1016/0092-8674(87)90107-3; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; ROSENTHAL A, 1992, NAT GENET, V2, P107, DOI 10.1038/ng1092-107; SADOUL R, 1989, J NEUROCHEM, V53, P1471, DOI 10.1111/j.1471-4159.1989.tb08540.x; SALTON SRJ, 1983, J NEUROSCI, V3, P2420; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; STALLCUP WB, 1985, P NATL ACAD SCI USA, V82, P1276, DOI 10.1073/pnas.82.4.1276; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAYLOR LK, 1994, J BIOL CHEM, V269, P308; TORDAI A, 1994, J BIOL CHEM, V269, P7538; VONBOHLEN F, 1992, EUR J NEUROSCI, V4, P896; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WILLIAMS EJ, 1992, J CELL BIOL, V119, P883, DOI 10.1083/jcb.119.4.883; WILLIAMS EJ, 1994, J NEUROCHEM, V62, P1281; Wong EV, 1996, J NEUROCHEM, V66, P779; WONG EV, 1995, TRENDS NEUROSCI, V18, P168, DOI 10.1016/0166-2236(95)93896-6	61	88	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18217	18223		10.1074/jbc.271.30.18217	http://dx.doi.org/10.1074/jbc.271.30.18217			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663493	hybrid			2022-12-27	WOS:A1996UY93500094
J	Blum, R; Feick, P; Puype, M; Vandekerckhove, J; Klengel, R; Nastainczyk, W; Schulz, I				Blum, R; Feick, P; Puype, M; Vandekerckhove, J; Klengel, R; Nastainczyk, W; Schulz, I			Tmp21 and p24A, two type I proteins enriched in pancreatic microsomal membranes, are members of a protein family involved in vesicular trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; ACINAR-CELLS; TRANSMEMBRANE PROTEINS; RAT PANCREAS; COILED COILS; RETENTION; IDENTIFICATION; TRANSPORT; SECRETION; BINDING	We report here on the isolation, cloning, and expression of two M(r)21,000 proteins from rat pancreatic acinar cells, the rat-Tmp21 (transmembrane protein, M(r) 21,000) and the rat-p24A. Both proteins are transmembrane proteins with type I topology and share weak but significant homology to one another (23% identity). We further show the cloning and characterization of the human homologs, hum-Tmp21, which is expressed in two variants (Tmp21-I and Tmp21-II), and hum-p24A. Tmp21 proteins and p24A have highly conserved COOH-terminal tails, which contain motifs related to the endoplasmic reticulum retention and retrieval consensus sequence KKXX. The rat-p24 sequence is identical to the hamster CHOp24, a recently characterized component of coatomer-coated transport vesicles, which defines a family of proteins (called the p24 family) proposed to be involved in vesicular transport processes (Stamnes, M. A., Craighead, M. W., Hoe, M. H., Lampen, N., Geromanos, S., Tempst, P., and Rothman, J. E. (1995) Proc. Natl. Acad. Sci. U.S.A. 92, 8011-8015). Sequence alignment and structural features identify the Tmp21 protein as a new member of this p24 family. Northern analysis of various tissues indicates that the Tmp21 proteins and the p24A protein are ubiquitously expressed. The integral membrane components Tmp21 and p24A are localized in microsomal membranes, zymogen granule membranes, and the plasma membrane and are absent from the cytosol. Both p24A and Tmp21 show weak homology to the yeast protein Emp24p, which recently has been shown to be involved in secretory protein transport from the endoplasmic reticulum to the Golgi apparatus. This leads us to conclude that the receptor-like Tmp21 and p24A are involved in vesicular targeting and protein transport.	UNIV SAARLAND,INST PHYSIOL 2,D-66421 HOMBURG,GERMANY; UNIV SAARLAND,INST MED BIOCHEM,D-66421 HOMBURG,GERMANY; STATE UNIV GHENT,LAB FYSIOL SCHEIKUNDE,B-9000 GHENT,BELGIUM	Saarland University; Saarland University; Ghent University			Blum, Robert/E-8899-2013	Blum, Robert/0000-0002-5270-3854				BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; BAYERDORFFER E, 1985, J MEMBRANE BIOL, V84, P45, DOI 10.1007/BF01871647; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DELSAL G, 1988, NUCLEIC ACIDS RES, V16, P9878; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FULLER CM, 1989, PFLUG ARCH EUR J PHY, V413, P385, DOI 10.1007/BF00584488; HOLTHUIS JCM, 1995, BIOCHEM J, V312, P205, DOI 10.1042/bj3120205; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; KAPPELER F, 1994, J BIOL CHEM, V269, P6279; KIMURA M, 1983, NEUTRAL THEORY MOL E, P149; KYRIAZIA AP, 1982, AM J PATHOL, V106, P205; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lowe M, 1995, J BIOL CHEM, V270, P31364, DOI 10.1074/jbc.270.52.31364; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Martire G, 1996, J BIOL CHEM, V271, P3541; OAS TG, 1994, TRENDS BIOCHEM SCI, V19, P51, DOI 10.1016/0968-0004(94)90030-2; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHIMMOLLER F, 1995, EMBO J, V131, P895; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STREB H, 1983, AM J PHYSIOL, V245, pG347, DOI 10.1152/ajpgi.1983.245.3.G347; WADA I, 1991, J BIOL CHEM, V266, P19599; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619; ZEUZEM S, 1991, FEBS LETT, V288, P143, DOI 10.1016/0014-5793(91)81021-Y; ZIMMERMANN P, 1992, AM J PHYSIOL, V263, pG396, DOI 10.1152/ajpgi.1992.263.3.G396	39	84	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17183	17189		10.1074/jbc.271.29.17183	http://dx.doi.org/10.1074/jbc.271.29.17183			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663407	hybrid			2022-12-27	WOS:A1996UX94300033
J	Charest, H; Zhang, WW; Matlashewski, G				Charest, H; Zhang, WW; Matlashewski, G			The developmental expression of Leishmania donovani A2 amastigote-specific genes is post-transcriptionally mediated and involves elements located in the 3'-untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN-83; TRYPANOSOMA-BRUCEI; GENOMIC ORGANIZATION; TUBULIN GENES; ARRANGEMENT; ENRIETTII; AMAZONENSIS; SEQUENCE; RNA	Leishmania donovani is a protozoan parasite that exists as a free-living promastigote in the sandfly insect vector and as an amastigote inside the mammalian host macrophage phagolysosome compartment. The L. donovani A2 genes have been described previously as developmentally expressed in amastigotes but can be induced experimentally in promastigotes by a combination of pH and temperature shifts, conditions that mimic the phagolysosomal compartment of the macrophage cell. Considering the importance of the amastigote stage in human infections, we have examined the molecular basis for amastigote stage-specific gene expression. Our results provide evidence that A2 developmental expression during the promastigote-to-amastigote cytodiffer entiation is mediated through differential RNA stability and involves the A2 mRNA 3'-untranslated region. The site of processing in the S' untranslated region was a major factor for the accumulation of A2 mRNAs in cells incubated under phagolysosomal conditions. The stability of reporter gene transcripts bearing the A2 8'-untranslated region was increased in cells incubated at low pH, further confirming the importance of pH shift as an inducer for A2 expression. These observations contribute to defining the mechanism of amastigote-specific gene regulation in L. donovani. We also demonstrate the feasibility of using the A2 locus to express heterologous genes differentially in the amastigote form of the L. donovani parasite.	MCGILL UNIV, INST PARASITOL, Ste Anne De Bellevue, PQ H9X 3V9, CANADA	McGill University				Zhang, Wenwei/0000-0003-1996-876X				ARGAMAN M, 1994, MOL BIOCHEM PARASIT, V64, P95, DOI 10.1016/0166-6851(94)90138-4; Beverley S M, 1993, Methods Mol Biol, V21, P333; BOCK JH, 1993, MOL BIOCHEM PARASIT, V62, P187, DOI 10.1016/0166-6851(93)90108-A; BONEN L, 1993, FASEB J, V7, P40, DOI 10.1096/fasebj.7.1.8422973; BRANDAU S, 1995, BIOCHEM J, V310, P225, DOI 10.1042/bj3100225; CHAREST H, 1994, MOL CELL BIOL, V14, P2975, DOI 10.1128/MCB.14.5.2975; CLAYTON C, 1992, PROG NUCLEIC ACID RE, V43, P37, DOI 10.1016/S0079-6603(08)61043-0; COBURN CM, 1991, MOL BIOCHEM PARASIT, V46, P169, DOI 10.1016/0166-6851(91)90210-W; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; DELAFAILLE MAC, 1992, J BIOL CHEM, V267, P23839; DESCOTEAUX A, 1989, MOL CELL BIOL, V9, P5223, DOI 10.1128/MCB.9.11.5223; FLINN HM, 1992, NUCLEIC ACIDS RES, V20, P755, DOI 10.1093/nar/20.4.755; HUANG PL, 1984, MOL CELL BIOL, V4, P1372, DOI 10.1128/MCB.4.7.1372; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P87, DOI 10.1016/0166-6851(93)90161-P; JEFFERIES D, 1991, MOL CELL BIOL, V11, P338, DOI 10.1128/MCB.11.1.338; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LANDFEAR SM, 1983, MOL CELL BIOL, V3, P1070, DOI 10.1128/MCB.3.6.1070; LEBOWITZ JH, 1993, GENE DEV, V7, P996, DOI 10.1101/gad.7.6.996; LEE MGS, 1988, NUCLEIC ACIDS RES, V16, P9567, DOI 10.1093/nar/16.20.9567; Molyneux DH, 1987, LEISHMANIASES BIOL M, V1, P121; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; PAPADOPOULOU B, 1994, MOL BIOCHEM PARASIT, V65, P39, DOI 10.1016/0166-6851(94)90113-9; PAYS E, 1993, EUKARYOTIC MICROBIAL, P99; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAPIRA M, 1989, EUR J BIOCHEM, V185, P231, DOI 10.1111/j.1432-1033.1989.tb15107.x; TEIXEIRA SMR, 1995, J BIOL CHEM, V270, P22586, DOI 10.1074/jbc.270.38.22586; WALTON BC, 1987, LEISHMANIASIS BIOL M, V2; WILSON K, 1991, NUCLEIC ACIDS RES, V19, P5787, DOI 10.1093/nar/19.20.5787; World Health Organization (WHO), 1993, TROP DIS RES PROGR 1; ZHANG WW, 1996, IN PRESS MOL BIOCH P	31	117	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17081	17090		10.1074/jbc.271.29.17081	http://dx.doi.org/10.1074/jbc.271.29.17081			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663340	hybrid			2022-12-27	WOS:A1996UX94300018
J	Yanagihara, N; Oishi, Y; Yamamoto, H; Tsutsui, M; Kondoh, J; Sugiura, T; Miyamoto, E; Izumi, F				Yanagihara, N; Oishi, Y; Yamamoto, H; Tsutsui, M; Kondoh, J; Sugiura, T; Miyamoto, E; Izumi, F			Phosphorylation of chromogranin A and catecholamine secretion stimulated by elevation of intracellular Ca2+ in cultured bovine adrenal medullary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; 56 MM K+; TYROSINE-HYDROXYLASE; CHROMAFFIN CELLS; NERVOUS-TISSUE; PC12 CELLS; RAT-BRAIN; ACTIVATION; PURIFICATION; STAUROSPORINE	We have recently isolated a new endogenous substrate of 70 kDa for Ca2+/calmodulin dependent protein kinase II (CaM kinase II) from bovine adrenal medullary cells (Yanagihara, N., Toyohira, Y., Yamamoto, H., Ohta, Y., Tsutsui, M., Miyamoto, E., and Izumi, F. (1994) Mol. Pharmacol. 46, 423-430). Here we report the sequence analysis of the 70-kDa protein and examine its phosphorylation by various protein kinases in vitro and by depolarization of the cultured cells, Protein sequencing and immunoblotting revealed that the 70-kDa protein is chromogranin A (CgA) or a closely related protein. Partially purified CgA was phosphorylated by cyclic AMP-dependent protein kinase and protein kinase C as well as CaM kinase II, Tryptic phosphopeptide mapping patterns of CgA differed among these protein kinases. In P-32-labeled bovine adrenal medullary cells, 56 mM K+ increased the phosphorylation of CgA and catecholamine secretion in similar time- and concentration-dependent manners, both of which were inhibited by 20 mM MgSO4, an inhibitor of voltage-dependent Ca2+ channels. These findings suggest that CgA serves as a substrate for several multifunctional protein kinases and that the elevation of the intracellular Ca2+ stimulates the phosphorylation of CgA associated with catecholamine secretion in cultured adrenal medullary cells.	UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,DEPT IMMUNOL,KITAKYUSHU,FUKUOKA 807,JAPAN; UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,DEPT INTERNAL MED 2,KITAKYUSHU,FUKUOKA 807,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT PHARMACOL,KUMAMOTO 860,JAPAN; MITSUBISHI KAGAKU CORP,RES CTR,YOKOHAMA,KANAGAWA 224,JAPAN	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; Kumamoto University	Yanagihara, N (corresponding author), UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,DEPT PHARMACOL,YAHATANISHI KU,1-1 ISEIGAOKA,KITAKYUSHU,FUKUOKA 807,JAPAN.							AMY CM, 1981, J NEUROCHEM, V36, P847, DOI 10.1111/j.1471-4159.1981.tb01671.x; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTE A, 1986, NEUROSCIENCE, V19, P629, DOI 10.1016/0306-4522(86)90286-1; DOUGLAS WW, 1961, J PHYSIOL-LONDON, V159, P40, DOI 10.1113/jphysiol.1961.sp006791; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FUKUNAGA K, 1982, J NEUROCHEM, V39, P1607, DOI 10.1111/j.1471-4159.1982.tb07994.x; GEORGE RJ, 1989, J NEUROCHEM, V52, P274, DOI 10.1111/j.1471-4159.1989.tb10928.x; GRIFFITH LC, 1988, J BIOL CHEM, V263, P9542; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HAYCOCK JW, 1982, J BIOL CHEM, V257, P2641; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KONDO N, 1992, J BIOL CHEM, V267, P473; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P51, DOI 10.1016/0005-2744(81)90107-8; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MIYAMOTO E, 1974, J BIOL CHEM, V249, P2769; MIYAMOTO E, 1973, J BIOL CHEM, V248, P179; NAGATSU T, 1973, BIOCH CATECHOLAMINES, P170; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OCONNOR DT, 1984, J BIOL CHEM, V259, P3237; POCOTTE SL, 1986, J NEUROCHEM, V46, P610, DOI 10.1111/j.1471-4159.1986.tb13011.x; POLLARD HB, 1976, J BIOL CHEM, V251, P4544; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; ROSKOSKI R, 1983, METHOD ENZYMOL, V79, P3; SOMOGYI P, 1984, BRAIN RES REV, V8, P193, DOI 10.1016/0165-0173(84)90007-9; SUGIURA T, 1994, INT ARCH ALLERGY IMM, V103, P341, DOI 10.1159/000236652; TACHIKAWA E, 1986, MOL PHARMACOL, V30, P476; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TERBUSH DR, 1988, J BIOL CHEM, V263, P18873; TSUTSUI M, 1994, MOL PHARMACOL, V46, P1041; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WAYMIRE JC, 1988, J BIOL CHEM, V263, P12439; WAYMIRE JC, 1983, J NEUROSCI METH, V7, P329, DOI 10.1016/0165-0270(83)90026-2; WEILMALHERBE H, 1952, BIOCHEM J, V51, P311, DOI 10.1042/bj0510311; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1993, J ANAT, V183, P237; WOOTEN MW, 1987, EUR J BIOCHEM, V164, P461, DOI 10.1111/j.1432-1033.1987.tb11079.x; YANAGIHARA N, 1987, BIOCHEM PHARMACOL, V36, P3823, DOI 10.1016/0006-2952(87)90444-8; YANAGIHARA N, 1994, MOL PHARMACOL, V46, P423; YANAGIHARA N, 1984, MOL PHARMACOL, V26, P141; YANAGIHARA N, 1991, J NEUROCHEM, V56, P294, DOI 10.1111/j.1471-4159.1991.tb02595.x; YANAGIHARA N, 1979, FEBS LETT, V105, P296, DOI 10.1016/0014-5793(79)80633-X; YOO SH, 1990, J BIOL CHEM, V265, P14414	44	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17463	17468		10.1074/jbc.271.29.17463	http://dx.doi.org/10.1074/jbc.271.29.17463			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663339	hybrid			2022-12-27	WOS:A1996UX94300074
J	Holst, C; Zipfel, PF				Holst, C; Zipfel, PF			A zinc finger gene from Onchocerca volvulus encodes a protein with a functional signal peptide and an unusual Ser-His finger motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIIA; BINDING-PROTEIN; POLYADENYLATION; CLEAVAGE; SEQUENCES; HOMOLOGY; DOMAINS; KRUPPEL; ELEMENT; MEMBER	The filarial parasite Onchocerca volvulus is the causative agent of river blindness. In order to identify genes potentially involved in parasite development we cloned a zinc finger-encoding gene from this species. The ovzf-1 gene represents one member of a family of related zinc finger genes. The predicted ovzf-1 translation product of 447 amino acids includes a hydrophobic signal peptide, which is followed by 13 contiguous finger motifs. The domains of fingers II-XIII display several conserved amino acids and a typical Kruppel-like Cys(2)-His(2) motif. The first finger domain has the two conserved Cys residues replaced with Ser residues; however, it includes all additional amino acids typical of zinc finger domains. The N-terminal domain functions as a signal peptide, as it directs secretion of a reporter protein and a truncated Ovzf protein. Expression of an Ovzf protein via the secretory pathway was also confirmed by demonstrating attachment of N-linked carbohydrates to the recombinant protein. Although the recombinant Ovzf protein also includes a signal peptide, immunofluorescence analyses localize it inside a specific compartment of the infected insect cell. Expression of ovzf mRNA is developmentally regulated; no specific transcript is detected in adult female worms but in the infective L3. Identification of a secreted protein that might function in modulating gene expression of host cells provides an interesting tool for the study of parasite-host interaction on a biochemical and molecular level.	BERNHARD NOCHT INST TROP MED,DEPT MOLEC BIOL,D-20359 HAMBURG,GERMANY	Bernhard Nocht Institut fur Tropenmedizin								BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; Bianco A.E., 1991, P138; BLACKLOCK D. B., 1926, ANN TROP MED & PARASITOL, V20, P1; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; ELBARADI T, 1991, MECH DEVELOP, V35, P155, DOI 10.1016/0925-4773(91)90015-X; GREENE BM, 1992, J INFECT DIS, V166, P15, DOI 10.1093/infdis/166.1.15; Haehling E, 1995, INT J PARASITOL, V25, P1393, DOI 10.1016/0020-7519(95)00080-1; HAMMOND MP, 1992, PARASITOL TODAY, V8, P299, DOI 10.1016/0169-4758(92)90100-G; HEHL A, 1994, P NATL ACAD SCI USA, V91, P370, DOI 10.1073/pnas.91.1.370; HEUCKESHOVEN J, 1986, ELECTROPHORESIS, V6, P103; HOLST C, 1993, TROP MED PARASITOL, V44, P147; JASMER DP, 1994, MOL BIOCHEM PARASIT, V67, P225, DOI 10.1016/0166-6851(94)00131-6; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRISTENSEN T, 1986, J IMMUNOL, V136, P3407; KUHN S, 1995, GENE, V162, P225, DOI 10.1016/0378-1119(95)00360-I; KUHN S, 1995, J IMMUNOL, V155, P5663; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFEAR J, 1991, BIOCHEM BIOPH RES CO, V179, P1220, DOI 10.1016/0006-291X(91)91702-E; LIEBAU E, 1994, MOL BIOCHEM PARASIT, V63, P305, DOI 10.1016/0166-6851(94)90067-1; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MAYER RJ, 1987, IMMUNOCHEMICAL METHO; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MULLER HJ, 1991, P NATL ACAD SCI USA, V88, P10079, DOI 10.1073/pnas.88.22.10079; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SCHULZKEY H, 1977, TROPENMED PARASITOL, V28, P428; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; VASSILATIS DK, 1992, J BIOL CHEM, V267, P18459; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; *WHO EXP COMM ONCH, 3 WHO EXP COMM ONCH; ZARKOWER D, 1993, NUCLEIC ACIDS RES, V21, P3691, DOI 10.1093/nar/21.16.3691; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X; ZIPFEL PF, 1994, IMMUNOL TODAY, V15, P121, DOI 10.1016/0167-5699(94)90155-4	45	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16725	16733		10.1074/jbc.271.28.16725	http://dx.doi.org/10.1074/jbc.271.28.16725			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663215	hybrid			2022-12-27	WOS:A1996UX12600049
J	Wojcikiewicz, RJH; Oberdorf, JA				Wojcikiewicz, RJH; Oberdorf, JA			Degradation of inositol 1,4,5-trisphosphate receptors during cell stimulation is a specific process mediated by cysteine protease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; ENDOPLASMIC-RETICULUM; NEUROBLASTOMA-CELLS; KINASE-C; CALCIUM; PROTEINS; BINDING; TRISPHOSPHATE; INHIBITION; AUTOPHAGY	Inositol 1,4,5-trisphosphate (InsP(3)) receptors are down-regulated in response to chronic activation of certain cell surface receptors because their degradation is accelerated, Studies on the nature of the down-regulatory process and the protease(s) responsible for receptor degradation are described here, InsP(3) receptor down-regulation was not accompanied by parallel changes in the concentrations of several other relevant proteins (endoplasmic reticulum Ca2+-ATPase, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, and protein kinases alpha and epsilon). Thus, the down-regulatory process selectively targets InsP(3) receptors for degradation, Furthermore, down-regulation was unaffected by brefeldin A and NH4Cl, indicating that InsP(3) receptor degradation occurs without removal of receptors from the endoplasmic reticulum and independently of functional lysosomes, Analysis of InsP(3) receptor immunofluorescence confirmed that the receptors are not redistributed prior to or during down-regulation, Finally, of a range of protease inhibitors tested, only N-acetyl-Leu-Leu-norleucinal blocked down-regulation. Thus, cysteine protease activity accounts for InsP(3) receptor degradation and analysis of proteolysis in permeabilized cells indicates that this activity is calpain, Thus, InsP(3) receptor downregulation appears to result from the highly selective calpain-mediated degradation of InsP(3) receptors, Calpain activity may be stimulated by the high concentrations of Ca2+ that are thought to be found in the vicinity of activated InsP(3) receptors.			Wojcikiewicz, RJH (corresponding author), SUNY HLTH SCI CTR, COLL MED, DEPT PHARMACOL, 750 E ADAMS ST, SYRACUSE, NY 13210 USA.			Oberdorf, Jon/0000-0002-0589-7115	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049194, R29DK049194] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49194] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANNO Y, 1995, J BIOL CHEM, V270, P4318, DOI 10.1074/jbc.270.9.4318; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DAWSON AP, 1995, BIOCHEM J, V310, P371, DOI 10.1042/bj3100371; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; ETO A, 1995, J BIOL CHEM, V270, P25115, DOI 10.1074/jbc.270.42.25115; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V62, P1989; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GORDON PB, 1993, J BIOL CHEM, V268, P26107; INOUE S, 1992, J BIOL CHEM, V267, P9080; INOUE S, 1991, J BIOL CHEM, V266, P13311; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; KILEY SC, 1991, J BIOL CHEM, V266, P23761; LIEVREMONT JP, 1994, BIOCHEM J, V300, P419, DOI 10.1042/bj3000419; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MA H, 1994, J BIOL CHEM, V269, P24430; MAGNUSSON A, 1993, FEBS LETT, V323, P229, DOI 10.1016/0014-5793(93)81345-Z; MEIGS TE, 1992, J BIOL CHEM, V267, P13547; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIMURA Y, 1995, BIOL PHARM BULL, V18, P945; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHEA TB, 1994, FEBS LETT, V350, P223, DOI 10.1016/0014-5793(94)00769-1; SITIA R, 1992, MOL BIOL CELL, V3, P1067, DOI 10.1091/mbc.3.10.1067; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; TAYLOR CW, 1995, BIOCHEM SOC T, V23, P637, DOI 10.1042/bst0230637; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; WOJCIKIEWICZ RJH, 1992, J NEUROCHEM, V59, P383, DOI 10.1111/j.1471-4159.1992.tb08916.x; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WOJCIKIEWICZ RJH, 1991, J BIOL CHEM, V266, P22234; WUWONG JYR, 1993, MOL PHARMACOL, V44, P422; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	44	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16652	16655		10.1074/jbc.271.28.16652	http://dx.doi.org/10.1074/jbc.271.28.16652			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663308	hybrid			2022-12-27	WOS:A1996UX12600037
J	Knezevic, I; Leisner, TM; Lam, SCT				Knezevic, I; Leisner, TM; Lam, SCT			Direct binding of the platelet integrin alpha(IIb)beta(3) (GPIIb-IIIa) to talin - Evidence that interaction is mediated through the cytoplasmic domains of both alpha(IIb) and beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; ACTIVATED PLATELETS; FOCAL ADHESIONS; LIGAND-BINDING; RECEPTOR; PROTEIN; VINCULIN; CYTOSKELETON; PURIFICATION; ASSOCIATION	As a consequence of platelet activation and fibrinogen binding, glycoprotein (GP)IIb-IIIa (integrin alpha(IIb)beta(3)) becomes associated with the cytoskeleton. Although talin has been suggested to act as a Linkage protein mediating the attachment of GPIIb-IIIa to actin filaments, direct binding of GPIIb-IIIa to this cytoskeletal protein has not been demonstrated, in the present study, we examined the interaction of GPIIb-IIIa with purified talin using a solid-phase binding assay, Soluble GPIIb-IIIa bound in a time- and dose dependent manner to microtiter wells coated with talin but not with BSA. Time course studies demonstrated that steady-state binding was achieved after 4-5 h incubation at 37 degrees C. Binding isotherms with varying concentrations of GPIIb-IIIa showed that half-saturation binding was achieved at approximately 15 nM GPIIb-IIIa. At saturation, there was 211 +/- 8 fmol of GPIIb-IIIa bound per well containing 117 +/- 10 fmol of immobilized talin. Besides binding to immobilized talin, GPIIb-IIIa also bound to talin captured by the anti-talin monoclonal antibody 8d4, Moreover, the interaction of GPIIb-IIIa to 8d4-captured talin was blocked by mAb10B2, a monoclonal antibody raised against a synthetic peptide encompassing the entire cytoplasmic sequence of GPIIb. The interaction of talin with the cytoplasmic domain of GPIIb-IIIa was further investigated using peptide-coated wells, Purified talin was found to bind to both synthetic peptides corresponding 60 the cytoplasmic sequences of GPIIb (P2b) and GPIIIa (P3a), As expected, the binding of talin to P2b-coated wells was specifically blocked by mAb10B2. Thus, these results demonstrate direct binding of GPIIb-IIIa to talin and suggest a role of the cytoplasmic sequences of both GPIIb and GPIIIa in mediating this interaction.	UNIV ILLINOIS,DEPT PHARMACOL MC868,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NHLBI NIH HHS [HL-41793] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041793, R29HL041793] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKERLE MC, 1989, J CELL BIOL, V109, P3333, DOI 10.1083/jcb.109.6.3333; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BERTAGNOLLI ME, 1993, J CELL BIOL, V121, P1329, DOI 10.1083/jcb.121.6.1329; BERTAGNOLLI ME, 1993, J CELL SCI, V106, P1189; BORG C, 1993, BIOCHEM PHARMACOL, V45, P2071, DOI 10.1016/0006-2952(93)90018-R; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; COLLIER NC, 1982, J BIOL CHEM, V257, P6937; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GILMORE AP, 1992, J CELL SCI, V103, P719; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; ISENBERG WM, 1987, J CELL BIOL, V150, pA130; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; KOUNS WC, 1991, J BIOL CHEM, V266, P13891; LAM SCT, 1992, J BIOL CHEM, V267, P5649; LEE SW, 1992, J BIOL CHEM, V267, P16355; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOFTUS JC, 1988, J BIOL CHEM, V263, P11025; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MCEVER RP, 1980, J CLIN INVEST, V66, P1311, DOI 10.1172/JCI109983; MUGURUMA M, 1990, BIOCHEM BIOPH RES CO, V171, P1217, DOI 10.1016/0006-291X(90)90815-5; MUIR TW, 1994, BIOCHEMISTRY-US, V33, P7701, DOI 10.1021/bi00190a025; NORTH AJ, 1993, J CELL BIOL, V120, P1159, DOI 10.1083/jcb.120.5.1159; OTEY C, 1990, HYBRIDOMA, V9, P57, DOI 10.1089/hyb.1990.9.57; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTTO JJ, 1983, J CELL BIOL, V97, P1283, DOI 10.1083/jcb.97.4.1283; PAINTER RG, 1985, J CELL BIOL, V100, P652, DOI 10.1083/jcb.100.2.652; PAVALKO FM, 1994, P SOC EXP BIOL MED, V205, P282; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1992, SEMIN THROMB HEMOST, V18, P324, DOI 10.1055/s-2007-1002571; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; PLOW EF, 1986, BIOCH PLATELETS, P226; SHADLE PJ, 1984, J CELL BIOL, V99, P2056, DOI 10.1083/jcb.99.6.2056; SIMMON KO, 1991, J CELL BIOL, V115, pA351; TAPLEY P, 1989, ONCOGENE, V4, P325; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER CE, 1989, EUR J CELL BIOL, V49, P202; TUSZYNSKI GP, 1984, J BIOL CHEM, V259, P5247; WENCELDRAKE JD, 1990, AM J PATHOL, V136, P61; WENCELDRAKE JD, 1993, BLOOD, V81, P62; WHEELER ME, 1984, J CLIN INVEST, V74, P1080, DOI 10.1172/JCI111475; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; 1968, J BIOL CHEM, V243, P3557	53	113	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16416	16421		10.1074/jbc.271.27.16416	http://dx.doi.org/10.1074/jbc.271.27.16416			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663236	hybrid			2022-12-27	WOS:A1996UW35200082
J	Valenzuela, CF; Xiong, ZG; MacDonald, JF; Weiner, JL; Frazier, CJ; Dunwiddie, TV; Kazlauskas, A; Whiting, PJ; Harris, RA				Valenzuela, CF; Xiong, ZG; MacDonald, JF; Weiner, JL; Frazier, CJ; Dunwiddie, TV; Kazlauskas, A; Whiting, PJ; Harris, RA			Platelet-derived growth factor induces a long-term inhibition of N-methyl-D-aspartate receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; RAT HIPPOCAMPAL-NEURONS; DEVELOPMENTAL EXPRESSION; ALPHA-RECEPTOR; PDGF; CALCIUM; CHANNELS; PROTEIN; SUPPRESSION; CULTURE	Platelet-derived growth factor (PDGF) is a multifunctional protein that plays important roles in many tissues, including the mammalian central nervous system. PDGF and PDGF receptors (PDGFRs) are expressed in virtually every region of the central nervous system where they are involved in the development, survival, growth, and differentiation of both neuronal and glial cells. We now report that a brief activation of PDGFRs produced a long-lasting inhibition of N-methyl-D-aspartate (NMDA) dependent excitatory postsynaptic currents in CA1 pyramidal neurons in rat hippocampal slices. PDGF also inhibited NMDA receptors (NMDA-Rs) in cultured hippocampal neurons by a mechanism that involves a decrease in single channel open probability. Non-NMDA receptor function was not affected by PDGF in hippocampal neurons. Experiments with mutant PDGFRs and chelation of intracellular Ca2+ in Xenopus oocytes indicate that this inhibition depends on a phospholipase C-gamma-induced elevation of intracellular Ca2+ levels. The PDGF-induced inhibition of NMDA-Rs is produced by a mechanism different than the well characterized phenomenon of Ca2+-dependent NMDA-R run down because the effect of PDGF was blocked by the phosphatase inhibitor, calyculin A, and was not affected by the microtubule polymerizing agent, phalloidin. Because elevations of PDGF levels are associated with neurological trauma or disease, we propose that PDGF can exert neuroprotective effects by inhibiting NMDA-R-dependent excitotoxicity.	UNIV COLORADO,HLTH SCI CTR,PROGRAM NEUROSCI,DENVER,CO 80262; UNIV TORONTO,DEPT PHYSIOL,TORONTO,ON M5S 1A8,CANADA; VET ADM MED CTR,DENVER,CO 80220; NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206; MERCK SHARP & DOHME RES LABS,HARLOW,ESSEX,ENGLAND	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Toronto; US Department of Veterans Affairs; Veterans Health Administration (VHA); National Jewish Health; Merck & Company	Valenzuela, CF (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,BOX C236,4200 E 9TH AVE,DENVER,CO 80262, USA.			Whiting, Paul/0000-0002-4121-1379	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006399, R37AA006399, P50AA003527, F32AA005399] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA03527, AA05399, AA06399] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; CHENG B, 1995, J NEUROCHEM, V65, P2525; CHENG B, 1995, J NEUROSCI, V15, P7095; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; HANAI K, 1987, J CELL BIOL, V104, P1675, DOI 10.1083/jcb.104.6.1675; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; IIHARA K, 1994, J CEREBR BLOOD F MET, V14, P818, DOI 10.1038/jcbfm.1994.102; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; LEBOURDELLES B, 1994, J NEUROCHEM, V62, P2091; LEGENDRE P, 1993, J NEUROSCI, V13, P674; LESSMANN V, 1994, NEUROREPORT, V6, P21; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIU LF, 1995, NEUROSCI LETT, V192, P5, DOI 10.1016/0304-3940(95)11593-L; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; LUPICA CR, 1992, J NEUROSCI, V12, P3753; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MAYER ML, 1985, J PHYSIOL-LONDON, V361, P65, DOI 10.1113/jphysiol.1985.sp015633; MEDINA L, 1995, J PHYSIOL-LONDON, V482, P567; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; NISTER M, 1994, BRIT J CANCER, V69, P952, DOI 10.1038/bjc.1994.184; ORRURTREGER A, 1992, DEVELOPMENT, V115, P289; OTHBERG A, 1995, EXP BRAIN RES, V105, P111; PLATASALAMAN CR, 1988, NEUROSCI LETT, V94, P161, DOI 10.1016/0304-3940(88)90288-1; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; ROSENMUND C, 1993, J PHYSIOL-LONDON, V470, P705, DOI 10.1113/jphysiol.1993.sp019884; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SMITS A, 1991, P NATL ACAD SCI USA, V88, P8159, DOI 10.1073/pnas.88.18.8159; SMITS A, 1993, EUR J NEUROSCI, V5, P986, DOI 10.1111/j.1460-9568.1993.tb00950.x; STANLEY BG, 1993, BRAIN RES, V630, P41; TAKAYAMA S, 1994, BRAIN RES, V653, P131, DOI 10.1016/0006-8993(94)90381-6; TIMPE LC, 1994, J NEUROSCI, V14, P1195, DOI 10.1523/JNEUROSCI.14-03-01195.1994; TONG G, 1994, J NEUROPHYSIOL, V72, P754, DOI 10.1152/jn.1994.72.2.754; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; Valenzuela CF, 1995, MOL PHARMACOL, V48, P1099; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VASSBOTN FS, 1994, J CELL PHYSIOL, V158, P381, DOI 10.1002/jcp.1041580221; VIGNAIS L, 1995, NEUROREPORT, V6, P1993, DOI 10.1097/00001756-199510010-00010; VYKLICKY L, 1993, J PHYSIOL-LONDON, V470, P575, DOI 10.1113/jphysiol.1993.sp019876; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WILLIAMS JP, 1995, J CELL BIOCHEM, V57, P415, DOI 10.1002/jcb.240570307; YEH HJ, 1993, P NATL ACAD SCI USA, V90, P1952, DOI 10.1073/pnas.90.5.1952; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K; YU HJ, 1993, MOL PHARMACOL, V44, P689; ZHONG J, 1995, J NEUROCHEM, V64, P531	56	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16151	16159		10.1074/jbc.271.27.16151	http://dx.doi.org/10.1074/jbc.271.27.16151			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663218	hybrid			2022-12-27	WOS:A1996UW35200046
J	Ettinger, SL; Lauener, RW; Duronio, V				Ettinger, SL; Lauener, RW; Duronio, V			Protein kinase C delta specifically associates with phosphatidylinositol 3-kinase following cytokine stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; HEMATOPOIETIC-CELLS; GM-CSF; ACTIVATION; INTERLEUKIN-3; GROWTH; RECEPTOR; LINE; 3,4,5-TRISPHOSPHATE	Phosphatidylinositol (PI) 3-kinase is activated as a result of cytokine-induced association of the enzyme with specific tyrosine phosphorylated proteins. PI 3-kinase lipid products, PI 3,4-P-2 and PI 3,4,5-P-3, have been shown, in vitro, to directly activate novel and atypical protein kinase C (PKC) isozymes. However, the mechanism by which PI 3-kinase may be involved in regulation of PKC isoforms in vivo is presently unknown. We investigated a possible relationship by looking for associations between these enzymes. We found that in a human erythroleukemia cell line, as well as in rabbit platelets, PI 3-kinase and PKC delta associate in a specific manner that is modulated by cell activation. Granulocyte-macrophage colony-stimulating factor treatment of cells caused increased association of PKC delta and PI S-kinase as did treatment of platelets with platelet-activating factor. Results using two PIS-kinase inhibitors, wortmannin and LY-294002, showed that the former inhibited this association, while the latter did not, suggesting that PI 3-kinase lipid products may not be a prerequisite for the PI 3-kinase/PKC delta association. Our results also suggest that tyrosine phosphorylation of PKC delta is not involved in its association with PI 3-kinase.	UNIV BRITISH COLUMBIA,JACK BELL RES CTR,DEPT MED,VANCOUVER,BC V6H 3Z6,CANADA	University of British Columbia								ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BASTA P, 1992, BIOCHIM BIOPHYS ACTA, V1132, P154, DOI 10.1016/0167-4781(92)90006-L; BOURGOIN S, 1990, J EXP MED, V172, P767, DOI 10.1084/jem.172.3.767; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V81, P3204; DURONIO V, 1989, BIOCHEM BIOPH RES CO, V164, P804, DOI 10.1016/0006-291X(89)91530-1; DURONIO V, 1992, J BIOL CHEM, V267, P21856; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FARRAR WL, 1985, NATURE, V315, P235, DOI 10.1038/315235a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GOLD MR, 1992, J IMMUNOL, V148, P2012; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; LI WQ, 1994, J BIOL CHEM, V269, P2349; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MYERS MG, 1994, J BIOL CHEM, V269, P28788; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OHNO S, 1994, J BIOL CHEM, V269, P17495; OKUDA K, 1992, BLOOD, V79, P2880; PELECH SL, 1990, J IMMUNOL, V144, P1759; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; PINKARD RN, 1984, J IMMUNOL, V123, P1847; ROBINSON M, 1991, J IMMUNOL, V147, P2624; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; TOKER A, 1994, J BIOL CHEM, V269, P32358; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1992, J IMMUNOL, V149, P1683	40	82	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14514	14518		10.1074/jbc.271.24.14514	http://dx.doi.org/10.1074/jbc.271.24.14514			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663229	hybrid			2022-12-27	WOS:A1996UQ66000085
J	Nediani, C; Fiorillo, C; Marchetti, E; Pacini, A; Liguri, G; Nassi, P				Nediani, C; Fiorillo, C; Marchetti, E; Pacini, A; Liguri, G; Nassi, P			Stimulation of cardiac sarcoplasmic reticulum calcium pump by acylphosphatase - Relationship to phospholamban phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3'-5'-MONOPHOSPHATE-DEPENDENT PROTEIN-KINASE; HEART SARCOLEMMA; TRANSPORT; MECHANISM; ATPASE; CALMODULIN; PHOSPHATE; COMPONENT; MUSCLE; ASSAY	Ca2+ transport by cardiac sarcoplasmic reticulum is tightly coupled with the enzymatic activity of Ca2+-dependent ATPase, which forms and decomposes an intermediate phosphoenzyme, Heart sarcoplasmic reticulum Ca2+ pump is regulated by cAMP-dependent protein kinase (PRA) phospholamban phosphorylation, which results in a stimulation of the initial rates of Ca2+ transport and Ca2+ ATPase activity. In the present studies we found that acylphosphatase from heart muscle, used at concentrations within the physiological range, actively hydrolyzes the phosphoenzyme of cardiac sarcoplasmic reticulum Ca2+ pump, with all apparent K-m on the order of 10(-7) M, suggesting an high affinity of the enzyme for this special substrate. In umphosphorylated vesicles acylphosphatase enhanced the rate of ATP hydrolysis and Ca2+ uptake with a concomitant significant decrease in apparent K-m, for Ca2+ and ATP. In vesicles whose phospholamban was PKA-phosphorylated, acylphosphatase also stimulated the rate of Ca2+ uptake and ATP hydrolysis but to a lesser extent, and the K-m values for Ca2+ and ATP were not significantly different with respect to those found in the absence of acylphosphatase. These findings suggest that acylphosphatase, owing to its hydrolytic effect, accelerates the turnover of the phosphoenzyme intermediate with the consequence of an enhanced activity of Ca2+ pump, It is known that phosphorylation of phospholamban results in an increase of the rate at which the phosphoenzyme is decomposed. Thus, as discussed, a competition between phospholamban and acylphosphatase effect on the phosphoenzyme might be proposed to explain why the stimulation induced by this enzyme is less marked in PKA-phosphorylated than in unphosphorylated heart vesicles.	UNIV FLORENCE, DIPARTIMENTO SCI BIOCHIM, I-50134 FLORENCE, ITALY	University of Florence			Nediani, Chiara/R-2201-2019; Nediani, Chiara/AAO-8919-2020	Nediani, Chiara/0000-0003-3190-3539; Fiorillo, Claudia/0000-0003-1165-1581	Telethon [686] Funding Source: Medline	Telethon(Fondazione Telethon)		BASTIDE F, 1973, J BIOL CHEM, V248, P8485; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BEEKMAN RE, 1989, BIOCHEM J, V259, P229, DOI 10.1042/bj2590229; BEISENHERZ G, 1953, Z NATURFORSCH B, V8, P555; BERTI A, 1987, ITAL J BIOCHEM, V36, P82; BERTI A, 1977, ITAL J BIOCHEM, V26, P377; CAMICI G, 1976, EXPERIENTIA, V32, P535, DOI 10.1007/BF01920843; CARONI P, 1983, EUR J BIOCHEM, V132, P451, DOI 10.1111/j.1432-1033.1983.tb07383.x; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; GUPTA RC, 1988, MEMBRANE BIOCHEM, V7, P73; HICKS MJ, 1979, CIRC RES, V44, P384, DOI 10.1161/01.RES.44.3.384; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; JONES LR, 1979, J BIOL CHEM, V254, P530; KATZ AM, 1970, BIOCHIM BIOPHYS ACTA, V205, P473, DOI 10.1016/0005-2728(70)90113-1; KIRCHBERGER MA, 1974, J BIOL CHEM, V249, P6166; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU YZ, 1993, BIOCHEMISTRY-US, V32, P3105, DOI 10.1021/bi00063a023; MARTONOSI A, 1969, J BIOL CHEM, V244, P613; MOVSESIAN MA, 1992, BASIC RES CARDIOL, V87, P92; NASSI P, 1991, J BIOL CHEM, V266, P10867; NASSI P, 1993, BIOCHIM BIOPHYS ACTA, V1147, P19, DOI 10.1016/0005-2736(93)90311-M; NEDIANI C, 1992, BIOCHEM INT, V26, P715; PASTORE A, 1992, J MOL BIOL, V224, P427, DOI 10.1016/0022-2836(92)91005-A; PLANK B, 1983, BIOCHIM BIOPHYS ACTA, V732, P99, DOI 10.1016/0005-2736(83)90191-8; RAMPONI G, 1966, EXPERIENTIA, V22, P705, DOI 10.1007/BF01901326; RAMPONI G, 1967, EXPERIENTIA, V23, P1019, DOI 10.1007/BF02136422; RAMPONI G, 1969, ARCH BIOCHEM BIOPHYS, V130, P362, DOI 10.1016/0003-9861(69)90045-9; RAMPONI G, 1961, G BIOCH, V10, P189; REMACLE JA, 1980, BIOCHIM BIOPHYS ACTA, V630, P57, DOI 10.1016/0304-4165(80)90137-3; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SHIGEKAWA M, 1976, J BIOL CHEM, V251, P6894; SHIGEKAWA M, 1979, J BIOL CHEM, V254, P4726; STEFANI M, 1985, ITAL J BIOCHEM, V34, P94; TADA M, 1975, J BIOL CHEM, V250, P2640; TADA M, 1979, J BIOL CHEM, V254, P319; TADA M, 1974, J BIOL CHEM, V249, P6174; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TADA M, 1988, METHOD ENZYMOL, V157, P107; Taddei N, 1996, BIOCHEMISTRY-US, V35, P7077, DOI 10.1021/bi952900b; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; WUYTACK F, 1980, BIOCHEM J, V190, P827, DOI 10.1042/bj1900827; XU ZC, 1989, J BIOL CHEM, V264, P16644	42	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19066	19073		10.1074/jbc.271.32.19066	http://dx.doi.org/10.1074/jbc.271.32.19066			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702578	hybrid			2022-12-27	WOS:A1996VB68400012
J	Sleat, DE; Sohar, I; Lackland, H; Majercak, J; Lobel, P				Sleat, DE; Sohar, I; Lackland, H; Majercak, J; Lobel, P			Rat brain contains high levels of mannose-6-phosphorylated glycoproteins including lysosomal enzymes and palmitoyl-protein thioesterase, an enzyme implicated in infantile neuronal lipofuscinosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; ALPHA-L-IDURONIDASE; CATHEPSIN-D; PROTECTIVE PROTEIN; BETA-GALACTOSIDASE; ARYLSULFATASE-A; MOLECULAR-CLONING; ACID-HYDROLASES; MESSENGER-RNA; EXPRESSION	Mannose 6-phosphate (Man-B-P) is a posttranslational carbohydrate modification typical of newly synthesized acid hydrolases that signals targeting from the Gels apparatus to the lysosome via Man-B-P receptors (MPRs), Using iodinated cation independent MPR as a probe in a Western blot assay, we surveyed levels of Man-B-P glycoproteins in a number of different rat tissues, Considerable variation was observed with respect to total amounts and types of Man-B-P glycoproteins in the different tissues, Brain contained 2-8-fold more Man-B-P glycoproteins than other tissues, with relative abundance being brain much greater than testis approximate to heart > lung approximate to kidney approximate to ovary approximate to spleen > skeletal muscle approximate to liver approximate to serum, Analysis of 16 different lysosomal enzyme activities revealed that brain contains lower activities than other tissues which suggested that decreased removal of Man-6-P results in increased levels of Man-B-P glycoproteins, This was directly demonstrated by comparing activities of phosphorylated lysosomal enzymes, purified by im mobilized MPR affinity chromatography, with total activities, The phosphorylated forms accounted for a considerable proportion of the MPR-targeted activities measured in brain (on average, 36.2%) but very little in lung, kidney, and liver (on average, 5.5, 2.3, and 0.7%, respectively), Man-B-P glycoproteins were also isolated from rat brain by MPR affinity chromatography on a preparative scale. Of the 18 bands resolvable by SDS-polyacrylamide gel electrophoresis, seven bands were NH2-terminally sequenced and identified as the known lysosomal enzymes cathepsin L, cathepsin A, cathepsin D, alpha-galactosidase A, arylsulfatase A, and alpha-iduronidase, One of the major Man-6-P glycoproteins was identified as palmitoyl protein thioesterase, which was not previously thought to be lysosomal, This finding raises important questions about the cellular location and function of palmitoyl protein thioesterase, mutations in which result in the neurodegenerative disorder, infantile neuronal ceroid lipofuscinosis.	RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,GRAD PROGRAM MOL BIOL & BIOCHEM,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,DEPT PHARMACOL,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center					NIDDK NIH HHS [DK45992] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045992] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLESTEROS M, 1990, BIOCHEM BIOPH RES CO, V172, P775, DOI 10.1016/0006-291X(90)90741-5; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Barrett AJ, 1977, LYSOSOMES LABORATORY, P19; BHAVSAR JH, 1994, ANAL BIOCHEM, V221, P234, DOI 10.1006/abio.1994.1407; BIRCH NP, 1990, NUCLEIC ACIDS RES, V18, P6445, DOI 10.1093/nar/18.21.6445; BRUNETTI CR, 1994, J BIOL CHEM, V269, P17067; BUTOR C, 1995, J CELL SCI, V108, P2213; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CLARKE LA, 1994, GENOMICS, V24, P311, DOI 10.1006/geno.1994.1621; DONG JM, 1989, J BIOL CHEM, V264, P7377; EINSTEIN R, 1989, J CELL BIOL, V109, P1037, DOI 10.1083/jcb.109.3.1037; EINSTEIN R, 1991, J CELL BIOL, V112, P81, DOI 10.1083/jcb.112.1.81; FAUST PL, 1987, J CELL BIOL, V105, P1947, DOI 10.1083/jcb.105.5.1947; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FUJII T, 1992, BIOCHIM BIOPHYS ACTA, V1122, P93, DOI 10.1016/0167-4838(92)90132-W; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GABEL CA, 1993, MECH INTRACELLULAR T, P103; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; GALJART NJ, 1990, J BIOL CHEM, V265, P4678; GARCIA M, 1990, ONCOGENE, V5, P1809; *GEN COMP GROUP, 1991, PROGR MAN GCG PACK V; Harlow E., 1988, ANTIBODIES LAB MANUA; HERZOG V, 1987, EMBO J, V6, P555, DOI 10.1002/j.1460-2075.1987.tb04790.x; HOFLACK B, 1993, ADV CELL MOL BIOL M, V1, P51; HOOGEVEEN AT, 1983, J BIOL CHEM, V258, P2143; HUANG JS, 1979, J BIOL CHEM, V254, P1405; ISHIDOH K, 1987, FEBS LETT, V223, P69, DOI 10.1016/0014-5793(87)80511-2; KIRSCHKE H, 1977, EUR J BIOCHEM, V74, P293, DOI 10.1111/j.1432-1033.1977.tb11393.x; KOLODNY EH, 1976, CLIN CHIM ACTA, V70, P247, DOI 10.1016/0009-8981(76)90426-5; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KREYSING J, 1994, GENOMICS, V19, P249, DOI 10.1006/geno.1994.1055; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZZARINO D, 1990, J BIOL CHEM, V265, P11864; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYES JS, 1977, BIOCHIM BIOPHYS ACTA, V484, P408, DOI 10.1016/0005-2744(77)90096-1; MORREAU H, 1992, J BIOL CHEM, V267, P17949; MYEROWITZ R, 1981, J BIOL CHEM, V256, P3044; O'Brien D. A., 1994, Molecular Biology of the Cell, V5, p221A; OELTJEN JC, 1995, L46651; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; RICHO GR, 1994, J BIOL CHEM, V269, P14806; SCOTT HS, 1991, P NATL ACAD SCI USA, V88, P9695, DOI 10.1073/pnas.88.21.9695; SKLAR MM, 1989, J BIOL CHEM, V264, P16733; SLEAT DE, 1995, CANCER RES, V55, P3424; SOHAR I, 1972, BIOL CHEM HOPPESEYLE, V373, P567; STEIN C, 1989, J BIOL CHEM, V264, P1252; STOLTZFUS LJ, 1992, J BIOL CHEM, V267, P6570; TODDERUD G, 1988, J BIOL CHEM, V263, P17893; TOWATARI T, 1988, FEBS LETT, V236, P57, DOI 10.1016/0014-5793(88)80285-0; TSUJI S, 1987, EUR J BIOCHEM, V165, P275, DOI 10.1111/j.1432-1033.1987.tb11438.x; VALENZANO KJ, 1993, ANAL BIOCHEM, V209, P156, DOI 10.1006/abio.1993.1096; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; YONEZAWA S, 1988, J BIOL CHEM, V263, P16504	55	97	98	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19191	19198		10.1074/jbc.271.32.19191	http://dx.doi.org/10.1074/jbc.271.32.19191			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702598	hybrid			2022-12-27	WOS:A1996VB68400032
J	Bastian, LS; Yagi, M; Chan, C; Roth, GJ				Bastian, LS; Yagi, M; Chan, C; Roth, GJ			Analysis of the megakaryocyte glycoprotein IX promoter identifies positive and negative regulatory domains and functional GATA and Ets sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BERNARD-SOULIER-SYNDROME; LEUCINE-RICH GLYCOPROTEINS; ERYTHROLEUKEMIA CELL-LINE; PU.1 TRANSCRIPTION FACTOR; PLATELET FACTOR-IV; IB-IX; GENE-EXPRESSION; MEMBRANE-GLYCOPROTEINS; GEL-ELECTROPHORESIS; BINDING PROTEINS	The glycoprotein (GP) Ib-V-IX multisubunit complex binds to von Willebrand factor and mediates the adhesion of platelets to the subendothelium of damaged blood vessels, Expression of the GPIX subunit is required for stability of the complex, and its absence in platelets is associated with the rare bleeding disorder Bernard-Soulier syndrome, Comparative analyses indicate that the four GPIb-V-IX subunits are members of the leucine rich repeat family and suggest that GPIX resembles a possible primitive progenitor of this group, To characterize GPIX transcriptional regulation, a series of 5' deletion constructs was made linking the GPIX upstream flanking sequence to the luciferase marker gene, and promoter activity was measured in transiently transfected human erythroleukemia cells. This analysis identified two negative regulatory domains between -686 to -423 and -311 to -203 and two positive regulatory domains at -323 to -311 and -151 to -100 relative to the GPIX transcription start site. In addition, site-directed mutagenesis experiments and in vitro gel retardation assays identified Ets and GATA elements at -42 and -65, which positively regulate GPIX promoter activity and specifically bind nuclear factors derived from human erythroleukemia cells, DNase I protection experiments identified a protein-dependent ''footprint'' and hypersensitive site within the GPIX Ets sequence, These results provide a framework for comparison of the GPIX promoter with others of the GPIb-V-IX system, other megakaryocyte-specific genes, and other members of the leucine-rich repeat family.	VET AFFAIRS MED CTR, MED SERV, HEMATOL SECT, SEATTLE, WA 98108 USA; VET AFFAIRS MED CTR, RES SERV, SEATTLE, WA 98108 USA; UNIV WASHINGTON, DEPT MED, DIV HEMATOL, SEATTLE, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009265, R01HL039947] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL0793, HL39947, F32 HL09265] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LC, 1979, INT J CANCER, V23, P143, DOI 10.1002/ijc.2910230202; AUSABEL FM, 1991, CURRENT PROTOCOLS MO; BERKOW RL, 1984, J LAB CLIN MED, V103, P811; BLOCK KL, 1995, STEM CELLS, V13, P135, DOI 10.1002/stem.5530130205; BLOCK KL, 1994, BLOOD, V84, P3385; BOCKAMP EO, 1994, BIOESSAYS, V16, P481, DOI 10.1002/bies.950160707; BRETONGORIUS J, 1986, SEMIN HEMATOL, V23, P43; CALVERLEY DC, 1995, BLOOD, V86, P1361, DOI 10.1182/blood.V86.4.1361.bloodjournal8641361; CHAN GCK, 1991, J BIOL CHEM, V266, P22634; CLEMETSON KJ, 1982, J CLIN INVEST, V70, P304, DOI 10.1172/JCI110618; DAI W, 1993, BLOOD, V81, P1214; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; DU XP, 1994, J BIOL CHEM, V269, P18287; DU XP, 1987, BLOOD, V69, P1524; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; EISMAN R, 1990, BLOOD, V76, P336; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FONG AM, 1994, J BIOL CHEM, V269, P18441; FOX JEB, 1987, J BIOL CHEM, V262, P12627; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GORDON JI, 1976, PLATELETS BIOL PATHO; Gumina RJ, 1995, BLOOD, V86, P1797; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HICKEY MJ, 1993, P NATL ACAD SCI USA, V90, P8327, DOI 10.1073/pnas.90.18.8327; HICKEY MJ, 1993, J BIOL CHEM, V268, P3438; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HROMAS R, 1993, BLOOD, V82, P2998; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KORNHAUSER JM, 1994, MOL BRAIN RES, V23, P100, DOI 10.1016/0169-328X(94)90216-X; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LI CY, 1995, BLOOD, V86, P3805, DOI 10.1182/blood.V86.10.3805.bloodjournal86103805; LONG MW, 1981, BLOOD, V58, P1032; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; Ludlow LB, 1995, BLOOD, V86, P314; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MAJUMDAR S, 1991, J BIOL CHEM, V266, P5785; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MARTIN F, 1993, J BIOL CHEM, V268, P21606; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MAZUR EM, 1994, THROMBOSIS HEMORRHAG, P161; MEYER SC, 1995, J BIOL CHEM, V270, P14693, DOI 10.1074/jbc.270.24.14693; MICHAEL SF, 1994, BIOTECHNIQUES, V16, P410; MILLER JL, 1992, BLOOD, V79, P439; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; MOUTHON MA, 1993, BLOOD, V81, P647; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OGURA M, 1985, BLOOD, V66, P1384; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PAN JL, 1993, J BIOL CHEM, V268, P22600; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; Prandini MH, 1995, BLOOD, V86, P2198; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAMACHANDRAN B, 1995, EXP HEMATOL, V23, P49; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; REDDY ESP, 1988, ONCOGENE RES, V3, P239; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROTH GJ, 1995, MOL BASIS THROMBOSIS, P561; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; THIEBAUD P, 1990, GENE DEV, V4, P1999, DOI 10.1101/gad.4.11.1999; VICENTE V, 1990, J BIOL CHEM, V265, P274; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WRIGHT SD, 1993, BLOOD, V81, P2339; Yagi M, 1995, BIOCHEMISTRY-US, V34, P16132, DOI 10.1021/bi00049a028	80	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18554	18560		10.1074/jbc.271.31.18554	http://dx.doi.org/10.1074/jbc.271.31.18554			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702504	hybrid			2022-12-27	WOS:A1996VB68300042
J	Kupiec, JJ; Hazebrouck, S; LesteLasserre, T; Sonigo, P				Kupiec, JJ; Hazebrouck, S; LesteLasserre, T; Sonigo, P			Conversion of thymidylate synthase into an HIV protease substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS PROTEASE; ESCHERICHIA-COLI; RETROVIRAL PROTEASES; SITE; SELECTION; SYSTEM; GENE	Thymidylate synthase (TS) is an essential enzyme of DNA metabolism. We have carried out an extensive insertional mutagenesis of the Escherichia coli TS gene (thyA) using three different methods. Insertion of exogenous sequences at unique restriction sites or at random positions produced defective mutants, whereas comparison of TS sequences from different species allowed us to identify six zones permissive for insertions of exogenous sequences. The insertion of Human immunodeficiency virus type 1 (HIV-1) protease substrate sequences into the permissive sites converted TS to an HIV-1 protease substrate, and the in vivo cleavage of these insertions by the cloned HIV-1 protease conferred a thymidylate synthase-deficient phenotype in some of our E. coli mutant strains, In agreement with crystallographic data, these results show that the permissive sites are located in regions of the TS protein not essential for enzyme activity and accessible to cleavage by HIV protease, These results also show that it is possible to control a growth phenotype in E. coli through the protease-mediated destruction of an essential metabolic enzyme, Because both wild type and thymidylate synthase-deficient phenotypes are selectable on the appropriate growth medium, these thyA mutants could be used for genetic selections of protease inhibitors and analysis of protease specificities.	INST COCHIN GENET MOL, CNRS UPR 415, F-75014 PARIS, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite				Sonigo, Pierre/0000-0003-2686-1303				BALINT RF, 1995, BIO-TECHNOL, V13, P507, DOI 10.1038/nbt0595-507; BAUM EZ, 1990, P NATL ACAD SCI USA, V87, P10023, DOI 10.1073/pnas.87.24.10023; BAUM EZ, 1990, P NATL ACAD SCI USA, V87, P5573, DOI 10.1073/pnas.87.14.5573; BELFORT M, 1983, P NATL ACAD SCI-BIOL, V80, P4914, DOI 10.1073/pnas.80.16.4914; BELFORT M, 1984, J BACTERIOL, V160, P371, DOI 10.1128/JB.160.1.371-378.1984; BEYNON RJ, 1994, PROTEOLYTIC ENZYMES; BLOCK TM, 1990, ANTIMICROB AGENTS CH, V34, P2337, DOI 10.1128/AAC.34.12.2337; CARRERAS CW, 1994, J BIOL CHEM, V269, P12444; DEBOUCK C, 1987, P NATL ACAD SCI USA, V84, P8903, DOI 10.1073/pnas.84.24.8903; FARMERIE WG, 1987, SCIENCE, V236, P305, DOI 10.1126/science.2436298; FITZGERALD PMD, 1991, ANNU REV BIOPHYS BIO, V20, P299, DOI 10.1146/annurev.biophys.20.1.299; GOLDBERG AL, 1972, P NATL ACAD SCI USA, V69, P422, DOI 10.1073/pnas.69.2.422; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; Hellen Christopher U. T., 1992, Current Opinion in Biotechnology, V3, P643, DOI 10.1016/0958-1669(92)90010-G; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; MATTHEWS DA, 1990, J MOL BIOL, V214, P937, DOI 10.1016/0022-2836(90)90347-O; MCCALL JO, 1994, BIO-TECHNOL, V12, P1012, DOI 10.1038/nbt1094-1012; MICHAELS ML, 1990, P NATL ACAD SCI USA, V87, P3957, DOI 10.1073/pnas.87.10.3957; ROBERTS D, 1966, BIOCHEMISTRY-US, V5, P3546, DOI 10.1021/bi00875a022; SCHARPE S, 1991, BIOCHIMIE, V73, P121, DOI 10.1016/0300-9084(91)90084-E; STACEY KA, 1965, J BACTERIOL, V90, P554, DOI 10.1128/JB.90.2.554-555.1965; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TOMASSELLI AG, 1994, METHOD ENZYMOL, V241, P279	24	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18465	18470		10.1074/jbc.271.31.18465	http://dx.doi.org/10.1074/jbc.271.31.18465			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702491	hybrid			2022-12-27	WOS:A1996VB68300029
J	McIntosh, DB; Parrish, JC; Wallace, CJA				McIntosh, DB; Parrish, JC; Wallace, CJA			Definition of a nucleotide binding site on cytochrome c by photoaffinity labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; LIVER ALCOHOL-DEHYDROGENASE; ELECTRON-TRANSFER ACTIVITY; ATP-BINDING; PURINE NUCLEOSIDES; OXIDATION-STATE; CHEMICAL MODIFICATION; IONIC-STRENGTH; OXIDASE; CONFORMATION	We have used TNP-8N(3)-AMP (2'(3')-O-(2,4,6-trinitrophenyl)-8-azidoadenosine monophosphate) and TNP-8N(3)-ATP to probe the ATP binding site(s) of cytochrome c. Irradiation of cytochrome c with close to stoichiometric amounts of TNP-8N(3)-AMP at low ionic strength derivatized approximately half of the protein, with the mono-derivatized species being associated with four peaks (B, 6%; C, 17%; D, 24%; E, 4%) eluted from a cation exchange column, Irradiation in the presence of ATP suggested that the main peaks C and D resulted from more specific nucleotide binding, Thermolysin digestion and TNP-peptide purification and sequencing revealed that peak C was associated with derivatization of mainly Lys-86 and to a lesser extent Lys-72 and peak D with mainly Lys-87 and less so with Lys-72, Minor peaks B and E could not be identified, TNP-8N(3)-ATP photolabeling produced similar results, showing favored interaction of the adenyl ring with Lys-86 and Lys-87 and to a lesser extent with Lys-72, The results are compatible with previous findings that suggest that the principal locus of ATP binding is at nearby Arg-91 (Corthesy, B. E., and Wallace, C, J. A. (1986) Biochem, J. 236, 359-364), Molecular modeling with energy-minimized docking of ATP between the 60s helix and the 80s stretch with the gamma-phosphate constrained to interact with Arg-91, places the 8 position close to Lys-86 and Lys-87 in the anti conformation about the glycosidic bond and to Lys-72 in the syn conformation, and the ribose hydroxyls within H-bonding distance of Glu-69.	DALHOUSIE UNIV,DEPT BIOCHEM,HALIFAX,NS B3H 4H7,CANADA; UNIV CAPE TOWN,SCH MED,MRC,BIOMEMBRANE RES UNIT,ZA-7925 CAPE TOWN,SOUTH AFRICA; UNIV CAPE TOWN,SCH MED,DEPT CHEM PATHOL,ZA-7925 CAPE TOWN,SOUTH AFRICA	Dalhousie University; University of Cape Town; University of Cape Town								ABDALLAH MA, 1975, EUR J BIOCHEM, V50, P475, DOI 10.1111/j.1432-1033.1975.tb09885.x; BRAUTIGAN DL, 1978, J BIOL CHEM, V253, P130; BUSHNELL GW, 1990, J MOL BIOL, V214, P585, DOI 10.1016/0022-2836(90)90200-6; CORTHESY BE, 1988, BIOCHEM J, V252, P349, DOI 10.1042/bj2520349; CORTHESY BE, 1986, BIOCHEM J, V236, P359, DOI 10.1042/bj2360359; CRAIG DB, 1995, BIOCHEMISTRY-US, V34, P2686, DOI 10.1021/bi00008a036; CRAIG DB, 1991, BIOCHEM J, V279, P781, DOI 10.1042/bj2790781; CRAIG DB, 1993, PROTEIN SCI, V2, P966, DOI 10.1002/pro.5560020610; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; FERGUSONMILLER S, 1976, J BIOL CHEM, V251, P1104; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GRONENBORN AM, 1982, J MOL BIOL, V157, P155, DOI 10.1016/0022-2836(82)90518-6; HIRATSUKA T, 1985, J BIOL CHEM, V260, P4784; IKEHARA M, 1972, BIOCHEMISTRY-US, V11, P830, DOI 10.1021/bi00755a023; KOPPENOL WH, 1978, BIOCHIM BIOPHYS ACTA, V503, P499, DOI 10.1016/0005-2728(78)90149-4; LAPPALAINEN P, 1995, BIOCHEMISTRY-US, V34, P5824, DOI 10.1021/bi00017a014; LIN J, 1995, BIOCHEMISTRY-US, V34, P2678, DOI 10.1021/bi00008a035; MARGALIT R, 1973, EUR J BIOCHEM, V32, P500, DOI 10.1111/j.1432-1033.1973.tb02634.x; MARGOLIASH E, 1983, TRENDS BIOCHEM SCI, V8, P316, DOI 10.1016/0968-0004(83)90100-7; MARGOLIASH E, 1970, NATURE, V228, P723, DOI 10.1038/228723a0; MCINTOSH DB, 1994, J BIOL CHEM, V269, P21587; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; NICHOLLS P, 1974, BIOCHIM BIOPHYS ACTA, V346, P261, DOI 10.1016/0304-4173(74)90003-2; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; Pettigrew G.W., 1987, CYTOCHROME C BIOL AS; RYTOMAA M, 1992, J BIOL CHEM, V267, P22243; RYTOMAA M, 1994, J BIOL CHEM, V269, P1770; SEEBREGTS CJ, 1989, J BIOL CHEM, V264, P2043; SPECK SH, 1983, FEBS LETT, V164, P379, DOI 10.1016/0014-5793(83)80321-4; STELLWAG.E, 1973, J MOL BIOL, V75, P683, DOI 10.1016/0022-2836(73)90301-X; STOLARSKI R, 1984, EUR J BIOCHEM, V138, P187, DOI 10.1111/j.1432-1033.1984.tb07898.x; TABORSKY G, 1978, J BIOL CHEM, V254, P7069; TAKENAKA H, 1978, P NATL ACAD SCI USA, V75, P4229, DOI 10.1073/pnas.75.9.4229; TAVALE SS, 1970, J MOL BIOL, V48, P109, DOI 10.1016/0022-2836(70)90222-6; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; WALLACE CJA, 1986, PROTEIN ENG, V1, P23, DOI 10.1093/protein/1.1.23; WANIO NW, 1960, J BIOL CHEM, V235, P1521; YU CA, 1975, J BIOL CHEM, V250, P1383	39	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18379	18386		10.1074/jbc.271.31.18379	http://dx.doi.org/10.1074/jbc.271.31.18379			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702481	hybrid			2022-12-27	WOS:A1996VB68300019
J	Ohnuma, S; Hirooka, K; Hemmi, H; Ishida, C; Ohto, C; Nishino, T				Ohnuma, S; Hirooka, K; Hemmi, H; Ishida, C; Ohto, C; Nishino, T			Conversion of product specificity of archaebacterial geranylgeranyl-diphosphate synthase - Identification of essential amino acid residues for chain length determination of prenyltransferase reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; PYROPHOSPHATE SYNTHETASE; ESCHERICHIA-COLI; ARTIFICIAL SUBSTRATE; BIOSYNTHETIC-PATHWAY; CONSERVED ASPARTATE; DOLICHYL PHOSPHATE; DOMAIN-II	Prenyltransferases catalyze the consecutive condensation of isopentenyl diphosphate with allylic diphosphates to produce prenyl diphosphates whose chain lengths are absolutely determined by each enzyme, To investigate the mechanism of the consecutive reaction and the determination of the ultimate chain length, a random mutational approach was planned, A geranylgeranyl-diphosphate synthase gene from Sulfolobus acidocaldarius was randomly mutagenized by NaNO2 treatment to construct a library of mutated geranylgeranyl-diphosphate synthase genes on a yeast expression vector, The library was screened for suppression of a pet phenotype of yeast C296-LH(3), which is deficient in hexaprenyl diphosphate synthase, Five mutants that could grow on a YEPG plate, which contained only glycerol as an energy source instead of glucose, were selected from similar to 1,400 mutants, All selected mutated enzymes catalyzed the formation of polyprenyl diphosphates with prenyl chains longer than geranylgeranyl diphosphate. Especially mutants 1, 3, and 5 showed the strongest elongation activity to produce large amounts of geranylfarnesyl diphosphate with a concomitant amount of hexaprenyl diphosphate. Sequence analysis revealed that each mutant contained a few amino acid substitutions and that the mutation of Phe-77, which is located on the fifth amino acid upstream from the first aspartate-rich consensus motif, is the most effective for elongating the ultimate product, Amino acid alignment of known prenyltransferases around this position and our previous observations on farnesyl-diphosphate synthase (Ohnuma, S.-i,, Nakazawa, T., Hemmi, H,, Hallberg, A.-M,, Koyama, T,, Ogura, K,, and Nishino, T, (1996) J, Biol, Chem, 271, 10087-10095) clearly indicate that the amino acid at the position of all prenyltransferases must regulate the chain elongation.	TOYOTA MOTOR CO LTD,BIORES LAB,TOYOTA 47171,JAPAN	Toyota Motor Corporation	Ohnuma, S (corresponding author), TOHOKU UNIV,DEPT BIOCHEM & ENGN,AOBA KU,SENDAI,MIYAGI 98077,JAPAN.		Hemmi, Hisashi/I-6868-2014; Hirooka, Kazutake/K-9827-2017; Ohto, Chikara/GQB-4702-2022	Hemmi, Hisashi/0000-0002-9538-809X; Hirooka, Kazutake/0000-0001-5879-936X; Ohnuma, Shin-ichi/0000-0002-3305-5126				ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; ASAI K, 1994, BIOCHEM BIOPH RES CO, V202, P340, DOI 10.1006/bbrc.1994.1933; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BLANCHARD L, 1993, GENE, V125, P185, DOI 10.1016/0378-1119(93)90326-X; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CASEY AC, 1973, CANCER RES, V33, P1183; CHEN AJ, 1994, PROTEIN SCI, V3, P600; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CRICK DC, 1989, BIOCHIM BIOPHYS ACTA, V1004, P180, DOI 10.1016/0005-2760(89)90266-X; EGGENS I, 1983, BIOCHIM BIOPHYS ACTA, V751, P355, DOI 10.1016/0005-2760(83)90294-1; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; FUJII H, 1980, BIOCHEM BIOPH RES CO, V96, P1648, DOI 10.1016/0006-291X(80)91363-7; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; ITOH N, 1984, J BIOL CHEM, V259, P3923; JOLY A, 1993, J BIOL CHEM, V268, P26983; KOIKETAKESHITA A, 1995, J BIOL CHEM, V270, P18396, DOI 10.1074/jbc.270.31.18396; KOYAMA T, 1988, TETRAHEDRON LETT, V29, P3807, DOI 10.1016/S0040-4039(00)82120-6; KOYAMA T, 1994, CAN J CHEM, V72, P75, DOI 10.1139/v94-012; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MATH SK, 1992, P NATL ACAD SCI USA, V89, P6761, DOI 10.1073/pnas.89.15.6761; MATSUOKA S, 1991, J BIOL CHEM, V266, P3464; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; NAZIR DJ, 1964, BIOCHEM J, V90, P268, DOI 10.1042/bj0900268; NISHINO T, 1977, BIOCHEMISTRY-US, V16, P605, DOI 10.1021/bi00623a008; OHNUMA S, 1992, J BIOCHEM-TOKYO, V112, P743, DOI 10.1093/oxfordjournals.jbchem.a123969; OHNUMA S, 1989, TETRAHEDRON, V45, P6145, DOI 10.1016/S0040-4020(01)85127-9; OHNUMA S, 1994, J BIOL CHEM, V269, P14792; OHNUMA S, 1993, BIOCHEM BIOPH RES CO, V192, P407, DOI 10.1006/bbrc.1993.1430; Ohnuma SI, 1996, J BIOL CHEM, V271, P10087, DOI 10.1074/jbc.271.17.10087; OHNUMA SI, 1989, FEBS LETT, P71; PENNOCK JF, 1983, BIOSYNTHESIS ISOPREN, P191; POULTER CD, 1982, BIOSYNTHESIS ISOPREN, P161; SAKAKIHARA Y, 1985, J NEUROCHEM, V44, P1535, DOI 10.1111/j.1471-4159.1985.tb08792.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER H, 1982, J BIOL CHEM, V257, P789; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BACTERIOL, V122, P826, DOI 10.1128/JB.122.3.826-831.1975; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607	41	111	124	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18831	18837		10.1074/jbc.271.31.18831	http://dx.doi.org/10.1074/jbc.271.31.18831			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702542	hybrid			2022-12-27	WOS:A1996VB68300080
J	Whitehead, IP; KhosraviFar, R; Kirk, H; TrigoGonzalez, G; Her, CJ; Kay, R				Whitehead, IP; KhosraviFar, R; Kirk, H; TrigoGonzalez, G; Her, CJ; Kay, R			Expression cloning of lsc, a novel oncogene with structural similarities to the Dbl family of guanine nucleotide exchange factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; ACTIN STRESS FIBERS; RAS TRANSFORMATION; SEQUENCE SIMILARITY; SIGNALING PATHWAYS; MOLECULAR-CLONING; CDNA LIBRARIES; CDC42 GTPASES; RHO; GENE	In a screen for genes with oncogenic potential expressed by the murine B6SUtA(1) myeloid progenitor cell line, we isolated a 2.5-kilobase pair cDNA whose expression causes strong morphological transformation and deregulated proliferation of NIH 3T3 cells. The transforming cDNA encodes a truncated protein (designated Lsc) with a region of sequence similarity to the product of the lbc oncogene. This region includes the tandem Dbl homology and pleckstrin homology domains that are hallmarks of the Dbl-like proteins, a family of presumptive or demonstrated guanine nucleotide exchange factors that act on Rho family GTPases. Lsc requires intact Dbl homology and pleckstrin homology domains for its oncogenic activity. The transforming activity of Lsc in NIH 3T3 cells is reduced by cotransfection with p190 (a GTPase activating protein for Rho family GTPases) and the Rho family dominant-negative mutants RhoA(19N), CDC42(17N), and Racl(17N), These results indicate a role for the Rho family of GTPases in mediating the transforming activity of Lsc and are consistent with the exchange specificities that have been attributed to Dbl family members. The Ise gene is expressed in a variety of tissues and is particularly abundant in hemopoietic tissues (thymus, spleen, and bone marrow). Lsc is a member of a growing family of proteins that may function as activators of Rho family GTPases in a developmental or tissue-specific manner.	BRITISH COLUMBIA CANC AGCY,TERRY FOX LAB,VANCOUVER,BC V5Z 4E6,CANADA; UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER,BC V6T 1Z1,CANADA; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GENET & MOL BIOL,CHAPEL HILL,NC 27599	British Columbia Cancer Agency; University of British Columbia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Khosravi-Far, Roya/C-3789-2008	Der, Channing/0000-0002-7751-2747				ADAMS JM, 1992, ONCOGENE, V7, P611; ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BUSTELO XR, 1994, ONCOGENE, V9, P2405; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHAN AML, 1994, ONCOGENE, V9, P1057; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; Goldschmidt-Clermont P. J., 1992, Current Biology, V2, P669, DOI 10.1016/0960-9822(92)90135-W; GORMAN CM, 1983, NUCLEIC ACIDS RES, V11, P7631, DOI 10.1093/nar/11.21.7631; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HODGSON CP, 1987, NUCLEIC ACIDS RES, V15, P6295, DOI 10.1093/nar/15.15.6295; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PASTERIS NG, 1994, CELL, V79, P669; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUILLIAM LA, 1995, BIOESSAYS, V17, P309; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; TAN EC, 1993, J BIOL CHEM, V268, P27291; TOKSOZ D, 1994, ONCOGENE, V9, P621; VOGELI G, 1985, ANAL BIOCHEM, V151, P442, DOI 10.1016/0003-2697(85)90202-7; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	72	85	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18643	18650		10.1074/jbc.271.31.18643	http://dx.doi.org/10.1074/jbc.271.31.18643			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702517	Green Published, hybrid			2022-12-27	WOS:A1996VB68300055
J	Bai, XM; Esko, JD				Bai, XM; Esko, JD			An animal cell mutant defective in heparan sulfate hexuronic acid 2-O-sulfation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; POLYMER-MODIFICATION REACTIONS; BIOLOGICAL-ACTIVITIES; N-SULFOTRANSFERASE; PROTEIN INTERACTIONS; DIMETHYL-SULFOXIDE; BIOSYNTHESIS; GLYCOSAMINOGLYCANS; DEPOLYMERIZATION; OLIGOSACCHARIDES	The interaction of heparan sulfate with protein ligands depends on unique oligosaccharide sequences containing iduronic acid (IdUA), N-sulfated glucosamine residues, and O-sulfated sugars, To study the role of O-sulfation in greater detail, we isolated a Chinese hamster ovary cell mutant defective in 2-O-sulfation of iduronic acid, The mutant, pgsF-17, was identified by a colony blotting assay in which colonies of mutagen-treated cells were replica plated to two disks of polyester cloth, One disk was blotted with I-125-labeled basic fibroblast growth factor (bFGF) to measure binding to cell surface proteoglycans. The other disk was incubated with (SO4)-S-35, to measure proteoglycan biosynthesis. Autoradiography revealed a colony that did not bind I-125-bFGF, but incorporated (SO4)-S-35, normally (mutant pgsF-17), Complete deaminative cleavage of heparan sulfate revealed that material from pgsF-17 lacked IdUA(2OSO(3))-GlcNSO(3) and IdUA(2OSO(3))-GlcNSO(3)(6OSO(3)), but contained a higher proportion of glucuronic acid GlcUA-GlcNSO(3)(6OSO(3)) and IdUA-GlcNSO(3)(6OSO(3)). Assay of the 2-O-sulfotransferase that acts on IdUA residues showed that mutant 17 lacked enzyme activity, Interestingly, the alteration resulted in accumulation of Glc NSO3 groups, suggesting that under normal conditions 2-O-sulfation decreases GlcNAc N-deacetylation/N-sulfation, and that the reactions occur simultaneously, The formation of IdUA and 6-O-sulfated glucosaminyl residues appears to be independent of a O-sulfation. pgsF-17 also lacks 2-O-sulfated GlcUA residues, suggesting that the same enzyme is responsible for 2-O-sulfation of IdUA and GlcUA residues, Mutant 17 provides a useful tool for studying the regulation of heparan sulfate biosynthesis and the relationship of heparan sulfate fine structure to its biological function.	UNIV ALABAMA, SCH MED, DEPT MOLEC GENET & BIOCHEM, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham								ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; BAME KJ, 1994, BIOCHEM J, V303, P81, DOI 10.1042/bj3030081; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BAME KJ, 1991, J BIOL CHEM, V266, P12461; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; ELGAVISH A, 1988, J BIOL CHEM, V263, P18607; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; ESKO JD, 1989, METHOD CELL BIOL, V32, P387; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; GUO YC, 1988, ANAL BIOCHEM, V168, P54, DOI 10.1016/0003-2697(88)90009-7; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HAM RG, 1965, P NATL ACAD SCI USA, V53, P288, DOI 10.1073/pnas.53.2.288; INOUE Y, 1976, CARBOHYD RES, V46, P87, DOI 10.1016/S0008-6215(00)83533-8; ISHIHARA M, 1992, ANAL BIOCHEM, V206, P400, DOI 10.1016/0003-2697(92)90385-K; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P451, DOI 10.1093/glycob/4.4.451; ISHIHARA M, 1995, J BIOCHEM-TOKYO, V118, P1255, DOI 10.1093/oxfordjournals.jbchem.a125015; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; KUSCHE M, 1990, J BIOL CHEM, V265, P15403; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIU ZC, 1992, CARBOHYD RES, V228, P29, DOI 10.1016/S0008-6215(00)90546-9; LLOYD AG, 1971, BIOCHEM PHARMACOL, V20, P637, DOI 10.1016/0006-2952(71)90150-X; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MATALON R, 1971, BIOCHEM BIOPH RES CO, V42, P340, DOI 10.1016/0006-291X(71)90108-2; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NORGARDSUMNICHT KE, 1995, J BIOL CHEM, V270, P27634, DOI 10.1074/jbc.270.46.27634; OLWIN BB, 1990, J CELL BIOL, V110, P503, DOI 10.1083/jcb.110.2.503; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; RAETZ CRH, 1982, P NATL ACAD SCI-BIOL, V79, P3223, DOI 10.1073/pnas.79.10.3223; Razi N, 1995, GLYCOBIOLOGY, V5, P807, DOI 10.1093/glycob/5.8.807; RENOSTO F, 1977, ARCH BIOCHEM BIOPHYS, V180, P416, DOI 10.1016/0003-9861(77)90056-X; ROBBINS PW, 1962, METHOD ENZYMOL, V5, P964, DOI 10.1016/S0076-6879(62)05343-4; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; Toma L, 1996, J BIOL CHEM, V271, P3897; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; WLAD H, 1994, J BIOL CHEM, V269, P24538	56	110	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17711	17717		10.1074/jbc.271.30.17711	http://dx.doi.org/10.1074/jbc.271.30.17711			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663454	hybrid			2022-12-27	WOS:A1996UY93500021
J	Feinstein, DL; Galea, E; Aquino, DA; Li, GC; Xu, H; Reis, DJ				Feinstein, DL; Galea, E; Aquino, DA; Li, GC; Xu, H; Reis, DJ			Heat shock protein 70 suppresses astroglial-inducible nitric-oxide synthase expression by decreasing NF kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CNS GLIAL-CELLS; INTERFERON-GAMMA; STRESS PROTEINS; GLUCOCORTICOID RECEPTOR; MAMMALIAN-CELLS; GLIOMA-CELLS; INDUCTION; HSP70; ASTROCYTES; GENE	In brain glial cells, expression of calcium independent nitric oxide synthase (NOS-2) is induced following stimulation with bacterial endotoxin (lipopolysaccharide (LPS)) and/or pro-inflammatory cytokines. We have investigated the effects of heat shock (HS), which can re duce inflammatory responses in several cell types, on the induction of glial NOS-2 expression. Preincubation of cells for 20-60 min at 43 degrees C decreased subsequent levels of NOS-2 induction, with a maximal 80% reduction after 60 min of HS. Following HS, cells were refractory to NOS inducers for up to 4 h, after which time little or no suppression was observed. HS reduced cytosolic NOS-2 enzymatic activity (3-fold), steady state mRNA levels (2-3-fold), and gene promoter activity (by 50%). HS also reduced LPS induced nuclear accumulation of transcription factor NF kappa B p65 subunit, suggesting perturbation of NF kappa B activation. A role for HS protein (HSP) 70 in NOS-2 suppression by HS is supported by the demonstration that 1) transfection with human HSP70 cDNA partially replicated HS effects; 2) antisense, but not sense, oligonucleotides directed against rat HSP70 partially blocked HS effects; and 3) rat fibroblasts stably expressing human HSP70 did not express NOS-2 in response to LPS plus cytokines. As with heat-shocked cells, HSP70 expressing cells also exhibited decreased NF kappa B p65 subunit nuclear accumulation. These results demonstrate that in glial cells, as well as other cell types, NOS-2 induction can be modulated by the HS response, mediated at least in part by HSP70 expression.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT NEUROL, BRONX, NY 10461 USA; MEM SLOAN KETTERING CANC CTR, RADIAT & HYPERTHERMIA BIOL LAB, NEW YORK, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center	Feinstein, DL (corresponding author), CORNELL UNIV, COLL MED, DIV NEUROBIOL, 411 E 69TH ST, NEW YORK, NY 10021 USA.		Galea, Elena/E-1362-2011; feinstein, doug/M-9414-2019	Galea, Elena/0000-0003-4537-9897; 				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BROSNAN CF, 1994, DEV NEUROSCI-BASEL, V16, P152, DOI 10.1159/000112102; CHANDLER LJ, 1995, AM J PHYSIOL-CELL PH, V268, pC700, DOI 10.1152/ajpcell.1995.268.3.C700; COLASANTI M, 1995, J BIOL CHEM, V270, P26731, DOI 10.1074/jbc.270.45.26731; CORBETT JA, 1993, FASEB J, V7, P369, DOI 10.1096/fasebj.7.2.8440413; CROSS AH, 1994, J CLIN INVEST, V93, P2684, DOI 10.1172/JCI117282; DANG CV, 1989, J BIOL CHEM, V264, P18019; DIEHL EE, 1993, BIOCHEMISTRY-US, V32, P13510, DOI 10.1021/bi00212a016; DONG ZY, 1993, J LEUKOCYTE BIOL, V53, P53, DOI 10.1002/jlb.53.1.53; ENDOH M, 1993, NEUROSCI LETT, V154, P125, DOI 10.1016/0304-3940(93)90187-P; FEINSTEIN DL, 1993, J NEUROCHEM, V60, P1945, DOI 10.1111/j.1471-4159.1993.tb13425.x; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P811; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; GALEA E, 1994, J NEUROSCI RES, V37, P406, DOI 10.1002/jnr.490370313; Galea E, 1996, J NEUROIMMUNOL, V64, P19, DOI 10.1016/0165-5728(95)00143-3; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRISCAVAGE JM, 1993, J IMMUNOL, V151, P6329; HEWETT SJ, 1993, NEUROSCI LETT, V164, P229, DOI 10.1016/0304-3940(93)90898-U; HOTCHKISS R, 1993, AM J PHYSIOL, V265, pR1447, DOI 10.1152/ajpregu.1993.265.6.R1447; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; IMATAKA H, 1994, J BIOL CHEM, V269, P20668; JAATTELA M, 1993, J IMMUNOL, V151, P4286; KATO K, 1993, J BIOCHEM-TOKYO, V114, P640, DOI 10.1093/oxfordjournals.jbchem.a124230; KERTH V, 1994, EUR J PHARMACOL, V265, P83; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MARGULIS BA, 1991, DIABETES, V40, P1418, DOI 10.2337/diabetes.40.11.1418; MAULIK N, 1994, MOL CELL BIOCHEM, V137, P17, DOI 10.1007/BF00926035; MESTRIL R, 1994, BIOCHEM J, V298, P561, DOI 10.1042/bj2980561; MILLER EK, 1991, J NEUROCHEM, V56, P2060, DOI 10.1111/j.1471-4159.1991.tb03467.x; MULSCH A, 1993, FEBS LETT, V321, P215, DOI 10.1016/0014-5793(93)80111-7; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NISHIMURA RN, 1988, J NEUROSCI RES, V20, P12, DOI 10.1002/jnr.490200103; ORTREMSKI I, 1994, BR J RHEUMATOL, V33, P721; PARK SK, 1994, NEUROPHARMACOLOGY, V33, P1419, DOI 10.1016/0028-3908(94)90044-2; PARK SK, 1994, BIOCHEM BIOPH RES CO, V201, P762, DOI 10.1006/bbrc.1994.1766; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, pC69, DOI 10.1016/0303-7207(90)90198-H; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; RIBEIRO SP, 1993, AM REV RESPIR DIS, V147, pA95; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; SAMBROOK J, 1989, MOL CLONING LABORATO, P192; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SIMMONS ML, 1993, EUR J NEUROSCI, V5, P825, DOI 10.1111/j.1460-9568.1993.tb00934.x; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; SNYDER YM, 1992, J LEUKOCYTE BIOL, V51, P181, DOI 10.1002/jlb.51.2.181; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; SRINIVASAN G, 1994, MOL ENDOCRINOL, V8, P189, DOI 10.1210/me.8.2.189; VILLAR J, 1993, AM REV RESPIR DIS, V147, P177, DOI 10.1164/ajrccm/147.1.177; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WALLACE MN, 1994, NEUROSCIENCE, V59, P905, DOI 10.1016/0306-4522(94)90294-1; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; Wong HR, 1995, AM J PHYSIOL-LUNG C, V269, pL843, DOI 10.1152/ajplung.1995.269.6.L843; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	67	251	274	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17724	17732		10.1074/jbc.271.30.17724	http://dx.doi.org/10.1074/jbc.271.30.17724			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663604	hybrid			2022-12-27	WOS:A1996UY93500023
J	Feng, ZY; Aggeler, R; Haughton, MA; Capaldi, RA				Feng, ZY; Aggeler, R; Haughton, MA; Capaldi, RA			Conformational changes in the Escherichia coli ATP synthase (ECF(1)F(0)) monitored by nucleotide-dependent differences in the reactivity of Cys-87 of the gamma subunit in the mutant beta Glu-381->Ala	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1 ADENOSINE-TRIPHOSPHATASE; COUPLING FACTOR-I; CRYOELECTRON MICROSCOPY; EPSILON-SUBUNIT; CATALYTIC SITES; MONOCLONAL-ANTIBODIES; STRUCTURAL-CHANGES; CYSTEINE RESIDUES; N-ETHYLMALEIMIDE; CROSS-LINKING	Cys-87, one of two intrinsic cysteines of the gamma subunit of the Escherichia coli ATP synthase (ECF(1)F(0)), is in a short segment of this subunit that binds to the bottom domain of a beta subunit close to a glutamate (Glu-381), Cys-87 was unreactive to maleimides under all conditions in wild-type ECF(1) and ECF(1)F(0) but became reactive when Glu-381 of beta was replaced by a cysteine or alanine, The reactivity of Cys-87 with maleimides was nucleotide-dependent, occurring with ATP or ADP + EDTA in catalytic sites, in the presence of AMP PNP + Mg2+ but not with ADP + Mg2+ bound, whether P-i was present or not, and not when nucleotide binding sites were empty, Binding of N-ethylmaleimide had no effect, whereas 7 diethyl-amino 3-(4'-maleimidylphenyl)-4-methylcoumarin increased the ATPase activity of ECF, more than 2-fold by reaction with Cys-87, In ECF(1)F(0), these reagents inhibited activity, The nucleotide dependence of the reaction of Cys-87 of the gamma subunit depended on the presence of the epsilon subunit, In epsilon subunit-free ECF(1), maleimides reacted with Cys-87 under all nucleotide conditions, including when catalytic sites were empty, These results are discussed in terms of nucleotide-dependent movements of the gamma subunit during functioning of the F1F0-type ATPase.	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403	University of Oregon			Haughton, Margaret/F-8033-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL24526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1993, J BIOL CHEM, V268, P14576; AGGELER R, 1992, J BIOL CHEM, V267, P21355; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1987, BIOCHEMISTRY-US, V26, P7107, DOI 10.1021/bi00396a036; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNCAN TM, 1995, T BIOCH SOC, V23, P736; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; FOSTER DL, 1979, J BIOL CHEM, V254, P8230; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; Gruber G, 1996, BIOCHEMISTRY-US, V35, P3875, DOI 10.1021/bi952949h; HATEFI Y, 1993, EUR J BIOCHEM, V218, P759, DOI 10.1111/j.1432-1033.1993.tb18431.x; HAUGHTON MA, 1995, J BIOL CHEM, V270, P20568, DOI 10.1074/jbc.270.35.20568; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; MCCARTY RE, 1973, BIOCHEMISTRY-US, V12, P1503, DOI 10.1021/bi00732a006; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; MORONEY JV, 1984, J BIOL CHEM, V259, P7281; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SOTEROPOULOS P, 1994, J BIOL CHEM, V269, P19810; TIEDGE H, 1985, P NATL ACAD SCI USA, V82, P7874, DOI 10.1073/pnas.82.23.7874; TURINA P, 1994, J BIOL CHEM, V269, P13465; TURINA P, 1994, BIOCHEMISTRY-US, V33, P14275, DOI 10.1021/bi00251a040; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; WEBER J, 1994, J BIOL CHEM, V269, P20462; WISE JG, 1981, J BIOL CHEM, V256, P383; ZIEGLER M, 1994, J BIOL CHEM, V269, P4233	38	17	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17986	17989		10.1074/jbc.271.30.17986	http://dx.doi.org/10.1074/jbc.271.30.17986			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663500	hybrid			2022-12-27	WOS:A1996UY93500062
J	Higazi, AAR; Ganz, T; Kariko, K; Cines, DB				Higazi, AAR; Ganz, T; Kariko, K; Cines, DB			Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; NEUTROPHIL DEFENSINS; PEPTIDE DEFENSINS; CRYSTAL-STRUCTURE; PANETH CELLS; HUMAN-PLASMA; ANNEXIN-II; T-PA; RECEPTOR; IDENTIFICATION	Defensins are naturally occurring antimicrobial peptides that may participate in host defense against microorganisms. We previously reported that the amino acid sequence of leukocyte defensins resembles the lysine-binding site in the kringles of plasminogen and that defensin inhibits fibrinolysis mediated by tissue-type plasminogen activator (tPA) and plasminogen. In the present paper we analyze the mechanisms of this inhibition. Defensin binds specifically to cultured human umbilical vein endothelial cells (HUVEC) (half maximal binding = 3 mu M) as well as to fibrin. At saturating concentrations (5-10 mu M), defensin stimulates the maximum binding of plasminogen to HUVEC and to fibrin approximately 10-fold. However, defensin inhibits plasminogen binding to both surfaces at concentrations >10 mu M. Defensin also inhibits tPA and plasminogen-mediated fibrinolysis in a dose-dependent manner at all concentrations tested. Fibrinolysis is almost totally inhibited by 6 mu M defensin, a concentration that stimulates the binding of plasminogen to fibrin. Discordance between the enhancement of plasminogen binding and its activation cannot be explained by an inhibitory effect of defensin on tPA binding nor by inhibition of plasmin activity, each of which occur only at higher concentrations. Rather, these results suggest that plasminogen bound to fibrin in the presence of defensin is less susceptible to activation by tPA.	UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT NEUROSURG,PHILADELPHIA,PA 19104; UNIV CALIF LOS ANGELES,DEPT MED,DIV PULM & CRIT CARE,LOS ANGELES,CA 90095	University of Pennsylvania; University of Pennsylvania; University of California System; University of California Los Angeles			Ganz, Tomas/AAN-3308-2020; Ganz, Tomas/D-4567-2009	Ganz, Tomas/0000-0002-2830-5469	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387, R01HL049517] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50970, HL49517, HL40387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNATHAN ES, 1988, J BIOL CHEM, V263, P7792; BEEBE DP, 1989, BLOOD, V74, P2034; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CINES DB, 1984, J CLIN INVEST, V73, P611, DOI 10.1172/JCI111251; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DEVOS AM, 1992, BIOCHEMISTRY-US, V31, P270, DOI 10.1021/bi00116a037; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; EDWARDS RL, 1978, SCIENCE, V200, P541, DOI 10.1126/science.644314; FLESS GM, 1984, J BIOL CHEM, V259, P1470; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GANZ T, 1987, INFECT IMMUN, V55, P568, DOI 10.1128/IAI.55.3.568-571.1987; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; HAJJAR KA, 1990, J BIOL CHEM, V265, P2908; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1988, J CLIN INVEST, V82, P1769, DOI 10.1172/JCI113790; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; HIGAZI AA, 1994, BIOCHEM J, V300, P251, DOI 10.1042/bj3000251; HIGAZI AAR, 1995, J BIOL CHEM, V270, P9472, DOI 10.1074/jbc.270.16.9472; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HU CK, 1994, BIOCHEMISTRY-US, V33, P11760, DOI 10.1021/bi00205a011; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; KAGAN BL, 1994, TOXICOLOGY, V87, P131, DOI 10.1016/0300-483X(94)90158-9; LICHTENSTEIN A, 1986, BLOOD, V68, P1407; LICHTENSTEIN AK, 1988, J IMMUNOL, V140, P2686; LICHTENSTEIN AK, 1988, CELL IMMUNOL, V114, P104, DOI 10.1016/0008-8749(88)90258-4; LIU JN, 1994, BIOCHEMISTRY-US, V33, P2554, DOI 10.1021/bi00175a026; Menkin V, 1938, PHYSIOL REV, V18, P366, DOI 10.1152/physrev.1938.18.3.366; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; OKRENT DG, 1990, AM REV RESPIR DIS, V141, P179, DOI 10.1164/ajrccm/141.1.179; PANYUTICH A, 1991, AM J RESP CELL MOL, V5, P101, DOI 10.1165/ajrcmb/5.2.101; PANYUTICH AV, 1995, AM J RESP CELL MOL, V12, P351, DOI 10.1165/ajrcmb.12.3.7873202; PANYUTICH AV, 1993, J LAB CLIN MED, V122, P202; PANYUTICH AV, 1994, FEBS LETT, V356, P169, DOI 10.1016/0014-5793(94)01261-X; SELSTED ME, 1985, J CLIN INVEST, V76, P1436, DOI 10.1172/JCI112121; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; VICTOR J., 1994, HEMOSTASIS THROMBOSI, P1023	39	61	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17650	17655		10.1074/jbc.271.30.17650	http://dx.doi.org/10.1074/jbc.271.30.17650			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663495	hybrid			2022-12-27	WOS:A1996UY93500013
J	Ishibashi, S; Schwarz, M; Frykman, PK; Herz, J; Russell, DW				Ishibashi, S; Schwarz, M; Frykman, PK; Herz, J; Russell, DW			Disruption of cholesterol 7 alpha-hydroxylase gene in mice .1. Postnatal lethality reversed by bile acid and vitamin supplementation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION CLONING; BIOSYNTHESIS; HEPATITIS; MUTATIONS; ENZYME	Mice deficient in cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme of bile acid biosynthesis, were constructed by targeted disruption of the Cyp7 gene. The introduced mutation removed exons 3-5 of the gene and gave rise to a null allele that encoded no immunoreactive or enzymatically active protein. Heterozygous carriers of the disrupted gene (Cyp7(+/-)) were phenotypically normal. Homozygous animals (Cyp7(-/-)) appeared normal at birth, but died within the first 18 days of life. Approximately 40% of the animals died between postnatal days 1 and 4 and 45% between days 11 and 18. The addition of vitamins to the water of nursing mothers prevented deaths in the early period, whereas the addition of cholic acid to chow prevented deaths in the later period. Newborn Cyp7(-/-) mice whose mothers were maintained on unsupplemented chow failed to gain weight at a normal rate and developed oily coats, hyperkeratosis, and apparent vision defects. These symptoms waned at 3 weeks of life, and their disappearance was accompanied by a marked increase in survival. In the accompanying study, the induction of an alternate pathway of bile acid biosynthesis is shown to underlie this unusual time course (Schwarz, M., Lund, E. G., Setchell, K. D. R., Kayden, H. J., Zerwekh, J. E., Bjorkhem, I., Herz, J., and Russell, D. W. (1996) J. Biol. Chem. 271, 18024-18031). We conclude that cholesterol 7 alpha hydroxylase is an essential enzyme for normal post natal development.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Russell, David/0000-0002-0277-403X	NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; Bjorkhem I., 1995, METABOLIC MOL BASES, P2073; CALI JJ, 1991, J BIOL CHEM, V266, P7779; CLAYTON PT, 1987, J CLIN INVEST, V79, P1031, DOI 10.1172/JCI112915; DANIELSSON H, 1967, EUR J BIOCHEM, V2, P44, DOI 10.1111/j.1432-1033.1967.tb00103.x; DARBY WJ, 1945, P SOC EXP BIOL MED, V60, P259, DOI 10.3181/00379727-60-15154P; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HOLMAN R. T., 1968, Progress in the Chemistry of Fats and Other Lipids, V9, P275; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; Jones James H., 1945, JOUR NUTRITION, V29, P127; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; SETCHELL KDR, 1988, J CLIN INVEST, V82, P2148, DOI 10.1172/JCI113837; TURLEY SD, 1982, LIVER BIOL PATHOBIOL, P467; TZUNG KW, 1994, GENOMICS, V21, P244, DOI 10.1006/geno.1994.1250; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; WONG MH, 1994, J BIOL CHEM, V269, P1340; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365	19	181	186	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18017	18023		10.1074/jbc.271.30.18017	http://dx.doi.org/10.1074/jbc.271.30.18017			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663429	Green Submitted, hybrid, Green Accepted			2022-12-27	WOS:A1996UY93500066
J	vonDippe, P; Amoui, M; Stellwagen, RH; Levy, D				vonDippe, P; Amoui, M; Stellwagen, RH; Levy, D			The functional expression of sodium-dependent bile acid transport in Madin-Darby canine kidney cells transfected with the cDNA for microsomal epoxide hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; COTRANSPORT SYSTEM; PLASMA-MEMBRANES; LIVER; PROTEIN; TAUROCHOLATE; NA+; OXIDATION; DNA	Previous studies have suggested that the enzyme microsomal epoxide hydrolase (mEH) is able to mediate sodium-dependent transport of bile acids such as taurocholate into hepatocytes (von Dippe, P,, Amoui, M,, Alves, C,, and Levy, D, (1993) Am, J, Physiol, 264, G528-G534), In order to characterize directly the putative transport properties of the enzyme, a pCB6 vector containing the cDNA for this protein (pCB6-mEH) was transfected into Madin-Darby canine kidney (MDCK) cells, and stable transformants were isolated that could express mEH at levels comparable with the levels expressed in hepatocytes. Sodium-dependent transport of taurocholate was shown to be dependent on the expression of mEH and to be inhibited by the bile acid transport inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS), as well as by other bile acids, Kinetic analysis of this system indicated a K-m of 26.3 mu M and a V-max of 117 pmol/mg protein/min, The K-m value is essentially the same as that observed in intact hepatocytes. The transfected MDCK cells also exhibited sodium-dependent transport of cholate at levels 150% of taurocholate in contrast to hepatocytes where cholate transport is only 30% of taurocholate levels, suggesting that total hepatocyte bile acid transport is a function of multiple transport systems with different substrate specificities, where mEH preferentially transports cholate, This hypothesis is further supported by the observation that a monoclonal antibody that partially protects (26%) taurocholate transport from inhibition by DIDS in hepatocytes provides almost complete protection (88%) from DIDS inhibition of hepatocyte cholate transport, suggesting that taurocholate is also taken up by an alternative system not recognized by this antibody, Additional support for this concept is provided by the observation that the taurocholate transport system is almost completely protected (92%) from DIDS inhibition by this antibody in MDCK cells that express mEH as the only bile acid transporter, These results demonstrate that mEH is expressed on the surface of hepatocytes as well as on transfected MDCK cells and is able to mediate sodium-dependent transport of taurocholate and cholate.	UNIV SO CALIF,SCH MED,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033	University of Southern California					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 25836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVES C, 1993, J BIOL CHEM, V268, P20148; ANANTHANARAYANAN M, 1988, J BIOL CHEM, V263, P8338; ANANTHANARAYANAN M, 1991, AM J PHYSIOL, V261, pG810, DOI 10.1152/ajpgi.1991.261.5.G810; ANWER MS, 1978, H-S Z PHYSIOL CHEM, V359, P181; BOYER JL, 1994, AM J PHYSIOL, V266, pG382, DOI 10.1152/ajpgi.1994.266.3.G382; CALI JJ, 1991, J BIOL CHEM, V266, P7774; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; HAGENBUCH B, 1994, CELL PHYSIOL BIOCHEM, V4, P198, DOI 10.1159/000154726; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HARDIKAR W, 1995, J BIOL CHEM, V270, P20841, DOI 10.1074/jbc.270.35.20841; HONSCHA W, 1995, BIOCHEM J, V311, P975, DOI 10.1042/bj3110975; HONSCHA W, 1993, EUR J PHARM-MOLEC PH, V246, P227, DOI 10.1016/0922-4106(93)90035-8; HORSEFIELD BP, 1992, BIOCHEM PHARMACOL, V44, P815, DOI 10.1016/0006-2952(92)90420-N; KHANG JT, 1991, J BIOL CHEM, V266, P18224; KOHLI KK, 1990, J CELL PHYSIOL, V142, P194, DOI 10.1002/jcp.1041420124; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEPER J, 1990, HEPATOLOGY, V11, P850, DOI 10.1002/hep.1840110521; PETZINGER E, 1994, REV PHYSIOL BIOCH P, V123, P47, DOI 10.1007/BFb0030903; PORTER TD, 1986, ARCH BIOCHEM BIOPHYS, V248, P121, DOI 10.1016/0003-9861(86)90408-X; ROBIN MA, 1995, GASTROENTEROLOGY, V108, P1110, DOI 10.1016/0016-5085(95)90210-4; Sambrook J., 2002, MOL CLONING LAB MANU; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; SKACH WR, 1993, J BIOL CHEM, V268, P6903; STASIECKI P, 1980, EUR J CELL BIOL, V21, P79; STOLZ A, 1989, ANNU REV PHYSIOL, V51, P161, DOI 10.1146/annurev.ph.51.030189.001113; STOMING TA, 1974, CANCER RES, V34, P2810; SUCHY FJ, 1982, PEDIATR RES, V16, P282, DOI 10.1203/00006450-198204000-00007; Tavoloni N., 1993, HEPATIC TRANSPORT BI; THOMAS H, 1990, PRINCIPLES MECH BIOL, P278; VONDIPPE P, 1993, AM J PHYSIOL, V264, pG528, DOI 10.1152/ajpgi.1993.264.3.G528; VONDIPPE P, 1990, J BIOL CHEM, V265, P14812; VONDIPPE P, 1983, J BIOL CHEM, V258, P8896; VONDIPPE P, 1983, J BIOL CHEM, V258, P8890; VONDIPPE P, 1990, J BIOL CHEM, V265, P5942; WEISZ OA, 1992, J BIOL CHEM, V267, P22282; WIXTROM RN, 1985, BIOCH PHARM TOXICOLO, V1, P1; WU DF, 1992, HEPATOLOGY, V15, P515, DOI 10.1002/hep.1840150326; YAMAZAKI M, 1993, AM J PHYSIOL, V264, pG693, DOI 10.1152/ajpgi.1993.264.4.G693; ZAHLTEN RN, 1973, P NATL ACAD SCI USA, V70, P3213, DOI 10.1073/pnas.70.11.3213; ZIEGLER K, 1989, BIOCHIM BIOPHYS ACTA, V980, P161, DOI 10.1016/0005-2736(89)90395-7; [No title captured]	44	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18176	18180		10.1074/jbc.271.30.18176	http://dx.doi.org/10.1074/jbc.271.30.18176			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663355	hybrid			2022-12-27	WOS:A1996UY93500088
J	Doi, T; Fakler, B; Schultz, JH; Schulte, U; Brandle, U; Weidemann, S; Zenner, HP; Lang, F; Ruppersberg, JP				Doi, T; Fakler, B; Schultz, JH; Schulte, U; Brandle, U; Weidemann, S; Zenner, HP; Lang, F; Ruppersberg, JP			Extracellular K+ and intracellular pH allosterically regulate renal K(ir)1.1 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER POTASSIUM CHANNEL; INWARD-RECTIFIER; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; RAT-BRAIN; RECTIFICATION; MODULATION; MECHANISM; TUBULE; FAMILY	The channels that control K+ homeostasis by mediating K+ secretion across the apical membrane of renal tubular cells have recently been cloned and designated ROMK1, -2, and -3. Native apical K+ channels are indirectly regulated by the K+ concentration at the basolateral membrane through a cascade of intracellular second messengers. It is shown here that ROMK1 (K(ir)1.1) channels are also directly regulated by the extracellular (apical) K+ concentration, and that this K+ regulation is coupled to intracellular pH. The K+ regulation and its coupling to pH were assigned to different structural parts of the channel protein. K+ regulation is determined by the core region, which comprises the two hydrophobic segments M1 and M2 and the P region. Decoupling from pH was achieved by exchanging the N terminus of ROMK1 by that of the pH-insensitive channel IRK1 (K(ir)2.1). These results suggest an allosteric regulation of ROMK1 channels by extracellular K+ and intracellular pH, which may represent a novel link between K+ homeostasis and pH control.	UNIV TUBINGEN, EAR NOSE & THROAT HOSP, DEPT SENSORY BIOPHYS, TUBINGEN, GERMANY; UNIV TUBINGEN, INST PHYSIOL, D-72076 TUBINGEN, GERMANY	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen								ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BIELEN FV, 1993, J PHYSIOL-LONDON, V465, P699, DOI 10.1113/jphysiol.1993.sp019701; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; BOND CT, 1995, FEBS LETT, V367, P61, DOI 10.1016/0014-5793(95)00497-W; BOND CT, 1994, RECEPTOR CHANNEL, V2, P183; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CHEPILKO S, 1995, AM J PHYSIOL-CELL PH, V268, pC389, DOI 10.1152/ajpcell.1995.268.2.C389; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; FAKLER B, 1994, FEBS LETT, V356, P199, DOI 10.1016/0014-5793(94)01258-X; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FALKER B, 1994, NEURON, V13, P1413; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; KOYAMA H, 1994, FEBS LETT, V341, P303, DOI 10.1016/0014-5793(94)80478-8; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LANG F, 1992, PHYSIOL REV, V72, P1, DOI 10.1152/physrev.1992.72.1.1; LEE WS, 1995, AM J PHYSIOL-RENAL, V268, pF1124, DOI 10.1152/ajprenal.1995.268.6.F1124; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; MOODY WJ, 1982, J GEN PHYSIOL, V79, P115, DOI 10.1085/jgp.79.1.115; MORISHIGE KI, 1994, FEBS LETT, V346, P251, DOI 10.1016/0014-5793(94)00483-8; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TANG WM, 1994, FEBS LETT, V348, P239, DOI 10.1016/0014-5793(94)00612-1; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; WANG WH, 1993, J GEN PHYSIOL, V101, P673, DOI 10.1085/jgp.101.5.673; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; WANG WH, 1990, AM J PHYSIOL, V259, pF494, DOI 10.1152/ajprenal.1990.259.3.F494; WANG WH, 1992, ANNU REV PHYSIOL, V54, P81; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809	37	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17261	17266		10.1074/jbc.271.29.17261	http://dx.doi.org/10.1074/jbc.271.29.17261			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663367	hybrid			2022-12-27	WOS:A1996UX94300045
J	Hanai, R; Liu, RP; Benedetti, P; Caron, PR; Lynch, AS; Wang, JC				Hanai, R; Liu, RP; Benedetti, P; Caron, PR; Lynch, AS; Wang, JC			Molecular dissection of a protein SopB essential for Escherichia coli F plasmid partition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINI-F; SEQUENCE DETERMINATION; NUCLEOTIDE-SEQUENCE; REPLICATOR REGION; GENES; ORGANIZATION; PURIFICATION; MAINTENANCE; EXPRESSION; CELLS	Biochemical and genetic experiments were carried out to deduce the structural and functional domains of SopB protein involved in the equipartition of F plasmid, The protein is dimeric, Proteolytic and chemical footprinting studies support earlier genetic analyses that the binding of SopB to specific sites within the F plasmid sopC locus involves mainly the C-terminal region. In vivo, the expression of a high level of SopB protein is known to repress sopC-linked genes, This silencing activity is shown to be unaffected by the deletion of 35 N-terminal residues, but abolished when 71 or more were removed from the N terminus, An excess of SopB protein does not extend its in vitro binding outside sopC, implicating participation of a host factor(s) in SopB-mediated gene silencing. A data base search identified a number of SopB homologues, including both chromosomally encoded bacterial proteins and phage- and plasmid-encoded proteins known to be involved in partition, Sequence homology is limited to the N-terminal half, suggesting that the N-terminal regions of these proteins are conserved to interact with a conserved cellular structure(s), whereas the C-terminal regions have diverged to bind different nucleotide sequences.	HARVARD UNIV,DEPT CELLULAR & MOLEC BIOL,CAMBRIDGE,MA 02138; VERTEX PHARMACEUT,CAMBRIDGE,MA 02139; CNR,IST BIOL CELLULARE,I-00137 ROME,ITALY	Harvard University; Vertex Pharmaceuticals; Consiglio Nazionale delle Ricerche (CNR)				Hanai, Ryo/0000-0002-6561-7613	NIGMS NIH HHS [GM24544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024544, R37GM024544] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELES AL, 1985, J MOL BIOL, V185, P261, DOI 10.1016/0022-2836(85)90402-4; ADLER B, 1989, MOL MICROBIOL, V3, P627, DOI 10.1111/j.1365-2958.1989.tb00210.x; BIEK DP, 1995, J MOL BIOL, V246, P388, DOI 10.1006/jmbi.1994.0094; BIEK DP, 1994, P NATL ACAD SCI USA, V91, P8027, DOI 10.1073/pnas.91.17.8027; DEROSSI E, 1995, L39923 EMBLGENBANKDD; EZAKI B, 1991, J BACTERIOL, V173, P6643, DOI 10.1128/jb.173.20.6643-6646.1991; Gros E., 1967, METHOD ENZYMOL, V11, P238; HANAI R, 1994, P NATL ACAD SCI USA, V91, P11904, DOI 10.1073/pnas.91.25.11904; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KORNACKI JA, 1987, J MOL BIOL, V198, P211, DOI 10.1016/0022-2836(87)90307-X; KUSUKAWA N, 1987, MOL GEN GENET, V208, P365, DOI 10.1007/BF00328125; LIN ZC, 1994, MOL MICROBIOL, V13, P513, DOI 10.1111/j.1365-2958.1994.tb00446.x; LOOMAN AC, 1987, EMBO J, V6, P2489, DOI 10.1002/j.1460-2075.1987.tb02530.x; LUDTKE DN, 1989, J MOL BIOL, V209, P393, DOI 10.1016/0022-2836(89)90005-3; LYNCH AS, 1994, J MOL BIOL, V236, P679, DOI 10.1006/jmbi.1994.1179; LYNCH AS, 1995, P NATL ACAD SCI USA, V92, P1896, DOI 10.1073/pnas.92.6.1896; MORI H, 1989, J BIOL CHEM, V264, P15535; MORI H, 1986, J MOL BIOL, V192, P1, DOI 10.1016/0022-2836(86)90459-6; NISHIGUCHI R, 1987, MOL GEN GENET, V206, P1, DOI 10.1007/BF00326529; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABATA S, 1989, J BACTERIOL, V171, P1665, DOI 10.1128/jb.171.3.1665-1672.1989; THEOPHILUS BDM, 1987, NUCLEIC ACIDS RES, V15, P7443, DOI 10.1093/nar/15.18.7443; THIELE S, 1993, X75356 EMBL GEN BANK; TURNER SL, 1995, X89447 EMBL GENBANK; WATANABE E, 1989, MOL GEN GENET, V218, P431, DOI 10.1007/BF00332406; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1	29	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17469	17475		10.1074/jbc.271.29.17469	http://dx.doi.org/10.1074/jbc.271.29.17469			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663262	hybrid			2022-12-27	WOS:A1996UX94300075
J	Johnson, MD; Wang, XH				Johnson, MD; Wang, XH			Differentially expressed forms of 1-L-myo-inositol-1-phosphate synthase (EC 5.5.1.4) in Phaseolus vulgaris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYO-INOSITOL-1-PHOSPHATE SYNTHASE; CATALYTIC PROPERTIES; STRUCTURAL GENE; TRANSIT PEPTIDE; INOSITOL; BIOSYNTHESIS; PURIFICATION; 1-PHOSPHATE; PROTEINS; 6-PHOSPHATE	We have characterized two distinct polypeptides with 1-L-myo-inositol-1-phosphate synthase (MI-1-P synthase) activity that are differentially expressed during development in Phaseolus vulgaris. Western analyses, enzyme assays, and partial purification of MI-1-P synthase during embryonic and postembryonic development show that its expression is temporally and spatially regulated. Developmental Western analyses of soluble proteins detect a small protein, approximately 33 kDa, with MI-1-P synthase activity during the globular stage (stage II) of embryogenesis and in mature roots. Expression of this small protein is also enriched in thylakoidal membranes of fractionated leaf chloroplasts, although Western analyses of total soluble leaf proteins show no cross-reacting material, In contrast, a larger protein, approximately 56 kDa, with MI-1-P synthase activity is present during the cotyledonary phase (stage IV) of embryogenesis in green cotyledons of seedlings and in young roots.			Johnson, MD (corresponding author), UNIV ALABAMA, DEPT SCI BIOL, BOX 870344, TUSCALOOSA, AL 35487 USA.							ADHIKARI J, 1987, PLANT PHYSIOL, V85, P611, DOI 10.1104/pp.85.3.611; BARNETT JEG, 1970, BIOCHEM J, V119, P183, DOI 10.1042/bj1190183; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI D, 1993, PLANT J, V3, P383, DOI 10.1046/j.1365-313X.1993.t01-21-00999.x; CERFF R, 1982, METHODS CHLOROPLAST, P683; CHEN IW, 1966, J BIOL CHEM, V241, P2194; Colas de Francs C., 1985, PLANT PHYSIOL, V78, P178; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; DROBAK BK, 1992, BIOCHEM J, V288, P697, DOI 10.1042/bj2880697; EISENBERG F, 1964, BIOCHEM BIOPH RES CO, V14, P419, DOI 10.1016/0006-291X(64)90079-8; EISENBERG F, 1963, BIOCHEM BIOPH RES CO, V12, P72, DOI 10.1016/0006-291X(63)90416-9; HILL R, 1960, NATURE, V186, P136, DOI 10.1038/186136a0; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; IMHOFF V, 1973, PHYTOCHEMISTRY, V12, P331, DOI 10.1016/0031-9422(73)80014-7; JOHNSON MD, 1995, PLANT PHYSIOL, V107, P613, DOI 10.1104/pp.107.2.613; JOHNSON MD, 1994, PLANT PHYSIOL, V105, P1023, DOI 10.1104/pp.105.3.1023; JOHNSON MD, 1995, PLANT PHYSIOL, V109, P721; KIELY DE, 1975, J AM CHEM SOC, V97, P6810, DOI 10.1021/ja00856a035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LOEWUS FA, 1962, BIOCHEM BIOPH RES CO, V7, P204, DOI 10.1016/0006-291X(62)90175-4; LOEWUS FA, 1990, INOSITOL METABOLISM, V9, P13; LOEWUS MW, 1971, PLANT PHYSIOL, V48, P255, DOI 10.1104/pp.48.3.255; LOEWUS MW, 1986, ACTA BOT NEERL, V35, P347, DOI 10.1111/j.1438-8677.1986.tb01296.x; LOEWUS MW, 1973, PLANT SCI LETT, V1, P65; LUCK H, 1962, CATALASE METHODS ENZ, P885; MAEDA T, 1980, J BIOL CHEM, V255, P8458; OGUNYEMI EO, 1978, H-S Z PHYSIOL CHEM, V359, P613; ROBINSON C, 1988, ISOLATION ANAL CHLOR, P1; SHERMAN WR, 1977, J BIOL CHEM, V252, P5672; SMITH IK, 1973, BIOCHIM BIOPHYS ACTA, V321, P156, DOI 10.1016/0005-2744(73)90069-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREVELYAN WE, 1950, NATURE, V166, P444, DOI 10.1038/166444b0; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; WALBOT V, 1972, PHYTOMORPHOLOGY, V22, P59; WANG CT, 1971, BIOCHIM BIOPHYS ACTA, V241, P200, DOI 10.1016/0005-2736(71)90317-8; WANG X, 1995, PLANT PHYSIOL, V110, P336; WONG YHH, 1985, J BIOL CHEM, V260, P1083	41	34	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17215	17218		10.1074/jbc.271.29.17215	http://dx.doi.org/10.1074/jbc.271.29.17215			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663488	hybrid			2022-12-27	WOS:A1996UX94300038
J	Taylor, MF; Paulauskis, JD; Weller, DD; Kobzik, L				Taylor, MF; Paulauskis, JD; Weller, DD; Kobzik, L			In vitro efficacy of morpholino-modified antisense oligomers directed against tumor necrosis factor-alpha mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; PRIMARY MACROPHAGES; GENE-EXPRESSION; INHIBITION; TNF; ACTIVATION; ENHANCERS; PROMOTER; CELLS	Chemical modification of antisense oligonucleotides to increase nuclease resistance may improve their efficacy within enzyme-rich cellular targets (e.g. macrophages). We evaluated a panel of morpholino antisense oligomers (M-AS) for their ability to inhibit macrophage tumor necrosis factor-alpha. (TNF-alpha) release and compared them to phosphodiester (O-AS) and phosphorothioate (S-AS) types of oligonucleotides, M-AS inhibited translation in vitro (rabbit reticulocyte lysate) of target mRNA at concentrations as low as 200 nM (e.g. percent inhibition by M-AS 2 at 0.2, 1.0, and 2.0 mu M was 40.9 +/- 5.3% 50.2 +/- 4.6%, and 57.7 +/- 3.6%, respectively, n = 4,p less than or equal to 0.002 versus control). Similarly, M-AS 2 effectively, albeit partially, inhibited TNF-alpha production by LPS-stimulated macrophages (RAW 264.7 cells). Incubation of cells with 25 mu M M-AS 2 resulted in 32.6 +/- 2.6% (n = 3, p = 0.002 versus control) decrease in TNF-alpha release. In contrast, S-AS inhibited translation of the target mRNA in the rabbit reticulocyte lysate assay, but not in the cell-based assay. In fact, S-AS nonspecifically augmented TNF-alpha release, O-AS were without effect in either system, Uptake studies with fluorescent M-AS revealed that inhibitory effects were seen despite relatively low cellular uptake (intracellular concentration 30.5 +/- 6.7 nM; efficiency of uptake 0.1%). In contrast, flow cytometric and confocal analysis revealed that S-AS were avidly taken up by RAW 264.7 cells, confirming that their lack of efficacy was not due to lack of uptake, With improved methods of delivery, M-AS may represent an important therapeutic modality.	HARVARD UNIV, SCH PUBL HLTH, PHYSIOL PROGRAM, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; ANTIVIRALS INC, CORVALLIS, OR 97333 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital					NHLBI NIH HHS [HL43510, HL07118] Funding Source: Medline; NIEHS NIH HHS [ES00002] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; Bennett C, 1993, ANTISENSE RES APPL, P547; BENNETT CF, 1994, J IMMUNOL, V152, P3530; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; CROOKE RM, 1993, ANTISENSE RES APPLIC, P471; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; DENIS M, 1991, AM J RESP CELL MOL, V5, P477, DOI 10.1165/ajrcmb/5.5.477; DROUET C, 1991, J IMMUNOL, V147, P1694; GAO WY, 1992, MOL PHARMACOL, V41, P223; Ghosh M K, 1992, Antisense Res Dev, V2, P111; HUDZIAK RM, 1996, UNPUB; LEEPERWOODFORD SK, 1991, AM REV RESPIR DIS, V143, P1076, DOI 10.1164/ajrccm/143.5_Pt_1.1076; MALCOLM ADB, 1992, BIOCHEM SOC T, V20, P745, DOI 10.1042/bst0200745; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; MIRABELLI CK, 1993, ANTISENSE RES APPL, P7; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; PENNICA D, 1985, P NATL ACAD SCI USA, V82, P6060, DOI 10.1073/pnas.82.18.6060; PEREZ JR, 1994, P NATL ACAD SCI USA, V91, P5957, DOI 10.1073/pnas.91.13.5957; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; STEIN CA, 1988, CANCER RES, V48, P2659; SUMMERTON J, 1993, ANTISENSE RES DEV, V3, P306; Summerton JE, 1993, US Pat., Patent No. [5,185,444, 5185444]; TRACEY KJ, 1990, ANN NY ACAD SCI, V587, P325, DOI 10.1111/j.1749-6632.1990.tb00173.x; TRACEY KJ, 1988, AM REV RESPIR DIS, V138, P1377, DOI 10.1164/ajrccm/138.6.1377; ULICH TR, 1993, AM J PATHOL, V142, P1335; VANDERKROL AR, 1988, BIOTECHNIQUES, V6, P958; VOGEL SN, 1990, INFECT IMMUN, V58, P2397, DOI 10.1128/IAI.58.7.2397-2400.1990; WARREN JS, 1989, J CLIN INVEST, V84, P1873, DOI 10.1172/JCI114374; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	30	59	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17445	17452		10.1074/jbc.271.29.17445	http://dx.doi.org/10.1074/jbc.271.29.17445			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663413	hybrid			2022-12-27	WOS:A1996UX94300072
J	Waggoner, DW; GomezMunoz, A; Dewald, J; Brindley, DN				Waggoner, DW; GomezMunoz, A; Dewald, J; Brindley, DN			Phosphatidate phosphohydrolase catalyzes the hydrolysis of ceramide 1-phosphate, lysophosphatidate, and sphingosine 1-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; 2ND MESSENGER; PHOSPHOLIPASE-D; RAT-LIVER; INDEPENDENT PATHWAY; PLASMA-MEMBRANE; MIXED MICELLES; NADPH OXIDASE; ACID; ACTIVATION	A Mg2+-independent phosphatidate phosphohydrolase was purified from rat liver plasma membranes in two distinct forms, an anionic protein and a cationic protein. Both forms of the enzyme dephosphorylated phosphatidate, ceramide 1-phosphate, lysophosphatidate, and sphingosine 1-phosphate. When assayed at a constant molar ratio of lipid to Triton X-100 of 1:500, the apparent K-m values of the anionic phosphohydrolase for the lipid substrates was 3.5, 1.9, 0.4, and 4.0 mu M, respectively. The relative catalytic efficiency of the enzyme for phosphatidate, ceramide 1-phosphate, lysophosphatidate, and sphingosine 1-phosphate was 0.16, 0.14, 0.48, and 0.04 liter (min . mg)(-1), respectively. The hydrolysis of phosphatidate was inhibited competitively by ceramide l-phosphate, lysophosphatidate, and sphingosine 1-phosphate. The K-i(app) values were 5.5, 5.9, and 4.0 mu M, respectively. The hydrolysis of phosphatidate by the phosphohydrolase conformed to a surface dilution kinetic model. It is concluded that the enzyme is a lipid phosphomonoesterase that could modify the balance of phosphatidate, ceramide 1-phosphate, lysophosphatidate, and sphingosine 1-phosphate relative to diacylglycerol, ceramide, monoacylglycerol, and sphingosine, respectively. The enzyme could thus play an important role in regulating cell activation and signal transduction.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,SIGNAL TRANSDUCT LABS,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta				GOMEZ MUNOZ, ANTONIO/0000-0002-2539-016X				AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BELOCOPITOW E, 1982, EUR J BIOCHEM, V125, P167, DOI 10.1111/j.1432-1033.1982.tb06664.x; BHAT BG, 1994, J BIOL CHEM, V269, P13172; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOUDKER O, 1993, J BIOL CHEM, V268, P22150; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CARNERO A, 1993, J CELL BIOCHEM, V52, P440, DOI 10.1002/jcb.240520408; CHAO CP, 1994, J BIOL CHEM, V269, P5849; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DESAI NN, 1992, J BIOL CHEM, V267, P23122; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; Fiske CH, 1925, J BIOL CHEM, V66, P375; FLEMING IN, 1995, BIOCHEM J, V308, P983, DOI 10.1042/bj3080983; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; GOMEZMUNOZ A, 1992, BIOCHIM BIOPHYS ACTA, V1127, P49, DOI 10.1016/0005-2760(92)90200-F; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; JONES GA, 1993, J BIOL CHEM, V268, P20845; KANOH H, 1992, J BIOL CHEM, V267, P25309; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; MARTIN A, 1994, SIGNAL ACTIVATED PHO, P139; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MERRILL AH, 1992, NUTR REV, V50, P78; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; MORITZ A, 1992, J BIOL CHEM, V267, P7207; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; RIP JW, 1981, J BIOL CHEM, V256, P1929; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SEGEL IH, 1973, ENZYME KINETICS, P108; SPIEGEL S, 1993, ADV LIPID RES, V25, P105; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; WAGGONER DW, 1995, J BIOL CHEM, V270, P19422, DOI 10.1074/jbc.270.33.19422; WEDGWOOD JF, 1980, J BIOL CHEM, V255, P1120; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZHANG H, 1990, J BIOL CHEM, V265, P76	47	121	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16506	16509		10.1074/jbc.271.28.16506	http://dx.doi.org/10.1074/jbc.271.28.16506			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663293	hybrid			2022-12-27	WOS:A1996UX12600015
J	Dascher, C; Balch, WE				Dascher, C; Balch, WE			Mammalian Sly1 regulates syntaxin 5 function in endoplasmic reticulum to Golgi transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; PROTEIN; HOMOLOG; ALIGNMENT; SEQUENCE; COMPLEX; ELEGANS; MUTANTS; N-SEC1; YPT1	Members of the syntaxin gene family are components of protein complexes which regulate vesicle docking and/or fusion during transport of cargo through the secretory pathway of eukaryotic cells, We have previously demonstrated that syntaxin 5 is specifically required for endoplasmic reticulum to Golgi transport (Dascher, C., Matteson, J., and Balch, W. E, (1994) J. Biol. Chem, 269, 29363-29366). To extend these observations we have now cloned a protein from rat liver membranes which forms a native complex with syntaxin 5. We demonstrate that this protein is the mammalian homologue to yeast Sly1p, previously identified as a protein which genetically and biochemically interacts with the small GTPase Ypt1p and Sed5p, proteins involved in docking/fusion in the early secretory pathway of yeast. Using transient expression we find that overexpression of rat liver Sly1 (rSly1) can neutralize the dominant negative effects of excess syntaxin 5 on endoplasmic reticulum to Golgi transport. These results suggest that rSly1 functions to positively regulate syntaxin 5 function.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92130 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92130 USA	Scripps Research Institute; Scripps Research Institute					NCRR NIH HHS [RR08176, RRO7273] Funding Source: Medline; NIGMS NIH HHS [GM 42336] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR007273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; AALTO MK, 1991, YEAST, V7, P643, DOI 10.1002/yea.320070613; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARLOWE C, 1995, FEBS LETT, V369, P93, DOI 10.1016/0014-5793(95)00618-J; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DASCHER C, 1994, J BIOL CHEM, V269, P29363; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; Fleischer S, 1974, Methods Enzymol, V31, P6; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Halachmi N, 1996, J NEUROCHEM, V66, P889; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HARLOW E, 1988, ANTIBODIES LABORATOR, P312; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HODEL A, 1994, J BIOL CHEM, V269, P8623; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; NUOFFER C, 1996, METHOD ENZYMOL, V257, P3; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PALADE GE, 1976, SCIENCE, V189, P347; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	33	73	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15866	15869		10.1074/jbc.271.27.15866	http://dx.doi.org/10.1074/jbc.271.27.15866			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663406	hybrid			2022-12-27	WOS:A1996UW35200006
J	diRago, JP; Bruel, C; Graham, LA; Slonimski, P; Trumpower, BL				diRago, JP; Bruel, C; Graham, LA; Slonimski, P; Trumpower, BL			Heterologous complementation of a rieske iron-sulfur protein-deficient Saccharomyces cerevisiae by the Rip1 gene of Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONAL ANALYSIS; CYTOCHROME-BC1 COMPLEX; ELECTRON-TRANSFER; Q-CYCLE; TRANSFORMATION; CLUSTER	A cDNA carrying the Rip1 gene, which encodes the Rieske iron-sulfur protein of Schizosaccharomyces pombe, has been cloned by complementing the respiratory deficiency of a Saccharomyces cerevisiae strain in which the endogenous copy of the RLP1 gene has been deleted, The deduced amino acid sequences of the S. pombe and S. cerevisiae iron-sulfur proteins are 50% identical, with the highest region of identity being in the C termini of the proteins, where the 2Fe:2S cluster is bound, When expressed in the S, cerevisiae deletion strain, the S, pombe iron-sulfur protein restores 25-30% of the ubiquinol-cytochrome c reductase activity. The kinetics of cytochrome c reduction, the effects of inhibitors which act at defined sites in the cytochrome bc(1) complex, and the optical properties of cytochrome b in membranes from the S, cerevisiae deletion strain complemented with S, pombe iron-sulfur protein indicate that the S. pombe protein interacts with cytochrome b to restore an apparently normal ubiquinol oxidase site, but that interaction between the iron-sulfur protein and cytochrome c(1) is partially impaired, This is the first heterologous replacement of an electron transfer protein in a respiratory enzyme complex in S. cerevisiae.	DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755; UNIV PARIS 06,CNRS,CTR GENET MOLEC,LAB PROPRE,F-91198 GIF SUR YVETTE,FRANCE	Dartmouth College; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay					NIGMS NIH HHS [GM 20379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKMANN JD, 1989, J BIOL CHEM, V264, P3713; BLOCH JC, 1978, MOL GEN GENET, V165, P123, DOI 10.1007/BF00269900; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; GRAHAM LA, 1991, J BIOL CHEM, V266, P22485; Gutz H., 1974, HDB GENETICS, V1, P395; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; LJUNGDAHL PO, 1989, J BIOL CHEM, V264, P3723; Sambrook J., 2002, MOL CLONING LAB MANU; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P102; WANG BL, 1991, BIOTECHNIQUES, V10, P198	17	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15341	15345		10.1074/jbc.271.26.15341	http://dx.doi.org/10.1074/jbc.271.26.15341			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663290	hybrid			2022-12-27	WOS:A1996UV29900009
J	Caldenhoven, E; vanDijk, TB; Solari, R; Armstrong, J; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L; deGroot, RP				Caldenhoven, E; vanDijk, TB; Solari, R; Armstrong, J; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L; deGroot, RP			STAT3 beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HUMAN EOSINOPHILS; INTERFERON-ALPHA; TYROSINE PHOSPHORYLATION; HUMAN INTERLEUKIN-5; MESSENGER-RNA; GM-CSF; ACTIVATOR; RECEPTOR; GENE	The 89-kDa STAT3 protein is a latent transcription factor which is activated in response to cytokines (interleukin (IL)-5 and -6) and growth factors (epidermal growth factor). Binding of IL-5 to its specific receptor activates JAK2 which leads to the tyrosine phosphorylation of STAT3 proteins. Here we report the cloning of a cDNA encoding a variant of the transcription factor STAT3 (named STAT3 beta) which was isolated by screening an eosinophil cDNA library. Compared to wild-type STAT3, STAT3 beta lacks an internal domain of 50 base pairs located near the C terminus, This splice product is a naturally occurring isoform of STAT3 and encodes a 80-kDa protein. We found by reconstitution of the human IL-5R in COS cells that like STAT3, STAT3 beta is phosphorylated on tyrosine and binds to the pIRE from the ICAM-1 promoter after IL-5 stimulation. However, STAT3 beta fails to activate a pIRE containing promoter in transient transfection assays. Instead, co-expression of STAT3 beta inhibits the transactivation potential of STAT3. These results suggests that STAT3 beta functions as a negative regulator of transcription.	UNIV UTRECHT HOSP,DEPT PULM DIS,3584 CX UTRECHT,NETHERLANDS; GLAXO WELLCOME MED RES CTR,STEVENAGE SG1 2NY,HERTS,ENGLAND	Utrecht University; Utrecht University Medical Center; GlaxoSmithKline			Koenderman, Leo/AAE-7870-2020	Koenderman, Leo/0000-0002-5636-6453	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; CAMPBELL HD, 1987, P NATL ACAD SCI USA, V84, P6629, DOI 10.1073/pnas.84.19.6629; CHIHARA J, 1990, J EXP MED, V172, P1347, DOI 10.1084/jem.172.5.1347; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Fattah D, 1996, CYTOKINE, V8, P248, DOI 10.1006/cyto.1996.0034; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRAHAM FL, 1973, MOL CELL BIOL, V2, P607; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; INGLEY E, 1991, BLOOD, V78, P339; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; KRESS C, 1990, DEVELOPMENT, V109, P775; KUANG AA, 1993, MOL CELL BIOL, V13, P2536, DOI 10.1128/MCB.13.4.2536; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OGAWA M, 1993, BLOOD, V81, P2844; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; SANDERSON CJ, 1985, J EXP MED, V162, P60, DOI 10.1084/jem.162.1.60; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHEN S, 1993, MECH DEVELOP, V40, P177, DOI 10.1016/0925-4773(93)90075-9; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; VANDERBRUGGEN T, 1994, J IMMUNOL, V153, P2729; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; VANDERBRUGGEN T, 1993, J LEUKOCYTE BIOL, V53, P347, DOI 10.1002/jlb.53.4.347; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YAN RQ, 1995, NUCLEIC ACIDS RES, V23, P459, DOI 10.1093/nar/23.3.459; ZANDERS ED, 1994, EUR CYTOKINE NETW, V5, P35; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	61	306	319	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13221	13227		10.1074/jbc.271.22.13221	http://dx.doi.org/10.1074/jbc.271.22.13221			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8675499	hybrid			2022-12-27	WOS:A1996UN47400082
J	Bantle, S; Keller, S; Haussmann, I; Auerbach, D; Perriard, E; Muhlebach, S; Perriard, JC				Bantle, S; Keller, S; Haussmann, I; Auerbach, D; Perriard, E; Muhlebach, S; Perriard, JC			Tissue-specific isoforms of chicken myomesin are generated by alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-BAND PROTEINS; MUSCLE A-BAND; SKELETAL-MUSCLE; CREATINE-KINASE; MESSENGER-RNA; M-LINE; DIFFERENTIAL EXPRESSION; 3-DIMENSIONAL STRUCTURE; STRIATED-MUSCLE; PECTORAL MUSCLE	Myomesin is a high molecular weight protein that is present in the M-band of all fiber types of cross-striated skeletal muscle and heart. We have isolated two cDNAs encoding tissue-specific isoforms of chicken myomesin with calculated molecular masses of 174 kDa in skeletal muscle and 152 kDa in heart, Distinct sequences are found at the 3'-end of the two cDNAs, giving rise to different C-terminal domains. Partial analysis of the gene structure has shown that in chicken, both isoforms are generated by alternative splicing of a composite exon. Amino acid sequences show that the main body of myomesin consists of five fibronectin type III (class I motifs) and seven immunoglobulin-like domains (class Il motifs), An identical structure was found in RI-protein and human 190K protein (the human counterpart of chicken myomesin), and a comparable domain arrangement occurs in the M-band associated protein skelemin. We postulate that myomesin, M-protein, and skelemin belong to the same subfamily of high molecular weight RI-band-associated proteins of the immunoglobulin superfamily and that they probably have the same ancestor in evolution.	ETH HONGGERBERG, INST CELL BIOL, CH-8093 ZURICH, SWITZERLAND	ETH Zurich				Haussmann, Irmgard Ursula/0000-0002-7427-8342				CARLSSON E, 1987, CELL TISSUE RES, V248, P169, DOI 10.1007/BF01239978; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; DOETSCHMAN TC, 1984, EUR J CELL BIOL, V33, P265; EDMAN AC, 1988, J ULTRA MOL STRUCT R, V100, P1, DOI 10.1016/0889-1605(88)90054-7; EPPENBERGER HM, 1981, J CELL BIOL, V89, P185, DOI 10.1083/jcb.89.2.185; FURST DO, 1989, J CELL SCI, V94, P119; FURST DO, 1992, J CELL SCI, V102, P769; GROVE BK, 1985, J CELL BIOL, V101, P1413, DOI 10.1083/jcb.101.4.1413; GROVE BK, 1984, J CELL BIOL, V98, P518, DOI 10.1083/jcb.98.2.518; GROVE BK, 1989, CRIT REV NEUROBIOL, V4, P201; GROVE BK, 1989, J HISTOCHEM CYTOCHEM, V37, P447, DOI 10.1177/37.4.2926123; GROVE BK, 1987, DIFFERENTIATION, V34, P106, DOI 10.1111/j.1432-0436.1987.tb00056.x; HOSSLE JP, 1986, NUCLEIC ACIDS RES, V14, P1449, DOI 10.1093/nar/14.3.1449; KNAPPEIS GG, 1968, J CELL BIOL, V38, P202, DOI 10.1083/jcb.38.1.202; KORNBLIHTT AR, 1984, NUCLEIC ACIDS RES, V12, P5853, DOI 10.1093/nar/12.14.5853; LABEIT S, 1990, NATURE, V345, P273, DOI 10.1038/345273a0; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; LUTHER P, 1978, J MOL BIOL, V125, P313, DOI 10.1016/0022-2836(78)90405-9; LUTHER PK, 1981, J MOL BIOL, V151, P703, DOI 10.1016/0022-2836(81)90430-7; LUTHER PK, 1980, J MOL BIOL, V141, P409, DOI 10.1016/0022-2836(80)90254-5; MANI RS, 1978, BIOCHIM BIOPHYS ACTA, V536, P134, DOI 10.1016/0005-2795(78)90059-4; MASAKI T, 1972, J BIOCHEM, V71, P355, DOI 10.1093/oxfordjournals.jbchem.a129774; MASAKI T, 1974, J BIOCHEM, V75, P367, DOI 10.1093/oxfordjournals.jbchem.a130403; NAVE R, 1989, J CELL BIOL, V109, P2177, DOI 10.1083/jcb.109.5.2177; NOGUCHI J, 1992, J BIOL CHEM, V267, P20302; PASK HT, 1994, J MUSCLE RES CELL M, V15, P633, DOI 10.1007/BF00121071; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PIEROBONBORMIOLI S, 1981, J MUSCLE RES CELL M, V2, P401, DOI 10.1007/BF00711967; PRICE MG, 1987, J CELL BIOL, V104, P1325, DOI 10.1083/jcb.104.5.1325; PRICE MG, 1993, J BIOL CHEM, V268, P21800; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SCHAFER BW, 1988, J CELL BIOL, V106, P1161, DOI 10.1083/jcb.106.4.1161; SJOSTROM M, 1977, J MOL BIOL, V109, P49, DOI 10.1016/S0022-2836(77)80045-4; STREET SF, 1983, J CELL PHYSIOL, V114, P346, DOI 10.1002/jcp.1041140314; STREHLER EE, 1983, J MOL BIOL, V166, P141, DOI 10.1016/S0022-2836(83)80003-5; STREHLER EE, 1979, EXP CELL RES, V124, P39, DOI 10.1016/0014-4827(79)90255-6; TURNER DC, 1973, P NATL ACAD SCI USA, V70, P702, DOI 10.1073/pnas.70.3.702; VINKEMEIER U, 1993, J CELL SCI, V106, P319; WALLIMANN T, 1983, J MUSCLE RES CELL M, V4, P429, DOI 10.1007/BF00711948; WALLIMANN T, 1983, J CELL BIOL, V96, P1772, DOI 10.1083/jcb.96.6.1772; WANG K, 1983, J CELL BIOL, V96, P562, DOI 10.1083/jcb.96.2.562; WEBER FE, 1993, EUR J BIOCHEM, V216, P661, DOI 10.1111/j.1432-1033.1993.tb18186.x; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	45	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19042	19052		10.1074/jbc.271.32.19042	http://dx.doi.org/10.1074/jbc.271.32.19042			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702575	hybrid			2022-12-27	WOS:A1996VB68400009
J	Konan, KV; Taylor, MW				Konan, KV; Taylor, MW			Importance of the two interferon-stimulated response-element (ISRE) sequences in the regulation of the human indoleamine 2,3-dioxygenase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING FACTOR; HUMAN-FIBROBLASTS; DIFFERENTIAL REGULATION; TRANSCRIPTIONAL CONTROL; HOST-CELLS; GAMMA; EXPRESSION; ACTIVATION; ALPHA; INVOLVEMENT	Indoleamine 2,3-dioxygenase (INDO) is the rate-limiting enzyme in the catabolism of the essential amino acid L-tryptophan. It is induced strongly in many cell lines following interferon-gamma treatment. We report the cloning and characterization of the full-length human INDO promoter. This promoter is 1,245 base pairs long and includes two interferon-stimulated response elements (ISRE) separated by an approximately 1-kilobase sequence. The presence of these two ISREs is critical for maximum INDO promoter activity (50-fold induction). When the ISREs are present in two separate fragments cloned upstream of the chloramphenicol acetyltransferase (CAT) reporter vector, the INDO promoter activity drops significantly (7-fold induction). 5' end deletions of the wild type promoter sequence indicate that removal of the ISRE (ISRE1) at position -1126 reduces the induction level to approximately 25-fold. This activity does not change appreciably when the promoter is deleted down to position -241. Furthermore, site-directed mat-agenesis of ISRE1 also decreases the promoter activity in a similar way. When ISRE1 is kept intact, deletion of the second ISRE (ISRE2) at position -111 leads to only 11-fold induction of the promoter. A similar result is obtained when substitution mutations are introduced in ISRE2. Deletion of a 748-base pair sequence between the two ISREs only shows a slight decrease in the INDO promoter activity. These data indicate that the two ISRE sequences are required for the fall transcriptional induction of the interferon-gamma-inducible human INDO gene, INDO activity is not. induced in the hepatic cell line HepG2. An analysis of INDO-CAT activity in this cell line indicated that the lack of INDO activity was at the transcriptional level and could reflect either the presence of a repressor or lack of a transcription factor, This lack of induction could be correlated with a truncated or unstable IRF-1, However, the levels of IRF-2, JAK2, and STAT 91 were similar in both ME180 and HepG2 cells.	INDIANA UNIV,DEPT BIOL,INST MOL & CELLULAR BIOL,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington								Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CAPLEN HS, 1988, J BIOL CHEM, V263, P332; CARLIN JM, 1987, J IMMUNOL, V139, P2414; CHON SY, 1995, J INTERF CYTOK RES, V15, P517, DOI 10.1089/jir.1995.15.517; DAI W, 1990, J BIOL CHEM, V265, P19871; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DORN A, 1987, P NATL ACAD SCI USA, V84, P6249, DOI 10.1073/pnas.84.17.6249; FROLOVA LY, 1993, GENE, V128, P237, DOI 10.1016/0378-1119(93)90568-N; GUPTA SL, 1994, INFECT IMMUN, V62, P2277, DOI 10.1128/IAI.62.6.2277-2284.1994; HASSANAIN HH, 1993, J BIOL CHEM, V268, P5077; KADOYA A, 1992, BIOCHEM BIOPH RES CO, V189, P530, DOI 10.1016/0006-291X(92)91590-M; KLEIN SB, 1994, J INTERFERON RES, V14, P333, DOI 10.1089/jir.1994.14.333; KONAN KV, 1995, THESIS INDIANA U BLO; Kunkel T. A., 1989, RECOMBINANT DNA METH, P587; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; MUSSO T, 1995, BLOOD, V35, P1408; NICOLET CM, 1994, J IMMUNOL, V152, P153; OZES ON, 1994, J INTERFERON RES, V14, P25, DOI 10.1089/jir.1994.14.25; PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; THOMAS SM, 1993, J IMMUNOL, V150, P5529	25	84	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19140	19145		10.1074/jbc.271.32.19140	http://dx.doi.org/10.1074/jbc.271.32.19140			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702590	hybrid			2022-12-27	WOS:A1996VB68400024
J	Petersen, CE; Ha, CE; Jameson, DM; Bhagavan, NV				Petersen, CE; Ha, CE; Jameson, DM; Bhagavan, NV			Mutations in a specific human serum albumin thyroxine binding site define the structural basis of familial dysalbuminemic hyperthyroxinemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; FLUORESCENCE; HORMONE; AFFINITY; EXCESS; GENE; CONFORMATION; PROTEIN; VARIANT; PLASMA	The familiar dysalbuminemic hyperthyroxinemia (FDR) phenotype results hom a natural human serum albumin (HSA) mutant with histidine instead of arginine at amino acid position 218. This mutation results in an enhanced affinity for thyroxine, Site-directed mutagenesis and a yeast protein expression system were used to synthesize wild type BSA and FDN HSA as well as several other HSA mutants. Studies oil the binding of thyroxine to these HSA species using equilibrium dialysis and quenching of tryptophan 214 fluorescence suggest that the FDH mutation affects a single thyroxine binding site located in the 2A subdomain of HSA. Site-directed mutagenesis of HSA and thyroxine analogs mere used to obtain information about the mechanism of thyroxine binding to both wild type and FDH HSA. These studies suggest that the guanidino group of arginine at,amino acid position 218 in wild type RSA is involved in an unfavorable binding interaction with the amino group of thyroxine, whereas histidine at amino acid position 218 in FDR HSA is involved in a favorable binding interaction with thyroxine. Neither arginine at amino acid position 222 nor tryptophan at amino acid position 214 appears to favorably influence the binding of thyroxine to wild type HSA.	UNIV HAWAII MANOA,DEPT BIOCHEM & BIOPHYS,HONOLULU,HI 96822	University of Hawaii System; University of Hawaii Manoa								BARLOW JW, 1982, J CLIN ENDOCR METAB, V55, P244, DOI 10.1210/jcem-55-2-244; BORST GC, 1982, AM J MED, V73, P283, DOI 10.1016/0002-9343(82)90190-5; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; CARTER DC, 1992, NATURE, V358, P208; CHATELAIN P, 1994, J PHARM SCI, V83, P674, DOI 10.1002/jps.2600830516; DOCTER R, 1981, CLIN ENDOCRINOL, V15, P363, DOI 10.1111/j.1365-2265.1981.tb00676.x; DUGHI C, 1993, PHOTOCHEM PHOTOBIOL, V57, P416, DOI 10.1111/j.1751-1097.1993.tb02311.x; FOSTER T, 1948, ANN PHYS, V2, P55; GLATZ JFC, 1983, J BIOCHEM BIOPH METH, V8, P57, DOI 10.1016/0165-022X(83)90021-0; KAMIKUBO K, 1990, J PROTEIN CHEM, V9, P461, DOI 10.1007/BF01024622; LALLOZ MRA, 1983, CLIN ENDOCRINOL, V18, P11, DOI 10.1111/j.1365-2265.1983.tb03181.x; LEE WNP, 1979, J CLIN ENDOCR METAB, V49, P292, DOI 10.1210/jcem-49-2-292; LEVINE RL, 1977, CLIN CHEM, V23, P2292; MINGHETTI PP, 1986, J BIOL CHEM, V261, P6747; OKABE N, 1976, J BIOCHEM-TOKYO, V80, P455, DOI 10.1093/oxfordjournals.jbchem.a131298; OKABE N, 1985, J BIOCHEM-TOKYO, V97, P1317, DOI 10.1093/oxfordjournals.jbchem.a135183; PETERSEN CE, 1995, BIOCHEM BIOPH RES CO, V214, P1121, DOI 10.1006/bbrc.1995.2402; PETERSEN CE, 1994, J MED GENET, V31, P355, DOI 10.1136/jmg.31.5.355; REED RG, 1975, BIOCHEMISTRY-US, V14, P4578, DOI 10.1021/bi00692a004; RUI ZM, 1984, NEW ENGL J MED, V306, P635; SCOTTOLINI AG, 1984, CLIN CHEM, V30, P1179; STEINER RF, 1966, J BIOL CHEM, V241, P560; STERLING K, 1964, J CLIN INVEST, V43, P1721, DOI 10.1172/JCI105047; STERLING K, 1961, J BIOL CHEM, V236, P2241; STERLING K, 1962, J CLIN INVEST, V41, P1021, DOI 10.1172/JCI104552; STOCKIGT JR, 1981, J CLIN ENDOCR METAB, V53, P353, DOI 10.1210/jcem-53-2-353; SUDLOW G, 1976, MOL PHARMACOL, V12, P1052; SUDLOW G, 1975, CLIN EXP PHARMACOL P, V2, P129, DOI 10.1111/j.1440-1681.1975.tb01826.x; SUDLOW G, 1975, MOL PHARMACOL, V11, P824; SUNTHORNTHEPVARAKUL T, 1994, BIOCHEM BIOPH RES CO, V202, P781, DOI 10.1006/bbrc.1994.1998; SUTERCRAZZOLARA C, 1995, BIOTECHNIQUES, V19, P204; TABACHNICK M, 1979, ARCH BIOCHEM BIOPHYS, V198, P403, DOI 10.1016/0003-9861(79)90513-7; TABACHNICK M, 1964, ARCH BIOCHEM BIOPHYS, V105, P563, DOI 10.1016/0003-9861(64)90051-7; TABACHNICK M, 1970, ARCH BIOCHEM BIOPHYS, V136, P467, DOI 10.1016/0003-9861(70)90218-3; TABACHNICK M, 1964, J BIOL CHEM, V239, P1242; TOKUOKA R, 1980, J BIOCHEM-TOKYO, V87, P1729, DOI 10.1093/oxfordjournals.jbchem.a132917; TRAVIS J, 1976, BIOCHEM J, V157, P301, DOI 10.1042/bj1570301; TRITSCH GL, 1961, J BIOL CHEM, V236, P3163; VOELKER JR, 1989, J PHARMACOL EXP THER, V250, P772; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WILTING J, 1980, J BIOL CHEM, V255, P3032	41	51	54	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19110	19117		10.1074/jbc.271.32.19110	http://dx.doi.org/10.1074/jbc.271.32.19110			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702585	hybrid			2022-12-27	WOS:A1996VB68400019
J	Chen, Q; Crosa, JH				Chen, Q; Crosa, JH			Antisense RNA, fur, iron, and the regulation of iron transport genes in Vibrio anguillarum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI; MOLECULAR-CLONING; PLASMID PJM1; VIRULENCE PLASMID; MESSENGER-RNA; UPTAKE SYSTEM; SIDEROPHORE; EXPRESSION; TRANSCRIPTION	The negative regulation of the expression of iron transport genes fatA and fatB in Vibrio anguillarum is mediated by a chromosome-encoded Fur protein and a plasmid pJM1-derived antisense RNA (RNA alpha), which is preferentially expressed under iron-rich conditions, In this work, we characterized the RNA alpha promoter region, and by using promoter fusion and rifampicin experiments we were able to demonstrate that iron regulates RNA alpha synthesis posttranscriptionally by stabilizing RNA alpha half-life rather than enhancing transcription initiation, The Fur protein is also essential for RNA alpha synthesis at the transcription initiation level, independently of the iron status of the cell, From experiments assessing the relative contribution of Fur and RNA alpha, we were able to show that RNA alpha may indeed play an important role on the negative regulation of the expression of the iron transport genes under physiological conditions.	OREGON HLTH SCI UNIV,SCH MED,DEPT MOL MICROBIOL & IMMUNOL L220,PORTLAND,OR 97201	Oregon Health & Science University					NIAID NIH HHS [AI19018] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019018] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACTIS LA, 1988, J BIOL CHEM, V263, P2853; ACTIS LA, 1985, J BACTERIOL, V161, P736, DOI 10.1128/JB.161.2.736-742.1985; ACTIS LA, 1995, MOL MICROBIOL, V17, P197, DOI 10.1111/j.1365-2958.1995.mmi_17010197.x; ARDITTI R, 1973, J BACTERIOL, V114, P652, DOI 10.1128/JB.114.2.652-655.1973; BAGG A, 1987, MICROBIOL REV, V51, P509, DOI 10.1128/MMBR.51.4.509-518.1987; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOLIVAR F, 1978, GENE, V4, P121, DOI 10.1016/0378-1119(78)90025-2; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRICKMAN TJ, 1990, J MOL BIOL, V212, P669, DOI 10.1016/0022-2836(90)90229-F; BROSIUS J, 1984, GENE, V27, P151, DOI 10.1016/0378-1119(84)90136-7; Bullen J J, 1978, Curr Top Microbiol Immunol, V80, P1; CHEN Q, 1994, J BACTERIOL, V176, P4226, DOI 10.1128/jb.176.14.4226-4234.1994; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; CROSA JH, 1977, INFECT IMMUN, V18, P509, DOI 10.1128/IAI.18.2.509-513.1977; CROSA JH, 1980, NATURE, V284, P566, DOI 10.1038/284566a0; CROSA JH, 1989, MICROBIOL REV, V53, P517, DOI 10.1128/MMBR.53.4.517-530.1989; CROSA JH, 1980, INFECT IMMUN, V27, P897, DOI 10.1128/IAI.27.3.897-902.1980; DELORENZO V, 1987, J BACTERIOL, V169, P2624, DOI 10.1128/jb.169.6.2624-2630.1987; DICKSON RC, 1975, SCIENCE, V187, P27, DOI 10.1126/science.1088926; FASANO A, 1990, INFECT IMMUN, V58, P3737; FOSTER JW, 1992, J BACTERIOL, V174, P4317, DOI 10.1128/JB.174.13.4317-4323.1992; GILBERT W, 1976, RNA POLYMERASE, P192; GRIGGS DW, 1989, J BACTERIOL, V171, P1048, DOI 10.1128/jb.171.2.1048-1054.1989; INOUYE M, 1988, CELL, V53, P5, DOI 10.1016/0092-8674(88)90480-1; KOSTER WL, 1991, J BIOL CHEM, V266, P23829; LITWIN CM, 1993, CLIN MICROBIOL REV, V6, P137, DOI 10.1128/CMR.6.2.137-149.1993; NIEDERHOFFER EC, 1990, J BACTERIOL, V172, P1930, DOI 10.1128/jb.172.4.1930-1938.1990; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; PRINCE RW, 1993, J BACTERIOL, V175, P2589, DOI 10.1128/JB.175.9.2589-2598.1993; REZNIKOFF WS, 1992, J BACTERIOL, V174, P655, DOI 10.1128/jb.174.3.655-658.1992; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; SALINAS PC, 1989, P NATL ACAD SCI USA, V86, P3529, DOI 10.1073/pnas.86.10.3529; SALINAS PC, 1992, GENE AMST, V123, P33; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONS RW, 1988, ANNU REV GENET, V22, P567, DOI 10.1146/annurev.ge.22.120188.003031; THEIL EC, 1994, BIOCHEM J, V304, P1; TOLMASKY ME, 1994, J BACTERIOL, V176, P213, DOI 10.1128/JB.176.1.213-220.1994; TOLMASKY ME, 1991, BIOL MET, V4, P33, DOI 10.1007/BF01135554; TOLMASKY ME, 1984, J BACTERIOL, V160, P860, DOI 10.1128/JB.160.3.860-866.1984; TOLMASKY ME, 1988, J BACTERIOL, V170, P1913, DOI 10.1128/jb.170.4.1913-1919.1988; VONGABAIN A, 1983, P NATL ACAD SCI-BIOL, V80, P653; WALDBESER LS, 1995, MOL MICROBIOL, V17, P747, DOI 10.1111/j.1365-2958.1995.mmi_17040747.x; WALDBESER LS, 1993, J BIOL CHEM, V268, P10433; WEINBERG ED, 1989, Q REV BIOL, V64, P261, DOI 10.1086/416359	44	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18885	18891		10.1074/jbc.271.31.18885	http://dx.doi.org/10.1074/jbc.271.31.18885			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702549	hybrid			2022-12-27	WOS:A1996VB68300087
J	Li, RG; Hodny, Z; Luciakova, K; Barath, P; Nelson, BD				Li, RG; Hodny, Z; Luciakova, K; Barath, P; Nelson, BD			Sp1 activates and inhibits transcription from separate elements in the proximal promoter of the human adenine nucleotide translocase 2 (ANT2) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE-DEPENDENT GENES; SUBUNIT-IV GENE; BOX-BINDING-PROTEINS; RNA POLYMERASE-II; ADP/ATP TRANSLOCASE; DNA-BINDING; MOLECULAR-CLONING; EXPRESSION; DISTINCT; FAMILY	Expression of the adenine nucleotide translocator 2 (ANT2) gene is growth regulated, We report a feature of the ANT2 promoter that involves a novel regulatory function for the Spl transfactor. We show that expression from the ANT2 proximal promoter is modulated through three Spl elements, two of which activate and one of which partially inhibits transcription, The inhibitor site, box C, is juxtaposed to transcription start (nucleotides -7 to -2), Spl bound to box C decreases transcription initiation, This was demonstrated by introducing mutations in box C which (a) increased chloramphenicol acetyltransferase expression in the transient transfection assay and (b) inhibited binding of both purified Spl and Spl in crude nuclear extracts, The activating elements (A and B boxes) are located at adjacent sites in the distal region of the proximal promoter, Mutation of either box inhibits transfection by 90%, indicating that they act in a synergistic manner, Supershift experiments with crude nuclear extracts showed that only Spl was bound to the three GC boxes, The finding that Spl acts as an activator/inhibitor within the same promoter region was verified in NIH3T3, HeLa, JEG3, and COS-1, indicating that this dual effect of Spl is widely preserved, These data suggest a unique role for Spl and raise the possibility that growth activation of the ANT2 gene is regulated by the interaction of Spl on the A, B, and C boxes.	UNIV STOCKHOLM,ARRHENIUS LAB,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN	Stockholm University			Hodny, Zdenek/C-9384-2009; Barath, Peter/T-7563-2019	Barath, Peter/0000-0001-7330-955X				BATTINI R, 1987, J BIOL CHEM, V262, P4355; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; DATTA PK, 1995, NUCLEIC ACIDS RES, V15, P5444; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMANUEL PA, 1993, P NATL ACAD SCI USA, V90, P8449, DOI 10.1073/pnas.90.18.8449; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HIRSCHHORN RR, 1984, P NATL ACAD SCI-BIOL, V81, P6004, DOI 10.1073/pnas.81.19.6004; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KACZMAREK L, 1985, P NATL ACAD SCI USA, V82, P5375, DOI 10.1073/pnas.82.16.5375; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KU DH, 1990, J BIOL CHEM, V265, P16060; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LI K, 1989, J BIOL CHEM, V264, P13998; LIU HT, 1985, MOL CELL BIOL, V5, P2936, DOI 10.1128/MCB.5.11.2936; LUNARDI J, 1991, J BIOL CHEM, V266, P16534; LUNARDI J, 1992, J BIOL CHEM, V267, P15267; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; RITTLING SR, 1986, P NATL ACAD SCI USA, V83, P3316, DOI 10.1073/pnas.83.10.3316; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SUZUKI K, 1995, MOL CELL BIOL, V15, P5243; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670	36	70	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18925	18930		10.1074/jbc.271.31.18925	http://dx.doi.org/10.1074/jbc.271.31.18925			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702555	hybrid			2022-12-27	WOS:A1996VB68300093
J	Weber, J; Bowman, C; Senior, AE				Weber, J; Bowman, C; Senior, AE			Specific tryptophan substitution in catalytic sites of Escherichia coli F-1-ATPase allows differentiation between bound substrate ATP and product ADP in steady-state catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART MITOCHONDRIAL ATPASE; NUCLEOTIDE-BINDING; BETA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; MEMBRANE SECTOR; MUTANT STRAINS; F1-ATPASE; MECHANISM; PROTEIN; COMPLEX	Tryptophan was specifically inserted as the residue immediately preceding the P-loop sequence in F-1-ATPase catalytic sites. The mutant enzyme (beta F148W) showed normal enzymatic characteristics. The fluorescence responses of beta-tryptophan 148 enabled us to differentiate between nucleoside di- and triphosphate bound in catalytic sites; MgADP quenched at 350 nm, whereas MgAMPPNP and MgADP . BeFx complex enhanced the fluorescence at 325 nm. With MgATP, both effects were seen simultaneously. This allowed analysis of bound catalytic site nucleotides directly under steady-state MgATP hydrolysis conditions. At mM concentration of MgATP (V-max conditions) one of the three catalytic sites was filled with substrate MgATP and the other two sites were filled with product MgADP. A model for F-1-ATPase steady-state turnover is presented that encompasses these findings. Given the structural similarity of the P-loop in nucleotide-binding proteins, this approach may prove widely useful.			Weber, J (corresponding author), UNIV ROCHESTER, MED CTR, DEPT BIOCHEM, ROCHESTER, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025349, R01GM025349] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P886, DOI 10.1021/bi00118a034; ALSHAWI MK, 1992, BIOCHEMISTRY-US, V31, P878, DOI 10.1021/bi00118a033; BIVIN DB, 1993, P NATL ACAD SCI USA, V90, P6791, DOI 10.1073/pnas.90.14.6791; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DOWNIE JA, 1981, J BACTERIOL, V145, P200, DOI 10.1128/JB.145.1.200-210.1981; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; RAO R, 1988, J BIOL CHEM, V263, P5569; SENIOR AE, 1992, J BIOENERG BIOMEMBR, V24, P479, DOI 10.1007/BF00762365; SENIOR AE, 1979, BIOCHEM J, V180, P111, DOI 10.1042/bj1800111; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1995, BIOCHEM SOC T, V23, P747, DOI 10.1042/bst0230747; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; SHEN HG, 1994, J BIOL CHEM, V269, P9424; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEBB MR, 1980, J BIOL CHEM, V255, P1637; WEBER J, 1994, J BIOL CHEM, V269, P20462; WEBER J, 1992, J BIOL CHEM, V267, P1712; WEBER J, 1992, BIOCHEMISTRY-US, V31, P5112, DOI 10.1021/bi00137a004; WEBER J, 1993, J BIOL CHEM, V268, P20126; WEBER J, 1995, J BIOL CHEM, V270, P12653, DOI 10.1074/jbc.270.21.12653; Weber J, 1996, J BIOL CHEM, V271, P3474; WILKEMOUNTS S, 1994, ARCH BIOCHEM BIOPHYS, V309, P363, DOI 10.1006/abbi.1994.1125; [No title captured]	42	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18711	18718		10.1074/jbc.271.31.18711	http://dx.doi.org/10.1074/jbc.271.31.18711			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702526	hybrid			2022-12-27	WOS:A1996VB68300064
J	Yasuda, H; Lindorfer, MA; Woodfork, KA; Fletcher, JE; Garrison, JC				Yasuda, H; Lindorfer, MA; Woodfork, KA; Fletcher, JE; Garrison, JC			Role of the prenyl group on the G protein gamma subunit in coupling trimeric G proteins to A1 adenosine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; HETEROTRIMERIC G-PROTEINS; BETA-GAMMA; SIGNAL-TRANSDUCTION; ALPHA-SUBUNITS; GTP-BINDING; PHOSPHOLIPASE-C; SF9 CELLS; DIMERS; RECONSTITUTION	The coupling of receptors to heterotrimeric G proteins is determined by interactions between the receptor and the G protein alpha subunits and by the composition of the beta gamma dimers, To determine the role of the gamma subunit prenyl modification in this interaction, the CaaX motifs in the gamma(1), and gamma(2) subunits were altered to direct modification with different prenyl groups, recombinant beta gamma dimers expressed in the baculovirus/Sf9 insect cell system, and the dimers purified, The activity of the beta gamma dimers was compared in two assays: formation of the high affinity agonist binding conformation of the Al adenosine receptor and receptor-catalyzed exchange of GDP for GTP on the a subunit, The beta(1) gamma(1) dimer (modified with farnesyl) was significantly less effective than beta(1) gamma(2) (modified with geranylgeranyl) in either assay, The beta(1) gamma(1)-S74L dimer (modified with geranylgeranyl) was nearly as effective as beta(1) gamma(2) in either assay, The beta(1) gamma(2)-L71S dimer (modified with farnesyl) was significantly less active than beta(1) gamma(2). Using I-125-labeled beta gamma subunits, it was determined that native and altered beta gamma dimers reconstituted equally well into Sf9 membranes containing Al adenosine receptors. These data suggest that the prenyl group on the gamma subunit is an important determinant of the interaction between receptors and G protein gamma subunits.			Yasuda, H (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,BOX 448,CHARLOTTESVILLE,VA 22908, USA.				NIDDK NIH HHS [R01-DK-19952] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUER PH, 1991, MOL PHARMACOL, V39, P579; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CASEY PJ, 1992, J LIPID RES, V33, P1731; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DIETRICH A, 1994, EUR J BIOCHEM, V219, P171, DOI 10.1111/j.1432-1033.1994.tb19927.x; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EXTON JH, 1994, ANNU REV PHYSIOL, V56, P349; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GRABER SG, 1996, METH NEUROSCI, V29, P207; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; INIGUEZLLUHI JA, 1993, TRENDS CELL BIOL, V3, P2300; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LINDEN J, 1985, CIRC RES, V56, P279, DOI 10.1161/01.RES.56.2.279; Lindorfer MA, 1996, J BIOL CHEM, V271, P18582, DOI 10.1074/jbc.271.31.18582; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MATSUDA T, 1994, J BIOL CHEM, V269, P30358; MORISHITA R, 1995, J BIOL CHEM, V270, P29469, DOI 10.1074/jbc.270.49.29469; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MULLER S, 1993, P NATL ACAD SCI USA, V90, P10439, DOI 10.1073/pnas.90.22.10439; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; ONG OC, 1995, J BIOL CHEM, V270, P8495, DOI 10.1074/jbc.270.15.8495; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; RYBA NJP, 1995, J BIOL CHEM, V270, P6757, DOI 10.1074/jbc.270.12.6757; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TAYLOR CW, 1990, BIOCHEM J, V272, P1; TAYLOR SS, 1993, RECEPTOR, V3, P165; TUCKER AL, 1992, FEBS LETT, V297, P107, DOI 10.1016/0014-5793(92)80338-H; UEDA N, 1994, J BIOL CHEM, V269, P4388; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	61	89	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18588	18595		10.1074/jbc.271.31.18588	http://dx.doi.org/10.1074/jbc.271.31.18588			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702509	hybrid			2022-12-27	WOS:A1996VB68300047
J	Ahn, K; Erlander, M; Leturcq, D; Peterson, PA; Fruh, K; Yang, Y				Ahn, K; Erlander, M; Leturcq, D; Peterson, PA; Fruh, K; Yang, Y			In vivo characterization of the proteasome regulator PA28	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE; 26-S PROTEASOME; 11-S REGULATOR; COMPLEX; ACTIVATOR; FORMS; PURIFICATION; EXPRESSION; SUBUNITS; GAMMA	A proteasome regulator, termed PA28, has been shown to modulate peptidase activities of the proteasomes in vitro. Two different but homologous PA28 molecules, designated as PA28 alpha and PA28 beta, have been cloned. Both alpha and beta polypeptides of PA28 are found in PA28 complexes isolated from cells, indicating that both are constituents of functional PA28 complexes. Using antisera specific to PA28 alpha, PA28 beta, and epitope-tagged PA28 molecules, we show that expression of PA28 alpha and PA28 beta is coordinately induced by various cytokines in different cell lines and that PA28 subunits and proteasomes have almost identical half-lives. In addition, we show that PA28 complexes are associated with 20 S but not 26 S proteasomes in vivo. Moreover, we demonstrate that PA28 complex is a heterohexamer composed of both alpha and beta subunits with a stoichiometry of alpha(3) beta(3) in an alternating order.	Scripps Res Inst, RW JOHNSON PHARMACEUT RES INST, DEPT IMMUNOL, IMM23, LA JOLLA, CA 92037 USA	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute				Frueh, Klaus/0000-0001-8014-3877				AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; CHUPING M, 1993, J BIOL CHEM, V268, P22514; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; EYTAN E, 1993, J BIOL CHEM, V268, P4668; FRUH K, 1995, EMBO J, V375, P415; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; LEE BS, 1995, P NATL ACAD SCI USA, V92, P10354, DOI 10.1073/pnas.92.22.10354; LINDSTEDT R, 1995, IMMUNITY, V3, P561, DOI 10.1016/1074-7613(95)90127-2; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1994, J BIOL CHEM, V269, P3539; MOTT JD, 1994, J BIOL CHEM, V269, P31466; MYKLES DL, 1989, ARCH BIOCHEM BIOPHYS, V274, P216, DOI 10.1016/0003-9861(89)90433-5; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PETERS JM, 1994, J BIOL CHEM, V269, P7709; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; REALINI C, 1994, J BIOL CHEM, V269, P20727; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050	30	85	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18237	18242		10.1074/jbc.271.30.18237	http://dx.doi.org/10.1074/jbc.271.30.18237			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663520	hybrid			2022-12-27	WOS:A1996UY93500097
J	Lasken, RS; Schuster, DM; Rashtchian, A				Lasken, RS; Schuster, DM; Rashtchian, A			Archaebacterial DNA polymerases tightly bind uracil-containing DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETICS; ARCHAEA; CLONING; GENE	We show that archaebacterial DNA polymerases are strongly inhibited by the presence of small amounts of uracil-containing DNA. Inhibition appears to be competitive, with the DNA polymerase exhibiting similar to 6500-fold greater affinity for binding the inhibitor than a DNase I-activated DNA substrate. All six archaebacterial DNA polymerases tested were inhibited, while no eubacterial, eukaryotic, or bacteriophage enzymes showed this effect, Only a small inhibition resulted when uracil was present as the deoxynucleoside triphosphate, dUTP. The rate of DNA synthesis was reduced by similar to 40% when dUTP was used in place of dTTP for archaebacterial DNA polymerases. Furthermore, an incorporated dUMP served as a productive 3'-primer terminus for subsequent elongation. In contrast, the presence of an oligonucleotide containing as little as a single dUrd residue was extremely inhibitory to DNA polymerase activity on other primer-template DNA.			Lasken, RS (corresponding author), LIFE TECHNOL INC,SG II,LAB 15,8717 GROVEMONT CIRCLE,POB 6009,GAITHERSBURG,MD 20884, USA.							BERGSEID M, 1992, STRATEGIES, V5, P50; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CHATTERJEE DK, 1991, GENE, V97, P13, DOI 10.1016/0378-1119(91)90004-U; CLINE JM, 1992, STRATEGIES, V4, P34; CREIGHTON S, 1995, J BIOL CHEM, V270, P4759, DOI 10.1074/jbc.270.9.4759; DOOLITTLE RF, 1995, P NATL ACAD SCI USA, V92, P2421, DOI 10.1073/pnas.92.7.2421; ELLENBERGER T, 1995, CHEM BIOL, V2, P351, DOI 10.1016/1074-5521(95)90213-9; KONG HM, 1993, J BIOL CHEM, V268, P1965; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; Lehninger A, 1978, BIOCHEMISTRY; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; PERLER FB, 1992, P NATL ACAD SCI USA, V89, P5577, DOI 10.1073/pnas.89.12.5577; PISANI FM, 1992, NUCLEIC ACIDS RES, V20, P2722; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; RASHTCHIAN A, 1992, ANAL BIOCHEM, V206, P91, DOI 10.1016/S0003-2697(05)80015-6; Rashtchian Ayoub, 1995, Current Opinion in Biotechnology, V6, P30, DOI 10.1016/0958-1669(95)80006-9; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SLUPPHAUG G, 1992, ANAL BIOCHEM, V221, P164; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	20	72	117	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17692	17696		10.1074/jbc.271.30.17692	http://dx.doi.org/10.1074/jbc.271.30.17692			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663453	hybrid			2022-12-27	WOS:A1996UY93500018
J	Surolia, A; Sharon, N; Schwarz, FP				Surolia, A; Sharon, N; Schwarz, FP			Thermodynamics of monosaccharide and disaccharide binding to Erythrina corallodendron lectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEAN PSOPHOCARPUS-TETRAGONOLOBUS; FLUORESCENT-INDICATOR LIGAND; CONCANAVALIN-A; CARBOHYDRATE COMPLEXES; THERMAL-DENATURATION; RIBONUCLEASE-A; PROTEIN; AGGLUTININ; OLIGOSACCHARIDES; ENERGETICS	Isothermal titration calorimetry measurements of the binding of 2'-fucosyllactose, lactose, N-acetyllactosamine, galactopyranose, 2-acetamido-2-deoxygalactopyranoside, methyl alpha-N-dansylgalactosaminide (Me-alpha-DNS-GalN), methyl alpha-D-galactopyranoside, methyl beta-D-galactopyranoside, and fucose to Erythrina corallodendron lectin (ECorL), a dimer with one binding site per subunit, were performed at 283-286 and 297-299 K. The site binding enthalpies, Delta H-b, with the exception of Me-alpha-DNS-GalN, are the same at both temperatures and range from -47.1 +/- 1.0 kJ mol(-1) for N-acetyllactosamine to -4.4 +/- 0.3 kJ mol(-1) for fucose, and the site binding constants range from 3.82 +/- 0.9 x 10(5) M(-1) for Me-alpha-DNS-GalN at 283.2 K to 0.46 +/- 0.05 x 10(3) M(-1) for fucose at 297.2 K, The binding reactions are mainly enthalpically driven except for fucose and exhibit enthalpy-entropy compensation, The binding enthalpies of the disaccharides are about twice the binding enthalpies of the monosaccharides in contrast to concanavalin A where the binding enthalpies do not double for the disaccharides, Differential scanning calorimetry measurements show that denaturation of the ECorL dimer results in dissociation into its monomer subunits, The binding constants from the increase in denaturation temperature of ECorL in the presence of saccharides are in agreement with values from isothermal titration calorimetry results, The thermal denaturation of ECorL occurs around 333 K, well below the 344-360 K denaturation temperature of other legume lectins of similar size and tertiary structure, undoubtedly due to the difference in its quaternary structure relative to other legume lectins, This is also apparent from the independent unfolding of its two domains.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL; CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850; NIST,ROCKVILLE,MD 20850	Weizmann Institute of Science; National Institute of Standards & Technology (NIST) - USA	Surolia, A (corresponding author), INDIAN INST SCI,MOLEC BIOPHYS UNIT,BANGALORE 560012,KARNATAKA,INDIA.		SUROLIA, AVADESHA/C-5442-2009					ACHARYA S, 1990, J BIOL CHEM, V265, P11586; ADAR R, 1996, IN PRESS EUR J BIOCH; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BOURNE Y, 1992, J BIOL CHEM, V267, P197; BRADEN BC, 1994, J MOL BIOL, V243, P767, DOI 10.1016/0022-2836(94)90046-9; DEBOECK H, 1984, ARCH BIOCHEM BIOPHYS, V234, P297, DOI 10.1016/0003-9861(84)90352-7; EFTINK MR, 1983, BIOCHEMISTRY-US, V22, P3884, DOI 10.1021/bi00285a025; FUKADA H, 1983, J BIOL CHEM, V258, P3193; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; KINZY WR, 1992, GLYCOCONJUGATE J, V9, P225, DOI 10.1007/BF00731133; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMIEUX RU, 1994, CAN J CHEM, V72, P158, DOI 10.1139/v94-024; LIS H, 1985, PHYTOCHEMISTRY, V24, P2803, DOI 10.1016/0031-9422(85)80004-2; MANLY SP, 1985, BIOCHEMISTRY-US, V24, P3842, DOI 10.1021/bi00336a004; NAGHIBI H, 1995, P NATL ACAD SCI USA, V92, P5597, DOI 10.1073/pnas.92.12.5597; PURI KD, 1994, PURE APPL CHEM, V66, P497, DOI 10.1351/pac199466030497; RAMKUMAR R, 1995, BIOCHEM J, V308, P237, DOI 10.1042/bj3080237; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; SCHELLMAN JA, 1975, BIOPOLYMERS, V14, P999, DOI 10.1002/bip.1975.360140509; SCHWARZ FP, 1991, J BIOL CHEM, V266, P24344; SCHWARZ FP, 1988, BIOCHEMISTRY-US, V27, P8429, DOI 10.1021/bi00422a020; SCHWARZ FP, 1988, THERMOCHIM ACTA, V128, P267, DOI 10.1016/0040-6031(88)85371-1; SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668; SCHWARZ FP, 1996, IN PRESS BIOCH J; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHARON N, 1993, TRENDS BIOCHEM SCI, V18, P221, DOI 10.1016/0968-0004(93)90193-Q; SHARON N, 1989, LECTINS; TOONE EJ, 1994, CURR OPIN STRUC BIOL, V4, P719, DOI 10.1016/S0959-440X(94)90170-8; VANLANDSCHOOT A, 1980, EUR J BIOCHEM, V103, P307; WILLIAMS BA, 1992, J BIOL CHEM, V267, P22907; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; YANG CP, 1990, OMEGA DATA ORIGIN, P66; YOUNG NM, 1995, J BIOL CHEM, V270, P2563, DOI 10.1074/jbc.270.6.2563	34	78	79	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17697	17703		10.1074/jbc.271.30.17697	http://dx.doi.org/10.1074/jbc.271.30.17697			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663419	hybrid			2022-12-27	WOS:A1996UY93500019
J	Kohn, EC; Alessandro, R; Probst, J; Jacobs, W; Brilley, E; Felder, CC				Kohn, EC; Alessandro, R; Probst, J; Jacobs, W; Brilley, E; Felder, CC			Identification and molecular characterization of a m5 muscarinic receptor in A2058 human melanoma cells - Coupling to inhibition of adenylyl cyclase and stimulation of phospholipase A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; PROTEIN-KINASE-C; A9 L-CELLS; ACETYLCHOLINE-RECEPTOR; CALCIUM INFLUX; PHOSPHOINOSITIDE TURNOVER; INTRACELLULAR CALCIUM; CEREBRAL-CORTEX; MESSENGER-RNAS; CA2+ INFLUX	We report the identification and biochemical characterization of an endogenous m5 muscarinic acetylcholine receptor (mAChR) in the A2058 human melanoma cell line. This is the first demonstration of a m5AChR outside the central nervous system. The unusual effector coupling of this endogenous m5AChR is presented. The coding region amplified by polymerase chain reaction was identical to the known m5AChR sequence. Binding studies indicated a K-d of 99 +/- 6 pM and a B-max of 45 +/- 4 fmol/mg membrane protein. This m5AChR coupled to stimulation of arachidonic acid release and to a 50% inhibition of forskolin-stimulated cAMP accumulation. The inhibition of cAMP production was insensitive to pertussis toxin treatment, but was dependent upon extracellular calcium. In contrast to the odd mAChR pattern, no cAMP was produced in response 60 carbachol (CC) stimulation. Moreover, no release of inositol phosphates could be measured after CC treatment despite the presence of at least 2 phospholipase C isoforms in A2058 cells. CC-stimulated arachidonic acid release (EC(50) = 17.8 +/- 0.1 mu M) was dependent upon external Ca2+, with marked reduction after coincubation with EGTA, Co2+, Or high doses of verapamil (IC50 = 166 mu M) or diltiazem (IC50 = 243 mu M). Brief exposure to phorbol la-myristate 13-acetate augmented CC-stimulated arachidonic acid release, whereas prolonged phorbol 12-myristate 13-acetate treatment resulted in down-regulation of release. Activation of the m5AChR resulted in Ca2+ influx that was attenuated by muscarinic antagonism and removal of extracellular Ca2+. A2058 cells exposed to CC had no alteration of cell shape or growth potential in monolayer culture, however, a statistically significant reduction in density-independent growth was observed over the range of CC concentrations from 0.1 to 100 mu M. This endogenous m5AChR has a novel signal transduction coupling profile and receptor activation reduces clonogenic potential.	NIMH,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Kohn, EC (corresponding author), NCI,PATHOL LAB,SIGNAL TRANSDUCT & PREVENT UNIT,BLDG 10,RM 2A33,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.			Felder, Christian/0000-0003-1134-8881				ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BAUMGOLD J, 1994, CELL SIGNAL, V6, P103, DOI 10.1016/0898-6568(94)90065-5; BLUML K, 1994, J BIOL CHEM, V269, P11537; BONNER TI, 1992, TRENDS PHARMACOL SCI, V13, P48, DOI 10.1016/0165-6147(92)90021-W; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BRANN MR, 1988, FEBS LETT, V230, P90, DOI 10.1016/0014-5793(88)80648-3; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; CHALLISS RAJ, 1994, NEUROPHARMACOLOGY, V33, P15, DOI 10.1016/0028-3908(94)90092-2; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DEBERNARDI MA, 1991, P NATL ACAD SCI USA, V88, P9257, DOI 10.1073/pnas.88.20.9257; DORJE F, 1991, MOL PHARMACOL, V40, P459; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; FELDER CC, 1990, J PHARMACOL EXP THER, V255, P1140; FELDER CC, 1991, P NATL ACAD SCI USA, V88, P6477, DOI 10.1073/pnas.88.15.6477; FELDER CC, 1991, J PHARMACOL EXP THER, V257, P967; FELDER CC, 1989, J BIOL CHEM, V264, P20356; FELDER CC, 1990, P NATL ACAD SCI USA, V87, P2187, DOI 10.1073/pnas.87.6.2187; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P1706, DOI 10.1073/pnas.90.5.1706; FELDER CC, 1995, FASEB J, V9, P619, DOI 10.1096/fasebj.9.8.7768353; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; FUKUDA K, 1987, NATURE, V327, P623, DOI 10.1038/327623a0; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; HOSEY MM, 1992, FASEB J, V6, P845, DOI 10.1096/fasebj.6.3.1740234; HULME EC, 1993, CELL SIGNAL, V5, P687, DOI 10.1016/0898-6568(93)90030-P; JONES SVP, 1991, MOL PHARMACOL, V40, P242; KOHN EC, 1990, BIOCHEM BIOPH RES CO, V166, P757, DOI 10.1016/0006-291X(90)90874-M; KOHN EC, 1994, CANCER RES, V54, P935; KOHN EC, 1995, P NATL ACAD SCI USA, V92, P1307, DOI 10.1073/pnas.92.5.1307; LIAO CF, 1990, J BIOL CHEM, V265, P11273; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAEDA A, 1988, FEBS LETT, V239, P339, DOI 10.1016/0014-5793(88)80947-5; MAUDUIT P, 1993, AM J PHYSIOL, V264, pC1550, DOI 10.1152/ajpcell.1993.264.6.C1550; OETTLING G, 1992, J DEV PHYSIOL, V17, P147; ROCHE S, 1993, BIOCHEM J, V289, P117, DOI 10.1042/bj2890117; SHARP JD, 1991, J BIOL CHEM, V266, P14850; STEIN R, 1988, EMBO J, V7, P3031, DOI 10.1002/j.1460-2075.1988.tb03167.x; TENCE M, 1994, J PHARMACOL EXP THER, V269, P646; VILARO MT, 1994, MOL BRAIN RES, V21, P30, DOI 10.1016/0169-328X(94)90375-1	44	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17476	17484		10.1074/jbc.271.29.17476	http://dx.doi.org/10.1074/jbc.271.29.17476			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663391	hybrid			2022-12-27	WOS:A1996UX94300076
J	Raman, B; Ramakrishna, T; Rao, CM				Raman, B; Ramakrishna, T; Rao, CM			Refolding of denatured and denatured/reduced lysozyme at high concentrations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; EGG-WHITE LYSOZYME; PARTIALLY FOLDED STATE; LACTIC-DEHYDROGENASE; ESCHERICHIA-COLI; REDUCED LYSOZYME; MOLECULAR CHAPERONES; ALPHA-LACTALBUMIN; RENATURATION; REACTIVATION	Refolding of proteins at high concentrations often results in aggregation, To gain insight into the molecular aspects of refolding and to improve the yield of active protein, we have studied the refolding of lysozyme either from its denatured state or from its denatured/ reduced state. Refolding of denatured lysozyme, even at 1 mg/ml, yields fully active enzyme without aggregation, However, refolding of denatured/reduced lysozyme into buffer that lacks thiol/disulfide reagents leads to aggregation. Thiol/disulfide redox reagents such as cysteine/cystine and reduced/oxidized glutathione facilitate the renaturation, with the yield depending on their absolute concentrations, We have obtained an similar to 70% renaturation yield upon refolding of lysozyme at 150 mu g/ml. The cysteine/cystine redox system is more efficient compared with the glutathione redox system, When lysozyme is refolded in the absence of redox reagents, a transient intermediate that has regained a significant amount of secondary structure is formed. The tryptophans in this intermediate are as exposed to water as in the fully unfolded protein, It shows increased exposure of hydrophobic surfaces compared with the native or completely unfolded enzyme, This aggregation-prone intermediate folds to active enzyme upon addition of oxidized glutathione before the aggregation process starts. These properties of the intermediate in the refolding pathway of lysozyme are similar to those proposed for the molten globule.	CTR CELLULAR & MOLEC BIOL,HYDERABAD 500007,ANDHRA PRADESH,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)				Tangirala, Ramakrishna/0000-0002-0738-329X				AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; ALEXANDRESCU AT, 1994, J MOL BIOL, V235, P587, DOI 10.1006/jmbi.1994.1015; ANDERSON WL, 1976, J BIOL CHEM, V251, P3147; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BALDWIN RL, 1993, CURR OPIN STRUC BIOL, V3, P84, DOI 10.1016/0959-440X(93)90206-Z; BUCK M, 1993, BIOCHEMISTRY-US, V32, P669, DOI 10.1021/bi00053a036; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; FISCHER B, 1993, ARCH BIOCHEM BIOPHYS, V306, P183, DOI 10.1006/abbi.1993.1498; FISCHER B, 1992, PROTEIN ENG, V5, P593, DOI 10.1093/protein/5.6.593; FISCHER B, 1992, ARCH BIOCHEM BIOPHYS, V298, P361, DOI 10.1016/0003-9861(92)90422-S; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GOLDBERG ME, 1994, PROTEIN SCI, V3, P883; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAENICKE R, 1974, EUR J BIOCHEM, V46, P149, DOI 10.1111/j.1432-1033.1974.tb03607.x; KANE JF, 1988, TRENDS BIOCHTECHNOL, V6, P87; KUMAR TKS, 1994, INT J BIOL MACROMOL, V16, P171; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LONDON J, 1974, EUR J BIOCHEM, V47, P409, DOI 10.1111/j.1432-1033.1974.tb03707.x; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; NOIVA R, 1992, J BIOL CHEM, V267, P3553; ORSINI G, 1978, J BIOL CHEM, V253, P3453; ORSINI G, 1975, EUR J BIOCHEM, V59, P433, DOI 10.1111/j.1432-1033.1975.tb02471.x; PERRAUDIN JP, 1983, J BIOL CHEM, V258, P1834; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; PUIG A, 1994, J BIOL CHEM, V269, P7764; RUDOLPH R, 1976, EUR J BIOCHEM, V63, P409, DOI 10.1111/j.1432-1033.1976.tb10242.x; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SOPHIANOPOULOS AJ, 1962, J BIOL CHEM, V237, P1107; TEIPEL JW, 1971, BIOCHEMISTRY-US, V10, P792, DOI 10.1021/bi00781a011; WILLS PR, 1980, BIOPHYS CHEM, V11, P71, DOI 10.1016/0301-4622(80)85009-5; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007	41	92	97	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17067	17072		10.1074/jbc.271.29.17067	http://dx.doi.org/10.1074/jbc.271.29.17067			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663382	hybrid			2022-12-27	WOS:A1996UX94300016
J	Will, H; Atkinson, SJ; Butler, GS; Smith, B; Murphy, G				Will, H; Atkinson, SJ; Butler, GS; Smith, B; Murphy, G			The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation - Regulation by TIMP-2 and TIMP-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; TISSUE INHIBITOR; 72-KDA GELATINASE; HUMAN FIBROBLASTS; IV COLLAGENASE; PURIFICATION; INDUCTION; SURFACE; BINDING; CELLS	It has been proposed that the cell-mediated activation of progelatinase A requires binding of the C-terminal domain of the proenzyme to a membrane-associated complex of the membrane type matrix metalloproteinase MT1-MMP and TIMP-2. Subsequent sequential proteolysis of the propeptide by MT1-MMP and gelatinase A is thought to generate the active form of gelatinase A, We have prepared the preform of the catalytic domain of the MT1-MMP and demonstrated that this may be activated in vitro by trypsin proteolysis to yield a functional proteinase capable of cleaving typical metalloproteinase peptide substrates, gelatin and casein, The active catalytic domain of MT1-MMP was also shown to activate progelatinase A to a fully active form, Using the inactive mutant pro-E375A gelatinase A, we dissected the propeptide processing events that occur, MT1-MMP cleaves the propeptide at the sequence Asn(37)-Leu(38) only, Further cleavage of the mutant enzyme propeptide at Asn(80)-Tyr(81), equivalent to that of the active wild type gelatinase A, could only be effected by addition of gelatinase A to the system, TIMP-1 was essentially unable to prevent MT1-MMP processing of wild type or E375A progelatinase A, whereas TIMP-2 and TIMP-3 were good inhibitors of these events. Analysis of the rate of binding of TIMPs to the catalytic domain of MT1-MMP using kinetic methods showed that TIMP-1 is an extremely poor inhibitor of MT1-MMP, In comparison, TIMP-2 and TIMP-3 are excellent inhibitors, binding more rapidly to the catalytic domain of MT1-MMP than to the catalytic domain of gelatinase A, These data demonstrate the basic mechanism of MT1-MMP action on progelatinase A and the reason for the lack of inhibition by TIMP-1 previously demonstrated in cell-based activation studies.	STRANGEWAYS RES LAB,DEPT MOLEC & CELL BIOL,CAMBRIDGE CB1 4RN,ENGLAND; IN VITEK GMBH,D-13125 BERLIN,GERMANY; CELLTECH LTD,RES,SLOUGH SL1 4EN,BERKS,ENGLAND	Celltech Group Ltd			Butler, Georgina/GQP-7553-2022	Butler, Georgina/0000-0003-1172-1578	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; CRABBE T, 1994, FEBS LETT, V345, P14, DOI 10.1016/0014-5793(94)00412-9; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P14419, DOI 10.1021/bi00252a007; CRABBE T, 1993, EUR J BIOCHEM, V218, P431, DOI 10.1111/j.1432-1033.1993.tb18393.x; HIPPS DS, 1991, BIOL CHEM H-S, V372, P287, DOI 10.1515/bchm3.1991.372.1.287; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; REPONEN P, 1995, DEV DYNAM, V202, P388, DOI 10.1002/aja.1002020408; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TSUCHIYA Y, 1994, INT J CANCER, V56, P46; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023	27	488	506	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17119	17123		10.1074/jbc.271.29.17119	http://dx.doi.org/10.1074/jbc.271.29.17119			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663332	hybrid			2022-12-27	WOS:A1996UX94300023
J	Mehlen, P; SchulzeOsthoff, K; Arrigo, AP				Mehlen, P; SchulzeOsthoff, K; Arrigo, AP			Small stress proteins as novel regulators of apoptosis - Heat shock protein 27 blocks Fas/APO-1- and staurosporine-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; ALPHA-CRYSTALLIN; HSP27 GENE; EXPRESSION; RESISTANCE; INDUCTION; SURVIVAL; ABSENCE; GROWTH; BCL-2	Small stress protein expression enhances the survival of mammalian cells exposed to numerous injuries that induce necrotic cell death. The cell surface receptor Fas/APO-1 and its ligand have been recently identified as important mediators of apoptosis. Here, we show that constitutive expression of human heat shock protein (hsp)27 in murine L929 cells blocks Fas/APO-1-mediated cell death. Expression of human hsp27 prevented anti-APO-1-induced DNA fragmentation and morphological changes. These results strongly suggest that human hsp27 acts as a cellular inhibitor of Fas/APO-1-induced apoptosis. We also report that the expression of small stress proteins from different species, such as human hsp27, Drosophila Dhsp27, or human alpha B-crystallin, confers resistance to apoptotic cell death induced by staurosporine, a protein kinase C inhibitor. Hence, small stress proteins are novel regulators that are able to block apoptosis induced by different pathways.	UNIV LYON 1, CTR MOLEC GENET & CELLULAIRE, CNRS UMR 5534, LAB STRESS CELLULAIRE, F-69622 VILLEURBANNE, FRANCE; UNIV FREIBURG, INST BIOCHEM & MOLEC BIOL, D-79104 FREIBURG, GERMANY	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Freiburg			Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; ARRIGO AP, 1994, HEAT SHOCK PROTEINS, P335; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; COULDWELL WT, 1994, FEBS LETT, V345, P43, DOI 10.1016/0014-5793(94)00415-3; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; GRELL M, 1994, EUR J IMMUNOL, V24, P2563, DOI 10.1002/eji.1830241045; HANASH SM, 1993, P NATL ACAD SCI USA, V90, P3314, DOI 10.1073/pnas.90.8.3314; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; MEHLEN P, 1995, J IMMUNOL, V154, P363; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; Osborne Barbara A., 1994, Trends in Cell Biology, V4, P394; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Schulze-Osthoff Klaus, 1994, Trends in Cell Biology, V4, P421, DOI 10.1016/0962-8924(94)90102-3; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SPECTOR NL, 1992, J IMMUNOL, V148, P1668; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TANGUAY RM, 1993, DEV GENET, V14, P112, DOI 10.1002/dvg.1020140205; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TOMASOVIC SP, 1994, INT J HYPERTHER, V10, P247, DOI 10.3109/02656739409009346; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WONG GHW, 1994, J IMMUNOL, V152, P1751; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	44	560	584	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16510	16514		10.1074/jbc.271.28.16510	http://dx.doi.org/10.1074/jbc.271.28.16510			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663291	hybrid			2022-12-27	WOS:A1996UX12600016
J	Payne, JA; Stevenson, TJ; Donaldson, LF				Payne, JA; Stevenson, TJ; Donaldson, LF			Molecular characterization of a putative K-Cl cotransporter in rat brain - A neuronal-specific isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVITY-DEPENDENT DISINHIBITION; MAMMALIAN CORTICAL-NEURONS; DORSAL-ROOT-GANGLIA; KCL CO-TRANSPORT; RED-BLOOD-CELLS; BASOLATERAL MEMBRANE; CHLORIDE TRANSPORT; IONIC BASIS; INHIBITION; PROTEIN	Using a combination of data base searching, polymerase chain reaction, and library screening, we have identified a putative K-Cl cotransporter isoform (KCCB) in rat brain that is specifically localized in neurons, A cDNA of 5566 bases was obtained from overlapping clones and encoded a protein of 1116 amino acids with a deduced molecular mass of 123.6 kDa, Over its full length, the amino acid sequence of KCC2 is 67% identical to the widely distributed K-Cl cotransporter isoform (KCC1) identified in rat brain and rabbit kidney (Gillen, C., Brill, S., Payne, J.A., and Forbush, B., III (1996) J. Biol. Chem. 271, 16237-16244) but only similar to 25% identical to other members of the cation-chloride cotransporter gene family, including ''loop'' diuretic-sensitive Na-K-Cl cotransport and thiazide-sensitive Na-Cl cotransport, Based on analysis of the primary structure as well as homology with other cation-chloride cotransporters, we predict 12 transmembrane segments bounded by N- and C-terminal cytoplasmic regions, Four sites for N-linked glycosylation are predicted on an extracellular intermembrane loop between putative transmembrane segments 5 and 6, Northern blot analysis using a KCC2-specific cDNA probe revealed a very highly expressed similar to 5,6-kilobase transcript only in brain, Reverse transcriptase-polymerase chain reaction revealed that KCC1 was present in rat primary astrocytes and rat C6 glioma cells but that KCC2 was completely absent from these cells, suggesting KCC2 was not of glial cell origin. In situ hybridization studies demonstrated that the KCC2 transcript was expressed at high levels in neurons throughout the central nervous system, including CA1-CA4 pyramidal neurons of the hippocampus, granular cells and Purkinje neurons of the cerebellum, and many groups of neurons throughout the brainstem.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	University of California System; University of California Davis	Payne, JA (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT HUMAN PHYSIOL,DAVIS,CA 95616, USA.			Donaldson, Lucy/0000-0002-4242-5790				AICKIN CC, 1984, NEUROSCI LETT, V47, P239, DOI 10.1016/0304-3940(84)90520-2; AICKIN CC, 1982, J PHYSIOL-LONDON, V329, P319, DOI 10.1113/jphysiol.1982.sp014305; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ALVAREZLEEFMANS FJ, 1990, INTRACELLULAR CL REG, P109; ASCHER P, 1976, J PHYSIOL-LONDON, V256, P441, DOI 10.1113/jphysiol.1976.sp011332; BIZE I, 1994, AM J PHYSIOL, V266, pC759, DOI 10.1152/ajpcell.1994.266.3.C759; BRUGNARA C, 1989, AM J PHYSIOL, V256, pC994, DOI 10.1152/ajpcell.1989.256.5.C994; CANTRELL A, 1987, PLANT MOL BIOL, V9, P453, DOI 10.1007/BF00015877; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; DESCHENES M, 1976, BRAIN RES, V118, P486, DOI 10.1016/0006-8993(76)90318-8; DONALDSON LF, 1992, MOL BRAIN RES, V16, P143, DOI 10.1016/0169-328X(92)90204-O; DUBREIL V, 1995, COMP BIOCHEM PHYS A, V111, P263, DOI 10.1016/0300-9629(95)00003-P; GALLAGHER JP, 1978, J PHYSIOL-LONDON, V275, P263, DOI 10.1113/jphysiol.1978.sp012189; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; GREGER R, 1983, PFLUG ARCH EUR J PHY, V396, P325, DOI 10.1007/BF01063938; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; Hertz L., 1989, DISSECTION TISSUE CU, P105; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; IGARASHI P, 1995, AM J PHYSIOL-RENAL, V269, pF405, DOI 10.1152/ajprenal.1995.269.3.F405; INOUE M, 1991, NEUROSCI LETT, V134, P75, DOI 10.1016/0304-3940(91)90512-R; JENNINGS ML, 1991, J GEN PHYSIOL, V97, P799, DOI 10.1085/jgp.97.4.799; KAJI DM, 1993, AM J PHYSIOL, V264, pC376, DOI 10.1152/ajpcell.1993.264.2.C376; KAJI DM, 1991, AM J PHYSIOL, V260, pC178; KREGENOW FM, 1971, J GEN PHYSIOL, V58, P372, DOI 10.1085/jgp.58.4.372; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSON M, 1984, J MEMBRANE BIOL, V81, P219, DOI 10.1007/BF01868715; LAUF PK, 1984, J MEMBRANE BIOL, V77, P57, DOI 10.1007/BF01871100; LYTLE C, 1992, AM J PHYSIOL, V262, pC1009, DOI 10.1152/ajpcell.1992.262.4.C1009; ORRINGER EP, 1991, AM J PHYSIOL, V261, pC591, DOI 10.1152/ajpcell.1991.261.4.C591; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; REUSS L, 1983, NATURE, V305, P723, DOI 10.1038/305723a0; Rohrbough J, 1996, J NEUROSCI, V16, P82; RUSSELL JM, 1972, J GEN PHYSIOL, V60, P499, DOI 10.1085/jgp.60.5.499; SASAKI S, 1988, J CLIN INVEST, V81, P194, DOI 10.1172/JCI113294; SHIROYA T, 1989, J BIOL CHEM, V264, P17416; STARKE LC, 1993, AM J PHYSIOL, V264, pC118, DOI 10.1152/ajpcell.1993.264.1.C118; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P512, DOI 10.1152/jn.1989.61.3.512; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P501, DOI 10.1152/jn.1989.61.3.501; THOMPSON SM, 1988, J NEUROPHYSIOL, V60, P105, DOI 10.1152/jn.1988.60.1.105; THOMPSON SM, 1988, NEUROSCI LETT, V89, P49, DOI 10.1016/0304-3940(88)90479-X; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201; ZEUTHEN T, 1994, J PHYSIOL-LONDON, V478, P203, DOI 10.1113/jphysiol.1994.sp020243	49	428	436	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16245	16252		10.1074/jbc.271.27.16245	http://dx.doi.org/10.1074/jbc.271.27.16245			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663311	hybrid			2022-12-27	WOS:A1996UW35200057
J	Stull, JT				Stull, JT			Myosin minireview series	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ACTIN; PHOSPHORYLATION; CHAIN				Stull, JT (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235, USA.							ADELSTEIN RS, 1975, NATURE, V256, P597, DOI 10.1038/256597a0; CLARKE M, 1977, ANNU REV BIOCHEM, V46, P797, DOI 10.1146/annurev.bi.46.070177.004053; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; EBASHI S, 1965, J BIOCHEM-TOKYO, V58, P107, DOI 10.1093/oxfordjournals.jbchem.a128157; Engelhardt WA, 1939, NATURE, V144, P668, DOI 10.1038/144668b0; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; GORECKA A, 1976, BIOCHEM BIOPH RES CO, V71, P325, DOI 10.1016/0006-291X(76)90286-2; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KAMM KE, 1996, BIOCH SMOOTH MUSCLE, P355; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KUHNE W, 1859, ARCH ANAT PHYSL WISS, P748; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SMALL JV, 1977, EUR J BIOCHEM, V76, P521, DOI 10.1111/j.1432-1033.1977.tb11622.x; STRAUB FB, 1943, STUD I MED CHEM U SZ, V2, P3; STULL JT, 1996, BIOCH SMOOTH MUSCLE, P119; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; TRYBUS KM, 1994, J MUSCLE RES CELL M, V15, P587, DOI 10.1007/BF00121066	21	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15849	15849		10.1074/jbc.271.27.15849	http://dx.doi.org/10.1074/jbc.271.27.15849			1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663555	hybrid			2022-12-27	WOS:A1996UW35200001
J	Friedl, EM; Matthias, P				Friedl, EM; Matthias, P			Mapping of the transcriptional repression domain of the lymphoid-specific transcription factor Oct-2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POU DOMAIN; GENE; CELLS; PROTEIN; ACTIVATION; EXPRESSION; PROMOTERS; PRODUCTS; DNA	The lymphoid-specific transcription factor Oct-Ba is implicated in B cell-specific transcriptional activity via the octamer motif. Structure/function analysis of various Oct-2a effector regions in the context of the GAL4 DNA-binding domain revealed that Oct-Ba contains two functionally different activation domains at the N and the C termini. The transcriptional activity of both domains is strongly potentiated by interactions with distinct B cell-specific coactivators. Recently, we have identified a repression domain located within the N terminus of Oct-Ba (amino acids 2-99). When this domain was transferred to a potent activator, transcription was strongly inhibited. In this study we present a deletion analysis of the N-terminal region of Oct-Ba to determine the minimal repression domain. We identified a stretch of 23 amino acids, rich in serine and threonine residues, which was responsible for most of the repression activity. We show that repression is strongly dependent on the type of enhancer present in the reporter plasmid as well as on the cell line tested. The possibility that Oct-Ba can act as an activator and/or a repressor may have important consequences for the function of Oct-Ba in B cell differentiation and other developmental processes.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								ANNWEILER A, 1994, NUCLEIC ACIDS RES, V22, P4250, DOI 10.1093/nar/22.20.4250; AUSTIN RJ, 1995, MOL CELL BIOL, V15, P4683; Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CORCORAN LM, 1994, IMMUNITY, V1, P635, DOI 10.1016/1074-7613(94)90035-3; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FELDHAUS AL, 1993, EMBO J, V12, P2763, DOI 10.1002/j.1460-2075.1993.tb05937.x; FRIEDL EM, 1995, EUR J BIOCHEM, V234, P308, DOI 10.1111/j.1432-1033.1995.308_c.x; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; HATZOPOULOS AK, 1990, DEVELOPMENT, V109, P349; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JUNKER S, 1988, EMBO J, V7, P3093, DOI 10.1002/j.1460-2075.1988.tb03175.x; KONIG H, 1995, GENE DEV, V9, P1598, DOI 10.1101/gad.9.13.1598; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LICHT JD, 1994, MOL CELL BIOL, V14, P4057, DOI 10.1128/MCB.14.6.4057; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; LILLYCROP KA, 1994, MOL CELL BIOL, V14, P7633, DOI 10.1128/MCB.14.11.7633; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; ROBERTS SGE, 1995, NATURE, V375, P105, DOI 10.1038/375105a0; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STOYKOVA AS, 1992, NEURON, V8, P541, DOI 10.1016/0896-6273(92)90282-I; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; UM M, 1995, MOL CELL BIOL, V15, P5007; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; YEUNG KC, 1994, TRENDS GENET, V11, P173	42	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13927	13930		10.1074/jbc.271.24.13927	http://dx.doi.org/10.1074/jbc.271.24.13927			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663230	hybrid			2022-12-27	WOS:A1996UQ66000001
J	Miller, SP; Karschnia, EJ; Ikeda, TP; LaPorte, DC				Miller, SP; Karschnia, EJ; Ikeda, TP; LaPorte, DC			Isocitrate dehydrogenase kinase/phosphatase - Kinetic characteristics of the wild-type and two mutant proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING-SITE; KINASE PHOSPHATASE; ESCHERICHIA-COLI; PHOSPHORYLATION; ADAPTATION; MECHANISM; CYCLE	Isocitrate dehydrogenase (IDH) of Escherichia coti is regulated by a bifunctional protein, IDH kinase/phosphatase. In addition to the kinase and phosphatase activities, this protein catalyzes an intrinsic ATPase reaction. The initial velocity kinetics of these activities exhibited extensive similarities, IDH kinase and phosphatase both yielded intersecting double-reciprocal plots. In addition, we observed similar values for the kinetic constants describing interactions of the kinase and phosphatase with their protein substrates and the interactions of all three activities with ATP, In contrast, while the maximum velocities of IDH kinase and IDH phosphatase were nearly equal, they were 10-fold less than the maximum velocity of the ATPase. Although the IDH phosphatase reaction required either ATP or ADP, it was not supported by the nonhydrolyzable ATP analogue 5'-adenylyl imidodiphosphate. The kinetic properties of wild-type IDH kinase/phosphatase were compared with those of two mutant derivatives of this protein, The mutations in these proteins selectively inhibit IDH phosphatase activity. Inhibition of IDH phosphatase resulted from three factors: decreases in the maximum velocities, reduced affinities for phospho-IDH, and a loss of coupling between ATP and phospho-IDH, These mutations also affected the properties of IDH kinase, increasing the maximum velocities and decreasing the affinities for ATP and phospho-IDH. The intrinsic ATPase activities also exhibited reduced affinity for ATP, These results are discussed in the context of a model which proposes that all three activities occur at the same active site.	UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities					NIDDK NIH HHS [DK40486.1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040486] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXELSON JT, 1981, ANAL BIOCHEM, V116, P357, DOI 10.1016/0003-2697(81)90371-7; BAIS R, 1975, ANAL BIOCHEM, V63, P271, DOI 10.1016/0003-2697(75)90215-8; Cleland W W, 1979, Methods Enzymol, V63, P103; Cleland W.W., 1970, ENZYMES, P1; COLEMAN JE, 1983, ADV ENZYMOL RAMB, V55, P381; GARNAK M, 1979, SCIENCE, V203, P1111, DOI 10.1126/science.34215; GARNAK M, 1979, J BIOL CHEM, V254, P7915; HOLMS WH, 1971, J GEN MICROBIOL, V65, P57, DOI 10.1099/00221287-65-1-57; IKEDA T, 1991, J BACTERIOL, V173, P1801, DOI 10.1128/jb.173.5.1801-1806.1991; IKEDA TP, 1992, J BACTERIOL, V174, P1414, DOI 10.1128/jb.174.4.1414-1416.1992; KLUMPP DJ, 1988, J BACTERIOL, V170, P2763, DOI 10.1128/jb.170.6.2763-2769.1988; LAPORTE DC, 1983, NATURE, V305, P286, DOI 10.1038/305286a0; LAPORTE DC, 1993, J CELL BIOCHEM, V51, P14, DOI 10.1002/jcb.240510104; LAPORTE DC, 1985, J BIOL CHEM, V260, P563; LAPORTE DC, 1985, J BIOL CHEM, V260, P5291; LAPORTE DC, 1982, NATURE, V300, P458, DOI 10.1038/300458a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; STUELAND CS, 1987, J BIOL CHEM, V262, P16095; STUELAND CS, 1989, J BIOL CHEM, V264, P13775; VARELA I, 1988, FEBS LETT, V231, P361, DOI 10.1016/0014-5793(88)80850-0	20	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19124	19128		10.1074/jbc.271.32.19124	http://dx.doi.org/10.1074/jbc.271.32.19124			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702587	hybrid			2022-12-27	WOS:A1996VB68400021
J	Kekuda, R; Prasad, PD; Fei, YJ; TorresZamorano, V; Sinha, S; YangFeng, TL; Leibach, FH; Ganapathy, V				Kekuda, R; Prasad, PD; Fei, YJ; TorresZamorano, V; Sinha, S; YangFeng, TL; Leibach, FH; Ganapathy, V			Cloning of the sodium-dependent, broad-scope, neutral amino acid transporter B-O from a human placental choriocarcinoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLUTAMATE TRANSPORTER; BORDER MEMBRANE-VESICLES; XENOPUS-OOCYTES; NEUROTRANSMITTER TRANSPORTERS; FUNCTIONAL-CHARACTERIZATION; NA+/GLUCOSE COTRANSPORTER; MOLECULAR-CLONING; HUMAN BRAIN; SYSTEM-B; EXPRESSION	We have isolated a cDNA from a human placental choriocarcinoma cell cDNA library which, when expressed in HeLa cells, induces a Na+-dependent amino acid transport system with preference for zwitterionic amino acids, Anionic amino acids, cationic amino acids, imino acids, and N-methylated amino acids are excluded by this system, These characteristics are identical to those described for the amino acid transporter B-o. When expressed in Xenopus laevis oocytes that do not have detectable endogenous activity of the amino acid transporter B-o, the cloned transporter increases alanine transport in the oocytes severalfold and induces alanine-evoked inward currents in the presence of Na+. The cDNA codes for a polypeptide containing 541 amino acids with 10 putative transmembrane domains, Amino acid sequence homology predicts this transporter (hATB(o)) to be a member of a superfamily consisting of the glutamate transporters, the neutral amino acid transport system ASCT, and the insulin-activable neutral/anionic amino acid transporter, Chromosomal assignment studies with somatic cell hybrid analysis and fluorescent in situ hybridization have located the ATB(o) gene to human chromosome 19q13.3.	MED COLL GEORGIA, DEPT BIOCHEM & MOL BIOL, AUGUSTA, GA 30912 USA; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	University System of Georgia; Augusta University; Yale University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024451] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 24451] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; CAMPA MJ, 1989, J CELL PHYSIOL, V141, P645, DOI 10.1002/jcp.1041410324; CHRISTENSEN HN, 1989, METHOD ENZYMOL, V173, P576; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CLARK JA, 1993, BIOESSAYS, V15, P323, DOI 10.1002/bies.950150506; Ganapathy Vadivel, 1994, P1773; JONES EMC, 1994, GENOMICS, V23, P490, DOI 10.1006/geno.1994.1529; KANAI Y, 1994, J BIOL CHEM, V269, P20599; KAWAKAMI H, 1994, BIOCHEM BIOPH RES CO, V199, P171, DOI 10.1006/bbrc.1994.1210; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KONG CT, 1993, J BIOL CHEM, V268, P1509; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVY HL, 1989, METABOLIC BASIS INHE, P2515; LIAO K, 1995, BIOCHEM BIOPH RES CO, V208, P1008, DOI 10.1006/bbrc.1995.1434; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; LYNCH AM, 1987, BIOCHIM BIOPHYS ACTA, V899, P176, DOI 10.1016/0005-2736(87)90398-1; MACKENZIE B, 1994, J BIOL CHEM, V269, P22488; MACKENZIE B, 1994, PFLUG ARCH EUR J PHY, V426, P121, DOI 10.1007/BF00374679; MAENZ DD, 1992, J BIOL CHEM, V267, P22079; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; PAN M, 1995, J BIOL CHEM, V270, P3582, DOI 10.1074/jbc.270.8.3582; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PLAKIDOUDYMOCK S, 1994, BIOCHEM J, V301, P399, DOI 10.1042/bj3010399; RAMAMOORTHY S, 1994, BIOCHEM J, V300, P893, DOI 10.1042/bj3000893; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; SHAFQAT S, 1993, MOL ENDOCRINOL, V7, P1517, DOI 10.1210/me.7.12.1517; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; SHAPER NL, 1992, GENOMICS, V12, P613, DOI 10.1016/0888-7543(92)90458-5; SHASHIDHARAN P, 1994, BRAIN RES, V662, P245, DOI 10.1016/0006-8993(94)90819-2; SHASHIDHARAN P, 1994, BBA-BIOMEMBRANES, V1191, P393, DOI 10.1016/0005-2736(94)90192-9; STEVENS BR, 1982, J MEMBRANE BIOL, V66, P213, DOI 10.1007/BF01868496; TAYLOR PM, 1989, J MEMBRANE BIOL, V112, P149, DOI 10.1007/BF01871276; VANWINKLE LJ, 1985, J BIOL CHEM, V260, P2118; VANWINKLE LJ, 1993, BIOCHIM BIOPHYS ACTA, V1154, P157, DOI 10.1016/0304-4157(93)90009-D; VOGELI G, 1987, METHOD ENZYMOL, V152, P407; YANGFENG TL, 1995, BIOCHEM BIOPH RES CO, V210, P874, DOI 10.1006/bbrc.1995.1739	37	208	220	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18657	18661		10.1074/jbc.271.31.18657	http://dx.doi.org/10.1074/jbc.271.31.18657			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702519	hybrid			2022-12-27	WOS:A1996VB68300057
J	Kovarik, A; Lu, PJ; Peat, N; Morris, J; TaylorPapadimitriou, J				Kovarik, A; Lu, PJ; Peat, N; Morris, J; TaylorPapadimitriou, J			Two GC boxes (Sp1 sites) are involved in regulation of the activity of the epithelium-specific MUC1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP1; BINDING-PROTEINS; GENE-EXPRESSION; CARCINOMA CELLS; CORE PROTEIN; CLONING; ACTIVATION; FAMILY; ASSAY; DNA	In this report, we have analyzed the function of two Spl sites present in the epithelium-specific MUC1 promoter, Using promoter-reporter gene (CAT) constructs, we found that mutagenesis of either of the Sp1 binding motifs at -576/-568 and -99/-90, reduced transcription in MUC1-expressing epithelial cell lines, However, abolition of the binding site at -99/-91 by mutagenesis also resulted in increased transcriptional activity in non-epithelial cell lines, suggesting involvement of the site in tissue-specific expression, In vitro binding assays revealed a novel binding motif at -101/-89 (AGGGGGCGGGGTT), which overlaps but differs from the Sp1 consensus motif by having an adenine residue in the 5'-flanking sequence, The 5'-flanking sequence appeared to be important for binding of an Sp1-unrelated factor (SpA) but not for binding of Sp1, Site-directed mutagenesis of the motif into a site able to bind Sp1, but unable to bind SpA, resulted in an increased level of transcription of the CAT reporter gene in all cell lines tested, suggesting a repressive effect of the novel factor on transcription, The ratio between the Sp1 and SpA binding activity in nuclear extracts correlated with both promoter activity and the levels of endogenous transcription in different breast cancer cell lines, Our results are consistent with the idea that the relative activities of the two factors may be involved in the upregulation of expression of the MUC1 gene seen in breast and other carcinomas.	IMPERIAL CANC RES FUND, EPITHELIAL CELL BIOL LAB, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Kovarik, Ales/H-1952-2014	Kovarik, Ales/0000-0003-2896-0698; Morris, Joanna/0000-0001-9762-8133				ABE M, 1993, P NATL ACAD SCI USA, V90, P282, DOI 10.1073/pnas.90.1.282; ABE M, 1990, J CELL PHYSIOL, V143, P226, DOI 10.1002/jcp.1041430205; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; BURCHELL J, 1987, CANCER RES, V47, P5476; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM RA, 1995, INT J TUMOR TARGETIN, V1, P211; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HOLLINGSWORTH MA, 1994, NUCLEIC ACIDS RES, V22, P1138, DOI 10.1093/nar/22.7.1138; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; PEAT N, 1992, CANCER RES, V52, P1954; SHIROTANI K, 1994, J BIOL CHEM, V269, P15030; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; TAYLORPAPADIMITRIOU J, 1993, ANN NY ACAD SCI, V690, P69; VOS HL, 1991, BIOCHEM BIOPH RES CO, V181, P121, DOI 10.1016/S0006-291X(05)81390-7; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	23	53	56	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18140	18147		10.1074/jbc.271.30.18140	http://dx.doi.org/10.1074/jbc.271.30.18140			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663395	hybrid			2022-12-27	WOS:A1996UY93500083
J	Waters, SB; Chen, D; Kao, AW; Okada, S; Holt, KH; Pessin, JE				Waters, SB; Chen, D; Kao, AW; Okada, S; Holt, KH; Pessin, JE			Insulin and epidermal growth factor receptors regulate distinct pools of Grb2-SOS in the control of ras activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; PHEOCHROMOCYTOMA PC12 CELLS; TYROSINE KINASES; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; GUANINE-NUCLEOTIDES; SH3 DOMAINS; PROTEIN; P21(RAS); CLONING	Insulin and epidermal growth factor (EGF) stimulate a rapid but transient increase in the amount of GTP bound to Ras that returns to the basal GDP bound state within 10-30 min, Although insulin stimulation resulted in a dissociation of the Grb2 . SOS complex, EGF did not affect the Grb2 . SOS complex but instead induced dissociation of Grb2-SOS from tyrosine-phosphorylated Shc. The dissociation of Grb2-SOS from Shc was not due to dephosphorylation as She remained persistently tyrosine-phosphorylated during this time, Furthermore, there was no decrease in the extent of insulin receptor substrate 1, insulin receptor, or EGF receptor tyrosine phosphorylation. Surprisingly, however, despite the EGF-induced decrease in the amount of Grb2-SOS bound to Shc, the extent of Grb2 associated with Shc remained constant, and there was a concomitant increase in the amount of SOS associated with Grb2, In addition, after the insulin-stimulated dissociation of Grb2 from SOS, EGF treatment induced the reassociation of the Grb2 SOS complex. Quantitative immunoprecipitation demonstrated that only a small fraction of the total cellular pool of Grb2 was associated with SOS, Similarly, only a small fraction of SOS and Grb2 were co-immunoprecipitated with Shc. Together, these data suggest the presence of distinct Grb2-SOS pools that are independently utilized by insulin and EGF in their recruitment to tyrosine-phosphorylated Shc.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa					NIDDK NIH HHS [DK33823, DK25925] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, R01DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BERNARDS A, 1995, BBA-REV CANCER, V1242, P43, DOI 10.1016/0304-419X(95)00003-X; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, ONCOGENE, V11, P1327; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; Holt KH, 1996, MOL CELL BIOL, V16, P577; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KLARLUND JK, 1995, J BIOL CHEM, V270, P2342; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; OSTEROP APRM, 1993, EUR J BIOCHEM, V212, P477, DOI 10.1111/j.1432-1033.1993.tb17684.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SERTH J, 1992, BIOCHEMISTRY-US, V31, P6361, DOI 10.1021/bi00143a001; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WHITE MF, 1994, J BIOL CHEM, V269, P1; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	48	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18224	18230		10.1074/jbc.271.30.18224	http://dx.doi.org/10.1074/jbc.271.30.18224			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663461	hybrid			2022-12-27	WOS:A1996UY93500095
J	Motohashi, K; Yohda, M; Endo, I; Yoshida, M				Motohashi, K; Yohda, M; Endo, I; Yoshida, M			A novel factor required for the assembly of the DnaK and DnaJ chaperones of Thermus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI-DNAJ; MOLECULAR CHAPERONES; REPLICATION PROTEIN; GEL-ELECTROPHORESIS; NUCLEOTIDE-SEQUENCE; ATPASE ACTIVITY; RNA-POLYMERASE; GENE-PRODUCT; GRPE	We previously reported the isolation of T.DnaK . DnaJ chaperone complex from Thermus thermophilus, Here, we show that a novel factor is necessary for the assembly of T.DnaK and T.DnaJ into the complex. A dnaK gene cluster of T. thermophilus contained five genes, dnaK-grpE-dnaJ-orf4-clpB. Interestingly, T.DnaJ lacks the whole ''cysteine-rich region'' that has been postulated to be necessary to bind unfolded proteins, The orf4 gene encodes a novel 78-amino acid protein, Curiously, T.DnaK and T.DnaJ expressed in Escherichia coli did not form the complex, Careful reexamination of the T.DnaK . DnaJ complex revealed the presence of a small protein in the complex, which turned out to be a product of orf4. As expected, expression of three genes, dnaK-dnaJ-orf4, resulted in production of a T.DnaK . DnaJ complex in E, coli that was indistinguishable from the authentic complex in its ability to interact with nucleotide and denatured protein. The product of orf4 was also required for in vitro reconstitution of the complex and named T.DafA (T.DnaK . DnaJ assembly factor A). The complex comprises three copies each of T.DnaK, T.DnaJ, and T.DafA, Even though a definite homolog of T.DafA has not been found in the data base, this finding raises a possibility that interaction between DnaK and DnaJ chaperones in other organisms is also mediated by a small protein yet unnoticed.	TOKYO INST TECHNOL, RESOURCES UTILIZAT RES LAB, YOKOHAMA, KANAGAWA 226, JAPAN; RIKEN, INST PHYS & CHEM RES, WAKO, SAITAMA 35101, JAPAN	Tokyo Institute of Technology; RIKEN			Motohashi, Ken/I-4970-2019; Yohda, Masafumi/A-5149-2013	Motohashi, Ken/0000-0002-8414-2836; Yohda, Masafumi/0000-0001-8307-9671				AMADA K, 1995, J BIOCHEM-TOKYO, V118, P347, DOI 10.1093/oxfordjournals.jbchem.a124913; BARDWELL JCA, 1986, J BIOL CHEM, V261, P1782; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BUCCA G, 1995, MOL MICROBIOL, V17, P663, DOI 10.1111/j.1365-2958.1995.mmi_17040663.x; BUCCA G, 1993, GENE, V130, P141, DOI 10.1016/0378-1119(93)90358-A; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIPINSKA B, 1988, NUCLEIC ACIDS RES, V16, P7545, DOI 10.1093/nar/16.15.7545; LYMAN SK, 1995, J CELL BIOL, V131, P1163, DOI 10.1083/jcb.131.5.1163; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MOTOHASHI K, 1994, J BIOL CHEM, V269, P27074; OHKI M, 1986, J BIOL CHEM, V261, P1778; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SCOTT MG, 1988, BIOCHEM BIOPH RES CO, V155, P1353, DOI 10.1016/S0006-291X(88)81290-7; SHERMAN MY, 1991, J BACTERIOL, V173, P7249, DOI 10.1128/jb.173.22.7249-7256.1991; SHERMAN MY, 1992, EMBO J, V11, P71; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGITO K, 1995, FEBS LETT, V358, P161, DOI 10.1016/0014-5793(94)01417-Y; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WETZSTEIN M, 1992, J BACTERIOL, V174, P3300, DOI 10.1128/jb.174.10.3300-3310.1992; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591; [No title captured]	56	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17343	17348		10.1074/jbc.271.29.17343	http://dx.doi.org/10.1074/jbc.271.29.17343			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663379	hybrid			2022-12-27	WOS:A1996UX94300056
J	Grun, F; Noy, N; Hammerling, U; Buck, J				Grun, F; Noy, N; Hammerling, U; Buck, J			Purification, cloning, and bacterial expression of retinol dehydratase from Spodoptera frugiperda	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEINS; CELLS; ANHYDRORETINOL; VITAMIN	Anhydroretinol and 14-hydroxy-4,14-retro-retinol, retro-retinoids endogenous to both mammals and insects, act as agonist and antagonist, respectively, in controlling proliferation in lymphoblasts and other retinol-dependent cells. We describe here the identification, purification, cloning, and bacterial expression of the enzyme retinol dehydratase, which converts retinol to anhydroretinol in Spodoptera frugiperda. Retinol dehydratase has nanomolar affinity for its substrate and is, therefore, the first enzyme characterized able to utilize free retinol at physiological intracellular concentrations. The enzyme shows sequence homology to the sulfotransferases and requires 3'-phosphoadenosine 5'phosphosulfate for activity.	CORNELL UNIV MED COLL,DEPT PHARMACOL,NEW YORK,NY 10021; CORNELL UNIV,DEPT NUTR SCI,ITHACA,NY 14850; MEM SLOAN KETTERING CANC CTR,DEPT IMMUNOL,NEW YORK,NY 10021	Cornell University; Cornell University; Memorial Sloan Kettering Cancer Center			Grun, Felix/C-8271-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048022] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48022] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BHAT PV, 1979, J LIPID RES, V20, P357; Blaner William S., 1994, P229; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COUGHTRIE MWH, 1994, CHEM-BIOL INTERACT, V92, P247, DOI 10.1016/0009-2797(94)90067-1; DERGUINI F, 1995, J BIOL CHEM, V270, P18875, DOI 10.1074/jbc.270.32.18875; DERGUINI F, 1994, BIOCHEMISTRY-US, V33, P623, DOI 10.1021/bi00169a001; DERGUINI F, 1994, ANGEW CHEM INT EDIT, V33, P1837, DOI 10.1002/anie.199418371; DUFFEL MW, 1994, CHEM-BIOL INTERACT, V92, P3, DOI 10.1016/0009-2797(94)90048-5; Embree ND, 1939, J BIOL CHEM, V128, P187; EPPINGER TM, 1993, J EXP MED, V178, P1995, DOI 10.1084/jem.178.6.1995; GARBE A, 1992, J EXP MED, V176, P109, DOI 10.1084/jem.176.1.109; Gudas Lorraine J., 1994, P443; HOBKIRK R, 1985, CAN J BIOCHEM CELL B, V63, P1227; KOMATSU K, 1994, BIOCHEM BIOPH RES CO, V204, P1178, DOI 10.1006/bbrc.1994.2587; MCCLEAN SW, 1982, CLIN CHEM, V28, P693; NAKAMURA J, 1987, J PHARMACOBIO-DYNAM, V10, P736, DOI 10.1248/bpb1978.10.736; NORRIS AW, 1994, BBA-PROTEIN STRUCT M, V1209, P10, DOI 10.1016/0167-4838(94)90130-9; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; Ong D, 1980, Methods Enzymol, V67, P288; ONG DE, 1978, J BIOL CHEM, V253, P828; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Sporn M.B., 1994, RETINOIDS BIOL CHEM; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P10868, DOI 10.1074/jbc.270.18.10868; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313	30	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16135	16138		10.1074/jbc.271.27.16135	http://dx.doi.org/10.1074/jbc.271.27.16135			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663216	hybrid			2022-12-27	WOS:A1996UW35200043
J	Meisenholder, GW; Martin, SJ; Green, DR; Nordberg, J; Babior, BM; Gottlieb, RA				Meisenholder, GW; Martin, SJ; Green, DR; Nordberg, J; Babior, BM; Gottlieb, RA			Events in apoptosis - Acidification is downstream of protease activation and BCL-2 protection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Cytoplasmic acidification is now recognized as a feature of apoptosis in a variety of systems, However, its relation to other events in the process of apoptosis is not yet characterized, In this work, we examined the effect of BCL-2 overexpression on acidification mediated by cycloheximide treatment or Fas Ligation in Jurkat T-lymphoblasts. We find that BCL-2 overexpression attenuates cytoplasmic acidification and apoptosis detected by annexin V labeling, Acidification and phosphatidylserine externalization were found to occur concurrently. We also examined the requirement for protease activation for cytoplasmic acidification to occur and found that inhibition of interleukin-1 beta converting enzyme/CED-3 family proteases (using carbobenzoxy-Val-Ala-Asp-fluoromethylketone, an inhibitor of these proteases) prevents acidification and apoptosis mediated by Fas ligation, These studies suggest that BCL-2 acts at a point upstream of acidification and that protease activation is also upstream of acidification.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; LA JOLLA INST ALLERGY & IMMUNOL, LA JOLLA, CA 92037 USA; VET AFFAIRS MED CTR, SAN DIEGO, CA 92161 USA	Scripps Research Institute; La Jolla Institute for Immunology; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013501] Funding Source: NIH RePORTER; NIAID NIH HHS [AI01345] Funding Source: Medline; NIA NIH HHS [AG13501] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; GOTTLIEB RA, 1995, BLOOD, V86, P2414, DOI 10.1182/blood.V86.6.2414.bloodjournal8662414; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; ITOH N, 1993, J IMMUNOL, V151, P621; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7	13	94	94	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16260	16262		10.1074/jbc.271.27.16260	http://dx.doi.org/10.1074/jbc.271.27.16260			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663307	hybrid			2022-12-27	WOS:A1996UW35200059
J	Torok, Z; Vigh, L; Goloubinoff, P				Torok, Z; Vigh, L; Goloubinoff, P			Fluorescence detection of symmetric GroEL(14)(GroES(7))(2) heterooligomers involved in protein release during the chaperonin cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; GROEL; HYDROLYSIS; SURFACE; HSP60; ATP	The GroEL(14) chaperonin from Escherichia coli was labeled with 5-((((2-iodoacetyl)amino)ethyl)amino) naphthalene-l-sulfonic acid (I-AEDANS), a hydrophobic probe whose fluorescent emission is sensitive to structural changes within the protein. Increasing concentrations of ATP or adenylyl imidodiphosphate but not ADP caused two successive GroES(7)-dependent changes in the fluorescence intensity of AEDANS-GroEL(14), corresponding to the sequential binding of two GroES(7) heptamers and the formation of two types of chaperonin heterooligomers, GroEL(14)GroES(7) and GroEL(14)(GroES(7))(2). The binding of thermally denatured malate dehydrogenase (MDH) caused a specific increase in fluorescence intensity of AEDANS-GroEL(14) that allowed the direct measurement in solution at equilibrium of ATP- and GroES(7)-dependent protein release from the chaperonin. Structure/function analysis during the generation of ATP from ADP indicated the following sequence of events: 1) ADP-stabilized MDH-GroEL(14)GroES(7) particles bind newly formed ATP. 2) MDH-GroEL(14)GroES(7) particles bind a second GroES(7). 3) MDH-GroEL(14)(GroES(7))(2) particles productively release MDH. 4) Released MDH completes folding. Therefore, the symmetrical GroEL(14)(GroES(7))(2) heterooligomer is an intermediate after the formation of which the protein substrate is productively released during the chaperonin-mediated protein folding cycle.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BOT,IL-91904 JERUSALEM,ISRAEL; BIOL RES CTR,INST BIOCHEM,H-6701 SZEGED,HUNGARY	Hebrew University of Jerusalem; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center				Goloubinoff, Pierre/0000-0002-4802-0807				ALATOSSAVA T, 1985, J BACTERIOL, V162, P413, DOI 10.1128/JB.162.1.413-419.1985; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; Azem A, 1995, P NATL ACAD SCI USA, V92, P12021, DOI 10.1073/pnas.92.26.12021; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DIAMANT S, 1995, J BIOL CHEM, V270, P28387; DIAMANT S, 1995, BIOCHEMISTRY-US, V34, P273, DOI 10.1021/bi00001a033; ENGEL A, 1995, SCIENCE, V265, P653; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HANSEN JE, 1994, J BIOL CHEM, V269, P6286; HARRIS JR, 1994, J STRUCT BIOL, V112, P216, DOI 10.1006/jsbi.1994.1022; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; Llorca O, 1996, J BIOL CHEM, V271, P68, DOI 10.1074/jbc.271.1.68; LORIMER GH, 1996, FASEB J, V1, P5; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TODD MJ, 1995, BIOCHEMISTRY-US, V34, P14932, DOI 10.1021/bi00045a038; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5	38	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16180	16186		10.1074/jbc.271.27.16180	http://dx.doi.org/10.1074/jbc.271.27.16180			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663256	hybrid			2022-12-27	WOS:A1996UW35200049
J	Ware, FE; Lehrman, MA				Ware, FE; Lehrman, MA			Expression cloning of a novel suppressor of the Lec15 and Lec35 glycosylation mutations of Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE N-ACETYLGLUCOSAMINE-1-PHOSPHATE TRANSFERASE; ENDOPLASMIC-RETICULUM; ANCHOR BIOSYNTHESIS; MOLECULAR-CLONING; GENE; CDNA; SEQUENCE; MANNOSE; YEAST; GLCNAC	Lec15 and Lec35 are recessive Chinese hamster ovary (CHO) cell glycosylation mutations characterized by inefficient synthesis and utilization, respectively, of mannose-P-dolichol (MPD). Consequently, Lec15 and Lec35 cells accumulate Man(5)GlcNAc(2)-P-P-dolichol and glucosaminyl-acylphosphatidylinositol. This report describes the cloning of a suppressor (termed SL15) of the Lec15 and Lec35 mutations from a CHO cDNA library by functional expression in Lec15 cells, employing phyto-hemagglutinin/swainsonine selection. The SL15 protein has a predicted molecular weight of 26,693 with two potential membrane spanning regions and a likely C-terminal endoplasmic reticulum retention signal (Lys-Lys-Glu-Gln). Lec15 cells transfected with SL15 have normal levels of MPD synthase activity in vitro and convert Man(5)GlcNAc(2)-P-P-dolichol to Glc(0-3)Man(9)GlcNAc(2)-P-P-dolichol in vivo. Surprisingly, SL15 also corrects the defective mannosylation in Lec35 cells. The SL15 protein bears no apparent similarity to Saccharomyces cerevisiae MPD synthase (the DPM1 protein), but is highly similar to the hypothetical F38E1.9 protein encoded on Caenorhabditis elegans chromosome 5, These results indicate a novel function for the SL15 protein and suggest that MPD synthesis is more complex than previously suspected.			Ware, FE (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.				NIGMS NIH HHS [GM38545] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM038545, R01GM038545] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK PJ, 1990, SOMAT CELL MOLEC GEN, V16, P539, DOI 10.1007/BF01233094; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; CAMP LA, 1993, J BIOL CHEM, V268, P6721; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HARTOG KO, 1987, NUCLEIC ACIDS RES, V15, P3627, DOI 10.1093/nar/15.8.3627; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HEMMING FW, 1985, GLYCOLIPIDS, P261; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; INOUE N, 1993, J BIOL CHEM, V268, P6882; KAMITANI T, 1993, J BIOL CHEM, V268, P20733; KEAN EL, 1980, J BIOL CHEM, V255, P1921; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEHRMAN MA, 1989, J BIOL CHEM, V264, P1584; LEHRMAN MA, 1988, J BIOL CHEM, V263, P19796; LENNARZ WJ, 1987, BIOCHEMISTRY-US, V26, P7205, DOI 10.1021/bi00397a001; LIU X, 1992, MOL CELL BIOL, V12, P4112, DOI 10.1128/MCB.12.9.4112; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; RAJPUT B, 1992, BIOCHEM J, V285, P985, DOI 10.1042/bj2850985; RINE J, 1983, P NATL ACAD SCI-BIOL, V80, P6750, DOI 10.1073/pnas.80.22.6750; ROSENWALD AG, 1990, J BIOL CHEM, V265, P14544; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCOCCA JR, 1990, J BIOL CHEM, V265, P20621; SMITH PL, 1994, J BIOL CHEM, V269, P15162; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; STOLL J, 1982, P NATL ACAD SCI-BIOL, V79, P2296, DOI 10.1073/pnas.79.7.2296; TEHEESEN S, 1994, EUR J BIOCHEM, V224, P71, DOI 10.1111/j.1432-1033.1994.tb19996.x; ZENG Y, 1991, ANAL BIOCHEM, V193, P266, DOI 10.1016/0003-2697(91)90020-T; ZENG YC, 1990, J BIOL CHEM, V265, P2296; ZHU XY, 1990, J BIOL CHEM, V265, P14250; ZOU J, 1995, ARCH BIOCHEM BIOPHYS, V317, P487, DOI 10.1006/abbi.1995.1192	36	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13935	13938		10.1074/jbc.271.24.13935	http://dx.doi.org/10.1074/jbc.271.24.13935			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663248	hybrid			2022-12-27	WOS:A1996UQ66000003
J	Burns, JL; Guzder, SN; Sung, P; Prakash, S; Prakash, L				Burns, JL; Guzder, SN; Sung, P; Prakash, S; Prakash, L			An affinity of human replication protein A for ultraviolet-damaged DNA - Implications for damage recognition in nucleotide excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SACCHAROMYCES-CEREVISIAE; GENE; ENCODES; ENDONUCLEASE; BINDING; HELICASE; RAD1	Replication protein A (RPA), a heterotrimeric protein of 70-, 32-, and 14-kDa subunits, is an essential factor for DNA replication. Biochemical studies with human and yeast RPA have indicated that it is a DNA-binding protein that has higher affinity for single-stranded DNA. Interestingly, in vitro nucleotide excision repair studies with purified protein components have shown an absolute requirement for RPA in the incision of UV-damaged DNA. Here we use a mobility shift assay to demonstrate that human RPA binds a UV damaged duplex DNA fragment preferentially. Complex formation between RPA and the UV-irradiated DNA is not affected by prior enzymatic photo-reactivation of the DNA, suggesting an affinity of RPA for the (6-4) photoproduct. We also show that Mg2+ in the millimolar range is required for preferential binding of RPA to damaged DNA. These findings identify a novel property of RPA and implicate RPA in damage recognition during the incision of UV-damaged DNA.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261	NCI NIH HHS [CA41261] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041261, R37CA041261] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOURRE F, 1987, NUCLEIC ACIDS RES, V15, P8861, DOI 10.1093/nar/15.21.8861; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HABRAKEN Y, 1994, NUCLEIC ACIDS RES, V22, P3312, DOI 10.1093/nar/22.16.3312; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; MA LB, 1994, NUCLEIC ACIDS RES, V22, P4095, DOI 10.1093/nar/22.20.4095; MITSIS PG, 1993, BIOCHEMISTRY-US, V32, P5257, DOI 10.1021/bi00070a038; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; SANCAR GB, 1985, BIOCHEMISTRY-US, V24, P1849, DOI 10.1021/bi00329a007; SPIVAK G, 1988, MUTAT RES, V193, P97, DOI 10.1016/0167-8817(88)90040-5; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0	30	109	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11607	11610		10.1074/jbc.271.20.11607	http://dx.doi.org/10.1074/jbc.271.20.11607			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8690733	hybrid			2022-12-27	WOS:A1996UL25000004
J	Wakarchuk, W; Martin, A; Jennings, MP; Moxon, ER; Richards, JC				Wakarchuk, W; Martin, A; Jennings, MP; Moxon, ER; Richards, JC			Functional relationships of the genetic locus encoding the glycosyltransferase enzymes involved in expression of the Lacto-N-neotetraose terminal lipopolysaccharide structure in Neisseria meningitidis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOSACCHARIDE COMPONENT; CORE OLIGOSACCHARIDES; MONOCLONAL-ANTIBODIES; COUPLING-CONSTANTS; LIPOOLIGOSACCHARIDES; BIOSYNTHESIS; POLYSACCHARIDE; GONORRHOEAE; SPECIFICITY; HAEMOPHILUS	The biosynthetic function of the lgtABE genetic locus of Neisseria meningitidis was determined by structural analysis of lipopolysaccharide (LPS) derived from mutant strains and enzymic assay for glycosyltransferase activity, LPS was obtained from mutants generated by insertion of antibiotic resistance cassets in each of the three genes IgtA, IgtB, lgtE of the N. meningitidis immunotype L3 strain phi 3 MC58. LPS from the parent strain expresses the terminal lacto-N-neotetraose structure, Gal beta 1 --> 4GlcNAc beta 1 --> 3Gal beta 1 --> 4Glc. Mild hydrazine treatment of the LPS afforded O-deacylated samples that were analyzed directly by electrospray ionization mass spectrometry (ESI-IMS) in the negative ion mode, In conjunction with results from sugar analysis, ESI-RIS revealed successive loss of the sugars Gal, GlcNAc, and Gal in lgt B, lgt A, and lgt E LPS, respectively, The structure of a sample of O- and N-deacylated LPS derived by aqueous KOH treatment of Igt B LPS was determined in detail by two-dimensional home- and heteronuclear NMR methods. Using a synthetic beta-GlcNAc acceptor and a beta-lactose acceptor, the glycosyltransferase activities encoded by the lgtB and IgtA genes were unambiguously established, These data provide the first definitive evidence that the three genes encode the respective glycosyltransferases required for biosynthesis of the terminal trisaccharide moiety of the lacto-N-neotetraose structure in Neisseria LPS, From ESI-MS data, it was also determined that the Gal-deficient LPS expressed by the I,st E mutant is identical to that of the major component expressed by immunotype L3 galE-defieient strains, The galE gene which encodes for UDP-glucose 4-epimerase plays an essential role in the incorporation of Gal into meningococcal LPS.	NATL RES COUNCIL CANADA, INST BIOL SCI, OTTAWA, ON K1A 0R6, CANADA; JOHN RADCLIFFE HOSP, INST MOL MED, MOL INFECT DIS GRP, OXFORD OX3 3DU, ENGLAND; JOHN RADCLIFFE HOSP, INST MOL MED, DEPT PAEDIAT, OXFORD OX3 3DU, ENGLAND	National Research Council Canada; University of Oxford; University of Oxford			Wakarchuk, Warren/Q-9514-2017; Wakarchuk, Warren/AAO-2774-2020; Jennings, Michael P/G-4822-2013	Wakarchuk, Warren/0000-0002-1539-1679; Wakarchuk, Warren/0000-0002-1539-1679; Jennings, Michael P/0000-0002-1027-4684	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTONA C, 1980, ORG MAGN RESONANCE, V13, P417, DOI 10.1002/mrc.1270130606; AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; Auriola S, 1996, ACS SYM SER, V619, P149; BAX A, 1983, J MAGN RESON, V52, P330, DOI 10.1016/0022-2364(83)90206-8; BAX A, 1981, J MAGN RESON, V42, P164, DOI 10.1016/0022-2364(81)90022-6; BOCK K, 1982, ANNU REP NMR SPECTRO, V13, P1; CARLSON RW, 1988, CARBOHYD RES, V176, P127, DOI 10.1016/0008-6215(88)84064-3; DIFABIO JL, 1990, CAN J CHEM, V68, P1029, DOI 10.1139/v90-160; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; GAMIAN A, 1992, J BIOL CHEM, V267, P922; Gibson BW, 1996, ACS SYM SER, V619, P166; GIBSON BW, 1993, J BACTERIOL, V175, P2702, DOI 10.1128/JB.175.9.2702-2712.1993; GOTSCHLICH EC, 1994, J EXP MED, V180, P2181, DOI 10.1084/jem.180.6.2181; GRIFFISS JM, 1988, REV INFECT DIS S2, V10, P287; HOLST O, 1991, J BACTERIOL, V173, P1862, DOI 10.1128/jb.173.6.1862-1866.1991; HOLST O, 1993, EUR J BIOCHEM, V214, P703, DOI 10.1111/j.1432-1033.1993.tb17971.x; Holst O, 1992, BACTERIAL ENDOTOXIC, VI, P135; JENNINGS HJ, 1983, CARBOHYD RES, V121, P233, DOI 10.1016/0008-6215(83)84020-8; JENNINGS MP, 1993, MOL MICROBIOL, V10, P361, DOI 10.1111/j.1365-2958.1993.tb01962.x; Jennings MP, 1995, MOL MICROBIOL, V18, P729, DOI 10.1111/j.1365-2958.1995.mmi_18040729.x; JONES DM, 1992, MICROB PATHOGENESIS, V13, P219, DOI 10.1016/0882-4010(92)90022-G; Kelly J, 1996, ANAL BIOCHEM, V233, P15, DOI 10.1006/abio.1996.0002; KOMURO T, 1988, J CHROMATOGR, V450, P381, DOI 10.1016/S0021-9673(01)83593-7; KULSHIN VA, 1991, EUR J BIOCHEM, V198, P697, DOI 10.1111/j.1432-1033.1991.tb16069.x; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEE FKN, 1995, INFECT IMMUN, V63, P2508, DOI 10.1128/IAI.63.7.2508-2515.1995; MANDRELL RE, 1988, J EXP MED, V168, P107, DOI 10.1084/jem.168.1.107; MASOUD H, 1994, BIOCHEMISTRY-US, V33, P10568, DOI 10.1021/bi00201a002; MICHON F, 1990, J BIOL CHEM, V265, P7243; MORAN AP, 1995, J TOXICOL-TOXIN REV, V14, P47, DOI 10.3109/15569549509089968; PAVLIAK V, 1993, J BIOL CHEM, V268, P14146; PELTOLA H, 1983, REV INFECT DIS, V5, P71; PELTOLA H, 1977, NEW ENGL J MED, V297, P686, DOI 10.1056/NEJM197709292971302; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; ROBERTSON BD, 1993, MOL MICROBIOL, V8, P891, DOI 10.1111/j.1365-2958.1993.tb01635.x; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SCHOLTEN RJPM, 1994, J MED MICROBIOL, V41, P236, DOI 10.1099/00222615-41-4-236; TSAI CM, 1991, INFECT IMMUN, V59, P3604, DOI 10.1128/IAI.59.10.3604-3609.1991; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VERHEUL AFM, 1993, MICROBIOL REV, V57, P34, DOI 10.1128/MMBR.57.1.34-49.1993; Virji M, 1995, MOL MICROBIOL, V18, P741, DOI 10.1111/j.1365-2958.1995.mmi_18040741.x; VIRJI M, 1990, MICROB PATHOGENESIS, V9, P441, DOI 10.1016/0882-4010(90)90062-U; WAKARCHUK WW, 1994, PROTEIN SCI, V3, P467; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; Yang QL, 1996, J EXP MED, V183, P323, DOI 10.1084/jem.183.1.323; YORK WS, 1985, CARBOHYD RES, V138, P109, DOI 10.1016/0008-6215(85)85228-9; ZHOU DG, 1994, J BIOL CHEM, V269, P11162; ZOLLINGER WD, 1980, INFECT IMMUN, V28, P451; ZOLLINGER WD, 1977, INFECT IMMUN, V18, P424, DOI 10.1128/IAI.18.2.424-433.1977	52	103	122	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19166	19173		10.1074/jbc.271.32.19166	http://dx.doi.org/10.1074/jbc.271.32.19166			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702594	Green Published, hybrid			2022-12-27	WOS:A1996VB68400028
J	Park, IS; Michel, LO; Pearson, MA; Jabri, E; Karplus, PA; Wang, SK; Dong, J; Scott, RA; Koehler, BP; Johnson, MK; Hausinger, RP				Park, IS; Michel, LO; Pearson, MA; Jabri, E; Karplus, PA; Wang, SK; Dong, J; Scott, RA; Koehler, BP; Johnson, MK; Hausinger, RP			Characterization of the mononickel metallocenter in H134A mutant urease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLEBSIELLA-AEROGENES UREASE; MAGNETIC CIRCULAR-DICHROISM; ABSORPTION FINE-STRUCTURE; MICROBIAL UREASES; ACTIVE-SITE; NICKEL; COMPLEXES; BINDING; PROTEIN	A mutant form of Klebsiella aerogenes urease possessing Ala instead of His at position 134 (H134A) is inactive and binds approximately half the normal complement of nickel (Park, I.-S., and Hausinger, R. P. (1993) Protein Sci. 2, 1034-1041). The crystal structure of the H134A protein was obtained at 2.0-Angstrom resolution, and it confirms that only Ni-l of the two nickel ions found in the native enzyme is present. In contrast to the pseudotetrahedral geometry observed for Ni-l in native urease (where it is liganded by His-246, His-272, one oxygen atom of carbamylated Lys-217, and a water molecule at partial occupancy), the mononickel metallocenter in the H134A protein was found to possess octahedral geometry and was coordinated by the above protein ligands plus three water molecules. The nickel site of H134A urease was probed by UV-visible, variable temperature magnetic circular dichroism, and x-ray absorption spectroscopies, The spectroscopic data are consistent with the presence of Ni(II) in octahedral geometry coordinated by two histidylimidazoles and additional oxygen and/or nitrogen donors, These data underscore the requirement of Ni-2 for formation of active urease and demonstrate the important role of Ni-2 in establishing the proper Ni-l coordination geometry.	MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; CORNELL UNIV,BIOCHEM MOL & CELL BIOL SECT,ITHACA,NY 14853; UNIV GEORGIA,DEPT CHEM & BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,DEPT MOL BIOL,ATHENS,GA 30602; UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602	Michigan State University; Michigan State University; Cornell University; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia				Karplus, Paul/0000-0001-8725-6292; Scott, Robert/0000-0003-2236-1336; Hausinger, Robert/0000-0002-3643-2054; Michel, Linda/0000-0001-7957-7248	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042025] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45686, R01 DK045686] Funding Source: Medline; NIGMS NIH HHS [GM42025] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berg JM., 1994, PRINCIPLES BIOINORGA; BRUNGER AT, 1993, XPLOR VERSION 3 0; COLPAS GJ, 1991, INORG CHEM, V30, P920, DOI 10.1021/ic00005a010; DELEON JM, 1991, PHYS REV B, V44, P4146, DOI 10.1103/PhysRevB.44.4146; FINNEGAN MG, 1991, J AM CHEM SOC, V113, P4030, DOI 10.1021/ja00010a076; Hausinger R.P., 1993, BIOCH NICKEL, V12, P23; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; JABRI E, 1992, J MOL BIOL, V227, P934, DOI 10.1016/0022-2836(92)90232-9; JOHNSON MK, 1988, ACS SYM SER, V372, P326; KIICK KL, 1991, THESIS U GEORGIA ATH; KOWAL AT, 1988, INORG CHEM, V27, P1162, DOI 10.1021/ic00280a015; LEE MH, 1993, PROTEIN SCI, V2, P1042, DOI 10.1002/pro.5560020617; MOBLEY HLT, 1995, MICROBIOL REV, V59, P451, DOI 10.1128/MMBR.59.3.451-480.1995; MOBLEY HLT, 1989, MICROBIOL REV, V53, P85, DOI 10.1128/MMBR.53.1.85-108.1989; MULROONEY SB, 1990, J BACTERIOL, V172, P5837, DOI 10.1128/jb.172.10.5837-5843.1990; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARK IS, 1993, PROTEIN SCI, V2, P1034, DOI 10.1002/pro.5560020616; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; REHR JJ, 1990, PHYS REV B, V41, P8139, DOI 10.1103/PhysRevB.41.8139; ROSENBERG RC, 1975, J AM CHEM SOC, V97, P21, DOI 10.1021/ja00834a006; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; TODD MJ, 1989, J BIOL CHEM, V264, P15835; WANG S, 1994, INORG CHEM, V33, P1589, DOI 10.1021/ic00086a006; ZONIA LE, 1995, PLANT PHYSIOL, V107, P1097, DOI 10.1104/pp.107.4.1097	25	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18632	18637		10.1074/jbc.271.31.18632	http://dx.doi.org/10.1074/jbc.271.31.18632			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702515	hybrid			2022-12-27	WOS:A1996VB68300053
J	Sadhukhan, R; Sen, GC; Sen, I				Sadhukhan, R; Sen, GC; Sen, I			Synthesis and cleavage-secretion of enzymatically active rabbit angiotensin-converting enzyme in Pichia pastoris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; CATALYTIC PROPERTIES; YEAST; GROWTH; INHIBITOR; SUBUNITS; PEPTIDE	Many biologically important ectoproteins that are anchored in the plasma membrane via a hydrophobic domain undergo a proteolytic cleavage process, which releases the ectodomain to the extracellular milieu in a regulated fashion. Ansotensin-converting enzyme (ACE) is one such protein that is secreted from human and mouse cells by its cleavage at one of two alternative sites in the ectodomain. Here, we report similar cleavage-secretion of ACE in the yeast Pichia pastoris. The cleavage site used in yeasts was identical to one of the two sites used in mouse cells. Moreover, as in mammalian cells, ACE secretion in yeast was inhibited by compound 3, a potent inhibitor of the metzincin family of metalloproteases. ACE proteins cleavage-secreted from yeast and from mammalian cells had identical enzymatic properties. These results demonstrate the existence of a secretase activity in yeast whose properties closely resemble those of the mammalian ACE secretase.	CLEVELAND CLIN FDN,DEPT MOL CARDIOL,RES INST,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation; Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048258] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48258] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; Ehlers M R, 1991, Protein Expr Purif, V2, P1, DOI 10.1016/1046-5928(91)90001-Y; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ELDORRY HA, 1982, J BIOL CHEM, V257, P4128; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; KUMAR RS, 1989, J BIOL CHEM, V264, P16754; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; RAMCHANDRAN R, 1995, BIOCHEMISTRY-US, V34, P12645, DOI 10.1021/bi00039a021; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; RAMCHANDRAN R, 1996, IN PRESS AM J PHYSL; ROBERTS SB, 1994, J BIOL CHEM, V269, P3111; Sadhukhan R, 1996, J BIOL CHEM, V271, P6429, DOI 10.1074/jbc.271.11.6429; SEN I, 1991, J BIOL CHEM, V266, P21985; SEN I, 1993, J BIOL CHEM, V268, P25748; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; ZHANG HY, 1994, J BIOL CHEM, V269, P27799	23	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18310	18313		10.1074/jbc.271.31.18310	http://dx.doi.org/10.1074/jbc.271.31.18310			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702467	hybrid			2022-12-27	WOS:A1996VB68300005
J	Berdiev, BK; Prat, AG; Cantiello, HF; Ausiello, DA; Fuller, CM; Jovov, B; Benos, DJ; Ismailov, II				Berdiev, BK; Prat, AG; Cantiello, HF; Ausiello, DA; Fuller, CM; Jovov, B; Benos, DJ; Ismailov, II			Regulation of epithelial sodium channels by short actin filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; CYTOCHALASIN-D; CELL-VOLUME; APICAL MEMBRANE; ATP HYDROLYSIS; HIGH-AFFINITY; KIDNEY-CELLS; POLYMERIZATION; BINDING; PROTEIN	Cytoskeletal elements play an important role in the regulation of ion transport in epithelia. We have studied the effects of actin filaments of different length on the alpha, beta, gamma-rENaC (rat epithelial Na+ channel) in planar lipid bilayers. We found the following. 1) Short actin filaments caused a a-fold decrease in unitary conductance and a a-fold increase in open probability (P-o) of alpha,beta,gamma-rENaC. 2) alpha,beta,gamma-rENaC could be transiently activated by protein kinase A (PKA) plus ATP in the presence, but not in the absence, of actin. 3) ATP in the presence of actin was also able to induce a transitory activation of alpha,beta,gamma-rENaC, although with a shortened time course and with a lower magnitude of change in P-o. 4) DNase I, an agent known to prohibit elongation of actin filaments, prevented activation of alpha,beta,gamma-rENaC by ATP or PKA plus ATP. 5) Cytochalasin D, added after rundown of alpha,beta,gamma-rENaC activity following ATP or PKA plus ATP treatment, produced a second transient activation of alpha,beta,gamma-rENaC. 6) Gelsolin, a protein that stabilizes polymerization of actin filaments at certain lengths, evoked a sustained activation of alpha,beta,gamma-rENaC at actin/gelsolin ratios of <32:1, with a maximal effect at an actin/gelsolin ratio of 2:1. These results suggest that short actin filaments activate alpha,beta,gamma-rENaC. PKA-mediated phosphorylation augments activation of this channel by decreasing the rate of elongation of actin filaments. These results are consistent with the hypothesis that cloned alpha,beta,gamma-rENaCs form a core conduction unit of epithelial Na+ channels and that interaction of these channels with other associated proteins, such as short actin filaments, confers regulation to channel activity.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; HARVARD UNIV,MASSACHUSETTS GEN HOSP E,SCH MED,RENAL UNIT,BOSTON,MA 02129	University of Alabama System; University of Alabama Birmingham; Harvard University; Harvard Medical School			Fuller, Cathy/B-4046-2011		NIDDK NIH HHS [DK-37206, DK-19406] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019406, R01DK037206, R56DK037206, R37DK019406] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AWAYDA MS, 1995, AM J PHYSIOL-CELL PH, V268, pC1450, DOI 10.1152/ajpcell.1995.268.6.C1450; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; BRANCO LGS, 1992, J MEMBRANE BIOL, V127, P121; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANTIELLO HF, 1995, KIDNEY INT, V48, P970, DOI 10.1038/ki.1995.379; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; CANTIELLO HF, 1995, AM J PHYSIOL-RENAL, V269, pF637, DOI 10.1152/ajprenal.1995.269.5.F637; CANTIELLO HF, 1993, J BIOL CHEM, V268, P4596; CARLIER MF, 1986, J BIOL CHEM, V261, P785; COOPER JA, 1983, BIOCHEMISTRY-US, V22, P2193, DOI 10.1021/bi00278a021; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; EDELSTEIN NG, 1988, BIOCHEMISTRY-US, V27, P1818, DOI 10.1021/bi00406a003; FRINGS S, 1988, J MEMBRANE BIOL, V106, P157, DOI 10.1007/BF01871398; GODDETTE DW, 1986, J BIOL CHEM, V261, P5974; GODDETTE DW, 1986, J BIOL CHEM, V261, P5970; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; Hille B., 1992, IONIC CHANNELS EXCIT, P607; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; Ismailov II, 1996, J BIOL CHEM, V271, P807, DOI 10.1074/jbc.271.2.807; JANMEY PA, 1990, NATURE, V347, P96; JORGENSEN PL, 1984, BIOCHIM BIOPHYS ACTA, V775, P105; KINOSIAN HJ, 1990, BIOCHIM BIOPHYS ACTA, V1077, P151; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; PALMER LG, 1990, J GEN PHYSIOL, V96, P23, DOI 10.1085/jgp.96.1.23; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1982, TRENDS BIOCHEM SCI, V7, P55, DOI 10.1016/0968-0004(82)90076-7; PRAT AG, 1995, AM J PHYSIOL-CELL PH, V268, pC1552, DOI 10.1152/ajpcell.1995.268.6.C1552; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; PRAT AG, 1993, AM J PHYSIOL, V265, pC218, DOI 10.1152/ajpcell.1993.265.1.C218; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SACKIN H, 1989, P NATL ACAD SCI USA, V86, P1731, DOI 10.1073/pnas.86.5.1731; SARIBANSOHRABY S, 1992, AM J PHYSIOL, V263, pC1111, DOI 10.1152/ajpcell.1992.263.5.C1111; SCHLIWA M, 1982, J CELL BIOL, V92, P79, DOI 10.1083/jcb.92.1.79; SCHWARTZ MA, 1988, J CELL BIOL, V107, P201, DOI 10.1083/jcb.107.1.201; SCHWIEBERT EM, 1994, J BIOL CHEM, V269, P7081; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SMITH PR, 1996, IN PRESS CURR TOP ME; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; SRIMIVASAN Y, 1988, NATURE, V333, P177; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; TOUSSON A, 1996, IN PRESS J CELL SCI; UBL J, 1988, J MEMBRANE BIOL, V104, P223, DOI 10.1007/BF01872324; WANG WH, 1994, AM J PHYSIOL-RENAL, V267, pF592, DOI 10.1152/ajprenal.1994.267.4.F592; WATSON AJM, 1992, J BIOL CHEM, V267, P956; WEIHING RR, 1985, CAN J BIOCHEM CELL B, V63, P397, DOI 10.1139/o85-059; YIN HL, 1980, J BIOL CHEM, V255, P9494	55	141	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17704	17710		10.1074/jbc.271.30.17704	http://dx.doi.org/10.1074/jbc.271.30.17704			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663510	hybrid			2022-12-27	WOS:A1996UY93500020
J	Bock, JB; Lin, RC; Scheller, RH				Bock, JB; Lin, RC; Scheller, RH			A new syntaxin family member implicated in targeting of intracellular transport vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED COILS; PROTEINS; RECEPTORS; FUSION; YEAST	Despite the central role vesicular trafficking occupies in protein targeting, the molecular coding of the trafficking signals and the mechanism of vesicle docking and fusion are just beginning to be understood. We report here the cloning and initial characterization of a new member of the syntaxin family of vesicular transport receptors, Syntaxin 6 is a 255-amino acid protein with two domains predicted to form coiled coils, as well as a carboxyl-terminal membrane anchor. Syntaxin 6 is broadly expressed and localizes in the region of the Golgi apparatus, In vitro binding studies established that syntaxin 6 binds to alpha-soluble NSF attachment protein (alpha-SNAP). The sequence homology, topology, localization, and alpha-SNAP binding suggest that syntaxin 6 is involved in intracellular vesicle trafficking.	STANFORD UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Howard Hughes Medical Institute; Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; DASCHER C, 1994, J BIOL CHEM, V269, P29363; Genetic Computer Group, 1994, PROGR MAN WISC PACK; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; JONES EW, 1977, GENETICS, V85, P23; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, METHOD ENZYMOL, V266, P513; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0	31	123	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17961	17965		10.1074/jbc.271.30.17961	http://dx.doi.org/10.1074/jbc.271.30.17961			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663448	hybrid			2022-12-27	WOS:A1996UY93500058
J	Pazhanisamy, S; Stuver, CM; Cullinan, AB; Margolin, N; Rao, BG; Livingston, DJ				Pazhanisamy, S; Stuver, CM; Cullinan, AB; Margolin, N; Rao, BG; Livingston, DJ			Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 PROTEINASE; INHIBITOR; SENSITIVITY; SELECTION; SITE	Passage of human immunodeficiency virus type-1 (HTV-1) in T-lymphocyte cell lines in the presence of increasing concentrations of the hydroxylethylamino sulfonamide inhibitor VX-478 or VB-11328 results in sequential accumulation of mutations in HIV 1 protease, We have characterized recombinant HTV-1 proteases that contain these mutations either individually (L10F, M46I, I47V, I50V) or in combination (the double mutant L10F/I50V and the triple mutant M46I/I47V/I50V). The catalytic properties and affinities for sulfonamide inhibitors and other classes of inhibitors were determined, For the I50V mutant, the efficiency (k(cat)/K-m) of processing peptides designed to mimic cleavage junctions in the HIV-1 gag-pol polypeptide was decreased up to 25-fold. The triple mutant had a a-fold higher processing efficiency than the I50V single mutant for peptide substrates with Phe/Pro and Tyr/Pro cleavage sites, suggesting that the M46I and I47V mutations are compensatory, The effects of mutation on processing efficiency were used in conjunction with the inhibition constant (K-i) to evaluate the advantage of the mutation for viral replication in the presence of drug. These analyses support the virological observation that the addition of M46I and I47V mutations on the I50V mutant background enables increased survival of the HIV-1 virus as it replicates in the presence of VX-478, Crystal structures and molecular models of the active site of the HTV-1 protease mutants suggest that changes in the active site can selectively affect the binding energy of inhibitors with little corresponding change in substrate binding.			Pazhanisamy, S (corresponding author), VERTEX PHARMACEUT INC,130 WEAVERLY ST,CAMBRIDGE,MA 02139, USA.							COLLINS JR, 1995, NAT STRUCT BIOL, V2, P334, DOI 10.1038/nsb0495-334; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Darke P L, 1994, Adv Pharmacol, V25, P399, DOI 10.1016/S1054-3589(08)60438-X; DEBOUCK C, 1991, ADV EXP MED BIOL, V306, P407; DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001; ELFARRASH MA, 1994, J VIROL, V68, P233, DOI 10.1128/JVI.68.1.233-239.1994; GRANT SK, 1991, BIOCHEMISTRY-US, V30, P8424, DOI 10.1021/bi00098a021; GRIFFITHS JT, 1992, BIOCHEMISTRY-US, V31, P5193, DOI 10.1021/bi00137a015; GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1994, J VIROL, V68, P2016, DOI 10.1128/JVI.68.3.2016-2020.1994; JACOBSEN H, 1995, VIROLOGY, V206, P527, DOI 10.1016/S0042-6822(95)80069-7; KAPLAN AH, 1994, P NATL ACAD SCI USA, V91, P5597, DOI 10.1073/pnas.91.12.5597; KIM EE, 1995, J AM CHEM SOC, V117, P1181, DOI 10.1021/ja00108a056; KING RW, 1995, ANTIVIR CHEM CHEMOTH, V6, P80, DOI 10.1177/095632029500600202; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIN YZ, 1995, BIOCHEMISTRY-US, V34, P1143, DOI 10.1021/bi00004a007; MARKOWITZ M, 1995, J VIROL, V69, P701, DOI 10.1128/JVI.69.2.701-706.1995; MEEK TD, 1992, J ENZYM INHIB, V6, P65, DOI 10.3109/14756369209041357; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; *MOL SIM INC, 1992, QUANT VERS 3 3; NITSCHKO H, 1994, ANTIVIR CHEM CHEMOTH, V5, P236, DOI 10.1177/095632029400500405; OTTO MJ, 1993, P NATL ACAD SCI USA, V90, P7543, DOI 10.1073/pnas.90.16.7543; PARTALEDIS JA, 1995, J VIROL, V69, P5228, DOI 10.1128/JVI.69.9.5228-5235.1995; PATICK AK, 1995, J VIROL, V69, P2148, DOI 10.1128/JVI.69.4.2148-2152.1995; PETTIT SC, 1994, J VIROL, V68, P8017, DOI 10.1128/JVI.68.12.8017-8027.1994; PILLAY D, 1995, REV MED VIROL, V5, P23, DOI 10.1002/rmv.1980050104; RICHARDS AD, 1990, J BIOL CHEM, V265, P7733; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; THAISRIVONGS S, 1994, ANNU REP MED CHEM, V29, P133; TISDALE M, 1995, ANTIMICROB AGENTS CH, V39, P1704, DOI 10.1128/AAC.39.8.1704; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; WEST ML, 1995, TRENDS PHARMACOL SCI, V16, P67, DOI 10.1016/S0165-6147(00)88980-4; WINSLOW DL, 1995, AIDS RES HUM RETROV, V11, P107, DOI 10.1089/aid.1995.11.107; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551	36	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17979	17985		10.1074/jbc.271.30.17979	http://dx.doi.org/10.1074/jbc.271.30.17979			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663409	hybrid			2022-12-27	WOS:A1996UY93500061
J	Witte, S; Neumann, F; Krawinkel, U; Przybylski, M				Witte, S; Neumann, F; Krawinkel, U; Przybylski, M			Mass spectrometric identification of leucine zipper-like homodimer complexes of the autoantigen L7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSPRAY-IONIZATION; CELL BIOLOGY; AMINO-ACIDS; PROTEINS; SEQUENCE	The eucaryotic protein L7 has been shown to associate in the cytoplasm with the large subunit of ribosomes and to interact specifically with as yet unknown cognate sites of mRNA, thereby inhibiting cell-free translation (Neumann, F,, Hemmerich, P,, von Mikecz, A., Peter, Il, H., and Krawinkel, U, (1995) Nucleic Acids Res, 23, 195-202), The N-terminal region of protein L7 contains a sequence motif similar to the leucine zipper domain of eucaryotic transcription factors, which promotes dimerization through alpha-helical coiled coil formation, Using electrospray-ionization mass spectrometry as a method of molecular specificity, we have directly identified the dimeric complexes comprising the leucine zipper-like region of protein L7 and have determined the dissociation constant of L7 homodimers in an affinity binding assay, We also demonstrate the high content of cu-helicity of the dimer by circular dichroism spectra and computer-based structure simulation and show that the leucine zipper region of protein L7 is fully sufficient to mediate the inhibition of cell-free mRNA translation, A structural basis for the function of L7 to regulate translation is discussed, From the present results we con elude that L7 interacts with double stranded mRNA in a similar fashion as leucine zipper proteins with specific cognate sites on double stranded DNA.	UNIV KONSTANZ, FAK CHEM, D-78434 CONSTANCE, GERMANY	University of Konstanz	Witte, S (corresponding author), UNIV KONSTANZ, FAK BIOL, POSTFACH 5560, D-78434 CONSTANCE, GERMANY.							Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; ALLEN MH, 1992, J AM SOC MASS SPECTR, V3, P18, DOI 10.1016/1044-0305(92)85014-B; Ausubel FM, 1991, CURRENT PROTOCOLS MO; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FORMOSA T, 1991, METHOD ENZYMOL, V208, P24; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLOCKER MO, 1994, BIOCONJUGATE CHEM, V5, P583, DOI 10.1021/bc00030a014; Hadjiolov A.A., 1985, CELL BIOL MONOGRAPHS, V12; HEMMERICH P, 1993, NUCLEIC ACIDS RES, V21, P223, DOI 10.1093/nar/21.2.223; KALPIN RF, 1994, BIOTECHNIQUES, V17, P730; KARAS M, 1991, MASS SPECTROM REV, V10, P335, DOI 10.1002/mas.1280100503; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LI YT, 1993, J AM CHEM SOC, V115, P8409, DOI 10.1021/ja00071a058; LIN A, 1987, J BIOL CHEM, V262, P12665; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; NEU E, 1995, CLIN EXP IMMUNOL, V100, P198; NEUMANN F, 1995, NUCLEIC ACIDS RES, V23, P195, DOI 10.1093/nar/23.2.195; NIELSEN PF, 1990, MASS SPECTROMETRY LA, P194; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Przybylski M, 1995, TOXICOL LETT, V82-3, P567, DOI 10.1016/0378-4274(95)03502-8; Przybylski M, 1995, ADV MASS SPECTROM, V13, P257; Przybylski M, 1996, ANGEW CHEM INT EDIT, V35, P807; PRZYBYLSKI M, 1994, PEPTIDES CHEM STRUCT, P338; SMITH RD, 1993, BIOL MASS SPECTROM, V22, P493, DOI 10.1002/bms.1200220902; SMITH RD, 1991, MASS SPECTROM REV, V10, P359, DOI 10.1002/mas.1280100504; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKACS BJ, 1991, J IMMUNOL METHODS, V143, P231, DOI 10.1016/0022-1759(91)90048-K; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; TAN EM, 1991, CELL, V67, P841, DOI 10.1016/0092-8674(91)90356-4; TSURUGI K, 1976, J BIOL CHEM, V251, P7940; VONMIKECZ A, 1994, IMMUNOBIOLOGY, V192, P137, DOI 10.1016/S0171-2985(11)80413-4; VONMIKECZ AH, 1995, CLIN EXP IMMUNOL, V100, P205; WENDT H, 1995, PROTEIN SCI, V4, P1563, DOI 10.1002/pro.5560040814; ZHU BY, 1993, PROTEIN SCI, V2, P383	39	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18171	18175		10.1074/jbc.271.30.18171	http://dx.doi.org/10.1074/jbc.271.30.18171			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663440	hybrid			2022-12-27	WOS:A1996UY93500087
J	Carlberg, M; Dricu, A; Blegen, H; Wang, M; Hjertman, M; Zickert, P; Hoog, A; Larsson, O				Carlberg, M; Dricu, A; Blegen, H; Wang, M; Hjertman, M; Zickert, P; Hoog, A; Larsson, O			Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface - Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme A reductase and cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; HUMAN-MELANOMA CELLS; HMG-COA REDUCTASE; ENDOPLASMIC-RETICULUM; DOLICHYL-PHOSPHATE; GLYCOPROTEIN-SYNTHESIS; PROTEIN GLYCOSYLATION; ISOPRENOID SYNTHESIS; ATHYMIC MICE; TUNICAMYCIN	Depletion of mevalonic acid (MVA), obtained by inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase using lovastatin, depressed the biosynthesis of dolichyl-phosphate and the rate of N-linked glycosylation and caused growth arrest in the melanoma cell line SK-MEL-2. The growth arrest was partially prevented by addition of high concentrations of insulin-like growth factor-1 (IGF-1) to the cells, indicating that MVA depletion may inhibit cell growth through decreasing the number of IGF-1 receptors (IGF-1R) at the cell surface, Such a decrease in receptor number might be a result of a lowered translocation of de novo synthesized receptors to the cell membrane which in turn might be a result of a decreased N-linked glycosylation of the receptor proteins, We could also demonstrate that IGF-1R became underglycosylated and that the amount of de novo synthesized IGF-1R proteins at the cell membrane was drastically decreased upon MVA depletion, Analysis of receptor proteins cross-linked with IGF-1, as well as binding assays and immunocytostaining confirmed that the number of functional membrane bound IGF-1R was substantially reduced. The N-linked glycosylation and the expression of de novo synthesized IGF-1R proteins at the cell surface as well as the number of IGF-1 binding sites were completely restored upon replenishment of MVA. These effects of MVA were efficiently abrogated by the glycosylation inhibitor tunicamycin, The translocation of IGF-1R to the cell membrane was shown to take place just prior to initiation of DNA synthesis in arrested cells stimulated with MVA, Additionally, there was a clear correlation between IGF-1 binding and initiation of DNA synthesis with regard to the MVA dose requirement, It was confirmed that inhibition of HMG-CoA reductase activity and N-linked glycosylation also depressed the expression of functional IGF-1R in other cell types (i.e. hepatoblastoma cells and colon cancer cells), Our data suggest that this mechanism is involved in MVA-regulated cell growth.	KAROLINSKA INST,DEPT TUMOR PATHOL,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet								ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; ADAIR WL, 1985, METHOD ENZYMOL, V111, P201; ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; BENNIS F, 1993, INT J CANCER, V55, P640, DOI 10.1002/ijc.2910550421; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; BROWN MS, 1980, J LIPID RES, V21, P505; CARLBERG M, 1994, EXP CELL RES, V212, P359, DOI 10.1006/excr.1994.1155; CARSON DD, 1981, J BIOL CHEM, V256, P4679; CAVENEE WK, 1981, J BIOL CHEM, V256, P2675; CLARK JH, 1977, RECEPTORS HORMONE AC; COLLIER E, 1993, BIOCHEMISTRY-US, V32, P7818, DOI 10.1021/bi00081a029; DOYLE JW, 1993, J CELL PHYSIOL, V155, P171, DOI 10.1002/jcp.1041550122; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; FURLANETTO RW, 1993, CANCER RES, V53, P2522; GAMMELTOFT S, 1985, EMBO J, V4, P3407, DOI 10.1002/j.1460-2075.1985.tb04097.x; GAMMELTOFT S, 1990, PEPTIDE HORMONE ACTI, P1; GAROFALO RS, 1992, J BIOL CHEM, V267, P11470; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; HEIFETZ A, 1979, BIOCHEMISTRY-US, V18, P2186, DOI 10.1021/bi00578a008; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KABAKOFF BD, 1990, ARCH BIOCHEM BIOPHYS, V276, P382, DOI 10.1016/0003-9861(90)90736-I; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KULL FC, 1983, J BIOL CHEM, V258, P6561; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNARZ WJ, 1987, BIOCHEMISTRY-US, V26, P7205, DOI 10.1021/bi00397a001; LIU DL, 1992, J VIROL, V66, P374, DOI 10.1128/JVI.66.1.374-385.1992; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V650, P209, DOI 10.1016/0304-4157(82)90017-X; PIETRZKOWSKI Z, 1992, MOL CELL BIOL, V12, P3883, DOI 10.1128/MCB.12.9.3883; PLANTNER JJ, 1980, ARCH BIOCHEM BIOPHYS, V201, P527, DOI 10.1016/0003-9861(80)90541-X; PRIVES J, 1980, TISSUE CULTURE NEURO, P35; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; RESNICOFF M, 1994, CANCER RES, V54, P4848; RIP JW, 1985, PROG LIPID RES, V24, P269, DOI 10.1016/0163-7827(85)90008-6; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sheeler P., 1981, CENTRIFUGATION BIOL; SIPERSTEIN MD, 1984, J LIPID RES, V25, P1462; STRACKE ML, 1988, BIOCHEM BIOPH RES CO, V153, P1076, DOI 10.1016/S0006-291X(88)81338-X; STRUCK DK, 1978, J BIOL CHEM, V253, P5332; STRUCK DK, 1981, BIOCH GLYCOPROTEINS, P35; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; VU H, 1991, TETRAHEDRON LETT, V32, P3005, DOI 10.1016/0040-4039(91)80672-S; WARREN L, 1974, MEMBRANE TRANSFORMAT, P1	48	114	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17453	17462		10.1074/jbc.271.29.17453	http://dx.doi.org/10.1074/jbc.271.29.17453			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663239	hybrid			2022-12-27	WOS:A1996UX94300073
J	Clemens, JC; Ursuliak, Z; Clemens, KK; Price, JV; Dixon, JE				Clemens, JC; Ursuliak, Z; Clemens, KK; Price, JV; Dixon, JE			A Drosophila protein-tyrosine phosphatase associates with an adapter protein required for axonal guidance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; SH3; IDENTIFICATION; HYBRIDIZATION; BINDING; SUBUNIT; GENE	We have used the yeast two-hybrid system to isolate a novel Drosophila adapter protein, which interacts with the Drosophila protein-tyrosine phosphatase (PTP) dPTP61F. Absence of this protein in Drosophila causes the mutant photoreceptor axon phenotype dreadlocks (doch) (Garrity, P, A, Rao, Y,, Salecker, I., and Zipursky, S, L, (1996) Cell 85, 639-650), Dock is similar to the mammalian oncoprotein Nck and contains three Src homology 3 (SH3) domains and one Src homology 2 (SH2) domain, The interaction of dPTP61F with Dock was confirmed in vivo by immune precipitation experiments, A sequence containing five PXXP motifs from the noncatalytic domain of the PTP is sufficient for interaction with Dock, This suggests that binding to the PTP is mediated by one or more of the SH3 domains of Dock. Immune precipitations of Dock also co precipitate two tyrosine-phosphorylated proteins having molecular masses of 190 and 145 kDa. Interactions between Dock and these tyrosine-phosphorylated proteins are likely mediated by the Dock SH2 domain, These findings identify potential signal-transducing partners of Dock and propose a role for dPTP61F and the unidentified phosphoproteins in axonal guidance.	SIMON FRASER UNIV,INST MOL BIOL & BIOCHEM,BURNABY,BC V5A 1S6,CANADA; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	Simon Fraser University; University of Michigan System; University of Michigan				Price, James/0000-0001-9068-7317	NIDDK NIH HHS [NIDDK 18849] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018849] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HARPER JW, 1993, CELL, V75, P805; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; [No title captured]	22	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17002	17005		10.1074/jbc.271.29.17002	http://dx.doi.org/10.1074/jbc.271.29.17002			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663600	hybrid			2022-12-27	WOS:A1996UX94300006
J	Feng, JF; Rhee, SG; Im, MJ				Feng, JF; Rhee, SG; Im, MJ			Evidence that phospholipase delta 1 is the effector in the G(h) (transglutaminase II)-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNITS; C ISOZYMES; G-PROTEIN; ACTIVATION; PURIFICATION; RECONSTITUTION; BINDING; FAMILY; ALPHA(1)-ADRENOCEPTOR; MEDIATOR	A new class of GTP-binding protein transglutaminase II (G(h)) couples to a 69 kDa phospholipase C (PLC). An 8-amino acid region (LeU(665)-Lys(672)) of the alpha-subunit of G(h) (G alpha(h)) is involved in interaction and activation of PLC, an observation that has now been used to characterize the 69-kDa PLC further. A 20-amino acid peptide 673 corresponding to Leu(654)-Leu(673) of G alpha(h) was used to prepare an affinity resin. On incubation with a partially purified PLC preparation from rat liver membranes, the affinity resin-bound similar to 69- and 85-kDa proteins were recognized by an antibody to the 69-kDa PLC. Both purified 69-kDa PLC and PLC-delta 1 bound to the affinity resin; moreover, antibodies to PLC-delta 1 recognized the 69-kDa PLC, and antibodies to the 69 kDa PLC recognized PLC-delta 1. A synthetic peptide corresponding to LeU(661)-Lys(672) of G alpha(h) inhibited the binding of PLC-delta 1 to the affinity resin and also stimulated PLC-delta 1. Reconstitution of PLC-delta 1 with GTP gamma S (guanosine 5'-3-O-(thio)triphosphate)-activated G(h) resulted in activation of PLC-delta 1. Antibodies to G alpha(h) also coimmunoprecipitated PLC-delta 1 upon activation of G(h). These findings indicate that PLC-delta 1 is the effector of G(h)-mediated signaling.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC CARDIOL FFB37,CLEVELAND,OH 44195; NHLBI,LAB CELL SIGNALING,NIH,BETHESDA,MD 20892	Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045985] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45985] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baek KJ, 1996, BIOCHEMISTRY-US, V35, P2651, DOI 10.1021/bi9522965; BAEK KJ, 1993, J BIOL CHEM, V268, P27390; BANNO Y, 1994, J BIOL CHEM, V269, P15846; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; DAS T, 1993, J BIOL CHEM, V268, P27398; GINGER RS, 1992, EUR J BIOCHEM, V210, P155, DOI 10.1111/j.1432-1033.1992.tb17403.x; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HARRIS BA, 1985, SCIENCE, V229, P1274, DOI 10.1126/science.3839937; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HWANG KC, 1995, J BIOL CHEM, V270, P27058, DOI 10.1074/jbc.270.45.27058; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1992, J BIOL CHEM, V267, P8887; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MELDRUM E, 1991, BIOCHIM BIOPHYS ACTA, V1092, P49, DOI 10.1016/0167-4889(91)90177-Y; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; PARK DG, 1993, J BIOL CHEM, V268, P4573; RHEE SG, 1991, BIOCHEM SOC T, V19, P337, DOI 10.1042/bst0190337; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAYLOR GD, 1992, BIOCHEM BIOPH RES CO, V188, P1176, DOI 10.1016/0006-291X(92)91355-T; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WU DQ, 1992, J BIOL CHEM, V267, P25798; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179	26	159	161	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16451	16454		10.1074/jbc.271.28.16451	http://dx.doi.org/10.1074/jbc.271.28.16451			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663582	hybrid			2022-12-27	WOS:A1996UX12600006
J	Hatakeyama, T; Furukawa, M; Nagatomo, H; Yamasaki, N; Mori, T				Hatakeyama, T; Furukawa, M; Nagatomo, H; Yamasaki, N; Mori, T			Oligomerization of the hemolytic lectin CEL-III from the marine invertebrate Cucumaria echinata induced by the binding of carbohydrate ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCAL ALPHA-TOXIN; PERTUSSIS TOXIN; LIPID DISPERSIONS; MEMBRANES; PROTEIN; AUREUS; MECHANISM; AEROLYSIN; CHANNEL; MONOMER	The hemolytic lectin GEL-III is a Ca2+-dependent, galactose/GalNAc-specific lectin purified from the marine invertebrate Cucumaria echinata (Holothuroidea). We found that this lectin forms ion-permeable pores in erythrocyte and artificial lipid membranes that have specific carbohydrate ligands on the surface. The hemolytic activity of GEL-III exhibited characteristic pH dependence; activity increased remarkably with pH in the alkaline region, especially above pH 9, When rabbit erythrocyte membrane was examined by immunoblot ting using anti-CEL-III antiserum after treatment with GEL-III, the irreversible binding of the GEL-III oligomer increased with pH, indicating that the increase in hemolytic activity at higher pH is associated closely with the amount of oligomer irreversibly bound to the membrane, Surface hydrophobicity of GEL-III, as measured by the fluorescent probe 8-anilino-1-naphthalenesulfonate, increased markedly with the binding of specific ligands such as lactose, lactulose, and N-acetyllactosamine at pH 9-10 in the presence of 1 M NaCl. The enhancement of surface hydrophobicity induced by the binding of carbohydrates was also accompanied by the formation of a GEL-III oligomer, which was found to be the same size on sodium dodecyl sulfate-polyacrylamide gel electrophoresis as the oligomer that formed in CEL-III-treated erythrocyte membranes. Far-UV circular dichroism spectra of CEL-III and the oligomer revealed a definite difference in secondary structure, These data suggest that the binding of GEL-III to specific carbohydrate ligands on the erythrocyte surface induces a conformational change in the protein, leading to the exposure of a hydrophobic region which triggers oligomerization and the irreversible binding of the protein to the membrane.	KYUSHU UNIV, FAC AGR, BIOCHEM LAB, FUKUOKA 81281, JAPAN; KYUSHU UNIV, FAC AGR, ZOOL LAB, FUKUOKA 81281, JAPAN	Kyushu University; Kyushu University				Hatakeyama, Tomomitsu/0000-0002-9505-1980				BHAKDI S, 1981, P NATL ACAD SCI-BIOL, V78, P5475, DOI 10.1073/pnas.78.9.5475; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; BRENNAN MJ, 1988, J BIOL CHEM, V263, P4895; COWELL JL, 1978, BIOCHIM BIOPHYS ACTA, V507, P230, DOI 10.1016/0005-2736(78)90419-4; DONOVAN JJ, 1985, J BIOL CHEM, V260, P8817; DUNCAN JL, 1975, J CELL BIOL, V67, P160, DOI 10.1083/jcb.67.1.160; FORTI S, 1989, EUR J BIOCHEM, V181, P767, DOI 10.1111/j.1432-1033.1989.tb14790.x; FREER JH, 1968, J BACTERIOL, V95, P1153, DOI 10.1128/JB.95.3.1153-1168.1968; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; GOLDBERG RJ, 1953, J PHYS CHEM-US, V57, P194, DOI 10.1021/j150503a014; GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828; HATAKEYAMA T, 1995, J BIOL CHEM, V270, P3560, DOI 10.1074/jbc.270.8.3560; HATAKEYAMA T, 1994, J BIOCHEM, V116, P209, DOI 10.1093/oxfordjournals.jbchem.a124495; HILAIRE PMS, 1994, BIOCHEMISTRY-US, V33, P14452; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; IKIGAI H, 1987, J BIOL CHEM, V262, P2156; IKIGAI H, 1985, BIOCHEM BIOPH RES CO, V130, P175, DOI 10.1016/0006-291X(85)90398-5; JURSCH R, 1994, INFECT IMMUN, V62, P2249, DOI 10.1128/IAI.62.6.2249-2256.1994; MORGAN PJ, 1994, J BIOL CHEM, V269, P25315; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; SAUKKONEN K, 1992, P NATL ACAD SCI USA, V89, P118, DOI 10.1073/pnas.89.1.118; SINGH Y, 1994, J BIOL CHEM, V269, P29039; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMYTH CJ, 1975, BIOCHIM BIOPHYS ACTA, V382, P479, DOI 10.1016/0005-2736(75)90216-3; SPANGLER BD, 1993, ARCH BIOCHEM BIOPHYS, V305, P153, DOI 10.1006/abbi.1993.1405; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; WALKER B, 1992, J BIOL CHEM, V267, P21782; WEBER G, 1964, J BIOL CHEM, V239, P1415; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x; YANG JT, 1986, METHOD ENZYMOL, V130, P208	33	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16915	16920		10.1074/jbc.271.28.16915	http://dx.doi.org/10.1074/jbc.271.28.16915			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663224	hybrid			2022-12-27	WOS:A1996UX12600074
J	Kurokawa, M; Tanaka, T; Tanaka, K; Hirano, N; Ogawa, S; Mitani, K; Yazaki, Y; Hirai, H				Kurokawa, M; Tanaka, T; Tanaka, K; Hirano, N; Ogawa, S; Mitani, K; Yazaki, Y; Hirai, H			A conserved cysteine residue in the runt homology domain of AML1 is required for the DNA binding ability and the transforming activity on fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; DROSOPHILA SEGMENTATION GENE; TRANSCRIPTION FACTOR; REDOX REGULATION; POLYOMAVIRUS ENHANCER; NUCLEAR FACTOR; ACTIVATION; PROTEIN; INVITRO	The AML1 gene encodes DNA-binding proteins that contain the runt homology domain and is found at the breakpoints of t(8;21), t(3;21), and t(12;21) translocations associated with myelogenous leukemias, AML1 heterodimerizes with PEBP2 beta/CBF beta, resulting in the enhanced affinity with DNA, The runt homology domain is responsible for binding with DNA and heterodimerizing with PEBP2 beta/CBF beta. AML1 is suggested to perform a pivotal role in myeloid cell differentiation, whereas it can cause neoplastic transformation when overexpressed in fibroblasts. In this study, we demonstrated that the reducing reagent, dithiothreitol (DTT), markedly enhances the DNA binding of AML1 expressed in COS7 cells, Oxidation by diamide or modification by N-ethylmaleimide of the free sulfhydryl residues inhibited the interaction of AML1 with DNA. The diamide effect was reversible with excess of DTT, whereas DTT could not restore the DNA binding of AML1 treated with N-ethylmaleimide. Site-directed mutagenesis of the amino acid residue 72, a highly conserved cysteine in the runt homology domain of AML1, to serine almost completely abolished DNA binding without altering the interaction with PEBP2 beta/CBF beta. This substitution also impaired transactivation through the consensus DNA sequence and transformation of fibroblasts induced by AML1b, These data indicate an essential role of the conserved cysteine residue in DNA binding of AML1, and it is possible that the redox state of AML1 could contribute to the regulation of its function.	UNIV TOKYO, FAC SCI, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo			Tanaka, Tomoyuki U/A-4775-2008; Tanaka, Kozo/Y-6566-2018	Tanaka, Kozo/0000-0001-6086-2858				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; ERICKSON P, 1992, BLOOD, V80, P1825; FURUKAWA K, 1990, CELL GROWTH DIFFER, V1, P135; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GOODMAN MG, 1979, J IMMUNOL, V122, P1433; GRASSER FA, 1992, ONCOGENE, V7, P1005; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HEDGE RS, 1992, NATURE, V359, P505; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Kurokawa M, 1996, ONCOGENE, V12, P883; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU J, 1995, MOL CELL BIOL, V15, P1651; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NUCIFORA G, 1993, BLOOD, V81, P2728; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SATAKE M, 1988, ONCOGENE, V3, P69; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SUTHANTHIRAN M, 1990, P NATL ACAD SCI USA, V87, P3343, DOI 10.1073/pnas.87.9.3343; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	50	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16870	16876		10.1074/jbc.271.28.16870	http://dx.doi.org/10.1074/jbc.271.28.16870			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663420	hybrid			2022-12-27	WOS:A1996UX12600069
J	Li, BJ; Warner, JR				Li, BJ; Warner, JR			Mutation of the Rab6 homologue of Saccharomyces cerevisiae, YPT6, inhibits both early Golgi function and ribosome biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PATHWAY; PROTEIN-TRANSPORT; YEAST; GENE; RNA; APPARATUS; COMPLEX; IDENTIFICATION; MORPHOGENESIS; COMPONENT	A screen was designed to identify temperature-sensitive mutants of Saccharomyces cerevisiae, whose transcription of both ribosomal RNA and ribosomal protein genes is repressed at the nonpermissive temperature, The gene from one such mutant was cloned by complementation, The gene encodes a predicted product that is nearly 65% identical to the human GTPase, Rab6, and is likely to be identical to the yeast gene YPT6. It is essential for growth only at elevated temperatures, The mutant strain is partially defective in the maturation of the vacuolar protein carboxypeptidase Y, as well as in the secretion of invertase, which accumulates as a core-glycosylated form characteristic of the endoplasmic reticulum or the cis-Golgi, suggesting that Ypt6p is involved in an early step of the secretory pathway, earlier than that reported for the mammalian Rab6., The mutant protein, a truncation at codon 64 of 215, has a stronger phenotype than the null allele of YPT6. Four other mutants selected for defective ribosome synthesis at the nonpermissive temperature were also found to have defects in carboxypeptidase Y maturation, giving emphasis to our previous finding that a functional secretory pathway is essential for continued ribosome synthesis, Cloning of extragenic suppressors of the ts allele of YPT6 has revealed two additional proteins that influence the secretory pathway: Ssd1p, a suppressor of many mutations, and Imh1p, which bears some homology to the C-terminal portion of the cytoskeletal proteins integrin and myosin.	ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025532] Funding Source: NIH RePORTER; NCI NIH HHS [CA13330] Funding Source: Medline; NIGMS NIH HHS [GM 25532] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; BERANGER F, 1994, MOL CELL BIOL, V14, P744, DOI 10.1128/MCB.14.1.744; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Dean N, 1996, GLYCOBIOLOGY, V6, P73, DOI 10.1093/glycob/6.1.73; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOSEFF AI, 1995, GENETICS, V141, P857; EAKLE KA, 1988, MOL CELL BIOL, V8, P4098, DOI 10.1128/MCB.8.10.4098; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; GOUD B, 1994, ANN NY ACAD SCI, V710, P192, DOI 10.1111/j.1749-6632.1994.tb26627.x; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; HENGST L, 1990, EMBO J, V9, P1949, DOI 10.1002/j.1460-2075.1990.tb08322.x; JEDD G, 1995, J CELL BIOL, V131, P583, DOI 10.1083/jcb.131.3.583; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; KAISER CA, 1986, MOL CELL BIOL, V6, P2382, DOI 10.1128/MCB.6.7.2382; KIM CH, 1983, MOL CELL BIOL, V3, P457, DOI 10.1128/MCB.3.3.457; KIM YJ, 1994, J CELL BIOL, V127, P1381, DOI 10.1083/jcb.127.5.1381; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; LIANG S, 1993, EUR J CELL BIOL, V62, P270; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MIZUTA K, 1994, MOL CELL BIOL, V14, P2493, DOI 10.1128/MCB.14.4.2493; Mondesert G, 1996, J CELL BIOL, V132, P137, DOI 10.1083/jcb.132.1.137; NEUMANSILBERBERG FS, 1995, MOL CELL BIOL, V15, P3187; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SEOG DH, 1994, J BIOCHEM-TOKYO, V116, P1341, DOI 10.1093/oxfordjournals.jbchem.a124685; SHUAI K, 1991, NUCLEIC ACIDS RES, V19, P5059, DOI 10.1093/nar/19.18.5059; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; TAKIZAWA PA, 1993, CELL, V75, P593, DOI 10.1016/0092-8674(93)90477-8; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; UESONO Y, 1994, GENE, V143, P135; WARNER JR, 1977, CELL, V11, P201, DOI 10.1016/0092-8674(77)90331-2; WARNER JR, 1978, NATURE, V275, P338, DOI 10.1038/275338a0; WILSON RB, 1991, MOL CELL BIOL, V11, P3369, DOI 10.1128/MCB.11.6.3369	44	87	89	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16813	16819		10.1074/jbc.271.28.16813	http://dx.doi.org/10.1074/jbc.271.28.16813			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663225	hybrid			2022-12-27	WOS:A1996UX12600061
J	Mucsi, I; Skorecki, KL; Goldberg, HJ				Mucsi, I; Skorecki, KL; Goldberg, HJ			Extracellular signal-regulated kinase and the small GTP-binding protein, Rac, contribute to the effects of transforming growth factor-beta 1 on gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; COLLAGEN PROMOTER; ACTIVATION; P21RAS; CELLS; SITE	The kinases and regulatory proteins that convey signals initiated by transforming growth factor-beta (TGF-beta) to the nucleus are poorly characterized. To study the role of the extracellular signal-regulated kinase (ERK) pathway in this process, we transiently transfected NIH 3T3 fibroblasts with TGF-beta-responsive luciferase re porter genes and expression vectors designed to interrupt this kinase cascade. Mitogen-activated protein (MAP) kinase phosphatase-1 and a dominant negative MAP/ERK kinase 1 mutant reduced stimulation of plasminogen activator inhibitor-1 (PAI-1) promoter activity by TGF-beta 1 from 11.5 to 4-fold and 4.9-fold, respectively. Similar results were observed with the type I collagen promoters. TGF-beta 1 increased ERK1 activity 4.5 fold at 5 min and 3.1-fold at 3 h, while Jun kinase and p38 activity were not affected. Cotransfection of a dominant negative mutant of the small G protein, Rac, but not dominant negative Ras, Cdc42, or Rho mutants, reduced the effects of TGF-beta 1 on the PAI-1 promoter by approximately half. In support of a role for Rac in signaling by TGF-beta, GTP binding to Pac was increased 3.7-fold following exposure of NIH 3T3 cells to TGF-beta 1 for 3 min. These findings indicate that TGF-beta 1 modulates gene expression partly through ERK and Rac in NIH 3T3 cells.	UNIV TORONTO,DIV NEPHROL,DEPT PEDIAT,HOSP SICK CHILDREN,TORONTO,ON M5G 1X8,CANADA; TECHNION ISRAEL INST TECHNOL,DIV NEPHROL,IL-31096 HAIFA,ISRAEL; RAMBAM MED CTR,IL-31096 HAIFA,ISRAEL	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology								ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; AFTI A, 1995, P NATL ACAD SCI USA, V92, P12110; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHANG E, 1995, J BIOL CHEM, V270, P4473, DOI 10.1074/jbc.270.9.4473; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, J BIOL CHEM, V269, P21103; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DEVRIESSMITS AMM, 1995, METHOD ENZYMOL, V255, P156; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FLORDELLIS CS, 1995, J BIOL CHEM, V270, P3491, DOI 10.1074/jbc.270.8.3491; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; HALSTEAD J, 1995, J BIOL CHEM, V270, P13600, DOI 10.1074/jbc.270.23.13600; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HIPSKIND RA, 1994, MOL CELL BIOL, V9, P621; HUWILER A, 1994, FEBS LETT, V354, P255, DOI 10.1016/0014-5793(94)01132-X; IMAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; JONES CL, 1991, KIDNEY INT, V40, P1020, DOI 10.1038/ki.1991.310; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Knoepp SM, 1996, J BIOL CHEM, V271, P1678, DOI 10.1074/jbc.271.3.1678; KOLEH W, 1993, NATURE, V364, P249; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULDER KM, 1992, J BIOL CHEM, V267, P5029; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; PANG L, 1995, BIOCHEM J, V307, P513, DOI 10.1042/bj3070513; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SANDLER MA, 1994, J BIOL CHEM, V269, P21500; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sugimoto T, 1996, J BIOL CHEM, V271, P544, DOI 10.1074/jbc.271.1.544; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WARNER LC, 1993, ONCOGENE, V8, P3249; WEISER R, 1995, EMBO J, V14, P2199; WEISS RH, 1995, KIDNEY INT, V48, P738, DOI 10.1038/ki.1995.345; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WOOD WM, 1989, J BIOL CHEM, V264, P14840; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xu RH, 1996, P NATL ACAD SCI USA, V93, P834, DOI 10.1073/pnas.93.2.834; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN ZF, 1994, J BIOL CHEM, V269, P13231	68	161	165	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16567	16572		10.1074/jbc.271.28.16567	http://dx.doi.org/10.1074/jbc.271.28.16567			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663331	hybrid			2022-12-27	WOS:A1996UX12600024
J	Centrella, M; Ji, CH; Casinghino, S; McCarthy, TL				Centrella, M; Ji, CH; Casinghino, S; McCarthy, TL			Rapid flux in transforming growth factor-beta receptors on bone cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT BONE; OSTEOBLAST-ENRICHED CULTURES; TGF-BETA; PROTEIN-KINASE; II RECEPTOR; MOLECULAR CHARACTERIZATION; PARIETAL BONE; EXPRESSION; BINDING; COLLAGEN	The proportion of transforming growth factor-beta (TGF-beta) binding among conventional membrane receptors on bone cells can vary with hormone or growth factor treatment or with the state of osteoblast-like activity and appears to determine the nature of its biological effects. Therefore, functional TGF-beta receptor stability could be an important aspect of regulation, Suppression of protein synthesis reduced TGF-beta binding to types I and II receptors with t(1/2) of 2 h and to betaglycan with t(1/2) of 6 h. In contrast, suppression of mRNA transcription reduced TGF-beta binding at least 3-fold more slowly at each receptor site, Preexposure to TGF-beta decreased its binding at all three sites within 4 h in osteoblast-enriched cultures. This effect was transient with lower TGF-beta concentrations, where the receptor profile was nearly fully restored within 24-48 h, In contrast, less differentiated bone cells were less sensitive to ligand-dependent receptor down-regulation. Agents that alter protein kinase and phosphatase activity also modified the TGF-beta binding profile in specific ways, Together, these results indicate that cell surface TGF-beta receptors turn over rapidly by ligand-independent and ligand-dependent mechanisms, demonstrate that the binding capacity of TGF-beta receptors is less stable than their mRNAs, and that functional receptor levels may be determined in part by post-transcriptional events.			Centrella, M (corresponding author), YALE UNIV,SCH MED,DEPT SURG,SECT PLAST SURG,333 CEDAR ST,POB 208041,NEW HAVEN,CT 06520, USA.				NCRR NIH HHS [BRSG/RR-05358] Funding Source: Medline; NIAMS NIH HHS [AR-39201] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039201, R29AR039201] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611; CENTRELLA M, 1988, P NATL ACAD SCI USA, V85, P5889, DOI 10.1073/pnas.85.16.5889; CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; CENTRELLA M, 1992, ENDOCRINOLOGY, V131, P2863, DOI 10.1210/en.131.6.2863; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CENTRELLA M, 1992, J CLIN INVEST, V89, P1076, DOI 10.1172/JCI115687; CENTRELLA M, 1991, MOL CELL BIOL, V11, P4490, DOI 10.1128/MCB.11.9.4490; CENTRELLA M, 1995, HORMONAL REGULATION, P221; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DERYNCK R, 1994, CYTOKINE HDB, P419; FROLIK CA, 1984, J BIOL CHEM, V259, P995; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; IIMURA T, 1994, BIOCHEM BIOPH RES CO, V204, P918, DOI 10.1006/bbrc.1994.2547; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU F, 1995, MOL CELL BIOL, V15, P3479; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOWRY OH, 1957, METHOD ENZYMOL, V4, P366, DOI 10.1016/0076-6879(57)04065-3; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; ROY SK, 1995, ENDOCRINOLOGY, V136, P4610, DOI 10.1210/en.136.10.4610; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TSUCHIDA K, 1993, BIOCHEM BIOPH RES CO, V191, P790, DOI 10.1006/bbrc.1993.1286; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	37	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18616	18622		10.1074/jbc.271.31.18616	http://dx.doi.org/10.1074/jbc.271.31.18616			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702513	hybrid			2022-12-27	WOS:A1996VB68300051
J	Mo, JY; Schaaper, RM				Mo, JY; Schaaper, RM			Fidelity and error specificity of the alpha catalytic subunit of Escherichia coli DNA polymerase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUS MUTATION; REVERSE-TRANSCRIPTASE; BASE SUBSTITUTION; MISMATCH REPAIR; LACI GENE; PRONE REPLICATION; HOLOENZYME; EXONUCLEASE; MUTAGENESIS; MECHANISMS	Escherichia coli DNA polymerase III holoenzyme is the replicative enzyme primarily responsible for the duplication of the E. coli chromosome. This process occurs with high accuracy, less than 10(-9) to 10(-10) errors being committed per base pair per round of replication. As a first step in understanding the mechanisms responsible for the high fidelity of this process, we have purified the polymerase III alpha catalytic subunit, free of exonuclease activity, and analyzed its fidelity in vitro. We employed a newly developed gap-filling assay using the N-terminal 250 bases of the loci gene as a forward mutational target. When synthesizing across this target, alpha subunit produced mutations at a frequency of 0.6%. DNA sequencing revealed that the mutants created in vitro consisted mostly of frameshift mutations, although some base substitutions were also observed, The frameshifts, occurring at more than 120-fold above the background, consisted largely of -1 deletions. Among them, about 80% were the deletion of a purine template base with a pyrimidine 5'-neighbor, These results suggest that the alpha subunit (i) has a relatively low ability to extend from misincorporated bases, accounting for the low level of observed base substitutions, and (ii) has a relatively high capability of extension after misalignment of a misincorporated base on the next (complementary) template base, accounting for the high level of frameshift mutations. This model is supported by an experiment in which alpha subunit was required to initiate DNA synthesis from a terminal mispair in a sequence context that allowed slippage on the next template base. Among the products of this reaction, frameshifts outnumbered base pair substitutions by greater than 70-fold. A comparison to in vivo mutational spectra suggests that the pol III accessory factors may play a major role in modulating the fidelity of DNA synthesis.	NIEHS, MOL GENET LAB, NIH, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Schaaper, Roel M/E-6680-2019	Schaaper, Roel M/0000-0003-1344-3196				BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; CAI H, 1995, J BIOL CHEM, V270, P15327, DOI 10.1074/jbc.270.25.15327; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CARRAWAY M, 1990, MOL MICROBIOL, V4, P1645, DOI 10.1111/j.1365-2958.1990.tb00541.x; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; ECHOLS H, 1983, P NATL ACAD SCI-BIOL, V80, P2189, DOI 10.1073/pnas.80.8.2189; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; FERSHT AR, 1981, P NATL ACAD SCI-BIOL, V78, P4251, DOI 10.1073/pnas.78.7.4251; Fijalkowska IJ, 1996, P NATL ACAD SCI USA, V93, P2856, DOI 10.1073/pnas.93.7.2856; HUYNH TV, 1985, DNA CLONING, V1, P56; JOYCE CM, 1992, J BIOL CHEM, V267, P24485; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kornberg A., 1992, DNA REPLICATION, P165; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1989, MOL CELL BIOL, V9, P4447, DOI 10.1128/MCB.9.10.4447; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MAKI H, 1991, J BIOL CHEM, V266, P5055; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI H, 1988, J BIOL CHEM, V263, P6570; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; OLLER AR, 1994, GENETICS, V138, P263; OLLER AR, 1992, P NATL ACAD SCI USA, V89, P11036, DOI 10.1073/pnas.89.22.11036; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAAPER RM, 1991, GENETICS, V129, P317; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; SCHAAPER RM, 1985, GENE, V39, P181, DOI 10.1016/0378-1119(85)90312-9; SCHAAPER RM, 1986, J MOL BIOL, V189, P273, DOI 10.1016/0022-2836(86)90509-7; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; SCHAAPER RM, 1993, GENETICS, V134, P1031; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; STREISINGER G, 1985, GENETICS, V109, P633; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YU H, 1992, J BIOL CHEM, V267, P10888	58	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18947	18953		10.1074/jbc.271.31.18947	http://dx.doi.org/10.1074/jbc.271.31.18947			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702558	hybrid			2022-12-27	WOS:A1996VB68300096
J	Channareddy, S; Jose, SS; Eryomin, VA; Rubin, E; Taraschi, TF; Janes, N				Channareddy, S; Jose, SS; Eryomin, VA; Rubin, E; Taraschi, TF; Janes, N			Saturable ethanol binding in rat liver microsomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONELECTROLYTE PARTITION; MEMBRANES; WATER; COEFFICIENTS; LIPOSOMES	The binding of ethanol to rat liver microsomes is shown to be saturable at clinically relevant ethanol concentrations, whereas this effect is not observed in extracted microsomal phospholipids. Brief exposure of the microsomes to heat abolishes saturable ethanol binding. Equilibrium binding data analysis, although only approximate in this context, suggests the presence of at least two groups of specific sites: high capacity sites with affinities near the pharmacological range and low capacity sites at lesser levels. The results indicate that the specificity of ethanol for tissue is considerably greater than previously recognized.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186, K21AA000163] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07215, AA07186, AA00163] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bennett J., 1985, NEUROTRANSMITTER REC, V2nd, P61; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DEITRICH RA, 1989, PHARMACOL REV, V41, P489; DEPIERRE JW, 1977, ANNU REV BIOCHEM, V46, P201, DOI 10.1146/annurev.bi.46.070177.001221; Dubey AK, 1996, BIOPHYS J, V70, P2307, DOI 10.1016/S0006-3495(96)79796-5; ELLINGSON JS, 1991, BIOCHIM BIOPHYS ACTA, V1062, P199, DOI 10.1016/0005-2736(91)90393-M; ELMAGHRABI EA, 1992, P NATL ACAD SCI USA, V89, P4329, DOI 10.1073/pnas.89.10.4329; HOEK JB, 1992, FASEB J, V6, P2386, DOI 10.1096/fasebj.6.7.1563591; JANES N, 1992, BIOCHEMISTRY-US, V31, P9467, DOI 10.1021/bi00154a020; JOLY JG, 1973, BIOCHEM PHARMACOL, V22, P1532, DOI 10.1016/0006-2952(73)90334-1; Kates M, 1986, LAB TECHNIQUES BIOCH, V3; KATZ Y, 1974, J MEMBRANE BIOL, V17, P87, DOI 10.1007/BF01870174; KATZ Y, 1974, J MEMBRANE BIOL, V17, P69, DOI 10.1007/BF01870173; KATZ Y, 1974, J MEMBRANE BIOL, V17, P101, DOI 10.1007/BF01870175; KLOTZ IM, 1982, SCIENCE, V217, P1247, DOI 10.1126/science.6287580; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; Lieber C. S., 1992, MED NUTR COMPLICATIO; NILSSON R, 1973, J CELL BIOL, V56, P762, DOI 10.1083/jcb.56.3.762; OMURA T, 1964, J BIOL CHEM, V239, P2379; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; TARASCHI TF, 1985, BIOCHEMISTRY-US, V24, P7096, DOI 10.1021/bi00346a012; TARASCHI TF, 1985, LAB INVEST, V52, P120	22	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17625	17628		10.1074/jbc.271.30.17625	http://dx.doi.org/10.1074/jbc.271.30.17625			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663606	hybrid			2022-12-27	WOS:A1996UY93500009
J	OFlaherty, JT; Kuroki, M; Nixon, AB; Wijkander, J; Yee, E; Lee, SL; Smitherman, PK; Wykle, RL; Daniel, LW				OFlaherty, JT; Kuroki, M; Nixon, AB; Wijkander, J; Yee, E; Lee, SL; Smitherman, PK; Wykle, RL; Daniel, LW			5-oxo-eicosanoids and hematopoietic cytokines cooperate in stimulating neutrophil function and the mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYLMETHIONYL-LEUCYL-PHENYLALANINE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PHORBOL-MYRISTATE ACETATE; TUMOR-NECROSIS-FACTOR; MAP KINASE; TYROSINE PHOSPHORYLATION; 5-OXO-6,8,11,14-EICOSATETRAENOIC ACID; 5-LIPOXYGENASE PRODUCTS; ALVEOLAR MACROPHAGES; LEUKOTRIENES	The newly defined eicosatetraenoates (ETEs), 5-oxoETE and 5-oxo-15(OH)-ETE, share structural motifs, synthetic origins, and bioactions with leukotriene B-4 (LTB(4)). All three eicosanoids stimulate Ca2+ transients and chemotaxis in human neutrophils (PMN). However, unlike LTB(4), 5-oxoETE and 5-oxo-15(OH)-ETE alone cause little degranulation and no superoxide anion production. However, we show herein that, in PMN pretreated with granulocyte-macrophage or granulocyte colony-stimulating factor (GM-CSF or G-CSF), the oxoETEs become potent activators of the last responses. The oxoETEs also induce translocation of secretory vesicles from the cytosol to the plasmalemma, an effect not requiring cytokine priming. To study the mechanism of PMN activation in response to the eicosanoids, we examined the activation of mitogen-activated protein kinase (MAPK) and cytosolic phospholipase A(2) (cPLA(2)). PMN expressed three proteins (40, 42, and 44 kDa) that reacted with anti MAPK antibodies. The oxoETEs, LTB(4), GM-CSF, and G-CSF all stimulated PMN to activate the MAPKs and cPLA(2), as defined by shifts in these proteins' electrophoretic mobility and tyrosine phosphorylation of the MAPKs. However, the speed and duration of the MAPK response varied markedly depending on the stimulus. 5-OxoETE caused a very rapid and transient activation of MAPK. In contrast, the response to the cytokines was rather slow and persistent. PMN pretreated with GM-CSF demonstrated a dramatic increase in the extent of MAPK tyrosine phosphorylation and electrophoretic mobility shift in response to 5-oxoETE. Similarly, 5-oxoETE induced PMN to release some preincorporated [C-14]arachidonic acid, while GM-CSF greatly enhanced the extent of this release. Thus, the synergism exhibited by these agents is prominent at the level of MAPK stimulation and phospholipid deacylation. Pertussis toxin, but not Ca2+ depletion, inhibited MAPK responses to 5-oxoETE and LTB(4), indicating that responses to both agents are coupled through G proteins but not dependent upon Ca2+ transients. 15-OxoETE and 15(OH)-ETE were inactive while 5-oxo-15(OH)-ETE and 5(OH)-ETE had 3- and 10-fold less potency than 5-oxoETE, indicating a rather strict structural specificity for the 5-keto group. LY 255283, a LTB(4) antagonist, blocked the responses to LTB(4) but not to 5-oxoETE. Therefore, the oxoETEs do not appear to operate through the LTB(4) receptor. In summary, the oxoETEs are potent activators of PMN that share some but not all activities with LTB(4). The response to the oxoETEs is greatly enhanced by pretreatment with cytokines, indicating that combinations of these mediators may be very important in the pathogenesis of inflammation.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center			Nixon, Andrew/AAJ-4712-2020	Nixon, Andrew/0000-0003-3971-2964; wijkander, jonny/0000-0002-2310-9039	NHLBI NIH HHS [HL-26257, HL-27799] Funding Source: Medline; NIAID NIH HHS [AI-17287] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026257, R01HL027799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017287] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTIONE C, 1992, BIOCHIM BIOPHYS ACTA, V1128, P139; BASHEY A, 1994, BLOOD, V83, P949, DOI 10.1182/blood.V83.4.949.bloodjournal834949; BILLAH MM, 1985, J BIOL CHEM, V260, P6899; BORREGAARD N, 1992, J CLIN INVEST, V90, P86, DOI 10.1172/JCI115860; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; COPAS JL, 1982, PROSTA LEUKOTR MED, V8, P105, DOI 10.1016/S0262-1746(82)80002-4; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P403; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GOMEZCAMBRONERO J, 1993, BIOCHEM J, V291, P211, DOI 10.1042/bj2910211; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; JOHNSON GM, 1995, J LEUKOCYTE BIOL, V57, P692, DOI 10.1002/jlb.57.4.692; KEPPLER D, 1992, REV PHYSIOL BIOCH P, V121, P1, DOI 10.1007/BFb0033192; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MAELO PE, 1989, PROSTAGLANDINS, V37, P539; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; OFLAHERTY JT, 1988, J IMMUNOL, V140, P4323; OFLAHERTY JT, 1990, J CELL PHYSIOL, V142, P299, DOI 10.1002/jcp.1041420212; OFLAHERTY JT, 1982, LAB INVEST, V47, P314; OFLAHERTY JT, 1993, BIOCHEM BIOPH RES CO, V192, P129, DOI 10.1006/bbrc.1993.1391; OFLAHERTY JT, 1994, BBA-GEN SUBJECTS, V1201, P505, DOI 10.1016/0304-4165(94)90083-3; OFLAHERTY JT, 1992, BIOCHEM J, V288, P241, DOI 10.1042/bj2880241; OFLAHERTY JT, 1993, J BIOL CHEM, V268, P14708; OHTA S, 1992, EUR J BIOCHEM, V206, P895, DOI 10.1111/j.1432-1033.1992.tb16998.x; OKUDA K, 1992, BLOOD, V79, P2880; PACEASCIAK CR, 1991, ADV EXP MED BIOL, V314, P133; PALMANTIER R, 1994, LAB INVEST, V70, P696; PETERS SP, 1982, J IMMUNOL, V129, P797; POWELL WS, 1994, BIOCHEMISTRY-US, V33, P3927, DOI 10.1021/bi00179a019; POWELL WS, 1994, J BIOL CHEM, V269, P25373; POWELL WS, 1993, J BIOL CHEM, V268, P9280; POWELL WS, 1992, J BIOL CHEM, V267, P19233; POWELL WS, 1995, J IMMUNOL, V154, P4123; PUERINGER RJ, 1992, J APPL PHYSIOL, V73, P781, DOI 10.1152/jappl.1992.73.2.781; RAFIEE P, 1995, J IMMUNOL, V154, P4785; RAINES MA, 1992, BLOOD, V79, P3350; RESICK MB, 1993, AM J RESPIR CELL MOL, V8, P349; ROBINSON DS, 1993, THORAX, V48, P845, DOI 10.1136/thx.48.8.845; ROLLET E, 1994, J IMMUNOL, V153, P353; ROSSI AG, 1991, LIPIDS, V26, P1184, DOI 10.1007/BF02536528; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAITO H, 1985, PROSTA LEUKOTR MED, V18, P271, DOI 10.1016/0262-1746(85)90059-9; SALARI H, 1985, J EXP MED, V162, P1904, DOI 10.1084/jem.162.6.1904; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHWENK U, 1992, J BIOL CHEM, V267, P12482; STERN A, 1991, ADV EXP MED BIOL, V314, P103; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; THOMPSON HL, 1994, J BIOL CHEM, V269, P9486; TORRES M, 1993, J IMMUNOL, V150, P1563; WATERMAN WH, 1995, BIOCHEM J, V307, P39, DOI 10.1042/bj3070039; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; YOSS EB, 1990, AM J RESP CELL MOL, V2, P69, DOI 10.1165/ajrcmb/2.1.69; YUO A, 1993, BIOCHIM BIOPHYS ACTA, V1156, P197, DOI 10.1016/0304-4165(93)90136-V	62	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17821	17828		10.1074/jbc.271.30.17821	http://dx.doi.org/10.1074/jbc.271.30.17821			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663432	hybrid			2022-12-27	WOS:A1996UY93500038
J	Park, CT; Wright, SD				Park, CT; Wright, SD			Plasma lipopolysaccharide-binding protein is found associated with a particle containing apolipoprotein A-I, phospholipid, and factor H-related proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT FACTOR-H; HIGH-DENSITY LIPOPROTEINS; (LPS)-BINDING PROTEIN; MOLECULAR-CLONING; SERUM; CD14; NEUTROPHIL; ENDOTOXIN; LPS; VESICLES	Neutrophils exhibit a dramatic enhancement of integrin-mediated cell adhesion in response to lipopolysaccharide (LPS). This response requires CD14 on the neutrophil and plasma proteins in solution, We have purified the factor from plasma that facilitates the adhesive response of neutrophil to LPS by using a combination of affinity and ion-exchange chromatography. Previous work has shown that the activity is associated with apolipoprotein A-I (apoA-I), and here we show that this activity is associated with an apoA-I-bearing complex of protein and phospholipid, Native polyacrylamide gel electrophoresis (PAGE) analysis showed a ladder of bands in the M(r) 200,000 region, and electron microscopy revealed round, indented particles of 11.4 +/- 0.12 nm in diameter. Characterization of these particles revealed a density of 1.219-1.264 g/ml and similar to 10 molecules of lipid phosphate per M(r) 200,000 complex, SDS-PAGE showed that each of the bands seen in native PAGE was composed of several polypeptides. These were identified as apoA-I, LPS binding protein (LBP), and factor H-related proteins (FHRPs), Physical association of apoA-I, LBP, and FHRP in these particles was further confirmed using double immunodiffusion, and association of LBP and FHRP in plasma was confirmed by coimmunoprecipitation, FHRPs are the numerically dominant protein components in these particles, and all plasma FHRP-1 appears to be associated with these particles. We suggest that FHRPs may be the defining constituent of this novel ''lipoprotein'' particle.	ROCKEFELLER UNIV, CELLULAR PHYSIOL & IMMUNOL LAB, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT PEDIAT, NEW YORK, NY 10021 USA	Rockefeller University; Memorial Sloan Kettering Cancer Center					NIAID NIH HHS [AI-30556, AI-01333-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001333, R01AI030556] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES BN, 1960, J BIOL CHEM, V235, P769; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CALVANO SE, 1994, ARCH SURG-CHICAGO, V129, P220; DARR WH, 1985, J LIPID RES, V26, P672; DAY JR, 1994, J BIOL CHEM, V269, P9388; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; DETMERS PA, 1994, J IMMUNOL, V153, P2137; ESTALLER C, 1991, J IMMUNOL, V146, P3190; FONTAINE M, 1989, BIOCHEM J, V258, P927, DOI 10.1042/bj2580927; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAJDUK SL, 1989, J BIOL CHEM, V264, P5210; HASLETT C, 1987, AM REV RESPIR DIS, V136, P9, DOI 10.1164/ajrccm/136.1.9; IIDA M, 1994, BIOCHEM BIOPH RES CO, V203, P1295, DOI 10.1006/bbrc.1994.2323; JAESCHKE H, 1991, AM J PHYSIOL, V261, pG1051, DOI 10.1152/ajpgi.1991.261.6.G1051; Mills G. L., 1984, LABORATORY TECHNIQUE, P18; MORISAKI T, 1991, CLIN IMMUNOL IMMUNOP, V61, P365, DOI 10.1016/S0090-1229(05)80008-X; MUTA T, 1991, J BIOL CHEM, V266, P6554; ORAM JF, 1981, J BIOL CHEM, V256, P8348; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; POLZ E, 1979, FEBS LETT, V102, P183, DOI 10.1016/0014-5793(79)80955-2; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SCHWAEBLE W, 1991, IMMUNOBIOLOGY, V182, P307, DOI 10.1016/S0171-2985(11)80665-0; SKERKA C, 1991, J BIOL CHEM, V266, P12015; SKERKA C, 1992, J IMMUNOL, V148, P3313; SKERKA C, 1993, J BIOL CHEM, V268, P2904; SMITH AB, 1995, SCIENCE, V268, P284, DOI 10.1126/science.7716520; TALL AR, 1983, J LIPID RES, V24, P277; TIMMANN C, 1991, J IMMUNOL, V146, P1265; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; VANKESSEL KPM, 1994, J IMMUNOL METHODS, V172, P25; VEZINA CA, 1988, J LIPID RES, V29, P573; WRIGHT SD, 1992, J EXP MED, V176, P719, DOI 10.1084/jem.176.3.719; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025; WURM H, 1984, INT J BIOCHEM, V16, P511, DOI 10.1016/0020-711X(84)90168-X; ZIPFEL PF, 1994, IMMUNOL TODAY, V15, P121, DOI 10.1016/0167-5699(94)90155-4	40	83	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18054	18060		10.1074/jbc.271.30.18054	http://dx.doi.org/10.1074/jbc.271.30.18054			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663389	hybrid			2022-12-27	WOS:A1996UY93500070
J	Kralli, A; Yamamoto, KR				Kralli, A; Yamamoto, KR			An FK506-sensitive transporter selectively decreases intracellular levels and potency of steroid hormones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; GLUCOCORTICOID RECEPTOR; MULTIDRUG-RESISTANCE; SACCHAROMYCES-CEREVISIAE; MDR-GENE; MINERALOCORTICOID RECEPTOR; CYCLOSPORINE-A; FK506; YEAST; EXPRESSION	Steroid hormones bind and activate intracellular receptors that are ligand-regulated transcription factors. Mammalian steroid receptors can confer hormone-dependent transcriptional enhancement when expressed in yeast, thereby enabling the genetic identification of nonreceptor proteins that function in the hormone signal transduction pathway. Pdr5p (Lem1/Sts/Ydr1p), a yeast ATP-binding cassette transporter, selectively decreases the intracellular levels of particular steroid hormones, indicating that active processes can affect the passage of steroids across biological membranes. In yeast, the immunosuppressive drug FK506 inhibited Pdr5p, thereby potentiating activation of the glucocorticoid receptor by dexamethasone, a Ligand that is exported by Pdr5p. In mammalian L929 cells but not in HeLa cells, FK506 potentiated dexamethasone responsiveness and increased dexamethasone accumulation, without altering the hormone-binding properties of the glucocorticoid receptor. We suggest that an FK506-sensitive transporter in L929 cells selectively decreases intracellular hormone levels and, consequently, the potency of particular steroids. Thus, steroid transporters may modulate, in a cell-specific manner, an initial step in signaling, the availability of hormone to the receptor.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	Kralli, A (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT CELLULAR & MOLEC PHARMACOL, SAN FRANCISCO, CA 94143 USA.							ALLERA A, 1992, J STEROID BIOCHEM, V42, P737, DOI 10.1016/0960-0760(92)90115-Y; ARAI K, 1995, STEROIDS, V60, P173, DOI 10.1016/0039-128X(94)00007-Y; ARCECI RJ, 1992, BLOOD, V80, P1528; BACKMAN L, 1994, TRANSPLANTATION, V57, P519; BALZI E, 1994, J BIOL CHEM, V269, P2206; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; BOURGEOIS S, 1993, MOL ENDOCRINOL, V7, P840, DOI 10.1210/me.7.7.840; BRONNEGARD M, 1995, J STEROID BIOCHEM, V52, P345, DOI 10.1016/0960-0760(94)00178-O; CHILDS S, 1995, CANCER RES, V55, P2029; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; EGNER R, 1995, MOL CELL BIOL, V15, P5879; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GARABEDIAN MJ, 1992, MOL BIOL CELL, V3, P1245, DOI 10.1091/mbc.3.11.1245; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROSS SR, 1970, J CELL BIOL, V44, P103, DOI 10.1083/jcb.44.1.103; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; KOMESAROFF PA, 1994, J CLIN ENDOCR METAB, V79, P27, DOI 10.1210/jc.79.1.27; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; KUCHLER K, 1992, P NATL ACAD SCI USA, V89, P2302, DOI 10.1073/pnas.89.6.2302; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; MURLAS C, 1982, J APPL PHYSIOL, V52, P1084, DOI 10.1152/jappl.1982.52.4.1084; NAITO M, 1992, CANCER CHEMOTH PHARM, V29, P195, DOI 10.1007/BF00686252; NING YM, 1993, J BIOL CHEM, V268, P6073; NORDEEN SK, 1994, ENDOCRINOLOGY, V134, P1723, DOI 10.1210/en.134.4.1723; OVERDUIN P, 1988, MOL MICROBIOL, V2, P767, DOI 10.1111/j.1365-2958.1988.tb00088.x; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; RAO US, 1994, MOL PHARMACOL, V45, P773; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RENOIR JM, 1995, P NATL ACAD SCI USA, V92, P4977, DOI 10.1073/pnas.92.11.4977; Ribeiro RCJ, 1996, J BIOL CHEM, V271, P17147, DOI 10.1074/jbc.271.29.17147; SAEKI T, 1993, J BIOL CHEM, V268, P6077; SCHINKEL AH, 1995, J CLIN INVEST, V96, P1698, DOI 10.1172/JCI118214; SHEPPARD KE, 1994, J STEROID BIOCHEM, V48, P337, DOI 10.1016/0960-0760(94)90073-6; SIKORSKI RS, 1989, GENETICS, V122, P19; TAI PKK, 1994, BIOCHEMISTRY-US, V33, P10666, DOI 10.1021/bi00201a014; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; UEDA K, 1992, J BIOL CHEM, V267, P24248; VANKALKEN CK, 1993, BRIT J CANCER, V67, P284, DOI 10.1038/bjc.1993.54; VIVANCO MD, 1995, EMBO J, V14, P2217, DOI 10.1002/j.1460-2075.1995.tb07216.x; VOGEL JP, 1993, J BIOL CHEM, V268, P3040; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; YEM AW, 1992, J BIOL CHEM, V267, P2868; ZENNARO MC, 1994, J CLIN ENDOCR METAB, V79, P32, DOI 10.1210/jc.79.1.32	48	111	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17152	17156		10.1074/jbc.271.29.17152	http://dx.doi.org/10.1074/jbc.271.29.17152			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663352	hybrid			2022-12-27	WOS:A1996UX94300028
J	Leonova, T; Qi, XY; Bencosme, A; Ponce, E; Sun, Y; Grabowski, GA				Leonova, T; Qi, XY; Bencosme, A; Ponce, E; Sun, Y; Grabowski, GA			Proteolytic processing patterns of prosaposin in insect and mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOLIPID ACTIVATOR PROTEIN-2; LYSOSOMAL PROTECTIVE PROTEIN; MESSENGER-RNA; METACHROMATIC LEUKODYSTROPHY; SULFATIDE ACTIVATOR; BETA-GLUCOSIDASE; GAUCHER DISEASE; VARIANT FORM; GENE; SAP-2	Prosaposin is a multifunctional protein encoded at a single locus in humans and mice. The precursor contains, in tandem, four glycoprotein activators or saposins, termed A, B, C, and D, that are essential for specific glycosphingolipid hydrolase activities. Prosaposin appears to be a potent neurotrophic factor, To explore the proteolytic processing from prosaposin to mature activator proteins, metabolic labeling was done with human prosaposin expressed in insect cells, human fibroblasts, neuronal stem cells (NT2) and retinoic acid-differentiated NT2 neurons. In all cell types, the major processing pathway was through a tetrasaposin, A-B-C-D, from which saposin A was then removed. In mammalian cells monosaposins were derived from the trisaposin B-C-D by cleavage 60 the disaposins, B-C and C-D, that were processed to monosaposins. In insect cells the major end products were the disaposins, with A-B and C-D derived from the tetrasaposin, A-B-C-D, or with B-C and C-D derived from the trisaposin, B-C-D. In insect and mammalian cells, the nonsignal NH2-terminal peptide preceding saposin A (termed Nter) was usually removed prior to saposin A cleavage, In NH2-derived differentiated neurons, precursor tetrasaposins containing A-B-C-D were secreted with and without Nter. Immunofluorescence studies using prosaposin-specific antisera showed large steady state amounts of uncleaved prosaposin in Purkinje cells, cortical neurons, and other specific cell types in adult mice. These studies indicate that prosaposin processing is highly regulated at a proteolytic level to produce prosaposin, tetrasaposins, or mature monosaposins in specific mammalian cells.	CHILDRENS HOSP,MED CTR,DIV HUMAN GENET,RES FDN,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation					NINDS NIH HHS [NS 34071] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034071] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; COLLARD MW, 1988, BIOCHEMISTRY-US, V27, P4557, DOI 10.1021/bi00412a050; FUJIBAYASHI S, 1985, AM J HUM GENET, V37, P741; FUJIBAYASHI S, 1986, BIOCHIM BIOPHYS ACTA, V875, P554; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GALJART NJ, 1991, J BIOL CHEM, V266, P14754; GAVRIELIRORMAN E, 1989, GENOMICS, V5, P486; GAVRIELIRORMAN E, 1992, GENOMICS, V13, P312; Harlow E., 1988, ANTIBODIES LAB MANUA; HINENO T, 1991, BIOCHEM BIOPH RES CO, V176, P668, DOI 10.1016/S0006-291X(05)80236-0; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V304, P110, DOI 10.1006/abbi.1993.1328; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V303, P326, DOI 10.1006/abbi.1993.1291; INUI K, 1985, HUM GENET, V69, P197, DOI 10.1007/BF00293023; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; KONDOH K, 1993, J COMP NEUROL, V334, P590, DOI 10.1002/cne.903340407; KONDOH K, 1991, BIOCHEM BIOPH RES CO, V181, P286, DOI 10.1016/S0006-291X(05)81415-9; KOTANI Y, 1996, IN PRESS J NEUROCHEM; LEE VMY, 1986, J NEUROSCI, V6, P514; MORIMOTO S, 1988, BIOCHEM BIOPH RES CO, V156, P403, DOI 10.1016/S0006-291X(88)80855-6; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; MORIMOTO S, 1990, P NATL ACAD SCI USA, V87, P3493, DOI 10.1073/pnas.87.9.3493; MORREAU H, 1992, J BIOL CHEM, V267, P17949; MUNFORD RS, 1995, J LIPID RES, V36, P1653; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1995, FASEB J, V9, P681, DOI 10.1096/fasebj.9.8.7768361; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; QI XY, 1994, J BIOL CHEM, V269, P16746; Qi XY, 1996, J BIOL CHEM, V271, P6874, DOI 10.1074/jbc.271.12.6874; RAFI MA, 1990, BIOCHEM BIOPH RES CO, V166, P1017, DOI 10.1016/0006-291X(90)90912-7; RAFI MA, 1993, SOMAT CELL MOLEC GEN, V19, P1, DOI 10.1007/BF01233949; REINER O, 1989, J MOL NEUROSCI, V1, P225; SANDHOFF K, 1995, METABOLIC MOL BASES, P2427; SANO A, 1992, BIOCHIM BIOPHYS ACTA, V1120, P75, DOI 10.1016/0167-4838(92)90426-E; SCHNABEL D, 1992, J BIOL CHEM, V267, P3312; SCHNABEL D, 1991, FEBS LETT, V284, P57, DOI 10.1016/0014-5793(91)80760-Z; SPRECHERLEVY H, 1993, CELL MOL BIOL, V39, P287; SUMMERS MD, 1987, TEX AGR EXP STA B, V1555, P5; SUN Y, 1994, AM J PATHOL, V145, P1390; VACCARO AM, 1995, J BIOL CHEM, V270, P9953, DOI 10.1074/jbc.270.17.9953; Xu YH, 1996, PEDIATR RES, V39, P313, DOI 10.1203/00006450-199602000-00021; ZHANG XL, 1991, HUM GENET, V87, P211, DOI 10.1007/BF00204185; ZHANG XL, 1990, P NATL ACAD SCI USA, V87, P1426, DOI 10.1073/pnas.87.4.1426	46	74	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17312	17320		10.1074/jbc.271.29.17312	http://dx.doi.org/10.1074/jbc.271.29.17312			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663398	hybrid			2022-12-27	WOS:A1996UX94300052
J	Klarlund, JK; Cherniack, AD; McMahon, M; Czech, MP				Klarlund, JK; Cherniack, AD; McMahon, M; Czech, MP			Role of the Raf/mitogen-activated protein kinase pathway in p21(ras) desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; RAS; GRB2; GROWTH; PHOSPHORYLATION; TRANSFORMATION; RECEPTOR; BINDING; DOMAIN; SH2	Desensitization of p21(ras) after stimulation of cells by growth factors and phorbol 12-myristate 13-acetate (PMA) correlates with hyperphosphorylation of the guanine nucleotide exchange factor Son-of-sevenless (Sos) and its dissociation from the adaptor protein Grb2 (Cherniack, A., Klarlund, J. K., Conway, B. R., and Czech, M. P. (1995) J. Biol. Chem. 270, 1485-1488). To test the role of the Raf/mitogen-activated protein (MAP) kinase pathway, we utilized cells expressing a chimera composed of the catalytic domain of p74Raf-1 and the hormone binding domain of the estradiol receptor (Delta Raf-1:ER), Estradiol markedly stimulated Delta Raf-1:ER and the downstream MEK and MAP kinases in these cells as well as Sos phosphorylation, However, the dissociation of Grb2 from Sos observed in response to PMA was not apparent upon Delta Raf-1:ER activation, Furthermore, stimulation of Delta Raf-1:ER did not impair GTP loading of p21(ras) in response to platelet derived growth factor or epidermal growth factor, We conclude that activation of the Raf/MAP kinase pathway alone in these cells is insufficient to cause disassembly of Sos from Grb2 or to interrupt the ability of Sos to catalyze activation of p21(ras).	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304	University of Massachusetts System; University of Massachusetts Worcester; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Klarlund, JK (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.		Cherniack, Andrew D./AAY-8132-2020; McMahon, Martin/L-3303-2013	Cherniack, Andrew D./0000-0003-0470-0111; McMahon, Martin/0000-0003-2812-1042	NIDDK NIH HHS [DK 30648] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FINGAR DC, 1994, ENDOCRINOLOGY, V134, P728, DOI 10.1210/en.134.2.728; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARUTA H, 1994, BIOESSAYS, V16, P489, DOI 10.1002/bies.950160708; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; OSTEROP APRM, 1993, EUR J BIOCHEM, V212, P477, DOI 10.1111/j.1432-1033.1993.tb17684.x; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; VANDENBERGHE N, 1994, MOL CELL BIOL, V14, P2372, DOI 10.1128/MCB.14.4.2372; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WEISMULLER L, 1994, CELL SIGNAL, V6, P247; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421	44	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16674	16677		10.1074/jbc.271.28.16674	http://dx.doi.org/10.1074/jbc.271.28.16674			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663295	hybrid			2022-12-27	WOS:A1996UX12600041
J	Weinberg, DH; Sirinathsinghji, DJS; Tan, CP; Shiao, LL; Morin, N; Rigby, MR; Heavens, RH; Rapoport, DR; Bayne, ML; Cascieri, MA; Strader, CD; Linemeyer, DL; MacNeil, DJ				Weinberg, DH; Sirinathsinghji, DJS; Tan, CP; Shiao, LL; Morin, N; Rigby, MR; Heavens, RH; Rapoport, DR; Bayne, ML; Cascieri, MA; Strader, CD; Linemeyer, DL; MacNeil, DJ			Cloning and expression of a novel neuropeptide Y receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; PEPTIDE-YY; BRAIN	The neuropeptide Y family of peptides, which includes neuropeptide Y (NPY), peptide YY (PYY), and pancreatic polypeptide (PP), are found in the central and peripheral nervous system and display a wide array of biological activities. These actions are believed to be mediated through pharmacologically distinct G protein-coupled receptors, and, to date, three members of the NPY receptor family have been cloned. In this study we describe the cloning and expression of a novel NPY receptor from mouse genomic DNA. This receptor, designated NPY Y5, shares 60% amino acid identity to the murine NPY Y1 receptor. The pharmacology of this novel receptor resembles that of the NPY Y1 receptor and is distinct from that described for the NPY Y2, Y3, and Y4 receptors. In situ hybridization of mouse brain sections reveals expression of this receptor within discrete regions of the hypothalamus including the suprachiasmatic nucleus, anterior hypothalamus, bed nucleus stria terminalis, and the ventromedial nucleus with no localization apparent elsewhere in the brain.			Weinberg, DH (corresponding author), MERCK & CO INC,MERCK SHARP & DOHME RES LABS,DEPT MOLEC PHARMACOL & BIOCHEM,POB 2000,R80M-213,RAHWAY,NJ 07065, USA.			MacNeil, Doug/0000-0001-7089-0668				AKABAYASHI A, 1994, MOL BRAIN RES, V21, P55, DOI 10.1016/0169-328X(94)90377-8; ALLEN YS, 1983, SCIENCE, V221, P877, DOI 10.1126/science.6136091; BALLANTYNE GH, 1993, AM J PHYSIOL, V264, pG848, DOI 10.1152/ajpgi.1993.264.5.G848; BARD JA, 1995, J BIOL CHEM, V270, P26762, DOI 10.1074/jbc.270.45.26762; CASCIERI MA, 1992, MOL PHARMACOL, V42, P458; EVA C, 1992, FEBS LETT, V314, P285, DOI 10.1016/0014-5793(92)81490-D; EVA C, 1990, FEBS LETT, V271, P81, DOI 10.1016/0014-5793(90)80377-U; FUHLENDORFF J, 1990, P NATL ACAD SCI USA, V87, P182, DOI 10.1073/pnas.87.1.182; GERALD C, 1995, J BIOL CHEM, V270, P26758, DOI 10.1074/jbc.270.45.26758; GRUNDEMAR L, 1991, J PHARMACOL EXP THER, V258, P633; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LUNDELL I, 1995, J BIOL CHEM, V270, P29123, DOI 10.1074/jbc.270.49.29123; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; QUIN JA, 1995, J SURG RES, V58, P111, DOI 10.1006/jsre.1995.1018; ROSE PM, 1995, J BIOL CHEM, V270, P22661, DOI 10.1074/jbc.270.39.22661; SIRINATHSINGHJI DJS, 1995, NEUROSCIENCE, V65, P51, DOI 10.1016/0306-4522(94)00485-N; SIRINATHSINGHJI DS, 1993, MOL IMAGING NEUROSCI, P43; Stanley B.G., 1993, BIOL NEUROPEPTIDE RE, P457, DOI [10.1007/978-1-59259-465-8_11, DOI 10.1007/978-1-59259-465-8_11]; STANLEY BG, 1985, P NATL ACAD SCI USA, V82, P3940, DOI 10.1073/pnas.82.11.3940; STANLEY BG, 1993, BRAIN RES, V604, P304; STANLEY BG, 1992, PEPTIDES, V13, P581, DOI 10.1016/0196-9781(92)90093-I; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167-0115(86)90048-0; WAHLESTEDT C, 1993, ANN REV PHARM TOXICO, V32, P309	26	242	262	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16435	16438		10.1074/jbc.271.28.16435	http://dx.doi.org/10.1074/jbc.271.28.16435			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663568				2022-12-27	WOS:A1996UX12600002
J	Lee, WJ; Hawkins, RA; Peterson, DR; Vina, JR				Lee, WJ; Hawkins, RA; Peterson, DR; Vina, JR			Role of oxoproline in the regulation of neutral amino acid transport across the blood-brain barrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYL-TRANSPEPTIDASE; TRANSFERASE TRANSPEPTIDASE; ENDOTHELIAL-CELLS; MEMBRANE-VESICLES; PLASMA-MEMBRANE; SYSTEM; RAT; GLUTAMYLTRANSFERASE; GLUTATHIONE; LOCALIZATION	Regulation of neutral amino acid transport was studied using isolated plasma membrane vesicles derived from the bovine blood-brain barrier, Neutral amino acids cross the blood-brain barrier by facilitative transport system L1, which may allow both desirable and undesirable amino acids to enter the brain, The sodium-dependent amino acid systems A and B-o,B-+ are located exclusively on abluminal membranes, in a position to pump unwanted amino acids out, gamma-Glutamyl transpeptidase, the first enzyme of the gamma-glutamyl cycle, is an integral protein of the luminal membrane of the blood-brain barrier, We demonstrate that oxoproline, an intracellular product of the gamma-glutamyl cycle, stimulates the sodium-dependent systems A and B-o,B-+ by 70 and 20%, respectively. Study of system A showed that 2 mM oxoproline increased the affinity for its specific substrate N-methylaminoisobutyrate by 50%. This relationship between the activity of the gamma-glutamyl cycle and system A transport may provide a short term regulatory mechanism by which the entry of potentially deleterious amino acids (i.e. neurotransmitters or their precursors) may be retarded and their removal from brain accelerated.	FINCH UNIV HLTH SCI CHICAGO MED SCH, DEPT PHYSIOL & BIOPHYS, N CHICAGO, IL 60064 USA; UNIV VALENCIA, MOL FAC MED & FARM, DEPT BIOQUIM & BIOL, VALENCIA 46010, SPAIN	Chicago Medical School; University of Valencia			Viña, Juan R/ABE-5698-2021	Viña, Juan R/0000-0002-4035-3615	NINDS NIH HHS [NS31017] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031017] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLISON RD, 1981, J BIOL CHEM, V256, P2988; BARKER GA, 1990, EXP PHYSIOL, V75, P3, DOI 10.1113/expphysiol.1990.sp003382; BELL JG, 1987, J COMP PHYSIOL B, V157, P161, DOI 10.1007/BF00692360; BETZ AL, 1980, BRAIN RES, V192, P17, DOI 10.1016/0006-8993(80)91004-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANCILLA PA, 1983, J NEUROPATH EXP NEUR, V42, P191, DOI 10.1097/00005072-198303000-00008; CHRISTENSEN HN, 1989, METHOD ENZYMOL, V173, P576; CHRISTENSEN HN, 1965, J BIOL CHEM, V240, P3609; COTGREAVE IA, 1994, BBA-MOL CELL RES, V1222, P375, DOI 10.1016/0167-4889(94)90043-4; CURTO KA, 1988, J HISTOCHEM CYTOCHEM, V36, P159, DOI 10.1177/36.2.2891746; DELPINO MMS, 1992, J BIOL CHEM, V267, P25951; DELPINO MMS, 1995, J BIOL CHEM, V270, P14907, DOI 10.1074/jbc.270.25.14907; DELPINO MMS, 1995, J BIOL CHEM, V270, P14913, DOI 10.1074/jbc.270.25.14913; GARVEY TQ, 1976, GASTROENTEROLOGY, V71, P778; GRAMMAS P, 1992, NEUROPHARMACOLOGY, V31, P409, DOI 10.1016/0028-3908(92)90075-Z; HAWKINS RA, 1986, FASEB J, V45, P2055; HSU BYL, 1984, J MEMBRANE BIOL, V80, P167, DOI 10.1007/BF01868772; KILBERG MS, 1986, TRENDS BIOCHEM SCI, V11, P183, DOI 10.1016/0968-0004(86)90138-6; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; LASH LH, 1984, J BIOL CHEM, V259, P4508; LAUTERBURG BH, 1979, GASTROENTEROLOGY, V77, pA24; MACDONALD RC, 1994, BBA-BIOMEMBRANES, V1191, P362, DOI 10.1016/0005-2736(94)90187-2; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTER A, 1973, SCIENCE, V180, P33, DOI 10.1126/science.180.4081.33; MEISTER A, 1983, METABOLIC BASIS INHE, P348; MUNCK LK, 1992, BIOCHIM BIOPHYS ACTA, V1116, P91, DOI 10.1016/0304-4165(92)90104-3; ORLOWSKI M, 1970, P NATL ACAD SCI USA, V67, P1248, DOI 10.1073/pnas.67.3.1248; OXENDER DL, 1963, J BIOL CHEM, V238, P3686; PAYNE GM, 1984, BIOCHEM J, V218, P147, DOI 10.1042/bj2180147; PELLEFIGUE F, 1976, BIOCHEM BIOPH RES CO, V73, P997, DOI 10.1016/0006-291X(76)90221-7; PUENTE IR, 1979, FEBS LETT, V126, P250; SACKS W, 1982, J NEUROSCI RES, V7, P431, DOI 10.1002/jnr.490070409; SCHENERMAN MA, 1986, BIOCHIM BIOPHYS ACTA, V856, P428, DOI 10.1016/0005-2736(86)90133-1; SEPULVEDA FV, 1982, BIOCHEM J, V208, P509, DOI 10.1042/bj2080509; SHOTWELL MA, 1981, J BIOL CHEM, V256, P5422; SMITH QR, 1991, ADV EXP MED BIOL, V291, P55; SMITH QR, 1987, J NEUROCHEM, V49, P1651, DOI 10.1111/j.1471-4159.1987.tb01039.x; STRAUSS G, 1986, BIOCHIM BIOPHYS ACTA, V858, P169, DOI 10.1016/0005-2736(86)90303-2; SWEIRY JH, 1995, J PHYSIOL-LONDON, V485, P167, DOI 10.1113/jphysiol.1995.sp020721; VANDERWE.P, 1974, P NATL ACAD SCI USA, V71, P1026; VANDERWERF P, 1975, ADV ENZYMOL RAMB, V43, P519; VINA J, 1981, BIOCHEM J, V194, P99, DOI 10.1042/bj1940099; VINA JR, 1989, AM J PHYSIOL, V257, pE916, DOI 10.1152/ajpendo.1989.257.6.E916; VINA JR, 1990, FEBS LETT, V269, P86, DOI 10.1016/0014-5793(90)81125-8; VINA JR, 1985, BIOL NEONATE, V48, P250, DOI 10.1159/000242178; VINA JR, 1981, BIOCHEM J, V200, P705, DOI 10.1042/bj2000705	47	41	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19129	19133		10.1074/jbc.271.32.19129	http://dx.doi.org/10.1074/jbc.271.32.19129			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702588	hybrid			2022-12-27	WOS:A1996VB68400022
J	Murray, RC; Williams, FMR; Flintoff, WF				Murray, RC; Williams, FMR; Flintoff, WF			Structural organization of the reduced folate carrier gene in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN KB CELLS; BINDING-PROTEIN; METHOTREXATE UPTAKE; MOLECULAR-CLONING; LEUKEMIA-CELLS; GENOMIC ORGANIZATION; TRANSPORT-DEFICIENT; MEMBRANE CARRIER; CDNA; DNA	The reduced folate carrier gene (rfc) encodes a putative protein that is involved in the intracellular accumulation of folates. In this report, we describe the organization of the I fe gene from Chinese hamster ovary cells. The hamster rfc gene contains ? exons and 6 introns, which span 15.3 kilobases. It codes for two alternatively spliced messenger RNAs, one that, contains all 7 exons and one that lacks exon 2 but contains the remaining 6 exons. The transcriptional start of the gene has been mapped to six sites approximately 200 base pairs upstream of the putative ATG initiation codon. The promoter region has no TATA box-like sequence but contains a consensus Spl binding site, This is the first report of the genomic structure of the reduced folate carrier gene from any species.	UNIV WESTERN ONTARIO, DEPT MICROBIOL & IMMUNOL, LONDON, ON N6A 5C1, CANADA	Western University (University of Western Ontario)								ANTONY AC, 1985, J BIOL CHEM, V260, P4911; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CHAN FPH, 1995, CYTOGENET CELL GENET, V71, P148, DOI 10.1159/000134095; CONEY LR, 1991, CANCER RES, V51, P6125; DEUTSCH JC, 1989, ARCH BIOCHEM BIOPHYS, V274, P327, DOI 10.1016/0003-9861(89)90446-3; DIXON KH, 1994, J BIOL CHEM, V269, P17; ELWOOD PC, 1986, J BIOL CHEM, V261, P5416; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FAN JG, 1991, J BIOL CHEM, V266, P14862; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLINTOFF WF, 1976, IN VITRO CELL DEV B, V12, P749, DOI 10.1007/BF02835450; FLINTOFF WF, 1976, SOMAT CELL GENET, V2, P245, DOI 10.1007/BF01538963; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; JANSEN G, 1989, CANCER RES, V49, P1959; KANE MA, 1989, LAB INVEST, V60, P737; KANE MA, 1986, J BIOL CHEM, V261, P44; KANE MA, 1986, J BIOL CHEM, V261, P5625; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LEIBBRANDT MEI, 1994, CELL GROWTH DIFFER, V5, P17; MATHERLY LH, 1994, BIOCHEM PHARMACOL, V47, P1094, DOI 10.1016/0006-2952(94)90423-5; MATHERLY LH, 1992, J BIOL CHEM, V267, P23253; MATHERLY LH, 1991, CANCER RES, V51, P3420; MOSCOW JA, 1995, CANCER RES, V55, P3790; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P7853, DOI 10.1021/bi00420a040; RAGOUSSIS J, 1992, GENOMICS, V14, P423, DOI 10.1016/S0888-7543(05)80236-8; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SADASIVAN E, 1992, BIOCHIM BIOPHYS ACTA, V1131, P91, DOI 10.1016/0167-4781(92)90103-7; SADASIVAN E, 1994, J BIOL CHEM, V269, P4725; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; UNDERHILL TM, 1989, MOL CELL BIOL, V9, P1754, DOI 10.1128/MCB.9.4.1754; UNDERHILL TM, 1989, SOMAT CELL MOLEC GEN, V15, P49, DOI 10.1007/BF01534669; UNDERHILL TM, 1992, SOMAT CELL MOLEC GEN, V18, P337, DOI 10.1007/BF01235757; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468	41	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19174	19179		10.1074/jbc.271.32.19174	http://dx.doi.org/10.1074/jbc.271.32.19174			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702595	hybrid			2022-12-27	WOS:A1996VB68400029
J	Prado, GN; Suzuki, H; Wilkinson, N; Cousins, B; Navarro, J				Prado, GN; Suzuki, H; Wilkinson, N; Cousins, B; Navarro, J			Role of the C terminus of the interleukin 8 receptor in signal transduction and internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINUS; AMINO TERMINUS; DESENSITIZATION; PHOSPHORYLATION; EXPRESSION; PROTEIN; SITES; BETA; IL-8	Interleukin 8 (IL-8) is a potent neutrophil chemoattractant and activator. Two IL-8 receptor subtypes, A and B, are expressed in neutrophils. In this work, we analyzed the role of the C terminus domain of the IL-8 receptor on the signal transduction and receptor internalization mechanisms, The IL-8 receptor A was tagged with an epitope corresponding to the monoclonal antibody 1D4 to monitor the, localization of the IL-8 receptor, We demonstrated IL-S-dependent. receptor internalization by monitoring the density of surface I-125-labeled IL-8 binding sites and by immunofluorescence microscopy, Truncation of the last 27 amino acids of the IL-8 receptor A severely impaired the IL-8-induced internalization of the receptor. Of importance was tire observation that binding of IL-8 to receptors A and B triggered a dramatically faster rate of internalization of receptor B than receptor A, suggesting that the heterologous C termini among receptor subtypes modulate the rate of internalization of IL-8 receptors. However, substitution of the C terminus of the receptor subtype A for the C terminus of receptor B reduced the internalization rate of receptor A. Furthermore, we found that the rate of internalization of IL-8 receptor B triggered by IL-8 was faster than the one induced by the IL-S-related peptide, melanoma growth stimulatory activity, Studies with human neutrophils pretreated with 100 nM IL-8 for 5 min revealed a positive and a negative calcium response mediated by receptors A and B, respectively. In contrast, neutrophils pretreated with melanoma growth stimulatory activity showed positive calcium responses to both receptors A and B. These data suggest that the neutrophil responses mediated by IL-8 are modulated by the rate of internalization of receptors.			Prado, GN (corresponding author), UNIV TEXAS, MED BRANCH, SEALY CTR MOL SCI, DEPT PHYSIOL & BIOPHYS, RT F0641, GALVESTON, TX 77555 USA.			Navarro, Javier/0000-0001-7098-4373	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034031] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI34031] Funding Source: Medline; NIA NIH HHS [AG00115] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENBARUCH A, 1995, J BIOL CHEM, V270, P9121, DOI 10.1074/jbc.270.16.9121; BLOUNT P, 1993, J BIOL CHEM, V268, P16388; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LEE J, 1992, J BIOL CHEM, V267, P16283; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; MACKENZIE D, 1984, BIOCHEMISTRY-US, V23, P6544, DOI 10.1021/bi00321a041; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PRADO GN, 1994, J BIOL CHEM, V269, P12391; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SUZUKI H, 1994, J BIOL CHEM, V269, P18263; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207	23	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19186	19190		10.1074/jbc.271.32.19186	http://dx.doi.org/10.1074/jbc.271.32.19186			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702597	hybrid			2022-12-27	WOS:A1996VB68400031
J	Bedoyan, JK; Lejnine, S; Makarov, VL; Langmore, JP				Bedoyan, JK; Lejnine, S; Makarov, VL; Langmore, JP			Condensation of rat telomere-specific nucleosomal arrays containing unusually short DNA repeats and histone H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-ORDER STRUCTURE; CHROMATIN STRUCTURE; SACCHAROMYCES-CEREVISIAE; LINKER LENGTH; CEREBRAL-CORTEX; UNIT LENGTH; ORGANIZATION; PROTEIN; FORMALDEHYDE; SEQUENCE	Vertebrate telomeres contain arrays of nucleosomes with unusually short and regular repeat lengths (Makarov, V. L., Lejnine, S., Bedoyan, J,, and Langmore, J. P. (1993) Cell 73, 775-787; Lejnine, S., Makarov, V,, and Langmore, J. P, (1995) Proc, Natl. Acad. Sci. U. S. A. 92, 2393-2397), In order to better define the specific structural features of telomere chromatin, we examined the condensation and H1 content of telomere nucleoproteins from rat liver, Velocity sedimentation analysis shows that telomeric nucleosome arrays condense with increasing ionic strength and molecular weight in a manner comparable with that of bulk chromatin despite the very short repeat length. However, these condensed structures do not exhibit the similar to 100-base pair deoxyribonuclease II repeat characteristic of condensed bulk chromatin, Frictional coefficient calculations suggest that telomere-specific higher order structure is more compact than bulk chromatin. Nucleoprotein gel electrophoresis shows that telomeric dinucleosomes from soluble chromatin contain H1, Finally, direct isolation and analysis of telomere nucleoproteins from formaldehyde-cross-linked nuclei indicate the presence of core histone proteins and H1, These results are consistent with the view that a major fraction of the long telomeres of rat are organized as specialized nucleosome arrays with features similar but not identical to those of bulk chromatin.	UNIV MICHIGAN, DIV BIOPHYS RES, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, GRAD PROGRAM CELLULAR & MOL BIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT BIOL SCI, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007315] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM07315] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1984, J CELL BIOL, V98, P1320, DOI 10.1083/jcb.98.4.1320; ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; ALTENBURGER W, 1976, NATURE, V264, P517, DOI 10.1038/264517a0; ATHEY BD, 1990, J CELL BIOL, V111, P795, DOI 10.1083/jcb.111.3.795; BAVYKIN SG, 1990, J MOL BIOL, V212, P495, DOI 10.1016/0022-2836(90)90328-J; BIROC SL, 1976, BIOCHEMISTRY-US, V15, P1440, DOI 10.1021/bi00652a014; BLACKBURN EH, 1991, TRENDS BIOCHEM SCI, V16, P378, DOI 10.1016/0968-0004(91)90155-O; BLACKBURN EH, 1981, P NATL ACAD SCI-BIOL, V78, P2263, DOI 10.1073/pnas.78.4.2263; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRADBURY EM, 1975, EUR J BIOCHEM, V57, P97, DOI 10.1111/j.1432-1033.1975.tb02280.x; BUTLER PJG, 1980, J MOL BIOL, V140, P505, DOI 10.1016/0022-2836(80)90268-5; BUTLER PJG, 1984, EMBO J, V3, P2599, DOI 10.1002/j.1460-2075.1984.tb02180.x; CANTOR CR, 1980, BIOPHYSICAL CHEM 1, P220; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P608; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; CHUNG HMM, 1990, EMBO J, V9, P2611, DOI 10.1002/j.1460-2075.1990.tb07443.x; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; COLES LS, 1987, J BIOL CHEM, V262, P9656; FAJKUS J, 1995, MOL GEN GENET, V247, P633, DOI 10.1007/BF00290355; FOE VE, 1985, J CELL BIOL, V100, P1623, DOI 10.1083/jcb.100.5.1623; GOTTSCHLING DE, 1984, CELL, V38, P501, DOI 10.1016/0092-8674(84)90505-1; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HORZ W, 1980, J MOL BIOL, V144, P329, DOI 10.1016/0022-2836(80)90094-7; HORZ W, 1980, J MOL BIOL, V144, P305, DOI 10.1016/0022-2836(80)90093-5; HUANG SY, 1989, METHOD ENZYMOL, V170, P116; JACKSON V, 1981, CELL, V23, P121, DOI 10.1016/0092-8674(81)90277-4; JACKSON V, 1978, CELL, V15, P945, DOI 10.1016/0092-8674(78)90278-7; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEJNINE S, 1995, P NATL ACAD SCI USA, V92, P2393, DOI 10.1073/pnas.92.6.2393; LENNOX RW, 1984, J BIOL CHEM, V259, P669; LOUTERS L, 1985, BIOCHEMISTRY-US, V24, P3080, DOI 10.1021/bi00334a002; LOWARY PT, 1989, P NATL ACAD SCI USA, V86, P8266, DOI 10.1073/pnas.86.21.8266; MAKAROV VL, 1993, CELL, V73, P775, DOI 10.1016/0092-8674(93)90256-P; MCCARTY KS, 1974, ANAL BIOCHEM, V61, P165, DOI 10.1016/0003-2697(74)90343-1; MCCARTY KS, 1968, ANAL BIOCHEM, V24, P314, DOI 10.1016/0003-2697(68)90185-1; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; MITA K, 1981, BIOPOLYMERS, V20, P1103, DOI 10.1002/bip.1981.360200602; MORRIS NR, 1976, CELL, V8, P357; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; MUYLDERMANS S, 1994, NUCLEIC ACIDS RES, V22, P5635, DOI 10.1093/nar/22.25.5635; NIMMO ER, 1994, EMBO J, V13, P3801, DOI 10.1002/j.1460-2075.1994.tb06691.x; NOLL H, 1967, NATURE, V215, P360, DOI 10.1038/215360a0; OSIPOVA TN, 1980, EUR J BIOCHEM, V113, P183; PEARSON EC, 1983, EMBO J, V2, P1367, DOI 10.1002/j.1460-2075.1983.tb01593.x; PEARSON EC, 1984, EUR J BIOCHEM, V144, P353, DOI 10.1111/j.1432-1033.1984.tb08471.x; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; PENNINGS S, 1992, NUCLEIC ACIDS RES, V20, P6667, DOI 10.1093/nar/20.24.6667; RAWLINS DJ, 1991, CHROMOSOMA, V100, P424, DOI 10.1007/BF00364552; SILVER JC, 1979, BIOCHIM BIOPHYS ACTA, V561, P261, DOI 10.1016/0005-2787(79)90509-4; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; STARLING JA, 1990, NUCLEIC ACIDS RES, V18, P6881, DOI 10.1093/nar/18.23.6881; THOMAS JO, 1976, FEBS LETT, V66, P274, DOI 10.1016/0014-5793(76)80521-2; THOMAS JO, 1977, CELL, V10, P633, DOI 10.1016/0092-8674(77)90096-4; THOMAS JO, 1980, J MOL BIOL, V144, P89, DOI 10.1016/0022-2836(80)90215-6; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; VANHOLDE KE, 1989, CHROMATIN, P90; VARSHAVSKY AJ, 1976, NUCLEIC ACIDS RES, V3, P477, DOI 10.1093/nar/3.2.477; VICENZ C, 1992, THESIS U MICHIGAN AN; VINCENZ C, 1991, NUCLEIC ACIDS RES, V19, P1325, DOI 10.1093/nar/19.6.1325; WILLIAMS SP, 1991, BIOPHYS J, V59, P606, DOI 10.1016/S0006-3495(91)82276-7; WILLIAMS SP, 1986, BIOPHYS J, V49, P233, DOI 10.1016/S0006-3495(86)83637-2; WORKMAN JL, 1985, BIOCHEMISTRY-US, V24, P4731, DOI 10.1021/bi00339a004; WRIGHT JH, 1995, NUCLEIC ACIDS RES, V23, P1454, DOI 10.1093/nar/23.9.1454; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	72	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18485	18493		10.1074/jbc.271.31.18485	http://dx.doi.org/10.1074/jbc.271.31.18485			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702494	hybrid			2022-12-27	WOS:A1996VB68300032
J	Holthuis, JCM; Jansen, EJR; Martens, GJM				Holthuis, JCM; Jansen, EJR; Martens, GJM			Secretogranin III is a sulfated protein undergoing proteolytic processing in the regulated secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE CONVERTASE PC2; CHROMOGRANIN-A; XENOPUS-LAEVIS; PEPTIDE; CELLS; 7B2; DOPAMINE; VESICLES; SEQUENCE; GRANULE	Secretogranin III (SgIII) is an acidic protein of unknown function that is present in the storage vesicles of many neuroendocrine cells, It is coexpressed with the prohormone proopiomelanocortin in the intermediate pituitary of Xenopus laevis, We developed an antiserum to investigate the biosynthesis of SgIII in pulse-chase incubated Xenopus neurointermediate lobes, SgIII was synthesized as a 61- or 63-kDa (N-glycosylated) protein and processed to a 48-kDa form which, in turn, was partially cleaved to fragments of 28 and 20 kDa, The 48-, 28-, and 20-kDa cleavage products, but not their precursors, were secreted, This secretion is regulated and can be blocked in parallel with that of proopiomelanocortin-derived peptides by the hypothalamic factors dopamine, gamma-aminobutyric acid, and neuropeptide Y. Coexpression of Xenopus SgIII with prohormone convertase (PC)1 or PC2 in transfected fibroblasts was sufficient to reconstitute the processing events observed in the neurointermediate lobes, Site-directed mutagenesis revealed that Xenopus SgIII is cleaved at two dibasic sites, namely Lys(68)-Arg(69) and Arg(237)-Arg(238), Pulse-chase incubations of lobes with Na-2[S-35]SO4 showed that SgIII is sulfated in the trans-Golgi network before it is processed, Finally, SgIII processing was found in several neuroendocrine cell types from various species, We conclude that SgIII is a precursor protein and that the intact molecule can only have an intracellular function, whereas an extracellular role can only be attributed to its cleavage products.	UNIV NIJMEGEN,DEPT ANIM PHYSIOL,NL-6525 ED NIJMEGEN,NETHERLANDS	Radboud University Nijmegen			Jansen, Eric J.R./A-3158-2013; Holthuis, Joost/AAL-9157-2020; Martens, Gerard JM/D-1925-2010	Holthuis, Joost/0000-0001-8912-1586				BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; BRAKS JAM, 1992, FEBS LETT, V305, P45, DOI 10.1016/0014-5793(92)80652-W; CREEMERS JWM, 1992, FEBS LETT, V300, P82, DOI 10.1016/0014-5793(92)80169-H; DERIJK EPCT, 1992, J NEUROSCI, V12, P864; DEVAULT A, 1983, J BIOL CHEM, V259, P5146; GALINDO E, 1991, P NATL ACAD SCI USA, V88, P1426, DOI 10.1073/pnas.88.4.1426; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALBAN PA, 1994, BIOCHEM J, V299, P1; HOLTHUIS JCM, 1995, J CELL SCI, V108, P3295; HOLTHUIS JCM, 1996, IN PRESS J NEUROCHEM; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HUTTNER WB, 1995, CURR BIOL, V5, P242, DOI 10.1016/S0960-9822(95)00049-2; KINGSLEY DM, 1990, EMBO J, V9, P395, DOI 10.1002/j.1460-2075.1990.tb08123.x; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MARTENS GJM, 1985, J BIOL CHEM, V260, P3685; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; OTTIGER HP, 1990, J NEUROSCI, V10, P3135; SARIA A, 1993, NEUROSCIENCE, V54, P1, DOI 10.1016/0306-4522(93)90377-R; SEIDAH NG, 1994, METHOD ENZYMOL, V244, P175; SIGAFOOS J, 1993, J ANAT, V183, P253; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; TOOZE SA, 1991, J CELL BIOL, V115, P1491, DOI 10.1083/jcb.115.6.1491; VERBURGVANKEMENADE BML, 1986, BRAIN RES BULL, V17, P697, DOI 10.1016/0361-9230(86)90203-0; VERBURGVANKEMENADE BML, 1987, PEPTIDES, V8, P61, DOI 10.1016/0196-9781(87)90166-5; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	32	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17755	17760		10.1074/jbc.271.30.17755	http://dx.doi.org/10.1074/jbc.271.30.17755			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663421	Green Published, hybrid			2022-12-27	WOS:A1996UY93500028
J	Thompson, SA; Harris, A; Hoang, DE; Ferrer, M; Johnson, GR				Thompson, SA; Harris, A; Hoang, DE; Ferrer, M; Johnson, GR			COOH-terminal extended recombinant amphiregulin with bioactivity comparable with naturally derived growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; HUMAN GASTRIC CARCINOMAS; FACTOR RECEPTOR; FACTOR-ALPHA; IMMUNOHISTOCHEMICAL DETECTION; ESCHERICHIA-COLI; HEPARAN-SULFATE; FACTOR FAMILY; EXPRESSION; BINDING	The mature secreted form of the epidermal growth factor (EGF) receptor ligand amphiregulin (AR) is reported to be an 84-amino acid residue polypeptide, which is generated by proteolytic processing of a 252-amino acid precursor. This form of recombinant AR (rAR84) and two forms with COOH-terminal extensions corresponding to sequences from the AR precursor (rAR87 and rAR92) were expressed at high levels in Escherichia coli, oxidized to the correct disulfide arrangement, and purified to homogeneity. rAR84 competed poorly for binding of radiolabeled EGF to the EGF receptor and had little ability to stimulate growth of Balb/c/3T3 cells. In striking contrast, rAR87 and rAR92 possessed 42- and 20-fold greater receptor binding activity and 55- and 14-fold greater bioactivity, respectively. Furthermore, addition of the COOH-terminal four amino acids from transforming growth factor cu to the COOH terminus of rAR84 improved the activity of rAR84 by 100- and 1000-fold, respectively, in these assays. rAR87 was found to have similar to 32% of the specific activity of natural AR from MCF-7 cells when compared in two different bioassays. These findings strongly suggest that the 84-amino acid sequence is not the correct structure of the naturally occurring secreted form of AR and that natural AR contains additional amino acid residues at the COOH-terminal end.	BERLEX BIOSCI,DEPT PROT CHEM & BIOPHYS,RICHMOND,CA 94804; NATL CTR TOXICOL RES,DEPT GENET TOXICOL,JEFFERSON,AR 72079; US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)								ADAM R, 1995, BBA-MOL CELL RES, V1266, P83, DOI 10.1016/0167-4889(94)00224-3; CARPENTER G, 1975, J BIOL CHEM, V250, P4297; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1992, CANCER RES, V52, P3224; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; EBERT M, 1994, CANCER RES, V54, P3959; HANIU M, 1993, BIOCHEMISTRY-US, V32, P2431, DOI 10.1021/bi00060a039; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; JOHNSON GR, 1991, BIOCHEM BIOPH RES CO, V180, P481, DOI 10.1016/S0006-291X(05)81090-3; JOHNSON GR, 1993, J BIOL CHEM, V268, P18835; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; JOHNSON GR, 1995, TRENDS GLYCOSCI GLYC, V7, P261; Kenney Nicholas, 1993, Molecular and Cellular Differentiation, V1, P163; KENNEY NJ, 1995, MOL REPROD DEV, V41, P277, DOI 10.1002/mrd.1080410302; KITADAI Y, 1993, JPN J CANCER RES, V84, P879, DOI 10.1111/j.1349-7006.1993.tb02061.x; LI SW, 1992, J CELL PHYSIOL, V153, P103, DOI 10.1002/jcp.1041530114; LYSIAK JJ, 1995, PLACENTA, V16, P359, DOI 10.1016/0143-4004(95)90093-4; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MARTINEZLACACI I, 1995, ENDOCRINOLOGY, V136, P3983, DOI 10.1210/en.136.9.3983; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; NORMANNO N, 1993, INT J ONCOL, V2, P903; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; SAEKI T, 1992, CANCER RES, V52, P3467; SAEKI T, 1994, INT J ONCOL, V5, P215; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SPEAR KL, 1991, TECHNIQUES PROTEIN C, V2, P233; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; VLAHOS CJ, 1991, J BIOL CHEM, V266, P10070; WOODWORTH CD, 1995, P NATL ACAD SCI USA, V92, P2840, DOI 10.1073/pnas.92.7.2840; YOKOYAMA M, 1995, INT J ONCOL, V6, P625	40	19	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17927	17931		10.1074/jbc.271.30.17927	http://dx.doi.org/10.1074/jbc.271.30.17927			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663535	hybrid			2022-12-27	WOS:A1996UY93500052
J	Chon, SY; Hassanain, HH; Gupta, SL				Chon, SY; Hassanain, HH; Gupta, SL			Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma-inducible expression of human indoleamine 2,3-dioxygenase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDIA-PSITTACI REPLICATION; OXIDE SYNTHASE GENE; HUMAN-FIBROBLASTS; DIFFERENTIAL REGULATION; TRYPTOPHAN CATABOLISM; BINDING PROTEIN; INDUCTION; MECHANISM; ALPHA; LIPOPOLYSACCHARIDE	Interferon (IFN)-gamma induces the expression of the indoleamine 2,3-dioxygenase (INDO) gene in human cells, which plays a role in the inhibitory effect of IFN-gamma on intracellular pathogens and on cell proliferation, Earlier studies established that the IFN-gamma-inducible expression of the INDO gene was dependent on two upstream elements: (i) a 14-base pair sequence homologous to an interferon-stimulated response element (ISRE) sequence found in IFN-alpha-inducible genes and (ii) a 9-base pair palindromic sequence (palindromic element (PE) II) homologous to an interferon-gamma-activated site (GAS) element found in IFN-gamma-inducible genes. A second GAS element (PE I), between ISRE and PE II, was ineffective in supporting a response to IFN-gamma, Studies were carried out to determine the distinction between the two GAS elements and the relative role of the two elements (ISRE and PE II) required for a response to IFN-gamma. The PE I element was able to form a complex with IFN-gamma-activated p91 (STAT1) factor but with lower efficiency than the complex formed with PE II sequence. However, switching the positions of PE I and II sequences in reporter plasmid constructs (containing chloramphenicol acetyltransferase gene) showed that both PE I and PE II were able to support a response to IFN-gamma if located at the position of PE II but not at the position of PE I. Increasing the distance between the ISRE and PE II also affected the level of response, suggesting that the relative position of the two elements is important for optimal stimulus. To explore whether an interaction between the IFN-gamma-regulated factors (IRF-1 and p91) binding to the ISRE and PE II might be important, we tested whether the ISRE sequence could be replaced by another response element, NF-kappa B. The plasmid construct with NF-kappa B element in place of the ISRE was responsive to IFN-gamma, indicating that an interaction between the IRF-1 and p91 factors was not required. The results indicate that the response of INDO gene to IFN-gamma depends on a cooperative role of IFN-gamma-responsive factors binding to the ISRE and GAS elements.	HIPPLE CANC RES CTR,DAYTON,OH 45439						NCI NIH HHS [CA-29991] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029991] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baron S, 1992, INTERFERON PRINCIPLE; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRNE GI, 1986, INFECT IMMUN, V53, P347, DOI 10.1128/IAI.53.2.347-351.1986; CAPLEN HS, 1988, J BIOL CHEM, V263, P332; CARLIN JM, 1989, J INTERFERON RES, V9, P329, DOI 10.1089/jir.1989.9.329; CHON SY, 1995, J INTERF CYTOK RES, V15, P517, DOI 10.1089/jir.1995.15.517; DAI W, 1990, J BIOL CHEM, V265, P19871; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GUPTA SL, 1994, INFECT IMMUN, V62, P2277, DOI 10.1128/IAI.62.6.2277-2284.1994; HABARAOHKUBO A, 1993, INFECT IMMUN, V61, P1810, DOI 10.1128/IAI.61.5.1810-1813.1993; HASSANAIN HH, 1993, J BIOL CHEM, V268, P5077; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; OZAKI Y, 1988, P NATL ACAD SCI USA, V85, P1242, DOI 10.1073/pnas.85.4.1242; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PFEFFERKORN ER, 1986, J INTERFERON RES, V6, P267, DOI 10.1089/jir.1986.6.267; PFEFFERKORN ER, 1986, MOL BIOCHEM PARASIT, V20, P215, DOI 10.1016/0166-6851(86)90101-5; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEN GC, 1992, J BIOL CHEM, V267, P5017; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WRIGHT TM, 1991, J EXP MED, V173, P417, DOI 10.1084/jem.173.2.417; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	33	128	135	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17247	17252		10.1074/jbc.271.29.17247	http://dx.doi.org/10.1074/jbc.271.29.17247			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663541	hybrid			2022-12-27	WOS:A1996UX94300043
J	Hsieh, CM; Yoshizumi, M; Endege, WO; Kho, CJ; Jain, MK; Kashiki, S; delosSantos, R; Lee, WS; Perrella, MA; Lee, ME				Hsieh, CM; Yoshizumi, M; Endege, WO; Kho, CJ; Jain, MK; Kashiki, S; delosSantos, R; Lee, WS; Perrella, MA; Lee, ME			APEG-1, a novel gene preferentially expressed in aortic smooth muscle cells, is down-regulated by vascular injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL DISPLAY; PROTEIN-KINASE; MESSENGER-RNA; MYOD FAMILY; ATHEROSCLEROSIS; GROWTH; ATHEROGENESIS; PATHOGENESIS; ANGIOGENESIS; SYSTEMS	Despite the importance of phenotypic alterations in arterial smooth muscle cells (ASMC) during the pathogenesis of arteriosclerosis, little is known about genes that define differentiated ASMC. Using differential mRNA display, we isolated a novel gene preferentially expressed in the rat aorta and termed this gene APEG-1. The cDNA of rat APEG-1 contained an open reading frame encoding 113 amino acids, which would predict a basic protein of 12.7 kDa. The amino acid sequence of rat APEG-1 was highly conserved among human and mouse homologues (97 and 98% respectively). Using an APEG-1 fusion protein containing an N-terminal c-Myc tag, we identified APEG-1 as a nuclear protein. By in situ hybridization, APEG-1 mRNA was expressed in rat ASMC. Although APEG-1 was expressed highly in differentiated ASMC in vivo, its expression was quickly down-regulated and disappeared in dedifferentiated ASMC in culture. In vivo, APEG-1 mRNA levels decreased by more than 80% in response to vascular injury as ASMC changed from a quiescent to a proliferative phenotype. Taken together, these data indicate that APEG-1 is a novel marker for differentiated ASMC and may have a role in regulating growth and differentiation of this cell type.	HARVARD UNIV,SCH MED,CARDIOVASC BIOL LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV PULM,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital					NHLBI NIH HHS [KO8-HL03194] Funding Source: Medline; NIGMS NIH HHS [R01-GM53249] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CLAYCOMB WC, 1992, TRENDS CARDIOVAS MED, V2, P231, DOI 10.1016/1050-1738(92)90030-V; CLOWES AW, 1983, LAB INVEST, V49, P327; DUBAND JL, 1993, DIFFERENTIATION, V55, P1, DOI 10.1111/j.1432-0436.1993.tb00027.x; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1992, ADV EXP MED BIOL, V313, P355; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GORSKI DH, 1993, MOL CELL BIOL, V13, P3722, DOI 10.1128/MCB.13.6.3722; GORSKI DH, 1995, CARDIOVASC RES, V30, P585; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HASS TA, 1994, CURR OPIN CELL BIOL, V6, P656; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LEE WS, 1993, ENDOCRINOLOGY, V132, P2136, DOI 10.1210/en.132.5.2136; LI XM, 1994, J BIOL CHEM, V269, P19653; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIBBY P, 1991, LAB INVEST, V64, P5; MUNRO JM, 1988, LAB INVEST, V58, P249; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OSBOURN JK, 1995, GENE, V154, P249, DOI 10.1016/0378-1119(94)00847-L; OWENS GK, 1995, PHYSIOL REV, V75, P487; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PAULY RR, 1992, CIRCULATION, V86, P68; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; TAN MS, 1994, KIDNEY INT, V46, P690, DOI 10.1038/ki.1994.322; Tsai JC, 1996, J CLIN INVEST, V97, P146, DOI 10.1172/JCI118383; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WINDER SJ, 1991, ADV EXP MED BIOL, V304, P37; YANO H, 1995, J BIOL CHEM, V270, P23661, DOI 10.1074/jbc.270.40.23661; YOSHIZUMI M, 1995, J CLIN INVEST, V95, P2275, DOI 10.1172/JCI117918	39	37	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17354	17359		10.1074/jbc.271.29.17354	http://dx.doi.org/10.1074/jbc.271.29.17354			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663449	hybrid			2022-12-27	WOS:A1996UX94300058
J	Pisegna, JR; Wank, SA				Pisegna, JR; Wank, SA			Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor - Evidence for dual coupling to adenylate cyclase and phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; FUNCTIONAL EXPRESSION; G-PROTEINS; MOLECULAR-CLONING; BINDING-SITES; CELLS; PACAP; NEUROPEPTIDE; BRAIN; GLYCOSYLATION	Alternative splicing of two exons of the rat pituitary adenylate cyclase activating polypeptide (PACAP) receptor gene generates four major splice variants that are differentially expressed in specific tissues and variably coupled to intracellular second messengers, To evaluate the potential implications of these findings in human physiology, the human PACAP receptor gene was cloned, Alternative splicing about two exons of the gene allowed for four major splice variants that were subsequently identified on cDNA cloning. Each of the four splice variant cDNAs (null, SV-1, SV-2, and SV-3) was stably expressed in NIH/3T3 cells at similar receptor densities. For each splice variant, PACAP (both PACAP-38 and PACAP-27) had similar affinity and potency for stimulating either adenylate cyclase or phospholipase C. However, each receptor splice variant differed in their ligand-stimulated maximal response (efficacy) for total inositol phosphate accumulation with the SV-2 showing the greatest efficacy, followed by the null, SV-1, and SV-3 splice variants. Therefore, unlike the rat, PACAP binds and stimulates signal transduction with nearly equal affinity and potency for each of the receptor splice variants although with varying efficacy for the stimulation of phospholipase C. These results suggest a novel and potentially important mechanism for a single hormone to not only couple to dual signal transduction cascades but also elicit tissue-specific differential activation of phospholipase C in humans.	NIDDKD,NIH,DIGEST DIS BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)					NIDDK NIH HHS [P30 DK041301] Funding Source: Medline; RRD VA [I01 RX000194] Funding Source: Medline; BLRD VA [I01 BX004560] Funding Source: Medline; VA [5I01RX000194-03] Funding Source: Federal RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); RRD VA; BLRD VA; VA(US Department of Veterans Affairs)		ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CHOCHOLA J, 1993, J BIOL CHEM, V268, P2312; CHRISTOPHE J, 1993, BIOCHIM BIOPHYS ACTA, V1154, P183, DOI 10.1016/0304-4157(93)90011-C; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; GODFREY P, 1993, NAT GENET, V4, P227, DOI 10.1038/ng0793-227; HAGER J, 1995, NAT GENET, V9, P299, DOI 10.1038/ng0395-299; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; HOSHINO M, 1993, NEUROSCI LETT, V159, P35, DOI 10.1016/0304-3940(93)90792-J; HOSHINO M, 1993, INT S VAS INT PEPT P, P577; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; ISOBE K, 1993, ENDOCRINOLOGY, V132, P1757, DOI 10.1210/en.132.4.1757; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KOCH B, 1992, REGUL PEPTIDES, V38, P45, DOI 10.1016/0167-0115(92)90071-2; KUSUI T, 1994, BIOCHEMISTRY-US, V33, P12968, DOI 10.1021/bi00248a005; KYTE J, 1982, J MOL BIOL, V157, P106; LAM HC, 1990, EUR J BIOCHEM, V193, P725, DOI 10.1111/j.1432-1033.1990.tb19392.x; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; MOODY TW, 1993, PEPTIDES, V14, P241, DOI 10.1016/0196-9781(93)90036-G; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURTHY KS, 1994, J BIOL CHEM, V269, P15977; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; OGI K, 1993, BIOCHEM BIOPH RES CO, V196, P1511, DOI 10.1006/bbrc.1993.2423; PANDYA PK, 1994, BBA-MOL CELL RES, V1224, P117, DOI 10.1016/0167-4889(94)90119-8; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; RAWLINGS SR, 1995, ENDOCRINOLOGY, V136, P2088, DOI 10.1210/en.136.5.2088; ROBBERECHT P, 1991, FEBS LETT, V286, P133, DOI 10.1016/0014-5793(91)80958-6; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHOMERUS E, 1994, ENDOCRINOLOGY, V134, P315, DOI 10.1210/en.134.1.315; SCHWORER H, 1992, N-S ARCH PHARMACOL, V346, P511; SHEN ZX, 1992, CELL TISSUE RES, V269, P369, DOI 10.1007/BF00319630; SHIVERS BD, 1991, ENDOCRINOLOGY, V128, P3055, DOI 10.1210/endo-128-6-3055; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SUDA K, 1991, J CLIN ENDOCR METAB, V72, P958, DOI 10.1210/jcem-72-5-958; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; VARRAULT A, 1992, MOL PHARMACOL, V41, P999; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; YADA T, 1994, J BIOL CHEM, V269, P1290; ZHU X, 1994, MOL PHARMACOL, V46, P460	49	166	168	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17267	17274		10.1074/jbc.271.29.17267	http://dx.doi.org/10.1074/jbc.271.29.17267			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663363	Green Accepted, hybrid			2022-12-27	WOS:A1996UX94300046
J	Staels, B; Martin, G; Martinez, M; Albert, C; PeinadoOnsurbe, J; Saladin, R; Hum, DW; Reina, M; Vilaro, S; Auwerx, J				Staels, B; Martin, G; Martinez, M; Albert, C; PeinadoOnsurbe, J; Saladin, R; Hum, DW; Reina, M; Vilaro, S; Auwerx, J			Expression and regulation of the lipoprotein lipase gene in human adrenal cortex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SIDE-CHAIN CLEAVAGE; HEPARAN-SULFATE PROTEOGLYCANS; HORMONE-RECEPTOR SUPERFAMILY; STEROID HYDROXYLASE GENES; CAMP-RESPONSIVE ELEMENT; PROTEIN KINASE-A; MESSENGER-RNA; CYCLIC-AMP; TRANSCRIPTIONAL REGULATION	Lipoprotein lipase (LPL), an enzyme which hydrolyzes triglycerides and participates in the catabolism of remnant lipoproteins, plays a crucial role in energy and lipid metabolism, The goal of this study was to analyze the expression and regulation of the LPL gene in human adrenals, Reverse transcriptase-polymerase chain reaction amplification and sequence analysis demonstrated the presence of LPL mRNA in fetal and adult human adrenal cortex, Furthermore, the human adrenocortical carcinoma cell line, NCI-H295, expresses LPL mRNA and protein, which is localized to the outer cellular membrane as demonstrated by immunofluorescence confocal microscopy and can be released in the medium by heparin addition, To asses whether the LPL gene is regulated by agents regulating adrenal steroidogenesis, NCI-H295 cells were treated with activators of second messenger systems, Whereas the calcium-ionophore A23187 did not affect LPL gene expression, treatment with phorbol 12-myristate 13-acetate decreased LPL mRNA levels in a time- and dose-dependent manner. This decrease after phorbol 12-myristate 13-acetate was associated with diminished heparin-releasable LPL mass and activity in the culture medium, Addition of the cAMP analog 8-Br-cAMP to NCI-H295 cells resulted in a rapid, but transient dose-dependent induction of LPL mRNA, Treatment with the protein synthesis inhibitor cycloheximide gradually induced, whereas simultaneous addition of cAMP and cycloheximide superinduced LPL mRNA levels, Nuclear run-on analysis indicated that the effects of cAMP and cycloheximide occurred at the transcriptional and post-transcriptional level, respectively, Transient co-transfection assays demonstrated that the first 230 base pairs of the proximal LPL promoter contain a cAMP-responsive element activated by protein kinase A and transcription factors belonging to the CREB/CREM family, These data indicate that LPL is expressed in human adrenal cortex and regulated in NCI-H295 adrenocortical carcinoma cells by activators of the protein kinase A and protein kinase C second messenger pathways in a manner comparable to P450sec, which catalyzes the first step in adrenal steroidogenesis. These observations suggest a role for LPL in adrenal energy and/or lipid metabolism and possibly in steroidogenesis.	UNIV BARCELONA, DEPT CELL BIOL, E-08028 BARCELONA, SPAIN; UNIV BARCELONA, DEPT BIOCHEM & MOLEC BIOL, BARCELONA, SPAIN; CHU LAVAL, MOLEC ENDOCRINOL LAB, QUEBEC CITY, PQ G1V 4G2, CANADA	University of Barcelona; University of Barcelona; Laval University	Staels, B (corresponding author), INST PASTEUR, DEPT ATHEROSCLEROSE, U325 INSERM, 1 RUE CALMETTE, F-59019 LILLE, FRANCE.		Auwerx, Johan/ABE-9307-2021; Peinado-Onsurbe, Julia/A-4677-2016; Staels, Bart/N-9497-2016; Reina, Manuel/D-4655-2014	Peinado-Onsurbe, Julia/0000-0002-3880-5061; Staels, Bart/0000-0002-3784-1503; Reina, Manuel/0000-0002-0701-200X; Auwerx, Johan/0000-0002-5065-5393				AUWERX J, 1992, CRIT REV CL LAB SCI, V29, P243, DOI 10.3109/10408369209114602; AUWERX JH, 1989, BIOCHEMISTRY-US, V28, P4563, DOI 10.1021/bi00437a009; AUWERX JH, 1988, BIOCHEMISTRY-US, V27, P2651, DOI 10.1021/bi00408a003; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENSADOUN A, 1986, BIOCHIM BIOPHYS ACTA, V879, P253, DOI 10.1016/0005-2760(86)90214-6; BURGAYA F, 1989, BIOCHEM J, V259, P159, DOI 10.1042/bj2590159; BUSCA R, 1995, J LIPID RES, V36, P939; CARR BR, 1981, ENDOCR REV, V2, P306, DOI 10.1210/edrv-2-3-306; CHAJEK T, 1977, ATHEROSCLEROSIS, V26, P549, DOI 10.1016/0021-9150(77)90122-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; CLEMENS JW, 1994, ENDOCRINOLOGY, V134, P1499, DOI 10.1210/en.134.3.1499; DEEB SS, 1989, BIOCHEMISTRY-US, V28, P4132, DOI 10.1021/bi00436a001; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIBLASIO AM, 1987, J CLIN ENDOCR METAB, V65, P170; ECKEL RH, 1984, P NATL ACAD SCI-BIOL, V81, P7604, DOI 10.1073/pnas.81.23.7604; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FRIEDMAN G, 1992, BIOCHIM BIOPHYS ACTA, V1137, P237, DOI 10.1016/0167-4889(92)90207-R; GAFVELS M, 1991, J ENDOCRINOL, V129, P213, DOI 10.1677/joe.0.1290213; GAZDAR AF, 1990, CANCER RES, V50, P5488; GOLDBERG IJ, 1989, J LIPID RES, V30, P1569; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTODA T, 1989, NUCLEIC ACIDS RES, V17, P2351, DOI 10.1093/nar/17.6.2351; GUILLON G, 1995, ENDOCRINOLOGY, V136, P1285, DOI 10.1210/en.136.3.1285; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HASHIMOTO T, 1992, J BIOCHEM-TOKYO, V112, P573, DOI 10.1093/oxfordjournals.jbchem.a123941; HONDA S, 1993, J BIOL CHEM, V268, P7494; HONDA SI, 1990, J BIOCHEM-TOKYO, V108, P1042, DOI 10.1093/oxfordjournals.jbchem.a123303; ILLINGWORTH DR, 1983, METABOLISM, V32, P1045, DOI 10.1016/0026-0495(83)90075-6; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; JOHN ME, 1984, P NATL ACAD SCI-BIOL, V81, P5628, DOI 10.1073/pnas.81.18.5628; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KNOBLER H, 1984, BIOCHIM BIOPHYS ACTA, V795, P363, DOI 10.1016/0005-2760(84)90087-0; KOVANEN PT, 1979, ENDOCRINOLOGY, V104, P599, DOI 10.1210/endo-104-3-599; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LALLI E, 1994, J BIOL CHEM, V269, P17359; LAUE L, 1987, J CLIN ENDOCR METAB, V64, P531, DOI 10.1210/jcem-64-3-531; LEITERSDORF E, 1986, BIOCHIM BIOPHYS ACTA, V878, P320, DOI 10.1016/0005-2760(86)90239-0; LUND J, 1990, J BIOL CHEM, V265, P3304; MILLER WL, 1995, ADRENAL CORTEX; MOORE CCD, 1992, MOL ENDOCRINOL, V6, P2045, DOI 10.1210/me.6.12.2045; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; MULDER M, 1993, J BIOL CHEM, V268, P9369; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; NEVINS JR, 1987, METHOD ENZYMOL, V152, P234; ONG JM, 1992, MOL ENDOCRINOL, V6, P61, DOI 10.1210/me.6.1.61; PEINADOONSURBE J, 1992, BIOCHEMISTRY-US, V31, P10121, DOI 10.1021/bi00156a036; RAMIREZ I, 1985, BIOCHEM J, V232, P229, DOI 10.1042/bj2320229; REYLAND ME, 1993, MOL ENDOCRINOL, V7, P1021, DOI 10.1210/me.7.8.1021; RINGLER GE, 1989, MOL CELL ENDOCRINOL, V61, P13, DOI 10.1016/0303-7207(89)90185-8; RUMSEY SC, 1992, J CLIN INVEST, V90, P1504, DOI 10.1172/JCI116018; Santamarina-Fojo Silvia, 1994, Current Opinion in Lipidology, V5, P117; SCHOONJANS K, 1993, FEBS LETT, V329, P89, DOI 10.1016/0014-5793(93)80200-E; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; SPARKES R S, 1987, Genomics, V1, P138, DOI 10.1016/0888-7543(87)90005-X; STAELS B, 1993, MOL ENDOCRINOL, V7, P423, DOI 10.1210/me.7.3.423; STAELS B, 1992, DEVELOPMENT, V115, P1035; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TOKUNAGA K, 1987, CANCER RES, V47, P5616; VILELLA E, 1993, J LIPID RES, V34, P1555; WATANABE N, 1993, EUR J BIOCHEM, V214, P521, DOI 10.1111/j.1432-1033.1993.tb17950.x; WATANABE N, 1994, EUR J BIOCHEM, V222, P825, DOI 10.1111/j.1432-1033.1994.tb18929.x; WATERMAN MR, 1994, J BIOL CHEM, V269, P27783; WATERMAN MR, 1989, RECENT PROG HORM RES, V45, P533; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; WONG M, 1989, J BIOL CHEM, V264, P12867; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147	76	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17425	17432		10.1074/jbc.271.29.17425	http://dx.doi.org/10.1074/jbc.271.29.17425			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663337	hybrid			2022-12-27	WOS:A1996UX94300069
J	Taura, F; Morimoto, S; Shoyama, Y				Taura, F; Morimoto, S; Shoyama, Y			Purification and characterization of cannabidiolic-acid synthase from Cannabis sativa L. Biochemical analysis of a novel enzyme that catalyzes the oxidocyclization of cannabigerolic acid to cannabidiolic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOTERPENE CYCLASE; PROTEINS	We identified a unique enzyme that catalyzes the oxidocyclization of cannabigerolic acid to cannabidiolic acid (CBDA) in Cannabis sativa L, (CBDA strain), The enzyme, named CBDA synthase, was purified to apparent homogeneity by a four-step procedure: ammonium sulfate precipitation followed by chromatography on DEAE-cellulose, phenyl-Sepharose CL-4B, and hydroxylapatite, The active enzyme consists of a single polypeptide with a molecular mass of 74 kDa and a pI of 6.1, The NH2-terminal amino acid sequence of CBDA synthase is similar to that of Delta(1)-tetrahydrocannabinolic-acid synthase, CBDA synthase does not require coenzymes, molecular oxygen, hydrogen peroxide, and metal ion cofactors for the oxidocyclization reaction, These results indicate that CBDA synthase is neither an oxygenase nor a peroxidase and that the enzymatic cyclization does not proceed via oxygenated intermediates, CBDA synthase catalyzes the formation of CBDA from cannabinerolic acid as well as cannabigerolic acid, although the k(cat) for the former (0.03 s(-1)) is lower than that for the latter (0.19 s(-1)), Therefore, we conclude that CBDA is predominantly biosynthesized from cannabigerolic acid rather than cannabinerolic acid.	KYUSHU UNIV,FAC PHARMACEUT SCI,HIGASHI KU,FUKUOKA 812,JAPAN	Kyushu University								ALONSO WR, 1991, ARCH BIOCHEM BIOPHYS, V286, P511, DOI 10.1016/0003-9861(91)90073-R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANE DE, 1987, ARCH BIOCHEM BIOPHYS, V254, P421, DOI 10.1016/0003-9861(87)90120-2; CONSROE P, 1991, PHARMACOL BIOCHEM BE, V40, P701, DOI 10.1016/0091-3057(91)90386-G; CONSROE P, 1986, INT J NEUROSCI, V30, P277, DOI 10.3109/00207458608985678; CROMBIE L, 1992, PHYTOCHEMISTRY, V31, P451, DOI 10.1016/0031-9422(92)90016-J; CROTEAU R, 1987, CHEM REV, V87, P929, DOI 10.1021/cr00081a004; GAONI R, 1964, J AM CHEM SOC, V86, P1946; HOHN TM, 1989, ARCH BIOCHEM BIOPHYS, V272, P137, DOI 10.1016/0003-9861(89)90204-X; IMAI Y, 1967, EUR J BIOCHEM, V1, P419, DOI 10.1111/j.1432-1033.1967.tb00090.x; KAJIMA M, 1982, PHYTOCHEMISTRY, V21, P67, DOI 10.1016/0031-9422(82)80016-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MECHOULAM R, 1970, SCIENCE, V168, P1159, DOI 10.1126/science.168.3936.1159; MECHOULAM R, 1969, J CHEM SOC CHEM COMM, P343, DOI 10.1039/c29690000343; MECHOULAM R, 1969, TETRAHEDRON LETT, P5349; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Petri G., 1988, BIOTECHNOLOGY AGR FO, V4, P333; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V296, P49, DOI 10.1016/0003-9861(92)90543-6; SHOYAMA Y, 1970, CHEM PHARM BULL, V18, P1327; SHOYAMA Y, 1975, PHYTOCHEMISTRY, V14, P2189, DOI 10.1016/S0031-9422(00)91096-3; SHOYAMA Y, 1978, J LABELLED COMPD RAD, V14, P835, DOI 10.1002/jlcr.2580140607; TAHARA S, 1995, PHYTOCHEMISTRY, V38, P1073, DOI 10.1016/0031-9422(94)00788-U; TAURA F, 1995, PHYTOCHEMISTRY, V39, P457, DOI 10.1016/0031-9422(94)00887-Y; TAURA F, 1995, J AM CHEM SOC, V117, P9766, DOI 10.1021/ja00143a024	24	115	144	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17411	17416		10.1074/jbc.271.29.17411	http://dx.doi.org/10.1074/jbc.271.29.17411			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663284	hybrid			2022-12-27	WOS:A1996UX94300067
J	Jacoby, DB; Wensink, PC				Jacoby, DB; Wensink, PC			DNA binding specificities of YPF1, a Drosophila homolog to the DNA binding subunit of human DNA-dependent protein kinase, Ku	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-40 T-ANTIGEN; RNA POLYMERASE-II; AUTOANTIGEN-KU; PURIFICATION; SEQUENCE; IDENTIFICATION; MELANOGASTER; ELEMENT; PHOSPHORYLATION; AUTOANTIBODIES	YPF1, a heterodimeric protein from Drosophila melanogaster, is a homolog to Ku, the DNA binding subunit of human DNA-dependent protein kinase, This kinase is crucial in transcriptional activation, V(D)J recombination, double-strand break repair, and both topoisomerase and helicase activities. To investigate functional homology between YPF1 and Ku, we examined DNA binding properties of YPF1, Like Ku, at 100 mm KCl, YPF1 binding has no detectable DNA sequence specificity, requires a DNA terminus, and has a concentration-dependent stoichiometry consistent with subsequent translocation along DNA, YPF1 differs from Ku by having a 10(5)-fold higher affinity. At 400 mhz KCl, YPF1 still prefers DNA termini but shows binding specificities not observed previously with Ku. In descending order of affinity, YPF1 binds to: specific DNA sequences with a specific polarity and spacing relative to DNA termini; nonspecific linear DNA; and circular DNA, At this higher ionic strength, binding stoichiometry is concentration independent, indicating that YPF1 remains bound to ends, These results demonstrate a strong functional homology between YPF1 and Ku at physiological ionic strength. The strong binding of YPF1 has also allowed us to detect underlying binding specificities that may be specific to YPF1 and its function.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254	Brandeis University; Brandeis University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013334, R01GM021626] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM21626, F32 GM13334] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BARNETT T, 1981, ICN UCLA S MOL CELL, V23, P97; Beall EL, 1996, GENE DEV, V10, P921, DOI 10.1101/gad.10.8.921; BEALL EL, 1994, P NATL ACAD SCI USA, V91, P12681, DOI 10.1073/pnas.91.26.12681; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; CHEN YR, 1991, J VIROL, V65, P5131, DOI 10.1128/JVI.65.10.5131-5140.1991; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FALZON M, 1993, J BIOL CHEM, V268, P10546; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FRANCOEUR AM, 1986, J IMMUNOL, V136, P1648; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; FROELICHAMMON SJ, 1994, J BIOL CHEM, V269, P7719; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; HUNG MC, 1981, NUCLEIC ACIDS RES, V9, P6407, DOI 10.1093/nar/9.23.6407; IIJIMA S, 1992, EUR J BIOCHEM, V206, P595, DOI 10.1111/j.1432-1033.1992.tb16964.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACOBY DB, 1994, J BIOL CHEM, V269, P11484; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; MARTIN KJ, 1987, J MOL BIOL, V195, P741, DOI 10.1016/0022-2836(87)90193-8; MAY G, 1991, J BIOL CHEM, V266, P3052; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MITSIS PG, 1989, J BIOL CHEM, V264, P5188; MITSIS PG, 1989, J BIOL CHEM, V264, P5195; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; Niu Huifeng, 1995, Gene Expression, V4, P111; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; PORGES AJ, 1990, J IMMUNOL, V145, P4222; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RIO DC, 1988, P NATL ACAD SCI USA, V85, P8929, DOI 10.1073/pnas.85.23.8929; ROBERTS MR, 1989, CELL REGUL, V1, P151, DOI 10.1091/mbc.1.1.151; ROBERTS MR, 1994, P NATL ACAD SCI USA, V91, P6354, DOI 10.1073/pnas.91.14.6354; Sambrook J., 2002, MOL CLONING LAB MANU; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; YANEVA M, 1985, BIOCHIM BIOPHYS ACTA, V841, P22, DOI 10.1016/0304-4165(85)90270-3; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	51	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16827	16832		10.1074/jbc.271.28.16827	http://dx.doi.org/10.1074/jbc.271.28.16827			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663250	hybrid			2022-12-27	WOS:A1996UX12600063
J	ManzanoWinkler, B; Novina, CD; Roy, AL				ManzanoWinkler, B; Novina, CD; Roy, AL			TFII-I is required for transcription of the naturally TATA-less but initiator containing V beta promoter (vol 271, pg 12076, 1996)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction, Addition																		ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076	1	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16982	16982						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663593				2022-12-27	WOS:A1996UX12600084
J	Fimia, GM; Gottifredi, V; Passananti, C; Maione, R				Fimia, GM; Gottifredi, V; Passananti, C; Maione, R			Double-stranded internucleosomal cleavage of apoptotic DNA is dependent on the degree of differentiation in muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN HEAVY-CHAIN; FRAGMENTS PRIOR; DEATH; ABSENCE; EXPRESSION; CALCIUM; GENE	Apoptotic cell death has been correlated to DNA fragmentation into discrete segments corresponding to the length of nucleosomal protected fragments of 180-200 base pairs or multiples of it, This DNA degradation has been ascribed to endonuclease activity that cleaves internucleosomally, thus giving rise to a ladder distribution upon electrophoretic migration. This strict correlation was, however, shown to have notable exceptions, since in some cases only single strand cleavage in the internucleosomal DNA regions has been observed (Tomei, D. L,, Shapiro, P, J,, and Cope, O. F. (1993) Proc, Natl. Acad. Sci, U. S. A. 90, 853-857), In the present work we show that mouse muscle cells, able to differentiate in vitro, if subjected to apoptosis present no DNA degradation into ladder form unless differentiation is previously induced. Furthermore, C3H/10T1/2 fibroblast cells, known to undergo apoptosis without DNA ladder formation, if converted to a myogenic program by MyoD expression, display internucleosomal DNA degradation upon induction of differentiation.	UNIV ROMA LA SAPIENZA,DIPARTIMENTO BIOPATOL UMANA,SEZ BIOL CELLULARE,I-00161 ROME,ITALY; CNR,IST TECNOL BIOMED,I-00161 ROME,ITALY	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)			Fimia, Gian Maria/K-3232-2016; Passananti, Claudio/K-9593-2016; Gottifredi, Vanesa/AAI-1788-2019	Fimia, Gian Maria/0000-0003-4438-3325; Gottifredi, Vanesa/0000-0001-9656-5951; PASSANANTI, CLAUDIO/0000-0002-9288-5736				BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2352; BERTRAND R, 1991, BIOCHEM PHARMACOL, V42, P77, DOI 10.1016/0006-2952(91)90683-V; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BORTNER DC, 1995, TRENDS BIOL SCI, V5, P21; BROWN DG, 1993, J BIOL CHEM, V268, P3037; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW SC, 1995, EXP CELL RES, V216, P149, DOI 10.1006/excr.1995.1019; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Eastman A, 1994, Cell Death Differ, V1, P7; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; Hughes F M Jr, 1994, Cell Death Differ, V1, P11; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; MAIONE R, 1994, CELL GROWTH DIFFER, V5, P231; MARTELLI F, 1994, ONCOGENE, V9, P3579; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; OBERHAMMER F, 1993, HEPATOLOGY, V18, P1238; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Peitsch M C, 1994, Cell Death Differ, V1, P1; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; TOMEI LD, 1993, P NATL ACAD SCI USA, V90, P853, DOI 10.1073/pnas.90.3.853; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WEYDERT A, 1985, P NATL ACAD SCI USA, V82, P7183, DOI 10.1073/pnas.82.21.7183; Wyllie A H, 1980, Int Rev Cytol, V68, P251	29	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15575	15579		10.1074/jbc.271.26.15575	http://dx.doi.org/10.1074/jbc.271.26.15575			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663405	hybrid			2022-12-27	WOS:A1996UV29900042
J	Claessens, F; Alen, P; Devos, A; Peeters, B; Verhoeven, G; Rombauts, W				Claessens, F; Alen, P; Devos, A; Peeters, B; Verhoeven, G; Rombauts, W			The androgen-specific probasin response element 2 interacts differentially with androgen and glucocorticoid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATIC BINDING-PROTEIN; ESTROGEN-RECEPTOR; C3(1) GENE; DNA; SEQUENCES; PROMOTER; TRANSCRIPTION; INTRON; DOMAIN; SITE	The nuclear receptors constitute a large family of transcription factors characterized by a well conserved DNA-binding domain. The receptors for glucocorticoids, progestins, mineralocorticoids, and androgens constitute a subgroup because they bind in vitro with high affinity to DNA elements containing a partial palindrome of the core sequence 5'-TGTTCT-3'. In vivo, however, the corresponding steroids differentially regulate the expression of their target genes, even when more than one receptor type is present in a particular cell. The DNA-binding domains of the androgen and of the glucocorticoid receptors bind most androgen response elements with similar relative affinities. In contrast, one element (5'-GGTTCTTGGAGTACT-3') which was recently described in the promoter region of the probasin gene selectively interacts with the DNA-binding domain of the androgen receptor and not with that of the glucocorticoid receptor. From studies with chimeric elements, it can be deduced that it is the left subsequence 5'-GGTTCT-3' which excludes the glucocorticoid receptor domain from binding. In co-transfection experiments where the ARE of the C3(1) gene is responsive to both androgens and glucocorticoids, the probasin element is induced only by androgens and not by glucocorticoids. The existence of response elements which are recognized preferentially by the androgen receptor provides yet another possible mechanism to explain the differences of the in vivo effects between androgens and other steroids of the subgroup.	CATHOLIC UNIV LEUVEN,FAC MED,LAB EXPTL MED & ENDOCRINOL,B-3000 LOUVAIN,BELGIUM	KU Leuven	Claessens, F (corresponding author), CATHOLIC UNIV LEUVEN,FAC MED,DIV BIOCHEM,CAMPUS GASTHUISBERG,B-3000 LOUVAIN,BELGIUM.		Claessens, Frank/M-8565-2016	Claessens, Frank/0000-0002-8676-7709				ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; CELIS L, 1993, MOL CELL ENDOCRINOL, V94, P165, DOI 10.1016/0303-7207(93)90165-G; CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P355, DOI 10.1089/dna.1990.9.355; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; CLAESSENS F, 1990, MOL CELL ENDOCRINOL, V74, P203, DOI 10.1016/0303-7207(90)90225-W; CLAESSENS F, 1993, BIOCHEM BIOPH RES CO, V191, P688, DOI 10.1006/bbrc.1993.1272; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; DEVOS A, 1995, THESIS U LEUVEN LEUV; DEVOS P, 1993, MOL CELL ENDOCRINOL, V90, pR11, DOI 10.1016/0303-7207(93)90160-L; DEVOS P, 1991, J BIOL CHEM, V266, P3439; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GORDON DA, 1995, EXP CELL RES, V217, P368, DOI 10.1006/excr.1995.1099; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; KASPER S, 1994, J BIOL CHEM, V269, P31763; LIEBERMAN BA, 1993, MOL ENDOCRINOL, V7, P515, DOI 10.1210/me.7.4.515; LOMBES M, 1993, BIOCHEM J, V292, P577, DOI 10.1042/bj2920577; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADER S, 1993, NUCLEIC ACIDS RES, V21, P1125, DOI 10.1093/nar/21.5.1125; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; ROY AK, 1995, CRIT REV EUKAR GENE, V5, P157, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.30; RUNDLETT SE, 1995, MOL CELL ENDOCRINOL, V109, P1, DOI 10.1016/0303-7207(95)03477-O; RUSHMERE NK, 1987, MOL CELL ENDOCRINOL, V51, P259, DOI 10.1016/0303-7207(87)90036-0; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	32	111	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19013	19016		10.1074/jbc.271.32.19013	http://dx.doi.org/10.1074/jbc.271.32.19013			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702568	hybrid			2022-12-27	WOS:A1996VB68400002
J	Feng, WJ; Bedows, E; Norton, SE; Ruddon, RW				Feng, WJ; Bedows, E; Norton, SE; Ruddon, RW			Novel covalent chaperone complexes associated with human chorionic gonadotropin beta subunit folding intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; LINKED OLIGOSACCHARIDES; PROTEIN; BIP; CALNEXIN; KINETICS; PATHWAY	Molecular chaperones facilitate the folding of proteins in the endoplasmic reticulum (ER) of mammalian cells, The glycoprotein hormone chorionic gonadotropin beta subunit is a secretory protein whose folding in the ER has been demonstrated (Huth, J, R,, Mountjoy, K,, Perini, F,, and Ruddon, R, W, (1992) J, Biol, Chem, 267, 8870-8879), Because folding of wild type hCG-beta subunit occurs in the ER with a t(1/2) = 4-5 min, stable association of ER chaperones with hCG-beta have been difficult to detect probably because they have a short half-life, However, beta-chaperone complexes containing the ER chaperones BiP, ERp72, and ERp94 have been detected in slow folding mutants of hCG-beta subunit that lack both of the N-linked oligosaccharides (Feng, W,, Matzuk, M, M,, Mountjoy, K., Bedows, E,, Ruddon, R, W,, and Boime, I, (1995) J, Biol, Chem, 270, 11851-11859), The questions addressed here are 1) whether the detection of chaperone-containing complexes is related to the absence of carbohydrate or to the rate of hCG-beta subunit folding, 2) whether such complexes are dead-end or whether they lead to formation of a secreted, mature hCG-beta form, and 3) what the nature of the hCG-beta-chaperone binding is, The data obtained indicate that the amount of detectable hCG-beta-chaperone complexes correlates with the rate or extent of folding, that the complexes of hCG-beta with ER chaperones lead to the formation of secretable beta, and that the complexes of hCG-beta with chaperones involve the formation of intermolecular disulfide bonds.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOL BIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NCI NIH HHS [CA32949, P30 CA36727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA032949] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDOWS E, 1992, J BIOL CHEM, V267, P8880; BEDOWS E, 1994, J BIOL CHEM, V269, P10574; BEDOWS E, 1993, J BIOL CHEM, V268, P11655; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; FENG W, 1995, J BIOL CHEM, V270, P11851, DOI 10.1074/jbc.270.20.11851; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HUTH JR, 1992, J BIOL CHEM, V267, P21396; HUTH JR, 1992, J BIOL CHEM, V267, P8870; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MATZUK MM, 1988, J BIOL CHEM, V263, P17106; MELNICK J, 1992, J BIOL CHEM, V267, P21303; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PETERS BP, 1984, J BIOL CHEM, V259, P5123; PUIG A, 1994, J BIOL CHEM, V269, P25889; TIAN GL, 1995, J BIOL CHEM, V270, P23910, DOI 10.1074/jbc.270.41.23910; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9	22	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18543	18548		10.1074/jbc.271.31.18543	http://dx.doi.org/10.1074/jbc.271.31.18543			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702502	hybrid			2022-12-27	WOS:A1996VB68300040
J	Melendez, JA; Davies, KJA				Melendez, JA; Davies, KJA			Manganese superoxide dismutase modulates interleukin-1 alpha levels in HT-1080 fibrosarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; MESSENGER-RNA; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; TRANSIENT ADAPTATION; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; INDUCTION; ACTIVATION	Reactive oxygen species of mitochondrial origin have been implicated in regulating the expression of several tumor necrosis factor (TNF)-induced genes. Manganese superoxide dismutase (Mn-SOD) is one of many genes, but only antioxidant enzyme, induced in response to tumor necrosis factor, Mn SOD is a nuclear-encoded mitochondrial matrix protein and serves a protective function by detoxifying superoxide, To address the role of superoxide in regulating gene expression in response to TNF, we have constitutively overexpressed Mn-SOD in a human fibrosarcoma cell line and asked what effect this has on the expression of a number of TNF-responsive genes using reverse transcription-polymerase chain reaction, Of the TNF-induced transcripts analyzed, only interleukin-1 alpha (IL-1 alpha) was modulated in response to Mn-SOD overexpression. In all cases of Mn-SOD overexpression, IL-la protein and mRNA levels were lowered constitutively and in response to TNF when compared to the parental and mock-transfected cell lines. The induction of IL-la by TNF can also be decreased by growth in 3% oxygen as compared to growth in 21% O-2; in addition, growth in low oxygen lowers the basal level of IL-1 alpha protein, The effect of Mn-SOD overexpression on IL-1 alpha expression can be overcome by treatment with the protein kinase C activator, phorbol 12-myristate 13-acetate. Mn-SOD overexpression and low oxygen alter IL-1 alpha mRNA levels by decreasing the stability of the IL-1 alpha mRNA. These findings indicate that both Mn-SOD and O-2 may regulate the levels of a cellular oxidant involved in both basal and TNF induced IL-1 alpha expression, presumably superoxide.	UNIV SO CALIF,ETHEL PERCY ANDRUS GERONTOL CTR,LOS ANGELES,CA 90089; ALBANY MED COLL,DEPT BIOCHEM MOL BIOL,NEW YORK,NY 12208	University of Southern California; Albany Medical College				Davies, Kelvin/0000-0001-7790-3003; Melendez, Juan/0000-0001-8021-3097	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R23ES003598, R56ES003598, R01ES003598] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03598] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AKASHI M, 1995, J BIOL CHEM, V270, P15864, DOI 10.1074/jbc.270.26.15864; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; AMES BN, 1989, MUTAT RES, V214, P41, DOI 10.1016/0027-5107(89)90196-6; ASOH K, 1989, BIOCHEM BIOPH RES CO, V162, P794, DOI 10.1016/0006-291X(89)92380-2; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BECK Y, 1987, NUCLEIC ACIDS RES, V15, P9076, DOI 10.1093/nar/15.21.9076; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; CARTER BZ, 1991, LAB INVEST, V65, P610; DAVIES JMS, 1995, ARCH BIOCHEM BIOPHYS, V317, P1, DOI 10.1006/abbi.1995.1128; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; GOROSPE M, 1993, J BIOL CHEM, V268, P6214; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HARRIS CA, 1991, J IMMUNOL, V147, P149; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q; LEE WY, 1994, J BIOL CHEM, V269, P17971; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; MCCORD JM, 1982, CAN J PHYSIOL PHARM, V60, P1346, DOI 10.1139/y82-201; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MELENDEZ JA, 1992, FREE RADICAL BIO MED, V12, P151, DOI 10.1016/0891-5849(92)90009-6; MELENDEZ JA, 1993, FREE RADICAL BIO MED, V14, P601, DOI 10.1016/0891-5849(93)90141-G; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SUZUKI YJ, 1992, BIOCHEM BIOPH RES CO, V189, P1709, DOI 10.1016/0006-291X(92)90275-P; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; VISNER GA, 1990, J BIOL CHEM, V265, P2856; VOLKYL A, 1994, CELL BIOL LAB HDV, P550; WALDMAN AS, 1991, BIOTECHNIQUES, V10, P138; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WONG GHW, 1992, MOL BIOL FREE RADICA, P69; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	38	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18898	18903		10.1074/jbc.271.31.18898	http://dx.doi.org/10.1074/jbc.271.31.18898			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702551	hybrid			2022-12-27	WOS:A1996VB68300089
J	Clementi, E; Riccio, M; Sciorati, C; Nistico, G; Meldolesi, J				Clementi, E; Riccio, M; Sciorati, C; Nistico, G; Meldolesi, J			The type 2 ryanodine receptor of neurosecretory PC12 cells is activated by cyclic ADP-ribose - Role of the nitric oxide cGMP pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-INDUCED CA2+ RELEASE; DEPENDENT PROTEIN-KINASE; INTRACELLULAR CA2+; INOSITOL 1,4,5-TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; CALCIUM RELEASE; BRAIN; CHANNEL; NEURONS; MUSCLE	Of two neurosecretory PC12 cell clones that respond to NO donors and 8-bromo-cGMP with similar increases in cADP-ribose and that possess molecularly similar Ca2+ stores, only one (clone 16A) expresses the type 2 ryanodine receptor, whereas the other (clone 27) is devoid of ryanodine receptors. In PC12-16A cells, activation of the NO/cGMP pathway induced slow [Ca2+](i) responses, sustained by release from Ca2+ stores. In contrast, PC12 27 cells were insensitive to NO donors. Likewise, in PC12-16A cells preincubated with NO donors, Ca2+ stores were partially depleted, as revealed by a test with thapsigargin, whereas those in clone 27 were unchanged. The NO-induced Ca2+ release was increased synergistically by caffeine, and the corresponding store depletion was magnified by ryanodine. The specificity for the NO/cGMP pathway was confirmed by the effects of two blockers of cGMP-dependent protein kinase I, while the role of cADP-ribose was demonstrated by the effects of its antagonist, 8-amino-cADP-ribose, administered to permeabilized cells. These results demonstrate in neurosecretory cells a ryanodine receptor activation pathway similar to that known in sea urchin oocytes. The signaling events described here could be of great physiological importance, especially in the nervous system.	UNIV REGGIO CALABRIA,FAC PHARM,DEPT PHARMACOL,I-88021 CATANZARO,ITALY; UNIV ROMA TOR VERGATA,MONDINO NEUROBIOL CTR,DEPT BIOL,I-00133 ROME,ITALY; CNR,MOL & CELLULAR PHARMACOL CTR,I-20132 MILAN,ITALY; UNIV MILAN,B CECCARELLI CTR,DEPT PHARMACOL,DIPARTIMENTO BIOTECNOL,SAN RAFFAELE SCI INST,I-20132 MILAN,ITALY	Universita Mediterranea di Reggio Calabria; University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			sciorati, clara/K-4823-2016	sciorati, clara/0000-0003-2030-9366				ALDERSON BH, 1989, ARCH BIOCHEM BIOPHYS, V272, P162, DOI 10.1016/0003-9861(89)90207-5; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; CLEMENTI E, 1995, MOL PHARMACOL, V47, P517; CLEMENTI E, 1995, EUR J PHARM-MOLEC PH, V289, P113, DOI 10.1016/0922-4106(95)90176-0; CLEMENTI E, 1992, EUR J NEUROSCI, V4, P944, DOI 10.1111/j.1460-9568.1992.tb00121.x; COLYER J, 1989, BIOCHEM J, V262, P439, DOI 10.1042/bj2620439; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FRUEN BR, 1994, FEBS LETT, V352, P123, DOI 10.1016/0014-5793(94)00931-7; FURUICHI T, 1994, J NEUROSCI, V14, P4794; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; HABY C, 1994, J NEUROCHEM, V62, P496; HORTON JK, 1995, 9 INT C 2 MESS PHOSP, P354; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, J BIOL CHEM, V268, P293; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; RUTTER GA, 1994, CELL CALCIUM, V16, P71, DOI 10.1016/0143-4160(94)90002-7; SITSAPESAN R, 1995, TRENDS PHARMACOL SCI, V16, P386, DOI 10.1016/S0165-6147(00)89080-X; SITSAPESAN R, 1995, AM J PHYSIOL-CELL PH, V268, pC1235, DOI 10.1152/ajpcell.1995.268.5.C1235; SITSAPESAN R, 1994, CIRC RES, V75, P596, DOI 10.1161/01.RES.75.3.596; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; VILLA A, 1992, NEUROSCIENCE, V49, P467, DOI 10.1016/0306-4522(92)90111-E; VILLA A, 1993, J CELL BIOL, V121, P1041, DOI 10.1083/jcb.121.5.1041; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X; Willmott N, 1996, J BIOL CHEM, V271, P3699; WILLMOTT NJ, 1995, CELL CALCIUM, V18, P411, DOI 10.1016/0143-4160(95)90056-X; ZACCHETTI D, 1991, J BIOL CHEM, V266, P20152; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213	42	100	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17739	17745		10.1074/jbc.271.30.17739	http://dx.doi.org/10.1074/jbc.271.30.17739			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663443	hybrid			2022-12-27	WOS:A1996UY93500025
J	Harding, TM; HefnerGravink, A; Thumm, M; Klionsky, DJ				Harding, TM; HefnerGravink, A; Thumm, M; Klionsky, DJ			Genetic and phenotypic overlap between autophagy and the cytoplasm to vacuole protein targeting pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MUTANTS; YEAST	We have explored the phenotypic and genetic overlap between autophagocytosis and cytoplasm to vacuole targeting in the yeast Saccharomyces cerevisiae. Complementation analysis was performed with mutants in each of these groups (aut and cvt, respectively), and three complementation groups were found to overlap. Also, most of the unique aut mutants accumulated precursor aminopeptidase I in the cytoplasm, while maintaining wild type kinetics and maturation of proteins targeted to the vacuole via the secretory pathway, The majority of the non-overlapping cvt mutants were found to be at least partially defective in autophagy. Some mutants in each group, however, appear to be only marginally affected in the other phenotype, implying that these pathways only partially overlap, We propose that import of aminopeptidase I into the vacuole shares a number of components required for bulk autophagocytosis, but is made specific, saturable, and constitutive by the presence of a receptor or other interacting protein(s).	UNIV STUTTGART,INST BIOCHEM,D-70569 STUTTGART,GERMANY	University of Stuttgart	Harding, TM (corresponding author), UNIV CALIF DAVIS,MICROBIOL SECT,DAVIS,CA 95616, USA.		Thumm, Michael/A-8033-2015	Thumm, Michael/0000-0003-3238-4857	NIGMS NIH HHS [GM53396] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BAUM P, 1978, P NATL ACAD SCI USA, V75, P4962, DOI 10.1073/pnas.75.10.4962; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; HIRSCH HH, 1992, EUR J BIOCHEM, V207, P641; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Oda MN, 1996, J CELL BIOL, V132, P999, DOI 10.1083/jcb.132.6.999; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Scott SV, 1995, J CELL BIOL, V131, P1727, DOI 10.1083/jcb.131.6.1727; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; YOSHIHISA T, 1989, BIOCHEM BIOPH RES CO, V163, P908, DOI 10.1016/0006-291X(89)92308-5	17	207	215	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17621	17624		10.1074/jbc.271.30.17621	http://dx.doi.org/10.1074/jbc.271.30.17621			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663607	hybrid			2022-12-27	WOS:A1996UY93500008
J	Martin, SS; Haruta, T; Morris, AJ; Klippel, A; Williams, LT; Olefsky, JM				Martin, SS; Haruta, T; Morris, AJ; Klippel, A; Williams, LT; Olefsky, JM			Activated phosphatidylinositol 3-kinase is sufficient to mediate actin rearrangement and GLUT4 translocation in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE TRANSPORTER GLUT4; PLASMA-MEMBRANE; INSULIN-RECEPTOR; DNA-SYNTHESIS; INTACT-CELLS; STIMULATION; TERMINUS; SUBUNIT; SITE; P85	Insulin stimulation of 3T3-L1 adipocytes causes rapid translocation of actin and the GLUT4 glucose transporter to the plasma membrane, Both processes depend on the activity of phosphatidylinositol 3-kinase, Using single cell microinjection, we have transiently expressed a constitutively activated mutant of phosphatidylinositol 3-kinase, p110*, in 3T3-L1 adipocytes, Fluorescent detection of GLUT4 protein and actin within these cells demonstrates that expression of p110* is sufficient to cause translocation of GLUT4 to the plasma membrane and the formation of actin membrane ruffles, These effects are inhibited by wortmannin in the p110*-expressing cells, indicating that the phosphatidylinositol 3-kinase activity of the protein is required, Overexpression of an identical protein containing a point mutation in the kinase domain, p110*Delta kin, was incapable of mediating either action, confirming that neither the microinjection process nor a nonspecific effect of the protein was responsible for the observed effects, These data suggest that although insulin is capable of inducing numerous signaling pathways, the isolated activation of phosphatidylinositol 3-kinase can initiate the signaling cascade leading to both actin rearrangement and GLUT4 translocation in the absence of insulin stimulation.	UNIV CALIF SAN DIEGO,DEPT MED 9111G,VET ADM MED CTR,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; CHIRON CORP,EMERYVILLE,CA 94608	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Novartis					NIDDK NIH HHS [DK09415, DK33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, F32DK009415, R37DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALDINI G, 1991, J BIOL CHEM, V266, P4037; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KELADA ASM, 1992, J BIOL CHEM, V267, P7021; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; MARCUSOHN J, 1995, CURR BIOL, V5, P1296, DOI 10.1016/S0960-9822(95)00256-9; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; OLEFSKY JM, 1994, ELLENBERG RIFKINS DI, P121; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SMITH RM, 1993, ARCH BIOCHEM BIOPHYS, V300, P238, DOI 10.1006/abbi.1993.1033; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934	24	186	189	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17605	17608		10.1074/jbc.271.30.17605	http://dx.doi.org/10.1074/jbc.271.30.17605			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663595	hybrid			2022-12-27	WOS:A1996UY93500004
J	Rachez, C; Sautiere, P; Formstecher, P; Lefebvre, P				Rachez, C; Sautiere, P; Formstecher, P; Lefebvre, P			Identification of amino acids critical for the DNA binding and dimerization properties of the human retinoic acid receptor alpha - Importance of lysine 360, lysine 365, and valine 361	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; GLUCOCORTICOID RECEPTOR; LIGAND-BINDING; NUCLEAR RECEPTOR; DIRECT REPEATS; X-RECEPTOR; STRUCTURAL DETERMINANTS; RESPONSE ELEMENTS; STEROID BINDING; RXR-ALPHA	Retinoic acid receptors (RARs) and retinoid X receptors (RXRs) activate target genes by binding to retinoic acid response elements (RAREs) as heterodimeric, asymmetrical complexes, and display a high degree of cooperativity in binding to RAREs, We have examined here the effect of lysine, cysteine, arginine, histidine, and tyrosine side chain chemical modification on the DNA binding, homo and heterodimerization properties of the full-length human retinoic acid receptor alpha (hRAR alpha). Lysines are the only residues to be engaged in the dimerization with human retinoid X receptor alpha (hRXR alpha) in the absence of DNA, whereas histidines are selectively involved in the homodimerization of hRAR alpha in the presence of a RARE. Arginine modification affected the DNA binding activity of each type of dimer, whereas cysteines and tyrosines were primarily involved in the homo- or heterodimerization process in the presence of the same RARE. Modified lysines, interfering with the dimerization with hRXR alpha, were identified by receptor labeling and peptide mapping. They are located in the hormone binding domain eighth heptad repeat, at positions 360 and 365. In keeping with these results, mutation of Lys(360), Val(361), and Lys(365) diminished strongly the DNA binding activity of hRAR alpha as a homodimer or a heterodimer. Our results thus provide direct evidence for the differential involvement of basic, polar, or aromatic amino acids in the DNA binding, homodimerization, and heterodimerization properties of hRAR alpha. Furthermore, they demonstrate the use of distinct dimerization interfaces and identify the type of amino acids involved in these protein-protein interactions.	FAC MED LILLE,CJF INSERM 9203,LAB BIOCHIM STRUCT,F-59045 LILLE,FRANCE; INST PASTEUR,CNRS URA 1309,F-59019 LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Rachez, Christophe/GLR-0102-2022; Lefebvre, Philippe/F-2685-2010	Lefebvre, Philippe/0000-0002-9366-5129; Rachez, Christophe/0000-0001-8502-4738				ALI M, 1992, BIOCHEM BIOPH RES CO, V182, P1032, DOI 10.1016/0006-291X(92)91835-E; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BLICQ S, 1988, BIOCHEMISTRY-US, V27, P8436, DOI 10.1021/bi00422a021; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; BUROLLAUD T, 1993, J STEROID BIOCHEM, V44, P217, DOI 10.1016/0960-0760(93)90082-8; CHAKRABORTI PK, 1990, ENDOCRINOLOGY, V127, P2530, DOI 10.1210/endo-127-5-2530; CHENG KC, 1989, J BIOL CHEM, V264, P19666; DALLERY N, 1993, BIOCHEMISTRY-US, V32, P12428, DOI 10.1021/bi00097a022; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLAZER AN, 1985, LAB TECHNIQUES BIOCH, V4, P68; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KNEGTEL RMA, 1993, J BIOMOL NMR, V3, P1, DOI 10.1007/BF00242472; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEE MS, 1994, EUR J BIOCHEM, V224, P639, DOI 10.1111/j.1432-1033.1994.00639.x; LEFEBVRE B, 1995, BIOCHEMISTRY-US, V34, P5477, DOI 10.1021/bi00016a019; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUPISELLA JA, 1995, J BIOL CHEM, V270, P24884, DOI 10.1074/jbc.270.42.24884; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NUROKAWA R, 1993, GENE DEV, V7, P1423; OPOKU J, 1994, J BIOL CHEM, V269, P503; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; SAUTIERE P, 1988, J BIOL CHEM, V263, P11059; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; STANCATO LF, 1993, BIOCHEMISTRY-US, V32, P3729, DOI 10.1021/bi00065a027; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TULLY DB, 1994, FASEB J, V8, P343, DOI 10.1096/fasebj.8.3.8143940; YAMASAKI RB, 1980, ANAL BIOCHEM, V109, P32, DOI 10.1016/0003-2697(80)90006-8; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	49	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17996	18006		10.1074/jbc.271.30.17996	http://dx.doi.org/10.1074/jbc.271.30.17996			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663386	hybrid			2022-12-27	WOS:A1996UY93500064
J	Vertommen, D; Bertrand, L; Sontag, B; DiPietro, A; Louckx, MP; Vidal, H; Hue, L; Rider, MH				Vertommen, D; Bertrand, L; Sontag, B; DiPietro, A; Louckx, MP; Vidal, H; Hue, L; Rider, MH			The ATP-binding site in the 2-kinase domain of liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase - Study of the role of Lys-54 and Thr-55 by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MITOCHONDRIAL F1-ATPASE; AMINO-ACID-SEQUENCE; RAT-LIVER; ESCHERICHIA-COLI; 6-PHOSPHOFRUCTO-2-KINASE FRUCTOSE-2,6-BISPHOSPHATASE; NUCLEOTIDE-BINDING; FRUCTOSE 2,6-BISPHOSPHATASE; ADENYLATE KINASE; PROTEIN-KINASE; CATALYTIC SITE	All known 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isozymes contain a sequence (GX(4)GK(S/T)) in the 6-phosphofructo-2-kinase domain corresponding to the so-called nucleotide binding fold signature or Walker A motif, Mutagenesis and crystal structure data from several nucleotide binding proteins, which also contain this sequence, showed the importance of the lysine and serine/threonine residues in nucleotide binding, We have studied the role of Lys-54 and Thr-55 in MgATP binding in the 6-phosphofructo-2-kinase domain of rat liver 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase by site directed mutagenesis, Lys-54 was mutated to methionine, whereas Thr-55 was mutated to valine, serine, and cysteine, Three mutants, Lys-54 to Met and Thr-55 to Cys or Val, displayed more than a 5000-fold decrease in 6-phosphofructo-2-kinase activity compared with the wild type, The mutations had no effect on fructose-2,6-bisphosphatase activity and did not affect the activation of fructose-2,6-bisphosphatase after phosphorylation by cyclic 3',5'-AMP-dependent protein kinase, Binding experiments with ATP, ADP, and their analogs (3'-N-methylanthraniloyl derivatives) showed that these two residues do not play the same role, Lys-54 is involved in ATP binding, whereas Thr-55 is important for catalysis.	INT INST CELLULAR & MOLEC PATHOL,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; UNIV CATHOLIQUE LOUVAIN,SCH MED,B-1200 BRUSSELS,BELGIUM; INST BIOL & CHIM PROT,CNRS,F-69367 LYON 07,FRANCE; FAC MED ALEXIS CARREL,INSERM U197,F-69372 LYON 08,FRANCE	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Vidal, Hubert/M-6674-2017	Vidal, Hubert/0000-0002-9467-0317; Vertommen, Didier/0000-0001-7648-8282; Bertrand, Luc/0000-0003-0655-7099				BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; COLOSIA AD, 1987, BIOCHEM BIOPH RES CO, V143, P1092, DOI 10.1016/0006-291X(87)90364-0; CREPIN KM, 1989, BIOCHEM J, V264, P151, DOI 10.1042/bj2640151; CREPIN KM, 1992, J BIOL CHEM, V267, P21698; DARVILLE MI, 1987, FEBS LETT, V224, P317, DOI 10.1016/0014-5793(87)80476-3; DIVITA G, 1993, J BIOL CHEM, V268, P13178; FALSON P, 1993, BIOCHEMISTRY-US, V32, P10387, DOI 10.1021/bi00090a014; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HWANG YW, 1989, ARCH BIOCHEM BIOPHYS, V274, P394, DOI 10.1016/0003-9861(89)90452-9; JAULT JM, 1993, J BIOL CHEM, V268, P20762; KITAJIMA S, 1984, J BIOL CHEM, V259, P6896; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KRETSCHMER M, 1984, BIOCHEM BIOPH RES CO, V124, P793, DOI 10.1016/0006-291X(84)91027-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1992, J BIOL CHEM, V267, P4386; LIVELY MO, 1988, J BIOL CHEM, V263, P839; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14550, DOI 10.1021/bi00252a023; MUELLER DM, 1989, J BIOL CHEM, V264, P16552; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PILKIS SJ, 1984, J BIOL CHEM, V259, P949; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; RIDER MH, 1995, BIOCHEM J, V309, P341, DOI 10.1042/bj3090341; RIDER MH, 1994, BIOCHEM J, V300, P111, DOI 10.1042/bj3000111; RIDER MH, 1992, BIOCHEM J, V285, P405, DOI 10.1042/bj2850405; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAKATA J, 1991, J BIOL CHEM, V266, P15764; SAKATA J, 1990, P NATL ACAD SCI USA, V87, P4951, DOI 10.1073/pnas.87.13.4951; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P761; SCHULZ GE, 1974, NATURE, V250, P120, DOI 10.1038/250120a0; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V124, P143; VIJAYAKUMAR EKS, 1984, BIOPOLYMERS, V23, P877, DOI 10.1002/bip.360230505; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017	39	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17875	17880		10.1074/jbc.271.30.17875	http://dx.doi.org/10.1074/jbc.271.30.17875			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663445	hybrid			2022-12-27	WOS:A1996UY93500045
J	Basse, F; Stout, JG; Sims, PJ; Wiedmer, T				Basse, F; Stout, JG; Sims, PJ; Wiedmer, T			Isolation of an erythrocyte membrane protein that mediates Ca2+-dependent transbilayer movement of phospholipid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; LIPID ASYMMETRY; PROCOAGULANT ACTIVITY; RED-CELLS; FACTOR-VA; PLATELETS; EXPOSURE; CALCIUM; PHOSPHATIDYLSERINE; REDISTRIBUTION	Elevation of intracellular Ca2+ in erythrocytes, platelets, and other cells initiates rapid redistribution of plasma membrane phospholipids (PL) between inner and outer leaflets, collapsing the normal asymmetric distribution. Consequently, phosphatidylserine and other lipids normally sequestered to the inner leaflet become exposed at the cell surface. This Ca2+-induced mobilization of phosphatidylserine to the surface of activated, injured, or apoptotic cells confers a procoagulant property to the plasma membrane, which promotes fibrin clotting and provides a signal for cell removal by the reticuloendothelial system, To identify the constituent of the membrane that mediates this Ca2+-dependent ''PL scramblase'' activity, we undertook purification and reconstitution of membrane component(s) with this activity from detergent extracts of erythrocyte ghosts depleted of cytoskeleton. Active fractions were identified by their capacity to mediate the Ca2+-dependent redistribution of 7-nitrobenz-2-oxa-1,3-diazol-4-yl-labeled PL between leaflets of reconstituted proteoliposomes. This PL scramblase activity co-eluted through multiple chromatographic steps with a single polypeptide of similar to 37 kDa, which was purified to apparent homogeneity as resolved by silver staining. The activity associated with this protein band was inactivated by trypsin, The isolated protein reconstituted in proteoliposomes mediated nonselective, bidirectional transport of 7-nitrobenz-2-oxa-1,3-diazol-4-yl-PL between membrane leaflets, with half-maximal activation between 20 and 60 mu M Ca2+ (saturation >100 mu M), mimicking the Ca2+-dependent transbilayer lipid movement intrinsic to the erythrocyte membrane.	BLOOD CTR SE WISCONSIN INC,BLOOD RES INST,MILWAUKEE,WI 53201	Versiti Blood Center of Wisconsin			Wunder, Stephanie L/B-5066-2012; Zdilla, Michael J/B-4145-2011		NHLBI NIH HHS [HL36946] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASSE F, 1993, BIOCHEMISTRY-US, V32, P2337, DOI 10.1021/bi00060a027; BEVERS EM, 1991, BLOOD REV, V5, P146, DOI 10.1016/0268-960X(91)90031-7; BEVERS EM, 1995, BLOOD, V86, P1983, DOI 10.1182/blood.V86.5.1983.bloodjournal8651983; BRATTON DL, 1994, J BIOL CHEM, V269, P22517; CHANG CP, 1993, J BIOL CHEM, V268, P7171; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; CONNOR J, 1987, BIOCHEMISTRY-US, V26, P5099, DOI 10.1021/bi00390a031; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; FADOK VA, 1992, J IMMUNOL, V148, P2207; FOX JEB, 1990, BLOOD, V76, P2510; GAFFET P, 1995, BIOCHEMISTRY-US, V34, P6762, DOI 10.1021/bi00020a022; KOJIMA H, 1994, J CLIN INVEST, V94, P2237, DOI 10.1172/JCI117586; MARTIN DW, 1995, J BIOL CHEM, V270, P10468, DOI 10.1074/jbc.270.18.10468; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; POMORSKI T, 1994, MOL MEMBR BIOL, V11, P39, DOI 10.3109/09687689409161028; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; SMEETS EF, 1994, BBA-BIOMEMBRANES, V1195, P281, DOI 10.1016/0005-2736(94)90268-2; Steck T L, 1974, Methods Enzymol, V31, P172; SULPICE JC, 1994, J BIOL CHEM, V269, P6347; VERHOVEN B, 1992, BIOCHIM BIOPHYS ACTA, V1104, P15, DOI 10.1016/0005-2736(92)90126-7; VONDENHOF A, 1994, BIOCHEMISTRY-US, V33, P4517, DOI 10.1021/bi00181a011; WIEDMER T, 1990, BIOCHEMISTRY-US, V29, P623, DOI 10.1021/bi00455a005; WILLIAMSON P, 1995, BIOCHEMISTRY-US, V34, P10448, DOI 10.1021/bi00033a017; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027	25	253	261	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17205	17210		10.1074/jbc.271.29.17205	http://dx.doi.org/10.1074/jbc.271.29.17205			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663431	hybrid			2022-12-27	WOS:A1996UX94300036
J	Sock, E; Enderich, J; Rosenfeld, MG; Wegner, M				Sock, E; Enderich, J; Rosenfeld, MG; Wegner, M			Identification of the nuclear localization signal of the POU domain protein Tst-1/Oct6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SCIP; SV40 T-ANTIGEN; DNA-BINDING DOMAIN; GENE-EXPRESSION; SYNTHETIC PEPTIDE; CRYSTAL-STRUCTURE; JC VIRUS; OCT-6; PHOSPHORYLATION; SEQUENCES	POU domain proteins are important regulators of development and terminal differentiation based upon their transcriptional activity in the nucleus. Here, we analyzed the mechanism underlying the nuclear localization of Tst-1/Oct6, a member of this family that regulates events during neurogenesis and myelination. Nuclear localization of Tst-1/Oct6 was dependent on the POU domain, as its deletion prevented access to the nucleus, whereas its transfer to the amino terminus of beta-galactosidase was sufficient to prompt nuclear accumulation of this normally cytosolic protein. Interestingly, nuclear localization and high affinity DNA binding were two independent functions of the POU domain and could be separated in several mutants. While specific high affinity binding to DNA required the presence of both the POU-specific and the POU homeodomain, the POU-specific domain was dispensable for nuclear localization of Tst-1/Oct6. Rather, the nuclear localization function was selectively contained within the POU homeodomain. Specifically, a basic cluster (GRKRKKRT) preceding helix 1 of the homeodomain was shown by deletion mutagenesis to be involved in the nuclear localization of Tst-1/Oct6. This sequence, which is highly conserved among POU domain proteins, was by itself capable of translocating beta-galactosidase to the nucleus defining it as the bona fide nuclear localization signal of Tst-1/Oct6 and presumably other POU domain factors.	UNIV HAMBURG, ZENTRUM MOL NEUROBIOL, D-20246 HAMBURG, GERMANY; UNIV CALIF SAN DIEGO, SCH MED, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; Howard Hughes Medical Institute; University of California System; University of California San Diego				Wegner, Michael/0000-0002-4586-3294; Sock, Elisabeth/0000-0001-9925-3136				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ALVAREZBOLADO G, 1995, J COMP NEUROL, V355, P237, DOI 10.1002/cne.903550207; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; CAELLES C, 1995, MOL CELL BIOL, V15, P6694; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COLLARINI EJ, 1992, DEVELOPMENT, V116, P193; DAY RN, 1994, MOL ENDOCRINOL, V8, P374, DOI 10.1210/me.8.3.374; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263; FRANTZ GD, 1994, J NEUROSCI, V14, P472; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HALL MN, 1990, P NATL ACAD SCI USA, V87, P6954, DOI 10.1073/pnas.87.18.6954; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HAY BA, 1994, DEVELOPMENT, V120, P2121; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KUHN R, 1991, MOL CELL BIOL, V11, P4642, DOI 10.1128/MCB.11.9.4642; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LENTZ MR, 1993, J VIROL, V67, P1414, DOI 10.1128/JVI.67.3.1414-1423.1993; LUO Y, 1995, MOL CELL BIOL, V15, P4115; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; MEIJER D, 1990, NUCLEIC ACIDS RES, V18, P7357, DOI 10.1093/nar/18.24.7357; MEIJER D, 1992, NUCLEIC ACIDS RES, V20, P2241, DOI 10.1093/nar/20.9.2241; MONUKI ES, 1993, P NATL ACAD SCI USA, V90, P9978, DOI 10.1073/pnas.90.21.9978; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MONUKI ES, 1989, NEURON, V3, P783, DOI 10.1016/0896-6273(89)90247-X; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; Newmeyer DD, 1993, CURR OPIN CELL BIOL, V5, P395, DOI 10.1016/0955-0674(93)90003-9; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; POULAT F, 1995, J CELL BIOL, V128, P737, DOI 10.1083/jcb.128.5.737; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; RADULESCU RT, 1994, TRENDS BIOCHEM SCI, V19, P278, DOI 10.1016/0968-0004(94)90004-3; RENNER K, 1994, P NATL ACAD SCI USA, V91, P6433, DOI 10.1073/pnas.91.14.6433; RIBS HP, 1989, EMBO J, V8, P1479; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROHDEWOHLD H, 1992, MAMM GENOME, V3, P119, DOI 10.1007/BF00431256; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHERER SS, 1994, J NEUROSCI, V14, P1930; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHREIBER V, 1992, EMBO J, V11, P3263, DOI 10.1002/j.1460-2075.1992.tb05404.x; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SMITH MR, 1992, VIROLOGY, V187, P316, DOI 10.1016/0042-6822(92)90320-O; Sock E, 1996, J VIROL, V70, P1512, DOI 10.1128/JVI.70.3.1512-1520.1996; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; SUGIMOTO A, 1994, EMBO J, V125, P547; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TILLMANN U, 1994, MOL CELL BIOL, V14, P3030, DOI 10.1128/MCB.14.5.3030; TOBLER A, 1993, NUCLEIC ACIDS RES, V21, P1043, DOI 10.1093/nar/21.4.1043; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; VOSS JW, 1993, MOL ENDOCRINOL, V7, P1551, DOI 10.1210/me.7.12.1551; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1431, DOI 10.1210/mend-5-10-1431; WEGNER M, 1993, P NATL ACAD SCI USA, V90, P4743, DOI 10.1073/pnas.90.10.4743; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WEINSTEIN DE, 1995, MOL CELL NEUROSCI, V6, P212, DOI 10.1006/mcne.1995.1018; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YONEDA Y, 1992, EXP CELL RES, V201, P313, DOI 10.1016/0014-4827(92)90279-H; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	80	66	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17512	17518		10.1074/jbc.271.29.17512	http://dx.doi.org/10.1074/jbc.271.29.17512			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663425	hybrid			2022-12-27	WOS:A1996UX94300081
J	Duan, HJ; Orth, K; Chinnaiyan, AM; Poirier, GG; Froelich, CJ; He, WW; Dixit, VM				Duan, HJ; Orth, K; Chinnaiyan, AM; Poirier, GG; Froelich, CJ; He, WW; Dixit, VM			ICE-LAP6, a novel member of the ICE/Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; DEATH; ENZYME; CED-3	Members of the ICE/Ced-3 gene family are likely effector components of the cell death machinery. Here, we characterize a novel member of this family designated ICE-LAP6. By phylogenetic analysis, ICE-LAP6 is classified into the Ced-3 subfamily which includes Ced-3, Yama/CPP32/apopain, Mch2, and ICE-LAP3/Mch3/CMH-1. Interestingly, ICE-LAP6 contains an active site QACGG pentapeptide, rather than the QACRG pentapeptide shared by other family members. Overexpression of ICE-LAP6 induces apoptosis in MCF7 breast carcinoma cells. More importantly, ICE-LAP6 is proteolytically processed into an active cysteine protease by granzyme B, an important component of cytotoxic T cell-mediated apoptosis. Once activated, ICE-LAP6 is able to cleave the death substrate poly(ADP ribose) polymerase into signature apoptotic fragments.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV LAVAL,CTR HOSP,DEPT MOLEC ENDOCRINOL,RES CTR,ST FOY,PQ G1V 4G2,CANADA; NORTHWESTERN UNIV,SCH MED,EVANSTON,IL 60201; EVANSTON HOSP CORP,DEPT MED,EVANSTON,IL 60201; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	University of Michigan System; University of Michigan; Laval University; Northwestern University; NorthShore University Health System; GlaxoSmithKline; Human Genome Sciences Inc			Orth, Kim/AAV-4421-2021; dixit, vishva m/A-4496-2012	Orth, Kim/0000-0002-0678-7620; dixit, vishva m/0000-0001-6983-0326; Poirier, Guy/0000-0002-4869-1424	NATIONAL CANCER INSTITUTE [R01CA064803] Funding Source: NIH RePORTER; NCI NIH HHS [CA64803] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DUAN H, 1996, J BIOL CHEM, V271, P35013; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; Sambrook J., 2002, MOL CLONING LAB MANU; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	36	282	305	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16720	16724		10.1074/jbc.271.28.16720	http://dx.doi.org/10.1074/jbc.271.28.16720			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663294	hybrid			2022-12-27	WOS:A1996UX12600048
J	Li, Y; Ndubuka, C; Rubin, CS				Li, Y; Ndubuka, C; Rubin, CS			A kinase anchor protein 75 targets regulatory (RII) subunits of cAMP-dependent protein kinase II to the cortical actin cytoskeleton in non-neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-PROTEIN; EPITHELIAL-CELLS; GOLGI-COMPLEX; E-CADHERIN; EXPRESSION; BETA; CLONING; CALCIUM; PHOSPHORYLATION; IDENTIFICATION	Neuronal A kinase anchor protein (AKAP) homologs, such as AKAPs 75 and 150, tether cAMP-dependent protein kinase II (PKAII) isoforms to the postsynaptic cytoskeleton, thereby creating target sites for cAMP action, These AKAPs, which bind regulatory subunits (RIIs) of PKAII, are also expressed in certain non-neuronal cells, Non-neuronal cell lines that stably express wild type and mutant AKAP75 transgenes were generated to investigate the extraneuronal function of AKAPs, In non neuronal cells, AKAP75 accumulates selectively in the actin-rich, cortical cytoskeleton in close proximity with the plasma membrane, AKAP75 efficiently sequesters cytoplasmic RII alpha and RII beta (PKAII isoforms) and translocates these polypeptides to the cell cortex, Two structural modules in AKAP75, T-1 (residues 27-48), and T-2 (residues 77-100), are essential for targeting AKAP75 . RII complexes to the cortical cytoskeleton, Deletions or amino acid substitutions in T-1 and/or T-2 result in the dispersion of both AKAP75 and RII subunits throughout the cytoplasm, AKAP75 is co localized with F-actin and fodrin in the cortical cytoskeleton, Incubation of cells with 5 mu M cytochalasin D disrupts actin filaments and dissociates actin from the cell cortex, In contrast, the bulk of AKAP75 and fodrin remain associated with the cortical region of cytochalasin D-treated cells, Thus, targeting of AKAP75 does not depend upon direct binding with F-actin, Rather, AKAP75 (like fodrin) may be associated with a multiprotein complex that interacts with integral plasma membrane proteins.	ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,ATRAN LABS,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NIGMS NIH HHS [GM22792, GM7288] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1994, MOL BIOL CELL, P793; ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BERG DT, 1993, BIOTECHNIQUES, V14, P972; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BROKAW CJ, 1987, J CELL BIOCHEM, V35, P175, DOI 10.1002/jcb.240350302; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; CITI S, 1992, J CELL BIOL, V117, P169, DOI 10.1083/jcb.117.1.169; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; CORBIN JD, 1977, J BIOL CHEM, V252, P3854; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAND M, 1994, J BIOL CHEM, V269, P9234; LEISER M, 1986, J BIOL CHEM, V261, P1904; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; LIU JS, 1990, BIOTECHNIQUES, V9, P738; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; MCCARTNEY S, 1995, J BIOL CHEM, V270, P9327, DOI 10.1074/jbc.270.16.9327; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; TASH JS, 1982, BIOL REPROD, V26, P745, DOI 10.1095/biolreprod26.4.745; WHEELOCK MJ, 1992, J CELL BIOL, V117, P415, DOI 10.1083/jcb.117.2.415; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0	44	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16862	16869		10.1074/jbc.271.28.16862	http://dx.doi.org/10.1074/jbc.271.28.16862			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663279	hybrid			2022-12-27	WOS:A1996UX12600068
J	Liu, LM; Roberts, RM				Liu, LM; Roberts, RM			Silencing of the gene for the beta subunit of human chorionic gonadotropin by the embryonic transcription factor Oct-3/4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; CYCLIC-AMP; POU-DOMAIN; STEM-CELLS; EXPRESSION; MOUSE; ENHANCER; IDENTIFICATION; SECRETION; INVITRO	The transcription factor Oct-3/4 may be important in maintaining embryonic cells in an undifferentiated state, It is probably down-regulated at about the time that human chorionic gonadotropin (hCG) is first expressed in embryonic trophectoderm Here we report that Oct-3/4 strongly inhibits the hCG beta subunit (hCG beta) promoter in JAr choriocarcinoma cells. Oct-3/4 reduced chloramphenicol acetyltransferase (CAT) reporter expression from the -305hCG beta promoter by about 90% in transient co transfection assays, but had no effect on expression from the -249hCG beta promoter, The -305/-249 hCG beta fragment specifically bound synthetic Oct-3/4 protein as measured in electrophoretic mobility shift assays, and the Oct-3/4-binding site was localized around -270 by methylation interference footprinting, Site directed mutagenesis of this binding site abolished Oct-3/4 repression, When stably transfected into JAr cells, Oct-3/4 reduced the amounts of both endogenous hCG beta messenger RNA and hCG protein to less than 10% of controls. We suggest that silencing of Oct-3/4 in trophectoderm is a prerequisite for hCG up-regulation in early human embryos at the time of maternal recognition of pregnancy.	UNIV MISSOURI,DEPT ANIM SCI,ANIM SCI CTR 158,COLUMBIA,MO 65211; UNIV MISSOURI,DEPT BIOL SCI,ANIM SCI CTR 158,COLUMBIA,MO 65211	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia					NICHD NIH HHS [R37 HD21896, HD29483] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021896, R01HD029483] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSEN B, 1990, MOL ENDOCRINOL, V4, P573, DOI 10.1210/mend-4-4-573; ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; Ausubel FM, 1988, MOL REPROD DEV; BHAT K, 1988, MOL CELL BIOL, V8, P3251, DOI 10.1128/MCB.8.8.3251; BO M, 1992, J BIOL CHEM, V267, P3179; CLEARY MA, 1995, MOL CELL BIOL, V15, P2090; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DOKRAS A, 1991, HUM REPROD, V6, P1143, DOI 10.1093/oxfordjournals.humrep.a137500; EDMONDS DK, 1982, FERTIL STERIL, V38, P447; ELSHOLTZ HP, 1990, GENE DEV, V4, P43, DOI 10.1101/gad.4.1.43; HAY DL, 1988, J CLIN ENDOCR METAB, V67, P1322, DOI 10.1210/jcem-67-6-1322; HEARN JP, 1991, J REPROD FERTIL, V92, P497; HERR W, 1992, TRANSCRIPTIONAL REGU, P1103; JAMESON JL, 1987, J CLIN ENDOCR METAB, V64, P319, DOI 10.1210/jcem-64-2-319; JAMESON JL, 1988, MOL CELL BIOL, V8, P5100, DOI 10.1128/MCB.8.12.5100; JAMESON JL, 1993, ENDOCR REV, V14, P203, DOI 10.1210/er.14.2.203; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; LILLYCROP KA, 1994, MOL CELL BIOL, V14, P7633, DOI 10.1128/MCB.14.11.7633; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OTANI T, 1988, J BIOL CHEM, V263, P7322; PALMIERI SL, 1994, DEV BIOL, V166, P259, DOI 10.1006/dbio.1994.1312; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; POLICASTRO P, 1983, J BIOL CHEM, V258, P1492; ROBERTS RM, 1992, ENDOCR REV, V13, P432, DOI 10.1210/er.13.3.432; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Sambrook J., 2002, MOL CLONING LAB MANU; *SAS I INC, 1995, JMP STAT GRAPH GUID, P139; SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SESHAGIRI PB, 1993, HUM REPROD, V8, P279, DOI 10.1093/oxfordjournals.humrep.a138038; SHIMAZAKI T, 1993, EMBO J, V12, P4489, DOI 10.1002/j.1460-2075.1993.tb06138.x; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; STEGER DJ, 1993, MOL ENDOCRINOL, V7, P1579, DOI 10.1210/me.7.12.1579; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; TALMADGE K, 1984, NUCLEIC ACIDS RES, V12, P8415, DOI 10.1093/nar/12.22.8415; TALWAR GP, 1994, P NATL ACAD SCI USA, V91, P8532, DOI 10.1073/pnas.91.18.8532; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WEIS L, 1992, FASEB J, V6, P3330; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	50	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16683	16689		10.1074/jbc.271.28.16683	http://dx.doi.org/10.1074/jbc.271.28.16683			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663260	hybrid			2022-12-27	WOS:A1996UX12600043
J	Olson, LK; Schroeder, W; Robertson, RP; Goldberg, ND; Walseth, TF				Olson, LK; Schroeder, W; Robertson, RP; Goldberg, ND; Walseth, TF			Suppression of adenylate kinase catalyzed phosphotransfer precedes and is associated with glucose-induced insulin secretion in intact HIT-T15 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; SENSITIVE K-CHANNELS; HIT CELLS; POTASSIUM CHANNELS; B-CELLS; ATP; RELEASE; METABOLISM; ISLETS; LINE	Adenine nucleotide metabolism was characterized in intact insulin secreting HIT-T15 cells during the transition from non-stimulated (i.e. 0.2 mM glucose) to the glucose-stimulated secretory state. Metabolic dynamics were monitored by assessing rates of appearance of O-18-labeled phosphoryls of endogenous nucleotides in cells incubated in medium enriched in [O-18]water. Most prominent of the metabolic alterations associated with stimulated insulin secretion was the suppression in the rate of adenylate kinase (AK)-catalyzed phosphorylation of AMP by ATP, This was manifest as a graded decrease of up to 50% in the rate of appearance of beta-O-18-labeled species of ADP and ATP and corresponded to the magnitude of the secretory response elicited over a range of stimulatory glucose concentrations, The only nucleotide exhibiting a significant concentration change associated with suppression of AK activity was AMP, which decreased by about 50%, irrespective of the glucose concentration, Leucine-stimulated secretion also decreased the rate of AK-catalyzed phosphotransfer. This secretory stimulus-related suppression of AK-catalyzed phosphotransfer occurs within 45 s of glucose addition, precedes insulin secretion, depends on the internalization and metabolism of glucose, and is independent of membrane depolarization and the influx of extracellular calcium. The secretory stimulus-induced decrease in AK-catalyzed phosphotransfer, therefore occurs prior to or at the time of K-ATP(+) channel closure but it is not associated with or a consequence of events occurring subsequent to K-ATP(+) channel closure. These results indicate that AK-catalyzed phosphotransfer may be a determinant of ATP to ADP conversion rates in the K-ATP(+) channel microenvironment; secretory stimuli-linked decreased rates of AK-catalyzed ADP generation from ATP (and AMP) would translate into an increased probability of ATP-liganded and, therefore, closed state of the channel.	UNIV MINNESOTA,DEPT PHARMACOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT MED,DIV ENDOCRINOL DIABET & METAB,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Walseth, Timothy F/F-9518-2010; Roberston, R Paul/AAX-5613-2021	Walseth, Timothy F/0000-0003-2558-7859; 	NIDDK NIH HHS [DK-38325] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK038325, R01DK038325] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHCROFT SJ, 1973, BIOCHEM J, V132, P223, DOI 10.1042/bj1320223; ASHCROFT SJH, 1986, DIABETOLOGIA, V29, P727, DOI 10.1007/BF00870283; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; ASHCROFT SJH, 1987, FEBS LETT, V219, P311, DOI 10.1016/0014-5793(87)80242-9; ASPUND K, 1978, DIABETES, V27, P611; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; EDDLESTONE GT, 1989, J MEMBRANE BIOL, V109, P123, DOI 10.1007/BF01870851; GHOSH A, 1991, J BIOL CHEM, V266, P22887; HELLMAN B, 1969, DIABETES, V18, P509, DOI 10.2337/diab.18.8.509; HOPKINS WF, 1992, J MEMBRANE BIOL, V129, P287; KASPRZAK AA, 1980, EUR J BIOCHEM, V104, P443, DOI 10.1111/j.1432-1033.1980.tb04446.x; LARSSON O, 1993, J PHYSIOL-LONDON, V463, P349, DOI 10.1113/jphysiol.1993.sp019598; LEVIN SR, 1978, J CLIN INVEST, V62, P692, DOI 10.1172/JCI109177; LOWRY OH, 1964, J BIOL CHEM, V239, P18; MALAISSE WJ, 1982, J BIOL CHEM, V257, P8731; MALAISSE WJ, 1979, DIABETOLOGIA, V16, P331, DOI 10.1007/BF01223623; MALAISSE WJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P190, DOI 10.1016/0167-4889(87)90134-0; MATSCHIN.FM, 1972, DIABETES, V21, P555, DOI 10.2337/diab.21.2.S555; MEGLASSON MD, 1987, DIABETES, V36, P477, DOI 10.2337/diabetes.36.4.477; MEGLASSON MD, 1986, DIABETES, V35, P1340, DOI 10.2337/diabetes.35.12.1340; MEGLASSON MD, 1989, AM J PHYSIOL, V256, pE173, DOI 10.1152/ajpendo.1989.256.1.E173; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; NIKI I, 1989, PFLUG ARCH EUR J PHY, V415, P47, DOI 10.1007/BF00373140; OGUCHI M, 1973, J BIOL CHEM, V248, P5562; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PETERSEN OH, 1987, PHYSIOL REV, V67, P1054, DOI 10.1152/physrev.1987.67.3.1054; PIERCE M, 1978, ENDOCRINOLOGY, V103, P971, DOI 10.1210/endo-103-3-971; ROBERTSON RP, 1987, DIABETES, V36, P1047, DOI 10.2337/diabetes.36.9.1047; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SENER A, 1978, BIOCHEM J, V176, P217, DOI 10.1042/bj1760217; SHIMIZU T, 1988, DIABETES, V37, P563, DOI 10.2337/diabetes.37.5.563; STANFIELD PR, 1987, TRENDS NEUROSCI, V10, P335, DOI 10.1016/0166-2236(87)90091-9; TRUS M, 1980, DIABETES, V29, P1, DOI 10.2337/diabetes.29.1.1; WALSETH TF, 1988, METHOD ENZYMOL, V159, P60; ZELEZNIKAR RJ, 1990, J BIOL CHEM, V265, P300; ZELEZNIKAR RJ, 1995, J BIOL CHEM, V270, P7311, DOI 10.1074/jbc.270.13.7311; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44	38	43	44	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16544	16552		10.1074/jbc.271.28.16544	http://dx.doi.org/10.1074/jbc.271.28.16544			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663240	hybrid			2022-12-27	WOS:A1996UX12600021
J	Osawa, H; Sutherland, C; Robey, RB; Printz, RL; Granner, DK				Osawa, H; Sutherland, C; Robey, RB; Printz, RL; Granner, DK			Analysis of the signaling pathway involved in the regulation of hexokinase II gene transcription by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN S6 KINASE; GLUCOSE-TRANSPORT; TYROSINE PHOSPHORYLATION; SKELETAL-MUSCLE; PLASMA-MEMBRANE; MESSENGER-RNA; TRANSLOCATION	The hexokinases, by converting glucose to glucose 6-phosphate, help maintain the glucose concentration gradient that results in the movement of glucose into cells through the facilitative glucose transporters. Hexokinase II (HKII) is the major hexokinase isoform in skeletal muscle, heart, and adipose tissue, Insulin induces HKII gene transcription in L6 myotubes, and this, in turn, increases HKII mRNA and the rates of HKII protein synthesis and glucose phosphorylation in these cells. Inhibitors of distinct insulin signaling pathways were used to dissect the molecular mechanism by which HKII gene expression is induced by insulin in L6 myotubes, Treatment with wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase), or with rapamycin, an inhibitor of the pathway from the insulin receptor to p70/p85 ribosomal S6 protein kinase (p70(s6k)), prevented the induction of HKII mRNA by insulin, In contrast, treatment with PD98059, an inhibitor of mitogen-activated protein kinase activation, had no effect on insulin-induced HKII mRNA. In addition, rapamycin blocked the insulin-induced expression of an HKII promoter-chloramphenicol acetyltransferase fusion gene transiently transfected into L6 myotubes, whereas PD98059 had no such effect. These results suggest that a phosphatidylinositol 3-kinase/p70(s6k)-dependent pathway is required for regulation of HKII gene transcription by insulin and that the Ras-mitogen-activated protein kinase-dependent pathway is probably not involved.	VANDERBILT UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,SCH MED,NASHVILLE,TN 37232	Vanderbilt University			Robey, R. Brooks/J-7099-2013	Robey, R. Brooks/0000-0001-5059-3965; Sutherland, Calum/0000-0003-4398-7434	NIDDK NIH HHS [DK46867, DK35107, DK42502] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035107, R01DK046867, R01DK035107] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; HANSEN R, 1967, ENDOCRINOLOGY, V81, P1397, DOI 10.1210/endo-81-6-1397; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; MANDARINO LJ, 1995, AM J PHYSIOL-ENDOC M, V269, pE701; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; OSAWA H, 1995, DIABETES, V44, P1426, DOI 10.2337/diabetes.44.12.1426; POSTIC C, 1993, DIABETES, V42, P922, DOI 10.2337/diabetes.42.6.922; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; Robey RB, 1996, BIOTECHNIQUES, V20, P40; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SOMMERCORN J, 1993, J CLIN INVEST, V91, P509, DOI 10.1172/JCI116229; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Vestergaard H, 1995, J CLIN INVEST, V96, P2639, DOI 10.1172/JCI118329; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	42	105	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16690	16694		10.1074/jbc.271.28.16690	http://dx.doi.org/10.1074/jbc.271.28.16690			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663315	hybrid			2022-12-27	WOS:A1996UX12600044
J	Salih, E; Zhou, HY; Glimcher, MJ				Salih, E; Zhou, HY; Glimcher, MJ			Phosphorylation of purified bovine bone sialoprotein and osteopontin by protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT BONE; SECRETED PHOSPHOPROTEIN; MATRIX; PURIFICATION; IDENTIFICATION; SEQUENCE; TRANSFORMATION; PROTEOGLYCAN; FIBRONECTIN; ATTACHMENT	The large number of covalently bound phosphates on the extracellular phosphoproteins osteopontin (OPN) and bone sialoprotein (BSP) have been implicated in biological functions such as mineral deposition and osteoclast binding. In the present study the state of phosphorylation of BSP and OPN was evaluated by in vitro P-32 labeling using a series of protein kinases and quantification. Both the purified bovine BSP and OPN were radiolabeled by [P-32]ATP and factor-independent protein kinase. Quantification of P-32 radioactivity incorporated on dephosphorylated BSP and OPN provided 6.6 and 8.9 mol of phosphate incorporated/mol, respectively. Native OPN incorporated 1.07 and BSP 2.46 mol of phosphate/mol by factor-independent protein kinase. These data led to calculations that OPN and BSP, respectively, contain 7.83 and 4.14 mol of phosphate/mol in their natural state. Thrombin digests of P-32-labeled BSP showed radioactivity to be associated with fragment of similar to molecular mass values 30 kDa (N-terminal half), with no observable radioactivity associated with the 40-kDa fragment (C-terminal half). Similar experiments with P-32-labeled OPN provided two radiolabeled thrombin fragments, with molecular mass 30 kDa (N-terminal half) and 20 kDa (C-terminal half), both were radioactive. The major phosphorylation was associated with the N-terminal half containing 7.0 mol of phosphate, and 1.9 mol of phosphate were associated with the C-terminal half. Additional experiments of in vitro phosphorylation of OPN and BSP by several other known protein kinases were carried out. cAMP-dependent protein kinase showed no phosphorylation of OPN or ESP, while protein kinase C and cGMP-dependent protein kinase led to minor phosphorylation, each of the latter introduced about 1 mol of phosphate/mol of OPN and BSP molecule.	CHILDRENS HOSP, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital	Salih, E (corresponding author), HARVARD UNIV, SCH MED, DEPT ORTHOPAED SURG, LAB STUDY SKELETAL DISORDERS & REHABIL, BOSTON, MA 02115 USA.			Salih, Erdjan/0000-0003-3322-2323	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR034078] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR34078] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDREWS ATB, 1967, BIOCHEM J, V104, P705, DOI 10.1042/bj1040705; ASHKAR S, 1995, ANN NY ACAD SCI, V760, P296, DOI 10.1111/j.1749-6632.1995.tb44639.x; ASHKAR S, 1991, BIOCHEM BIOPH RES CO, P126; CARR C, 1987, BIOCHEMISTRY-US, V26, P7090, DOI 10.1021/bi00396a034; CHENU C, 1994, J BONE MINER RES, V9, P417; COHENSOLAL L, 1979, BIOCHEM J, V177, P81, DOI 10.1042/bj1770081; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; DIJIK SW, 1993, J BONE MINER RES, V8, P1499; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; EKRYLANDER B, 1994, J BIOL CHEM, V269, P14853; ENDO A, 1989, CONNECT TISSUE RES, V21, P509, DOI 10.3109/03008208909050008; FISHER LW, 1983, J BIOL CHEM, V258, P2723; FISHER LW, 1990, J BIOL CHEM, V265, P2347; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FLORES ME, 1993, J BONE MINER RES, V8, pS397; FRANZEN A, 1985, BIOCHEM J, V232, P715, DOI 10.1042/bj2320715; FRANZEN A, 1985, CHEM BIOL MINERALIZE, P132; GLIMCHER MJ, 1984, PHILOS T R SOC B, V304, P479, DOI 10.1098/rstb.1984.0041; GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205; GOTOH Y, 1990, EUR J BIOCHEM, V187, P49, DOI 10.1111/j.1432-1033.1990.tb15276.x; GOTOH Y, 1990, BIOCHEM BIOPH RES CO, V173, P471, DOI 10.1016/S0006-291X(05)81082-4; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HEINEGARD D, 1989, CONNECT TISSUE RES, V12, P3; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HORTON MA, 1995, ANN NY ACAD SCI, V760, P190, DOI 10.1111/j.1749-6632.1995.tb44630.x; KEMP BE, 1991, PEPTIDES PROTEIN PHO, P43; KINNE RW, 1987, J BIOL CHEM, V262, P10206; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KUBOTA T, 1989, BIOCHEM BIOPH RES CO, V162, P1453, DOI 10.1016/0006-291X(89)90837-1; LEE SL, 1981, CALCIFIED TISSUE INT, V33, P385, DOI 10.1007/BF02409461; MIKUNITAKAGAKI Y, 1990, BIOCHEM J, V268, P585, DOI 10.1042/bj2680585; MINTZ KP, 1993, J BONE MINER RES, V8, P985; NAGATA T, 1965, BIOCHEM BIOPH RES CO, P234; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; SALIH E, 1995, ANN NY ACAD SCI, V760, P357, DOI 10.1111/j.1749-6632.1995.tb44656.x; SALIH E, 1996, IN PRESS J BONE MINE; SALIH E, 1996, IN PRESS CONNECT TIS; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; SENGER DR, 1994, MOL BIOL CELL, V5, P565, DOI 10.1091/mbc.5.5.565; SENGER DR, 1989, ANTICANCER RES, V9, P1291; SFEIR C, 1995, J BONE MINER RES, V10, P607; SOMERMAN MJ, 1987, J BONE MINER RES, V2, P259; SORENSEN ES, 1995, PROTEIN SCI, V4, P2040, DOI 10.1002/pro.5560041009; SORENSEN ES, 1993, J DAIRY RES, V60, P535, DOI 10.1017/S0022029900027886; TANABE J, 1993, J BIOL CHEM, V268, P27143; TAUJON PT, 1991, ADV SEC MESS PHOSPH, P123; UCHIYAMA A, 1986, BIOCHEMISTRY-US, V25, P7572, DOI 10.1021/bi00371a047; UCHIYAMA A, 1985, CHEM BIOL MINERALIZE, P182; Veis A, 1983, BIOMINERALIZATION BI, V240, p[273, 35]; WU CB, 1992, J BIOL CHEM, V267, P16588; XUAN JW, 1994, J CELL BIOCHEM, V54, P247, DOI 10.1002/jcb.240540213; ZHANG R, 1990, J BIOL CHEM, V265, P15375; [No title captured]	57	51	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16897	16905		10.1074/jbc.271.28.16897	http://dx.doi.org/10.1074/jbc.271.28.16897			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663267	hybrid			2022-12-27	WOS:A1996UX12600072
J	Kremer, R; Sebag, M; Champigny, C; Meerovitch, K; Hendy, GN; White, J; Goltzman, D				Kremer, R; Sebag, M; Champigny, C; Meerovitch, K; Hendy, GN; White, J; Goltzman, D			Identification and characterization of 1,25-dihydroxyvitamin D-3-responsive repressor sequences in the rat parathyroid hormone-related peptide gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCALCIN GENE; RETINOIC ACID; CELL-LINE; EXPRESSION; RECEPTOR; KERATINOCYTES; GROWTH; PROTEINS; ELEMENTS; BINDING	Parathyroid hormone-related peptide (PTHRP) gene transcription is suppressed by 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3), the active metabolite of vitamin D-3. In the present report, we examined 1,25(OH)(2)D-3-mediated repression of PTHRP expression by transfection of PTHRP promoter/reporter constructs in normal human keratinocytes and by DNA binding, We localized an element conferring 1,25(OH)(2)D-3-mediated repression in vivo to a 47-base pair (bp) region located -1121 to -1075 from the transcriptional start site, Mobility shift analysis revealed that this vitamin D response element (VDRE) forms DNA-protein complexes. The addition of a monoclonal antibody that recognizes the DNA binding region of the vitamin D receptor (VDR) attenuated binding of the receptor to the 47-bp sequence, whereas the addition of monoclonal antibody raised against the retinoid X receptor (RXR) further retarded the mobility of the protein-DNA complex. Consequently, the PTHRP promoter element binds a VDR-RXR heterodimer, Examination of this VDRE revealed complete sequence homology with a half-site of the human and rat osteocalcin VDRE: (GGGTGA). Furthermore, mutation analysis suggests that a 16-bp domain consisting of an almost perfect repeat separated by a 3-base pair ''spacer'' GGGTGGAGAGGGGTGA is responsible for the DNA-protein interaction within this 47-bp sequence. Our results therefore indicate the existence of an inhibitory VDRE within the PTHRP promoter that is similar in sequence composition and cellular factor requirement to classical upregulatory VDREs.	MCGILL UNIV,DEPT MED,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3A 1A1,CANADA	McGill University; McGill University	Kremer, R (corresponding author), ROYAL VICTORIA HOSP,CALCIUM RES LAB,ROOM H467,687 PINE AVE W,MONTREAL,PQ H3A 1A1,CANADA.		white, john h/N-9782-2013	white, john h/0000-0002-4785-2687; Kremer, Richard/0000-0002-7053-2139				ALROY I, 1995, MOL CELL BIOL, V15, P5789; BIKLE DD, 1986, BIOCHEMISTRY-US, V25, P1545, DOI 10.1021/bi00355a013; BOYCE ST, 1985, J TISSUE CULTURE MET, V9, P83; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; KAISER SM, 1992, J BIOL CHEM, V267, P13623; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KREMER R, 1991, J CLIN INVEST, V87, P884, DOI 10.1172/JCI115094; Liu SM, 1996, MOL ENDOCRINOL, V10, P206, DOI 10.1210/me.10.2.206; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; Mackey SL, 1996, MOL ENDOCRINOL, V10, P298, DOI 10.1210/me.10.3.298; Maniatis T., 1982, MOL CLONING; MANOLAGAS SC, 1990, KIDNEY INT, V38, pS9; MERENDINO JJ, 1986, SCIENCE, V231, P338; MOSELEY JM, 1987, P NATL ACAD SCI USA, V84, P5048, DOI 10.1073/pnas.84.14.5048; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; SEBAG M, 1994, AM J PHYSIOL, V267, pC723, DOI 10.1152/ajpcell.1994.267.3.C723; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SELDEN RF, 1987, CURRENT PROTOCOLS MO; SMITH EL, 1986, J INVEST DERMATOL, V86, P709, DOI 10.1111/1523-1747.ep12276343; STEWART AF, 1987, BIOCHEM BIOPH RES CO, V146, P672, DOI 10.1016/0006-291X(87)90581-X; STREWLER GJ, 1987, J CLIN INVEST, V80, P1803, DOI 10.1172/JCI113275; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	25	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16310	16316		10.1074/jbc.271.27.16310	http://dx.doi.org/10.1074/jbc.271.27.16310			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663213	hybrid			2022-12-27	WOS:A1996UW35200067
J	Almaula, N; Ebersole, BJ; Zhang, DQ; Weinstein, H; Sealfon, SC				Almaula, N; Ebersole, BJ; Zhang, DQ; Weinstein, H; Sealfon, SC			Mapping the binding site pocket of the serotonin 5-hydroxytryptamine(2A) receptor - Ser(3.36(159)) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; LIGAND-BINDING; DIRECTED MUTAGENESIS; IDENTIFICATION; RESIDUES; ACTIVATION; MUTATION; PROTEINS; SERINE; ROLES	Like other amine neurotransmitters that activate G-protein coupled receptors, 5-hydroxytryptamine (5-HT) binds to the 5-HT2A receptor through the interaction of its cationic primary amino group with the conserved Asp(3.32(155)) in transmembrane helix 3. Computational experiments with a 5-HT2A receptor model suggest that the same functional group of B-hydroxytryptamine also forms a hydrogen bond with the side chain of Ser(3.36(159)), which is adjacent in space to Asp(3.32(155)), However, other 5-HT2A receptor ligands like lysergic acid diethylamide (LSD), in which the amine nitrogen is embedded in a heterocycle, or N,N-dimethyl 5-HT, in which the side chain is a tertiary amine, are found in the computational simulations to interact with the aspartate but not with the serine, due mainly to steric hindrance, The predicted difference in the interaction of various ligands in the same receptor binding pocket was tested with site directed mutagenesis of Ser(3.36(159)) --> Ala and Ser(3.36(159)) --> Cys, The alanine substitution led to an 18-fold reduction in 5-HT affinity and the cysteine substitution to an intermediate 5-fold decrease, LSD affinity, in contrast, was unaffected by either mutation, N,N-Dimethyl 5-HT affinity was unaffected by the cysteine mutation and had a comparatively small 3-fold decrease in affinity for the alanine mutant, These findings identify a mode of ligand-receptor complexation that involves two receptor side chains interacting with the same functional group of specific serotonergic ligands, This interaction serves to orient the ligands in the binding pocket and may influence the degree of receptor activation.	MT SINAI SCH MED, FISHBERG RES CTR NEUROBIOL, NEW YORK, NY 10029 USA; MT SINAI SCH MED, DEPT ANESTHESIOL, NEW YORK, NY 10029 USA; MT SINAI SCH MED, DEPT PHYSIOL & BIOPHYS, NEW YORK, NY 10029 USA; MT SINAI SCH MED, DEPT NEUROL, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai			WEINSTEIN, HAREL/O-8245-2019	WEINSTEIN, HAREL/0000-0003-3473-9818; SEALFON, Stuart/0000-0001-5791-1217	NIDA NIH HHS [R01 DA09088, T32 DA07135, R01 DA09083] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007135, R01DA009088, R01DA009083] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHOUDHARY MS, 1992, MOL PHARMACOL, V42, P627; CHOUDHARY MS, 1995, MOL PHARMACOL, V47, P450; CHOUDHARY MS, 1993, MOL PHARMACOL, V43, P755; FRASER CM, 1989, MOL PHARMACOL, V36, P840; Glennon R. A., 1991, SEROTONIN RECEPTOR S, P19; GRAY TM, 1984, J MOL BIOL, V175, P75, DOI 10.1016/0022-2836(84)90446-7; GREGORET LM, 1991, PROTEINS, V9, P99, DOI 10.1002/prot.340090204; HO BY, 1992, FEBS LETT, V312, P259, DOI 10.1016/0014-5793(92)80948-G; JOHNSON MP, 1994, MOL PHARMACOL, V45, P277; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUO XC, 1994, PROTEIN ENG, V7, P1441, DOI 10.1093/protein/7.12.1441; SALTZMAN AG, 1991, BIOCHEM BIOPH RES CO, V181, P1469, DOI 10.1016/0006-291X(91)92105-S; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P16470; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; WANG CD, 1993, MOL PHARMACOL, V43, P931; WANG CD, 1991, MOL PHARMACOL, V40, P168; ZHANG DQ, 1994, FEBS LETT, V337, P207, DOI 10.1016/0014-5793(94)80274-2; ZHANG DQ, 1993, J MED CHEM, V36, P934, DOI 10.1021/jm00059a021; ZHANG DQ, 1993, MED CHEM RES, V3, P357	25	125	127	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14672	14675		10.1074/jbc.271.25.14672	http://dx.doi.org/10.1074/jbc.271.25.14672			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663249	hybrid			2022-12-27	WOS:A1996UT10600007
J	Cestele, S; Sampieri, F; Rochat, H; Gordon, D				Cestele, S; Sampieri, F; Rochat, H; Gordon, D			Tetrodotoxin reverses brevetoxin allosteric inhibition of scorpion alpha-toxin binding on rat brain sodium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-SITE; NEUROTOXIN BINDING; SYNAPTOSOMES; VERATRIDINE; MODULATION; MEMBRANES; SAXITOXIN; RESIDUES	Voltage-sensitive sodium channels are responsible for the initiation of action potentials in many excitable cells, Several neurotoxins bind to distinct receptor sites on sodium channels and reveal strong allosteric interactions among them, Scorpion alpha toxins, which inhibit sodium channel inactivation by binding to receptor site 3, have been very important tools to study sodium channel structure and function, Recently, we have shown that brevetoxin induce a strong negative allosteric modulation on scorpion alpha-toxin binding on rat brain sodium channels, in contrast to previously published studies. In this report we have examined the reasons for this discrepancy and found new, unexpected allosteric interactions between the tetrodotoxin and brevetoxin receptor sites, using scorpion alpha-toxin as sensitive probe for subtle conformational changes on sodium channels. Tetrode-toxin reverses the negative modulation induced by brevetoxin on scorpion alpha-toxin binding, revealing new dynamic interactions in sodium channel structure.	FAC MED NORD,JEAN ROCHE INST,BIOCHEM LAB,CNRS URA 1455,F-13916 MARSEILLE 20,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite								BADEN DG, 1989, FASEB J, V3, P1807, DOI 10.1096/fasebj.3.7.2565840; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; CATTERALL WA, 1981, MOL PHARMACOL, V19, P345; CATTERALL WA, 1977, J BIOL CHEM, V252, P8660; CATTERALL WA, 1985, TOXICON, V23, P497, DOI 10.1016/0041-0101(85)90034-0; CATTERALL WA, 1992, PHYSIOL REV, V72, P15; CESTELE S, 1995, J BIOL CHEM, V270, P15153, DOI 10.1074/jbc.270.25.15153; DODD PR, 1981, BRAIN RES, V226, P107, DOI 10.1016/0006-8993(81)91086-6; EDWARDS RA, 1992, MOL BRAIN RES, V14, P64, DOI 10.1016/0169-328X(92)90011-Y; GAWLEY RE, 1992, TOXICON, V30, P780, DOI 10.1016/0041-0101(92)90014-V; HUANG JMC, 1984, J PHARMACOL EXP THER, V229, P615; JOVER E, 1980, BIOCHEMISTRY-US, V19, P463, DOI 10.1021/bi00544a010; KHARRAT R, 1990, TOXICON, V28, P509, DOI 10.1016/0041-0101(90)90295-I; KHARRAT R, 1989, EUR J BIOCHEM, V181, P381, DOI 10.1111/j.1432-1033.1989.tb14735.x; MIRANDA F, 1970, EUR J BIOCHEM, V16, P514, DOI 10.1111/j.1432-1033.1970.tb01111.x; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; POLI MA, 1986, MOL PHARMACOL, V30, P129; RAY R, 1978, J BIOL CHEM, V253, P7307; Rogers J. C., 1996, Biophysical Journal, V70, pA319; SHARKEY RG, 1987, MOL PHARMACOL, V31, P273; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; TRAINER VL, 1991, MOL PHARMACOL, V40, P988; TRAINER VL, 1994, J BIOL CHEM, V269, P19904; TRAINER VL, 1993, J BIOL CHEM, V268, P17114; WU CH, 1987, ANN REV PHARM TOXICO, V28, P141	27	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18329	18332		10.1074/jbc.271.31.18329	http://dx.doi.org/10.1074/jbc.271.31.18329			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702472	hybrid			2022-12-27	WOS:A1996VB68300010
J	Kainulainen, V; Nelimarkka, L; Jarvelainen, H; Laato, M; Jalkanen, M; Elenius, K				Kainulainen, V; Nelimarkka, L; Jarvelainen, H; Laato, M; Jalkanen, M; Elenius, K			Suppression of syndecan-1 expression tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; MAMMARY EPITHELIAL-CELLS; FIBROBLAST GROWTH-FACTOR; EMBRYONIC TOOTH MESENCHYME; SURFACE PROTEOGLYCAN; ENDOTHELIAL-CELLS; MALIGNANT TRANSFORMATION; VASCULAR ENDOTHELIUM; KAPPA-B; BINDING	Syndecan-1 is a cell surface proteoglycan that binds extracellular matrix components and modulates the activity of heparin-binding growth factors, The expression of syndecan-1 is modified during development, carcinogenesis, and tissue regeneration, During cutaneous wound healing, syndecan-1 expression is transiently induced in newly-formed capillaries of granulation tissue as well as in proliferating keratinocytes, To study the mechanisms underlying this regulation we investigated the effects of several growth factors/cytokines on syndecan-1 expression in two human cell lines: EA.hy 926 endothelial cells and HaCaT keratinocytes. None of these factors significantly altered syndecan-1 mRNA expression in cultured keratinocytes, but when given to endothelial cells, tumor necrosis factor-alpha (TNF-alpha) specifically and dose-dependently suppressed syndecan-1 expression at both mRNA and protein levels, TNF-alpha reduced the amount of syndecan-1 protein in EA.hy 926 cells in both the presence and absence of serum and, at the same time, induced the expression of intercellular adhesion molecule-1 (ICAM-1). The suppressive effect of TNF-alpha on endothelial syndecan-1 expression was reproducible in in vivo experiments in which TNF-alpha coated beads were administered directly to healing skin wounds of mice. Data supporting these findings were further obtained by injecting TNF-alpha into an experimental rat granulation tissue model, In this tissue TNF a suppressed syndecan-1 mRNA expression by approximately 80%. These results indicate that TNF-alpha is capable of down-regulating syndecan-1 expression in endothelial cells both in vitro and in vivo and suggest that similar mechanisms may be responsible for the changes in syndecan-1 expression observed during various regenerative, developmental, and malignant processes.	UNIV TURKU, DEPT SURG, TURKU 20520, FINLAND; UNIV TURKU, DEPT INTERNAL MED, TURKU 20520, FINLAND; UNIV TURKU, DEPT BIOCHEM MED, TURKU 20520, FINLAND; UNIV TURKU, TURKU CTR BIOTECHNOL, TURKU 20520, FINLAND	University of Turku; University of Turku; University of Turku; University of Turku				Elenius, Klaus/0000-0001-5700-0827				AIRAS L, 1993, J IMMUNOL, V151, P4228; AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIZMECISMITH G, 1993, J BIOL CHEM, V268, P18740; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; ELENIUS K, 1994, J CELL SCI, V107, P2975; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; EMEIS JJ, 1988, BLOOD, V71, P1669; FAJARDO LF, 1992, AM J PATHOL, V140, P539; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; HAVELL EA, 1988, J EXP MED, V167, P1067, DOI 10.1084/jem.167.3.1067; HAYAMIZU TF, 1991, DEV BIOL, V145, P164, DOI 10.1016/0012-1606(91)90222-O; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HINKES MT, 1993, J BIOL CHEM, V268, P11440; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; INKI P, 1994, BRIT J CANCER, V70, P319, DOI 10.1038/bjc.1994.300; INKI P, 1991, AM J PATHOL, V139, P1333; INKI P, 1994, EUR J CELL BIOL, V63, P43; JAATTELA M, 1991, LAB INVEST, V64, P724; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; JALKANEN M, 1993, TRENDS GLYCOSCI GLYC, V5, P107; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; KATO M, 1995, MOL BIOL CELL, V6, P559, DOI 10.1091/mbc.6.5.559; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KLAGSBRUN M, 1991, PEPTIDE GROWTH FACTO, P549; KODA JE, 1985, J BIOL CHEM, V260, P8157; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KRISTENSEN M, 1993, CLIN EXP IMMUNOL, V94, P354; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; LINZ DN, 1994, J PEDIATR SURG, V29, P1065, DOI 10.1016/0022-3468(94)90280-1; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MALI M, 1990, J BIOL CHEM, V265, P6884; MALI M, 1993, J BIOL CHEM, V268, P24215; MALI M, 1994, J BIOL CHEM, V269, P27795; MERTENS G, 1992, J BIOL CHEM, V267, P20435; MOONEY DP, 1990, ANN SURG, V211, P124, DOI 10.1097/00000658-199002000-00002; NIINIKOSKI J, 1971, SURG GYNECOL OBSTETR, V133, P1003; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PALLADINO MA, 1987, J IMMUNOL, V138, P4023; POBER JS, 1987, J IMMUNOL, V138, P3319; RAPALA K, 1991, EUR SURG RES, V23, P261, DOI 10.1159/000129163; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REICHSLOTKY R, 1994, J BIOL CHEM, V269, P32279; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; SALOMON GD, 1991, ANN SURG, V214, P175, DOI 10.1097/00000658-199108000-00012; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VAINIO S, 1989, J CELL BIOL, V108, P1945, DOI 10.1083/jcb.108.5.1945; VAINIO S, 1992, DEV BIOL, V152, P221, DOI 10.1016/0012-1606(92)90130-9; VIHINEN T, 1993, J BIOL CHEM, V268, P17261; VILJANTO J, 1962, ANN MED EXP BIOL FEN, V40, P118; VOGEL A, 1993, DEVELOPMENT, V119, P199; WRIDE MA, 1993, DEV DYNAM, V198, P225, DOI 10.1002/aja.1001980308; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	70	56	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18759	18766		10.1074/jbc.271.31.18759	http://dx.doi.org/10.1074/jbc.271.31.18759			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702532	hybrid			2022-12-27	WOS:A1996VB68300070
J	Tu, LW; Santarelli, V; Sheng, ZF; Skach, W; Pain, D; Deutsch, C				Tu, LW; Santarelli, V; Sheng, ZF; Skach, W; Pain, D; Deutsch, C			Voltage-gated K+ channels contain multiple intersubunit association sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; PROTEINS; RECOGNITION; EXPRESSION; ACTIVATION; SUBUNITS; PACKING	A domain in the cytoplasmic NH2 terminus of voltage-gated K+ channels supervises the proper assembly of specific tetrameric channels (Li, M., Jan, J. M., and Jan, L. Y. (1992) Science 257, 1225-1230; Shen, N. V., Chen X., Boyer, M. RI., and Pfaffinger, P. (1993) Neuron 11, 67-76). It is referred to as a first tetramerization domain, or TI (Shen, N. V., Chen X., Boyer, RI. M., and Pfaffinger, P. (1993) Neuron 11, 67-76). However, a deletion mutant of Kv1.3 that lacks the first 141 amino acids, Kv1.3 (T1(-)) forms functional channels, suggesting that additional association sites in the central core of Kv1.3 mediate oligomerization. To characterize these sites, we have tested the abilities of cRNA Kv1.3 (T1(-)) fragments coinjected with Kv1.3 (T1(-)) to suppress current in Xenopus oocytes. The fragments include portions of the six putative transmembrane segments, S1 through S6, specifically: S1, S1-S2, S1-S2-S3, S2-S3, S2-S3-S4, S3-S4, S3-S4-S5, S2 through COOH, S3 through COOH, S4 through COOH, and S5-S6-COOH. Electrophysiologic experiments show that the fragments S1-S2-S3, S3-S4-S5, S2 through COOH, and S3 through COOH strongly suppress Kv1.3 (T1(-)) current, while others do not. Suppression of expressed current is due to specific effects of the translated peptide Kv1.3 fragments, as validated by in vivo immunoprecipitation studies of a strong suppressor and a nonsuppressor. Pulse-chase experiments indicate that translation of truncated peptide fragments neither prevents translation of Kv1.3 (T1(-)) nor increases its rate of degradation. Co-immunoprecipitation experiments suggest that suppression involves direct association of a peptide fragment with Kv1.3 (T1(-)). Fragments that strongly suppress Kv1.3 (T1(-)) also suppress an analogous NH2-terminal deletion mutant of Kv2.1 (Kv2.1 (Delta N139)), an isoform belonging to a different subfamily. Our results indicate that sites in the central core of Kv1.3 facilitate intersubunit association and that there are suppression sites in the central core, which are promiscuous across voltage-gated K+ channel subfamilies.	UNIV PENN,SCH MED,DEPT PHYSIOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MOL & CELLULAR ENGN,PHILADELPHIA,PA 19104; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PHYSIOL,PHILADELPHIA,PA 19107	University of Pennsylvania; University of Pennsylvania; Jefferson University					NATIONAL CANCER INSTITUTE [K11CA001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041476, R01GM052302] Funding Source: NIH RePORTER; NCI NIH HHS [CA 01614] Funding Source: Medline; NIGMS NIH HHS [GM 52302, GM 41476] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR J, 1993, AM J PHYSIOL, V265, pC1571, DOI 10.1152/ajpcell.1993.265.6.C1571; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BEZANILLA F, 1995, BIOPHYS J, V68, P137; BOULAY F, 1988, J CELL BIOL, V106, P629, DOI 10.1083/jcb.106.3.629; CHAHINE M, 1992, J MOL CELL CARDIOL, V24, P1231, DOI 10.1016/0022-2828(92)93090-7; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; GILSON MK, 1988, PROTEINS, V3, P32, DOI 10.1002/prot.340030104; HOPKINS WF, 1994, J NEUROSCI, V14, P1385, DOI 10.1523/JNEUROSCI.14-03-01385.1994; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PLANELLSCASES R, 1995, P NATL ACAD SCI USA, V92, P9422, DOI 10.1073/pnas.92.20.9422; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; RUSSELL AJ, 1993, SUBCELL BIOCH, V21, P41; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SHEN NV, 1993, NEURON, V11, P67; TU L, 1995, BIOPHYS J, V68, P266; TU LW, 1995, BIOPHYS J, V68, P147, DOI 10.1016/S0006-3495(95)80169-4; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761	21	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18904	18911		10.1074/jbc.271.31.18904	http://dx.doi.org/10.1074/jbc.271.31.18904			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702552	hybrid			2022-12-27	WOS:A1996VB68300090
J	Wastfelt, M; StalhammarCarlemalm, M; Delisse, AM; Cabezon, T; Lindahl, G				Wastfelt, M; StalhammarCarlemalm, M; Delisse, AM; Cabezon, T; Lindahl, G			Identification of a family of streptococcal surface proteins with extremely repetitive structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-B-STREPTOCOCCI; MOUSE-PROTECTIVE ANTIBODIES; C-PROTEIN; IGA RECEPTOR; SEQUENCE; GENE; ANTIGENS; ALPHA; IMMUNITY	The group B Streptococcus (GBS) causes the majority of life threatening bacterial infections in newborn children. Most GBS strains isolated from such infections express a surface protein, designated Rib, that confers protective immunity and therefore is of interest for analysis of pathogenetic mechanisms. Sequence analysis demonstrated that Rib has an exceptionally long signal peptide (55 amino acid residues) and 12 repeats (79 amino acid residues each) that account for >80% of the sequence of the mature protein. The repeats are identical even at the DNA level, indicating that an efficient mechanism operates to maintain a highly repetitive structure in Rib. The structure of Rib is similar to that of alpha, a previously characterized surface protein that is common among GBS strains lacking Rib, However, highly purified preparations of Rib and alpha did not crossreact immunologically, although the two proteins show extensive amino acid residue identity (47% in the repeat region). When analyzed in Western blots, Rib and alpha give rise to a regularly spaced ladder pattern, apparently due to hydrolysis of acid-labile Asp Pro bonds in the repeats. We conclude that Rib and alpha are members of a novel family of streptococcal surface proteins with unusual repetitive structure.	LUND UNIV, DEPT MED MICROBIOL, S-22362 LUND, SWEDEN; SMITHKLINE BEECHAM BIOL, B-1330 RIXENSART, BELGIUM	Lund University; GlaxoSmithKline								Baker C., 1995, INFECT DIS FETUS NEW, V4th ed., P980; BEVANGER L, 1985, ACTA PATH MICRO IM B, V93, P121; BEVANGER L, 1979, ACTA PATH MICRO IM B, V87, P51; GALLI J, 1993, J BIOL CHEM, V268, P11888; HEDEN LO, 1991, EUR J IMMUNOL, V21, P1481, DOI 10.1002/eji.1830210623; HOLLINGSHEAD SK, 1986, J BIOL CHEM, V261, P1677; JERLSTROM PG, 1991, MOL MICROBIOL, V5, P843, DOI 10.1111/j.1365-2958.1991.tb00757.x; LANCEFIELD RC, 1975, J EXP MED, V142, P165, DOI 10.1084/jem.142.1.165; Landon, 1977, Methods Enzymol, V47, P145; LINDAHL G, 1990, EUR J IMMUNOL, V20, P2241, DOI 10.1002/eji.1830201013; MADOFF LC, 1991, INFECT IMMUN, V59, P2638, DOI 10.1128/IAI.59.8.2638-2644.1991; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MICHEL JL, 1991, GENETICS AND MOLECULAR BIOLOGY OF STREPTOCOCCI, LACTOCOCCI, AND ENTEROCOCCI, P214; MICHEL JL, 1991, INFECT IMMUN, V59, P2023, DOI 10.1128/IAI.59.6.2023-2028.1991; MICHEL JL, 1992, P NATL ACAD SCI USA, V89, P10060, DOI 10.1073/pnas.89.21.10060; MITA K, 1988, J MOL BIOL, V203, P917, DOI 10.1016/0022-2836(88)90117-9; MUSSER JM, 1989, P NATL ACAD SCI USA, V86, P4731, DOI 10.1073/pnas.86.12.4731; PAAVONEN J, 1983, SCAND J INFECT DIS, P31; RUSSELLJONES GJ, 1984, J EXP MED, V160, P1467, DOI 10.1084/jem.160.5.1467; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; STALHAMMARCARLEMALM M, 1993, J EXP MED, V177, P1593, DOI 10.1084/jem.177.6.1593; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; WESSELS MR, 1990, J CLIN INVEST, V86, P1428, DOI 10.1172/JCI114858; WILKINSON HW, 1971, INFECT IMMUN, V4, P596, DOI 10.1128/IAI.4.5.596-604.1971; ZHENG XT, 1995, INFECT IMMUN, V63, P891, DOI 10.1128/IAI.63.3.891-898.1995; [No title captured]	29	107	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18892	18897		10.1074/jbc.271.31.18892	http://dx.doi.org/10.1074/jbc.271.31.18892			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702550	hybrid			2022-12-27	WOS:A1996VB68300088
J	Bisotto, S; Minorgan, S; Rehfuss, RP				Bisotto, S; Minorgan, S; Rehfuss, RP			Identification and characterization of a novel transcriptional activation domain in the CREB-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CAMP; CBP	The CREB-binding protein (CBP) plays a central role in the regulation of gene expression by several different second messenger pathways including serum growth factors, cAMP and phorbol esters, CBP specifically binds to the phosphorylated forms of CREB and c-Jun and is thought to activate transcription through a C-terminal activation domain, In this report, we demonstrate that the C terminus of CBP is dispensable for its ability to stimulate phospho-CREB activity, and, further, that the deletion of this domain produces highly active, mutant forms of CBP. The novel N-terminal activation identified by this deletional analysis consists of the first 714 amino acids of CBP and is sufficient for high levels of transcriptional activity, This domain is also capable of stimulating the activity of a second cAMP-regulated factor, ATF-1. Surprisingly, ATF-1 activity is not significantly stimulated by full-length CBP suggesting that the C terminal domain of CBP may also serve to regulate ATF-1/CBP activity, Additionally, the demonstration that one of our hyperactive CBP mutants is able to activate a nonphosphorylatable mutant of CREB (M1 CREB) provides the first evidence that CBP may play a role in regulating the basal transcriptional activity of CREB.			Bisotto, S (corresponding author), MCGILL UNIV,ROYAL VICTORIA HOSP,MOLEC ENDOCRINOL LAB,MONTREAL,PQ H3A 1A1,CANADA.							ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; ELLIS MJC, 1995, MOL ENDOCRINOL, V9, P255, DOI 10.1210/me.9.2.255; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LALLI E, 1994, J BIOL CHEM, V269, P17359; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MAYER TE, 1993, ENDOCR REV, V14, P269; NORDHEIM A, 1994, NATURE, V370, P177, DOI 10.1038/370177a0; Parker D, 1996, MOL CELL BIOL, V16, P694; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SUN PQ, 1995, J BIOL CHEM, V270, P7041, DOI 10.1074/jbc.270.13.7041; XING LP, 1995, J BIOL CHEM, V270, P17488, DOI 10.1074/jbc.270.29.17488	21	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17746	17750		10.1074/jbc.271.30.17746	http://dx.doi.org/10.1074/jbc.271.30.17746			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663603	hybrid			2022-12-27	WOS:A1996UY93500026
J	JewellMotz, EA; Liggett, SB				JewellMotz, EA; Liggett, SB			G protein-coupled receptor kinase specificity for phosphorylation and desensitization of alpha(2)-adrenergic receptor subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD INTRACELLULAR LOOP; AGONIST-PROMOTED DESENSITIZATION; BETA-GAMMA-SUBUNITS; ADRENERGIC-RECEPTOR; ALPHA-2-ADRENERGIC RECEPTOR; ALPHA(2A)-ADRENERGIC RECEPTOR; EXPRESSION; FAMILY; MEMBER; CLONING	The alpha-adrenergic receptor (alpha(2)AR) subtype alpha(2)C10 undergoes rapid agonist-promoted desensitization which is due to phosphorylation of the receptor. One kinase that has been shown to phosphorylate alpha(2)C10 in an agonist-dependent manner is the beta AR kinase (beta ARK), a member of the family of G protein-coupled receptor kinases (GRKs). In contrast, the alpha(2)C4 subtype has not been observed to undergo agonist-promoted desensitization or phosphorylation by beta ARK, However, the substrate specificities of the GRKs for phosphorylating alpha(2)AR subtypes are not known. We considered that differential capacities of various GRKs to phosphorylate alpha(2)C10 and alpha(2)C4 might be a key factor in dictating in a given cell the presence or extent of agonist-promoted desensitization of these receptors, COS-7 cells were co-transfected with alpha(2)C10 or alpha(2)C4 without or with the following GRKs: beta ARK, beta ARK2, GRK5, or GRK6. Intact cell phosphorylation studies were carried out by labeling cells with P-32(i), exposing some to agonist, and purifying the alpha(2)AR by immunoprecipitation and SDS-polyacrylamide gel electrophoresis. beta ARK and beta ARK2 were both found to phosphorylate alpha(2)C10 to equal extents (>2-fold over that of the endogenous kinases), On the other hand, GRK5 and GRK6 did not phosphorylate alpha(2)C10, In contrast to the findings with alpha(2)C10, alpha(2)C4 was not phosphorylated by any of these kinases, Functional studies carried out in transfected HEK293 cells expressing alpha(2)C10 or alpha(2)C4 and selected GRKs were consistent with these phosphorylation results, With the marked expression of these receptors, no agonist-promoted desensitization was observed in the absence of GRK co-expression, However, desensitization was imparted to alpha(2)C10 by co-expression of beta ARK but not GRK6, while alpha(2)C4 failed to desensitize with co-expression of beta ARK. These results indicate that short term agonist-promoted desensitization of alpha(2)ARs by phosphorylation is dependent on both the receptor subtype and the expressed GRK isoform.	UNIV CINCINNATI,COLL MED,DEPT PULM MED,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT PHARMACOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati			liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382, R01HL053436, P01HL041496] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53436, HL07382, HL41496] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; DECHASSEVAL R, 1995, NUCLEIC ACIDS RES, V20, P245; Diviani D, 1996, J BIOL CHEM, V271, P5049; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; EASON MG, 1994, MOL PHARMACOL, V45, P696; EASON MG, 1992, J BIOL CHEM, V267, P25473; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GREEN SA, 1994, J BIOL CHEM, V269, P26215; JEWELLMOTZ EA, 1995, BIOCHEMISTRY-US, V34, P11946, DOI 10.1021/bi00037a036; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KUROSE H, 1993, MOL PHARMACOL, V43, P444; KUROSE H, 1994, J BIOL CHEM, V269, P10093; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; Liggett SB, 1993, REGULATION CELLULAR, P71; LIGGETT SB, 1996, ALPHA2 ADRENERGIC RE; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791	30	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18082	18087		10.1074/jbc.271.30.18082	http://dx.doi.org/10.1074/jbc.271.30.18082			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663433	hybrid			2022-12-27	WOS:A1996UY93500074
J	Margulies, C; Kaguni, JM				Margulies, C; Kaguni, JM			Ordered and sequential binding of DnaA protein to oriC, the chromosomal origin of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION ORIGIN; MINICHROMOSOME REPLICATION; FIS PROTEIN; ENZYMATIC REPLICATION; INITIATION; SITES; K-12; OVERPRODUCTION; COMPLEXES; INVITRO	DnaA protein of Escherichia coli acts in initiation of chromosomal DNA replication by binding specific sequences, termed DnaA boxes in the chromosomal origin, oriC, On binding, it induces a localized unwinding to create a structure recognized by other replication proteins that act subsequently in the initiation process, In this report, we examined the binding of DnaA protein to each of the DnaA boxes in oriC, By gel mobility shift assays, DnaA protein formed at least six discrete complexes. ATP or ADP included in the reaction mixture prior to electrophoresis was required, Chemical cleavage of isolated complexes with 1,10-phenanthroline-copper revealed that DnaA protein binds in an ordered manner to the DnaA boxes in oriC, Preferential binding to one DnaA box (RA) was confirmed by demonstration that a DNA fragment containing it was bound with greater affinity than another DnaA box sequence (R1), In vitro replication activity correlated with a complex formed at a ratio of 30 DnaA monomers/oriC in which all DnaA boxes are occupied, The last site bound is DnaA box R3. This event may be critical in promoting initiation from oriC as it correlates with in vivo observations that binding of DnaA protein to box R3 occurs at the time of initiation of chromosomal replication, whereas other DnaA boxes are bound by DnaA protein throughout the cell cycle (Cassler, M, R,, Grimwade, J. E,, and Leonard, A, C, (1995) EMBO J, 14, 5833-5841).	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University				Kaguni, Jon/0000-0002-3096-4447	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033992] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM033992, GM33992] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASAI T, 1990, EMBO J, V9, P4065, DOI 10.1002/j.1460-2075.1990.tb07628.x; ATLUNG T, 1987, MOL GEN GENET, V206, P51, DOI 10.1007/BF00326535; BAKER TA, 1988, CELL, V55, P1113; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CASSLER MR, 1995, EMBO J, V14, P101; CROOKE E, 1993, J MOL BIOL, V233, P16, DOI 10.1006/jmbi.1993.1481; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; FILUTOWICZ M, 1990, New Biologist, V2, P818; FILUTOWICZ M, 1992, J BACTERIOL, V174, P398, DOI 10.1128/jb.174.2.398-407.1992; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GARNER MM, 1981, BIOCHEMISTRY-US, V20, P306, DOI 10.1021/bi00505a012; GILLE H, 1991, NUCLEIC ACIDS RES, V19, P4167, DOI 10.1093/nar/19.15.4167; HELMSTETTER CE, 1987, J BACTERIOL, V169, P3489, DOI 10.1128/jb.169.8.3489-3494.1987; HIASA H, 1994, J BIOL CHEM, V269, P24999; HOLZ A, 1992, MOL GEN GENET, V233, P81, DOI 10.1007/BF00587564; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1988, J BIOL CHEM, V263, P10625; HWANG DS, 1992, J BIOL CHEM, V267, P23083; KOPPES LJH, 1987, J BACTERIOL, V169, P430, DOI 10.1128/jb.169.1.430-433.1987; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LOBNEROLESEN A, 1989, CELL, V57, P881, DOI 10.1016/0092-8674(89)90802-7; MATSUI M, 1985, J MOL BIOL, V184, P529, DOI 10.1016/0022-2836(85)90299-2; POLACZEK P, 1990, New Biologist, V2, P265; SAMITT CE, 1989, EMBO J, V8, P989, DOI 10.1002/j.1460-2075.1989.tb03462.x; SCHAEFER C, 1991, MOL GEN GENET, V226, P34, DOI 10.1007/BF00273584; SCHAPER S, 1995, J BIOL CHEM, V270, P17622, DOI 10.1074/jbc.270.29.17622; SKARSTAD K, 1989, MOL GEN GENET, V218, P50, DOI 10.1007/BF00330564; SKARSTAD K, 1993, J BIOL CHEM, V268, P5365; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SKARSTAD K, 1993, DNA REPLICATION CELL, V43, P15; YUNG BYM, 1990, J BIOL CHEM, V265, P1282	37	89	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17035	17040		10.1074/jbc.271.29.17035	http://dx.doi.org/10.1074/jbc.271.29.17035			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663334	hybrid			2022-12-27	WOS:A1996UX94300011
J	Cox, D; Chang, P; Kurosaki, T; Greenberg, S				Cox, D; Chang, P; Kurosaki, T; Greenberg, S			Syk tyrosine kinase is required for immunoreceptor tyrosine activation motif-dependent actin assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-RECEPTOR; PHAGOCYTOSIS; NEUTROPHILS; LEUKOCYTES; SUBUNIT; CHAIN	Clustering of several multisubunit receptors on hematopoetic cells results in a signaling cascade involving the phosphorylation of immunoreceptor tyrosine activation motifs, or ''ITAMs,'' and actin polymerization. Recent experiments indicate that direct clustering of the ITAM-binding protein, p72(syk) (Syk), is capable of transmitting a phagocytic signal in COS cells (Greenberg, S., Chang, P., Wang, D., Xavier, R., and Seed, B. (1996) Proc. Natl. Acad. Sci. U. S. A, 93, 1103-1107). However, the possibility of redundant signaling pathways makes it difficult to test the requirement for Syk in ITAM-dependent actin polymerization in hematopoetic cells. We developed a model system to study ITAM dependent actin assembly. DT40 lymphocytes were transfected with fusion proteins encoding the transmembrane and cytosolic domains of the ITAM-containing gamma subunit of Fc receptors. Clustering the gamma-containing fusion proteins with IgG-coated erythrocytes triggered submembranous actin assembly. This response depended on an intact ITAM, was absent in cell lines that had been engineered to lack Syk, and was augmented in cell lines that stably overexpressed Syk. These experiments demonstrate an absolute requirement for Syk tyrosine kinase in ITAM-dependent actin assembly in transfected lymphocytes.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DIV PULM,NEW YORK,NY 10032; LEDERLE LABS,DEPT CARDIOVASC MOLEC BIOL,NEW YORK,NY 10965; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Columbia University; Columbia University; Yale University			Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Cox, Dianne/0000-0002-0591-9767	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054164] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02641, HL54164] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BONNEROT C, 1992, EMBO J, V11, P2747, DOI 10.1002/j.1460-2075.1992.tb05340.x; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DARBY C, 1994, J IMMUNOL, V152, P5429; EDBERG JC, 1992, J IMMUNOL METHODS, V148, P179, DOI 10.1016/0022-1759(92)90171-O; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; GREENBERG S, 1995, TRENDS CELL BIOL, V5, P93, DOI 10.1016/S0962-8924(00)88957-6; GREENBERG S, 1993, J EXP MED, V177, P539; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; HUTCHINSON MJ, 1995, EUR J IMMUNOL, V25, P481, DOI 10.1002/eji.1830250226; INDIK ZK, 1995, BLOOD, V85, P1175, DOI 10.1182/blood.V85.5.1175.bloodjournal8551175; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MICHL J, 1983, J EXP MED, V157, P1746, DOI 10.1084/jem.157.6.1746; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; PARK JG, 1993, J CLIN INVEST, V92, P2073, DOI 10.1172/JCI116804; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; REDMOND T, 1993, CELL MOTIL CYTOSKEL, V26, P7, DOI 10.1002/cm.970260103; SALMON JE, 1991, J IMMUNOL, V146, P997; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; SHEETZ MP, 1992, CELL MOTIL CYTOSKEL, V22, P160, DOI 10.1002/cm.970220303; SHETERLINE P, 1984, EUR J CELL BIOL, V34, P80; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; ZHU ZX, 1995, J BIOL CHEM, V270, P17652, DOI 10.1074/jbc.270.30.17652	39	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16597	16602		10.1074/jbc.271.28.16597	http://dx.doi.org/10.1074/jbc.271.28.16597			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663235	hybrid			2022-12-27	WOS:A1996UX12600029
J	Luo, W; Kuwada, TS; Chandrasekaran, L; Zheng, J; Tanzer, ML				Luo, W; Kuwada, TS; Chandrasekaran, L; Zheng, J; Tanzer, ML			Divergent secretory behavior of the opposite ends of aggrecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONIC-ACID; CORE PROTEIN; CLONING; PROTEOGLYCANS; CDNA	The proteoglycan, aggrecan has a globular domain, G1, at the N terminus and a different globular domain, G3, at the C terminus, Aggrecan produced by mutant nanomelic chickens is truncated due to a premature stop codon and consequently lacks G3 and a minor portion of its chondroitin sulfate domain (Li, H., Schwartz, N. B., and Vertel, B. M. (1993) J. Biol. Chem. 268, 23504-23511). The mutant protein is retained in the endoplasmic reticulum and fails to enter the Golgi stacks (Vertel, B. M., Walters, L. M., Grier, B., Maine, N., and Goetinck, P. F. (1993) J. Cell Sci. 104, 939-948). The homozygous mutant is lethal because of failure of chondrogenesis and osteogenesis, while the heterozygous mutant is dwarfed, To further elucidate the pathogenetic mechanisms underlying nanomelia and to determine if G1 and G3 are themselves secreted, we expressed them in transfected host cells. Expression was performed in wild type Chinese hamster ovary (CHO) cells and in mutant CHO cells which are unable to link glycosaminoglycan (GAG) chains to core proteins. We compared: (a) secretion of expressed G1 and G3 constructs containing contiguous GAG chain consensus sites and (b) GAG chain modification of the secreted proteins. We find that: 1) G3 is 24-100 times more rapidly secreted than G1; 2) secreted G3 contains contiguous chondroitin sulfate GAG chains, while secreted G1 lacks contiguous GAG chains; 3) G3 secretion is not coupled to xylosylation of contiguous GAG chain consensus sites. These results imply that G1 and G3 intrinsically differ in passage through the cell secretory route.	UNIV CONNECTICUT,CTR HLTH,SCH DENT MED,DEPT BIOSTRUCT & FUNCT,FARMINGTON,CT 06030	University of Connecticut					NIAMS NIH HHS [AR12683] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR012683, R01AR012683] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; CHANDRASEKARAN L, 1992, BIOCHEM J, V288, P903, DOI 10.1042/bj2880903; DRICKAMER K, 1993, PROG NUCLEIC ACID RE, V45, P207, DOI 10.1016/S0079-6603(08)60870-3; Dudhia J, 1996, BIOCHEM J, V313, P933, DOI 10.1042/bj3130933; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HARDINGHAM TE, 1973, BIOCHEM J, V135, P905, DOI 10.1042/bj1350905; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JANSSEN JJM, 1995, J BIOL CHEM, V270, P11222, DOI 10.1074/jbc.270.19.11222; LI H, 1993, J BIOL CHEM, V268, P23504; Maniatis T., 1989, MOL CLONING LAB MAN; PRIMORAC D, 1994, MATRIX BIOL, V14, P297, DOI 10.1016/0945-053X(94)90195-3; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAI S, 1986, P NATL ACAD SCI USA, V83, P5081, DOI 10.1073/pnas.83.14.5081; SCHWARTZ NB, 1995, TRENDS GLYCOSCI GLYC, V7, P429, DOI 10.4052/tigg.7.429; VERTEL BM, 1993, J CELL SCI, V104, P939; VERTEL BM, 1995, TRENDS CELL BIOL, V5, P458, DOI 10.1016/S0962-8924(00)89115-1; YAMADA H, 1994, J BIOL CHEM, V269, P10119; ZHANG L, 1995, J BIOL CHEM, V270, P12557, DOI 10.1074/jbc.270.21.12557; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295	22	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16447	16450		10.1074/jbc.271.28.16447	http://dx.doi.org/10.1074/jbc.271.28.16447			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663569	hybrid			2022-12-27	WOS:A1996UX12600005
J	RamseyEwing, A; Moss, B				RamseyEwing, A; Moss, B			Recombinant protein synthesis in Chinese hamster ovary cells using a vaccinia virus/bacteriophage T7 hybrid expression system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; MAMMALIAN-CELLS; VIRUS; GENES	The vaccinia virus/bacteriophage T7 expression system was adapted to Chinese hamster ovary (CHO) cells, Vaccinia virus undergoes abortive infection in CHO cells, which is characterized by a sharp reduction in protein synthesis at the stage of viral intermediate gene expression. We determined that expression of a T7 promoter-regulated chloramphenicol acetyltransferase gene was at least 20 times more efficient in permissive BS-C-1 than in CHO cells. The encephalomyocarditis virus 5'-untranslated region, which confers cap-independent translatability to mRNA, stimulated recombinant protein synthesis by 10-fold in both cell lines, maintaining the advantage of the BS-C-1 cells over CHO cells, Since the cowpox virus hr gene overcomes vaccinia virus host range restriction in CHO cells, we constructed a recombinant virus that carries an intact hr gene in addition to the T7 RNA polymerase gene, With this virus, synthesis of T7 RNA polymerase was enhanced and production of a recombinant protein occurred in CHO cells at the level observed in permissive cell lines. Extension of the vaccinia virus/bacteriophage T7 expression system to CHO cells should be of wide interest, as these cells have advantages for preparation of recombinant proteins in research and biotechnology.	NIAID,VIRAL DIS LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Moss, Bernard/0000-0002-2154-8564				ALEXANDER WA, 1992, J VIROL, V66, P2934, DOI 10.1128/JVI.66.5.2934-2942.1992; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLEN D, 1984, J PHARMACOL EXP THER, V231, P146; DRILLIEN R, 1978, J VIROL, V28, P843, DOI 10.1128/JVI.28.3.843-850.1978; Earl P, 1991, CURRENT PROTOCOLS MO; EGRIE JC, 1985, EXPT APPROACHES STUD, P339; ELBEIN AD, 1991, TRENDS BIOTECHNOL, V9, P346, DOI 10.1016/0167-7799(91)90117-Z; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FUERST TR, 1989, J MOL BIOL, V206, P333, DOI 10.1016/0022-2836(89)90483-X; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HUBBARD RC, 1992, NEW ENGL J MED, V326, P812, DOI 10.1056/NEJM199203193261207; INK BS, 1995, J VIROL, V69, P661, DOI 10.1128/JVI.69.2.661-668.1995; KOTWAL GJ, 1988, VIROLOGY, V167, P524, DOI 10.1016/S0042-6822(88)90115-8; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; PATZER EJ, 1986, BIO-TECHNOL, V4, P630, DOI 10.1038/nbt0786-630; RAMSEYEWING A, 1995, VIROLOGY, V206, P984, DOI 10.1006/viro.1995.1021; SCAHILL SJ, 1983, P NATL ACAD SCI-BIOL, V80, P4654, DOI 10.1073/pnas.80.15.4654; SPEHNER D, 1988, J VIROL, V62, P1297, DOI 10.1128/JVI.62.4.1297-1304.1988; WARD GA, 1995, P NATL ACAD SCI USA, V92, P6773, DOI 10.1073/pnas.92.15.6773; ZETTLMEISSL G, 1987, BIO-TECHNOL, V5, P720, DOI 10.1038/nbt0787-720	22	10	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16962	16966		10.1074/jbc.271.28.16962	http://dx.doi.org/10.1074/jbc.271.28.16962			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663285	hybrid			2022-12-27	WOS:A1996UX12600081
J	Simon, JP; Ivanov, IE; Bo, SS; Hersh, D; Adesnik, M; Sabatini, DD				Simon, JP; Ivanov, IE; Bo, SS; Hersh, D; Adesnik, M; Sabatini, DD			The in vitro generation of post-Golgi vesicles carrying viral envelope glycoproteins requires an ARF-like GTP-binding protein and a protein kinase C associated with the Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; CONSTITUTIVE SECRETORY VESICLES; AMYLOID PRECURSOR PROTEIN; COP-COATED VESICLES; TRIMERIC G-PROTEINS; CELL-FREE SYSTEM; BREFELDIN-A; ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; PHOSPHOLIPASE-D	We have developed a system that recreates in vitro the generation of post-Golgi vesicles from an isolated Golgi fraction prepared from vesicular stomatitis virus- or influenza virus infected Madin-Darby canine kidney or HepG2 cells. In this system, vesicle generation is temperature and ATP-dependent and requires a supply of cytosolic proteins, including an N-ethylmaleimide-sensitive factor distinct from NSF, Cytosolic proteins obtained from yeast were as effective as mammalian cytosolic proteins in supporting vesicle formation and had the same requirements, The vesicles produced (50-80 nm in diameter) are depleted of the trans Golgi marker sialyltransferase, contain the viral glycoprotein molecules with their cytoplasmic tails exposed, and do not show an easily recognizable protein coat, Vesicle generation was inhibited by brefeldin A, which indicates that it requires the activation of an Arf-like GTP-binding protein that promotes assembly of a vesicle coat, Vesicles formed in the presence of the nonhydrolyzable GTP analogue guanosine 5'-3-O-(thio)triphosphate retained a nonclathrin protein coat resembling that of COP-coated vesicles, and sedimented more rapidly in a sucrose gradient than the uncoated ones generated in its absence, This indicates that GTP hydrolysis is not required for vesicle generation but that it is for vesicle uncoating, The activity of a Golgi-associated protein kinase C (PKC) was found to be necessary for the release of post-Golgi vesicles, as indicated by the capacity of a variety of inhibitors and antibodies to PKC to suppress it, as well as by the stimulatory effect of the PRC activator 12-O-tetradecanoylphorbol-13-acetate.	NYU,SCH MED,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043583] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43583] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOLL W, 1991, P NATL ACAD SCI USA, V88, P8592, DOI 10.1073/pnas.88.19.8592; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; BREWER CB, 1995, J CELL SCI, V108, P789; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUNPHY WG, 1986, P NATL ACAD SCI USA, V83, P1622, DOI 10.1073/pnas.83.6.1622; FABBRI M, 1994, J BIOL CHEM, V269, P26848; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HIEBSCH RR, 1991, J BIOL CHEM, V266, P20323; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KREIS TE, 1994, CURR OPIN CELL BIOL, V6, P533, DOI 10.1016/0955-0674(94)90073-6; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; NARULA N, 1995, P NATL ACAD SCI USA, V92, P2874, DOI 10.1073/pnas.92.7.2874; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHASHI M, 1994, J BIOL CHEM, V269, P24897; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; OLSON SC, 1991, J BIOL CHEM, V266, P17236; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROSA P, 1992, EUR J CELL BIOL, V59, P265; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SABATINI DD, 1995, METABOLIC BASIS INHE, V1, P459; SAGIEISENBERG R, 1989, TRENDS BIOCHEM SCI, V14, P355, DOI 10.1016/0968-0004(89)90001-7; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SALAMERO J, 1990, P NATL ACAD SCI USA, V87, P7717, DOI 10.1073/pnas.87.19.7717; SAUCAN L, 1994, J CELL BIOL, V125, P733, DOI 10.1083/jcb.125.4.733; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STROUS GJ, 1985, J CELL BIOL, V101, P531, DOI 10.1083/jcb.101.2.531; STROUS GJAM, 1983, J CELL BIOL, V97, P1815, DOI 10.1083/jcb.97.6.1815; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; THYBERG J, 1985, EXP CELL RES, V159, P1, DOI 10.1016/S0014-4827(85)80032-X; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980	87	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16952	16961		10.1074/jbc.271.28.16952	http://dx.doi.org/10.1074/jbc.271.28.16952			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663371	hybrid			2022-12-27	WOS:A1996UX12600080
J	Paolini, R; Serra, A; Kinet, JP				Paolini, R; Serra, A; Kinet, JP			Persistence of tyrosine-phosphorylated Fc epsilon RI in deactivated cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; IMMUNOGLOBULIN-E RECEPTORS; ANTIGEN RECEPTOR; CROSS-LINKING; MAST-CELLS; SIGNAL TRANSDUCTION; RBL-2H3 CELLS; KINASES; DEPHOSPHORYLATION	Engagement of the high affinity IgE receptor (Fc epsilon RI) with a multimeric antigen leads to immediate tyrosine phosphorylation of its beta and gamma subunits, recruitment, and activation of the tyrosine kinase Syk, and later to cell degranulation, Monovalent hapten treatment reverses these events, resulting in receptor dephosphorylation and an abrupt arrest of cell degranulation, Thus far, it has been assumed that there is a direct linkage between receptor tyrosine phosphorylation, Syk activation and phosphorylation, and cell degranulation. However, we show here that when Fc epsilon RI receptors are crosslinked for extended periods of time, hapten-mediated receptor dephosphorylation is delayed, These receptors, which remain tyrosine-phosphorylated despite the addition of hapten, are progressively targeted to a Triton X-100-insoluble fraction, suggesting their progressive association with the membrane skeleton, In contrast to Fc epsilon RI receptors, hapten-induced Syk dephosphorylation and the consequent arrest of degranulation are not affected by prolonged cross-linking, Thus, some tyrosine-phosphorylated receptors persist in deactivated cells, We propose that, with time, some tyrosine-phosphorylated receptors become unaccessible to phosphatases and, in addition, unable to activate Syk. This inactive status of tyrosine-phosphorylated Fc epsilon RI may be the result of membrane skeleton compartmentalization. However, another population of clustered receptors that includes the ones most recently formed is still immediately sensitive to hapten deactivation, This latter population is critical in maintaining Syk activity and cell degranulation. The shift from a transiently active state of phosphorylated receptors toward an inactive state could be a general mechanism of desensitization also utilized by other antigen receptors.	NIAID,MOLEC ALLERGY & IMMUNOL SECT,NIH,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				PAOLINI, Rossella/0000-0001-7605-1531				ADAMCZEWSKI M, 1992, J BIOL CHEM, V267, P18126; ADAMCZEWSKI MA, 1991, CHEM IMMUNOL, V59, P173; APGAR JR, 1990, J IMMUNOL, V145, P3814; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CONNELLY PA, 1991, BIOCHEM BIOPH RES CO, V177, P192, DOI 10.1016/0006-291X(91)91967-H; EISEMAN E, 1992, NATURE, V355, P78; FEWTRELL C, 1985, CALCIUM BIOL SYSTEMS, P129; HOLOWKA D, 1990, CELLULAR MOL MECHANI, V1, P173; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; Jouvin M H, 1995, Semin Immunol, V7, P29, DOI 10.1016/1044-5323(95)90005-5; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KAGEYSOBOTKA A, 1982, FED PROC, V41, P12; KENT UM, 1994, P NATL ACAD SCI USA, V91, P3087, DOI 10.1073/pnas.91.8.3087; KIHARA H, 1994, J BIOL CHEM, V269, P22427; KINET JP, 1990, FC RECEPTORS ACTION, P239; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LUO K, 1990, ONCOGENE, V5, P921; METZGER H, 1992, J IMMUNOL, V149, P1477; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; OLSON KR, 1995, J CELL BIOL, V130, P639, DOI 10.1083/jcb.130.3.639; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; Paolini R, 1994, Immunomethods, V4, P35, DOI 10.1006/immu.1994.1005; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PRIBLUDA VS, 1992, P NATL ACAD SCI USA, V89, P11446, DOI 10.1073/pnas.89.23.11446; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; ROBERTSON D, 1986, J IMMUNOL, V136, P4565; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SEAGRAVE J, 1990, J CELL PHYSIOL, V144, P128, DOI 10.1002/jcp.1041440117; SEAGRAVE JC, 1987, CYTOMETRY, V8, P287, DOI 10.1002/cyto.990080309; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; VALLE A, 1995, FEBS LETT, V357, P41, DOI 10.1016/0014-5793(94)01329-Y; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WOFSY C, 1995, J BIOL CHEM, V270, P20264, DOI 10.1074/jbc.270.35.20264; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251	41	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15987	15992		10.1074/jbc.271.27.15987	http://dx.doi.org/10.1074/jbc.271.27.15987			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663241	hybrid			2022-12-27	WOS:A1996UW35200024
J	Clark, EA; Hynes, RO				Clark, EA; Hynes, RO			Ras activation is necessary for integrin-mediated activation of extracellular signal-regulated kinase 2 and cytosolic phospholipase A(2) but not for cytoskeletal organization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; FIBROBLASTS; PROTEIN; CELLS	Cell adhesion to the extracellular matrix triggers a cascade of intracellular biochemical signals regulated by the integrin family of receptors, Recent evidence suggests that integrin engagement may activate a mitogen-activated protein (MAP) kinase cascade that may cooperate with more clearly defined mitogenic signaling pathways to regulate cell proliferation, adhesion, and migration. Here we report that the adhesion-dependent activation of the MAP kinase Erk2 (extracellular signal-regulated kinase 2) occurs in serum-starved NIH3T3 cells, and that this activation of Erk2 is preceded by the activation of the small GTP-binding protein Ras in fibronectin adherent cells, Inhibition of Ras signaling by expression of a dominant inhibitory mutant of Ras (N17Ras) in NIH3T3 cells blocked adhesion-dependent activation of Erk2, although the focal adhesion kinase (FAK) was still activated in these cells, Furthermore, activation of this Ras-MAP kinase pathway activated cytosolic phospholipase A(2), leading to the release of arachidonic acid metabolites, and N17Ras also inhibited these events, However, N17Ras expression does not inhibit cell adhesion, spreading, or focal contact and stress fiber formation, These results suggest that, while integrin-dependent activation of this MAP kinase pathway is Ras-dependent, the integrin-dependent activation of FAK and several morphological events are Ras independent, Thus, integrin-mediated signals involved in regulating cell morphology appear to diverge from those regulating MAP kinase activation at a level upstream of Ras activation.	MIT,HOWARD HUGHES MED INST,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R01CA017007] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA17007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUER KL, 1995, MOL BIOL CELL, V6, P1305, DOI 10.1091/mbc.6.10.1305; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BORSCHHAUBOLD AG, 1995, J BIOL CHEM, V270, P25885, DOI 10.1074/jbc.270.43.25885; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUN JS, 1992, MOL BIOL CELL, V3, P481, DOI 10.1091/mbc.3.5.481; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PLOPPER CE, 1995, MOL BIOL CELL, V6, P1349; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; VAILLANCOURT RR, 1994, METHOD ENZYMOL, V238, P255; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WARNER LC, 1993, ONCOGENE, V8, P3249; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	31	157	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14814	14818		10.1074/jbc.271.25.14814	http://dx.doi.org/10.1074/jbc.271.25.14814			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663348	hybrid			2022-12-27	WOS:A1996UT10600029
J	Kaliman, P; Vinals, F; Testar, X; Palacin, M; Zorzano, A				Kaliman, P; Vinals, F; Testar, X; Palacin, M; Zorzano, A			Phosphatidylinositol 3-kinase inhibitors block differentiation of skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; INSULIN-RECEPTOR SUBSTRATE-1; FOCAL ADHESION KINASE; GROWTH FACTOR-II; DNA-BINDING; PHOSPHOINOSITIDE 3-KINASE; MYOGENIC LINEAGE; L6E9 CELLS; MYOD; EXPRESSION	Skeletal muscle differentiation involves myoblast alignment, elongation, and fusion into multinucleate myotubes, together with the induction of regulatory and structural muscle-specific genes, were we show that two phosphatidylinositol 3-kinase inhibitors, LY294002 and wortmannin, blocked an essential step in the differentiation of two skeletal muscle cell models, Both inhibitors abolished the capacity of L6E9 myoblasts to form myotubes, without affecting myoblast proliferation, elongation, or alignment, Myogenic events like the induction of myogenin and of glucose carrier GLUT4 were also blocked and myoblasts could not exit the cell cycle, as measured by the lack of mRNA induction of p21 cyclin-dependent kinase inhibitor, Overexpression of MyoD in 10T1/2 cells was not sufficient to bypass the myogenic differentiation blockade by LY294002. Upon serum withdrawal, 10T1/2-MyoD cells formed myotubes and showed increased levels of myogenin and p21, In contrast, LY294002-treated cells exhibited none of these myogenic characteristics and maintained high levels of Id, a negative regulator of myogenesis. These data indicate that whereas phosphatidylinositol 3-kinase is not indispensable for cell proliferation or in the initial events of myoblast differentiation, i.e. elongation and alignment, it appears to be essential for terminal differentiation of muscle cells.	UNIV BARCELONA,FAC BIOL,DEPT BIOQUIM & BIOL MOL,BARCELONA 08028,SPAIN	University of Barcelona			Viñals, Francesc/F-5928-2016; Palacín, Manuel/G-9786-2015; Vinals, Francesc/P-6278-2019; Zorzano, Antonio/R-5479-2018	Viñals, Francesc/0000-0002-9918-6751; Palacin, Manuel/0000-0002-8670-293X				ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CARUSO M, 1993, ONCOGENE, V8, P267; CASTELLO A, 1994, J BIOL CHEM, V269, P5905; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P136; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EWTON DZ, 1987, ENDOCRINOLOGY, V120, P115, DOI 10.1210/endo-120-1-115; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KALIMAN P, 1995, BIOCHEM J, V312, P471, DOI 10.1042/bj3120471; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KONG YF, 1995, MOL CELL BIOL, V15, P5205; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM K, 1994, J BIOL CHEM, V269, P20648; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; MATSUOKA K, 1995, J CELL BIOL, V130, P1307, DOI 10.1083/jcb.130.6.1307; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MUTHUCHAMY M, 1992, J BIOL CHEM, V267, P18728; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PUJADES C, 1992, J CELL SCI, V102, P815; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; Rosen K., 1990, FOCUS, V12, P23; ROSENTHAL SM, 1994, ENDOCRINOLOGY, V135, P38, DOI 10.1210/en.135.1.38; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P535, DOI 10.1006/bbrc.1995.1846; SILVERMAN LA, 1995, ENDOCRINOLOGY, V136, P720, DOI 10.1210/en.136.2.720; STACK JH, 1994, J BIOL CHEM, V269, P31552; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TANTI JF, 1994, BIOCHEM J, V304, P17, DOI 10.1042/bj3040017; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	56	183	183	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19146	19151		10.1074/jbc.271.32.19146	http://dx.doi.org/10.1074/jbc.271.32.19146			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702591	hybrid, Green Published			2022-12-27	WOS:A1996VB68400025
J	PinkasKramarski, R; Shelly, M; Glathe, S; Ratzkin, BJ; Yarden, Y				PinkasKramarski, R; Shelly, M; Glathe, S; Ratzkin, BJ; Yarden, Y			Neu differentiation factor neuregulin isoforms activate distinct receptor combinations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; HEREGULIN ISOFORMS; NDF HEREGULIN; GROWTH-FACTOR; COMPLEX; ERBB3; HETERODIMERIZATION; PROTEINS; DOMAIN	The multiple isoforms of Neu differentiation factor (NDF/neuregulin) induce a pleiotropic cellular response that is isoform-specific and cell type-dependent. The molecular basis of this heterogeneity was addressed by comparing the two major groups of isoforms, alpha and beta. Both groups bind to the catalytically impaired receptor tyrosine kinase ErbB-3, whose mitogenic stimulation by NDF requires transactivation by other ErbB proteins, either ErbB-1 or ErbB-2. By expressing each pair of receptors in interleukin S-dependent myeloid cells, we found that both isoforms induced mitogenic signals in cells co-expressing the combination of ErbB-3 with ErbB-2. However, only the beta isoform stimulated cells that expressed both ErbB-3 and ErbB-1, and neither isoform was active on cells expressing ErbB-3 alone. Both isoforms bind to all ErbB-3-expressing cells, albeit with different affinities, but the co-stimulatory mitogenic effect is correlated with the ability of each auxiliary receptor to transphosphorylate ErbB-3. These results imply that NDF isoforms differ in their ability to induce receptor heterodimers; whereas both types of isoforms signal through ErbB-3/ErbB-2 heterodimers, only beta isoforms are able to stabilize ErbB-3/ErbB-1 heterodimers.	WEIZMANN INST SCI,DEPT MOLEC CELL BIOL,IL-76100 REHOVOT,ISRAEL; AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	Weizmann Institute of Science; Amgen			Mieszkowska, Magdalena/O-6753-2017; YARDEN, YOSEF/K-1467-2012	Pinkas-Kramarski, Ronit/0000-0002-1000-369X; shelly, maya/0000-0002-2211-1751	NCI NIH HHS [CA51712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; GULLICK WJ, 1994, EUR J CANCER, V30A, P2186, DOI 10.1016/0959-8049(94)00365-C; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; Zhang K, 1996, J BIOL CHEM, V271, P3884	30	125	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19029	19032		10.1074/jbc.271.32.19029	http://dx.doi.org/10.1074/jbc.271.32.19029			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702572	hybrid			2022-12-27	WOS:A1996VB68400006
J	Ruddock, LW; Coen, JJF; Cheesman, C; Freedman, RB; Hirst, TR				Ruddock, LW; Coen, JJF; Cheesman, C; Freedman, RB; Hirst, TR			Assembly of the B subunit pentamer of Escherichia coli heat-labile enterotoxin - Kinetics and molecular basis of rate-limiting steps in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; CHOLERA-TOXIN; CRYSTAL-STRUCTURE; VIBRIO-CHOLERAE; CARBOXYL TERMINUS; PROTEINS; STABILITY; SECRETION; OLIGOMER; HOMOLOG	The B subunits of Escherichia coli heat-labile enterotoxin (EtxB) and cholera toxin (CtxB) assemble in vivo into exceptionally stable homopentameric complexes, which maintain their quaternary structure in a range of conditions that would normally be expected to cause protein denaturation, Recently, we showed that the simultaneous protonation of two of the COOH-terminal carboxylates in pentameric EtxB was required to cause its disassembly at pH values below 2.0 (Ruddock, L., Ruston, S. P., Kelly, S. M., Price, N. C., Freedman, R. B., and Hirst., T. R. (1995) J. Biol. Chem. 270, 29953-29958), Here, we investigate the influence of environmental parameters on the kinetics of reassembly of acid-generated EtxB monomers in vitro. Such monomers were found to undergo a further acid-mediated conformational change, with an activation energy of 76 +/- 2 J degrees mol(-1)degrees K-1, consistent with isomerization of the cis-proline residue at position 93, and which prevented subsequent EtxB reassembly. By using rapid neutralization of acid-generated monomers, a high proportion of the B-subunits adopted an assembly-competent conformation, which resulted in up to 75% of the protein reassembling into a stable pentameric complex, indistinguishable from native EtxB pentamers. The rate-limiting step in reassembly, over a concentration range of 50-200 mu g/ml, was shown 60 be due to an intramolecular event, which exhibited a pH dependence with a pK(a) of 7.0, Modification of EtxB with amine-specific probes revealed that the protonation state of the NH2-terminal alanine residue was responsible for the pH dependence of reassembly, The implications of these findings for the biogenesis of Escherichia coli enterotoxin and related enterotoxins in vivo, are considered.	UNIV KENT,RES SCH BIOSCI,CANTERBURY CT2 7NJ,KENT,ENGLAND	University of Kent				Ruddock, Lloyd/0000-0002-6247-686X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMIN T, 1994, PROTEIN EXPRES PURIF, V5, P198, DOI 10.1006/prep.1994.1031; BLOND S, 1985, J MOL BIOL, V182, P597, DOI 10.1016/0022-2836(85)90245-1; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; BURNS DL, 1982, J BIOL CHEM, V257, P8648; DOMENIGHINI M, 1995, MOL MICROBIOL, V15, P1165, DOI 10.1111/j.1365-2958.1995.tb02289.x; Freedman Robert B., 1992, P455; HARDY SJS, 1988, P NATL ACAD SCI USA, V85, P7109, DOI 10.1073/pnas.85.19.7109; HAYANO T, 1991, BIOCHEMISTRY-US, V30, P3041, DOI 10.1021/bi00226a009; HIRST TR, 1987, P NATL ACAD SCI USA, V84, P7418, DOI 10.1073/pnas.84.21.7418; HIRST TR, 1995, BACTERIAL TOXINS VIR, P123; HOL WGJ, 1995, BACTERIAL TOXINS VIR, P185; Holmes RK, 1995, BACTERIAL TOXINS VIR, P225; HOLMGREN J, 1985, GASTROENTEROLOGY, V89, P27, DOI 10.1016/0016-5085(85)90741-3; IIDA T, 1989, J BIOL CHEM, V264, P14065; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JOBLING MG, 1991, MOL MICROBIOL, V5, P1755, DOI 10.1111/j.1365-2958.1991.tb01925.x; JOBLING MG, 1992, INFECT IMMUN, V60, P4915, DOI 10.1128/IAI.60.11.4915-4924.1992; KAPER JB, 1995, CLIN MICROBIOL REV, V8, P48, DOI 10.1128/CMR.8.1.48; LEVINE MM, 1983, MICROBIOL REV, V47, P510, DOI 10.1128/MMBR.47.4.510-550.1983; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; MCGHEE JR, 1992, VACCINE, V10, P75, DOI 10.1016/0264-410X(92)90021-B; MERRITT EA, 1994, PROTEIN SCI, V3, P166; MOSS J, 1978, J CLIN INVEST, V62, P281, DOI 10.1172/JCI109127; NASHAR TO, 1993, VACCINE, V11, P235, DOI 10.1016/0264-410X(93)90023-Q; Price N. C., 1994, MECH PROTEIN FOLDING, P160; RUDDOCK LW, 1995, J BIOL CHEM, V270, P29953; SANDKVIST M, 1993, MOL MICROBIOL, V10, P635, DOI 10.1111/j.1365-2958.1993.tb00935.x; SANDKVIST M, 1987, J BACTERIOL, V169, P4570, DOI 10.1128/jb.169.10.4570-4576.1987; SANDKVIST M, 1990, J BIOL CHEM, V265, P15239; SCHMID FX, 1978, P NATL ACAD SCI USA, V75, P4764, DOI 10.1073/pnas.75.10.4764; SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209; SPANGLER BD, 1992, MICROBIOL REV, V56, P622, DOI 10.1128/MMBR.56.4.622-647.1992; STREATFIELD SJ, 1992, P NATL ACAD SCI USA, V89, P12140, DOI 10.1073/pnas.89.24.12140; YU J, 1992, MOL MICROBIOL, V6, P1949, DOI 10.1111/j.1365-2958.1992.tb01368.x; ZHANG RG, 1995, J MOL BIOL, V251, P563, DOI 10.1006/jmbi.1995.0456; ZHANG RG, 1995, J MOL BIOL, V251, P550, DOI 10.1006/jmbi.1995.0455	36	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19118	19123		10.1074/jbc.271.32.19118	http://dx.doi.org/10.1074/jbc.271.32.19118			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702586	hybrid			2022-12-27	WOS:A1996VB68400020
J	Matos, M; Fann, MC; Yan, RT; Maloney, PC				Matos, M; Fann, MC; Yan, RT; Maloney, PC			Enzymatic and biochemical probes of residues external to the translocation pathway of UhpT, the sugar phosphate carrier of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE GELS; PROTEIN; MEMBRANE; TOPOLOGY; CHANNEL; IDENTIFICATION; NITROCELLULOSE; RECONSTITUTION; TRANSPORTER	Part of the substrate translocation pathway through UhpT, the Escherichia coli sugar phosphate carrier, has been assigned to a transmembrane helix extending between residues 260 and 282, To set limits on the external portion of the pathway, we identified nearby residues fully exposed to the periplasm, In one case, we used Western blots to evaluate cleavage by extracellular trypsin, The protease cleaved UhpT variants retaining lysine 294, but not those lacking lysine 294, indicating that trypsin acts at a single extracellular site, lysine 294, In other work we labeled single-cysteine variants with 3-(N-maleimidylpropionyl)biocytin and scored accessibility to extracellular streptavidin by shifts of SDS-polyacrylamide gel electrophoresis mobility, Positions 283 and 284 were fully exposed to the periplasm, since the modified residue was bound by streptavidin in the native protein; by contrast, although the biotin-linked probe modified position 276, streptavidin decoration was not achieved without protein denaturation. We conclude that a 12-residue stretch (283-294) of UhpT is sufficiently exposed to be accessible to large probes (trypsin, streptavidin), while position 276 and more proximal residues are more deeply buried or otherwise shielded from the external phase.			Matos, M (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205, USA.				NIGMS NIH HHS [GM24195] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024195, R56GM024195] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEN ZG, 1983, J MOL BIOL, V164, P283, DOI 10.1016/0022-2836(83)90078-5; CHIGNELL CF, 1975, J BIOL CHEM, V250, P5622; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; ELMES ML, 1986, J GEN MICROBIOL, V132, P1429; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; FRIEDRICH MJ, 1987, J BACTERIOL, V169, P3556, DOI 10.1128/jb.169.8.3556-3563.1987; GOTT P, 1988, MOL MICROBIOL, V2, P655, DOI 10.1111/j.1365-2958.1988.tb00074.x; GREEN NM, 1971, BIOCHEM J, V125, P781, DOI 10.1042/bj1250781; ISLAND MD, 1992, J BACTERIOL, V174, P2754, DOI 10.1128/JB.174.9.2754-2762.1992; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIVE L, 1968, J BIOL CHEM, V243, P2373; LLOYD AD, 1990, J BACTERIOL, V172, P1688, DOI 10.1128/jb.172.4.1688-1693.1990; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; QIU XQ, 1994, J BIOL CHEM, V269, P7483; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	29	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18571	18575		10.1074/jbc.271.31.18571	http://dx.doi.org/10.1074/jbc.271.31.18571			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702506	hybrid			2022-12-27	WOS:A1996VB68300044
J	Stole, E; Bryant, FR				Stole, E; Bryant, FR			Reengineering the nucleotide cofactor specificity of the RecA protein by mutation of aspartic acid 100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RECOMBINATION; EXCHANGE; COMPLEX	We have recently obtained evidence for a direct linkage between the S-0.5 (S-0.5 is the substrate concentration required for half-maximal velocity) value of a nucleoside triphosphate and the conformational state of the RecA-ssDNA complex, with an S-0.5 value of 125 mu M or less required for stabilization of the strand exchange-active conformation, For example, although ATP and ITP are hydrolyzed by the RecA protein with the same turnover number (18 min(-1)), ATP (S-0.5 = 45 mu M) functions as a cofactor for the strand exchange reaction, whereas ITP (S-0.5 = 500 mu M) is inactive as a strand exchange cofactor, The RecA protein crystal structure suggests that cofactor specificity is determined by Asp(100), which likely forms a hydrogen bond with the exocyclic 6-amino group of ATP; the higher S-0.5 value for ITP is presumably due to unfavorable interactions between Asp(100) and the 6-carbonyl group of the inosine ring, To test this hypothesis, we prepared a mutant RecA protein in which Asp(100) was replaced by an asparagine residue. The S-0.5(ITP) for the [D100N]RecA protein is 125 mu M, indicating favorable interactions between the Asn(100) side chain and the 6-carbonyl group of ITP, Correspondingly, ITP functions as a cofactor for the strand exchange activity of the [D100N]RecA protein. This result demonstrates the importance of the residue at position 100 in determining nucleotide cofactor specificity and underscores the importance of the S-0.5 value in the RecA protein-promoted strand exchange reaction.	JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	Johns Hopkins University					NIGMS NIH HHS [F32 GM16284, R01 GM 36516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016284, R01GM036516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYANT FR, 1988, J BIOL CHEM, V263, P8716; COTTERILL SM, 1982, BIOCHEMISTRY-US, V21, P4332, DOI 10.1021/bi00261a023; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; EGELMAN EH, 1993, CURR OPIN STRUC BIOL, V3, P189, DOI 10.1016/S0959-440X(05)80151-4; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; MEAH YS, 1993, J BIOL CHEM, V268, P23991; MENGE KL, 1992, BIOCHEMISTRY-US, V31, P5151, DOI 10.1021/bi00137a009; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; STOLE E, 1994, J BIOL CHEM, V269, P7919; STOLE E, 1995, J BIOL CHEM, V270, P20322, DOI 10.1074/jbc.270.35.20322; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126	13	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18326	18328		10.1074/jbc.271.31.18326	http://dx.doi.org/10.1074/jbc.271.31.18326			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702471	hybrid			2022-12-27	WOS:A1996VB68300009
J	Sun, J; Williams, J; Yan, HC; Amin, KM; Albelda, SM; DeLisser, HM				Sun, J; Williams, J; Yan, HC; Amin, KM; Albelda, SM; DeLisser, HM			Platelet endothelial cell adhesion molecule-1 (PECAM-1) hemophilic adhesion is mediated by immunoglobulin-like domains 1 and 2 and depends on the cytoplasmic domain and the level of surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; IN-VIVO; CD31; BINDING; INTEGRIN; REDISTRIBUTION; ACTIVATION; MONOCYTES; ISOFORMS; LIGAND	PECAM-1/CD31 is vascular cell adhesion and signaling molecule of the Ig superfamily that plays a role in neutrophil recruitment at inflammatory sites and may be involved the release of leukocytes from the bone marrow and in cardiovascular development, The interactions of PECAM-1 with its ligands are complex in that it is able to bind both with itself (homophilic adhesion) or with non-PECAM-1 ligands (heterophilic adhesion), Although the factors that regulate ligand binding are not fully understood, these interactions are regulated in part by its large cytoplasmic domain, a region of 118 amino acids encoded by 8 exons of its gene (exons 9-16), The purpose of this work was to better define the mechanisms of PECAM-1-dependent homophilic adhesion by analyzing the binding interactions of L-cells expressing full-length and selectively mutated forms of human, murine, and human/murine chimeric PECAM-1 molecules in an established aggregation assay, These studies demonstrate that 1) the minimal length of the cytoplasmic domain required for cellular aggregation is represented within the sequences encoded by exons 9 and 10, 2) removal or addition of the sequences encoded by exon 14 from the cytoplasmic domain can determine whether the mechanism of aggregation is a heterophilic calcium-dependent process or a hemophilic calcium-independent process, 3) high levels of surface expression of PECAM-1 on the cell surface change the mechanism of aggregation from heterophilic to homophilic, and 4) PECAM-1-dependent homophilic binding appears to involve the direct interaction of only the first two extracellular Ig-like domains, These data suggest that PECAM-1-ligand interactions can be regulated through multiple pathways including alterations of the cytoplasmic domain and the level of surface expression.	UNIV PENN, MED CTR, DEPT MED, DIV PULM & CRIT CARE, PHILADELPHIA, PA 19104 USA	University of Pennsylvania			DeLisser, Horace/AFM-1942-2022		NHLBI NIH HHS [HL-03382, HL-46311] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046311, K14HL003382, R29HL046311] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; BERMAN ME, 1995, J IMMUNOL, V154, P299; BOGEN S, 1994, J EXP MED, V179, P1059, DOI 10.1084/jem.179.3.1059; Buckley CD, 1996, J CELL SCI, V109, P437; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; FAWCETT J, 1995, J CELL BIOL, V128, P1229, DOI 10.1083/jcb.128.6.1229; GRUMET M, 1988, J CELL BIOL, V106, P487, DOI 10.1083/jcb.106.2.487; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KIRSCHBAUM NE, 1994, BLOOD, V84, P4028, DOI 10.1182/blood.V84.12.4028.bloodjournal84124028; LASTRES P, 1994, J IMMUNOL, V153, P4206; LEAVESLEY DI, 1994, J IMMUNOL, V153, P4673; LIAO F, 1995, J EXP MED, V182, P1337, DOI 10.1084/jem.182.5.1337; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; MUROHARA T, 1996, J IMMUNOL, V156, P350; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; NEWMAN PJ, 1994, ANN NY ACAD SCI, V714, P165, DOI 10.1111/j.1749-6632.1994.tb12041.x; OIKAWA S, 1992, BIOCHEM BIOPH RES CO, V186, P881, DOI 10.1016/0006-291X(92)90828-9; Patel KD, 1995, J CELL BIOL, V131, P1893, DOI 10.1083/jcb.131.6.1893; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; ROMER LH, 1995, J IMMUNOL, V154, P6582; SIEBER F, 1981, J CELL BIOL, V90, P55, DOI 10.1083/jcb.90.1.55; SUN QH, 1995, J BIOL CHEM, V270, P23672; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; WATT SM, 1993, BLOOD, V82, P2649; WEITZMAN JB, 1995, J CELL SCI, V108, P3635; XIE Y, 1993, P NATL ACAD SCI USA, V90, P5569, DOI 10.1073/pnas.90.12.5569; YAN HC, 1995, CELL ADHES COMMUN, V3, P45, DOI 10.3109/15419069509081277; ZEHNDER JL, 1992, J BIOL CHEM, V267, P5243	37	122	122	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18561	18570		10.1074/jbc.271.31.18561	http://dx.doi.org/10.1074/jbc.271.31.18561			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702505	hybrid			2022-12-27	WOS:A1996VB68300043
J	Derossi, D; Calvet, S; Trembleau, A; Brunissen, A; Chassaing, G; Prochiantz, A				Derossi, D; Calvet, S; Trembleau, A; Brunissen, A; Chassaing, G; Prochiantz, A			Cell internalization of the third helix of the antennapedia homeodomain is receptor-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX PEPTIDE; GROWTH; ENDOCYTOSIS; INVITRO; SIGNAL; ACID	We have recently reported that a 16-amino acid long polypeptide corresponding to the third helix of the DNA binding domain (homeodomain) of Antennapedia, a Drosophila transcription factor, is internalized by cells in culture (Derossi, D., Joliot, A. H., Chassaing, G., and Prochiantz, A. (1994) J. Biol. Chem. 269, 10444-10450). The capture of the homeodomain and of its third helix at temperatures below 10 degrees C raised the problem of the mechanism of internalization. The present demonstration, that a reverse helix and a helix composed of D-enantiomers still translocate across biological membranes at 4 and 37 degrees C strongly suggests that the third helix of the homeodomain is internalized by a receptor-independent mechanism. The finding that introducing 1 or 3 prolines in the structure does not hamper internalization also demonstrates that the alpha-helical structure is not necessary. The data presented are compatible with a translocation process based on the establishment of direct interactions with the membrane phospholipids. The third helix of the homeodomain has been used successfully to address biologically active substances to the cytoplasm and nucleus of cells in culture (Theodore, L., Derossi, D., Chassaing, G., Llirbat, B., Kubes, M., Jordan, P., Chneiweiss, H., Godement, P., and Prochiantz, A. (1995) J. Neurosci. 15, 7158-7167). Therefore, in addition to their physiological implications (Prochiantz, A., and Theodore, L. (1995) BioEssays 17, 39-45), the present results open the way to the molecular design of cellular vectors.	UNIV PARIS 06,CNRS URA 493,F-75005 PARIS,FRANCE; ECOLE NORMALE SUPER,CNRS URA 1414,F-75230 PARIS 05,FRANCE	UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)				Trembleau, Alain/0000-0002-8290-0795				ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919; BLOCHGALLEGO E, 1993, J CELL BIOL, V120, P485, DOI 10.1083/jcb.120.2.485; Chatelin L, 1996, MECH DEVELOP, V55, P111, DOI 10.1016/0925-4773(95)00478-5; de Kruijff B., 1985, PROGR PROTEIN LIPID, P89; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; HALL MN, 1990, P NATL ACAD SCI USA, V87, P6954, DOI 10.1073/pnas.87.18.6954; ILLINGER D, 1991, BIOL CELL, V73, P131, DOI 10.1016/0248-4900(91)90095-5; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; JOLIOT AH, 1991, NEW BIOL, V3, P1121; LAFONT F, 1992, DEVELOPMENT, V114, P17; LEAMON CP, 1993, P NATL ACAD SCI USA, V90, P9100; LEROUX I, 1995, FEBS LETT, V368, P311, DOI 10.1016/0014-5793(95)00681-X; LEROUX I, 1993, P NATL ACAD SCI USA, V90, P9120, DOI 10.1073/pnas.90.19.9120; PEREZ F, 1994, MOL ENDOCRINOL, V8, P1278, DOI 10.1210/me.8.9.1278; PROCHIANTZ A, 1995, BIOESSAYS, V17, P39, DOI 10.1002/bies.950170109; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; Sandvig Kirsten, 1994, Trends in Cell Biology, V4, P275, DOI 10.1016/0962-8924(94)90211-9; THEODORE L, 1995, J NEUROSCI, V15, P7158; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; Troy CM, 1996, J NEUROSCI, V16, P253; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761	23	911	1026	2	54	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18188	18193		10.1074/jbc.271.30.18188	http://dx.doi.org/10.1074/jbc.271.30.18188			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663410	hybrid			2022-12-27	WOS:A1996UY93500090
J	Hu, JF; Vu, TH; Hoffman, AR				Hu, JF; Vu, TH; Hoffman, AR			Promoter-specific modulation of insulin-like growth factor II genomic imprinting by inhibitors of DNA methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILMS-TUMOR; GENE; MOUSE; IGF2; EXPRESSION; ACTIVATION; H19; RELAXATION; PROTEIN; ALLELE	The insulin-like growth factor II (IGF-II) gene is maternally imprinted in most normal tissues with only the paternal allele being transcribed, In several human tumors, however, IGF-II is expressed from both parental alleles. To explore the underlying mechanism of IGF-II imprinting, we have examined the effect of DNA demethylation in cultured human and mouse astrocyte cells. An increased expression of IGF-II was observed when these cells were treated with the DNA demethylating agents, 5-azacytidine or 2-deoxy-5-azacytidine. Allelic analysis indicated that, following DNA demethylation, the increment in IGF-II mRNA was primarily derived from the normally suppressed maternal allele. Examination of promoter usage revealed that only the most proximal promoter (mP3 in mouse and hP4 in human) responded to DNA demethylating agents, whereas the expression of IGF-II from the other promoters remained unchanged. The enhanced expression of IGF-II from these promoters suggests the presence of a methylation response element in or near mP3 and hP4. This study indicates that DNA demethylating agents increase IGF-II expression primarily by stimulating the normally imprinted allele through the activation of the most proximal IGF-II promoter.	DEPT VET AFFAIRS MED CTR,MED SERV 111,PALO ALTO,CA 94304; STANFORD UNIV,DEPT MED,DIV ENDOCRINOL GERONTOL & METAB,PALO ALTO,CA 94304	Stanford University			Hu, Jifan/Q-3003-2019	HU, Jifan/0000-0002-2174-0361	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036054] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36054] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; CARR BI, 1988, BRIT J CANCER, V57, P395, DOI 10.1038/bjc.1988.89; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; EVERSOLECIRE P, 1993, MOL CELL BIOL, V13, P4928, DOI 10.1128/MCB.13.8.4928; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GROUDINE M, 1981, NATURE, V292, P311, DOI 10.1038/292311a0; HU JF, 1995, MOL ENDOCRINOL, V9, P628, DOI 10.1210/me.9.5.628; JAENISCH R, 1985, P NATL ACAD SCI USA, V82, P1451, DOI 10.1073/pnas.82.5.1451; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1994, DEVELOPMENT, V120, P361; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; PEDONE PV, 1994, J BIOL CHEM, V269, P23970; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; SAPIENZA C, 1987, NATURE, V328, P251, DOI 10.1038/328251a0; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SUSSENBACH JS, 1992, GROWTH REGULAT, V2, P1; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TANIGUCHI T, 1995, ONCOGENE, V11, P751; TAYLOR SM, 1982, J MOL BIOL, V162, P679, DOI 10.1016/0022-2836(82)90395-3; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; VU TH, 1995, J CLIN ENDOCR METAB, V80, P1670, DOI 10.1210/jc.80.5.1670; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; Vu TH, 1996, J BIOL CHEM, V271, P9014, DOI 10.1074/jbc.271.15.9014; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; ZARRILLI R, 1994, MOL CELL ENDOCRINOL, V101, pR1, DOI 10.1016/0303-7207(94)90253-4; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344	37	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18253	18262		10.1074/jbc.271.30.18253	http://dx.doi.org/10.1074/jbc.271.30.18253			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663390	hybrid			2022-12-27	WOS:A1996UY93500099
J	Hudrisier, D; Mazarguil, H; Laval, F; Oldstone, MBA; Gairin, JE				Hudrisier, D; Mazarguil, H; Laval, F; Oldstone, MBA; Gairin, JE			Binding of viral antigens to major histocompatibility complex class I H-2D(b) molecules is controlled by dominant negative elements at peptide non-anchor residues - Implications for peptide selection and presentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; T-CELL EPITOPES; 3-DIMENSIONAL STRUCTURE; GLYCOPROTEIN EPITOPE; ANGSTROM RESOLUTION; CTL RECOGNITION; MHC; NUCLEOPROTEIN; AFFINITY; POCKETS	Binding of viral antigens to major histocompatibility complex (MHC) class I molecules is a critical step in the activation process of CD8(+) cytotoxic T lymphocytes, In this study, we investigated the impact of structural factors at non-anchor residues in peptide-MHC interaction using the model of lymphocytic choriomeningitis virus (LCMV) infection of its natural host, the mouse, Altering viral genes by making reassortants, recombinants, and using synthetic peptides, CD8(+) cytotoxic T lymphocytes were shown to recognize only three H-2D(b)-restricted epitopes, GP amino acids 33-41/43, GP 276-286, and NP 396-404, However, LCMV NP and GP proteins contain 31 other peptides bearing the H-2D(b) motif, These 34 LCMV peptides and 11 other known H2-D-b-restricted peptides were synthesized and examined for MHC binding properties, Despite the presence of the H-2D(b) binding motif, the majority of LCMV peptides showed weak or no affinity for H-2D(b), We observed that dominant negative structural elements located at non-anchor positions played a crucial role in peptide-MHC interaction, By comparative sequence analysis of strong versus non-binders and using molecular modeling, we delineated these negative elements and evaluated their impact on peptide-MHC interaction, Our findings were validated by showing that a single mutation of a favorable non-anchor residue in the sequence of known viral epitopes for a negative element resulted in dramatic reduction of antigen presentation properties, while conversely, substitution of one negative for a positive element in the sequence of a non-binder conferred to the peptide an ability to now bind to MHC molecules.	INST PHARMACOL & BIOL STRUCT, CNRS, F-31400 TOULOUSE, FRANCE; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Scripps Research Institute			LAUZERAL-VIZCAINO, Françoise/W-8898-2019	LAUZERAL-VIZCAINO, Françoise/0000-0002-9741-3252; Hudrisier, Denis/0000-0002-3631-9561	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009484, R01AI009484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG004342] Funding Source: NIH RePORTER; NIAID NIH HHS [AI09484] Funding Source: Medline; NIA NIH HHS [AG04342] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALEXANDER J, 1990, IMMUNOGENETICS, V31, P169; BARBER LD, 1994, J EXP MED, V180, P1191, DOI 10.1084/jem.180.4.1191; BORROW P, 1995, J VIROL, V69, P1059, DOI 10.1128/JVI.69.2.1059-1070.1995; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; CHEN WS, 1994, J EXP MED, V180, P1471, DOI 10.1084/jem.180.4.1471; COLBERT RA, 1994, IMMUNITY, V1, P121, DOI 10.1016/1074-7613(94)90105-8; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; DECKHUT AM, 1992, J VIROL, V66, P440, DOI 10.1128/JVI.66.1.440-447.1992; Dockter J, 1996, J VIROL, V70, P1799, DOI 10.1128/JVI.70.3.1799-1803.1996; ELLIOTT T, 1993, CURR BIOL, V3, P854, DOI 10.1016/0960-9822(93)90219-E; ENGELHARD VH, 1994, CURR OPIN IMMUNOL, V6, P13, DOI 10.1016/0952-7915(94)90028-0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GAIRIN JE, 1992, J VIROL, V66, P6755, DOI 10.1128/JVI.66.11.6755-6762.1992; GAIRIN JE, 1995, J VIROL, V69, P2297, DOI 10.1128/JVI.69.4.2297-2305.1995; GAIRIN JE, 1993, J VIROL, V67, P2903, DOI 10.1128/JVI.67.5.2903-2907.1993; Gavin Marc A., 1993, Journal of Cellular Biochemistry Supplement, V17, P45; GREY HM, 1995, CANCER SURV, V22, P37; HARTY JT, 1992, J EXP MED, V175, P1531, DOI 10.1084/jem.175.6.1531; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HIOE CE, 1994, IMMUNOGENETICS, V40, P222, DOI 10.1007/BF00167083; HUDRISIER D, 1995, MOL IMMUNOL, V32, P895, DOI 10.1016/0161-5890(95)00043-E; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KLAVINSKIS LS, 1990, VIROLOGY, V178, P393, DOI 10.1016/0042-6822(90)90336-P; KOUP RA, 1994, J EXP MED, V180, P779, DOI 10.1084/jem.180.3.779; LANZAVECCHIA A, 1993, SCIENCE, V260, P937, DOI 10.1126/science.8493532; LEWICKI H, 1995, VIROLOGY, V210, P29, DOI 10.1006/viro.1995.1314; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MARRACK P, 1994, NATURE, V368, P397, DOI 10.1038/368397a0; MATSUI M, 1993, P NATL ACAD SCI USA, V90, P674, DOI 10.1073/pnas.90.2.674; MATSUI M, 1994, HUM IMMUNOL, V41, P160, DOI 10.1016/0198-8859(94)90010-8; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; OLDSTONE MBA, 1988, J EXP MED, V168, P559, DOI 10.1084/jem.168.2.559; OLDSTONE MBA, 1995, J VIROL, V69, P7423, DOI 10.1128/JVI.69.12.7423-7429.1995; OUKKA M, 1994, J IMMUNOL, V152, P4843; OZATO K, 1980, J IMMUNOL, V125, P2473; PARKER KC, 1994, J IMMUNOL, V152, P163; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; POGUE RR, 1995, P NATL ACAD SCI USA, V92, P8166, DOI 10.1073/pnas.92.18.8166; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; ROHREN EM, 1993, J EXP MED, V177, P1713, DOI 10.1084/jem.177.6.1713; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SCHONBACH C, 1995, J IMMUNOL, V154, P5951; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; SETTE A, 1994, J IMMUNOL, V153, P5586; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANBLEEK GM, 1990, NATURE, V348, P213; VONHERRATH MG, 1994, J EXP MED, V180, P1901, DOI 10.1084/jem.180.5.1901; vonHerrath MG, 1995, IMMUNITY, V3, P727, DOI 10.1016/1074-7613(95)90062-4; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	57	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17829	17836		10.1074/jbc.271.30.17829	http://dx.doi.org/10.1074/jbc.271.30.17829			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663374	hybrid			2022-12-27	WOS:A1996UY93500039
J	Robey, FA; HarrisKelson, T; RobertGuroff, M; Batinic, D; Ivanov, B; Lewis, MS; Roller, PP				Robey, FA; HarrisKelson, T; RobertGuroff, M; Batinic, D; Ivanov, B; Lewis, MS; Roller, PP			A synthetic conformational epitope from the C4 domain of HIV Gp120 that binds CD4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; AUTOMATED SYNTHESIS; MODIFIED PEPTIDES; T4 MOLECULE; RECEPTOR; TYPE-1; PROTEIN; INFECTION; SWITCH	The fourth conserved domain of the human immunodeficiency virus type 1 (HIV-1) envelope, the C4 region of glycoprotein 120 (gp120), is believed to be a major part of gp120 that is necessary for binding to CD4, Recently, we found that C4 in gp120 is probably an alpha-helix, because antibodies made against helical constructs of C4 react with native and recombinant gp120 but antibodies against linear C4 constructs do not. For the present study, we performed experiments to determine, first, if CD4 could bind to the helical C4 constructs and, second, if the binding was comparable with CD4 binding to gp120. Immobilized helical constructs derived from the C4s from HTV-1 and HIV-2 bound biotinylated recombinant CD4 with K-d values of 8.59 nM and 14.59 nM, respectively. Recombinant soluble CD4 inhibited the binding of biotinylated CD4 to the C4 construct from HIV-1 with a K-d of 9.88 nM, and recombinant gp120 blocked the binding of CD4 to the immobilized helical construct from C4 of HIV-1 with a K-d of 8.08 nn. The C4 peptide-(419-436) from HIV-1 (KIKQIINMWQEVGKAMYA-NH2) blocked CD4 binding to gp120 but only in a buffer con containing 0.03% Brij 35 where the peptide displayed 17 +/- 1% alpha-helix; without the Brij 35, peptide-(419-436) displayed no helical content, The K-d for the peptide-(419-436) blocking CD4 binding to gp120 in Brij 35-containing buffer was found to be 42 mu M. These results indicate that C4 constructs from HTV-1 and HIV-2 do bind CD4, but the constructs must display an alpha-helical conformation to do so. In addition, the results reported here will provide answers to key questions about structural requirements for HIV vaccines and therapeutics that hinge on under standing the molecular nature of the gp120-CD4 interaction as the first step in the HIV infection process.	NCI, TUMOR CELL BIOL LAB, NIH, BETHESDA, MD 20892 USA; NCI, MED CHEM LAB, NIH, BETHESDA, MD 20892 USA; NATL CTR RES RESOURCES, BIOMED ENGN & INSTRUMENTAT PROGRAM, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA	Robey, FA (corresponding author), NIDR, PEPTIDE & IMMUNOCHEM UNIT, NIH, BLDG 30, RM 211, BETHESDA, MD 20892 USA.							ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ATTRI AK, 1992, ANAL ULTRACENTRIFUGA, P139; CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; CORDONNIER A, 1989, NATURE, V340, P571, DOI 10.1038/340571a0; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FINBERG RW, 1990, SCIENCE, V249, P287, DOI 10.1126/science.2115689; HARVEST RL, 1993, BIOORGANIC MED LETT, V3, P2851; IVANOV B, 1995, BIOCONJUGATE CHEM, V6, P269, DOI 10.1021/bc00033a006; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LIFSON JD, 1988, SCIENCE, V241, P712, DOI 10.1126/science.2969619; LINDNER W, 1987, INT J PEPT PROT RES, V30, P794; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MOORE JP, 1990, AIDS, V4, P297, DOI 10.1097/00002030-199004000-00003; MOORE JP, 1992, VIROLOGY, V188, P537, DOI 10.1016/0042-6822(92)90508-M; MORRISON HG, 1995, VIROLOGY, V210, P448, DOI 10.1006/viro.1995.1361; OLSHEVSKY U, 1990, J VIROL, V64, P5701, DOI 10.1128/JVI.64.12.5701-5707.1990; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; REED J, 1994, BIOCHEMISTRY-US, V33, P10993, DOI 10.1021/bi00202a019; REED J, 1991, BIOCHEMISTRY-US, V30, P4521, DOI 10.1021/bi00232a022; REED J, 1993, P NATL ACAD SCI USA, V90, P6761, DOI 10.1073/pnas.90.14.6761; Robey F A, 1994, Methods Mol Biol, V35, P73; ROBEY FA, 1989, ANAL BIOCHEM, V177, P373, DOI 10.1016/0003-2697(89)90068-7; ROBEY FA, 1995, J BIOL CHEM, V270, P23918, DOI 10.1074/jbc.270.41.23918; ROBEY FA, 1992, CHIM OGGI, P27; ROBEY FA, 1992, CURRENT PROTOCOLS IM; ROYER RE, 1995, J MED CHEM, V38, P2427, DOI 10.1021/jm00013a018; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SCHOLS D, 1989, P NATL ACAD SCI USA, V86, P3322, DOI 10.1073/pnas.86.9.3322; SMALLHEER JM, 1993, ANTIVIR CHEM CHEMOTH, V4, P27, DOI 10.1177/095632029300400104; STEIN CA, 1991, J ACQ IMMUN DEF SYND, V4, P686; VONSTOSCH AG, 1995, J MOL BIOL, V250, P507, DOI 10.1006/jmbi.1995.0394; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0	35	27	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17990	17995		10.1074/jbc.271.30.17990	http://dx.doi.org/10.1074/jbc.271.30.17990			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663408	hybrid			2022-12-27	WOS:A1996UY93500063
J	Sadar, MD; Ash, R; Sundqvist, J; Olsson, PE; Andersson, TB				Sadar, MD; Ash, R; Sundqvist, J; Olsson, PE; Andersson, TB			Phenobarbital induction of CYP1A1 gene expression in a primary culture of rainbow trout hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARYL-HYDROCARBON HYDROXYLASE; ADULT-RAT HEPATOCYTES; HEPATOMA-CELL LINE; AH RECEPTOR; DIOXIN RECEPTOR; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL EXPRESSION; METABOLIZING-ENZYMES	In mammals, phenobarbital (PB) is an in vivo inducer of the cytochrome P4502B (CYP2B) family, whereas in teleosts PB induction of cytochrome P450 is unclear. We show that teleost cytochrome P4502K1 (CYP2K1) protein levels and 7-pentoxyresorufin-O-deethylase activity were not induced by exposure of primary cultures of rainbow trout hepatocytes to PB. Instead, cytochrome P4501A1 (CYP1A1) gene expression was strongly induced by PB, based upon observations of marked increases in CYP1A1 mRNA, CYP1A1 protein, and 7-ethoxyresorufin-O-deethylase activity. In accordance with these data we provide a temporal study employing antibodies for the aromatic hydrocarbon (Ah) receptor that showed an increase in Ah receptor in nuclear extracts prepared from cells exposed to PB, Employment of the electrophoretic mobility shift assay (EMSA) showed PB to cause activation or ''transformation'' of the Ah receptor in nuclear extracts. Studies employing actinomycin D and cycloheximide indicated that PB induction of CYP1A1 was regulated at both the transcriptional and post-transcriptional levels. Nuclear run-off experiments confirm that PB causes an increase in CYP1A1 transcription. Inhibition of protein synthesis led to the superinduction of CYP1A1 mRNA, suggesting the regulation of teleost CYP1A1 may involve a labile repressor protein. These findings suggest that PB induction of the CYP1A1 gene involves the Ah receptor and is via transcriptional activation.	GOTHENBURG UNIV,DEPT ZOOPHYSIOL,S-40031 GOTHENBURG,SWEDEN; UNIV BRADFORD,DEPT BIOMED SCI,BRADFORD BD7 1DP,W YORKSHIRE,ENGLAND; ASTRA HASSLE AB,DEPT PHARMACOKINET & DRUG METAB,S-43183 MOLNDAL,SWEDEN	University of Gothenburg; University of Bradford			Sadar, Marianne/E-9136-2012	Sadar, Marianne/0000-0003-0599-9215; Olsson, Per-Erik/0000-0001-7336-6335				AIX L, 1994, BIOCHEM BIOPH RES CO, V202, P1483, DOI 10.1006/bbrc.1994.2098; ALBAYATI ZAF, 1988, RES COMMUN CHEM PATH, V60, P47; ANDERSSON T, 1992, AQUAT TOXICOL, V24, P1, DOI 10.1016/0166-445X(92)90014-E; ANKLEY GT, 1987, BIOCHEM PHARMACOL, V36, P1379, DOI 10.1016/0006-2952(87)90099-2; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; AUBRECHT J, 1993, BIOCHEM BIOPH RES CO, V190, P1023, DOI 10.1006/bbrc.1993.1151; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BACH J, 1989, XENOBIOTICA, V19, P1; BAYAD J, 1991, BIOCHEM PHARMACOL, V42, P1345, DOI 10.1016/0006-2952(91)90444-A; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BERNDTSON AK, 1994, ARCH BIOCHEM BIOPHYS, V310, P187, DOI 10.1006/abbi.1994.1156; BOMBICK DW, 1988, P NATL ACAD SCI USA, V85, P4128, DOI 10.1073/pnas.85.12.4128; BOMBICK DW, 1985, BIOCHEM BIOPH RES CO, V127, P296, DOI 10.1016/S0006-291X(85)80158-3; BOOBIS AR, 1986, XENOBIOTICA, V16, P233, DOI 10.3109/00498258609043526; BRADFIELD CA, 1991, MOL PHARMACOL, V39, P13; BROCKENBROUGH JS, 1991, CANCER RES, V51, P130; BUHLER DR, 1994, ARCH BIOCHEM BIOPHYS, V312, P45, DOI 10.1006/abbi.1994.1278; BURKE MD, 1994, BIOCHEM PHARMACOL, V48, P923, DOI 10.1016/0006-2952(94)90363-8; BURKE MD, 1985, BIOCHEM PHARMACOL, V34, P3337, DOI 10.1016/0006-2952(85)90355-7; BURKE MD, 1974, DRUG METAB DISPOS, V2, P583; BURNS KA, 1976, COMP BIOCHEM PHYS B, V53, P443, DOI 10.1016/0305-0491(76)90195-4; BYUS CV, 1976, P NATL ACAD SCI USA, V73, P1241, DOI 10.1073/pnas.73.4.1241; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CHAUHAN VPS, 1987, LIFE SCI, V40, P89, DOI 10.1016/0024-3205(87)90256-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOMCZYNSKI P, 1989, TEL TEST INC B, V3; COLLIER TK, 1991, ARCH ENVIRON CON TOX, V20, P462, DOI 10.1007/BF01065834; CURIPEDROSA R, 1994, J PHARMACOL EXP THER, V269, P384; DAUJAT M, 1992, BIOCHEM BIOPH RES CO, V188, P820, DOI 10.1016/0006-291X(92)91130-I; EISELE TA, 1984, AQUAT TOXICOL, V5, P211, DOI 10.1016/0166-445X(84)90021-3; FORLIN L, 1978, COMP BIOCHEM PHYS C, V60, P193, DOI 10.1016/0306-4492(78)90093-X; FORLIN L, 1982, ECOTOX ENVIRON SAFE, V6, P41, DOI 10.1016/0147-6513(82)90079-3; FORSTER U, 1986, DRUG METAB DISPOS, V14, P353; FRY JR, 1980, BIOCHEM PHARMACOL, V29, P577, DOI 10.1016/0006-2952(80)90379-2; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GIACHELLI CM, 1991, J BIOL CHEM, V266, P3981; GOKSOYR A, 1992, AQUAT TOXICOL, V22, P287, DOI 10.1016/0166-445X(92)90046-P; GOKSOYR A, 1987, TOXICOL APPL PHARM, V89, P347, DOI 10.1016/0041-008X(87)90154-2; GRADIN K, 1994, J BIOL CHEM, V269, P23800; GUTMAN Y, 1971, BIOCHEM PHARMACOL, V20, P3547, DOI 10.1016/0006-2952(71)90463-1; HAASCH ML, 1994, BIOCHEM PHARMACOL, V47, P893, DOI 10.1016/0006-2952(94)90490-1; HAHN ME, 1993, AQUAT TOXICOL, V26, P185, DOI 10.1016/0166-445X(93)90030-5; HEILMANN LJ, 1988, DNA-J MOLEC CELL BIO, V7, P379, DOI 10.1089/dna.1.1988.7.379; ISREAL DI, 1985, J BIOL CHEM, V260, P5648; JENSEN EG, 1991, AQUAT TOXICOL, V21, P81, DOI 10.1016/0166-445X(91)90007-V; KARENLAMPI SO, 1989, BIOCHEM PHARMACOL, V38, P1517, DOI 10.1016/0006-2952(89)90192-5; KAUFMANN WK, 1988, CARCINOGENESIS, V9, P779, DOI 10.1093/carcin/9.5.779; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; KLEINOW KM, 1990, COMP BIOCHEM PHYS C, V96, P259, DOI 10.1016/0742-8413(90)90006-U; LAPEYRE JN, 1974, J MOL BIOL, V89, P137, DOI 10.1016/0022-2836(74)90167-3; LOCKWOOD AP, 1961, COMP BIOCHEM PHYSIOL, V2, P241, DOI 10.1016/0010-406X(61)90113-X; LORENZEN A, 1990, TOXICOL APPL PHARM, V106, P53, DOI 10.1016/0041-008X(90)90105-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBET RA, 1985, ARCH BIOCHEM BIOPHYS, V238, P43, DOI 10.1016/0003-9861(85)90138-9; LUSSKA A, 1992, J BIOL CHEM, V267, P15146; Maniatis T., 1982, MOL CLONING; MCMANUS ME, 1986, BIOCHEM BIOPH RES CO, V137, P120, DOI 10.1016/0006-291X(86)91184-8; MERCHANT M, 1990, ARCH BIOCHEM BIOPHYS, V281, P84, DOI 10.1016/0003-9861(90)90416-V; MIRANDA CL, 1990, BIOCHIM BIOPHYS ACTA, V1037, P155, DOI 10.1016/0167-4838(90)90161-8; NEBERT DW, 1970, J BIOL CHEM, V245, P160; NEWMAN S, 1982, P NATL ACAD SCI-BIOL, V79, P2922, DOI 10.1073/pnas.79.9.2922; OKEY AB, 1980, J BIOL CHEM, V255, P1415; OKEY AB, 1984, BIOCHEM PHARMACOL, V33, P531, DOI 10.1016/0006-2952(84)90303-4; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; OKINO ST, 1992, J BIOL CHEM, V267, P6991; OWENS IS, 1975, MOL PHARMACOL, V11, P94; PAINE AJ, 1990, CHEM-BIOL INTERACT, V74, P1, DOI 10.1016/0009-2797(90)90055-R; PASCO DS, 1988, J BIOL CHEM, V263, P8671; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PERDEW GH, 1991, ARCH BIOCHEM BIOPHYS, V291, P284, DOI 10.1016/0003-9861(91)90136-7; PESONEN M, 1991, XENOBIOTICA, V21, P461, DOI 10.3109/00498259109039486; PESONEN M, 1992, ARCH BIOCHEM BIOPHYS, V292, P228, DOI 10.1016/0003-9861(92)90072-5; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1976, J BIOL CHEM, V251, P4936; PUGA A, 1992, FASEB J, V6, P777, DOI 10.1096/fasebj.6.2.1311272; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; REINERS JJ, 1993, ARCH BIOCHEM BIOPHYS, V301, P449, DOI 10.1006/abbi.1993.1170; REINERS JJ, 1992, BIOCHEM BIOPH RES CO, V183, P193, DOI 10.1016/0006-291X(92)91627-3; RIDDICK DS, 1994, J BIOL CHEM, V269, P12118; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SCHUETZ EG, 1986, BIOCHEMISTRY-US, V25, P1124, DOI 10.1021/bi00353a027; SCHWARZ LR, 1993, HDB EXPT PHARM, V105, P399; Schwarzbauer J., 1990, EXTRACELLULAR MATRIX, P195; SILVER G, 1988, J BIOL CHEM, V263, P11802; SODERKVIST P, 1988, CANCER RES, V48, P3045; STEGEMAN JJ, 1990, BIOCHEM SOC T, V18, P19, DOI 10.1042/bst0180019; Stegeman JJ, 1993, AQUATIC TOXICOLOGY M, P87; SWANSON HI, 1991, TOXICOL LETT, V58, P85, DOI 10.1016/0378-4274(91)90194-B; TEIFELD RM, 1989, DNA-J MOLEC CELL BIO, V8, P329, DOI 10.1089/dna.1.1989.8.329; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER NA, 1988, ARCH BIOCHEM BIOPHYS, V263, P204, DOI 10.1016/0003-9861(88)90629-7; UENG TH, 1992, AQUAT TOXICOL, V23, P49; WHITLOCK JP, 1986, ANNU REV PHARMACOL, V26, P333; WIEBEL FJ, 1984, CHEM-BIOL INTERACT, V52, P151, DOI 10.1016/0009-2797(84)90069-3; XU LC, 1990, BIOCHEM PHARMACOL, V40, P1399	96	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17635	17643		10.1074/jbc.271.30.17635	http://dx.doi.org/10.1074/jbc.271.30.17635			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663422	hybrid			2022-12-27	WOS:A1996UY93500011
J	Sugiura, I; Furie, B; Walsh, CT; Furie, BC				Sugiura, I; Furie, B; Walsh, CT; Furie, BC			Prefactor IX propeptide and glutamate substrate binding sites on the vitamin K-dependent carboxylase identified by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYLATION; BLOOD-COAGULATION; RECOGNITION SITE; ENZYME-ACTIVITY; EXPRESSION; INVITRO; CELLS; PROTEINS; SEQUENCE; REGION	The vitamin K-dependent carboxylase, a constituent of the endoplasmic reticulum membrane, catalyzes the conversion of reduced vitamin K to vitamin K epoxide and the concomitant conversion of glutamic acid to gamma-carboxyglutamic acid, To study structure-function relationships in the enzyme, seventeen clusters of charged residues of the bovine gamma-glutamyl carboxylase were substituted with alanines using site-specific mutagenesis, Wild-type and mutant carboxylase species were expressed in Chinese hamster ovary cells with an immunodetectable octapeptide inserted at their amino-terminal ends, Out of 17 mutant carboxylase species that contain a total of 41 charged residue to alanine substitutions, K217A/K218A (CBX217/218), R234A/H235A (CBX234/235), R359A/H360A/K361A. (CBX359/360/361), R406A/H408A (CBX406/408), and R513A/K515A (CEX513/515) had impaired carboxylase activity compared with the wild-type enzyme, The vitamin K epoxidase activities of these mutants were reduced in parallel with the carboxylase activities, CBX217/218 appears to be inactive, High propeptide concentrations were required for stimulation of carboxylation of FLEEL by CBX234/235, CBX406/408, and CBX513/515, suggesting defects in the propeptide binding site, CBX359/360/361 showed normal affinity for the propeptide, FLEEL, proPT28, and vitamin K hydroquinone but exhibited a low catalytic rate for carboxylation. These results suggest that residue 217, residue 218, or both are either critical for catalysis or for maintaining the structure of a catalytically active enzyme, Regions around residues 234, 406, and 513 define in part the propeptide binding site, while the regions around residue 359 are involved in catalysis.	TUFTS UNIV,NEW ENGLAND MED CTR,DEPT BIOCHEM,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,BOSTON,MA 02111; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Tufts Medical Center; Tufts University; Tufts University; Harvard University; Harvard Medical School	Sugiura, I (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,DEPT MED,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL ONCOL,BOSTON,MA 02111, USA.				PHS HHS [42443] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BUITENHUIS HC, 1990, BIOCHIM BIOPHYS ACTA, V1034, P170, DOI 10.1016/0304-4165(90)90072-5; CARLISLE TL, 1980, BIOCHEMISTRY-US, V19, P1161, DOI 10.1021/bi00547a019; CHEUNG A, 1989, ARCH BIOCHEM BIOPHYS, V274, P574, DOI 10.1016/0003-9861(89)90472-4; FOSTER DC, 1987, BIOCHEMISTRY-US, V26, P7003, DOI 10.1021/bi00396a022; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HAM SW, 1990, J AM CHEM SOC, V112, P1660, DOI 10.1021/ja00160a073; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUBBARD BR, 1989, J BIOL CHEM, V264, P14145; JONES JP, 1977, J BIOL CHEM, V252, P7738; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; KULIOPULOS A, 1992, BIOCHEMISTRY-US, V31, P9436, DOI 10.1021/bi00154a016; KULIOPULOS A, 1994, J BIOL CHEM, V269, P21364; LARSON AE, 1981, J BIOL CHEM, V256, P1032; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MCTIGUE JJ, 1983, J BIOL CHEM, V258, P2129; MORRIS DP, 1993, J BIOL CHEM, V268, P8735; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; REHEMTULLA A, 1993, P NATL ACAD SCI USA, V90, P4611, DOI 10.1073/pnas.90.10.4611; ROTH DA, 1993, P NATL ACAD SCI USA, V90, P8372, DOI 10.1073/pnas.90.18.8372; ROTH DA, 1995, J BIOL CHEM, V270, P5305, DOI 10.1074/jbc.270.10.5305; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SOUTE BAM, 1992, THROMB HAEMOSTASIS, V68, P521; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; UOTILA L, 1988, ARCH BIOCHEM BIOPHYS, V264, P135, DOI 10.1016/0003-9861(88)90578-4; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; VERMEER C, 1990, BIOCHEM J, V266, P625, DOI 10.1042/bj2660625; WOOD GM, 1988, J BIOL CHEM, V263, P3234; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; WU SM, 1991, P NATL ACAD SCI USA, V88, P2236, DOI 10.1073/pnas.88.6.2236; YAMADA M, 1995, BIOCHEMISTRY-US, V34, P481, DOI 10.1021/bi00002a012	34	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17837	17844		10.1074/jbc.271.30.17837	http://dx.doi.org/10.1074/jbc.271.30.17837			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663364	hybrid			2022-12-27	WOS:A1996UY93500040
J	Hurme, R; Berndt, KD; Namork, E; Rhen, M				Hurme, R; Berndt, KD; Namork, E; Rhen, M			DNA binding exerted by a bacterial gene regulator with an extensive coiled-coil domain (vol 271, pg 12626, 1996)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction, Addition									KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN; NATL PUBL HLTH INST,ELECTRON MICROSCOPY UNIT,N-0403 OSLO,NORWAY	Karolinska Institutet	Hurme, R (corresponding author), KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,BOX 280,S-17177 STOCKHOLM,SWEDEN.		Berndt, Kurt/J-8574-2015	Berndt, Kurt/0000-0002-3049-967X				Hurme R, 1996, J BIOL CHEM, V271, P12626, DOI 10.1074/jbc.271.21.12626	1	1	1	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17592	17592						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663602				2022-12-27	WOS:A1996UX94300091
J	Regan, LM; StearnsKurosawa, DJ; Kurosawa, S; Mollica, J; Fukudome, K; Esmon, CT				Regan, LM; StearnsKurosawa, DJ; Kurosawa, S; Mollica, J; Fukudome, K; Esmon, CT			The endothelial cell protein C receptor - Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-V; BLOOD-COAGULATION; THROMBOMODULIN; THROMBIN; INACTIVATION; CLEAVAGE; BINDING; IDENTIFICATION; SPECIFICITY; RESISTANCE	A soluble form of the endothelial cell protein C receptor (EPCR) was analyzed for the ability to modulate the functional properties of protein C and activated protein C (APC). in a plasma clotting system initiated with factor Xa, EPCR blocked the anticoagulant activity of APC in a dose-dependent fashion. EPCR had no influence on clotting in the absence of APC. Consistent with the plasma results, EPCR slowed the proteolytic inactivation of factor Va by slowing both of the key proteolytic cleavages in the heavy chain of factor Va. EPCR did not prevent protein C activation by the soluble thrombin-thrombomodulin complex, did not alter the inactivation of APC by alpha(1)-antitrypsin or protein C inhibitor, and did not influence the kinetics of peptide paranitroanilide substrate cleavage significantly. We conclude that EPCR binds to an exosite on APC that selectively modulates the enzyme specificity in a manner reminiscent of the influence of thrombomodulin on thrombin.	UNIV OKLAHOMA,HLTH SCI CTR,OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,DEPT BIOCHEM,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,DEPT MOL BIOL,OKLAHOMA CITY,OK 73104; HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute	Regan, LM (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,DEPT PATHOL,OKLAHOMA CITY,OK 73104, USA.			Stearns-Kurosawa, Deborah/0000-0003-2486-923X	NHLBI NIH HHS [P01 HL 54804] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1994, J CLIN INVEST, V94, P923, DOI 10.1172/JCI117458; DITTMAN WA, 1990, BLOOD, V75, P329; ESMON CT, 1995, TRENDS CARDIOVAS MED, V5, P141, DOI 10.1016/1050-1738(95)00054-D; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON NL, 1983, J BIOL CHEM, V258, P2238; ESMON NL, 1983, J BIOL CHEM, V258, P5548; ESPANA F, 1991, BLOOD, V77, P1754; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; FUKUDOME K, 1996, J BIOL CHEM, V271, P17499; GALVIN JB, 1986, CIRCULATION, V74, P65; GUINTO ER, 1982, J BIOL CHEM, V257, P38; GUINTO ER, 1983, THESIS U OKLAHOMA HL; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KISIEL W, 1981, METHOD ENZYMOL, V80, P320; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MATHER T, 1995, 21 EMBO S STRUCT FUN, P151; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; OWEN WG, 1974, J BIOL CHEM, V249, P594; PHILLIPS JE, 1994, J BIOL CHEM, V269, P16696; POLGAR J, 1986, THROMB RES, V43, P585, DOI 10.1016/0049-3848(86)90079-4; REGAN LM, 1994, J BIOL CHEM, V269, P9445; REZAIE AR, 1995, J BIOL CHEM, V270, P25336, DOI 10.1074/jbc.270.43.25336; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; YE J, 1992, J BIOL CHEM, V267, P11023	35	95	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17499	17503		10.1074/jbc.271.29.17499	http://dx.doi.org/10.1074/jbc.271.29.17499			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663474	hybrid			2022-12-27	WOS:A1996UX94300079
J	Sette, C; Conti, M				Sette, C; Conti, M			Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase - Involvement of serine 54 in the enzyme activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CATESBIANA ROD PHOTORECEPTORS; CGMP PHOSPHODIESTERASE; AMP PHOSPHODIESTERASE; INHIBITORY SUBUNIT; RAT ADIPOCYTES; STIMULATING-HORMONE; HUMAN-PLATELETS; SERTOLI-CELL; INSULIN	A cAMP-specific phosphodiesterase (PDE4D3) is activated in rat thyroid cells by TSH through a cAMP-dependent phosphorylation (Sette, C., Iona, S., and Conti, M. (1994) J. Biol. Chem, 269, 9245-9252). This short term activation may be involved in the termination of the hormonal stimulation and/or in the induction of desensitization. Here, we have further characterized the protein kinase A (PKA)-dependent phosphorylation of this PDE4D3 variant and identified the phosphorylation site involved in the PDE activation, The PKA-dependent incorporation of phosphate in the partially purified, re-combinant rat PDE4D3 followed a time course similar to that of activation, Half-maximal activation of the enzyme was obtained with 0.6 mu M ATP and 30 nM of the catalytic subunit of PKA, Phosphorylation altered the V-max of the PDE without affecting the K-m for cAMP. Phosphorylation also modified the Mg2+ requirements and the pattern of inhibition by rolipram, Cyanogen bromide cleavage of the P-32-labeled rat PDE4D3 yielded two or three major phosphopeptide bands, providing a first indication that the enzyme may be phosphorylated at multiple sites in a cell free system, Site-directed mutagenesis was performed on the serine residues present at the amino terminus of this PDE in the context of preferred motifs for PKA phosphorylation. The PKA-dependent incorporation of P-32 was reduced to the largest extent in mutants with both Ser(13) --> Ala and Ser(54) --> Ala substitutions, confirming the presence of more than one phosphorylation site in rat PDE4D3, While substitution of serine 13 with alanine did not affect the activation by PKA, substitution of Ser(54) completely suppressed the kinase activation, Similar conclusions were reached with wild type and mutated PDE4D3 proteins expressed in MA-10 cells, where the endogenous PKA was activated by dibutyryl cAMP. Again, the PDE with the Ser(54) --> Ala substitution could not be activated by the endogenous PKA in the intact cell, These findings support the hypothesis that the PDE4D3 variant contains a regulatory domain target for phosphorylation at the amino terminus of the protein and that Ser(54) in this domain plays a crucial role in activation.	STANFORD UNIV, MED CTR, DEPT GYNECOL & OBSTET, DIV REPROD BIOL, STANFORD, CA 94305 USA	Stanford University			Sette, Claudio/S-4307-2019	Sette, Claudio/0000-0003-2864-8266	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALVAREZ R, 1995, MOL PHARMACOL, V48, P616; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS F, 1992, BIOCHEM J, V283, P487, DOI 10.1042/bj2830487; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONTI M, 1995, BIOCHEMISTRY-US, V34, P7979, DOI 10.1021/bi00025a003; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; CONTI M, 1982, ENDOCRINOLOGY, V110, P1189, DOI 10.1210/endo-110-4-1189; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FLOCKHART DA, 1982, CRC CR REV BIOCH MOL, V12, P133, DOI 10.3109/10409238209108705; FLORIO VA, 1994, BIOCHEMISTRY-US, V33, P8948, DOI 10.1021/bi00196a012; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRANT PG, 1988, P NATL ACAD SCI USA, V85, P9071, DOI 10.1073/pnas.85.23.9071; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P10884; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KINCAID RL, 1985, J BIOL CHEM, V260, P9009; KOVALA T, 1994, J BIOL CHEM, V269, P8680; LOPEZAPARICIO P, 1993, BIOCHEM BIOPH RES CO, V193, P1137, DOI 10.1006/bbrc.1993.1744; LOTEN EG, 1978, J BIOL CHEM, V253, P746; MACPHEE CH, 1988, J BIOL CHEM, V263, P10353; MANGANIELLO VC, 1992, ADV SEC MESS PHOSPH, V25, P147; MARCHMONT RJ, 1980, NATURE, V286, P904, DOI 10.1038/286904a0; MONACO L, 1994, J BIOL CHEM, V269, P347; MUCA C, 1994, ONCOGENE, V9, P3647; NEMOZ G, 1995, MOL ENDOCRINOL, V9, P1279, DOI 10.1210/me.9.10.1279; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; RASCON A, 1994, J BIOL CHEM, V269, P11962; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHNEIDER HH, 1986, EUR J PHARMACOL, V127, P105, DOI 10.1016/0014-2999(86)90210-4; SETTE C, 1994, MOL CELL ENDOCRINOL, V100, P75, DOI 10.1016/0303-7207(94)90282-8; SETTE C, 1994, J BIOL CHEM, V269, P9245; SETTE C, 1994, J BIOL CHEM, V269, P18271; SHARMA RK, 1991, BIOCHEMISTRY-US, V30, P5963, DOI 10.1021/bi00238a021; SHARMA RK, 1986, J BIOL CHEM, V261, P1322; SHARMA RK, 1985, P NATL ACAD SCI USA, V82, P2603, DOI 10.1073/pnas.82.9.2603; SHIBATA H, 1991, J BIOL CHEM, V266, P17948; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; STROOP SD, 1989, J BIOL CHEM, V264, P13718; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TORPHY TJ, 1992, J PHARMACOL EXP THER, V263, P1195; TORPHY TJ, 1995, J BIOL CHEM, V270, P23598, DOI 10.1074/jbc.270.40.23598; TORPHY TJ, 1992, J BIOL CHEM, V267, P1798; TSUBOI S, 1994, J BIOL CHEM, V269, P15024; TSUBOI S, 1994, J BIOL CHEM, V269, P15016; UDOVICHENKO IP, 1993, BIOCHEM J, V295, P49, DOI 10.1042/bj2950049; UDOVICHENKO IP, 1994, J BIOL CHEM, V269, P9850; VERGHESE MW, 1995, MOL PHARMACOL, V47, P1164; WHALIN ME, 1988, BIOCHIM BIOPHYS ACTA, V972, P79; WYATT TA, 1994, FASEB J, V8, pA372	57	339	353	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16526	16534		10.1074/jbc.271.28.16526	http://dx.doi.org/10.1074/jbc.271.28.16526			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663227				2022-12-27	WOS:A1996UX12600019
J	Wall, L; Destroismaisons, N; Delvoye, N; Guy, LG				Wall, L; Destroismaisons, N; Delvoye, N; Guy, LG			CAAT/enhancer-binding proteins are involved in beta-globin gene expression and are differentially expressed in murine erythroleukemia and K562 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-RELATED PROTEINS; LOCUS-CONTROL REGION; HUMAN GAMMA-GLOBIN; MOLECULAR-CLONING; TRANSGENIC MICE; NUCLEAR-PROTEIN; DNA-BINDING; PROMOTER; ENHANCER; FAMILY	Acting in cis with the beta-globin locus control region, the CAAT box of the beta-globin gene promoter stimulates transcription 10 fold in murine erythroleukemia (MEL) cells but is without effect in K562 cells. Our previous studies suggested that of four proteins from MEL cells that bind to this CAAT box region (CP1, GATA-1, and two factors that were denoted DSFr and DSF1) DSFr is involved in the up regulation of transcription. In the present report, the DSFr protein in MEL cells was identified as C/EBP gamma through expression cloning and antibody studies, C/EBP gamma DNA binding activity could not be detected in K562 cells, However, K562 cells, but not MEL cells, were found to express LIP, which is a truncated form of C/EBP beta and is an inhibitor of transcription, Thus, the differential expression of C/EBP members could account for the ability of the beta-globin CAAT box to stimulate transcription in MEL cells, but not function in K562 cells, Juxtaposing a specific C/EBP binding sequence next to the >beta-globin promoter, in constructs in which the CAAT box had been rendered inactive by mutation or deletion, restored full promoter activity in MEL cells only if CP1 still bound to the promoter, In conjunction with previous mutation analyses, these results suggest that C/EBP gamma may collaborate with CP1 to enhance transcription through the beta-globin CAAT box.	UNIV MONTREAL,DEPT MED,MONTREAL,PQ H2L 4M1,CANADA	Universite de Montreal	Wall, L (corresponding author), UNIV MONTREAL,INST CANC MONTREAL,CTR RECH LC SIMARD,MONTREAL,PQ H2L 4M1,CANADA.							AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANTONIOU M, 1990, GENE DEV, V4, P1007, DOI 10.1101/gad.4.6.1007; AUMONT FL, 1993, DIFFERENTIATION, V52, P169, DOI 10.1111/j.1432-0436.1993.tb00627.x; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BUCK M, 1994, EMBO J, V13, P851, DOI 10.1002/j.1460-2075.1994.tb06328.x; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; COOPER C, 1992, J IMMUNOL, V149, P3225; DELVOYE NL, 1993, MOL CELL BIOL, V13, P6969, DOI 10.1128/MCB.13.11.6969; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DILLON N, 1995, MOL BIOL HEMOGLOBIN, P23; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FENG WC, 1913, J BIOL CHEM, V269, P269; HANSCOMBE O, 1991, GENE DEV, V5, P1384; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LUMELSKY N, 1991, MOL CELL BIOL, V11, P352; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; NISHIZAWA M, 1991, FEBS LETT, V282, P95, DOI 10.1016/0014-5793(91)80452-9; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; PERKINS AC, 1995, NATURE, V375, P318; PETERSON KR, 1993, MOL CELL BIOL, V13, P4836, DOI 10.1128/MCB.13.8.4836; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; STAMATOYANNOPOU.G, 1987, DEV CONTROL GLOBIN G; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; THOMASSIN H, 1992, NUCLEIC ACIDS RES, V20, P3091, DOI 10.1093/nar/20.12.3091; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VONASSENDELFT B, 1989, CELL, V56, P969; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	36	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16477	16484		10.1074/jbc.271.28.16477	http://dx.doi.org/10.1074/jbc.271.28.16477			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663270	hybrid			2022-12-27	WOS:A1996UX12600011
J	Chen, H; Strickland, DK; Mosher, DF				Chen, H; Strickland, DK; Mosher, DF			Metabolism of thrombospondin 2 - Binding and degradation by 3T3 cells and glycosaminoglycan-variant Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HUMAN CARCINOMA-CELLS; HUMAN-MELANOMA CELLS; PLATELET THROMBOSPONDIN; HEPARIN-BINDING; I REPEATS; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; GENE FAMILY; WEAK BASES	Thrombospondin 1 (TSP1) and thrombospondin 2 (TSP2) are members of the thrombospondin family that have a similar structural organization but somewhat different functional activities. Iodinated recombinant mouse TSP2 bound to NIH 3T3 cells and was internalized and degraded through a chloroquine-inhibitable pathway. TSP2 degradation was saturable, specific, and similar to the kinetics of degradation of TSP1. Human platelet TSP1, recombinant mouse TSP1, and recombinant mouse TSP2 cross-competed with one another for degradation by 3T3 cells. Degradation of TSP2 was less sensitive to inhibition by heparin than degradation of TSP1. This is in agreement with differences in heparin-binding affinity of the two TSPs. Degradation of TSP2 was slower in cultures of Chinese hamster ovary (CHO) cells lacking heparan sulfate proteoglycans than in wild type CHO cells or in cultures of 3T3 cells treated with heparitinase than in untreated 3T3 cells. Degradation of TSP2 was inhibited by antibodies against the low density lipoprotein receptor-related protein (LRP) or by the 39-kDa receptor-associated protein, a known antagonist of LRP. This study indicates that TSP2 and TSP1 are metabolized by a common internalization and degradation pathway involving heparan sulfate proteoglycan and LRP. Competition for this pathway is a possible mechanism whereby cells can control the levels and ratio of TSP1 and TSP2 in the extracellular milieu.	UNIV WISCONSIN, DEPT MED, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT BIOMOLEC CHEM, MADISON, WI 53706 USA; AMER RED CROSS, DEPT BIOCHEM, ROCKVILLE, MD 20855 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; American Red Cross					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054462, R01HL049111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54462, HL49111] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JC, 1994, MOL BIOL CELL, V5, P423, DOI 10.1091/mbc.5.4.423; ADAMS JC, 1993, J CELL SCI, V104, P1061; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BORNSTEIN P, 1993, GENOMICS, V15, P607, DOI 10.1006/geno.1993.1114; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; BORNSTEIN P, 1991, P NATL ACAD SCI USA, V88, P8636, DOI 10.1073/pnas.88.19.8636; BORNSTEIN PG, 1964, J CLIN INVEST, V43, P1813, DOI 10.1172/JCI105055; CHEN H, 1994, J BIOL CHEM, V269, P32226; DIXIT VM, 1984, J BIOL CHEM, V259, P100; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; KAESBERG PR, 1989, J CLIN INVEST, V83, P994, DOI 10.1172/JCI113986; KOSFELD MD, 1993, J BIOL CHEM, V268, P8808; LABELL TL, 1993, GENOMICS, V17, P225, DOI 10.1006/geno.1993.1308; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1993, J CELL BIOL, V120, P1059, DOI 10.1083/jcb.120.4.1059; LAWLER J, 1989, BLOOD, V74, P2022; LAWLER J, 1995, J BIOL CHEM, V270, P2809, DOI 10.1074/jbc.270.6.2809; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1987, SEMIN THROMB HEMOST, V13, P245, DOI 10.1055/s-2007-1003499; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LAWLER J, 1991, J BIOL CHEM, V266, P8039; LAWLER J, 1991, GENOMICS, V11, P587, DOI 10.1016/0888-7543(91)90066-N; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; LISKA DJ, 1994, J CELL PHYSIOL, V158, P495, DOI 10.1002/jcp.1041580314; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MANSFIELD PJ, 1990, J CELL BIOL, V111, P3077, DOI 10.1083/jcb.111.6.3077; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1984, J CELL BIOL, V98, P22, DOI 10.1083/jcb.98.1.22; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOSHER DF, 1975, J BIOL CHEM, V250, P6614; MOSHER DF, 1990, ANNU REV MED, V41, P85; MURPHYULLRICH JE, 1987, SEMIN THROMB HEMOST, V13, P343, DOI 10.1055/s-2007-1003510; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; NEWTON G, 1994, GENOMICS, V24, P435, DOI 10.1006/geno.1994.1649; NICKOLOFF BJ, 1988, AM J PATHOL, V132, P543; NICOSIA RF, 1994, J CELL BIOL, V124, P183, DOI 10.1083/jcb.124.1.183; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; PELLERIN S, 1994, MOL CELL ENDOCRINOL, V106, P181, DOI 10.1016/0303-7207(94)90201-1; PELLERIN S, 1993, J BIOL CHEM, V268, P4304; PHAN SH, 1989, BIOCHEM BIOPH RES CO, V163, P56, DOI 10.1016/0006-291X(89)92098-6; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; QABAR AN, 1994, J BIOL CHEM, V269, P1262; RAUGI GJ, 1984, THROMB RES, V36, P165, DOI 10.1016/0049-3848(84)90338-4; RAUGI GJ, 1982, J CELL BIOL, V95, P351, DOI 10.1083/jcb.95.1.351; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SHINGU T, 1993, GENOMICS, V16, P78, DOI 10.1006/geno.1993.1143; SUN X, 1992, SEMIN THROMB HEMOST, V18, P243, DOI 10.1055/s-2007-1002430; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TUSZYNSKI GP, 1989, EXP CELL RES, V182, P473, DOI 10.1016/0014-4827(89)90251-6; TUSZYNSKI GP, 1987, SCIENCE, V236, P1570, DOI 10.1126/science.2438772; VOGEL T, 1993, J CELL BIOCHEM, V53, P74, DOI 10.1002/jcb.240530109; VOS HL, 1992, J BIOL CHEM, V267, P12192; WATSON JB, 1994, J CLIN INVEST, V94, P261, DOI 10.1172/JCI117316; WILLIAMS SE, 1994, ANN NY ACAD SCI, V737, P1, DOI 10.1111/j.1749-6632.1994.tb44297.x; YABKOWITZ R, 1993, J CELL PHYSIOL, V157, P24, DOI 10.1002/jcp.1041570104; YABKOWITZ R, 1991, CANCER RES, V51, P3648; YABKOWITZ R, 1993, CANCER RES, V53, P378	79	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15993	15999		10.1074/jbc.271.27.15993	http://dx.doi.org/10.1074/jbc.271.27.15993			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663244	hybrid			2022-12-27	WOS:A1996UW35200025
J	Lin, DL; Chang, CS				Lin, DL; Chang, CS			p53 is a mediator for radiation-repressed human TR2 orphan receptor expression in MCF-7 cells, a new pathway from tumor suppressor to member of the steroid receptor superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN; DNA	p53 may function as a checkpoint by arresting the G(1) cell cycle in response to DNA damage induced by radiation or other stimuli. We have found that the expression of the TR2 orphan receptor (TR2), a member of the steroid receptor superfamily, was down-regulated by ionizing irradiation, Our data shown in the present study demonstrate that irradiation can repress TR2 at both the translational and transcriptional levels. Transient transfection assays further link p53 to this repression by proving that endogenously induced or exogenously transfected p53 can repress TR2 gene expression, and this repression can be reversed by the co-transfection of SV40 large T antigen. Together, our data demonstrate for the first time that radiation and p53 can repress TR2, possibly providing a new pathway to link ionizing irradiation and p53 to members of the steroid receptor superfamily.	UNIV WISCONSIN,WISCONSIN CLIN CANC CTR,DEPT MED,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison					NIDDK NIH HHS [DK47258] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; CHANG C, 1989, J STEROID BIOCHEM, V34, P391; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; Gupta N, 1996, RADIAT RES, V145, P289, DOI 10.2307/3578984; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; JIANG D, 1993, ONCOGENE, V8, P2805; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIZOKAMI A, 1994, J BIOL CHEM, V269, P25655; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UEMURA H, 1995, J BIOL CHEM, V270, P5427, DOI 10.1074/jbc.270.10.5427; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WARD JF, 1994, RADIAT RES, V138, P585; WEICHSELBAUM R, 1993, MOL BIOL ONCOLOGISTS, P213; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8	30	43	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14649	14652		10.1074/jbc.271.25.14649	http://dx.doi.org/10.1074/jbc.271.25.14649			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663350	hybrid			2022-12-27	WOS:A1996UT10600001
J	MirandaVizuete, A; RodriguezAriza, A; Toribio, F; Holmgren, A; LopezBarea, J; Pueyo, C				MirandaVizuete, A; RodriguezAriza, A; Toribio, F; Holmgren, A; LopezBarea, J; Pueyo, C			The levels of ribonucleotide reductase, thioredoxin, glutaredoxin 1, and GSH are balanced in Escherichia coli K12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-REDUCTASE; SULFATE REDUCTION; HYDROGEN DONOR; CONSTRUCTION; PURIFICATION; LIVER; K-12; DEOXYRIBONUCLEOTIDE; CHROMATOGRAPHY; SENSITIVITY	The dithiol forms of thioredoxin and glutaredoxin are hydrogen donors for ribonucleotide reductase, We have determined the intracellular levels of ribonucleotide reductase (RRase), thioredoxin (Trx), glutaredoxin 1 (Grx1), and glutathione (GSH) and the glutathione redox status in new Escherichia coli K12 strains lacking thioredoxin (trxA(-)), glutaredoxin 1 (grxA(-)), and/or GSH (gshA(-)) or overproducing Trx or Grx1 from multicopy plasmids, We propose a regulatory network in which RRase levels are balanced with those of Trx, Grx1, and GSH so that deficiency or overproduction of one component would promote the opposite effect on the others to maintain a balanced supply of deoxyribonucleotides. GSH deficiency strongly increased both Grx1 levels and RRase activity, even more than Trx deficiency, Double gshA(-)trxA(-) bacteria were viable, whereas additional deficiency in lipoate synthesis (gshA(-)trxA(-)lipA(-)) caused the inability to grow in minimal medium plates supplemented with acetate plus succinate instead of lipoic acid, Thus, lipoate might be the only substitute of GSH for glutaredoxin reduction in gshA(-)trxA(-) cells, although the extremely high Grx1 content (55-fold) of these bacteria suggests that electron transfer from lipoate might be an inefficient reduction mechanism of glutaredoxins. Moreover, the enhanced Grx1 level of gshA(-)trxA(-) cells could obviate the need for a large increase in RRase activity, in contrast to grxA(-)trxA(-) double mutant cells, Impairment of the sulfate assimilation pathway, leading to very low GSH concentrations, and an oxidized glutathione redox state might explain the inability of grxA(-)trxA(-) cells to grow in minimal medium, Restoration of nearly normal levels of both GSH content and redox status cure the growth defect.	UNIV CORDOBA,DEPT BIOQUIM & BIOL MOL,CORDOBA 14071,SPAIN; UNIV CORDOBA,CTR EXPERIMENTAC BIOL,CORDOBA 14071,SPAIN; KAROLINSKA INST,MED NOBEL INST BIOCHEM,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN	Universidad de Cordoba; Universidad de Cordoba; Karolinska Institutet			Pueyo, Carmen/B-4509-2016; IBIS, REDOX/J-7473-2017; Rodriguez-Ariza, Antonio/U-4854-2017; Miranda-Vizuete, Antonio/D-6927-2012; Lopez-Barea, Juan/K-7258-2014	Pueyo, Carmen/0000-0002-2624-2011; Rodriguez-Ariza, Antonio/0000-0001-5304-5745; Miranda-Vizuete, Antonio/0000-0002-6856-5396; Lopez-Barea, Juan/0000-0002-2280-3379				ABRIL N, 1992, ENVIRON MOL MUTAGEN, V19, P288, DOI 10.1002/em.2850190405; ALONSOMORAGA A, 1987, MOL CELL BIOCHEM, V73, P61; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Bjornberg O, 1991, Protein Expr Purif, V2, P287, DOI 10.1016/1046-5928(91)90085-W; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS RW, 1980, MANUAL GENETIC ENG A; DYSON HJ, 1989, BIOCHEMISTRY-US, V28, P7074, DOI 10.1021/bi00443a044; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1977, J BIOL CHEM, V252, P4600; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1985, METHOD ENZYMOL, V113, P525; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOOG JO, 1986, GENE, V43, P13, DOI 10.1016/0378-1119(86)90003-X; Jordan A, 1996, J BIOL CHEM, V271, P8779, DOI 10.1074/jbc.271.15.8779; KREDICH NM, 1987, ESCHERICHIA COLI SAL, V1, P419; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; Mannervik B., 1983, FUNCTIONS GLUTATHION, P385; MATA AM, 1984, Z NATURFORSCH C, V39, P908; MIRANDAVIZUETE A, 1994, J BIOL CHEM, V269, P16631; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; RODRIGUEZARIZA A, 1994, J CHROMATOGR B, V656, P311, DOI 10.1016/0378-4347(94)00111-1; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; TSANG MLS, 1981, J BACTERIOL, V146, P1059, DOI 10.1128/JB.146.3.1059-1066.1981; TUGGLE CK, 1985, J BACTERIOL, V162, P448, DOI 10.1128/JB.162.1.448-450.1985; WALLACE BJ, 1984, GENE, V32, P399, DOI 10.1016/0378-1119(84)90015-5	31	56	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19099	19103		10.1074/jbc.271.32.19099	http://dx.doi.org/10.1074/jbc.271.32.19099			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702583	hybrid			2022-12-27	WOS:A1996VB68400017
J	Zheng, Y; Zangrilli, D; Cerione, RA; Eva, A				Zheng, Y; Zangrilli, D; Cerione, RA; Eva, A			The pleckstrin homology domain mediates transformation by oncogenic Dbl through specific intracellular targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; BETA-GAMMA-SUBUNITS; PH DOMAIN; SIGNALING PROTEINS; CRYSTAL-STRUCTURE; BINDING; RAS; IDENTIFICATION; PRODUCT; KINASE	The pleckstrin homology (PH) domain is an similar to 100 amino acid structural motif found in many cellular signaling molecules, including the Dbl oncoprotein and related, putative guanine nucleotide exchange factors (GEFs). Here we have examined the role of the Dbl PH (dPH) domain in the activities of oncogenic Dbl. We report that the dPH domain is not involved in the interaction of Dbl with small GTP-binding proteins and is incapable of transforming NIH 3T3 fibroblasts. On the other hand, co-expression of the dPH domain with on cogenic Dbl inhibits Dbl-induced transformation. A deletion mutant of Dbl that lacks a significant portion of the PH domain retains full GEF activity, but is completely inactive in transformation assays. Replacement of the PH domain by the membrane-targeting sequence of Ras is not sufficient for the recovery of transforming activity. However, subcellular fractionations of Dbl and Dbl mutants revealed that the PH domain is necessary and sufficient for the association of Dbl with the Triton X-100-insoluble cytoskeletal components. Thus, our results suggest that the dPH domain mediates cellular transformation by targeting the Dbl protein to specific cytoskeletal locations to activate Rho-type small GTP-binding proteins.	CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853; NCI,CELLULAR & MOL BIOL LAB,BETHESDA,MD 20892	Cornell University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Eva, Alessandra/J-8268-2016; Zheng, Yi/J-7235-2015	Eva, Alessandra/0000-0003-2949-078X; Zheng, Yi/0000-0001-7089-6074	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47458] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GRAZIANI G, 1989, ONCOGENE, V4, P823; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; RON D, 1991, NEW BIOL, V3, P372; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TOKSOZ D, 1994, ONCOGENE, V9, P621; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	33	107	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19017	19020		10.1074/jbc.271.32.19017	http://dx.doi.org/10.1074/jbc.271.32.19017			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702569	hybrid			2022-12-27	WOS:A1996VB68400003
J	Warriar, N; Page, N; Govindan, MV				Warriar, N; Page, N; Govindan, MV			Expression of human glucocorticoid receptor gene and interaction of nuclear proteins with the transcriptional control element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; POLYMYOSITIS OVERLAP SYNDROME; DNA-BINDING PROTEINS; MAJOR LATE PROMOTER; KU AUTOANTIGEN; EFFICIENT TRANSCRIPTION; CELL-PROLIFERATION; MOLECULAR-CLONING; AUTO-ANTIGEN; SEQUENCE	We have identified sequences responsible for the expression of the human glucocorticoid receptor gene (GR gene) using a set of 5' promoter deletion mutants in HeLa, human placenta, and human breast tumor (MCF-7) cells, The chimeric gene construct -892 5'-GAAGTGACACACTTC3' -878-CAT was sufficient for high level of expression in HeLa and placenta cells in culture, Deletion of palindromic sequences decreased levels of GR expression in these cells, By oligonucleotide-affinity chromatography with the palindromic glucocorticoid receptor enhancing factor-binding element (GREFE), we have isolated from human placenta nu clear extract two novel proteins glucocorticoid receptor enhancing factors 1 and 2 (GREF1 and GREF2), with apparent molecular masses of 80 and 62 kDa, respectively, These proteins, similar to the DNA-binding autoantigen Ku are, like Ku, heterodimers of polypeptide subunits p80 and p62, immunologically related to factors binding to proximal sequence element 1 in the promoter of small nuclear RNA (PSE1) and transferrin receptor enhancing factors, Both Ku80 and Ku70 polypeptides were present in high concentrations in human placenta and HeLa cells, In MCF-7 cells, however, only a high level of p62 was detected. While cotransfection of pcDNA-Ku80 with pHGR(-892 to -878)-CAT potentiated the expression of CAT, introduction of pcDNA-Ku70 did not affect the expression of CAT in transfected MCF-7 cells, UV cross-linking analysis showed that only GREF1 contacted DNA directly. Supershift assays with monoclonal antibodies Ab 111 (Ku80) or Ab N3H10 (Ku70) showed a direct interaction of GREF1 and GREF2 heterodimers with the palindrome, Partial peptide fingerprinting of GREF1 and GREF2 using alpha-chymotrypsin and immunoblotting with Ab 111 and Ab N3H10 confirmed their identities as Ku80 and Ku70, respectively.	UNIV LAVAL,DEPT MOL ENDOCRINOL,HOSP CTR,ST FOY,PQ G1V 4G2,CANADA	Laval University								ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; BLASCO MJ, 1986, HORM METAB RES, V18, P638, DOI 10.1055/s-2007-1012393; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; CASEY JL, 1988, NUCLEIC ACIDS RES, V16, P629, DOI 10.1093/nar/16.2.629; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; CHAN JYC, 1989, J BIOL CHEM, V264, P3651; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRANCOEUR AM, 1986, J IMMUNOL, V136, P1648; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOVINDAN MV, 1991, J STEROID BIOCHEM, V40, P317, DOI 10.1016/0960-0760(91)90197-D; GOVINDAN MV, 1982, P NATL ACAD SCI-BIOL, V79, P5157, DOI 10.1073/pnas.79.17.5157; GOVINDAN MV, 1987, SER S, P187; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; GUNDERSON SI, 1990, GENE DEV, V4, P2048, DOI 10.1101/gad.4.12a.2048; HEN R, 1982, P NATL ACAD SCI-BIOL, V79, P7132, DOI 10.1073/pnas.79.23.7132; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADANOGA JT, 1978, CELL, V51, P1079; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; LECLERC S, 1991, J BIOL CHEM, V266, P17333; LECLERC S, 1991, J BIOL CHEM, V266, P8711; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MAY G, 1991, J BIOL CHEM, V266, P3052; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1984, J BIOL CHEM, V259, P560; MISKIMINS WK, 1986, J CELL BIOL, V103, P1781, DOI 10.1083/jcb.103.5.1781; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURPHY BEP, 1981, J STEROID BIOCHEM, V14, P811; MURPHY JT, 1987, J BIOL CHEM, V262, P1795; NOBUKUNI Y, 1995, BIOCHEMISTRY-US, V34, P8207, DOI 10.1021/bi00025a028; OUYANG Q, 1993, MOL CELL BIOL, V13, P1796, DOI 10.1128/MCB.13.3.1796; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PEPIN MC, 1992, MOL PHARMACOL, V41, P1016; PRABHAKAR BS, 1990, J CLIN INVEST, V86, P1301, DOI 10.1172/JCI114838; REEVES WH, 1989, J BIOL CHEM, V264, P5047; REEVES WH, 1985, J EXP MED, V161, P18, DOI 10.1084/jem.161.1.18; ROBERTS MR, 1989, CELL REGUL, V1, P151, DOI 10.1091/mbc.1.1.151; ROBERTS MR, 1994, P NATL ACAD SCI USA, V91, P6354, DOI 10.1073/pnas.91.14.6354; ROMANCER ML, 1994, J BIOL CHEM, V269, P17464; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; STRAHLE U, 1992, P NATL ACAD SCI USA, V89, P6731, DOI 10.1073/pnas.89.15.6731; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; STUIVER MH, 1990, J EXP MED, V172, P1049, DOI 10.1084/jem.172.4.1049; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; WU L, 1986, P NATL ACAD SCI USA, V83, P629; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANEVA M, 1985, BIOCHIM BIOPHYS ACTA, V841, P22, DOI 10.1016/0304-4165(85)90270-3; YANEVA M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P181, DOI 10.1016/0167-4781(91)90099-8; YANEVA M, 1986, BIOCHEMISTRY-US, V25, P5057, DOI 10.1021/bi00366a013; YANEVA M, 1989, J BIOL CHEM, V264, P13407; ZONG J, 1990, MOL CELL BIOL, V10, P5580, DOI 10.1128/MCB.10.10.5580	70	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18662	18671		10.1074/jbc.271.31.18662	http://dx.doi.org/10.1074/jbc.271.31.18662			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702520	hybrid			2022-12-27	WOS:A1996VB68300058
J	Zhang, WL; Lane, RD; Mellgren, RL				Zhang, WL; Lane, RD; Mellgren, RL			The major calpain isozymes are long-lived proteins - Design of an antisense strategy for calpain depletion in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PROTEASES; MU-CALPAIN; NEUTRAL PROTEASE; HUMAN PLATELETS; MUSCLE-CELLS; INVOLVEMENT; CALPASTATIN; ANTIBODIES; DIFFERENTIATION; PROLIFERATION	Calpains are intracellular Ca2+-dependent proteases that are thought to participate in Ca2+-associated signal transduction pathways, It has been proposed that calpains are activated by an autoproteolytic mechanism, If this is true one would expect a relatively short half-life for calpain protein in cells, To test this hypothesis, WI-38 human diploid fibroblasts were pulse-labeled with [S-35]methionine, and calpain was immunoprecipitated at various times after chasing with nonradioactive methionine to determine residual radioactivity, The results demonstrated that the two major calpain isozymes, m-calpain and mu-calpain, had metabolic half-lives of approximately 5 days, Calpains were long-lived proteins in several human cell lines, A-431, HeLa, VA-13, C-33A, and TE2 cells, In addition, calpastatin, the calpain-specific inhibitor protein, also had a long metabolic half-life, These observations suggest that the model for calpain activation by autoproteolysis requires re-investigation. Based on a knowledge of calpain metabolic stability, a protocol was devised for chronic exposure of WI-38 cells and HeLa cells to a calpain small subunit antisense oligodeoxyribonucleotide. Depletion of calpain small subunit after 5 or more days of treatment led to inhibition of cell proliferation that could be reversed by removal of antisense oligodeoxyribonucleotide from the culture medium, Together with previous studies, these results indicate a requirement for calpains in mammalian cell proliferation.	MED COLL OHIO, DEPT PHARMACOL, TOLEDO, OH 43690 USA; MED COLL OHIO, DEPT THERAPEUT, TOLEDO, OH 43690 USA; MED COLL OHIO, DEPT ANAT, TOLEDO, OH 43690 USA						NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAGLI J, 1993, BIOCHEM J, V289, P93, DOI 10.1042/bj2890093; ANAGLI J, 1991, BIOCHEM J, V274, P497, DOI 10.1042/bj2740497; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CONG JY, 1989, J BIOL CHEM, V264, P10096; COTTIN P, 1994, BBA-MOL CELL RES, V1223, P170, DOI 10.1016/0167-4889(94)90223-2; Crawford C., 1990, INTRACELLULAR CALCIU, P75; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; EMORI Y, 1994, J BIOL CHEM, V269, P25137; JOHNSON P, 1990, INT J BIOCHEM, V22, P811, DOI 10.1016/0020-711X(90)90284-A; KWAK KB, 1993, BIOCHIM BIOPHYS ACTA, V1175, P243, DOI 10.1016/0167-4889(93)90212-8; LANE RD, 1992, EXP CELL RES, V203, P5, DOI 10.1016/0014-4827(92)90033-5; Maki M., 1990, INTRACELLULAR CALCIU, P37; MARCH KL, 1993, CIRC RES, V72, P413, DOI 10.1161/01.RES.72.2.413; MELLGREN RL, 1988, BIOCHIM BIOPHYS ACTA, V954, P154, DOI 10.1016/0167-4838(88)90066-0; MELLGREN RL, 1994, EXP CELL RES, V215, P164, DOI 10.1006/excr.1994.1328; MELLGREN RL, 1980, FEBS LETT, V109, P129, DOI 10.1016/0014-5793(80)81326-3; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MOLINARI M, 1994, J BIOL CHEM, V269, P27992; MOLINARI M, 1995, J BIOL CHEM, V270, P14576, DOI 10.1074/jbc.270.24.14576; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURACHI T, 1981, BIOCHEM INT, V2, P651; NAGAO S, 1994, J BIOCHEM, V115, P1178, DOI 10.1093/oxfordjournals.jbchem.a124476; RESING KA, 1993, J BIOL CHEM, V268, P25139; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAMIS JA, 1987, BIOCHEM J, V246, P481, DOI 10.1042/bj2460481; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V12, P103, DOI 10.1016/0968-0004(87)90048-X; SUZUKI K, 1988, ADV ENZYME REGUL, V27, P153; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6	33	73	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18825	18830		10.1074/jbc.271.31.18825	http://dx.doi.org/10.1074/jbc.271.31.18825			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702541	Green Submitted, hybrid			2022-12-27	WOS:A1996VB68300079
J	Amano, T; Hisabori, T; Muneyuki, E; Yoshida, M				Amano, T; Hisabori, T; Muneyuki, E; Yoshida, M			Catalytic activities of alpha(3)beta(3)gamma complexes of F-1-ATPase with 1, 2, or 3 incompetent catalytic sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOPHILIC BACTERIUM PS3; NUCLEOTIDE-BINDING-SITES; MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; ESCHERICHIA-COLI F1-ATPASE; SINGLE BETA-SUBUNIT; ATP SYNTHASE; GLUTAMIC-ACID; H+-ATPASE; MECHANISM; HYDROLYSIS	In order to know how many functional catalytic sites are necessary for ATPase activity of F-1-ATPase from a thermophilic Bacillus PS3, a new method of isolating homogeneous preparations of the alpha(3) beta(3) gamma complex with 1, 2, or 3 incompetent catalytic sites was developed. Ten glutamic acids (Glu . Tag) were linked to the C terminus of the catalytically incompetent beta(E190Q) subunit. The Glu Tag itself did not affect ATPase activity of the complexes. Two kinds of alpha(3) beta(3) gamma complexes, one containing beta(wild-type) and the other Glu Tag-linked beta(E190Q), were mixed, urea-denatured, and dialyzed, and alpha(3) beta(3) gamma complexes were reconstituted. Each of the complexes containing a different number of Glu . Tag-linked beta(E190Q) was separated by anion-exchange chromatography and analyzed. The results were as follows. 1) Normal steady state ATPase activity requires three intact catalytic sites. 2) Chase-acceleration, a catalytic cooperativity, requires at least two intact catalytic sites. 3) Single-site catalysis can be mediated by a single intact catalytic site alone. Rescrambling of subunits between complexes could occur when the complex was aged under certain conditions, and this might be one of the reasons for previous contradictory results (Miwa, K., Ohtsubo, M., Denda, K., Hisabori, T., Date, T., and Yoshida, M. (1989) J. Biochem. (Tokyo) 106, 730-734).	TOKYO INST TECHNOL, RESOURCES UTILIZAT RES LAB, YOKOHAMA, KANAGAWA 226, JAPAN	Tokyo Institute of Technology			Hisabori, Toru/E-5205-2014	Hisabori, Toru/0000-0003-2046-0277				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AMANO T, 1994, FEBS LETT, V348, P93, DOI 10.1016/0014-5793(94)00588-5; AMANO T, 1994, FEBS LETT, V351, P1, DOI 10.1016/0014-5793(94)00796-9; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CROSS RL, 1981, ANNU REV BIOCHEM, V50, P681, DOI 10.1146/annurev.bi.50.070181.003341; CROSS RL, 1982, J BIOL CHEM, V257, P2874; CUNNINGHAM D, 1988, J BIOL CHEM, V263, P18850; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FERGUSON SJ, 1975, EUR J BIOCHEM, V54, P117, DOI 10.1111/j.1432-1033.1975.tb04120.x; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HARADA M, 1991, BIOCHIM BIOPHYS ACTA, V1056, P279, DOI 10.1016/S0005-2728(05)80059-3; HAUGHTON MA, 1995, J BIOL CHEM, V270, P20568, DOI 10.1074/jbc.270.35.20568; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; HISABORI T, 1992, J BIOL CHEM, V267, P4551; ISSARTEL JP, 1991, BIOCHEMISTRY-US, V30, P4726, DOI 10.1021/bi00233a013; Kaibara C, 1996, J BIOL CHEM, V271, P2433, DOI 10.1074/jbc.271.5.2433; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBBEN M, 1984, EUR J BIOCHEM, V143, P483, DOI 10.1111/j.1432-1033.1984.tb08396.x; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; MELESE T, 1988, J BIOL CHEM, V263, P5833; MIWA K, 1989, J BIOCHEM-TOKYO, V106, P730; MONTICELLO RA, 1992, J BACTERIOL, V174, P3370, DOI 10.1128/jb.174.10.3370-3376.1992; MUNEYUKI E, 1994, BBA-BIOENERGETICS, V1188, P108, DOI 10.1016/0005-2728(94)90028-0; NOUMI T, 1986, J BIOL CHEM, V261, P9196; ODAKA M, 1994, J BIOCHEM-TOKYO, V115, P789, DOI 10.1093/oxfordjournals.jbchem.a124410; OHTSUBO M, 1987, BIOCHEM BIOPH RES CO, V146, P705, DOI 10.1016/0006-291X(87)90586-9; PENEFSKY HS, 1988, J BIOL CHEM, V263, P6020; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; RAO R, 1987, J BIOL CHEM, V262, P17450; SAIKA K, 1995, FEBS LETT, V368, P207, DOI 10.1016/0014-5793(95)00644-O; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Stiggall D L, 1979, Methods Enzymol, V55, P308; VANDONGEN MBM, 1986, BIOCHIM BIOPHYS ACTA, V850, P359, DOI 10.1016/0005-2728(86)90192-1; WEBER J, 1994, J BIOL CHEM, V269, P20462; YOHDA M, 1987, J BIOCHEM-TOKYO, V102, P875, DOI 10.1093/oxfordjournals.jbchem.a122128; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; YOSHIDA M, 1981, J BIOL CHEM, V256, P148; YOSHIDA M, 1982, J BIOL CHEM, V257, P33; YOSHIDA M, 1983, J BIOL CHEM, V258, P4407; YOSHIDA M, 1990, J BIOL CHEM, V265, P2483	47	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18128	18133		10.1074/jbc.271.30.18128	http://dx.doi.org/10.1074/jbc.271.30.18128			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663463	hybrid			2022-12-27	WOS:A1996UY93500081
J	deMora, JF; Guerrero, C; Mahadevan, D; Coque, JJR; Rojas, JM; Esteban, LM; Rebecchi, M; Santos, E				deMora, JF; Guerrero, C; Mahadevan, D; Coque, JJR; Rojas, JM; Esteban, LM; Rebecchi, M; Santos, E			Isolated Sos1 PH domain exhibits germinal vesicle breakdown-inducing activity in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN-HOMOLOGY DOMAIN; X-LINKED AGAMMAGLOBULINEMIA; BRUTON TYROSINE KINASE; MEIOTIC MATURATION; ONCOGENE PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; BETA-SPECTRIN; RAS PROTEINS; INSULIN; INDUCTION	Purified, bacterially expressed PH domains of Sos1, IRS-1, beta ARK, and PLC delta(1) were analyzed functionally by means of microinjection into full grown, stage VI Xenopus laevis oocytes, Whereas the PH domains from IRS-1, beta ARK, or PLC delta(1) did not show any effect in the oocytes, injection of the purified Sos1 PH domain resulted in induction of significant rates of germinal vesicle breakdown and meiotic maturation, Furthermore, the Sos1 PH domain exhibited also significant synergy with insulin or coinjected normal Ras protein in induction of germinal vesicle breakdown, although it did not affect the rate of progesterone-induced maturation. These results suggest that purified, isolated PH domains retain, at least in part, their functional specificity and that Xenopus oocytes may constitute a useful biological system to analyze the functional role of the Sos1 PH domain in Ras signaling pathways.	NCI,CELLULAR & MOLEC BIOL LAB,NIH,BETHESDA,MD 20892; SUNY STONY BROOK,DEPT ANESTHESIOL & PHYSIOL & BIOPHYS,STONY BROOK,NY 11794	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			de Mora, Jaime Font/AAK-7591-2021; Rojas, José M./AAA-3354-2021; Rojas, José M/D-3718-2018; Coque, Juan Jose Rubio/AAV-2049-2021; de Mora, Jaime Font/H-6304-2015; Guerrero, Carmen/F-1776-2010	de Mora, Jaime Font/0000-0002-6816-2095; Rojas, José M./0000-0002-7547-2825; Rojas, José M/0000-0002-5383-3482; Coque, Juan Jose Rubio/0000-0001-8221-7817; de Mora, Jaime Font/0000-0002-6816-2095; Guerrero, Carmen/0000-0002-8747-6831				BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GRAZIANI G, 1992, ONCOGENE, V7, P229; GRIGORESCU F, 1994, HORM RES, V42, P55, DOI 10.1159/000184146; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KATZAV S, 1995, ONCOGENE, V11, P1079; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LUTRELL LM, 1995, J BIOL CHEM, V270, P12984; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P2095, DOI 10.1021/bi00007a002; Maller James L., 1994, Seminars in Developmental Biology, V5, P183, DOI 10.1006/sedb.1994.1024; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P6661, DOI 10.1128/MCB.13.11.6661; NEBREDA AR, 1993, ONCOGENE, V8, P467; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WANG DS, 1994, BIOCHEM BIOPH RES CO, V203, P29, DOI 10.1006/bbrc.1994.2144; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0	41	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18272	18276		10.1074/jbc.271.30.18272	http://dx.doi.org/10.1074/jbc.271.30.18272			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663537	hybrid			2022-12-27	WOS:A1996UY93500101
J	Maccarana, M; Sakura, Y; Tawada, A; Yoshida, K; Lindahl, U				Maccarana, M; Sakura, Y; Tawada, A; Yoshida, K; Lindahl, U			Domain structure of heparan sulfates from bovine organs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; D-GLUCOSAMINYLTRANSFERASE REACTIONS; POLYMER-MODIFICATION REACTIONS; ACID DEAMINATIVE CLEAVAGE; NITROUS-ACID; BINDING SEQUENCE; CONCERTED ACTION; FINE-STRUCTURE; C-5 EPIMERASE; BIOSYNTHESIS	Samples of heparan sulfate, isolated from bovine aorta, lung, intestine, and kidney, were degraded by digestion with a mixture of heparitinases or by treatment with nitrous acid, with or without previous N-deacetylation, Analysis of the resulting oligosaccharides showed that the various heparan sulfate samples all contained regions of up to 8 or 9 consecutive N-acetylated glucosamine residues, as well as contiguous N-sulfated sequences. L-Iduronic acid accounted for a remarkably constant proportion, 50-60%, of the total hexuronic acid units within the latter structures. Of the total iduronic acid units, 36-55% were located outside the contiguous N-sulfated regions, presumably in sequences composed of alternating N-acetylated and N-sulfated disaccharide residues. While most of the iduronic acid units within the N-sulfated blocks were 2-O-sulfated, those located outside were almost exclusively nonsulfated. The heparan sulfate preparations differed markedly with regard to the content of 6-O-sulfated glucosamine units, more than half of which were located outside the N-sulfated block regions. These findings suggest that the formation of iduronic acid residues and their subsequent 2-O-sulfation are coupled within but not outside the contiguous N-sulfated regions of the heparan sulfate chains and, furthermore, that the 2-O- and 6-O-sulfotransferase reactions are differentially regulated during heparan sulfate biosynthesis.	UNIV UPPSALA,CTR BIOMED,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN; SEIKAGAKU CORP,TOKYO RES INST,HIGASHIYAMATO,TOKYO 207,JAPAN	Uppsala University; Seikagaku Corporation			maccarana, marco/AAB-4764-2021	Maccarana, Marco/0000-0003-3549-8921				BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; CAMPBELL P, 1994, J BIOL CHEM, V269, P26953; CIFONELLI JA, 1972, CARBOHYD RES, V21, P173, DOI 10.1016/S0008-6215(00)82144-8; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; GALLAGHER JT, 1992, GLYCOBIOLOGY, V2, P523, DOI 10.1093/glycob/2.6.523; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; KARIYA Y, 1992, COMP BIOCHEM PHYS B, V103, P473, DOI 10.1016/0305-0491(92)90323-J; KATO M, 1994, J BIOL CHEM, V269, P18881; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KUSCHE M, 1991, J BIOL CHEM, V266, P7400; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIND T, 1993, J BIOL CHEM, V268, P20705; LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Lindahl U., 1989, HEPARIN, P159; LINKER A, 1973, CARBOHYD RES, V29, P41, DOI 10.1016/S0008-6215(00)82069-8; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1987, BIOCHEM J, V242, P493, DOI 10.1042/bj2420493; LYON M, 1994, J BIOL CHEM, V269, P11208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; NAKANISHI H, 1992, BIOCHEM J, V288, P215, DOI 10.1042/bj2880215; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; PEJLER G, 1987, J BIOL CHEM, V262, P5036; RIESENFELD J, 1982, J BIOL CHEM, V257, P421; RIESENFELD J, 1982, J BIOL CHEM, V257, P7050; SANDERSON PN, 1984, BIOCHEM J, V223, P495, DOI 10.1042/bj2230495; SANDERSON PN, 1983, BIOCHEM J, V211, P677, DOI 10.1042/bj2110677; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; TAYLOR RL, 1973, BIOCHEMISTRY-US, V12, P3633, DOI 10.1021/bi00743a010; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; WLAD H, 1994, J BIOL CHEM, V269, P24538	54	238	241	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17804	17810		10.1074/jbc.271.30.17804	http://dx.doi.org/10.1074/jbc.271.30.17804			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663266	hybrid			2022-12-27	WOS:A1996UY93500035
J	Takagi, Y; Nomizu, M; Gullberg, D; MacKrell, AJ; Keene, DR; Yamada, Y; Fessler, JH				Takagi, Y; Nomizu, M; Gullberg, D; MacKrell, AJ; Keene, DR; Yamada, Y; Fessler, JH			Conserved neuron promoting activity in Drosophila and vertebrate laminin alpha 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; A-CHAIN; EXTRACELLULAR-MATRIX; ADHESION MOLECULE; SYNTHETIC PEPTIDE; NEURITE OUTGROWTH; GLOBULAR DOMAIN; HEPARIN-BINDING; CELL ATTACHMENT; IKVAV SEQUENCE	Drosophila S2 cells were transfected with constructs that code for two portions of the Drosophila laminin cu chain. Construct rec alpha L coded for domains III, I/II, and G of laminin alpha., Construct rec alpha S coded for only the COOH- most 12% of the I/II domain and the G domain, The corresponding polypeptides were isolated and characterized from the culture media. The rec alpha L chain partly formed disulfide-linked heterotrimers with the endogenously produced beta and gamma laminin chains. Like normal Drosophila laminin, a substrate coating of either rec alpha L or rec alpha S supported neuron differentiation and neurite extension of primary Drosophila embryo cell cultures. However, at the same low concentrations, only Drosophila laminin-1, but neither rec alpha L nor rec alpha S supported myogenesis in these cultures. Previously, an overlapping set of dodecapeptides that covered a region of the murine laminin alpha 1 chain similar to rec alpha S had been synthesized and tested for cell culture support properties (Nomizu, M., Rim, W. H., Yamamura, K., Utani, A., Otaka, A., Roller, P. P., Kleinman, H. K., and Yamada, Y. (1995) J. Biol. Chem. 270, 20583-20590). The Drosophila laminin cu homologues of the six most active vertebrate dodecapeptides were now synthesized and tested as substrates for differentiation of primary Drosophila embryo cells. Peptides that contained either the Drosophila sequence SIKVGV or the murine homologue, SIKVAV, provided support for neurite extension.	UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90095; SHRINERS HOSP CRIPPLED CHILDRENS,PORTLAND,OR 97201; NIDR,DEV BIOL LAB,NIH,BETHESDA,MD 20892	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gullberg, Donald/H-2495-2016	Gullberg, Donald/0000-0002-7245-4437	NATIONAL INSTITUTE ON AGING [R01AG002128] Funding Source: NIH RePORTER; NIA NIH HHS [AG02128] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABBOTT LA, 1992, MECH DEVELOP, V37, P43, DOI 10.1016/0925-4773(92)90014-B; BECK K, 1993, J MOL BIOL, V231, P311, DOI 10.1006/jmbi.1993.1284; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BERNIER SM, 1995, MATRIX BIOL, V14, P447, DOI 10.1016/0945-053X(95)90002-0; BRANCACCIO A, 1995, FEBS LETT, V368, P139, DOI 10.1016/0014-5793(95)00628-M; BROWER DL, 1984, P NATL ACAD SCI-BIOL, V81, P7485, DOI 10.1073/pnas.81.23.7485; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CALOF AL, 1994, NEURON, V13, P117, DOI 10.1016/0896-6273(94)90463-4; CHI HC, 1989, J BIOL CHEM, V264, P1543; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; FESSLER JH, 1989, ANNU REV CELL BIOL, V5, P309, DOI 10.1146/annurev.cb.05.110189.001521; FESSLER JH, 1994, METHOD CELL BIOL, V44, P303, DOI 10.1016/S0091-679X(08)60921-8; FESSLER JH, 1996, LAMININS, P235; FESSLER JH, 1984, ROLE EXTRACELLULAR M, P207; FESSLER LI, 1987, J CELL BIOL, V105, P2383, DOI 10.1083/jcb.105.5.2383; FESSLER LI, 1994, METHOD ENZYMOL, V245, P271; FOGERTY FJ, 1994, DEVELOPMENT, V120, P1747; GARRISON K, 1991, J BIOL CHEM, V266, P22899; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GOTWALS PJ, 1994, P NATL ACAD SCI USA, V91, P11447, DOI 10.1073/pnas.91.24.11447; GOTWALS PJ, 1994, CURR OPIN CELL BIOL, V6, P734, DOI 10.1016/0955-0674(94)90101-5; GRANT DS, 1992, J CELL PHYSIOL, V153, P614, DOI 10.1002/jcp.1041530324; GULLBERG D, 1994, DEV DYNAM, V199, P116, DOI 10.1002/aja.1001990205; HAREL R, 1993, FASEB J, V7, P1115, DOI 10.1096/fasebj.7.12.8375610; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HENCHCLIFFE C, 1993, DEVELOPMENT, V118, P325; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KIEHART DP, 1986, J CELL BIOL, V103, P1517, DOI 10.1083/jcb.103.4.1517; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; KUSCHEGULLBERG M, 1992, EMBO J, V11, P4519, DOI 10.1002/j.1460-2075.1992.tb05553.x; LALLIER T, 1994, DEV BIOL, V162, P451, DOI 10.1006/dbio.1994.1101; MACKRELL AJ, 1993, FASEB J, V7, P375, DOI 10.1096/fasebj.7.2.8440414; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; MONTELL DJ, 1989, J CELL BIOL, V109, P2441, DOI 10.1083/jcb.109.5.2441; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; NOMIZU M, 1992, J BIOL CHEM, V267, P14118; NOMIZU M, 1995, FEBS LETT, V365, P227, DOI 10.1016/0014-5793(95)00475-O; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; PATTARAMALAI S, 1994, ARCH ORAL BIOL, V39, P925, DOI 10.1016/0003-9969(94)90075-2; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; STREULI CH, 1995, J CELL BIOL, V129, P591, DOI 10.1083/jcb.129.3.591; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TEPASS U, 1994, DEV BIOL, V161, P563, DOI 10.1006/dbio.1994.1054; THOMPSON HL, 1991, IMMUNOLOGY, V72, P144; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; VOLK T, 1990, CELL, V63, P525, DOI 10.1016/0092-8674(90)90449-O; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P881; YARNITZKY T, 1995, DEV BIOL, V169, P609, DOI 10.1006/dbio.1995.1173; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356	60	23	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18074	18081		10.1074/jbc.271.30.18074	http://dx.doi.org/10.1074/jbc.271.30.18074			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663504	hybrid			2022-12-27	WOS:A1996UY93500073
J	Wang, XN; Coons, LB; Taylor, DB; Stevens, ES; Gartner, TK				Wang, XN; Coons, LB; Taylor, DB; Stevens, ES; Gartner, TK			Variabilin, a novel RGD-containing antagonist of glycoprotein IIb-IIIa and platelet aggregation inhibitor from the hard tick Dermacentor variabilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; VONWILLEBRAND-FACTOR; ORNITHODOROS-MOUBATA; MONOCLONAL-ANTIBODY; FIBRINOGEN BINDING; ALPHA-SUBUNIT; VIPER VENOMS; GPIIB-IIIA; RECEPTOR; COMPLEX	A novel inhibitor of human platelet aggregation, named variabilin, was isolated from salivary glands of the hard tick Dermacentor variabilis using a combination of gel filtration and high pressure liquid chromatography, Variabilin was a potent antagonist of the fibrinogen receptor glycoprotein IIb-IIIa (GPIIb-IIIa; alpha(IIb)beta(3)) and the vitronectin receptor alpha(v) beta(3). Amino acid sequence analysis by Edman degradation revealed that it has 47 residues, with a molecular weight of 4968.5. Like many other naturally occurring antagonists of GPIIb-IIIa, variabilin contains the RGD (Arg-Gly-Asp) motif. However, unlike the RGD-containing antagonists of GPIIb-IIIa, the RGD sequence of variabilin is not positioned in a loop bracketed by cysteine residues, It has little sequence homology to the other known naturally occurring antagonists of GPIIb-IIIa, including the disintegrins from snakes, decorsin and ornatin from leeches, and disagregin from soft ticks. Variabilin is the first RGD containing antagonist isolated from ticks.	MEMPHIS UNIV,DEPT BIOL,DIV MOL SCI & MICROBIOL,MEMPHIS,TN 38152; ILLINOIS BENEDICTINE COLL,DEPT BIOL,LISLE,IL 60532	University of Memphis					NHLBI NIH HHS [HL 46152] Funding Source: Medline; NIAID NIH HHS [AI 33665] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033665] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDER M, 1991, Science (Washington D C), V253, P445; BEACHAM DA, 1992, J BIOL CHEM, V267, P3409; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BERLINER S, 1988, J BIOL CHEM, V263, P7500; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; CHERESH DA, 1989, CELL, V58, P845; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; COOKE RM, 1991, EUR J BIOCHEM, V202, P323, DOI 10.1111/j.1432-1033.1991.tb16379.x; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GARTNER TK, 1993, THROMB RES, V71, P47; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; KARCZEWSKI J, 1994, J BIOL CHEM, V269, P6702; KREZEL AM, 1994, SCIENCE, V264, P1944, DOI 10.1126/science.8009227; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MAZUR P, 1991, EUR J BIOCHEM, V202, P1073, DOI 10.1111/j.1432-1033.1991.tb16472.x; MCDOWELL RS, 1992, BIOCHEMISTRY-US, V31, P4766, DOI 10.1021/bi00135a004; NEWMAN PJ, 1985, BLOOD, V65, P227; PETERSON DM, 1987, BLOOD, V69, P625; PHILLIPS DR, 1992, METHOD ENZYMOL, V215, P244; PHILLIPS DR, 1988, BLOOD, V71, P831; PONCZ M, 1987, J BIOL CHEM, V262, P8476; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SEYMOUR JL, 1990, J BIOL CHEM, V265, P10143; Sonenshine DE, 1991, BIOL TICKS, V1; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; WAXMAN L, 1993, J BIOL CHEM, V268, P5445; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; 1994, NEW ENGL J MED, V330, P956	38	74	84	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17785	17790		10.1074/jbc.271.30.17785	http://dx.doi.org/10.1074/jbc.271.30.17785			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663513	hybrid			2022-12-27	WOS:A1996UY93500032
J	Maiti, S; Doskow, J; Li, SL; Nhim, RP; Lindsey, JS; Wilkinson, MF				Maiti, S; Doskow, J; Li, SL; Nhim, RP; Lindsey, JS; Wilkinson, MF			The Pem homeobox gene - Androgen-dependent and -independent promoters and tissue-specific alternative RNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOFETAL GENE; MESSENGER-RNA; CELL DEVELOPMENT; BINDING-PROTEIN; MOUSE TESTIS; GERM-CELL; BOX GENE; EXPRESSION; SPERMATOGENESIS; DIFFERENTIATION	The Pem gene encodes an atypical homeodomain protein, distantly related to Prd/Pax family members, that we demonstrate is regulated in a complex transcriptional and post-transcriptional manner. We show that the rat Pem genomic structure includes three 5'-untranslated (5'-UT) exons and four coding exons, three of which encode the homeodomain, Several alternatively spliced transcripts were identified, including one that skips an internal coding exon, enabling this mRNA to express a novel form of the Pem protein, Other alternatively spliced mRNAs were characterized that possess different 5'-UT regions, including a muscle specific transcript, The different 5'-UT termini present in Pem transcripts conferred different levels of translatability in vitro. Two promoters containing multiple transcription initiation sites were identified: a distal promoter (P-d) in the first 5'-UT exon and a proximal promoter (P-p) located in the ''intron'' upstream of the first coding exon, The P-d was active in placenta, ovary, tumor cell Lines, and to a lesser extent in skeletal muscle, In contrast, transcripts from the P-p were only detectable in testis and epididymis and were only expressed in epididymis in the presence of testosterone, To our knowledge no transcription factors have previously been identified that exhibit androgen-dependent expression in the epididymis.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT IMMUNOL, HOUSTON, TX 77030 USA; OREGON HLTH SCI UNIV, DEPT MOLEC MICROBIOL & IMMUNOL, PORTLAND, OR 97201 USA	University of Texas System; UTMD Anderson Cancer Center; Oregon Health & Science University			Li, Shulin/D-6478-2011		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027233] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [T32EY007123] Funding Source: NIH RePORTER; NEI NIH HHS [T32 EY07123] Funding Source: Medline; NICHD NIH HHS [HD 27233] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSEN B, 1993, P NATL ACAD SCI USA, V90, P11084, DOI 10.1073/pnas.90.23.11084; ARIEL M, 1994, NAT GENET, V7, P59, DOI 10.1038/ng0594-59; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BLAQUIER JA, 1988, ANN NY ACAD SCI, V541, P292, DOI 10.1111/j.1749-6632.1988.tb22266.x; CHAREST NJ, 1989, ENDOCRINOLOGY, V125, P942, DOI 10.1210/endo-125-2-942; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Copeland JWR, 1996, NATURE, V379, P162, DOI 10.1038/379162a0; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; CORNWALL GA, 1995, J ANDROL, V16, P379; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; FICKENSCHER HR, 1993, DNA CELL BIOL, V12, P381, DOI 10.1089/dna.1993.12.381; GRAHAM A, 1988, GENE DEV, V2, P1424, DOI 10.1101/gad.2.11.1424; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; GU W, 1995, J BIOL CHEM, V270, P236, DOI 10.1074/jbc.270.1.236; HACKER A, 1995, DEVELOPMENT, V121, P1603; HAKE LE, 1993, J BIOL CHEM, V268, P4788; HECHT NB, 1995, DEV GENET, V16, P95, DOI 10.1002/dvg.1020160202; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; KAMPER J, 1995, CELL, V81, P73, DOI 10.1016/0092-8674(95)90372-0; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LABOSKY PA, 1993, DEV BIOL, V159, P232, DOI 10.1006/dbio.1993.1236; LIN TP, 1994, DEV BIOL, V166, P170, DOI 10.1006/dbio.1994.1305; Lopez AJ, 1995, DEV BIOL, V172, P396, DOI 10.1006/dbio.1995.8050; MACLEOD CL, 1990, CELL GROWTH DIFFER, V1, P271; MAITI S, 1996, IN PRESS GENOMICS; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MOORE HDM, 1986, J REPROD FERTIL, V78, P327, DOI 10.1530/jrf.0.0780327; NORTON JN, 1989, ENDOCRINOLOGY, V124, P2711, DOI 10.1210/endo-124-6-2711; ORGEBINCRIST MC, 1996, IN PESS PHARM BIOL C; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; Preslocsk J P, 1980, Endocr Rev, V1, P132; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; QIAN L, 1993, J IMMUNOL, V151, P6801; RAVNIK SE, 1995, DEV GENET, V16, P171, DOI 10.1002/dvg.1020160209; RAYLE RE, 1991, DEV BIOL, V146, P255, DOI 10.1016/0012-1606(91)90467-H; RESKO JA, 1980, J CLIN ENDOCR METAB, V50, P900, DOI 10.1210/jcem-50-5-900; Robaire B., 1988, P999; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANTULLI R, 1990, ENDOCRINOLOGY, V126, P95, DOI 10.1210/endo-126-1-95; SAR M, 1993, SERTOLI CELL, P510; SASAKI AW, 1991, MECH DEVELOP, V34, P155, DOI 10.1016/0925-4773(91)90052-8; Schafer M, 1995, DEV BIOL, V172, P344, DOI 10.1006/dbio.1995.8049; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; SINGH J, 1995, ENDOCRINOLOGY, V136, P5311, DOI 10.1210/en.136.12.5311; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; SUN YT, 1990, ENDOCRINOLOGY, V127, P1215, DOI 10.1210/endo-127-3-1215; TINDALL DJ, 1975, ENDOCRINOLOGY, V97, P636, DOI 10.1210/endo-97-3-636; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; WANG YM, 1989, MOL CELL ENDOCRINOL, V63, P85, DOI 10.1016/0303-7207(89)90084-1; WATRIN F, 1993, DEV BIOL, V156, P136, DOI 10.1006/dbio.1993.1064; WILKINSON M, 1991, ESSENTIAL MOL BIOL, V1, P69; WILKINSON MF, 1990, DEV BIOL, V141, P451, DOI 10.1016/0012-1606(90)90400-D; WOLGEMUTH DJ, 1991, ANN NY ACAD SCI, V637, P300, DOI 10.1111/j.1749-6632.1991.tb27317.x; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YIU GK, 1994, NUCLEIC ACIDS RES, V22, P4599, DOI 10.1093/nar/22.22.4599	58	65	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17536	17546		10.1074/jbc.271.29.17536	http://dx.doi.org/10.1074/jbc.271.29.17536			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663309	hybrid			2022-12-27	WOS:A1996UX94300084
J	Milgram, SL; Mains, RE; Eipper, BA				Milgram, SL; Mains, RE; Eipper, BA			Identification of routing determinants in the cytosolic domain of a secretory granule-associated integral membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; TRANS-GOLGI NETWORK; PEPTIDE PROCESSING ENZYME; ATT-20 CELLS; CYTOPLASMIC DOMAIN; P-SELECTIN; TRAFFICKING; EXPRESSION; SIGNAL; LOCALIZATION	We have investigated the trafficking of integral membrane peptidylglycine alpha-amidating monooxygenase (PAM) in the neuroendocrine AtT-20 cell line, This bifunctional enzyme has two domains which together catalyze the COOH-terminal alpha-amidation of peptidylglycine substrates yielding amidated products stored in secretory granules, As soluble proteins, both catalytic domains were independently targeted to secretory granules, In contrast, membrane PAM was largely localized to the trans-Golgi network (TGN), Upon truncation of its cytoplasmic COOH-terminal domain, membrane PAM was less efficiently cleaved by secretory granule enzymes and accumulated on the plasma membrane, When transferred to the lumenal domain of the interleukin 2 receptor alpha-chain (Tac protein), the cytoplasmic domain of PAM caused rerouting of Tac from the surface to the TGN and supported internalization of Tac antibody from the plasma membrane, To define sequences in the cytoplasmic domain of integral membrane PAM involved in its trafficking, we expressed PAM proteins containing truncations, deletions, or point mutations in the COOH-terminal cytoplasmic domain. PAM proteins were not retained in the TGN when half of the cytoplasmic domain was deleted; such proteins accumulated on the plasma membrane, were not efficiently internalized, and were cleaved to generate a bifunctional PAM protein that was not stored in secretory granules, A tyrosine-based internalization motif was identified, which was not required for efficient cleavage of full-length integral membrane PAM by secretory granule enzymes, Deletion of an 18-amino acid domain surrounding this Tyr residue both diminished cleavage of membrane PAM by secretory granule enzymes and eliminated internalization of PAM from the plasma membrane, The cytoplasmic domain is responsible for retaining membrane PAM in the TGN and for retrieving membrane PAM from the cell surface, while the lumenal catalytic domains of PAM appear to be responsible for targeting the protein to secretory granules.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHYSIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Milgram, SL (corresponding author), UNIV N CAROLINA, DEPT PHYSIOL, CB 7545, CHAPEL HILL, NC 27599 USA.				NIDDK NIH HHS [DK-32948] Funding Source: Medline; NIGMS NIH HHS [GM015293] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032948, R56DK032948, R37DK032948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015293] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arvan Peter, 1992, Trends in Cell Biology, V2, P327; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHIDGEY MAJ, 1993, BIOESSAYS, V15, P317, DOI 10.1002/bies.950150505; COLOMER V, 1994, EMBO J, V13, P3711, DOI 10.1002/j.1460-2075.1994.tb06680.x; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; EIPPER BA, 1993, PROTEIN SCI, V2, P489; FRICKER LD, 1993, J NEUROCHEM, V61, P1404, DOI 10.1111/j.1471-4159.1993.tb13634.x; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; HALBAN PA, 1994, BIOCHEM J, V299, P1; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; KOEDAM JA, 1992, J CELL BIOL, V116, P617, DOI 10.1083/jcb.116.3.617; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MALTESE JY, 1993, ENDOCRINOLOGY, V133, P2579, DOI 10.1210/en.133.6.2579; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MILGRAM SL, 1994, J CELL SCI, V107, P737; MILGRAM SL, 1995, MOL BIOL CELL, V6, P412; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NJUS D, 1993, BIOCHIM BIOPHYS ACTA, V1144, P235, DOI 10.1016/0005-2728(93)90108-R; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; OYARCE AM, 1993, J NEUROCHEM, V60, P1105, DOI 10.1111/j.1471-4159.1993.tb03261.x; REAVES BJ, 1991, MOL CELL ENDOCRINOL, V79, pC141, DOI 10.1016/0303-7207(91)90085-7; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; SMEEKENS SP, 1993, BIO-TECHNOL, V11, P182, DOI 10.1038/nbt0293-182; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; SUBRAMANIAM M, 1993, MOL BIOL CELL, V4, P791, DOI 10.1091/mbc.4.8.791; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; YUN HY, 1993, ARCH BIOCHEM BIOPHYS, V301, P77, DOI 10.1006/abbi.1993.1117; YUN HY, 1995, J BIOL CHEM, V270, P30075	43	66	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17526	17535		10.1074/jbc.271.29.17526	http://dx.doi.org/10.1074/jbc.271.29.17526			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663411	hybrid			2022-12-27	WOS:A1996UX94300083
J	Retzler, C; Wiedemann, H; Kulbe, G; Rauch, U				Retzler, C; Wiedemann, H; Kulbe, G; Rauch, U			Structural and electron microscopic analysis of neurocan and recombinant neurocan fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; SITE-DIRECTED MUTAGENESIS; CELL-ADHESION MOLECULES; NITROCELLULOSE SHEETS; NEURITE OUTGROWTH; MAMMALIAN-CELLS; CORE PROTEIN; BRAIN; GLYCOSAMINOGLYCAN; IDENTIFICATION	Neurocan, a nervous tissue-specific chondroitin sulfate proteoglycan of the aggrecan family which has been shown to interact with neural cell adhesion molecules and tenascin, could be visualized by rotary shadowing electron microscopy as two globular domains interconnected by an extended flexible filament of 60-90 nm, Several recombinant neurocan fragments generated in the human embryonic kidney cell line 293 represent as observed by electron microscopy the expected parts of this structure, which indicates a correct folding of these molecules. Biological activity of the recombinant N-terminal globular domain could be demonstrated by its coelution with hyaluronan in gel permeation chromatography. In addition, the modification of the recombinant fragments with certain carbohydrate structures was analyzed. High mannose oligosaccharides could be mapped to the N-terminal globular domain of the brain-derived molecule. Only recombinant fragments containing parts of the central region of the molecule were modified with chondroitin sulfate chains and with the HNK-1 epitope, and could be considerably altered in their migratory behavior on SDS-polyacrylamide gel electrophoresis by neuraminidase treatment, These findings and the electron microscopic shape indicate a mucin-like character for the central neurocan region.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society								BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GLASS WF, 1981, ANAL BIOCHEM, V115, P219, DOI 10.1016/0003-2697(81)90549-2; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; IWATA M, 1993, J NEUROSCI, V13, P195; IWATA M, 1993, J BIOL CHEM, V268, P15061; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KIMURA F, 1994, J BIOL CHEM, V269, P19751; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI H, 1993, J BIOL CHEM, V268, P23504; LIN JH, 1994, J BIOL CHEM, V269, P25021; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; MANN DM, 1990, J BIOL CHEM, V265, P5317; MATSUI F, 1994, NEUROCHEM INT, V25, P425, DOI 10.1016/0197-0186(94)90018-3; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MEYERPUTTLITZ B, 1995, J NEUROCHEM, V65, P2327; MILLER J, 1988, P NATL ACAD SCI USA, V85, P1359, DOI 10.1073/pnas.85.5.1359; MORGELIN M, 1994, BIOPHYS CHEM, V50, P113, DOI 10.1016/0301-4622(94)85024-0; NEAME PJ, 1993, EXPERIENTIA, V49, P393, DOI 10.1007/BF01923584; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; OOHIRA A, 1994, NEUROSCIENCE, V60, P145, DOI 10.1016/0306-4522(94)90210-0; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; RAUCH U, 1986, BIOCHEM J, V238, P465, DOI 10.1042/bj2380465; SLAYTER HS, 1973, J BIOL CHEM, V248, P3405; THINAKARAN G, 1994, J BIOL CHEM, V269, P22099; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYTGAT KMAJ, 1995, BIOCHEM J, V310, P1053, DOI 10.1042/bj3101053; UPHOLT WB, 1993, EXPERIENTIA, V49, P384, DOI 10.1007/BF01923583; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617	39	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17107	17113		10.1074/jbc.271.29.17107	http://dx.doi.org/10.1074/jbc.271.29.17107			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663259	hybrid			2022-12-27	WOS:A1996UX94300021
J	Keith, DE; Murray, SR; Zaki, PA; Chu, PC; Lissin, DV; Kang, L; Evans, CJ; vonZastrow, M				Keith, DE; Murray, SR; Zaki, PA; Chu, PC; Lissin, DV; Kang, L; Evans, CJ; vonZastrow, M			Morphine activates opioid receptors without causing their rapid internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; NG108-15 HYBRID-CELLS; MU-OPIATE RECEPTOR; PHARMACOLOGICAL CHARACTERIZATION; INTRACELLULAR TRAFFICKING; ADRENERGIC-RECEPTOR; PHOSPHORYLATION; ENKEPHALIN; MEMBRANE; CLONING	We have examined the endocytic trafficking of epitope-tagged delta and mu opioid receptors expressed in human embryonic kidney (HEK) 293 cells, These receptors are activated by peptide agonists (enkephalins) as well as by the alkaloid agonist drugs etorphine and morphine. Enkephalins and etorphine cause opioid receptors to internalize rapidly (t(1/2) similar to 6 min) by a mechanism similar to that utilized by a number of other classes of receptor, as indicated by localization of internalized opioid receptors in transferrin-containing endosomes and inhibition of opioid receptor internalization by hypertonic media, Remarkably, morphine does not stimulate the rapid internalization of either delta or mu opioid receptors, even at high concentrations that strongly inhibit adenylyl cyclase, These data indicate that agonist ligands, which have similar effects on receptor-mediated signaling, can have dramatically different effects on the intracellular trafficking of a G protein-coupled receptor.	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,NINA IRELAND LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT CELLULAR & MOLEC PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF LOS ANGELES,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles					NCI NIH HHS [CA-16042] Funding Source: Medline; NIDA NIH HHS [DA-00218, DA-05010, P50 DA005010] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA005010] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARDEN JR, 1995, J NEUROCHEM, V65, P1636; EVANS CJ, 1992, SCIENCE, V258, P1952, DOI 10.1126/science.1335167; FUKUDA K, 1995, FEBS LETT, V373, P177, DOI 10.1016/0014-5793(95)01034-C; GARLAND AM, 1994, BIOCHEM J, V303, P177, DOI 10.1042/bj3030177; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUGHES J, 1977, BRIT MED BULL, V33, P157, DOI 10.1093/oxfordjournals.bmb.a071416; JASPER JR, 1992, BIOCHEM PHARMACOL, V43, P119, DOI 10.1016/0006-2952(92)90268-N; KAUFMAN DL, 1995, J BIOL CHEM, V270, P15877, DOI 10.1074/jbc.270.26.15877; KONG HY, 1993, J BIOL CHEM, V268, P23055; Kosterlitz H W, 1978, Adv Biochem Psychopharmacol, V18, P31; LAW PY, 1984, J BIOL CHEM, V259, P4096; LAW SK, 1982, P NATL ACAD SCI USA, V72, P1; LOUIE AK, 1988, BIOCHEM BIOPH RES CO, V152, P1369, DOI 10.1016/S0006-291X(88)80436-4; MESTEK A, 1995, J NEUROSCI, V15, P2396, DOI 10.1523/JNEUROSCI.15-03-02396.1995; METZGER TG, 1995, FEBS LETT, V375, P1, DOI 10.1016/0014-5793(95)01185-H; NESTLER EJ, 1993, CRIT REV NEUROBIOL, V7, P23; Okayama H, 1992, Biotechnology, V24, P270; PEI G, 1995, MOL PHARMACOL, V48, P173; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; SCHMID I, 1988, CYTOMETRY, V9, P533, DOI 10.1002/cyto.990090605; SMITH CFC, 1983, LIFE SCI, V33, P327, DOI 10.1016/0024-3205(83)90509-X; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VONZASTROW M, 1994, REGUL PEPTIDES, V54, P315, DOI 10.1016/0167-0115(94)90516-9; VONZASTROW M, 1993, MOL PHARMACOL, V44, P166; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; YASUDA K, 1993, P NATL ACAD SCI USA, V90, P6736, DOI 10.1073/pnas.90.14.6736	32	462	471	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19021	19024		10.1074/jbc.271.32.19021	http://dx.doi.org/10.1074/jbc.271.32.19021			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702570	hybrid			2022-12-27	WOS:A1996VB68400004
J	Nikitovic, D; Holmgren, A				Nikitovic, D; Holmgren, A			S-nitrosoglutathione is cleaved by the thioredoxin system with liberation of glutathione and redox regulating nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS; OXIDATION; REDUCTASE; CYSTEINE; NITROSO; SELENODIGLUTATHIONE; NITROSYLATION; ACTIVATION; MECHANISM; RESIDUES	In activated human neutrophils a burst of nitric oxide (NO) converts intracellular GSH to S-nitrosoglutathione (GSNO) which is subsequently cleaved to restore GSH by an unknown mechanism, We discovered that GSNO is an NADPH oxidizing substrate for human or calf thymus thioredoxin reductase (TR) with an apparent K-m value of 60 mu M and a K-cat of 0.6 x s(-1). Addition of human thioredoxin (Trx) stimulated the initial NADPH oxidation rate severalfold but was accompanied by progressive inactivation of TR. Escherichia coli TR lacked activity with GSNO, but with E. coli Trx present, GSNO was reduced without inhibition of the enzyme, Chemically reduced E. coli Trx (SH)(2) was oxidized to Trx-S-2 by GSNO with a rate constant of 760 M(-1) s(-1) (7-fold faster than by GSSG) as measured by tryptophan fluorescence. Analysis of this reaction in the presence of oxymyoglobin revealed quantitative formation of metmyoglobin indicative of NO. release, Analysis of GSNO reduction demonstrated that oxidation of NADPH produced a stoichiometric amount of free GSH. These results demonstrate a homolytic cleavage mechanism of GSNO, giving rise to GSH and NO.. GSNO efficiently inhibited the protein disulfide reductase activity of the complete human or calf thymus thioredoxin systems, Our results demonstrate enzymatic cleavage of GSNO by TR or Trx and suggest novel mechanisms for redox signaling.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,MED NOBEL INST BIOCHEM,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet			Nikitovic, Dragana/AAS-6215-2020	Nikitovic, Dragana/0000-0003-3882-7399				ANNELLE JS, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; BAZYLINSKI DA, 1985, J AM CHEM SOC, V107, P79828; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BJORNSTEDT M, 1992, J BIOL CHEM, V267, P8030; CLANCY RM, 1992, ANAL BIOCHEM, V204, P365, DOI 10.1016/0003-2697(92)90253-4; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GOLDMAN R, 1995, BIOCHEMISTRY-US, V34, P4765, DOI 10.1021/bi00014a034; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007	31	287	295	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19180	19185		10.1074/jbc.271.32.19180	http://dx.doi.org/10.1074/jbc.271.32.19180			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702596	hybrid			2022-12-27	WOS:A1996VB68400030
J	Bangs, JD; Brouch, EM; Ransom, DM; Roggy, JL				Bangs, JD; Brouch, EM; Ransom, DM; Roggy, JL			A soluble secretory reporter system in Trypanosoma brucei - Studies on endoplasmic reticulum targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; AFRICAN TRYPANOSOMES; BLOOD-STREAM; NUCLEOTIDE-SEQUENCE; FLAGELLAR POCKET; ACID-PHOSPHATASE; RETENTION SIGNAL; GIARDIA-LAMBLIA; MEMBRANE ANCHOR; PROTEIN	A homolog of the endoplasmic reticulum (ER) hsp70 protein, binding protein (BiP), from the parasitic protozoan Trypanosoma brucei (Bangs, J. D., Uyetake, L., Brickman, M. J., Balber, A. E., and Boothroyd, J. C. (1993) J. Cell Sci, 105, 1101-1113) is further characterized, In co-precipitation experiments, BiP transiently associates with newly synthesized secretory proteins, including variant surface glycoprotein (VSG), confirming its role as a molecular chaperone, To study the molecular signals targeting BiP to the ER, we have developed soluble secretory reporters for expression in transformed procyclic trypanosomes. Deletion of the BiP C-terminal tetrapeptide (MDDL) and the glycosylphosphatidylinositol-anchor addition sequence of VSG converts these proteins to secreted forms, Attachment of MDDL to VSG results in intracellular retention confirming that MDDL is a trypanosomal ER localization signal, Secretion of both reporters is inefficient, but further truncation of the BiP C-terminal peptide binding domain allows quantitative export (t1/2 similar to 1 h) of the N-terminal ATPase domain (BiPN), consistent with the conserved domain structure of hsp70 proteins, This is the first demonstration of soluble protein secretion in African trypanosomes. Using the BiPN reporter, the sequence specificity of C-terminal tetrapeptide retention signals in trypanosomes is analyzed and found to be similar to higher eukaryotes. These results indicate that the basic signals mediating protein targeting to the ER lumen are conserved throughout the wide range of eukaryotic evolution.			Bangs, JD (corresponding author), UNIV WISCONSIN, SCH MED, DEPT MED MICROBIOL & IMMUNOL, 1300 UNIV AVE, MADISON, WI 53706 USA.				NIAID NIH HHS [AI35739-02, AI07414-04, R01 AI035739, R29 AI035739] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI035739, R01AI035739, T32AI007414] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDRES DA, 1991, J BIOL CHEM, V266, P14277; ANDREWS NW, 1989, MOL BIOCHEM PARASIT, V33, P249, DOI 10.1016/0166-6851(89)90086-8; BALBER AE, 1990, CRIT REV IMMUNOL, V10, P177; BANGS JD, 1993, J CELL SCI, V105, P1101; BANGS JD, 1988, J BIOL CHEM, V263, P17697; BANGS JD, 1986, J CELL BIOL, V103, P255, DOI 10.1083/jcb.103.1.255; BATES PA, 1987, MOL BIOCHEM PARASIT, V26, P289, DOI 10.1016/0166-6851(87)90081-8; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CLAYTON C, 1995, MICROBIOL REV, V59, P325, DOI 10.1128/MMBR.59.3.325-344.1995; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; FIELD MC, 1994, J BIOL CHEM, V269, P10830; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GUPTA RS, 1994, P NATL ACAD SCI USA, V91, P2895, DOI 10.1073/pnas.91.8.2895; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HENDERSHOT LM, 1995, MOL BIOL CELL, V6, P283, DOI 10.1091/mbc.6.3.283; HIRUMI H, 1994, PARASITOL TODAY, V10, P81; HSU MP, 1989, BIOCHEMISTRY-US, V28, P6440, DOI 10.1021/bi00441a042; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P8; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; ILG T, 1991, J CELL SCI, V99, P175; KEKU TO, 1993, EXP PARASITOL, V77, P306, DOI 10.1006/expr.1993.1088; KIMMEL BE, 1985, GENE, V35, P237, DOI 10.1016/0378-1119(85)90002-2; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KUMAR N, 1992, MOL BIOCHEM PARASIT, V56, P353, DOI 10.1016/0166-6851(92)90187-O; LANGRETH SG, 1975, J PROTOZOOL, V22, P40, DOI 10.1111/j.1550-7408.1975.tb00943.x; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NWAGWU M, 1988, T ROY SOC TROP MED H, V82, P577, DOI 10.1016/0035-9203(88)90515-9; OLSSON T, 1991, EUR J IMMUNOL, V21, P2447, DOI 10.1002/eji.1830211022; OVERATH P, 1986, EUR J BIOCHEM, V160, P175, DOI 10.1111/j.1432-1033.1986.tb09955.x; OVERATH P, 1994, PARASITOL TODAY, V10, P53, DOI 10.1016/0169-4758(94)90393-X; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PIDOUX AL, 1992, EMBO J, V11, P1583, DOI 10.1002/j.1460-2075.1992.tb05203.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHERMAN DR, 1991, EMBO J, V10, P3379, DOI 10.1002/j.1460-2075.1991.tb04902.x; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; STEBECK CR, 1994, EXP PARASITOL, V78, P432, DOI 10.1006/expr.1994.1050; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; VICKERMAN K, 1969, J PROTOZOOL, V16, P54, DOI 10.1111/j.1550-7408.1969.tb02233.x; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4	47	121	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18387	18393		10.1074/jbc.271.31.18387	http://dx.doi.org/10.1074/jbc.271.31.18387			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702482	hybrid			2022-12-27	WOS:A1996VB68300020
J	Jensen, J; Serup, P; Karlsen, C; Nielsen, TF; Madsen, OD				Jensen, J; Serup, P; Karlsen, C; Nielsen, TF; Madsen, OD			mRNA profiling of rat islet tumors reveals Nkx 6.1 as a beta-cell-specific homeodomain transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ALPHA-CELLS; GENE-RELATED PEPTIDE; INSULIN GENE; SOMATOSTATIN EXPRESSION; BINDING PROTEINS; TRANSGENIC MICE; HOMEOBOX FACTOR; NEUROPEPTIDE-Y; LINES; POLYPEPTIDE	Development of a high capacity multiplex reverse transcriptase-polymerase chain reaction protocol has allowed us to screen lineage related rat islet tumors classified as alpha-, beta-, and delta-like as judged by their hormone profile for differential expression of more than 50 selected genes, We find that in addition to insulin the insulinoma express the normal beta-cell markers Pdx-1, IAPP, and Glut-2, and that these markers are absent from the glucagonoma: a reflection of the normal alpha-cell, Furthermore, this study suggests that the GLP-1, glucagon, GIP, IGF-1, and insulin receptors as well as E-cadherin, R-cadherin, Id-1, and Id-2 are differentially expressed within the islet of Langerhans, Importantly, insulinoma-specific expression of the recently cloned homeodomain protein Nkx 6.1 predicted beta-cell-specific expression in the normal islet, Immunohistochemistry using antibodies raised against recombinant Nkx 6.1 did indeed localize Nkx 6.1 expression exclusively to the nuclei of normal islet beta-cells, Apart from pancreatic islets only the antral part of the stomach contained Nkx 6.1 mRNA, We conclude that multiplex reverse transcriptase-polymerase chain reaction-based mRNA profiling is a powerful tool to identify differentially expressed genes within phenotypically related cells and propose that Nkx 6.1 is involved in specifying the unique characteristics of the beta-cell.	HAGEDORN RES INST, DK-2820 GENTOFTE, DENMARK	Novo Nordisk; Hagedorn Research Institute			Madsen, Ole D./A-7415-2011; Serup, Palle/A-7407-2011	Madsen, Ole D./0000-0002-2753-5203; Serup, Palle/0000-0002-0858-590X; Jensen, Jan/0000-0003-0657-4032				ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ATAR D, 1989, J IMMUNOL, V143, P533; BORDI C, 1974, VIRCHOWS ARCH B, V17, P13; BRETHERTONWATT D, 1992, ANN NY ACAD SCI, V657, P299, DOI 10.1111/j.1749-6632.1992.tb22777.x; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EBIOU JC, 1992, ENDOCRINOLOGY, V130, P1371, DOI 10.1210/en.130.3.1371; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GRUPE A, 1995, CELL, V83, P69, DOI 10.1016/0092-8674(95)90235-X; GUZ Y, 1995, DEVELOPMENT, V121, P11; HAMAGUCHI K, 1990, DIABETES, V39, P415, DOI 10.2337/diabetes.39.4.415; JAMAL H, 1991, ENDOCRINOLOGY, V129, P3372, DOI 10.1210/endo-129-6-3372; JETTON TL, 1994, J BIOL CHEM, V269, P3641; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LARSSON LI, 1994, ENDOCRINE, V2, P759; LARSSON LI, 1975, AM J PATHOL, V79, P271; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MADSEN OD, 1993, ENDOCRINOLOGY, V133, P2022, DOI 10.1210/en.133.5.2022; MADSEN OD, 1986, J CELL BIOL, V103, P2025, DOI 10.1083/jcb.103.5.2025; MADSEN OD, 1988, P NATL ACAD SCI USA, V85, P6652, DOI 10.1073/pnas.85.18.6652; MADSEN OD, 1991, MOL ENDOCRINOL, V5, P143, DOI 10.1210/mend-5-1-143; MOLLER CJ, 1992, MOL ENDOCRINOL, V6, P1332, DOI 10.1210/me.6.8.1332; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; NIELSEN JH, 1989, MOL ENDOCRINOL, V3, P165, DOI 10.1210/mend-3-1-165; NIELSEN JH, 1989, EXP CLIN ENDOCRINOL, V93, P277; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; PANG K, 1994, P NATL ACAD SCI USA, V91, P9559, DOI 10.1073/pnas.91.20.9559; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; SERUP P, 1995, BIOCHEM J, V310, P997, DOI 10.1042/bj3100997; SERUP P, 1992, DIABETOLOGIA, V35, pA118; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; UPCHURCH BH, 1994, DEVELOPMENT, V120, P245	41	191	196	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18749	18758		10.1074/jbc.271.31.18749	http://dx.doi.org/10.1074/jbc.271.31.18749			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702531	hybrid			2022-12-27	WOS:A1996VB68300069
J	Vecchi, M; Baulida, J; Carpenter, G				Vecchi, M; Baulida, J; Carpenter, G			Selective cleavage of the heregulin receptor ErbB-4 by protein kinase C activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; SMOOTH-MUSCLE CELLS; HUMAN-BREAST; TYROSINE KINASE; PHORBOL ESTER; DOWN-REGULATION; EGF RECEPTORS; MESSENGER-RNA; GENE-PRODUCT	The 180-kDa transmembrane tyrosine kinase ErbB-4 is a receptor for the growth factor heregulin, I-125-Heregulin binding to NIH 3T3 cells overexpressing the ErbB-4 receptor is rapidly decreased by 12-O-tetradecanoylphorbol-13-acetate (TPA) pretreatment. Immunologic analysis demonstrates that TPA treatment of cells induces the proteolytic cleavage of ErbB-4, producing an 80-kDa cytoplasmic domain fragment, which contains a low level of phosphotyrosine, and a 120-kDa ectodomain fragment, which is released into the extracellular medium, Cleavage of ErbB-4 was also enhanced by other protein kinase C activators, i,e, platelet-derived growth factor, ionomycin, and synthetic diacylglycerol, while protein kinase C inhibition or down-regulation suppressed the TPA stimulation of ErbB-4 degradation, TPA did not induce the degradation of related receptors (ErbB-1, ErbB-2, and ErbB-3) in the EGF receptor family, The phorbol ester-induced cleavage of ErbB-4 occurs within or close to the ectodomain, as the 80-kDa cytoplasmic domain fragment is recognized by antibody to the ErbB-4 carboxyl terminus and is membrane-associated, Coprecipitation experiments show that, while the 80-kDa ErbB-4 fragment is associated with the SH2-containing molecules PLC-gamma 1 and She, TPA did not induce the phosphorylation of these substrates in intact cells, In addition, kinase assays in vitro indicate that the 80-kDa fragment is not an active tyrosine kinase, These results show that protein kinase C negatively regulates heregulin signaling through the ErbB-4 receptor by the activation of a selective proteolytic mechanism.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University			Vecchi, Manuela/L-3502-2017	Vecchi, Manuela/0000-0002-2750-9160	NCI NIH HHS [CA24071] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA024071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; Baulida J, 1996, J BIOL CHEM, V271, P5251; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN KD, 1979, BIOCHEM BIOPH RES CO, V86, P1037, DOI 10.1016/0006-291X(79)90221-3; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; CAO HN, 1991, ONCOGENE, V6, P705; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CHIDA K, 1986, J BIOL CHEM, V261, P3013; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; DONG Z, 1995, CELL, V15, P585; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; FRIEDMAN BA, 1987, J CELL BIOCHEM, V34, P1, DOI 10.1002/jcb.240340102; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; MAGUN BE, 1980, J BIOL CHEM, V255, P6373; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MUDGE AW, 1993, CURR BIOL, V3, P361, DOI 10.1016/0960-9822(93)90201-X; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; OLASHAW NE, 1987, J CELL BIOCHEM, V34, P143, DOI 10.1002/jcb.240340208; OLASHAW NE, 1986, P NATL ACAD SCI USA, V83, P3834, DOI 10.1073/pnas.83.11.3834; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RAAB G, 1994, BIOCHEM BIOPH RES CO, V204, P592, DOI 10.1006/bbrc.1994.2500; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLER C, 1995, GUIDEBOOK CYTOKINES, P194; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; TEMIZER DH, 1992, J BIOL CHEM, V267, P24892; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; YEE NS, 1993, J BIOL CHEM, V268, P14189; YEE NS, 1994, J BIOL CHEM, V269, P31991	53	111	116	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18989	18995		10.1074/jbc.271.31.18989	http://dx.doi.org/10.1074/jbc.271.31.18989			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702564	hybrid			2022-12-27	WOS:A1996VB68300102
J	Wilms, R; Freiberg, C; Wegerle, E; Meier, I; Mayer, F; Muller, V				Wilms, R; Freiberg, C; Wegerle, E; Meier, I; Mayer, F; Muller, V			Subunit structure and organization of the genes of the A(1)A(0) ATPase from the archaeon Methanosarcina mazei Go1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; CHEMIOSMOTIC ENERGY-CONVERSION; MEMBRANE-ASSOCIATED ATPASE; SACCHAROMYCES-CEREVISIAE; SULFOLOBUS-ACIDOCALDARIUS; TRANSLOCATING ATPASE; POLYACRYLAMIDE GELS; NUCLEOTIDE-SEQUENCE; CHROMAFFIN GRANULES; HALOFERAX-VOLCANII	The proton-translocating A(1)A(0) ATP synthase/hydrolase of Methanosarcina mazei Go1 was purified and shown to consist of six subunits of molecular masses of 65, 49, 40, 36, 25, and 7 kDa. Electron microscopy revealed that this enzyme is organized in two domains, the hydrophilic A(1) and the hydrophobic A(0) domain, which are connected by a stalk. Genes coding for seven hydrophilic subunits were cloned and sequenced. From these data it is evident that the 65-, 49-, 40- and 25-kDa subunits are encoded by ahaA, ahaB, ahaC, and ahaD, respectively; they are part of the A, domain or the stalk. In addition there are three more genes, ahaE, ahaF, and ahaG, encoding hydrophilic subunits, which were apparently lost during the purification of the protein. The A(0) domain consists of at least the 7-kDa proteolipid and the 36 kDa subunit for which the genes have not yet been found. In summary, it is proposed that the A(1)A(0) ATPase of Methanosarcina mazei Go1 contains at least nine subunits, of which seven are located in A(1) and/or the stalk and two in A(0).	UNIV GOTTINGEN,INST MICROBIOL,D-37077 GOTTINGEN,GERMANY	University of Gottingen			Mueller, Volker/ABE-4305-2021	Mueller, Volker/0000-0001-7955-5508				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ANDERSSON LO, 1972, FEBS LETT, V20, P199, DOI 10.1016/0014-5793(72)80793-2; ANRAKU Y, 1992, J EXP BIOL, V172, P67; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BECHER B, 1994, J BACTERIOL, V176, P243; BROSIUS J, 1992, METHOD ENZYMOL, V216, P469; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; CHEN W, 1993, J BACTERIOL, V175, P5677, DOI 10.1128/JB.175.17.5677-5682.1993; DANE M, 1992, Z NATURFORSCH C, V47, P835; DENDA K, 1990, J BIOL CHEM, V265, P21509; DENDA K, 1988, J BIOL CHEM, V263, P6012; DENDA K, 1988, J BIOL CHEM, V263, P17251; DENDA K, 1989, J BIOL CHEM, V264, P7119; DEPPENMEIER U, 1995, EUR J BIOCHEM, V227, P261, DOI 10.1111/j.1432-1033.1995.tb20383.x; DEVREUX J, 1984, NUCLEIC ACIDS RES, V12, P387; EGGEN RIL, 1992, SYST APPL MICROBIOL, V15, P582, DOI 10.1016/S0723-2020(11)80118-9; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FOURY F, 1990, J BIOL CHEM, V265, P18554; GRAF R, 1994, J BIOL CHEM, V269, P3767; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; HIPPE H, 1979, P NATL ACAD SCI USA, V76, P494, DOI 10.1073/pnas.76.1.494; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; HOCHSTEIN LI, 1987, BIOCHEM BIOPH RES CO, V147, P295, DOI 10.1016/S0006-291X(87)80120-1; IHARA K, 1991, ARCH BIOCHEM BIOPHYS, V286, P111, DOI 10.1016/0003-9861(91)90015-B; INATOMI K, 1989, BIOCHEM BIOPH RES CO, V162, P1585, DOI 10.1016/0006-291X(89)90856-5; INATOMI K, 1993, J BACTERIOL, V175, P80, DOI 10.1128/JB.175.1.80-84.1993; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; KAKINUMA Y, 1985, J BIOL CHEM, V260, P2086; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUBBEN M, 1989, J BACTERIOL, V171, P6106; LUBBEN M, 1988, BIOL CHEM H-S, V369, P1259, DOI 10.1515/bchm3.1988.369.2.1259; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MUKOHATA Y, 1990, BIOENERGETICS, P205; Muller V, 1993, METHANOGENESIS, P360; NAKAMOTO RK, 1995, J BIOL CHEM, V270, P14042, DOI 10.1074/jbc.270.23.14042; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON N, 1992, J EXP BIOL, V172, P19; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; NILSSON K, 1984, METHOD ENZYMOL, V104, P56; PAN YX, 1991, FEBS LETT, V293, P89, DOI 10.1016/0014-5793(91)81158-5; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFER G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P232, DOI 10.1016/0005-2728(92)90233-R; SCHEEL E, 1990, EUR J BIOCHEM, V187, P727, DOI 10.1111/j.1432-1033.1990.tb15360.x; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; STEINERT K, 1995, BBA-PROTEIN STRUCT M, V1249, P137, DOI 10.1016/0167-4838(95)00033-Q; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; TAKASE K, 1993, J BIOL CHEM, V268, P11610; TAKASE K, 1994, J BIOL CHEM, V269, P11037; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TIEDGE H, 1983, EUR J BIOCHEM, V132, P37, DOI 10.1111/j.1432-1033.1983.tb07322.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANHILLE B, 1993, J BIOL CHEM, V268, P7075; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WANG SY, 1988, J BIOL CHEM, V263, P17638	62	43	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18843	18852		10.1074/jbc.271.31.18843	http://dx.doi.org/10.1074/jbc.271.31.18843			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702544	hybrid			2022-12-27	WOS:A1996VB68300082
J	Zeng, WZ; Xu, X; Muallem, S				Zeng, WZ; Xu, X; Muallem, S			G beta gamma transduces [Ca2+](i) oscillations and G alpha(q) a sustained response during stimulation of pancreatic acinar cells with [Ca2+](i)-mobilizing agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; PHOSPHOLIPASE-C ISOZYMES; EVOKED CALCIUM RELEASE; PROTEIN ALPHA-SUBUNIT; CA2+ RELEASE; MUSCARINIC RECEPTOR; INOSITOL 1,4,5-TRISPHOSPHATE; INTRACELLULAR STORES; ACTIVATION; KINASE	A central unresolved question in agonist-evoked [Ca2+](i) signaling is the pathway by which [Ca2+](i) oscillations and a sustained response are transduced. We show here that activation of G beta gamma signal [Ca2+](i) oscillations and activation of G alpha(q) signal a sustained response during stimulation by a number of Ca2+-modilizing agonists. Thus, infusion of purified G beta gamma into pancreatic acinar cells through a patch pipette evokes [Ca2+](i) oscillations by Ca2+ release from internal stores, which were inhibited by two independent scavengers of G beta gamma, the beta-adrenergic receptor kinase fragment, and a mutated G alpha(i1G203A). These proteins, as well as an inhibitory antibody against G alpha(q/11), prevent [Ca2+](i) oscillations and the sustained response when applied before cell stimulation, possibly by preventing the dissociation of G(q) into its subunits. After cell stimulation and dissociation of G(q) into G beta gamma and G alpha(q), scavenging G beta gamma stabilized the sustained response and inhibited reassociation of the subunits on termination of cell stimulation with antagonist, whereas scavenging G alpha(q) inhibited the sustained response and uncovered the G beta gamma-dependent oscillations. These findings provide a general mechanism by which Ca2+-mobilizing agonists can control the type of [Ca2+](i) signal to be transduced to the cell interior.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK46591, DK38938] Funding Source: Medline; NIGMS NIH HHS [GM31954] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046591, R01DK038938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUALLEM S, 1988, AM J PHYSIOL, V255, pG229; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; KASE H, 1991, PFLUG ARCH EUR J PHY, V419, P668, DOI 10.1007/BF00370314; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LEE E, 1992, J BIOL CHEM, V267, P1212; LIU J, 1995, P NATL ACAD SCI USA, V92, P11642, DOI 10.1073/pnas.92.25.11642; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; MUALLEM S, 1988, BIOCHEM J, V255, P301; MUALLEM S, 1989, J BIOL CHEM, V264, P205; MUALLEM S, 1988, AM J PHYSIOL, V255, pG221, DOI 10.1152/ajpgi.1988.255.2.G221; MUALLEM S, 1992, ADV SEC MESS PHOSPH, P351; PARK DG, 1993, J BIOL CHEM, V268, P4573; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; Williams John A., 1993, P167; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1992, J BIOL CHEM, V267, P1811; Xu X, 1996, J PHYSIOL-LONDON, V491, P647, DOI 10.1113/jphysiol.1996.sp021246; Xu X, 1996, J BIOL CHEM, V271, P11737, DOI 10.1074/jbc.271.20.11737; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; ZHAO H, 1994, J GEN PHYSIOL, V104, P57, DOI 10.1085/jgp.104.1.57; ZHAO H, 1990, J BIOL CHEM, V265, P14822	49	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18520	18526		10.1074/jbc.271.31.18520	http://dx.doi.org/10.1074/jbc.271.31.18520			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702499	hybrid			2022-12-27	WOS:A1996VB68300037
J	Zhu, GH; Spreitzer, RJ				Zhu, GH; Spreitzer, RJ			Directed mutagenesis of chloroplast ribulose-1,5-bisphosphate carboxylase/oxygenase - Loop 6 substitutions complement for structural stability but decrease catalytic efficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; LARGE-SUBUNIT; ACTIVE-SITE; CO2/O-2 SPECIFICITY; CHLAMYDOMONAS-REINHARDII; 1,5-BISPHOSPHATE CARBOXYLASE; RHODOSPIRILLUM-RUBRUM; SUBSTRATE-SPECIFICITY; ANACYSTIS-NIDULANS; RBCL GENE	The structure of active site loop 6 plays a role in determining the CO2/O-2 specificity of chloroplast ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco, EC 4.1.1.39), Rubisco from the green alga Chlamydomonas reinhardtii differs from higher plant Rubisco within the loop 6 region, and the C, reinhardtii enzyme has a CO2/O-2 specificity 25% lower than that of higher plant enzymes, To examine whether differences in sequence may account for differences in catalytic efficiency, we focused on a conserved pair of residues that are in van der Waals contact at the base of loop 6, C, reinhardtii Rubisco contains Leu-326 and Met-349, whereas higher plant enzymes contain Ile-326 and Leu-349, By employing in vitro mutagenesis and chloroplast transformation, L326I and M349L substitutions were created within the Rubisco large subunit of C, reinhardtii. M349L had little effect, but L326I destabilized the holoenzyme in vivo and in vitro, When present together, the M349L substitution partially alleviated the instability resulting from the L326I substitution, but caused a 21% decrease in CO2/O-2 specificity and a 74% decrease in the V-max of carboxylation, Interactions between loop 6 and other structural regions are likely to be responsible for both holoenzyme stability and catalytic efficiency in higher plant Rubisco enzymes.	UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68588	University of Nebraska System; University of Nebraska Lincoln								ALDRICH J, 1986, NUCLEIC ACIDS RES, V14, P9535, DOI 10.1093/nar/14.23.9535; ALDRICH J, 1986, NUCLEIC ACIDS RES, V14, P9534, DOI 10.1093/nar/14.23.9534; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN Z, 1988, P NATL ACAD SCI USA, V85, P4696, DOI 10.1073/pnas.85.13.4696; CHEN ZX, 1992, PHOTOSYNTH RES, V31, P157, DOI 10.1007/BF00028792; CHEN ZX, 1991, PLANTA, V183, P597, DOI 10.1007/BF00194282; CHEN ZX, 1991, BIOCHEMISTRY-US, V30, P8846, DOI 10.1021/bi00100a017; CHEN ZX, 1989, J BIOL CHEM, V264, P3051; DAY AG, 1993, BIOCHEMISTRY-US, V32, P1940, DOI 10.1021/bi00059a009; DRON M, 1982, J MOL BIOL, V162, P775, DOI 10.1016/0022-2836(82)90547-2; FINER JJ, 1992, PLANT CELL REP, V11, P323, DOI 10.1007/BF00233358; GUTTERIDGE S, 1993, J BIOL CHEM, V268, P7818; HARPEL MR, 1992, J BIOL CHEM, V267, P6475; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; HWANG SR, 1991, J BIOL CHEM, V266, P6271; JORDAN DB, 1981, NATURE, V291, P513, DOI 10.1038/291513a0; JORDAN DB, 1981, PLANT PHYSIOL, V67, P237, DOI 10.1104/pp.67.2.237; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KUEHN GD, 1978, BIOCHEM J, V175, P909, DOI 10.1042/bj1750909; LAING WA, 1974, PLANT PHYSIOL, V54, P678, DOI 10.1104/pp.54.5.678; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LARSON EM, 1995, BIOCHEMISTRY-US, V34, P4531, DOI 10.1021/bi00014a005; LEE GJ, 1993, PROTEIN SCI, V2, P1147, DOI 10.1002/pro.5560020709; LEE GJ, 1992, BIOCHEMISTRY-US, V31, P2304, DOI 10.1021/bi00123a014; LORIMER GH, 1993, BIOCHEMISTRY-US, V32, P9018, DOI 10.1021/bi00086a006; MCINTOSH L, 1980, NATURE, V288, P556, DOI 10.1038/288556a0; MOON E, 1987, NUCLEIC ACIDS RES, V15, P611, DOI 10.1093/nar/15.2.611; NEWMAN SM, 1991, MOL GEN GENET, V230, P65, DOI 10.1007/BF00290652; PARRY MAJ, 1992, PLANTA, V187, P109, DOI 10.1007/BF00201631; PIERCE J, 1980, BIOCHEMISTRY-US, V19, P934, DOI 10.1021/bi00546a018; PIERCE J, 1986, J BIOL CHEM, V261, P248; POULSEN C, 1981, CARLSBERG RES COMMUN, V46, P259, DOI 10.1007/BF02906502; READ BA, 1994, ARCH BIOCHEM BIOPHYS, V312, P210, DOI 10.1006/abbi.1994.1301; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHREUDER HA, 1993, P NATL ACAD SCI USA, V90, P9968, DOI 10.1073/pnas.90.21.9968; SHINOZAKI K, 1983, P NATL ACAD SCI-BIOL, V80, P4050, DOI 10.1073/pnas.80.13.4050; SOPER TS, 1988, PROTEIN ENG, V2, P39, DOI 10.1093/protein/2.1.39; SPREITZER RJ, 1981, PLANT PHYSIOL, V67, P565, DOI 10.1104/pp.67.3.565; SPREITZER RJ, 1982, FEBS LETT, V148, P117, DOI 10.1016/0014-5793(82)81255-6; SPREITZER RJ, 1985, P NATL ACAD SCI USA, V82, P5460, DOI 10.1073/pnas.82.16.5460; SPREITZER RJ, 1987, CURR GENET, V11, P611, DOI 10.1007/BF00393924; SPREITZER RJ, 1993, ANNU REV PLANT PHYS, V44, P411, DOI 10.1146/annurev.pp.44.060193.002211; SPREITZER RJ, 1995, PLANT PHYSIOL, V109, P681, DOI 10.1104/pp.109.2.681; THOW G, 1994, BIOCHEMISTRY-US, V33, P5109, DOI 10.1021/bi00183a014; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHU GH, 1990, PLANT PHYSIOL, V93, P244, DOI 10.1104/pp.93.1.244; ZHU GH, 1994, J BIOL CHEM, V269, P3952; ZURAWSKI G, 1981, NUCLEIC ACIDS RES, V9, P3251, DOI 10.1093/nar/9.14.3251	49	40	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18494	18498		10.1074/jbc.271.31.18494	http://dx.doi.org/10.1074/jbc.271.31.18494			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702495	hybrid			2022-12-27	WOS:A1996VB68300033
J	Duplay, P; Alcover, A; Fargeas, C; Sekaly, RP; Branton, PE				Duplay, P; Alcover, A; Fargeas, C; Sekaly, RP; Branton, PE			An activated epidermal growth factor receptor/Lck chimera restores early T cell receptor-mediated calcium response in a CD45-deficient T cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PROTEIN-KINASE; CD45 PHOSPHOTYROSINE PHOSPHATASE; HUMAN LYMPHOCYTES-T; ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; SH2 DOMAIN; INTERLEUKIN-2 PRODUCTION; FUNCTIONAL COMPLEX; ZAP-70 KINASE; CROSS-LINKING	In T cells, cell surface expression of CD45, a transmembrane tyrosine phosphatase, is required for T cell receptor (TCR) signal transduction, Indirect evidence suggests that CD45 function in TCR signaling involves the dephosphorylation of the C-terminal negative regulatory site of p56(lck), Tyr-505, To evaluate the importance of CD45-mediated dephosphorylation of p56(lck) Tyr-505 in TCR signaling, we established CD45(-) Jurkat cell lines expressing various forms of a chimera containing the extracellular and transmembrane domains of the epidermal growth factor receptor (EGFR) fused to p56(lck) We report that an activated EGFR/Lck chimera is able to reconstitute a Ca2+ response after CD3 stimulation in the absence of CD45 expression, In addition, the wild-type and kinase inactive versions of the EGFR/Lck chimera fail to restore early signaling, Restoration of the response by EGFR/LckF505 required EGF binding to the chimeric kinase, Altogether, these results provide the first direct evidence that the lack of efficient dephosphorylation of p56(lck) Tyr-505 ist in part, responsible for the unresponsiveness of CD45(-) cells, They also indicate that a second event is required for p56(lck) function in TCR signaling in addition to its dephosphorylation at Tyr-505.	INST PASTEUR,UNITE BIOL INTERACT CELLULAIRES,CNRS URA 1960,F-75724 PARIS 15,FRANCE; INST RECH CLIN MONTREAL,IMMUNOL LAB,MONTREAL,PQ H2W 1R7,CANADA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Duplay, P (corresponding author), MCGILL UNIV,DEPT BIOCHEM,MCINTYRE MED SCI BLDG,MONTREAL,PQ H3G 1Y6,CANADA.			Alcover, Andres/0000-0002-9507-3450				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ADAM D, 1993, J BIOL CHEM, V268, P19882; ALCOVER A, 1988, EMBO J, V7, P1973, DOI 10.1002/j.1460-2075.1988.tb03035.x; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BALDARI CT, 1995, EUR J IMMUNOL, V25, P919, DOI 10.1002/eji.1830250409; BIFFEN M, 1994, EMBO J, V13, P1920, DOI 10.1002/j.1460-2075.1994.tb06461.x; BURNS CM, 1994, J BIOL CHEM, V269, P13594; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DANOVAN JA, 1994, J BIOL CHEM, V269, P22921; DEANS JP, 1992, EUR J IMMUNOL, V22, P661, DOI 10.1002/eji.1830220308; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DESAI DM, 1994, J BIOL CHEM, V269, P22830; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; FISHER EH, 1991, SCIENCE, V253, P401; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; GERVAIS FG, 1995, MOL CELL BIOL, V15, P2393; GUTTINGER M, 1992, INT IMMUNOL, V4, P1325, DOI 10.1093/intimm/4.11.1325; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JUNE CH, 1990, J IMMUNOL, V144, P1591; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; Lee JM, 1996, ONCOGENE, V12, P253; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; NIKLINSKA BB, 1994, MOL CELL BIOL, V14, P8078, DOI 10.1128/MCB.14.12.8078; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; PERI KG, 1993, ONCOGENE, V8, P2765; PEYRON JF, 1991, INT IMMUNOL, V3, P1357, DOI 10.1093/intimm/3.12.1357; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1992, EUR J IMMUNOL, V22, P1857, DOI 10.1002/eji.1830220727; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SOULA M, 1993, J BIOL CHEM, V268, P27420; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOME M, 1995, J EXP MED, V181, P1997, DOI 10.1084/jem.181.6.1997; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDENBERGHE PA, 1990, J IMMUNOL METHODS, V127, P197, DOI 10.1016/0022-1759(90)90069-8; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	66	15	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17896	17902		10.1074/jbc.271.30.17896	http://dx.doi.org/10.1074/jbc.271.30.17896			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663450	hybrid			2022-12-27	WOS:A1996UY93500048
J	GharaeeKermani, M; Denholm, EM; Phan, SH				GharaeeKermani, M; Denholm, EM; Phan, SH			Costimulation of fibroblast collagen and transforming growth factor beta(1) gene expression by monocyte chemoattractant protein-1 via specific receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PULMONARY FIBROSIS; TUMOR-NECROSIS-FACTOR; IN-SITU HYBRIDIZATION; MESSENGER-RNA; ALVEOLAR MACROPHAGES; INSITU HYBRIDIZATION; HUMAN BASOPHILS; FACTOR-ALPHA; BLEOMYCIN; RAT	Recent studies indicate potential roles of monocyte chemotactic protein-1 (MCP-1) in recruitment of monocytes to sites of inflammation, However, their increased expression does not always correlate with monocyte influx, suggesting other possible biological activities for this member of the C-C chemokine family. In view of its potential role in regulating extracellular matrix expression in fibrotic disorders, the effects of MCP-1 on lung fibroblast collagen expression were evaluated. Isolated rat lung fibroblasts were treated with increasing doses of MCP-1 for variable periods of time and examined for effects on collagen synthesis and expression of procollagen alpha(1)(I) mRNA expression, The results show that MCP-1 was able to stimulate collagen expression in these cells in a dose-dependent manner but required over 24 h for significant elevation to occur, In view of this delayed time course, the possibility of mediation via endogenous transforming growth factor beta (TGF beta) was tested by the ability of anti-TGF beta antibody to inhibit this MCP-1 stimulation of collagen expression. Significant but incomplete inhibition by this antibody was observed. Pretreatment of the cells with antisense but not by sense or missense TGF beta(1) oligodeoxyribonucleotides caused essentially complete inhibition of this MCP-1 stimulatory effect. Furthermore, MCP-1 treatment was found to also stimulate TGF beta secretion and mRNA expression, which was also abolished by pretreatment with antisense TGF beta(1) oligodeoxyribonucleotides. The kinetics of TGF beta expression indicates that significant increase preceded that for collagen expression. Binding studies using I-125-labeled MCP-1 indicated the presence of specific and saturable binding sites with a dissociation constant consistent with the dose response curves for stimulation of fibroblast collagen synthesis and TGF beta activity by MCP-1. These results taken together suggest that MCP-1 stimulates fibroblast collagen expression via specific receptors and endogenous up-regulation of TGF beta expression. The latter then results in autocrine and/or juxtacrine stimulation of collagen gene expression.	UNIV MICHIGAN, SCH MED, DEPT PATHOL M0602, ANN ARBOR, MI 48109 USA; ICOS CORP, BOTHELL, WA 98021 USA	University of Michigan System; University of Michigan; Icos Corporation			Phan, Sem H/A-7033-2009	Phan, Sem H/0000-0002-3711-2159	NHLBI NIH HHS [HL31963, HL28737, HL46487] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031963, P50HL046487, R37HL028737, R01HL028737] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMSON IYR, 1974, AM J PATHOL, V77, P185; ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P5371, DOI 10.1073/pnas.89.12.5371; BISCHOFF SC, 1992, J EXP MED, V175, P1271, DOI 10.1084/jem.175.5.1271; BREEN E, 1992, AM J RESP CELL MOL, V6, P146, DOI 10.1165/ajrcmb/6.2.146; BRIELAND JK, 1993, AM J RESP CELL MOL, V9, P300, DOI 10.1165/ajrcmb/9.3.300; BURDICK MD, 1994, AM J PATHOL, V146, P130; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONTI P, 1995, IMMUNOLOGY, V86, P434; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; DESMOULIERE A, 1992, LAB INVEST, V67, P716; ELIAS JA, 1990, CHEST, V97, P1439, DOI 10.1378/chest.97.6.1439; FLORY CM, 1993, LAB INVEST, V69, P396; HOYT DG, 1988, J PHARMACOL EXP THER, V246, P765; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; JAATTELA M, 1991, LAB INVEST, V64, P724; JIANG YL, 1992, J IMMUNOL, V148, P2423; JONES ML, 1992, LAB INVEST, V66, P498; KUNA P, 1992, J IMMUNOL, V149, P636; LARJAVA H, 1990, LAB INVEST, V62, P96; LEONARD EJ, 1991, ADV EXP MED BIOL, V305, P57; LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8; LLOYD RV, 1988, AM J PATHOL, V133, P397; LUKACS NW, 1993, J EXP MED, V177, P1551, DOI 10.1084/jem.177.6.1551; MAUVIEL A, 1988, BIOCHEM J, V252, P247, DOI 10.1042/bj2520247; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PELTONEN J, 1991, J INVEST DERMATOL, V97, P240, DOI 10.1111/1523-1747.ep12480289; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; PHAN SH, 1985, J CLIN INVEST, V76, P241, DOI 10.1172/JCI111953; PHAN SH, 1992, EXP LUNG RES, V18, P29, DOI 10.3109/01902149209020649; PHAN SH, 1992, J IMMUNOL, V149, P103; PHAN SH, 1991, J CLIN INVEST, V87, P148, DOI 10.1172/JCI114964; PHAN SH, 1989, LUNG CELL BIOL, P907; PIGUET PF, 1989, J EXP MED, V170, P655, DOI 10.1084/jem.170.3.655; PIGUET PF, 1990, NATURE, V344, P245, DOI 10.1038/344245a0; RAGHOW R, 1989, J CLIN INVEST, V84, P1836, DOI 10.1172/JCI114369; REKHTER MD, 1993, AM J PATHOL, V143, P1634; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROLFE MW, 1992, AM J PHYSIOL, V263, pL536, DOI 10.1152/ajplung.1992.263.5.L536; ROLLINS BJ, 1992, AM J RESP CELL MOL, V7, P126, DOI 10.1165/ajrcmb/7.2.126; ROLLINS BJ, 1991, BLOOD, V78, P1112; SCHARFFETTER K, 1989, J INVEST DERMATOL, V93, P405, DOI 10.1111/1523-1747.ep12280295; SCHRIER DJ, 1983, AM REV RESPIR DIS, V127, P614, DOI 10.1164/arrd.1983.127.5.614; SMITH RE, 1995, J LEUKOCYTE BIOL, V57, P782, DOI 10.1002/jlb.57.5.782; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; STANDIFORD TJ, 1991, J BIOL CHEM, V266, P9912; STRIETER RM, 1993, ADV EXP MED BIOL, V351, P19; STRIETER RM, 1989, BIOCHEM BIOPH RES CO, V162, P694, DOI 10.1016/0006-291X(89)92366-8; STRIETER RM, 1989, J BIOL CHEM, V264, P10621; SUWABE A, 1988, AM J PATHOL, V132, P512; THRALL RS, 1981, AM J PATHOL, V105, P76; VALENTE AJ, 1988, BIOCHEMISTRY-US, V27, P4162, DOI 10.1021/bi00411a039; YOSHIMURA T, 1990, J IMMUNOL, V144, P2377; YOSHIMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P504, DOI 10.1016/0006-291X(91)91445-I; YOSHIMURA T, 1989, J IMMUNOL, V142, P1956; ZHANG K, 1994, LAB INVEST, V70, P192; ZHANG K, 1994, J IMMUNOL, V153, P4733; ZHANG K, 1994, AM J PATHOL, V145, P114	58	372	385	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17779	17784		10.1074/jbc.271.30.17779	http://dx.doi.org/10.1074/jbc.271.30.17779			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663511	hybrid			2022-12-27	WOS:A1996UY93500031
J	Ninomiya, Y; Kishimoto, T; Miyashita, Y; Kasai, H				Ninomiya, Y; Kishimoto, T; Miyashita, Y; Kasai, H			Ca2+-dependent exocytotic pathways in Chinese hamster ovary fibroblasts revealed by a caged-Ca2+ compound	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CHROMAFFIN CELLS; CAPACITANCE MEASUREMENTS; EXOCRINE PANCREAS; SECRETION; CA2+; ENDOCYTOSIS; MEMBRANE; RELEASE	Ca2+-dependent exocytosis and endocytosis of Chinese hamster ovary (CHO) fibroblasts were investigated using capacitance measurement and rapid photolysis of a caged-Ca2+ compound, dimethoxynitrophenamine tetrasodium salt. CHO cells exhibited large and fast in creases in membrane capacitance (1.9 +/- 1 picofarads, or 13 +/- 7% of total membrane area, mean +/- S.D., n = 37) upon Ca2+ jumps to [Ca2+](i) larger than 20 mu M. The fast exocytosis occurred with a delay (20-80 ms), and exhibited a rate constant that was strongly dependent on [Ca2+](i). The maximal rate constant of exocytosis was 2.8/s, and a half-maximal rate was achieved at 30 mu M. The fast exocytosis was followed by rapid endocytosis in 28% of the cells. The endocytosis often began after a delay of 0.5-2 s. Ca2+ jumps also induced stepwise increases in membrane capacitance of 10-134 femtofarads in 40% of the cells, indicating fusion of large vesicles with diameters of 0.4-1.5 mu m. The exocytosis of the large vesicles could selectively be induced with smaller Ca2+ jumps (6-20 mu M), and occurred slowly with a rate constant of 0.3/s. These data indicate that CHO fibroblasts possess Ca2+-dependent exocytotic mechanisms, Moreover, two parallel exocytotic pathways may exist reminiscent of those of neurons and endocrine cells. A kinetic model was constructed to account for the fast exocytosis of CHO cells.	UNIV TOKYO,FAC MED,DEPT PHYSIOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Miyashita, Yasushi/B-7171-2019	Miyashita, Yasushi/0000-0003-3496-8637; Kasai, Haruo/0000-0003-2327-9027				ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; BAUDET S, 1994, PRACTICAL GUIDE STUD, P94; DAN Y, 1992, NATURE, V359, P733, DOI 10.1038/359733a0; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; FIDLER N, 1989, BIOPHYS J, V56, P1153, DOI 10.1016/S0006-3495(89)82762-6; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HEINEMANN C, 1994, BIOPHYS J, V67, P2546, DOI 10.1016/S0006-3495(94)80744-1; IATRIDOU H, 1994, CELL CALCIUM, V15, P190, DOI 10.1016/0143-4160(94)90058-2; JOHNSTON PA, 1989, EMBO J, V8, P2836; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1996, IN PRESS J PHYSL; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; KISS JZ, 1994, EMBO J, V13, P5284, DOI 10.1002/j.1460-2075.1994.tb06862.x; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; MORIMOTO T, 1995, NEURON, V15, P689, DOI 10.1016/0896-6273(95)90156-6; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; ROSENBOOM H, 1994, P NATL ACAD SCI USA, V91, P5267, DOI 10.1073/pnas.91.12.5267; SUDHOF TC, 1995, NATURE, V756, P6357; THOMAS P, 1994, J CELL BIOL, V124, P667, DOI 10.1083/jcb.124.5.667; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; THOMASREETZ AC, 1994, FASEB J, V8, P209, DOI 10.1096/fasebj.8.2.7907072; ZUCKER RS, 1992, CELL CALCIUM, V13, P29, DOI 10.1016/0143-4160(92)90027-P	25	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17751	17754		10.1074/jbc.271.30.17751	http://dx.doi.org/10.1074/jbc.271.30.17751			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663485	hybrid			2022-12-27	WOS:A1996UY93500027
J	Scheid, MP; Duronio, V				Scheid, MP; Duronio, V			Phosphatidylinositol 3-OH kinase activity is not required for activation of mitogen-activated protein kinase by cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; WORTMANNIN; 3-KINASE; INSULIN; INHIBITOR; CELLS; RAS; PHOSPHORYLATION; NEUTROPHILS; PATHWAY	Hemopoietic cells respond to cytokines by initiating tyrosine phosphorylation of receptors and receptor-associated proteins, leading to the activation of numerous cytosolic and membrane associated enzymes, including phosphatidylinositol 3-OH kinase (PI 3-kinase). Recent reports have suggested that PIS-kinase may serve as an upstream activator of mitogen-activated protein (MAP) kinase. After stimulation with interleukin-3 and granulocyte-macrophage colony stimulating factor, we show here that inhibition of MAP kinase activity by two inhibitors of PI 3-kinase, wortmannin and LY-294002, does not correlate with their ability to inhibit PI 3-kinase or p70 S6 kinase phosphorylation. Complete inhibition of phosphatidylinositol 3,4,5-trisphosphate production occurred at approximately 100 nM WM or 25 mu M LY-294002, but at these concentrations, WM significantly inhibited MAP kinase activation, while LY-294002 had virtually no effect on MAP kinase activity. Furthermore, WM does not inhibit phorbol ester-mediated MAP kinase activation, but LY-294002 does. Together these results suggest WM and LY-294002 are differentially inhibiting enzymes other than PI 3-kinase that function upstream of MAP kinase.	UNIV BRITISH COLUMBIA,DEPT MED,JACK BELL RES CTR,VANCOUVER,BC V6H 3Z6,CANADA	University of British Columbia								ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; GOLD MR, 1994, J BIOL CHEM, V269, P5403; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3249; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; Nishioka N, 1995, FEBS LETT, V377, P393, DOI 10.1016/0014-5793(95)01382-2; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; POWIS G, 1994, CANCER RES, V54, P2419; SAKANAKA C, 1994, BIOCHEM BIOPH RES CO, V205, P18, DOI 10.1006/bbrc.1994.2623; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; UEHARA T, 1995, BIOCHEM BIOPH RES CO, V210, P574, DOI 10.1006/bbrc.1995.1698; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	36	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18134	18139		10.1074/jbc.271.30.18134	http://dx.doi.org/10.1074/jbc.271.30.18134			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663437	hybrid			2022-12-27	WOS:A1996UY93500082
J	Yin, M; Yang, SQ; Lin, HZ; Lane, MD; Chatterjee, S; Diehl, AM				Yin, M; Yang, SQ; Lin, HZ; Lane, MD; Chatterjee, S; Diehl, AM			Tumor necrosis factor alpha promotes nuclear localization of cytokine-inducible CCAAT/enhancer binding protein isoforms in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TNF RECEPTOR; 3 C/EBP ISOFORMS; PARTIAL-HEPATECTOMY; LIVER-REGENERATION; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; GEL-ELECTROPHORESIS; GENE-EXPRESSION; LEUCINE ZIPPER; KAPPA-B	Hepatocytes were cultured in the presence of recombinant tumor necrosis factor (TNF) alpha or mutated TNF alpha peptides that specifically activate either p55 or p75 TNF receptors to determine if TNF alpha can activate cytokine inducible CCAAT/enhancer binding protein (C/EBP) isoforms by post-transcriptional mechanisms that are initiated by TNF receptors, Within 5-10 min after treatment with any of these agents, nuclear concentrations of C/EBP beta and C/EBP delta double and remain 2-4-fold greater than control cultures for 30 min (p < 0.01), Consistent with these results, gel mobility shift assays demonstrate S-fold increased nuclear C/EBP beta- and C/EBP delta-DNA binding activity in TNF alpha-treated cells, and immunocytochemistry confirms rapid redistribution of these C/EBP isoforms into the nucleus, In contrast, mRNA and whole cell protein concentrations of C/EBP beta and delta are not altered by TNF alpha exposure, and nuclear concentrations of another C/EBP isoform, C/EBP alpha, are decreased by 80%, This novel evidence that TNF alpha initiates post-transcriptional activation of cytokine-inducible C/EBP isoforms identifies a mechanism that enables hepatocytes to respond immediately to inflammatory stress.	JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT BIOL CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT PEDIAT,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University								AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ALAM T, 1992, J BIOL CHEM, V267, P5021; BEG AA, 1994, ONCOGENE, V9, P1487; BRAISER A R, 1990, EMBO (European Molecular Biology Organization) Journal, V9, P3933; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU JY, 1983, MOL CELL BIOL, V3, P1013, DOI 10.1128/MCB.3.6.1013; CHUNG MK, 1990, CIRC RES, V67, P753, DOI 10.1161/01.RES.67.3.753; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DIEHL AM, 1994, GASTROENTEROLOGY, V106, P1625, DOI 10.1016/0016-5085(94)90420-0; DIEHL AM, 1994, HEPATOLOGY, V19, P447; Diehl AM, 1996, J BIOL CHEM, V271, P7343, DOI 10.1074/jbc.271.13.7343; DIEHL AM, 1995, HEPATOLOGY, V22, P252, DOI 10.1016/0270-9139(95)90379-8; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GEHR G, 1992, J IMMUNOL, V149, P911; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; HIGASHITSUJI H, 1995, J SURG RES, V58, P267, DOI 10.1006/jsre.1995.1042; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; MENON SD, 1995, J BIOL CHEM, V270, P18881; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MOHN KL, 1990, J BIOL CHEM, V265, P21914; NAUME B, 1991, J IMMUNOL, V146, P3045; OCONNELL MA, 1995, J BIOL CHEM, V270, P7399, DOI 10.1074/jbc.270.13.7399; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RAN B, 1995, J BIOL CHEM, V270, P18123; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SATOH M, 1991, Molecular Biotherapy, V3, P136; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WINSTON BW, 1995, J BIOL CHEM, V270, P27391, DOI 10.1074/jbc.270.46.27391	45	93	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17974	17978		10.1074/jbc.271.30.17974	http://dx.doi.org/10.1074/jbc.271.30.17974			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663327	hybrid			2022-12-27	WOS:A1996UY93500060
J	Fukudome, K; Kurosawa, S; StearnsKurosawa, DJ; He, XH; Rezaie, AR; Esmon, CT				Fukudome, K; Kurosawa, S; StearnsKurosawa, DJ; He, XH; Rezaie, AR; Esmon, CT			The endothelial cell protein C receptor - Cell surface expression and direct ligand binding by the soluble receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION; TISSUE FACTOR; ACTIVE-SITE; ACTIVATION; THROMBIN; THROMBOMODULIN; DISTINCT; CALCIUM; VECTOR	Expression of the endothelial cell protein C receptor (EPCR) gene in mammalian cells imparts the capacity to bind activated protein C (APC) or protein C. Immunochemical analysis of CCD41, apparently the murine homologue of EPCR, suggested centrosomal localization, raising questions about the location of the EPCR gene product and its role in protein C binding, In this study, we express a soluble form of EPCR, demonstrate EPCR expression on the cell surface, and direct binding between soluble EPCR and protein C/APC. Affinity purified polyclonal and a monoclonal antibody against EPCR bound to the cell surface of EPCR-transfected cells but not to control cells. A 49-kDa protein, a mass similar to soluble EPCR, was immunoprecipitated from the cell surface of endothelium and cells transfected with human EPCR but not from control cells, The FLAG(TM) antibody and APC bound to cells expressing an EPCR construct containing the FLAG(TM) epitope located in a putative extracellular domain, whereas an EPCR construct truncated just before the putative transmembrane domain produced only soluble EPCR antigen, Soluble EPCR inhibited APC binding to EPCR expressing cells in a concentration-dependent fashion, K-d (app) = 29 nM and bound to immobilized protein C in a Ca2+-dependent fashion. Thus, EPCR is a type 1 transmembrane protein that binds directly to APC.	UNIV OKLAHOMA,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA MED RES FDN,HLTH SCI CTR,DEPT BIOCHEM,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA MED RES FDN,HLTH SCI CTR,DEPT MOL BIOL,OKLAHOMA CITY,OK 73104; HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute	Fukudome, K (corresponding author), UNIV OKLAHOMA,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA MED RES FDN,HLTH SCI CTR,DEPT PATHOL,OKLAHOMA CITY,OK 73104, USA.			Stearns-Kurosawa, Deborah/0000-0003-2486-923X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANGALORE N, 1994, THROMB HAEMOSTASIS, V72, P465; BERG DT, 1992, NUCLEIC ACIDS RES, V20, P5485, DOI 10.1093/nar/20.20.5485; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; ESMON CT, 1995, TRENDS CARDIOVAS MED, V5, P141, DOI 10.1016/1050-1738(95)00054-D; ESMON CT, 1993, METHOD ENZYMOL, V222, P359; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FUKUDOME K, 1995, J BIOL CHEM, V270, P5571, DOI 10.1074/jbc.270.10.5571; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GREY ST, 1994, J IMMUNOL, V153, P3664; GRINNELL BW, 1994, GLYCOBIOLOGY, V4, P221, DOI 10.1093/glycob/4.2.221; KISIEL W, 1981, METHOD ENZYMOL, V80, P320; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; REGAN L, 1995, BLOOD, V86, P197; REGAN LM, 1996, J BIOL CHEM, V271, P17504; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; RIVARD GE, 1995, J PEDIATR-US, V126, P646, DOI 10.1016/S0022-3476(95)70369-1; ROTHBARTH K, 1993, J CELL SCI, V104, P19; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKIYA F, 1995, J BIOL CHEM, V270, P14325, DOI 10.1074/jbc.270.24.14325; STERNS DJ, 1988, J BIOL CHEM, V263, P826; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; YE J, 1991, J BIOL CHEM, V266, P23016	31	126	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17491	17498		10.1074/jbc.271.29.17491	http://dx.doi.org/10.1074/jbc.271.29.17491			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663475	hybrid			2022-12-27	WOS:A1996UX94300078
J	Gavin, AL; Hamilton, JA; Hogarth, PM				Gavin, AL; Hamilton, JA; Hogarth, PM			Extracellular mutations of non-obese diabetic mouse Fc gamma RI modify surface expression and ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; CROSS-LINKING; EPSILON-RI; CELL-LINE; HUMAN MONOCYTES; IGE RECEPTOR; MACROPHAGES; ASSOCIATION; ACTIVATION; SUBUNIT	The non-obese diabetic mouse (NOD) expresses a unique form of the high affinity receptor for IBG (Fc gamma RI), containing multiple mutations that result in substitutions and insertions of amino acids and a truncated cytoplasmic tail, As a result of these major changes, receptor affinity for IgG increases 10-fold over that of wild-type Fc gamma RI from BALB/c mice, while the specificity for ligand is retained, Kinetic analysis revealed that while the association rate of IgG with Fc gamma RI from NOD mice (Fc gamma RI-NOD) and Fc gamma RI from BALB/c mice (Fc gamma RI-BALB) is similar, IgG bound much more tightly to Fc gamma RI-NOD as revealed by a profoundly diminished dissociation rate. Transfection studies demonstrated that Fc gamma RI-NOD was expressed at one-tenth of the level of Fc gamma RI-BALB, Although mouse Fc gamma RI was previously not known to associate with the Fc epsilon RI gamma-subunit, transfection of COS-7 cells demonstrates that like human Fc gamma RI, mouse Fc gamma RI is also able to associate with this signaling subunit. Furthermore, expression levels of Fc gamma RI-NOD were not restored by the presence of the Fc epsilon RI gamma-subunit, The difference in the levels of expression was mapped to mutations in the extracellular region of Fc gamma RI-NOD as replacement of the extracellular domains with those of human Fc gamma RI or Fc gamma RI-BALB restored expression to that of human Fc gamma RI or Fc gamma RI-BALB.	AUSTIN HOSP,AUSTIN RES INST,HEIDELBERG,VIC 3084,AUSTRALIA; UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT MED,MELBOURNE,VIC 3050,AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Royal Melbourne Hospital; University of Melbourne				Hamilton, John A/0000-0002-9493-9224; Hogarth, Mark/0000-0002-0360-7890; Hamilton, James/0000-0002-4747-7071				ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEBETS JMH, 1990, J IMMUNOL, V144, P1304; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; GRAZIANO RF, 1989, MOL IMMUNOL, V26, P959; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Harlow E., 1988, ANTIBODIES LAB MANUA; HARRISON PT, 1994, J BIOL CHEM, V269, P24396; HIBBS ML, 1989, SCIENCE, V246, P1608, DOI 10.1126/science.2531918; HIBBS ML, 1994, J IMMUNOL, V152, P4466; HOGARTH PM, 1982, IMMUNOLOGY, V46, P135; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HULETT MD, 1995, J BIOL CHEM, V270, P21188, DOI 10.1074/jbc.270.36.21188; HULETT MD, 1993, EUR J IMMUNOL, V23, P640, DOI 10.1002/eji.1830230310; HULETT MD, 1991, J IMMUNOL, V147, P1863; HUTCHINSON MJ, 1995, BIOCHEM SOC T, V23, pS121, DOI 10.1042/bst023121s; KRUTMANN J, 1990, J IMMUNOL, V145, P1337; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LOPEZ AF, 1983, IMMUNOLOGY, V48, P503; MARSH CB, 1995, J IMMUNOL, V155, P3161; MASUDA M, 1993, J IMMUNOL, V151, P7188; OAKEY RJ, 1992, IMMUNOGENETICS, V35, P279, DOI 10.1007/BF00166834; OSMAN N, 1992, J IMMUNOL, V148, P1570; PELTZ G, 1988, MOL IMMUNOL, V25, P243, DOI 10.1016/0161-5890(88)90015-6; PFEFFERKORN LC, 1989, J BIOL CHEM, V264, P14112; PRINS JB, 1993, SCIENCE, V260, P695, DOI 10.1126/science.8480181; QUILLIAM AL, 1993, IMMUNOLOGY, V78, P358; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLL PR, 1992, J IMMUNOL, V149, P1751; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; SCHONEICH JT, 1992, J IMMUNOL, V148, P2181; SEARS DW, 1990, J IMMUNOL, V144, P371; SERREZE DV, 1993, P NATL ACAD SCI USA, V90, P9625, DOI 10.1073/pnas.90.20.9625; SIVO J, 1993, J LEUKOCYTE BIOL, V54, P451, DOI 10.1002/jlb.54.5.451; TATE BJ, 1992, IMMUNOL CELL BIOL, V70, P79, DOI 10.1038/icb.1992.12; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; UNKELESS JC, 1977, J EXP MED, V145, P931, DOI 10.1084/jem.145.4.931; UNKELESS JC, 1975, J EXP MED, V142, P1520, DOI 10.1084/jem.142.6.1520; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; VANDEWINKEL JGJ, 1990, SCAND J IMMUNOL, V31, P315; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WALKER WS, 1977, J IMMUNOL, V119, P367; WARMERDAM PAM, 1990, J EXP MED, V172, P19, DOI 10.1084/jem.172.1.19	44	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17091	17099		10.1074/jbc.271.29.17091	http://dx.doi.org/10.1074/jbc.271.29.17091			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663283	hybrid			2022-12-27	WOS:A1996UX94300019
J	Kempe, K; Hsu, FF; Bohrer, A; Turk, J				Kempe, K; Hsu, FF; Bohrer, A; Turk, J			Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; ISOLATED PANCREATIC-ISLETS; N-ACYLATED GLYCEROPHOSPHOLIPIDS; MEDIATED SIGNAL-TRANSDUCTION; ENZYMATIC-SYNTHESIS; INSULIN-SECRETION; ANANDAMIDE; IDENTIFICATION; PHOSPHOLIPIDS; LOCALIZATION	Arachidonylethanolamide (AEA) isolated from porcine brain binds to cannabinoid receptors, mimics nabinoid pharmacologic effects, and has been proposed as an endogenous cannabinoid receptor ligand, Demonstration of co-distribution of AEA and cannabinoid receptors in various brain regions could provide supportive evidence for this role, are have performed isotope dilution mass spectrometric measurements of AEA and have demonstrated AEA production by rat tissue homogenates in vitro from exogenous arachidonate and ethanolamine, No detectable endogenous AEA (<3.5 pmol/g of tissue) was observed in fresh rat brain, whether or not inhibitors of AEA hydrolysis were present during tissue processing, AEA (>1 nmol/g) was produced during saponification of brain phospholipid extracts, This appears not to reflect hydrolysis of N-arachidonylethanolamine phospholipid precursors of AEA, because Streptomyces chromfucsis phospholipase D, which is active against NAPE, failed to generate AEA from brain phospholipids despite substantial conversion of phospholipids to phosphatidic acid. Such experiments suggested that the abundance of N-arachidonylethanolamine phospholipid in fresh rat brain may be less than 1 in 10(6) phospholipid molecules, AEA generated during saponification of tissue phospholipids appears to arise from base-catalyzed aminolysis of arachidonate containing glycerolipids, because AEA was produced from synthetic (1-stearoyl, 2-arachidonoyl)-phosphatidylethanolamine under saponification conditions, and the amount produced increased 300-fold when free ethanolamine was included in the hydrolysis solution, Although AEA was not detectable (<0.17 pmol/mg of protein) in fresh rat brain, AEA accumulated post mortem to levels of 126 pmol/mg of brain protein. These findings do not exclude the possibility that AEA is rapidly synthesized and degraded locally in vivo, but they indicate that the AEA content of fresh rat brain and of NAPE precursors from which AEA might be derived are exceedingly low and that AEA can be produced artifactually from biological materials.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV ENDOCRINOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV DIABET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV METAB & LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV METAB & LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV DIABET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV ENDOCRINOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)				Hsu, Fong-Fu/0000-0001-5368-0183	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034388] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR-00954] Funding Source: Medline; NIDDK NIH HHS [R37-DK-34388] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURNSTEIN S, 1991, BIOCHEM PHARMACOL, V27, P1275; CHILDERS SR, 1994, BIOCHEM PHARMACOL, V47, P711, DOI 10.1016/0006-2952(94)90134-1; COREY EJ, 1984, J AM CHEM SOC, V106, P1503, DOI 10.1021/ja00317a064; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEUTSCH DG, 1993, BIOCHEM PHARMACOL, V46, P791, DOI 10.1016/0006-2952(93)90486-G; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; DEVANE WA, 1994, TRENDS PHARMACOL SCI, V15, P40, DOI 10.1016/0165-6147(94)90106-6; DEVANE WA, 1992, SCIENCE, V258, P946; DEWEY WL, 1986, PHARMACOL REV, V38, P151; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; EVANS DM, 1994, J PHARMACOL EXP THER, V268, P1271; FELDER CC, 1992, MOL PHARMACOL, V42, P838; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P7656, DOI 10.1073/pnas.90.16.7656; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; HERKENHAM M, 1990, P NATL ACAD SCI USA, V87, P1932, DOI 10.1073/pnas.87.5.1932; HOLLISTER LE, 1986, PHARMACOL REV, V38, P1; IVERSEN L, 1994, NATURE, V372, P619, DOI 10.1038/372619a0; JOHNSON DE, 1993, PROSTAG LEUKOTR ESS, V48, P429, DOI 10.1016/0952-3278(93)90048-2; KRUSZKA KK, 1994, J BIOL CHEM, V269, P14345; LAYCHOCK SG, 1986, BIOCHEM PHARMACOL, V35, P2003, DOI 10.1016/0006-2952(86)90733-1; MACKIE K, 1993, MOL PHARMACOL, V44, P498; MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1991, PHARMACOL BIOCHEM BE, V40, P461, DOI 10.1016/0091-3057(91)90347-5; NATARAJAN V, 1985, BIOCHIM BIOPHYS ACTA, V835, P426, DOI 10.1016/0005-2760(85)90111-0; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P5339, DOI 10.1021/bi00071a009; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P13499, DOI 10.1021/bi00212a015; REICHMAN M, 1991, MOL PHARMACOL, V40, P547; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; SCHMID PC, 1986, CHEM PHYS LIPIDS, V41, P195, DOI 10.1016/0009-3084(86)90022-8; TURK J, 1985, BIOCHIM BIOPHYS ACTA, V835, P1, DOI 10.1016/0005-2760(85)90023-2; TURK J, 1984, BIOCHIM BIOPHYS ACTA, V794, P125, DOI 10.1016/0005-2760(84)90305-9; TURK J, 1985, BIOCHIM BIOPHYS ACTA, V834, P23, DOI 10.1016/0005-2760(85)90172-9; UEDA N, 1995, J BIOL CHEM, V270, P23823, DOI 10.1074/jbc.270.40.23823; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x; WOLF BA, 1986, J BIOL CHEM, V261, P3510; WREN JJ, 1964, BIOCHEM J, V90, pP3	42	99	101	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17287	17295		10.1074/jbc.271.29.17287	http://dx.doi.org/10.1074/jbc.271.29.17287			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663381	hybrid			2022-12-27	WOS:A1996UX94300049
J	MacColl, R; Eisele, LE; Williams, EC; Bowser, SS				MacColl, R; Eisele, LE; Williams, EC; Bowser, SS			The discovery of a novel R-phycoerythrin from an Antarctic Red Alga	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIN ATTACHMENT SITES; ENERGY-TRANSFER; GAMMA-SUBUNITS; CYANOBACTERIUM; SYNECHOCOCCUS	A novel biliprotein, named R-phycoerythrin IV, has been discovered, It absorbs blue light better than any other known red algal biliprotein. The protein was found in Phyllophora antarctica, a benthic macroalga, which grows beneath the coastal waters of McMurdo Sound, Antarctica. Fluorescence emission and fluorescence excitation polarization spectroscopy demonstrated that R-phycoerythrin IV behaved as a typical R-phycoerythrin in the functioning of energy migration and has an emission maximum at 577 nn. The circular dichroism (CD) spectrum of the chromophores was compared with visible absorption spectrum, and both were deconvoluted. This process showed the energy states of various individual chromophores. The molecular weight of the protein suggested a alpha(6) beta(6) gamma polypeptide structure, and far UV CD studies revealed polypeptides with highly alpha-helical secondary structures, Dynamic light scattering indicated that the protein had a 5.54 nm radius, and its shape was nonspherical, R-phycoerythrin was also purified from a second benthic Antarctic red alga, Iridaea cordata. Its spectroscopic properties were similar to those of some R-phycoerythrins from nonpolar regions. The unique spectroscopic properties of R-phycocerythrin IV may help enable the alga to occupy its niche deeper in the water column than the red alga that has the typical R-phycoerythrin.	SUNY ALBANY,DEPT BIOMED SCI,ALBANY,NY 12201	State University of New York (SUNY) System; State University of New York (SUNY) Albany	MacColl, R (corresponding author), NYSDOH,WADSWORTH CTR,POB 509,ALBANY,NY 12201, USA.							ALBERTE RS, 1984, PLANT PHYSIOL, V75, P732, DOI 10.1104/pp.75.3.732; DAGNOLO E, 1994, PHYTOCHEMISTRY, V35, P693, DOI 10.1016/S0031-9422(00)90589-2; GANTT E, 1981, ANNU REV PLANT PHYS, V32, P327, DOI 10.1146/annurev.pp.32.060181.001551; HOLZWARTH AR, 1991, PHYSIOL PLANTARUM, V83, P518, DOI 10.1111/j.1399-3054.1991.tb00129.x; KLOTZ AV, 1985, J BIOL CHEM, V260, P4856; KURSAR TA, 1981, P NATL ACAD SCI USA, V78, P1; MacColl R., 1987, P1; Maccoll R, 1991, J Fluoresc, V1, P135, DOI 10.1007/BF00865209; MACCOLL R, 1995, J BIOL CHEM, V270, P27555, DOI 10.1074/jbc.270.46.27555; MILLER KA, 1991, AM ZOOL, V31, P35; NAGY JO, 1985, J BIOL CHEM, V260, P4864; ONG LJ, 1991, J BIOL CHEM, V266, P9515; ONG LJ, 1984, SCIENCE, V224, P80, DOI 10.1126/science.224.4644.80; RENNIS DS, 1992, PHYCOLOGIA, V31, P192, DOI 10.2216/i0031-8884-31-2-192.1; SCHEER H, 1981, ANGEW CHEM INT EDIT, V20, P241, DOI 10.1002/anie.198102411; Sidler W., 1988, PHOTOSYNTHETIC LIGHT, P49; STADNICHUK I N, 1984, Molekulyarnaya Biologiya (Moscow), V18, P343; STADNICHUK IN, 1993, J PHOTOCH PHOTOBIO B, V18, P169, DOI 10.1016/1011-1344(93)80059-I; STADNICHUK IN, 1993, PHOTOSYNTHETICA, V29, P55; WOOD AM, 1985, NATURE, V316, P353; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YU MH, 1981, PLANT PHYSIOL, V68, P482, DOI 10.1104/pp.68.2.482; ZILINSKAS BA, 1986, PHOTOSYNTH RES, V10, P7, DOI 10.1007/BF00024183	23	38	42	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17157	17160		10.1074/jbc.271.29.17157	http://dx.doi.org/10.1074/jbc.271.29.17157			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663533	hybrid			2022-12-27	WOS:A1996UX94300029
J	Revan, S; Montesinos, MC; Naime, D; Landau, S; Cronstein, BN				Revan, S; Montesinos, MC; Naime, D; Landau, S; Cronstein, BN			Adenosine A(2) receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; SUPEROXIDE ANION GENERATION; CHEMOATTRACTANT RECEPTORS; A2 RECEPTORS; CYCLIC-AMP; TRANSDUCTION; MODULATION; AFFINITY; SUBUNITS; OXIDASE	Adenosine modulates generation of superoxide anion by neutrophils via occupancy of specific adenosine A, receptors, However, the intracellular signal transduction pathways by which occupancy of neutrophil aden osine A, receptors inhibits superoxide anion generation (O-2 (radical ion)) are not web understood. We, therefore, tested the hypothesis that signaling at polymorphonuclear leukocyte (PMN) adenosine receptors proceeds via activation of a serine/threonine protein phosphatase (pp), Both the specific pp1 inhibitor calyculin A (10 nM) and the pp2A inhibitor okadaic acid (10 mu M) enhanced O-2(radical ion) generation (185 +/- 24 and 189 +/- 35% of control, respectively, p < 0.0001 for both, n = 8), as reported previously, Calyculin A, but not okadaic acid, completely reversed inhibition of stimulated O-2(radical ion) generation by the adenosine A2 receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA; IC50 = 30 nM ; p < 0.0001, analysis of variance). Calyculin A also reversed the adenosine receptor-mediated desensitization of bound chemoattractant receptors in neutrophils. Treatment of PMNs with NECA increased the pp1 activity of crude membrane preparations in a time- and dose-dependent fashion (EC(50) = 40 nM; p < 0.001, analysis of variance, n = 5). NECA inhibited cytosolic protein phosphatase activity by 78 +/- 12% (p < 0.003, n = 6) but did not shift pp1 catalytic subunit from cytosol to plasma membrane. Similar changes were observed in neutrophil cytoplasts depleted of organelles and nucleus. Moreover, the selective protein kinase A inhibitor KT5720 (10 mu M) reversed the capacity of dibutyryl cAMP but mt NECA to increase pp1 activity (p < 0.01, n = 5) in keeping with its effects on O-2 generation. Western blot analysis of PMN subcellular fractions demonstrated the presence of pp1 alpha and pp1 gamma 1 but not pp1 gamma(2) isotypes in both cytosol and plasma membrane but not in azurophil or specific granules. We conclude from these studies that signal transduction by adenosine in PMN proceeds via a novel pathway: cAMP-independent activation of a serine/threonine protein phosphatase in the plasma membrane.	NYU, MED CTR, DEPT MED, DIV RHEUMATOL, NEW YORK, NY 10016 USA	New York University			Cronstein, Bruce N/D-4678-2011; Montesinos, M. Carmen/G-8852-2015	Cronstein, Bruce N/0000-0002-4295-7383; Montesinos, M. Carmen/0000-0003-1801-311X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR011949, R01AR011949, R01AR041911] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19721] Funding Source: Medline; NIAMS NIH HHS [AR11949, AR/AI41911] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHUN YS, 1994, P NATL ACAD SCI USA, V91, P3319, DOI 10.1073/pnas.91.8.3319; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CRONSTEIN BN, 1983, J EXP MED, V158, P1160, DOI 10.1084/jem.158.4.1160; CRONSTEIN BN, 1988, BIOCHEM J, V252, P709, DOI 10.1042/bj2520709; CRONSTEIN BN, 1985, J IMMUNOL, V135, P1366; CRONSTEIN BN, 1992, BIOCHEM J, V281, P631, DOI 10.1042/bj2810631; CRONSTEIN BN, 1992, BLOOD, V80, P1052; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; CRONSTEIN BN, 1992, J IMMUNOL, V148, P2201; CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547; CURNUTTE JT, 1994, J BIOL CHEM, V269, P10813; DING JB, 1992, J BIOL CHEM, V267, P6442; DING JB, 1993, J BIOL CHEM, V268, P17326; FIRESTEIN GS, 1995, J IMMUNOL, V154, P326; GOLDSTEIN IM, 1975, J CLIN INVEST, V56, P1155, DOI 10.1172/JCI108191; GUPTA RC, 1993, J PHARMACOL EXP THER, V266, P16; HUBBARD MJ, 1991, METHOD ENZYMOL, V201, P414; JESAITIS AJ, 1988, J CELL BIOL, V107, P921, DOI 10.1083/jcb.107.3.921; JESAITIS AJ, 1984, J CELL BIOL, V98, P1378, DOI 10.1083/jcb.98.4.1378; KIRNBAUER R, 1991, J INVEST DERMATOL, V96, P484, DOI 10.1111/1523-1747.ep12470181; KITAGAWA Y, 1990, BIOCHEM BIOPH RES CO, V171, P230, DOI 10.1016/0006-291X(90)91381-2; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; LU DJ, 1993, BLOOD CELLS, V19, P343; LU DJ, 1992, AM J PHYSIOL, V262, pC39, DOI 10.1152/ajpcell.1992.262.1.C39; MARQUARDT DL, 1994, AGENTS ACTIONS, V43, P7, DOI 10.1007/BF02005755; MATEO J, 1995, J NEUROCHEM, V64, P77; PHILIPS MR, 1991, J BIOL CHEM, V266, P1289; ROOS D, 1983, J CELL BIOL, V97, P368, DOI 10.1083/jcb.97.2.368; SALMON JE, 1990, J IMMUNOL, V145, P2235; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TUCKER AL, 1993, CARDIOVASC RES, V27, P62, DOI 10.1093/cvr/27.1.62; VANCALKER D, 1979, J NEUROCHEM, V33, P999, DOI 10.1111/j.1471-4159.1979.tb05236.x	35	80	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17114	17118		10.1074/jbc.271.29.17114	http://dx.doi.org/10.1074/jbc.271.29.17114			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663342	hybrid			2022-12-27	WOS:A1996UX94300022
J	Tolbert, LM; Lameh, J				Tolbert, LM; Lameh, J			Human muscarinic cholinergic receptor Hm1 internalizes via clathrin-coated vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRANSFERRIN RECEPTOR; 3RD CYTOPLASMIC LOOP; ACETYLCHOLINE-RECEPTORS; HUMAN-FIBROBLASTS; PLASMA-MEMBRANE; CAVEOLAE; LOCALIZATION; ENDOCYTOSIS; CELLS; DOMAIN	The mechanism by which muscarinic receptors internalize upon agonist exposure is poorly understood. To determine the endocytic pathways responsible for muscarinic receptor internalization, we have stably transfected human embryonic kidney (HEK 293) cells with the Hm1 (human muscarinic subtype 1) receptor tagged at the amino terminus with the epitope EYMPME. The subcellular location of the receptor was visualized by immunofluorescence confocal microscopy and quantified with the use of binding studies. The receptor redistributed into intracellular compartments following agonist treatment, This process was reversible upon removal of agonist and inhibited by antagonist, Acid treatment of the cells, which disrupts internalization via clathrin coated vesicles, inhibited carbachol-stimulated internalization. Phorbol 12-myristate 13-acetate, on the other hand, which inhibits caveolae-mediated endocytosis, had no effect on carbachol-induced endocytosis, Double-labeling confocal microscopy was used to characterize the intracellular vesicles containing Hm1 receptor following agonist treatment. The Hm1 receptor was shown to be colocalized with clathrin and alpha-adaptin, a subunit of the AP2 adaptor protein which links endocytosed proteins with clathrin in the intracellular vesicles, In addition, endosomes containing Hm1 also contained the transferrin receptor, which internalizes via clathrin-coated vesicles, In contrast, caveolin, the protein that comprises caveolae, did not colocalize with Hml in intracellular vesicles following agonist treatment, indicating that caveolae are not involved in the agonist-induced internalization of Hm1. These results indicate that agonist-induced internalization of the Hm1 receptor occurs via clathrin-coated vesicles in HEK cells.	UNIV CALIF SAN FRANCISCO,DEPT BIOPHARMACEUT SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [GM 08388, GM 43102] Funding Source: Medline; NIMH NIH HHS [K21 MH 00996] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008388, R01GM043102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K21MH000996] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; AOKI C, 1994, BRAIN RES, V650, P181, DOI 10.1016/0006-8993(94)91782-5; AOKI C, 1989, BRAIN RES, V493, P331, DOI 10.1016/0006-8993(89)91168-2; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; FONESCA ML, 1995, J BIOL CHEM, V270, P8902; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GARLAND EF, 1996, MOL PHARMACOL, V49, P438; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; HOPKINS CR, 1985, CELL, V40, P199, DOI 10.1016/0092-8674(85)90323-X; HUET C, 1980, CELL, V21, P429, DOI 10.1016/0092-8674(80)90479-1; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SARGENT PB, 1994, NEUROIMAGE, V1, P288, DOI 10.1006/nimg.1994.1013; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SILVA WI, 1986, J BIOL CHEM, V261, P4788; Slowiejko DM, 1996, J NEUROCHEM, V66, P186; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; SNENOYSCARIA AM, 1994, J CELL BIOL, V126, P353; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WONG DH, 1992, J CELL BIOL, V117, P1171, DOI 10.1083/jcb.117.6.1171	39	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17335	17342		10.1074/jbc.271.29.17335	http://dx.doi.org/10.1074/jbc.271.29.17335			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663385	hybrid			2022-12-27	WOS:A1996UX94300055
J	White, MA; Vale, T; Camonis, JH; Schaefer, E; Wigler, MH				White, MA; Vale, T; Camonis, JH; Schaefer, E; Wigler, MH			A role for the Ral guanine nucleotide dissociation stimulator in mediating Ras-induced transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-KINASE; ACTIVATION; PATHWAY; CELLS	Oncogenic Ras transforms cells through the activation of multiple downstream pathways mediated by separate effector molecules, one of which is Raf. Here we report the identification of a second ras-binding protein that can induce cellular transformation in parallel with activation of the Raf/mitogen-activated protein kinase cascade. The Ral guanine nucleotide dissociation stimulator (RalGDS) was isolated from a screen for Ras-binding proteins that specifically interact with a Ras effector-loop mutant, ras(12V,37G), that uncouples Ras from activation of Raf1. RalGDS, like ras(12V,37G), cooperates synergistically with mutationally activated Raf to induce foci of growth and morphologically transformed NIH 3T3 cells. RalGDS does not significantly enhance MAP kinase activation by activated Raf, suggesting that the cooperativity in focus formation is due to a distinct pathway acting downstream of Ras and parallel to Raf.	INST CURIE,INSERM U248,SECT RECH,F-75231 PARIS,FRANCE; PROMEGA CORP,MADISON,WI 53711; COLD SPRING HARBOR LABS,COLD SPRING HARBOR,NY 10021	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Promega Corporation; Cold Spring Harbor Laboratory	White, MA (corresponding author), UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.			Wigler, Michael/0000-0003-4396-1971				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHEN SY, 1994, ONCOGENE, V9, P2691; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FRECH M, 1990, J BIOL CHEM, V265, P6353; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	31	223	224	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16439	16442		10.1074/jbc.271.28.16439	http://dx.doi.org/10.1074/jbc.271.28.16439			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663585	hybrid, Green Accepted			2022-12-27	WOS:A1996UX12600003
J	Guo, QP; Wang, LH; Ruan, KH; Kulmacz, RJ				Guo, QP; Wang, LH; Ruan, KH; Kulmacz, RJ			Role of Val(509) in time-dependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ANTI-INFLAMMATORY DRUGS; G/H SYNTHASE-1; ASPIRIN; SITE; REQUIREMENTS; PURIFICATION; SYNTHETASE; TEMPLATES; PROTEIN	Prostaglandin H synthase (PGHS), a hey enzyme in prostanoid biosynthesis, exists as two isoforms. PGHS-1 is considered a basal enzyme; PGHS-2 is associated with inflammation and cell proliferation A number of highly selective inhibitors for PGHS-2 cyclooxygenase activity are known. Inhibition by these agents involves an initial reversible binding, followed by a time-dependent transition to a much higher affinity enzyme-inhibitor complex, making these agents potent and poorly reversible PGHS-2 inhibitors, To investigate the PGHS-2 structural features that influence the time-dependent action of the selective inhibitors, we have constructed a three-dimensional model of human PGHS-2 by homologous modeling, Examination of the PGHS-2 model identified Val(509) as a cyclooxygenase active site residue, that was not conserved in PGHS-1. Recombinant human PGHS-2 with Val(509) mutated to either Ile (the corresponding residue in PGHS-1), Ala, Glu, or Lys was expressed by transient transfection of COS-l cells to evaluate the effects of the mutations on cyclooxygenase activity and on inhibition by four agents reported to be selective for PGHS-2 (NS398, nimesulide, DuP697, and SC58125), All the recombinant proteins were of the expected mass, The mutants exhibited 45-210% of wild-type cyclooxygenase activity, with K-m values for arachidonate of 2.1-7.6 mu M (wild-type PGHS-2, 3.8 mu M), indicating that changes in position 509 had modest effects on cyclooxygenase catalysis, Each of the agents inhibited wild-type PGHS-2 in a Dime-dependent fashion, and all but nimesulide did the same for the V509A mutant, In contrast, the V509E and V509I PGHS-2 mutants, like recombinant human PGHS-1, did not show time-dependent inhibition with any of the agents, and the V509K mutant responded in a time-dependent manlier only to DuP697, Reversible inhibition was still observed with Val(509) mutants that did not show time-dependent inhibition, Thus, the side chain structure at position 509 markedly influenced the ability of PGHS-2 to undergo the time-dependent transition without removing inhibitor or substrate binding, These results indicate that Val(509) in PGHS-2 has a major role in the structural transition that underlies time-dependent inhibition by the isoform-selective agents.	UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV HEMATOL,HOUSTON,TX 77030; UNIV HOUSTON,DEPT BIOL,HOUSTON,TX 77204	University of Texas System; University of Texas Health Science Center Houston; University of Houston System; University of Houston					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052170] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 52170] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; Callan OH, 1996, J BIOL CHEM, V271, P3548; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Johnson JL, 1995, ARCH BIOCHEM BIOPHYS, V324, P26, DOI 10.1006/abbi.1995.9934; KULMACZ RJ, 1989, J BIOL CHEM, V264, P14136; KULMACZ RJ, 1985, J BIOL CHEM, V260, P2572; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; MANCINI JA, 1995, J BIOL CHEM, V270, P29372, DOI 10.1074/jbc.270.49.29372; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; OUELLET M, 1995, BIOCHEM J, V306, P247, DOI 10.1042/bj3060247; PERCIVAL MD, 1994, ARCH BIOCHEM BIOPHYS, V315, P111, DOI 10.1006/abbi.1994.1478; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REN Y, 1995, ARCH BIOCHEM BIOPHYS, V316, P751, DOI 10.1006/abbi.1995.1100; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; ROTH GJ, 1983, BIOCHEMISTRY-US, V22, P4672, DOI 10.1021/bi00289a010; RUAN KH, 1994, PROTEIN ENG, V7, P1345, DOI 10.1093/protein/7.11.1345; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SMITH WL, 1994, MET IONS BIOL SYST, V30, P163; STANFORD N, 1977, PROSTAGLANDINS, V13, P669, DOI 10.1016/0090-6980(77)90237-4; WENNOGLE LP, 1995, FEBS LETT, V371, P315, DOI 10.1016/0014-5793(95)00930-8	32	112	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19134	19139		10.1074/jbc.271.32.19134	http://dx.doi.org/10.1074/jbc.271.32.19134			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702589	hybrid			2022-12-27	WOS:A1996VB68400023
J	Caldeira, J; Feicht, R; White, H; Teixeira, M; Moura, JJG; Simon, H; Moura, I				Caldeira, J; Feicht, R; White, H; Teixeira, M; Moura, JJG; Simon, H; Moura, I			EPR and Mossbauer spectroscopic studies on enoate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; DESULFOVIBRIO-GIGAS; 4FE-4S CLUSTER; ACTIVATED ACONITASE; PROTEIN; HYDROGENASE; BINDING; CENTERS; INTERCONVERSIONS; DEHYDRATASE	Enoate reductase (EC 1.3.1.31) is a protein isolated from Clostridium tyrobutyricum that contains iron, labile sulfide, FAD, and FMN. The enzyme reduces the alpha,beta carbon-carbon double bond of nonactivated 2-enoates and in a reversible way that of 2-enals at the expense of NADH or reduced methyl viologen, UV-visible and EPR potentiometric titrations detect a semiquinone species in redox intermediate states characterized by an isotropic EPR signal at g = 2.0 without contribution at 580 nm, EPR redox titration shows two widely spread mid-point redox potentials (-190 and -350 mV at pH 7.0), and a nearly stoichiometric amount of this species is detected, The data suggest the semiquinone radical has an anionic nature. In the reduced form, the [Fe-S] moiety is characterized by a single rhombic EPR spectrum, observed in a wide range of temperatures (4.2-60 K) with g values at 2.013, 1.943, and 1.860 (-180 mV at pH 7.0). The g(max) value is low when compared with what has been reported for other iron-sulfur clusters, Mossbauer studies reveal the presence of a [4Fe-4S](+2/+1) center, One of the subcomponents of the spectrum shows an unusually large value of quadrupole splitting (ferrous character) in both the oxidized and reduced states, Substrate binding to the reduced enzyme induces subtle changes in the spectroscopic Mossbauer parameters, The Mossbauer data together with known kinetic information suggest the involvement of this iron-sulfur center in the enzyme mechanism.	UNIV NOVA LISBOA,FAC CIENCIAS & TECNOL,DEPT QUIM,P-2825 MONTE DE CAPARICA,PORTUGAL; UNIV NOVA LISBOA,FAC CIENCIAS & TECNOL,CTR QUIM FINA & BIOTECNOL,P-2825 MONTE DE CAPARICA,PORTUGAL; INST SUPER CIENCIAS SAUDE SUL,P-2825 MONTE DE CAPARICA,PORTUGAL; TECH UNIV MUNICH,LEHRSTUHL ORGAN CHEM & BIOCHEM,D-85747 GARCHING,GERMANY; UNIV NOVA LISBOA,INST TECNOL QUIM & BIOL,P-2780 OEIRAS,PORTUGAL	Universidade Nova de Lisboa; Universidade Nova de Lisboa; Technical University of Munich; Universidade Nova de Lisboa			Teixeira, Miguel/M-1509-2019; Moura, José J G/D-6426-2013; Teixeira, Miguel/A-9098-2011; Moura, Isabel/D-6339-2013; Caldeira, Jorge/A-5702-2016	Teixeira, Miguel/0000-0003-4124-6237; Moura, José J G/0000-0002-4726-2388; Teixeira, Miguel/0000-0003-4124-6237; Moura, Isabel/0000-0003-0971-4977; Caldeira, Jorge/0000-0002-0976-2111				BADER J, 1983, FEMS MICROBIOL LETT, V20, P171; BARBER MJ, 1992, J BIOL CHEM, V267, P6611; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BUHLER M, 1982, H-S Z PHYSIOL CHEM, V363, P609, DOI 10.1515/bchm2.1982.363.1.609; BUHLER M, 1981, THESIS TU MUNICH GER; CALDEIRA J, 1994, EUR J BIOCHEM, V220, P987, DOI 10.1111/j.1432-1033.1994.tb18703.x; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CHRISTNER JA, 1983, J BIOL CHEM, V258, P1157; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; DUTTON PL, 1971, BIOCHIM BIOPHYS ACTA, V226, P63, DOI 10.1016/0005-2728(71)90178-2; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; EMPTAGE MH, 1988, METAL CLUSTERS PROTE, P343; FLINT DH, 1993, J BIOL CHEM, V268, P14732; FRANKLUND CV, 1993, J BACTERIOL, V175, P3002, DOI 10.1128/JB.175.10.3002-3012.1993; GEARY PJ, 1981, BIOCHEM J, V195, P199, DOI 10.1042/bj1950199; GERLT JA, 1992, J AM CHEM SOC, V114, P5929; GIESEL H, 1983, ARCH MICROBIOL, V135, P51, DOI 10.1007/BF00419482; KENT TA, 1985, J BIOL CHEM, V260, P6871; KENT TA, 1982, P NATL ACAD SCI-BIOL, V79, P1096, DOI 10.1073/pnas.79.4.1096; KUNO S, 1985, BIOL CHEM H-S, V366, P463, DOI 10.1515/bchm3.1985.366.1.463; LAMPREIA J, 1990, EUR J BIOCHEM, V188, P653, DOI 10.1111/j.1432-1033.1990.tb15447.x; MIDDLETON P, 1980, EUR J BIOCHEM, V104, P289, DOI 10.1111/j.1432-1033.1980.tb04427.x; MIDDLETON P, 1978, EUR J BIOCHEM, V88, P135, DOI 10.1111/j.1432-1033.1978.tb12430.x; MOURA JJG, 1994, METHOD ENZYMOL, V243, P165; MOURA JJG, 1982, J BIOL CHEM, V257, P6259; MOURA L, 1990, J AM CHEM SOC, V110, P1075; PALMER G, 1971, FLAVINS FLAVOPROTEIN; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; SCHERF U, 1993, EUR J BIOCHEM, V215, P421, DOI 10.1111/j.1432-1033.1993.tb18049.x; SEDLMAIER H, 1979, FEBS LETT, V100, P129, DOI 10.1016/0014-5793(79)81147-3; SIMON H, 1985, ANGEW CHEM INT EDIT, V24, P539, DOI 10.1002/anie.198505391; SIMON H, 1991, CHEM BIOCH FLAVOENZY, V2, P317; SWITZER R L, 1989, Biofactors, V2, P77; TEIXEIRA M, 1990, EUR J BIOCHEM, V189, P381, DOI 10.1111/j.1432-1033.1990.tb15499.x; TEIXEIRA M, 1989, J BIOL CHEM, V264, P16435; THANOS I, 1988, BIOL CHEM H-S, V369, P451, DOI 10.1515/bchm3.1988.369.1.451; TISCHER W, 1979, EUR J BIOCHEM, V97, P103, DOI 10.1111/j.1432-1033.1979.tb13090.x; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0	40	11	11	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18743	18748		10.1074/jbc.271.31.18743	http://dx.doi.org/10.1074/jbc.271.31.18743			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702530	hybrid			2022-12-27	WOS:A1996VB68300068
J	Wilkins, PP; McEver, RP; Cummings, RD				Wilkins, PP; McEver, RP; Cummings, RD			Structures of the O-glycans on P-selectin glycoprotein ligand-1 from HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; LINKED OLIGOSACCHARIDES; MYELOID CELLS; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; EXPRESSION CLONING; TYROSINE SULFATION; HUMAN-GRANULOCYTES; MOLECULAR-CLONING; HUMAN NEUTROPHILS; CYSTIC-FIBROSIS	P-selectin glycoprotein ligand-1 (PSGL-1) is a disulfide-bonded homodimeric mucin-like glycoprotein on leukocytes that interacts with both P- and E-selectin. In this report we describe the structures of the Ser/Thr-linked O-glycans of PSGL-1 synthesized by HL-60 cells metabolically radiolabeled with H-3-sugar precursors. In control studies, the O-glycans on CD43 (leukosialin), a mucin-like glycoprotein also expressed by HL 60 cells, were analyzed and compared to those of PSGL-1, O-Glycans were released from Ser/Thr residues by mild base/borohydride treatment of purified glycoproteins, and glycan structures were determined by a combination of techniques, In contrast to expectations, PSGL-1 is not heavily fucosylated; a majority of the O-glycans are disialylated or neutral forms of the core-2 tetrasaccharide GaI beta 1-4GlcNAc beta 1-6(Gal beta 1-->3)GaINAcOH, A minority of the O-glycans are alpha-1,3-fucosylated that occur as two major species containing the sialyl Lewis x antigen; one species is a disialylated, monofucosylated glycan, [GRAPHICS] and the other is a monosialylated, trifucosylated glycan having a polylactosamine backbone. [GRAPHICS] CD43 lacks the fucosylated glycans found on PSGL-1 and is enriched for the nonfucosylated, disialylated core-2 hexasaccharide. These results demonstrate that PSGL-1 contains unique fucosylated O-glycans that are predicted to be critical for high affinity interactions between PSGL-1 and selectins.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,HLTH SCI CTR,W K WARREN MED RES INST,OKLAHOMA CITY,OK 73190; UNIV OKLAHOMA,HLTH SCI CTR,DEPT MED,OKLAHOMA CITY,OK 73190; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73190	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BREG J, 1987, EUR J BIOCHEM, V168, P57, DOI 10.1111/j.1432-1033.1987.tb13387.x; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; CECCONI O, 1994, J BIOL CHEM, V269, P15060; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; CUMMINGS RD, 1993, GLYCOBIOLOGY PRACTIC, P243; CUMMINGS RD, 1989, METHOD CELL BIOL, V32, P142; DeBoseBoyd R, 1996, EXP PARASITOL, V82, P1, DOI 10.1006/expr.1996.0001; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; FUKUDA M, 1984, J BIOL CHEM, V259, P925; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P11104; IMAI Y, 1993, NATURE, V361, P555; IYER RN, 1971, ARCH BIOCHEM BIOPHYS, V142, P101, DOI 10.1016/0003-9861(71)90263-3; KOBATA A, 1993, GLYCOBIOLOGY PRACTIC, P165; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LI E, 1978, J BIOL CHEM, V253, P7762; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; LI SC, 1975, J BIOL CHEM, V250, P6786; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; LOWE JB, 1991, J BIOL CHEM, V266, P17467; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NELSON RM, 1993, BLOOD, V82, P3253; Nelson RM, 1995, ANNU REV CELL DEV BI, V11, P601, DOI 10.1146/annurev.cellbio.11.1.601; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; NORMAN KE, 1995, BLOOD, V86, P4417, DOI 10.1182/blood.V86.12.4417.bloodjournal86124417; PATEL KD, 1995, J CLIN INVEST, V96, P1887, DOI 10.1172/JCI118234; PATEL TP, 1994, BIOCHEMISTRY-US, V33, P14815, DOI 10.1021/bi00253a021; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SANO M, 1992, J BIOL CHEM, V267, P1522; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SKINNER MP, 1989, BIOCHEM BIOPH RES CO, V164, P1373, DOI 10.1016/0006-291X(89)91821-4; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; SRIVATSAN J, 1992, J BIOL CHEM, V267, P20196; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; SUEYOSHI S, 1994, J BIOL CHEM, V269, P32342; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VANDENEIJNDEN DH, 1995, BIOCHEM SOC T, V23, P175, DOI 10.1042/bst0230175; VARKI A, 1994, METHOD ENZYMOL, V230, P16; VARKI A, 1983, J BIOL CHEM, V258, P2808; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; YUREWICZ EC, 1987, J BIOL CHEM, V262, P4733; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	61	234	244	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18732	18742		10.1074/jbc.271.31.18732	http://dx.doi.org/10.1074/jbc.271.31.18732			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702529	hybrid			2022-12-27	WOS:A1996VB68300067
J	Zhang, J; Ferguson, SG; Barak, LS; Menard, L; Caron, MG				Zhang, J; Ferguson, SG; Barak, LS; Menard, L; Caron, MG			Dynamin and beta-arrestin reveal distinct mechanisms for G protein-coupled receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE FORMATION; ANGIOTENSIN-II RECEPTOR; ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; SEQUESTRATION; MUTANT; ENDOCYTOSIS; PHOSPHORYLATION; EXPRESSION	The process of agonist-promoted internalization (sequestration) of G protein-coupled receptors (GPCRs) is intimately linked to the regulation of GPCR responsiveness, Following agonist-mediated desensitization, sequestration of GPCR is presumably associated with the dephosphorylation and recycling of functional receptors, However, the exact mechanisms responsible for GPCR sequestration, even for the prototypic beta(2)-adrenergic receptor (beta(2)AR), have remained controversial, We demonstrate here that dynamin, a GTPase that regulates the formation and internalization of clathrin-coated vesicles, is essential for the agonist-promoted sequestration of the beta(2)AR, suggesting that the beta(2)AR internalizes via the clathrin-coated vesicle-mediated endocytic pathway, In contrast, internalization of the angiotensin II type 1A receptor (AT(1A)R), another typical GPCR, does not require dynamin, In addition, the AT(1A)R internalizes independent of the function of beta-arrestin, a critical component for beta(2)AR cellular trafficking, but additional AT(1A)Rs are mobilized to the dynamin-dependent pathway upon overexpression of beta- arrestin. These findings demonstrate that GPCRs can utilize distinct endocytic pathways, distinguishable by dynamin and beta-arrestin, and that beta-arrestins function as adaptor proteins specifically targeting GPCRs for dynamin-dependent endocytosis via clathrin-coated vesicles.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University; Duke University					NINDS NIH HHS [NS 19576] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASHWORTH R, 1995, P NATL ACAD SCI USA, V92, P512, DOI 10.1073/pnas.92.2.512; BARAK LS, 1994, J BIOL CHEM, V269, P2790; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GUERVICH VV, 1995, J BIOL CHEM, V270, P720; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; INAGAMI T, 1994, J HYPERTENS, V12, pS83; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; MOORE RH, 1995, J CELL SCI, V108, P2983; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; Robinson MS, 1996, CELL, V84, P13, DOI 10.1016/S0092-8674(00)80988-5; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; SCHWINN DA, 1992, HEART CARDIOVASCULAR; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TAN PK, 1993, J CELL BIOL, V123, P1707, DOI 10.1083/jcb.123.6.1707; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; YU SS, 1993, J BIOL CHEM, V268, P337	36	397	406	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18302	18305		10.1074/jbc.271.31.18302	http://dx.doi.org/10.1074/jbc.271.31.18302			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702465	hybrid			2022-12-27	WOS:A1996VB68300003
J	Hsu, JL; Hsieh, YS; Tu, CK; OConnor, D; Nick, HS; Silverman, DN				Hsu, JL; Hsieh, YS; Tu, CK; OConnor, D; Nick, HS; Silverman, DN			Catalytic properties of human manganese superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-STEAROTHERMOPHILUS; THERMUS-THERMOPHILUS; ESCHERICHIA-COLI; PULSE-RADIOLYSIS; ENZYME; IRON; RESOLUTION; PROTEIN; MODEL	The depletion of superoxide catalyzed by human manganese superoxide dismutase (MnSOD) was observed spectrophotometrically by measuring the absorbance of superoxide at 250-280 nm following pulse radiolysis and by stopped-flow spectrophotometry. Catalysis showed an initial burst of activity lasting approximately 1 ms followed by the rapid emergence of a greatly inhibited catalysis of zero-order rate. These catalytic properties of human MnSOD are qualitatively similar to those reported for MnSOD from Thermus thermophilus (Bull, C,, Niederhoffer, E, C,, Yoshida, T,, and Fee, J, A. (1991) J, Am, Chem, Sec. 113, 4069-4076), However, there are significant quantitative differences; the emergence of the inhibited form is approximately 30-fold more rapid for human MnSOD. The turnover number for human MnSOD at pH 9.4 and 20 degrees C was k(cat) = 4 x 10(4) s(-1) and k(cat)/K-m 8 x 10(8) M(-1) s(-1), determined by a simulated fit of the model of Bull ct al, (1991) to the pulse radiolysis data, We also report that the maximum of the visible absorption spectrum of human MnSOD (epsilon(480) = 525 M(-1) cm(-1)) showed a strong dependence on pH that could be described by an ionization of pK(a) 9.4 +/- 0.1 with a maximum at low pH.	UNIV FLORIDA, CTR HLTH, COLL MED, DEPT THERAPEUT & PHARMACOL, GAINESVILLE, FL 32610 USA; UNIV FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA; UNIV TEXAS, CTR FAST KINET RES, AUSTIN, TX 78712 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Texas System; University of Texas Austin								BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BECK Y, 1987, NUCLEIC ACIDS RES, V15, P9076, DOI 10.1093/nar/15.21.9076; BECK Y, 1988, BIO-TECHNOL, V6, P930, DOI 10.1038/nbt0888-930; BEYER W, 1991, PROG NUCLEIC ACID RE, V40, P221; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; BULL C, 1991, J AM CHEM SOC, V113, P4069, DOI 10.1021/ja00011a003; BULL C, 1985, J AM CHEM SOC, V107, P3295, DOI 10.1021/ja00297a040; LAH MS, 1995, BIOCHEMISTRY-US, V34, P1646, DOI 10.1021/bi00005a021; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LUDWIG ML, 1991, J MOL BIOL, V219, P335, DOI 10.1016/0022-2836(91)90569-R; MCADAM ME, 1977, BIOCHEM J, V165, P71, DOI 10.1042/bj1650071; MCADAM ME, 1977, BIOCHEM J, V165, P81, DOI 10.1042/bj1650081; McCord JM, 1977, SUPEROXIDE SUPEROXID, P129; PARKER MW, 1988, J MOL BIOL, V199, P649, DOI 10.1016/0022-2836(88)90308-7; RABANI J, 1969, J PHYS CHEM-US, V73, P3736, DOI 10.1021/j100845a030; STODDARD BL, 1990, PROTEIN ENG, V4, P113, DOI 10.1093/protein/4.2.113; TAINER JA, 1991, STUDY ENZYMES, V2, P499; TANHAUSER SM, 1992, GENE, V117, P113, DOI 10.1016/0378-1119(92)90498-E; VALENTINE JS, 1975, J AM CHEM SOC, V97, P224, DOI 10.1021/ja00834a058; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	21	127	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17687	17691		10.1074/jbc.271.30.17687	http://dx.doi.org/10.1074/jbc.271.30.17687			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663465	hybrid			2022-12-27	WOS:A1996UY93500017
J	Tachibana, H; Ushio, Y; Krungkasem, C; Shirahata, S				Tachibana, H; Ushio, Y; Krungkasem, C; Shirahata, S			Inducing the loss of immunoglobulin lambda light chain production and the rearrangement of a previously excluded allele in human plasma B cell lines with concanavalin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINATION-ACTIVATING GENE; V(D)J RECOMBINATION; FEEDBACK INHIBITION; TRANSGENIC MICE; EXPRESSION; LYMPHOMA; MU; CARBOHYDRATE; ANTIBODIES; GENERATION	We investigated the expression of differential lambda light chains in human B cell lines secreting immunoglobulin (Ig), When these cell lines mere cultured with concanavalin A for a long period of time, a subpopulation of some but not all of these cell Lines was induced to express new lambda light chains replacing the original lambda chain (light chain shifting), Production of the new lambda chain, which replaces the original lambda chain, results from a VJ rearrangement at a previously excluded allele and a dramatic reduction of the original lambda chain transcript, although no difference was found in the level of heavy chain transcript, Recombination activating genes RAG-1 and RAG-2, which are normally expressed during specific early stages of lymphocyte development, were expressed in not only the light chain shifting-inducible lines but also in the non-inducible cells, Treatment of these Ig secreting cell lines with dibutyryl cAMP, which is known to enhance expression of the RAG genes, could not induce the creation of new lambda Light chain-producing cells from the inducible lines, suggesting that the expression of the two RAG genes is not sufficient for inducing new lambda light chain production. Concanavalin A induced a gradual but significant production lost of the original lambda chain in a subpopulation of the light chain shifting-inducible cells but not in the non-inducible cells, Association of new lambda light chain production with loss of original lambda chain raises the possibility that, when the RAG genes are expressed, concanavalin A may act on a novel intracellular mechanism controlling lambda light chain allelic exclusion in these plasma cell lines.			Tachibana, H (corresponding author), KYUSHU UNIV, GRAD SCH GENET RESOURCES TECHNOL, HIGASHI KU, 6-10-1 HAKOZAKI, FUKUOKA 812, JAPAN.							ABE T, 1994, J IMMUNOL, V152, P5504; AKAMATSU Y, 1994, J IMMUNOL, V153, P4520; BERINSTEIN N, 1989, SCIENCE, V244, P337, DOI 10.1126/science.2496466; CHANG LY, 1995, MOL IMMUNOL, V32, P49, DOI 10.1016/0161-5890(94)00135-N; CLARK EA, 1989, ADV CANCER RES, V52, P81; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; GURTSEVITCH VE, 1988, INT J CANCER, V41, P87, DOI 10.1002/ijc.2910410117; GUY K, 1990, INT J CANCER, V45, P109, DOI 10.1002/ijc.2910450120; HALLEK K, 1995, BLOOD, V85, P1289; HARADA K, 1991, J EXP MED, V173, P409, DOI 10.1084/jem.173.2.409; HARDY RR, 1986, P NATL ACAD SCI USA, V83, P1438, DOI 10.1073/pnas.83.5.1438; HESKETH R, 1990, J IMMUNOL, V145, P2571; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEVY S, 1989, J EXP MED, V170, P1, DOI 10.1084/jem.170.1.1; LING NR, 1987, LEUCOCYTE TYPING, V3, P302; MA A, 1992, EMBO J, V11, P2727, DOI 10.1002/j.1460-2075.1992.tb05338.x; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P9324, DOI 10.1073/pnas.87.23.9324; MURAKAMI H, 1985, IN VITRO CELL DEV B, V21, P593; NADKARNI JS, 1969, CANCER, V23, P64, DOI 10.1002/1097-0142(196901)23:1<64::AID-CNCR2820230107>3.0.CO;2-M; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OHARE MJ, 1982, PROTIDES BIOL FLUIDS, V30, P265; ROBBINS DL, 1990, ARTHRITIS RHEUM-US, V33, P1188; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; STIERNHOLM NBJ, 1995, J IMMUNOL, V154, P1748; STIERNHOLM NBJ, 1993, EUR J IMMUNOL, V23, P1501, DOI 10.1002/eji.1830230716; STORB U, 1987, ANNU REV IMMUNOL, V5, P151, DOI 10.1146/annurev.iy.05.040187.001055; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TACHIBANA H, 1993, BIOCHIM BIOPHYS ACTA, V1182, P257, DOI 10.1016/0925-4439(93)90067-B; TACHIBANA H, 1992, BIOCHEM BIOPH RES CO, V189, P625, DOI 10.1016/0006-291X(92)92246-T; TACHIBANA H, 1994, J BIOL CHEM, V269, P29061; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARNER GL, 1991, CELL IMMUNOL, V138, P404, DOI 10.1016/0008-8749(91)90164-7; WEAVER D, 1985, CELL, V42, P117, DOI 10.1016/S0092-8674(85)80107-0; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2	43	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17404	17410		10.1074/jbc.271.29.17404	http://dx.doi.org/10.1074/jbc.271.29.17404			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663345	hybrid			2022-12-27	WOS:A1996UX94300066
J	Goffin, V; Kinet, S; Ferrag, F; Binart, N; Martial, JA; Kelly, PA				Goffin, V; Kinet, S; Ferrag, F; Binart, N; Martial, JA; Kelly, PA			Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; EXTRACELLULAR DOMAIN; BIOLOGICAL PROPERTIES; LACTOGENIC HORMONES; BOVINE PROLACTIN; CELL-LINE; RECEPTOR; BINDING; BIOACTIVITY; CULTURES	Based on the assumption that the prolactin receptor (PRLR) is activated by PRL-induced sequential dimerization, potential human PRL (hPRL) antagonists were designed that sterically interfere with binding site 2. We previously reported the unexpected agonistic properties of these hPRL analogs in the rat Nb2 bioassay (Goffin, V., Struman, I., Mainfroid, V., Kinet, S., and Martial, J. A. (1994) J. Biol. Chem. 269, 3259832606). In order to investigate whether such paradoxical agonistic behavior might result from characteristic features of the Nb2 assay (e.g. species specificity), we transfected in the same cell system the cDNA encoding the PRLR from rat or human species along with reporter genes containing PRL-responsive DNA sequences. We characterized the agonistic, self-antagonistic and/or antagonistic effects of wild type rat PRL, wild type hPRL, and three hPRL analogs, mutated either at binding site 1 or at binding site 2. Our results clearly show that the agonistic/antagonistic properties of PRLs are species-specific. We thus propose different models of receptor activation, depending on the relative affinities of each hormonal binding site, which is directed by species specificity. Finally, this is the first report of hPRL binding site 2 analogs showing antagonistic properties on human and, to a lesser extent, rat receptors.	UNIV LIEGE, LAB MOLEC BIOL & GENET ENGN, B-4000 SART, BELGIUM	University of Liege	Goffin, V (corresponding author), INSERM U344, 156 RUE VAUGIRARD, F-75730 PARIS 15, FRANCE.		GOFFIN, Vincent/G-3322-2013; Binart, Nadine/F-2949-2013; Kelly, Paul/A-7951-2008	GOFFIN, Vincent/0000-0002-8021-3086; Binart, Nadine/0000-0002-5606-3866; kinet, sandrina/0000-0003-0699-108X				ALI S, 1991, J BIOL CHEM, V266, P20110; ASTRUC ME, 1995, ENDOCRINOLOGY, V136, P824, DOI 10.1210/en.136.3.824; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BIGNON C, 1994, J BIOL CHEM, V269, P3318; BINDER L, 1990, MOL ENDOCRINOL, V4, P1060, DOI 10.1210/mend-4-7-1060; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN WY, 1995, MOL ENDOCRINOL, V9, P292, DOI 10.1210/me.9.3.292; CHEN WY, 1994, J BIOL CHEM, V269, P15892; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CLARKSON T, 1995, SCIENCE, V267, P383; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DATTANI MT, 1995, J BIOL CHEM, V270, P9222, DOI 10.1074/jbc.270.16.9222; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GERTLER A, 1993, FEBS LETT, V319, P277, DOI 10.1016/0014-5793(93)80562-9; GOFFIN V, 1994, J BIOL CHEM, V269, P32598; GOFFIN V, 1992, MOL ENDOCRINOL, V6, P1381, DOI 10.1210/me.6.9.1381; GOFFIN V, 1993, EUR J BIOCHEM, V214, P483, DOI 10.1111/j.1432-1033.1993.tb17945.x; Goffin V, 1995, PROTEIN ENG, V8, P1215, DOI 10.1093/protein/8.12.1215; GOUT PW, 1980, CANCER RES, V40, P2433; HOOPER KP, 1993, J BIOL CHEM, V268, P22347; HORSEMAN ND, 1994, ENDOCR REV, V15, P627, DOI 10.1210/er.15.5.627; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; Kinet S, 1996, J BIOL CHEM, V271, P14353, DOI 10.1074/jbc.271.24.14353; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LEWIS UJ, 1992, TRENDS ENDOCRIN MET, V3, P117, DOI 10.1016/1043-2760(92)90099-M; LOCHNAN HA, 1995, MOL CELL ENDOCRINOL, V114, P91, DOI 10.1016/0303-7207(95)03645-N; LUCK DN, 1991, MOL ENDOCRINOL, V5, P1880, DOI 10.1210/mend-5-12-1880; LUCK DN, 1990, MOL ENDOCRINOL, V4, P1011, DOI 10.1210/mend-4-7-1011; MEITES J, 1988, INT CONGR SER, V819, P123; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; Mode A, 1996, ENDOCRINOLOGY, V137, P447, DOI 10.1210/en.137.2.447; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; PARIS N, 1990, BIOTECHNOL APPL BIOC, V12, P436; SANDOWSKI Y, 1995, MOL CELL ENDOCRINOL, V115, P1, DOI 10.1016/0303-7207(95)03664-S; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; TCHELET A, 1995, J ENDOCRINOL, V144, P393, DOI 10.1677/joe.0.1440393; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x	47	99	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16573	16579		10.1074/jbc.271.28.16573	http://dx.doi.org/10.1074/jbc.271.28.16573			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663214	hybrid			2022-12-27	WOS:A1996UX12600025
J	Isaacs, RJ; Harris, AL; Hickson, ID				Isaacs, RJ; Harris, AL; Hickson, ID			Regulation of the human topoisomerase II alpha gene promoter in confluence-arrested cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; DNA TOPOISOMERASES; NIH-3T3 CELLS; EXPRESSION; FORMS; PROLIFERATION; LOCALIZATION; SEQUENCE; CLONING; REGION	Expression of DNA topoisomerase II alpha mRNA and protein reflects the proliferative state of mammalian cell lines and tissues with high levels in actively cycling cells but marked down-regulation during serum deprivation or cell density-induced growth arrest, Using stably integrated gene fusions comprising the human topoisomerase II alpha promoter with a growth hormone reporter gene, we have localized elements required for the differential activity of the topoisomerase II alpha promoter in proliferating and confluence-arrested cells, Deletion analysis localized the region of the promoter that responded to changes in the cellular growth state to between -101 and -144 base pairs, Mutation analysis identified an inverted CCAAT box (ICE) located at -108 to -104 as necessary for promoter down-regulation in confluence-arrested cells, while several other potential cis-acting elements, including four additional ICBs, were shown not to be required, The critical ICE was recognized in vitro by the CCAAT box binding factor, NF-Y, with levels of binding activity higher in extracts from proliferating cells than from confluence-arrested cells, We conclude that the differential regulation of topoisomerase II alpha gene expression in cycling and confluence-arrested cells is mediated, at least in part, through proliferation-specific binding of factors to an ICE element in the gene promoter.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,IMPERIAL CANC RES FUND LABS,OXFORD OX3 9DU,ENGLAND	Cancer Research UK; University of Oxford			Hickson, Ian/AAJ-7548-2020; Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409; Hickson, Ian/0000-0002-0583-566X				AUSTIN CA, 1993, BIOCHIM BIOPHYS ACTA, V1172, P283, DOI 10.1016/0167-4781(93)90215-Y; BECK WT, 1993, ADV ENZYME REGUL, V33, P113; BOEGE F, 1995, AM J PATHOL, V146, P1302; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHARNAY P, 1984, CELL, V38, P251, DOI 10.1016/0092-8674(84)90547-6; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; DANDREA MR, 1994, APPL IMMUNOHISTOCHEM, V2, P177; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; FIRTH JD, 1992, J CLIN INVEST, V90, P1023, DOI 10.1172/JCI115915; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HOCHHAUSER D, 1992, J BIOL CHEM, V267, P18961; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NG SW, 1995, J BIOL CHEM, V270, P25850, DOI 10.1074/jbc.270.43.25850; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; POMMIER Y, 1993, CANCER CHEMOTH PHARM, V32, P103, DOI 10.1007/BF00685611; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; SHARMA A, 1995, CURR OPIN STRUC BIOL, V5, P39, DOI 10.1016/0959-440X(95)80007-N; Sinha S, 1996, MOL CELL BIOL, V16, P328; TAN KB, 1992, CANCER RES, V52, P231; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WASSERMAN RA, 1993, CANCER RES, V53, P3591; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WOESSNER RD, 1990, CANCER RES, V50, P2901; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266	40	85	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16741	16747		10.1074/jbc.271.28.16741	http://dx.doi.org/10.1074/jbc.271.28.16741			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663303	hybrid			2022-12-27	WOS:A1996UX12600051
J	Li, LT; Kaplan, J				Li, LT; Kaplan, J			Characterization of yeast methyl sterol oxidase (ERG25) and identification of a human homologue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MUTANTS; PROTEINS	A yeast mutant (LT06) was isolated that showed no growth on iron-limited medium but normal growth on iron-replete medium, A gene cloned from a genomic yeast library complemented the defect, allowing growth on low iron medium, Allelic segregation analysis demonstrated that the cloned gene was the normal allele rather than a high copy suppressor, A disruption mutant was nonviable, indicating that the gene was essential, Sequence analysis and functional assays indicated that the cloned gene was identical to ERG25, a gene that codes for methyl sterol oxidase, Incubation of LT06 in low iron medium resulted in marked changes in lipid metabolism, including the accumulation of fatty acids, triglycerides, methyl sterols, and other sterol precursors, A human homologue of ERG25 was cloned, sequenced, and mapped to human chromosome 4q32-34. Analysis of the data base with both ERG25 and the human homologue resulted in the identification of a putative set of metal binding motifs with similarity to that seen in a family of membrane desaturases hydroxylases. Western analysis using antibodies to an Erg25-GST fusion protein detected two proteins of 34 and 75 kDa. Both proteins are membrane bound and contain one N-glycosyl unit, Immunofluorescence data suggest that the proteins are present in the endoplasmic reticulum and plasma membrane, Although ERG25 transcripts are not iron regulated, there is a large increase in the concentration of transcript in the mutant LT06 grown in low iron medium, These results suggest that the enzyme is regulated not by iron but by an end product of the ergosterol pathway.	UNIV UTAH,SCH MED,DEPT PATHOL,DIV CELL BIOL & IMMUNOL,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah					NCI NIH HHS [NCI BP 30CA 42014] Funding Source: Medline; NIDDK NIH HHS [NIDDK 5-30534, NIDDK 49219] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049219] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Bard M, 1996, P NATL ACAD SCI USA, V93, P186, DOI 10.1073/pnas.93.1.186; DESFARGES L, 1993, YEAST, V9, P267, DOI 10.1002/yea.320090306; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DIX DR, 1994, J BIOL CHEM, V269, P26092; EIDE D, 1992, J BIOL CHEM, V267, P20774; EIDE D, 1992, J GEN MICROBIOL, V138, P34; FAUST JR, 1988, BIOL CHOLESTEROL; FOX BG, 1994, BIOCHEMISTRY-US, V33, P12776, DOI 10.1021/bi00209a008; GEITZ RD, 1988, GENE, V74, P527; Harlow E., ANTIBODIES LAB MANUA; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PARKS LW, 1985, METHOD ENZYMOL, V111, P333; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; Sambrook J., 2002, MOL CLONING LAB MANU; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; SPENCE JT, 1977, J BIOL CHEM, V252, P5852; TURI TG, 1992, J BIOL CHEM, V267, P2046; WHITE JR, 1977, BIOCHEM BIOPH RES CO, V77, P387, DOI 10.1016/S0006-291X(77)80209-X; WILLIAMS MT, 1977, CANCER RES, V37, P1377; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x	23	83	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16927	16933		10.1074/jbc.271.28.16927	http://dx.doi.org/10.1074/jbc.271.28.16927			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663358	hybrid			2022-12-27	WOS:A1996UX12600076
J	Mata, M; Merritt, SE; Fan, G; Yu, GG; Holzman, LB				Mata, M; Merritt, SE; Fan, G; Yu, GG; Holzman, LB			Characterization of dual leucine zipper-bearing kinase, a mixed lineage kinase present in synaptic terminals whose phosphorylation state is regulated by membrane depolarization via calcineurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PHOSPHORYLATION; DROSOPHILA-MELANOGASTER; DYNAMIN GTPASE; VESICLES; DEPHOSPHORYLATION; PHOSPHOPROTEINS; IDENTIFICATION; JUNCTIONS; DOMAINS; CALCIUM	The biochemistry and regulation of dual leucine zipper bearing kinase (DLK), a member of the mixed lineage kinase or MLK subfamily of protein kinases, was examined in the nervous system, DLK transcript expression in the nervous system was predominantly neuronal, DLK protein was present in synaptic terminals where it was associated with both plasma membrane and cytosol fractions. Within these two fractions, DLK had differing characteristics. Cytosolic DLK existed in both a phosphorylated and dephosphorylated state; DLK associated with plasma membrane existed in the dephosphorylated state only, On nonreducing SDS-polyacrylamide gel electrophoresis, cytosolic DLK migrated at 130 kDa, while membrane associated DLK migrated with an apparent M(r) greater than or equal to 260,000, Similarly, DLK transiently expressed in COS 7 cells autophosphorylated in vivo and migrated at approximately 260 kDa when separated by nonreducing SDS polyacrylamide gel electrophoresis, In cotransfection experiments, FLAG-tagged DLK or a FLAG-tagged truncated DLK mutant (F-Delta 520) was coimmunoprecipitated with Myc-tagged DLK and formed complexes under nonreducing conditions consistent with the conclusion that DLK formed covalently associated homodimers in overexpressing COS 7 cells, In aggregating neuronal-glial cultures, depolarization of plasma membrane lead to dephosphorylation of DLK, Treatment of aggregates with 5 nM or 200 nM okadaic acid lead to a shift in electrophoretic mobility consistent with phosphorylation of DLK, Treatment with cyclosporin A, a specific inhibitor of the calcium/calmodulin-dependent protein phosphatase 2B (calcineurin), had no effect on DLK phosphorylation under basal conditions, However, cyclosporin A completely inhibited DLK dephosphorylation upon membrane depolarization.	UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,DIV NEPHROL,ANN ARBOR,MI 48109; UNIV PITTSBURGH,SCH MED,DEPT NEUROL,PITTSBURGH,PA 15261; DEPT VET AFFAIRS,ANN ARBOR,MI 48105	University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Holzman, Lawrence/0000-0002-8961-234X				Ausubel FM, 1992, CURRENT PROTOCOLS MO; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CATTERALL WA, 1992, PHYSIOL REV, V72, P15; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HONEGGER P, 1985, CELL CULTURE NEUROSC, P223; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; IKEDA K, 1976, NATURE, V259, P489, DOI 10.1038/259489a0; JOHNSTON PA, 1990, J BIOL CHEM, V265, P8869; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOENIG JH, 1983, J CELL BIOL, V96, P1517, DOI 10.1083/jcb.96.6.1517; KOENIG JH, 1989, J NEUROSCI, V9, P1937; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KREUGER BK, 1977, J BIOL CHEM, V252, P2764; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; MATA M, 1992, J NEUROCHEM, V59, P622, DOI 10.1111/j.1471-4159.1992.tb09415.x; MATA M, 1996, IN PRESS CELL MOL NE; MATTHIEU JM, 1990, NEUROL NEUR, V59, P109; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NICHOLS RA, 1994, J BIOL CHEM, V269, P23817; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; RAMAKRISHNAN R, 1994, J VIROL, V68, P7083, DOI 10.1128/JVI.68.11.7083-7091.1994; ROBINSON PJ, 1994, TRENDS NEUROSCI, V17, P348, DOI 10.1016/0166-2236(94)90179-1; ROBINSON PJ, 1983, J NEUROCHEM, V41, P909, DOI 10.1111/j.1471-4159.1983.tb09034.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SHIELDS SM, 1985, J NEUROSCI, V5, P3414; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SIHRA TS, 1992, J BIOL CHEM, V267, P1983; SIM ATR, 1991, NEUROSCI LETT, V126, P203, DOI 10.1016/0304-3940(91)90554-7; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; TUMA PL, 1993, J BIOL CHEM, V268, P17240; UEDA T, 1979, J CELL BIOL, V83, P308, DOI 10.1083/jcb.83.2.308; VICTOR RG, 1995, P NATL ACAD SCI USA, V92, P6269, DOI 10.1073/pnas.92.14.6269; WALAAS SI, 1991, PHARMACOL REV, V43, P299	45	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16888	16896		10.1074/jbc.271.28.16888	http://dx.doi.org/10.1074/jbc.271.28.16888			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663324	hybrid			2022-12-27	WOS:A1996UX12600071
J	Revelle, BM; Scott, D; Beck, PJ				Revelle, BM; Scott, D; Beck, PJ			Single amino acid residues in the E- and P-selectin epidermal growth factor domains can determine carbohydrate binding specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; LEUKOCYTE ADHESION MOLECULE-1; CELL-ADHESION; GLYCOPROTEIN FETUIN; LIGAND RECOGNITION; SIALYL-LEX; INFLAMMATION; TISSUES; ELAM-1; LEWIS	E-selectin and P-selectin are two closely related vascular cell adhesion proteins, Each selectin has an amino-terminal C-type lectin domain that is thought to possess the carbohydrate binding site that binds the sialylated Lewis(x) antigen (sLe(x) or CD15s) (Neu5Ac alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc), In addition to the sLe(x) carbohydrate, P-selectin binds sulfated proteoglycan, 3-sulfated galactosyl ceramide (sulfatide), and heparin, Both E- and P-selectin have an EGF-like (EGF) domain that is immediately adjacent to and COOH-terminal to the lectin domain, Ne report that mutagenic substitution of single amino acid residues in either the P- or E-selectin EGF domain can dramatically alter selectin binding to sLe(x), heparin, or sulfatide, Substitution of E- and P-selectin EGF domain residue Ser(128) with an arginine results in E- and P selectin proteins that have lost the requirement for alpha 1-3-linked fucose and are thus able to bind to sialyllactosamine. A similar phenotype is reported for an E-selectin mutation within the lectin domain, Additionally, we have determined that conservative substitution of EGF domain residues 124 and 128 can alter E-selectin binding such that it is able to adhere to heparin or sulfatide and can reduce P-selectin adherence to these ligands, The distance between the substituted EGF domain amino acid residues and the primary carbohydrate binding site within the lectin domain and their relative positioning as determined by the three-dimensional crystal structure of the E-selectin lectin and EGF domains (Graves, B. J., Crowther, R. L., Chandran, C., Rumberger, J. B., Li, S., Huang, D.-S., Presby, D. H., Familletti, P. C., Wolitzky, B. A., and Burns, D. K. (1994) Nature 367, 532-538) suggest that there is little direct contact between the two domains, However, we report mutant binding characteristics which indicate that selectin oligosaccharide binding may be modulated by both domains and that wild-type E- and P-selectin/sLe(x) binding interactions may be significantly different from those previously hypothesized.	TEXAS BIOTECHNOL CORP, DEPT BIOL MOLEC, HOUSTON, TX 77030 USA; UNIV TEXAS, SCH MED, DEPT INTERNAL MED, HOUSTON, TX 77030 USA	University of Texas System								ANOSTARIO M, 1995, J BIOL CHEM, V270, P8138, DOI 10.1074/jbc.270.14.8138; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; BAJORATH J, 1994, BIOCHEMISTRY-US, V33, P1332, DOI 10.1021/bi00172a007; BENDIAK B, 1989, BIOCHEMISTRY-US, V28, P6491, DOI 10.1021/bi00441a050; BEVILACQUA MP, 1994, ANNU REV MED, V45, P361, DOI 10.1146/annurev.med.45.1.361; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; CUMMING DA, 1989, BIOCHEMISTRY-US, V28, P6500, DOI 10.1021/bi00441a051; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FOX N, 1983, CANCER RES, V43, P669; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FUKUDA M, 1980, NATURE, V285, P405, DOI 10.1038/285405a0; FUKUSHI Y, 1985, CANCER RES, V45, P3711; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GIBSON RM, 1995, BLOOD, V85, P151, DOI 10.1182/blood.V85.1.151.bloodjournal851151; Ginsburg V., 1984, BIOL CARBOHYDRATES; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; GREEN ED, 1988, J BIOL CHEM, V263, P18253; Harlow E., 1988, ANTIBODIES LAB MANUA; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUTILA MA, 1992, J EXP MED, V175, P1565, DOI 10.1084/jem.175.6.1565; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; KOGAN TP, 1995, J BIOL CHEM, V270, P14047, DOI 10.1074/jbc.270.23.14047; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LI SH, 1994, J BIOL CHEM, V269, P4431; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MUNRO JM, 1992, AM J PATHOL, V141, P1397; MURPHY JF, 1994, BIOCHEM J, V303, P619, DOI 10.1042/bj3030619; NELSON RM, 1993, BLOOD, V82, P3253; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; Revelle BM, 1996, J BIOL CHEM, V271, P4289; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; VONANDRIAN UH, 1993, J CLIN INVEST, V91, P2893, DOI 10.1172/JCI116535; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WENZEL K, 1994, HUM MOL GENET, V3, P1935, DOI 10.1093/hmg/3.11.1935; WENZEL K, 1994, HUM GENET, V94, P452; YOSHIMA H, 1982, J BIOCHEM, V91, P233, DOI 10.1093/oxfordjournals.jbchem.a133680	45	96	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16160	16170		10.1074/jbc.271.27.16160	http://dx.doi.org/10.1074/jbc.271.27.16160			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663282	hybrid			2022-12-27	WOS:A1996UW35200047
J	Chou, MY; Li, SC; Li, YT				Chou, MY; Li, SC; Li, YT			Cloning and expression of sialidase L, a NeuAc alpha 2->3Gal-specific sialidase from the leech, Macrobdella decora	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURAMINIDASE GENE; ESCHERICHIA-COLI; CLOSTRIDIUM-PERFRINGENS; CONSERVED SEQUENCES; BACTERIAL; PROTEINS; NANH; AMPLIFICATION; ACID	Sialidase L is a NeuAc alpha 2-->3Gal linkage-specific sialidase that releases 2,7-anhydro-NeuAc instead of NeuAc from sialoglycoconjugates (Chou, M.-Y., Li, S.-C., Kiso, M,, Hasegawa, A., and Li, Y.-T, (1994) J. Biol, Chem. 269, 18821-18826), A 2.5-kilobase cDNA of sialidase L was cloned by a combination of methods based on polymerase chain reactions, The composite cDNA sequence reveals an open reading frame coding for 762 amino acids, including a putative 28-residue signal peptide at the N terminus that is similar to the signal sequence of the Clostridium septicum sialidase, The result suggests that sialidase L is a secretory enzyme, The coding sequence excluding the putative signal peptide of sialidase L was overexpressed in Escherichia coli. The purified recombinant enzyme was characterized to be as active as the enzyme isolated from the leech, It also possessed the strict NeuAc alpha 2-->3Gal linkage specificity and released the unique cleavage product, 2,7-anhydro-NeuAc from sialoglycoconjugates. The deduced amino acid sequence of sialidase L exhibits little similarity with other reported sialidases, However, sialidase L contains a conserved ''FRIP region'' and four repeating ''Asp box'' motifs that align well with the corresponding positions of bacterial sialidases. The predicted beta-strand structures near the conserved motifs of sialidase L are similar to those of Salmonella typhimurium sialidase. Several conserved single amino acid residues of bacterial sialidases, including those known to be involved in the active site of Salmonella enzyme, are conserved in the deduced amino acid sequence of sialidase L, This observation suggests that part of the catalytic mechanism of sialidase L may be similar to the ordinary sialidase.	TULANE UNIV,SCH MED,DEPT BIOCHEM,NEW ORLEANS,LA 70112	Tulane University					NINDS NIH HHS [NS 09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKIMOTO S, 1994, BIOCHEM BIOPH RES CO, V203, P914, DOI 10.1006/bbrc.1994.2269; CAMARA M, 1994, INFECT IMMUN, V62, P3688; CHOU MY, 1994, J BIOL CHEM, V269, P18821; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; FERRARI J, 1994, GLYCOBIOLOGY, V4, P367, DOI 10.1093/glycob/4.3.367; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HARRIS G, 1954, CHEM IND-LONDON, P249; HENNINGSEN M, 1991, BIOL CHEM H-S, V372, P1065, DOI 10.1515/bchm3.1991.372.2.1065; HOYER LL, 1992, MOL MICROBIOL, V6, P873, DOI 10.1111/j.1365-2958.1992.tb01538.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI YT, 1990, J BIOL CHEM, V265, P21629; LIU XW, 1993, NUCLEIC ACIDS RES, V21, P4954, DOI 10.1093/nar/21.21.4954; MIYAGI T, 1993, J BIOL CHEM, V268, P26435; ROGGENTIN P, 1989, GLYCOCONJUGATE J, V6, P349, DOI 10.1007/BF01047853; ROGGENTIN P, 1993, MOL MICROBIOL, V9, P915, DOI 10.1111/j.1365-2958.1993.tb01221.x; ROGGENTIN P, 1988, FEBS LETT, V238, P31, DOI 10.1016/0014-5793(88)80219-9; ROGGENTIN T, 1992, GLYCOCONJUGATE J, V9, P235, DOI 10.1007/BF00731135; ROTHE B, 1989, J GEN MICROBIOL, V135, P3087; ROTHE B, 1991, MOL GEN GENET, V226, P190, DOI 10.1007/BF00273603; RUSSO TA, 1990, J BACTERIOL, V172, P2594, DOI 10.1128/jb.172.5.2594-2600.1990; Saito M, 1995, BIOL SIALIC ACIDS, P261, DOI [10.1007/978-1-4757-9504-2_8, DOI 10.1007/978-1-4757-9504-2_8]; SAKURADA K, 1992, J BACTERIOL, V174, P6896, DOI 10.1128/JB.174.21.6896-6903.1992; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAUER R, 1982, SIALIC ACIDS CHEM ME, P1; SCHAUER R, 1983, STRUCTURAL CARBOHYDR, P83; SINNOTT ML, 1993, J AM CHEM SOC, V115, P3334, DOI 10.1021/ja00061a044; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VIMR ER, 1988, J BACTERIOL, V170, P1495, DOI 10.1128/jb.170.4.1495-1504.1988	31	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19219	19224		10.1074/jbc.271.32.19219	http://dx.doi.org/10.1074/jbc.271.32.19219			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702601	hybrid			2022-12-27	WOS:A1996VB68400035
J	Wieland, SJ; Gong, QH; Poblete, H; Fletcher, JE; Chen, LQ; Kallen, RG				Wieland, SJ; Gong, QH; Poblete, H; Fletcher, JE; Chen, LQ; Kallen, RG			Modulation of human muscle sodium channels by intracellular fatty acids is dependent on the channel isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SKELETAL-MUSCLE; FUNCTIONAL EXPRESSION; CELLS; NA+; CONDUCTANCE	Free fatty acids (FFAs), including arachidonic acid (AA), are implicated in the direct and indirect modulation of a spectrum of voltage-gated ion channels, Skeletal muscle sodium channels can be either activated or inhibited by FFA exposure; the response is dependent on both FFA structure and site of exposure. Recombi nant human skeletal muscle sodium channels (hSkM1) were transfected into heterologous human renal epithelium HEK293t cells, Cytoplasmic delivery of 5 mu M AA augmented the voltage-activated sodium current of hSkM1 channels by 190% (+/- 54 S.E., n = 7) over a 20-min period, Similar results were seen with 5 mu M oleic acid, Sodium currents in HEK293t cells transfected with human cardiac muscle sodium channels (hH1) were insensitive to AA treatment, and exposure to oleic acid inhibited the hH1 currents over a 20-min period by 29% (+/- 13 S.E., n = 5), The increase in hSkM1 current was not accompanied by shifts in voltage dependence of activation, steady-state inactivation, or markedly altered kinetics of inactivation of the macroscopic current, The FFA-induced increase in sodium currents was not dependent on protein kinase C activity, In contrast, both isoforms were reversibly inhibited by external application of unsaturated FFA, Thus, the differential effects of FFA on skeletal muscle sodium channels first noted in cultured muscle cells can be reproduced by expressing recombinant sodium channels in epithelial cells, Although the responses to applied FFAs could be direct or indirect, we suggest that: 1) SkM1 has two classes of response to FFA, one which produces augmentation of macroscopic currents with intracellular FFA, and a second which produces inhibition with extracellular FFA; 2) H1 has only one class of response, which produces inhibition with extracellular FFA, A testable hypothesis is that the presence or absence of each response is due to a specific structure in SkM1 or H1. These specific structures may directly interact with FFA or may interact with intermediate components.	MED COLL PENN & HAHNEMANN UNIV,DEPT ANESTHESIOL,PHILADELPHIA,PA 19102; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19102	Drexel University; University of Pennsylvania	Wieland, SJ (corresponding author), MED COLL PENN & HAHNEMANN UNIV,DEPT NEUROBIOL & ANAT,MAIL STOP 408,BROAD & VINE,PHILADELPHIA,PA 19102, USA.							Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BELL RM, 1991, J BIOL CHEM, V266, P4661; CANNON SC, 1993, NEURON, V10, P317, DOI 10.1016/0896-6273(93)90321-H; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GEORGE AL, 1992, ANN NEUROL, V31, P131, DOI 10.1002/ana.410310203; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 1992, IONIC CHANNELS EXCIT, P250; HUANG JMC, 1992, P NATL ACAD SCI USA, V89, P6452, DOI 10.1073/pnas.89.14.6452; HWANG TC, 1990, P NATL ACAD SCI USA, V87, P5706, DOI 10.1073/pnas.87.15.5706; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LINDEN DJ, 1989, J PHYSIOL-LONDON, V419, P95, DOI 10.1113/jphysiol.1989.sp017863; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; UKOMADU C, 1992, NEURON, V8, P663, DOI 10.1016/0896-6273(92)90088-U; Wieland S. J., 1995, Society for Neuroscience Abstracts, V21, P1820; WIELAND SJ, 1990, J CELL PHYSIOL, V142, P643, DOI 10.1002/jcp.1041420326; WIELAND SJ, 1992, AM J PHYSIOL, V263, pC308, DOI 10.1152/ajpcell.1992.263.2.C308; WU JT, 1991, J BIOL CHEM, V266, P14893; YANG JSJ, 1991, NEURON, V7, P421, DOI 10.1016/0896-6273(91)90294-A	22	26	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19037	19041		10.1074/jbc.271.32.19037	http://dx.doi.org/10.1074/jbc.271.32.19037			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702574	hybrid			2022-12-27	WOS:A1996VB68400008
J	Corbett, AH; Silver, PA				Corbett, AH; Silver, PA			The NTF2 gene encodes an essential, highly conserved protein that functions in nuclear transport in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; GTPASE-ACTIVATING PROTEIN; RNA-BINDING PROTEINS; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; IMPORT SUBSTRATE; PORE COMPLEXES; CYTOSOLIC FACTORS; MEDIATED BINDING; RAN/TC4 HOMOLOG	The small protein p10/Ntf2p has been implicated in protein import in vitro (Moore, M, S,, and Blobel, G. (1994) Proc, Natl. Acad. Sci, U, S, A, 91, 10212-10216; Paschal, B, M,, and Gerace, L, (1995) J, Cell Biol, 129, 925-937), Here we present the first evidence that demonstrates an essential in vivo role for the NTF2 gene product in nuclear transport, The NTF2 locus was identified in a screen for temperature-sensitive Saccharomyces cerevisiae mutants defective in the localization of nuclear proteins. Genetic analysis demonstrates that the NTF2 gene is essential for viability in budding yeast. Two temperature-sensitive mutants, ntf2-1 and ntf2-2, that each contain single point mutations in highly conserved amino acid residues show defects in the localization of nuclear proteins but not in the export of poly(A)(+) RNA following a shift to the nonpermissive temperature. An epitope tagged version of Ntf2p was used to show that the protein is concentrated at the nuclear envelope, Finally, the human gene under the control of the yeast promoter fully substitutes for the deleted yeast gene, Taken together, these results demonstrate the exquisite functional conservation of this protein throughout evolution and indicate a critical in vivo role in nuclear transport.	DANA FARBER CANC INST, DIV CELLULAR & MOL BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School			Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BOHN H, 1980, ARCH GYNECOL, V230, P167, DOI 10.1007/BF02108272; BOSSIE MA, 1992, MOL BIOL CELL, V3, P875, DOI 10.1091/mbc.3.8.875; CHENG Y, 1995, SCIENCE, V267, P1807, DOI 10.1126/science.7534442; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; DOYE V, 1995, TRENDS GENET, V11, P235, DOI 10.1016/S0168-9525(00)89057-5; ELION EA, 1993, CURRENT PROTOCOLS MO; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; FLACH J, 1994, MOL CELL BIOL, V14, P8399, DOI 10.1128/MCB.14.12.8399; FLEISCHMANN M, 1991, MOL GEN GENET, V227, P417, DOI 10.1007/BF00273932; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; HAARER BK, 1996, IN PRESS GENETICS; Henry M, 1996, GENETICS, V142, P103; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; KADOWAKI T, 1992, P NATL ACAD SCI USA, V89, P2312, DOI 10.1073/pnas.89.6.2312; KAHANA JA, 1995, P NATL ACAD SCI USA, V92, P9707, DOI 10.1073/pnas.92.21.9707; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; KRAEMER DM, 1995, J BIOL CHEM, V270, P19017, DOI 10.1074/jbc.270.32.19017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; MAUL GR, 1977, INT REV CYTOL      S, V6, P75; MELCHIOR F, 1993, MOL BIOL CELL, V4, P569, DOI 10.1091/mbc.4.6.569; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MORELAND RB, 1987, MOL CELL BIOL, V7, P4048, DOI 10.1128/MCB.7.11.4048; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P4318, DOI 10.1073/pnas.92.10.4318; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NELSON M, 1989, MOL CELL BIOL, V9, P384, DOI 10.1128/MCB.9.2.384; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORRWEAVER TL, 1983, P NATL ACAD SCI-BIOL, V80, P4417, DOI 10.1073/pnas.80.14.4417; OUSPENSKI II, 1995, J BIOL CHEM, V270, P1975, DOI 10.1074/jbc.270.5.1975; Pante N, 1995, J CELL SCI, P1; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SWEET DJ, 1995, TRENDS CELL BIOL, V5, P444, DOI 10.1016/S0962-8924(00)89108-4; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	67	92	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18477	18484		10.1074/jbc.271.31.18477	http://dx.doi.org/10.1074/jbc.271.31.18477			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702493	hybrid			2022-12-27	WOS:A1996VB68300031
J	DeLuca, A; Santra, M; Baldi, A; Giordano, A; Iozzo, RV				DeLuca, A; Santra, M; Baldi, A; Giordano, A; Iozzo, RV			Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA-CELLS; HEPARAN-SULFATE PROTEOGLYCAN; P53-MEDIATED G(1) ARREST; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; CANCER-CELLS; FACTOR-BETA; INDUCTION; HYPOMETHYLATION; DIFFERENTIATION	The secreted proteoglycan decorin has been impli cated in the negative control of cell proliferation primarily by virtue of its ability to block transforming growth factor-beta, Moreover, decorin expression is markedly up-regulated during quiescence but suppressed upon viral transformation, whereas de novo decorin expression in colon carcinoma cells abrogates the malignant phenotype by arresting the cells in the G(1) phase of the cell cycle, Here we show that this decorin-induced growth arrest is associated with up-regulation of p21 mRNA and protein in a transforming growth factor-beta- and p53-independent pathway, The augmented p21 protein is present as a multimeric complex with various cyclins and cyclin-dependent kinases in the nuclei of decorin-expressing cells, thereby leading to suppression of cyclin-dependent kinase activity and block of cell division, Through the usage of decorin-specific antisense oligodeoxynucleotide treatment, we demonstrate that the expression of decorin is closely linked to that of p21 and that abrogation of decorin leads to suppression of p21 and restoration of cell division, Collectively, our results provide a plausible mechanism by which decorin may contribute to retard and suppress the growth of tumor cells in vivo.	THOMAS JEFFERSON UNIV,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,KIMMEL CANC CTR,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University			De Luca, Antonio/AAD-9562-2020; Giordano, Antonio/F-1927-2010; Iozzo, Renato/AAS-1980-2020; Baldi, Alfonso/ABG-2397-2021	De Luca, Antonio/0000-0002-3905-6154; Giordano, Antonio/0000-0002-5959-016X; Baldi, Alfonso/0000-0002-8693-3842; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA60999, R01 CA47282, R01 CA39481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060999, R01CA047282, R01CA039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADANY R, 1991, BIOCHEM J, V276, P301, DOI 10.1042/bj2760301; ADANY R, 1990, J BIOL CHEM, V265, P11389; ASUNDI VK, 1992, EUR J CELL BIOL, V59, P314; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; DODGE GR, 1990, J BIOL CHEM, V265, P18023; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; IOZZO RV, 1993, EXPERIENTIA, V49, P447, DOI 10.1007/BF01923588; IOZZO RV, 1985, J BIOL CHEM, V260, P7464; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; IOZZO RV, 1984, J CELL BIOL, V99, P403, DOI 10.1083/jcb.99.2.403; JIANG HP, 1994, ONCOGENE, V9, P3397; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; MICHIELI P, 1994, CANCER RES, V54, P3391; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WALDMAN T, 1995, CANCER RES, V55, P5187; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	37	211	214	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18961	18965		10.1074/jbc.271.31.18961	http://dx.doi.org/10.1074/jbc.271.31.18961			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702560	hybrid			2022-12-27	WOS:A1996VB68300098
J	GagnouxPalacios, L; Vailly, J; DurandClement, M; Wagner, E; Ortonne, JP; Meneguzzi, G				GagnouxPalacios, L; Vailly, J; DurandClement, M; Wagner, E; Ortonne, JP; Meneguzzi, G			Functional re-expression of laminin-5 in laminin-gamma 2-deficient human keratinocytes modifies cell morphology, motility, and adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; MONOCLONAL-ANTIBODY GB3; BASEMENT-MEMBRANES; INITIAL BINDING; ALPHA-3 CHAIN; DNA COMPLEXES; HEMIDESMOSOMES; NICEIN/KALININ; INTEGRIN; KALININ	Herlitz junctional epidermolysis bullosa (H-JEB) is characterized by a reduced adherence of keratinocytes consequent to deficient expression of the extracellular adhesive ligand laminin-5, To complement the genetic defect causing H-JEB, we transferred an eukaryotic cassette expressing the cDNA for the gamma 2 chain of laminin-5 into H-JEB keratinocytes in which the expression of the polypeptide is hampered by a homozygous mutation generating a premature termination codon. Transfection using adenovirus-polylysin-transferrin DNA complexes resulted in a transient synthesis of the recombinant laminin gamma 2 chain that associated with the endogenous alpha 3 and beta 3 chains to form laminin-5 molecules readily deposited on the tissue culture substrate, Furthermore, retroviral mediated transduction of the gamma 2 cDNA yielded persistent expression and polarized secretion of laminin-5, The protein incorporated into the basement membrane produced by the revertant cells inoculated subcutaneously in nude mice. In these transfectants, re-expression of laminin-5 induced changes in cell morphology and reorganization of focal adhesions that assumed the shape and distribution of the counterparts detected in normal keratinocytes. These observations correlated with an enhanced cell-substrate adhesion and a reduced motility of the transfected cells, Our results demonstrate that a restored expression of laminin-5 induces a phenotypic reversion of genetically altered H-JEB keratinocytes and open new perspectives to the analysis of the mechanisms regulating adhesion of epithelial cells.	FAC MED NICE, UFR MED, INSERM U385, F-06107 NICE 2, FRANCE; HOP LOUIS PASTEUR, SERV DERMATOL, F-06002 NICE 1, FRANCE; BENDER AG, A-1121 VIENNA, AUSTRIA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice			Gagnoux, Laurent/O-9954-2016; Gagnoux, Laurent/O-9990-2016; Wagner, Ernst/ABB-5976-2020; Wagner, Ernst/A-7435-2012	Wagner, Ernst/0000-0001-8413-0934; Wagner, Ernst/0000-0001-8413-0934; Meneguzzi, Guerrino/0000-0002-1609-6540				ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; BAUDOIN C, 1994, J CLIN INVEST, V93, P862, DOI 10.1172/JCI117041; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CEPKO C, 1989, NEUROMETHODS, V16, P177; CHEN JD, IN PRESS LAB INVEST; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; ENGVALL E, 1993, KIDNEY INT, V43, P2, DOI 10.1038/ki.1993.2; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; GALLIANO MF, 1995, J BIOL CHEM, V270, P21820, DOI 10.1074/jbc.270.37.21820; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; GIL SG, 1994, J INVEST DERMATOL, V103, pS31, DOI 10.1111/1523-1747.ep12398953; GREEN TL, 1992, J BIOL CHEM, V267, P2014; HORMIA M, 1995, J INVEST DERMATOL, V105, P557, DOI 10.1111/1523-1747.ep12323451; IZZARD CS, 1976, J CELL SCI, V21, P129; JIANG CK, 1991, J INVEST DERMATOL, V97, P969, DOI 10.1111/1523-1747.ep12491889; KRUEGER JG, 1991, J INVEST DERMATOL, V97, P849, DOI 10.1111/1523-1747.ep12491525; KUBLER MD, 1993, J INVEST DERMATOL, V100, P785, DOI 10.1111/1523-1747.ep12476492; LANGHOFER M, 1993, J CELL SCI, V105, P753; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MATSUI C, 1995, J BIOL CHEM, V270, P23496, DOI 10.1074/jbc.270.40.23496; MATSUI C, 1995, J INVEST DERMATOL, V105, P648, DOI 10.1111/1523-1747.ep12324108; MCCLAY DR, 1981, P NATL ACAD SCI-BIOL, V78, P4975, DOI 10.1073/pnas.78.8.4975; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Miquel C, 1996, EXP CELL RES, V224, P279, DOI 10.1006/excr.1996.0138; OrianRousseau V, 1996, DEV DYNAM, V206, P12, DOI 10.1002/(SICI)1097-0177(199605)206:1<12::AID-AJA2>3.0.CO;2-3; ROSDY M, 1993, BRIT J DERMATOL, V129, P227, DOI 10.1111/j.1365-2133.1993.tb11839.x; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RYAN MC, 1994, J BIOL CHEM, V269, P22779; SONNENBERG A, 1993, J CELL SCI, V106, P1083; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; STAEDEL C, 1994, J INVEST DERMATOL, V102, P768, DOI 10.1111/1523-1747.ep12377673; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; VERRANDO P, 1987, EXP CELL RES, V170, P116, DOI 10.1016/0014-4827(87)90121-2; VERRANDO P, 1993, J INVEST DERMATOL, V101, P738, DOI 10.1111/1523-1747.ep12371685; VERRANDO P, 1994, LAB INVEST, V71, P567; VIDAL F, 1995, GENOMICS, V30, P273, DOI 10.1006/geno.1995.9877; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WOODLEY DT, 1991, WOUND HEALING, P91; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	48	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18437	18444		10.1074/jbc.271.31.18437	http://dx.doi.org/10.1074/jbc.271.31.18437			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702488	hybrid			2022-12-27	WOS:A1996VB68300026
J	Hwang, SC; Jhon, DY; Bae, YS; Kim, JH; Rhee, SG				Hwang, SC; Jhon, DY; Bae, YS; Kim, JH; Rhee, SG			Activation of phospholipase C-gamma by the concerted action of tau proteins and arachidonic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES PHOSPHOINOSITIDE HYDROLYSIS; PLACENTAL-LACTOGEN RELEASE; UNSATURATED FATTY-ACIDS; CYTOSOLIC PHOSPHOLIPASE-A2; INTERFACIAL CATALYSIS; SIGNAL-TRANSDUCTION; PHOSPHATIDIC-ACID; KINASE-C; DOMAIN; CELLS	Phospholipase C-gamma (PLC-gamma) isozymes are thought to be activated by receptor-induced tyrosine phosphorylation. Proteins that activate PLC-gamma 1 have now been purified from bovine brain and identified as members of the tan family of microtubule-associated proteins. Activation of PLC-gamma by tau was enhanced in the presence of unsaturated fatty acids such as arachidonic acid, saturated fatty acids being ineffective. Maximal (15-20-fold) activation was apparent in the presence of 0.15 mu M tau and 25 mu M arachidonic acid (AA). The effect of tau and AA was specific to PLC-gamma isozymes in the presence of submicromolar concentrations of Ca2+ and was markedly inhibited by phosphatidylcholine. These results suggest that in cells that express tau, receptor to cytosolic phospholipase A, may activate PLC-gamma isozymes indirectly in the absence of tyrosine phosphorylation through the hydrolysis of phosphatidylcholine to generate AA.	NHLBI, LAB CELL SIGNALING, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)				Hwang, Sung Chul/0000-0003-2401-619X				BAUDIER J, 1987, J BIOL CHEM, V262, P17584; BOGUSLAVSKY V, 1994, BIOCHEMISTRY-US, V33, P3032, DOI 10.1021/bi00176a036; CHOW SC, 1990, J BIOL CHEM, V265, P902; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CURRIE S, 1992, J BIOL CHEM, V267, P6056; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GERZER R, 1986, BIOCHIM BIOPHYS ACTA, V886, P383, DOI 10.1016/0167-4889(86)90173-4; Glick J, 1996, J BIOL CHEM, V271, P2949, DOI 10.1074/jbc.271.6.2949; GLICK R, 1996, BIOCHIM BIOPHYS ACTA, V271, P2949; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; IRVINE RF, 1979, BIOCHEM J, V178, P497, DOI 10.1042/bj1780497; JAMES SR, 1995, J BIOL CHEM, V270, P11872, DOI 10.1074/jbc.270.20.11872; JONES GA, 1993, J BIOL CHEM, V268, P20845; KAST R, 1993, J BIOL CHEM, V268, P16795; KRAMER RM, 1994, SIGNAL ACTIVATED PHO, P13; LEE G, 1990, CELL MOTIL CYTOSKEL, V15, P199, DOI 10.1002/cm.970150402; LYNCH MA, 1990, J NEUROCHEM, V55, P215, DOI 10.1111/j.1471-4159.1990.tb08841.x; MANDELKOW EM, 1993, TRENDS BIOCHEM SCI, V18, P480, DOI 10.1016/0968-0004(93)90011-B; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; NEGISHI M, 1990, BIOCHEM BIOPH RES CO, V169, P773, DOI 10.1016/0006-291X(90)90398-7; NISHIKAWA M, 1988, BIOCHEM PHARMACOL, V37, P3079, DOI 10.1016/0006-2952(88)90304-8; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; PARK D, 1992, J BIOL CHEM, V267, P16048; PIOMELLI D, 1989, P NATL ACAD SCI USA, V86, P8550, DOI 10.1073/pnas.86.21.8550; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SIESS W, 1983, J BIOL CHEM, V258, P1236; SUMIDA C, 1993, PROSTAG LEUKOTR ESS, V48, P117, DOI 10.1016/0952-3278(93)90019-S; TAKENAWA T, 1981, J BIOL CHEM, V256, P6769; TAYLOR GD, 1992, BIOCHEM BIOPH RES CO, V188, P1176, DOI 10.1016/0006-291X(92)91355-T; TOUNY SE, 1990, J BIOL CHEM, V265, P16437; WOLF BA, 1986, J BIOL CHEM, V261, P3501; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; ZEITLER P, 1985, MOL PHARMACOL, V28, P549; ZEITLER P, 1991, LIFE SCI, V48, P2089, DOI 10.1016/0024-3205(91)90166-9	41	162	168	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18342	18349		10.1074/jbc.271.31.18342	http://dx.doi.org/10.1074/jbc.271.31.18342			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702475	hybrid			2022-12-27	WOS:A1996VB68300013
J	Jensen, LT; Howard, WR; Strain, JJ; Winge, DR; Culotta, VC				Jensen, LT; Howard, WR; Strain, JJ; Winge, DR; Culotta, VC			Enhanced effectiveness of copper ion buffering by CUP1 metallothionein compared with CRS5 metallothionein in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; YEAST METALLOTHIONEIN; CANDIDA-GLABRATA; GENE-TRANSCRIPTION; EXPRESSION; AMPLIFICATION; DISRUPTION; SEQUENCE; PRODUCT; VECTORS	The bakers' yeast Saccharomyces cerevisiae contains a metallothionein (MT) gene family comprised of the amplified CUP1 locus and the single copy CRS5 gene, We demonstrate that CUP1 plays the dominant role in copper detoxification, A single copy of CUP1 was far more effective in conferring copper resistance than was CRS5. The CUP1 promoter contributes to this resistance; in a promoter exchange experiment, the Crs5 MT conferred strong copper resistance when its expression was driven by the CUP1 promoter, and conversely, the CRS5 promoter reduced the effectiveness of Cup1 MT, Unlike CUP1, the CRS5 promoter appears to be refractory to high concentrations of copper, The CUP1 coding sequences also contribute to copper tolerance, presumably reflecting the enhanced binding avidity of Cup1 MT for Cu(I) ions, In studies with the bathocuproine Cu(I) chelator, the Cu(I) ions bound to Crs5 were kinetically more labile than the Cu(I) binding to Cup1. Our findings are consistent with the assembly of Crs5 into two metal-binding clusters, similar to mammalian MTs, but unlike Cup1. Overall, the striking differences in gene structure regulation, and function of CUP1 and CRS5 are remarkably reminiscent of the MTI and MTII genes of the pathogenic yeast Candida glabrata.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT ENVIRONM HLTH SCI, DIV TOXICOL SCI, BALTIMORE, MD 21205 USA; UNIV UTAH, HLTH SCI CTR, SALT LAKE CITY, UT 84132 USA	Johns Hopkins University; Utah System of Higher Education; University of Utah			Howard, William/ABC-9952-2021	Jensen, Laran/0000-0003-3199-1743	NIEHS NIH HHS [ES 07141, R01 ES 03817, R29 ES 05794] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES005794, R01ES003817] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BELTRAMINI M, 1989, BIOCHEM J, V260, P189, DOI 10.1042/bj2600189; BUCHMAN C, 1989, MOL CELL BIOL, V9, P4091, DOI 10.1128/MCB.9.9.4091; BUTT TR, 1984, P NATL ACAD SCI-BIOL, V81, P3332, DOI 10.1073/pnas.81.11.3332; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; ECKER DJ, 1986, J BIOL CHEM, V261, P6895; FOGEL S, 1982, P NATL ACAD SCI-BIOL, V79, P5342, DOI 10.1073/pnas.79.17.5342; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GEORGE GN, 1988, J BIOL CHEM, V263, P8199; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HAMER DH, 1985, SCIENCE, V228, P685, DOI 10.1126/science.3887570; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; KARIN M, 1985, CELL, V41, P9, DOI 10.1016/0092-8674(85)90051-0; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P337, DOI 10.1073/pnas.81.2.337; KILLE P, 1994, BBA-PROTEIN STRUCT M, V1205, P151, DOI 10.1016/0167-4838(94)90228-3; LEHMANMCKEEMAN LD, 1991, METALLOTHIONEIN BIOL, P121; LIU XF, 1992, J BIOL CHEM, V267, P18298; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; MEHRA RK, 1992, GENE, V114, P75, DOI 10.1016/0378-1119(92)90709-X; MEHRA RK, 1990, J BIOL CHEM, V265, P6369; MEHRA RK, 1989, J BIOL CHEM, V264, P19747; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; NARULA SS, 1993, BIOCHEMISTRY-US, V32, P6773, DOI 10.1021/bi00077a032; NIELSON KB, 1985, J BIOL CHEM, V260, P5342; OTVOS JD, 1993, METALLOTHIONEIN, V3, P57; Palmiter R D, 1987, Experientia Suppl, V52, P63; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; PETERING DH, 1986, ENVIRON HEALTH PERSP, V65, P217, DOI 10.2307/3430185; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING; SCHNEIDER JC, 1991, METHOD ENZYMOL, V194, P373; SIKORSKI RS, 1989, GENETICS, V122, P19; SZCZYPKA MS, 1989, MOL CELL BIOL, V9, P421, DOI 10.1128/MCB.9.2.421; THIELE DJ, 1986, MOL CELL BIOL, V6, P1158, DOI 10.1128/MCB.6.4.1158; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THIELE DJ, 1995, TOXICOLOGIST, V15, P1; Thorvaldsen JL, 1995, YEAST, V11, P1501, DOI 10.1002/yea.320111505; WAALKES M, 1991, RES TOXICOL, V3, P281; WELCH J, 1989, EMBO J, V8, P255, DOI 10.1002/j.1460-2075.1989.tb03371.x; WINGE DR, 1985, J BIOL CHEM, V260, P4464	43	90	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18514	18519		10.1074/jbc.271.31.18514	http://dx.doi.org/10.1074/jbc.271.31.18514			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702498	hybrid			2022-12-27	WOS:A1996VB68300036
J	Krebs, A; Kuchumov, AR; Sharma, PK; Braswell, EH; Zipper, P; Weber, RE; Chottard, G; Vinogradov, SN				Krebs, A; Kuchumov, AR; Sharma, PK; Braswell, EH; Zipper, P; Weber, RE; Chottard, G; Vinogradov, SN			Molecular shape, dissociation, and oxygen binding of the dodecamer subunit of Lumbricus terrestris hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; EXTRACELLULAR HEMOGLOBIN; EARTHWORM HEMOGLOBIN; QUATERNARY STRUCTURE; PROTEIN; ERYTHROCRUORIN; TRIMER; CHAINS; MODELS; PH	Small angle x-ray scattering of the 213-kDa dodecamer of Lumbricus terrestris Hb yielded radius of gyration = 3.74 +/- 0.01 nm, maximum diameter = 10.59 +/- 0.01 nm, and volume = 255 +/- 10 nm(3), with no difference between the oxy and deoxy states. Sedimentation velocity studies indicate the dodecamer to have a spherical shape and concentration- and Ca2+-dependent equilibria with its constituent subunits, the disulfide-bonded trimer of chains a-e and chain d. Equilibrium sedimentation data were fitted best with a trimer-dodecamer model, In K-4 = 7 (association K in liters(3)/g(3)) at 1 degrees C and 4 at 25 degrees C, providing Delta H = -20 kcal/mol and Delta S = 4.4 eu/mol. Oxydodecamer dissociation at pH 8.0, in urea, GdmCl, heteropolytungstate K-8[SiW11O39] and of metdodecamer at pH 7, was followed by gel filtration. Elution profiles were fitted with exponentially modified gaussians to represent the three peaks. Two exponentials were necessary to fit all the dissociations except in [SiW11O39](-8). Equilibrium oxygen binding measurements at pH 6.5-8.5, provided P-50 = 8.5, 11.5-11.9 and 11.9-13.5 torr, and n(50) = 5.2-9.5, 3.2-4.9, and 1.8-2.7 for blood, Hb, and dodecamer, respectively, at pH 7.5, 25 degrees C, P-50 was decreased 3- and 2-fold in similar to 100 nM Ca2+ and Mg2+, respectively, with concomitant but smaller increases in cooperativity.	WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,DETROIT,MI 48201; GRAZ UNIV,INST PHYS CHEM,A-8010 GRAZ,AUSTRIA; UNIV CONNECTICUT,DEPT MOL & CELL BIOL,STORRS,CT 06260; AARHUS UNIV,INST BIOL SCI,AARHUS 8000 C,DENMARK; UNIV PARIS 06,URA 419,CHIM MET TRANSIT LAB,F-75252 PARIS,FRANCE	Wayne State University; University of Graz; University of Connecticut; Aarhus University; UDICE-French Research Universities; Sorbonne Universite					NIDDK NIH HHS [DK38674] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038674] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANSEVIN AT, 1970, ANAL BIOCHEM, V34, P237, DOI 10.1016/0003-2697(70)90103-X; BLOOMFIE.V, 1967, BIOPOLYMERS, V5, P135, DOI 10.1002/bip.1967.360050202; CHOTTARD G, 1992, BIOCHIM BIOPHYS ACTA, V1122, P113, DOI 10.1016/0167-4838(92)90312-2; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; deHaas F, 1996, J MOL BIOL, V255, P140, DOI 10.1006/jmbi.1996.0012; deHaas F, 1996, BIOPHYS J, V70, P1973, DOI 10.1016/S0006-3495(96)79762-X; FUSHITANI K, 1986, J BIOL CHEM, V261, P8414; FUSHITANI K, 1988, J BIOL CHEM, V263, P6502; GLATTER O, 1980, ACTA PHYS AUSTRIACA, V52, P243; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KLEMPERER WG, 1990, INORG SYN, V27, P71, DOI 10.1002/9780470132586.ch14; Kratky O, 1982, SMALL ANGLE XRAY SCA, DOI [10.1002/actp.1985.010360520, DOI 10.1002/ACTP.1985.010360520]; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martin PD, 1996, J MOL BIOL, V255, P170, DOI 10.1006/jmbi.1996.0014; Martin PD, 1996, J MOL BIOL, V255, P154, DOI 10.1006/jmbi.1996.0013; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Novak J., 1987, CHROMATOGRAPHIC THEO, P103; OCHIAI T, 1993, BIOCHIM BIOPHYS ACTA, V1203, P310, DOI 10.1016/0167-4838(93)90100-6; Pilz I, 1979, Methods Enzymol, V61, P148; REH E, 1995, TRAC-TREND ANAL CHEM, V14, P1, DOI 10.1016/0165-9936(95)91139-J; SANTUCCI R, 1984, J MOL BIOL, V179, P713, DOI 10.1016/0022-2836(84)90163-3; Sharma PK, 1996, J BIOL CHEM, V271, P8754, DOI 10.1074/jbc.271.15.8754; SHISHIKURA F, 1986, BIOCHIM BIOPHYS ACTA, V869, P314, DOI 10.1016/0167-4838(86)90071-3; SHISHIKURA F, 1987, J BIOL CHEM, V262, P3123; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; SUZUKI T, 1993, J BIOL CHEM, V268, P13548; Szabo Z. G., 1969, COMPREHENSIVE CHEM K, V2, P1; VIDUGIRIS GJA, 1993, J BIOL CHEM, V268, P26190; Vinogradov S.N., 1985, P9; Vinogradov S. N., 1982, ELECTRON MICROS, P135; VINOGRADOV SN, 1994, METHOD ENZYMOL, V231, P112; VINOGRADOV SN, 1977, BIOCHIM BIOPHYS ACTA, V492, P136, DOI 10.1016/0005-2795(77)90221-5; VINOGRADOV SN, 1986, P NATL ACAD SCI USA, V83, P8034, DOI 10.1073/pnas.83.21.8034; VINOGRADOV SN, 1991, J BIOL CHEM, V266, P13091; VINOGRADOV SN, 1993, COMP BIOCHEM PHYS B, V106, P1, DOI 10.1016/0305-0491(93)90002-M; WEBER RE, 1987, J COMP PHYSIOL B, V157, P145, DOI 10.1007/BF00692358; WEBER RE, 1995, J MOL BIOL, V251, P703, DOI 10.1006/jmbi.1995.0466; WEBER RE, 1981, NATURE, V292, P386, DOI 10.1038/292386a0; WEBER RE, 1992, J APPL PHYSIOL, V72, P1611, DOI 10.1152/jappl.1992.72.4.1611; YPHANTIS DA, 1960, ANN NY ACAD SCI, V88, P586, DOI 10.1111/j.1749-6632.1960.tb20055.x	40	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18695	18704		10.1074/jbc.271.31.18695	http://dx.doi.org/10.1074/jbc.271.31.18695			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702524	hybrid			2022-12-27	WOS:A1996VB68300062
J	MacLeod, JN; BurtonWurster, N; Gu, DN; Lust, G				MacLeod, JN; BurtonWurster, N; Gu, DN; Lust, G			Fibronectin mRNA splice variant in articular cartilage lacks bases encoding the V, III-15, and I-10 protein segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ED-A; GENE; CHONDROCYTES; EXPRESSION; EXTRACTION; CULTURE; PLASMA; DOMAIN; FORM	Fibronectin is an extracellular matrix glycoprotein encoded by a single gene. Alternative RNA splicing has been reported at three sites, ED (extra type III domain)-A, ED-B, and the variable or V region. Articular cartilage fibronectin monomers are rarely (ED-A)(+), but approximately 25% are (ED-B)(+). RNA gel electrophoresis and Northern blot analysis identified two (ED-B)(+) and two (ED-B)(-) fibronectin transcripts in cartilage, each pair differing by similar to 750 bases, This difference results from a previously unreported RNA splicing pattern that eliminates not only the V region but also nucleotides encoding protein segments III-15 and I-10, This new splice variant, which we designate (V+C)(-), represents the majority of fibronectin transcripts in equine, canine, and rabbit articular cartilage but is absent in the liver, Reverse transcriptase-polymerase chain reaction analyses of II additional equine tissues failed to detect the (V+C)(-) splice variant, except for very low levels in lymph node, bone, aorta, and skin, Furthermore, chondrocytes grown in monolayer culture main tain high levels of fibronectin expression but stop expressing (V+C)(-) transcripts over time. The tissue-specific expression pattern of this novel fibronectin isoform suggests that it may have an important function in the matrix organization of cartilage.	CORNELL UNIV,COLL VET MED,JAMES A BAKER INST ANIM HLTH,DEPT MICROBIOL & IMMUNOL,ITHACA,NY 14853	Cornell University	MacLeod, JN (corresponding author), CORNELL UNIV,COLL VET MED,JAMES A BAKER INST ANIM HLTH,DEPT PHYSIOL,HUNGERFORD HILL RD,ITHACA,NY 14853, USA.							ADAMS ME, 1992, ANAL BIOCHEM, V202, P89, DOI 10.1016/0003-2697(92)90211-O; BENNETT VD, 1991, J BIOL CHEM, V266, P5918; BURTONWURSTER N, 1989, ARCH BIOCHEM BIOPHYS, V269, P32, DOI 10.1016/0003-9861(89)90084-2; BURTONWURSTER N, 1988, BIOCHEM BIOPH RES CO, V154, P1088, DOI 10.1016/0006-291X(88)90252-5; BURTONWURSTER N, 1993, ARCH BIOCHEM BIOPHYS, V306, P309, DOI 10.1006/abbi.1993.1517; BURTONWURSTER N, 1986, J RHEUMATOL, V13, P175; BURTONWURSTER N, 1989, BIOCHEM BIOPH RES CO, V165, P782, DOI 10.1016/S0006-291X(89)80034-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; HOMANDBERG GA, 1992, J BIOL CHEM, V267, P3597; Hynes RO, 1990, FIBRONECTINS; ICHIHARATANAKA K, 1995, J CELL SCI, V108, P907; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LEIPOLD HR, 1992, J ORTHOP RES, V10, P33, DOI 10.1002/jor.1100100105; LEVINE RA, 1993, NUCLEIC ACIDS RES, V21, P4426, DOI 10.1093/nar/21.18.4426; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; NIXON AJ, 1992, AM J VET RES, V53, P2364; NORTON PA, 1987, MOL CELL BIOL, V7, P4297, DOI 10.1128/MCB.7.12.4297; ODERMATT E, 1985, P NATL ACAD SCI USA, V82, P6571, DOI 10.1073/pnas.82.19.6571; PANDE H, 1987, EUR J BIOCHEM, V162, P403, DOI 10.1111/j.1432-1033.1987.tb10616.x; RENCIC A, 1995, OSTEOARTHR CARTILAGE, V3, P187, DOI 10.1016/S1063-4584(05)80053-6; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARZBAUER JE, 1991, BIOESSAYS, V13, P527, DOI 10.1002/bies.950131006; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SCHWARZBAUER JE, 1985, P NATL ACAD SCI USA, V82, P1424, DOI 10.1073/pnas.82.5.1424; TAMKUN JW, 1984, P NATL ACAD SCI-BIOL, V81, P5140, DOI 10.1073/pnas.81.16.5140; VIBEPEDERSEN K, 1984, EMBO J, V3, P2511, DOI 10.1002/j.1460-2075.1984.tb02165.x; VIBEPEDERSEN K, 1986, FEBS LETT, V207, P287, DOI 10.1016/0014-5793(86)81506-X; WURSTER NB, 1982, BIOCHEM BIOPH RES CO, V109, P1094, DOI 10.1016/0006-291X(82)91889-7; ZHANG D, 1995, MATRIX BIOL, V14, P623; ZHANG DW, 1995, J BIOL CHEM, V270, P1817, DOI 10.1074/jbc.270.4.1817	30	75	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18954	18960		10.1074/jbc.271.31.18954	http://dx.doi.org/10.1074/jbc.271.31.18954			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702559	hybrid			2022-12-27	WOS:A1996VB68300097
J	Maisner, A; Liszewski, MK; Atkinson, JP; SchwartzAlbiez, R; Herrler, G				Maisner, A; Liszewski, MK; Atkinson, JP; SchwartzAlbiez, R; Herrler, G			Two different cytoplasmic tails direct isoforms of the membrane cofactor protein (CD46) to the basolateral surface of Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; MDCK CELLS; MEASLES-VIRUS; ANCHORED PROTEINS; MULTIPLE ISOFORMS; TARGETING SIGNAL; LDL RECEPTOR; N-GLYCANS; DOMAIN	Membrane cofactor protein (MCP; CD46), a widely distributed regulatory protein of the complement system, was analyzed for expression in polarized epithelial cells, Both a human and a simian (Vero C1008) cell line were found to contain endogenous MCP mainly on the basolateral surface, Transfected Madin-Darby canine kidney cells stably expressing human MCP delivered this protein also predominantly to the basolateral surface, A deletion mutant lacking the cytoplasmic tail was transported in a nonpolarized fashion, indicating that the targeting signal for the basolateral transport is located in the cytoplasmic domain, A characteristic feature of MCP is the presence of various isoforms that contain either of two different cytoplasmic tails as a consequence of alternative splicing, Two isoforms differing only in the cytoplasmic tail (tail 1 or 2) were analyzed for polarized expression in Madin-Darby canine kidney cells, Surface biotinylation, as well as confocal immuno fluorescence microscopy, indicated that both proteins were transported to the basolateral surface, Because no sequence similarity has been observed, the two tails contain different basolateral targeting signals, A deletion mutant lacking the only tyrosine residue in tail 1 retained the polarized expression indicating that, in contrast to most basolateral sorting signals, the transport signal of the tail 1 isoform is not dependent on tyrosine, The maintenance of a targeting motif in two distinct cytoplasmic tails suggests that the basolateral expression of MCP in polarized epithelial cells is of physiological importance.	UNIV MARBURG,INST VIROL,D-35037 MARBURG,GERMANY; UNIV WASHINGTON,SCH MED,DEPT INTERNAL MED,DIV RHEUMATOL,ST LOUIS,MO 63110; DEUTSCH KREBSFORSCHUNGSZENTRUM,D-69120 HEIDELBERG,GERMANY	Philipps University Marburg; Washington University (WUSTL); Helmholtz Association; German Cancer Research Center (DKFZ)				Atkinson, John/0000-0002-2514-3441				AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BLAU DM, 1995, VIROLOGY, V210, P91, DOI 10.1006/viro.1995.1320; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CAPLAN M, 1989, FUNCTIONAL EPITHELIA, P71; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; FUHRER C, 1991, J CELL BIOL, V114, P423, DOI 10.1083/jcb.114.3.423; FULLER SD, 1985, EMBO J, V4, P297, DOI 10.1002/j.1460-2075.1985.tb03629.x; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; INOUE H, 1994, ACTA MED OKAYAMA, V48, P271; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LISZEWSKI MK, 1994, J BIOL CHEM, V269, P10776; LISZEWSKI MK, 1992, CURR TOP MICROBIOL, V178, P45; MAISNER A, 1994, J VIROL, V68, P6299, DOI 10.1128/JVI.68.10.6299-6304.1994; MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; POST TW, 1991, J EXP MED, V174, P93, DOI 10.1084/jem.174.1.93; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; SCHULTZE B, 1991, J VIROL, V65, P6232, DOI 10.1128/JVI.65.11.6232-6237.1991; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SRINIVAS RV, 1986, J VIROL, V58, P689, DOI 10.1128/JVI.58.2.689-693.1986; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031	40	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18853	18858		10.1074/jbc.271.31.18853	http://dx.doi.org/10.1074/jbc.271.31.18853			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702545	hybrid			2022-12-27	WOS:A1996VB68300083
J	McLeod, RS; Wang, YW; Wang, S; Rusinol, A; Links, P; Yao, ZM				McLeod, RS; Wang, YW; Wang, S; Rusinol, A; Links, P; Yao, ZM			Apolipoprotein B sequence requirements for hepatic very low density lipoprotein assembly - Evidence that hydrophobic sequences within apolipoprotein B48 mediate lipid recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL TRUNCATION; HEP G2 CELLS; ENDOPLASMIC-RETICULUM; RAT-LIVER; APO-B; MESSENGER-RNA; INTRACELLULAR-DISTRIBUTION; MONOCLONAL-ANTIBODIES; MCA-RH7777 CELLS; PAUSE TRANSFER	We studied the structural requirements of apolipoprotein (apo) B for assembly of very low density lipoproteins (VLDL) using rat hepatoma McA-RH7777 cells expressing human apoB (h-apoB), Recombinant h-apoB48, like endogenous rat apoB48 (r-apoB48), was secreted as VLDL in addition to high density lipoproteins (HDL) by transfected cells, indicating that the N-terminal 48% of apoB contains sequences sufficient for VLDL assembly, Truncation of the C terminus of h-apo-B48 to -B42 or -B37 had little effect on the ability of apoB to assemble VLDL, whereas truncation to -B34 or -B29 markedly diminished or abolished VLDL formation, None of the truncations affected the integration of apoB into HDL, To determine whether the ability to assemble VLDL is governed by apoB length or by sequences beyond apoB29, we created chimeric proteins that contained human apoA-I and a segment derived from between the C-terminal 29 and 34%, 34 and 37%, or 37 and 42% of apoB100, The resulting chimeras, namely AI/B29-34, AI/B34-37, and AI/B37-42, were secreted by the transfected cells as lipoproteins with buoyant density (d < 1.006 g/ml), electrophoretic mobility (pre-beta), and size characteristics of human plasma VLDL, The chimeras could assemble discrete VLDL particles devoid of endogenous of apoB100, and could actively recruit triglycerides and phospholipids into the lipoproteins. However, these chimeras were secreted inefficiently, Pulse-chase analysis showed that less than 5% of the newly synthesized AI/B proteins were secreted, and more than 70% was degraded intracellularly, Degradation of the chimeras could be blocked by the cysteine protease inhibitor N-acetyl-leucyl-leucyl-norleucinal, but the treatment did not enhance their secretion, Protease protection analysis of microsomes isolated from transfected cells indicated that > 65% of AI/B chimeras (compared with < 25% of r-apoB100) were inaccessible to exogenous trypsin, These data suggest that the recruitment of large quantitles of triglycerides during VLDL formation is not governed simply by apoB length, but is mediated by short hydrophobic sequences ranging from 152 to 237 amino acids (3-5%) of apoB, The existence of multiple such hydrophobic sequences within apoB48 may facilitate efficient assembly of hepatic VLDL particles.	UNIV OTTAWA,INST HEART,DEPT PATHOL & LAB MED,LIPOPROT & ATHEROSCLEROSIS GRP,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,INST HEART,DEPT BIOCHEM,OTTAWA,ON K1Y 4E9,CANADA; UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 2M8,CANADA	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of Alberta			McLeod, Roger/F-8014-2015	McLeod, Roger/0000-0002-6740-5569				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; CARTWRIGHT IJ, 1993, J BIOL CHEM, V268, P20937; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN SH, 1986, J BIOL CHEM, V261, P2918; CHRISTENSEN NJ, 1983, J LIPID RES, V24, P1229; CHUCK SL, 1993, J BIOL CHEM, V268, P22794; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DU EZ, 1994, J BIOL CHEM, V269, P24169; ELOVSON J, 1992, CIRCULATION S1, V86, P693; FAZIO S, 1995, ARTERIOSCL THROM VAS, V15, P593, DOI 10.1161/01.ATV.15.5.593; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; GREEVE J, 1993, J LIPID RES, V34, P1367; GRETCH DG, 1996, J BIOL CHEM, V270, P8682; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LINTON MF, 1993, J LIPID RES, V34, P521; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCEL YL, 1984, J BIOL CHEM, V259, P6952; MARSH JB, 1982, P SOC EXP BIOL MED, V170, P178, DOI 10.3181/00379727-170-41415; MCLEOD RS, 1994, BIOCHEM J, V302, P641, DOI 10.1042/bj3020641; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; NAKAHARA DH, 1994, J BIOL CHEM, V269, P7617; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; RUSINOL AE, 1995, J BIOL CHEM, V270, P13318, DOI 10.1074/jbc.270.22.13318; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; SEGREST JP, 1992, J LIPID RES, V33, P141; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SELBY SL, 1995, ARTERIOSCL THROM VAS, V15, P1900, DOI 10.1161/01.ATV.15.11.1900; SHELNESS GS, 1995, CIRCULATION S1, V92, P362; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; SWIFT LL, 1995, J LIPID RES, V36, P395; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; WHITE AL, 1992, J BIOL CHEM, V267, P15657; WONG L, 1987, EUR J BIOCHEM, V164, P357, DOI 10.1111/j.1432-1033.1987.tb11066.x; WONG L, 1987, BIOCHIM BIOPHYS ACTA, V918, P16, DOI 10.1016/0005-2760(87)90004-X; YAO ZM, 1993, ARTERIOSCLER THROMB, V13, P1476, DOI 10.1161/01.ATV.13.10.1476; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YAO ZM, 1992, J BIOL CHEM, V267, P1175	47	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18445	18455		10.1074/jbc.271.31.18445	http://dx.doi.org/10.1074/jbc.271.31.18445			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702489	hybrid			2022-12-27	WOS:A1996VB68300027
J	Novak, U; Mui, A; Miyajima, A; Paradiso, L				Novak, U; Mui, A; Miyajima, A; Paradiso, L			Formation of STAT5-containing DNA binding complexes in response to colony-stimulating factor-1 and platelet-derived growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; INTERFERON-ALPHA; SERINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; STAT3 ACTIVATION; FACTOR-RECEPTOR; GENE FAMILY; CELL-LINE; PROLACTIN	Colony-stimulating factor (CSF-1) activates several members belonging to the STAT (signal transducers and activators of transcription) family of transcription factors. We investigated the DNA binding complexes activated by CSF-1 in several cell lines and compared them with complexes activated by platelet-derived growth factor and interleukin 3. Our results indicate that the SIE-A complex activated by CSF-1 and platelet-derived growth factor may contain STAT3/STAT5 heterodimers binding to the high affinity SIF binding site, m67. In addition, both growth factors activate one or several STATE-containing protein complexes binding to the prolactin-inducible element, PIE. The formation of these complexes was cell type and growth factor specific, Interleukin 3 activated only PIE binding complexes containing STAT5A and STAT5B and did not activate m67 binding complexes. It appears, therefore, that STATE cannot bind to m67 as a homodimer, but it can bind if it is dimerized with STAT3, whereas it can bind to the PIE element without being either complexed with STAT3 or any other known STAT protein, possibly as a homodimer or as STAT5A/STAT5B heterodimer. However, in addition, STATE may heterodimerize with other proteins and form novel PIE binding complexes.	DNAX RES INST MOL & CELLULAR BIOL INC,DEPT CELL BIOL,PALO ALTO,CA 94304; UNIV TOKYO,INST MOL & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Tokyo	Novak, U (corresponding author), UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT MED,MELBOURNE,VIC 3050,AUSTRALIA.							BACON CM, 1995, FEBS LETT, V370, P63, DOI 10.1016/0014-5793(95)00796-C; BARAHMANDPOUR F, 1995, FEBS LETT, V360, P29, DOI 10.1016/0014-5793(95)00072-H; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; EILERS A, 1995, MOL CELL BIOL, V15, P3579; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P5705; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIU ALF, 1996, EMBO J, V15, P2425; MUI ALF, 1995, EMBO J, V14, P1165; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; NOVAK U, 1996, IN PRESS GROWTH FACT; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	38	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18350	18354		10.1074/jbc.271.31.18350	http://dx.doi.org/10.1074/jbc.271.31.18350			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702476	hybrid			2022-12-27	WOS:A1996VB68300014
J	tHart, LM; Lindhout, D; VanderZon, GCM; Kayserilli, H; Apak, MY; Kleijer, WJ; VanderVorm, ER; Maassen, JA				tHart, LM; Lindhout, D; VanderZon, GCM; Kayserilli, H; Apak, MY; Kleijer, WJ; VanderVorm, ER; Maassen, JA			An insulin receptor mutant (Asp(707)->Ala), involved in leprechaunism, is processed and transported to the cell surface but unable to bind insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; ALPHA-SUBUNIT; STRUCTURAL BASIS; MUTATION; REGION; IDENTIFICATION; GENE; SUBSTITUTION; DETERMINANTS; SPECIFICITY	We have identified a homozygous mutation near the carboxyl terminus of the insulin receptor (IR) alpha subunit from a leprechaun patient, changing Asp(707) into Ala, Fibroblasts from this patient had no high affinity insulin binding sites, To examine the effect of the mutation on IR properties, the mutant IR was stably expressed in Chinese hamster ovary cells, Western blot analysis and metabolic labeling showed a normal processing of the mutant receptor to alpha and beta subunits, No increase in high affinity insulin binding sites was observed on Chinese hamster ovary cells expressing the mutant receptor, and also, affinity cross-linking of I-125-labeled insulin by di-succinimidyl suberate to these cells failed to label the mutant alpha subunit, Biotinylation of cell surface proteins by biotin succinimidyl ester resulted in efficient biotinylation of the mutant IR alpha and beta subunits, showing its presence on the cell surface, On solubilization of the mutant insulin receptor in Triton X-100-containing buffers, I-125-insulin was efficiently cross-linked to the receptor alpha subunit by disuccinimidyl suberate, These studies demonstrate that Ala(707) IR is normally processed and transported to the cell surface and that the mutation distorts the insulin binding site, Detergent restores this site, This is an example of a naturally occurring mutation in the insulin receptor that affects insulin binding without affecting receptor transport and processing, This mutation points to a major contribution of the alpha subunit carboxyl terminus to insulin binding.	LEIDEN UNIV,DEPT MED BIOCHEM,NL-2333 AL LEIDEN,NETHERLANDS; ERASME UNIV HOSP,DEPT CLIN GENET,NL-3015 GE ROTTERDAM,NETHERLANDS; UNIV ISTANBUL,INST CHILD HLTH,MED GENET UNIT,TR-34390 ISTANBUL,TURKEY; JULIANA CHILDRENS HOSP,NL-2566 ER THE HAGUE,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Istanbul University			't Hart, Leen/ABG-3185-2021; Lindhout, Dick/AAH-5765-2019; Kayserili, Hülya/AAA-5593-2021	't Hart, Leen/0000-0003-4401-2938; Kayserili, Hülya/0000-0003-0376-499X; Lindhout, Dick/0000-0001-9580-624X				ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FABRY M, 1992, J BIOL CHEM, V267, P8950; GARVEY WT, 1993, BAILLIERE CLIN ENDOC, V7, P785; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI T, 1991, J BIOL CHEM, V266, P21224; KLINKHAMER MP, 1989, EMBO J, V8, P2503, DOI 10.1002/j.1460-2075.1989.tb08387.x; KUROSE T, 1994, J BIOL CHEM, V269, P29190; LANE MD, 1985, BIOCHIMIE, V67, P1069, DOI 10.1016/S0300-9084(85)80104-8; Mckusick V.A., 1994, MENDELIAN INHERITANC; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; PASHMFOROUSH M, 1994, J BIOL CHEM, V269, P32639; RAFAELOFF R, 1989, J BIOL CHEM, V264, P15900; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SEINO S, 1990, DIABETES, V39, P123, DOI 10.2337/diabetes.39.1.123; TAOUIS M, 1994, J BIOL CHEM, V269, P14912; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERVORM ER, 1992, J BIOL CHEM, V267, P66; YIP CC, 1992, J CELL BIOCHEM, V48, P19, DOI 10.1002/jcb.240480105; YIP CC, 1988, BIOCHEM BIOPH RES CO, V157, P321, DOI 10.1016/S0006-291X(88)80050-0; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858	26	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18719	18724		10.1074/jbc.271.31.18719	http://dx.doi.org/10.1074/jbc.271.31.18719			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702527	hybrid, Green Published			2022-12-27	WOS:A1996VB68300065
J	McCudden, CR; PowersLee, SG				McCudden, CR; PowersLee, SG			Required allosteric effector site for N-acetylglutamate on carbamoyl-phosphate synthetase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL PROTEIN CAD; COOH-TERMINAL DOMAIN; ACETYL-L-GLUTAMATE; ESCHERICHIA-COLI; BINDING-SITES; CROSS-LINKS; AMIDOTRANSFERASE DOMAIN; CATALYTIC SUBUNIT; LIVER; RAT	Carbamoyl-phosphate synthetase I (CPSase I) catalyzes the entry and rate-limiting step in the urea cycle, the pathway by which mammals detoxify ammonia, One facet of CPSase I regulation is a requirement for N-acetylglutamate (AGA), which induces an active enzyme conformation and does not participate directly in the chemical reaction, We have utilized labeling with carbodiimide-activated [C-14]AGA to identify peptides 120-127, 234-237, 625-630, and 1351-1356 as potentially being near the binding site for AGA, Identification of peptide 1351-1356 confirms the previous demonstration (Rodriquez-Aparicio, L, B,, Guadalajara, A. M., and Rubio, V, (1989) Biochemistry 28, 3070-3074) that the C-terminal region is involved in binding AGA, Identification of peptides 120-127 and 234-237 constitutes the first evidence that the N-terminal region of the synthetase is involved in ligand binding, Since peptides 631-638 and 1327-1348 have been identified near the ATP site of CPSase I (Potter, M, D,, and Powers-Lee, S, G, (1992) J, Biol, Chem, 267, 2023-2031), the present finding of involvement of peptides 625-630 and 1351-1356 at an ''allosteric'' activator site was unexpected, The idea that portions of the AGA effector site might be derived from an ancestral glutamine substrate site via a gene duplication and diversification event was considered.	NORTHEASTERN UNIV, DEPT BIOL, BOSTON, MA 02115 USA	Northeastern University					NIDDK NIH HHS [DK-33460, DK-1319] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033460, K04DK001319] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN G, 1989, SEQUENCING PROTEINS, P233; ANDERSON PM, 1965, BIOCHEMISTRY-US, V4, P2803, DOI 10.1021/bi00888a034; ANDERSON PM, 1995, NITROGEN METABOLISM, P33; BECK JT, 1989, BIOCHEMISTRY-US, V28, P6931, DOI 10.1021/bi00443a023; BEIN K, 1991, J BIOL CHEM, V266, P3791; BOSCH J, 1985, TETRAHEDRON, V41, P2557, DOI 10.1016/S0040-4020(01)96651-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER SE, 1995, NATURE, V378, P140, DOI 10.1038/378140a0; BRITTON HG, 1990, EUR J BIOCHEM, V188, P47, DOI 10.1111/j.1432-1033.1990.tb15369.x; BRITTON HG, 1979, EUR J BIOCHEM, V102, P521, DOI 10.1111/j.1432-1033.1979.tb04268.x; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P2065, DOI 10.1021/bi00431a015; BUECHLER JA, 1988, BIOCHEMISTRY-US, V27, P7356, DOI 10.1021/bi00419a027; BUESO J, 1994, BIOCHEM BIOPH RES CO, V203, P1083, DOI 10.1006/bbrc.1994.2293; Carraway K L, 1972, Methods Enzymol, V25, P616, DOI 10.1016/S0076-6879(72)25060-1; CERVERA J, 1993, J BIOL CHEM, V268, P12504; COHEN NS, 1985, BIOCHEM J, V229, P205, DOI 10.1042/bj2290205; EVANS DR, 1988, BIOCHIM BIOPHYS ACTA, V953, P185, DOI 10.1016/0167-4838(88)90023-4; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; GUY HI, 1995, J BIOL CHEM, V270, P2190, DOI 10.1074/jbc.270.5.2190; GUY HI, 1994, J BIOL CHEM, V269, P7702; HELBING CC, 1994, J BIOL CHEM, V269, P11743; HENDERSON GB, 1980, J BIOL CHEM, V255, P4829; HONG J, 1994, J MOL BIOL, V243, P131, DOI 10.1006/jmbi.1994.1638; HORSPOOL W, 1992, ORG PHOTOCHEM, P444; ITALIEN JJ, 1986, METHODS PROTEIN MICR, P279; KIM HS, 1992, J BIOL CHEM, V267, P7177; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU X, 1994, J BIOL CHEM, V269, P27747; LUSTY CJ, 1983, J BIOL CHEM, V258, P4466; MARAS B, 1994, J BIOL CHEM, V269, P18429; MARSHALL M, 1988, ARCH BIOCHEM BIOPHYS, V262, P455, DOI 10.1016/0003-9861(88)90397-9; MEIJER AJ, 1979, TRENDS BIOCHEM SCI, V4, P83, DOI 10.1016/0968-0004(79)90188-9; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; NYUNOYA H, 1984, J BIOL CHEM, V259, P9790; PAULUS H, 1983, CURR TOP CELL REGUL, V22, P177; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PIERARD A, 1978, J BACTERIOL, V134, P167; PIETTE J, 1984, P NATL ACAD SCI-BIOL, V81, P4134, DOI 10.1073/pnas.81.13.4134; POST LE, 1990, J BIOL CHEM, V265, P7742; POTTER MD, 1992, J BIOL CHEM, V267, P2023; POTTER MD, 1993, ARCH BIOCHEM BIOPHYS, V306, P377, DOI 10.1006/abbi.1993.1526; POWERS SG, 1983, J BIOL CHEM, V258, P7545; POWERS SG, 1981, J BIOL CHEM, V256, P1160; POWERS SG, 1977, J BIOL CHEM, V252, P3558; POWERS SG, 1978, J BIOL CHEM, V253, P800; POWERSLEE SG, 1986, J BIOL CHEM, V261, P5349; POWERSLEE SG, 1987, J BIOL CHEM, V262, P9052; PRICE CW, 1978, J GEN MICROBIOL, V106, P145, DOI 10.1099/00221287-106-1-145; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; RUBIO V, 1983, EUR J BIOCHEM, V134, P337, DOI 10.1111/j.1432-1033.1983.tb07572.x; RUBIO V, 1991, BIOCHEMISTRY-US, V30, P1068, DOI 10.1021/bi00218a027; RUBIO V, 1979, EUR J BIOCHEM, V93, P245, DOI 10.1111/j.1432-1033.1979.tb12817.x; Rubio V, 1995, BIOCHEM SOC T, V23, P879, DOI 10.1042/bst0230879; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; Smith JL, 1995, BIOCHEM SOC T, V23, P894, DOI 10.1042/bst0230894; SOTTRUPJENSEN L, 1990, J BIOL CHEM, V265, P17727; SOUCIET JL, 1987, MOL GEN GENET, V207, P314, DOI 10.1007/BF00331595; STRITTMATTER P, 1990, J BIOL CHEM, V265, P21709; TROTTA PP, 1971, P NATL ACAD SCI USA, V68, P2599, DOI 10.1073/pnas.68.10.2599; vandenHoff MJB, 1995, J MOL EVOL, V41, P813, DOI 10.1007/BF00173161; WAGNER C, 1984, ARCH BIOCHEM BIOPHYS, V233, P457, DOI 10.1016/0003-9861(84)90467-3; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203	66	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18285	18294		10.1074/jbc.271.30.18285	http://dx.doi.org/10.1074/jbc.271.30.18285			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663466	hybrid			2022-12-27	WOS:A1996UY93500103
J	Nelson, KL; Becker, NA; Pahwa, GS; Hollingsworth, MA; Maher, LJ				Nelson, KL; Becker, NA; Pahwa, GS; Hollingsworth, MA; Maher, LJ			Potential for H-DNA in the human MUC1 mucin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KI-RAS PROMOTER; SUPERCOILED DNA; BINDING-PROTEIN; MIRROR REPEATS; TRIPLEXES; SEQUENCE; HOMOPURINE; PLASMIDS; EXPRESSION; ELEMENTS	Similar imperfect purine/pyrimidine mirror repeat (PMR) elements have previously been identified up stream of the human MUC1 mucin and CFTR genes. These elements confer S1 nuclease sensitivity on isolated plasmid DNA at low pH. We now present a detailed characterization of the non-B DNA structure responsible for S1 nuclease sensitivity upstream of the MUC1 gene. A similar to 90-base pair (bp) DNA fragment containing a 32-bp PMR element termed M-PMR3 was subcloned into a recombinant vector. This fragment conferred S1 nuclease sensitivity on the resulting supercoiled plasmid. High resolution mapping of sites reactive to S1 and P1 nucleases demonstrates that cleavage occurs within the M-PMR3 element. High resolution mapping with chemical agents selective for non-B DNA provides evidence that M-PMR3 adopts an H-DNA structure (intramolecular triple helix) in the less common H-y5 isomer at low pH. This result is observed in the presence or absence of Mg2+. Mutation of the native M-PMR3 element to create perfect homopurine/homopyrimidine mirror symmetry alters the preferred folding to the more common H-y3 tripler DNA isomer. These results demonstrate that imperfections in mirror symmetry can alter the relative stabilities of different H-DNA isomers.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198	Mayo Clinic; University of Nebraska System; University of Nebraska Medical Center					NATIONAL CANCER INSTITUTE [R01CA057362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047814] Funding Source: NIH RePORTER; NCI NIH HHS [CA57362] Funding Source: Medline; NIDDK NIH HHS [DK44762] Funding Source: Medline; NIGMS NIH HHS [GM47814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE M, 1993, P NATL ACAD SCI USA, V90, P282, DOI 10.1073/pnas.90.1.282; BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; BERNUES J, 1990, NUCLEIC ACIDS RES, V18, P4067, DOI 10.1093/nar/18.14.4067; BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; CADDLE MS, 1990, J MOL BIOL, V211, P19, DOI 10.1016/0022-2836(90)90008-A; CHAMBERS JA, 1994, J CELL SCI, V107, P415; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GLASER RL, 1990, J MOL BIOL, V211, P751, DOI 10.1016/0022-2836(90)90075-W; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; HOLLINGSWORTH MA, 1994, INT J CANCER, V57, P198, DOI 10.1002/ijc.2910570212; HOLLINGSWORTH MA, 1994, NUCLEIC ACIDS RES, V22, P1138, DOI 10.1093/nar/22.7.1138; HOOPES BC, 1981, NUCLEIC ACIDS RES, V9, P5493, DOI 10.1093/nar/9.20.5493; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; KANG S, 1992, J BIOL CHEM, V267, P1259; KANG S, 1992, J BIOL CHEM, V267, P20889; KOHWI Y, 1993, GENE DEV, V7, P1766, DOI 10.1101/gad.7.9.1766; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWI Y, 1992, J MOL BIOL, V223, P817, DOI 10.1016/0022-2836(92)90242-C; KOHWISHIGEMATSU T, 1985, CELL, V43, P199, DOI 10.1016/0092-8674(85)90024-8; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; LAPIDOT A, 1989, NUCLEIC ACIDS RES, V17, P883, DOI 10.1093/nar/17.3.883; LEE JS, 1987, NUCLEIC ACIDS RES, V15, P1047, DOI 10.1093/nar/15.3.1047; LILLEY DMJ, 1980, P NATL ACAD SCI-BIOL, V77, P6468, DOI 10.1073/pnas.77.11.6468; LYAMICHEV VI, 1986, J BIOMOL STRUCT DYN, V3, P667, DOI 10.1080/07391102.1986.10508454; MCDONALD CD, 1994, GENE, V150, P267, DOI 10.1016/0378-1119(94)90436-7; MURAISO T, 1992, NUCLEIC ACIDS RES, V20, P6631, DOI 10.1093/nar/20.24.6631; PELEG M, 1995, NUCLEIC ACIDS RES, V23, P1292, DOI 10.1093/nar/23.8.1292; PESTOV DG, 1991, NUCLEIC ACIDS RES, V19, P6527, DOI 10.1093/nar/19.23.6527; RADHAKRISHNAN I, 1994, BIOCHEMISTRY-US, V33, P11405, DOI 10.1021/bi00204a001; RAGHU G, 1994, NUCLEIC ACIDS RES, V22, P3271, DOI 10.1093/nar/22.16.3271; ROONEY SM, 1995, P NATL ACAD SCI USA, V92, P2141, DOI 10.1073/pnas.92.6.2141; Sambrook J., 2002, MOL CLONING LAB MANU; SCHROTH GP, 1995, NUCLEIC ACIDS RES, V23, P1977, DOI 10.1093/nar/23.11.1977; SHIMIZU M, 1994, J MOL BIOL, V235, P185, DOI 10.1016/S0022-2836(05)80025-7; SHIROTANI K, 1994, J BIOL CHEM, V269, P15030; TOMIZAWA J, 1984, CELL, V38, P861, DOI 10.1016/0092-8674(84)90281-2; TREZISE AEO, 1993, HUM MOL GENET, V2, P213, DOI 10.1093/hmg/2.3.213; VOJTISKOVA M, 1988, FEBS LETT, V234, P295, DOI 10.1016/0014-5793(88)80102-9; VOLOSHIN ON, 1988, NATURE, V333, P475, DOI 10.1038/333475a0; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	50	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18061	18067		10.1074/jbc.271.30.18061	http://dx.doi.org/10.1074/jbc.271.30.18061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663482	hybrid			2022-12-27	WOS:A1996UY93500071
J	Giardina, B; Ascenzi, P; Clementi, ME; DeSanctis, G; Rizzi, M; Coletta, M				Giardina, B; Ascenzi, P; Clementi, ME; DeSanctis, G; Rizzi, M; Coletta, M			Functional modulation by lactate of myoglobin - A monomeric allosteric hemoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOGLOBIN; BINDING; OXYGEN	The effect of lactate on O-2 binding properties of sperm whale and horse heart myoglobins (Mb) has been investigated at moderately acid pH (i.e. pH 6.5, a condition which may be achieved in vivo under a physical effort). Addition of lactate brings about a decrease of O-2 affinity (i.e. an increase of P-50) in sperm whale and horse heart myoglobins. Accordingly, lactate shows a different affinity for the deoxygenated and oxygenated form, behaving as a heterotropic modulator. The lactate effect on O-2 affinity appears to differ for sperm whale and horse heart Mb, delta logP(50) being approximate to 1.0 and approximate to 0.4, respectively. From the kinetic viewpoint, the variation of O-2 affinity for both myoglobins can be attributed mainly to a decrease of the kinetic association rate constant for ligand binding.	UNIV CAMERINO, DEPT MOLEC CELLULAR & ANIM BIOL, I-62032 CAMERINO, MC, ITALY; UNIV CATTOLICA SACRO CUORE, CNR, CTR RECEPTOR CHEM, I-00168 ROME, ITALY; UNIV CATTOLICA SACRO CUORE, INST CHEM & CLIN CHEM, I-00168 ROME, ITALY; UNIV ROME 3, DEPT BIOL, I-00154 ROME, ITALY; UNIV ROMA TOR VERGATA, DEPT EXPTL MED & BIOCHEM SCI, I-00133 ROME, ITALY; UNIV PAVIA, DEPT GENET & MICROBIOL, I-27100 PAVIA, ITALY	University of Camerino; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR); Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Roma Tre University; University of Rome Tor Vergata; University of Pavia			Clementi, Maria Elisabetta/E-5936-2017; Clementi, Maria Elisabetta/AAA-1450-2022; Coletta, Massimo/N-9049-2015; Coletta, Massimiliano/GSN-5927-2022	Clementi, Maria Elisabetta/0000-0002-4615-7826; Clementi, Maria Elisabetta/0000-0002-4615-7826; COLETTA, Massimiliano/0000-0002-5489-9467				ANSARI A, 1994, BIOCHEMISTRY-US, V33, P5128, DOI 10.1021/bi00183a017; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BROOKS GA, 1986, MED SCI SPORT EXER, V18, P360, DOI 10.1249/00005768-198606000-00019; DAVIS JA, 1985, MED SCI SPORT EXER, V17, P6; Giardina B, 1981, Methods Enzymol, V76, P417; GIBSON QH, 1973, P NATL ACAD SCI USA, V70, P1, DOI 10.1073/pnas.70.1.1; HOCHACHKA PW, 1984, BIOCH ADAPTATION, P183; KOMIYAMA NH, 1995, NATURE, V373, P244, DOI 10.1038/373244a0; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; SENO Y, 1990, J MOL BIOL, V216, P111, DOI 10.1016/S0022-2836(05)80064-6; WITTENBE.JB, 1966, J BIOL CHEM, V241, P104; WYMAN J, 1966, J BIOL CHEM, V241, P115; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4	15	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					16999	17001		10.1074/jbc.271.29.16999	http://dx.doi.org/10.1074/jbc.271.29.16999			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663546	hybrid			2022-12-27	WOS:A1996UX94300005
J	Katagiri, H; Asano, T; Ishihara, H; Inukai, K; Shibasaki, Y; Kikuchi, M; Yazaki, Y; Oka, Y				Katagiri, H; Asano, T; Ishihara, H; Inukai, K; Shibasaki, Y; Kikuchi, M; Yazaki, Y; Oka, Y			Overexpression of catalytic subunit p110 alpha of phosphatidylinositol 3-kinase increases glucose transport activity with translocation of glucose transporters in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; INSULIN; EXPRESSION; CLONING; LOCALIZATION; PI3-KINASE; COMPLEXES; PROTEINS; BINDING; DOMAINS	To elucidate the mechanisms of phosphatidylinositol (PI) 3-kinase involvement in insulin-stimulated glucose transport activity, the epitope-tagged p110 alpha subunit of PI 3-kinase was overexpressed in 3T3-L1 adipocytes using an adenovirus-mediated gene transduction system, Overexpression of p110 alpha was confirmed by immunoblot using anti-tagged epitope antibody, p110 alpha overexpression induced a 2.5-fold increase in PI 3-kinase activity associated with its regulatory subunits in the basal state, an increase exceeding that of the maximally insulin-stimulated control cells, while PI 3-kinase activity associated with phosphotyrosyl protein was only modestly elevated, Overexpression of p110 alpha induced an approximately 14-fold increase in the basal glucose transport rate, which was also greater than that observed in the stimulated control. No apparent difference was observed in the cellular expression level of either GLUT1 or GLUT4 proteins between control and p110 alpha-overexpressing 3T3-L1 adipocytes, Subcellular fractionation revealed translocation of glucose transporters from intracellular to plasma membranes in basal p110 alpha-overexpressing cells, The translocation of GLUT4 protein to the plasma membrane was further confirmed using a membrane sheet assay, These findings indicate that an increment in PI 3-kinase activity induced by overexpression of p110 alpha of PI 3-kinase stimulates glucose transport activity with translocation of glucose transporters, i,e,, mimics the effect of insulin.	ASAHI LIFE FDN,INST ADULT DIS,SHINJUKU KU,TOKYO 160,JAPAN; YAMAGUCHI UNIV,SCH MED,DEPT INTERNAL MED 3,UBE,YAMAGUCHI 755,JAPAN	Asahi Life Foundation; Yamaguchi University	Katagiri, H (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN.							ASANO T, 1992, J BIOL CHEM, V267, P19636; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4903; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FINGAR DC, 1994, J BIOL CHEM, V269, P10127; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; JAMES DE, 1993, J CELL SCI, V104, P607; KAMOHARA S, 1995, P NATL ACAD SCI USA, V92, P1077, DOI 10.1073/pnas.92.4.1077; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KATAGIRI H, 1992, J BIOL CHEM, V267, P22550; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; MARCUSOHN J, 1995, CURR BIOL, V5, P1296, DOI 10.1016/S0960-9822(95)00256-9; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OKA Y, 1988, J BIOL CHEM, V263, P13432; OKADA T, 1994, J BIOL CHEM, V269, P3568; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PIPER RC, 1991, AM J PHYSIOL, V260, pC571; PONS S, 1995, MOL CELL BIOL, V15, P4453; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	36	156	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					16987	16990		10.1074/jbc.271.29.16987	http://dx.doi.org/10.1074/jbc.271.29.16987			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663584	hybrid			2022-12-27	WOS:A1996UX94300002
J	Knauper, V; Will, H; LopezOtin, C; Smith, B; Atkinson, SJ; Stanton, H; Hembry, RM; Murphy, G				Knauper, V; Will, H; LopezOtin, C; Smith, B; Atkinson, SJ; Stanton, H; Hembry, RM; Murphy, G			Cellular mechanisms for human procollagenase-3 (MMP-13) activation - Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; TISSUE INHIBITOR; MATRIX METALLOPROTEINASES; CYSTEINE SWITCH; COLLAGENASE; CELLS; PROGELATINASE; STROMELYSIN; CATALYSIS; RECEPTOR	Gelatinase A and membrane-type metalloproteinase (MT1-MMP) were able to process human procollagenase 3 (M(r) 60,000) to the fully active enzyme (Tyr(85) N terminus; M(r) 48,000). MT1-MMP activated procollagenase-3 via a M(r) 56,000 intermediate (Ile(36) N terminus) to 48,000 which was the result of the cleavage of the Glu(84)-Tyr(85) peptide bond. We have established that the activation rate of procollagenase-3 by MT1-MMP was enhanced in the presence of progelatinase A, thereby demonstrating a unique new activation cascade consisting of three members of the matrix metalloproteinase family. In addition, procollagenase-3 can be activated by plasmin, which cleaved the Lys(38)-GlU(39) and Arg(76)-Cys(77) peptide bonds in the propeptide domain, Autoproteolysis then resulted in the release of the rest of She propeptide domain generating Tyr(85) N-terminal active collagenase 3. However, plasmin cleaved the C-terminal domain of collagenase-3 which results in the loss of its collagenolytic activity. Concanavalin A-stimulated fibroblasts expressing MT1-MMP and fibroblast-derived plasma membranes were able to process human procollagenase-3 via a M, 56,000 intermediate form to the final M(r) 48,000 active enzyme which, by analogy with progelatinase A activation, may represent a model system for in vivo activation. Inhibition experiments using tissue inhibitor of metalloproteinases, plasminogen activator inhibitor-a, or aprotinin demonstrated that activation in the cellular model system was due to MT1-MMP/gelatinase A and excluded the participation of serine proteinases such as plasmin during procollagenase-3 activation, We have established that progelatinase A can considerably potentiate the activation rate of procollagenase-3 by crude plasma membrane preparations from concanavalin A-stimulated fibroblasts, thus confirming our results using purified progelatinase A and MT1-MMP. This new activation cascade may be significant in human breast cancer pathology, where all three enzymes have been implicated as playing important roles.	IN VITEK GMBH,D-13125 BERLIN,GERMANY; UNIV OVIEDO,DEPT BIOL FUNC,E-33006 OVIEDO,SPAIN; CELLTECH LTD,SLOUGH SL1 4EN,BERKS,ENGLAND	University of Oviedo; Celltech Group Ltd	Knauper, V (corresponding author), STRANGEWAYS RES LAB,DEPT CELL & MOLEC BIOL,WORTS CAUSEWAY,CAMBRIDGE CB1 4RN,ENGLAND.		López-Otín, Carlos/AAB-2106-2020	López-Otín, Carlos/0000-0001-6964-1904; STANTON, HEATHER/0000-0002-3427-5614; Knauper, Vera/0000-0002-3965-9924	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; BECKER JW, 1995, PROTEIN SCI, V4, P1966, DOI 10.1002/pro.5560041002; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; CAWSTON TE, 1981, BIOCHIM BIOPHYS ACTA, V657, P73, DOI 10.1016/0005-2744(81)90131-5; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; DANE K, 1985, ADV CANCER RES, V44, P139; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; EECKHOUT Y, 1977, BIOCHEM J, V166, P21, DOI 10.1042/bj1660021; FREIJE JMP, 1994, J BIOL CHEM, V269, P16765; HEMBRY RM, 1986, J CELL SCI, V81, P105; HOLZ RC, 1992, J AM CHEM SOC, V114, P9611, DOI 10.1021/ja00050a048; KNAUPER V, 1993, BIOCHEM J, V295, P581; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MONTEAGUDO C, 1990, AM J PATHOL, V136, P585; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; Murphy G, 1992, Matrix Suppl, V1, P224; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; OMURA TH, 1994, J BIOL CHEM, V269, P24994; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; POLETTE M, 1993, INVAS METAST, V13, P31; PUENTE XS, 1996, IN PRESS CANC RES; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; WARD ES, 1992, J MOL BIOL, V224, P885, DOI 10.1016/0022-2836(92)90455-S; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WITTER JP, 1995, J BONE MINER RES, V10, pS439	40	584	599	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17124	17131		10.1074/jbc.271.29.17124	http://dx.doi.org/10.1074/jbc.271.29.17124			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663255	hybrid			2022-12-27	WOS:A1996UX94300024
J	Takahashi, T; Tanaka, M; Ogasawara, J; Suda, T; Murakami, H; Nagata, S				Takahashi, T; Tanaka, M; Ogasawara, J; Suda, T; Murakami, H; Nagata, S			Swapping between Fas and granulocyte colony-stimulating factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; GROWTH-HORMONE; EXPRESSION; ACTIVATION; APOPTOSIS	Fas belongs to the tumor necrosis factor/nerve growth factor receptor family. The Fas ligand binds to its receptor, Fas, and induces apoptosis in Fas-bearing cells. The granulocyte colony-stimulating factor receptor (G-CSFR) is a member of the hemopoietic growth factor receptor family. G-CSF induces its dimerization and regulates the proliferation and differentiation of neutrophilic granulocytes, We constructed hybrid receptors between Fas and G-CSFR and expressed them in the mouse T cell line WR19L or the mouse myeloid interleukin-3-dependent FDC-P1 cell line. The Fas ligand or an agonistic anti-Fas antibody stimulated proliferation of the FDC-P1 transformants expressing a chimera consisting of the Fas extracellular and G-CSFR cytoplasmic regions. On the other hand, G-CSF could not induce apoptosis in the transformants expressing the chimera consisting of the G-CSFR extracellular and Fas cytoplasmic regions, but these cells were killed by a polyclonal antibody against G-CSFR. These results indicated that receptors belonging to different receptor families can be functionally exchanged and confirm that a homodimer of G-CSFR can transduce the growth signal, whereas Fas must be oligomerized (probably trimerized) to transduce the apoptotic signal.	OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT GENET,SUITA,OSAKA 565,JAPAN	Osaka University			Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIES DR, 1995, FASEB J, V9, P50, DOI 10.1096/fasebj.9.1.7821759; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DHEIN J, 1992, J IMMUNOL, V149, P3166; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; ITO Y, 1994, EUR J BIOCHEM, V220, P881, DOI 10.1111/j.1432-1033.1994.tb18691.x; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KISCHKEL F, 1995, EMBO J, V14, P6579; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1993, GROWTH FACTORS, V8, P99, DOI 10.3109/08977199309046930; NAGATA S, 1994, CYTOKINE HDB, P371; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YOSHIKAWA A, 1995, EMBO J, V14, P5288, DOI 10.1002/j.1460-2075.1995.tb00213.x	42	24	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17555	17560		10.1074/jbc.271.29.17555	http://dx.doi.org/10.1074/jbc.271.29.17555			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663376	hybrid			2022-12-27	WOS:A1996UX94300086
J	Armstrong, RC; Aja, T; Xiang, JL; Gaur, S; Krebs, JF; Hoang, K; Bai, X; Korsmeyer, J; Karanewsky, DS; Fritz, LC; Tomaselli, KJ				Armstrong, RC; Aja, T; Xiang, JL; Gaur, S; Krebs, JF; Hoang, K; Bai, X; Korsmeyer, J; Karanewsky, DS; Fritz, LC; Tomaselli, KJ			Fas-induced activation of the cell death-related protease CPP32 is inhibited by Bcl-2 and by ICE family protease inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; SURVIVAL; ENZYME	The human proto oncogene bcl-2 and its Caenorhabditis elegans homologue ced-9 inhibit programmed cell death, In contrast, members of the human interleukin-lp converting enzyme (ICE) family of cysteine proteases and their C, elegans homologue CED-3 promote the death program, Genetic experiments in C, elegans have shown that ced-9 is formally a negative regulator of ced-3 function, but neither those studies nor others have determined whether CED-9 or Bcl-2 proteins act biochemically upstream or downstream of CED-3/ICE proteases, CPP32, like all known members of the CED-3/ICE family, is synthesized as a proenzyme that is subsequently processed into an active protease with specificity for cleavage at Asp-X peptide bonds, In this report, we demonstrate that the CPP32 proenzyme is proteolytically processed and activated in Jurkat cells induced to die by Fas ligation, CPP32 activation is blocked by cell-permeable inhibitors of aspartate-directed, cysteine proteases, suggesting that pro-CPP32 is cleaved by active CPP32 or by other ICE family members, Heterologous expression of Bcl-2 in Jurkat cells prevents Fas-induced cell death as well as proteolytic processing and activation of CPP32, Thus, Bcl-2 acts at or upstream of the CPP32 activation step to inhibit apoptosis induced by Fas stimulation.	IDUN PHARMACEUT INC,LA JOLLA,CA 92037; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL)								BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boulakia CA, 1996, ONCOGENE, V12, P529; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Demuth H U, 1990, J Enzyme Inhib, V3, P249, DOI 10.3109/14756369009030375; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; ESSER RE, 1994, ARTHRITIS RHEUM, V37, P236, DOI 10.1002/art.1780370213; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMR.T, 1995, CANCER RES, V55, P3737; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GRAYBILL TL, 1994, INT J PEPT PROT RES, V44, P173; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; RANJIT GB, 1995, CLIN CANCER RES, V1, P223; RASNICK D, 1985, ANAL BIOCHEM, V149, P461, DOI 10.1016/0003-2697(85)90598-6; REVESZ L, 1994, TETRAHEDRON LETT, V35, P9693, DOI 10.1016/0040-4039(94)88361-0; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	51	314	324	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16850	16855		10.1074/jbc.271.28.16850	http://dx.doi.org/10.1074/jbc.271.28.16850			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663439	hybrid			2022-12-27	WOS:A1996UX12600066
J	Babichuk, CK; Duggan, BL; Bleackley, RC				Babichuk, CK; Duggan, BL; Bleackley, RC			In vivo regulation of murine granzyme B gene transcription in activated primary T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTES-T; SERINE PROTEASE GENES; LOCUS-CONTROL REGION; ENHANCER; EXPRESSION; CHAIN; PROMOTER; BINDING; PURIFICATION; CHROMATIN	A murine granzyme B promoter fragment that extends 243 base pairs upstream of the transcription start site confers high levels of luciferase reporter gene activity in transient transfection assays into T cells and mouse L cell fibroblasts, This promoter fragment contains canonical binding sites for the transcription factors AP-1, core binding factor (CBF), Ikaros, and the cyclic AMP responsive element binding protein (CREB). Oligonucleotides containing the granzyme B AP-1 or CBF elements form specific complexes with proteins present in nuclear extracts from activated CD8(+) splenocytes, MTL cells, EL4 T cells, and L cells, A strong DNase1 hypersensitive site that coincides with the closely associated AP-1, CBF, Ikaros, and CRE elements is present in activated CD8(+) T cells but not in resting T cells or L cells, Both in vitro and in vivo footprints are observed at these sequence elements in activated cytotoxic T cells (CTL) but not in resting T cells, The endogenous granzyme B gene is CTL-specific as no mRNA is detectable in EL4 or L cells, We propose that a condensed chromatin structure at the granzyme B promoter is responsible for transcription factor inaccessibility and repression of transcription in non T cells.			Babichuk, CK (corresponding author), UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA.							BLEACKLEY RC, 1982, J IMMUNOL, V128, P758; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; CHIEN YH, 1993, IMMUNOL TODAY, V14, P597, DOI 10.1016/0167-5699(93)90199-U; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; CROSBY JL, 1990, GENOMICS, V6, P252, DOI 10.1016/0888-7543(90)90564-B; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FELSENFELD G, 1993, GENE, V135, P119, DOI 10.1016/0378-1119(93)90056-9; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; FREGEAU CJ, 1991, NUCLEIC ACIDS RES, V19, P5583; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HADDAD P, 1993, EUR J IMMUNOL, V23, P625, DOI 10.1002/eji.1830230307; HALLBERG B, 1992, NUCLEIC ACIDS RES, V20, P6495, DOI 10.1093/nar/20.24.6495; HANSON RD, 1990, MOL CELL BIOL, V10, P5655, DOI 10.1128/MCB.10.11.5655; HANSON RD, 1993, BLOOD, V82, P2749; HANSON RD, 1990, P NATL ACAD SCI USA, V87, P960, DOI 10.1073/pnas.87.3.960; HAVELE C, 1986, J IMMUNOL, V137, P1448; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HSIANG YHH, 1993, J IMMUNOL, V150, P3905; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KAUFMANN Y, 1981, P NATL ACAD SCI-BIOL, V78, P2502, DOI 10.1073/pnas.78.4.2502; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; LU J, 1995, MOL CELL BIOL, V15, P1651; MILLER MR, 1978, BIOCHEMISTRY-US, V17, P1073, DOI 10.1021/bi00599a021; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; MUELLER PR, 1992, CURRENT PROTOCOLS MO; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; PAETKAU V, 1986, MEDIATORS IMMUNE REG, P3; PRENDERGAST JA, 1992, J BIOL CHEM, V267, P5090; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; REDMOND MJ, 1987, J IMMUNOL, V139, P3184; REITMAN M, 1993, MOL CELL BIOL, V13, P3990, DOI 10.1128/MCB.13.7.3990; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Sambrook J., MOL CLONING LAB MANU; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SELDON RF, 1992, CURRENT PROTOCOLS MO; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; ZAIMAN AL, 1995, J VIROL, V69, P2898, DOI 10.1128/JVI.69.5.2898-2906.1995	53	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16485	16493		10.1074/jbc.271.28.16485	http://dx.doi.org/10.1074/jbc.271.28.16485			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663264	hybrid			2022-12-27	WOS:A1996UX12600012
J	Gross, M; Hessefort, S				Gross, M; Hessefort, S			Purification and characterization of a 66-kDa protein from rabbit reticulocyte lysate which promotes the recycling of Hsp 70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; REGULATED EIF-2-ALPHA KINASE; CHAIN BINDING-PROTEIN; NUCLEOTIDE-SEQUENCE; HSP70-LIKE PROTEIN; SUPERNATANT FACTOR; HEMIN; EXPRESSION; CHAPERONE; CLONING	We have purified to apparent homogeneity a 66-kDa protein from rabbit reticulocyte lysate which is associated with hsp 70. Our characterization of this 66-kDa protein demonstrates that its physiological role is to promote the recycling of hsp 70 by catalyzing the dissociation of hsp 70-bound ADP in exchange for ATP, We have therefore termed the 66-kDa protein RF-hsp 70, a recycling factor for hsp 70. RF-hsp 70 promotes stoichiometric binding of ATP to hsp 70, and it increases about B-fold the rate of dissociation of hsp 70 ADP in the presence of ATP. This process represents adenine nucleotide exchange, since dissociation of ADP does not occur unless ATP is added; dATP, GTP, and ITP cannot substitute for ATP, The mechanism of action of RF-hsp 70 is to lower the K-D of hsp 70 for ATP about 6-7-fold to a value that is close to the K-D of hsp 70 for ADP, RF-hsp 70 also stimulates the ATPase activity of hsp 70, including the 42-kDa amino-terminal portion of hsp 70 generated by chymotrypsin, demonstrating that RF hsp 70 interacts with that part of hsp 70 known to contain the ATP/ADP binding site. Confirming its recycling function, RF hsp 70 stimulates about 7-10-fold the ability of hsp 70 to reactivate heat-denatured firefly luciferase. In addition, RF-hsp 70 acts catalytically to recycle hsp 70, since, at 0.2 times the molar concentration of hsp 70, RF-hsp 70 increases the rate of renaturation of luciferase by hsp 70 about 3-4-fold, The action of RF-hsp 70 is also partially species-specific since it is most effective with rabbit reticulocyte hsp 70, less effective with bovine brain hsp 70, even less effective with human hsp 70, and ineffective with broad bean hsp 70.			Gross, M (corresponding author), UNIV CHICAGO,DEPT PATHOL,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030121] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-30121] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CYR DM, 1992, J BIOL CHEM, V267, P20927; DELUCAFLAHERTY C, 1990, NUCLEIC ACIDS RES, V18, P5569, DOI 10.1093/nar/18.18.5569; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GROSS M, 1987, J BIOL CHEM, V262, P6899; GROSS M, 1991, BIOCHEM BIOPH RES CO, V181, P1500, DOI 10.1016/0006-291X(91)92109-W; GROSS M, 1994, J BIOL CHEM, V269, P22738; GROSS M, 1992, J BIOL CHEM, V267, P2073; GROSS M, 1983, BIOCHIM BIOPHYS ACTA, V740, P255, DOI 10.1016/0167-4781(83)90134-3; GROSS M, 1981, BIOCHIM BIOPHYS ACTA, V654, P219, DOI 10.1016/0005-2787(81)90175-1; GROSS M, 1976, BIOCHIM BIOPHYS ACTA, V447, P445, DOI 10.1016/0005-2787(76)90082-4; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HATTORI H, 1993, J CELL SCI, V104, P629; HONORE B, 1992, J BIOL CHEM, V267, P8485; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MATTS RL, 1993, BIOCHEMISTRY-US, V32, P7323, DOI 10.1021/bi00080a001; MATTS RL, 1992, J BIOL CHEM, V267, P18168; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; NIMMESGERN E, 1993, FEBS LETT, V331, P25, DOI 10.1016/0014-5793(93)80290-B; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; OMALLEY K, 1985, MOL CELL BIOL, V5, P3476, DOI 10.1128/MCB.5.12.3476; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WETTENHALL REH, 1986, J BIOL CHEM, V261, P2444	38	47	47	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16833	16841		10.1074/jbc.271.28.16833	http://dx.doi.org/10.1074/jbc.271.28.16833			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663320				2022-12-27	WOS:A1996UX12600064
J	True, HL; Celander, DW				True, HL; Celander, DW			Ribonuclease P of Tetrahymena thermophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESSENTIAL RNA COMPONENT; METAL-ION REQUIREMENTS; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; SUBSTRATE BINDING; RIBOSOMAL-RNA; CATALYTIC RNA; M1 RNA; GENE; SUBUNIT	Ribonuclease P (RNase P) is responsible for the generation of mature 5' termini of tRNA. The RNA component of this complex encodes the enzymatic activity in bacteria and is itself catalytically active under appropriate conditions in vitro. The role of the subunits in eucaryotes has not yet been established. We have partially purified RNase P activity from the ciliate protozoan Tetrahymena thermophila to learn more about the biochemical characteristics of RNase P from a lower eucaryote, The Tetrahymena RNase P displays a pH optimum and temperature optimum characteristic of RNase P enzymes isolated from other organisms, The K-m of the T. thermophila enzyme for pre-tRNA(Gln) is 1.6 x 10(-7) M, which is comparable to the values reported for other examples of RNase P, The Tetrahymena RNase P is a ribonucleoprotein complex, as supported by its sensitivity to micrococcal nuclease and proteinase K, The buoyant density of the enzyme in Cs2SO4 is 1.42 g/ml, which suggests that the RNA component of the Tetrahymena enzyme comprises a significantly greater percentage of the holoenzyme than that determined for RNase P of other Eucarya or Archaea. The holoenzyme has a requirement for divalent cations displaying characteristics that are unique for RNase P but closely resemble preferences reported for the Tetrahymena group I intron RNA. Puromycin inhibits pre-tRNA processing by the Tetrahymena complex, and implications of the similarities between recognition of tRNA by ribosomal components and RNase P are discussed.	UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801; UNIV ILLINOIS,COLL MED,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			True, Heather/D-2979-2012		NIGMS NIH HHS [R01 GM47854] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047854] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABOSHI E, 1980, BIOCHEM BIOPH RES CO, V96, P831, DOI 10.1016/0006-291X(80)91430-8; ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; DARR SC, 1990, J BIOL CHEM, V265, P12927; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; DOERSEN CJ, 1985, J BIOL CHEM, V260, P5942; DORIA M, 1991, NUCLEIC ACIDS RES, V19, P2315, DOI 10.1093/nar/19.9.2315; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; GUERRIERTAKADA C, 1986, BIOCHEMISTRY-US, V25, P1509, DOI 10.1021/bi00355a006; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAMILTON MG, 1971, METHOD ENZYMOL, V20, P512; HANSEN FG, 1985, GENE, V38, P85, DOI 10.1016/0378-1119(85)90206-9; KOLE R, 1980, CELL, V19, P881, DOI 10.1016/0092-8674(80)90079-3; KRUPP G, 1986, EMBO J, V5, P1697, DOI 10.1002/j.1460-2075.1986.tb04413.x; KUCHINO Y, 1985, P NATL ACAD SCI USA, V82, P4758, DOI 10.1073/pnas.82.14.4758; LATHAM JA, 1990, METHOD ENZYMOL, V181, P558; LAWRENCE N, 1987, COLD SPRING HARB SYM, V52, P233, DOI 10.1101/SQB.1987.052.01.028; LEE JY, 1989, MOL CELL BIOL, V9, P2536, DOI 10.1128/MCB.9.6.2536; LEE JY, 1991, MOL CELL BIOL, V11, P721, DOI 10.1128/MCB.11.2.721; LYGEROU Z, 1994, GENE DEV, V8, P1423, DOI 10.1101/gad.8.12.1423; MARCHFELDER A, 1994, PLANT PHYSIOL, V105, P1247, DOI 10.1104/pp.105.4.1247; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; MCKEE T, 1991, J PROTOZOOL, V38, P465, DOI 10.1111/j.1550-7408.1991.tb04818.x; MORALES MJ, 1989, NUCLEIC ACIDS RES, V17, P6865, DOI 10.1093/nar/17.17.6865; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NATHANS D, 1963, NATURE, V197, P1076, DOI 10.1038/1971076a0; Neff RJ, 1964, METHODS CELL PHYSL, P55; OLSEN GJ, 1993, FASEB J, V7, P113, DOI 10.1096/fasebj.7.1.8422957; PACE NR, 1995, J BACTERIOL, V177, P1919, DOI 10.1128/jb.177.8.1919-1928.1995; PALACIAN E, 1979, EUR J BIOCHEM, V101, P469, DOI 10.1111/j.1432-1033.1979.tb19741.x; POTUSCHAK T, 1993, NUCLEIC ACIDS RES, V21, P3239, DOI 10.1093/nar/21.14.3239; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; REED RE, 1982, CELL, V30, P627, DOI 10.1016/0092-8674(82)90259-8; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; SAKANO H, 1974, NUCLEIC ACIDS RES, V1, P355, DOI 10.1093/nar/1.3.355; SCHEDL P, 1973, P NATL ACAD SCI USA, V70, P2091, DOI 10.1073/pnas.70.7.2091; SCHLEGEL M, 1991, J MOL EVOL, V32, P64, DOI 10.1007/BF02099930; SEARS LE, 1992, BIOTECHNIQUES, V13, P626; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; SMITH D, 1992, J BIOL CHEM, V267, P2429; STARK BC, 1978, P NATL ACAD SCI USA, V75, P3717, DOI 10.1073/pnas.75.8.3717; STATHOPOULOS C, 1995, EUR J BIOCHEM, V228, P976, DOI 10.1111/j.1432-1033.1995.0976m.x; STRAUS JW, 1992, J PROTOZOOL, V39, P655, DOI 10.1111/j.1550-7408.1992.tb04445.x; VIOQUE A, 1989, FEBS LETT, V246, P137, DOI 10.1016/0014-5793(89)80269-8; WALLER CW, 1953, J AM CHEM SOC, V75, P2025, DOI 10.1021/ja01104a537; WANG MJ, 1990, NUCLEIC ACIDS RES, V18, P6625, DOI 10.1093/nar/18.22.6625; WANG MJ, 1988, EMBO J, V7, P1567, DOI 10.1002/j.1460-2075.1988.tb02981.x; WAUGH DS, 1990, J BACTERIOL, V172, P6316, DOI 10.1128/jb.172.11.6316-6322.1990; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; ZAUG AJ, 1980, CELL, V19, P331, DOI 10.1016/0092-8674(80)90507-3	55	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16559	16566		10.1074/jbc.271.28.16559	http://dx.doi.org/10.1074/jbc.271.28.16559			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663280	hybrid			2022-12-27	WOS:A1996UX12600023
J	Biesiada, E; Razandi, M; Levin, ER				Biesiada, E; Razandi, M; Levin, ER			Egr-1 activates basic fibroblast growth factor transcription - Mechanistic implications for astrocyte proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENTS; COLONY-STIMULATING FACTOR; TERNARY COMPLEX FACTORS; DNA-BINDING DOMAINS; RAT MESANGIAL CELLS; TUMOR GENE-PRODUCT; RNA POLYMERASE-II; PROTEIN-KINASE-C; EXPRESSION; PROMOTER	The mechanisms controlling the proliferation of astrocytes are of great interest but are not well defined, We have previously shown that the endogenous neuropeptides, endothelin-3 (ET-3), and atrial natriuretic peptide (ANP), modulate the proliferation of astrocytes through positively and negatively regulating the transcription of the immediate-early gene egr-1 which transactivates basic fibroblast growth factor (bFGF) by unknown mechanisms, In these studies, we determined the involvement of MAP kinase (Erk) activation by ET-3 in the transcription of egr-1, and the molecular determinants by which Egr-1 transactivates bFGF. Transfection of astrocytes with a mitogen-activated protein (MAP) kinase (MAPK) expression vector increased the transcription of a cotransfected egr-chloramphenicol acetyltransferase (CAT) construct 3-fold, This induction was totally abolished by a dominant negative MAPK mutant, A 3-fold induction of egr-CAT expression by ET-3 was significantly reduced by treatment with ANP, or a cotransfected dominant negative MAPK plasmid, Using mobility shift assays, we showed that ET-3 induced the expression of Egr-1 protein which bound specifically to several early growth-related protein (Egr-1) binding sites on the bFGF promoter, and that this effect was significantly reversed by treatment with ANP, We also found that the Spl transcriptional factor was bound at these same sites, but was not stimulated by ET-3, Deletion experiments indicated that only the site at -160 bp of the bFGF promoter was significant for bFGF transactivation by Egr-1, We conclude that the astrocyte mitogen, ET-3, stimulates egr-1 transcription through a MAP kinase (Erk) related mechanism, and that Egr-1 transactivates bFGF through a specific noncanonical, Egr-1 site on the promoter. ANP inhibits each of these steps, providing a pathway for its anti-proliferative action.	VET AFFAIRS MED CTR, MED SERV 111I, LONG BEACH, CA 90822 USA; UNIV CALIF IRVINE, DEPT MED, IRVINE, CA 92716 USA; UNIV CALIF IRVINE, DEPT PHARMACOL, IRVINE, CA 92716 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine			Levin, Ellis/J-5402-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030521] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50161] Funding Source: Medline; NINDS NIH HHS [NS-30521] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ALEXANDROPOULOS K, 1992, NUCLEIC ACIDS RES, V20, P2355, DOI 10.1093/nar/20.9.2355; ARENANDER AT, 1989, J NEUROSCI RES, V24, P107, DOI 10.1002/jnr.490240115; BENO DWA, 1995, J BIOL CHEM, V270, P3642, DOI 10.1074/jbc.270.8.3642; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CAZAUBON S, 1993, BIOCHEM J, V293, P381, DOI 10.1042/bj2930381; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; DEFRANCO C, 1993, MOL ENDOCRINOL, V7, P365, DOI 10.1210/me.7.3.365; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Emoto N, 1989, GROWTH FACTORS, V2, P21, DOI 10.3109/08977198909069078; GASSER UE, 1990, J NEUROSCI, V10, P1276; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P277, DOI 10.1093/nar/23.2.277; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HU RM, 1994, J CLIN INVEST, V93, P1820, DOI 10.1172/JCI117167; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KHARBANDA S, 1994, CELL GROWTH DIFFER, V5, P259; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1987, ONCOGENE, V1, P263; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MCMAHON SB, 1995, MOL CELL BIOL, V15, P1086; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MORRIS JF, 1991, ONCOGENE, V6, P2339; MURPHY PR, 1988, MOL ENDOCRINOL, V2, P1196, DOI 10.1210/mend-2-12-1196; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; Prins BA, 1996, J BIOL CHEM, V271, P14156, DOI 10.1074/jbc.271.24.14156; PRINS BA, 1994, J BIOL CHEM, V269, P11938; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; RUPPRECHT HD, 1993, AM J PHYSIOL, V265, pF351, DOI 10.1152/ajprenal.1993.265.3.F351; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; SHINGU T, 1994, J BIOL CHEM, V269, P32551; SHINODA H, 1989, SCIENCE, V245, P415, DOI 10.1126/science.2569236; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; THIEL G, 1994, J BIOL CHEM, V269, P15294; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WOODWARD WR, 1992, J NEUROSCI, V12, P142	57	188	190	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18576	18581		10.1074/jbc.271.31.18576	http://dx.doi.org/10.1074/jbc.271.31.18576			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702507	hybrid			2022-12-27	WOS:A1996VB68300045
J	Hinz, M; Moore, MJ; Bindereif, A				Hinz, M; Moore, MJ; Bindereif, A			Domain analysis of human U5 RNA - Cap trimethylation, protein binding, and spliceosome assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; YEAST PRP8 PROTEIN; SNRNP PROTEIN; SPLICING FACTOR; U2 SNRNP; SITE; SM; CONSERVATION; PURIFICATION	We have analyzed the sequence requirements of the human U5 RNA during small nuclear ribonucleoprotein (snRNP) and spliceosome assembly. A collection of mutant derivatives of the human U5 RNA gene was constructed in a U1 expression vector and transiently transfected in mammalian cells. Using immunoprecipitation and affinity selection assays, the cap trimethylation, the binding of Sm proteins and of the U5 snRNP-specific protein p220, as well as the assembly of the U4/U5/U6 triple snRNP and of spliceosomes were determined. By mutational analysis we were able to assign distinct functions to several structural elements of the human U5 RNA. Efficient binding of the Sm proteins requires the 3' stem-loop. Both the Sm protein-binding site and the 3' stem-loop are necessary for the formation of the trimethyl guanosine cap, consistent with Sm protein binding being a prerequisite for cap trimethylation. Specific elements of the U5 RNA 5' stem-loop contribute to efficient p220 association, in particular stem Ib. Interestingly, the highly conserved loop I appears to be a multifunctional element; in addition to its function in splice-site selection the 5' loop is involved in binding of p220 and in the assembly of the U4/U5/U6 triple snRNP. In sum, this mutational analysis has identified four functional domains of the human U5 RNA.	HUMBOLDT UNIV BERLIN, FAK MED, INST BIOCHEM, D-10117 BERLIN, GERMANY; BRANDEIS UNIV, DEPT BIOCHEM, WALTHAM, MA 02254 USA	Humboldt University of Berlin; Brandeis University			Hinz, Michael/HCI-0550-2022	Hinz, Michael/0000-0003-2611-4121				ACH RA, 1987, MOL CELL BIOL, V7, P2070, DOI 10.1128/MCB.7.6.2070; ANDERSON GJ, 1989, NATURE, V342, P819, DOI 10.1038/342819a0; BACH M, 1989, P NATL ACAD SCI USA, V86, P6038, DOI 10.1073/pnas.86.16.6038; BACH M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P139, DOI 10.1016/0167-4781(91)90164-H; BARABINO SML, 1989, EMBO J, V8, P4171, DOI 10.1002/j.1460-2075.1989.tb08602.x; Baserga S., 1993, RNA WORLD, P359; BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BRINGMANN P, 1983, EMBO J, V2, P1129, DOI 10.1002/j.1460-2075.1983.tb01557.x; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORTES JJ, 1993, EMBO J, V12, P5181, DOI 10.1002/j.1460-2075.1993.tb06213.x; CROSS M, 1991, MOL CELL BIOL, V11, P5516, DOI 10.1128/MCB.11.11.5516; FRANK DN, 1994, MOL CELL BIOL, V14, P2180, DOI 10.1128/MCB.14.3.2180; GARCIABLANCO MA, 1990, P NATL ACAD SCI USA, V87, P3082, DOI 10.1073/pnas.87.8.3082; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HODGES PE, 1995, YEAST, V11, P337; JACKSON SP, 1988, MOL CELL BIOL, V8, P1067, DOI 10.1128/MCB.8.3.1067; JARMOLOWSKI A, 1993, EMBO J, V12, P223, DOI 10.1002/j.1460-2075.1993.tb05648.x; Kramer A., 1995, PREMRNA PROCESSING, P35; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LOSSKY M, 1987, CELL, V51, P1019, DOI 10.1016/0092-8674(87)90588-5; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MACMILLAN AM, 1994, GENE DEV, V8, P3008, DOI 10.1101/gad.8.24.3008; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; Moore M., 1993, RNA WORLD, P303; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; SEGAULT V, 1995, EMBO J, V14, P4010, DOI 10.1002/j.1460-2075.1995.tb00072.x; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; TEIGELKAMP S, 1995, NUCLEIC ACIDS RES, V23, P320, DOI 10.1093/nar/23.3.320; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; WHITTAKER E, 1991, NUCLEIC ACIDS RES, V19, P5483, DOI 10.1093/nar/19.20.5483; WOLFF T, 1992, EMBO J, V11, P345, DOI 10.1002/j.1460-2075.1992.tb05057.x; WOLFF T, 1993, GENE DEV, V7, P1377, DOI 10.1101/gad.7.7b.1377; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814	44	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					19001	19007		10.1074/jbc.271.31.19001	http://dx.doi.org/10.1074/jbc.271.31.19001			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702566	hybrid			2022-12-27	WOS:A1996VB68300104
J	Kamata, T; Irie, A; Tokuhira, M; Takada, Y				Kamata, T; Irie, A; Tokuhira, M; Takada, Y			Critical residues of integrin alpha IIb subunit for binding of alpha IIb beta 3 (glycoprotein IIb-IIIa) to fibrinogen and ligand-mimetic antibodies (PAC-1, OP-G2, and LJ-CP3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; PLATELET INTEGRIN; GPIIB-IIIA; CELL-ADHESION; GAMMA-CHAIN; I-DOMAIN; ALPHA-2-BETA-1 VLA-2; RECOGNITION SITE; IIB/IIIA COMPLEX; BETA(3) INTEGRIN	Integrin alpha IIb beta 3 plays a critical role in platelet aggregation through its interaction with fibrinogen, Elucidation of the mechanisms of alpha IIb beta 3-fibrinogen interaction is critical to understanding hemostasis and thrombosis. Here we report that mutations of Gly-184, Tyr-189, Tyr-190, Phe-191, and Gly-193 within the predicted turn structure of the third amino-terminal repeat of alpha IIb significantly block binding of alpha IIb beta 3 to soluble fibrinogen. These mutations also block binding of alpha IIb beta 3 to ligand-mimetic monoclonal antibodies PAC-1, OP-G2, LJ-CP3, which have an RGD-related RYD sequence in their antigen-binding sites, These mutations do not significantly affect the expression of alpha IIb beta 3, in contrast to most of the natural alpha IIb mutations occurring in Glanzmann's thrombasthenic patients, The data suggest that these residues are critically involved in alpha IIb beta 3-ligand interactions.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; KEIO UNIV, SCH MED, DEPT INTERNAL MED, SHINJUKU KU, TOKYO 160, JAPAN	Scripps Research Institute; Keio University				takada, yoshikazu/0000-0001-5481-9589	NIGMS NIH HHS [GM49899, GM47157] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047157, R01GM049899] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAJT ML, 1992, J BIOL CHEM, V267, P3789; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BRAY PF, 1994, THROMB HAEMOSTASIS, V72, P492; CALVETE JJ, 1992, EUR J BIOCHEM, V206, P759, DOI 10.1111/j.1432-1033.1992.tb16982.x; CALVETE JJ, 1993, FEBS LETT, V335, P132, DOI 10.1016/0014-5793(93)80454-3; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; COOK JJ, 1992, BIOCHIM BIOPHYS ACTA, V1119, P312, DOI 10.1016/0167-4838(92)90219-4; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FARRELL DH, 1994, J BIOL CHEM, V269, P226; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; GULINO D, 1992, J BIOL CHEM, V267, P1001; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; KLOCZEWIAK M, 1982, BIOCHEM BIOPH RES CO, V107, P181, DOI 10.1016/0006-291X(82)91686-2; KODANDAPANI R, 1995, J BIOL CHEM, V270, P2268, DOI 10.1074/jbc.270.5.2268; LAM SCT, 1992, J BIOL CHEM, V267, P5649; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; LASZ EC, 1993, BIOCHEM BIOPH RES CO, V190, P118, DOI 10.1006/bbrc.1993.1019; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LOFTUS J, 1994, INTEGRINS  BIOL PROB, P55; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; Loftus JC, 1996, J BIOL CHEM, V271, P2033, DOI 10.1074/jbc.271.4.2033; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; NIIYA K, 1987, BLOOD, V70, P475; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PHILLIPS DR, 1988, BLOOD, V71, P831; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RANDI AM, 1994, J BIOL CHEM, V269, P12395; RINDERKNECHT H, 1962, NATURE, V193, P167, DOI 10.1038/193167b0; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANTORO SA, 1988, BIOCHEM BIOPH RES CO, V153, P217, DOI 10.1016/S0006-291X(88)81211-7; SMITH JW, 1990, J BIOL CHEM, V265, P12267; STEINER B, 1993, J BIOL CHEM, V268, P6870; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAUB R, 1989, J BIOL CHEM, V264, P259; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; TOMIYAMA Y, 1992, BLOOD, V79, P2303; TUCKWELL DS, 1994, CELL ADHES COMMUN, V2, P385, DOI 10.3109/15419069409004450; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; WOODS VL, 1984, BLOOD, V63, P368; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; YLANNE J, 1988, BLOOD, V72, P1478; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	58	82	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18610	18615		10.1074/jbc.271.31.18610	http://dx.doi.org/10.1074/jbc.271.31.18610			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702512	hybrid			2022-12-27	WOS:A1996VB68300050
J	Rivard, N; LAllemain, G; Bartek, J; Pouyssegur, J				Rivard, N; LAllemain, G; Bartek, J; Pouyssegur, J			Abrogation of p27(Kip1) by cDNA antisense suppresses quiescence (G(0) state) in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; CELL-CYCLE CONTROL; GROWTH-FACTOR-BETA; HAMSTER FIBROBLASTS; POTENTIAL MEDIATOR; DNA-REPLICATION; CDK6 INHIBITOR; PROTEIN; EXPRESSION; GENE	Progression of eukaryotic cells through the cell cycle is governed by the sequential formation, activation, and subsequent inactivation of a series of cyclin-dependent kinase (Cdk) complexes, p27(Kip1) (p27) is a Cdk inhibitor that blocks, in vitro, the activity of cyclin D-Cdk4, cyclin D-Cdk6, cyclin E-Cdk2 as well as cyclin A-Cdk2, a complex active during S phase, The level of p27 protein expression, usually high in G(0)/G(1) resting cells, declines as cells progress toward S phase and enforced expression of p27 in fibroblasts causes G(1) arrest. This situation prevails in CCL39, a Chinese hamster lung fibroblast cell line (this report), However, in addition to p27, several other Cdk inhibitors known to alter G(1) progression coexist in most mammalian cells, To investigate the specific contribution of p27 in the control of the mitogen-sensitive G(0)/G(1) arrest, we specifically reduced its synthesis by expressing a full-length p27 antisense cDNA in CCL39 cells. Interestingly, reduction of up to 90% of p27 protein expression increased both basal and serum-stimulated gene transcription of cyclin D1, cyclin A, dihydrofolate reductase, and DNA synthesis reinitiation. Moreover, overexpression of this antisense allows cells to grow for several generations in a serum-free medium supplemented with insulin and transferrin only, thus suggesting that p27-depleted cells cannot exit the cell cycle. These effects were fully reversed by coexpression of a plasmid encoding p27 sense. We conclude that p27, by setting the level of growth factor requirement, plays a pivotal role in controlling cell cycle exit, a fundamental step in growth control.	DANISH CANC SOC,DEPT CELL CYCLE & CANC,DIV CANC BIOL,DK-2100 COPENHAGEN,DENMARK	Danish Cancer Society	Rivard, N (corresponding author), UNIV NICE,CTR BIOCHIM,CNRS,PARC VALROSE,F-06108 NICE,FRANCE.		Bartek, Jiri/G-5870-2014					BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HERBER B, 1994, ONCOGENE, V9, P1295; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI Y, 1994, ONCOGENE, V9, P2261; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MCKENZIE FR, 1996, J BIOL CHEM, V271, P15762; MORI T, 1994, CANCER RES, V54, P3396; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Noel J, 1996, J CELL SCI, V109, P929; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANOBBERGHENSCHILLING E, 1983, EXP CELL RES, V147, P369, DOI 10.1016/0014-4827(83)90219-7; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINBERG R, 1994, CELL, V81, P323; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	47	200	217	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18337	18341		10.1074/jbc.271.31.18337	http://dx.doi.org/10.1074/jbc.271.31.18337			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702474	hybrid			2022-12-27	WOS:A1996VB68300012
J	Prat, AG; Holtzman, EJ; Brown, D; Cunningham, CC; Reisin, IL; Kleyman, TR; McLaughlin, M; Jackson, GR; Lydon, J; Cantiello, HF				Prat, AG; Holtzman, EJ; Brown, D; Cunningham, CC; Reisin, IL; Kleyman, TR; McLaughlin, M; Jackson, GR; Lydon, J; Cantiello, HF			Renal epithelial protein (Apx) is an actin cytoskeleton-regulated Na+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE SODIUM-CHANNEL; CORTICAL COLLECTING TUBULE; PLANAR LIPID BILAYERS; APICAL MEMBRANE; AMILORIDE; ACTIVATION; SUBUNIT; CELLS; VASOPRESSIN; RECORDINGS	Apr, the amphibian protein associated with renal amiloride-sensitive Na+ channel activity and with properties consistent with the pore-forming 150-kDa subunit of an epithelial Na+ channel complex initially purified by Benos et al. (Benos, D. J., Saccomani, G., and Sariban-Sohraby, S. (1987) J. Biol. Chem. 262, 10613-10618), has previously failed to generate amiloride-sensitive Na+ currents (Staub, O., Verrey, F., Kleyman, T. R., Benos, D. J., Rossier, B. C., and Kraehenbuhl, J.-P. (1992) J. Cell Biol. 119, 1497-1506). Renal epithelial Na+ channel activity is tonically inhibited by endogenous actin filaments (Cantiello, H. F., Stow, J., Prat, A. G;., and Ausiello, D. A. (1991) Am. J. Physiol. 261, C882-C888). Thus, Apr was expressed and its function examined in human melanoma cells with a defective actin-based cytoskeleton. Apx-transfection was associated with a 60-900% increase in amiloride-sensitive (K-i = 3 mu M) Na+ currents. Single channel Na+ currents had a similar functional fingerprint to the vasopressin sensitive, and actin-regulated epithelial Na+ channel of A6 cells, including a 6-7 pS single channel conductance and a perm-selectivity of Na+:K+ of 4:1. Na+ channel activity was either spontaneous, or induced by addition of actin or protein kinase A plus ATP to the bathing solution of excised inside-out patches. Therefore, Apr may be responsible for the ionic conductance involved in the vasopressin-activated Na+ reabsorption in the amphibian kidney.	MASSACHUSETTS GEN HOSP E,RENAL UNIT,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; FAC FARM & BIOQUIM,CATEDRA QUIM GEN & INORGAN,BUENOS AIRES,DF,ARGENTINA; UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; VET ADM MED CTR,PHILADELPHIA,PA 19104	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Buenos Aires; University of Pennsylvania; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA)								AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; Alvarez O., 1986, ION CHANNEL RECONSTI, P115; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; BENOS DJ, 1986, P NATL ACAD SCI USA, V83, P8525, DOI 10.1073/pnas.83.22.8525; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; CANTIELLO HF, 1993, J BIOL CHEM, V268, P4596; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; GARTY H, 1994, FASEB J, V8, P522, DOI 10.1096/fasebj.8.8.8181670; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; HAMILTON KL, 1986, MEMBRANE BIOCHEM, V6, P149, DOI 10.3109/09687688609065447; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; LIGHT DB, 1988, AM J PHYSIOL, V255, pF278, DOI 10.1152/ajprenal.1988.255.2.F278; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; MARUNAKA Y, 1992, AM J PHYSIOL, V263, pF392, DOI 10.1152/ajprenal.1992.263.3.F392; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; OH Y, 1993, AM J PHYSIOL, V264, pC1489, DOI 10.1152/ajpcell.1993.264.6.C1489; OH YS, 1993, AM J PHYSIOL, V265, pC85, DOI 10.1152/ajpcell.1993.265.1.C85; PALMER LG, 1986, P NATL ACAD SCI USA, V83, P2767, DOI 10.1073/pnas.83.8.2767; PALMER LG, 1988, J GEN PHYSIOL, V92, P121, DOI 10.1085/jgp.92.1.121; PRAT AG, 1995, AM J PHYSIOL-CELL PH, V268, pC1552, DOI 10.1152/ajpcell.1995.268.6.C1552; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; PRAT AG, 1993, AM J PHYSIOL, V265, pC218, DOI 10.1152/ajpcell.1993.265.1.C218; ROTIN D, 1994, EMBO J, V13, P440; SARIBANSOHRABY S, 1992, AM J PHYSIOL, V263, pC1111, DOI 10.1152/ajpcell.1992.263.5.C1111; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; STAUB O, 1992, J CELL BIOL, V119, P1497, DOI 10.1083/jcb.119.6.1497	32	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18045	18053		10.1074/jbc.271.30.18045	http://dx.doi.org/10.1074/jbc.271.30.18045			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663566	hybrid			2022-12-27	WOS:A1996UY93500069
J	Zhang, YH; Mannering, DE; Davidson, AL; Yao, NH; Manson, MD				Zhang, YH; Mannering, DE; Davidson, AL; Yao, NH; Manson, MD			Maltose-binding protein containing an interdomain disulfide bridge confers a dominant-negative phenotype for transport and chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED CROSS-LINKING; ESCHERICHIA-COLI; ACTIVE-TRANSPORT; MEMBRANE-COMPONENTS; 3-DIMENSIONAL STRUCTURES; RHODOBACTER-CAPSULATUS; SALMONELLA-TYPHIMURIUM; CYTOPLASMIC MEMBRANE; DEPENDENT TRANSPORT; ASPARTATE RECEPTOR	Bacterial substrate-binding proteins exist in an equilibrium among four forms: open/substrate-free, open/substrate-bound, closed/substrate-free, and closed/substrate-bound. Ligands stabilize the closed conformation, whereas the open conformation predominates in the substrate-free species, In its closed form, the NH2-terminal and COOH-terminal domains of maltose-binding protein (MBP) are proposed to be aligned to allow residues in both domains to interact simultaneously with complementary sites on the MalF and MalG proteins of the maltodextrin uptake system or with the Tar chemotactic signal transducer. However, the initial interaction might occur with an open/substrate-bound form of the binding protein, which would then close in contact with MalFG or Tar, Ligand would help stabilize this complex, We introduced cysteines (G69C and S337C) by site-directed mutagenesis into each domain of MBP and found that they formed an interdomain disulfide cross-link that should hold the protein in a closed conformation, This mutant MEP confers a dominant-negative phenotype for growth on maltose, for maltose transport, and for maltose chemotaxis. The growth and transport defects are partially reversed when the cells are exposed to the reducing agent dithiothreitol. We conclude that the cross-linked form of MBP competes with wild-type MBP in vivo for interaction with MalFG and Tar.	TEXAS A&M UNIV,DEPT BIOL,COLLEGE STN,TX 77843; BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030	Texas A&M University System; Texas A&M University College Station; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine					NIGMS NIH HHS [GM49261, GM39736] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049261, R01GM049261, R01GM039736] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1973, J GEN MICROBIOL, V74, P77, DOI 10.1099/00221287-74-1-77; BOHL E, 1995, J THEOR BIOL, V172, P83, DOI 10.1006/jtbi.1995.0006; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; CAREAGA CL, 1995, BIOCHEMISTRY-US, V34, P3048, DOI 10.1021/bi00009a036; DASSA E, 1985, EMBO J, V4, P2287, DOI 10.1002/j.1460-2075.1985.tb03928.x; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DEBARBOUILLE M, 1978, J MOL BIOL, V124, P359, DOI 10.1016/0022-2836(78)90304-2; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; FIKES JD, 1987, J BACTERIOL, V169, P2352, DOI 10.1128/jb.169.6.2352-2359.1987; FLOCCO MM, 1994, J BIOL CHEM, V269, P8931; FROSHAUER S, 1984, J BIOL CHEM, V259, P896; GARDINA P, 1992, J BACTERIOL, V174, P1528, DOI 10.1128/jb.174.5.1528-1536.1992; GARDINA P, 1995, THESIS TEXAS A M U; HAZELBAUER GL, 1975, J BACTERIOL, V122, P206, DOI 10.1128/JB.122.1.206-214.1975; HOR LI, 1993, J MOL BIOL, V233, P659, DOI 10.1006/jmbi.1993.1543; JACOBSON BL, 1992, J MOL BIOL, V223, P27, DOI 10.1016/0022-2836(92)90712-S; JOYCE CM, 1984, J BACTERIOL, V158, P636, DOI 10.1128/JB.158.2.636-643.1984; KELLERMANN O, 1974, EUR J BIOCHEM, V47, P139, DOI 10.1111/j.1432-1033.1974.tb03677.x; KONDO T, 1988, J BIOL CHEM, V263, P9470; KOSHLAND D, 1980, CELL, V20, P749, DOI 10.1016/0092-8674(80)90321-9; KOSSMANN M, 1988, J BACTERIOL, V170, P4516, DOI 10.1128/jb.170.10.4516-4521.1988; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSON MD, 1985, J BIOL CHEM, V260, P9727; MANSON MD, 1986, J BACTERIOL, V165, P34, DOI 10.1128/jb.165.1.34-40.1986; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Miller J.H., 1972, EXPT MOL GENETICS; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; OH BH, 1993, J BIOL CHEM, V268, P11348; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHARFF AJ, 1993, BIOCHEMISTRY-US, V32, P10553, DOI 10.1021/bi00091a004; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHILTON BH, 1995, PROTEIN SCI, V4, P1346, DOI 10.1002/pro.5560040710; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SHUMAN HA, 1981, J BIOL CHEM, V256, P560; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STODDARD BL, 1992, NATURE, V358, P774, DOI 10.1038/358774a0; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; WALKER KW, 1994, J BIOL CHEM, V269, P28487; WALMSLEY AR, 1992, BIOCHEMISTRY-US, V31, P11175, DOI 10.1021/bi00160a031; WALMSLEY AR, 1992, J BIOL CHEM, V267, P8064; WOLF A, 1994, J BIOL CHEM, V269, P23051; WOLF A, 1995, J BIOL CHEM, V270, P16097, DOI 10.1074/jbc.270.27.16097; WOLFF C, 1988, J BACTERIOL, V170, P4509, DOI 10.1128/jb.170.10.4509-4515.1988; ZHANG YH, 1992, J BIOL CHEM, V267, P22813	53	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17881	17889		10.1074/jbc.271.30.17881	http://dx.doi.org/10.1074/jbc.271.30.17881			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663400	hybrid			2022-12-27	WOS:A1996UY93500046
J	Chambliss, KL; Slaughter, CA; Schreiner, R; Hoffmann, GF; Gibson, KM				Chambliss, KL; Slaughter, CA; Schreiner, R; Hoffmann, GF; Gibson, KM			Molecular cloning of human phosphomevalonate kinase and identification of a consensus peroxisomal targeting sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEVALONATE-ACTIVATING ENZYMES; RAT-LIVER; STEROL; PURIFICATION; ACIDURIA; ASSAY	Two overlapping cDNAs which encode human liver phosphomevalonate kinase (PMKase) were isolated. The human PMKase cDNAs predict a 191-amino acid protein with a molecular weight of 21,862, consistent with previous reports for mammalian PMKase (M(r) = 21,000 - 22,500), Further verification of the clones was obtained by expression of PMKase activity in bacteria using a composite 1024-base pair cDNA clone. Northern blot analysis of several human tissues revealed a doublet of transcripts at approximately 1 kilobase (kb) in heart, liver, skeletal muscle, kidney, and pancreas and lower but detectable transcript levels in brain, placenta, and lung. Analysis of transcripts from human lymphoblasts subcultured in lipid-depleted sera (LDS) and LDS supplemented with lovastatin indicated that PMKase gene expression is subject to regulation by sterol at the level of transcription. Southern blotting indicated that PMKase is a single copy gene covering less than 15 kb in the human genome. The human PMKase amino acid sequence contains a consensus peroxisomal targeting sequence (PTS-1), Ser-Arg-Leu, at the C terminus of the protein. This is the first report of a cholesterol biosynthetic protein which contains a consensus PTS-1, providing further evidence for the concept that early cholesterol and nonsterol isoprenoid biosynthesis may occur in the peroxisome.	BAYLOR RES INST,INST METAB DIS,DALLAS,TX 75226; BAYLOR UNIV,MED CTR,DALLAS,TX 75226; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DALLAS,TX 75235; UNIV MARBURG,DEPT METAB DIS & NEUROPEDIAT,D-35033 MARBURG,GERMANY; UNIV TEXAS,SW MED CTR,DEPT NEUROL,DALLAS,TX 75235	Baylor Scott & White Health; Baylor University Medical Center; Baylor University; Baylor University Medical Center; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Philipps University Marburg; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BAZAES S, 1990, BIOCHEMISTRY-US, V19, P2300; Biardi L, 1996, J BIOL CHEM, V271, P1784, DOI 10.1074/jbc.271.3.1784; CHAMBLISS KL, 1995, J BIOL CHEM, V270, P461, DOI 10.1074/jbc.270.1.461; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; DORSEY JK, 1968, J BIOL CHEM, V243, P4667; ERICSSON J, 1992, J BIOL CHEM, V267, P18708; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Gibson K. M., 1995, American Journal of Human Genetics, V57, pA313; GIBSON KM, 1989, ENZYME, V41, P47, DOI 10.1159/000469050; GONZALEZPACANOWSKA D, 1988, ENZYME, V39, P90; GONZALEZPACANOWSKA D, 1986, BIOCHIM BIOPHYS ACTA, V875, P605, DOI 10.1016/0005-2760(86)90083-4; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; JABALQUINTO AM, 1981, ARCH BIOCHEM BIOPHYS, V210, P132, DOI 10.1016/0003-9861(81)90173-9; KRISANS SK, 1994, J BIOL CHEM, V269, P14165; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; LEE CS, 1985, BIOCHIM BIOPHYS ACTA, V839, P83, DOI 10.1016/0304-4165(85)90184-9; MARCO C, 1986, BIOCHIM BIOPHYS ACTA, V878, P238, DOI 10.1016/0005-2760(86)90151-7; OSSENDORP BC, 1993, BIOCHIMIE, V75, P191, DOI 10.1016/0300-9084(93)90077-6; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; TANAKA RD, 1990, J BIOL CHEM, V265, P2391; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; Toth MJ, 1996, J BIOL CHEM, V271, P7895, DOI 10.1074/jbc.271.14.7895; TSAY YH, 1991, MOL CELL BIOL, V11, P620, DOI 10.1128/MCB.11.2.620; Weinberger C, 1996, TRENDS ENDOCRIN MET, V7, P1, DOI 10.1016/1043-2760(95)00180-8; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463; [No title captured]	28	36	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17330	17334		10.1074/jbc.271.29.17330	http://dx.doi.org/10.1074/jbc.271.29.17330			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663599	hybrid			2022-12-27	WOS:A1996UX94300054
J	Lesecq, S; Baudin, V; Kister, J; Marden, MC; Poyart, C; Pagnier, J				Lesecq, S; Baudin, V; Kister, J; Marden, MC; Poyart, C; Pagnier, J			Functional studies and polymerization of recombinant hemoglobin Glu-alpha(2)beta(2)6(A3)->Val/Glu-7(A4)->Ala	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL HEMOGLOBIN; DEOXYHEMOGLOBIN-S; ESCHERICHIA-COLI; FIBERS; BETA-7	In hemoglobin (Hb) S the hydrophobic mutated residue Val-beta 6(A3) (donor site) closely interacts with the hydrophobic side groups of Phe-beta 85(F1) and Leu-beta 88(F4) (EF pocket, acceptor site) of a neighboring tetramer, resulting in decreased solubility and polymerization of the deoxy-Hb. The beta 6(A3) residue is followed by two charged residues Glu-beta 7(A4) and Lys-beta 8(A5). This cluster has no attraction for the hydrophobic EF pocket. We have modified the beta 7(A4) residue next to the donor site Val-beta 6(A3), replacing the charged Glu by a hydrophobic Ala-(rHb beta E6V/E7A). The single mutant Glu-beta 7 --> Ala-(rHb beta E7A) was also engineered. Both rHbs exhibit a heat instability and an increased oxygen affinity compared to Hb A and Hb S. There was a concentration dependence of the ligand binding properties (1-300 mu M in heme) indicating an increased amount of dimers relative to Hb A. The deoxy form of rHb beta EGV/E7A polymerizes in vitro, with a decreased rate of polymer formation relative to Hb S, while the single mutant beta E7A does not polymerize in the same experimental conditions, The Glu-beta 7(A4) --> Ala substitution does not increase the hydrophobic interaction between donor and acceptor site. We speculate that the loss of the normal saline bridge between Glu-beta 7(A4) and Lys-beta 132(H10) leads to an increased flexibility of the A helix and may account for the difference of the polymerization for this Hb S mutant.	HOP BICETRE,INSERM U299,F-94275 LE KREMLIN BICETR,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Marden, Michael C/G-3139-2012; Marden, Michael/AAA-5923-2020; BAUDIN-CREUZA, Véronique/K-7309-2017	Marden, Michael C/0000-0002-5254-6385; BAUDIN-CREUZA, Véronique/0000-0003-1032-3236				ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ADACHI K, 1991, HEMOGLOBIN, V15, P417, DOI 10.3109/03630269108998861; ADACHI K, 1979, J BIOL CHEM, V254, P7765; ANDERSEN ME, 1971, J BIOL CHEM, V246, P4790; BAUDINCHICH V, 1990, P NATL ACAD SCI USA, V87, P1845, DOI 10.1073/pnas.87.5.1845; BIHOREAU MT, 1992, PROTEIN SCI, V1, P145; BOOKCHIN RM, 1971, J MOL BIOL, V60, P263, DOI 10.1016/0022-2836(71)90292-0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CARRAGHER B, 1988, J MOL BIOL, V199, P315, DOI 10.1016/0022-2836(88)90316-6; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P118; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; EDELSTEIN SJ, 1975, ANNU REV BIOCHEM, V44, P209, DOI 10.1146/annurev.bi.44.070175.001233; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FERMI G, 1981, ATLAS MOL STRUCTURE, V2, P56; KISTER J, 1987, J BIOL CHEM, V262, P12085; MARDEN MC, 1988, BIOCHEMISTRY-US, V27, P1659, DOI 10.1021/bi00405a041; NAGAI K, 1985, P NATL ACAD SCI USA, V82, P7252, DOI 10.1073/pnas.82.21.7252; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NAGEL RL, 1973, BIOCHEM BIOPH RES CO, V53, P1240, DOI 10.1016/0006-291X(73)90598-6; PADLAN EA, 1985, J BIOL CHEM, V260, P8272; POYART C, 1981, NOUV REV FR HEMATOL, V23, P17; RHODA MD, 1986, HEMOGLOBIN, V10, P21, DOI 10.3109/03630268609072468; RODGERS DW, 1987, P NATL ACAD SCI USA, V84, P6157, DOI 10.1073/pnas.84.17.6157; ROTH EF, 1977, J LAB CLIN MED, V90, P837; WAJCMAN H, 1973, NOUV REV FR HEMATOL, V13, P89; YAMASHIRO DJ, 1994, J BIOL CHEM, V269, P23996	26	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17211	17214		10.1074/jbc.271.29.17211	http://dx.doi.org/10.1074/jbc.271.29.17211			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663330	hybrid, Green Published			2022-12-27	WOS:A1996UX94300037
J	Nascimento, AAC; Cheney, RE; Tauhata, SBF; Larson, RE; Mooseker, MS				Nascimento, AAC; Cheney, RE; Tauhata, SBF; Larson, RE; Mooseker, MS			Enzymatic characterization and functional domain mapping of brain myosin-V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEINS; RABBIT SKELETAL-MUSCLE; UNCONVENTIONAL MYOSIN; LIGHT-CHAINS; ACANTHAMOEBA-CASTELLANII; PROTEOLYTIC FRAGMENTS; CALCIUM-CALMODULIN; VERTEBRATE BRAIN; INVITRO MOTILITY; ATPASE ACTIVITY	The actin binding and ATPase properties, as well as the functional domain structure of chick brain myosin-V, a two-headed, unconventional myosin, is reported here, Compared to conventional myosin from skeletal muscle, brain myosin-V exhibits low K-EDTA- and Ca-ATPase activities (1.8 and 0.8 ATP/s per head), The physiologically relevant Mg-ATPase is also low (similar to 0.3 ATP/s), unless activated by the presence of both F-actin and Ca2+ (V-max of 27 ATP/s), Ca2+ stimulates the actin-activated Mg-ATPase over a narrow concentration range between 1 and 3 mu M. In the presence of saturating Ca2+ and 75 mM KCl, surprisingly low concentrations of F-actin activate the Mg-ATPase in a hyperbolic manner (K-ATPase of 1.3 mu M). Brain myosin-V also binds with relatively high affinity (compared to other known myosins) to F-actin in the presence of ATP, as assayed by cosedimentation, Digestion of brain myosin-V with calpain yielded a 65-kDa head domain fragment that cosediments with actin in an ATP-sensitive manner and a 80-kDa tail fragment that does not interact with F-actin, The 80-kDa fragment results from cleavage one residue beyond the proline-, glutamate-, serine-, threonine-rich region, Our data indicate that the Mg-ATPase cycle of brain myosin-V is tightly regulated by Ca2+, probably via direct binding to the calmodulin light chains in the neck domain, which like brush border myosin-I, results in partial (similar to 30%) dissociation of the calmodulin associated with brain myosin-V, The effect of Ca2+ binding, which appears to relieve suppression by the neck domain, can be mimicked by calpain cleavage near the head/neck junction.	YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06520 USA; YALE UNIV, DEPT CELL BIOL, NEW HAVEN, CT 06520 USA; YALE UNIV, DEPT PATHOL, NEW HAVEN, CT 06520 USA; UNIV SAO PAULO, SCH MED, DEPT BIOCHEM, BR-14049900 RIBEIRAO PRETO, SP, BRAZIL	Yale University; Yale University; Yale University; Universidade de Sao Paulo				Tauhata, Sinji/0000-0002-6617-4244; Cheney, Richard/0000-0001-6565-7888	NIDDK NIH HHS [DK25387, DK38979] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025387, R37DK025387, R56DK025387, P01DK038979] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; ALBANESI JP, 1983, J BIOL CHEM, V258, P176; BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; Bidlingmeyer BA, 1986, METHODS PROTEIN SEQU, P229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARBONI JM, 1988, J CELL BIOL, V4107, P1749; CHALOVICH JM, 1984, J BIOL CHEM, V259, P2617; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COELHO MV, 1993, BRAZ J MED BIOL RES, V26, P465; CONZELMAN KA, 1987, J CELL BIOL, V105, P313, DOI 10.1083/jcb.105.1.313; COOKE R, 1989, CELL MOTIL CYTOSKEL, V14, P183, DOI 10.1002/cm.970140204; COOPER DMF, 1988, J CELL BIOCHEM, V36, P417, DOI 10.1002/jcb.240360410; ESPINDOLA FS, 1992, J CELL BIOL, V118, P359, DOI 10.1083/jcb.118.2.359; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LARSON RE, 1990, J NEUROCHEM, V54, P1288, DOI 10.1111/j.1471-4159.1990.tb01961.x; LARSON RE, 1988, BRAZ J MED BIOL RES, V21, P213; Larson RE, 1996, BRAZ J MED BIOL RES, V29, P309; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; MORNET D, 1989, J MUSCLE RES CELL M, V10, P10, DOI 10.1007/BF01739853; POINTING CP, 1995, TRENDS BIOCHEM SCI, V20, P265; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; PORTER JA, 1993, SCIENCE, V262, P1038, DOI 10.1126/science.8235618; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; SANDERS G, 1992, FEBS LETT, V311, P295, DOI 10.1016/0014-5793(92)81123-4; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; SZENTGYORGYI AG, 1994, MYOLOGY, P506; TAKIGUCHI K, 1990, J BIOCHEM-TOKYO, V107, P671, DOI 10.1093/oxfordjournals.jbchem.a123106; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WELLS C, 1994, NATURE, V313, P306; WOLENSKI JS, 1993, J CELL BIOL, V122, P613, DOI 10.1083/jcb.122.3.613; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	46	103	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17561	17569		10.1074/jbc.271.29.17561	http://dx.doi.org/10.1074/jbc.271.29.17561			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663447	hybrid			2022-12-27	WOS:A1996UX94300087
J	Silos, SA; Tamai, K; Li, KH; Kivirikko, S; Kouba, D; Christiano, AM; Uitto, J				Silos, SA; Tamai, K; Li, KH; Kivirikko, S; Kouba, D; Christiano, AM; Uitto, J			Cloning of the gene for human pemphigus vulgaris antigen (desmoglein 3), a desmosomal cadherin - Characterization of the promoter region and identification of a keratinocyte-specific cis-element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; L-CAM; DIFFERENTIATION; TRANSCRIPTION; EXPRESSION; SEQUENCES; SURFACE; AUTOANTIBODIES; ORGANIZATION; ENHANCER	Pemphigus vulgaris antigen is a cadherin-like desmosomal cell adhesion molecule expressed primarily in suprabasal keratinocytes within the epidermis, Previously characterized structural features have defined this molecule as a desmoglein, DSG3. In this study, we have cloned the human DSG3 gene and examined the transcriptional regulation of its expression. The total gene consisted of 15 exons and was estimated to span >23 kilobases, Comparison of exon-intron organization of DSG3 with bovine DSG1 and several classical cadherin genes revealed striking conservation of the structure, Up to 2.8 kilobases of the upstream genomic sequences were sequenced and found to contain several putative cis-regulatory elements. The promoter region was GC-rich and TATA-less, similar to previously characterized mammalian cadherin promoters, The putative promoter region was subcloned into a vector containing chloramphenicol acetyl transferase reporter gene, Transient transfections with a series of deletion clones indicated that the DSG3 promoter demonstrated keratinocyte-specific expression, as compared with dermal fibroblasts examined in parallel, and fine mapping identified a 30-base pair segment at -200 to -170 capable of conferring epidermal specific expression. The results provide evidence for the transcriptional regulation of the pemphigus vulgaris antigen gene, potentially critical for development of the epidermis and physiologic terminal differentiation of keratinocytes.	THOMAS JEFFERSON UNIV,DEPT DERMATOL & CUTANEOUS BIOL,JEFFERSON MED COLL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOLEC BIOL,JEFFERSON MED COLL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,MOLEC DERMATOL SECT,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038923, T32AR007561] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR38923, T32-AR07561] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; ANHALT GJ, 1982, NEW ENGL J MED, V306, P1189, DOI 10.1056/NEJM198205203062001; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; BUXTON RS, 1993, J CELL BIOL, V121, P481, DOI 10.1083/jcb.121.3.481; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FARALDO MLM, 1993, J MOL BIOL, V231, P935, DOI 10.1006/jmbi.1993.1341; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; Grunwald GB, 1993, CURR OPIN CELL BIOL, V5, P797, DOI 10.1016/0955-0674(93)90028-O; HASHIMOTO K, 1967, J INVEST DERMATOL, V48, P540, DOI 10.1038/jid.1967.86; HASHIMOTO K, 1983, J EXP MED, V157, P259, DOI 10.1084/jem.157.1.259; HATTA M, 1991, NUCLEIC ACIDS RES, V19, P4437, DOI 10.1093/nar/19.16.4437; HUFF CA, 1993, J BIOL CHEM, V268, P377; ISHIKAWA H, 1994, MAMM GENOME, V5, P803, DOI 10.1007/BF00292018; KARPATI S, 1993, J CELL BIOL, V122, P409, DOI 10.1083/jcb.122.2.409; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; MIYATANI S, 1992, P NATL ACAD SCI USA, V89, P8443, DOI 10.1073/pnas.89.18.8443; PUTAGUNTA S, 1993, J BIOL CHEM, V269, P1949; RINGWALD M, 1991, NUCLEIC ACIDS RES, V19, P6533, DOI 10.1093/nar/19.23.6533; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWAMURA D, 1992, J INVEST DERMATOL, V98, P942; SCHILTZ JR, 1976, J INVEST DERMATOL, V67, P254, DOI 10.1111/1523-1747.ep12513454; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SORKIN BC, 1993, P NATL ACAD SCI USA, V90, P11356, DOI 10.1073/pnas.90.23.11356; SORKIN BC, 1988, P NATL ACAD SCI USA, V85, P7617, DOI 10.1073/pnas.85.20.7617; STANLEY JR, 1990, JAMA-J AM MED ASSOC, V264, P1714, DOI 10.1001/jama.264.13.1714; STANLEY JR, 1982, J CLIN INVEST, V70, P281, DOI 10.1172/JCI110615; TAMAI K, 1993, J CLIN INVEST, V92, P814, DOI 10.1172/JCI116655; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WALLIS J, 1994, GENOMICS, V22, P172, DOI 10.1006/geno.1994.1358; WANG YM, 1994, GENOMICS, V20, P492, DOI 10.1006/geno.1994.1207; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767	39	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17504	17511		10.1074/jbc.271.29.17504	http://dx.doi.org/10.1074/jbc.271.29.17504			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663392	hybrid			2022-12-27	WOS:A1996UX94300080
J	Wang, J; Han, W; Zborowska, E; Liang, JR; Wang, XF; Willson, JKV; Sun, LZ; Brattain, MG				Wang, J; Han, W; Zborowska, E; Liang, JR; Wang, XF; Willson, JKV; Sun, LZ; Brattain, MG			Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; TGF-BETA; DIFFERENTIAL SENSITIVITY; GENE-EXPRESSION; CANCER CELLS; INHIBITION; FACTOR-BETA-1; CLONING; COMPLEX; LINES	Transforming growth factor beta (TGF beta) type I (RI) and type II (RII) receptors are essential for TGF beta signal transduction, A human colon carcinoma cell line, designated GEO, is marginally responsive to TGF beta and expresses a low level of RI mRNA relative to colon carcinoma cells, which are highly responsive to TGF beta, Hence, the role of RI as a limiting factor for TGF beta sensitivity and the contribution of low RI levels to the malignant phenotype of GEO cells were examined, Stable transfection of a tetracycline-regulatable rat RI cDNA increased TGF beta(1) binding to RI and resulted in increased growth inhibition by exogenous TGF beta(1). In contrast, although stable transfection of an RII expression vector into the same GEO cells increased TGF beta(1) binding to RII, growth inhibition by exogenous TGF beta(1) was not altered, This indicated that the low level of RI is a limiting factor for the growth-inhibitory effects of TGF beta in GEO cells, RI-transfected cells were growth-arrested at a lower saturation density than GEO control cells. They also showed reduced growth and clonogenicity in plating efficiency and soft agarose assays, whereas RII-transfected cells did not show any differences from the NEO control cells in these assays, Tetracycline repressed RI expression in transfected cells and reversed the reduction in plating efficiency of RI-transfected clones, confirming that growth effects were due to increased RI expression in transfected cells. TGF beta(1) neutralizing antibody stimulated the proliferation of RI-transfected cells but had little effect on GEO control cells, indicating that increased autocrine-negative TGF beta activity also resulted from increased RI expression. Tumorigenicity in athymic nude mice was significantly delayed in RI-transfected cells, These results indicate that low RI expression can be a limiting factor for response to exogenous TGF beta, as well as TGF beta autocrine-negative activity, and that reduction of RI expression can contribute to malignant progression.	MED COLL OHIO,DEPT BIOCHEM & MOLEC BIOL,TOLEDO,OH 43699; CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,IRELAND CANC CTR,CLEVELAND,OH 44106; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; UNIV KENTUCKY,COLL MED,DEPT PHARMACOL,LEXINGTON,KY 40536	Case Western Reserve University; Case Western Reserve University; Duke University; University of Kentucky			, LuZhe/AAW-4095-2021		NATIONAL CANCER INSTITUTE [R29CA063480, R37CA038173, R01CA038173, R01CA050457] Funding Source: NIH RePORTER; NCI NIH HHS [CA63480, CA50457, CA38173] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BASSING CH, 1994, J BIOL CHEM, V269, P14861; BOYD DD, 1988, CANCER RES, V48, P2469; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; CARMICHAEL J, 1987, CANCER RES, V53, P4319; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KIMICHI A, 1988, SCIENCE, V240, P196; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MANNING AM, 1991, ONCOGENE, V6, P1471; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARKOWITZ SD, 1994, J CLIN INVEST, V93, P1005, DOI 10.1172/JCI117048; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Roberts A., 1991, PEPTIDE GROWTH FACTO, P419; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SUN LZ, 1994, J BIOL CHEM, V269, P26449; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; WU SP, 1992, J CELL BIOL, V116, P186	40	115	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17366	17371		10.1074/jbc.271.29.17366	http://dx.doi.org/10.1074/jbc.271.29.17366			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663343	hybrid			2022-12-27	WOS:A1996UX94300060
J	Dessauer, CW; Gilman, AG				Dessauer, CW; Gilman, AG			Purification and characterization of a soluble form of mammalian adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; SITE-MEDIATED INHIBITION; BETA-GAMMA-SUBUNITS; PROTEIN; IDENTIFICATION; REQUIREMENTS; ADENOVIRUS; EXPRESSION; FORSKOLIN; ADENOSINE	An engineered, soluble form of mammalian adenylyl cyclase has been expressed in Escherichia coli and purified by three chromatographic steps, The enzyme utilizes one molecule of ATP to synthesize one molecule of cyclic AMP and pyrophosphate at a maximal specific activity of 12.8 mu mol/min/mg, corresponding to a turnover number of 720 min(-1), Although devoid of membrane spans, the enzyme displays all of the regulatory properties that are common to mammalian adenylyl cyclases, It is activated synergistically by G(S alpha) and forskolin and is inhibited by adenosine (P-site) analogs with kinetic patterns that are identical to those displayed by the native enzymes, The purified enzyme is also inhibited directly by the G protein py subunit complex, After adenovirus-mediated expression in adenylyl cyclase-deficient HC-1 cells, the enzyme can be stimulated synergistically by G(S)-coupled receptors and forskolin.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM16905, GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AWAD JA, 1983, J BIOL CHEM, V258, P2960; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; BUSHFIELD M, 1990, MOL PHARMACOL, V38, P848; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HAYAISHI O, 1971, J BIOL CHEM, V246, P5840; HELLEVUO K, 1995, J BIOL CHEM, V270, P11581, DOI 10.1074/jbc.270.19.11581; INSEL PA, 1976, MOL PHARMACOL, V12, P1062; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LACHMANN PJ, 1986, CIBA F SYMP, V119, P25; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MUMBY S, 1988, J BIOL CHEM, V263, P2020; REDDY R, 1995, J BIOL CHEM, V270, P14340, DOI 10.1074/jbc.270.24.14340; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; Segel I.H, 1968, BIOCH CALCULATIONS; SHIMIZU H, 1969, J NEUROCHEM, V16, P1609, DOI 10.1111/j.1471-4159.1969.tb10360.x; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; WEINRYB I, 1974, BIOCHIM BIOPHYS ACTA, V334, P218, DOI 10.1016/0005-2744(74)90165-X; WOLFF J, 1978, ARCH BIOCHEM BIOPHYS, V191, P161, DOI 10.1016/0003-9861(78)90078-4; WU ZL, 1993, J BIOL CHEM, V268, P23766; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	44	79	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16967	16974		10.1074/jbc.271.28.16967	http://dx.doi.org/10.1074/jbc.271.28.16967			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663304	hybrid			2022-12-27	WOS:A1996UX12600082
J	Igal, RA; Coleman, RA				Igal, RA; Coleman, RA			Acylglycerol recycling from triacylglycerol to phospholipid, not lipase activity, is defective in neutral lipid storage disease fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; CULTURED FIBROBLASTS; METABOLISM; CELLS; ACID; BIOSYNTHESIS; LIPOPROTEIN; ICHTHYOSIS; INHIBITION; TRIACSINS	Neutral lipid storage disease (NLSD) is an autosomal recessive disorder in which excess triacylglycerol (TG) accumulates in most cells, Although it has been hypothesized that the TG accumulation is caused by a functional defect in cytosolic lipase activity, we were able to expose TG hydrolysis in NLSD cells by using triacsin C, an inhibitor of acyl-CoA synthetase that blocks the reincorporation of hydrolyzed fatty acids into glycerolipids, Our data suggest that TG lipolysis in NLSD cells is masked by rapid TG resynthesis, occurring because released acylglycerols cannot be used for phospholipid synthesis, In uptake studies, triacsin C blocked the incorporation of [H-3]glycerol into glycerolipids, incorporation of [C-14]oleate into TG, but not incorporation of [C-14]oleate into phospholipid, Thus, the drug inhibited both de novo synthesis of glycerolipids via the glycerol-3-phosphate pathway and the synthesis of TG from diacylglycerol. The drug did not appear to block reacylation of lysophospholipids. Triacsin C caused a loss of about 60% of the TG mass from both NLSD and oleate-loaded control cells, Rates of TG lipolysis were similar in NLSD cells and oleate-loaded control cells labeled with [6-(7-nitro-2,1,3-benzoxadiazol-4-yl)-amino]hexanoic acid or labeled with [C-14]oleate or [H-3]glycerol and chased in the presence of triacsin C, During a 96-h chase, [C-14]oleate reincorporation into the different phospholipid species increased only in control cells, Similar results were observed when NLSD, and control cells were chased after labeling with [H-3]glycerol. These data strongly suggest that normal human fibroblasts mobilize stored TG for phospholipid synthesis and that recycling to PC occurs via a TG-derived mono- or diacylglycerol intermediate, Normal recycling to phosphatidylethanolamine may primarily involve TG derived acyl groups rather than an acylglycerol precursor. NLSD cells appear to have a block in this recycling pathway with the result that both hydrolyzed fatty acids and the acylglycerol backbone are re-esterified to form TG, Because the NLSD phenotype includes ichthyosis, fatty liver, myopathy, cardiomyopathy, and mental retardation, the recycling pathway appears to be critical for the normal function of skin, liver, muscle, heart, and the central nervous system.	UNIV N CAROLINA,DEPT NUTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019068] Funding Source: NIH RePORTER; NIAMS NIH HHS [5-P60 AR3070] Funding Source: Medline; NICHD NIH HHS [HD 19068] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERGMAN R, 1991, J INHERIT METAB DIS, V14, P241, DOI 10.1007/BF01800597; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHANARIN I, 1975, BRIT MED J, V1, P553, DOI 10.1136/bmj.1.5957.553; COLEMAN R, 1977, J BIOL CHEM, V252, P3050; COOK HW, 1985, CAN J BIOCHEM CELL B, V63, P919, DOI 10.1139/o85-114; DIDONATO S, 1988, NEUROLOGY, V38, P1107; GEORGE TP, 1989, BIOCHIM BIOPHYS ACTA, V1004, P283, DOI 10.1016/0005-2760(89)90075-1; GIBBONS GF, 1990, BIOCHEM J, V268, P1; HILAIRE N, 1995, J BIOL CHEM, V270, P27027, DOI 10.1074/jbc.270.45.27027; HILAIRE N, 1993, FEBS LETT, V328, P230, DOI 10.1016/0014-5793(93)80933-L; HILAIRE N, 1994, BIOCHEM J, V297, P467, DOI 10.1042/bj2970467; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; HOLMSEN H, 1992, THROMB RES, V67, P313, DOI 10.1016/0049-3848(92)90006-V; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; KNOLL LJ, 1995, J BIOL CHEM, V270, P20090, DOI 10.1074/jbc.270.34.20090; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; MCINTYRE JC, 1993, CHEM PHYS LIPIDS, V66, P171, DOI 10.1016/0009-3084(93)90002-K; PAGANO RE, 1983, J BIOL CHEM, V258, P2034; RADOM J, 1989, BIOCHIM BIOPHYS ACTA, V1005, P130, DOI 10.1016/0005-2760(89)90178-1; SALVAYRE R, 1989, FEBS LETT, V250, P35, DOI 10.1016/0014-5793(89)80679-9; SIMPSON CMF, 1991, J BIOL CHEM, V266, P15902; TOMODA H, 1991, J BIOL CHEM, V266, P4214; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; WILLIAMS ML, 1991, BIOCHIM BIOPHYS ACTA, V1096, P162, DOI 10.1016/0925-4439(91)90055-E; WILLIAMS ML, 1988, J INHERIT METAB DIS, V11, P131, DOI 10.1007/BF01799862	26	102	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16644	16651		10.1074/jbc.271.28.16644	http://dx.doi.org/10.1074/jbc.271.28.16644			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663220	Green Published, hybrid			2022-12-27	WOS:A1996UX12600036
J	Ohshima, K; Kang, S; Larson, JE; Wells, RD				Ohshima, K; Kang, S; Larson, JE; Wells, RD			TTA center dot TAA triplet repeats in plasmids form a non-H bonded structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVELY SUPERCOILED DNA; DIETHYL PYROCARBONATE; OSMIUM-TETROXIDE; CRUCIFORM EXTRUSION; IONIC ENVIRONMENT; TRANSGENIC MICE; CHEMICAL PROBE; SEQUENCE DNA; PM2 DNA; TEMPERATURE	CTG . CAG, CGG . CCG, and AAG . CTT triplet repeats proximal to or in disease genes expand by a non-Mendelian genetic process to cause several human hereditary syndromes, As part of our physical, biological, and genetic studies on the 10 possible triplet repeats, we discovered that the TTA . TAA repeat, isolated from the up-stream region of the variant surface glycoprotein gene of Trypanosoma brucei, shows a propensity to adopt a non-H bonded structure under appropriate conditions. The other nine triplet repeat sequences do not exhibit this property. (TTA . TAA)(n), where n = 90, 60, 30, and 18, cloned into pUC19 was studied by chemical and enzymatic probes as well as two-dimensional gel electrophoretic analyses under a variety of conditions. The helix opening was observed for all four inserts in supercoiled plasmids as a function of temperature, pH, metal ions, and buffer conditions using OsO4, diethyl pyrocarbonate, and chloroacetaldehyde probes, This unusual property of the TTA . TAA repeat suggests that it plays a different role from the other nine triplet repeats in gene expression.	TEXAS A&M UNIV, TEXAS MED CTR,CTR GENOME RES, DEPT BIOCHEM & BIOPHYS,INST BIOSCI & TECHNOL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Texas A&M University System; University of Texas System; University of Texas Health Science Center Houston					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52982] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BEER M, 1966, BIOCHEMISTRY-US, V5, P2283, DOI 10.1021/bi00871a017; BOWATER R, 1991, BIOCHEMISTRY-US, V30, P11495, DOI 10.1021/bi00113a003; BOWATER RP, 1994, NUCLEIC ACIDS RES, V22, P2042, DOI 10.1093/nar/22.11.2042; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; CAMPBELL DA, 1984, NUCLEIC ACIDS RES, V12, P2759, DOI 10.1093/nar/12.6.2759; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHANG CH, 1977, BIOCHEMISTRY-US, V16, P33, DOI 10.1021/bi00620a006; Chastain PD, 1995, BIOCHEMISTRY-US, V34, P16125, DOI 10.1021/bi00049a027; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; DAYN A, 1991, J BACTERIOL, V173, P2658, DOI 10.1128/jb.173.8.2658-2664.1991; FURLONG JC, 1986, NUCLEIC ACIDS RES, V14, P3995, DOI 10.1093/nar/14.10.3995; FURLONG JC, 1989, BIOCHEMISTRY-US, V28, P2009, DOI 10.1021/bi00431a008; GASTIER JM, 1995, HUM MOL GENET, V4, P1829, DOI 10.1093/hmg/4.10.1829; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GLIKIN GC, 1984, NUCLEIC ACIDS RES, V12, P1725, DOI 10.1093/nar/12.3.1725; GREAVES DR, 1985, J MOL BIOL, V185, P461, DOI 10.1016/0022-2836(85)90064-6; Haaf T, 1996, NAT GENET, V12, P183, DOI 10.1038/ng0296-183; HANIFORD DB, 1985, NUCLEIC ACIDS RES, V13, P4343, DOI 10.1093/nar/13.12.4343; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1989, J BIOL CHEM, V264, P5950; HERR W, 1985, P NATL ACAD SCI USA, V82, P8009, DOI 10.1073/pnas.82.23.8009; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; KANG S, 1992, J BIOL CHEM, V267, P20887; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KAYASUGAMIKADO K, 1980, CHEM PHARM BULL, V28, P932; KLYSIK J, 1992, J BIOL CHEM, V267, P17430; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWISHIGEMATSU T, 1983, P NATL ACAD SCI-BIOL, V80, P4389, DOI 10.1073/pnas.80.14.4389; KOHWISHIGEMATSU T, 1987, P NATL ACAD SCI USA, V84, P2223, DOI 10.1073/pnas.84.8.2223; KOWALSKI D, 1984, NUCLEIC ACIDS RES, V12, P7071, DOI 10.1093/nar/12.18.7071; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; LILLEY DMJ, 1984, EMBO J, V3, P1187, DOI 10.1002/j.1460-2075.1984.tb01949.x; LILLEY DMJ, 1983, NUCLEIC ACIDS RES, V11, P3097, DOI 10.1093/nar/11.10.3097; LINDBLAD K, 1994, NAT GENET, V7, P124, DOI 10.1038/ng0694-124; LOZANO G, 1991, MOL CARCINOGEN, V4, P3, DOI 10.1002/mc.2940040103; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCCLELLAN JA, 1987, J MOL BIOL, V197, P707, DOI 10.1016/0022-2836(87)90477-3; MCCLELLAN JA, 1986, NUCLEIC ACIDS RES, V14, P9291, DOI 10.1093/nar/14.23.9291; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; OHSHIMA K, 1996, J BIOL CHEM, V271, P38696; RICHARDS RI, 1993, HUM MOL GENET, V2, P1429, DOI 10.1093/hmg/2.9.1429; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; SCHOLTEN PM, 1986, NUCLEIC ACIDS RES, V14, P3981, DOI 10.1093/nar/14.10.3981; SHEFLIN LG, 1984, NUCLEIC ACIDS RES, V12, P7087, DOI 10.1093/nar/12.18.7087; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SINGLETON CK, 1983, J BIOL CHEM, V258, P7661; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; STALLINGS RL, 1994, GENOMICS, V21, P116, DOI 10.1006/geno.1994.1232; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; VOGT N, 1988, J MOL BIOL, V201, P773, DOI 10.1016/0022-2836(88)90474-3; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WELLS RD, 1993, GENOME ANAL, V7, P107; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; ZACHARIAS W, 1983, BIOCHEMISTRY-US, V22, P2398, DOI 10.1021/bi00279a015	66	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16784	16791		10.1074/jbc.271.28.16784	http://dx.doi.org/10.1074/jbc.271.28.16784			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663378				2022-12-27	WOS:A1996UX12600057
J	Deng, P; Rettenmier, CW; Pattengale, PK				Deng, P; Rettenmier, CW; Pattengale, PK			Structural requirements for the ectodomain cleavage of human cell surface macrophage colony-stimulating factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; MEMBRANE-BOUND PRECURSOR; ANCHORED GROWTH-FACTORS; O-LINKED GLYCOSYLATION; FACTOR TNF RECEPTOR; FACTOR-I CSF-1; ALPHA PRECURSOR; TGF-ALPHA; EXPRESSION; FMS	One form of human macrophage colony-stimulating factor (CSF-1(256), M-CSF alpha) is a member of a restricted set of cell surface transmembrane proteins, which is selected to undergo proteolytic ectodomain cleavage. To determine the substrate requirements for this cleavage, we have constructed a series of mutations in the cytoplasmic tail, transmembrane domain, and juxtamembrane region of CSF-1(256) and stably expressed the mutated genes in NIH 3T3 cells. Our results demonstrate that membrane association of the CSF-1 precursor is required for cleavage of its growth factor ectodomain and furthermore that the juxtamembrane region Pro(161)-Gln(162)-Leu(163)-Gln(164)-Glu(165) (PQLQE) (residues 161-165 of the ectodomain) is an essential determinant of cell surface CSF-1(256) cleavage and that the cleavage site is partially sequence-specific. Furthermore, a mechanism of steric hindrance, which likely involves interference with protease accessibility, is postulated to explain the observed decreases in the cleavage efficiency in certain CSF-1 mutants. Finally, our results strongly suggest that the CSF-1 ectodomain is cleaved at or very near the cell surface by a membrane-associated proteolytic system.	CHILDRENS HOSP LOS ANGELES, DEPT PATHOL, LOS ANGELES, CA 90027 USA; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040603] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40603] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; DECOSTER E, 1995, J BIOL CHEM, V270, P18473, DOI 10.1074/jbc.270.31.18473; DOVER GA, 1991, CELL, V65, P9, DOI 10.1016/0092-8674(91)90401-J; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; GORDON MY, 1991, CANCER CELL-MON REV, V3, P127; GULLBERG U, 1992, EUR J CELL BIOL, V58, P307; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HALENBECK R, 1988, J BIOTECHNOL, V8, P45, DOI 10.1016/0168-1656(88)90067-3; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOZARSKY K, 1988, P NATL ACAD SCI USA, V85, P4335, DOI 10.1073/pnas.85.12.4335; KUO SC, 1974, BIOCHEM BIOPH RES CO, V58, P287, DOI 10.1016/0006-291X(74)90925-5; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V179, P1670, DOI 10.1016/0006-291X(91)91767-7; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MULLBERG J, 1995, J IMMUNOL, V155, P5198; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; REDDY P, 1989, J BIOL CHEM, V264, P17329; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; RETTENMIER CW, 1989, HEMATOL ONCOL CLIN N, V3, P479, DOI 10.1016/S0889-8588(18)30543-4; RETTENMIER CW, 1988, MOL CELL BIOL, V8, P5026, DOI 10.1128/MCB.8.11.5026; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SAHASRABUDHE SR, 1992, J BIOL CHEM, V267, P25602; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STANLEY ER, 1985, METHOD ENZYMOL, V116, P564; Steffan NH, 1989, GENE, V77, P51; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; STEIN J, 1991, ONCOGENE, V6, P601; SUZU S, 1992, J BIOL CHEM, V267, P4345; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	49	27	28	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16338	16343		10.1074/jbc.271.27.16338	http://dx.doi.org/10.1074/jbc.271.27.16338			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663232	hybrid			2022-12-27	WOS:A1996UW35200071
J	Ohba, T; Seki, T; Azuma, Y; Nishimoto, T				Ohba, T; Seki, T; Azuma, Y; Nishimoto, T			Premature chromatin condensation induced by loss of RCC1 is inhibited by GTP- and GTP gamma S-Ran, but not GDP-Ran	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOME CONDENSATION; BINDING PROTEIN; CELL-CYCLE; REGULATOR; MITOSIS	RCC1 is a guanine nucleotide exchanging factor acting on nuclear G protein Ran, Premature chromatin condensation occurs in the temperature sensitive rcc1(-) mutant of the BHK21 cell line, tsBN2, at the restrictive temperature, This observation can be explained if the premature activation of MPF is normally inhibited by GTP-Ran, In the absence of RCC1, GDP-Ran predominates, resulting in MPF activation, However, experiments with Ran mutants to determine whether GTP- or GDP-Ran prevents activation of MPF have yielded conflicting results, In order to clarify this point, we have microinjected nucleotide-bound Ran, instead of mutated Ran, into the nuclei of tsBN2 cells treated to reduce RCC1 mediated guanine nucleotide exchange, GTP-Ran, GTP gamma S-Ran, and GDP-Ran all inhibited chromatin condensation. However, the inhibition of chromatin condensation by GDP-Ran could be completely abolished by co-injection with GDP, but not GTP, Thus, we conclude that GTP-Ran blocks the activation of MPF and that hydrolysis of GTP is not required to prevent MPF activation.	KYUSHU UNIV, GRAD SCH MED SCI, DEPT BIOL MOLEC, HIGASHI KU, FUKUOKA 812, JAPAN	Kyushu University			Oba, Tomoyuki/ABT-2152-2022	Oba, Tomoyuki/0000-0002-6715-7892				BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; CLARKE PR, 1995, J CELL SCI, V108, P1217; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; KLEBE C, 1993, BIOCHEMISTRY-US, V32, P11923, DOI 10.1021/bi00095a023; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; NISHIMOTO T, 1978, SOMAT CELL GENET, V4, P323, DOI 10.1007/BF01542846; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; REN MD, 1994, MOL CELL BIOL, V14, P4216, DOI 10.1128/MCB.14.6.4216; SAZAR S, 1992, EMBO J, V13, P606; SEINO H, 1991, COLD SPRING HARB SYM, V56, P367; SEKI T, 1992, MOL BIOL CELL, V3, P1373, DOI 10.1091/mbc.3.12.1373; STOCCHI V, 1987, ANAL BIOCHEM, V167, P181, DOI 10.1016/0003-2697(87)90150-3; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577	22	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14665	14667		10.1074/jbc.271.25.14665	http://dx.doi.org/10.1074/jbc.271.25.14665			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663347	hybrid, Green Accepted			2022-12-27	WOS:A1996UT10600005
J	Wang, ZD; Gurel, O; Baatz, JE; Notter, RH				Wang, ZD; Gurel, O; Baatz, JE; Notter, RH			Acylation of pulmonary surfactant protein-C is required for its optimal surface active interactions with phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE SP-C; NATURAL LUNG SURFACTANT; AIR-WATER-INTERFACE; SP-B; BIOPHYSICAL ACTIVITY; SECONDARY STRUCTURE; DIPALMITOYL PHOSPHATIDYLCHOLINE; MIXTURES; LIPIDS; SEPARATION	This study investigates the importance of thioester-linked acyl groups in lung surfactant protein C (SP-C) in facilitating interactions with phospholipids that yield functionally important surface active behaviors, Native SP-C, palmitoylated at cysteine residues at positions 5 and 6, was isolated from bovine lung surfactant by liquid chromatography, Deacylated SP C (dSP-C), unchanged in composition and sequence from SP-C but having a decreased alpha-helical content in films with dipalmitoyl phosphatidylcholine (DPPC) of 52 versus 70%, was obtained by treatment with 0.1 M sodium carbonate buffer at pH 10, Surface activity was studied for SP-C and dSP-C combined with column-purified phospholipids (PPL) from calf lung surfactant or with synthetic phospholipids (DPPC or a synthetic phospholipid mixture (SPL) containing 50:35:15, DPPC:egg phosphatidylcholine:egg phosphatidylglycerol). Interfacial measurements included surface pressure time adsorption isotherms for dispersed surfactants with diffusion minimized, dynamic surface pressure area isotherms and respreading for films in the Wilhelmy balance, and overall surface tension lowering at physiologic cycling rate in oscillating bubble experiments, Dispersions of PPL:SP-C and SPL:SP-C rapidly adsorbed to high equilibrium surface pressures of 47-48 mN/m, significantly better than corresponding dispersions containing dSP-C. The adsorption of PPL:dSP-C was essentially unchanged from that of PPL alone, and the adsorption of SPL:dSP-C was improved only slightly over SPL alone, In Wilhelmy balance studies, dynamic respreading was significantly improved over phospholipids alone in films of SP-C plus PPL, SPL, or DPPC. Respreading was improved less markedly by dSP-C in corresponding films with SPL or DPPC and not at all in films with PPL. Maximum surface pressures were also higher in cycled films of SP-C vel sus dSP-C combined with PPL or SPL, In bubble experiments (37 degrees C, 20 cycles/min), dispersions of PPL:SP-C and SPL:SP-C reached low minimum surface tensions of <1 and 5 mN/m, respectively, whereas PPL:dSP-C and SPL:dSP-C only reached minima of similar to 20 mN/m as did PPL and SPL alone, Acylation in SP-C is crucial for its interactions with phospholipids over the full spectrum of adsorption and dynamic surface behaviors important for lung surfactant.	UNIV ROCHESTER,DEPT PEDIAT,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT ENVIRONM MED,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT CHEM ENGN,ROCHESTER,NY 14642; MED UNIV S CAROLINA,DEPT PEDIAT,CHARLESTON,SC 29425	University of Rochester; University of Rochester; University of Rochester; Medical University of South Carolina				Baatz, John/0000-0001-5870-1000	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL036543] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36543] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAATZ JE, 1992, CHEM PHYS LIPIDS, V63, P91, DOI 10.1016/0009-3084(92)90026-L; CLEMENTS JA, 1957, P SOC EXP BIOL MED, V95, P170; CREUWELS LAJM, 1993, J BIOL CHEM, V268, P26752; CREUWELS LAJM, 1995, BBA-LIPID LIPID MET, V1254, P326, DOI 10.1016/0005-2760(94)00195-5; CREUWELS LAJM, 1995, J BIOL CHEM, V270, P16225, DOI 10.1074/jbc.270.27.16225; CURSTEDT T, 1987, EUR J BIOCHEM, V168, P255, DOI 10.1111/j.1432-1033.1987.tb13414.x; CURSTEDT T, 1990, P NATL ACAD SCI USA, V87, P2985, DOI 10.1073/pnas.87.8.2985; ELLEDGE B W, 1989, American Review of Respiratory Disease, V139, pA285; ENHORNING G, 1977, J APPL PHYSIOL, V43, P198, DOI 10.1152/jappl.1977.43.2.198; GLASSER SW, 1988, J BIOL CHEM, V263, P9; GUNTHER A, 1993, AM J PHYSIOL, V265, pL186, DOI 10.1152/ajplung.1993.265.2.L186; HALL SB, 1993, J APPL PHYSIOL, V75, P468, DOI 10.1152/jappl.1993.75.1.468; HALL SB, 1994, J LIPID RES, V35, P1386; HAWCO MW, 1981, J APPL PHYSIOL, V51, P509, DOI 10.1152/jappl.1981.51.2.509; HOROWITZ AD, 1993, BIOCHEMISTRY-US, V32, P9513, DOI 10.1021/bi00088a001; HOROWITZ AD, 1995, CHEM PHYS LIPIDS, V76, P27, DOI 10.1016/0009-3084(94)02426-6; HOROWITZ AD, 1992, BIOCHIM BIOPHYS ACTA, V1107, P44, DOI 10.1016/0005-2736(92)90327-I; JAMES G, 1989, J BIOL CHEM, V264, P20998; JOHANSSON J, 1995, FEBS LETT, V362, P261, DOI 10.1016/0014-5793(95)00216-V; JOHANSSON J, 1994, EUR RESPIR J, V7, P372, DOI 10.1183/09031936.94.07020372; JOHANSSON J, 1995, BIOCHEM J, V307, P535, DOI 10.1042/bj3070535; JOHANSSON J, 1988, FEBS LETT, V232, P61, DOI 10.1016/0014-5793(88)80386-7; JOHANSSON J, 1994, BIOCHEMISTRY-US, V33, P6015, DOI 10.1021/bi00185a042; JOHANSSON J, 1991, FEBS LETT, V281, P119, DOI 10.1016/0014-5793(91)80373-B; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KELLER A, 1992, AM J RESP CELL MOL, V6, P601, DOI 10.1165/ajrcmb/6.6.601; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; NOTTER R H, 1989, P19; NOTTER RH, 1980, J LIPID RES, V21, P10; NOTTER RH, 1982, PEDIATR RES, V16, P515, DOI 10.1203/00006450-198207000-00003; NOTTER RH, 1983, CHEM PHYS LIPIDS, V33, P67, DOI 10.1016/0009-3084(83)90009-9; NOTTER RH, 1986, PEDIATR RES, V20, P97, DOI 10.1203/00006450-198601000-00026; PASTRANA B, 1991, BIOCHEMISTRY-US, V30, P10058, DOI 10.1021/bi00105a033; PATTLE RE, 1955, NATURE, V175, P1125, DOI 10.1038/1751125b0; PEREZGIL J, 1993, BIOCHIM BIOPHYS ACTA, V1168, P261, DOI 10.1016/0005-2760(93)90181-8; PEREZGIL J, 1992, BIOPHYS J, V63, P197, DOI 10.1016/S0006-3495(92)81582-5; PEREZGIL J, 1994, BIOCHEM SOC T, V22, pS372, DOI 10.1042/bst022372s; QANBAR R, 1995, BBA-LIPID LIPID MET, V1255, P251, DOI 10.1016/0005-2760(94)00224-M; ROSS GF, 1986, J BIOL CHEM, V261, P14283; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SEEGER W, 1991, BIOCHIM BIOPHYS ACTA, V1081, P45, DOI 10.1016/0005-2760(91)90248-G; SHIFFER K, 1993, BIOCHEMISTRY-US, V32, P590, DOI 10.1021/bi00053a026; SHIN YS, 1962, ANAL CHEM, V34, P1164, DOI 10.1021/ac60189a043; SIMATOS GA, 1990, BIOCHEMISTRY-US, V29, P5807, DOI 10.1021/bi00476a023; SMALL DM, 1986, HDB LIPID RES PHYSIC, V4; STULTS JT, 1991, AM J PHYSIOL, V261, pL118, DOI 10.1152/ajplung.1991.261.2.L118; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; TABAK SA, 1977, REV SCI INSTRUM, V48, P1196, DOI 10.1063/1.1135220; TOUCHSTONE JC, 1980, LIPIDS, V15, P61, DOI 10.1007/BF02534120; TURCOTTE JG, 1977, BIOCHIM BIOPHYS ACTA, V488, P235, DOI 10.1016/0005-2760(77)90181-3; VANDENBUSSCHE G, 1992, EUR J BIOCHEM, V203, P201, DOI 10.1111/j.1432-1033.1992.tb19848.x; VANGOLDE LMG, 1988, PHYSIOL REV, V68, P374, DOI 10.1152/physrev.1988.68.2.374; VORBROKER DK, 1992, BIOCHIM BIOPHYS ACTA, V1105, P161, DOI 10.1016/0005-2736(92)90175-L; VOSS T, 1992, BIOCHIM BIOPHYS ACTA, V1138, P261, DOI 10.1016/0925-4439(92)90002-5; WANG ZD, 1995, J LIPID RES, V36, P1283; WHITSETT JA, 1992, PULMONARY SURFACTANT, P55; ZHANG YP, 1992, BIOCHEMISTRY-US, V31, P11579, DOI 10.1021/bi00161a042	58	57	64	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	1996	271	32					19104	19109		10.1074/jbc.271.32.19104	http://dx.doi.org/10.1074/jbc.271.32.19104			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB684	8702584	hybrid			2022-12-27	WOS:A1996VB68400018
J	Colombo, MI; Taddese, M; Whiteheart, SW; Stahl, PD				Colombo, MI; Taddese, M; Whiteheart, SW; Stahl, PD			A possible predocking attachment site for N-ethylmaleimide-sensitive fusion protein - Insights from in vitro endosome fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; ALPHA-SNAP; REGULATED EXOCYTOSIS; MEMBRANE-FUSION; VESICLES; NSF; HYDROLYSIS; REQUIRES; RECEPTOR; PARTICLE	N-Ethylmaleimide-sensitive fusion protein (NSF) is an ubiquitous protein required for multiple vesicular transport events, We have investigated the role of the two nucleotide-binding regions of NSF in endosomal fusion by analyzing NSF mutants in a cell-free system, Our results indicate that mutations on the first ATP-binding domain, that render a protein defective in either ATP binding or ATP hydrolysis, results in almost complete inhibition of endosomal fusion, A mutation in the second ATP-binding site of NSF was only slightly inhibitory. The inhibitory effect was observed only when the mutant proteins were added at early times during the fusion reaction indicating that NSF may be required for an early step during the docking/fusion process, Binding studies using Western blotting reveal that the binding of NSF mutants to endosomal membranes is differentially affected by Ca2+, Our results indicate that NSF, depending on its nucleotide state, may interact with membranes via an alternate mechanism, Our findings suggest the existence of a predocking binding site either independent of the docking complex or a site that leads to the formation of the SNAP-SNARE complex (e,g, 20 S particle).	UNIV KENTUCKY,COLL MED,DEPT BIOCHEM,ALBERT B CHANDLER MED CTR,LEXINGTON,KY 40536	University of Kentucky	Colombo, MI (corresponding author), WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.		Stahl, Philip/D-6315-2012	Whiteheart, Sidney/0000-0001-5577-0473				BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; COLOMBO MI, 1992, METHOD ENZYMOL, V219, P32; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Steel GJ, 1996, EMBO J, V15, P745, DOI 10.1002/j.1460-2075.1996.tb00410.x; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUMIDA M, 1994, J BIOL CHEM, V269, P20636; SZTUL E, 1993, J BIOL CHEM, V268, P1876; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	34	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18810	18816		10.1074/jbc.271.31.18810	http://dx.doi.org/10.1074/jbc.271.31.18810			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702539	hybrid			2022-12-27	WOS:A1996VB68300077
J	Hoffman, JF; Linderman, JJ; Omann, GM				Hoffman, JF; Linderman, JJ; Omann, GM			Receptor up-regulation, internalization, and interconverting receptor states - Critical components of a quantitative description of N-formyl peptide-receptor dynamics in the neutrophil	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEINS; METHIONYL-LEUCYL-PHENYLALANINE; REAL-TIME ANALYSIS; SIGNAL TRANSDUCTION; CHEMOTACTIC PEPTIDE; HUMAN-GRANULOCYTES; POLYMORPHONUCLEAR LEUKOCYTES; CHEMOATTRACTANT RECEPTORS; CYTOSKELETAL ACTIVATION; OXIDANT PRODUCTION	High resolution kinetic data of the binding of fluorescent peptide to the N-formyl peptide receptor of neutrophils at 37 degrees C has allowed for the development of a ligand binding model that predicts statistically larger binding rate constants than those previously reported for intact neutrophils. The new model accounts for ligand association and dissociation, receptor up-regulation, ligand-receptor complex internalization, a change in receptor affinity, and the quenching of internalized fluorescent ligand. We determined that receptor up-regulation is both agonist- and temperature-induced and is inhibited by both phenylarsine oxide and pertussis toxin treatment. Model fits of ligand association to pertussis toxin-treated cells show that while receptor upregulation was inhibited, rate constants for ligand binding, receptor affinity conversion, and internalization of ligand-receptor complexes were unaffected. Results suggest G(1)-protein mediated receptor up-regulation and G(1)-protein-independent receptor affinity conversion, Simulation of ligand infusion using our model gives insight into the quantitative and dynamic relationship between the low affinity ligand-receptor complex and the actin polymerization response.	VET ADM MED CTR, RES SERV 151, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, DEPT CHEM ENGN, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, SCH MED, DEPT SURG, ANN ARBOR, MI 48105 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008353] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08353] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1995, THESIS U MICHIGAN AN; ANDERSON BO, 1990, J TRAUMA, V30, pS44; DECKERT M, 1994, BIOCHEM J, V297, P567, DOI 10.1042/bj2970567; FAY SP, 1991, BIOCHEMISTRY-US, V30, P5066, DOI 10.1021/bi00234a033; FINNEY DA, 1983, CYTOMETRY, V4, P54, DOI 10.1002/cyto.990040108; FLETCHER MP, 1983, BLOOD, V62, P792; FOREHAND JR, 1989, J CLIN INVEST, V83, P74, DOI 10.1172/JCI113887; GIERSCHIK P, 1992, CURR TOP MICROBIOL, V175, P69; GOLDMAN DW, 1986, J IMMUNOL, V137, P1971; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; HOFFMAN JF, 1995, THESIS U MICHIGAN AN, P153; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; JESAITIS A J, 1988, P325; JESAITIS AJ, 1988, J CELL BIOL, V107, P921, DOI 10.1083/jcb.107.3.921; JESAITIS AJ, 1993, EUR J HAEMATOL, V51, P288; JESAITIS AJ, 1983, J BIOL CHEM, V258, P1968; JESAITIS AJ, 1984, J CELL BIOL, V98, P1378, DOI 10.1083/jcb.98.4.1378; JESAITIS AJ, 1989, J CELL BIOL, V109, P2783, DOI 10.1083/jcb.109.6.2783; JOHANSSON B, 1993, J CELL BIOL, V121, P1281, DOI 10.1083/jcb.121.6.1281; KLOTZ KN, 1994, BIOESSAYS, V16, P193, DOI 10.1002/bies.950160310; KLOTZ KN, 1994, J IMMUNOL, V152, P801; KOO C, 1982, BIOCHEM BIOPH RES CO, V106, P442, DOI 10.1016/0006-291X(82)91130-5; KOREN R, 1976, BIOCHEMISTRY-US, V15, P1165, DOI 10.1021/bi00650a032; KUBES P, 1993, CAN J PHYSIOL PHARM, V71, P88, DOI 10.1139/y93-013; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; LOW DA, 1981, P NATL ACAD SCI-BIOL, V78, P2340, DOI 10.1073/pnas.78.4.2340; LU DJ, 1990, J BIOL CHEM, V265, P13721; MIKLAVC A, 1990, BIOCHEM PHARMACOL, V40, P663, DOI 10.1016/0006-2952(90)90299-Z; MOOD AM, 1974, INTRO THEORY STATIST; NEUBIG RR, 1993, MOL PHARMACOL, V43, P734; NIEDEL J, 1979, J BIOL CHEM, V254, P700; NORGAUER J, 1991, J IMMUNOL, V146, P975; NORGAUER J, 1989, J CELL BIOL, V109, P1133, DOI 10.1083/jcb.109.3.1133; OLSSON I, 1980, ALLERGY, V35, P1, DOI 10.1111/j.1398-9995.1980.tb01711.x; OMANN GM, 1988, J CELL BIOL, V107, P951, DOI 10.1083/jcb.107.3.951; OMANN GM, 1987, PHYSIOL REV, V67, P285, DOI 10.1152/physrev.1987.67.1.285; OMANN GM, 1992, J IMMUNOL, V149, P2172; ONARAN HO, 1993, MOL PHARMACOL, V43, P245; PAINTER RG, 1987, J CELL BIOL, V105, P2959, DOI 10.1083/jcb.105.6.2959; POSNER RG, 1994, MOL PHARMACOL, V45, P65; SCHONBRUNN A, 1978, J BIOL CHEM, V253, P6473; Seber G., 1989, NONLINEAR REGRESSION; SENGELOV H, 1994, BIOCHEM J, V299, P473, DOI 10.1042/bj2990473; SENGELOV H, 1993, J IMMUNOL, V150, P1535; Sklar L A, 1984, Contemp Top Immunobiol, V14, P29; SKLAR LA, 1984, J BIOL CHEM, V259, P5661; SKLAR LA, 1989, J BIOL CHEM, V264, P8483; SKLAR LA, 1986, ADV IMMUNOL, V39, P95; SKLAR LA, 1987, J BIOL CHEM, V262, P135; SKLAR LA, 1985, J BIOL CHEM, V260, P1461; SKLAR LA, 1982, CYTOMETRY, V3, P161, DOI 10.1002/cyto.990030304; SKLAR LA, 1987, ANNU REV BIOPHYS BIO, V16, P479, DOI 10.1146/annurev.biophys.16.1.479; SKLAR LA, 1985, MOL PHARMACOL, V28, P323; SKLAR LA, 1985, J CELL BIOL, V101, P1161, DOI 10.1083/jcb.101.3.1161; SKLAR LA, 1985, BIOPHYS J, V47, pA165; TENNENBERG SD, 1988, J IMMUNOL, V141, P3937; TOLLEY JO, 1987, J LEUKOCYTE BIOL, V42, P43, DOI 10.1002/jlb.42.1.43; WILEY HS, 1982, J BIOL CHEM, V257, P4222; YEE J, 1993, J IMMUNOL, V150, P1988; ZIGMOND SH, 1982, J CELL BIOL, V92, P34, DOI 10.1083/jcb.92.1.34	60	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18394	18404		10.1074/jbc.271.31.18394	http://dx.doi.org/10.1074/jbc.271.31.18394			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702483	hybrid			2022-12-27	WOS:A1996VB68300021
J	Ling, L; Templeton, D; Kung, HJ				Ling, L; Templeton, D; Kung, HJ			Identification of the major autophosphorylation sites of Nyk/Mer, an NCAM-related receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; INSULIN-RECEPTOR; DIRECTED MUTAGENESIS; EXPRESSION ANALYSIS; MOLECULAR-CLONING; INTACT-CELLS; PROTEIN-S; V-RYK; DOMAIN	Nyk/Mer receptor tyrosine kinase is a new member of the Ufo/Axl tyrosine kinase family and is characterized by its neural cell adhesion molecule-like extracellular domain, By using a vaccinia virus expression system to express a constitutively activated form of Nyk, we identified the major sites of Nyk autophosphorylation in tryptic peptide IY(749)SGDY(753)Y(754)R. Tyr-749, Tyr-753, and Tyr-754 in this peptide lie in the activation loop of the kinase domain, We also studied a series of Nyk mutants in which the three tyrosine residues were replaced individually, in pairs, or all together by phenylalanine. Single mutations of Tyr 749 or Tyr-753 to phenylalanine reduced Nyk kinase activity toward exogenous substrate to 39 or 10% of that of the wild type Nyk, respectively, whereas the Tyr-754 mutant is completely inactive, All of the double and triple Tyr-Phe mutants reduced Nyk kinase activity to a level below the background, Similar results were obtained when Nyk autophosphorylation levels were examined, Our studies suggest that full activity of Nyk/Mer kinase requires phosphorylation of all three tyrosine residues in the kinase domain (Tyr-749, Tyr-753, and Tyr-754) and that Nyk kinase activity is modulated by the level of autophosphorylation in the kinase domain, Given the highly conserved nature of this region among the Ufo/Axl receptor family members, the information presented in this report may provide insight to the biochemical properties of other members of this family.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT MOL BIOL & MICROBIOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT PATHOL, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University			Kung, Hsing-Jien/C-7651-2013; Templeton, Dennis J/F-7695-2011		NCI NIH HHS [CA60171, CA57179, CA39207] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA057179, R37CA039207, P20CA060171, R01CA057179, R01CA039207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CALALB MB, 1995, MOL CELL BIOL, V15, P954; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAI W, 1994, ONCOGENE, V9, P975; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FAUST M, 1992, ONCOGENE, V7, P1287; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GUITON M, 1994, J BIOL CHEM, V269, P30370; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HERNANDEZSANCHEZ C, 1995, J BIOL CHEM, V270, P29176, DOI 10.1074/jbc.270.49.29176; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; JIA R, 1994, J BIOL CHEM, V269, P1839; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; LAI C, 1994, ONCOGENE, V9, P2567; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEVINE BA, 1991, J BIOL CHEM, V266, P3565; LEVINE BA, 1991, J BIOL CHEM, V266, P13405; LING L, 1995, MOL CELL BIOL, V15, P6582; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MARK MR, 1994, J BIOL CHEM, V269, P10720; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; RESCIGNO J, 1991, ONCOGENE, V6, P1909; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; Taylor ICA, 1995, ONCOGENE, V11, P2619; TOSHIMA J, 1995, BIOCHEM BIOPH RES CO, V209, P656, DOI 10.1006/bbrc.1995.1549; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHANG B, 1991, J BIOL CHEM, V266, P990	49	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18355	18362		10.1074/jbc.271.31.18355	http://dx.doi.org/10.1074/jbc.271.31.18355			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702477	hybrid			2022-12-27	WOS:A1996VB68300015
J	Lu, L; Berkey, KA; Casero, RA				Lu, L; Berkey, KA; Casero, RA			RGFGIGS is an amino acid sequence required for acetyl coenzyme A binding and activity of human spermidine/spermine N(1)acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN N-ACETYLTRANSFERASE; SPERMINE N1-ACETYLTRANSFERASE; CHOLINE-ACETYLTRANSFERASE; MELANOMA XENOGRAFTS; ANTITUMOR-ACTIVITY; POLYAMINE; INDUCTION; CELLS; N-1-ACETYLTRANSFERASE; ANALOGS	Polyamine catabolism is rate limited by spermidine/spermine N-1-acetyltransferase (SSAT), Although the amino acid sequence of SSAT is known, the substrate binding and catalytic sites are not, The goal of this study was to define the region responsible for acetyl coenzyme A binding, Human SSAT contains a region of 20 amino acids homologous to several microbial antibiotic N-acetyltransferases. The highest;homology is represented in the Campylobacter coli streptothricin acetyltransferase sat4 gene, where 16 identical or highly conserved amino acids exist in a 20-residue stretch, The most conserved residues within this region are RGF-GIGS beginning at Arg-101 in the human SSAT, Site-directed mutations to Arg-101, Gly-104, and Gly-106 resulted in proteins with no measurable activity, The G102D mutation produced a partially active protein with a decreased affinity for acetyl coenzyme A and with a K-m >10-fold that of the wild-type protein, Analysis using the PredictProtein program suggests a common structure among the microbial and eukaryotic N-acetyltransferases in the region corresponding to the RGF-GIGS of human SSAT consisting of an cu-helix usually preceded by a glycine loop, Our data are consistent with the hypothesis that Arg-101 and the proximal glycine loop are necessary for the activity of human SSAT.	JOHNS HOPKINS ONCOL CTR LABS, BALTIMORE, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine				Casero, Robert/0000-0001-5653-3306	NATIONAL CANCER INSTITUTE [R01CA051085, P50CA058184] Funding Source: NIH RePORTER; NCI NIH HHS [CA51085, CA58184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNACKI RJ, 1992, CANCER RES, V52, P2424; BORJIGIN J, 1995, NATURE, V378, P783, DOI 10.1038/378783a0; CARBINI L, 1990, BRAIN RES BULL, V24, P119, DOI 10.1016/0361-9230(90)90295-B; CASERO RA, 1990, BIOCHEM J, V270, P615, DOI 10.1042/bj2700615; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1991, J BIOL CHEM, V266, P810; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; CHANG BK, 1992, CANCER CHEMOTH PHARM, V30, P179, DOI 10.1007/BF00686308; COLEMAN CS, 1995, BIOCHEMISTRY-US, V34, P13423, DOI 10.1021/bi00041a020; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; CURRIER SF, 1974, P NATL ACAD SCI USA, V71, P3355, DOI 10.1073/pnas.71.9.3355; DELLARAGIONE F, 1983, BIOCHEM J, V213, P707, DOI 10.1042/bj2130707; DELLARAGIONE F, 1983, BIOCHEM J, V213, P701, DOI 10.1042/bj2130701; FOGELPETROVIC M, 1993, BIOCHIM BIOPHYS ACTA, V1216, P255, DOI 10.1016/0167-4781(93)90152-4; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; FUKUCHI J, 1994, J BIOL CHEM, V269, P22581; FULLER DJM, 1990, BIOCHEM J, V267, P601, DOI 10.1042/bj2670601; GERNER EW, 1993, BIOCHEM J, V294, P491, DOI 10.1042/bj2940491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEI X, 1992, BIOCHEM BIOPH RES CO, V187, P1493, DOI 10.1016/0006-291X(92)90471-V; LIBBY PR, 1991, ARCH BIOCHEM BIOPHYS, V284, P238, DOI 10.1016/0003-9861(91)90291-P; PEGG AE, 1992, BIOCHIM BIOPHYS ACTA, V1171, P106, DOI 10.1016/0167-4781(92)90148-S; PERSSON L, 1984, J BIOL CHEM, V259, P2364; PORTER CW, 1991, CANCER RES, V51, P3715; PORTER CW, 1993, CANCER RES, V53, P581; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; Seiler N, 1988, Adv Exp Med Biol, V250, P127; SHAPPELL NW, 1993, FEBS LETT, V321, P179, DOI 10.1016/0014-5793(93)80103-2; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; WU DH, 1995, J BIOL CHEM, V270, P29111, DOI 10.1074/jbc.270.49.29111; Xiao L, 1996, BIOCHEM J, V313, P691, DOI 10.1042/bj3130691	35	75	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18920	18924		10.1074/jbc.271.31.18920	http://dx.doi.org/10.1074/jbc.271.31.18920			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702554	hybrid			2022-12-27	WOS:A1996VB68300092
J	Lechleider, RJ; deCaestecker, MP; Dehejia, A; Polymeropoulos, MH; Roberts, AB				Lechleider, RJ; deCaestecker, MP; Dehejia, A; Polymeropoulos, MH; Roberts, AB			Serine phosphorylation, chromosomal localization, and transforming growth factor-beta signal transduction by human bsp-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; EPITHELIAL-CELLS; RECEPTOR; GENE; ACTIVATION; DROSOPHILA; PATHWAYS; HOMOLOG; PATTERN	The transforming growth factor-beta (TGF-beta) superfamily regulates a multitude of cellular and developmental events. TGF-beta family ligands signal through transmembrane serine/threonine kinase receptors whose downstream effecters are largely unknown, Using genetic data from the fruit fly, we have identified a downstream effector of TGF-beta-induced signaling. TGF-beta signaling protein-1 (BSP-1) is rapidly phosphorylated in response to TGF-beta. Localization of bsp-l to chromosome 4q28 suggests a role in carcinogenesis. These data suggest that BSP-1 is the prototype of a new class of signaling molecules.	NATL CTR HUMAN GENOME RES,LAB GENET DIS RES,GENE MAPPING UNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Lechleider, RJ (corresponding author), NCI,CHEMOPREVENT LAB,NIH,41 LIB DR,BETHESDA,MD 20892, USA.							ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ATFI A, 1994, J BIOL CHEM, V269, P30688; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; AUFFRAY C, 1995, CR ACAD SCI III-VIE, V318, P263; Boige V., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P551; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GELBART WM, 1989, DEVELOPMENT, V107, P65; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KIM SJ, 1992, J BIOL CHEM, V267, P13702; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MULDER KM, 1992, J BIOL CHEM, V267, P5029; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; RAFTERY LA, 1995, GENETICS, V139, P241; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Sambrook J., 2002, MOL CLONING LAB MANU; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN ZF, 1994, J BIOL CHEM, V269, P13231; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2	36	74	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17617	17620		10.1074/jbc.271.30.17617	http://dx.doi.org/10.1074/jbc.271.30.17617			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663601	hybrid			2022-12-27	WOS:A1996UY93500007
J	Piersen, CE; Prasad, R; Wilson, SH; Lloyd, RS				Piersen, CE; Prasad, R; Wilson, SH; Lloyd, RS			Evidence for an imino intermediate in the DNA polymerase beta deoxyribose phosphate excision reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; AMINO-TERMINUS; SITE; BINDING; REPAIR; IDENTIFICATION; RESIDUES; DOMAIN; T4-ENDONUCLEASE-V; ENDONUCLEASE	A recent study demonstrated that rat DNA polymerase beta (beta-pol) releases 5'-deoxyribose phosphate (dRP) termini from preincised apurinic/apyrimidinic DNA, a substrate generated during certain types of base excision repair, This catalytic activity resides within the amino-terminal, 8-kDa domain of beta-pol and occurs via beta-elimination as opposed to hydrolysis (Matsumoto, Y., and Rim, K. (1995) Science 269, 699-702), The latter finding suggested that the dRP excision reaction might proceed via an imine intermediate. In order to test this hypothesis, we attempted to trap beta-pol on preincised apurinic/apyrimidinic DNA using NaBH4 as the reducing agent, Both 8-kDa domain-DNA and intact beta-pol-DNA complexes were detected and identified by autoradiography coupled to immunoblotting, Our results indicate that the chemical mechanism of the beta-pol dRpase reaction does proceed through an imine enzyme-DNA intermediate and that the active site residue responsible for dRP release must therefore contain a primary amine.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293; Lloyd, R. Stephen/0000-0001-7273-372X; Piersen, Colleen/0000-0002-2913-4956	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, R01ES004091, R01ES006492] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04091, ES06676, ES06492] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAILLY V, 1989, BIOCHEM J, V259, P751, DOI 10.1042/bj2590751; BASU A, 1989, BIOCHEMISTRY-US, V28, P6305, DOI 10.1021/bi00441a023; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; FISCHER EH, 1958, J AM CHEM SOC, V80, P2906, DOI 10.1021/ja01544a082; FRIDOVICH I, 1962, J AM CHEM SOC, V84, P3208, DOI 10.1021/ja00875a050; HARLOW E, 1988, ANTIBODIES LABORATOR; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LIU DJ, 1994, BIOCHEMISTRY-US, V33, P9537, DOI 10.1021/bi00198a020; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PELLETIER H, 1996, IN PRESS BIOCHEMISTR; PIERSEN CE, 1995, J BIOL CHEM, V270, P23475, DOI 10.1074/jbc.270.40.23475; PRASAD R, 1993, J BIOL CHEM, V268, P22746; PRASAD R, 1994, J BIOL CHEM, V269, P18096; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SPECK JC, 1963, J AM CHEM SOC, V85, P1012, DOI 10.1021/ja00890a048; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; WARREN S, 1966, BIOCHEMISTRY-US, V5, P817, DOI 10.1021/bi00867a002; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842	27	149	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17811	17815		10.1074/jbc.271.30.17811	http://dx.doi.org/10.1074/jbc.271.30.17811			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663612	hybrid			2022-12-27	WOS:A1996UY93500036
J	Rondinone, CM; Smith, U				Rondinone, CM; Smith, U			Okadaic acid exerts a full insulin-like effect on glucose transport and glucose transporter 4 translocation in human adipocytes - Evidence for a phosphatidylinositol 3-kinase-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; 3-KINASE ACTIVITY; RECEPTOR SUBSTRATE-1; SKELETAL-MUSCLE; STIMULATED GLUCOSE; PHOSPHATASE INHIBITOR; SIGNALING SYSTEM; PLASMA-MEMBRANE; PROTEIN; PHOSPHORYLATION	The effects of the serine/threonine phosphatase inhibitor, okadaic acid, and insulin on glucose transport activity, glucose transporter 4 translocation to the plasma membrane, and the signaling pathway of insulin were examined in human adipocytes, Okadaic acid consistently produced a greater increase than insulin in the rate of glucose transport, and both agents together had a partial additive effect, Both insulin alone and okadaic acid alone stimulated the translocation of glucose transporter 4 to the plasma membrane, Insulin, but not okadaic acid, stimulated phosphatidylinositol 3-kinase (PI 3-kinase) activity, and wortmannin completely inhibited the effect of insulin on glucose transport, When the cells were incubated with both agents, okadaic acid inhibited insulin-stimulated PI 3-kinase activity but did not block the association of the p85 or p110 subunits of PI 3-kinase with insulin receptor substrate 1, Insulin-stimulated tyrosine phosphorylation of insulin receptor substrate 1 was only slightly reduced (15-30%) by okadaic acid, These data demonstrate that okadaic acid exerts a full insulin-like effect independent of the activation of PI 3-kinase. Thus, PI 3-kinase lipid kinase is not essential for glucose transporter 4 translocation in human adipocytes, and different pathways exist that lead to glucose transporter 4 translocation and increased glucose transport.			Rondinone, CM (corresponding author), SAHLGRENS UNIV HOSP,DEPT INTERNAL MED,LUNDBERG LAB DIABET RES,S-41345 GOTHENBURG,SWEDEN.							AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; CAREY JO, 1995, DIABETES, V44, P682, DOI 10.2337/diabetes.44.6.682; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CORVERA S, 1991, J BIOL CHEM, V266, P9271; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; FOLEY JE, 1983, J CLIN INVEST, V72, P1901, DOI 10.1172/JCI111153; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; HESS SL, 1991, J CELL BIOCHEM, V45, P374, DOI 10.1002/jcb.240450411; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JULLIEN D, 1993, J BIOL CHEM, V268, P15246; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KAPELLER R, 1994, BIOESSAYS, V16, P656; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KOZKA IJ, 1995, DIABETOLOGIA, V38, P661, DOI 10.1007/s001250050334; LAM K, 1994, J BIOL CHEM, V269, P20648; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, J BIOL CHEM, V269, P28783; OKADA T, 1994, J BIOL CHEM, V269, P3568; SATOH S, 1993, J BIOL CHEM, V268, P17820; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SIMPSON IA, 1984, DIABETES, V33, P13, DOI 10.2337/diabetes.33.1.13; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH U, 1972, J LIPID RES, V13, P822; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TANTI JF, 1994, J BIOL CHEM, V269, P6051; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	43	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18148	18153		10.1074/jbc.271.30.18148	http://dx.doi.org/10.1074/jbc.271.30.18148			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663361	hybrid			2022-12-27	WOS:A1996UY93500084
J	Crechet, JB; Bernardi, A; Parmeggiani, A				Crechet, JB; Bernardi, A; Parmeggiani, A			Distal switch II region of Ras2p is required for interaction with guanine nucleotide exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SDC25 C-DOMAIN; SACCHAROMYCES-CEREVISIAE; H-RAS; GTP EXCHANGE; PROTEINS; CDC25; GDP; IDENTIFICATION; BINDING; MUTANTS	The interaction of Saccharomyces cerevisiae Ras2p with the catalytic domain of the GDP/GTP exchange factors (GEFs) mouse CDC25(Mm), yeast Cdc25p, and Sdc25p was analyzed by introducing the substitution R80D/N81D into Ras2p S24N, a mutant that is shown to interfere with the Ras2p wild type (wt)-GEF interaction by forming a stable complex. The triple mutant, Like Ras2p R80D/N81D, did not interfere with the action of GEF on Ras2p wt (or H-Ras p21) and was unable to form a stable complex with GEF. The GEF stimulation of the nucleotide dissociation of the triple mutant was virtually abolished and strongly decreased with the double mutant. The affinity of Ras2p S24N/R80D/N81D for GDP and GTP was decreased 3 and 4 orders of magnitude, respectively, hire that of Ras2p S24N, whereas the double mutant behaved as Ras2p wt. Like Ras2p S24N and unlike Ras2p R80D/N81D, the GTP-bound triple mutant did not activate adenylyl cyclase. Thus, the triple mutant and Ras2p S24N have opposite properties toward the binding to GEF but similarly modified behaviors toward GDP, GTP, and adenylyl cyclase. This work emphasizes the determinant role of the distal switch II region of Ras2p for the interaction with GEF and the different structural background of the interaction with adenylyl cyclase.	ECOLE POLYTECH,GRP BIOPHYS EQUIPE 2,F-91128 PALAISEAU,FRANCE; CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE; UNIV PARIS 07,INST JACQUES MONOD,F-75251 PARIS,FRANCE	Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite								BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN SY, 1994, ONCOGENE, V9, P2691; CRECHET JB, 1986, EUR J BIOCHEM, V161, P647, DOI 10.1111/j.1432-1033.1986.tb10489.x; CRECHET JB, 1990, J BIOL CHEM, V265, P1563; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; CRECHET JB, 1993, J BIOL CHEM, V268, P14836; DEVENDITTIS E, 1986, EUR J BIOCHEM, V161, P473; DEVENDITTIS E, 1986, EMBO J, V15, P3657; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HALL A, 1986, J BIOL CHEM, V261, P10693; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HOWE LR, 1993, ONCOGENE, V8, P2583; HWANG YW, 1993, J BIOL CHEM, V268, P24692; JACQUET E, 1992, J BIOL CHEM, V267, P24181; JACQUET E, 1995, BIOCHEMISTRY-US, V34, P12347, DOI 10.1021/bi00038a031; JACQUET E, 1994, BIOCHEM BIOPH RES CO, V199, P497, DOI 10.1006/bbrc.1994.1256; JOHN J, 1993, J BIOL CHEM, V268, P923; JUNG V, 1994, MOL CELL BIOL, V12, P2091; KAVOUNIS C, 1991, FEBS LETT, V281, P235, DOI 10.1016/0014-5793(91)80401-N; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MILLER AF, 1992, BIOCHEMISTRY-US, V31, P10208, DOI 10.1021/bi00157a007; MIRISOLA MG, 1994, J BIOL CHEM, V269, P15740; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARMEGGIANI A, 1993, RAS SUPERFAMILIES GT, P467; POULLET P, 1995, EUR J BIOCHEM, V227, P537, DOI 10.1111/j.1432-1033.1995.tb20421.x; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STOUTEN PFW, 1993, FEBS LETT, V320, P1, DOI 10.1016/0014-5793(93)81644-F; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x	40	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17234	17240		10.1074/jbc.271.29.17234	http://dx.doi.org/10.1074/jbc.271.29.17234			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663268	hybrid			2022-12-27	WOS:A1996UX94300041
J	DeLeo, FR; Ulman, KV; Davis, AR; Jutila, KL; Quinn, MT				DeLeo, FR; Ulman, KV; Davis, AR; Jutila, KL; Quinn, MT			Assembly of the human neutrophil NADPH oxidase involves binding of p67(phox) and flavocytochrome b to a common functional domain in p47(phox)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; CYTOSOLIC PROTEINS P47-PHOX; CELL-FREE SYSTEM; PLASMA-MEMBRANE; DEFECTIVE TRANSLOCATION; CYTOCHROME B(558); ACTIVATION; COMPONENTS; P67-PHOX	The human neutrophil NADPH oxidase is a multi-component complex composed of membrane-bound and cytosolic proteins, During activation, cytosolic proteins p47(phox) P67(phox), Rac2, and possibly p40(phox) translocate to the plasma membrane and associate with flavocytochrome 5 to form the active superoxide-generating system, To further investigate the role of p67(phox), this complex assembly process, experiments were performed to identify possible regions of interaction between p67(phox) and other NADPH oxidase proteins, Using random sequence peptide phage display library analysis of p67(phox) we identified a novel region in p47(phox) encompassing residues 323-332 and a previously identified SH3 binding domain encompassing p47(phox) residues 361-370 as p67(phox) binding sites, Synthetic peptides mimicking p47(phox) residues 323-332 inhibited the p47(phox)-p67(phox) binding interaction in an affinity binding assay; however, peptides mimicking flanking regions were inactive, Surprisingly, this same region of p47(phox) was found previously to represent a site of binding interaction for flavocytochrome b (DeLeo, F, R,, Nauseef, W, M,, Jesaitis, A. J,, Burritt, J, B,, Clark, R, A., and Quinn, M. T, (1995) J, Biol. Chem, 270, 26246-26251), and this observation was confirmed in the present report using two different in vitro assays that were not evaluated previously, Using affinity binding assays, we also found that p67(phox) and flavocytochrome 5 competed for binding to p47(phox) after activation, suggesting that prior to full NADPH oxidase assembly the 323-332 region of p47(phox) is associated with p67(phox) and at some point in the activation process is transferred to flavocytochrome b, Thus, taken together our data demonstrate that both p67(phox) and flavocytochrome b utilize a common binding site in p47(phox) presumably at distinct stages during the activation process, and this p47(phox) region plays a key role in regulating NADPH oxidase assembly.	MONTANA STATE UNIV,DEPT VET MOL BIOL,BOZEMAN,MT 59715	Montana State University System; Montana State University Bozeman					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040929] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40929] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BURRITT JB, 1995, J BIOL CHEM, V270, P16974, DOI 10.1074/jbc.270.28.16974; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CROSS AR, 1995, J BIOL CHEM, V270, P6443; De Mendez I., 1995, Molecular Biology of the Cell, V6, p240A; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; DUSI S, 1993, BIOCHEM J, V290, P173, DOI 10.1042/bj2900173; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FAUST LP, 1995, J CLIN INVEST, V96, P1499, DOI 10.1172/JCI118187; FINAN P, 1994, J BIOL CHEM, V269, P13752; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; FUJITA I, 1987, BIOCHIM BIOPHYS ACTA, V931, P41, DOI 10.1016/0167-4889(87)90048-6; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; HAYAKAWA T, 1986, J BIOL CHEM, V261, P9109; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Hong Y., 1995, Journal of Investigative Medicine, V43, p287A; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; KOSHKIN V, 1993, FEBS LETT, V327, P67; Leto T. L., 1995, Molecular Biology of the Cell, V6, p241A; LETO TL, 1991, J BIOL CHEM, V266, P19812; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LETO TL, 1990, SCIENCE, V248, P737; LEUSEN JHW, 1994, J CLIN INVEST, V93, P2120, DOI 10.1172/JCI117207; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MALY FE, 1994, J BIOL CHEM, V269, P18743; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; Sambrook J., 2002, MOL CLONING LAB MANU; SEGAL AW, 1985, NATURE, V316, P547, DOI 10.1038/316547a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SMITH DB, 1994, CURRENT PROTOCOLS MO; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SUMIMOTO H, 1994, P NATL AC SCI US, V91, P6845; TAMURA M, 1992, J BIOL CHEM, V267, P7629; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557	55	102	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17013	17020		10.1074/jbc.271.29.17013	http://dx.doi.org/10.1074/jbc.271.29.17013			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663333	hybrid			2022-12-27	WOS:A1996UX94300008
J	Nakajima, Y; Yoshida, S; Inoue, Y; Ono, T				Nakajima, Y; Yoshida, S; Inoue, Y; Ono, T			Occupation of the Q(B)-binding pocket by a photosystem II inhibitor triggers dark cleavage of the D1 protein subjected to brief preillumination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC ELECTRON-TRANSPORT; REACTION CENTER POLYPEPTIDES; CHLOROPLAST MEMBRANES; OXYGEN EVOLUTION; INVIVO DEGRADATION; HERBICIDE BINDING; SINGLET OXYGEN; QB SITE; LIGHT; PHOTOINHIBITION	The D1 protein of the photosystem (PS) II reaction center turns over very rapidly in a light-dependent man ner initiated by its selective and specific cleavage. The cleavage of D1 was studied by using a PS II inhibitor, N-octyl-3-nitro-2,4,6-trihydroxybenzamide (PNO8), as a molecular probe. The following results were obtained. (i) D1 was selectively cleaved into 23-kDa N-terminal and 9-kDa C-terminal fragments in complete darkness by PNO8 at a single site in a D-E loop connecting membrane-spanning helices D and E, (ii) The cleavage was markedly enhanced when PS II was illuminated for a brief period before the addition of PNO8 in darkness. (iii) The effect of preillumination was slowly lost during incubation in the dark, with a decay half-time of similar to 1 h at 25 degrees C. (iv) The light intensity of preillumination required for the cleavage was much lower than that required for O-2 evolution. (v) The light-triggered cleavage of D1 was observed in thylakoids, PS II membranes, and PS II core particles, but not in purified PS II reaction centers. More than 60% of D1 was cleaved into the two fragments with no other by-products. (vi) The cleavage reaction revealed a marked pH dependence that was considerably different from that for inhibition of PS II activity. The results are interpreted as indicating that the binding of PNO8 to the Q(B)-binding pocket triggers proteolytic cleavage of D1 that has been previously modified during illumination.	RIKEN, INST PHYS & CHEM RES, SOLAR ENERGY RES GRP, PHOTOSYNTH RES LAB, WAKO, SAITAMA 35101, JAPAN; RIKEN, INST PHYS & CHEM RES, REGULAT PLANT FUNCT LAB, WAKO, SAITAMA 35101, JAPAN	RIKEN; RIKEN			Nakajima, Yoshihiro/M-6935-2018	Nakajima, Yoshihiro/0000-0002-7422-730X				ANANYEV G, 1994, PHOTOSYNTH RES, V41, P327, DOI 10.1007/BF00019410; Andersson B., 1994, P143; ANTONOV VK, 1993, CHEM PROTEOLYSIS, P33; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; CANOVAS PM, 1993, FEBS LETT, V324, P341, DOI 10.1016/0014-5793(93)80147-M; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DELASRIVAS J, 1992, FEBS LETT, V301, P246, DOI 10.1016/0014-5793(92)80250-K; DEPAULA JC, 1985, BIOCHEMISTRY-US, V24, P8114, DOI 10.1021/bi00348a042; ENAMI I, 1989, BIOCHIM BIOPHYS ACTA, V977, P33, DOI 10.1016/S0005-2728(89)80006-4; GIARDI MT, 1988, BIOCHIM BIOPHYS ACTA, V934, P64, DOI 10.1016/0005-2728(88)90120-X; GONG H, 1991, J BIOL CHEM, V266, P21293; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; HONDA I, 1990, AGR BIOL CHEM TOKYO, V54, P1071, DOI 10.1080/00021369.1990.10870085; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P695; ITOH S, 1986, FEBS LETT, V205, P275, DOI 10.1016/0014-5793(86)80912-7; JANSEN MAK, 1990, Z NATURFORSCH C, V45, P408; JANSEN MAK, 1993, J BIOL CHEM, V268, P21246; KIRILOVSKY D, 1994, BIOCHEMISTRY-US, V33, P3087, DOI 10.1021/bi00176a043; KUHN M, 1990, PHOTOSYNTH RES, V23, P291, DOI 10.1007/BF00034859; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTOO AK, 1984, P NATL ACAD SCI-BIOL, V81, P1380, DOI 10.1073/pnas.81.5.1380; MISHRA NP, 1994, BBA-BIOENERGETICS, V1186, P81, DOI 10.1016/0005-2728(94)90138-4; MIYAO M, 1995, BIOCHEMISTRY-US, V34, P10019, DOI 10.1021/bi00031a025; MIYAO M, 1994, BIOCHEMISTRY-US, V33, P9722, DOI 10.1021/bi00198a043; NAKAJIMA Y, 1995, BBA-BIOENERGETICS, V1230, P38, DOI 10.1016/0005-2728(95)00030-M; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; OETTMEIER W, 1992, PHOTOSYSTEMS STRUCTU, P349; OHAD I, 1984, J CELL BIOL, V99, P481, DOI 10.1083/jcb.99.2.481; ONO T, 1989, BIOCHIM BIOPHYS ACTA, V973, P443, DOI 10.1016/S0005-2728(89)80386-X; PAKRASI HB, 1992, PHOTOSYSTEMS STRUCTU, P231; POWLES SB, 1984, ANNU REV PLANT PHYS, V35, P15, DOI 10.1146/annurev.pp.35.060184.000311; PRASIL O, 1992, PHOTOSYSTEMS STRUCTU, P295, DOI DOI 10.1016/B978-0-444-89440-3.50017-5; RINTAMAKI E, 1995, PLANTA, V195, P379, DOI 10.1007/BF00202595; RINTAMAKI E, 1995, PHYSIOL PLANTARUM, V93, P191, DOI 10.1034/j.1399-3054.1995.930127.x; RIVAS JD, 1993, BIOCHEMISTRY-US, V32, P6944, DOI 10.1021/bi00078a019; SALTER AH, 1992, BIOCHEMISTRY-US, V31, P3990, DOI 10.1021/bi00131a014; SHIPTON CA, 1990, Z NATURFORSCH C, V45, P388; TELFER A, 1994, J BIOL CHEM, V269, P13244; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREBST A, 1988, PHOTOSYNTH RES, V18, P163, DOI 10.1007/BF00042983; TREBST A, 1984, Z NATURFORSCH C, V39, P405; TREBST A, 1987, Z NATURFORSCH C, V42, P742; VANWIJK KJ, 1994, J BIOL CHEM, V269, P28382; WEDEL N, 1992, FEBS LETT, V314, P61, DOI 10.1016/0014-5793(92)81462-U; YONEYAMA K, 1990, Z NATURFORSCH C, V45, P317; ZER H, 1994, J BIOL CHEM, V269, P17670; ZER H, 1995, EUR J BIOCHEM, V231, P448, DOI 10.1111/j.1432-1033.1995.tb20718.x	50	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17383	17389		10.1074/jbc.271.29.17383	http://dx.doi.org/10.1074/jbc.271.29.17383			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663245	hybrid			2022-12-27	WOS:A1996UX94300063
J	Pennybacker, M; Liessem, B; Moczall, H; Tifft, CJ; Sandhoff, K; Proia, RL				Pennybacker, M; Liessem, B; Moczall, H; Tifft, CJ; Sandhoff, K; Proia, RL			Identification of domains in human beta-hexosaminidase that determine substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAY-SACHS DISEASE; ACTIVATOR PROTEIN; EXTENSIVE HOMOLOGY; EXPRESSION; DEGRADATION; GENES; GM2	The lysosomal beta-hexosaminidases are dimers composed of alpha and beta subunits, beta-Hexosaminidase A (alpha beta) is a heterodimer, whereas hexosaminidase B (beta beta) and S (alpha alpha) are homodimers, Although containing a high degree of amino acid identity, each subunit expresses a unique active site that can be distinguished by a differential ability to hydrolyze charged substrates. The site on the beta-subunit primarily degrades neutral substrates, whereas the alpha-subunit site is, in addition, active against sulfated substrates. Isozyme specificity is also exhibited with glycolipid substrates, Among human isozymes, only beta-hexosaminidase A together with the G(M2) activator protein can degrade the natural substrate, G(M2) ganglioside, at physiologically significant rates. To identify the domains of the human beta-hexosaminidase subunits that determine substrate specificity, we have generated chimeric subunits containing both alpha- and beta-subunit sequences, The chimeric constructs were expressed in HeLa cells to screen for activity and then selected constructs were produced in the baculovirus expression system to assess their ability to degrade G(M2) ganglioside in the presence of G(M2) activator protein, Generation of activity against the sulfated substrate required the substitution of two noncontinuous alpha-subunit sequences (amino acids 1-191 and 403-529) into analogous positions of the beta-subunit, Chimeric constructs containing only one of these regions linked to the beta-subunit sequence showed either neutral substrate activity only (amino acids 1-191) or lacked enzyme activity entirely (amino acids 403-529), Neither the chimeras nor the wild-type subunits displayed activator-dependent G(M2)-hydrolyzing activity when expressed alone, However, one chimeric subunit containing alpha amino acids 1-191 fused with beta amino acids 225 to 556, when co-expressed with the wild-type alpha-subunit, showed activity comparable with that of recombinant beta-hexosaminidase A formed by the co-expression of the alpha- and beta subunits. This result indicates that the beta-subunit amino acids 225-556 contribute an essential function in the G(M2)-hydrolyzing activity of beta-hexosaminidase A.	NIDDK,SECT BIOCHEM GENET,GENET & BIOCHEM BRANCH,NIH,BETHESDA,MD 20892; UNIV BONN,INST ORGAN CHEM & BIOCHEM,D-53121 BONN,GERMANY	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Bonn			Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270				BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; Boose J A, 1990, Protein Expr Purif, V1, P111, DOI 10.1016/1046-5928(90)90003-H; BROWN CA, 1991, J BIOL CHEM, V266, P15855; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; CONZELMANN E, 1982, EUR J BIOCHEM, V123, P455, DOI 10.1111/j.1432-1033.1982.tb19789.x; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; Gravel R. A., 1995, METABOLIC MOL BASIS, P2839; HASILIK A, 1980, J BIOL CHEM, V255, P4937; KLIMA H, 1993, BIOCHEM J, V292, P571, DOI 10.1042/bj2920571; KORNELUK RG, 1986, J BIOL CHEM, V261, P8407; KYTZIA HJ, 1985, J BIOL CHEM, V260, P7568; LIESSEM B, 1995, J BIOL CHEM, V270, P23693, DOI 10.1074/jbc.270.40.23693; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; PROIA RL, 1988, P NATL ACAD SCI USA, V85, P1883, DOI 10.1073/pnas.85.6.1883; Sambrook J., 2002, MOL CLONING LAB MANU; Sandhoff K, 1989, METABOLIC BASIS INHE, VII, P1807; SONDERFELDFRESKO S, 1988, J BIOL CHEM, V263, P13463; SUZUKI K, 1991, DEV NEUROSCI-BASEL, V13, P288, DOI 10.1159/000112175; YAMANAKA S, 1994, GENOMICS, V21, P588, DOI 10.1006/geno.1994.1318	20	24	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17377	17382		10.1074/jbc.271.29.17377	http://dx.doi.org/10.1074/jbc.271.29.17377			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663217	hybrid			2022-12-27	WOS:A1996UX94300062
J	Raport, CJ; Gosling, J; Schweickart, VL; Gray, PW; Charo, IF				Raport, CJ; Gosling, J; Schweickart, VL; Gray, PW; Charo, IF			Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1 beta, and MIP-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; THROMBIN RECEPTOR; EXPRESSION; CELLS; IDENTIFICATION; SPECIFICITY; CLUSTER; GENE	Chemokines affect leukocyte chemotactic and activation activities through specific G protein-coupled receptors. In an effort to map the closely linked CC chemokine receptor genes, we identified a novel chemokine receptor encoded 18 kilobase pairs downstream of the monocyte chemoattractant protein-1 (MCP-1) receptor (CCR2) gene on human chromosome 3p21. The deduced amino acid sequence of this novel receptor, designated CCR5, is most similar to CCR2B, sharing 71% identical residues. Transfected cells expressing the receptor bind RANTES (regulated on activation normal T cell expressed), MLP-1 beta, and MLP-1 alpha, with high affinity and generate inositol phosphates in response to these chemokines. This same combination of chemokines has recently been shown to potently inhibit human immunodeficiency virus replication in human peripheral blood leukocytes (Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C., and Lusso, P. (1995) Science 270, 1811-1815). CCR5 is expressed in lymphoid organs such as thymus and spleen, as well as in peripheral blood leukocytes, including macrophages and T cells, and is the first example of a human chemokine receptor that signals in response to MIP-1 beta.	ICOS CORP,BOTHELL,WA 98021; GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	Icos Corporation; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco					NHLBI NIH HHS [HL52773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052773] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHUJA SK, 1992, NAT GENET, V2, P31, DOI 10.1038/ng0992-31; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; Boring L, 1996, J BIOL CHEM, V271, P7551, DOI 10.1074/jbc.271.13.7551; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673; COMBADIERE C, 1995, J BIOL CHEM, V270, P30235; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; ERNST CA, 1994, J IMMUNOL, V152, P3541; FRANCI C, 1995, J IMMUNOL, V154, P6511; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GEMMILL RM, 1995, NATURE, V377, P299; GERARD NP, 1993, BIOCHEMISTRY-US, V32, P1243, DOI 10.1021/bi00056a007; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; ISHII K, 1993, J BIOL CHEM, V268, P9780; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; Naylor SL, 1996, CYTOGENET CELL GENET, V72, P90, DOI 10.1159/000134170; NEOTE K, 1993, J BIOL CHEM, V268, P12247; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; RAPORT CJ, 1995, GENE, V163, P295, DOI 10.1016/0378-1119(95)00336-5; Raport CJ, 1996, J LEUKOCYTE BIOL, V59, P18, DOI 10.1002/jlb.59.1.18; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SPORN SA, 1990, J IMMUNOL, V144, P4434; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	39	393	429	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17161	17166		10.1074/jbc.271.29.17161	http://dx.doi.org/10.1074/jbc.271.29.17161			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663314	hybrid			2022-12-27	WOS:A1996UX94300030
J	Si, KS; Das, K; Maitra, U				Si, KS; Das, K; Maitra, U			Characterization of multiple mRNAs that encode mammalian translation initiation factor 5 (eIF-5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; EXPRESSION; COMPLEX; MECHANISM; BINDING; RELEASE; CLONING; GENES; FORM	Eukaryotic translation initiation factor 5 (eIF-5) interacts with the 40 S initiation complex (40S . mRNA . Met-tRNA(f) . eIF-2 . GTP) to promote the hydrolysis of bound GTP with the concomitant joining of the 60 S ribosomal subunit to the 40 S initiation complex to form a functional 80 S initiation complex. In this paper, the multiple mRNAs that encode mammalian eIF-5 have been characterized. In rat tissues, three major eIF-5 mRNAs of 3.5, 2.8, and 2.2 kilobases in length are detected. All major eIF-5 mRNAs are initiated from a single transcription initiation site, contain identical 5'-untranslated and coding regions, but differ from one another only in the length of their 3'-untranslated regions, The different lengths of the 3'-untranslated region of eIF-5 mRNAs are generated by the use of alternative polyadenylation signals. Additionally, we demonstrate tissue-specific variations in eIF-5 mRNA expression as well as preference for polyadenylation sites, These results should lead to increased understanding of the regulation of eIF-5 gene expression.			Si, KS (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV & MOLEC BIOL,JACK & PEARL RESNICK CAMPUS,BRONX,NY 10461, USA.				NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA13330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN ML, 1992, J BIOL CHEM, V267, P23232; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P10524; CHAUDHURI J, 1994, BIOCHEMISTRY-US, V33, P4794, DOI 10.1021/bi00182a007; CHEVESICH J, 1993, J BIOL CHEM, V268, P20659; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DAS K, 1993, P NATL ACAD SCI USA, V90, P3058, DOI 10.1073/pnas.90.7.3058; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GHOSH S, 1989, J BIOL CHEM, V264, P5134; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JARAMILLO M, 1991, J BIOL CHEM, V266, P10446; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LINDER P, 1989, P NATL ACAD SCI USA, V86, P2286, DOI 10.1073/pnas.86.7.2286; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; NIELSEN PJ, 1988, EMBO J, V7, P2097, DOI 10.1002/j.1460-2075.1988.tb03049.x; PETERSON DT, 1979, J BIOL CHEM, V254, P7730; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2132; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2140; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P204, DOI 10.1073/pnas.75.1.204	27	20	21	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16934	16938		10.1074/jbc.271.28.16934	http://dx.doi.org/10.1074/jbc.271.28.16934			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663286	hybrid			2022-12-27	WOS:A1996UX12600077
J	Smith, BL; Krushelnycky, BW; MochlyRosen, D; Berg, P				Smith, BL; Krushelnycky, BW; MochlyRosen, D; Berg, P			The HIV Nef protein associates with protein kinase C theta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN T-CELLS; ANTIBODIES; ANTIGEN; PHOSPHORYLATION; LOCALIZATION; INHIBITION; ACTIVATION; INDUCTION; MEMBER; FAMILY	Expression of the human immunodeficiency virus (HIV) Nef protein has been linked to both decreased cell surface expression of CD4 and an impairment of signal transduction, The recently reported association of Nef with an unidentified serine kinase provides a clue as to how Nef might exert its effects, Considering the key role of protein kinase C (PKC) in T cell activation, we investigated the possibility that Nef interacts with PKC, Our results, using two approaches for detecting interactions between Nef and PKC isozymes in Jurkat cells, show that Nef interacts preferentially with beta PKC. The interaction of Nef and theta PKC is independent of calcium, enhanced by phospholipid activators of PKC and not affected by a PKC pseudosubstrate peptide, Phorbol 12-myristate 13-acetate and phytohemagglutinin stimulation of Jurkat cells expressing Nef fails to produce the usual translocation of theta PKC from the cytosol to the particulate fraction; translocation of beta PKC and epsilon PKC was unaffected, Indeed, there appears to be a net loss of theta PKC in Nef-expressing cells following stimulation, The loss of theta PKC, which may be a result of inhibition of its binding to RACKs due to Nef binding, could contribute to the various impairments of T cell function associated with HIV infection and Nef expression.	BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305; BECKMAN CTR,DEPT MOLEC PHARMACOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,STANFORD,CA 94305	Stanford University				Mochly-Rosen, Daria/0000-0002-6691-8733				AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; ALLAN JS, 1985, SCIENCE, V230, P810, DOI 10.1126/science.2997921; ALLEN BG, 1994, J BIOL CHEM, V269, P29288; AZAD AA, 1994, J GEN VIROL, V75, P651, DOI 10.1099/0022-1317-75-3-651; BAIER G, 1993, J BIOL CHEM, V268, P4997; BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BARJA P, 1994, CELL IMMUNOL, V153, P28, DOI 10.1006/cimm.1994.1003; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; BRODY JM, 1993, EMBO J, V12, P4923; COATES K, 1995, J GEN VIROL, V76, P837, DOI 10.1099/0022-1317-76-4-837; CULLEN BR, 1994, VIROLOGY, V205, P1, DOI 10.1006/viro.1994.1613; DE SK, 1994, J BIOL CHEM, V269, P6656; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; FRANCHINI G, 1986, VIROLOGY, V155, P593, DOI 10.1016/0042-6822(86)90219-9; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; ISAKOV N, 1987, J IMMUNOL, V138, P3100; KISHIMOTO A, 1983, J BIOL CHEM, V258, P11565; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Lang Sabine M., 1994, Journal of Medical Primatology, V23, P233; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; NEL AE, 1987, J IMMUNOL, V139, P2230; NIEDERMAN TMJ, 1992, J VIROL, V66, P6213, DOI 10.1128/JVI.66.10.6213-6219.1992; NIEDERMAN TMJ, 1993, VIROLOGY, V194, P338, DOI 10.1006/viro.1993.1264; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OVOD V, 1992, AIDS, V6, P25, DOI 10.1097/00002030-199201000-00003; RON D, 1994, J BIOL CHEM, V269, P21395; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SMITH BL, 1992, BIOCHEM BIOPH RES CO, V188, P1235, DOI 10.1016/0006-291X(92)91363-U; TSUTSUMI A, 1993, J IMMUNOL, V150, P1746; ZWAIG M, 1990, VIROLOGY, V179, P504	38	88	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16753	16757		10.1074/jbc.271.28.16753	http://dx.doi.org/10.1074/jbc.271.28.16753			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663223	hybrid			2022-12-27	WOS:A1996UX12600053
J	Spencer, JA; Misra, RP				Spencer, JA; Misra, RP			Expression of the serum response factor gene is regulated by serum response factor binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; GROWTH-FACTOR; TRANSCRIPTION FACTOR; FOS PROMOTER; ACTIN GENES; ELEMENT; ACTIVATION; INDUCTION; MUSCLE; STIMULATION	The serum response factor (SRF) is a ubiquitous transcription factor that plays a central role in the transcriptional response of mammalian cells to a variety of extracellular signals. Notably, SRF has been found to be a key regulator of members of a class of cellular response genes termed immediate-early genes (IEGs), many of which are believed to be involved in regulating cell growth and differentiation. The mechanism by which SRF activates transcription of IEGs in response to mitogenic agents has been extensively studied. Significantly less is known about how expression of the SRF gene itself is mediated. We and others have previously shown that the SRF gene is itself transiently induced by a variety of mitogenic agents and belongs to a class of ''delayed'' early response genes. We have cloned the SRF promoter and in the present study have analyzed the upstream regulatory sequences involved in mediating serum responsiveness of the SRF gene. Our analysis indicates that inducible SRF expression requires both SRF binding sites located within the first 63 nucleotides upstream from the start site of transcriptional initiation and an Sp1 site located 83 nucleotides upstream from the start site. Maximal transcriptional activity of the promoter also requires two CCAATT box sites located 90 and 123 nucleotides upstream of the start site.	MED COLL WISCONSIN, DEPT BIOCHEM, MILWAUKEE, WI 53226 USA	Medical College of Wisconsin					NIGMS NIH HHS [R55 GM/OD51856] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM051856] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDROPOULOS K, 1992, NUCLEIC ACIDS RES, V20, P2355, DOI 10.1093/nar/20.9.2355; AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; ARGENTIN S, 1994, MOL CELL BIOL, V14, P777, DOI 10.1128/MCB.14.1.777; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BOULDEN AM, 1992, MOL CELL BIOL, V12, P4769, DOI 10.1128/MCB.12.10.4769; BUSCHER M, 1988, ONCOGENE, V3, P301; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEGROOT RP, 1990, J CELL SCI, V97, P33; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELBLE R, 1992, MOL BIOL CELL, V3, P971, DOI 10.1091/mbc.3.9.971; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; FUJII M, 1994, J VIROL, V68, P7275, DOI 10.1128/JVI.68.11.7275-7283.1994; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GAUTHIERROUVIERE C, 1991, CELL REGUL, V2, P575, DOI 10.1091/mbc.2.7.575; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Groisman R, 1996, J BIOL CHEM, V271, P5258; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KLAMUT HJ, 1990, MOL CELL BIOL, V10, P193, DOI 10.1128/MCB.10.1.193; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; KUO MH, 1994, MOL CELL BIOL, V14, P348, DOI 10.1128/MCB.14.1.348; LATINKIC BV, 1991, NUCLEIC ACIDS RES, V19, P3261, DOI 10.1093/nar/19.12.3261; LATINKIC BV, 1994, J BIOL CHEM, V269, P23163; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MISRA RP, 1994, J BIOL CHEM, V269, P25483; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MUSCAT GE, 1988, MOL CELL BIOL, V8, P4120, DOI 10.1128/MCB.8.10.4120; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PHANDINHTUY F, 1988, EUR J BIOCHEM, V173, P507, DOI 10.1111/j.1432-1033.1988.tb14027.x; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Treisman R, 1992, CURR OPIN GENET DEV, V2, P221, DOI 10.1016/S0959-437X(05)80277-1; UETSUKI T, 1990, MOL CELL BIOL, V10, P2562, DOI 10.1128/MCB.10.6.2562; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	60	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16535	16543		10.1074/jbc.271.28.16535	http://dx.doi.org/10.1074/jbc.271.28.16535			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663310	hybrid			2022-12-27	WOS:A1996UX12600020
J	JabrilCuenod, B; Zhang, C; Scharenberg, AM; Paolini, R; Numerof, R; Beaven, MA; Kinet, JP				JabrilCuenod, B; Zhang, C; Scharenberg, AM; Paolini, R; Numerof, R; Beaven, MA; Kinet, JP			Syk-dependent phosphorylation of Shc - A potential link between Fc epsilon RI and the Ras/mitogen-activated protein kinase signaling pathway through Sos and Grb2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; T-CELL ACTIVATION; TYROSINE PHOSPHORYLATION; RBL-2H3 CELLS; RECEPTOR; RAS; TRANSDUCTION; DOMAIN; ASSOCIATION; ENGAGEMENT	Antigen receptors on T- and B-cells activate has through a signaling pathway that results in the tyrosine phosphorylation of She and the formation of a complex of Shc with the Grb2 adaptor protein. The high affinity receptor for immunoglobulin E (Fc epsilon RI) in cultured mast (RBL-2H3) cells has been reported to function differently. Here we show to the contrary that engagement of Fc epsilon RI with antigen leads to increased tyrosine phosphorylation of Shc and the association of Shc with Grb2 and other proteins (p120 and p140). Like the Fc epsilon RI-mediated activation of the mitogen-activated protein kinase cascade, these responses are dependent on the tyrosine kinase Syk; they are enhanced by overexpression of Syk and are blocked by expression of dominant-negative Syk. Sos is constitutively associated with Grb2 in these cells but dissociates from Shc on stimulation with antigen. These reactions are rapid, reversible, and associated with the activation of Ras. Therefore, the Syk-dependent tyrosine phosphorylation of Shc and its association with Grb2 may provide a pathway through Sos for activation of Ras by Fc epsilon RI.	NHLBI,LAB MOL IMMUNOL,NIH,BETHESDA,MD 20892; NIAID,MOLEC ALLERGY & IMMUNOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				PAOLINI, Rossella/0000-0001-7605-1531				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, ONCOGENE, V11, P1327; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; CROWE AJ, 1994, ONCOGENE, V9, P537; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EISEMAN E, 1992, NATURE, V355, P78; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GRAVES JD, 1992, J IMMUNOL, V148, P2417; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, J IMMUNOL, V152, P2123; HABIB T, 1994, J BIOL CHEM, V269, P25243; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HU ZQ, 1994, IMMUNOLOGY, V82, P482; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; OFFERMANNS S, 1994, J IMMUNOL, V152, P250; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SANTINI F, 1993, J BIOL CHEM, V268, P22716; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMIT L, 1994, J BIOL CHEM, V269, P20209; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251	49	104	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16268	16272		10.1074/jbc.271.27.16268	http://dx.doi.org/10.1074/jbc.271.27.16268			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663278	hybrid			2022-12-27	WOS:A1996UW35200061
J	Bai, YL; Zhang, SY; Kim, KS; Lee, JK; Kim, KH				Bai, YL; Zhang, SY; Kim, KS; Lee, JK; Kim, KH			Obese gene expression alters the ability of 30A5 preadipocytes to respond to lipogenic hormones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR	Leptin, the product of the oh gene, controls food-intake and weight loss in the ob mouse. Although the target(s) of the circulating leptin is presumed to be the brain which then orchestrates food-intake and weight loss, how leptin functions in the process of weight loss is unknown. In this report, we present evidence that ob gene expression in cultured cells suppresses acetyl-CoA carboxylase gene expression and lipid synthesis which are induced by hormone treatment. This is the first example in which leptin has been found to suppress defined biochemical reactions that contribute to Lipid accumulation without the participation of the brain.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL CANCER INSTITUTE [R01CA046882] Funding Source: NIH RePORTER; NCI NIH HHS [CA 46882] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AW, 1974, J BIOL CHEM, V249, P5241; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; HA JH, 1994, P NATL ACAD SCI USA, V91, P9951, DOI 10.1073/pnas.91.21.9951; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; PAPE ME, 1988, MOL ENDOCRINOL, V2, P395, DOI 10.1210/mend-2-5-395; PAPE ME, 1989, MOL CELL BIOL, V9, P974, DOI 10.1128/MCB.9.3.974; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAE HJ, 1995, J BIOL CHEM, V270, P21487, DOI 10.1074/jbc.270.37.21487; WILSON JE, 1982, ARCH BIOCHEM BIOPHYS, V215, P610, DOI 10.1016/0003-9861(82)90122-9; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	15	200	212	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13939	13942		10.1074/jbc.271.24.13939	http://dx.doi.org/10.1074/jbc.271.24.13939			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663251	hybrid			2022-12-27	WOS:A1996UQ66000004
J	FerrerMontiel, AV; Canaves, JM; DasGupta, BR; Wilson, MC; Montal, M				FerrerMontiel, AV; Canaves, JM; DasGupta, BR; Wilson, MC; Montal, M			Tyrosine phosphorylation modulates the activity of clostridial neurotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; BOTULINUM NEUROTOXINS; SIGNAL-TRANSDUCTION; SEROTYPE-A; PC12 CELLS; PROTEIN; SNAP-25; RELEASE; IDENTIFICATION; INHIBITION	Clostridial neurotoxins' metalloprotease domain selectively cleaves proteins implicated in the process of synaptic vesicle fusion with the plasma membrane and, accordingly, blocks neurotransmitter release into the synaptic cleft, Here we investigate the potential modulation of these neurotoxins by intracellular cascades triggered by environmental signals, which in turn may alter its activity on target substrates. We report that the nonreceptor tyrosine kinase Src phosphorylates botulinum neurotoxins A, B, and E and tetanus neurotoxin. Protein tyrosine phosphorylation of serotypes A and E dramatically increases both their catalytic activity and thermal stability, while dephosphorylation reverses the effect. This suggests that the biologically significant form of the neurotoxins inside neurons is phosphorylated. Indeed, in PC12 cells in which tyrosine kinases such as Src and PYK2 are highly abundant, stimulation by membrane depolarization in presence of extracellular calcium induces rapid and selective tyrosine phosphorylation of internalized light chain, the metalloprotease domain, of botulinum toxin A. These findings provide a conceptual framework to connect intracellular signaling pathways involving tyrosine kinases, G-proteins, phosphoinositides, and calcium with the action of botulinum neurotoxins in abrogating vesicle fusion and neurosecretion.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV WISCONSIN,MADISON,WI 53706; SCRIPPS CLIN & RES FDN,DEPT NEUROPHARMACOL,LA JOLLA,CA 92037	University of California System; University of California San Diego; University of Wisconsin System; University of Wisconsin Madison; Scripps Research Institute			Ferrer-Montiel, Antonio/C-3072-2015	Ferrer-Montiel, Antonio/0000-0002-2973-6607	NIMH NIH HHS [MH48989] Funding Source: Medline; NINDS NIH HHS [NS17742] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017742] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANERJEE A, 1993, NEUROSCI LETT, V164, P93, DOI 10.1016/0304-3940(93)90865-I; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BOROFF DA, 1971, MICROBIAL TOXINS   A, V2, P1; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; EVELETH DD, 1989, J NEUROSCI RES, V24, P67, DOI 10.1002/jnr.490240110; FERRERMONTIEL AV, 1995, P NATL ACAD SCI USA, V92, P8021, DOI 10.1073/pnas.92.17.8021; FERRERMONTIEL AV, 1991, P NATL ACAD SCI USA, V88, P6418; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; JANKOVIC J, 1994, CURR OPIN NEUROL, V7, P358, DOI 10.1097/00019052-199408000-00014; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SATHYAMOORTHY V, 1985, J BIOL CHEM, V260, P461; SCHELLER RH, 1995, NEURON, V14, P893; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, J BIOL CHEM, V267, P23479; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SELLIN LC, 1983, ACTA PHYSIOL SCAND, V119, P127, DOI 10.1111/j.1748-1716.1983.tb07317.x; SHONE CC, 1992, EUR J BIOCHEM, V207, P1009, DOI 10.1111/j.1432-1033.1992.tb17137.x; SIMPSON LL, 1981, PHARMACOL REV, V33, P155; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0	31	46	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18322	18325		10.1074/jbc.271.31.18322	http://dx.doi.org/10.1074/jbc.271.31.18322			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702470	hybrid			2022-12-27	WOS:A1996VB68300008
J	Kai, M; Wada, I; Imai, S; Sakane, F; Kanoh, H				Kai, M; Wada, I; Imai, S; Sakane, F; Kanoh, H			Identification and cDNA cloning of 35-kDa phosphatidic acid phosphatase (Type 2) bound to plasma membranes - Polymerase chain reaction amplification of mouse H2O2-inducible hic53 clone yielded the cDNA encoding phosphatidic acid phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; SIGNAL-TRANSDUCTION; PHOSPHOHYDROLASE; PROTEIN; KINASE; PURIFICATION; LIPIDS; CELLS	We previously described the purification of an 83-kDa phosphatidic acid phosphatase (PAP) from the porcine thymus membranes (Kanoh, H., Imai, S.-i., Yamada, K. and Sakane, F. (1992) J. Biol. Chem. 267, 25309-25314). However, we found that a minor 35-kDa protein could account for the PAP activity when the purified enzyme preparation was further analyzed. We thus determined the N-terminal sequence of the 35-kDa candidate protein and prepared antipeptide antibody against the determined sequence, MFDKTRLPYVALDVL. The antibody almost completely precipitated the purified enzyme activity. Furthermore, the antibody precipitated from the radioiodinated enzyme preparation a single 35-kDa protein, which was converted to a 29-kDa form when treated with N-glycanase. We also found that the immunoprecipitable PAP activity was exclusively associated with the plasma membranes of porcine thymocytes. These results indicated that the 35-kDa glycosylated protein represents the plasma membrane-bound (type 2) PAP. We surprisingly noted that the N-terminal sequence of the porcine PAP was almost completely conserved in the internal sequence encoded by a mouse partial cDNA clone, hic53, reported as a H2O2-inducible gene (Egawa, K., Yoshiwara, M., Shibanuma, M., and Nose, K. (1995) FEES Lett. 372, 74-77). We thus amplified from the mouse kidney RNA the hic53 clone by polymerase chain reaction, and obtained a cDNA encoding a novel protein of 283 amino acid residues with a calculated M(r) of 31,894. Methionine reported as an internal residue was found to serve as an initiator, and the C-terminal 64 residues were lacking in hic53. The protein contains several putative membrane-spanning domains and two N-glycosylation sites. When transfected into 293 cells, the cDNA gave more than 10-fold increase of the membrane-bound PAP activity, which could be precipitated by the antipeptide antibody. In [S-35]methionine-labeled cells, the translational product was confirmed to be a 35-kDa protein, which became 30 kDa in cells treated with tunicamycin, an inhibitor of N-glycosylation. We thus succeeded first in identifying the porcine type 2 PAP and subsequently in determining the primary structure of a mouse homolog of the PAP.	SAPPORO MED UNIV,SCH MED,DEPT BIOCHEM,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN	Sapporo Medical University			Sakane, Fumio/H-2693-2017	Sakane, Fumio/0000-0003-0857-0377; Wada, Ikuo/0000-0001-5668-6994				ARIDORPITERMAN O, 1992, EUR J BIOCHEM, V204, P561, DOI 10.1111/j.1432-1033.1992.tb16668.x; BARRNETT RJ, 1983, METHOD ENZYMOL, V96, P627; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DAY CP, 1993, CLIN SCI, V85, P281, DOI 10.1042/cs0850281; EGAWA K, 1995, FEBS LETT, V372, P74, DOI 10.1016/0014-5793(95)00957-B; EXTON JH, 1990, J BIOL CHEM, V265, P1; Fleischer S, 1974, Methods Enzymol, V31, P6; FLEMING IN, 1995, BIOCHEM J, V308, P983, DOI 10.1042/bj3080983; GOMEZMUNOZ A, 1992, FEBS LETT, V301, P103, DOI 10.1016/0014-5793(92)80219-7; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1992, J BIOL CHEM, V267, P25309; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN A, 1987, BIOCHEM J, V245, P347, DOI 10.1042/bj2450347; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MOOLENAAR WH, 1992, REV PHYSIOL BIOCH P, V119, P47; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OWENS RJ, 1984, EMBO J, V3, P945, DOI 10.1002/j.1460-2075.1984.tb01912.x; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIESS EA, 1996, FEBS LETT, V381, P1699; WAGGONER DW, 1995, J BIOL CHEM, V270, P19422, DOI 10.1074/jbc.270.33.19422; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	29	96	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18931	18938		10.1074/jbc.271.31.18931	http://dx.doi.org/10.1074/jbc.271.31.18931			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702556	hybrid			2022-12-27	WOS:A1996VB68300094
J	Lee, JS; Zhang, XL; Shi, Y				Lee, JS; Zhang, XL; Shi, Y			Differential interactions of the CREB/ATF family of transcription factors with p300 and adenovirus E1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROPERTIES; REGION 1A PROTEINS; MESSENGER-RNAS; ACTIVATES TRANSCRIPTION; TRANSFORMING GENES; FUNCTIONAL DOMAINS; CELLULAR PROTEINS; PRODUCTS; REPRESSION; PROMOTER	The adenovirus E1A-associated protein p300 is a transcriptional cofactor that interacts with YY1 and mediates the relief of YY1 transcriptional repression by E1A. These observations raise the possibility that p300 may function as a bridging factor between E1A and cellular transcription factors. Here we show that p300, but not a mutant defective for binding to E1A, activated cAMP-responsive element-binding protein/activating transcription factor (CREB/ATF) binding site-mediated transcription in the presence of E1A. Among proteins that can recognize the CREB/ATF site, CREB appeared to be modulated by E1A in a p300 binding-dependent manner. This effect of E1A was cor related with a specific physical interaction between CREB and p300. These results suggest that p300 plays a crucial role in mediating the functional interplay between E1A and certain members of the CREB/ATF family. Two separate domains within p300 were identified that are capable of activating transcription. One of the domains interacted with the basal factor TFIIB, suggesting that p300 may function as a coactivator by making contacts with both sequence-specific transcription factors and the basal transcriptional machinery. This pivotal role of p300 may make it a prime target for viral proteins such as E1A in programming the cellular transcription machinery.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,COMM VIROL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053874] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53874, GM 18221] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHOW LT, 1979, J MOL BIOL, V134, P265, DOI 10.1016/0022-2836(79)90036-6; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DEAN DC, 1987, P NATL ACAD SCI USA, V84, P1876, DOI 10.1073/pnas.84.7.1876; DEAN DC, 1989, MOL CELL BIOL, V9, P1498, DOI 10.1128/MCB.9.4.1498; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE JS, 1996, IN PRESS MOL CELL BI; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LEWIS JB, 1980, CELL, V21, P303, DOI 10.1016/0092-8674(80)90138-5; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1993, J BIOL CHEM, V268, P6714; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MARUYAMA K, 1987, ONCOGENE, V1, P361; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; NEVINS JR, 1992, SCIENCE, V258, P424; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; TAYLOR DA, 1993, MOL CELL BIOL, V13, P4714, DOI 10.1128/MCB.13.8.4714; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; VANDENELSEN P, 1982, GENE, V18, P175, DOI 10.1016/0378-1119(82)90115-9; VANDEREB AJ, 1979, COLD SPRING HARB SYM, V44, P383, DOI 10.1101/SQB.1980.044.01.043; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEBSTER KA, 1988, NATURE, V344, P260; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WINBERG G, 1984, EMBO J, V3, P1907, DOI 10.1002/j.1460-2075.1984.tb02066.x; YEE SP, 1983, J VIROL, V46, P1003, DOI 10.1128/JVI.46.3.1003-1013.1983; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	75	41	42	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17666	17674		10.1074/jbc.271.30.17666	http://dx.doi.org/10.1074/jbc.271.30.17666			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663457	hybrid			2022-12-27	WOS:A1996UY93500015
J	Gaczynska, M; Goldberg, AL; Tanaka, K; Hendil, KB; Rock, KL				Gaczynska, M; Goldberg, AL; Tanaka, K; Hendil, KB; Rock, KL			Proteasome subunits X and Y alter peptidase activities in opposite ways to the interferon-gamma-induced subunits LMP2 and LMP7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; MULTICATALYTIC PROTEINASE COMPLEX; CLASS-I MOLECULES; MHC; EXPRESSION; GENE; YEAST; MICE	Most antigenic peptides presented on major histocompatibility complex class I molecules are generated by proteasomes, Interferon-gamma, which stimulates antigen presentation, induces new proteasome beta-subunits LMP2 and LMP7, which replace the homologous beta-subunits Y (delta) and X (epsilon). As a result, the capacity of the proteasome to cleave model peptides increases after hydrophobic and basic residues and falls after acidic residues, To clarify the function of these subunits, are examined the effects of overexpressing subunits X (delta) and Y (epsilon). Transfection of the Y gene into HeLa cells stimulated the proteasomal cleavage after acidic residues without altering other peptidase activities. This effect was propertional to the amount of the Y subunits and opposite to the effect of its homolog, LMP2. Y appears to promote cleavages after acidic residues, Furthermore, in mutants lacking the LMP genes (in contrast to wild-type cells), interferon-gamma treatment increased the proteasome content of Y subunits and enhanced postacidic cleavages. Transfection with cDNA for the X subunit reduced hydrolysis after hydrophobic and basic residues, an effect opposite to transfection of LMP2 and LMP7, Surprisingly, transfection of X increased the amounts not only of X, but also of Y, while decreasing LMPB content. Thus, the loss of the Y subunit upon interferon-gamma treatment or LMPB transfection accounts for the suppression of postacidic cleavages, and the loss of X contributes to the increased hydrolysis after hydrophobic and basic residues. These adaptations should favor the production of the kinds of peptides that are presented on major histocompatibility complex class I molecules.	DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; UNIV COPENHAGEN,AUGUST KROGH INST,DK-2100 COPENHAGEN 0,DENMARK	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Tokushima University; University of Copenhagen								AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BELICH MP, 1994, CURR BIOL, V4, P769, DOI 10.1016/S0960-9822(00)00174-3; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; COUX O, 1995, IN PRESS ANN REV BIO; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; ENENKEL C, 1994, FEBS LETT, V341, P193, DOI 10.1016/0014-5793(94)80455-9; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRUH K, 1994, EMBO J, V13, P3236, DOI 10.1002/j.1460-2075.1994.tb06625.x; FRUH K, 1992, J BIOL CHEM, V267, P22131; GACZYNSKA M, 1993, ENZYME PROTEIN, V47, P354, DOI 10.1159/000468693; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; GACZYNSKA M, 1995, NATURE, V374, P290, DOI 10.1038/374290b0; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; GOLDBERG AL, 1996, PROTEIN KINESIS DYNA; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; KUCKELKORN U, 1995, EUR J IMMUNOL, V25, P2605, DOI 10.1002/eji.1830250930; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P2130; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SIBILLE C, 1995, CURR BIOL, V5, P923, DOI 10.1016/S0960-9822(95)00182-5; USTRELL V, 1995, P NATL ACAD SCI USA, V92, P584, DOI 10.1073/pnas.92.2.584; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; YEWDELL J, 1994, J IMMUNOL, V162, P11630; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	42	128	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17275	17280		10.1074/jbc.271.29.17275	http://dx.doi.org/10.1074/jbc.271.29.17275			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663318	hybrid			2022-12-27	WOS:A1996UX94300047
J	Iwasaki, S; Hattori, A; Sato, M; Tsujimoto, M; Kohno, M				Iwasaki, S; Hattori, A; Sato, M; Tsujimoto, M; Kohno, M			Characterization of the bone morphogenetic protein-2 as a neurotrophic factor - Induction of neuronal differentiation of PC12 cells in the absence of mitogen-activated protein kinase activation.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NIH 3T3 CELLS; MAP KINASE; FACTOR-BETA; SIGNAL-TRANSDUCTION; EMBRYONIC-DEVELOPMENT; OSTEOGENIC PROTEIN; FAMILY MEMBERS; RNA; IDENTIFICATION	Rat pheochromocytoma PC12 cells are shown to express a single class of high affinity binding sites for bone morphogenetic protein (BMP)-2 (1,300 receptors/cell, K-d = 31.3 pM). Affinity cross-linking using radiolabeled BMP-2 demonstrated the presence of six components with apparent molecular masses of 170, 155, 105, 90, 80, and 70 kDa. BMP-2 induced morphological changes in PC12 cells with the concomitant expression of three neurofilament proteins. Thus, BMP-2 would appear to be another neurotrophic factor that, like nerve growth factor or basic fibroblast growth factor, stimulates the neuronal differentiation of PC12 cells. Unlike nerve growth factor and basic fibroblast growth factor, how ever, BMP-2 failed to induce the activation of either 41- and 43-kDa mitogen-activated protein (MAP) kinases or the MAP kinase/extracellular signal-regulated kinase kinase (MEK). Also, BMP-2 did not induce the expression of the c-fos gene in PC12 cells. Activin A was also capable of inducing the neuronal differentiation of PC12 cells without activating MAP kinases and MEK. These findings show a clear dissociation between the requirement for the activation of the MAP kinase cascade and the ability of BMP-2 and activin A to induce PC12 cell neuronal differentiation. In addition, these results suggest that the activation of MAP kinases and MEK is not an absolute requirement for PC12 cell differentiation.	GIFU PHARMACEUT UNIV,CELL BIOL LAB,GIFU 502,JAPAN; SUNTORY INST BIOMED RES,MISHIMA,OSAKA 618,JAPAN	Gifu Pharmaceutical University; Suntory Holdings Ltd								AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDESON NG, 1990, NATURE, V843, P651; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CHALAZONITIS A, 1992, DEV BIOL, V152, P121, DOI 10.1016/0012-1606(92)90162-A; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; Chatani Y, 1995, J BIOL CHEM, V270, P30686, DOI 10.1074/jbc.270.51.30686; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DALE L, 1992, DEVELOPMENT, V115, P573; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; FUKUDA M, 1995, ONCOGENE, V11, P239; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; ISHIDA N, 1994, J BIOCHEM-TOKYO, V115, P279, DOI 10.1093/oxfordjournals.jbchem.a124329; IWASAKI S, 1995, J BIOL CHEM, V270, P5476, DOI 10.1074/jbc.270.10.5476; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LINBENBAUM MH, 1987, J BIOL CHEM, V262, P605; LINBENBAUM MH, 1988, J BIOL CHEM, V263, P5662; LIU F, 1995, MOL CELL BIOL, V15, P3479; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OZKAYNAK E, 1991, BIOCHEM BIOPH RES CO, V179, P116, DOI 10.1016/0006-291X(91)91342-A; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; PARALKAR VM, 1992, J CELL BIOL, V119, P1721, DOI 10.1083/jcb.119.6.1721; PERIDES G, 1993, J BIOL CHEM, V268, P25197; Reddi A. Hari, 1992, Current Opinion in Cell Biology, V4, P850; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; SAMMUELS ML, 1993, MOL CELL BIOL, V13, P6241; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SMITH DB, 1990, CURRENT PROTOCOLS MO, V2; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; WALL NA, 1993, J CELL BIOL, V120, P493, DOI 10.1083/jcb.120.2.493; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	54	75	85	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17360	17365		10.1074/jbc.271.29.17360	http://dx.doi.org/10.1074/jbc.271.29.17360			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663261	hybrid			2022-12-27	WOS:A1996UX94300059
J	Parekh, R; Bag, J				Parekh, R; Bag, J			Inhibition of myogenesis in mouse C2 cells by double-stranded phosphorothioate oligodeoxynucleotides containing mef-1 sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; BINDING; MYOD; ENHANCER; OLIGONUCLEOTIDES; FIBROBLASTS; ACTIVATION; INVITRO; VIVO	Phosphorothioate oligonucleotides containing the muscle creatinine kinase enhancer sequence (mef-1) and a mutant of the enhancer sequence (mmef-1) were tested for their ability to block muscle differentiation in mouse C2 cells in culture, Maximum inhibition of fusion of myoblasts was observed at 10 mu M concentration of mef-1 oligomer. No appreciable inhibition of fusion with the mmef-1 oligomer at the same concentration was observed. Synthesis of myogenin, muscle creatinine kinase, and myosin heavy chain polypeptides were reduced in mef-1 oligomer-treated cells. In contrast, no significant reduction in the synthesis of these polypeptides in mmef-1-treated cells was detected, The overall protein synthesis was not affected. These results suggest that muscle differentiation may be disrupted by competition of the oligomer with the endogenous promoter for specific transcription factor(s).	UNIV GUELPH, DEPT MOLEC BIOL & GENET, GUELPH, ON N1G 2W1, CANADA	University of Guelph								BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BROWN DA, 1994, J BIOL CHEM, V269, P26801; BUCKINGHAM M, 1994, CELL, V78, P15, DOI 10.1016/0092-8674(94)90568-1; CLUSEL C, 1993, NUCLEIC ACIDS RES, V21, P3405, DOI 10.1093/nar/21.15.3405; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ECK SL, 1993, MOL CELL BIOL, V13, P6530, DOI 10.1128/MCB.13.10.6530; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MARCUSSEKURA CJ, 1988, ANAL BIOCHEM, V172, P289, DOI 10.1016/0003-2697(88)90447-2; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; THINAKARAN G, 1991, EXP CELL RES, V192, P227, DOI 10.1016/0014-4827(91)90180-3; WANG XF, 1986, CELL, V47, P241, DOI 10.1016/0092-8674(86)90446-0; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WU H, 1990, GENE, V89, P203, DOI 10.1016/0378-1119(90)90007-E	21	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17372	17376		10.1074/jbc.271.29.17372	http://dx.doi.org/10.1074/jbc.271.29.17372			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663396	hybrid			2022-12-27	WOS:A1996UX94300061
J	Wu, RY; Durick, K; Zhou, SY; Cantley, LC; Taylor, SS; Gill, GN				Wu, RY; Durick, K; Zhou, SY; Cantley, LC; Taylor, SS; Gill, GN			Specificity of LIM domain interactions with receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; INSULIN-RECEPTOR; PROTEIN; GENE; MOTIF; INTERNALIZATION; BINDING; ENDOCYTOSIS; ELEGANS; SIGNALS	LIM domains, Cys-rich motifs containing approximately 50 amino acids found in a variety of proteins, are proposed to direct protein protein interactions, To identify structural targets recognized by LIM domains, we have utilized random peptide library selection, the yeast two-hybrid system, and glutathione S-transferase fusions, Enigma contains three LIM domains within its carboxyl terminus and LIM3 of Enigma specifically recognizes active but not mutant endocytic codes of the insulin receptor (InsR) (Wu, R Y,, and Gill, Gr, N, (1994) J. Biol, Chem. 269, 2508-25090). Interaction of two random peptide libraries nifh glutathione S-transferase-LIM3 of Enigma indicated specific binding to Gly-Pro-Hyd-Gly-Pro-Hyd-Tyr-Ala corresponding to the major endocytic code of InsR Peptide competition demonstrated that both Pro and Tyr residues were required for specific interaction of InsR with Enigma, In contrast to LIM3 of Enigma binding to InsR, LIM2 of Enigma associated specifically with the receptor tyrosine kinase, Ret. Ret was specific for LIM2 of Enigma and did not bind other LIM domains tested, Mutational analysis indicated that the residues responsible for binding to Enigma were localized to the carboxyl-terminal 61 amino acids of Ret, A peptide corresponding to the carboxyl-terminal 20 amino acids of Ret dissociated Enigma and Ret complexes, while a mutant that changed Asn-Lys-Leu-Tyr in the peptide to Ala-Lys-Leu-Ala or a peptide corresponding to exon16 of InsR failed to disrupt the complexes, indicating the Asn-Lys-Leu-Tyr sequence of Ret is essential to the recognition moth for LIM2 of Enigma, We conclude that LIM domains of Enigma recognize tyrosine-containing motifs with specificity residing in both the LIM domains and in the target structures.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA; HARVARD UNIV, SCH MED, CAMBRIDGE, MA 02115 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Harvard University			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NCI NIH HHS [T32CA 02523] Funding Source: Medline; NIDDK NIH HHS [DK 13149] Funding Source: Medline; NIGMS NIH HHS [R01 GM056203] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013149, R01DK013149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MIZUNO K, 1994, ONCOGENE, V9, P1605; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SOOS MA, 1992, J BIOL CHEM, V267, P12955; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WU RY, 1994, J BIOL CHEM, V269, P25085; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	46	80	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15934	15941		10.1074/jbc.271.27.15934	http://dx.doi.org/10.1074/jbc.271.27.15934			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663233	hybrid			2022-12-27	WOS:A1996UW35200018
J	Baillet, B; Kohorn, BD				Baillet, B; Kohorn, BD			Hydrophobic core but not amino-terminal charged residues are required for translocation of an integral thylakoid membrane protein in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CHLOROPLAST TRANSFORMATION; SECY HOMOLOG; TRANSPORT; CHLAMYDOMONAS; GENES; PATHWAYS; SEQUENCE; RNA	The integral membrane protein cytochrome f contains an amino-terminal signal sequence that is required for translocation into the thylakoid membrane, The signal sequence contains a hydrophobic core neighbored by an amino-terminal charged residue. Mutations that introduce charged amino acids into the hydrophobic core are inhibitory to cytochrome f translocation, and thus render cells non-photosynthetic. We have isolated both nuclear and chloroplast suppressors of these mutations by selecting for restoration of photosynthetic growth of Chlamydomonas. Here we describe the characterization of two chloroplast, second site suppressor mutations, Both suppressors remove the positively charged amino acid that borders the amino terminus of the hydrophobic core, and replace this arginine with either a cysteine or a leucine, The existence of these suppressors suggests that the hydrophobic core can be shifted in position within the signal sequence, and analysis of triple mutants in the signal confirms this hypothesis, Thus this signal that mediates translocation into the thylakoid membrane is characterized by a hydrophobic region whose exact amino acid content is not critical, and that need not be flanked on its amino terminus by a charged residue.	DUKE UNIV,LEVINE SCI RES CTR,DURHAM,NC 27708	Duke University								AUCHINCLOSS AH, 1992, J BIOL CHEM, V267, P10439; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BOYNTON JE, 1993, METHOD ENZYMOL, V217, P510; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; BUSCHLEN S, 1991, FEBS LETT, V284, P257, DOI 10.1016/0014-5793(91)80698-3; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; DOUGLAS SE, 1992, FEBS LETT, V298, P93, DOI 10.1016/0014-5793(92)80029-G; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; HENRY R, 1994, J BIOL CHEM, V269, P10189; HOWE G, 1993, P NATL ACAD SCI USA, V90, P1862, DOI 10.1073/pnas.90.5.1862; LAIDLER V, 1995, J BIOL CHEM, V270, P17664, DOI 10.1074/jbc.270.30.17664; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; NEWMAN SM, 1990, GENETICS, V126, P875; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; Sambrook J., 2002, MOL CLONING LAB MANU; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMITH TA, 1994, J CELL BIOL, V126, P365, DOI 10.1083/jcb.126.2.365; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WILLEY DL, 1984, CELL, V36, P555, DOI 10.1016/0092-8674(84)90248-4; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633; ZARLENGA DS, 1987, ANAL BIOCHEM, V162, P569, DOI 10.1016/0003-2697(87)90435-0	25	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18375	18378		10.1074/jbc.271.31.18375	http://dx.doi.org/10.1074/jbc.271.31.18375			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702480	hybrid			2022-12-27	WOS:A1996VB68300018
J	Ferraris, JD; Williams, CK; Jung, KY; Bedford, JJ; Burg, MB; GarciaPerez, A				Ferraris, JD; Williams, CK; Jung, KY; Bedford, JJ; Burg, MB; GarciaPerez, A			ORE, a eukaryotic minimal essential osmotic response element - The aldose reductase gene in hyperosmotic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL MEDULLARY CELLS; EXTRACELLULAR NACL; TRANSPORTER GENE; TRANSCRIPTION; INDUCTION; CLONING; RNA; PROMOTER	Organisms, almost universally, adapt to hyperosmotic stress through increased accumulation of organic osmolytes but the molecular mechanisms have only begun to be addressed, Among mammalian tissues, renal medullary cells are uniquely exposed to extreme hyperosmotic stress. Sorbitol, synthesized through aldose reductase, is a predominant osmolyte induced under hyperosmotic conditions in renal cells, Using a rabbit renal cell line, we originally demonstrated that hyperosmotic stress induces transcription of the aldose reductase gene, Recently, we cloned the rabbit aldose reductase gene, characterized its structure, and found the first evidence of an osmotic response region in a eukaryotic gene, Now, we have progressively subdivided this 3221-base pair (bp) region into discrete fragments in reporter gene constructs. Thereby, we have functionally defined the smallest sequence able to confer hyperosmotic response on a downstream gene independent of other putative cis-elements, that is, a minimal essential osmotic response element (ORE). The sequence of the ORE is CGGAAAATCAC(C) (bp -1105/-1094). A 17-bp fragment (-1108/-1092) containing the ORE used as a probe in electrophoretic mobility shift assays suggests hyperosmotic induction of a slowly migrating band. Isolation of trans-acting factor(s) and characterization of their interaction with the ORE should elucidate the basic mechanisms for regulation of gene expression by hyperosmotic stress.			Ferraris, JD (corresponding author), NHLBI,KIDNEY & ELECTROLYTE METAB LAB,NIH,BLDG 10,RM 6N307,10 CTR DR MSC 1598,BETHESDA,MD 20892, USA.							ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAGNASCO SM, 1987, P NATL ACAD SCI USA, V84, P1718, DOI 10.1073/pnas.84.6.1718; CHAUHAN SS, 1992, GENE, V120, P281, DOI 10.1016/0378-1119(92)90106-Y; COWLEY BD, 1990, AM J PHYSIOL, V258, pF154, DOI 10.1152/ajprenal.1990.258.1.F154; FERRARIS JD, 1994, P NATL ACAD SCI USA, V91, P10742, DOI 10.1073/pnas.91.22.10742; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GARCIAPEREZ A, 1989, J BIOL CHEM, V264, P16815; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; HAGENBUCHLE O, 1992, NUCLEIC ACIDS RES, V20, P3555, DOI 10.1093/nar/20.14.3555; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIU JM, 1991, VIROLOGY, V182, P361, DOI 10.1016/0042-6822(91)90682-2; LUCHT JM, 1994, FEMS MICROBIOL REV, V14, P3, DOI 10.1016/0168-6445(94)90008-6; MORIYAMA T, 1989, J BIOL CHEM, V264, P16810; MORIYAMA T, 1990, AM J PHYSIOL, V259, pF847, DOI 10.1152/ajprenal.1990.259.5.F847; ROBEY RB, 1991, J BIOL CHEM, V266, P10400; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; TAKENAKA M, 1995, P NATL ACAD SCI USA, V92, P1072, DOI 10.1073/pnas.92.4.1072; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; UCHIDA S, 1989, AM J PHYSIOL, V256, pC614, DOI 10.1152/ajpcell.1989.256.3.C614; UCHIDA S, 1987, AM J PHYSIOL, V253, pC230, DOI 10.1152/ajpcell.1987.253.2.C230; WANG K, 1993, J BIOL CHEM, V268, P16052; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	24	150	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18318	18321		10.1074/jbc.271.31.18318	http://dx.doi.org/10.1074/jbc.271.31.18318			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702469	hybrid			2022-12-27	WOS:A1996VB68300007
J	Spady, DK; Cuthbert, JA; Willard, MN; Meidell, RS				Spady, DK; Cuthbert, JA; Willard, MN; Meidell, RS			Feedback regulation of hepatic 7 alpha-hydroxylase expression by bile salts in the hamster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING CHOLESTEROL 7-ALPHA-HYDROXYLASE; ADENOVIRUS-MEDIATED TRANSFER; RAT HEPATOCYTE CULTURES; COENZYME-A REDUCTASE; MESSENGER-RNA LEVELS; ACID SYNTHESIS; TRANSCRIPTIONAL REGULATION; DUCT LIGATION; LIPOPROTEIN-X; FATTY-ACIDS	Hepatic 7 alpha-hydroxylase activity appears to be regulated at the transcriptional level by the quantity of bile salts fluxing through the enterohepatic circulation. Whether bile salts directly suppress 7 alpha-hydroxylase expression at the level of the hepatocyte or do so indirectly by promoting the release or absorption of an intestinal factor has not been resolved. We have investigated the ability of primary bile salts to suppress hepatic 7 alpha-hydroxylase expression in bile-diverted hamsters, Biliary diversion was accompanied by derepression of both hepatic 7 alpha-hydroxylase activity (4-5-fold) and bile salt secretion (similar to 3-fold). Derepression of hepatic 7 alpha-hydroxylase expression could be prevented by several interventions that increase the availability of bile salts within the hepatocyte including 1) overexpression of an exogenous 7 alpha-hydroxylase gene by adenovirus-mediated gene transfer, 2) obstruction of the common bile duct, and 3) intravenous infusions of taurocholate. In contrast, none of these interventions prevented derepression of hepatic cholesterol synthesis or significantly down-regulated hepatic low density lipoprotein receptor expression over the relatively short time course (24 h) of these studies. Together, these data indicate that primary bile salts contribute to the regulation of bile salt synthesis through feedback repression of 7 alpha-hydroxylase expression at the level of the hepatocyte.			Spady, DK (corresponding author), UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047551, R01HL038049, P50HL017669] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47551, HL-38049, HL-17669] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERLUND JE, 1990, J LIPID RES, V31, P2159; BJORKHEM I, 1978, J LIPID RES, V19, P359; BOTHAM KM, 1981, BIOCHIM BIOPHYS ACTA, V666, P238, DOI 10.1016/0005-2760(81)90113-2; CAREY MC, 1988, ENTEROHEPATIC CIRCUL, P573; CASTEELS M, 1988, J BIOL CHEM, V263, P4654; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; CHIANG JYL, 1991, METHOD ENZYMOL, V206, P483; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRONHOLM T, 1967, EUR J BIOCHEM, V2, P375, DOI 10.1111/j.1432-1033.1967.tb00148.x; DAVIS RA, 1988, J LIPID RES, V29, P202; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; DOERNER KC, 1995, J LIPID RES, V36, P1168; DUANE WC, 1988, J LIPID RES, V29, P212; DUELAND S, 1993, J LIPID RES, V34, P923; DUELAND S, 1991, BIOCHEM J, V280, P373, DOI 10.1042/bj2800373; EDWARDS CM, 1993, METABOLISM, V42, P807, DOI 10.1016/0026-0495(93)90051-O; EKLUND A, 1980, EUR J CLIN INVEST, V10, P349, DOI 10.1111/j.1365-2362.1980.tb00044.x; FUKUSHIMA K, 1995, J LIPID RES, V36, P315; GALEAZZI R, 1977, J CLIN INVEST, V60, P693, DOI 10.1172/JCI108821; GIELEN JE, 1976, ARCH TOXICOL, V36, P255, DOI 10.1007/BF00340533; GLASS CK, 1983, J BIOL CHEM, V258, P7161; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREIM H, 1972, GASTROENTEROLOGY, V63, P837; GURANTZ D, 1984, AM J PHYSIOL, V247, pG736, DOI 10.1152/ajpgi.1984.247.6.G736; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HEUMAN DM, 1988, HEPATOLOGY, V8, P358, DOI 10.1002/hep.1840080228; HEUMAN DM, 1989, J LIPID RES, V30, P1161; HOEKMAN MFM, 1993, GENE, V130, P217, DOI 10.1016/0378-1119(93)90422-Y; HOFFMAN NE, 1977, P SOC EXP BIOL MED, V154, P49; HORTON JD, 1993, J CLIN INVEST, V92, P743, DOI 10.1172/JCI116645; HORTON JD, 1995, J BIOL CHEM, V270, P5381, DOI 10.1074/jbc.270.10.5381; HULCHER FH, 1978, BIOCHIM BIOPHYS ACTA, V529, P409, DOI 10.1016/0005-2760(78)90085-1; HYLEMON PB, 1992, J BIOL CHEM, V267, P16866; ICHIMIYA H, 1987, J LIPID RES, V28, P1028; KINUGASA T, 1981, J LIPID RES, V22, P201; KUBASKA WM, 1985, J BIOL CHEM, V260, P3459; KWEKKEBOOM J, 1989, BIOCHEM BIOPH RES CO, V162, P619, DOI 10.1016/0006-291X(89)92355-3; MAHLEY RW, 1980, P NATL ACAD SCI-BIOL, V77, P225, DOI 10.1073/pnas.77.1.225; MEREDITH JT, 1986, ARCH PATHOL LAB MED, V110, P1123; MOLOWA DT, 1992, BIOCHEMISTRY-US, V31, P2539, DOI 10.1021/bi00124a014; MYANT NB, 1977, J LIPID RES, V18, P135; NERVI FO, 1978, J CLIN INVEST, V61, P895, DOI 10.1172/JCI109015; OKAMOTO S, 1994, HEPATOLOGY, V20, P95, DOI 10.1016/0270-9139(94)90139-2; PANDAK WM, 1995, GASTROENTEROLOGY, V108, P533, DOI 10.1016/0016-5085(95)90083-7; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; RAMIREZ MI, 1994, MOL CELL BIOL, V14, P2809, DOI 10.1128/MCB.14.4.2809; REDINGER RN, 1974, AM J PHYSIOL, V226, P776, DOI 10.1152/ajplegacy.1974.226.4.776; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SCHOENFIELD LJ, 1973, J LAB CLIN MED, V82, P858; SHEFER S, 1990, J CLIN INVEST, V85, P1191, DOI 10.1172/JCI114552; SHEFFER S, 1970, J LIPID RES, V11, P404; SINGHAL AK, 1983, BIOCHIM BIOPHYS ACTA, V752, P214, DOI 10.1016/0005-2760(83)90115-7; SPADY DK, 1983, J LIPID RES, V24, P303; SPADY DK, 1993, ANNU REV NUTR, V13, P355, DOI [10.1146/annurev.nutr.13.1.355, 10.1146/annurev.nu.13.070193.002035]; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; STANGE EF, 1988, HEPATOLOGY, V8, P879, DOI 10.1002/hep.1840080429; STRAKA MS, 1990, J BIOL CHEM, V265, P7145; STRAVITZ RT, 1993, J BIOL CHEM, V268, P13987; TAKITA M, 1988, J BIOCHEM-TOKYO, V103, P778, DOI 10.1093/oxfordjournals.jbchem.a122346; WALLI AK, 1984, J CLIN INVEST, V74, P867, DOI 10.1172/JCI111504; WEIS HJ, 1969, J CLIN INVEST, V48, P2398, DOI 10.1172/JCI106206; WHITING MJ, 1989, BIOCHIM BIOPHYS ACTA, V1001, P176, DOI 10.1016/0005-2760(89)90145-8; WILLARD JE, 1994, CIRCULATION, V89, P2190, DOI 10.1161/01.CIR.89.5.2190	63	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18623	18631		10.1074/jbc.271.31.18623	http://dx.doi.org/10.1074/jbc.271.31.18623			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702514	hybrid			2022-12-27	WOS:A1996VB68300052
J	Yoza, BK; Hu, JYQ; McCall, CE				Yoza, BK; Hu, JYQ; McCall, CE			Protein-tyrosine kinase activation is required for lipopolysaccharide induction of interleukin 1 beta and NF kappa B activation, but not NF kappa B nuclear translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROINTERLEUKIN-1-BETA GENE; TUMOR-NECROSIS-FACTOR; TRANSCRIPTIONAL REGULATION; PHOSPHORYLATION; MACROPHAGES; MECHANISMS; ENDOTOXIN; CELLS; SITE; CYTOKINES	In human monocytes, interleukin 1 beta protein production and steady state mRNA levels are increased in response to lipopolysaccharide, predominantly as a result of increased transcription of the interleukin 1 beta gene, Expression of interleukin 1 beta and other cytokines, such as interleukin 6 and tumor necrosis factor alpha, has been shown to be dependent on the activation of the transcription factor, NF kappa B. Since recent studies have shown that lipopolysaccharide-induced tyrosine kinase activation is not required for NF kappa B nuclear translocation, we sought to determine whether NF kappa B translocated in the absence of tyrosine kinase activity was active in stimulating transcription. We have found that, in the human pro-monocytic cell line, THP-1, the lipopolysaccharide-induced expression of interleukin 1 beta is dependent on tyrosine kinase activation. Tyrosine kinases are not required for lipopolysaccharide-mediated nuclear translocation of NF kappa B, However, in the absence of tyrosine kinase activity, the ability of NF kappa B to stimulate transcription is impaired. This inhibition of transcription is specific for NF kappa B; in the absence of tyrosine kinase activity, AP-1-dependent transcription is enhanced. These results suggest that, while lipopolysaccharide-induced expression of inflammatory mediators requires tyrosine kinase activity, tyrosine kinase activity is not obligatory for lipopolysaccharide signal transduction.			Yoza, BK (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,INFECT DIS SECT,300 S HAWTHORNE RD,WINSTON SALEM,NC 27157, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI009169, R01AI009169] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29293] Funding Source: Medline; NIAID NIH HHS [AI09169] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; CHEDID M, 1991, J IMMUNOL, V147, P867; COGSWELL JP, 1994, J IMMUNOL, V153, P712; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FENTON MJ, 1987, J IMMUNOL, V138, P3972; GENG Y, 1993, J IMMUNOL, V151, P6692; HAN JH, 1993, J BIOL CHEM, V268, P25009; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; LARUE KEA, 1994, J EXP MED, V180, P2269, DOI 10.1084/jem.180.6.2269; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WATSON RWG, 1994, J LEUKOCYTE BIOL, V56, P95, DOI 10.1002/jlb.56.1.95; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WEINSTEIN SL, 1993, J IMMUNOL, V151, P3829	27	67	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18306	18309		10.1074/jbc.271.31.18306	http://dx.doi.org/10.1074/jbc.271.31.18306			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702466	hybrid			2022-12-27	WOS:A1996VB68300004
J	Fannon, M; Nugent, MA				Fannon, M; Nugent, MA			Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY ENDOTHELIAL-CELLS; SMOOTH-MUSCLE CELLS; SIGNAL TRANSDUCTION; POINT MUTATION; FGF; AFFINITY; BFGF; DIFFERENTIATION; MITOGENESIS; TRANSCRIPTION	We have investigated the interaction of basic fibroblast growth factor (bFCTF) with its receptors and heparan sulfate proteoglycans (HSPG), It has been suggested that in the absence of HSPG, cells are not able to bind bFGF or respond to treatment with bFGF, In our stud ies, Balb/c3T3 fibroblasts were treated with 50 mM sodium chlorate to completely inhibit (99%) sulfation of proteoglycans, We found that bFGF was able to bind, be internalized, and stimulate DNA synthesis in the absence of HSPG in a dose-dependent manner, bFGF bound to its receptors on chlorate-treated cells with a lower apparent affinity and no change in receptor number, To determine if this decreased affinity bFGF-receptor interaction is functional, we quantitatively analyzed bFGF internalization and stimulation of DNA synthesis in control and chlorate-treated cells, Endocytotic rate constants (k(e)) for chlorate-treated and control cells were k(e) = 0.078 +/- 0.022 min(-1) and k(e) = 0.043 +/- 0.012 min(-1), respectively, suggesting that the process of bFGF internalization is not dramatically altered by HSPG, bFGF stimulated DNA synthesis to the same maximal level under both conditions, but chlorate-treated cells were significantly less responsive at low bFGF doses (similar to 10-fold increase in ED(50)). The differences observed for control and chlorate-treated cells in the dose-response curves for stimulation of DNA synthesis and receptor binding correlated directly, suggesting that receptors are equally capable of eliciting a mitogenic signal under both conditions, It is unlikely that these results are due to residual HSPG since heparinase (I and III) digestion of chlorate-treated cells had little effect, Although the presence of HSPG on the cell surface increases the affinity of bFGF for its receptors, our observations suggest that HSPG are not ''absolutely'' required for binding, internalization, or stimulation of mitogenic activity.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA	Boston University				Nugent, Matthew/0000-0002-8630-4712				AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COOK PW, 1995, J CELL PHYSIOL, V163, P418, DOI 10.1002/jcp.1041630222; EDELMAN ER, 1992, J CLIN INVEST, V89, P465, DOI 10.1172/JCI115607; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; HAWKER JR, 1992, AM J PHYSIOL, V262, pH1525, DOI 10.1152/ajpheart.1992.262.5.H1525; HOPKINS CR, 1994, BIOCHEM PHARMACOL, V47, P151, DOI 10.1016/0006-2952(94)90449-9; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NATHAN A, 1995, P NATL ACAD SCI USA, V92, P8130, DOI 10.1073/pnas.92.18.8130; NUGENT MA, 1992, J BIOL CHEM, V267, P21256; NUGENT MA, 1993, CIRC RES, V73, P1051, DOI 10.1161/01.RES.73.6.1051; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; QUARTO N, 1994, J CELL SCI, V107, P3201; RAKE JB, 1991, J BIOL CHEM, V266, P5348; RAPRAEGER A, 1989, ANAL BIOCHEM, V179, P361, DOI 10.1016/0003-2697(89)90145-0; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REILAND J, 1993, J CELL SCI, V105, P1085; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; SPEIR E, 1991, J CELL PHYSIOL, V147, P362, DOI 10.1002/jcp.1041470223; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; TRIPATHI RC, 1992, EXP EYE RES, V54, P447, DOI 10.1016/0014-4835(92)90056-X; TURNBULL JE, 1993, BIOCHEM SOC T, V21, P477, DOI 10.1042/bst0210477; WALKER A, 1994, J BIOL CHEM, V269, P931; WEDER HG, 1974, EUR J BIOCHEM, V42, P475, DOI 10.1111/j.1432-1033.1974.tb03361.x; WILEY HS, 1982, J BIOL CHEM, V257, P4222; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	47	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17949	17956		10.1074/jbc.271.30.17949	http://dx.doi.org/10.1074/jbc.271.30.17949			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663512	hybrid			2022-12-27	WOS:A1996UY93500056
J	Jiang, Y; Chen, CH; Li, ZJ; Guo, W; Gegner, JA; Lin, SC; Han, JH				Jiang, Y; Chen, CH; Li, ZJ; Guo, W; Gegner, JA; Lin, SC; Han, JH			Characterization of the structure and function of a new mitogen-activated protein kinase (p38 beta)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; TRANSCRIPTION FACTORS; GENE-PRODUCT; PHOSPHORYLATION; TYROSINE; BINDING; STRESS; FAMILY; CELLS; CAMP	Mitogen-activated protein (MAP) kinase cascades represent one of the major signal systems used by eukaryotic cells to transduce extracellular signals into cellular responses, Four MAP kinase subgroups have been identified in humans: ERK, JNK (SAPK), ERK5 (BMK), and p38, Here we characterize a new MAP kinase, p38 beta. p38 beta is a 372-amino acid protein most closely related to p38. It contains a TGY dual phosphorylation site, which is required for its kinase activity. Like p38, p38 beta is activated by proinflammatory cytokines and environmental stress. A comparison of events associated with the activation of p38 beta and p38 revealed differences, most notably in the preferred activation of p38 beta by MAP kinase kinase 6 (MKK6), whereas p38 was activated nearly equally by MKK3, MKK4, and MKK6. Moreover, in. vitro and in vivo experiments showed a strong substrate preference by p38 beta for activating transcription factor 2 (ATF2), Enhancement of ATF2-dependent gene expression by p38 beta was similar to 2O-fold greater than that of p38 and other MAP kinases tested, The data reported here suggest that while closely related, p38 beta and p38 may be regulated by differing mechanisms and may exert their actions on separate downstream targets.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, SINGAPORE 117548, SINGAPORE	Scripps Research Institute; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Lin, SC/G-4666-2010; Han, J/G-4671-2010		NIGMS NIH HHS [GM51417] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; AMARAL MC, 1993, J CLIN INVEST, V92, P848, DOI 10.1172/JCI116659; BENBROOK DM, 1990, ONCOGENE, V5, P295; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN JH, 1993, J BIOL CHEM, V268, P25009; HAN JH, 1991, BIOCHIM BIOPHYS ACTA, V1090, P22, DOI 10.1016/0167-4781(91)90032-H; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARLSSON R, 1993, ACTA CRYSTALLOGR D, V49, P381, DOI 10.1107/S0907444993002306; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHOU G, 1995, J BIOL CHEM, V270, P12664; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; ZU YL, 1994, BIOCHEM BIOPH RES CO, V200, P1118, DOI 10.1006/bbrc.1994.1566	49	640	720	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17920	17926		10.1074/jbc.271.30.17920	http://dx.doi.org/10.1074/jbc.271.30.17920			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663524	hybrid			2022-12-27	WOS:A1996UY93500051
J	Unno, M; Shimada, H; Toba, Y; Makino, R; Ishimura, Y				Unno, M; Shimada, H; Toba, Y; Makino, R; Ishimura, Y			Role of Arg(112) of cytochrome P450(cam) in the electron transfer from reduced putidaredoxin - Analyses with site-directed mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN ACTIVATION; CRYSTAL-STRUCTURE; TRANSFER COMPLEX; P-450CAM; REDUCTION; SURFACE; ASSOCIATION; MUTAGENESIS; PSEUDOMONAS; EQUILIBRIUM	The mechanism for the reduction of ferric cytochrome P450(cam) by reduced putidaredoxin, the physiological electron donor for the cytochrome, has been studied by using site-directed mutants of cytochrome P450(cam), in which Arg(112), an amino acid residue at the presumed binding site for putidaredoxin, was changed to several other amino acid residues. The affinity of reduced putidaredoxin for ferric cytochrome P450(cam) to form a diprotein complex was decreased greatly by changing Arg(112) to a neutral amino acid such as Cys, Met, or Tyr. The rate of intracomplex electron transfer from putidaredoxin to cytochrome P450(cam) also diminished upon replacing the basic residue with neutral ones, being 42, 18, 4.0, 1.3, and 0.16 s(-1) for Arg (wild type), Lys, Cys, Met, and Tyr enzymes, respectively. Furthermore, the oxidation-reduction potential of cytochrome P450(cam) (Fe3+/Fe2+ couple) decreased in a similar way to the decrease in the rate of electron transfer upon amino acid substitution; the values were -138, -162, -182, -200, and -195 mV for Arg (wild type), Lys, Cys, Met, and Tyr enzymes, respectively. These results indicate that the amino acid substitution at position 112 affects the oxidation-reduction potential of the heme iron in cytochrome P450(cam), thereby diminishing the rate of electron transfer between the two metal centers. The rate of electron transfer from putidaredoxin to oxyferrous cytochrome P450(cam) also diminished upon substitution of Arg(112) with a neutral amino acid.	KEIO UNIV, SCH MED, DEPT BIOCHEM, SHINJUKU KU, TOKYO 160, JAPAN; HIMEJI INST TECHNOL, FAC SCI, DEPT LIFE SCI, HIMEJI, HYOGO 67812, JAPAN	Keio University; University of Hyogo				Unno, Masashi/0000-0002-5016-6274				AIKENS J, 1994, J AM CHEM SOC, V116, P1143, DOI 10.1021/ja00082a051; BREWER CB, 1988, J BIOL CHEM, V263, P791; CAFFREY MS, 1991, ARCH BIOCHEM BIOPHYS, V285, P227, DOI 10.1016/0003-9861(91)90353-K; DAVIES AM, 1993, BIOCHEMISTRY-US, V32, P5431, DOI 10.1021/bi00071a019; DAVIES MD, 1992, BIOCHEMISTRY-US, V31, P11383, DOI 10.1021/bi00161a016; FISHER MT, 1985, J AM CHEM SOC, V107, P5018, DOI 10.1021/ja00303a045; GERBER NC, 1994, J BIOL CHEM, V269, P4260; GERBER NC, 1992, J AM CHEM SOC, V114, P8742, DOI 10.1021/ja00048a081; Gunsalus I C, 1978, Methods Enzymol, V52, P166; HINTZ MJ, 1981, J BIOL CHEM, V256, P6721; HINTZ MJ, 1982, J BIOL CHEM, V257, P4324; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; KOGA H, 1993, FEBS LETT, V331, P109, DOI 10.1016/0014-5793(93)80307-G; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; MAKINO R, 1986, J BIOL CHEM, V261, P1444; Makino R., 1982, OXYGENASES OXYGEN ME, P467; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NAKAMURA K, 1994, BBA-PROTEIN STRUCT M, V1207, P40, DOI 10.1016/0167-4838(94)90049-3; PEDERSON TC, 1977, MICROSOMES DRUG OXID, P275; POCHAPSKY TC, 1994, BIOCHEMISTRY-US, V33, P6433, DOI 10.1021/bi00187a007; POCHAPSKY TC, 1994, BIOCHEMISTRY-US, V33, P6424, DOI 10.1021/bi00187a006; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; RODGERS KK, 1991, J AM CHEM SOC, V113, P9419, DOI 10.1021/ja00024a087; SHIMADA H, 1994, CYTOCHROME P450, P299; SHIMADA H, 1991, INT S OXYGENASES OXY, P133; STAYTON PS, 1989, BIOCHEMISTRY-US, V28, P8201, DOI 10.1021/bi00446a035; STAYTON PS, 1990, BIOCHEMISTRY-US, V29, P7381, DOI 10.1021/bi00484a005; STAYTON PS, 1988, J BIOL CHEM, V263, P13544	31	82	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17869	17874		10.1074/jbc.271.30.17869	http://dx.doi.org/10.1074/jbc.271.30.17869			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663375	hybrid			2022-12-27	WOS:A1996UY93500044
J	Yoshikawa, F; Morita, M; Monkawa, T; Michikawa, T; Furuichi, T; Mikoshiba, K				Yoshikawa, F; Morita, M; Monkawa, T; Michikawa, T; Furuichi, T; Mikoshiba, K			Mutational analysis of the ligand binding site of the inositol 1,4,5-trisphosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CHANNEL RYANODINE RECEPTOR; CALCIUM RELEASE CHANNEL; TRISPHOSPHATE RECEPTOR; METABOLIC ENZYMES; MOLECULAR-CLONING; FUNCTIONAL-CHARACTERIZATION; MOUSE CEREBELLUM; INSP3 RECEPTOR; P400 PROTEIN	To define the structural determinants for inositol 1,4,5-trisphosphate (IP3) binding of the type 1 inositol 1,4,5-trisphosphate receptor (IP(3)R1), we developed a means of expressing the N-terminal 734 amino acids of IP(3)R1 (T734), which contain the IP3 binding region, in Escherichia coli. The T734 protein expressed in E. coli exhibited a similar binding specificity and affinity for IP3 as the native IP(3)R from mouse cerebellum. Deletion mutagenesis, in which T734 was serially deleted from the N terminus up to residue 215, markedly reduced IP3 binding activity. However, when deleted a little more toward the C terminus (to residues 220, 223, and 225), the binding activity was retrieved, Further N-terminal deletions over the first 228 amino acids completely abolished it again. C-terminal deletions up to residue 579 did not affect the binding activity, whereas those up to residue 568 completely abolished it. In addition, the expressed 356-amino acid polypeptide (residues 224-579) exhibited specific binding activity. Taken together, residues 226-578 were sufficient and close enough to the minimum region for the specific IP3 binding, and thus formed an IP3 binding ''core.'' Site-directed mutagenesis was performed on 41 basic Arg and Lys residues within the N-terminal 650 amino acids of T734. We showed that single amino acid substitutions for 10 residues, which were widely distributed within the binding core and conserved among all members of the IP(3)R family, significantly reduced the binding activity. Among them, three (Arg-265, Lys-508, and Arg-511) were critical for the specific binding, and Arg-568 was implicated in the binding specificity for various inositol phosphates. We suggest that some of these 10 residues form a basic pocket that interacts with the negatively charged phosphate groups of IP3.	UNIV TOKYO,INST MED SCI,DEPT MOLEC NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; JAPAN TOBACCO INC,PHARMACEUT BASIC RES LABS,YOKOHAMA,KANAGAWA 236,JAPAN; KEIO UNIV,SCH MED,DEPT INTERNAL MED,TOKYO 160,JAPAN; RIKEN,TSUKUBA LIFE SCI CTR,INST PHYS & CHEM RES,MOLEC NEUROBIOL LAB,TSUKUBA,IBARAKI 305,JAPAN	University of Tokyo; Japan Tobacco Inc.; Keio University; RIKEN			Monkawa, Toshiaki/F-2361-2010; Mikoshiba, Katsuhiko/N-7943-2015; Furuichi, Teiichi/B-5086-2014	Monkawa, Toshiaki/0000-0002-7876-7661; Furuichi, Teiichi/0000-0002-9676-1888; Morita, Mitsuhiro/0000-0002-9891-0242				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HIRATA M, 1993, J BIOL CHEM, V268, P19260; HIRATA M, 1990, J BIOL CHEM, V265, P8404; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; IKEMURA T, 1985, MOL BIOL EVOL, V2, P13; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLENNAN DH, 1992, SCIENCE, V256, P789, DOI 10.1126/science.1589759; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MOUREY RJ, 1993, BIOCHEMISTRY-US, V32, P1719, DOI 10.1021/bi00058a004; NAHORSKI SR, 1989, TRENDS PHARMACOL SCI, V10, P139, DOI 10.1016/0165-6147(89)90165-X; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; OROURKE F, 1990, BIOCHEM J, V267, P297, DOI 10.1042/bj2670297; OTSU K, 1990, J BIOL CHEM, V265, P13472; SAFRANY ST, 1991, FEBS LETT, V278, P252, DOI 10.1016/0014-5793(91)80128-P; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT TGM, 1993, PROTEIN ENG, V6, P109, DOI 10.1093/protein/6.1.109; SMITH JW, 1987, J BIOL CHEM, V262, P11964; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WHITE AM, 1991, BIOCHEM J, V278, P759, DOI 10.1042/bj2780759; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; YAMAMOTOHINO M, 1994, RECEPTOR CHANNEL, V2, P9; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	47	187	193	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					18277	18284		10.1074/jbc.271.30.18277	http://dx.doi.org/10.1074/jbc.271.30.18277			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663526	hybrid			2022-12-27	WOS:A1996UY93500102
J	Duclert, A; Savatier, N; Schaeffer, L; Changeux, JP				Duclert, A; Savatier, N; Schaeffer, L; Changeux, JP			Identification of an element crucial for the sub-synaptic expression of the acetylcholine receptor epsilon-subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVITY-DEPENDENT REGULATION; ADULT MUSCLE-FIBERS; ALPHA-SUBUNIT; ELECTRICAL-ACTIVITY; MESSENGER-RNA; GAMMA-SUBUNIT; TRANSGENIC MICE; SKELETAL-MUSCLE; MOUSE MUSCLE; NEUROMUSCULAR SYNAPSES	The adult neuromuscular junction displays an accumulation of both the acetylcholine receptor (AChR) protein in the subneural domain of the post-synaptic membrane and the mRNAs coding for all its subunits at the level of the subjunctional ''fundamental nuclei,'' In the course of end plate development, the epsilon-subunit, at variance with other subunits, becomes exclusively expressed at the level of the fundamental nuclei, yet at a rather late stage (around birth). To analyze the promoter region of the epsilon-subunit gene which directs its specific expression at the synapse, we used a quantitative transient in vivo expression assay in intact muscle tissue using constructs of the epsilon-subunit promoter placed upstream of the beta-galactosidase reporter gene. One crucial element for synapse-specific expression was detected between the -11 and -6 positions, Disruption of this element, either by a scanning mutation or single base mutations, greatly diminishes, or even completely inhibits, preferential expression of the transgene at the end plate. Gel shift experiments reveal the presence of a complex in nuclear muscle extracts that bind the core sequence of this element, The identification of such a site opens the possibility to identify regulatory factors responsible for compartmentalized expression at the neuromuscular junction.	INST PASTEUR,DEPT BIOTECHNOL,URA CNRS 0210 NEUROBIOL MOLEC,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				schaeffer, laurent/0000-0001-6600-503X				ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; BALDWIN TJ, 1988, J CELL BIOL, V107, P2271, DOI 10.1083/jcb.107.6.2271; BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; BRENNER HR, 1994, DEV BIOL, V165, P527, DOI 10.1006/dbio.1994.1272; BRENNER HR, 1990, NATURE, V344, P544, DOI 10.1038/344544a0; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; DUCLERT A, 1993, P NATL ACAD SCI USA, V90, P3043, DOI 10.1073/pnas.90.7.3043; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; DUTTON EK, 1993, P NATL ACAD SCI USA, V90, P2040, DOI 10.1073/pnas.90.5.2040; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FONTAINE B, 1988, EMBO J, V7, P603, DOI 10.1002/j.1460-2075.1988.tb02853.x; GOLDMAN D, 1988, NEURON, V1, P329, DOI 10.1016/0896-6273(88)90081-5; GOLDMAN D, 1989, NEURON, V3, P219, DOI 10.1016/0896-6273(89)90035-4; GUNDERSEN K, 1993, J CELL BIOL, V123, P1535, DOI 10.1083/jcb.123.6.1535; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; JIA HT, 1992, CELL MOL NEUROBIOL, V12, P241, DOI 10.1007/BF00712929; JO AS, 1995, NATURE, V373, P158; KLARSFELD A, 1987, MOL CELL BIOL, V7, P951, DOI 10.1128/MCB.7.2.951; KLARSFELD A, 1991, EMBO J, V10, P625, DOI 10.1002/j.1460-2075.1991.tb07990.x; KOELLE GB, 1949, P SOC EXP BIOL MED, V70, P617; KOIKE S, 1995, P NATL ACAD SCI USA, V92, P10624, DOI 10.1073/pnas.92.23.10624; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LAUFER R, 1989, MOL NEUROBIOL, V3, P1, DOI 10.1007/BF02935587; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; MERLIE JP, 1994, J BIOL CHEM, V269, P2461; MERLIE JP, 1989, NEURON, V2, P1295, DOI 10.1016/0896-6273(89)90067-6; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NUMBERGER M, 1991, EMBO J, V10, P2957, DOI 10.1002/j.1460-2075.1991.tb07846.x; PIETTE J, 1993, DEV BIOL, V157, P205, DOI 10.1006/dbio.1993.1124; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; PRODY CA, 1991, J BIOL CHEM, V266, P22588; PRODY CA, 1992, NUCLEIC ACIDS RES, V20, P2367, DOI 10.1093/nar/20.9.2367; SANES JR, 1991, DEVELOPMENT, V113, P1181; SIMON AM, 1992, DEVELOPMENT, V114, P545; TANG JC, 1994, DEVELOPMENT, V120, P1799; TSAY HJ, 1989, J CELL BIOL, V108, P1523, DOI 10.1083/jcb.108.4.1523; WANG XM, 1990, EMBO J, V9, P783, DOI 10.1002/j.1460-2075.1990.tb08174.x; WANG Y, 1988, NEURON, V1, P527, DOI 10.1016/0896-6273(88)90183-3; WITZEMANN V, 1991, J CELL BIOL, V114, P125, DOI 10.1083/jcb.114.1.125; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x	44	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17433	17438		10.1074/jbc.271.29.17433	http://dx.doi.org/10.1074/jbc.271.29.17433			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663316	hybrid			2022-12-27	WOS:A1996UX94300070
J	Miralem, T; Wang, AM; Whiteside, CI; Templeton, DM				Miralem, T; Wang, AM; Whiteside, CI; Templeton, DM			Heparin inhibits mitogen-activated protein kinase-dependent and -independent c-fos induction in mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE FACTOR; MYC MESSENGER-RNA; SELECTIVE-INHIBITION; SIGNAL-TRANSDUCTION; CALCIUM RELEASE; BINDING; TRANSCRIPTION; PHOSPHORYLATION	Heparin suppresses mitogenic responses in renal mesangial cells, and when quiescent mesangial cells are stimulated with serum, heparin blocks the induction of c-fos seen at 15 min, Because heparin is taken up by cells over a much longer time course, we addressed mechanisms whereby extracellular heparin might suppress c-fos induction at such early times, Quiescent cells were treated with serum, 12-O-tetradecanoylphorbol-13-acetate, or low concentrations of Ca2+ ionophores that produced increases in intracellular Ca2+ concentration ([Ca2+](i)) in the physiological range, Each treatment caused an increase in c-fos mRNA, but they did so by different mechanisms. Serum activated mitogen-activated protein kinase (MAPK) and increased [Ca2+](i) without affecting protein kinase C, Activation of protein kinase C with phorbol ester activated MAPK without much effect on [Ca2+](i). Ionophores increased [Ca2+](i) without affecting basal levels of protein kinase C or MAPK, Heparin (1 mu g/ml) suppressed the induction of c-fos initiated by all three treatments, It did not affect the activity of protein kinase C, but inhibited activation of MAPK by either serum or phorbol ester, suggesting a common site of action at or below the probable convergence of the induced signals at Ras/Raf-1 activation. Heparin also inhibited the serum-stimulated entry of extracellular Ca2+ to the same extent as verapamil, consistent with the ability of verapamil to block L-type Ca-2+ channels and the known presence of these channels in mesangial cells, However, this effect does not appear to be related to heparin's ability to inhibit induction of c-fos. First, verapamil had no effect on induction of c-fos by serum, Second, heparin had no effect on changes in [Ca2+](i) achieved by ionophores, we conclude that heparin suppresses induction of c-fos in mesangial cells by blocking at least two different points in signal transduction cascades, one upstream of MAPK and the other independent of MAPK but dependent on intracellular Ca2+.	UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO,ON M5G 1L5,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON M5G 1L5,CANADA; HOSP SICK CHILDREN,DEPT BIOCHEM,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Miralem, Tihomir/F-7576-2013	Miralem, Tihomir/0000-0001-7705-0442; Templeton, Douglas/0000-0003-0693-662X				ABBOUD HE, 1993, KIDNEY INT, V43, P252, DOI 10.1038/ki.1993.39; AHN NG, 1990, J BIOL CHEM, V265, P11487; AU YPT, 1994, CIRC RES, V75, P15, DOI 10.1161/01.RES.75.1.15; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CASTELLOT JJ, 1984, J CELL PHYSIOL, V120, P315, DOI 10.1002/jcp.1041200309; CASTELLOT JJ, 1986, AM J PATHOL, V125, P493; CASTELLOT JJ, 1989, J CELL BIOL, V109, P3147, DOI 10.1083/jcb.109.6.3147; CASTELLOT JJ, 1987, VASCULAR SMOOTH MUSC, P93; CURRAN T, 1987, ONCOGENE, V2, P79; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FLOEGE J, 1993, KIDNEY INT, V43, P369, DOI 10.1038/ki.1993.55; FLOEGE JF, 1992, KLIN WOCHENSCHR, V70, P857; GARCIA MC, 1995, PFLUG ARCH EUR J PHY, V431, P84, DOI 10.1007/BF00374380; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONG Z, 1992, BIOTECHNIQUES, V12, P74; GRANT D, 1994, AGENTS ACTIONS, V41, pC214, DOI 10.1007/BF01987642; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HILL TD, 1987, BIOCHEM BIOPH RES CO, V149, P897, DOI 10.1016/0006-291X(87)90492-X; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHNSON RJ, 1994, KIDNEY INT, V45, P1769, DOI 10.1038/ki.1994.230; KNAUS HG, 1990, J BIOL CHEM, V265, P11156; KNAUS HG, 1992, P NATL ACAD SCI USA, V89, P3586, DOI 10.1073/pnas.89.8.3586; KOBAYASHI S, 1988, BIOCHEM BIOPH RES CO, V153, P625, DOI 10.1016/S0006-291X(88)81141-0; LACINOVA L, 1993, J PHYSIOL-LONDON, V465, P181, DOI 10.1113/jphysiol.1993.sp019672; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPENNA D, 1992, BIOCHEM PHARMACOL, V44, P188, DOI 10.1016/0006-2952(92)90057-P; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCDERMOTT GF, 1993, CELL CALCIUM, V14, P387, DOI 10.1016/0143-4160(93)90043-6; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; MISRA RP, 1994, J BIOL CHEM, V269, P25483; MUHL H, 1994, BIOCHEM J, V303, P607; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OTTLINGER ME, 1993, J BIOL CHEM, V268, P19173; PUKAC LA, 1990, CELL REGUL, V1, P435, DOI 10.1091/mbc.1.5.435; PUKAC LA, 1992, J BIOL CHEM, V267, P3707; RAY LB, 1988, J BIOL CHEM, V263, P12721; REILLY CF, 1987, J CELL PHYSIOL, V131, P149, DOI 10.1002/jcp.1041310203; REILLY CF, 1986, J CELL PHYSIOL, V129, P11, DOI 10.1002/jcp.1041290103; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROSEN LB, 1995, ADV SEC MESS PHOSPH, V30, P225; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TEMPLETON DM, 1987, BIOCHIM BIOPHYS ACTA, V926, P94, DOI 10.1016/0304-4165(87)90186-3; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; Wang A, 1996, KIDNEY INT, V69, P437; WANG AM, 1994, J CELL PHYSIOL, V159, P295, DOI 10.1002/jcp.1041590213; WILLIAMS B, 1993, J CLIN INVEST, V92, P2889, DOI 10.1172/JCI116911; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; WRENSHALL LE, 1995, J IMMUNOL, V154, P871; WRIGHT TC, 1989, P NATL ACAD SCI USA, V86, P3199, DOI 10.1073/pnas.86.9.3199; ZVIBEL I, 1991, MOL CELL BIOL, V11, P108, DOI 10.1128/MCB.11.1.108	63	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17100	17106		10.1074/jbc.271.29.17100	http://dx.doi.org/10.1074/jbc.271.29.17100			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663360	hybrid			2022-12-27	WOS:A1996UX94300020
J	Oldenburg, KR; Epand, RF; DOrfani, A; Vo, K; Selick, H; Epand, RM				Oldenburg, KR; Epand, RF; DOrfani, A; Vo, K; Selick, H; Epand, RM			Conformational studies on analogs of recombinant parathyroid hormone and their interactions with phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; H-1-NMR SPECTROSCOPY; PROTEIN CONFORMATION; FRAGMENT; DESIGN; EXPRESSION; RECEPTORS; RESIDUES; BINDING; REGION	Through the use of oligonucleotide-directed mutagenesis we have generated variants of a recombinant human parathyroid (PTH) hormone-(1-34)-homoserine (RPTH) in which a positively charged residue (Arg or Lys), a negatively charged residue (Glu), or a neutral residue (Gly) has been substituted at every position throughout the peptide. These 106 PTH analogs have been tested for their ability to stimulate cAMP production in the rat osteosarcoma cell line, UMR106. Analysis of these peptides led to the construction of several analogs containing multiple substitutions at sites of potential structural importance. Several of these analogs were shown to have 3-5-fold enhanced activity and receptor affinity. Circular dichroism (CD) and lipid binding studies were then performed on these analogs. Circular dichroism demonstrates enhanced helical content in the presence of lipid vesicles, particularly anionic lipid. The [Arg(15,19,22),Lys(29)]RPTH (+6RPTH) analog requires higher concentrations of trifluoroethanol to attain enhanced helicity. The intrinsic tryptophan fluorescence of the peptides are blue shifted more in the presence of the anionic lipid dimyristoyl phosphatidylglycerol (DMPG) than with the zwitterionic lipid dimyristoyl phosphatidylcholine (DMPC), Effects of the peptides on the phase transition behavior of DMPC shows that +6RPTH has less effect on the lipid than does RPTH. This difference in lipid interaction is also exhibited with isothermal titration calorimetry, in which RPTH reacts exothermally with DMPG, while +6RPTH shows little or no heat change, The pH dependence of binding of the hydrophobic probe 1,1'-bis(4-anilino)naphthalene-5,5'-trisulfonic acid, also shows a difference in exposure of hydrophobic sites between RPTH and +6RPTH. The +6RPTH has about a 5-fold greater affinity for receptor binding, We suggest that this enhanced activity is a consequence of the altered lipid interaction of +6RPTH, combined with increased conformational flexibility, particularly in the carboxyl-terminal region of the molecule.	MCMASTER UNIV, HLTH SCI CTR, DEPT BIOCHEM, HAMILTON, ON L8N 3Z5, CANADA; AFFYMAX RES INST, PALO ALTO, CA 94304 USA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba			, Richard/R-2316-2019	, Richard/0000-0002-9602-9558				ABOUSAMRA AB, 1990, J BIOL CHEM, V265, P58; ARMSTRONG MD, 1949, J AM CHEM SOC, V71, P3399, DOI 10.1021/ja01178a037; AVNUR Z, 1994, 3 INT C NEW ACT PAR; BARDEN JA, 1989, EUR J BIOCHEM, V184, P379, DOI 10.1111/j.1432-1033.1989.tb15030.x; BARDEN JA, 1993, EUR J BIOCHEM, V215, P315, DOI 10.1111/j.1432-1033.1993.tb18037.x; BUTKO P, 1994, FEBS LETT, V340, P89, DOI 10.1016/0014-5793(94)80178-9; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHOREV M, 1990, BIOCHEMISTRY-US, V29, P1580, DOI 10.1021/bi00458a032; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; EPAND RM, 1985, INT J PEPT PROT RES, V25, P594; EPAND RM, 1990, COMPREHENSIVE MED CH, V3, P1023; FRELINGER AL, 1986, ARCH BIOCHEM BIOPHYS, V244, P641, DOI 10.1016/0003-9861(86)90632-6; GARDELLA TJ, 1995, J BIOL CHEM, V270, P6584, DOI 10.1074/jbc.270.12.6584; GARDELLA TJ, 1991, J BIOL CHEM, V266, P13141; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; JOUISHOMME H, 1992, ENDOCRINOLOGY, V130, P53, DOI 10.1210/en.130.1.53; KLAUS W, 1991, BIOCHEMISTRY-US, V30, P6936, DOI 10.1021/bi00242a018; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MARX UC, 1995, J BIOL CHEM, V270, P15194, DOI 10.1074/jbc.270.25.15194; MIOZZARI GF, 1978, J BACTERIOL, V133, P1457, DOI 10.1128/JB.133.3.1457-1466.1978; NEUGEBAUER W, 1992, BIOCHEMISTRY-US, V31, P2056, DOI 10.1021/bi00122a023; NUSSBAUM SR, 1985, J PROTEIN CHEM, V4, P391, DOI 10.1007/BF01025179; OLDENBURG KR, 1994, PROTEIN EXPRES PURIF, V5, P278, DOI 10.1006/prep.1994.1042; REPPE S, 1991, J BIOL CHEM, V266, P14198; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; Rosenblatt M, 1981, Pathobiol Annu, V11, P53; ROSENBLATT M, 1976, J BIOL CHEM, V251, P159; SCHWYZER R, 1995, BIOPOLYMERS, V37, P5, DOI 10.1002/bip.360370104; SEGRE GV, 1979, J BIOL CHEM, V254, P6980; SOMJEN D, 1990, BIOCHEM J, V272, P781; STRICKLAND LA, 1993, BIOCHEMISTRY-US, V32, P6050, DOI 10.1021/bi00074a016; UNENO S, 1992, CALCIFIED TISSUE INT, V51, P382, DOI 10.1007/BF00316884; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WRAY V, 1994, BIOCHEMISTRY-US, V33, P1684, DOI 10.1021/bi00173a010; ZULL JE, 1990, J BIOL CHEM, V265, P5671	36	17	22	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17582	17591						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663272				2022-12-27	WOS:A1996UX94300090
J	Ren, B; Thelen, A; Jump, DB				Ren, B; Thelen, A; Jump, DB			Peroxisome proliferator-activated receptor alpha inhibits hepatic S14 gene transcription - Evidence against the peroxisome proliferator-activated receptor a as the mediator of polyunsaturated fatty acid regulation of S14 gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA OXIDASE; BETA-OXIDATION ENZYMES; RETINOID-X-RECEPTOR; RAT-LIVER; HORMONE RECEPTOR; RESPONSE ELEMENT; CLOFIBRIC ACID; DESATURASE-1 GENE; OMEGA-HYDROXYLASE; LIPID-METABOLISM	The peroxisome proliferator-activated receptor (PPAR alpha) has been implicated in fatty acid regulation of gene transcription, Lipogenic gene transcription is inhibited by polyunsaturated fatty acids (PUFA), We have used the PUFA-sensitive rat liver S14 gene as a model to examine the role PPAR alpha plays in fatty acid regulation of hepatic lipogenic gene transcription, Both PPAR alpha and the potent peroxisome proliferator, WY14643, inhibit S14CAT activity in transfected primary hepatocytes. WY14643 and PPAR alpha target the S14 T-3 regulatory region (TRR, -2.8 to -2.5 kilobases), a region containing 3 T-3 response elements (TRE). Transfer of the TRR to the thymidine kinase (TK) promoter conferred negative control to the TKCAT gene following WY14643 and PPAR alpha treatment, Gel shift analysis showed that PPAR alpha, either alone or with RXR alpha, did not bind the S14TRR. However, PPAR alpha interfered with TR beta/RXR alpha binding to a TRE (DR+4). Functional studies showed that co-transfected RXR alpha, but not T-3 receptor beta(1) (TR beta 1), abrogated the inhibitory effect of PPAR alpha on S14 gene transcription. These results suggest that WY14643 and PPAR alpha functionally interfere with T-3 regulation of S14 gene transcription by inhibiting TR beta 1/RXR binding to S14 TREs. Previous studies had established that the cis-regulatory targets of PUFA control were located within the proximal promoter region of the S14 gene, i.e. between -220 and -80 bp. Finding that the cis-regulatory elements for WY14643/PPAR alpha and PUFA are functionally and spatially distinct argues against PPAR alpha as the mediator of PUFA suppression of S14 gene transcription.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT PHYSIOL,E LANSING,MI 48824	Michigan State University; Michigan State University					NIDDK NIH HHS [R01 DK043220, DK43220] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043220] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; CLARKE SD, 1990, J NUTR, V120, P225, DOI 10.1093/jn/120.2.225; CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FLATMARK T, 1988, BIOCHIM BIOPHYS ACTA, V962, P122, DOI 10.1016/0005-2760(88)90103-8; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GOTTLICHER M, 1993, BIOCHEM PHARMACOL, V46, P2177, DOI 10.1016/0006-2952(93)90607-X; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1992, BIOCHEM PHARMACOL, V43, P393, DOI 10.1016/0006-2952(92)90554-V; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HERTZ R, 1991, BIOCHEM J, V274, P745, DOI 10.1042/bj2740745; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; JUMP DB, 1993, P NATL ACAD SCI USA, V90, P8454, DOI 10.1073/pnas.90.18.8454; JUMP DB, 1994, J LIPID RES, V35, P1076; JUMP DB, 1995, FATTY ACIDS, V52, P107; KAIKAUS RM, 1993, J BIOL CHEM, V268, P9593; KAIKAUS RM, 1993, J BIOL CHEM, V268, P26866; KELLER H, 1995, MOL ENDOCRINOL, V9, P794, DOI 10.1210/me.9.7.794; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KREY G, 1995, MOL ENDOCRINOL, V9, P219, DOI 10.1210/me.9.2.219; LANDSCHULZ KT, 1994, BIOCHEM BIOPH RES CO, V200, P763, DOI 10.1006/bbrc.1994.1516; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LIIMATTA M, 1994, MOL ENDOCRINOL, V8, P1147, DOI 10.1210/me.8.9.1147; LIU HC, 1994, MOL ENDOCRINOL, V8, P1021, DOI 10.1210/me.8.8.1021; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; MACDOUGALD OA, 1991, BIOCHEM J, V280, P761, DOI 10.1042/bj2800761; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NEAT CE, 1980, BIOCHEM J, V186, P369, DOI 10.1042/bj1860369; NESTEL PJ, 1984, J CLIN INVEST, V74, P82, DOI 10.1172/JCI111422; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; OSUMI T, 1990, J BIOCHEM-TOKYO, V108, P614, DOI 10.1093/oxfordjournals.jbchem.a123252; OZASA H, 1985, J BIOCHEM, V97, P1273, DOI 10.1093/oxfordjournals.jbchem.a135178; PHILLIPSON BE, 1985, NEW ENGL J MED, V312, P1210, DOI 10.1056/NEJM198505093121902; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; RUSTAN AC, 1992, BIOCHEM J, V283, P333, DOI 10.1042/bj2830333; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; THOMASSEN MS, 1982, BIOCHEM J, V206, P195, DOI 10.1042/bj2060195; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VUDAC N, 1994, J BIOL CHEM, V269, P31012; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	55	68	68	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17167	17173		10.1074/jbc.271.29.17167	http://dx.doi.org/10.1074/jbc.271.29.17167			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663275	hybrid			2022-12-27	WOS:A1996UX94300031
J	Ewart, KV; Yang, DSC; Ananthanarayanan, VS; Fletcher, GL; Hew, CL				Ewart, KV; Yang, DSC; Ananthanarayanan, VS; Fletcher, GL; Hew, CL			Ca2+-dependent antifreeze proteins - Modulation of conformation and activity by divalent metal ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; LIGAND-BINDING; POLYPEPTIDE; LECTINS; FISH; RAT; SIMILARITY; RECEPTOR; DOMAIN	The antifreeze proteins (AFPs) are structurally diverse molecules that share an ability to bind to ice crystals and inhibit their growth, The type II fish AFPs of Atlantic herring and smelt are unique among known AFPs in their requirement of a cofactor for antifreeze activity. These AFPs are homologous with the carbohydrate-recognition domains of Ca2+-dependent (C-type) lectins and require Ca2+ for their activity. To investigate the role of metal ions in the structure and function of type II AFPs, the binding of Ca2+ and other divalent cations to herring AFP was investigated. Binding studies using Ca-45(2+) demonstrated that the AFP has a single Ca2+-binding site with a K-d of 9 mu M. Proteolysis protection studies and measurement of antifreeze activity revealed a conformational change from a protease-sensitive and inactive apoAFP to a protease resistant active AFP upon Ca2+ binding. Other divalent metal ions including Mn2+, Ba2+, and Zn2+ bind at the Ca2+-binding site and induce a similar change. A saturatable increase in tryptophan emission intensity at 340 nm also occurred upon Ca2+ addition, Whereas antifreeze activity appeared normal when Ca2+ or Mn2+ were bound, it was much lower in the presence of other metal ions. When Ba2+ was bound to the AFP, ice crystals showed a distinct difference in morphology. These studies demonstrate that herring AFP specifically binds Ca2+ and, consequently, adopts a conformation that is essential for its ice binding activity.	UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO,ON M5G 1L5,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5G 1L5,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO,ON M5G 1X8,CANADA; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA; MEM UNIV NEWFOUNDLAND,CTR OCEAN SCI,ST JOHNS,NF A1C 5S7,CANADA; MEM UNIV NEWFOUNDLAND,DEPT BIOL,ST JOHNS,NF A1C 5S7,CANADA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McMaster University; Memorial University Newfoundland; Memorial University Newfoundland			Hew, Choy Leong/I-1501-2012	Hew, Choy Leong/0000-0002-9441-0064				Ananthanarayanan VS, 1989, LIFE CHEM REPORTS, V7, P1; ANOSTARIO M, 1995, J BIOL CHEM, V270, P8138, DOI 10.1074/jbc.270.14.8138; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11313; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1993, PROG NUCLEIC ACID RE, V45, P207, DOI 10.1016/S0079-6603(08)60870-3; Ewart K. Vanya, 1993, Molecular Marine Biology and Biotechnology, V2, P20; EWART KV, 1992, BIOCHEM BIOPH RES CO, V185, P335, DOI 10.1016/S0006-291X(05)90005-3; EWART KV, 1990, CAN J ZOOL, V68, P1652, DOI 10.1139/z90-245; EWART KV, 1993, THESIS MEMORIAL U NE; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; KAO MH, 1986, CAN J ZOOL, V64, P578, DOI 10.1139/z86-085; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; LOEB JA, 1988, J BIOL CHEM, V263, P9752; MARTIN RL, 1989, J BIOL CHEM, V264, P11768; McDonald D. G., 1992, P55; NG NFL, 1992, J BIOL CHEM, V267, P16069; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SONNICHSEN FD, 1993, SCIENCE, V259, P1154, DOI 10.1126/science.8438165; SONNICHSEN FD, 1995, PROTEIN SCI, V4, P460; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	27	48	48	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16627	16632		10.1074/jbc.271.28.16627	http://dx.doi.org/10.1074/jbc.271.28.16627			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663288	hybrid			2022-12-27	WOS:A1996UX12600034
J	Morris, JK; Richards, JS				Morris, JK; Richards, JS			An E-box region within the prostaglandin endoperoxide synthase-2 (PGS-2) promoter is required for transcription in rat ovarian granulosa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; DEPENDENT PROTEIN-KINASE; PREOVULATORY FOLLICLES; H SYNTHASE; REGULATORY SUBUNIT; ENZYME EXPRESSION; COMPLEMENTARY-DNA; G/H SYNTHASE; GENE; OVULATION	The prostaglandin endoperoxide synthase-2 (PGS-2) gene encodes an isoform of prostaglandin synthase that is transiently induced by protein kinase A (luteinizing hormone/cAMP) and protein kinase C (gonadotropin-releasing hormone) agonists in granulosa cells of ovulating follicles. The promoter of the rat PGS-2 gene contains a CAAT enhancer-binding protein consensus site (CAAT box) which can confer hormone inducibility to a PGS-2-CAT reporter gene, as well as a putative E-box region. To determine if the E-box region was involved in hormone induced trans-activation of the rat PGS-2 gene, constructs with the CAAT box and E-box regions (-192 PGS-2-CAT), only the putative E-box (-110 PGS-2 CAT), or neither region (-52 PGS-2-CAT) were transiently transfected into rat granulosa cell cultures. CAT activity was induced in both the -192 and -110 PGS-S-CAT vectors by luteinizing hormone (10-fold) and gonadotropin releasing hormone (6-fold), whereas CAT activity of the -52 PGS-S-CAT construct did not differ from the promoterless vector (pCAT-Basic). Deletion of 1 base pair from the E-box within the -110 PGS-S CAT construct, as well as point mutations within the CAAT box, E-box, or both regions of the -192 PGS-S CAT construct, demonstrated that the E-box is critical for basal transcription, and that regions, in addition to the CAAT box, are involved in hormone induction of the PGS-S gene. An oligonucleotide spanning the rat PGS-2 E-box bound two specific protein complexes which were supershifted in the presence of antibody specific for the upstream stimulatory factor. Thus, in rat granulosa cells, the PGS-2 E-box region appears to interact with upstream cis-acting elements other than the CAAT box to confer hormonal regulation of the gene. The E-box region of the rat PGS-2 promoter does not contain ATF/CRE activity found in the human and mouse PGS-2 promoters, but is critical for basal transcription of the PGS-2 gene in rat granulosa cells and binds the upstream stimulatory factor (as do E-box regions of other genes regulated in the ovary).			Morris, JK (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.			Morris, Jacqueline/0000-0002-3515-0821	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007165, R01HD016229] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016229, R56HD016229] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-16229, HD-07165] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AINSWORTH L, 1979, BIOL REPROD, V21, P401, DOI 10.1095/biolreprod21.2.401; ARMSTRONG DT, 1972, PROSTAGL, V1, P21, DOI 10.1016/0090-6980(72)90062-7; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Espey Lawrence L., 1994, P725; ESPEY LL, 1982, PROSTAGLANDINS, V23, P329, DOI 10.1016/0090-6980(82)90078-8; ESPEY LL, 1980, BIOL REPROD, V22, P73, DOI 10.1095/biolreprod22.1.73; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; FITZPATRICK SL, 1991, ENDOCRINOLOGY, V129, P1452, DOI 10.1210/endo-129-3-1452; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GOETZ TL, 1995, BIOL REPROD S1, V50, P98; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HECKERT LL, 1992, MOL ENDOCRINOL, V6, P70, DOI 10.1210/me.6.1.70; HEDIN L, 1987, ENDOCRINOLOGY, V121, P722, DOI 10.1210/endo-121-2-722; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; KURTEN RC, 1992, MOL ENDOCRINOL, V6, P536, DOI 10.1210/me.6.4.536; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LAU IF, 1974, J REPROD FERTIL, V40, P467, DOI 10.1530/jrf.0.0400467; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MORIS JK, 1995, ENDOCRINOLOGY, V136, P1549; MORRIS JK, 1993, ENDOCRINOLOGY, V133, P770, DOI 10.1210/en.133.2.770; NATRAJ U, 1993, ENDOCRINOLOGY, V133, P761, DOI 10.1210/en.133.2.761; NOMURA M, 1995, J BIOL CHEM, V270, P7453, DOI 10.1074/jbc.270.13.7453; OGRADY JP, 1972, PROSTAGLANDINS, V2, P1; ORCZYK GP, 1972, PROSTAGL, V1, P3, DOI 10.1016/0090-6980(72)90061-5; RATOOSH SL, 1985, ENDOCRINOLOGY, V117, P917, DOI 10.1210/endo-117-3-917; RICHARDS JS, 1980, PHYSIOL REV, V60, P51, DOI 10.1152/physrev.1980.60.1.51; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; Sambrook J., 2002, MOL CLONING LAB MANU; SINGH IS, 1994, MOL ENDOCRINOL, V8, P1163, DOI 10.1210/me.8.9.1163; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SIROIS J, 1994, ENDOCRINOLOGY, V135, P841, DOI 10.1210/en.135.3.841; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SIROIS J, 1993, J BIOL CHEM, V268, P12199; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; TILLY JL, 1992, ENDOCRINOLOGY, V130, P1296, DOI 10.1210/en.130.3.1296; TSAFRIRI A, 1972, PROSTAGL, V2, P1, DOI 10.1016/0090-6980(72)90024-X; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; WONG WYL, 1992, ENDOCRINOLOGY, V130, P3512, DOI 10.1210/en.130.6.3512; WONG WYL, 1991, MOL ENDOCRINOL, V5, P1269, DOI 10.1210/mend-5-9-1269; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; YOKAYAMA C, 1988, FEBS LETT, V231, P347; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	65	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16633	16643		10.1074/jbc.271.28.16633	http://dx.doi.org/10.1074/jbc.271.28.16633			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663219	hybrid			2022-12-27	WOS:A1996UX12600035
J	Ohshima, K; Kang, S; Larson, JE; Wells, RD				Ohshima, K; Kang, S; Larson, JE; Wells, RD			Cloning, characterization, and properties of seven triplet repeat DNA sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPERCOILED DNA; REPLICATION; PLASMIDS; HELIX; ACCOUNTS; TRACTS; INVIVO; CELLS	Several neuromuscular and neurodegenerative diseases are caused by genetically unstable triplet repeat sequences (CTG . CAG, CGG . CCG, or AAG . CTT) in or near the responsible genes. We implemented novel cloning strategies with chemically synthesized oligonucleotides to clone seven of the triplet repeat sequences (GTA . TAC, GAT . ATC, GTT . AAC, CAC . GTG, AGG . CCT, TCG . CGA, and AAG . CTT), and the adjoining paper (Ohshima, K., hang, S., Larson, J. E., and Wells, R. D. (1996) J. Biol. Chem. 271, 16784-16791) describes studies on TTA . TAA. This approach in conjunction with in vivo expansion studies in Escherichia coli enabled the preparation of at least 81 plasmids containing the repeat sequences with lengths of similar to 16 up to 158 triplets in both orientations with varying extents of polymorphisms. The inserts were characterized by DNA sequencing as well as DNA polymerase pausings, two-dimensional agarose gel electrophoresis, and chemical probe analyses to evaluate the capacity to adopt negative supercoli induced non-B DNA conformations. AAG . CTT and AGG . CCT form intramolecular triplexes, and the other five repeat sequences do not form any previously characterized non-B structures. However, long tracts of TCG . CGA showed strong inhibition of DNA synthesis at specific loci in the repeats as seen in the cases of CTG . CAG and CGG . CCG (Kang, S., Ohshima, K., Shimizu, M., Amirhaeri, S., and Wells, R. D. (1995) J. Biol. Chem. 270, 27014-27021). This work along with other studies (Wells, R. D. (1996) J. Biol. Chem. 271, 2875-2878) on CTG . CAG, CGG . CCG, and TTA . TAA makes available long inserts of all 10 triplet repeat sequences for a variety of physical, molecular biological, genetic, and medical investigations, A model to explain the reduction in mRNA abundance in Friedreich's ataxia based on intermolecular tripler formation is proposed.	TEXAS A&M UNIV, TEXAS MED CTR,CTR GENOME RES, DEPT BIOCHEM & BIOPHYS,INST BIOSCI & TECHNOL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Texas A&M University System; University of Texas System; University of Texas Health Science Center Houston					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52982] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BIANCHI A, 1990, J BIOL CHEM, V265, P21789; BOWATER R, 1991, BIOCHEMISTRY-US, V30, P11495, DOI 10.1021/bi00113a003; BOWATER RP, 1994, NUCLEIC ACIDS RES, V22, P2042, DOI 10.1093/nar/22.11.2042; BRINTON BT, 1991, J BIOL CHEM, V266, P5153; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Chastain PD, 1995, BIOCHEMISTRY-US, V34, P16125, DOI 10.1021/bi00049a027; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; CHONG SS, 1995, NAT GENET, V10, P344, DOI 10.1038/ng0795-344; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; DAVIES KE, 1993, GENOME ANAL, V7; DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406; DERRY JMJ, 1995, GENOMICS, V29, P471, DOI 10.1006/geno.1995.9979; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; EICHLER EE, 1995, HUM MOL GENET, V4, P2199, DOI 10.1093/hmg/4.12.2199; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GACY AM, 1995, CELL, V81, P533; GAO XL, 1995, J AM CHEM SOC, V117, P8883, DOI 10.1021/ja00139a035; GASTIER JM, 1995, HUM MOL GENET, V4, P1829, DOI 10.1093/hmg/4.10.1829; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; Haaf T, 1996, NAT GENET, V12, P183, DOI 10.1038/ng0296-183; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1989, J BIOL CHEM, V264, P5950; HIRST MC, 1994, HUM MOL GENET, V3, P1553, DOI 10.1093/hmg/3.9.1553; IACANGELO A, 1988, FEBS LETT, V227, P115, DOI 10.1016/0014-5793(88)80880-9; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KOCH KS, 1995, NUCLEIC ACIDS RES, V23, P1098, DOI 10.1093/nar/23.7.1098; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; KRAHE R, 1995, HYPERVARIABLE GENETI, P29; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; LAFLEUR GJ, 1995, J MOL EVOL, V41, P505, DOI 10.1007/BF00160323; LANZ RB, 1995, NUCLEIC ACIDS RES, V23, P138, DOI 10.1093/nar/23.1.138; LAPIDOT A, 1989, NUCLEIC ACIDS RES, V17, P883, DOI 10.1093/nar/17.3.883; LINDBLAD K, 1994, NAT GENET, V7, P124, DOI 10.1038/ng0694-124; LUKOMSKI S, 1994, P NATL ACAD SCI USA, V91, P9980, DOI 10.1073/pnas.91.21.9980; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; MITCHELL JE, 1995, NUCLEIC ACIDS RES, V23, P1876, DOI 10.1093/nar/23.11.1876; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; MURCHIE AIH, 1992, BIOCHIM BIOPHYS ACTA, V1131, P1, DOI 10.1016/0167-4781(92)90091-D; Ohshima K, 1996, J BIOL CHEM, V271, P1853, DOI 10.1074/jbc.271.4.1853; Ohshima K, 1996, J BIOL CHEM, V271, P16784, DOI 10.1074/jbc.271.28.16784; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; RICKE DO, 1995, GENOMICS, V26, P5210; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; SHIMIZU M, 1990, BIOCHEMISTRY-US, V29, P4704, DOI 10.1021/bi00471a027; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SMITH GK, 1995, NUCLEIC ACIDS RES, V23, P4303; SNOW K, 1994, HUM MOL GENET, V3, P1543, DOI 10.1093/hmg/3.9.1543; STALLINGS RL, 1994, GENOMICS, V21, P116, DOI 10.1006/geno.1994.1232; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WEISMANSHOMER P, 1989, BIOCHEM BIOPH RES CO, V164, P1149, DOI 10.1016/0006-291X(89)91789-0; WELLS RD, 1977, CRC CR REV BIOCH MOL, V4, P305, DOI 10.3109/10409237709102561; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WELLS RD, 1993, GENOME ANAL, V7, P107; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WELLS RD, 1969, SCIENCE, V165, P75, DOI 10.1126/science.165.3888.75; WIERINGA B, 1994, HUM MOL GENET, V3, P1, DOI 10.1093/hmg/3.1.1-a; WOODFORD KJ, 1994, J BIOL CHEM, V269, P27029; ZHONG N, 1995, AM J HUM GENET, V57, P351	75	84	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16773	16783		10.1074/jbc.271.28.16773	http://dx.doi.org/10.1074/jbc.271.28.16773			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663377	hybrid			2022-12-27	WOS:A1996UX12600056
J	Pryzdial, ELG; Kessler, GE				Pryzdial, ELG; Kessler, GE			Autoproteolysis or plasmin-mediated cleavage of factor Xa alpha exposes a plasminogen binding site and inhibits coagulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-X; FACTOR-VA; ACTIVE-SITE; ACTIVATION; PROTEINS; SURFACE; PROTHROMBINASE; MECHANISM; PATHWAYS; CELLS	Blood coagulation factor Xa (FXa) has recently been shown to function as a plasminogen receptor in the presence of procoagulant phospholipid (phosphatidylserine; PS) and Ca2+. In the current work, the possible effect of autoproteolytic and plasmin-mediated cleavage of FXa on complex formation with plasminogen was investigated. I-125-plasminogen binding to derivatives of FXa electrotransferred to polyvinylidene difluoride revealed that the autoproteolytic conversion of FXa alpha to FXa beta was required for the expression of a plasminogen binding site. In the presence of PS and Ca2+, plasmin was shown to convert FXa alpha to a FXa beta-like species at least 3 orders of magnitude faster than the autoproteolytic mechanism. This also resulted in the exposure of a plasminogen binding site, Further processing by plasmin generated a fragment (33 kDa) due to cleavage at Gly(331) in, the FXa heavy chain. Production of this species enhanced apparent plasminogen binding compared with FXa beta and resulted in the loss of FXa amidolytic and clotting activity. In the absence of either PS or Ca2+, the plasmin mediated fragmentation of FXa alpha was altered to include a FXa beta-like molecule and a species (40 kDa) with intact beta-heavy chain disulfide linked to a COOH-terminal fragment of the light chain starting at Tyr(44). Neither of these products was observed to interact with plasminogen. The 40 kDa species had amidolytic activity comparable with FXa alpha but inhibited clotting activity. Cumulatively the data provide the first evidence for a functional difference between the FXa subforms and suggest a mechanism where autoproteolysis and plasmin-mediated cleavage modulate the function of FXa alpha from a procoagulant enzyme to a profibrinolytic plasminogen receptor.	UNIV OTTAWA,DEPT BIOCHEM,OTTAWA,ON K1G 4J5,CANADA	University of Ottawa	Pryzdial, ELG (corresponding author), UNIV OTTAWA,CANADIAN RED CROSS SOC,RES DEPT,OTTAWA,ON K1G 4J5,CANADA.							BAJAJ SP, 1981, PREP BIOCHEM, V11, P387; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; CHURCH WR, 1989, J BIOL CHEM, V264, P17882; DUDANI AK, 1993, THROMB RES, V69, P185, DOI 10.1016/0049-3848(93)90044-O; EBY CS, 1992, BLOOD S, V80, P306; FUJIKAWA K, 1975, P NATL ACAD SCI USA, V72, P3359, DOI 10.1073/pnas.72.9.3359; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; FUNG MR, 1985, P NATL ACAD SCI USA, V82, P3591, DOI 10.1073/pnas.82.11.3591; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HAJJAR KA, 1994, HEMOSTASIS THROMBOSI, P823; HOJRUP P, 1987, BIOCHEM J, V245, P887, DOI 10.1042/bj2450887; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JESTY J, 1974, J BIOL CHEM, V249, P5614; Jesty J, 1976, Methods Enzymol, V45, P95; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KRISHNASWAMY S, 1994, METHOD ENZYMOL, V222, P260; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CD, 1989, BLOOD, V73, P185; LINK RP, 1982, ARCH BIOCHEM BIOPHYS, V215, P215, DOI 10.1016/0003-9861(82)90297-1; Mann K.G., 1987, THROMB DIATH HAEMO, P505; MANN KG, 1990, BLOOD, V76, P1; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERTENS K, 1980, BIOCHEM J, V185, P647, DOI 10.1042/bj1850647; MESSIER TL, 1991, GENE, V99, P291, DOI 10.1016/0378-1119(91)90141-W; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; OMAR MN, 1987, J BIOL CHEM, V262, P9720; PACKHAM MA, 1984, BLOOD PLATELET FUNCT, P61; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PLOW EF, 1991, THROMB HAEMOSTASIS, V66, P32; PRYZDIAL ELG, 1987, J BIOL CHEM, V262, P1519; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; PRYZDIAL ELG, 1995, J BIOL CHEM, V270, P1871; RADCLIFFE RD, 1972, J BIOL CHEM, V247, P7735; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; YUEN SW, 1989, BIOTECHNIQUES, V7, P74	43	26	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16614	16620		10.1074/jbc.271.28.16614	http://dx.doi.org/10.1074/jbc.271.28.16614			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663221	hybrid			2022-12-27	WOS:A1996UX12600032
J	Rieu, P; Sugimori, T; Griffith, DL; Arnaout, MA				Rieu, P; Sugimori, T; Griffith, DL; Arnaout, MA			Solvent-accessible residues on the metal ion-dependent adhesion site face of integrin CR3 mediate its binding to the neutrophil inhibitory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT RECEPTOR TYPE-3; MOLECULE-1 ALPHA-SUBUNIT; AMINO-ACID SEQUENCE; MONOCLONAL-ANTIBODIES; DOMAIN; GLYCOPROTEIN; CD11B/CD18; CLONING	Neutrophil adhesion dependent functions such as chemotaxis, spreading, and phagocytosis are inhibited by neutrophil inhibitory factor (NIF), a glycoprotein produced by the hookworm Ancylostoma caninum. The NIF binding site has been localized to the A-domain of integrin CR3 (CD11b/CD18) and shown to be metal-dependent, The recently solved crystal structure of the A-domain from CD11b revealed a putative metal ion-dependent adhesion site (MIDAS) on the top of the structure. To determine if NIF binds to the A-domain at its MIDAS face, amino acid substitutions involving 24 residues present in surface loops and adjacent helices in the structure were created. The expressed CD11b A-domain and CR3 heterodimers were then tested in a blinded manner for their ability to bind to biotinylated NIF. The solvent-exposed Gly(143), Asp(149), Glu(178)-Glu(179), and Arg(208), all located on the MIDAS face, in close proximity to the metal ion, were involved in CR3-NIF interaction. These data show that the natural integrin antagonist, NIF, binds to CR3 through the MIDAS region and identify putative contact residues in this region that could be targeted therapeutically.	MASSACHUSETTS GEN HOSP,LEUKOCYTE BIOL & INFLAMMAT PROGRAM,DIV NEPHROL,DEPT MED,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,CHARLESTOWN,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University								ARNAOUT MA, 1990, BLOOD, V75, P1037; ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; DANA N, 1987, J CLIN INVEST, V79, P1010, DOI 10.1172/JCI112868; DANA N, 1986, J IMMUNOL, V137, P3259; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; Hubbard SJ, 1993, NACCESS COMPUTER PRO; KAUFMANN Y, 1991, J IMMUNOL, V147, P369; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Maniatis T, 1989, DECONTAMINATION DILU; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; Moyle M, 1994, J BIOL CHEM, V269, P1008; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; RIEU P, 1996, ADHESION MOL LUNG, V89, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOTHWICK FS, 1989, BLOOD, V73, P1973; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; WRIGHT SD, 1987, P NATL ACAD SCI USA, V84, P1965, DOI 10.1073/pnas.84.7.1965; XIE JL, 1995, J IMMUNOL, V155, P3619; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	28	55	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15858	15861		10.1074/jbc.271.27.15858	http://dx.doi.org/10.1074/jbc.271.27.15858			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663417	hybrid			2022-12-27	WOS:A1996UW35200004
J	Milev, P; Maurel, P; Haring, M; Margolis, RK; Margolis, RU				Milev, P; Maurel, P; Haring, M; Margolis, RK; Margolis, RU			TAG-1/axonin-1 is a high-affinity ligand of neurocan, phosphacan/protein-tyrosine phosphatase-zeta/beta, and N-CAM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; CHONDROITIN SULFATE; HOMOPHILIC BINDING; NEURITE OUTGROWTH; AXONIN-1; BRAIN; CLONING; PROTEIN; CD2; PROTEOGLYCANS	Proteoglycans appear to play an important role in modulating cell-cell and cell-matrix interactions during nervous tissue histogenesis, The nervous tissue-specific chondroitin sulfate proteoglycans neurocan and phosphacan/protein-tyrosine phosphatase-zeta/beta were found to be high-affinity ligands of the neural cell adhesion molecule TAG-1/axonin-1, with dissociation constants of 0.3 nM and 0.04 nM, respectively, Phosphacan binding was decreased by similar to 70% following chondroitinase treatment, whereas binding of neurocan was not affected. The contribution of chondroitin sulfate chains to the binding of neurocan and phosphacan to TAG-1/axonin-1 is therefore the opposite of that previously observed for their binding to two other Ig-superfamily neural cell adhesion molecules, Ng-CAM/L1 and N-CAM. Moreover, whereas phosphacan interactions with certain proteins are mediated at least in part by N-linked oligosaccharides on the proteoglycan, N-deglycosylation of phosphacan had no effect on its binding to TAG-1/axonin-1. In addition to the chondroitin sulfate proteoglycans described above, we have demonstrated that N-CAM is a high-affinity ligand of TAG-1/axonin-1 (K-d similar to 1 nM), and specific binding of TAG-1/axonin-1 to tenascin-C was also observed (K-d similar to 9 nM). Immunocytochemical studies of embryonic and early postnatal nervous tissue showed an overlapping localization of TAG-1/axonin-1 with all four of these ligands, further supporting the biological significance of their ability to interact in vitro.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; SUNY HLTH SCI CTR,DEPT PHARMACOL,BROOKLYN,NY 11203	New York University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center			Maurel, Patrice/E-9559-2017		NIMH NIH HHS [MH-00129] Funding Source: Medline; NINDS NIH HHS [NS-13876] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH000129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013876] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRUMMENDORF T, 1995, PROTEIN PROFILE, V2, P963; CHAN PY, 1991, J CELL BIOL, V115, P245, DOI 10.1083/jcb.115.1.245; CUATRECASAS P, 1976, ADV PROTEIN CHEM, V30, P252; CUNNINGHAM BA, 1995, CURR OPIN CELL BIOL, V7, P628, DOI 10.1016/0955-0674(95)80103-0; DENBURG JL, 1995, J COMP NEUROL, V354, P533, DOI 10.1002/cne.903540405; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DUSTIN ML, 1989, J EXP MED, V169, P503, DOI 10.1084/jem.169.2.503; Engel M, 1996, J COMP NEUROL, V366, P34; FELSENFELD DP, 1994, NEURON, V12, P675, DOI 10.1016/0896-6273(94)90222-4; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HASLER TH, 1993, EUR J BIOCHEM, V211, P329, DOI 10.1111/j.1432-1033.1993.tb19902.x; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LEVY JB, 1993, J BIOL CHEM, V268, P10573; MAEDA N, 1994, FEBS LETT, V354, P67, DOI 10.1016/0014-5793(94)01093-5; MARGOLIS RK, 1996, IN PRESS PERSPECT DE; MAUREL P, 1995, DNA SEQUENCE, V5, P323, DOI 10.3109/10425179509030989; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MEYERPUTTLITZ B, 1995, J NEUROCHEM, V65, P2327; MeyerPuttlitz B, 1996, J COMP NEUROL, V366, P44, DOI 10.1002/(SICI)1096-9861(19960226)366:1<44::AID-CNE4>3.0.CO;2-K; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MILOEV P, 1995, J BIOL CHEM, V270, P24650; MORAN N, 1988, FEBS LETT, V242, P121, DOI 10.1016/0014-5793(88)80998-0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; RADER C, 1993, EUR J BIOCHEM, V215, P133, DOI 10.1111/j.1432-1033.1993.tb18015.x; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; RUEGG MA, 1989, J CELL BIOL, V109, P2363, DOI 10.1083/jcb.109.5.2363; SAKURAI T, 1994, DEV BRAIN RES, V83, P99, DOI 10.1016/0165-3806(94)90183-X; Sakurai T, 1996, J NEUROSCI RES, V43, P694, DOI 10.1002/(SICI)1097-4547(19960315)43:6<694::AID-JNR6>3.3.CO;2-9; SHITARA K, 1994, J BIOL CHEM, V269, P20189; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; STOECKLI ET, 1991, J CELL BIOL, V112, P1449; STRUYK AF, 1995, J NEUROSCI, V15, P2141, DOI 10.1523/JNEUROSCI.15-03-02141.1995; SUTER DM, 1995, J CELL BIOL, V131, P1067, DOI 10.1083/jcb.131.4.1067; TSIOTRA PC, 1993, GENOMICS, V18, P562, DOI 10.1016/S0888-7543(05)80357-X; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; YOSHIHARA Y, 1995, J NEUROBIOL, V28, P51, DOI 10.1002/neu.480280106; ZUELLIG RA, 1992, EUR J BIOCHEM, V204, P453, DOI 10.1111/j.1432-1033.1992.tb16655.x	45	167	169	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15716	15723		10.1074/jbc.271.26.15716	http://dx.doi.org/10.1074/jbc.271.26.15716			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663515	hybrid			2022-12-27	WOS:A1996UV29900063
J	Ballestar, E; Abad, C; Franco, L				Ballestar, E; Abad, C; Franco, L			Core histones are glutaminyl substrates for tissue transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED CROSS-LINKING; FACTOR-XIIIA; NUCLEOSOMES; PROTEIN; IDENTIFICATION; POLYAMINES; CHROMATIN; APOPTOSIS; OCTAMER; DNA	Chicken erythrocyte core histones are glutaminyl substrates in the transglutaminase (TGase) reaction with monodansylcadaverine (DNC) as donor amine, The modification is very fast when compared with that of many native substrates of TGase, Out of the 18 glutamines of the four histones, nine (namely glutamine 95 of H2B; glutamines 5, 19, and 125 of H3; glutamines 27 and 93 of H4; and glutamines 24, 104, and 112 of H2A) are the amine accepters in free histones, The use of Gln(112) of H2A requires a temperature-dependent partial unfolding of the histone, showing that structural determinants are decisive for the glutamine specificity, The structures of H2A and H2B do not appreciably change upon modification with DNC as determined by circular dichroism, and core particles reconstituted from these DNC-modified histones are indistinguishable from native nucleosome cores, When the reaction is carried out with native nucleosomes, only glutamines 5 and 19 of H3, which are located in the N-terminal tail, and glutamine 22 of H2B, which is not labeled in free histone, are modified, Methylamine and putrescine also are incorporated into nucleosomes by the TGase reaction, Our results reveal several possibilities for the application of the TGase reaction in the chromatin field, and taking into account that histones are easily cross-linked or modified by polyamines in vitro, the possibility that they may be TGase substrates in vivo is discussed.	UNIV VALENCIA, DEPT BIOCHEM & MOL BIOL, E-46100 BURJASSOT, VALENCIA, SPAIN	University of Valencia			Ballestar, Esteban/ABG-8561-2020	Ballestar, Esteban/0000-0002-1400-2440; Franco, Luis/0000-0001-9610-6448				AESCHLIMANN D, 1992, J BIOL CHEM, V267, P11316; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; ALLEN G, 1989, SEQUENCING PROTEINS; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; CHODOSH LA, 1995, CURRENT PROTOCOLS MO, V2; COUSSONS PJ, 1992, BIOCHEM J, V282, P929, DOI 10.1042/bj2820929; COUSSONS PJ, 1991, BIOCHEM J, V273, P73, DOI 10.1042/bj2730073; DABAN JR, 1989, METHOD ENZYMOL, V170, P192; DELDUCA S, 1995, BIOCHEM J, V305, P233, DOI 10.1042/bj3050233; FERRANDIZ C, 1994, BIOCHEM BIOPH RES CO, V203, P359, DOI 10.1006/bbrc.1994.2190; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1980, J BIOL CHEM, V255, P3695; GROOTJANS JJ, 1995, J BIOL CHEM, V270, P22855, DOI 10.1074/jbc.270.39.22855; GURLEY LR, 1983, ANAL BIOCHEM, V129, P132, DOI 10.1016/0003-2697(83)90061-1; HAND D, 1993, INT J DEV NEUROSCI, V11, P709, DOI 10.1016/0736-5748(93)90060-Q; ISENBERG I, 1979, ANNU REV BIOCHEM, V48, P159, DOI 10.1146/annurev.bi.48.070179.001111; JENSEN PH, 1993, EUR J BIOCHEM, V214, P141, DOI 10.1111/j.1432-1033.1993.tb17906.x; Johns E W, 1977, Methods Cell Biol, V16, P183; KORNBERG RD, 1989, METHOD ENZYMOL, V170, P3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDSEY GG, 1990, BIOCHIM BIOPHYS ACTA, V1049, P9, DOI 10.1016/0167-4781(90)90077-F; LOIDL P, 1994, CHROMOSOMA, V103, P441; LUCIANO L, 1995, CELL DEATH DIFFER, V2, P259; LUTTER LC, 1989, METHOD ENZYMOL, V170, P264; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; MATTHEWS HR, 1993, BIOESSAYS, V15, P561, DOI 10.1002/bies.950150811; MCCONKEY DJ, 1994, IMMUNOL REV, V142, P343, DOI 10.1111/j.1600-065X.1994.tb00896.x; MICHALSKISCRIVE C, 1982, BIOCHIMIE, V64, P347, DOI 10.1016/S0300-9084(82)80439-2; MURTHY SNP, 1994, J BIOL CHEM, V269, P22907; PASCAUD LT, 1987, ANAL BIOCHEM, V167, P47; RICHMOND TJ, 1988, J MOL BIOL, V199, P161, DOI 10.1016/0022-2836(88)90386-5; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; RUSSELL DH, 1981, BIOCHEM BIOPH RES CO, V157, P115; Shimizu T, 1996, NATURE, V380, P32, DOI 10.1038/380032a0; TAKAGI J, 1995, EUR J BIOCHEM, V232, P773, DOI 10.1111/j.1432-1033.1995.773zz.x; USUI T, 1993, J BIOL CHEM, V268, P12311; van Holde K.E., 1988, CHROMATIN; WEINTRAUB H, 1975, CELL, V6, P85, DOI 10.1016/0092-8674(75)90077-X; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	42	99	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18817	18824		10.1074/jbc.271.31.18817	http://dx.doi.org/10.1074/jbc.271.31.18817			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702540	hybrid			2022-12-27	WOS:A1996VB68300078
J	Church, C; Chapon, C; Poyton, RO				Church, C; Chapon, C; Poyton, RO			Cloning and characterization of PET100, a gene required for the assembly of yeast cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; NUCLEAR GENE; CYOE GENE; PARACOCCUS-DENITRIFICANS; SUBUNIT COMPOSITION; SCO1 PROTEIN; BO OPERON; HEME; EXPRESSION	The biogenesis of cytochrome c oxidase in Saccharomyces cerevisiae requires a protein encoded by the nuclear gene, PET100. Cells carrying a recessive mutation (pet100-1) in PET100 are respiratory deficient and have reduced levels of cytochrome c oxidase activity. The PET100 gene has been cloned by complementation of pet100-1, sequenced and disrupted. PET100 is located adjacent to the PDC2 gene on chromosome IV and contains an open reading frame of 333 base pairs. The PET100 protein contains a possible membrane-spanning segment and a putative mitochondrial import sequence at its NH2 terminus. A strain carrying a null mutation in PET100 lacks cytochrome c oxidase activity and assembled cytochromes a and a(3), but the other respiratory chain carriers are present, The respiratory-deficient phenotype of this strain is not rescued by added hemin or heme A. These findings indicate that the mutation is specific for cytochrome c oxidase and does not affect the biosynthesis of heme A. In addition, mitochondria from the strain carrying a null mutation in PET100 contain each of the subunit polypeptides of cytochrome c oxidase. Together, these findings suggest that PET100p is not required for the synthesis or localization of cytochrome c oxidase subunits to mitochondria, but is required at a later step in their assembly into an active holoenzyme.	UNIV COLORADO, DEPT MOL CELLULAR & DEV BIOL, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder					NIGMS NIH HHS [GM30228] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030228] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN LA, 1995, J BIOL CHEM, V270, P110, DOI 10.1074/jbc.270.1.110; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; CHOU PY, 1978, ADV ENZYMOL RELAT AR; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; COSTER F, 1995, YEAST, V11, P85, DOI 10.1002/yea.320110111; DEWINDE JH, 1993, PROG NUCLEIC ACID RE, V46, P51, DOI 10.1016/S0079-6603(08)61018-1; DIECKMANN CL, 1994, INT REV CYTOL, V152, P145, DOI 10.1016/S0074-7696(08)62556-5; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERGUSONMILLER S, 1978, J BIOL CHEM, V253, P149; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; Gibson T.J., 1984, THESIS CAMBRIDGE U U; GLERUM DM, 1994, P NATL ACAD SCI USA, V91, P8452, DOI 10.1073/pnas.91.18.8452; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOHMANN S, 1993, MOL GEN GENET, V241, P657, DOI 10.1007/BF00279908; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KOTYLAK Z, 1977, MITOCHONDRIA 1977, P83; KRUMMECK G, 1990, CURR GENET, V18, P13, DOI 10.1007/BF00321109; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMARCHE AEP, 1992, J BIOL CHEM, V267, P22473; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MCEWEN JE, 1985, J BACTERIOL, V161, P831, DOI 10.1128/JB.161.3.831-835.1985; MCEWEN JE, 1993, CURR GENET, V23, P9, DOI 10.1007/BF00336742; MERLE P, 1980, EUR J BIOCHEM, V105, P499, DOI 10.1111/j.1432-1033.1980.tb04525.x; MYERS AM, 1987, J BIOL CHEM, V262, P16822; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; PATTERSON TE, 1986, J BIOL CHEM, V261, P7192; PON L, 1991, MOL CELLULAR BIOL YE, P333; POWER SD, 1984, J BIOL CHEM, V259, P6564; POWER SD, 1984, J BIOL CHEM, V47, P45; Poyton RO, 1995, METHOD ENZYMOL, V260, P97, DOI 10.1016/0076-6879(95)60133-3; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAIKI K, 1993, J BIOL CHEM, V268, P26041; SAIKI K, 1993, J BIOL CHEM, V268, P26927; SAIKI K, 1992, BIOCHEM BIOPH RES CO, V189, P1491, DOI 10.1016/0006-291X(92)90243-E; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SPENCER F, 1990, GENETICS, V124, P237; SVENSSON B, 1993, MOL MICROBIOL, V10, P193, DOI 10.1111/j.1365-2958.1993.tb00915.x; TAANMAN JW, 1992, J BIOL CHEM, V267, P22481; TAANMAN JW, 1993, J BIOL CHEM, V268, P18754; TRUEBLOOD CE, 1987, MOL CELL BIOL, V7, P3520, DOI 10.1128/MCB.7.10.3520; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, EMBO J, V9, P2759, DOI 10.1002/j.1460-2075.1990.tb07463.x; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; WATERLAND RA, 1991, J BIOL CHEM, V266, P4180; WRIGHT RM, 1986, J BIOL CHEM, V261, P7183; WRIGHT RM, 1987, CYTOCHROME SYSTEMS M, P253	61	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18499	18507		10.1074/jbc.271.31.18499	http://dx.doi.org/10.1074/jbc.271.31.18499			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702496	hybrid			2022-12-27	WOS:A1996VB68300034
J	Guzder, SN; Habraken, Y; Sung, P; Prakash, L; Prakash, S				Guzder, SN; Habraken, Y; Sung, P; Prakash, L; Prakash, S			RAD26, the yeast homolog of human Cockayne's syndrome group B gene, encodes a DNA-dependent ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; SACCHAROMYCES-CEREVISIAE; TRANSCRIBED STRAND; RECONSTITUTION; SEQUENCES; HELICASE; PROTEINS; NUCLEASE; TFIIH	Cells from Cockayne's syndrome (CS) patients are sensitive to ultraviolet light and defective in preferential repair of the transcribed DNA strand, CS patients suffer from complex clinical symptoms, including severe growth retardation, neurological degeneration, mental retardation, and cachexia, Two CS complementation groups, CSA and CSB, have been identified so far, RAD26 encodes the yeast counterpart of the CSB gene, Here, we purify Rad26 protein to near homogeneity from yeast cells and show that it is a DNA-dependent ATPase, In contrast to the Mfd protein that functions in transcription-coupled repair in Escherichia coli, and which is a weak and DNA independent ATPase, Rad26 is a much more active ATPase, with a strict dependence on DNA. The possible role of Rad26 ATPase in the displacement of stalled RNA polymerase II from the site of the DNA lesion and in the subsequent recruitment of a DNA repair component is discussed.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Satya/C-6420-2013; Prakash, Louise/C-7891-2012	Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261	NCI NIH HHS [CA35035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035035, R37CA035035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FRIEDBERG EC, 1995, DNA REPAIR; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; HABRAKEN Y, 1995, J BIOL CHEM, V270, P30194; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MOTT JE, 1985, P NATL ACAD SCI USA, V76, P4350; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; SAYER MH, 1992, J BIOL CHEM, V267, P23376; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; Sung P, 1996, J BIOL CHEM, V271, P10821, DOI 10.1074/jbc.271.18.10821; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890	20	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18314	18317		10.1074/jbc.271.31.18314	http://dx.doi.org/10.1074/jbc.271.31.18314			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702468	hybrid			2022-12-27	WOS:A1996VB68300006
J	Kaptein, JS; Lin, CKE; Wang, CL; Nguyen, TT; Kalunta, CI; Park, E; Chen, FS; Lad, PM				Kaptein, JS; Lin, CKE; Wang, CL; Nguyen, TT; Kalunta, CI; Park, E; Chen, FS; Lad, PM			Anti-IgM-mediated regulation of c-myc and its possible relationship to apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							EPSTEIN-BARR-VIRUS; PROGRAMMED CELL-DEATH; POST-TRANSCRIPTIONAL MECHANISMS; PROMYELOCYTIC LEUKEMIA-CELLS; MOUSE ERYTHROLEUKEMIA-CELLS; LYMPHOBLASTOID DAUDI CELLS; MESSENGER-RNA TURNOVER; CASEIN KINASE-II; B-CELL; BURKITTS-LYMPHOMA	Anti-IgM treatment of Burkitt's lymphoma cells is followed by either growth arrest or induction of apoptosis, In this study we have explored the role of c-myc in these events, Our results in Ramos cells indicate the following, (a) The decline in c-myc mRNA occurs at about 4 h; inhibition of about 80% being observed, (b) The stability of c-myc message is involved since the half life of c-my mRNA is decreased from about 30 min in untreated cells to about 15 min following treatment with anti-IgM, In the presence of cycloheximide, a protein synthesis inhibitor, the half-life is increased to about 50 min and was unaltered by treatment with anti-IgM. (c) By contrast, nuclear run-on experiments indicated no change in transcription rates for c-myc message due to treatment with anti-IgM, (d) A decrease in c-myc causes apoptosis since specific repression of c-myc with antisense oligonucleotides decreases the levels of c-Myc, inhibits growth rate, decreases viability, and induces apoptosis, (e) Anti-CD40 inhibition of apoptosis occurs without alteration in anti-IgM-induced down-regulation of c-myc mRNA, suggesting that it acts distally to c-myc down regulation, Other cell lines were also investigated, In Epstein-Barr virus (EBV)-positive cell lines (Daudi, Raji, and Namalwa), anti-IgM treatment for 24 h results in growth inhibition without induction of apoptosis, In EBV-negative cell lines (ST486 and CA46, as well as Ramos), a more heterogeneous pattern of responses to anti-IgM are observed, Ramos and ST486 cells both show growth inhibition and apoptosis upon anti-IgM treatment; CA46 cells shown only growth inhibition but not apoptosis, Anti-IgM causes a decline in c-myc mRNA levels in all of these lines, as well as in c-Myc protein level in the two lines investigated, Daudi and Ramos, regardless of apoptosis, Addition of antisense c-myc oligonucleotides to the cells reduced growth in both Daudi and Ramos cells lines, however it resulted in substantial apoptosis only in Ramos cells, These results suggest that anti-IgM destabilizes c-myc mRNA by a process that involves mRNA turnover, rather than transcription rates, However anti-IgM exerts differential effects in EBV positive and EBV-negative cell lines, EBV-positive cells are uniformly resistant to apoptosis, while EBV-negative cell lines show a tendency 60 apoptosis but with exceptions, Growth inhibition can be uncoupled from apoptosis in EBV-positive cell lines, but not in those EBV-negative cell lines prone to apoptosis, Furthermore, down-regulation of c-myc message correlates with growth inhibition in these cells, but is an insufficient link to apoptosis, By contrast inhibition of apoptosis by anti-CD40 occurs even though c-myc mRNA is decreased.	KAISER FDN HOSP, REG RES LAB, LOS ANGELES, CA 90027 USA	Kaiser Permanente					NCRR NIH HHS [RR-05521-19] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; ALNEMRI ES, 1992, CANCER RES, V52, P491; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; ARCINAS M, 1994, ONCOGENE, V9, P2699; ASSELIN C, 1989, ONCOGENE, V4, P549; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAZAR L, 1995, ONCOGENE, V10, P2229; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERBERICH SJ, 1995, ONCOGENE, V10, P2343; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BLACKWOOD EM, 1992, TOHOKU J EXP MED, V168, P195; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BORN TL, 1994, MOL CELL BIOL, V14, P5710, DOI 10.1128/MCB.14.9.5710; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CHERNEY BW, 1994, P NATL ACAD SCI USA, V91, P12967, DOI 10.1073/pnas.91.26.12967; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOU CC, 1987, P NATL ACAD SCI USA, V84, P2575, DOI 10.1073/pnas.84.9.2575; CHU E, 1995, MOL CELL BIOL, V15, P179, DOI 10.1128/MCB.15.1.179; CLEMENS MJ, 1986, BIOCHEM J, V237, P877, DOI 10.1042/bj2370877; CLEVELAND D W, 1989, New Biologist, V1, P121; Cleveland DW, 1989, CURR OPIN CELL BIOL, V1, P1148, DOI 10.1016/S0955-0674(89)80065-1; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; CORBO L, 1994, ONCOGENE, V9, P3299; CREWS S, 1982, SCIENCE, V218, P1319, DOI 10.1126/science.7146913; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEAN M, 1986, J BIOL CHEM, V261, P9161; DEFRANCO AL, 1993, ANNU REV CELL BIOL, V9, P377, DOI 10.1146/annurev.cellbio.9.1.377; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUKE RC, 1992, CURRENT PROTOCOLS IM; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FISCHER G, 1994, J EXP MED, V179, P221, DOI 10.1084/jem.179.1.221; GEWERT DR, 1981, EUR J BIOCHEM, V116, P487, DOI 10.1111/j.1432-1033.1981.tb05362.x; GEWERT DR, 1983, BIOCHEM J, V214, P983, DOI 10.1042/bj2140983; GEWERT DR, 1984, EUR J BIOCHEM, V139, P619, DOI 10.1111/j.1432-1033.1984.tb08049.x; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; HICKISH T, 1994, CANCER RES, V54, P2808; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; JOHNSTON JM, 1992, LEUKEMIA LYMPHOMA, V8, P431, DOI 10.3109/10428199209051025; KALUNTA CI, 1988, P NATL ACAD SCI USA, V85, P9204, DOI 10.1073/pnas.85.23.9204; KALUNTA CI, 1992, IMMUNOL LETT, V32, P167, DOI 10.1016/0165-2478(92)90110-A; KAMESAKI H, 1994, J IMMUNOL, V152, P3294; KAPTEIN JS, 1995, IMMUNOBIOLOGY, V193, P465, DOI 10.1016/S0171-2985(11)80431-6; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KIMURA S, 1995, CANCER RES, V55, P1379; KLEIN G, 1994, ANTIBIOT CHEMOTHER, V46, P110; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; KORSMEYER SJ, 1992, BLOOD, V80, P879; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; LACY J, 1989, EMBO J, V8, P1973, DOI 10.1002/j.1460-2075.1989.tb03603.x; LAIRDOFFRINGA IA, 1992, BIOESSAYS, V14, P119, DOI 10.1002/bies.950140209; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; MAJELLO B, 1995, ONCOGENE, V10, P1841; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; MORELLO D, 1989, ONCOGENE, V4, P955; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; Nilsson K, 1992, Hum Cell, V5, P25; NILSSON K, 1982, ADV CANCER RES, V37, P319, DOI 10.1016/S0065-230X(08)60886-6; OCONNOR PM, 1993, CANCER RES, V53, P4776; OSWALD F, 1994, ONCOGENE, V9, P2029; PARRY SL, 1994, J IMMUNOL, V152, P2821; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; PLET A, 1995, ONCOGENE, V10, P319; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RETH M, 1994, CURR OPIN IMMUNOL, V6, P3, DOI 10.1016/0952-7915(94)90026-4; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; RHEE KS, 1994, J BIOL CHEM, V269, P17035; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SAINI KS, 1991, BIOCHEM CELL BIOL, V69, P415, DOI 10.1139/o91-063; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIMPSON RU, 1987, J BIOL CHEM, V262, P4104; SNYDER R C, 1992, Critical Reviews in Oncogenesis, V3, P283; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STARNAUD R, 1988, ONCOGENE, V3, P553; SWARTWOUT SG, 1989, MOL CELL BIOL, V9, P288, DOI 10.1128/MCB.9.1.288; TELFORD WG, 1992, CYTOMETRY, V13, P137, DOI 10.1002/cyto.990130205; VALENTINE MA, 1992, EUR J IMMUNOL, V22, P3141, DOI 10.1002/eji.1830221217; VASTRIK I, 1994, CRIT REV ONCOGENESIS, V5, P59, DOI 10.1615/CritRevOncog.v5.i1.30; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WINGROVE TG, 1988, J BIOL CHEM, V263, P8918; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WONG KK, 1995, ONCOGENE, V10, P705; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363	104	45	51	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18875	18884		10.1074/jbc.271.31.18875	http://dx.doi.org/10.1074/jbc.271.31.18875			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702548	hybrid			2022-12-27	WOS:A1996VB68300086
J	LeClerc, GM; Grahame, DA				LeClerc, GM; Grahame, DA			Methylcobamide:coenzyme M methyltransferase isozymes from Methanosarcina barkeri - Physicochemical characterization, cloning, sequence analysis, and heterologous gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI ADA; ARCHAEAL PROMOTER; PROTEIN; ZINC; METHANOGENESIS; ACETATE; REPAIR; INVOLVEMENT; METHANE; BIOLOGY	A comparative study was made on the physicochemical characteristics of two isozymes of methylcobamide:coenzyme M methyltransferase (MT2). Both isozymes catalyzed S-methylation of 2-thioethanesulfonate (coenzyme M) and exhibited similar apparent K-m values for coenzyme M of 35 mu M (MT2-A) and 20 mu M (MT2-M). Weak binding to methylcobalamin was indicated by the apparent K-m of 14 mM for both isozymes. Cob(I)alamin was established as the major product of the reaction, demonstrating heterolytic cleavage of the methylcobamide carbon cobalt bond. The isozymes were shown to be zinc containing metalloproteins. Metal ion chelators strongly inhibited both isozymes. A variety of coenzyme M analogs were tested for activity and/or inhibition. One alternative substrate 3-mercaptopropionate was discovered, with apparent K-m 9 mM (MT2-A) and 10 mM (MT2-M). The results suggested an active site geometry in which coenzyme M is bound both by S-coordination to zinc, and electrostatic interaction of the sulfonate with a cationic group on the enzyme. Methanosarcina barkeri genes cmtA and cmtM encoding both isozymes were cloned and sequenced. Both genes encoded proteins with 339 amino acids and predicted molecular masses of 36-37 kDa. Active forms of both isozymes were expressed in Escherichia coli. A conserved segment with the potential for metal binding was found. The possibility of zinc involvement in catalysis of coenzyme M methylation is considered.	UNIFORMED SERV UNIV HLTH SCI,DEPT BIOCHEM,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA								BOCK AK, 1994, ARCH MICROBIOL, V161, P33, DOI 10.1007/BF00248891; BROWN JW, 1988, NUCLEIC ACIDS RES, V16, P135, DOI 10.1093/nar/16.1.135; BURKE SA, 1995, J BACTERIOL, V177, P4410, DOI 10.1128/jb.177.15.4410-4416.1995; DAAS PJH, 1993, J BACTERIOL, V175, P1278, DOI 10.1128/JB.175.5.1278-1283.1993; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIMARCO AA, 1990, ANNU REV BIOCHEM, V59, P355, DOI 10.1146/annurev.biochem.59.1.355; ELDER RC, 1978, INORG CHEM, V17, P1296, DOI 10.1021/ic50183a039; Ferguson DJ, 1996, J BIOL CHEM, V271, P5189; FERRY JG, 1992, CRIT REV BIOCHEM MOL, V27, P473, DOI 10.3109/10409239209082570; FERRY JG, 1992, J BACTERIOL, V174, P5489, DOI 10.1128/JB.174.17.5489-5495.1992; GRAHAME DA, 1989, J BIOL CHEM, V264, P12890; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HAIN J, 1992, NUCLEIC ACIDS RES, V20, P5423, DOI 10.1093/nar/20.20.5423; Harms U, 1996, EUR J BIOCHEM, V235, P653, DOI 10.1111/j.1432-1033.1996.00653.x; HOGENKAMP HPC, 1985, BIOCHEMISTRY-US, V24, P6428, DOI 10.1021/bi00344a018; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; INEICHEN G, 1995, PLANT PHYSIOL, V108, P423, DOI 10.1104/pp.108.1.423; Keltjens Jan T., 1993, P253; Kiel J A, 1992, DNA Seq, V2, P415, DOI 10.3109/10425179209020822; LATIMER MT, 1993, J BACTERIOL, V175, P6822, DOI 10.1128/jb.175.21.6822-6829.1993; LECLERC GM, 1995, ANN M AM SOC MICR MA, P320; LINDOY LF, 1974, INORG CHEM, V13, P2494, DOI 10.1021/ic50140a037; MYERS LC, 1993, SCIENCE, V261, P1164, DOI 10.1126/science.8395079; MYERS LC, 1993, BIOCHEMISTRY-US, V32, P14089, DOI 10.1021/bi00214a003; MYERS LC, 1995, J BIOL CHEM, V270, P6664, DOI 10.1074/jbc.270.12.6664; MYERS LC, 1992, BIOCHEMISTRY-US, V31, P4541, DOI 10.1021/bi00134a002; PALMER JR, 1995, J BACTERIOL, V177, P1844, DOI 10.1128/jb.177.7.1844-1849.1995; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; REEVE JN, 1992, ANNU REV MICROBIOL, V46, P165; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAYLOR CD, 1974, J BIOL CHEM, V249, P4886; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VANDERMEIJDEN P, 1984, J BACTERIOL, V160, P629, DOI 10.1128/JB.160.2.629-635.1984; VANDERMEIJDEN P, 1983, ARCH MICROBIOL, V134, P238, DOI 10.1007/BF00407765; WILKER JJ, 1995, J AM CHEM SOC, V117, P8682, DOI 10.1021/ja00138a031; WOLFE RS, 1991, ANNU REV MICROBIOL, V45, P1, DOI 10.1146/annurev.mi.45.100191.000245; YELISEEV A, 1993, ARCH MICROBIOL, V159, P530, DOI 10.1007/BF00249031; [No title captured]	39	73	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18725	18731		10.1074/jbc.271.31.18725	http://dx.doi.org/10.1074/jbc.271.31.18725			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702528	hybrid			2022-12-27	WOS:A1996VB68300066
J	Maekawa, H; Tollefsen, DM				Maekawa, H; Tollefsen, DM			Role of the proposed serpin-enzyme complex receptor recognition site in binding and internalization of thrombin-heparin cofactor II complexes by hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-PROTEINASE INHIBITOR; ANTITHROMBIN-III; SEC RECEPTOR; INVIVO CATABOLISM; NEUTROPHIL CHEMOATTRACTANT; PROTEINASE-INHIBITORS; PLASMA ELIMINATION; CDNA SEQUENCE; ELASTASE; ALPHA-1-ANTITRYPSIN	Several serpin-enzyme complexes bind to a receptor on hepatocytes that mediates their endocytosis and lysosomal degradation, Joslin et al, (Joslin, G,, Fallen, R, J,, Bullock, J,, Adams, S, P,, and Perlmutter, D, H, (1991) J, Biol, Chem, 266, 11282-11288) proposed that a sequence near the C-terminal end of the serpin (e,g, FVFLM in alpha 1-antitrypsin) binds to the serpin-enzyme complex receptor (SEC receptor), In experiments with synthetic peptides, they found that substitution of alanine at the fourth or fifth position in this sequence reduced the affinity of peptide binding to Hep G2 cells, To test the hypothesis that the corresponding sequence in heparin cofactor II (HCII), FLFLI (residues 456-460), mediates binding and uptake of the thrombin-HCII complex by Hep G2 cells, we constructed five recombinant HCII variants, F456A, L457A, F458A, L459A, and I460A, At 4 degrees C, the I-125-thrombin-HCII (native) complex bound reversibly to 0.6-2.6 x 10(5) sites per Hep G2 cell with a K-d of 19-32 nM. Binding was inhibited by excess unlabeled thrombin-HCII(native), thrombin-antithrombin, or elastase-alpha 1-antitrypsin, but not by free HCII or thrombin, which is consistent with the reported specificity of the SEC receptor, However, complexes of thrombin with each of the HCII variants inhibited binding as effectively as the complex with native HCII. Competitive binding experiments with various concentrations of unlabeled thrombin-HCII (native) or thrombin-HCII (I460A) indicated that these complexes bind to Hep G2 cells with equal affinity, At 37 degrees C, complexes of I-125-thrombin with each of the five HCII variants were internalized and degraded at the same rate as the complex with native HCII. Our data suggest that the pentapeptide FLFLI in HCII is not involved in binding, internalization, and degradation of thrombin-HCII complexes by Hep G2 cells.	WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV HEMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [HL-14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANDA MJ, 1988, J EXP MED, V167, P1608, DOI 10.1084/jem.167.5.1608; BANDA MJ, 1988, J BIOL CHEM, V263, P4481; BLINDER MA, 1988, BIOCHEMISTRY-US, V27, P752, DOI 10.1021/bi00402a039; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; FUCHS HE, 1982, BIOCHIM BIOPHYS ACTA, V716, P151, DOI 10.1016/0304-4165(82)90263-X; FUCHS HE, 1984, J CELL BIOCHEM, V24, P197, DOI 10.1002/jcb.240240302; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GONIAS SL, 1982, THROMB HAEMOSTASIS, V48, P208; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JOHNSON D, 1977, BIOCHEM J, V163, P639, DOI 10.1042/bj1630639; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; JOSLIN G, 1993, J BIOL CHEM, V268, P1886; JOSLIN G, 1992, J CLIN INVEST, V90, P1150, DOI 10.1172/JCI115934; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; PERLMUTTER DH, 1988, J CLIN INVEST, V81, P1774, DOI 10.1172/JCI113519; PERLMUTTER DH, 1988, J BIOL CHEM, V263, P16499; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PERLMUTTER DH, 1994, PEDIATR RES, V36, P271, DOI 10.1203/00006450-199409000-00001; PIZZO SV, 1988, BIOCHIM BIOPHYS ACTA, V967, P158, DOI 10.1016/0304-4165(88)90005-0; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PRATT CW, 1988, ARCH BIOCHEM BIOPHYS, V262, P111, DOI 10.1016/0003-9861(88)90173-7; PRATT CW, 1990, J BIOL CHEM, V265, P6092; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZE AJ, 1994, FEBS LETT, V344, P117, DOI 10.1016/0014-5793(94)00369-6; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; SHIFMAN MA, 1982, J BIOL CHEM, V257, P3243; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; ZHANG GS, 1994, BIOCHEMISTRY-US, V33, P3632, DOI 10.1021/bi00178a021	36	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 2	1996	271	31					18604	18609		10.1074/jbc.271.31.18604	http://dx.doi.org/10.1074/jbc.271.31.18604			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VB683	8702511	hybrid			2022-12-27	WOS:A1996VB68300049
J	Clauss, M; Weich, H; Breier, G; Knies, U; Rockl, W; Waltenberger, J; Risau, W				Clauss, M; Weich, H; Breier, G; Knies, U; Rockl, W; Waltenberger, J; Risau, W			The vascular endothelial growth factor receptor Flt-1 mediates biological activities - Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-DERIVED POLYPEPTIDE; PERMEABILITY FACTOR; TISSUE FACTOR; IN-VIVO; CELLS; BINDING; EXPRESSION; ANGIOGENESIS; HEPARIN; FLK-1	Two distinct receptors for vascular endothelial growth factor (VEGF), the tyrosine kinase receptors Flt-1 and Flk-1/KDR, have been described, In this study we show that monocytes, in contrast to endothelium, express only the VEGF receptor Flt-1, and that this receptor specifically binds also the VEGF homolog placenta growth factor (PlGF). Both VEGF and PlGF stimulate tissue factor production and chemotaxis in monocytes at equivalent doses. In contrast, endothelial cells expressing both the Flt-1 and the Flk-1/KDR receptors produce more tissue factor upon stimulation with VEGF than after stimulation with PlGF. Neutralizing antibodies to the KDR receptor reduce the VEGF-stimulated tissue factor induction in endothelial cells to levels obtained by stimulation with PlGF alone, but do not affect PlGF-induced tissue factor induction in endothelial cells nor the VEGF dependent tissue factor production in monocytes, These findings strongly suggest Flt-1 as a functional receptor for VEGF and PlGF in monocytes and endothelial cells and identify this receptor as a mediator of monocyte recruitment and procoagulant activity.	GESELL BIOTECHNOL FORSCH MBH,ABT GENEXPRESS,D-38124 BRAUNSCHWEIG,GERMANY; UNIV ULM,INNERE MED ABT 2,MED KLIN & POLIKLIN,D-89070 ULM,GERMANY	Gesellschaft fur Biotechnologische Forschung mbH; Ulm University	Clauss, M (corresponding author), MAX PLANCK INST PHYSIOL & CLIN RES,ABT MOL ZELLBIOL,D-61231 BAD NAUHEIM,GERMANY.		Breier, Georg/E-3580-2016; Waltenberger, Johannes/I-1813-2013	Breier, Georg/0000-0002-9467-780X; Waltenberger, Johannes/0000-0002-2417-9880; Clauss, Matthias/0000-0001-5180-3899				BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BANAI S, 1994, CIRCULATION, V89, P2183, DOI 10.1161/01.CIR.89.5.2183; BREIER G, 1992, DEVELOPMENT, V114, P521; BREIER G, 1995, DEV DYNAM, V204, P228, DOI 10.1002/aja.1002040303; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FIEBICH BL, 1993, EUR J BIOCHEM, V211, P19, DOI 10.1111/j.1432-1033.1993.tb19865.x; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KAO J, 1992, J BIOL CHEM, V267, P20239; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1992, GROWTH FACTORS OF THE VASCULAR AND NERVOUS SYSTEMS, P28; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NEMERSON Y, 1988, BLOOD, V71, P1; OLANDER JV, 1991, BIOCHEM BIOPH RES CO, V175, P68, DOI 10.1016/S0006-291X(05)81201-X; PARK JE, 1994, J BIOL CHEM, V269, P25646; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1990, J BIOL CHEM, V265, P22071; POLVERINI PJ, 1989, CYTOKINES, V1, P54; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RAVINDRANATH N, 1992, ENDOCRINOLOGY, V131, P254, DOI 10.1210/en.131.1.254; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHEN H, 1993, BLOOD, V81, P2767; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; STAVRI GT, 1995, FEBS LETT, V358, P311, DOI 10.1016/0014-5793(94)01458-D; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	36	738	767	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17629	17634		10.1074/jbc.271.30.17629	http://dx.doi.org/10.1074/jbc.271.30.17629			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663424	hybrid			2022-12-27	WOS:A1996UY93500010
J	Dlakic, M; Park, K; Griffith, JD; Harvey, SC; Harrington, RE				Dlakic, M; Park, K; Griffith, JD; Harvey, SC; Harrington, RE			The organic crystallizing agent 2-methyl-2,4-pentanediol reduces DNA curvature by means of structural changes in A-tracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRINSICALLY BENT DNA; T-G-G; CURVED DNA; KINETOPLAST DNA; B-DNA; MINOR-GROOVE; ADENINE TRACT; DIRECTED CURVATURE; SEQUENCE ELEMENTS; HYDRATION	Contemporary predictive models for sequence-dependent DNA structure provide a good estimation of overall DNA curvature in most cases, However, the two current models differ fundamentally in their view of the origin of DNA curvature, An earlier model that associates DNA bending primarily, although not exclusively, with stretches of adenines (A-tracts) is based on results of comparative gel retardation, cyclization kinetics, hydroxyl radical cutting, and other solution measurements. It represents an intersection of wedge and junction models, More recently, a non-A-tract bending model has been proposed, built on structural results from x-ray crystallography and molecular modeling, In this view, A-tracts are proposed to be straight and rigid, whereas mixed sequence DNA is bent. Because a key premise of the non-A-tract bending model is the crystallographic observation that A-tracts are straight, we have examined the effect in solution of 2-methyl-2,4-pentanediol (MPD), an organic solvent used in crystal preparation for crystallographic DNA structure determinations, Using cyclization analysis, DNase I cutting, chemical probing, and electron microscopy on DNA oligomers with and without A-tracts, we show that the presence of MPD in solution dramatically affects A-tracts and that the effect is specific to these sequence elements. Combined with the previous observation that MPD affects gel mobility of curved sequences with A-tracts, our findings support the bent A-tract model and call for caution in the interpretation of crystallographic results on DNA structure as these are presently obtained.	UNIV NEVADA,DEPT BIOCHEM 330,RENO,NV 89557; UNIV N CAROLINA,SCH MED,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; UNIV ALABAMA,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294	Nevada System of Higher Education (NSHE); University of Nevada Reno; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Alabama System; University of Alabama Birmingham			Dlakic, Mensur/S-2702-2019	Dlakic, Mensur/0000-0003-4315-1514	NATIONAL CANCER INSTITUTE [R01CA070274] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R55HG000656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NCI NIH HHS [CA70274] Funding Source: Medline; NHGRI NIH HHS [HG00656] Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLSHOY A, 1991, P NATL ACAD SCI USA, V88, P2312, DOI 10.1073/pnas.88.6.2312; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BRUKNER I, 1995, EMBO J, V14, P1812, DOI 10.1002/j.1460-2075.1995.tb07169.x; BRUKNER I, 1994, J MOL BIOL, V236, P26, DOI 10.1006/jmbi.1994.1115; BRUKNER I, 1990, NUCLEIC ACIDS RES, V18, P891, DOI 10.1093/nar/18.4.891; BRUKNER I, 1993, NUCLEIC ACIDS RES, V21, P1025, DOI 10.1093/nar/21.4.1025; BUCKIN VA, 1989, NUCLEIC ACIDS RES, V17, P4189, DOI 10.1093/nar/17.11.4189; BUCKIN VA, 1989, NATURE, V340, P321, DOI 10.1038/340321a0; BUCKIN VA, 1994, J AM CHEM SOC, V116, P9423, DOI 10.1021/ja00100a003; BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; BURKHOFF AM, 1988, NATURE, V331, P455, DOI 10.1038/331455a0; CALLADINE CR, 1988, J MOL BIOL, V201, P127, DOI 10.1016/0022-2836(88)90444-5; CHAN SS, 1993, BIOCHEMISTRY-US, V32, P11776, DOI 10.1021/bi00095a005; CHAN SS, 1990, BIOCHEMISTRY-US, V29, P6161, DOI 10.1021/bi00478a008; CHUPRINA VP, 1985, FEBS LETT, V186, P98, DOI 10.1016/0014-5793(85)81347-8; CHUPRINA VP, 1987, NUCLEIC ACIDS RES, V15, P293, DOI 10.1093/nar/15.1.293; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DESANTIS P, 1990, BIOCHEMISTRY-US, V29, P9269, DOI 10.1021/bi00491a023; Dickerson RE, 1996, J MOL BIOL, V256, P108, DOI 10.1006/jmbi.1996.0071; DIEKMANN S, 1987, NUCLEIC ACIDS RES, V15, P247, DOI 10.1093/nar/15.1.247; DIGABRIELE AD, 1989, P NATL ACAD SCI USA, V86, P1816, DOI 10.1073/pnas.86.6.1816; Dlakic M, 1996, P NATL ACAD SCI USA, V93, P3847, DOI 10.1073/pnas.93.9.3847; DLAKIC M, 1995, J BIOL CHEM, V270, P29945; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; DREW HR, 1987, J MOL BIOL, V195, P143, DOI 10.1016/0022-2836(87)90333-0; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; EDWARDS KJ, 1992, J MOL BIOL, V226, P1161, DOI 10.1016/0022-2836(92)91059-X; GOODSELL DS, 1994, NUCLEIC ACIDS RES, V22, P5497, DOI 10.1093/nar/22.24.5497; GOODSELL DS, 1994, J MOL BIOL, V239, P79, DOI 10.1006/jmbi.1994.1352; GOODSELL DS, 1993, P NATL ACAD SCI USA, V90, P2930, DOI 10.1073/pnas.90.7.2930; GRIFFITH J, 1986, CELL, V46, P717, DOI 10.1016/0092-8674(86)90347-8; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; GRZESKOWIAK K, 1993, BIOCHEMISTRY-US, V32, P8923, DOI 10.1021/bi00085a025; HAGERMAN PJ, 1986, NATURE, V321, P449, DOI 10.1038/321449a0; HAGERMAN PJ, 1990, J MOL BIOL, V212, P351, DOI 10.1016/0022-2836(90)90130-E; HAGERMAN PJ, 1985, BIOCHEMISTRY-US, V24, P7033, DOI 10.1021/bi00346a001; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; HARAN TE, 1994, J MOL BIOL, V244, P135, DOI 10.1006/jmbi.1994.1713; HARRINGTON RE, 1993, ELECTROPHORESIS, V14, P732, DOI 10.1002/elps.11501401116; HARVEY SC, 1995, J BIOMOL STRUCT DYN, V13, P301, DOI 10.1080/07391102.1995.10508841; HERRERA JE, 1989, BIOCHEMISTRY-US, V28, P1993, DOI 10.1021/bi00431a006; HOGAN ME, 1989, P NATL ACAD SCI USA, V86, P9273, DOI 10.1073/pnas.86.23.9273; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KITCHIN PA, 1986, J BIOL CHEM, V261, P1302; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; KUBINEC MG, 1992, J AM CHEM SOC, V114, P8739, DOI 10.1021/ja00048a079; LEVENE SD, 1983, J BIOMOL STRUCT DYN, V1, P429, DOI 10.1080/07391102.1983.10507452; LIEPINSH E, 1992, NUCLEIC ACIDS RES, V20, P6549, DOI 10.1093/nar/20.24.6549; LILLEY DMJ, 1992, METHOD ENZYMOL, V212, P133; LIVSHITS MA, 1994, MOL BIOL+, V28, P687; MARINI JC, 1984, J BIOL CHEM, V259, P8974; MARINI JC, 1982, P NATL ACAD SCI-BIOL, V79, P7664, DOI 10.1073/pnas.79.24.7664; MARKY LA, 1989, BIOCHEMISTRY-US, V28, P9982, DOI 10.1021/bi00452a016; MAROUN RC, 1988, BIOPOLYMERS, V27, P585, DOI 10.1002/bip.360270404; MCCARTHY JG, 1990, BIOCHEMISTRY-US, V29, P6071, DOI 10.1021/bi00477a027; MCNAMARA PT, 1991, J BIOL CHEM, V266, P12548; MILTON DL, 1990, NUCLEIC ACIDS RES, V18, P817, DOI 10.1093/nar/18.4.817; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; OLSON WK, 1993, J MOL BIOL, V232, P530, DOI 10.1006/jmbi.1993.1409; PARK YW, 1991, P NATL ACAD SCI USA, V88, P1551, DOI 10.1073/pnas.88.4.1551; PRICE MA, 1993, BIOCHEMISTRY-US, V32, P127, DOI 10.1021/bi00052a018; PRICE MA, 1992, METHOD ENZYMOL, V212, P194; QUINTANA JR, 1992, J MOL BIOL, V225, P379, DOI 10.1016/0022-2836(92)90928-D; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SCHELLMAN JA, 1995, BIOPHYS CHEM, V55, P95, DOI 10.1016/0301-4622(94)00144-9; SHORE D, 1983, J MOL BIOL, V170, P957, DOI 10.1016/S0022-2836(83)80198-3; SHORE D, 1981, P NATL ACAD SCI-BIOL, V78, P4833, DOI 10.1073/pnas.78.8.4833; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SPROUS D, 1995, NUCLEIC ACIDS RES, V23, P1816, DOI 10.1093/nar/23.10.1816; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; TRAVERS AA, 1987, TRENDS BIOCHEM SCI, V12, P108, DOI 10.1016/0968-0004(87)90050-8; TRIFONOV EN, 1991, TRENDS BIOCHEM SCI, V16, P467; TRIFONOV EN, 1980, P NATL ACAD SCI-BIOL, V77, P3816, DOI 10.1073/pnas.77.7.3816; TRIFONOV EN, 1985, CRC CR REV BIOCH MOL, V19, P89, DOI 10.3109/10409238509082540; TULLIUS TD, 1985, SCIENCE, V230, P679, DOI 10.1126/science.2996145; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; ULANOVSKY L, 1986, P NATL ACAD SCI USA, V83, P862, DOI 10.1073/pnas.83.4.862; ULANOVSKY LE, 1987, NATURE, V326, P720, DOI 10.1038/326720a0; WANG YH, 1991, BIOCHEMISTRY-US, V30, P5443, DOI 10.1021/bi00236a017; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZHURKIN VB, 1991, P NATL ACAD SCI USA, V88, P7046, DOI 10.1073/pnas.88.16.7046	89	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 26	1996	271	30					17911	17919		10.1074/jbc.271.30.17911	http://dx.doi.org/10.1074/jbc.271.30.17911			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UY935	8663567	hybrid, Green Published			2022-12-27	WOS:A1996UY93500050
J	Freter, RR; Alberta, JA; Hwang, GY; Wrentmore, AL; Stiles, CD				Freter, RR; Alberta, JA; Hwang, GY; Wrentmore, AL; Stiles, CD			Platelet-derived growth factor induction of the immediate-early gene MCP-1 is mediated by NF-kappa B and a 90-kDa phosphoprotein coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; C-FOS PROMOTER; MULTIPLE SEQUENCE ELEMENTS; FACTOR-INDUCIBLE GENE; 3T3 CELLS; TRANSCRIPTIONAL ACTIVATION; PROTO-ONCOGENE; CYCLIC-AMP; JE GENE; IDENTIFICATION	A broad panel of agents including serum, interleukin-1, double-stranded RNA, and platelet-derived growth factor (PDGF) stimulate transcription of the ''slow'' immediate-early gene MCP-1. These disparate inducers act through a tight cluster of regulatory elements in the distal 5'-flanking sequences of the MCP-1 gene, We describe a 22-base element in this cluster which, in single copy, confers PDGF-inducibility to a tagged MCP-1 reporter gene, In mobility shift assays, the element binds a PDGF-activated form of NF-kappa B, and a 90-kDa protein (p90) which binds constitutively, Antibody supershift and UV cross-linking experiments indicate that the PDGF-activated NF-kappa B species is a Rel A homodimer, The DNA binding form of p90 is a nuclear-restricted serine/threonine phosphoprotein. Mutagenesis of the 22-base element shows that the NF-kappa B and p90 binding sites overlap, but binding of the two species is mutually independent, Both sites, however, are required for optimum PDGF induction of MCP-1, Therefore, p90 appears to be a coactivator with NF-kappa B in PDGF-mediated induction of MCP-1.	HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, DIV CLIN ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DIV CELL & MOLEC BIOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NATIONAL CANCER INSTITUTE [R01CA022042] Funding Source: NIH RePORTER; NCI NIH HHS [CA22042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DEAN M, 1986, J BIOL CHEM, V261, P9161; DEBELLE I, 1991, MOL CELL BIOL, V11, P2752, DOI 10.1128/MCB.11.5.2752; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; FRETER RR, 1995, MOL CELL BIOL, V15, P315, DOI 10.1128/MCB.15.1.315; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HALL DJ, 1987, J BIOL CHEM, V262, P15302; HALL DJ, 1989, ONCOGENE RES, V4, P177; HALL DJ, 1989, MOL CELL BIOL, V9, P1705, DOI 10.1128/MCB.9.4.1705; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; KAWAHARA RS, 1991, J BIOL CHEM, V266, P13261; KELLY K, 1988, J BIOL CHEM, V263, P4828; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LAI JH, 1995, MOL CELL BIOL, V15, P4260; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RAMEH LE, 1992, MOL CELL BIOL, V12, P4612, DOI 10.1128/MCB.12.10.4612; ROLLINS BJ, 1987, SCIENCE, V238, P1269, DOI 10.1126/science.3685976; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; ROLLINS BJ, 1995, HEMATOPOIETIC GROWTH, P357; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; TAKEUCHI M, 1995, P NATL ACAD SCI USA, V92, P3561, DOI 10.1073/pnas.92.8.3561; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; UEDA A, 1994, J IMMUNOL, V153, P2052; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	63	73	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17417	17424		10.1074/jbc.271.29.17417	http://dx.doi.org/10.1074/jbc.271.29.17417			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663287	hybrid			2022-12-27	WOS:A1996UX94300068
J	Gross, M; Hessefort, S; Olin, A; Reddy, G				Gross, M; Hessefort, S; Olin, A; Reddy, G			Extensive sequencing of tryptic peptides of a rabbit reticulocyte 66-kDa protein that promotes recycling of Hsp 70 - Homology to stress-related proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; OUTER-MEMBRANE; GENE; FAMILY; MITOCHONDRIA; RECEPTOR; CLONING; MITOSIS	Trypsinization and sequence analysis of the 66-kDa rabbit reticulocyte protein (RF-hsp 70), shown in the preceding article to function as a recycling protein for hsp 70, demonstrates striking similarity to the transformation-sensitive human protein IEF SSP 3521 (Honore, B., Leffers, H., Madsen, P., Rasmussen, H. H., Vandekerckhove, J., and Cells, J. E. (1992) J. Biol. Chem. 267, 8485-8491) and mouse extendin (Blatch, G.L., Lassie, M., Takatori, T., Gandhi, T., Kundra, V., and Zetter, B. R. (1995) Proc. Am. Assoc. Cancer Res. 36, 68). The human and mouse proteins share 97% sequence identity, and sequencing of 20 polypeptides (225 residues) from RF-hsp 70 reveals only 10 differences be tween the rabbit and human proteins and 13 differences between the rabbit and mouse proteins (96 and 94% identity, respectively). In addition, all three proteins are of similar size, and each contains 11 cysteines. These findings strongly suggest that these three proteins are homologs of the same activity. All differences (but one) between the human and mouse proteins occur within the amino-terminal half of the protein, and there is only one difference among 121 sequenced residues between RF-hsp 70 and the human or mouse protein which occurs within the carboxyl-terminal 70% of the molecule. In addition, where partial sequences of RF-hsp 70 and p60, a chick oviduct protein that shows 70% identity to the human protein (Smith, D. F., Sullivan, W. P., Marion, T. N., Zaitsu, K., Madden, B., McCormick, D. J., and Toft, D. O., (1993) Mol. Cell. Biol. 13, 869-876), overlap (a total of 54 residues), RF hsp 70 and chick p60 show 78% sequence identity, Studies of the initial digestion of RF-hsp 70 by trypsin indicate that it is first converted to 58- and 54-kDa components, each of which is then converted to a 43-kDa polypeptide. This 43-kDa component is located in the human and mouse proteins at position 124 to about 470. It is converted subsequently to a 31-kDa polypeptide by trypsin hydrolysis at position 207. This 31-kDa component is finally split into 17- and 14-kDa polypeptides that are located at positions 208 to approximately 351 and 352 to approximately 470, respectively. The 14-kDa polypeptide is relatively resistant to further digestion with trypsin, and seven tryptic peptides from other parts of RF-hsp 70 contain internal lysine and/or arginine residues (as do several tryptic peptides produced from IEF SSP 3521 and chick p60). Both features may be due to interference with trypsin action by secondary structure in the protein, since trypsinization of reduced and carboxymethylated RF-hsp 70 results in hydrolysis of the 14-kDa polypeptide and reduces the level of peptides that contain internal lysine and/or arginine, although it does not eliminate them.			Gross, M (corresponding author), UNIV CHICAGO,DEPT PATHOL,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030121] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-30121] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blatch G. L., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P68; BOGUSKI MS, 1990, NATURE, V346, P114, DOI 10.1038/346114a0; CYR DM, 1992, J BIOL CHEM, V267, P20927; DOI A, 1990, GENE, V91, P123, DOI 10.1016/0378-1119(90)90172-N; Gross M, 1996, J BIOL CHEM, V271, P16833, DOI 10.1074/jbc.271.28.16833; GROSS M, 1992, J BIOL CHEM, V267, P2073; GROSS M, 1983, BIOCHIM BIOPHYS ACTA, V740, P255, DOI 10.1016/0167-4781(83)90134-3; HASE T, 1983, EMBO J, V2, P2169, DOI 10.1002/j.1460-2075.1983.tb01718.x; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HONORE B, 1992, J BIOL CHEM, V267, P8485; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; ODONNELL KL, 1991, J CELL SCI, V99, P711; RHEE SK, 1989, YEAST, V5, P149, DOI 10.1002/yea.320050304; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; TORRES JH, 1995, PLANT MOL BIOL, V27, P1221, DOI 10.1007/BF00020896	22	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16842	16849		10.1074/jbc.271.28.16842	http://dx.doi.org/10.1074/jbc.271.28.16842			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663319	hybrid			2022-12-27	WOS:A1996UX12600065
J	Xu, G; Goodridge, AG				Xu, G; Goodridge, AG			Characterization of a polypyrimidine/polypurine tract in the promoter of the gene for chicken malic enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; STRANDED-DNA; NUTRITIONAL REGULATION; EMBRYO HEPATOCYTES; NEUTRAL PH; H-DNA; TRANSCRIPTION; IDENTIFICATION; SEQUENCES; TRIPLEX	Starvation inhibits and refeeding stimulates transcription of the malic enzyme gene in chick liver. DNA between -320 and +72 base pairs (bp) is DNase I-hypersensitive in hepatic nuclei from fed but not starved chicks (Ma, X. J,, and Goodridge, A. G, (1992) Nucleic Acids Res. 20, 4997-5002). A polypyrimidine/polypurine (PPY/PPU) tract lies within the DNase I-hypersensitive region, In hepatocytes transiently transfected with plasmids containing triiodothyronine response elements and a minimal promoter from the malic enzyme gene linked to the chloramphenicol acetyltransferase gene, deletion of the PPY/PPU tract inhibited chloramphenicol acetyltransferase activity by about 90% with or without triiodothyronine, Fine mapping of S1 nuclease-sensitive sites suggests that the PPY/PPU tract can assume different isoforms of non-B-DNA, some of which may be tripler structures, The PPY/PPU tract contains specific binding sites for single- and double stranded DNA binding proteins and, with 8 bp 3' of the tract, can function as a promoter. A (CT)(7) repeat binds single-stranded DNA-binding protein and is essential for promoter activity, Two C-rich elements bind single-stranded DNA-binding proteins and may mediate inhibition of promoter function, The single- and double-stranded DNA-binding proteins that interact with the PPY/PPU tract may regulate transcription of the malic enzyme gene.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52240	University of Iowa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 21954, DK 25295] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BACOLLA A, 1995, J BIOL CHEM, V270, P24556, DOI 10.1074/jbc.270.41.24556; BAILLIE RA, 1993, J NUTR BIOCHEM, V4, P431, DOI 10.1016/0955-2863(93)90074-7; BEHE MJ, 1987, BIOCHEMISTRY-US, V26, P7870, DOI 10.1021/bi00398a050; BIRNBOIM HC, 1978, J MOL BIOL, V121, P541, DOI 10.1016/0022-2836(78)90399-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CLARK SP, 1990, NUCLEIC ACIDS RES, V18, P5119, DOI 10.1093/nar/18.17.5119; CONOVER W, 1986, PRACTICAL NONPARAMET, P1; DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FIRULLI AB, 1994, ARCH BIOCHEM BIOPHYS, V310, P236, DOI 10.1006/abbi.1994.1162; GAILLARD C, 1990, J MOL BIOL, V215, P245, DOI 10.1016/S0022-2836(05)80343-2; GARYHACK EJ, 1992, MOL CELL BIOL, V12, P3573; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GlucksmannKuis MA, 1996, CELL, V84, P147, DOI 10.1016/S0092-8674(00)81001-6; Goodridge AG, 1996, PROG NUCLEIC ACID RE, V52, P89, DOI 10.1016/S0079-6603(08)60965-4; GRABCZYK E, 1995, J BIOL CHEM, V270, P1791, DOI 10.1074/jbc.270.4.1791; HAMPEL KJ, 1991, BIOCHEMISTRY-US, V30, P4455, DOI 10.1021/bi00232a012; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; KANG S, 1992, J BIOL CHEM, V267, P20889; KOHWI Y, 1993, J MOL BIOL, V231, P1090, DOI 10.1006/jmbi.1993.1354; KOLLER E, 1991, NUCLEIC ACIDS RES, V19, P485, DOI 10.1093/nar/19.3.485; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; LANNIGAN DA, 1989, P NATL ACAD SCI USA, V86, P863, DOI 10.1073/pnas.86.3.863; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LEWIS CD, 1988, GENE DEV, V2, P863, DOI 10.1101/gad.2.7.863; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MA XJ, 1990, J BIOL CHEM, V265, P18435; MA XJ, 1992, NUCLEIC ACIDS RES, V20, P4997, DOI 10.1093/nar/20.19.4997; MA XJ, 1991, THESIS U IOWA; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2366; MALKOV VA, 1993, NUCLEIC ACIDS RES, V21, P105, DOI 10.1093/nar/21.1.105; MANOR H, 1988, J MOL EVOL, V27, P96, DOI 10.1007/BF02138367; MARTINEZBALBAS A, 1993, NUCLEIC ACIDS RES, V21, P2557, DOI 10.1093/nar/21.11.2557; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Moore DD, 1995, GLOB MOB SURV; MORGAN AR, 1994, INDIAN J BIOCH BIOPH, V3, P83; MURAISO T, 1992, NUCLEIC ACIDS RES, V20, P6631, DOI 10.1093/nar/20.24.6631; PAN GH, 1994, J BIOL CHEM, V269, P30101; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; QUIVY JP, 1993, NUCLEIC ACIDS RES, V21, P2779, DOI 10.1093/nar/21.11.2779; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; SALATI LM, 1991, J BIOL CHEM, V266, P4010; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; Shishido K, 1982, NUCLEASES, P155; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; ULRICH MJ, 1992, J BIOL CHEM, V267, P18649; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; WANG ZY, 1993, J BIOL CHEM, V268, P10681; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WILKISON WO, 1990, J BIOL CHEM, V265, P477; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949	64	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16008	16019		10.1074/jbc.271.27.16008	http://dx.doi.org/10.1074/jbc.271.27.16008			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663263	hybrid			2022-12-27	WOS:A1996UW35200027
